author,author_bio,author_gender,author_location,dailymotion_views,date,displayed_name,domain_url,engagement,external_author_id,external_id,external_provider,facebook_likes,facebook_shares,fluency_level,full_text,language,num_comments,num_followers,porn_level,post_type,reach,reply_to_author,reply_to_tweet_id,Sentiment,source_alexa_pageviews,source_alexa_unique_visitors,source_city,source_continent,source_country,source_country_code,source_name,source_region,source_type_detail,source_type_general,spam_level,tags_customer,tags_internal,title,trending_score,twitter_likes,twitter_shares,url,vkontakte_likes,vkontakte_shares,word_count,youtube_dislikes,youtube_likes,youtube_views,num_reposts,num_likes,official,outlier_author,outlier_text,sponsorship,HCP,topic,sentiment_positive,sentiment_negative,sentiment_neutral,key_content_text,sentiment
davidhenrymd,"Practicing MD Hematologist Oncologist 
Vice Chair Dept of Medicine Pennsylvania Hospital Blood&Cancer host Research-supportive care @MDedgeTweets @MDedgeHemeOnc",,"Philadelphia, PA",,2020-01-17 11:00:07+00:00,David Henry,http://twitter.com/,0.0,,1.218125841735045e+18,,0.0,0.0,,Study from #ASH19 analyzed yield of bone marrow biopsy in elderly pts w/ ITP where we worry MDS may be brewing. Nic‚Ä¶ https://t.co/12wNBO2tYu,en,0.0,1771.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/davidhenrymd/statuses/1218125841735045121,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,Study from #ASH19 analyzed yield of bone marrow biopsy in elderly pts w/ ITP where we worry MDS may be brewing. Nic‚Ä¶ https://t.co/12wNBO2tYu,true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-01-17 17:28:08+00:00,Oncology Tube,http://twitter.com/,0.0,,1.218223493222785e+18,,0.0,0.0,,"MANIFEST, a Phase 2 Study of CPI-0610 @MountSinaiNYC #ASH #ASH19: John Mascarenhas, MD of @MountSinaiNYC discusses‚Ä¶ https://t.co/VsYH6AjjRy",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1218223493222785026,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"MANIFEST, a Phase 2 Study of CPI-0610 @MountSinaiNYC #ASH #ASH19: John Mascarenhas, MD of @MountSinaiNYC discusses‚Ä¶ https://t.co/VsYH6AjjRy",true
DrJonnys,Consultant General Surgery . former doctor at (CAF)üëÆüèª‚Äç‚ôÇÔ∏è / Anatomist. #umanitoba #uwinnipeg @Harvard,,"Winnipeg, Manitoba",,2020-02-10 16:38:51+00:00,ùê∑ùëü. ùêΩùëú‚Ñéùëõùëõùë¶ ùëÜùë°ùëíùë§ùëéùëüùë°‚Å¶üá®üá¶‚Å©üåàüçÅ,http://twitter.com/,21.0,,1.226908397792002e+18,,0.0,0.0,,RT @DrRaulCordoba: @DrAlbertoLG presents results of a collaborative research between @Hospital_FJD and #somosclinico about cardiovascular t‚Ä¶,en,0.0,5806.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,11.0,10.0,https://twitter.com/DrJonnys/statuses/1226908397792002048,0.0,0.0,,0.0,0.0,0.0,10.0,11.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,RT @DrRaulCordoba: @DrAlbertoLG presents results of a collaborative research between @Hospital_FJD and #somosclinico about cardiovascular t‚Ä¶,false
AdityaSharma_MD,Pediatric hematologist/oncologist. Amateur photographer. Martini traveler.,,"Los Angeles, CA",,2020-02-11 06:00:08+00:00,"Aditya Sharma,MD",http://twitter.com/,72.0,,1.2271100475677983e+18,,0.0,0.0,,"RT @7eyeblink: Anti infective prophylaxis EBMT recommendations after CAR-T Cell infusion, now in #CART20 #CART2020 #CARTMeeting https://t.c‚Ä¶",en,0.0,59.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,50.0,22.0,https://twitter.com/AdityaSharma_MD/statuses/1227110047567798274,0.0,0.0,,0.0,0.0,0.0,22.0,50.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"RT @7eyeblink: Anti infective prophylaxis EBMT recommendations after CAR-T Cell infusion, now in #CART20 #CART2020 #CARTMeeting https://t.c‚Ä¶",true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-02-04 15:43:04+00:00,Oncology Tube,http://twitter.com/,0.0,,1.2247200305515602e+18,,0.0,0.0,,Dose Optimization Portion of the Phase 2 PRIMO Study in Relapsed or Refractory PTCL #ASH19 @sloan_kettering: Steven‚Ä¶ https://t.co/gVtI92tVdk,en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1224720030551560192,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,Dose Optimization Portion of the Phase 2 PRIMO Study in Relapsed or Refractory PTCL #ASH19 @sloan_kettering: Steven‚Ä¶ https://t.co/gVtI92tVdk,true
_VaibhavAgrawal,"Blood and Marrow Transplantation and Cellular Therapy Fellow @StanfordMed | MD, MBA, MJ, MSHA | @Stanford @StanfordHealth",,,,2020-02-21 17:09:14+00:00,Vaibhav Agrawal,http://twitter.com/,11.0,,1.2309023109283553e+18,,0.0,0.0,,RT @DrM_AbuZaid: Dr. Sherif Farag @IUSMDeptMed presenting results of ph2 study of sitagliptin to prevent acute GVHD. Sitagliptin reduced aG‚Ä¶,en,0.0,233.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,1.0,https://twitter.com/_VaibhavAgrawal/statuses/1230902310928355328,0.0,0.0,,0.0,0.0,0.0,1.0,10.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @DrM_AbuZaid: Dr. Sherif Farag @IUSMDeptMed presenting results of ph2 study of sitagliptin to prevent acute GVHD. Sitagliptin reduced aG‚Ä¶,true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-01-18 17:39:03+00:00,Oncology Tube,http://twitter.com/,0.0,,1.2185886279548764e+18,,0.0,0.0,,Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL: How This Affects Clinicians? #ASH19 #ASH: John Seymou‚Ä¶ https://t.co/b9R2H04W2C,en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1218588627954876416,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL: How This Affects Clinicians? #ASH19 #ASH: John Seymou‚Ä¶ https://t.co/b9R2H04W2C,true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-01-18 19:19:02+00:00,Oncology Tube,http://twitter.com/,0.0,,1.2186137898152591e+18,,0.0,0.0,,"Phase III Lumoxiti #ASH19: Robert Kreitman, MD of National Cancer Institute discusses Lumoxiti¬Æ phase III trial in‚Ä¶ https://t.co/m4E8VYQPRP",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1218613789815259136,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"Phase III Lumoxiti #ASH19: Robert Kreitman, MD of National Cancer Institute discusses Lumoxiti¬Æ phase III trial in‚Ä¶ https://t.co/m4E8VYQPRP",false
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-02-21 12:19:09+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,1.0,,1.2308293105687306e+18,,0.0,0.0,,#TCTM20 Ferrara: MAGIC biomarkers can be considered a ‚Äúliquid biopsy‚Äù to assess tissue damage occurring in setting‚Ä¶ https://t.co/3L8t875LCm,en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/hemedoc/statuses/1230829310568730627,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,#TCTM20 Ferrara: MAGIC biomarkers can be considered a ‚Äúliquid biopsy‚Äù to assess tissue damage occurring in setting‚Ä¶ https://t.co/3L8t875LCm,true
_VaibhavAgrawal,"Blood and Marrow Transplantation and Cellular Therapy Fellow @StanfordMed | MD, MBA, MJ, MSHA | @Stanford @StanfordHealth",,,,2020-02-21 23:07:33+00:00,Vaibhav Agrawal,http://twitter.com/,10.0,,1.230992482671956e+18,,0.0,0.0,,RT @AkshaySharmaMD: #TCTM20 Popat from @MDAndersonNews You can still give fractionated myeloablative chemotherapy and reduce toxicity but n‚Ä¶,en,0.0,233.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,5.0,https://twitter.com/_VaibhavAgrawal/statuses/1230992482671955973,0.0,0.0,,0.0,0.0,0.0,5.0,5.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @AkshaySharmaMD: #TCTM20 Popat from @MDAndersonNews You can still give fractionated myeloablative chemotherapy and reduce toxicity but n‚Ä¶,true
AimeeTalleurMD,Physician Scientist | Pediatric BMT & Immunotherapy | Clinical Trial Development | Med-ed | Academics | Twin Mom | opinions=my own | @stjuderesearch,,"Memphis, TN",,2020-02-21 22:53:26+00:00,"Aimee Talleur, MD",http://twitter.com/,1.0,,1.2309889318287892e+18,,0.0,0.0,,"Sitting in the ASTCT awards ceremony, feeling grateful for @ASTCT and the society‚Äôs support of new investigators li‚Ä¶ https://t.co/0VpdDDzXRu",en,0.0,345.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/AimeeTalleurMD/statuses/1230988931828789250,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Financial Performance,1.0,0.0,0.0,"Sitting in the ASTCT awards ceremony, feeling grateful for @ASTCT and the society‚Äôs support of new investigators li‚Ä¶ https://t.co/0VpdDDzXRu",true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-02-21 12:45:50+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,1.0,,1.2308360219249009e+18,,0.0,0.0,,"#TCTM20 Schroeder: IL22 protects intestinal stem cells, 70% ORR at day 28 in newly diagnosed gut GVHD https://t.co/2OtItgRsyA",en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/hemedoc/statuses/1230836021924900870,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"#TCTM20 Schroeder: IL22 protects intestinal stem cells, 70% ORR at day 28 in newly diagnosed gut GVHD https://t.co/2OtItgRsyA",true
marrow,"Clinical Haematologist, marrow transplanter. President World Marrow Donor Association (WMDA). Editor-in-Chief Internal Medicine Journal.",,"Melbourne, Australia",,2020-02-21 21:04:57+00:00,Jeff Szer,http://twitter.com/,21.0,,1.2309616317205627e+18,,0.0,0.0,,RT @BldCancerDoc: üëèüëçüôè to our üåü @ASTCT team for organizing üòéü§© #TCTM20 in collaboration with @CIBMTR,en,0.0,2195.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,20.0,1.0,https://twitter.com/marrow/statuses/1230961631720562690,0.0,0.0,,0.0,0.0,0.0,1.0,20.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,RT @BldCancerDoc: üëèüëçüôè to our üåü @ASTCT team for organizing üòéü§© #TCTM20 in collaboration with @CIBMTR,true
MediHumdani,"Director, BMT & Cellular Therapy Program @Froedtert & @MedicalCollege | Lymphoma | Clinical Trials | @CIBMTR | @BMTCTN | Personal views | Physician ‚â† Provider",,"Milwaukee, WI",,2020-02-21 12:29:13+00:00,Mehdi Hamadani,http://twitter.com/,1.0,,1.2308318435509248e+18,,0.0,0.0,,Commitment early AM @BMTCTN 1703/1801 investigator meeting. @sghmd @DrMiguelPerales leading updates and discussion.‚Ä¶ https://t.co/1bLNqMyS8I,en,0.0,4590.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/MediHumdani/statuses/1230831843550924801,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,Commitment early AM @BMTCTN 1703/1801 investigator meeting. @sghmd @DrMiguelPerales leading updates and discussion.‚Ä¶ https://t.co/1bLNqMyS8I,false
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-02-21 12:39:23+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,3.0,,1.2308343996100977e+18,,0.0,0.0,,"#TCTM20 Schroeder: ruxolitinib approved for SR-aGVHD based on phase 2 data, ORR 55% https://t.co/FxGy2HcEU0",da,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/hemedoc/statuses/1230834399610097664,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"#TCTM20 Schroeder: ruxolitinib approved for SR-aGVHD based on phase 2 data, ORR 55% https://t.co/FxGy2HcEU0",true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-02-21 12:15:39+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,0.0,,1.2308284269631488e+18,,0.0,0.0,,#TCTM20 Ferrara: obstacles to development of GVHD therapies: difficulties and inaccuracies in early staging of dise‚Ä¶ https://t.co/3MXsqWZ7HC,en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/hemedoc/statuses/1230828426963148801,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Drug Discovery,0.0,0.0,1.0,#TCTM20 Ferrara: obstacles to development of GVHD therapies: difficulties and inaccuracies in early staging of dise‚Ä¶ https://t.co/3MXsqWZ7HC,true
MichaelIsonMD,#TxID physician at @NM_IDSteward focusing on donor-derived and viral infections,,"Chicago, IL",,2020-02-21 01:53:34+00:00,Michael Ison,http://twitter.com/,9.0,,1.230671875371602e+18,,0.0,0.0,,RT @PergamIC: Slow recovery of immune reconstitution with CD4 cytopenia at over a year post-Haplo - plays important role in infections post‚Ä¶,en,0.0,1559.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,7.0,2.0,https://twitter.com/MichaelIsonMD/statuses/1230671875371601920,0.0,0.0,,0.0,0.0,0.0,2.0,7.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,RT @PergamIC: Slow recovery of immune reconstitution with CD4 cytopenia at over a year post-Haplo - plays important role in infections post‚Ä¶,true
DrM_AbuZaid,Cancer doctor @IUPUI with focus on bone marrow transplant and multiple myeloma,,"Indianapolis, IN",,2020-02-21 16:07:43+00:00,Mohammad Abu Zaid,http://twitter.com/,1.0,,1.2308868289427456e+18,,0.0,0.0,,Dr. Sherif Farag @IUSMDeptMed presenting results of ph2 study of sitagliptin to prevent acute GVHD. Sitagliptin red‚Ä¶ https://t.co/nEuGTfZffr,en,0.0,100.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/DrM_AbuZaid/statuses/1230886828942745601,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,Dr. Sherif Farag @IUSMDeptMed presenting results of ph2 study of sitagliptin to prevent acute GVHD. Sitagliptin red‚Ä¶ https://t.co/nEuGTfZffr,true
MichaelIsonMD,#TxID physician at @NM_IDSteward focusing on donor-derived and viral infections,,"Chicago, IL",,2020-02-21 01:53:23+00:00,Michael Ison,http://twitter.com/,12.0,,1.230671828496134e+18,,0.0,0.0,,RT @PergamIC: Azole prophylaxis = more breakthrough infections with resistant fungi (including R Aspergillus like A ustus) - pressure of az‚Ä¶,en,0.0,1559.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,9.0,3.0,https://twitter.com/MichaelIsonMD/statuses/1230671828496134144,0.0,0.0,,0.0,0.0,0.0,3.0,9.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,RT @PergamIC: Azole prophylaxis = more breakthrough infections with resistant fungi (including R Aspergillus like A ustus) - pressure of az‚Ä¶,true
HawazenAlsaedi,Pediatric Hematology and Oncology & Stem cell transplant physician,,,,2020-02-21 21:57:32+00:00,Hawazen Alsaedi,http://twitter.com/,7.0,,1.2309748628370678e+18,,0.0,0.0,,"RT @hemedoc: #TCTM20 Schroeder: ruxolitinib approved for SR-aGVHD based on phase 2 data, ORR 55% https://t.co/FxGy2HcEU0",da,0.0,76.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,3.0,https://twitter.com/HawazenAlsaedi/statuses/1230974862837067777,0.0,0.0,,0.0,0.0,0.0,3.0,4.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @hemedoc: #TCTM20 Schroeder: ruxolitinib approved for SR-aGVHD based on phase 2 data, ORR 55% https://t.co/FxGy2HcEU0",false
abhinav_deol,MD,,"Detroit, MI",,2020-02-21 22:25:51+00:00,Abhinav Deol,http://twitter.com/,8.0,,1.23098198984883e+18,,0.0,0.0,,"RT @hemedoc: #TCTM20 Popat: fractionated MAC Bu associated with 1yr PFS/OS 81%/85%, 1yr relapse risk 11% and 9% NRM. https://t.co/Zgz0HlbW7Q",en,0.0,251.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,3.0,https://twitter.com/abhinav_deol/statuses/1230981989848829952,0.0,0.0,,0.0,0.0,0.0,3.0,5.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @hemedoc: #TCTM20 Popat: fractionated MAC Bu associated with 1yr PFS/OS 81%/85%, 1yr relapse risk 11% and 9% NRM. https://t.co/Zgz0HlbW7Q",true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-02-21 21:40:31+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,4.0,,1.2309705804527288e+18,,0.0,0.0,,#TCTM20 Uchida: single dose of anti-CD117 ADC allowed engraftment  of autologous gene-marked HSC without chemo. https://t.co/qWl77WRpOA,en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,4.0,https://twitter.com/hemedoc/statuses/1230970580452728833,0.0,0.0,,0.0,0.0,0.0,4.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,#TCTM20 Uchida: single dose of anti-CD117 ADC allowed engraftment  of autologous gene-marked HSC without chemo. https://t.co/qWl77WRpOA,true
LabWaggoner,Research lab of Dr. Stephen Waggoner at Cincinnati Children's Hospital Medical Center,,"Cincinnati, OH",,2020-02-21 03:01:53+00:00,Waggoner Lab,http://twitter.com/,9.0,,1.230689069191045e+18,,0.0,0.0,,RT @PurveySneha: #TCTM20 @romeerizwan great talk- #NK cells- targeting relapse after haplo with men-like NK cells phase 1a/b https://t.co/m‚Ä¶,en,0.0,1587.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,7.0,2.0,https://twitter.com/LabWaggoner/statuses/1230689069191045120,0.0,0.0,,0.0,0.0,0.0,2.0,7.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @PurveySneha: #TCTM20 @romeerizwan great talk- #NK cells- targeting relapse after haplo with men-like NK cells phase 1a/b https://t.co/m‚Ä¶,true
szusmani,"Division Chief, Plasma Cell Disorders|Director, Clinical Research Hem Malignancies | Views are my own | RT not endorsement | Physician ‚â† Provider",,"Charlotte, NC",,2020-01-30 22:45:33+00:00,Saad Z. Usmani MD MBA FACP (he/his/him),http://twitter.com/,2.0,,1.223014415273988e+18,,0.0,0.0,,Best of #ASH19 updates in newly diagnosed #mmsm being presented by @manisha_bhutani @LevineCancer @OncLive ‚Äî adding‚Ä¶ https://t.co/xXBwIW8VzP,en,0.0,5512.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/szusmani/statuses/1223014415273988096,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,Best of #ASH19 updates in newly diagnosed #mmsm being presented by @manisha_bhutani @LevineCancer @OncLive ‚Äî adding‚Ä¶ https://t.co/xXBwIW8VzP,true
CAnaemiaNetwork,"We are a group of patients, carers, doctors, & scientists who are all interested in patients with #rare inherited #anaemia.  #haematology #blood",,"Oxford, England",,2020-03-12 00:38:57+00:00,@CongenitalAnaemia,http://twitter.com/,8.0,,1.2379008561517896e+18,,0.0,0.0,,"RT @thalassaemiaTIF: And remember‚ùó 

The best way to prevent illness is to avoid being exposed to this virus.

#coronavirus #COVID19 #TIF",en,0.0,163.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,5.0,https://twitter.com/CAnaemiaNetwork/statuses/1237900856151789569,0.0,0.0,,0.0,0.0,0.0,5.0,3.0,False,False,False,False,True,Covid,0.0,0.0,1.0,"RT @thalassaemiaTIF: And remember‚ùó 

The best way to prevent illness is to avoid being exposed to this virus.

#coronavirus #COVID19 #TIF",true
lepikurian,"Haematologist, researcher, biotech startup co-founder",,"Saint-Petersburg, Russia",,2020-03-12 05:16:44+00:00,Kirill Lepik M.D.,http://twitter.com/,72.0,,1.2379707623734354e+18,,0.0,0.0,,"RT @7eyeblink: Anti infective prophylaxis EBMT recommendations after CAR-T Cell infusion, now in #CART20 #CART2020 #CARTMeeting https://t.c‚Ä¶",en,0.0,89.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,50.0,22.0,https://twitter.com/lepikurian/statuses/1237970762373435393,0.0,0.0,,0.0,0.0,0.0,22.0,50.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"RT @7eyeblink: Anti infective prophylaxis EBMT recommendations after CAR-T Cell infusion, now in #CART20 #CART2020 #CARTMeeting https://t.c‚Ä¶",false
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-03-25 20:52:32+00:00,Oncology Tube,http://twitter.com/,0.0,,1.2429173069397484e+18,,0.0,0.0,,"Brentuximab Vedotin with Chemotherapy #ASH19: Thanos Zomas, MD of @TakedaOncology on brentuximab vedotin with chemo‚Ä¶ https://t.co/gTzrXljddm",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1242917306939748352,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"Brentuximab Vedotin with Chemotherapy #ASH19: Thanos Zomas, MD of @TakedaOncology on brentuximab vedotin with chemo‚Ä¶ https://t.co/gTzrXljddm",true
hidrhere,"Oncologist/Hematologist, Avid reader",,"Bengaluru, India",,2020-10-07 11:44:34+00:00,Dr.Santhosh kumar,http://twitter.com/,111.0,,1.3138074268529787e+18,,0.0,0.0,,RT @nvpatkar: Thrilled to know that we will be presenting @India_Alliance funded research on #AMLMRD using error corrected #NGS as oral pre‚Ä¶,en,0.0,636.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,102.0,9.0,https://twitter.com/hidrhere/statuses/1313807426852978688,0.0,0.0,,0.0,0.0,0.0,9.0,102.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @nvpatkar: Thrilled to know that we will be presenting @India_Alliance funded research on #AMLMRD using error corrected #NGS as oral pre‚Ä¶,true
SirohiBhawna,Medical oncologist | Breast & GI cancers | Proud to have been with NHS for 2 decades | women health equality | Global oncology | views personal.,,"Chennai, India",,2020-10-07 03:24:31+00:00,bhawna sirohi,http://twitter.com/,111.0,,1.313681585925886e+18,,0.0,0.0,,RT @nvpatkar: Thrilled to know that we will be presenting @India_Alliance funded research on #AMLMRD using error corrected #NGS as oral pre‚Ä¶,en,0.0,2510.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,102.0,9.0,https://twitter.com/SirohiBhawna/statuses/1313681585925885952,0.0,0.0,,0.0,0.0,0.0,9.0,102.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @nvpatkar: Thrilled to know that we will be presenting @India_Alliance funded research on #AMLMRD using error corrected #NGS as oral pre‚Ä¶,true
gvencut1,"Hematopathologist, lymphoma-niac, photographer (not necessarily in that order) at University of Chicago | Editor-in-Chief, ASH Image Bank | Sporadic Tweeter",,"Chicago, IL",,2020-10-07 12:41:35+00:00,Girish Venkataraman,http://twitter.com/,111.0,,1.313821776623829e+18,,0.0,0.0,,RT @nvpatkar: Thrilled to know that we will be presenting @India_Alliance funded research on #AMLMRD using error corrected #NGS as oral pre‚Ä¶,en,0.0,636.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,102.0,9.0,https://twitter.com/gvencut1/statuses/1313821776623828992,0.0,0.0,,0.0,0.0,0.0,9.0,102.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @nvpatkar: Thrilled to know that we will be presenting @India_Alliance funded research on #AMLMRD using error corrected #NGS as oral pre‚Ä¶,true
AnnalisaRugger1,"Hematologist, HCT and cellular therapy physician scientist,  secretary of CTIWP-EBMT, Eurocord",,,,2020-08-28 04:48:08+00:00,Annalisa Ruggeri,http://twitter.com/,10.0,,1.299207111214338e+18,,0.0,0.0,,"RT @CIBMTR: At the TCT Meetings, we shine a spotlight on innovative research in the field. Abstract submission is now open for #TCTM21. Sub‚Ä¶",en,0.0,139.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,4.0,https://twitter.com/AnnalisaRugger1/statuses/1299207111214338050,0.0,0.0,,0.0,0.0,0.0,4.0,6.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"RT @CIBMTR: At the TCT Meetings, we shine a spotlight on innovative research in the field. Abstract submission is now open for #TCTM21. Sub‚Ä¶",true
MarcoLDavila,"Duke MD, PhD (Immunology), NY/Cornell Internal Medicine Residency, MSKCC Medical Oncology Fellowship, now full time physician-scientist",,"Tampa, FL",,2020-05-11 13:17:33+00:00,Marco,http://twitter.com/,1.0,,1.2598350330550477e+18,,0.0,0.0,,#ASGCT20 Enjoying the Cell Therapy Workshop.  Thanks to all our speakers participating in the webinar format!  @ASGCTherapy,en,0.0,1097.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/MarcoLDavila/statuses/1259835033055047683,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,#ASGCT20 Enjoying the Cell Therapy Workshop.  Thanks to all our speakers participating in the webinar format!  @ASGCTherapy,false
CapitiniMD,Pediatric oncologist/researcher @UWMadison @UWCarbone #immunotherapy #NKcells #CARTcells #GVHD #childhoodcancer Tweets are my own; RTs don't imply endorsement,,"Madison, WI, USA",,2020-02-20 15:59:15+00:00,Christian Capitini,http://twitter.com/,6.0,,1.2305223089866383e+18,,0.0,0.0,,RT @hmgcoa2: #TCTM20 chronic gvhd biomarkers in children by @sophpacz # 1/2  still under investigation use of bm &gt; pbscs in children may co‚Ä¶,en,0.0,1587.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,3.0,https://twitter.com/CapitiniMD/statuses/1230522308986638336,0.0,0.0,,0.0,0.0,0.0,3.0,3.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,RT @hmgcoa2: #TCTM20 chronic gvhd biomarkers in children by @sophpacz # 1/2  still under investigation use of bm &gt; pbscs in children may co‚Ä¶,true
abhinav_deol,MD,,"Detroit, MI",,2020-02-20 16:06:57+00:00,Abhinav Deol,http://twitter.com/,3.0,,1.2305242467718636e+18,,0.0,0.0,,#TCTM20 Dr. Christopher: no reccureent mutations associted with relapse in AML post transplant or chemo https://t.co/4NsrAIadYy,en,0.0,251.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/abhinav_deol/statuses/1230524246771863556,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,#TCTM20 Dr. Christopher: no reccureent mutations associted with relapse in AML post transplant or chemo https://t.co/4NsrAIadYy,true
abhinav_deol,MD,,"Detroit, MI",,2020-02-20 13:29:08+00:00,Abhinav Deol,http://twitter.com/,34.0,,1.2304845331721953e+18,,0.0,0.0,,RT @BldCancerDoc: Remembering pioneers of #BMT #CellTherapy field we lost in 2019 #TCTM20 https://t.co/wa30prSFFo,en,0.0,251.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,28.0,6.0,https://twitter.com/abhinav_deol/statuses/1230484533172195329,0.0,0.0,,0.0,0.0,0.0,6.0,28.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @BldCancerDoc: Remembering pioneers of #BMT #CellTherapy field we lost in 2019 #TCTM20 https://t.co/wa30prSFFo,true
FranciscoMarty_,"Infectious diseases doctor who specializes in treating transplant and cancer patients, work at @BrighamWomens and @DanaFarber, @harvardmed.",,"Boston, MA",,2020-02-20 16:49:07+00:00,"Francisco Marty, MD",http://twitter.com/,17.0,,1.230534858692268e+18,,0.0,0.0,,"RT @PergamIC: Dr @monicaslavin noting that haploidentical patients have higher rates of DS-DNA viral infections, fungal and bacterial infec‚Ä¶",en,0.0,9990.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,12.0,5.0,https://twitter.com/FranciscoMarty_/statuses/1230534858692268032,0.0,0.0,,0.0,0.0,0.0,5.0,12.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"RT @PergamIC: Dr @monicaslavin noting that haploidentical patients have higher rates of DS-DNA viral infections, fungal and bacterial infec‚Ä¶",true
abhinav_deol,MD,,"Detroit, MI",,2020-02-20 16:43:58+00:00,Abhinav Deol,http://twitter.com/,0.0,,1.230533565504508e+18,,0.0,0.0,,#TCTM20 Dr.Vago: HLA loss in Haplo vs cord. Post Haplo relapse  different donor haplo vs. BITE/CAR T cells https://t.co/rS9xfxetuq,en,0.0,251.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/abhinav_deol/statuses/1230533565504507908,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,#TCTM20 Dr.Vago: HLA loss in Haplo vs cord. Post Haplo relapse  different donor haplo vs. BITE/CAR T cells https://t.co/rS9xfxetuq,false
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-02-20 16:48:20+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,1.0,,1.2305346631370465e+18,,0.0,0.0,,#TCTM20 Vago: non-genomic mechanisms of relapse include epigenetic silencing of MHC-II expression https://t.co/haqlQglFLT,ro,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/hemedoc/statuses/1230534663137046530,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,#TCTM20 Vago: non-genomic mechanisms of relapse include epigenetic silencing of MHC-II expression https://t.co/haqlQglFLT,true
drjgauthier,"MD, MSc, Assistant Professor @fredhutch @UW focused on #CARTcell #immunotherapy #tcellrx 
Interests also include #rstats #bmtsm #epitwitter #bayes",,"Seattle, WA",,2020-02-20 15:47:41+00:00,Jordan Gauthier,http://twitter.com/,17.0,,1.2305193979675195e+18,,0.0,0.0,,"RT @PergamIC: Dr @monicaslavin noting that haploidentical patients have higher rates of DS-DNA viral infections, fungal and bacterial infec‚Ä¶",en,0.0,3295.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,12.0,5.0,https://twitter.com/drjgauthier/statuses/1230519397967519744,0.0,0.0,,0.0,0.0,0.0,5.0,12.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"RT @PergamIC: Dr @monicaslavin noting that haploidentical patients have higher rates of DS-DNA viral infections, fungal and bacterial infec‚Ä¶",true
JJ_boelens,"Physician-scientist | Chief, Stem Cell Transplant & Cellular Therapies, MSK Kids | Memorial Sloan Kettering Cancer Center | Traveling around üåç",,"New York, NY",,2020-02-20 23:46:04+00:00,Jaap J Boelens,http://twitter.com/,9.0,,1.2306397906489098e+18,,0.0,0.0,,Richard O‚ÄôReilly about results #TCD protocol @sloan_kettering comparing 2 chemo-based regimens with a TBI regimen!‚Ä¶ https://t.co/9KakhikBua,en,0.0,1118.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,9.0,https://twitter.com/JJ_boelens/statuses/1230639790648909831,0.0,0.0,,0.0,0.0,0.0,9.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,Richard O‚ÄôReilly about results #TCD protocol @sloan_kettering comparing 2 chemo-based regimens with a TBI regimen!‚Ä¶ https://t.co/9KakhikBua,true
Prasshmehta,"Medical Oncologist,Hematoncologist and bone marrow transplant physician,
DM(AIIMS, Delhi)
Program Director- Leukemia/BMT( Asian Institute of Medical Sciences)",,,,2020-02-20 00:44:48+00:00,Prashant Mehta,http://twitter.com/,0.0,,1.230292180931162e+18,,0.0,0.0,,#TCTM20 Collaboration between east and west https://t.co/TSDEiJnHYJ,en,0.0,1065.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/Prasshmehta/statuses/1230292180931162112,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,#TCTM20 Collaboration between east and west https://t.co/TSDEiJnHYJ,true
adrianabello,"pediatrician, pediatric hematologyst, mother adribello@hotmail.com",,,,2020-02-20 23:47:04+00:00,Adriana Bello,http://twitter.com/,23.0,,1.23064003844839e+18,,0.0,0.0,,RT @JJ_boelens: Richard O‚ÄôReilly about results #TCD protocol @sloan_kettering comparing 2 chemo-based regimens with a TBI regimen! #TCTM20‚Ä¶,en,0.0,1968.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,14.0,9.0,https://twitter.com/adrianabello/statuses/1230640038448390145,0.0,0.0,,0.0,0.0,0.0,9.0,14.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @JJ_boelens: Richard O‚ÄôReilly about results #TCD protocol @sloan_kettering comparing 2 chemo-based regimens with a TBI regimen! #TCTM20‚Ä¶,true
Drroxmehran,"Interventional cardiologist, Professor of Medicine @mountsinaiNYC, trialist, outcomes researcher, wife and mother; opinions my own #ACCBOT @womenas1",,"Manhattan, NY",,2020-02-01 00:47:32+00:00,Roxana Mehran,http://twitter.com/,37.0,,1.223407501779067e+18,,0.0,0.0,,"RT @DeeDeeWangMD: Honored to be a part of 2020 @TCTConference PDC. Behind the scenes session planning, will be innovative #TCT2020 @crfhear‚Ä¶",en,0.0,9784.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,30.0,7.0,https://twitter.com/Drroxmehran/statuses/1223407501779066880,0.0,0.0,,0.0,0.0,0.0,7.0,30.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"RT @DeeDeeWangMD: Honored to be a part of 2020 @TCTConference PDC. Behind the scenes session planning, will be innovative #TCT2020 @crfhear‚Ä¶",false
Lyfebulb,"Founded by @KarinLyfebulb, MD, PhD. We work to improve quality of life for those living w/ chronic disease by supporting patient-driven innovation.",,"New York, USA",,2020-12-10 03:55:01+00:00,Lyfebulb,http://twitter.com/,0.0,,1.3368820833488364e+18,,0.0,0.0,,City of Hope Doctors Present Innovative Therapies to Better Treat Blood Cancers at American Society of Hematology V‚Ä¶ https://t.co/Uzs6hILjKe,en,0.0,17196.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/Lyfebulb/statuses/1336882083348836356,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,City of Hope Doctors Present Innovative Therapies to Better Treat Blood Cancers at American Society of Hematology V‚Ä¶ https://t.co/Uzs6hILjKe,true
drRajeshPatil86,"Clinical hematologist , hemato-oncologist and stem cell transplant physician
Proud GMCite/GSCite/CMCite",,Mumbai,,2020-02-24 03:52:28+00:00,Rajesh B Patil,http://twitter.com/,23.0,,1.2317889623788997e+18,,0.0,0.0,,"RT @satya_yadav: Why collaborate ? A great talk by #Horowitz 

Too few numbers BMT vs. breast cancer 

&gt;50% centres in USA too &lt;50 BMT annu‚Ä¶",en,0.0,173.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,20.0,3.0,https://twitter.com/drRajeshPatil86/statuses/1231788962378899457,0.0,0.0,,0.0,0.0,0.0,3.0,20.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,"RT @satya_yadav: Why collaborate ? A great talk by #Horowitz 

Too few numbers BMT vs. breast cancer 

&gt;50% centres in USA too &lt;50 BMT annu‚Ä¶",true
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-06-30 16:01:26+00:00,Cardiovascular Research Foundation,http://twitter.com/,2.0,,1.2779956703775007e+18,,0.0,0.0,,Calling all innovators! Do you have a novel technology for the diagnosis or treatment of heart disease? Submit to t‚Ä¶ https://t.co/r8t7pwxro0,en,0.0,12239.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/crfheart/statuses/1277995670377500672,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,Calling all innovators! Do you have a novel technology for the diagnosis or treatment of heart disease? Submit to t‚Ä¶ https://t.co/r8t7pwxro0,true
UrviShahMD,Oncologist and researcher on Myeloma service @sloan_kettering. Interested in nutrition for cancer and immune therapies. Views are my own,,"New York, NY",,2020-06-30 17:42:19+00:00,Urvi Shah,http://twitter.com/,12.0,,1.2780210571742167e+18,,0.0,0.0,,RT @BMTCTN: Thanks to all the workshop collaborators and @DrSarahHolstein for taking the lead on the summary article (again!).  And good ne‚Ä¶,en,0.0,1227.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,11.0,1.0,https://twitter.com/UrviShahMD/statuses/1278021057174216711,0.0,0.0,,0.0,0.0,0.0,1.0,11.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @BMTCTN: Thanks to all the workshop collaborators and @DrSarahHolstein for taking the lead on the summary article (again!).  And good ne‚Ä¶,true
donlaz4u,"Medical Doctor| Public Health Specialist| CEO, @TalkHealth9ja| Founder, @TestrogenHub| Co-Founder @AfrYPoD | Producer, #TalkingHealthWithDrLaz| @MakeOurHospWork",,"Abuja, Nigeria",,2020-04-23 15:28:16+00:00,Laz Ude Eze,http://twitter.com/,58.0,,1.2533449501268623e+18,,0.0,0.0,,"RT @accountlabng: Join us Friday, 24th April here @accountlabng for the April edition of #TIF as we discuss the #COVID19 pandemic 

Special‚Ä¶",en,0.0,7624.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,34.0,24.0,https://twitter.com/donlaz4u/statuses/1253344950126862337,0.0,0.0,,0.0,0.0,0.0,24.0,34.0,False,False,False,False,True,Covid,0.0,0.0,1.0,"RT @accountlabng: Join us Friday, 24th April here @accountlabng for the April edition of #TIF as we discuss the #COVID19 pandemic 

Special‚Ä¶",true
Jon1Lang,"MD/PhD student @Penn
PhD in AAV gene therapy @lab_davidson",,"Philadelphia, PA",,2020-05-13 19:43:59+00:00,Jon Lang,http://twitter.com/,1.0,,1.260657058166104e+18,,0.0,0.0,,Happy to present a poster tonight from a collaboration with Homology Medicines. Abstract #600. In Vivo Transduction‚Ä¶ https://t.co/gSZkyxgIjJ,en,0.0,46.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/Jon1Lang/statuses/1260657058166104064,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,Happy to present a poster tonight from a collaboration with Homology Medicines. Abstract #600. In Vivo Transduction‚Ä¶ https://t.co/gSZkyxgIjJ,false
coughlin582,"Oncologist and immunologist, working on the cure with immunotherapy, and mom. Chief Medical Officer at Rubius Therapeutics in Cambridge, Mass. Tweets are my own",,United States,,2020-05-12 22:07:40+00:00,Christina Coughlin,http://twitter.com/,9.0,,1.2603308290221916e+18,,0.0,0.0,,"RT @rubius_tx: Today @ASGCTherapy, Rubius presented preclinical data showing that RTX-321 for the Tx of #HPV-positive #cancers can expand t‚Ä¶",en,0.0,209.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,7.0,2.0,https://twitter.com/coughlin582/statuses/1260330829022191618,0.0,0.0,,0.0,0.0,0.0,2.0,7.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @rubius_tx: Today @ASGCTherapy, Rubius presented preclinical data showing that RTX-321 for the Tx of #HPV-positive #cancers can expand t‚Ä¶",true
dheeraj_insan,Senior Service Engineer in Transasia Bio-medicals Ltd./Blood Group (O+)/Die Hard Fan of Saint Dr. MSG Insan @Gurmeetramrahim üòçüòç,,"Panipat, India",,2020-05-08 10:26:03+00:00,Dheeraj Bisht,http://twitter.com/,3.0,,1.2587047121421312e+18,,0.0,0.0,,"RT @Transasia_1: We have been leading many Thalassaemia awareness campaigns. Our hematology analyzers help in the screening.  
Let us advoc‚Ä¶",en,0.0,863.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,2.0,1.0,https://twitter.com/dheeraj_insan/statuses/1258704712142131200,0.0,0.0,,0.0,0.0,0.0,1.0,2.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @Transasia_1: We have been leading many Thalassaemia awareness campaigns. Our hematology analyzers help in the screening.  
Let us advoc‚Ä¶",true
Transasia_1,"We are preferred partner to doctors and patients worldwide in meeting their needs for reliable, affordable and innovative medical diagnostic solutions.",,"Mumbai, India",,2020-05-08 05:14:24+00:00,Transasia Bio-Medicals,http://twitter.com/,1.0,,1.2586262818951496e+18,,0.0,0.0,,"We have been leading many Thalassaemia awareness campaigns. Our hematology analyzers help in the screening.  
Let u‚Ä¶ https://t.co/xmgbMTLXNy",en,0.0,667.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/Transasia_1/statuses/1258626281895149568,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"We have been leading many Thalassaemia awareness campaigns. Our hematology analyzers help in the screening.  
Let u‚Ä¶ https://t.co/xmgbMTLXNy",true
SaskiaRudat,"Scientist in Leukaemia Research | Postdoctoral Fellow @sangerinstitute | Former PhD Student @DKFZ, @NCT_HD and @UniHeidelberg | Views are my own",,"Cambridge, England",,2020-05-12 12:53:08+00:00,"Saskia Rudat, PhD",http://twitter.com/,20.0,,1.260191276978393e+18,,0.0,0.0,,"RT @EHA_Hematology: #EHA25Virtual will take place on Jun 11-21! What can you expect? 

‚û°Ô∏èJun 11 ‚Äì 14:  invited speakers, abstract presenter‚Ä¶",en,0.0,131.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,14.0,6.0,https://twitter.com/SaskiaRudat/statuses/1260191276978393088,0.0,0.0,,0.0,0.0,0.0,6.0,14.0,False,False,False,False,True,Thought Leadership,0.0,0.0,1.0,"RT @EHA_Hematology: #EHA25Virtual will take place on Jun 11-21! What can you expect? 

‚û°Ô∏èJun 11 ‚Äì 14:  invited speakers, abstract presenter‚Ä¶",true
GCHPedsChair,Pediatric Chair and Physician in Chief- Golisano Children‚Äôs Hospital University of Rochester. ‚ÄúHelping every Child Reach their fullest Potential‚Äù peds Neph ASPN,,"Rochester, NY",,2020-05-12 16:53:27+00:00,patrick brophy,http://twitter.com/,15.0,,1.2602517537501512e+18,,0.0,0.0,,RT @callieshubin: Great morning sessions at the virtual #ASGCT20 learning about innovative methods to improve CAR-T technology and versatil‚Ä¶,en,0.0,1992.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,12.0,3.0,https://twitter.com/GCHPedsChair/statuses/1260251753750151170,0.0,0.0,,0.0,0.0,0.0,3.0,12.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @callieshubin: Great morning sessions at the virtual #ASGCT20 learning about innovative methods to improve CAR-T technology and versatil‚Ä¶,true
graham74GC,Lymphoma specialist at Oxford Cancer and Haematology centre. Haematologist and clinical trialist. Chair of UK Hodgkin and T-cell study groups.,,Opinions are mine,,2020-05-18 07:20:14+00:00,Graham Collins,http://twitter.com/,8.0,,1.2622818277016576e+18,,0.0,0.0,,"Phillips et al - @NCRI_partners INCA trial
‚Ä¢ randomised trial in anthracycline unfit DLBCL 1L (1st ever?)
‚Ä¢ RGCVP v‚Ä¶ https://t.co/9HfkXG0MY0",en,0.0,6091.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,8.0,https://twitter.com/graham74GC/statuses/1262281827701657602,0.0,0.0,,0.0,0.0,0.0,8.0,0.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,"Phillips et al - @NCRI_partners INCA trial
‚Ä¢ randomised trial in anthracycline unfit DLBCL 1L (1st ever?)
‚Ä¢ RGCVP v‚Ä¶ https://t.co/9HfkXG0MY0",false
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-02-22 16:08:48+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,3.0,,1.2312494906460652e+18,,0.0,0.0,,#TCTM20 Gust: stereotypical MRI findings in pts with severe CAR-T associated ICANS: symmetric capsular white matter‚Ä¶ https://t.co/eUVR4SCJe9,en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/hemedoc/statuses/1231249490646065153,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,#TCTM20 Gust: stereotypical MRI findings in pts with severe CAR-T associated ICANS: symmetric capsular white matter‚Ä¶ https://t.co/eUVR4SCJe9,true
HindRafei,Hematology and Oncology Fellow at MD Anderson Cancer Center. #NKcellRx #immunoRx #immunology  Tweets are my own.,,"Houston, TX",,2020-02-22 11:29:20+00:00,Hind Rafei,http://twitter.com/,67.0,,1.2311791590634537e+18,,0.0,0.0,,RT @lab_rezvani: Congratulations to Dr. Uday Popat from the Department of Stem Cell Transplant @CancerMedMDA for being awarded the best abs‚Ä¶,en,0.0,935.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,53.0,14.0,https://twitter.com/HindRafei/statuses/1231179159063453696,0.0,0.0,,0.0,0.0,0.0,14.0,53.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @lab_rezvani: Congratulations to Dr. Uday Popat from the Department of Stem Cell Transplant @CancerMedMDA for being awarded the best abs‚Ä¶,true
Transplant_Doc,Stem Cell Transplant physician and clinical researcher at MD Anderson Cancer Center; special interest in myeloma. Opinions expressed are my own,,,,2020-02-22 17:32:46+00:00,Muzaffar Qazilbash,http://twitter.com/,67.0,,1.2312706202619494e+18,,0.0,0.0,,RT @lab_rezvani: Congratulations to Dr. Uday Popat from the Department of Stem Cell Transplant @CancerMedMDA for being awarded the best abs‚Ä¶,en,0.0,5455.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,53.0,14.0,https://twitter.com/Transplant_Doc/statuses/1231270620261949444,0.0,0.0,,0.0,0.0,0.0,14.0,53.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @lab_rezvani: Congratulations to Dr. Uday Popat from the Department of Stem Cell Transplant @CancerMedMDA for being awarded the best abs‚Ä¶,true
marrow,"Clinical Haematologist, marrow transplanter. President World Marrow Donor Association (WMDA). Editor-in-Chief Internal Medicine Journal.",,"Melbourne, Australia",,2020-02-22 15:45:06+00:00,Jeff Szer,http://twitter.com/,1.0,,1.231243523795583e+18,,0.0,0.0,,Enthralled audience at #WBMT session on international access to #HCT drugs at #TCTM20. Current speaker current spea‚Ä¶ https://t.co/xtnYgmoqib,en,0.0,2195.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/marrow/statuses/1231243523795582977,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Thought Leadership,0.0,0.0,1.0,Enthralled audience at #WBMT session on international access to #HCT drugs at #TCTM20. Current speaker current spea‚Ä¶ https://t.co/xtnYgmoqib,true
MunshiPashna,"Physician dedicated to Stem Cell Transplantation and Cellular Immunotherapy. Live with empathy, passion, and honesty. Make each birthday count!",,"Washington, DC",,2020-02-22 16:59:18+00:00,Pashna N. Munshi,http://twitter.com/,2.0,,1.231262197042598e+18,,0.0,0.0,,Possible new indication for Ruxolitinib?  Rouse presentation #TCTM20 #CARTtoxicity improved OS in murine models wit‚Ä¶ https://t.co/wCXPBzeWXJ,en,0.0,177.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/MunshiPashna/statuses/1231262197042597888,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,Possible new indication for Ruxolitinib?  Rouse presentation #TCTM20 #CARTtoxicity improved OS in murine models wit‚Ä¶ https://t.co/wCXPBzeWXJ,true
marrow,"Clinical Haematologist, marrow transplanter. President World Marrow Donor Association (WMDA). Editor-in-Chief Internal Medicine Journal.",,"Melbourne, Australia",,2020-02-22 20:27:36+00:00,Jeff Szer,http://twitter.com/,5.0,,1.2313146174833746e+18,,0.0,0.0,,@DamianoRondell1 concludes his great talk on his collaboration with Nepal. #TCTM20 https://t.co/Bgg8AOXlqK,en,0.0,2195.0,,,0.0,DamianoRondell1,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,5.0,https://twitter.com/marrow/statuses/1231314617483374593,0.0,0.0,,0.0,0.0,0.0,5.0,0.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,@DamianoRondell1 concludes his great talk on his collaboration with Nepal. #TCTM20 https://t.co/Bgg8AOXlqK,false
Jeremy_Ramdial,"Stem Cell Transplant and Cellular Therapy physician. Tweets, Retweets, and Likes are my own opinion and not medical advice. #HeforShe",,,,2020-02-22 22:05:48+00:00,Jeremy Ramdial,http://twitter.com/,67.0,,1.2313393332290847e+18,,0.0,0.0,,RT @lab_rezvani: Congratulations to Dr. Uday Popat from the Department of Stem Cell Transplant @CancerMedMDA for being awarded the best abs‚Ä¶,en,0.0,312.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,53.0,14.0,https://twitter.com/Jeremy_Ramdial/statuses/1231339333229084672,0.0,0.0,,0.0,0.0,0.0,14.0,53.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @lab_rezvani: Congratulations to Dr. Uday Popat from the Department of Stem Cell Transplant @CancerMedMDA for being awarded the best abs‚Ä¶,true
peneloperaraujo,"Medical Oncologist at Recife, BRAZIL. MD, MSc",,"Recife, Brasil",,2020-02-22 04:03:51+00:00,Penelope Araujo,http://twitter.com/,41.0,,1.2310670504094474e+18,,0.0,0.0,,"RT @DrRenatoCunha: Dr Wang - KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) with Relapsed/Refracto‚Ä¶",en,0.0,231.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,33.0,8.0,https://twitter.com/peneloperaraujo/statuses/1231067050409447424,0.0,0.0,,0.0,0.0,0.0,8.0,33.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @DrRenatoCunha: Dr Wang - KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) with Relapsed/Refracto‚Ä¶",true
YaleCancer,Yale Cancer Center is a collaboration between renowned cancer researchers and physicians at Yale University and Smilow Cancer Hospital.,,"New Haven, Connecticut",,2020-02-22 21:14:39+00:00,Yale Cancer Center,http://twitter.com/,10.0,,1.2313264584984945e+18,,0.0,0.0,,RT @Dr_RoryShallis: Dr. Lohith Gowda presenting at #TCTM20 Infection and Immune Reconstitution Working Committee proposing a study to evalu‚Ä¶,en,0.0,9957.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,9.0,1.0,https://twitter.com/YaleCancer/statuses/1231326458498494464,0.0,0.0,,0.0,0.0,0.0,1.0,9.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,RT @Dr_RoryShallis: Dr. Lohith Gowda presenting at #TCTM20 Infection and Immune Reconstitution Working Committee proposing a study to evalu‚Ä¶,true
marrow,"Clinical Haematologist, marrow transplanter. President World Marrow Donor Association (WMDA). Editor-in-Chief Internal Medicine Journal.",,"Melbourne, Australia",,2020-02-22 20:06:43+00:00,Jeff Szer,http://twitter.com/,1.0,,1.2313093631737856e+18,,0.0,0.0,,Dr Duarte describing great outcomes in a Latin American cooperative study in MDS transplants in International Works‚Ä¶ https://t.co/VOYGwZbHHF,en,0.0,2195.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/marrow/statuses/1231309363173785610,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,Dr Duarte describing great outcomes in a Latin American cooperative study in MDS transplants in International Works‚Ä¶ https://t.co/VOYGwZbHHF,true
EshaKaul1,"Mother , Hem/Oncologist, Bone Marrow Transplant Physician",,"Noida, India",,2020-02-22 15:45:23+00:00,Esha Kaul,http://twitter.com/,4.0,,1.2312435983200666e+18,,0.0,0.0,,Presenting our experience of treating children with Hepatitis C with DAAs concurrently with transplant today at‚Ä¶ https://t.co/rv23bHQNOW,en,0.0,532.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,4.0,https://twitter.com/EshaKaul1/statuses/1231243598320066560,0.0,0.0,,0.0,0.0,0.0,4.0,0.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,Presenting our experience of treating children with Hepatitis C with DAAs concurrently with transplant today at‚Ä¶ https://t.co/rv23bHQNOW,true
DrESHAJ9,"a passionate medical oncologist, a spiritual seeker",,,,2020-02-29 02:03:15+00:00,EJ,http://twitter.com/,67.0,,1.2335734169024594e+18,,0.0,0.0,,RT @lab_rezvani: Congratulations to Dr. Uday Popat from the Department of Stem Cell Transplant @CancerMedMDA for being awarded the best abs‚Ä¶,en,0.0,315.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,53.0,14.0,https://twitter.com/DrESHAJ9/statuses/1233573416902459392,0.0,0.0,,0.0,0.0,0.0,14.0,53.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @lab_rezvani: Congratulations to Dr. Uday Popat from the Department of Stem Cell Transplant @CancerMedMDA for being awarded the best abs‚Ä¶,false
DrESHAJ9,"a passionate medical oncologist, a spiritual seeker",,,,2020-02-29 02:03:55+00:00,EJ,http://twitter.com/,48.0,,1.2335735820742533e+18,,0.0,0.0,,RT @AimeeTalleurMD: Updating VOD diagnostic criteria and grading - hopefully will lead to better patient outcomes through earlier recogniti‚Ä¶,en,0.0,315.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,35.0,13.0,https://twitter.com/DrESHAJ9/statuses/1233573582074253312,0.0,0.0,,0.0,0.0,0.0,13.0,35.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @AimeeTalleurMD: Updating VOD diagnostic criteria and grading - hopefully will lead to better patient outcomes through earlier recogniti‚Ä¶,true
abhinav_deol,MD,,"Detroit, MI",,2020-03-06 01:58:38+00:00,Abhinav Deol,http://twitter.com/,14.0,,1.2357465800298332e+18,,0.0,0.0,,"RT @HemOncToday: From @ASTCT #TCTM20 - Duration of remission predictive of second HSCT in pediatric leukemia, myelodysplastic syndrome, stu‚Ä¶",en,0.0,251.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,9.0,5.0,https://twitter.com/abhinav_deol/statuses/1235746580029833217,0.0,0.0,,0.0,0.0,0.0,5.0,9.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @HemOncToday: From @ASTCT #TCTM20 - Duration of remission predictive of second HSCT in pediatric leukemia, myelodysplastic syndrome, stu‚Ä¶",true
ElmerEdward1,"I am a physician, Lives in Bergen,Norway .
Favourite field : Cardiology and general surgery 
Sport : Cricket  Cricket Cricket !!!
Music : All kind of music",,,,2020-04-17 12:30:41+00:00,Elmer Edward,http://twitter.com/,29.0,,1.2511259319362232e+18,,0.0,0.0,,RT @EHA_Hematology: üì¢ CALLING ALL RESEARCHERS! #EHA has launched a new research grant - the COVID-19 in Hematology research grant. The call‚Ä¶,en,0.0,41.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,16.0,13.0,https://twitter.com/ElmerEdward1/statuses/1251125931936223232,0.0,0.0,,0.0,0.0,0.0,13.0,16.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @EHA_Hematology: üì¢ CALLING ALL RESEARCHERS! #EHA has launched a new research grant - the COVID-19 in Hematology research grant. The call‚Ä¶,true
omendiz,Interventional Cardiologist. Director ICyCC Fundaci√≥n Favaloro. Cardiology and Soccer Fan. Fan√°tico del CAI. Tweets=muy opinion. Instagram @oamendiz,,Argentina,,2020-03-05 16:17:12+00:00,Oscar Mendiz,http://twitter.com/,25.0,,1.2356002574355866e+18,,0.0,0.0,,"RT @TCTConference: Submit your science for the chance to present at #TCT2020! The call for abstracts, challenging cases, innovation and the‚Ä¶",en,0.0,4542.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,13.0,12.0,https://twitter.com/omendiz/statuses/1235600257435586561,0.0,0.0,,0.0,0.0,0.0,12.0,13.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @TCTConference: Submit your science for the chance to present at #TCT2020! The call for abstracts, challenging cases, innovation and the‚Ä¶",true
dgermain21,MD-PhD. 2nd year Heme/Onc fellow focused on lymphoma and leukemia. Physician-scientist-in-training. Tweet/RT not medical advice or endorsement.,,"St. Louis, MO",,2020-05-15 14:55:08+00:00,David A. Russler-Germain,http://twitter.com/,28.0,,1.2613091450111508e+18,,0.0,0.0,,RT @tobyeyre82: Improvement in outcomes of CNS #mantle cell #lymphoma with #ibrutinib. A truly international collaboration #lymsm #EHA25,en,0.0,1612.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,22.0,6.0,https://twitter.com/dgermain21/statuses/1261309145011150848,0.0,0.0,,0.0,0.0,0.0,6.0,22.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,RT @tobyeyre82: Improvement in outcomes of CNS #mantle cell #lymphoma with #ibrutinib. A truly international collaboration #lymsm #EHA25,true
ChinRoza,"Onco-Hematology Fellowship at Poali Calmette institut, Marseille,France. Medical Oncologist, Department Oncology, Khmer Soviet Friendship Hospital, CAMBODIA.",,"Marseille, France",,2020-07-24 17:32:58+00:00,Roza CHIN,http://twitter.com/,17.0,,1.2867160157919642e+18,,0.0,0.0,,RT @VJHemOnc: VIDEO: Positive learnings in #Myeloma management to come out of #COVID19 pandemic w/ @Mohty_EBMT of @HopSaintAntoine: https:/‚Ä¶,en,0.0,36.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,11.0,6.0,https://twitter.com/ChinRoza/statuses/1286716015791964161,0.0,0.0,,0.0,0.0,0.0,6.0,11.0,False,False,False,False,True,Covid,0.0,0.0,1.0,RT @VJHemOnc: VIDEO: Positive learnings in #Myeloma management to come out of #COVID19 pandemic w/ @Mohty_EBMT of @HopSaintAntoine: https:/‚Ä¶,false
szusmani,"Division Chief, Plasma Cell Disorders|Director, Clinical Research Hem Malignancies | Views are my own | RT not endorsement | Physician ‚â† Provider",,"Charlotte, NC",,2020-07-24 01:10:23+00:00,Saad Z. Usmani MD MBA FACP (he/his/him),http://twitter.com/,32.0,,1.2864687375839764e+18,,0.0,0.0,,RT @MediHumdani: Congrats @drzsicklecell for leading @ASH_hematology New Daily in #ASH20 and also makes me really proud to see fourth conse‚Ä¶,en,0.0,5512.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,28.0,4.0,https://twitter.com/szusmani/statuses/1286468737583976453,0.0,0.0,,0.0,0.0,0.0,4.0,28.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @MediHumdani: Congrats @drzsicklecell for leading @ASH_hematology New Daily in #ASH20 and also makes me really proud to see fourth conse‚Ä¶,true
dgermain21,MD-PhD. 2nd year Heme/Onc fellow focused on lymphoma and leukemia. Physician-scientist-in-training. Tweet/RT not medical advice or endorsement.,,"St. Louis, MO",,2020-06-21 14:22:55+00:00,David A. Russler-Germain,http://twitter.com/,39.0,,1.2747093857391985e+18,,0.0,0.0,,"RT @graham74GC: S Borchmann: liquid biopsy in cHL
- 76 pts, adv
- no. of new mutations IDed
- IDed mutational clusters
- high mutn rates as‚Ä¶",en,0.0,1612.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,28.0,11.0,https://twitter.com/dgermain21/statuses/1274709385739198464,0.0,0.0,,0.0,0.0,0.0,11.0,28.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"RT @graham74GC: S Borchmann: liquid biopsy in cHL
- 76 pts, adv
- no. of new mutations IDed
- IDed mutational clusters
- high mutn rates as‚Ä¶",true
Cell4Cure,"Pediatric Hemato-Oncologist, BMT physician, PGIMER Chandigarh alumnus, Vegetarian, passionate about Wildlife, ChildHealth, #leukemias #BMT #PID",,"Calgary, Alberta",,2020-06-21 21:32:51+00:00,"Ravi Shah MBBS, MD",http://twitter.com/,39.0,,1.2748175839007908e+18,,0.0,0.0,,"RT @graham74GC: S Borchmann: liquid biopsy in cHL
- 76 pts, adv
- no. of new mutations IDed
- IDed mutational clusters
- high mutn rates as‚Ä¶",en,0.0,289.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,28.0,11.0,https://twitter.com/Cell4Cure/statuses/1274817583900790784,0.0,0.0,,0.0,0.0,0.0,11.0,28.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"RT @graham74GC: S Borchmann: liquid biopsy in cHL
- 76 pts, adv
- no. of new mutations IDed
- IDed mutational clusters
- high mutn rates as‚Ä¶",true
BroeckelmannPJ,"MD @UKKoeln & Physician Scientist Postdoc @MPIAGE. Hemato-Oncology. Lymphoma. Immunotherapies. DNA damage. Personal opinion, RT/like ‚â† endorsement.",,"Cologne, Germany",,2020-06-21 13:28:02+00:00,Paul Br√∂ckelmann,http://twitter.com/,39.0,,1.2746955762407424e+18,,0.0,0.0,,"RT @graham74GC: S Borchmann: liquid biopsy in cHL
- 76 pts, adv
- no. of new mutations IDed
- IDed mutational clusters
- high mutn rates as‚Ä¶",en,0.0,243.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,28.0,11.0,https://twitter.com/BroeckelmannPJ/statuses/1274695576240742405,0.0,0.0,,0.0,0.0,0.0,11.0,28.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"RT @graham74GC: S Borchmann: liquid biopsy in cHL
- 76 pts, adv
- no. of new mutations IDed
- IDed mutational clusters
- high mutn rates as‚Ä¶",true
nat_curto,Hematologist with interest in MPN and clinical trials; MD (Res) student; scientist; a kind of runner and music lover...views my own,,"Londres, Inglaterra",,2020-06-11 18:57:26+00:00,Natalia CurtoGarcia,http://twitter.com/,28.0,,1.2711545927059087e+18,,0.0,0.0,,RT @Heiko__Becker: THANK YOU to all Early Career and Keynote speakers who made the first fully virtual edition of the @young_eha Research M‚Ä¶,en,0.0,90.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,25.0,3.0,https://twitter.com/nat_curto/statuses/1271154592705908740,0.0,0.0,,0.0,0.0,0.0,3.0,25.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,RT @Heiko__Becker: THANK YOU to all Early Career and Keynote speakers who made the first fully virtual edition of the @young_eha Research M‚Ä¶,true
MarcoIsaacBand1,Medical Affairs Manager HIV. Medicina Interna. Infectologia. Doctor en Ciencias M√©dicas,,"Tlalpan, Distrito Federal",,2020-06-11 14:42:54+00:00,Marco Isaac Banda Lara,http://twitter.com/,13.0,,1.2710905357768622e+18,,0.0,0.0,,RT @GSK: #News for #investors and #media: We are sharing our latest oncology data at the @EHA_Hematology Annual Congress. Find out more: ht‚Ä¶,en,0.0,97.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,3.0,https://twitter.com/MarcoIsaacBand1/statuses/1271090535776862209,0.0,0.0,,0.0,0.0,0.0,3.0,10.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,RT @GSK: #News for #investors and #media: We are sharing our latest oncology data at the @EHA_Hematology Annual Congress. Find out more: ht‚Ä¶,false
SaskiaRudat,"Scientist in Leukaemia Research | Postdoctoral Fellow @sangerinstitute | Former PhD Student @DKFZ, @NCT_HD and @UniHeidelberg | Views are my own",,"Cambridge, England",,2020-06-11 15:48:45+00:00,"Saskia Rudat, PhD",http://twitter.com/,0.0,,1.271107108939993e+18,,0.0,0.0,,"Greatly enjoyed the #YoungEHA meeting today. Thanks to all the organisers, chairs and speakers. üëè

Looking forward‚Ä¶ https://t.co/Rbrtv4zbvx",en,0.0,131.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/SaskiaRudat/statuses/1271107108939993094,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,"Greatly enjoyed the #YoungEHA meeting today. Thanks to all the organisers, chairs and speakers. üëè

Looking forward‚Ä¶ https://t.co/Rbrtv4zbvx",true
dblipka1,"Physician Scientist @TMO_Heidelberg, @NCT_HD & @DKFZ, #epigenomics, #DNAmethylation, #singleCell, #precisiononcology, #hematopoiesis, #JMML",,"Heidelberg, Germany",,2020-06-11 10:48:01+00:00,Daniel Lipka,http://twitter.com/,2.0,,1.2710314290282906e+18,,0.0,0.0,,@SinaStaeble from my group presented our collaborative work with @MilsomMick and Matthias Schlesner on‚Ä¶ https://t.co/QkEksYc0Kt,en,0.0,498.0,,,0.0,SinaStaeble,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/dblipka1/statuses/1271031429028290560,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,@SinaStaeble from my group presented our collaborative work with @MilsomMick and Matthias Schlesner on‚Ä¶ https://t.co/QkEksYc0Kt,true
szusmani,"Division Chief, Plasma Cell Disorders|Director, Clinical Research Hem Malignancies | Views are my own | RT not endorsement | Physician ‚â† Provider",,"Charlotte, NC",,2020-06-11 14:34:14+00:00,Saad Z. Usmani MD MBA FACP (he/his/him),http://twitter.com/,10.0,,1.271088356840149e+18,,0.0,0.0,,RT @HansScheurer: #EHA25Virtual @MyelomaEurope #Myeloma Big thanks to speakers @Mohty_EBMT @H_Einsele @szusmani for this great session cove‚Ä¶,en,0.0,5512.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,4.0,https://twitter.com/szusmani/statuses/1271088356840148992,0.0,0.0,,0.0,0.0,0.0,4.0,6.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,RT @HansScheurer: #EHA25Virtual @MyelomaEurope #Myeloma Big thanks to speakers @Mohty_EBMT @H_Einsele @szusmani for this great session cove‚Ä¶,true
Haem_London,Consultant Haematologist,,"London, England",,2020-06-11 17:25:41+00:00,Dr Neil Chauhan,http://twitter.com/,1.0,,1.2711315011581747e+18,,0.0,0.0,,@EHA_Hematology Dr Bommer wearing a tuxedo has upped the speaker dress code for #EHA25 https://t.co/UJKYxmrLpC,en,0.0,60.0,,,0.0,EHA_Hematology,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/Haem_London/statuses/1271131501158174722,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Thought Leadership,0.0,0.0,1.0,@EHA_Hematology Dr Bommer wearing a tuxedo has upped the speaker dress code for #EHA25 https://t.co/UJKYxmrLpC,true
ADCReview,"ADC Review/J. Antibody-drug Conjugates, an open access journal, brings together researchers, scientists and physicians involved in the growing field of ADCs.",,"Phoenix, AZ (USA)",,2020-06-19 18:30:00+00:00,ADC Review,http://twitter.com/,0.0,,1.2740467919279473e+18,,0.0,0.0,,Loncastuximab Tesirine Demonstrates an Overall High Response Rates in Pivotal Phase II Single-agent Trial‚Ä¶ https://t.co/E148FH9sPs,en,0.0,905.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/ADCReview/statuses/1274046791927947265,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,Loncastuximab Tesirine Demonstrates an Overall High Response Rates in Pivotal Phase II Single-agent Trial‚Ä¶ https://t.co/E148FH9sPs,true
vishvdeepkhush,"Clinical Hemato-oncologist, transplanter, apolitical, TWITTER solely 4 education, tweets mine,RT not endorsement.",,"New Delhi, India",,2020-06-19 08:02:13+00:00,Vishvdeep Khushoo,http://twitter.com/,43.0,,1.2738888040430264e+18,,0.0,0.0,,"RT @tobyeyre82: Khwaja et al
UK collaboration examining outcomes in secondary #CNS #lymphoma 
Do check out the poster!
Largest SCNSL data s‚Ä¶",en,0.0,241.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,32.0,11.0,https://twitter.com/vishvdeepkhush/statuses/1273888804043026432,0.0,0.0,,0.0,0.0,0.0,11.0,32.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,"RT @tobyeyre82: Khwaja et al
UK collaboration examining outcomes in secondary #CNS #lymphoma 
Do check out the poster!
Largest SCNSL data s‚Ä¶",false
mpdrc,Executive Director- Mays Cancer Center at UT Health San Antonio MD Anderson; (Views on Twitter are personal opinion),,"UT Health San Antonio ,TX, USA",,2020-06-19 14:32:25+00:00,"Ruben A. Mesa, MD",http://twitter.com/,1.0,,1.2739870031856148e+18,,0.0,0.0,,Excited watching #EHA25Virtual this morning! Looking forward to the upcoming Live QA session on new therapies in MP‚Ä¶ https://t.co/VWrCeXkRHr,en,0.0,3222.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/mpdrc/statuses/1273987003185614849,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,Excited watching #EHA25Virtual this morning! Looking forward to the upcoming Live QA session on new therapies in MP‚Ä¶ https://t.co/VWrCeXkRHr,true
drraheel2034,"FCPS Medicine 
FCPS Clinical Hematology                     
Clinical Hematologist 
Stem cell Transplant Physician
NIBMT",,Pakistan,,2020-06-19 20:47:22+00:00,raheel iftikhar,http://twitter.com/,43.0,,1.274081360026665e+18,,0.0,0.0,,"RT @tobyeyre82: Khwaja et al
UK collaboration examining outcomes in secondary #CNS #lymphoma 
Do check out the poster!
Largest SCNSL data s‚Ä¶",en,0.0,44.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,32.0,11.0,https://twitter.com/drraheel2034/statuses/1274081360026664961,0.0,0.0,,0.0,0.0,0.0,11.0,32.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,"RT @tobyeyre82: Khwaja et al
UK collaboration examining outcomes in secondary #CNS #lymphoma 
Do check out the poster!
Largest SCNSL data s‚Ä¶",true
mpdrc,Executive Director- Mays Cancer Center at UT Health San Antonio MD Anderson; (Views on Twitter are personal opinion),,"UT Health San Antonio ,TX, USA",,2020-06-19 15:25:41+00:00,"Ruben A. Mesa, MD",http://twitter.com/,3.0,,1.2740004086509527e+18,,0.0,0.0,,Exciting data in Tagraxofusp data in high risk MF from social media luminary and wonderful investigator @doctorpemm‚Ä¶ https://t.co/IwfBmQKAYq,en,0.0,3222.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/mpdrc/statuses/1274000408650952704,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Financial Performance,1.0,0.0,0.0,Exciting data in Tagraxofusp data in high risk MF from social media luminary and wonderful investigator @doctorpemm‚Ä¶ https://t.co/IwfBmQKAYq,true
nycdoc29,"ASCO, ASH, EHA & ESMO Member, Hem/Onc - 11 MD specialty private practice, former full time academic, traveller, foodie & out of necessity now a business person!",,"Garden City, NY",,2020-06-19 17:37:13+00:00,NYCDoc29,http://twitter.com/,7.0,,1.2740335066587914e+18,,0.0,0.0,,"RT @LeukemiaMDA: .@doctorpemm of @MDAndersonNews #Leukemia presents 'Updated Results From a Phase 1/2 #ClinicalTrial of Tagraxofusp, A CD12‚Ä¶",en,0.0,664.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,3.0,https://twitter.com/nycdoc29/statuses/1274033506658791426,0.0,0.0,,0.0,0.0,0.0,3.0,4.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @LeukemiaMDA: .@doctorpemm of @MDAndersonNews #Leukemia presents 'Updated Results From a Phase 1/2 #ClinicalTrial of Tagraxofusp, A CD12‚Ä¶",true
alba_maiques,"Postdoctoral scientist @Idibaps. Interest TF, epigenetics & leukemia.Twin mum. Member @young_eha. Founder maiques_factory.  #womeninSTEM #creativity #mentoring",,"Barcelona, Espa√±a",,2020-06-22 06:23:44+00:00,Alba Maiques-Diaz,http://twitter.com/,12.0,,1.2749511834515415e+18,,0.0,0.0,,RT @Heiko__Becker: That was really fun! Amazing talks and the discussion could have gone forever! Really BIG thank you to the speakers! If‚Ä¶,en,0.0,482.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,2.0,https://twitter.com/alba_maiques/statuses/1274951183451541506,0.0,0.0,,0.0,0.0,0.0,2.0,10.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,RT @Heiko__Becker: That was really fun! Amazing talks and the discussion could have gone forever! Really BIG thank you to the speakers! If‚Ä¶,true
Kate_Ke_Xu,"Consultant Haematologist, UCLH",,"London, England",,2020-06-22 15:51:30+00:00,Kate XU,http://twitter.com/,7.0,,1.2750940692916838e+18,,0.0,0.0,,"RT @MM_Hub: üéûÔ∏è At #EHA25Virtual, we asked Pieter Sonneveld, @ErasmusMC: How should we diagnose and treat high-risk MM after EHA 2020? Watch‚Ä¶",en,0.0,81.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,1.0,https://twitter.com/Kate_Ke_Xu/statuses/1275094069291683842,0.0,0.0,,0.0,0.0,0.0,1.0,6.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"RT @MM_Hub: üéûÔ∏è At #EHA25Virtual, we asked Pieter Sonneveld, @ErasmusMC: How should we diagnose and treat high-risk MM after EHA 2020? Watch‚Ä¶",false
DaniEinthoven,"MD PhD, Haematologist and chess player. BMT consultant @ King‚Äôs College Hospital in London üá¨üáß

EBMT Young Ambassador 2021.",,,,2020-06-15 19:08:19+00:00,Daniele Avenoso,http://twitter.com/,20.0,,1.272606885150163e+18,,0.0,0.0,,RT @young_eha: New therapeutic options for AML patients unfit for intensive chemo nicely summarized by Courtney Di Nardo from @LeukemiaMDA‚Ä¶,en,0.0,223.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,16.0,4.0,https://twitter.com/DaniEinthoven/statuses/1272606885150162945,0.0,0.0,,0.0,0.0,0.0,4.0,16.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @young_eha: New therapeutic options for AML patients unfit for intensive chemo nicely summarized by Courtney Di Nardo from @LeukemiaMDA‚Ä¶,true
olga45093932,"MD,PhD, hematologist of @NationalCancerInst of @oncohematologyDepart",,"Kiev, Ukraine",,2020-06-22 07:07:10+00:00,Olga,http://twitter.com/,39.0,,1.2749621166221066e+18,,0.0,0.0,,"RT @graham74GC: S Borchmann: liquid biopsy in cHL
- 76 pts, adv
- no. of new mutations IDed
- IDed mutational clusters
- high mutn rates as‚Ä¶",en,0.0,64.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,28.0,11.0,https://twitter.com/olga45093932/statuses/1274962116622106624,0.0,0.0,,0.0,0.0,0.0,11.0,28.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"RT @graham74GC: S Borchmann: liquid biopsy in cHL
- 76 pts, adv
- no. of new mutations IDed
- IDed mutational clusters
- high mutn rates as‚Ä¶",true
AKeyzner,"hematologist #BMT #leuksm physician ‚â†provider immigrant, opinions my own, likes‚â†endorsement",,,,2020-06-21 03:59:23+00:00,Alla Keyzner,http://twitter.com/,36.0,,1.2745524710006784e+18,,0.0,0.0,,"RT @MPN_Hub: CONGRESS | #EHA25Virtual | Updated phase I/II trial results of tagraxofusp, an anti-CD123, demonstrated its clinical efficacy‚Ä¶",en,0.0,157.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,26.0,10.0,https://twitter.com/AKeyzner/statuses/1274552471000678400,0.0,0.0,,0.0,0.0,0.0,10.0,26.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @MPN_Hub: CONGRESS | #EHA25Virtual | Updated phase I/II trial results of tagraxofusp, an anti-CD123, demonstrated its clinical efficacy‚Ä¶",true
sanamloghavi,Hematopathologist/Molecular Pathologist @mdandersonnews #endcancer #hemepath #mpnsm #lymsm #leusm #hemepathMDA Tweets are my own.,,"Houston, TX",,2020-06-21 15:33:09+00:00,"Sanam Loghavi, MD",http://twitter.com/,39.0,,1.2747270628850117e+18,,0.0,0.0,,"RT @graham74GC: S Borchmann: liquid biopsy in cHL
- 76 pts, adv
- no. of new mutations IDed
- IDed mutational clusters
- high mutn rates as‚Ä¶",en,0.0,4797.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,28.0,11.0,https://twitter.com/sanamloghavi/statuses/1274727062885011465,0.0,0.0,,0.0,0.0,0.0,11.0,28.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"RT @graham74GC: S Borchmann: liquid biopsy in cHL
- 76 pts, adv
- no. of new mutations IDed
- IDed mutational clusters
- high mutn rates as‚Ä¶",true
mirobaloch,Emergency Physician from Bahrain.,,Bahrain,,2020-06-21 16:07:30+00:00,Yasir Al-Baloshi,http://twitter.com/,69.0,,1.2747357056342426e+18,,0.0,0.0,,"RT @NovartisCancer: What are you most concerned about for your #sicklecell patients during the current COVID-19 pandemic?

Learn more about‚Ä¶",en,0.0,283.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,57.0,12.0,https://twitter.com/mirobaloch/statuses/1274735705634242563,0.0,0.0,,0.0,0.0,0.0,12.0,57.0,False,False,False,False,True,Covid,0.0,0.0,1.0,"RT @NovartisCancer: What are you most concerned about for your #sicklecell patients during the current COVID-19 pandemic?

Learn more about‚Ä¶",true
ADCReview,"ADC Review/J. Antibody-drug Conjugates, an open access journal, brings together researchers, scientists and physicians involved in the growing field of ADCs.",,"Phoenix, AZ (USA)",,2020-06-21 18:30:00+00:00,ADC Review,http://twitter.com/,0.0,,1.2747715677512049e+18,,0.0,0.0,,Loncastuximab Tesirine Demonstrates an Overall High Response Rates in Pivotal Phase II Single-agent Trial‚Ä¶ https://t.co/HOTM7ihV2N,en,0.0,905.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/ADCReview/statuses/1274771567751204864,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,Loncastuximab Tesirine Demonstrates an Overall High Response Rates in Pivotal Phase II Single-agent Trial‚Ä¶ https://t.co/HOTM7ihV2N,false
graham74GC,Lymphoma specialist at Oxford Cancer and Haematology centre. Haematologist and clinical trialist. Chair of UK Hodgkin and T-cell study groups.,,Opinions are mine,,2020-06-21 12:52:06+00:00,Graham Collins,http://twitter.com/,11.0,,1.274686533963055e+18,,0.0,0.0,,"S Borchmann: liquid biopsy in cHL
- 76 pts, adv
- no. of new mutations IDed
- IDed mutational clusters
- high mutn‚Ä¶ https://t.co/sLMHLg9zcx",en,0.0,6091.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,11.0,https://twitter.com/graham74GC/statuses/1274686533963055109,0.0,0.0,,0.0,0.0,0.0,11.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"S Borchmann: liquid biopsy in cHL
- 76 pts, adv
- no. of new mutations IDed
- IDed mutational clusters
- high mutn‚Ä¶ https://t.co/sLMHLg9zcx",true
Dr_Daniel_Molin,Oncologist at Uppsala university hospital. Chair of the Swedish lymphoma group (SLG) and the Swedish Hodgkin lymphoma group.,,Uppsala,,2020-06-21 16:29:44+00:00,Daniel Molin,http://twitter.com/,39.0,,1.2747413010539807e+18,,0.0,0.0,,"RT @graham74GC: S Borchmann: liquid biopsy in cHL
- 76 pts, adv
- no. of new mutations IDed
- IDed mutational clusters
- high mutn rates as‚Ä¶",en,0.0,193.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,28.0,11.0,https://twitter.com/Dr_Daniel_Molin/statuses/1274741301053980677,0.0,0.0,,0.0,0.0,0.0,11.0,28.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"RT @graham74GC: S Borchmann: liquid biopsy in cHL
- 76 pts, adv
- no. of new mutations IDed
- IDed mutational clusters
- high mutn rates as‚Ä¶",true
GiuseppePurpari,"Euro citizen (Italy). Doctor, medical science manager oncology for a leading biopharma company. Speaking about diversity, science, economy-geopolitics & fashion",,"Bologna, Florence, Rome ",,2020-06-21 11:37:02+00:00,Giuseppe Purpari,http://twitter.com/,69.0,,1.2746676425787845e+18,,0.0,0.0,,"RT @NovartisCancer: What are you most concerned about for your #sicklecell patients during the current COVID-19 pandemic?

Learn more about‚Ä¶",en,0.0,939.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,57.0,12.0,https://twitter.com/GiuseppePurpari/statuses/1274667642578784262,0.0,0.0,,0.0,0.0,0.0,12.0,57.0,False,False,False,False,True,Covid,0.0,0.0,1.0,"RT @NovartisCancer: What are you most concerned about for your #sicklecell patients during the current COVID-19 pandemic?

Learn more about‚Ä¶",true
graham74GC,Lymphoma specialist at Oxford Cancer and Haematology centre. Haematologist and clinical trialist. Chair of UK Hodgkin and T-cell study groups.,,Opinions are mine,,2020-06-21 14:28:56+00:00,Graham Collins,http://twitter.com/,7.0,,1.2747109032887296e+18,,0.0,0.0,,"lonca-T R/R DLBCL. Carol-Stella Q&amp;A
- no prior CART pts; 13 had CART after lonca
- Relapses post Lonca usually CD19‚Ä¶ https://t.co/ABkNg0uWZW",en,0.0,6091.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,7.0,https://twitter.com/graham74GC/statuses/1274710903288729600,0.0,0.0,,0.0,0.0,0.0,7.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"lonca-T R/R DLBCL. Carol-Stella Q&amp;A
- no prior CART pts; 13 had CART after lonca
- Relapses post Lonca usually CD19‚Ä¶ https://t.co/ABkNg0uWZW",true
AkEisfeld,"AML Physician Scientist @OSU. TheEisfeldLab studies extramedullary disease, genotype-phenotype associations and treatment response. Science&Sparkling.",,,,2020-06-20 18:11:31+00:00,AK Eisfeld,http://twitter.com/,1.0,,1.2744045284110664e+18,,0.0,0.0,,#EHA25Virtual - what a treat at the end of a great week with 2 outstanding speakers presented by #YoungEHA!!‚Ä¶ https://t.co/h6NzzcHbpg,en,0.0,300.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/AkEisfeld/statuses/1274404528411066369,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,#EHA25Virtual - what a treat at the end of a great week with 2 outstanding speakers presented by #YoungEHA!!‚Ä¶ https://t.co/h6NzzcHbpg,true
Jeremy_Ramdial,"Stem Cell Transplant and Cellular Therapy physician. Tweets, Retweets, and Likes are my own opinion and not medical advice. #HeforShe",,,,2020-06-20 21:31:41+00:00,Jeremy Ramdial,http://twitter.com/,6.0,,1.274454902719361e+18,,0.0,0.0,,"RT @Transplant_Doc: More bad news for #elotuzumab. No benefit in improving the depth of response for newly-diagnosed, transplant-eligible #‚Ä¶",en,0.0,312.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,1.0,https://twitter.com/Jeremy_Ramdial/statuses/1274454902719361025,0.0,0.0,,0.0,0.0,0.0,1.0,5.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"RT @Transplant_Doc: More bad news for #elotuzumab. No benefit in improving the depth of response for newly-diagnosed, transplant-eligible #‚Ä¶",false
nycdoc29,"ASCO, ASH, EHA & ESMO Member, Hem/Onc - 11 MD specialty private practice, former full time academic, traveller, foodie & out of necessity now a business person!",,"Garden City, NY",,2020-06-20 10:04:07+00:00,NYCDoc29,http://twitter.com/,11.0,,1.2742818682261135e+18,,0.0,0.0,,"RT @cmlnet: ""S172 Interim analysis from the OPTIC trial, a dose-ranging study of 3 starting doses of Ponatinib"" 

 #CML Clinical Oral Sessi‚Ä¶",en,0.0,664.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,7.0,4.0,https://twitter.com/nycdoc29/statuses/1274281868226113536,0.0,0.0,,0.0,0.0,0.0,4.0,7.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @cmlnet: ""S172 Interim analysis from the OPTIC trial, a dose-ranging study of 3 starting doses of Ponatinib"" 

 #CML Clinical Oral Sessi‚Ä¶",true
DrChrisPFox,"Haematologist, Nottingham University Hospitals, UK. Associate Professor, University of Nottingham. Chair, NCRI high-grade lymphoma study group. (no med advice)",,United Kingdom,,2020-06-20 07:58:37+00:00,Christopher P Fox,http://twitter.com/,43.0,,1.27425028880384e+18,,0.0,0.0,,"RT @tobyeyre82: Khwaja et al
UK collaboration examining outcomes in secondary #CNS #lymphoma 
Do check out the poster!
Largest SCNSL data s‚Ä¶",en,0.0,332.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,32.0,11.0,https://twitter.com/DrChrisPFox/statuses/1274250288803840002,0.0,0.0,,0.0,0.0,0.0,11.0,32.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,"RT @tobyeyre82: Khwaja et al
UK collaboration examining outcomes in secondary #CNS #lymphoma 
Do check out the poster!
Largest SCNSL data s‚Ä¶",true
Transplant_Doc,Stem Cell Transplant physician and clinical researcher at MD Anderson Cancer Center; special interest in myeloma. Opinions expressed are my own,,,,2020-06-20 19:53:19+00:00,Muzaffar Qazilbash,http://twitter.com/,1.0,,1.2744301473624678e+18,,0.0,0.0,,"More bad news for #elotuzumab. No benefit in improving the depth of response for newly-diagnosed, transplant-eligib‚Ä¶ https://t.co/GGUsOZEZld",en,0.0,5455.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/Transplant_Doc/statuses/1274430147362467841,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"More bad news for #elotuzumab. No benefit in improving the depth of response for newly-diagnosed, transplant-eligib‚Ä¶ https://t.co/GGUsOZEZld",true
metadvice,"We are a digital health company developing state of the art AI driven decision support software for doctors and pharma, helping evolve precision healthcare.",,London,,2020-06-20 00:30:14+00:00,Metadvice,http://twitter.com/,97.0,,1.2741374474802954e+18,,0.0,0.0,,"RT @NovartisCancer: What is the role of TIM-3 in MDS/AML? How does it work? Let‚Äôs discuss with Dr Amer Zeidan, Prof Francesco Buccisano, an‚Ä¶",en,0.0,94.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,77.0,20.0,https://twitter.com/metadvice/statuses/1274137447480295426,0.0,0.0,,0.0,0.0,0.0,20.0,77.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,"RT @NovartisCancer: What is the role of TIM-3 in MDS/AML? How does it work? Let‚Äôs discuss with Dr Amer Zeidan, Prof Francesco Buccisano, an‚Ä¶",true
nycdoc29,"ASCO, ASH, EHA & ESMO Member, Hem/Onc - 11 MD specialty private practice, former full time academic, traveller, foodie & out of necessity now a business person!",,"Garden City, NY",,2020-06-20 10:05:17+00:00,NYCDoc29,http://twitter.com/,8.0,,1.2742821628633825e+18,,0.0,0.0,,RT @mpdrc: Exciting data in Tagraxofusp data in high risk MF from social media luminary and wonderful investigator @doctorpemm at #EHA25Vir‚Ä¶,en,0.0,664.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,3.0,https://twitter.com/nycdoc29/statuses/1274282162863382528,0.0,0.0,,0.0,0.0,0.0,3.0,5.0,False,False,False,False,True,Financial Performance,1.0,0.0,0.0,RT @mpdrc: Exciting data in Tagraxofusp data in high risk MF from social media luminary and wonderful investigator @doctorpemm at #EHA25Vir‚Ä¶,true
ADCReview,"ADC Review/J. Antibody-drug Conjugates, an open access journal, brings together researchers, scientists and physicians involved in the growing field of ADCs.",,"Phoenix, AZ (USA)",,2020-06-20 18:30:00+00:00,ADC Review,http://twitter.com/,0.0,,1.274409179541889e+18,,0.0,0.0,,Loncastuximab Tesirine Demonstrates an Overall High Response Rates in Pivotal Phase II Single-agent Trial‚Ä¶ https://t.co/mdBnj7ZJSz,en,0.0,905.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/ADCReview/statuses/1274409179541889025,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,Loncastuximab Tesirine Demonstrates an Overall High Response Rates in Pivotal Phase II Single-agent Trial‚Ä¶ https://t.co/mdBnj7ZJSz,false
mike_dickinson1,Clinical haematologist at Peter MacCallum Cancer Centre in Melbourne. Aggressive Lymphoma Lead. MDS/AML/myeloma.Early phase trials. Views are my own.,,Melbourne,,2020-06-20 21:08:30+00:00,Michael Dickinson,http://twitter.com/,19.0,,1.2744490670204436e+18,,0.0,0.0,,RT @lymphomahub: CONGRESS | #EHA25Virtual | @mike_dickinson1 from @PeterMacCC presented the phase I dose-escalation results of glofitamab t‚Ä¶,en,0.0,921.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,11.0,8.0,https://twitter.com/mike_dickinson1/statuses/1274449067020443648,0.0,0.0,,0.0,0.0,0.0,8.0,11.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @lymphomahub: CONGRESS | #EHA25Virtual | @mike_dickinson1 from @PeterMacCC presented the phase I dose-escalation results of glofitamab t‚Ä¶,true
chanyooncheah,Doctor for patients with lymphoma. Clinical researcher.,,"Perth, Western Australia",,2020-06-12 11:12:35+00:00,Chan Cheah,http://twitter.com/,2.0,,1.2713999993188352e+18,,0.0,0.0,,Pleased to be able to present this work on behalf of my co-investigators #lymSM #EHA25 https://t.co/e7h3GebcuC,en,0.0,1717.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/chanyooncheah/statuses/1271399999318835200,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Financial Performance,1.0,0.0,0.0,Pleased to be able to present this work on behalf of my co-investigators #lymSM #EHA25 https://t.co/e7h3GebcuC,true
dgermain21,MD-PhD. 2nd year Heme/Onc fellow focused on lymphoma and leukemia. Physician-scientist-in-training. Tweet/RT not medical advice or endorsement.,,"St. Louis, MO",,2020-06-12 18:58:55+00:00,David A. Russler-Germain,http://twitter.com/,92.0,,1.2715173539149128e+18,,0.0,0.0,,RT @DocHutchings: Pleased to present the final results from the dose escalation part of the Phase 1/2 study of epcoritamab in r/r B-NHL at‚Ä¶,en,0.0,1612.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,69.0,23.0,https://twitter.com/dgermain21/statuses/1271517353914912770,0.0,0.0,,0.0,0.0,0.0,23.0,69.0,False,False,False,False,True,Clinical Trials,1.0,0.0,0.0,RT @DocHutchings: Pleased to present the final results from the dose escalation part of the Phase 1/2 study of epcoritamab in r/r B-NHL at‚Ä¶,true
GruppSteve,"#CARTCell expert, bone marrow transplanter, pediatric oncologist, husband to my vastly better half. All opinions my own, not an investor. RT not=endorsementüåäüåä",,"Philadelphia, PA",,2020-06-12 20:33:58+00:00,Stephan Grupp MD PhD,http://twitter.com/,19.0,,1.271541275225985e+18,,0.0,0.0,,"RT @EmatoInfo: ""#EHA25 theme is Unfolding the future. The virtual aspect suddenly contributes to this theme working with the state- of-the-‚Ä¶",en,0.0,2534.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,16.0,3.0,https://twitter.com/GruppSteve/statuses/1271541275225985025,0.0,0.0,,0.0,0.0,0.0,3.0,16.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,"RT @EmatoInfo: ""#EHA25 theme is Unfolding the future. The virtual aspect suddenly contributes to this theme working with the state- of-the-‚Ä¶",true
EduardoFlavioO1,"MD, Hematologist, Brasilia/Brasil, main interest in CLL, Lymphoma and MM; dad and husband; tweets are my own opinion",,"Bras√≠lia, Brasil",,2020-06-12 17:53:19+00:00,Eduardo Flavio Oliveira Ribeiro,http://twitter.com/,1.0,,1.2715008432427172e+18,,0.0,0.0,,More about PMBL from Educational Program. Here are the take home messages. #EHA2020 #EHA25Virtual https://t.co/s9kpOqCnHU,en,0.0,545.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/EduardoFlavioO1/statuses/1271500843242717186,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Disease Advocacy,0.0,0.0,1.0,More about PMBL from Educational Program. Here are the take home messages. #EHA2020 #EHA25Virtual https://t.co/s9kpOqCnHU,true
DrESHAJ9,"a passionate medical oncologist, a spiritual seeker",,,,2020-06-16 16:23:02+00:00,EJ,http://twitter.com/,10.0,,1.272927677071016e+18,,0.0,0.0,,RT @MM_Hub: CONGRESS | #EHA25Virtual | @TCupedo's team from @ErasmusMC developed a model where a subset of inflammatory stromal fibroblasts‚Ä¶,en,0.0,315.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,4.0,https://twitter.com/DrESHAJ9/statuses/1272927677071015937,0.0,0.0,,0.0,0.0,0.0,4.0,6.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,RT @MM_Hub: CONGRESS | #EHA25Virtual | @TCupedo's team from @ErasmusMC developed a model where a subset of inflammatory stromal fibroblasts‚Ä¶,false
ADCReview,"ADC Review/J. Antibody-drug Conjugates, an open access journal, brings together researchers, scientists and physicians involved in the growing field of ADCs.",,"Phoenix, AZ (USA)",,2020-06-16 18:30:00+00:00,ADC Review,http://twitter.com/,0.0,,1.2729596290316247e+18,,0.0,0.0,,Loncastuximab Tesirine Demonstrates an Overall High Response Rates in Pivotal Phase II Single-agent Trial‚Ä¶ https://t.co/ydyteVD7YG,en,0.0,905.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/ADCReview/statuses/1272959629031624705,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,Loncastuximab Tesirine Demonstrates an Overall High Response Rates in Pivotal Phase II Single-agent Trial‚Ä¶ https://t.co/ydyteVD7YG,true
DrChrisHourigan,"Physician-Scientist, Acute Myeloid Leukemia Doctor, Human Immunologist, Laboratory PI, Measurable Residual Disease Advocate, Optimist.  Views are my own.",,"Washington, DC",,2020-06-16 13:17:50+00:00,Chris Hourigan,http://twitter.com/,9.0,,1.2728810696001454e+18,,0.0,0.0,,"RT @VJHemOnc: @DrChrisHourigan is discussing the impact of conditioning intensity and genomics on relapse after allo-HSCT for #MDS
@VJHemOn‚Ä¶",en,0.0,1169.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,7.0,2.0,https://twitter.com/DrChrisHourigan/statuses/1272881069600145408,0.0,0.0,,0.0,0.0,0.0,2.0,7.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @VJHemOnc: @DrChrisHourigan is discussing the impact of conditioning intensity and genomics on relapse after allo-HSCT for #MDS
@VJHemOn‚Ä¶",true
DrESHAJ9,"a passionate medical oncologist, a spiritual seeker",,,,2020-06-16 16:02:45+00:00,EJ,http://twitter.com/,92.0,,1.272922571994919e+18,,0.0,0.0,,RT @DocHutchings: Pleased to present the final results from the dose escalation part of the Phase 1/2 study of epcoritamab in r/r B-NHL at‚Ä¶,en,0.0,315.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,69.0,23.0,https://twitter.com/DrESHAJ9/statuses/1272922571994918913,0.0,0.0,,0.0,0.0,0.0,23.0,69.0,False,False,False,False,True,Clinical Trials,1.0,0.0,0.0,RT @DocHutchings: Pleased to present the final results from the dose escalation part of the Phase 1/2 study of epcoritamab in r/r B-NHL at‚Ä¶,true
DrESHAJ9,"a passionate medical oncologist, a spiritual seeker",,,,2020-06-16 16:18:04+00:00,EJ,http://twitter.com/,41.0,,1.2729264271767675e+18,,0.0,0.0,,RT @HemaClinicoVLC: üîñ ‚ÄúMidostaurin in Combination with Intensive Chemotherapy in FLT3 mutated Acute Myeloid #Leukemia: Spanish Experience‚Äù‚Ä¶,en,0.0,315.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,31.0,10.0,https://twitter.com/DrESHAJ9/statuses/1272926427176767488,0.0,0.0,,0.0,0.0,0.0,10.0,31.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @HemaClinicoVLC: üîñ ‚ÄúMidostaurin in Combination with Intensive Chemotherapy in FLT3 mutated Acute Myeloid #Leukemia: Spanish Experience‚Äù‚Ä¶,true
EduardoFlavioO1,"MD, Hematologist, Brasilia/Brasil, main interest in CLL, Lymphoma and MM; dad and husband; tweets are my own opinion",,"Bras√≠lia, Brasil",,2020-06-14 18:19:37+00:00,Eduardo Flavio Oliveira Ribeiro,http://twitter.com/,2.0,,1.2722322415282217e+18,,0.0,0.0,,"CLL educational program. Real practical points on choosing the right therapy into actual target drugs landscape, in‚Ä¶ https://t.co/t8kLKQBrnq",en,0.0,545.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/EduardoFlavioO1/statuses/1272232241528221711,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Disease Advocacy,0.0,0.0,1.0,"CLL educational program. Real practical points on choosing the right therapy into actual target drugs landscape, in‚Ä¶ https://t.co/t8kLKQBrnq",true
mpdrc,Executive Director- Mays Cancer Center at UT Health San Antonio MD Anderson; (Views on Twitter are personal opinion),,"UT Health San Antonio ,TX, USA",,2020-06-14 17:20:08+00:00,"Ruben A. Mesa, MD",http://twitter.com/,24.0,,1.2722172709080023e+18,,0.0,0.0,,RT @MPN_Hub: CONGRESS | #EHA25Virtual | T Barbui presented the LOW-PV phase II trial conducted by FROM Foundation @FormazioneHPG23. Ropeg-I‚Ä¶,en,0.0,3222.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,17.0,7.0,https://twitter.com/mpdrc/statuses/1272217270908002306,0.0,0.0,,0.0,0.0,0.0,7.0,17.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @MPN_Hub: CONGRESS | #EHA25Virtual | T Barbui presented the LOW-PV phase II trial conducted by FROM Foundation @FormazioneHPG23. Ropeg-I‚Ä¶,false
safaridoc,Blood doc. Part time clinical researcher.,,UK,,2020-06-14 09:30:35+00:00,AJW üíõ,http://twitter.com/,0.0,,1.272099102680105e+18,,0.0,0.0,,Very true. Poor use of terms leads to diagnostic confusion and mismanagement. However also the slide is missing the‚Ä¶ https://t.co/jbyzZE0g56,en,0.0,74.0,,,0.0,,,Negative,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/safaridoc/statuses/1272099102680104961,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,1.0,0.0,Very true. Poor use of terms leads to diagnostic confusion and mismanagement. However also the slide is missing the‚Ä¶ https://t.co/jbyzZE0g56,true
olga45093932,"MD,PhD, hematologist of @NationalCancerInst of @oncohematologyDepart",,"Kiev, Ukraine",,2020-06-10 17:59:24+00:00,Olga,http://twitter.com/,66.0,,1.2707776017207583e+18,,0.0,0.0,,"RT @AaronGerds: .@ASH_hematology is working hard to bring great content to #ASH20 during the pandemic. For updates check out: 

https://t.c‚Ä¶",en,0.0,64.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,54.0,12.0,https://twitter.com/olga45093932/statuses/1270777601720758273,0.0,0.0,,0.0,0.0,0.0,12.0,54.0,False,False,False,False,True,Covid,1.0,0.0,0.0,"RT @AaronGerds: .@ASH_hematology is working hard to bring great content to #ASH20 during the pandemic. For updates check out: 

https://t.c‚Ä¶",true
dgermain21,MD-PhD. 2nd year Heme/Onc fellow focused on lymphoma and leukemia. Physician-scientist-in-training. Tweet/RT not medical advice or endorsement.,,"St. Louis, MO",,2020-06-15 11:25:27+00:00,David A. Russler-Germain,http://twitter.com/,19.0,,1.272490397508436e+18,,0.0,0.0,,RT @lymphomahub: CONGRESS | #EHA25Virtual | @mike_dickinson1 from @PeterMacCC presented the phase I dose-escalation results of glofitamab t‚Ä¶,en,0.0,1612.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,11.0,8.0,https://twitter.com/dgermain21/statuses/1272490397508435969,0.0,0.0,,0.0,0.0,0.0,8.0,11.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @lymphomahub: CONGRESS | #EHA25Virtual | @mike_dickinson1 from @PeterMacCC presented the phase I dose-escalation results of glofitamab t‚Ä¶,true
DocLHenry,"GU Oncologist @LoyolaOnc. Med Director @theMednet. Co-creator @HOJournalClub. #OncMedEd | #MedEd. Introvert, idealist, over-thinker. Tweets all me (she/her).üåà",,"Chicago, IL",,2020-06-10 16:46:01+00:00,Liza Henry McDonald,http://twitter.com/,66.0,,1.2707591310503772e+18,,0.0,0.0,,"RT @AaronGerds: .@ASH_hematology is working hard to bring great content to #ASH20 during the pandemic. For updates check out: 

https://t.c‚Ä¶",en,0.0,1200.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,54.0,12.0,https://twitter.com/DocLHenry/statuses/1270759131050377216,0.0,0.0,,0.0,0.0,0.0,12.0,54.0,False,False,False,False,True,Covid,1.0,0.0,0.0,"RT @AaronGerds: .@ASH_hematology is working hard to bring great content to #ASH20 during the pandemic. For updates check out: 

https://t.c‚Ä¶",true
szusmani,"Division Chief, Plasma Cell Disorders|Director, Clinical Research Hem Malignancies | Views are my own | RT not endorsement | Physician ‚â† Provider",,"Charlotte, NC",,2020-06-10 16:45:37+00:00,Saad Z. Usmani MD MBA FACP (he/his/him),http://twitter.com/,66.0,,1.2707590340109066e+18,,0.0,0.0,,"RT @AaronGerds: .@ASH_hematology is working hard to bring great content to #ASH20 during the pandemic. For updates check out: 

https://t.c‚Ä¶",en,0.0,5512.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,54.0,12.0,https://twitter.com/szusmani/statuses/1270759034010906625,0.0,0.0,,0.0,0.0,0.0,12.0,54.0,False,False,False,False,True,Covid,1.0,0.0,0.0,"RT @AaronGerds: .@ASH_hematology is working hard to bring great content to #ASH20 during the pandemic. For updates check out: 

https://t.c‚Ä¶",true
MDedgeHemOnc,MDedge Hematology & Oncology provides the most important and up to date information and news for oncologists. Now part of the Medscape Professional Network.,,"Rockville, MD, Parsippany, NJ",,2020-06-27 19:13:02+00:00,MDedge Hematology & Oncology,http://twitter.com/,1.0,,1.2769567234761482e+18,,0.0,0.0,,CAPTIVATE MRD finds once-daily oral regimen of ibrutinib + venetoclax associated with deep molecular remissions in‚Ä¶ https://t.co/kaczEF9q3F,en,0.0,6726.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/MDedgeHemOnc/statuses/1276956723476148225,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,CAPTIVATE MRD finds once-daily oral regimen of ibrutinib + venetoclax associated with deep molecular remissions in‚Ä¶ https://t.co/kaczEF9q3F,false
MDedgeHemOnc,MDedge Hematology & Oncology provides the most important and up to date information and news for oncologists. Now part of the Medscape Professional Network.,,"Rockville, MD, Parsippany, NJ",,2020-06-27 01:38:01+00:00,MDedge Hematology & Oncology,http://twitter.com/,0.0,,1.2766912222083154e+18,,0.0,0.0,,A once-daily oral regimen of ibrutinib and venetoclax was linked to molecular remissions in both bone marrow and pe‚Ä¶ https://t.co/j31cF4BEw6,en,0.0,6726.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/MDedgeHemOnc/statuses/1276691222208315392,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,A once-daily oral regimen of ibrutinib and venetoclax was linked to molecular remissions in both bone marrow and pe‚Ä¶ https://t.co/j31cF4BEw6,true
ADCReview,"ADC Review/J. Antibody-drug Conjugates, an open access journal, brings together researchers, scientists and physicians involved in the growing field of ADCs.",,"Phoenix, AZ (USA)",,2020-06-17 18:30:00+00:00,ADC Review,http://twitter.com/,0.0,,1.2733220167378248e+18,,0.0,0.0,,Loncastuximab Tesirine Demonstrates an Overall High Response Rates in Pivotal Phase II Single-agent Trial‚Ä¶ https://t.co/VS0L239WSz,en,0.0,905.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/ADCReview/statuses/1273322016737824769,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,Loncastuximab Tesirine Demonstrates an Overall High Response Rates in Pivotal Phase II Single-agent Trial‚Ä¶ https://t.co/VS0L239WSz,true
EladSharonMD,"#MedicalOncologist tweeting on #immunotherapy, #drugdevelopment, #COVID19 & #HealthEcon. #NCI #CancerMoonshot Adult Immunotherapy Co-Chair. Tweets are mine.",,"Washington, DC",,2020-06-17 18:21:12+00:00,Elad Sharon,http://twitter.com/,15.0,,1.2733198003962225e+18,,0.0,0.0,,RT @Dr_AmerZeidan: My commentary on our first in human Phase 1 study of the protein degrader CC-90009 in refractory/relapsed aml that we pr‚Ä¶,en,0.0,2113.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,12.0,3.0,https://twitter.com/EladSharonMD/statuses/1273319800396222466,0.0,0.0,,0.0,0.0,0.0,3.0,12.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @Dr_AmerZeidan: My commentary on our first in human Phase 1 study of the protein degrader CC-90009 in refractory/relapsed aml that we pr‚Ä¶,true
dgermain21,MD-PhD. 2nd year Heme/Onc fellow focused on lymphoma and leukemia. Physician-scientist-in-training. Tweet/RT not medical advice or endorsement.,,"St. Louis, MO",,2020-06-17 12:20:45+00:00,David A. Russler-Germain,http://twitter.com/,9.0,,1.2732290910601871e+18,,0.0,0.0,,"RT @lymphomahub: CONGRESS | #EHA25Virtual |OAsIs I| Steven Le Gouill, @CHUnantes, reported data from the phase I/II trial of ibrutinib, ven‚Ä¶",en,0.0,1612.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,3.0,https://twitter.com/dgermain21/statuses/1273229091060187139,0.0,0.0,,0.0,0.0,0.0,3.0,6.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @lymphomahub: CONGRESS | #EHA25Virtual |OAsIs I| Steven Le Gouill, @CHUnantes, reported data from the phase I/II trial of ibrutinib, ven‚Ä¶",true
VincentRK,"Professor, Mayo Clinic; Editor, Blood Cancer Journal; Oncologist; Health Costs; COVID threads @SurvivedCOVID Opinions=personal views https://t.co/TMq9vc5hZk",,"Rochester, MN, USA",,2020-08-05 01:15:34+00:00,Vincent Rajkumar,http://twitter.com/,9.0,,1.290818696269767e+18,,0.0,0.0,,"RT @eponcology: S. Vincent Rajkumar, MD, provides insights from #EHA2020 on the treatment of relapsed/refractory multiple myeloma. https://‚Ä¶",en,0.0,33588.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,7.0,2.0,https://twitter.com/VincentRK/statuses/1290818696269766661,0.0,0.0,,0.0,0.0,0.0,2.0,7.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @eponcology: S. Vincent Rajkumar, MD, provides insights from #EHA2020 on the treatment of relapsed/refractory multiple myeloma. https://‚Ä¶",true
Kasia_HP,Physician pursuing #medtech #innovation and patient access. Medical affairs and market access leader. #scicom #healthtech,,"Las Vegas, NV",,2020-10-10 00:21:15+00:00,KasiaHP,http://twitter.com/,14.0,,1.3147226285533716e+18,,0.0,0.0,,"RT @terumobct: Our own Colleen Riley, Senior Vice President Innovation and Development and Delara Motlagh, Vice President Cell Therapy Tech‚Ä¶",en,0.0,8197.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,4.0,https://twitter.com/Kasia_HP/statuses/1314722628553371649,0.0,0.0,,0.0,0.0,0.0,4.0,10.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @terumobct: Our own Colleen Riley, Senior Vice President Innovation and Development and Delara Motlagh, Vice President Cell Therapy Tech‚Ä¶",false
justinburkhard1,30. Twin. Physician Assistant and biotech enthusiast. 10 years of rec trading. My tweets are not investment advice. co Ceo/founder High Tides,,"Palm City, FL",,2020-08-11 16:55:57+00:00,Justin Burkhardt,http://twitter.com/,41.0,,1.29322968131618e+18,,0.0,0.0,,"RT @JD4myfab4: Market cap comparison: 

$FTSV $5BILLION $GILD buyout

$ALXO $1.6BILLION MC

$TRIL $700MILLION 

While better monotherapy PR‚Ä¶",en,0.0,361.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,32.0,9.0,https://twitter.com/justinburkhard1/statuses/1293229681316179968,0.0,0.0,,0.0,0.0,0.0,9.0,32.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,"RT @JD4myfab4: Market cap comparison: 

$FTSV $5BILLION $GILD buyout

$ALXO $1.6BILLION MC

$TRIL $700MILLION 

While better monotherapy PR‚Ä¶",true
Kristel_GT,Medical Oncologist-Internal Medicine. Tweets are my own. Mexico.,,"Tamaulipas, M√©xico",,2020-11-26 05:20:19+00:00,Kristel Gonzalez,http://twitter.com/,49.0,,1.3318301197747569e+18,,0.0,0.0,,"RT @michaelwangmd: We have an ongoing CAR T cell  trial for relapsed mantle cell lymphoma, this trial is open for enrollment. Good data wil‚Ä¶",en,0.0,1096.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,39.0,10.0,https://twitter.com/Kristel_GT/statuses/1331830119774756864,0.0,0.0,,0.0,0.0,0.0,10.0,39.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @michaelwangmd: We have an ongoing CAR T cell  trial for relapsed mantle cell lymphoma, this trial is open for enrollment. Good data wil‚Ä¶",true
NitinJainMD,Leukemia Physician at MD Anderson Cancer Center | #Leukemia #CLL #ALL | Med School #AIIMS | Tweets are my own thoughts and opinions,,"Houston, Texas",,2020-06-01 16:35:35+00:00,Nitin Jain,http://twitter.com/,17.0,,1.2674950184928133e+18,,0.0,0.0,,"RT @HematologyTweet: Future Phase III trials in CLL
@NitinJainMD
#ASH19
#BASH2019 https://t.co/9hQo9qzCcP",en,0.0,2259.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,13.0,4.0,https://twitter.com/NitinJainMD/statuses/1267495018492813313,0.0,0.0,,0.0,0.0,0.0,4.0,13.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"RT @HematologyTweet: Future Phase III trials in CLL
@NitinJainMD
#ASH19
#BASH2019 https://t.co/9hQo9qzCcP",true
mkahaleh,"Dr. Kahaleh is the Clinical Director of Gastroenterology at Rutgers Robert Wood Johnson. He is an expert in Interventional endoscopy, ERCP, EUS, ESD and POEM",,New Brunswick,,2020-07-23 13:34:01+00:00,Michel Kahaleh,http://twitter.com/,1.0,,1.2862934907714929e+18,,0.0,0.0,,"Fabulous talk about TIF by Dr Tyberg #thisiswhatwedo #GERD #TIF #reflux #advancedendoscopy

https://t.co/Ul8Ywj9aSJ",en,0.0,1586.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/mkahaleh/statuses/1286293490771492866,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Side Effects,1.0,0.0,0.0,"Fabulous talk about TIF by Dr Tyberg #thisiswhatwedo #GERD #TIF #reflux #advancedendoscopy

https://t.co/Ul8Ywj9aSJ",true
victorshiyulin,BBiomed MD | Doctor @TheRMH | MPH Student @Sydney_Uni | Researcher @PeterMacCC | Co-Founder @auscancercomp @aushaemsoc,,,,2020-07-23 21:04:54+00:00,Victor Lin,http://twitter.com/,18.0,,1.286406962893058e+18,,0.0,0.0,,RT @EHA_Hematology: This year's @young_eha Research Meeting (YERM) at #EHA25Virtual covered topics like: normal hematopoiesis &amp; stem cell b‚Ä¶,en,0.0,96.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,13.0,5.0,https://twitter.com/victorshiyulin/statuses/1286406962893058048,0.0,0.0,,0.0,0.0,0.0,5.0,13.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @EHA_Hematology: This year's @young_eha Research Meeting (YERM) at #EHA25Virtual covered topics like: normal hematopoiesis &amp; stem cell b‚Ä¶,true
EduardoFlavioO1,"MD, Hematologist, Brasilia/Brasil, main interest in CLL, Lymphoma and MM; dad and husband; tweets are my own opinion",,"Bras√≠lia, Brasil",,2020-06-12 19:51:18+00:00,Eduardo Flavio Oliveira Ribeiro,http://twitter.com/,1.0,,1.27153053770283e+18,,0.0,0.0,,"PCNS Lymph: educational program. Young: MATRix is the best induction; WBRT = ASCT as consolid, but wt cognitive iss‚Ä¶ https://t.co/Aj02qd0wbH",en,0.0,545.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/EduardoFlavioO1/statuses/1271530537702830080,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Disease Advocacy,1.0,0.0,0.0,"PCNS Lymph: educational program. Young: MATRix is the best induction; WBRT = ASCT as consolid, but wt cognitive iss‚Ä¶ https://t.co/Aj02qd0wbH",false
StefanoLuminari,"Medical oncologist/hematologist , lymphomaniac, bike rider, chair of the Indolent Lymphoma committee of FIL @filinf.it  @unimore.it @irccs_re.it",,,,2020-06-12 19:46:00+00:00,"Stefano Luminari, MD",http://twitter.com/,28.0,,1.2715292034822103e+18,,0.0,0.0,,"RT @lymphomahub: CONGRESS |#EHA25Virtual| Emanuele Zucca, Oncology Institute of Southern Switzerland, presented data that investigated chem‚Ä¶",en,0.0,2250.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,19.0,9.0,https://twitter.com/StefanoLuminari/statuses/1271529203482210304,0.0,0.0,,0.0,0.0,0.0,9.0,19.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,"RT @lymphomahub: CONGRESS |#EHA25Virtual| Emanuele Zucca, Oncology Institute of Southern Switzerland, presented data that investigated chem‚Ä¶",true
harrisoncn1,"Mum, clinician, haematologist, educator. Views my own.",,"South East, England",,2020-06-14 18:08:02+00:00,Claire Harrison,http://twitter.com/,64.0,,1.2722293251867812e+18,,0.0,0.0,,"RT @EHA_Hematology: On-demand content at #EHA25Virtual is now available: Explore the invited speaker program, oral abstract and e-poster pr‚Ä¶",en,0.0,751.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,45.0,19.0,https://twitter.com/harrisoncn1/statuses/1272229325186781184,0.0,0.0,,0.0,0.0,0.0,19.0,45.0,False,False,False,False,True,Thought Leadership,0.0,0.0,1.0,"RT @EHA_Hematology: On-demand content at #EHA25Virtual is now available: Explore the invited speaker program, oral abstract and e-poster pr‚Ä¶",true
ADCReview,"ADC Review/J. Antibody-drug Conjugates, an open access journal, brings together researchers, scientists and physicians involved in the growing field of ADCs.",,"Phoenix, AZ (USA)",,2020-06-14 18:30:00+00:00,ADC Review,http://twitter.com/,0.0,,1.272234852897735e+18,,0.0,0.0,,Loncastuximab Tesirine Demonstrates an Overall High Response Rates in Pivotal Phase II Single-agent Trial‚Ä¶ https://t.co/8exWDT7CwM,en,0.0,905.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/ADCReview/statuses/1272234852897734658,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,Loncastuximab Tesirine Demonstrates an Overall High Response Rates in Pivotal Phase II Single-agent Trial‚Ä¶ https://t.co/8exWDT7CwM,true
chano_py,Sola Gracia. Medico Hematologo. Donante de √≥rganos. #DonaenVida. #HSCT Dr in #Paraguay. Patient Advocacy Co-Chair at #WBMT. Secretary at @LABMT2,,Paraguay,,2020-06-12 15:37:19+00:00,Cristobal Frutos,http://twitter.com/,0.0,,1.2714666199408763e+18,,0.0,0.0,,Diagnosis of #CMV end-organ disease.. Not everything is #COVID19... CMV documented in tissue... Ouch ü§ï #LMIC #SCT‚Ä¶ https://t.co/Er15NTNTWZ,en,0.0,903.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/chano_py/statuses/1271466619940876290,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,Diagnosis of #CMV end-organ disease.. Not everything is #COVID19... CMV documented in tissue... Ouch ü§ï #LMIC #SCT‚Ä¶ https://t.co/Er15NTNTWZ,true
ffranci3,Wife mum haematologist,,"Milano, Lombardia",,2020-06-12 14:13:04+00:00,ffranci,http://twitter.com/,6.0,,1.2714454178514862e+18,,0.0,0.0,,"RT @EHA_Hematology: (LIVE) Presidential Symposium at #EHA25Virtual, featuring 6 innovative oral abstracts, including‚¨áÔ∏è",en,0.0,68.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,2.0,https://twitter.com/ffranci3/statuses/1271445417851486213,0.0,0.0,,0.0,0.0,0.0,2.0,4.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @EHA_Hematology: (LIVE) Presidential Symposium at #EHA25Virtual, featuring 6 innovative oral abstracts, including‚¨áÔ∏è",true
EduardoFlavioO1,"MD, Hematologist, Brasilia/Brasil, main interest in CLL, Lymphoma and MM; dad and husband; tweets are my own opinion",,"Bras√≠lia, Brasil",,2020-06-12 17:25:19+00:00,Eduardo Flavio Oliveira Ribeiro,http://twitter.com/,3.0,,1.2714937989049016e+18,,0.0,0.0,,Unfolder Trial PMBL(subgroup): RCHOP 21 or 14 +/- RTx. RCHOP21 similar to 14. RT benefit more chemosensitive tumors‚Ä¶ https://t.co/Iul41z7osk,en,0.0,545.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/EduardoFlavioO1/statuses/1271493798904901633,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,Unfolder Trial PMBL(subgroup): RCHOP 21 or 14 +/- RTx. RCHOP21 similar to 14. RT benefit more chemosensitive tumors‚Ä¶ https://t.co/Iul41z7osk,false
DocHutchings,Haemato-oncologist. Clinical researcher. Mostly lymphoma and phase 1 haematology studies.,,,,2020-06-12 12:42:55+00:00,Martin Hutchings,http://twitter.com/,23.0,,1.2714227286046597e+18,,0.0,0.0,,Pleased to present the final results from the dose escalation part of the Phase 1/2 study of epcoritamab in r/r B-N‚Ä¶ https://t.co/u8FeSt88tN,en,0.0,284.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,23.0,https://twitter.com/DocHutchings/statuses/1271422728604659717,0.0,0.0,,0.0,0.0,0.0,23.0,0.0,False,False,False,False,True,Clinical Trials,1.0,0.0,0.0,Pleased to present the final results from the dose escalation part of the Phase 1/2 study of epcoritamab in r/r B-N‚Ä¶ https://t.co/u8FeSt88tN,true
DaniEinthoven,"MD PhD, Haematologist and chess player. BMT consultant @ King‚Äôs College Hospital in London üá¨üáß

EBMT Young Ambassador 2021.",,,,2020-06-12 14:35:25+00:00,Daniele Avenoso,http://twitter.com/,28.0,,1.271451043323351e+18,,0.0,0.0,,"RT @lymphomahub: CONGRESS |#EHA25Virtual| Emanuele Zucca, Oncology Institute of Southern Switzerland, presented data that investigated chem‚Ä¶",en,0.0,223.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,19.0,9.0,https://twitter.com/DaniEinthoven/statuses/1271451043323351041,0.0,0.0,,0.0,0.0,0.0,9.0,19.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,"RT @lymphomahub: CONGRESS |#EHA25Virtual| Emanuele Zucca, Oncology Institute of Southern Switzerland, presented data that investigated chem‚Ä¶",true
benwteh,ID physician & clinician researcher @NCICancer @PeterMacCC. #infection #immuneprofiling #myeloma #vaccination,,"Melbourne, Victoria",,2020-06-12 08:06:55+00:00,Ben Teh,http://twitter.com/,1.0,,1.2713532727044956e+18,,0.0,0.0,,3/3: next gen PI and increasing lines of therapy a/w risk for infection in pts with myeloma on new generation thera‚Ä¶ https://t.co/bySNrYk1nb,en,0.0,236.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/benwteh/statuses/1271353272704495618,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,3/3: next gen PI and increasing lines of therapy a/w risk for infection in pts with myeloma on new generation thera‚Ä¶ https://t.co/bySNrYk1nb,true
EduardoFlavioO1,"MD, Hematologist, Brasilia/Brasil, main interest in CLL, Lymphoma and MM; dad and husband; tweets are my own opinion",,"Bras√≠lia, Brasil",,2020-06-12 18:52:52+00:00,Eduardo Flavio Oliveira Ribeiro,http://twitter.com/,1.0,,1.271515830820524e+18,,0.0,0.0,,Primary Testicular Lymphoma: educational program. Depicting the Relevance of macrophages PDL1 expression and PD1+ l‚Ä¶ https://t.co/4qI7c1szG0,en,0.0,545.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/EduardoFlavioO1/statuses/1271515830820524034,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Disease Advocacy,0.0,0.0,1.0,Primary Testicular Lymphoma: educational program. Depicting the Relevance of macrophages PDL1 expression and PD1+ l‚Ä¶ https://t.co/4qI7c1szG0,true
alba_maiques,"Postdoctoral scientist @Idibaps. Interest TF, epigenetics & leukemia.Twin mum. Member @young_eha. Founder maiques_factory.  #womeninSTEM #creativity #mentoring",,"Barcelona, Espa√±a",,2020-06-12 15:41:05+00:00,Alba Maiques-Diaz,http://twitter.com/,1.0,,1.271467567815811e+18,,0.0,0.0,,"If you have a burnning question you wanted to ask a speaker but you could not, use the #EHAHub ! 

This year we lac‚Ä¶ https://t.co/XxgVF2QS4t",en,0.0,482.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/alba_maiques/statuses/1271467567815811074,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Thought Leadership,0.0,0.0,1.0,"If you have a burnning question you wanted to ask a speaker but you could not, use the #EHAHub ! 

This year we lac‚Ä¶ https://t.co/XxgVF2QS4t",true
adrianabello,"pediatrician, pediatric hematologyst, mother adribello@hotmail.com",,,,2020-06-12 17:06:36+00:00,Adriana Bello,http://twitter.com/,92.0,,1.2714890888650793e+18,,0.0,0.0,,RT @DocHutchings: Pleased to present the final results from the dose escalation part of the Phase 1/2 study of epcoritamab in r/r B-NHL at‚Ä¶,en,0.0,1968.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,69.0,23.0,https://twitter.com/adrianabello/statuses/1271489088865079298,0.0,0.0,,0.0,0.0,0.0,23.0,69.0,False,False,False,False,True,Clinical Trials,1.0,0.0,0.0,RT @DocHutchings: Pleased to present the final results from the dose escalation part of the Phase 1/2 study of epcoritamab in r/r B-NHL at‚Ä¶,false
nat_curto,Hematologist with interest in MPN and clinical trials; MD (Res) student; scientist; a kind of runner and music lover...views my own,,"Londres, Inglaterra",,2020-08-08 09:02:28+00:00,Natalia CurtoGarcia,http://twitter.com/,6.0,,1.2920233613133537e+18,,0.0,0.0,,"RT @MPN_Hub: Read on the @MPN_Hub about phase II results on KRT-232, a first-in-class inhibitor in treating R/R MF presented by Haifa Kathr‚Ä¶",en,0.0,90.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,1.0,https://twitter.com/nat_curto/statuses/1292023361313353729,0.0,0.0,,0.0,0.0,0.0,1.0,5.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @MPN_Hub: Read on the @MPN_Hub about phase II results on KRT-232, a first-in-class inhibitor in treating R/R MF presented by Haifa Kathr‚Ä¶",true
nycdoc29,"ASCO, ASH, EHA & ESMO Member, Hem/Onc - 11 MD specialty private practice, former full time academic, traveller, foodie & out of necessity now a business person!",,"Garden City, NY",,2020-06-13 14:16:39+00:00,NYCDoc29,http://twitter.com/,12.0,,1.2718087085117727e+18,,0.0,0.0,,"RT @lymphoma_connec: Herbaux et al present a primary analysis of a phase 2 trial from @LysaLymphoma at #EHA25Virtual 
#Atezolizumab + #obin‚Ä¶",en,0.0,664.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,6.0,https://twitter.com/nycdoc29/statuses/1271808708511772672,0.0,0.0,,0.0,0.0,0.0,6.0,6.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @lymphoma_connec: Herbaux et al present a primary analysis of a phase 2 trial from @LysaLymphoma at #EHA25Virtual 
#Atezolizumab + #obin‚Ä¶",true
alexisphero,"Cardiac surgeon, MD-PhD I fix hearts for living.üíñ I gave my heart to @anatarahes Tweets are for information & are not medical advice or views of my employer.",,"Waikoloa Village, HI",,2020-07-16 05:35:25+00:00,Alex,http://twitter.com/,6.0,,1.2836363330979471e+18,,0.0,0.0,,RT @crfheart: Submit your ideas and clinical data on the ramifications of #COVID19 on patients and/or the #cardiology community. Deadline i‚Ä¶,en,0.0,97.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,1.0,https://twitter.com/alexisphero/statuses/1283636333097947136,0.0,0.0,,0.0,0.0,0.0,1.0,5.0,False,False,False,False,True,Disease Advocacy,0.0,0.0,1.0,RT @crfheart: Submit your ideas and clinical data on the ramifications of #COVID19 on patients and/or the #cardiology community. Deadline i‚Ä¶,true
nycdoc29,"ASCO, ASH, EHA & ESMO Member, Hem/Onc - 11 MD specialty private practice, former full time academic, traveller, foodie & out of necessity now a business person!",,"Garden City, NY",,2020-06-13 22:19:26+00:00,NYCDoc29,http://twitter.com/,13.0,,1.2719302035147735e+18,,0.0,0.0,,"RT @tobyeyre82: #Loncastuximab terisine 
phase II R/R #DLBCL
n=145
anti-CD19 ADC
150ug/kg C1-2-&gt;75ug/kg
3 lines
58% ref last Rx
ORR 48% CR‚Ä¶",en,0.0,664.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,8.0,5.0,https://twitter.com/nycdoc29/statuses/1271930203514773505,0.0,0.0,,0.0,0.0,0.0,5.0,8.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @tobyeyre82: #Loncastuximab terisine 
phase II R/R #DLBCL
n=145
anti-CD19 ADC
150ug/kg C1-2-&gt;75ug/kg
3 lines
58% ref last Rx
ORR 48% CR‚Ä¶",true
ADCReview,"ADC Review/J. Antibody-drug Conjugates, an open access journal, brings together researchers, scientists and physicians involved in the growing field of ADCs.",,"Phoenix, AZ (USA)",,2020-06-13 18:30:00+00:00,ADC Review,http://twitter.com/,0.0,,1.2718724642268283e+18,,0.0,0.0,,Loncastuximab Tesirine Demonstrates an Overall High Response Rates in Pivotal Phase II Single-agent Trial‚Ä¶ https://t.co/MHChonvHzR,en,0.0,905.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/ADCReview/statuses/1271872464226828293,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,Loncastuximab Tesirine Demonstrates an Overall High Response Rates in Pivotal Phase II Single-agent Trial‚Ä¶ https://t.co/MHChonvHzR,true
TheUSONetwork,The US Oncology Network is one of the nation‚Äôs largest networks of community-based oncology physicians dedicated to advancing cancer care in America.,,"The Woodlands, Texas",,2020-06-22 14:04:12+00:00,US Oncology Network,http://twitter.com/,1.0,,1.2750670657206927e+18,,0.0,0.0,,"RT @ecancer: #EHA25: Dr Sudhir Manda of @ArizonaOncology outlines the latest results from the US MM-6 study, invest‚Ä¶ https://t.co/S7nJ7scteK",en,0.0,6914.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/TheUSONetwork/statuses/1275067065720692752,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,"RT @ecancer: #EHA25: Dr Sudhir Manda of @ArizonaOncology outlines the latest results from the US MM-6 study, invest‚Ä¶ https://t.co/S7nJ7scteK",false
MDedgeHemOnc,MDedge Hematology & Oncology provides the most important and up to date information and news for oncologists. Now part of the Medscape Professional Network.,,"Rockville, MD, Parsippany, NJ",,2020-07-02 01:05:01+00:00,MDedge Hematology & Oncology,http://twitter.com/,0.0,,1.2784948542810767e+18,,0.0,0.0,,A once-daily oral regimen of ibrutinib and venetoclax was linked to molecular remissions in both bone marrow and pe‚Ä¶ https://t.co/rWpMffyvGY,en,0.0,6726.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/MDedgeHemOnc/statuses/1278494854281076741,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,A once-daily oral regimen of ibrutinib and venetoclax was linked to molecular remissions in both bone marrow and pe‚Ä¶ https://t.co/rWpMffyvGY,true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-02-19 20:56:24+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,9.0,,1.2302347012537508e+18,,0.0,0.0,,"#TCTM20 Scott: MAC outcomes not affected by NGS positivity prior to alloHCT, but has large impact on relapse after‚Ä¶ https://t.co/QhL2amIkVz",en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,9.0,https://twitter.com/hemedoc/statuses/1230234701253750785,0.0,0.0,,0.0,0.0,0.0,9.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"#TCTM20 Scott: MAC outcomes not affected by NGS positivity prior to alloHCT, but has large impact on relapse after‚Ä¶ https://t.co/QhL2amIkVz",true
7eyeblink,MD. Hematolog√≠a cl√≠nica. √Åreas de inter√©s: CAR T y BMT. Tambi√©n escribo muchas tonter√≠as por el medio. (Opinions are mine)üìç A Coru√±a .,,Jam√°s en una ciudad sin playa.,,2020-02-20 08:30:01+00:00,Carolina Mart√≠nez,http://twitter.com/,46.0,,1.2304092589546127e+18,,0.0,0.0,,RT @MDonatoBMT: üëâüèªDr. Riddell ‚Å¶@fredhutch‚Å© #CART BCMA+ gamma secretase inhibitor ‚¨áÔ∏è‚¨áÔ∏èrelapse. Great worküôåüèª #TCTM20 #TCT2020 https://t.co/qu‚Ä¶,en,0.0,2163.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,32.0,14.0,https://twitter.com/7eyeblink/statuses/1230409258954612739,0.0,0.0,,0.0,0.0,0.0,14.0,32.0,False,False,False,False,True,Diagnosis Progression,1.0,0.0,0.0,RT @MDonatoBMT: üëâüèªDr. Riddell ‚Å¶@fredhutch‚Å© #CART BCMA+ gamma secretase inhibitor ‚¨áÔ∏è‚¨áÔ∏èrelapse. Great worküôåüèª #TCTM20 #TCT2020 https://t.co/qu‚Ä¶,true
abhinav_deol,MD,,"Detroit, MI",,2020-02-20 16:49:30+00:00,Abhinav Deol,http://twitter.com/,3.0,,1.2305349573884887e+18,,0.0,0.0,,#TCTM20 Dr. Vago: EZH2  maybe a the driver mutation leading to MHC class II down regulation https://t.co/hQVXR2c2fW,en,0.0,251.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/abhinav_deol/statuses/1230534957388488704,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,#TCTM20 Dr. Vago: EZH2  maybe a the driver mutation leading to MHC class II down regulation https://t.co/hQVXR2c2fW,true
ouholter,"Proud Oklahoma hematologist, wife, BMT physician, researcher, sooner, mom, loyal friend, thunder fan, and so proud of two amazing daughters! Tweets my own.",,"Oklahoma City, OK",,2020-02-19 15:48:04+00:00,J Holter Chakrabarty,http://twitter.com/,28.0,,1.2301571065500713e+18,,0.0,0.0,,RT @DrMiguelPerales: T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant ‚Å¶@fredhutch‚Å© ‚Å¶@Natu‚Ä¶,en,0.0,309.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,21.0,7.0,https://twitter.com/ouholter/statuses/1230157106550071298,0.0,0.0,,0.0,0.0,0.0,7.0,21.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @DrMiguelPerales: T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant ‚Å¶@fredhutch‚Å© ‚Å¶@Natu‚Ä¶,true
abhinav_deol,MD,,"Detroit, MI",,2020-02-19 16:02:24+00:00,Abhinav Deol,http://twitter.com/,0.0,,1.2301607151111168e+18,,0.0,0.0,,#TCTM20 real life issues with CAR T cell therapy : referral (1 -2  weeks)-&gt; insurance auth (2 weeks)-&gt; apheresis sc‚Ä¶ https://t.co/InsceClUMW,en,0.0,251.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/abhinav_deol/statuses/1230160715111116800,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Insurance Coverage,0.0,0.0,1.0,#TCTM20 real life issues with CAR T cell therapy : referral (1 -2  weeks)-&gt; insurance auth (2 weeks)-&gt; apheresis sc‚Ä¶ https://t.co/InsceClUMW,false
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-02-19 19:50:14+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,1.0,,1.2302180519137034e+18,,0.0,0.0,,#TCTM20 Ganguly: (ad hoc analysis of) HCT outcomes following Quizartinib vs SOC chemo on Quantum-R trial. Allo was‚Ä¶ https://t.co/f3A6qZBdBw,en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/hemedoc/statuses/1230218051913703425,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,#TCTM20 Ganguly: (ad hoc analysis of) HCT outcomes following Quizartinib vs SOC chemo on Quantum-R trial. Allo was‚Ä¶ https://t.co/f3A6qZBdBw,true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-02-19 14:44:16+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,1.0,,1.230141052335657e+18,,0.0,0.0,,#TCTM20 Mackall: outcomes with 19/22 CAR-T. Some patients getting to 1yr out. Still seeing CD19 neg relapse. https://t.co/PuVlsJ85Qf,en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/hemedoc/statuses/1230141052335656960,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,#TCTM20 Mackall: outcomes with 19/22 CAR-T. Some patients getting to 1yr out. Still seeing CD19 neg relapse. https://t.co/PuVlsJ85Qf,true
AimeeTalleurMD,Physician Scientist | Pediatric BMT & Immunotherapy | Clinical Trial Development | Med-ed | Academics | Twin Mom | opinions=my own | @stjuderesearch,,"Memphis, TN",,2020-02-19 18:16:17+00:00,"Aimee Talleur, MD",http://twitter.com/,13.0,,1.2301944075315692e+18,,0.0,0.0,,Updating VOD diagnostic criteria and grading - hopefully will lead to better patient outcomes through earlier recog‚Ä¶ https://t.co/9EGwkbpT8t,en,0.0,345.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,13.0,https://twitter.com/AimeeTalleurMD/statuses/1230194407531569153,0.0,0.0,,0.0,0.0,0.0,13.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,Updating VOD diagnostic criteria and grading - hopefully will lead to better patient outcomes through earlier recog‚Ä¶ https://t.co/9EGwkbpT8t,true
DrJonnys,Consultant General Surgery . former doctor at (CAF)üëÆüèª‚Äç‚ôÇÔ∏è / Anatomist. #umanitoba #uwinnipeg @Harvard,,"Winnipeg, Manitoba",,2020-02-19 12:53:43+00:00,ùê∑ùëü. ùêΩùëú‚Ñéùëõùëõùë¶ ùëÜùë°ùëíùë§ùëéùëüùë°‚Å¶üá®üá¶‚Å©üåàüçÅ,http://twitter.com/,7.0,,1.2301132317898547e+18,,0.0,0.0,,"RT @satya_yadav: #TCTM20 

Poster 325 put up now from @medanta @dhwaneethakkar #NehaRastogi 

Successful Umbilical Cord Blood Stem Cell Tra‚Ä¶",en,0.0,5805.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,2.0,https://twitter.com/DrJonnys/statuses/1230113231789854721,0.0,0.0,,0.0,0.0,0.0,2.0,5.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @satya_yadav: #TCTM20 

Poster 325 put up now from @medanta @dhwaneethakkar #NehaRastogi 

Successful Umbilical Cord Blood Stem Cell Tra‚Ä¶",true
HawazenAlsaedi,Pediatric Hematology and Oncology & Stem cell transplant physician,,,,2020-02-19 22:43:11+00:00,Hawazen Alsaedi,http://twitter.com/,48.0,,1.230261576285946e+18,,0.0,0.0,,RT @AimeeTalleurMD: Updating VOD diagnostic criteria and grading - hopefully will lead to better patient outcomes through earlier recogniti‚Ä¶,en,0.0,76.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,35.0,13.0,https://twitter.com/HawazenAlsaedi/statuses/1230261576285945860,0.0,0.0,,0.0,0.0,0.0,13.0,35.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @AimeeTalleurMD: Updating VOD diagnostic criteria and grading - hopefully will lead to better patient outcomes through earlier recogniti‚Ä¶,true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-02-19 21:01:16+00:00,Oncology Tube,http://twitter.com/,10.0,,1.230235928163078e+18,,0.0,0.0,,"RT @AML_Hub: CONGRESS | #TCTM20 | Bart L. Scott, @fredhutch, presents long-term FU from the BMT CTN 0901 (MAvRIC)  phase III trial of MAC v‚Ä¶",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,6.0,https://twitter.com/oncologytube/statuses/1230235928163078145,0.0,0.0,,0.0,0.0,0.0,6.0,4.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"RT @AML_Hub: CONGRESS | #TCTM20 | Bart L. Scott, @fredhutch, presents long-term FU from the BMT CTN 0901 (MAvRIC)  phase III trial of MAC v‚Ä¶",false
FranciscoMarty_,"Infectious diseases doctor who specializes in treating transplant and cancer patients, work at @BrighamWomens and @DanaFarber, @harvardmed.",,"Boston, MA",,2020-02-19 16:49:18+00:00,"Francisco Marty, MD",http://twitter.com/,10.0,,1.230172519069438e+18,,0.0,0.0,,"Hope to see many of you at #TCTM20 Thursday 20 Feb 10:30 am for a amazing session on #Infection after #Transplant,‚Ä¶ https://t.co/Ckh9CBDUpG",en,0.0,9990.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,10.0,https://twitter.com/FranciscoMarty_/statuses/1230172519069437953,0.0,0.0,,0.0,0.0,0.0,10.0,0.0,False,False,False,False,True,Side Effects,1.0,0.0,0.0,"Hope to see many of you at #TCTM20 Thursday 20 Feb 10:30 am for a amazing session on #Infection after #Transplant,‚Ä¶ https://t.co/Ckh9CBDUpG",true
abhinav_deol,MD,,"Detroit, MI",,2020-02-19 16:14:19+00:00,Abhinav Deol,http://twitter.com/,1.0,,1.2301637125998715e+18,,0.0,0.0,,#TCTM20 Sarah Cannon experience 30 out of 61 pts were able to get treatment with a coordinated team trying to get t‚Ä¶ https://t.co/u7LdS6O6zB,en,0.0,251.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/abhinav_deol/statuses/1230163712599871489,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,#TCTM20 Sarah Cannon experience 30 out of 61 pts were able to get treatment with a coordinated team trying to get t‚Ä¶ https://t.co/u7LdS6O6zB,true
DrJonnys,Consultant General Surgery . former doctor at (CAF)üëÆüèª‚Äç‚ôÇÔ∏è / Anatomist. #umanitoba #uwinnipeg @Harvard,,"Winnipeg, Manitoba",,2020-02-19 12:54:05+00:00,ùê∑ùëü. ùêΩùëú‚Ñéùëõùëõùë¶ ùëÜùë°ùëíùë§ùëéùëüùë°‚Å¶üá®üá¶‚Å©üåàüçÅ,http://twitter.com/,14.0,,1.230113322583937e+18,,0.0,0.0,,"RT @satya_yadav: Poster 236 put up! 

#Thiotepa Based Conditioning for #Haploidentical Stem Cell Transplantation with Post Transplant Cyclo‚Ä¶",en,0.0,5805.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,9.0,5.0,https://twitter.com/DrJonnys/statuses/1230113322583937030,0.0,0.0,,0.0,0.0,0.0,5.0,9.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @satya_yadav: Poster 236 put up! 

#Thiotepa Based Conditioning for #Haploidentical Stem Cell Transplantation with Post Transplant Cyclo‚Ä¶",true
lynn_odonnell,"Mother of 2 great kids, wife to 1 awesome husband, PhD like Dr Jill Biden",,"Columbus, Ohio, USA",,2020-02-19 15:54:41+00:00,Dr Lynn O'Donnell,http://twitter.com/,1.0,,1.2301587741508037e+18,,0.0,0.0,,@BMTCTN does many great things for TCT patients and community. @OSUCCC_James is a big part of that. Congratulations‚Ä¶ https://t.co/rEAMKn9gLq,en,0.0,54.0,,,0.0,BMTCTN,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/lynn_odonnell/statuses/1230158774150803456,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Disease Advocacy,1.0,0.0,0.0,@BMTCTN does many great things for TCT patients and community. @OSUCCC_James is a big part of that. Congratulations‚Ä¶ https://t.co/rEAMKn9gLq,true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-02-19 14:34:23+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,6.0,,1.2301385669168783e+18,,0.0,0.0,,#TCTM20 Mackall: true incidence of B-ALL relapse after CD19 CAR-T tx still not fully known due to relatively short‚Ä¶ https://t.co/wTVhIfxVDe,en,0.0,4813.0,,,0.0,,,Negative,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,6.0,https://twitter.com/hemedoc/statuses/1230138566916878337,0.0,0.0,,0.0,0.0,0.0,6.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,1.0,0.0,#TCTM20 Mackall: true incidence of B-ALL relapse after CD19 CAR-T tx still not fully known due to relatively short‚Ä¶ https://t.co/wTVhIfxVDe,true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-02-19 20:40:09+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,0.0,,1.2302306146343076e+18,,0.0,0.0,,#TCTM20 Menghrajani: LFS and OS similarly decreased for MLL+ as for adverse cytogenetics. Relapse risk similar rega‚Ä¶ https://t.co/L48zV6MAjQ,en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/hemedoc/statuses/1230230614634307585,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,#TCTM20 Menghrajani: LFS and OS similarly decreased for MLL+ as for adverse cytogenetics. Relapse risk similar rega‚Ä¶ https://t.co/L48zV6MAjQ,false
AGomez_MD,Hematologist-Oncologist |Stem Cell Transplant & Cellular Therapies | Assistant Professor @WeillCornell @nyphospital,,"New York, USA",,2020-02-19 20:38:16+00:00,Alexandra Gomez A.,http://twitter.com/,5.0,,1.2302301398307226e+18,,0.0,0.0,,So happy to present our data evaluating the predictors of post-relapse OS for pts with MM progressing after a Tcell‚Ä¶ https://t.co/piVqgYERCp,en,0.0,1062.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,5.0,https://twitter.com/AGomez_MD/statuses/1230230139830722560,0.0,0.0,,0.0,0.0,0.0,5.0,0.0,False,False,False,False,True,Diagnosis Progression,1.0,0.0,0.0,So happy to present our data evaluating the predictors of post-relapse OS for pts with MM progressing after a Tcell‚Ä¶ https://t.co/piVqgYERCp,true
marrow,"Clinical Haematologist, marrow transplanter. President World Marrow Donor Association (WMDA). Editor-in-Chief Internal Medicine Journal.",,"Melbourne, Australia",,2020-02-19 18:16:54+00:00,Jeff Szer,http://twitter.com/,34.0,,1.2301945630479852e+18,,0.0,0.0,,RT @BldCancerDoc: Remembering pioneers of #BMT #CellTherapy field we lost in 2019 #TCTM20 https://t.co/wa30prSFFo,en,0.0,2195.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,28.0,6.0,https://twitter.com/marrow/statuses/1230194563047985152,0.0,0.0,,0.0,0.0,0.0,6.0,28.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @BldCancerDoc: Remembering pioneers of #BMT #CellTherapy field we lost in 2019 #TCTM20 https://t.co/wa30prSFFo,true
lynn_odonnell,"Mother of 2 great kids, wife to 1 awesome husband, PhD like Dr Jill Biden",,"Columbus, Ohio, USA",,2020-02-19 16:22:58+00:00,Dr Lynn O'Donnell,http://twitter.com/,4.0,,1.2301658900979835e+18,,0.0,0.0,,To the Next Generation of transplant and cell therapy professionals: Check out the Career Board at #TCTM20. The ‚Å¶‚Ä¶ https://t.co/cO5FCynpeR,en,0.0,54.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,4.0,https://twitter.com/lynn_odonnell/statuses/1230165890097983488,0.0,0.0,,0.0,0.0,0.0,4.0,0.0,False,False,False,False,True,Long Term Benefits,0.0,0.0,1.0,To the Next Generation of transplant and cell therapy professionals: Check out the Career Board at #TCTM20. The ‚Å¶‚Ä¶ https://t.co/cO5FCynpeR,true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-02-19 20:00:52+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,2.0,,1.2302207258748396e+18,,0.0,0.0,,#TCTM20 Ganguly: this study supports FLT3i therapy before and after alloHCT for relapsed FLT3+ AML. #bmtctn 1506 Gi‚Ä¶ https://t.co/hE62mdGBPT,en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/hemedoc/statuses/1230220725874839552,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,#TCTM20 Ganguly: this study supports FLT3i therapy before and after alloHCT for relapsed FLT3+ AML. #bmtctn 1506 Gi‚Ä¶ https://t.co/hE62mdGBPT,true
DrJonnys,Consultant General Surgery . former doctor at (CAF)üëÆüèª‚Äç‚ôÇÔ∏è / Anatomist. #umanitoba #uwinnipeg @Harvard,,"Winnipeg, Manitoba",,2020-02-19 14:55:56+00:00,ùê∑ùëü. ùêΩùëú‚Ñéùëõùëõùë¶ ùëÜùë°ùëíùë§ùëéùëüùë°‚Å¶üá®üá¶‚Å©üåàüçÅ,http://twitter.com/,38.0,,1.230143987220144e+18,,0.0,0.0,,"RT @satya_yadav: #Mackall : If one CAR crashes then buy a new one ! 

If leukemia relapses after CD19 #CART cell therapy then CD22 CART cel‚Ä¶",en,0.0,5805.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,29.0,9.0,https://twitter.com/DrJonnys/statuses/1230143987220144129,0.0,0.0,,0.0,0.0,0.0,9.0,29.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @satya_yadav: #Mackall : If one CAR crashes then buy a new one ! 

If leukemia relapses after CD19 #CART cell therapy then CD22 CART cel‚Ä¶",true
chano_py,Sola Gracia. Medico Hematologo. Donante de √≥rganos. #DonaenVida. #HSCT Dr in #Paraguay. Patient Advocacy Co-Chair at #WBMT. Secretary at @LABMT2,,Paraguay,,2020-02-19 18:43:18+00:00,Cristobal Frutos,http://twitter.com/,38.0,,1.2302012077776443e+18,,0.0,0.0,,"RT @satya_yadav: #Mackall : If one CAR crashes then buy a new one ! 

If leukemia relapses after CD19 #CART cell therapy then CD22 CART cel‚Ä¶",en,0.0,903.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,29.0,9.0,https://twitter.com/chano_py/statuses/1230201207777644550,0.0,0.0,,0.0,0.0,0.0,9.0,29.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @satya_yadav: #Mackall : If one CAR crashes then buy a new one ! 

If leukemia relapses after CD19 #CART cell therapy then CD22 CART cel‚Ä¶",false
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-02-19 14:12:56+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,1.0,,1.2301331657690767e+18,,0.0,0.0,,"#TCTM20 Greenberg: WT1 TCR cells useful in remission, but do not yet clearly impact OS in patients treated for rela‚Ä¶ https://t.co/icCdXwJPGy",en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/hemedoc/statuses/1230133165769076738,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"#TCTM20 Greenberg: WT1 TCR cells useful in remission, but do not yet clearly impact OS in patients treated for rela‚Ä¶ https://t.co/icCdXwJPGy",true
HawazenAlsaedi,Pediatric Hematology and Oncology & Stem cell transplant physician,,,,2020-02-19 15:54:17+00:00,Hawazen Alsaedi,http://twitter.com/,38.0,,1.230158673995092e+18,,0.0,0.0,,"RT @satya_yadav: #Mackall : If one CAR crashes then buy a new one ! 

If leukemia relapses after CD19 #CART cell therapy then CD22 CART cel‚Ä¶",en,0.0,76.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,29.0,9.0,https://twitter.com/HawazenAlsaedi/statuses/1230158673995091968,0.0,0.0,,0.0,0.0,0.0,9.0,29.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @satya_yadav: #Mackall : If one CAR crashes then buy a new one ! 

If leukemia relapses after CD19 #CART cell therapy then CD22 CART cel‚Ä¶",true
PAMJ84,Ronin Haematologist,,Europe,,2020-02-19 15:56:25+00:00,P. A-M,http://twitter.com/,37.0,,1.2301592076740772e+18,,0.0,0.0,,RT @AndreWi54721839: Let‚Äôs not forget to honor and pay respect to BMT pioneers - gone but not forgotten! #TCTM20 https://t.co/0tQXoeaze3,en,0.0,110.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,29.0,8.0,https://twitter.com/PAMJ84/statuses/1230159207674077184,0.0,0.0,,0.0,0.0,0.0,8.0,29.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @AndreWi54721839: Let‚Äôs not forget to honor and pay respect to BMT pioneers - gone but not forgotten! #TCTM20 https://t.co/0tQXoeaze3,true
abhinav_deol,MD,,"Detroit, MI",,2020-02-19 20:20:19+00:00,Abhinav Deol,http://twitter.com/,0.0,,1.2302256235761705e+18,,0.0,0.0,,"#TCTM20 ATG and CD34+ selection allo SCT for MM: N=114, 26% NRM, 53% RELAPSED, early relapsers di worse as expected‚Ä¶ https://t.co/XFiCCbQ1PT",en,0.0,251.0,,,0.0,,,Negative,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/abhinav_deol/statuses/1230225623576170496,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,1.0,0.0,"#TCTM20 ATG and CD34+ selection allo SCT for MM: N=114, 26% NRM, 53% RELAPSED, early relapsers di worse as expected‚Ä¶ https://t.co/XFiCCbQ1PT",true
drjgauthier,"MD, MSc, Assistant Professor @fredhutch @UW focused on #CARTcell #immunotherapy #tcellrx 
Interests also include #rstats #bmtsm #epitwitter #bayes",,"Seattle, WA",,2020-02-19 06:02:46+00:00,Jordan Gauthier,http://twitter.com/,2.0,,1.230009812374569e+18,,0.0,0.0,,"Great to see acknowledged at #TCTM20 two #BMT pioneers from @fredhutch :
The late John Hansen and Robert Hickman...‚Ä¶ https://t.co/9sE8LEDUdp",en,0.0,3295.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/drjgauthier/statuses/1230009812374568965,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"Great to see acknowledged at #TCTM20 two #BMT pioneers from @fredhutch :
The late John Hansen and Robert Hickman...‚Ä¶ https://t.co/9sE8LEDUdp",true
CapitiniMD,Pediatric oncologist/researcher @UWMadison @UWCarbone #immunotherapy #NKcells #CARTcells #GVHD #childhoodcancer Tweets are my own; RTs don't imply endorsement,,"Madison, WI, USA",,2020-02-19 14:42:45+00:00,Christian Capitini,http://twitter.com/,0.0,,1.230140671102681e+18,,0.0,0.0,,The anchor @cm35c @StanfordCancer explains how relapse rates 29-57% for B cell #ALL after CD19 #CARTcells but if fo‚Ä¶ https://t.co/9UW2bXngBd,en,0.0,1587.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/CapitiniMD/statuses/1230140671102681088,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,The anchor @cm35c @StanfordCancer explains how relapse rates 29-57% for B cell #ALL after CD19 #CARTcells but if fo‚Ä¶ https://t.co/9UW2bXngBd,false
abhinav_deol,MD,,"Detroit, MI",,2020-02-19 23:53:20+00:00,Abhinav Deol,http://twitter.com/,1.0,,1.2302792298850345e+18,,0.0,0.0,,#TCTM20 Poster Session with team @karmanoscancer @waynemedicine @Dipenkmodi @primouberti  and @hrshah1  who is a fa‚Ä¶ https://t.co/kmc1WcCS2J,en,0.0,251.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/abhinav_deol/statuses/1230279229885034496,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,#TCTM20 Poster Session with team @karmanoscancer @waynemedicine @Dipenkmodi @primouberti  and @hrshah1  who is a fa‚Ä¶ https://t.co/kmc1WcCS2J,true
marrow,"Clinical Haematologist, marrow transplanter. President World Marrow Donor Association (WMDA). Editor-in-Chief Internal Medicine Journal.",,"Melbourne, Australia",,2020-02-19 15:49:28+00:00,Jeff Szer,http://twitter.com/,38.0,,1.2301574619292385e+18,,0.0,0.0,,"RT @satya_yadav: #Mackall : If one CAR crashes then buy a new one ! 

If leukemia relapses after CD19 #CART cell therapy then CD22 CART cel‚Ä¶",en,0.0,2195.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,29.0,9.0,https://twitter.com/marrow/statuses/1230157461929238529,0.0,0.0,,0.0,0.0,0.0,9.0,29.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @satya_yadav: #Mackall : If one CAR crashes then buy a new one ! 

If leukemia relapses after CD19 #CART cell therapy then CD22 CART cel‚Ä¶",true
abhinav_deol,MD,,"Detroit, MI",,2020-02-19 14:15:41+00:00,Abhinav Deol,http://twitter.com/,0.0,,1.2301338603791852e+18,,0.0,0.0,,"#TCTM20 : Dr. Greenberg: using ScRNA seq to undertand why leukemia relapse post WT1 TCR, T cells were not ""activate‚Ä¶ https://t.co/PnUpiW9lz0",en,0.0,251.0,,,0.0,,,Negative,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/abhinav_deol/statuses/1230133860379185152,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,1.0,0.0,"#TCTM20 : Dr. Greenberg: using ScRNA seq to undertand why leukemia relapse post WT1 TCR, T cells were not ""activate‚Ä¶ https://t.co/PnUpiW9lz0",true
abhinav_deol,MD,,"Detroit, MI",,2020-02-19 16:27:50+00:00,Abhinav Deol,http://twitter.com/,5.0,,1.2301671158581412e+18,,0.0,0.0,,#TCTM20  $ 20-30 billion is what is the expected cost of oncology care by 2031 for Medicare pts alone  ....... https://t.co/X0aRsHToFE,en,0.0,251.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,5.0,https://twitter.com/abhinav_deol/statuses/1230167115858141184,0.0,0.0,,0.0,0.0,0.0,5.0,0.0,False,False,False,False,True,Cost of Care,0.0,0.0,1.0,#TCTM20  $ 20-30 billion is what is the expected cost of oncology care by 2031 for Medicare pts alone  ....... https://t.co/X0aRsHToFE,true
CBCIDocs,Thoughts and perspectives from the hematology and transplant physicians at Colorado Blood Cancer Institute @ColoradoBlood @SarahCannonDocs @PresStLukesDenv,,"Denver, CO",,2020-02-19 17:56:28+00:00,CBCI,http://twitter.com/,7.0,,1.230189421317755e+18,,0.0,0.0,,RT @MikeTeesMD: Mackall from @stanford sharing CD19/22 #CART may be an option to reduce risk of relapse in #ALL. Can still see CD19 negativ‚Ä¶,en,0.0,782.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,2.0,https://twitter.com/CBCIDocs/statuses/1230189421317754881,0.0,0.0,,0.0,0.0,0.0,2.0,5.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @MikeTeesMD: Mackall from @stanford sharing CD19/22 #CART may be an option to reduce risk of relapse in #ALL. Can still see CD19 negativ‚Ä¶,true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-02-19 14:40:20+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,0.0,,1.230140060697342e+18,,0.0,0.0,,"#TCTM20 Mackall: CD22 CAR-T look promising to treat CD19neg relapse, but progression has been seen with low antigen‚Ä¶ https://t.co/PWtwUtZG2j",en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/hemedoc/statuses/1230140060697341952,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"#TCTM20 Mackall: CD22 CAR-T look promising to treat CD19neg relapse, but progression has been seen with low antigen‚Ä¶ https://t.co/PWtwUtZG2j",false
CapitiniMD,Pediatric oncologist/researcher @UWMadison @UWCarbone #immunotherapy #NKcells #CARTcells #GVHD #childhoodcancer Tweets are my own; RTs don't imply endorsement,,"Madison, WI, USA",,2020-02-19 22:36:33+00:00,Christian Capitini,http://twitter.com/,5.0,,1.2302599082825482e+18,,0.0,0.0,,Rock star ‚Å¶@GillSaar‚Å© reviews the 18 AML #CARTcell trials and only 7/46 have had remissions despite targeting Lewis‚Ä¶ https://t.co/GI9yZulaxd,en,0.0,1587.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,5.0,https://twitter.com/CapitiniMD/statuses/1230259908282548225,0.0,0.0,,0.0,0.0,0.0,5.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,Rock star ‚Å¶@GillSaar‚Å© reviews the 18 AML #CARTcell trials and only 7/46 have had remissions despite targeting Lewis‚Ä¶ https://t.co/GI9yZulaxd,true
abhinav_deol,MD,,"Detroit, MI",,2020-02-19 21:00:46+00:00,Abhinav Deol,http://twitter.com/,0.0,,1.2302358036342784e+18,,0.0,0.0,,"#TCTM20 Ahmed et al: Utilization/ cost effectiveness of stem cell collection for 2 ASCT for MM, only 3/31 pts eligi‚Ä¶ https://t.co/ld2miSok3R",en,0.0,251.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/abhinav_deol/statuses/1230235803634278400,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"#TCTM20 Ahmed et al: Utilization/ cost effectiveness of stem cell collection for 2 ASCT for MM, only 3/31 pts eligi‚Ä¶ https://t.co/ld2miSok3R",true
abhinav_deol,MD,,"Detroit, MI",,2020-02-19 15:35:53+00:00,Abhinav Deol,http://twitter.com/,37.0,,1.230154043982598e+18,,0.0,0.0,,RT @AndreWi54721839: Let‚Äôs not forget to honor and pay respect to BMT pioneers - gone but not forgotten! #TCTM20 https://t.co/0tQXoeaze3,en,0.0,251.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,29.0,8.0,https://twitter.com/abhinav_deol/statuses/1230154043982598144,0.0,0.0,,0.0,0.0,0.0,8.0,29.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @AndreWi54721839: Let‚Äôs not forget to honor and pay respect to BMT pioneers - gone but not forgotten! #TCTM20 https://t.co/0tQXoeaze3,true
drjgauthier,"MD, MSc, Assistant Professor @fredhutch @UW focused on #CARTcell #immunotherapy #tcellrx 
Interests also include #rstats #bmtsm #epitwitter #bayes",,"Seattle, WA",,2020-02-19 17:32:44+00:00,Jordan Gauthier,http://twitter.com/,34.0,,1.2301834490020372e+18,,0.0,0.0,,RT @BldCancerDoc: Remembering pioneers of #BMT #CellTherapy field we lost in 2019 #TCTM20 https://t.co/wa30prSFFo,en,0.0,3295.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,28.0,6.0,https://twitter.com/drjgauthier/statuses/1230183449002037248,0.0,0.0,,0.0,0.0,0.0,6.0,28.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @BldCancerDoc: Remembering pioneers of #BMT #CellTherapy field we lost in 2019 #TCTM20 https://t.co/wa30prSFFo,true
adrianabello,"pediatrician, pediatric hematologyst, mother adribello@hotmail.com",,,,2020-02-19 18:39:58+00:00,Adriana Bello,http://twitter.com/,9.0,,1.230200370485506e+18,,0.0,0.0,,RT @DrMiguelPerales: @TaniaJain11 @ASTCT @BldCancerDoc @BipinSavani Junior investigators are always the future of our field. We need to pro‚Ä¶,en,0.0,1968.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,7.0,2.0,https://twitter.com/adrianabello/statuses/1230200370485506048,0.0,0.0,,0.0,0.0,0.0,2.0,7.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,RT @DrMiguelPerales: @TaniaJain11 @ASTCT @BldCancerDoc @BipinSavani Junior investigators are always the future of our field. We need to pro‚Ä¶,true
cesardegali,"Doctorado en Biotecnolog√≠a. Licenciado en Bioqu√≠mica y en Ciencias Qu√≠micas. Apasionado de la ciencia. Ecologista, submarinista y lector.",,,,2020-03-01 21:06:39+00:00,C√©sar del Rio Merino,http://twitter.com/,11.0,,1.234223550451589e+18,,0.0,0.0,,"RT @DrRenatoCunha: Dr. Lunnig - Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel‚Ä¶",en,0.0,29.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,7.0,4.0,https://twitter.com/cesardegali/statuses/1234223550451589120,0.0,0.0,,0.0,0.0,0.0,4.0,7.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @DrRenatoCunha: Dr. Lunnig - Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel‚Ä¶",false
chano_py,Sola Gracia. Medico Hematologo. Donante de √≥rganos. #DonaenVida. #HSCT Dr in #Paraguay. Patient Advocacy Co-Chair at #WBMT. Secretary at @LABMT2,,Paraguay,,2020-02-23 15:02:12+00:00,Cristobal Frutos,http://twitter.com/,23.0,,1.2315951174730834e+18,,0.0,0.0,,RT @LABMT2: Happy to announce yesterday @LABMT2 President Sebasti√°n Galeano signed a Cooperation Agreement with @ASTCT President @BldCancer‚Ä¶,en,0.0,903.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,18.0,5.0,https://twitter.com/chano_py/statuses/1231595117473083393,0.0,0.0,,0.0,0.0,0.0,5.0,18.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @LABMT2: Happy to announce yesterday @LABMT2 President Sebasti√°n Galeano signed a Cooperation Agreement with @ASTCT President @BldCancer‚Ä¶,true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-02-23 16:26:47+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,4.0,,1.2316164035365683e+18,,0.0,0.0,,#TCTM20 Taplitz: resp virus infection by day 180 increases TRM risk in Haplo/PTCy recips. https://t.co/BqBqwVqRz9,en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,4.0,https://twitter.com/hemedoc/statuses/1231616403536568325,0.0,0.0,,0.0,0.0,0.0,4.0,0.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,#TCTM20 Taplitz: resp virus infection by day 180 increases TRM risk in Haplo/PTCy recips. https://t.co/BqBqwVqRz9,true
FranciscoMarty_,"Infectious diseases doctor who specializes in treating transplant and cancer patients, work at @BrighamWomens and @DanaFarber, @harvardmed.",,"Boston, MA",,2020-02-23 20:14:29+00:00,"Francisco Marty, MD",http://twitter.com/,19.0,,1.2316737045029642e+18,,0.0,0.0,,"RT @hemedoc: #TCTM20 Flower: adenovirus, CMV, EBV, BK specific CTLs for refractory infections, n=13, 100% ORR, 10/13 CR https://t.co/WRUzO2‚Ä¶",en,0.0,9990.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,13.0,6.0,https://twitter.com/FranciscoMarty_/statuses/1231673704502964224,0.0,0.0,,0.0,0.0,0.0,6.0,13.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"RT @hemedoc: #TCTM20 Flower: adenovirus, CMV, EBV, BK specific CTLs for refractory infections, n=13, 100% ORR, 10/13 CR https://t.co/WRUzO2‚Ä¶",true
FranciscoMarty_,"Infectious diseases doctor who specializes in treating transplant and cancer patients, work at @BrighamWomens and @DanaFarber, @harvardmed.",,"Boston, MA",,2020-02-23 20:13:52+00:00,"Francisco Marty, MD",http://twitter.com/,9.0,,1.2316735490872156e+18,,0.0,0.0,,"RT @hemedoc: #TCTM20 Taplitz: community respiratory virus infections by day +180 after Haplo/PTCy, Sib/PTCy, and Sib/CNI. Higher risk with‚Ä¶",en,0.0,9990.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,7.0,2.0,https://twitter.com/FranciscoMarty_/statuses/1231673549087215617,0.0,0.0,,0.0,0.0,0.0,2.0,7.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"RT @hemedoc: #TCTM20 Taplitz: community respiratory virus infections by day +180 after Haplo/PTCy, Sib/PTCy, and Sib/CNI. Higher risk with‚Ä¶",true
DrJonnys,Consultant General Surgery . former doctor at (CAF)üëÆüèª‚Äç‚ôÇÔ∏è / Anatomist. #umanitoba #uwinnipeg @Harvard,,"Winnipeg, Manitoba",,2020-02-23 17:41:50+00:00,ùê∑ùëü. ùêΩùëú‚Ñéùëõùëõùë¶ ùëÜùë°ùëíùë§ùëéùëüùë°‚Å¶üá®üá¶‚Å©üåàüçÅ,http://twitter.com/,19.0,,1.2316352920770683e+18,,0.0,0.0,,RT @BldCancerDoc: #TCTM20 @DrCCutler shows interim analysis of Ph2 trial of KD025 for refractory chronic #GVHD; overall response rate of ~6‚Ä¶,en,0.0,5805.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,11.0,8.0,https://twitter.com/DrJonnys/statuses/1231635292077068290,0.0,0.0,,0.0,0.0,0.0,8.0,11.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @BldCancerDoc: #TCTM20 @DrCCutler shows interim analysis of Ph2 trial of KD025 for refractory chronic #GVHD; overall response rate of ~6‚Ä¶,true
FranciscoMarty_,"Infectious diseases doctor who specializes in treating transplant and cancer patients, work at @BrighamWomens and @DanaFarber, @harvardmed.",,"Boston, MA",,2020-02-23 20:13:26+00:00,"Francisco Marty, MD",http://twitter.com/,29.0,,1.2316734420234158e+18,,0.0,0.0,,"RT @hemedoc: #TCTM20 Brunstein: relapse risk the same, but TRM significantly higher with cord. OS superior with haploBM! https://t.co/6MetY‚Ä¶",en,0.0,9990.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,19.0,10.0,https://twitter.com/FranciscoMarty_/statuses/1231673442023415810,0.0,0.0,,0.0,0.0,0.0,10.0,19.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @hemedoc: #TCTM20 Brunstein: relapse risk the same, but TRM significantly higher with cord. OS superior with haploBM! https://t.co/6MetY‚Ä¶",false
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-02-23 17:16:04+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,10.0,,1.2316288042689208e+18,,0.0,0.0,,"#TCTM20 Brunstein: relapse risk the same, but TRM significantly higher with cord. OS superior with haploBM! https://t.co/6MetYEaUFC",en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,10.0,https://twitter.com/hemedoc/statuses/1231628804268920832,0.0,0.0,,0.0,0.0,0.0,10.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"#TCTM20 Brunstein: relapse risk the same, but TRM significantly higher with cord. OS superior with haploBM! https://t.co/6MetYEaUFC",true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-02-23 16:23:56+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,2.0,,1.2316156868516782e+18,,0.0,0.0,,"#TCTM20 Taplitz: community respiratory virus infections by day +180 after Haplo/PTCy, Sib/PTCy, and Sib/CNI. Higher‚Ä¶ https://t.co/b5lNow3335",en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/hemedoc/statuses/1231615686851678208,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"#TCTM20 Taplitz: community respiratory virus infections by day +180 after Haplo/PTCy, Sib/PTCy, and Sib/CNI. Higher‚Ä¶ https://t.co/b5lNow3335",true
Transplant_Doc,Stem Cell Transplant physician and clinical researcher at MD Anderson Cancer Center; special interest in myeloma. Opinions expressed are my own,,,,2020-02-23 18:55:07+00:00,Muzaffar Qazilbash,http://twitter.com/,12.0,,1.231653730942161e+18,,0.0,0.0,,RT @hemedoc: #TCTM20 Cutler: median followup of 5mos for all surviving patients. KD025 very well tolerated. No increase in infection risk.‚Ä¶,en,0.0,5455.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,6.0,https://twitter.com/Transplant_Doc/statuses/1231653730942160896,0.0,0.0,,0.0,0.0,0.0,6.0,6.0,False,False,False,False,True,Disease Management,0.0,0.0,1.0,RT @hemedoc: #TCTM20 Cutler: median followup of 5mos for all surviving patients. KD025 very well tolerated. No increase in infection risk.‚Ä¶,true
FranciscoMarty_,"Infectious diseases doctor who specializes in treating transplant and cancer patients, work at @BrighamWomens and @DanaFarber, @harvardmed.",,"Boston, MA",,2020-02-23 14:46:42+00:00,"Francisco Marty, MD",http://twitter.com/,23.0,,1.2315912183516283e+18,,0.0,0.0,,"RT @satya_yadav: Why collaborate ? A great talk by #Horowitz 

Too few numbers BMT vs. breast cancer 

&gt;50% centres in USA too &lt;50 BMT annu‚Ä¶",en,0.0,9990.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,20.0,3.0,https://twitter.com/FranciscoMarty_/statuses/1231591218351628288,0.0,0.0,,0.0,0.0,0.0,3.0,20.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,"RT @satya_yadav: Why collaborate ? A great talk by #Horowitz 

Too few numbers BMT vs. breast cancer 

&gt;50% centres in USA too &lt;50 BMT annu‚Ä¶",true
drng,A Doctor Doctor. As seen fleetingly on Netflix. Author of this Magnum Opus in @NatureComms üëâ https://t.co/luZqhBspBt,,Australia,,2020-02-23 08:27:25+00:00,Lord Blood,http://twitter.com/,5.0,,1.231495767333884e+18,,0.0,0.0,,RT @marrow: Dr Duarte describing great outcomes in a Latin American cooperative study in MDS transplants in International Workshop at #TCTM‚Ä¶,en,0.0,2226.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,1.0,https://twitter.com/drng/statuses/1231495767333883904,0.0,0.0,,0.0,0.0,0.0,1.0,4.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @marrow: Dr Duarte describing great outcomes in a Latin American cooperative study in MDS transplants in International Workshop at #TCTM‚Ä¶,true
DrZackDeFilipp,BMT physician and researcher @MGHCancerCenter / Opinions are my own. #bmtsm #leusm #cancer,,"Boston, MA",,2020-02-23 17:32:33+00:00,Zachariah DeFilipp,http://twitter.com/,12.0,,1.2316329540630487e+18,,0.0,0.0,,RT @hemedoc: #TCTM20 Cutler: median followup of 5mos for all surviving patients. KD025 very well tolerated. No increase in infection risk.‚Ä¶,en,0.0,547.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,6.0,https://twitter.com/DrZackDeFilipp/statuses/1231632954063048710,0.0,0.0,,0.0,0.0,0.0,6.0,6.0,False,False,False,False,True,Disease Management,0.0,0.0,1.0,RT @hemedoc: #TCTM20 Cutler: median followup of 5mos for all surviving patients. KD025 very well tolerated. No increase in infection risk.‚Ä¶,false
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-02-23 17:56:50+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,3.0,,1.2316390644257628e+18,,0.0,0.0,,"#TCTM20 Lunning: TLS seen in only 1 patient, 12% infections. ORR 73%, CR 53%. Only high burden disease appears to b‚Ä¶ https://t.co/BHVQK4RRCt",en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/hemedoc/statuses/1231639064425762816,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"#TCTM20 Lunning: TLS seen in only 1 patient, 12% infections. ORR 73%, CR 53%. Only high burden disease appears to b‚Ä¶ https://t.co/BHVQK4RRCt",true
_VaibhavAgrawal,"Blood and Marrow Transplantation and Cellular Therapy Fellow @StanfordMed | MD, MBA, MJ, MSHA | @Stanford @StanfordHealth",,,,2020-02-23 17:51:51+00:00,Vaibhav Agrawal,http://twitter.com/,29.0,,1.2316378119351828e+18,,0.0,0.0,,"RT @hemedoc: #TCTM20 Brunstein: relapse risk the same, but TRM significantly higher with cord. OS superior with haploBM! https://t.co/6MetY‚Ä¶",en,0.0,233.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,19.0,10.0,https://twitter.com/_VaibhavAgrawal/statuses/1231637811935182848,0.0,0.0,,0.0,0.0,0.0,10.0,19.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @hemedoc: #TCTM20 Brunstein: relapse risk the same, but TRM significantly higher with cord. OS superior with haploBM! https://t.co/6MetY‚Ä¶",true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-02-23 17:25:37+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,4.0,,1.231631210314707e+18,,0.0,0.0,,#TCTM20 Cutler: KD025 phase II randomized (by dose) data for cGVHD after 2+ lines of therapy. Tho associated coiled‚Ä¶ https://t.co/wwns33MjHA,en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,4.0,https://twitter.com/hemedoc/statuses/1231631210314706945,0.0,0.0,,0.0,0.0,0.0,4.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,#TCTM20 Cutler: KD025 phase II randomized (by dose) data for cGVHD after 2+ lines of therapy. Tho associated coiled‚Ä¶ https://t.co/wwns33MjHA,true
davidmarks1958,"Expert in ALL,Bone marrow transplant, Trials and Data.Interest in ID in BMT  patients.Australian.Hawthorn supporter. Was MD Impact.Tweets are my personal views.",,"Bristol, England",,2020-02-23 01:05:02+00:00,David Marks,http://twitter.com/,0.0,,1.2313844354273567e+18,,0.0,0.0,,Posters at #TCTM20 so enjoyable seeing old friends #bronshaw&amp;#maryhorowitz-young investigators proud of their data reminds me of 20 yrs back,en,0.0,424.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/davidmarks1958/statuses/1231384435427356672,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Financial Performance,1.0,0.0,0.0,Posters at #TCTM20 so enjoyable seeing old friends #bronshaw&amp;#maryhorowitz-young investigators proud of their data reminds me of 20 yrs back,true
Yahveth,"MD @UDLAP| Research Fellow | Hematology and Internal Medicine | HSCT üá≤üáΩ at CHMI, Cl√≠nica Ruiz.",,M√©xico,,2020-02-23 00:58:10+00:00,"Yahveth Cantero-Fortiz, MD",http://twitter.com/,2.0,,1.2313827070595154e+18,,0.0,0.0,,"Final session poster from #TCTM20 
Quality of life in patients with multiple sclerosis after autologous stem cell t‚Ä¶ https://t.co/dIqqV6kBox",en,0.0,829.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/Yahveth/statuses/1231382707059515392,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"Final session poster from #TCTM20 
Quality of life in patients with multiple sclerosis after autologous stem cell t‚Ä¶ https://t.co/dIqqV6kBox",true
MichaelDJain,Oncologist @moffittnews. Lymphoma CAR T/BMT. üá®üá¶ in Florida (does not miss the cold).,,"Tampa, FL",,2020-02-23 20:46:08+00:00,Michael Jain,http://twitter.com/,14.0,,1.231681670761386e+18,,0.0,0.0,,RT @marrow: Jeremy Abramson from Boston presenting the TRANSCEND phase 1 study of liso-cel (lisocaptagene maraleucel) in lymphoma patients.‚Ä¶,en,0.0,212.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,9.0,5.0,https://twitter.com/MichaelDJain/statuses/1231681670761385984,0.0,0.0,,0.0,0.0,0.0,5.0,9.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @marrow: Jeremy Abramson from Boston presenting the TRANSCEND phase 1 study of liso-cel (lisocaptagene maraleucel) in lymphoma patients.‚Ä¶,false
rabonour1,myeloma doctor,,USA,,2020-02-23 14:07:43+00:00,Rafat Abonour,http://twitter.com/,0.0,,1.2315814049720975e+18,,0.0,0.0,,#BMT #TCT2020. #stem cell transplant. Partial breakfast pills. Now with esophageal irritation. https://t.co/8tSHgCxpsQ,en,0.0,1225.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/rabonour1/statuses/1231581404972097536,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,#BMT #TCT2020. #stem cell transplant. Partial breakfast pills. Now with esophageal irritation. https://t.co/8tSHgCxpsQ,true
sghmd,hematologist and bleeding-heart optimist üåÑ | clinical/translational #GVHD physician scientist | powerlifter üèãÔ∏è‚Äç‚ôÄÔ∏è | personal views |  physician ‚â† provider,,location:  in my head,,2020-02-23 17:11:13+00:00,Shernan Holtan MD,http://twitter.com/,14.0,,1.231627585093808e+18,,0.0,0.0,,RT @BldCancerDoc: #TCTM20 üëç talk by Dr Costanzo on fatigue after #BMT - 2/3rd patients report high levels of fatigue thru at least 5 yrs af‚Ä¶,en,0.0,1463.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,4.0,https://twitter.com/sghmd/statuses/1231627585093808129,0.0,0.0,,0.0,0.0,0.0,4.0,10.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,RT @BldCancerDoc: #TCTM20 üëç talk by Dr Costanzo on fatigue after #BMT - 2/3rd patients report high levels of fatigue thru at least 5 yrs af‚Ä¶,true
josudelafuente,"Haematologist, red cell disorders and marrow failure. Working towards definitive cure: #BMT #genetherapy. @ImperialNHS @ImperialImmuno @TheEBMT @ApothecariesLDN",,"London, England",,2020-02-23 16:28:19+00:00,Josu de la Fuente,http://twitter.com/,13.0,,1.2316167887414682e+18,,0.0,0.0,,"RT @satya_yadav: Respiratory viral infections post #Haplo #PTcy  @CIBMTR #Taplitz 

Higher infection with #PTCy 

Higher risk of TRM in PTC‚Ä¶",en,0.0,492.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,3.0,https://twitter.com/josudelafuente/statuses/1231616788741468165,0.0,0.0,,0.0,0.0,0.0,3.0,10.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"RT @satya_yadav: Respiratory viral infections post #Haplo #PTcy  @CIBMTR #Taplitz 

Higher infection with #PTCy 

Higher risk of TRM in PTC‚Ä¶",true
Transplant_Doc,Stem Cell Transplant physician and clinical researcher at MD Anderson Cancer Center; special interest in myeloma. Opinions expressed are my own,,,,2020-02-23 18:48:54+00:00,Muzaffar Qazilbash,http://twitter.com/,19.0,,1.231652166361899e+18,,0.0,0.0,,RT @BldCancerDoc: #TCTM20 @DrCCutler shows interim analysis of Ph2 trial of KD025 for refractory chronic #GVHD; overall response rate of ~6‚Ä¶,en,0.0,5455.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,11.0,8.0,https://twitter.com/Transplant_Doc/statuses/1231652166361899008,0.0,0.0,,0.0,0.0,0.0,8.0,11.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @BldCancerDoc: #TCTM20 @DrCCutler shows interim analysis of Ph2 trial of KD025 for refractory chronic #GVHD; overall response rate of ~6‚Ä¶,true
marrow,"Clinical Haematologist, marrow transplanter. President World Marrow Donor Association (WMDA). Editor-in-Chief Internal Medicine Journal.",,"Melbourne, Australia",,2020-02-23 17:59:40+00:00,Jeff Szer,http://twitter.com/,5.0,,1.2316397792525435e+18,,0.0,0.0,,Jeremy Abramson from Boston presenting the TRANSCEND phase 1 study of liso-cel (lisocaptagene maraleucel) in lympho‚Ä¶ https://t.co/nwytbL1yu2,en,0.0,2195.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,5.0,https://twitter.com/marrow/statuses/1231639779252543491,0.0,0.0,,0.0,0.0,0.0,5.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,Jeremy Abramson from Boston presenting the TRANSCEND phase 1 study of liso-cel (lisocaptagene maraleucel) in lympho‚Ä¶ https://t.co/nwytbL1yu2,true
FranciscoMarty_,"Infectious diseases doctor who specializes in treating transplant and cancer patients, work at @BrighamWomens and @DanaFarber, @harvardmed.",,"Boston, MA",,2020-02-23 20:13:55+00:00,"Francisco Marty, MD",http://twitter.com/,9.0,,1.2316735645642465e+18,,0.0,0.0,,RT @hemedoc: #TCTM20 Taplitz: resp virus infection by day 180 increases TRM risk in Haplo/PTCy recips. https://t.co/BqBqwVqRz9,en,0.0,9990.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,4.0,https://twitter.com/FranciscoMarty_/statuses/1231673564564246536,0.0,0.0,,0.0,0.0,0.0,4.0,5.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,RT @hemedoc: #TCTM20 Taplitz: resp virus infection by day 180 increases TRM risk in Haplo/PTCy recips. https://t.co/BqBqwVqRz9,false
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-02-23 17:30:24+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,6.0,,1.2316324144574218e+18,,0.0,0.0,,#TCTM20 Cutler: median followup of 5mos for all surviving patients. KD025 very well tolerated. No increase in infec‚Ä¶ https://t.co/wHSu6mYCBj,en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,6.0,https://twitter.com/hemedoc/statuses/1231632414457421825,0.0,0.0,,0.0,0.0,0.0,6.0,0.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,#TCTM20 Cutler: median followup of 5mos for all surviving patients. KD025 very well tolerated. No increase in infec‚Ä¶ https://t.co/wHSu6mYCBj,true
atunuguntla1,"Interventional Cardiologist, CHI Health Nebraska Heart, Lincoln, NE. Tweets = My Opinion & not medical advice #StructuralHeart #RadialFirst #ACCWIC",,"Nebraska, USA",,2020-03-14 01:22:25+00:00,"Anuradha Tunuguntla, MD, FACC, FSCAI",http://twitter.com/,15.0,,1.238636569705222e+18,,0.0,0.0,,"RT @crfheart: Due to the #COVID19 pandemic, CRF has decided to cancel #CRFFellows2020 to ensure the health &amp; safety of all attendees. We ar‚Ä¶",en,0.0,3619.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,7.0,8.0,https://twitter.com/atunuguntla1/statuses/1238636569705222146,0.0,0.0,,0.0,0.0,0.0,8.0,7.0,False,False,False,False,True,Covid,0.0,0.0,1.0,"RT @crfheart: Due to the #COVID19 pandemic, CRF has decided to cancel #CRFFellows2020 to ensure the health &amp; safety of all attendees. We ar‚Ä¶",true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-03-02 01:44:04+00:00,Oncology Tube,http://twitter.com/,0.0,,1.234293361206448e+18,,0.0,0.0,,"Phase 2 Study of Luspatercept Commonly Asked Questions #ASH19 @CleClinicMD: Aaron Gerds, MD of @CleClinicMD discuss‚Ä¶ https://t.co/zGLX79tY0T",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1234293361206448128,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"Phase 2 Study of Luspatercept Commonly Asked Questions #ASH19 @CleClinicMD: Aaron Gerds, MD of @CleClinicMD discuss‚Ä¶ https://t.co/zGLX79tY0T",true
subatomicdoc,"I'm a doctor dedicated to improving health. Lucky son, husband, father. Asking questions to help patients, health professionals, citizens. Neutral good.",,"Lowell MA, Manchester NH",,2020-03-14 21:05:26+00:00,"Matthew Katz, MD üá∫üá∏",http://twitter.com/,4.0,,1.2389342836428636e+18,,0.0,0.0,,RT @mtmdphd: @ADesaiMD @puhfu @JackWestMD @GlopesMd @agrothey @subatomicdoc I'm interested. Have published on infection/viruses in cancer.‚Ä¶,en,0.0,19810.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,1.0,https://twitter.com/subatomicdoc/statuses/1238934283642863625,0.0,0.0,,0.0,0.0,0.0,1.0,3.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,RT @mtmdphd: @ADesaiMD @puhfu @JackWestMD @GlopesMd @agrothey @subatomicdoc I'm interested. Have published on infection/viruses in cancer.‚Ä¶,true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-03-14 01:07:03+00:00,Oncology Tube,http://twitter.com/,1.0,,1.2386327013782323e+18,,0.0,0.0,,"Update on Phase I REGN1979 #ASH19 #ASH @RutgersCancer: Rajat Bannerji, MD of @RutgersCancer provides an update on P‚Ä¶ https://t.co/sggdpNMM6L",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/oncologytube/statuses/1238632701378232320,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"Update on Phase I REGN1979 #ASH19 #ASH @RutgersCancer: Rajat Bannerji, MD of @RutgersCancer provides an update on P‚Ä¶ https://t.co/sggdpNMM6L",true
MMaversMDPhD,Pediatric Stem Cell Transplanter | Physician Scientist | Focus on immune regulation of graft-versus-host disease | Views are my own & not medical advice,,,,2020-02-24 04:47:43+00:00,Melissa Mavers,http://twitter.com/,0.0,,1.231802867029336e+18,,0.0,0.0,,My first ever tweet! Thanks to #TCTM20 for a fantastic meeting and to my amazing colleagues‚ÄîI love working with thi‚Ä¶ https://t.co/25L2y4oXF8,en,0.0,38.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/MMaversMDPhD/statuses/1231802867029336064,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,My first ever tweet! Thanks to #TCTM20 for a fantastic meeting and to my amazing colleagues‚ÄîI love working with thi‚Ä¶ https://t.co/25L2y4oXF8,false
CancerMedMDA,"Mission of largest MD Anderson division is to eliminate cancer via best, integrated patient care, research & education programs. Appts.available 877-632-6789.",,"Houston, TX",,2020-02-24 14:26:22+00:00,Cancer Medicine,http://twitter.com/,67.0,,1.2319484886168945e+18,,0.0,0.0,,RT @lab_rezvani: Congratulations to Dr. Uday Popat from the Department of Stem Cell Transplant @CancerMedMDA for being awarded the best abs‚Ä¶,en,0.0,6443.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,53.0,14.0,https://twitter.com/CancerMedMDA/statuses/1231948488616894466,0.0,0.0,,0.0,0.0,0.0,14.0,53.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @lab_rezvani: Congratulations to Dr. Uday Popat from the Department of Stem Cell Transplant @CancerMedMDA for being awarded the best abs‚Ä¶,true
UrviShahMD,Oncologist and researcher on Myeloma service @sloan_kettering. Interested in nutrition for cancer and immune therapies. Views are my own,,"New York, NY",,2020-02-24 04:03:37+00:00,Urvi Shah,http://twitter.com/,29.0,,1.2317917652560118e+18,,0.0,0.0,,"RT @hemedoc: #TCTM20 Brunstein: relapse risk the same, but TRM significantly higher with cord. OS superior with haploBM! https://t.co/6MetY‚Ä¶",en,0.0,1227.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,19.0,10.0,https://twitter.com/UrviShahMD/statuses/1231791765256011776,0.0,0.0,,0.0,0.0,0.0,10.0,19.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @hemedoc: #TCTM20 Brunstein: relapse risk the same, but TRM significantly higher with cord. OS superior with haploBM! https://t.co/6MetY‚Ä¶",true
CBCIDocs,Thoughts and perspectives from the hematology and transplant physicians at Colorado Blood Cancer Institute @ColoradoBlood @SarahCannonDocs @PresStLukesDenv,,"Denver, CO",,2020-02-21 16:31:12+00:00,CBCI,http://twitter.com/,19.0,,1.2308927375469036e+18,,0.0,0.0,,"RT @hemedoc: #TCTM20 Scott: MAC outcomes not affected by NGS positivity prior to alloHCT, but has large impact on relapse after RIC. https:‚Ä¶",en,0.0,782.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,9.0,https://twitter.com/CBCIDocs/statuses/1230892737546903552,0.0,0.0,,0.0,0.0,0.0,9.0,10.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @hemedoc: #TCTM20 Scott: MAC outcomes not affected by NGS positivity prior to alloHCT, but has large impact on relapse after RIC. https:‚Ä¶",true
MichaelIsonMD,#TxID physician at @NM_IDSteward focusing on donor-derived and viral infections,,"Chicago, IL",,2020-02-21 01:53:10+00:00,Michael Ison,http://twitter.com/,12.0,,1.2306717733325947e+18,,0.0,0.0,,RT @michyong2: @FranciscoMarty_ #TCTM20 Personalized infection risk in HSCT. Lots of personalized and humorous slides! Breath fungal signat‚Ä¶,en,0.0,1559.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,2.0,https://twitter.com/MichaelIsonMD/statuses/1230671773332594689,0.0,0.0,,0.0,0.0,0.0,2.0,10.0,False,False,False,False,True,Side Effects,1.0,0.0,0.0,RT @michyong2: @FranciscoMarty_ #TCTM20 Personalized infection risk in HSCT. Lots of personalized and humorous slides! Breath fungal signat‚Ä¶,true
MedInContext,"Medical Advisor, Molecular Oncologist, Healthcare Consultant, Cancer Patient Friend",,United States,,2020-02-19 14:39:56+00:00,Susanne Max Radke,http://twitter.com/,0.0,,1.2301399634523832e+18,,0.0,0.0,,"First day at #TCTM20
Looking forward to listening to new research and networking with scientists. https://t.co/rkfZJ7B6ET",en,0.0,358.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/MedInContext/statuses/1230139963452383234,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"First day at #TCTM20
Looking forward to listening to new research and networking with scientists. https://t.co/rkfZJ7B6ET",true
drjgauthier,"MD, MSc, Assistant Professor @fredhutch @UW focused on #CARTcell #immunotherapy #tcellrx 
Interests also include #rstats #bmtsm #epitwitter #bayes",,"Seattle, WA",,2020-02-19 14:21:58+00:00,Jordan Gauthier,http://twitter.com/,28.0,,1.2301354424706253e+18,,0.0,0.0,,RT @DrMiguelPerales: T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant ‚Å¶@fredhutch‚Å© ‚Å¶@Natu‚Ä¶,en,0.0,3295.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,21.0,7.0,https://twitter.com/drjgauthier/statuses/1230135442470625288,0.0,0.0,,0.0,0.0,0.0,7.0,21.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @DrMiguelPerales: T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant ‚Å¶@fredhutch‚Å© ‚Å¶@Natu‚Ä¶,false
Prasshmehta,"Medical Oncologist,Hematoncologist and bone marrow transplant physician,
DM(AIIMS, Delhi)
Program Director- Leukemia/BMT( Asian Institute of Medical Sciences)",,,,2020-02-19 17:01:48+00:00,Prashant Mehta,http://twitter.com/,0.0,,1.230175662410875e+18,,0.0,0.0,,Remembering the pioneers #TCTM20 @imginatvrealist History always has a lot of lessons to learn https://t.co/l00qHzAwHd,en,0.0,1065.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/Prasshmehta/statuses/1230175662410874881,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,Remembering the pioneers #TCTM20 @imginatvrealist History always has a lot of lessons to learn https://t.co/l00qHzAwHd,true
abhinav_deol,MD,,"Detroit, MI",,2020-02-19 15:51:50+00:00,Abhinav Deol,http://twitter.com/,0.0,,1.2301580563041034e+18,,0.0,0.0,,#TCTM20  Medicare reimbursement for CAR T cell therapy is not financially feasible for centers providing the therap‚Ä¶ https://t.co/UyM3ZvIHfZ,en,0.0,251.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/abhinav_deol/statuses/1230158056304103424,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Insurance Coverage,0.0,0.0,1.0,#TCTM20  Medicare reimbursement for CAR T cell therapy is not financially feasible for centers providing the therap‚Ä¶ https://t.co/UyM3ZvIHfZ,true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-02-19 13:42:42+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,2.0,,1.2301255583082332e+18,,0.0,0.0,,#TCTM20 Kochenderfer: lots of room for improvement in CAR-T design. NCI group investigating a CAR construct with mo‚Ä¶ https://t.co/fqfDAQp7pU,en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/hemedoc/statuses/1230125558308233216,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,#TCTM20 Kochenderfer: lots of room for improvement in CAR-T design. NCI group investigating a CAR construct with mo‚Ä¶ https://t.co/fqfDAQp7pU,true
Drroxmehran,"Interventional cardiologist, Professor of Medicine @mountsinaiNYC, trialist, outcomes researcher, wife and mother; opinions my own #ACCBOT @womenas1",,"Manhattan, NY",,2020-03-04 13:57:19+00:00,Roxana Mehran,http://twitter.com/,25.0,,1.2352026663782769e+18,,0.0,0.0,,"RT @TCTConference: Submit your science for the chance to present at #TCT2020! The call for abstracts, challenging cases, innovation and the‚Ä¶",en,0.0,9784.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,13.0,12.0,https://twitter.com/Drroxmehran/statuses/1235202666378276867,0.0,0.0,,0.0,0.0,0.0,12.0,13.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @TCTConference: Submit your science for the chance to present at #TCT2020! The call for abstracts, challenging cases, innovation and the‚Ä¶",true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-02-19 14:08:17+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,2.0,,1.2301319967410012e+18,,0.0,0.0,,#TCTM20 Greenberg: WT1 TCR cells effectively prevent relapse in AML patients in CR https://t.co/KecAGXYE1j,en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/hemedoc/statuses/1230131996741001217,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,#TCTM20 Greenberg: WT1 TCR cells effectively prevent relapse in AML patients in CR https://t.co/KecAGXYE1j,true
DrChrisHourigan,"Physician-Scientist, Acute Myeloid Leukemia Doctor, Human Immunologist, Laboratory PI, Measurable Residual Disease Advocate, Optimist.  Views are my own.",,"Washington, DC",,2020-02-19 21:19:17+00:00,Chris Hourigan,http://twitter.com/,19.0,,1.2302404613711913e+18,,0.0,0.0,,"RT @hemedoc: #TCTM20 Scott: MAC outcomes not affected by NGS positivity prior to alloHCT, but has large impact on relapse after RIC. https:‚Ä¶",en,0.0,1169.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,9.0,https://twitter.com/DrChrisHourigan/statuses/1230240461371191296,0.0,0.0,,0.0,0.0,0.0,9.0,10.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @hemedoc: #TCTM20 Scott: MAC outcomes not affected by NGS positivity prior to alloHCT, but has large impact on relapse after RIC. https:‚Ä¶",false
GreggWStone,"Interventional cardiologist, trialist, innovator, provocateur, educator, husband, father, friend",,New York and the world,,2020-03-04 02:34:01+00:00,Gregg W. Stone MD,http://twitter.com/,25.0,,1.2350307091457556e+18,,0.0,0.0,,"RT @TCTConference: Submit your science for the chance to present at #TCT2020! The call for abstracts, challenging cases, innovation and the‚Ä¶",en,0.0,18925.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,13.0,12.0,https://twitter.com/GreggWStone/statuses/1235030709145755648,0.0,0.0,,0.0,0.0,0.0,12.0,13.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @TCTConference: Submit your science for the chance to present at #TCT2020! The call for abstracts, challenging cases, innovation and the‚Ä¶",true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-02-19 21:29:52+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,1.0,,1.230243124611625e+18,,0.0,0.0,,#TCTM20 Liegel: T cell responses and survival in ph1 DC-AML study. Ph2 proceeding now. https://t.co/gA27OSSxmk,en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/hemedoc/statuses/1230243124611624960,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,#TCTM20 Liegel: T cell responses and survival in ph1 DC-AML study. Ph2 proceeding now. https://t.co/gA27OSSxmk,true
Hazarapatriot,Pediatric Stem cell transplant physician.,,"Toronto, Canada",,2020-02-21 22:23:42+00:00,Ali,http://twitter.com/,15.0,,1.2309814480117432e+18,,0.0,0.0,,RT @AronFlaggMD: CD117 ADC showing exceptional preclinical promise to induce myeolablation and facilitate engraftment of autologous gene-mo‚Ä¶,en,0.0,440.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,13.0,2.0,https://twitter.com/Hazarapatriot/statuses/1230981448011743232,0.0,0.0,,0.0,0.0,0.0,2.0,13.0,False,False,False,False,True,Clinical Trials,1.0,0.0,0.0,RT @AronFlaggMD: CD117 ADC showing exceptional preclinical promise to induce myeolablation and facilitate engraftment of autologous gene-mo‚Ä¶,true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-02-21 20:45:25+00:00,Oncology Tube,http://twitter.com/,9.0,,1.2309567163819827e+18,,0.0,0.0,,RT @marrow: Best abstracts at #TCTM20. Michael Wang from @MDAndersonNews presenting ZUMA-2 study results of KTE-X17 CAR-T cels in relapsed/‚Ä¶,en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,7.0,2.0,https://twitter.com/oncologytube/statuses/1230956716381982721,0.0,0.0,,0.0,0.0,0.0,2.0,7.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @marrow: Best abstracts at #TCTM20. Michael Wang from @MDAndersonNews presenting ZUMA-2 study results of KTE-X17 CAR-T cels in relapsed/‚Ä¶,true
abhinav_deol,MD,,"Detroit, MI",,2020-02-21 22:24:21+00:00,Abhinav Deol,http://twitter.com/,10.0,,1.230981610507514e+18,,0.0,0.0,,RT @AkshaySharmaMD: #TCTM20 Popat from @MDAndersonNews You can still give fractionated myeloablative chemotherapy and reduce toxicity but n‚Ä¶,en,0.0,251.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,5.0,https://twitter.com/abhinav_deol/statuses/1230981610507513859,0.0,0.0,,0.0,0.0,0.0,5.0,5.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @AkshaySharmaMD: #TCTM20 Popat from @MDAndersonNews You can still give fractionated myeloablative chemotherapy and reduce toxicity but n‚Ä¶,true
LemaistreFred,"SVP and Physician in Chief Hematology, Sarah Cannon; past President of @FACTunmc and @ASTCT. @TexasMSD Thoughts and ideas are my own.",,"Nashville, TN",,2020-02-21 11:28:51+00:00,Fred LeMaistre,http://twitter.com/,23.0,,1.230816649252606e+18,,0.0,0.0,,RT @LABMT2: Happy to announce yesterday @LABMT2 President Sebasti√°n Galeano signed a Cooperation Agreement with @ASTCT President @BldCancer‚Ä¶,en,0.0,1163.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,18.0,5.0,https://twitter.com/LemaistreFred/statuses/1230816649252605952,0.0,0.0,,0.0,0.0,0.0,5.0,18.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @LABMT2: Happy to announce yesterday @LABMT2 President Sebasti√°n Galeano signed a Cooperation Agreement with @ASTCT President @BldCancer‚Ä¶,false
abhinav_deol,MD,,"Detroit, MI",,2020-02-21 15:57:47+00:00,Abhinav Deol,http://twitter.com/,22.0,,1.2308843283490202e+18,,0.0,0.0,,RT @PurveySneha: #TCTM20 @MSKHemOncTrials Excellent talk by @GunjanLShah on Medicare pts receiving #CARTcells https://t.co/SK6XardILx,en,0.0,251.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,17.0,5.0,https://twitter.com/abhinav_deol/statuses/1230884328349020160,0.0,0.0,,0.0,0.0,0.0,5.0,17.0,False,False,False,False,True,Insurance Coverage,1.0,0.0,0.0,RT @PurveySneha: #TCTM20 @MSKHemOncTrials Excellent talk by @GunjanLShah on Medicare pts receiving #CARTcells https://t.co/SK6XardILx,true
drjgauthier,"MD, MSc, Assistant Professor @fredhutch @UW focused on #CARTcell #immunotherapy #tcellrx 
Interests also include #rstats #bmtsm #epitwitter #bayes",,"Seattle, WA",,2020-02-21 20:57:50+00:00,Jordan Gauthier,http://twitter.com/,41.0,,1.2309598404046277e+18,,0.0,0.0,,"RT @DrRenatoCunha: Dr Wang - KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) with Relapsed/Refracto‚Ä¶",en,0.0,3295.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,33.0,8.0,https://twitter.com/drjgauthier/statuses/1230959840404627457,0.0,0.0,,0.0,0.0,0.0,8.0,33.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @DrRenatoCunha: Dr Wang - KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) with Relapsed/Refracto‚Ä¶",true
nycdoc29,"ASCO, ASH, EHA & ESMO Member, Hem/Onc - 11 MD specialty private practice, former full time academic, traveller, foodie & out of necessity now a business person!",,"Garden City, NY",,2020-02-21 16:39:32+00:00,NYCDoc29,http://twitter.com/,0.0,,1.2308948364269773e+18,,0.0,0.0,,"hopefully the future isn‚Äôt financed by increasing co-pays, decreasing face to face time with patients, increasing P‚Ä¶ https://t.co/THtrvlyVLA",en,0.0,664.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/nycdoc29/statuses/1230894836426977280,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Insurance Coverage,0.0,0.0,1.0,"hopefully the future isn‚Äôt financed by increasing co-pays, decreasing face to face time with patients, increasing P‚Ä¶ https://t.co/THtrvlyVLA",true
PennisiMartina,"Hematologist @IstTumori #milan. Lymphoma, Bone Marrow Transplant & Immunotherapy doc.",,"New York, NY",,2020-02-21 23:08:01+00:00,Martina Pennisi,http://twitter.com/,4.0,,1.2309926004522598e+18,,0.0,0.0,,congratssss @RShouval on your young investigator award from @ASTCT ! All the best for you! #TCTM20 https://t.co/kTr8ujzLhb,en,0.0,340.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,4.0,https://twitter.com/PennisiMartina/statuses/1230992600452259841,0.0,0.0,,0.0,0.0,0.0,4.0,0.0,False,False,False,False,True,Financial Performance,1.0,0.0,0.0,congratssss @RShouval on your young investigator award from @ASTCT ! All the best for you! #TCTM20 https://t.co/kTr8ujzLhb,true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-02-21 18:08:25+00:00,Oncology Tube,http://twitter.com/,20.0,,1.230917203102335e+18,,0.0,0.0,,RT @sagarpatel: Upcoming trial comparing ruxolitinib vs alloHCT based on available donor status @PeerView #MPNsm #BMTsm #TCTM20 https://t.c‚Ä¶,en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,12.0,8.0,https://twitter.com/oncologytube/statuses/1230917203102334976,0.0,0.0,,0.0,0.0,0.0,8.0,12.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @sagarpatel: Upcoming trial comparing ruxolitinib vs alloHCT based on available donor status @PeerView #MPNsm #BMTsm #TCTM20 https://t.c‚Ä¶,true
marrow,"Clinical Haematologist, marrow transplanter. President World Marrow Donor Association (WMDA). Editor-in-Chief Internal Medicine Journal.",,"Melbourne, Australia",,2020-02-23 15:12:46+00:00,Jeff Szer,http://twitter.com/,23.0,,1.2315977767037542e+18,,0.0,0.0,,RT @LABMT2: Happy to announce yesterday @LABMT2 President Sebasti√°n Galeano signed a Cooperation Agreement with @ASTCT President @BldCancer‚Ä¶,en,0.0,2195.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,18.0,5.0,https://twitter.com/marrow/statuses/1231597776703754240,0.0,0.0,,0.0,0.0,0.0,5.0,18.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @LABMT2: Happy to announce yesterday @LABMT2 President Sebasti√°n Galeano signed a Cooperation Agreement with @ASTCT President @BldCancer‚Ä¶,false
drng,A Doctor Doctor. As seen fleetingly on Netflix. Author of this Magnum Opus in @NatureComms üëâ https://t.co/luZqhBspBt,,Australia,,2020-02-23 10:40:27+00:00,Lord Blood,http://twitter.com/,23.0,,1.2315292456224604e+18,,0.0,0.0,,RT @DrMiguelPerales: Making sure to acknowledge that I was presenting a combined proposal that combined 9 proposals on behalf of 27 investi‚Ä¶,en,0.0,2226.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,19.0,4.0,https://twitter.com/drng/statuses/1231529245622460416,0.0,0.0,,0.0,0.0,0.0,4.0,19.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,RT @DrMiguelPerales: Making sure to acknowledge that I was presenting a combined proposal that combined 9 proposals on behalf of 27 investi‚Ä¶,true
FranciscoMarty_,"Infectious diseases doctor who specializes in treating transplant and cancer patients, work at @BrighamWomens and @DanaFarber, @harvardmed.",,"Boston, MA",,2020-02-23 20:12:05+00:00,"Francisco Marty, MD",http://twitter.com/,12.0,,1.23167310072875e+18,,0.0,0.0,,RT @hemedoc: #TCTM20 Cutler: median followup of 5mos for all surviving patients. KD025 very well tolerated. No increase in infection risk.‚Ä¶,en,0.0,9990.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,6.0,https://twitter.com/FranciscoMarty_/statuses/1231673100728750081,0.0,0.0,,0.0,0.0,0.0,6.0,6.0,False,False,False,False,True,Disease Management,0.0,0.0,1.0,RT @hemedoc: #TCTM20 Cutler: median followup of 5mos for all surviving patients. KD025 very well tolerated. No increase in infection risk.‚Ä¶,true
marrow,"Clinical Haematologist, marrow transplanter. President World Marrow Donor Association (WMDA). Editor-in-Chief Internal Medicine Journal.",,"Melbourne, Australia",,2020-02-23 20:30:48+00:00,Jeff Szer,http://twitter.com/,29.0,,1.2316778136794276e+18,,0.0,0.0,,"RT @hemedoc: #TCTM20 Brunstein: relapse risk the same, but TRM significantly higher with cord. OS superior with haploBM! https://t.co/6MetY‚Ä¶",en,0.0,2195.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,19.0,10.0,https://twitter.com/marrow/statuses/1231677813679427585,0.0,0.0,,0.0,0.0,0.0,10.0,19.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @hemedoc: #TCTM20 Brunstein: relapse risk the same, but TRM significantly higher with cord. OS superior with haploBM! https://t.co/6MetY‚Ä¶",true
marrow,"Clinical Haematologist, marrow transplanter. President World Marrow Donor Association (WMDA). Editor-in-Chief Internal Medicine Journal.",,"Melbourne, Australia",,2020-02-23 17:07:18+00:00,Jeff Szer,http://twitter.com/,2.0,,1.2316265999021425e+18,,0.0,0.0,,Erin S Costanzo from U Wisconsin- Madison showing us what predicts fatigue post transplant and shows us that if the‚Ä¶ https://t.co/YVMvJ9203S,en,0.0,2195.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/marrow/statuses/1231626599902142471,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,Erin S Costanzo from U Wisconsin- Madison showing us what predicts fatigue post transplant and shows us that if the‚Ä¶ https://t.co/YVMvJ9203S,true
Transplant_Doc,Stem Cell Transplant physician and clinical researcher at MD Anderson Cancer Center; special interest in myeloma. Opinions expressed are my own,,,,2020-02-23 18:58:33+00:00,Muzaffar Qazilbash,http://twitter.com/,29.0,,1.2316545979131208e+18,,0.0,0.0,,"RT @hemedoc: #TCTM20 Brunstein: relapse risk the same, but TRM significantly higher with cord. OS superior with haploBM! https://t.co/6MetY‚Ä¶",en,0.0,5455.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,19.0,10.0,https://twitter.com/Transplant_Doc/statuses/1231654597913120769,0.0,0.0,,0.0,0.0,0.0,10.0,19.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @hemedoc: #TCTM20 Brunstein: relapse risk the same, but TRM significantly higher with cord. OS superior with haploBM! https://t.co/6MetY‚Ä¶",true
ouholter,"Proud Oklahoma hematologist, wife, BMT physician, researcher, sooner, mom, loyal friend, thunder fan, and so proud of two amazing daughters! Tweets my own.",,"Oklahoma City, OK",,2020-02-23 00:28:03+00:00,J Holter Chakrabarty,http://twitter.com/,28.0,,1.2313751304141947e+18,,0.0,0.0,,RT @Kwudhikarn: Dr. Perales presents a combined proposal of infection in CAR T therapy. Very important question. @DrMiguelPerales #CART #TC‚Ä¶,en,0.0,309.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,22.0,6.0,https://twitter.com/ouholter/statuses/1231375130414194689,0.0,0.0,,0.0,0.0,0.0,6.0,22.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,RT @Kwudhikarn: Dr. Perales presents a combined proposal of infection in CAR T therapy. Very important question. @DrMiguelPerales #CART #TC‚Ä¶,false
michyong2,"Infectious diseases physician, CMV & viral infections, Clinician researcher, @NCICancer @PeterMacCC @TheRMH @TheDohertyInst",,"Melbourne, Victoria",,2020-02-23 16:50:46+00:00,Michelle Yong,http://twitter.com/,9.0,,1.2316224407925268e+18,,0.0,0.0,,RT @hemedoc: #TCTM20 Taplitz: resp virus infection by day 180 increases TRM risk in Haplo/PTCy recips. https://t.co/BqBqwVqRz9,en,0.0,386.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,4.0,https://twitter.com/michyong2/statuses/1231622440792526849,0.0,0.0,,0.0,0.0,0.0,4.0,5.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,RT @hemedoc: #TCTM20 Taplitz: resp virus infection by day 180 increases TRM risk in Haplo/PTCy recips. https://t.co/BqBqwVqRz9,true
michyong2,"Infectious diseases physician, CMV & viral infections, Clinician researcher, @NCICancer @PeterMacCC @TheRMH @TheDohertyInst",,"Melbourne, Victoria",,2020-02-23 16:54:59+00:00,Michelle Yong,http://twitter.com/,19.0,,1.2316234998207324e+18,,0.0,0.0,,"RT @hemedoc: #TCTM20 Flower: adenovirus, CMV, EBV, BK specific CTLs for refractory infections, n=13, 100% ORR, 10/13 CR https://t.co/WRUzO2‚Ä¶",en,0.0,386.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,13.0,6.0,https://twitter.com/michyong2/statuses/1231623499820732423,0.0,0.0,,0.0,0.0,0.0,6.0,13.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"RT @hemedoc: #TCTM20 Flower: adenovirus, CMV, EBV, BK specific CTLs for refractory infections, n=13, 100% ORR, 10/13 CR https://t.co/WRUzO2‚Ä¶",true
davidmarks1958,"Expert in ALL,Bone marrow transplant, Trials and Data.Interest in ID in BMT  patients.Australian.Hawthorn supporter. Was MD Impact.Tweets are my personal views.",,"Bristol, England",,2020-02-23 14:44:30+00:00,David Marks,http://twitter.com/,2.0,,1.231590662509908e+18,,0.0,0.0,,#TCTM20 #MaryHorowitz explaining the need for international collaboration in BMT &amp; IEC therapy.Small numbers is the‚Ä¶ https://t.co/9W7rTup8Ef,en,0.0,424.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/davidmarks1958/statuses/1231590662509907968,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,#TCTM20 #MaryHorowitz explaining the need for international collaboration in BMT &amp; IEC therapy.Small numbers is the‚Ä¶ https://t.co/9W7rTup8Ef,true
Transplant_Doc,Stem Cell Transplant physician and clinical researcher at MD Anderson Cancer Center; special interest in myeloma. Opinions expressed are my own,,,,2020-02-23 18:54:21+00:00,Muzaffar Qazilbash,http://twitter.com/,8.0,,1.2316535408730235e+18,,0.0,0.0,,RT @hemedoc: #TCTM20 Cutler: KD025 phase II randomized (by dose) data for cGVHD after 2+ lines of therapy. Tho associated coiled coil kinas‚Ä¶,en,0.0,5455.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,4.0,https://twitter.com/Transplant_Doc/statuses/1231653540873023488,0.0,0.0,,0.0,0.0,0.0,4.0,4.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @hemedoc: #TCTM20 Cutler: KD025 phase II randomized (by dose) data for cGVHD after 2+ lines of therapy. Tho associated coiled coil kinas‚Ä¶,true
marrow,"Clinical Haematologist, marrow transplanter. President World Marrow Donor Association (WMDA). Editor-in-Chief Internal Medicine Journal.",,"Melbourne, Australia",,2020-02-23 15:13:52+00:00,Jeff Szer,http://twitter.com/,49.0,,1.231598052613509e+18,,0.0,0.0,,RT @DrMiguelPerales: Important @CIBMTR study presented yesterday by Javier Bolanos-Meade &amp; Bronwen Shaw reporting multicenter phase 2 trial‚Ä¶,en,0.0,2195.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,35.0,14.0,https://twitter.com/marrow/statuses/1231598052613509120,0.0,0.0,,0.0,0.0,0.0,14.0,35.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @DrMiguelPerales: Important @CIBMTR study presented yesterday by Javier Bolanos-Meade &amp; Bronwen Shaw reporting multicenter phase 2 trial‚Ä¶,true
LemaistreFred,"SVP and Physician in Chief Hematology, Sarah Cannon; past President of @FACTunmc and @ASTCT. @TexasMSD Thoughts and ideas are my own.",,"Nashville, TN",,2020-02-23 02:29:32+00:00,Fred LeMaistre,http://twitter.com/,21.0,,1.231405700296958e+18,,0.0,0.0,,RT @BldCancerDoc: üôèüôèüôè to incredible group of colleagues who do üëçüëçüëç volunteer work for @ASTCT #TCTM20,en,0.0,1163.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,19.0,2.0,https://twitter.com/LemaistreFred/statuses/1231405700296957952,0.0,0.0,,0.0,0.0,0.0,2.0,19.0,False,False,False,False,True,Disease Advocacy,1.0,0.0,0.0,RT @BldCancerDoc: üôèüôèüôè to incredible group of colleagues who do üëçüëçüëç volunteer work for @ASTCT #TCTM20,false
adrianabello,"pediatrician, pediatric hematologyst, mother adribello@hotmail.com",,,,2020-02-23 07:21:47+00:00,Adriana Bello,http://twitter.com/,32.0,,1.2314792502193398e+18,,0.0,0.0,,RT @AkshaySharmaMD: Outstanding @StJudeResearch BMTCT team member Dr @AimeeTalleurMD presenting experience with haploidentical CD45 RAbdeol‚Ä¶,en,0.0,1968.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,24.0,8.0,https://twitter.com/adrianabello/statuses/1231479250219339777,0.0,0.0,,0.0,0.0,0.0,8.0,24.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @AkshaySharmaMD: Outstanding @StJudeResearch BMTCT team member Dr @AimeeTalleurMD presenting experience with haploidentical CD45 RAbdeol‚Ä¶,true
drng,A Doctor Doctor. As seen fleetingly on Netflix. Author of this Magnum Opus in @NatureComms üëâ https://t.co/luZqhBspBt,,Australia,,2020-02-23 09:33:06+00:00,Lord Blood,http://twitter.com/,5.0,,1.2315122955633828e+18,,0.0,0.0,,RT @marrow: Enthralled audience at #WBMT session on international access to #HCT drugs at #TCTM20. Current speaker current speaker is Emily‚Ä¶,en,0.0,2226.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,1.0,https://twitter.com/drng/statuses/1231512295563382784,0.0,0.0,,0.0,0.0,0.0,1.0,4.0,False,False,False,False,True,Thought Leadership,0.0,0.0,1.0,RT @marrow: Enthralled audience at #WBMT session on international access to #HCT drugs at #TCTM20. Current speaker current speaker is Emily‚Ä¶,true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-02-23 16:42:35+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,6.0,,1.231620379673858e+18,,0.0,0.0,,"#TCTM20 Flower: adenovirus, CMV, EBV, BK specific CTLs for refractory infections, n=13, 100% ORR, 10/13 CR https://t.co/WRUzO2tBhq",en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,6.0,https://twitter.com/hemedoc/statuses/1231620379673858048,0.0,0.0,,0.0,0.0,0.0,6.0,0.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"#TCTM20 Flower: adenovirus, CMV, EBV, BK specific CTLs for refractory infections, n=13, 100% ORR, 10/13 CR https://t.co/WRUzO2tBhq",true
AronFlaggMD,"Pediatric hematologist/oncologist excited about transplant, leukemia, infectious diseases, and how they all intersect. Opinions are my own.",,"New Haven, CT",,2020-02-21 21:46:23+00:00,"Aron Flagg, MD",http://twitter.com/,2.0,,1.23097205852126e+18,,0.0,0.0,,CD117 ADC showing exceptional preclinical promise to induce myeolablation and facilitate engraftment of autologous‚Ä¶ https://t.co/oBv8GkvvV0,en,0.0,549.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/AronFlaggMD/statuses/1230972058521260033,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Clinical Trials,1.0,0.0,0.0,CD117 ADC showing exceptional preclinical promise to induce myeolablation and facilitate engraftment of autologous‚Ä¶ https://t.co/oBv8GkvvV0,true
HarrysTorres01,Founding Director of Hepatitis C Clinic at MD Anderson Cancer Center. Medical Director of Internal Medicine Center. Tweets are my own,,United States,,2020-02-23 01:31:55+00:00,Harrys Torres,http://twitter.com/,15.0,,1.2313912022112256e+18,,0.0,0.0,,RT @OncLive: .@sgiraltbmtdoc of @sloan_kettering discusses the diagnostic challenges of transplant-associated thrombotic microangiopathy #T‚Ä¶,en,0.0,288.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,7.0,8.0,https://twitter.com/HarrysTorres01/statuses/1231391202211225601,0.0,0.0,,0.0,0.0,0.0,8.0,7.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @OncLive: .@sgiraltbmtdoc of @sloan_kettering discusses the diagnostic challenges of transplant-associated thrombotic microangiopathy #T‚Ä¶,true
marrow,"Clinical Haematologist, marrow transplanter. President World Marrow Donor Association (WMDA). Editor-in-Chief Internal Medicine Journal.",,"Melbourne, Australia",,2020-02-23 15:11:03+00:00,Jeff Szer,http://twitter.com/,16.0,,1.231597342836523e+18,,0.0,0.0,,"RT @satya_yadav: Just collaborate - a big message from #Horowitz for #APBMT #ISBMT and that‚Äôs the only way to improve outcomes 

@CIBMTR  h‚Ä¶",en,0.0,2195.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,13.0,3.0,https://twitter.com/marrow/statuses/1231597342836523011,0.0,0.0,,0.0,0.0,0.0,3.0,13.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,"RT @satya_yadav: Just collaborate - a big message from #Horowitz for #APBMT #ISBMT and that‚Äôs the only way to improve outcomes 

@CIBMTR  h‚Ä¶",false
Transplant_Doc,Stem Cell Transplant physician and clinical researcher at MD Anderson Cancer Center; special interest in myeloma. Opinions expressed are my own,,,,2020-02-23 13:08:28+00:00,Muzaffar Qazilbash,http://twitter.com/,25.0,,1.231566496406569e+18,,0.0,0.0,,RT @DrMiguelPerales: Congratulations to David Avigan @ninashah33 David Chung for leading this important @BMTCTN trial of a DC vaccine in pa‚Ä¶,en,0.0,5455.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,19.0,6.0,https://twitter.com/Transplant_Doc/statuses/1231566496406568961,0.0,0.0,,0.0,0.0,0.0,6.0,19.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @DrMiguelPerales: Congratulations to David Avigan @ninashah33 David Chung for leading this important @BMTCTN trial of a DC vaccine in pa‚Ä¶,true
EshaKaul1,"Mother , Hem/Oncologist, Bone Marrow Transplant Physician",,"Noida, India",,2020-02-21 21:47:59+00:00,Esha Kaul,http://twitter.com/,15.0,,1.230972461652611e+18,,0.0,0.0,,RT @hemedoc: #TCTM20 Uchida: single dose of anti-CD117 ADC allowed engraftment  of autologous gene-marked HSC without chemo. https://t.co/q‚Ä¶,en,0.0,532.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,11.0,4.0,https://twitter.com/EshaKaul1/statuses/1230972461652611072,0.0,0.0,,0.0,0.0,0.0,4.0,11.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @hemedoc: #TCTM20 Uchida: single dose of anti-CD117 ADC allowed engraftment  of autologous gene-marked HSC without chemo. https://t.co/q‚Ä¶,true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-02-21 20:42:19+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,1.0,,1.230955933112709e+18,,0.0,0.0,,#TCTM20 Wang: in response to Q: amongst the 30-40% who relapsed only 1 had CD19 Ag loss.,en,0.0,4813.0,,,0.0,,,Negative,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/hemedoc/statuses/1230955933112709121,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,1.0,0.0,#TCTM20 Wang: in response to Q: amongst the 30-40% who relapsed only 1 had CD19 Ag loss.,true
Jeremy_Ramdial,"Stem Cell Transplant and Cellular Therapy physician. Tweets, Retweets, and Likes are my own opinion and not medical advice. #HeforShe",,,,2020-02-21 00:10:17+00:00,Jeremy Ramdial,http://twitter.com/,24.0,,1.230645881407447e+18,,0.0,0.0,,RT @sghmd: The #PTCy platform now being tested in a randomized phase 3Ô∏è‚É£ study in @BMTCTN 1703 vs tac/MTX in RIC matched PBSCT had its begi‚Ä¶,en,0.0,312.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,20.0,4.0,https://twitter.com/Jeremy_Ramdial/statuses/1230645881407447047,0.0,0.0,,0.0,0.0,0.0,4.0,20.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,RT @sghmd: The #PTCy platform now being tested in a randomized phase 3Ô∏è‚É£ study in @BMTCTN 1703 vs tac/MTX in RIC matched PBSCT had its begi‚Ä¶,true
SethRotz,Pediatric Hematologist/Oncologist/BMT @Cleveland Clinic Children's; opinions my own,,"Cleveland, OH",,2020-02-21 14:06:27+00:00,seth rotz,http://twitter.com/,15.0,,1.2308563130407526e+18,,0.0,0.0,,"RT @satya_yadav: Powerful slides on #LateEffects of #BMT by #SmithaBhatia #TCTM20 

41% have long term morbidity 

26% non relapse mortalit‚Ä¶",en,0.0,416.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,11.0,4.0,https://twitter.com/SethRotz/statuses/1230856313040752641,0.0,0.0,,0.0,0.0,0.0,4.0,11.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @satya_yadav: Powerful slides on #LateEffects of #BMT by #SmithaBhatia #TCTM20 

41% have long term morbidity 

26% non relapse mortalit‚Ä¶",true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-02-21 21:55:26+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,3.0,,1.2309743329454694e+18,,0.0,0.0,,"#TCTM20 Popat: fractionated MAC Bu associated with 1yr PFS/OS 81%/85%, 1yr relapse risk 11% and 9% NRM. https://t.co/Zgz0HlbW7Q",en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/hemedoc/statuses/1230974332945469442,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"#TCTM20 Popat: fractionated MAC Bu associated with 1yr PFS/OS 81%/85%, 1yr relapse risk 11% and 9% NRM. https://t.co/Zgz0HlbW7Q",false
DrGoutomi,"MD , fellow in Pediatric hematology,oncology and bone marrow transplantation",,"Cardiff, Wales",,2020-02-21 16:48:39+00:00,Dr. Goutomi Chatterjee,http://twitter.com/,14.0,,1.2308971318099515e+18,,0.0,0.0,,"RT @satya_yadav: Poster 236 put up! 

#Thiotepa Based Conditioning for #Haploidentical Stem Cell Transplantation with Post Transplant Cyclo‚Ä¶",en,0.0,120.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,9.0,5.0,https://twitter.com/DrGoutomi/statuses/1230897131809951744,0.0,0.0,,0.0,0.0,0.0,5.0,9.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @satya_yadav: Poster 236 put up! 

#Thiotepa Based Conditioning for #Haploidentical Stem Cell Transplantation with Post Transplant Cyclo‚Ä¶",true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-02-21 16:14:11+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,1.0,,1.2308884585808443e+18,,0.0,0.0,,#TCTM20 Palaniyandi: GVL preserves in mice treated with defibrotide. A phase 3 study of defibrotide ppx for aGVHD p‚Ä¶ https://t.co/zCgtIfBZaT,en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/hemedoc/statuses/1230888458580844547,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,#TCTM20 Palaniyandi: GVL preserves in mice treated with defibrotide. A phase 3 study of defibrotide ppx for aGVHD p‚Ä¶ https://t.co/zCgtIfBZaT,true
DrJonnys,Consultant General Surgery . former doctor at (CAF)üëÆüèª‚Äç‚ôÇÔ∏è / Anatomist. #umanitoba #uwinnipeg @Harvard,,"Winnipeg, Manitoba",,2020-02-21 20:59:15+00:00,ùê∑ùëü. ùêΩùëú‚Ñéùëõùëõùë¶ ùëÜùë°ùëíùë§ùëéùëüùë°‚Å¶üá®üá¶‚Å©üåàüçÅ,http://twitter.com/,5.0,,1.2309601963291238e+18,,0.0,0.0,,"RT @hemedoc: #TCTM20 Walters: &gt;80% of RBCs continued the transgenic Hgb, leading to dramatic near eradication of veno-occlusive events afte‚Ä¶",en,0.0,5805.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,2.0,https://twitter.com/DrJonnys/statuses/1230960196329123840,0.0,0.0,,0.0,0.0,0.0,2.0,3.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @hemedoc: #TCTM20 Walters: &gt;80% of RBCs continued the transgenic Hgb, leading to dramatic near eradication of veno-occlusive events afte‚Ä¶",true
Ghoshomy,Medical Oncologist | Adult BMT/ Cell Therapy Physician-Scientist studying Immunotherapies in Hematologic Malignancies | Memorial Sloan Kettering Cancer Center,,"New York, USA",,2020-02-21 23:08:41+00:00,Arnab Ghosh,http://twitter.com/,31.0,,1.2309927700363264e+18,,0.0,0.0,,RT @PennisiMartina: congratssss @RShouval on your young investigator award from @ASTCT ! All the best for you! #TCTM20 https://t.co/kTr8ujz‚Ä¶,en,0.0,786.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,27.0,4.0,https://twitter.com/Ghoshomy/statuses/1230992770036326401,0.0,0.0,,0.0,0.0,0.0,4.0,27.0,False,False,False,False,True,Financial Performance,1.0,0.0,0.0,RT @PennisiMartina: congratssss @RShouval on your young investigator award from @ASTCT ! All the best for you! #TCTM20 https://t.co/kTr8ujz‚Ä¶,true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-02-21 13:36:36+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,3.0,,1.2308487992177705e+18,,0.0,0.0,,#TCTM20 Bhatia: morbidity burden after HCT. NRM crosses relapse related mortality at +20yrs without plateau (data i‚Ä¶ https://t.co/ElXwi8nLJv,en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/hemedoc/statuses/1230848799217770497,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,#TCTM20 Bhatia: morbidity burden after HCT. NRM crosses relapse related mortality at +20yrs without plateau (data i‚Ä¶ https://t.co/ElXwi8nLJv,true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-02-21 13:05:56+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,3.0,,1.2308410805533204e+18,,0.0,0.0,,"#TCTM20 Jagasia: abatacept gave PR in 44% in SR-cGVHD, reduction but not liberation from steroids. Phase 2 underway. https://t.co/1Rz9CBa8s1",en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/hemedoc/statuses/1230841080553320448,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"#TCTM20 Jagasia: abatacept gave PR in 44% in SR-cGVHD, reduction but not liberation from steroids. Phase 2 underway. https://t.co/1Rz9CBa8s1",false
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-02-21 20:55:30+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,2.0,,1.2309592528329114e+18,,0.0,0.0,,"#TCTM20 Walters: &gt;80% of RBCs continued the transgenic Hgb, leading to dramatic near eradication of veno-occlusive‚Ä¶ https://t.co/UIPsDWr1Di",en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/hemedoc/statuses/1230959252832911361,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"#TCTM20 Walters: &gt;80% of RBCs continued the transgenic Hgb, leading to dramatic near eradication of veno-occlusive‚Ä¶ https://t.co/UIPsDWr1Di",true
FranciscoMarty_,"Infectious diseases doctor who specializes in treating transplant and cancer patients, work at @BrighamWomens and @DanaFarber, @harvardmed.",,"Boston, MA",,2020-02-21 12:16:19+00:00,"Francisco Marty, MD",http://twitter.com/,12.0,,1.230828593531564e+18,,0.0,0.0,,RT @NCICancer: such an honour to share stage with the wonderful Cath Bollard and @FranciscoMarty_ in #TCTM20 session on infection after tra‚Ä¶,en,0.0,9990.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,2.0,https://twitter.com/FranciscoMarty_/statuses/1230828593531564032,0.0,0.0,,0.0,0.0,0.0,2.0,10.0,False,False,False,False,True,Side Effects,1.0,0.0,0.0,RT @NCICancer: such an honour to share stage with the wonderful Cath Bollard and @FranciscoMarty_ in #TCTM20 session on infection after tra‚Ä¶,true
EshaKaul1,"Mother , Hem/Oncologist, Bone Marrow Transplant Physician",,"Noida, India",,2020-02-20 16:55:12+00:00,Esha Kaul,http://twitter.com/,0.0,,1.2305363925031076e+18,,0.0,0.0,,"Epigenetic modulation post allo transplant ... HMAs, checkpoint inhibitors.,.. reducing relapse but risk of GVHD...‚Ä¶ https://t.co/sz6adWw2zy",en,0.0,532.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/EshaKaul1/statuses/1230536392503107584,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"Epigenetic modulation post allo transplant ... HMAs, checkpoint inhibitors.,.. reducing relapse but risk of GVHD...‚Ä¶ https://t.co/sz6adWw2zy",true
DrGoutomi,"MD , fellow in Pediatric hematology,oncology and bone marrow transplantation",,"Cardiff, Wales",,2020-02-20 09:23:21+00:00,Dr. Goutomi Chatterjee,http://twitter.com/,26.0,,1.2304226788481638e+18,,0.0,0.0,,"RT @satya_yadav: Revised diagnostic criteria for #VOD #TCTM20 #Cooke

Simplified so that early diagnosis can be made and appropriate treatm‚Ä¶",en,0.0,120.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,18.0,8.0,https://twitter.com/DrGoutomi/statuses/1230422678848163840,0.0,0.0,,0.0,0.0,0.0,8.0,18.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"RT @satya_yadav: Revised diagnostic criteria for #VOD #TCTM20 #Cooke

Simplified so that early diagnosis can be made and appropriate treatm‚Ä¶",true
sghmd,hematologist and bleeding-heart optimist üåÑ | clinical/translational #GVHD physician scientist | powerlifter üèãÔ∏è‚Äç‚ôÄÔ∏è | personal views |  physician ‚â† provider,,location:  in my head,,2020-02-20 14:08:06+00:00,Shernan Holtan MD,http://twitter.com/,4.0,,1.2304943385531884e+18,,0.0,0.0,,The #PTCy platform now being tested in a randomized phase 3Ô∏è‚É£ study in @BMTCTN 1703 vs tac/MTX in RIC matched PBSCT‚Ä¶ https://t.co/ckeemFAqRl,en,0.0,1463.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,4.0,https://twitter.com/sghmd/statuses/1230494338553188353,0.0,0.0,,0.0,0.0,0.0,4.0,0.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,The #PTCy platform now being tested in a randomized phase 3Ô∏è‚É£ study in @BMTCTN 1703 vs tac/MTX in RIC matched PBSCT‚Ä¶ https://t.co/ckeemFAqRl,true
Jaci_Joseph,BMT doc. tweet=own opinion; retweet‚â†endorsement,,"Memphis, TN",,2020-02-20 15:01:45+00:00,"Jacinth Joseph, MD",http://twitter.com/,0.0,,1.2305078390362808e+18,,0.0,0.0,,"@GreenbaumUri CB to be considered for some populations (eg. AYA due to better long term QOL and lower relapse, espe‚Ä¶ https://t.co/C2EKcEnWmv",en,0.0,55.0,,,0.0,GreenbaumUri,1.23048654950835e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/Jaci_Joseph/statuses/1230507839036280839,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"@GreenbaumUri CB to be considered for some populations (eg. AYA due to better long term QOL and lower relapse, espe‚Ä¶ https://t.co/C2EKcEnWmv",false
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-02-20 14:16:48+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,2.0,,1.2304965302112297e+18,,0.0,0.0,,"#TCTM20 Romee: GRFS better with marrow vs PB in haploHCT, with higher risk of relapse, though. MAC vs RIC condition‚Ä¶ https://t.co/9Itt8lH8NK",en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/hemedoc/statuses/1230496530211229702,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"#TCTM20 Romee: GRFS better with marrow vs PB in haploHCT, with higher risk of relapse, though. MAC vs RIC condition‚Ä¶ https://t.co/9Itt8lH8NK",true
hiendliu1,"Hematologist/Oncologist | Blood & Marrow Transplant | Medical Director, Apheresis Program @ Moffitt Cancer Center | Opinions my own",,"Tampa, FL",,2020-02-20 16:01:55+00:00,"Hien D. Liu, MD",http://twitter.com/,1.0,,1.2305229832461107e+18,,0.0,0.0,,excellent presentation by Dr Simone Minnie on role of memory T cells &amp; T cell exhaustion in myeloma relapse after t‚Ä¶ https://t.co/Af81KKkE21,en,0.0,874.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/hiendliu1/statuses/1230522983246110720,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Diagnosis Progression,1.0,0.0,0.0,excellent presentation by Dr Simone Minnie on role of memory T cells &amp; T cell exhaustion in myeloma relapse after t‚Ä¶ https://t.co/Af81KKkE21,true
FranciscoMarty_,"Infectious diseases doctor who specializes in treating transplant and cancer patients, work at @BrighamWomens and @DanaFarber, @harvardmed.",,"Boston, MA",,2020-02-20 16:47:15+00:00,"Francisco Marty, MD",http://twitter.com/,12.0,,1.2305343915390853e+18,,0.0,0.0,,RT @michyong2: @FranciscoMarty_ #TCTM20 Personalized infection risk in HSCT. Lots of personalized and humorous slides! Breath fungal signat‚Ä¶,en,0.0,9990.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,2.0,https://twitter.com/FranciscoMarty_/statuses/1230534391539085312,0.0,0.0,,0.0,0.0,0.0,2.0,10.0,False,False,False,False,True,Side Effects,1.0,0.0,0.0,RT @michyong2: @FranciscoMarty_ #TCTM20 Personalized infection risk in HSCT. Lots of personalized and humorous slides! Breath fungal signat‚Ä¶,true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-02-20 16:36:14+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,3.0,,1.2305316168854118e+18,,0.0,0.0,,"#TCTM20 Vago: genomic and non-genomic mechanisms of HLA loss in AML relapse. Genomic: Loss if heterozygosity, opera‚Ä¶ https://t.co/amkmJps5Fo",en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/hemedoc/statuses/1230531616885411845,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"#TCTM20 Vago: genomic and non-genomic mechanisms of HLA loss in AML relapse. Genomic: Loss if heterozygosity, opera‚Ä¶ https://t.co/amkmJps5Fo",true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-02-20 15:32:25+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,1.0,,1.2305155582879212e+18,,0.0,0.0,,#TCTM20 Vago: treatment options for relapse after alloHCT for AML https://t.co/yixLKxZARi,en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/hemedoc/statuses/1230515558287921153,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,#TCTM20 Vago: treatment options for relapse after alloHCT for AML https://t.co/yixLKxZARi,true
michyong2,"Infectious diseases physician, CMV & viral infections, Clinician researcher, @NCICancer @PeterMacCC @TheRMH @TheDohertyInst",,"Melbourne, Victoria",,2020-02-20 16:01:18+00:00,Michelle Yong,http://twitter.com/,1.0,,1.2305228267188388e+18,,0.0,0.0,,@monicaslavin @NCICancer #TCTM20 Late infection-related mortality is still high post-HSCT. 59% pathogen unknown. Hi‚Ä¶ https://t.co/wekkni5CzA,en,0.0,386.0,,,0.0,monicaslavin,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/michyong2/statuses/1230522826718838785,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,@monicaslavin @NCICancer #TCTM20 Late infection-related mortality is still high post-HSCT. 59% pathogen unknown. Hi‚Ä¶ https://t.co/wekkni5CzA,false
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-02-20 16:59:03+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,2.0,,1.2305373615257887e+18,,0.0,0.0,,#TCTM20 Vago: T cell exhaustion markers upregukates in effective cells and memory T cell compartments at relapse. https://t.co/RpELcZ2JIp,en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/hemedoc/statuses/1230537361525788680,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,#TCTM20 Vago: T cell exhaustion markers upregukates in effective cells and memory T cell compartments at relapse. https://t.co/RpELcZ2JIp,true
FranciscoMarty_,"Infectious diseases doctor who specializes in treating transplant and cancer patients, work at @BrighamWomens and @DanaFarber, @harvardmed.",,"Boston, MA",,2020-02-20 16:46:23+00:00,"Francisco Marty, MD",http://twitter.com/,7.0,,1.2305341711242117e+18,,0.0,0.0,,RT @PergamIC: Dr Bollard viral specific T-cells are more diverse then from infection #TCTM20 https://t.co/CMNYAfO2hr,en,0.0,9990.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,2.0,https://twitter.com/FranciscoMarty_/statuses/1230534171124211714,0.0,0.0,,0.0,0.0,0.0,2.0,5.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,RT @PergamIC: Dr Bollard viral specific T-cells are more diverse then from infection #TCTM20 https://t.co/CMNYAfO2hr,true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-02-20 14:51:40+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,1.0,,1.2305053031348756e+18,,0.0,0.0,,"#TCTM20 Milano: At centers with high cord expertise, outcomes appears similar to conventional sib/MUD alloHCT, and‚Ä¶ https://t.co/ZoGOZsVbUA",en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/hemedoc/statuses/1230505303134875653,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Thought Leadership,0.0,0.0,1.0,"#TCTM20 Milano: At centers with high cord expertise, outcomes appears similar to conventional sib/MUD alloHCT, and‚Ä¶ https://t.co/ZoGOZsVbUA",true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-02-20 16:30:15+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,12.0,,1.2305301107485942e+18,,0.0,0.0,,"RT @GomezDLeonMD: Compared to PTCy haplos, MUDs/UCB increase short-term out of pocket costs x2-3 üí∞when donor cells not covered #TCTM20 #BMT‚Ä¶",en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,2.0,https://twitter.com/hemedoc/statuses/1230530110748594187,0.0,0.0,,0.0,0.0,0.0,2.0,10.0,False,False,False,False,True,Insurance Coverage,0.0,0.0,1.0,"RT @GomezDLeonMD: Compared to PTCy haplos, MUDs/UCB increase short-term out of pocket costs x2-3 üí∞when donor cells not covered #TCTM20 #BMT‚Ä¶",true
EshaKaul1,"Mother , Hem/Oncologist, Bone Marrow Transplant Physician",,"Noida, India",,2020-02-20 15:56:49+00:00,Esha Kaul,http://twitter.com/,0.0,,1.2305216979184435e+18,,0.0,0.0,,So in the real world haplo results though good haven‚Äôt quite caught up with MSD or 8/8 MUD.... ? Late infections...‚Ä¶ https://t.co/sxI8COIHKp,en,0.0,532.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/EshaKaul1/statuses/1230521697918443522,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,So in the real world haplo results though good haven‚Äôt quite caught up with MSD or 8/8 MUD.... ? Late infections...‚Ä¶ https://t.co/sxI8COIHKp,true
saadghafoor,Pediatric Intensivist| sub specialize in Onc-Critical Care| Try to analyze problems from an open and enlightened perspective| opinions are my own,,USA,,2020-02-20 01:50:47+00:00,Saad Ghafoor,http://twitter.com/,48.0,,1.230308785463419e+18,,0.0,0.0,,RT @AimeeTalleurMD: Updating VOD diagnostic criteria and grading - hopefully will lead to better patient outcomes through earlier recogniti‚Ä¶,en,0.0,154.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,35.0,13.0,https://twitter.com/saadghafoor/statuses/1230308785463418880,0.0,0.0,,0.0,0.0,0.0,13.0,35.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @AimeeTalleurMD: Updating VOD diagnostic criteria and grading - hopefully will lead to better patient outcomes through earlier recogniti‚Ä¶,false
drjgauthier,"MD, MSc, Assistant Professor @fredhutch @UW focused on #CARTcell #immunotherapy #tcellrx 
Interests also include #rstats #bmtsm #epitwitter #bayes",,"Seattle, WA",,2020-02-20 00:48:43+00:00,Jordan Gauthier,http://twitter.com/,10.0,,1.2302931662820065e+18,,0.0,0.0,,"RT @AML_Hub: CONGRESS | #TCTM20 | Bart L. Scott, @fredhutch, presents long-term FU from the BMT CTN 0901 (MAvRIC)  phase III trial of MAC v‚Ä¶",en,0.0,3295.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,6.0,https://twitter.com/drjgauthier/statuses/1230293166282006533,0.0,0.0,,0.0,0.0,0.0,6.0,4.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"RT @AML_Hub: CONGRESS | #TCTM20 | Bart L. Scott, @fredhutch, presents long-term FU from the BMT CTN 0901 (MAvRIC)  phase III trial of MAC v‚Ä¶",true
VivekSubbiah,"Oncologist | Associate Prof | Executive Director-Research, MD Anderson Cancer Network | Medical Director, Clinical Center for Targeted Therapy. Tweets = my own.",,"Houston, TX",,2020-02-20 03:21:33+00:00,"Vivek Subbiah, MD",http://twitter.com/,6.0,,1.2303316288300442e+18,,0.0,0.0,,RT @kansagraMD: Q# How do we diagnose CRS and ICANS ? @ASTCT Consensus guidelines has since been published with great input from @drkomandu‚Ä¶,en,0.0,8354.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,3.0,https://twitter.com/VivekSubbiah/statuses/1230331628830044160,0.0,0.0,,0.0,0.0,0.0,3.0,3.0,False,False,False,False,True,Diagnostic Tools,1.0,0.0,0.0,RT @kansagraMD: Q# How do we diagnose CRS and ICANS ? @ASTCT Consensus guidelines has since been published with great input from @drkomandu‚Ä¶,true
michyong2,"Infectious diseases physician, CMV & viral infections, Clinician researcher, @NCICancer @PeterMacCC @TheRMH @TheDohertyInst",,"Melbourne, Victoria",,2020-02-20 16:27:50+00:00,Michelle Yong,http://twitter.com/,4.0,,1.230529505669845e+18,,0.0,0.0,,RT @michyong2: @monicaslavin @NCICancer #TCTM20 Late infection-related mortality is still high post-HSCT. 59% pathogen unknown. High risk h‚Ä¶,en,0.0,386.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,1.0,https://twitter.com/michyong2/statuses/1230529505669844994,0.0,0.0,,0.0,0.0,0.0,1.0,3.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,RT @michyong2: @monicaslavin @NCICancer #TCTM20 Late infection-related mortality is still high post-HSCT. 59% pathogen unknown. High risk h‚Ä¶,true
JulioCZuniga1,MD @unicahonduras | MPH Epidemiology @umichsph | Proud Honduran üá≠üá≥ and Latinx | Jazz üé∑ | MTB üöµ‚Äç‚ôÄÔ∏è | RT üö´ Endorsements,,"Ann Arbor, MI ",,2020-02-20 23:20:19+00:00,Julio C. Zuniga-Moya,http://twitter.com/,12.0,,1.2306333092832666e+18,,0.0,0.0,,RT @PergamIC: Azole prophylaxis = more breakthrough infections with resistant fungi (including R Aspergillus like A ustus) - pressure of az‚Ä¶,en,0.0,932.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,9.0,3.0,https://twitter.com/JulioCZuniga1/statuses/1230633309283266560,0.0,0.0,,0.0,0.0,0.0,3.0,9.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,RT @PergamIC: Azole prophylaxis = more breakthrough infections with resistant fungi (including R Aspergillus like A ustus) - pressure of az‚Ä¶,true
LukeMtjoy,Hematologist and transplant physician at Colorado Blood Cancer Institute. Former hem/onc fellow @MayoClinic AZ. view and opinions are my own,,"Denver, CO",,2020-02-20 02:37:05+00:00,LukeMtjoy,http://twitter.com/,19.0,,1.2303204395552315e+18,,0.0,0.0,,"RT @hemedoc: #TCTM20 Scott: MAC outcomes not affected by NGS positivity prior to alloHCT, but has large impact on relapse after RIC. https:‚Ä¶",en,0.0,137.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,9.0,https://twitter.com/LukeMtjoy/statuses/1230320439555231744,0.0,0.0,,0.0,0.0,0.0,9.0,10.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @hemedoc: #TCTM20 Scott: MAC outcomes not affected by NGS positivity prior to alloHCT, but has large impact on relapse after RIC. https:‚Ä¶",true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-02-20 14:29:22+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,3.0,,1.2304996926702223e+18,,0.0,0.0,,#TCTM20 Romee: Mem-like NK infusion for MRD+ AML being investigated. Massive expansion of these cells in vivo has b‚Ä¶ https://t.co/fPZpe3SHYT,en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/hemedoc/statuses/1230499692670222340,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,#TCTM20 Romee: Mem-like NK infusion for MRD+ AML being investigated. Massive expansion of these cells in vivo has b‚Ä¶ https://t.co/fPZpe3SHYT,false
EshaKaul1,"Mother , Hem/Oncologist, Bone Marrow Transplant Physician",,"Noida, India",,2020-02-20 16:15:24+00:00,Esha Kaul,http://twitter.com/,40.0,,1.2305263743912264e+18,,0.0,0.0,,RT @hemedoc: #TCTM20 Christopher: mHC class II downregulation observed in 30-50% of AML relapses after alloHCT. May be reversible via treat‚Ä¶,en,0.0,532.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,26.0,14.0,https://twitter.com/EshaKaul1/statuses/1230526374391226374,0.0,0.0,,0.0,0.0,0.0,14.0,26.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @hemedoc: #TCTM20 Christopher: mHC class II downregulation observed in 30-50% of AML relapses after alloHCT. May be reversible via treat‚Ä¶,true
FranciscoMarty_,"Infectious diseases doctor who specializes in treating transplant and cancer patients, work at @BrighamWomens and @DanaFarber, @harvardmed.",,"Boston, MA",,2020-02-20 15:21:58+00:00,"Francisco Marty, MD",http://twitter.com/,47.0,,1.2305129283418726e+18,,0.0,0.0,,"RT @FranciscoMarty_: Hope to see many of you at #TCTM20 Thursday 20 Feb 10:30 am for a amazing session on #Infection after #Transplant, whe‚Ä¶",en,0.0,9990.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,37.0,10.0,https://twitter.com/FranciscoMarty_/statuses/1230512928341872641,0.0,0.0,,0.0,0.0,0.0,10.0,37.0,False,False,False,False,True,Side Effects,1.0,0.0,0.0,"RT @FranciscoMarty_: Hope to see many of you at #TCTM20 Thursday 20 Feb 10:30 am for a amazing session on #Infection after #Transplant, whe‚Ä¶",true
AliyahBaluchTID,üè© #TxID #IDMedEd #MedEd #IDTwitter üè• physician leadership & ‚úàÔ∏èüèãüèº‚Äç‚ôÄÔ∏èüßó‚Äç‚ôÄÔ∏èüë©‚Äç‚öïÔ∏èTweets are my opinion üö´ med advice. Instagram: aliyahbaluchtid,,,,2020-02-22 12:37:25+00:00,Aliyah,http://twitter.com/,0.0,,1.2311962936047616e+18,,0.0,0.0,,Getting my nerd on learning about TA-TMA #InternalMedicine #infectiousdiseases #TxID #BMTCI #TCTM20 https://t.co/N4ySEi2RCN,en,0.0,165.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/AliyahBaluchTID/statuses/1231196293604761600,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,Getting my nerd on learning about TA-TMA #InternalMedicine #infectiousdiseases #TxID #BMTCI #TCTM20 https://t.co/N4ySEi2RCN,true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-02-22 18:29:38+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,1.0,,1.2312849312398295e+18,,0.0,0.0,,#TCTM20 Foran: Iomab-B will also be investigated as lymphodeplerion prior to CAR-T. https://t.co/WNkSWXOVX0,en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/hemedoc/statuses/1231284931239829509,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,#TCTM20 Foran: Iomab-B will also be investigated as lymphodeplerion prior to CAR-T. https://t.co/WNkSWXOVX0,true
Transplant_Doc,Stem Cell Transplant physician and clinical researcher at MD Anderson Cancer Center; special interest in myeloma. Opinions expressed are my own,,,,2020-02-22 10:40:02+00:00,Muzaffar Qazilbash,http://twitter.com/,41.0,,1.2311667526183608e+18,,0.0,0.0,,"RT @DrRenatoCunha: Dr Wang - KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) with Relapsed/Refracto‚Ä¶",en,0.0,5455.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,33.0,8.0,https://twitter.com/Transplant_Doc/statuses/1231166752618360832,0.0,0.0,,0.0,0.0,0.0,8.0,33.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @DrRenatoCunha: Dr Wang - KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) with Relapsed/Refracto‚Ä¶",true
drjgauthier,"MD, MSc, Assistant Professor @fredhutch @UW focused on #CARTcell #immunotherapy #tcellrx 
Interests also include #rstats #bmtsm #epitwitter #bayes",,"Seattle, WA",,2020-02-22 14:43:41+00:00,Jordan Gauthier,http://twitter.com/,12.0,,1.23122806807484e+18,,0.0,0.0,,RT @hemedoc: #TCTM20 Chen: damage to intestinal stem cell niche at the base of the crypts by infiltrating T cells is mediated by a4b7 expre‚Ä¶,en,0.0,3295.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,8.0,4.0,https://twitter.com/drjgauthier/statuses/1231228068074840064,0.0,0.0,,0.0,0.0,0.0,4.0,8.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @hemedoc: #TCTM20 Chen: damage to intestinal stem cell niche at the base of the crypts by infiltrating T cells is mediated by a4b7 expre‚Ä¶,false
CBCIDocs,Thoughts and perspectives from the hematology and transplant physicians at Colorado Blood Cancer Institute @ColoradoBlood @SarahCannonDocs @PresStLukesDenv,,"Denver, CO",,2020-02-22 21:30:26+00:00,CBCI,http://twitter.com/,0.0,,1.2313304320352502e+18,,0.0,0.0,,Nice depiction of infections to look out for post-transplant! #CBCI #ColoradoBlood #CBCIDocs #TCTM20 https://t.co/g3JbTLwbcv,en,0.0,782.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/CBCIDocs/statuses/1231330432035250176,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Side Effects,1.0,0.0,0.0,Nice depiction of infections to look out for post-transplant! #CBCI #ColoradoBlood #CBCIDocs #TCTM20 https://t.co/g3JbTLwbcv,true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-02-22 18:18:27+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,2.0,,1.2312821192231854e+18,,0.0,0.0,,#TCTM20 Foran: data leading to reapproval of gemtuzumab and nice review of data regarding risk of VOD. At lower dos‚Ä¶ https://t.co/honndojdSL,en,0.0,4813.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/hemedoc/statuses/1231282119223185408,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,#TCTM20 Foran: data leading to reapproval of gemtuzumab and nice review of data regarding risk of VOD. At lower dos‚Ä¶ https://t.co/honndojdSL,true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-02-22 14:41:57+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,4.0,,1.2312276338427617e+18,,0.0,0.0,,#TCTM20 Chen: damage to intestinal stem cell niche at the base of the crypts by infiltrating T cells is mediated by‚Ä¶ https://t.co/TpuCTnjEDP,en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,4.0,https://twitter.com/hemedoc/statuses/1231227633842761735,0.0,0.0,,0.0,0.0,0.0,4.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,#TCTM20 Chen: damage to intestinal stem cell niche at the base of the crypts by infiltrating T cells is mediated by‚Ä¶ https://t.co/TpuCTnjEDP,true
ajaynephro,"Nephrologist, transplant physician. Entrepreneur with a multi-speciality clinic - Vishwasth Clinic",,"Noida, India",,2020-02-22 19:45:40+00:00,Ajay Kher,http://twitter.com/,21.0,,1.2313040675251446e+18,,0.0,0.0,,RT @EshaKaul1: Presenting our experience of treating children with Hepatitis C with DAAs concurrently with transplant today at #TCTM20 http‚Ä¶,en,0.0,309.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,17.0,4.0,https://twitter.com/ajaynephro/statuses/1231304067525144576,0.0,0.0,,0.0,0.0,0.0,4.0,17.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,RT @EshaKaul1: Presenting our experience of treating children with Hepatitis C with DAAs concurrently with transplant today at #TCTM20 http‚Ä¶,true
VijayKher8,"Nephrologist .clinician -teacher,set up departments at SGPGI,Apollo,Fortis ,Medanta Loves and lives life.music and cricket other interests",,"Sector 39, Noida",,2020-02-22 16:54:47+00:00,Vijay Kher,http://twitter.com/,21.0,,1.2312610638338458e+18,,0.0,0.0,,RT @EshaKaul1: Presenting our experience of treating children with Hepatitis C with DAAs concurrently with transplant today at #TCTM20 http‚Ä¶,en,0.0,2475.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,17.0,4.0,https://twitter.com/VijayKher8/statuses/1231261063833845765,0.0,0.0,,0.0,0.0,0.0,4.0,17.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,RT @EshaKaul1: Presenting our experience of treating children with Hepatitis C with DAAs concurrently with transplant today at #TCTM20 http‚Ä¶,true
lab_rezvani,Lab of NK Cell Immunology and Immunotherapy in Cancer- MD Anderson Cancer Center @mdandersonnews,,"Houston, TX",,2020-02-22 03:41:24+00:00,Katy Rezvani & Lab,http://twitter.com/,14.0,,1.2310614022631956e+18,,0.0,0.0,,Congratulations to Dr. Uday Popat from the Department of Stem Cell Transplant @CancerMedMDA for being awarded the b‚Ä¶ https://t.co/pamJC44cG3,en,0.0,1456.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,14.0,https://twitter.com/lab_rezvani/statuses/1231061402263195649,0.0,0.0,,0.0,0.0,0.0,14.0,0.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,Congratulations to Dr. Uday Popat from the Department of Stem Cell Transplant @CancerMedMDA for being awarded the b‚Ä¶ https://t.co/pamJC44cG3,false
josudelafuente,"Haematologist, red cell disorders and marrow failure. Working towards definitive cure: #BMT #genetherapy. @ImperialNHS @ImperialImmuno @TheEBMT @ApothecariesLDN",,"London, England",,2020-02-22 12:28:54+00:00,Josu de la Fuente,http://twitter.com/,3.0,,1.2311941486880563e+18,,0.0,0.0,,#VCGConsortium2 breakfast meeting at #TCTM20 @ImperialNHS @VUMCHemOnc @aljurf100 @satya_yadav @hmgcoa2‚Ä¶ https://t.co/HYnHTxBOR1,en,0.0,492.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/josudelafuente/statuses/1231194148688056320,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,#VCGConsortium2 breakfast meeting at #TCTM20 @ImperialNHS @VUMCHemOnc @aljurf100 @satya_yadav @hmgcoa2‚Ä¶ https://t.co/HYnHTxBOR1,true
adrianabello,"pediatrician, pediatric hematologyst, mother adribello@hotmail.com",,,,2020-02-21 12:27:56+00:00,Adriana Bello,http://twitter.com/,1.0,,1.2308315184419676e+18,,0.0,0.0,,RT @hemedoc: #TCTM20 Ferrara: MAGIC biomarkers can be considered a ‚Äúliquid biopsy‚Äù to assess tissue damage occurring in setting of GVHD. Bi‚Ä¶,en,0.0,1968.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/adrianabello/statuses/1230831518441967616,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @hemedoc: #TCTM20 Ferrara: MAGIC biomarkers can be considered a ‚Äúliquid biopsy‚Äù to assess tissue damage occurring in setting of GVHD. Bi‚Ä¶,true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-01-03 22:47:32+00:00,Oncology Tube,http://twitter.com/,0.0,,1.2132304400954204e+18,,0.0,0.0,,"A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia #ASH19 @CleClinicMD: Aaron Gerds,‚Ä¶ https://t.co/KpqeaefnxX",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1213230440095420416,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia #ASH19 @CleClinicMD: Aaron Gerds,‚Ä¶ https://t.co/KpqeaefnxX",true
KristinCanavera,Pediatric Psychologist in #childhood cancer and #PedsICU critical illness @stjuderesearch; studying Bioethics @Loyolabioethics. Thoughts are my own.,,"Memphis, TN",,2020-01-13 05:31:30+00:00,"Dr. Kristin Canavera, PhD",http://twitter.com/,32.0,,1.2165935912268472e+18,,0.0,0.0,,RT @StJudeResearch: Study shows Venetoclax chemo combination is well-tolerated and effective in kids and young adults with relapsed or refr‚Ä¶,en,0.0,196.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,23.0,9.0,https://twitter.com/KristinCanavera/statuses/1216593591226847233,0.0,0.0,,0.0,0.0,0.0,9.0,23.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @StJudeResearch: Study shows Venetoclax chemo combination is well-tolerated and effective in kids and young adults with relapsed or refr‚Ä¶,true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-01-15 05:57:02+00:00,Oncology Tube,http://twitter.com/,0.0,,1.2173247961128591e+18,,0.0,0.0,,"MANIFEST, a Phase 2 Study of CPI-0610 @MountSinaiNYC #ASH #ASH19: John Mascarenhas, MD of @MountSinaiNYC discusses‚Ä¶ https://t.co/h1DAxwVVNd",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1217324796112859136,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"MANIFEST, a Phase 2 Study of CPI-0610 @MountSinaiNYC #ASH #ASH19: John Mascarenhas, MD of @MountSinaiNYC discusses‚Ä¶ https://t.co/h1DAxwVVNd",true
jerry_riehl,I enjoy learning and helping oncologists and urologists gain access to targeted therapy and immuno-therapy options for advanced cancer patients.,,"St. Louis, MO",,2020-01-09 05:29:28+00:00,Jerry Riehl,http://twitter.com/,39.0,,1.2151435310289183e+18,,0.0,0.0,,RT @LLSusa: Dr Amy Burd @LLSusa patients who elected targeted therapy via @LLSusa #BeatAML master trial had lower early death rate and supe‚Ä¶,en,0.0,121.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,31.0,8.0,https://twitter.com/jerry_riehl/statuses/1215143531028918272,0.0,0.0,,0.0,0.0,0.0,8.0,31.0,False,False,False,False,True,Disease Advocacy,0.0,0.0,1.0,RT @LLSusa: Dr Amy Burd @LLSusa patients who elected targeted therapy via @LLSusa #BeatAML master trial had lower early death rate and supe‚Ä¶,false
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-01-19 18:25:33+00:00,Oncology Tube,http://twitter.com/,0.0,,1.2189627153575404e+18,,0.0,0.0,,"Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL #ASH19 #ASH: John Seymour, PhD of @PeterMacCC discusse‚Ä¶ https://t.co/1JVQFyIyNh",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1218962715357540352,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL #ASH19 #ASH: John Seymour, PhD of @PeterMacCC discusse‚Ä¶ https://t.co/1JVQFyIyNh",true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-01-19 15:53:33+00:00,Oncology Tube,http://twitter.com/,0.0,,1.2189244654483743e+18,,0.0,0.0,,Follow-Up in Relapsed/Refractory MCL #ASH19: Professor Simon Rule of Plymouth University Medical School discusses l‚Ä¶ https://t.co/3kw7ngjcPE,en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1218924465448374277,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,Follow-Up in Relapsed/Refractory MCL #ASH19: Professor Simon Rule of Plymouth University Medical School discusses l‚Ä¶ https://t.co/3kw7ngjcPE,true
AKeyzner,"hematologist #BMT #leuksm physician ‚â†provider immigrant, opinions my own, likes‚â†endorsement",,,,2020-02-01 14:00:56+00:00,Alla Keyzner,http://twitter.com/,72.0,,1.2236071667933962e+18,,0.0,0.0,,"RT @7eyeblink: Anti infective prophylaxis EBMT recommendations after CAR-T Cell infusion, now in #CART20 #CART2020 #CARTMeeting https://t.c‚Ä¶",en,0.0,157.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,50.0,22.0,https://twitter.com/AKeyzner/statuses/1223607166793396224,0.0,0.0,,0.0,0.0,0.0,22.0,50.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"RT @7eyeblink: Anti infective prophylaxis EBMT recommendations after CAR-T Cell infusion, now in #CART20 #CART2020 #CARTMeeting https://t.c‚Ä¶",true
7eyeblink,MD. Hematolog√≠a cl√≠nica. √Åreas de inter√©s: CAR T y BMT. Tambi√©n escribo muchas tonter√≠as por el medio. (Opinions are mine)üìç A Coru√±a .,,Jam√°s en una ciudad sin playa.,,2020-02-01 10:31:35+00:00,Carolina Mart√≠nez,http://twitter.com/,22.0,,1.2235544797332562e+18,,0.0,0.0,,"Anti infective prophylaxis EBMT recommendations after CAR-T Cell infusion, now in #CART20 #CART2020 #CARTMeeting https://t.co/hmQ4RGE0aH",en,0.0,2163.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,22.0,https://twitter.com/7eyeblink/statuses/1223554479733256193,0.0,0.0,,0.0,0.0,0.0,22.0,0.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"Anti infective prophylaxis EBMT recommendations after CAR-T Cell infusion, now in #CART20 #CART2020 #CARTMeeting https://t.co/hmQ4RGE0aH",true
GruppSteve,"#CARTCell expert, bone marrow transplanter, pediatric oncologist, husband to my vastly better half. All opinions my own, not an investor. RT not=endorsementüåäüåä",,"Philadelphia, PA",,2020-02-01 15:52:08+00:00,Stephan Grupp MD PhD,http://twitter.com/,22.0,,1.2236351508163666e+18,,0.0,0.0,,"RT @BertrandBio: Manufacturing of CAR T cell in an industrial setting #CART2020

@BLLPHD UPenn/US - Academia-Industry partnering to develop‚Ä¶",en,0.0,2534.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,15.0,7.0,https://twitter.com/GruppSteve/statuses/1223635150816366592,0.0,0.0,,0.0,0.0,0.0,7.0,15.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,"RT @BertrandBio: Manufacturing of CAR T cell in an industrial setting #CART2020

@BLLPHD UPenn/US - Academia-Industry partnering to develop‚Ä¶",true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-01-19 20:38:33+00:00,Oncology Tube,http://twitter.com/,0.0,,1.218996185664385e+18,,0.0,0.0,,"MAIA Study Update #ASH19: Nizar Bahlis, MD of University of Calgary discusses patients with newly diagnosed multipl‚Ä¶ https://t.co/cNznrY0ov1",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1218996185664385024,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"MAIA Study Update #ASH19: Nizar Bahlis, MD of University of Calgary discusses patients with newly diagnosed multipl‚Ä¶ https://t.co/cNznrY0ov1",false
FranciscoMarty_,"Infectious diseases doctor who specializes in treating transplant and cancer patients, work at @BrighamWomens and @DanaFarber, @harvardmed.",,"Boston, MA",,2020-02-01 12:37:27+00:00,"Francisco Marty, MD",http://twitter.com/,72.0,,1.223586156710957e+18,,0.0,0.0,,"RT @7eyeblink: Anti infective prophylaxis EBMT recommendations after CAR-T Cell infusion, now in #CART20 #CART2020 #CARTMeeting https://t.c‚Ä¶",en,0.0,9990.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,50.0,22.0,https://twitter.com/FranciscoMarty_/statuses/1223586156710957057,0.0,0.0,,0.0,0.0,0.0,22.0,50.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"RT @7eyeblink: Anti infective prophylaxis EBMT recommendations after CAR-T Cell infusion, now in #CART20 #CART2020 #CARTMeeting https://t.c‚Ä¶",true
akbar_romana,Haematologist,,,,2020-02-01 13:54:12+00:00,Dr Romana Akbar,http://twitter.com/,11.0,,1.2236054729949594e+18,,0.0,0.0,,"RT @MM_Hub: CONGRESS | #CARTmeeting20 | Marie Jos√© Kersten, @amsterdamumc, discusses the management of CAR T therapy side effects in differ‚Ä¶",en,0.0,121.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,7.0,https://twitter.com/akbar_romana/statuses/1223605472994959360,0.0,0.0,,0.0,0.0,0.0,7.0,4.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"RT @MM_Hub: CONGRESS | #CARTmeeting20 | Marie Jos√© Kersten, @amsterdamumc, discusses the management of CAR T therapy side effects in differ‚Ä¶",true
ANZoncofert,The Future Fertility research group led by Dr. Anazodo undertakes research and advocacy about reproductive concerns of cancer patients #blackwomeninmedicine,,Sydney,,2020-01-25 19:07:19+00:00,Dr Antoinette Anazodo MD PhD (Future Fertility),http://twitter.com/,10.0,,1.2211475542109716e+18,,0.0,0.0,,RT @ASCOPost: Blinatumomab Outperforms Chemotherapy as Post-Reinduction Consolidation Therapy in Younger Patients With B-Cell ALL https://t‚Ä¶,en,0.0,864.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,7.0,3.0,https://twitter.com/ANZoncofert/statuses/1221147554210971650,0.0,0.0,,0.0,0.0,0.0,3.0,7.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @ASCOPost: Blinatumomab Outperforms Chemotherapy as Post-Reinduction Consolidation Therapy in Younger Patients With B-Cell ALL https://t‚Ä¶,true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-01-28 05:46:02+00:00,Oncology Tube,http://twitter.com/,1.0,,1.222033069810438e+18,,0.0,0.0,,"Phase 2 study of Frontline Brentuximab Vedotin #ASH19 @TheUSONetwork: Christopher Yasenchak, MD of @TheUSONetwork d‚Ä¶ https://t.co/u9aKasEUPQ",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/oncologytube/statuses/1222033069810438144,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"Phase 2 study of Frontline Brentuximab Vedotin #ASH19 @TheUSONetwork: Christopher Yasenchak, MD of @TheUSONetwork d‚Ä¶ https://t.co/u9aKasEUPQ",true
CancerMedMDA,"Mission of largest MD Anderson division is to eliminate cancer via best, integrated patient care, research & education programs. Appts.available 877-632-6789.",,"Houston, TX",,2020-01-28 20:49:51+00:00,Cancer Medicine,http://twitter.com/,9.0,,1.2222605213632635e+18,,0.0,0.0,,"RT @oncologytube: CAR T-cell therapy effective for relapsed/refractory MCL #ASH19 @michaelwangmd @MDAndersonNews: Michael Wang, MD @michael‚Ä¶",en,0.0,6443.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,3.0,https://twitter.com/CancerMedMDA/statuses/1222260521363263488,0.0,0.0,,0.0,0.0,0.0,3.0,6.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @oncologytube: CAR T-cell therapy effective for relapsed/refractory MCL #ASH19 @michaelwangmd @MDAndersonNews: Michael Wang, MD @michael‚Ä¶",true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-01-28 20:46:03+00:00,Oncology Tube,http://twitter.com/,3.0,,1.2222595657034834e+18,,0.0,0.0,,"CAR T-cell therapy effective for relapsed/refractory MCL #ASH19 @michaelwangmd @MDAndersonNews: Michael Wang, MD‚Ä¶ https://t.co/axwmjIOBR0",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/oncologytube/statuses/1222259565703483392,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"CAR T-cell therapy effective for relapsed/refractory MCL #ASH19 @michaelwangmd @MDAndersonNews: Michael Wang, MD‚Ä¶ https://t.co/axwmjIOBR0",false
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-01-25 19:07:33+00:00,Oncology Tube,http://twitter.com/,1.0,,1.2211476130234614e+18,,0.0,0.0,,"Update on Phase I REGN1979 #ASH19 #ASH @RutgersCancer: Rajat Bannerji, MD of @RutgersCancer provides an update on P‚Ä¶ https://t.co/B4z3j5Hvud",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/oncologytube/statuses/1221147613023461376,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"Update on Phase I REGN1979 #ASH19 #ASH @RutgersCancer: Rajat Bannerji, MD of @RutgersCancer provides an update on P‚Ä¶ https://t.co/B4z3j5Hvud",true
DachiRashid2,"Senior Medical Research and Consultancy, C.E.O.Dachi Group of Companies, Beekeeping Research and Apicuture Consultancy, Medical Psychologist,Bio-Pharmacetical",,"Dar es Salaam, Tanzania",,2020-02-02 05:23:06+00:00,Dachi Rashidi,http://twitter.com/,72.0,,1.2238392367108997e+18,,0.0,0.0,,"RT @7eyeblink: Anti infective prophylaxis EBMT recommendations after CAR-T Cell infusion, now in #CART20 #CART2020 #CARTMeeting https://t.c‚Ä¶",en,0.0,1308.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,50.0,22.0,https://twitter.com/DachiRashid2/statuses/1223839236710899713,0.0,0.0,,0.0,0.0,0.0,22.0,50.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"RT @7eyeblink: Anti infective prophylaxis EBMT recommendations after CAR-T Cell infusion, now in #CART20 #CART2020 #CARTMeeting https://t.c‚Ä¶",true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-01-23 04:19:04+00:00,Oncology Tube,http://twitter.com/,0.0,,1.220199241718481e+18,,0.0,0.0,,"A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia #ASH19 @CleClinicMD: Aaron Gerds,‚Ä¶ https://t.co/iYTADZrm1I",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1220199241718480896,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia #ASH19 @CleClinicMD: Aaron Gerds,‚Ä¶ https://t.co/iYTADZrm1I",true
Cancer_CCFla,#MarooneCancer at @CleveClinicFL is an Academic Comprehensive Cancer Center accredited by @CoC_ACS. Our physicians are at the forefront of emerging research.,,"Weston, FL",,2020-01-23 15:39:16+00:00,Maroone Cancer at Cleveland Clinic Florida,http://twitter.com/,22.0,,1.22037042008551e+18,,0.0,0.0,,RT @MWaldronPharmD: A fantastic presentation by @CarrawayHetty making sense of the whirlwind of investigational agents in #MDS treatment fr‚Ä¶,en,0.0,827.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,18.0,4.0,https://twitter.com/Cancer_CCFla/statuses/1220370420085510144,0.0,0.0,,0.0,0.0,0.0,4.0,18.0,False,False,False,False,True,Financial Performance,1.0,0.0,0.0,RT @MWaldronPharmD: A fantastic presentation by @CarrawayHetty making sense of the whirlwind of investigational agents in #MDS treatment fr‚Ä¶,true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-01-24 02:36:02+00:00,Oncology Tube,http://twitter.com/,0.0,,1.2205357017976873e+18,,0.0,0.0,,"HORIZON Study #ASH19 @RushMedical: Agne Paner, MD of @RushMedical discusses updated data from the phase 2 HORIZON s‚Ä¶ https://t.co/UtufeAezab",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1220535701797687296,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"HORIZON Study #ASH19 @RushMedical: Agne Paner, MD of @RushMedical discusses updated data from the phase 2 HORIZON s‚Ä¶ https://t.co/UtufeAezab",true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-01-22 17:06:03+00:00,Oncology Tube,http://twitter.com/,2.0,,1.2200298745863086e+18,,0.0,0.0,,"Phase 1 Clinical Study (CRB-402) of bb21217 #ASH19 @BerdejaJesus: Jesus Berdeja, MD @BerdejaJesus of Sarah Cannon C‚Ä¶ https://t.co/917C1CknxI",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/oncologytube/statuses/1220029874586308608,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"Phase 1 Clinical Study (CRB-402) of bb21217 #ASH19 @BerdejaJesus: Jesus Berdeja, MD @BerdejaJesus of Sarah Cannon C‚Ä¶ https://t.co/917C1CknxI",false
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-01-29 22:45:03+00:00,Oncology Tube,http://twitter.com/,0.0,,1.2226518996203643e+18,,0.0,0.0,,"Brentuximab Vedotin with Chemotherapy #ASH19: Thanos Zomas, MD of @TakedaOncology on brentuximab vedotin with chemo‚Ä¶ https://t.co/8gdC56c5j5",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1222651899620364288,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"Brentuximab Vedotin with Chemotherapy #ASH19: Thanos Zomas, MD of @TakedaOncology on brentuximab vedotin with chemo‚Ä¶ https://t.co/8gdC56c5j5",true
Adrianapordios,"Physician, Master in Public Health & Epidemiology, Hematology and Medical Affairs. Opinions are my own",,,,2020-01-22 02:20:07+00:00,Adriana Aguilar,http://twitter.com/,12.0,,1.2198069214288814e+18,,0.0,0.0,,"RT @AGP_hematology: FLAG-based regimens have an important role in the treatment of patients with newly diagnosed AML, and in the relapsed/r‚Ä¶",en,0.0,456.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,8.0,4.0,https://twitter.com/Adrianapordios/statuses/1219806921428881408,0.0,0.0,,0.0,0.0,0.0,4.0,8.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"RT @AGP_hematology: FLAG-based regimens have an important role in the treatment of patients with newly diagnosed AML, and in the relapsed/r‚Ä¶",true
WomenAs1,We aim to promote talent in medicine by offering unique professional opportunities to women physicians. Women in CV can sign up in our Talent Directory today!,,,,2020-01-31 14:59:25+00:00,Women As One,http://twitter.com/,37.0,,1.2232594975122145e+18,,0.0,0.0,,"RT @DeeDeeWangMD: Honored to be a part of 2020 @TCTConference PDC. Behind the scenes session planning, will be innovative #TCT2020 @crfhear‚Ä¶",en,0.0,4211.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,30.0,7.0,https://twitter.com/WomenAs1/statuses/1223259497512214537,0.0,0.0,,0.0,0.0,0.0,7.0,30.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"RT @DeeDeeWangMD: Honored to be a part of 2020 @TCTConference PDC. Behind the scenes session planning, will be innovative #TCT2020 @crfhear‚Ä¶",true
DrSheilaSahni,"Interventional Cardiologist | Physician @ChasingTheCure Focused on CVD Prevention & #WomenHeartHealth | #AHAEarlyCareerBlogger | Tweets=opinion, not med advice",,"New Jersey, USA",,2020-01-31 15:00:27+00:00,Dr. Sheila Sahni,http://twitter.com/,37.0,,1.2232597554451374e+18,,0.0,0.0,,"RT @DeeDeeWangMD: Honored to be a part of 2020 @TCTConference PDC. Behind the scenes session planning, will be innovative #TCT2020 @crfhear‚Ä¶",en,0.0,17676.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,30.0,7.0,https://twitter.com/DrSheilaSahni/statuses/1223259755445137409,0.0,0.0,,0.0,0.0,0.0,7.0,30.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"RT @DeeDeeWangMD: Honored to be a part of 2020 @TCTConference PDC. Behind the scenes session planning, will be innovative #TCT2020 @crfhear‚Ä¶",true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-01-31 16:59:33+00:00,Oncology Tube,http://twitter.com/,0.0,,1.223289727656186e+18,,0.0,0.0,,"Phase 2 CAPTIVATE Trial: What's Next? #ASH19 #ASH @PeterMacCC: Con Tam, MD of @PeterMacCC discusses the phase 2 CAP‚Ä¶ https://t.co/Fx2hqbIb5S",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1223289727656185856,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"Phase 2 CAPTIVATE Trial: What's Next? #ASH19 #ASH @PeterMacCC: Con Tam, MD of @PeterMacCC discusses the phase 2 CAP‚Ä¶ https://t.co/Fx2hqbIb5S",true
RajTayalMD,"Director, Structural Heart Program. Assistant Prof of Medicine, New York Medical College. Heart Failure trained Interventional Cardiologist. CHIP-CTO Enthusiast",,"New Jersey, USA",,2020-01-31 15:13:26+00:00,Raj Tayal,http://twitter.com/,37.0,,1.223263021381931e+18,,0.0,0.0,,"RT @DeeDeeWangMD: Honored to be a part of 2020 @TCTConference PDC. Behind the scenes session planning, will be innovative #TCT2020 @crfhear‚Ä¶",en,0.0,3732.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,30.0,7.0,https://twitter.com/RajTayalMD/statuses/1223263021381931008,0.0,0.0,,0.0,0.0,0.0,7.0,30.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"RT @DeeDeeWangMD: Honored to be a part of 2020 @TCTConference PDC. Behind the scenes session planning, will be innovative #TCT2020 @crfhear‚Ä¶",false
7eyeblink,MD. Hematolog√≠a cl√≠nica. √Åreas de inter√©s: CAR T y BMT. Tambi√©n escribo muchas tonter√≠as por el medio. (Opinions are mine)üìç A Coru√±a .,,Jam√°s en una ciudad sin playa.,,2020-01-31 13:20:03+00:00,Carolina Mart√≠nez,http://twitter.com/,0.0,,1.223234490354602e+18,,0.0,0.0,,Emotional issues can persist years after diagnosis of DBLCL and patients do not usually notice their doctors of the‚Ä¶ https://t.co/iET6w1i09W,en,0.0,2163.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/7eyeblink/statuses/1223234490354601987,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,Emotional issues can persist years after diagnosis of DBLCL and patients do not usually notice their doctors of the‚Ä¶ https://t.co/iET6w1i09W,true
ldiazpol,"MD. MHM. Hematologist interested in HSCT, cellular therapy and congenital blood disorders.",,"Barcelona, Espa√±a",,2020-02-03 07:19:13+00:00,Lizbeth Estefan√≠a D√≠az Polo,http://twitter.com/,72.0,,1.22423084586471e+18,,0.0,0.0,,"RT @7eyeblink: Anti infective prophylaxis EBMT recommendations after CAR-T Cell infusion, now in #CART20 #CART2020 #CARTMeeting https://t.c‚Ä¶",en,0.0,306.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,50.0,22.0,https://twitter.com/ldiazpol/statuses/1224230845864710144,0.0,0.0,,0.0,0.0,0.0,22.0,50.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"RT @7eyeblink: Anti infective prophylaxis EBMT recommendations after CAR-T Cell infusion, now in #CART20 #CART2020 #CARTMeeting https://t.c‚Ä¶",true
akbar_romana,Haematologist,,,,2020-01-31 11:01:58+00:00,Dr Romana Akbar,http://twitter.com/,14.0,,1.2231997380460997e+18,,0.0,0.0,,"RT @MM_Hub: CONGRESS | #CARTmeeting20 | Naoki Hosen from @osaka_univ_e summarizes preclinical data on MMG49 targeting integrin beta7, a nov‚Ä¶",en,0.0,121.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,8.0,6.0,https://twitter.com/akbar_romana/statuses/1223199738046099456,0.0,0.0,,0.0,0.0,0.0,6.0,8.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @MM_Hub: CONGRESS | #CARTmeeting20 | Naoki Hosen from @osaka_univ_e summarizes preclinical data on MMG49 targeting integrin beta7, a nov‚Ä¶",true
davidhenrymd,"Practicing MD Hematologist Oncologist 
Vice Chair Dept of Medicine Pennsylvania Hospital Blood&Cancer host Research-supportive care @MDedgeTweets @MDedgeHemeOnc",,"Philadelphia, PA",,2020-01-31 12:00:06+00:00,David Henry,http://twitter.com/,0.0,,1.2232143708068168e+18,,0.0,0.0,,From #ASH19 - 4 year analysis confirms sustained benefit of time-limited Venetoclax-Rituximab in relapsed/refractor‚Ä¶ https://t.co/wCWBKTgeNM,en,0.0,1771.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/davidhenrymd/statuses/1223214370806816768,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,From #ASH19 - 4 year analysis confirms sustained benefit of time-limited Venetoclax-Rituximab in relapsed/refractor‚Ä¶ https://t.co/wCWBKTgeNM,true
mabeky,Leukemia Department Administrator at MD Anderson Cancer Center,,"Houston, TX",,2020-01-21 23:01:10+00:00,M. Silverstein,http://twitter.com/,12.0,,1.2197568552089723e+18,,0.0,0.0,,"RT @AGP_hematology: FLAG-based regimens have an important role in the treatment of patients with newly diagnosed AML, and in the relapsed/r‚Ä¶",en,0.0,206.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,8.0,4.0,https://twitter.com/mabeky/statuses/1219756855208972288,0.0,0.0,,0.0,0.0,0.0,4.0,8.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"RT @AGP_hematology: FLAG-based regimens have an important role in the treatment of patients with newly diagnosed AML, and in the relapsed/r‚Ä¶",true
michaelwangmd,"Puddin Clarke Endowed Professor, #Lymphoma/#Myeloma @MDAndersonnews; #mantlecelllymphoma, B-Cell Lymphoma Moonshot, MD Anderson https://t.co/0WoQhmrFHO views=own",,"Houston, Texas",,2020-11-25 17:28:59+00:00,"Michael Wang, MD",http://twitter.com/,10.0,,1.3316511066787226e+18,,0.0,0.0,,"We have an ongoing CAR T cell  trial for relapsed mantle cell lymphoma, this trial is open for enrollment. Good dat‚Ä¶ https://t.co/1j7sGvtqy6",en,0.0,3809.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,10.0,https://twitter.com/michaelwangmd/statuses/1331651106678722562,0.0,0.0,,0.0,0.0,0.0,10.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"We have an ongoing CAR T cell  trial for relapsed mantle cell lymphoma, this trial is open for enrollment. Good dat‚Ä¶ https://t.co/1j7sGvtqy6",false
KargerHCP,@KargerPublisher is a globally active publishing house in health sciences. Healthcare caters to the needs of doctors in clinics/private practice & specialists.,,"Basel, Switzerland",,2020-11-25 07:37:26+00:00,Karger Healthcare Professionals,http://twitter.com/,22.0,,1.3315022372863631e+18,,0.0,0.0,,"RT @ASHClinicalNews: When Virtual Becomes the Reality: Bill Reed, @ASH_hematology‚Äôs Chief Event Strategy Officer gives a behind-the-scenes‚Ä¶",en,0.0,426.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,15.0,7.0,https://twitter.com/KargerHCP/statuses/1331502237286363137,0.0,0.0,,0.0,0.0,0.0,7.0,15.0,False,False,False,False,True,Thought Leadership,0.0,0.0,1.0,"RT @ASHClinicalNews: When Virtual Becomes the Reality: Bill Reed, @ASH_hematology‚Äôs Chief Event Strategy Officer gives a behind-the-scenes‚Ä¶",true
DrESHAJ9,"a passionate medical oncologist, a spiritual seeker",,,,2020-07-15 06:42:46+00:00,EJ,http://twitter.com/,39.0,,1.2832908973129114e+18,,0.0,0.0,,"RT @graham74GC: S Borchmann: liquid biopsy in cHL
- 76 pts, adv
- no. of new mutations IDed
- IDed mutational clusters
- high mutn rates as‚Ä¶",en,0.0,315.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,28.0,11.0,https://twitter.com/DrESHAJ9/statuses/1283290897312911360,0.0,0.0,,0.0,0.0,0.0,11.0,28.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"RT @graham74GC: S Borchmann: liquid biopsy in cHL
- 76 pts, adv
- no. of new mutations IDed
- IDed mutational clusters
- high mutn rates as‚Ä¶",true
AJoyBurns1,"Benign Hematology Physician Assistant @YaleCancer @YaleMed, opinions are my own",,"New Haven, CT",,2020-07-05 03:49:26+00:00,A Joy Burns,http://twitter.com/,11.0,,1.2796233975138017e+18,,0.0,0.0,,"RT @VJHemOnc: VIDEO: Cereblon and GSPT1 degrader in refractory/relapsed #AML w/ @Dr_AmerZeidan of @YaleMed: https://t.co/qIlBJCH1YB

@VJHem‚Ä¶",en,0.0,27.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,8.0,3.0,https://twitter.com/AJoyBurns1/statuses/1279623397513801728,0.0,0.0,,0.0,0.0,0.0,3.0,8.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @VJHemOnc: VIDEO: Cereblon and GSPT1 degrader in refractory/relapsed #AML w/ @Dr_AmerZeidan of @YaleMed: https://t.co/qIlBJCH1YB

@VJHem‚Ä¶",true
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-07-15 23:01:11+00:00,Cardiovascular Research Foundation,http://twitter.com/,1.0,,1.2835371240510382e+18,,0.0,0.0,,Submit your ideas and clinical data on the ramifications of #COVID19 on patients and/or the #cardiology community.‚Ä¶ https://t.co/UNTuXbXd9E,en,0.0,12239.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/crfheart/statuses/1283537124051038209,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Disease Advocacy,0.0,0.0,1.0,Submit your ideas and clinical data on the ramifications of #COVID19 on patients and/or the #cardiology community.‚Ä¶ https://t.co/UNTuXbXd9E,true
kwackergibs,"Lymphoma Nurse Clinician at The Christie, Manchester. Doctoral student. Own views.",,"Manchester, England",,2020-06-14 06:22:46+00:00,Jane Gibson,http://twitter.com/,13.0,,1.2720518380833874e+18,,0.0,0.0,,"RT @tobyeyre82: #Loncastuximab terisine 
phase II R/R #DLBCL
n=145
anti-CD19 ADC
150ug/kg C1-2-&gt;75ug/kg
3 lines
58% ref last Rx
ORR 48% CR‚Ä¶",en,0.0,266.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,8.0,5.0,https://twitter.com/kwackergibs/statuses/1272051838083387392,0.0,0.0,,0.0,0.0,0.0,5.0,8.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @tobyeyre82: #Loncastuximab terisine 
phase II R/R #DLBCL
n=145
anti-CD19 ADC
150ug/kg C1-2-&gt;75ug/kg
3 lines
58% ref last Rx
ORR 48% CR‚Ä¶",true
LukeMtjoy,Hematologist and transplant physician at Colorado Blood Cancer Institute. Former hem/onc fellow @MayoClinic AZ. view and opinions are my own,,"Denver, CO",,2020-06-14 15:58:33+00:00,LukeMtjoy,http://twitter.com/,92.0,,1.2721967395506872e+18,,0.0,0.0,,RT @DocHutchings: Pleased to present the final results from the dose escalation part of the Phase 1/2 study of epcoritamab in r/r B-NHL at‚Ä¶,en,0.0,137.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,69.0,23.0,https://twitter.com/LukeMtjoy/statuses/1272196739550687233,0.0,0.0,,0.0,0.0,0.0,23.0,69.0,False,False,False,False,True,Clinical Trials,1.0,0.0,0.0,RT @DocHutchings: Pleased to present the final results from the dose escalation part of the Phase 1/2 study of epcoritamab in r/r B-NHL at‚Ä¶,false
mpdrc,Executive Director- Mays Cancer Center at UT Health San Antonio MD Anderson; (Views on Twitter are personal opinion),,"UT Health San Antonio ,TX, USA",,2020-06-14 20:21:38+00:00,"Ruben A. Mesa, MD",http://twitter.com/,64.0,,1.2722629439761654e+18,,0.0,0.0,,"RT @EHA_Hematology: On-demand content at #EHA25Virtual is now available: Explore the invited speaker program, oral abstract and e-poster pr‚Ä¶",en,0.0,3222.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,45.0,19.0,https://twitter.com/mpdrc/statuses/1272262943976165377,0.0,0.0,,0.0,0.0,0.0,19.0,45.0,False,False,False,False,True,Thought Leadership,0.0,0.0,1.0,"RT @EHA_Hematology: On-demand content at #EHA25Virtual is now available: Explore the invited speaker program, oral abstract and e-poster pr‚Ä¶",true
DrESHAJ9,"a passionate medical oncologist, a spiritual seeker",,,,2020-06-18 14:54:45+00:00,EJ,http://twitter.com/,3.0,,1.2736302362114744e+18,,0.0,0.0,,"RT @ecancer: #EHA25: Dr Sudhir Manda of @ArizonaOncology outlines the latest results from the US MM-6 study, investigating long-term protea‚Ä¶",en,0.0,315.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,1.0,2.0,https://twitter.com/DrESHAJ9/statuses/1273630236211474435,0.0,0.0,,0.0,0.0,0.0,2.0,1.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,"RT @ecancer: #EHA25: Dr Sudhir Manda of @ArizonaOncology outlines the latest results from the US MM-6 study, investigating long-term protea‚Ä¶",true
drwenbin_xiao,"Hematopathologist @MSKpathology, physician scientist @RossLevinelab, @sloan_Kettering Tweets are my own.",,"Manhattan, NY",,2020-06-18 02:19:56+00:00,Wenbin Xiao,http://twitter.com/,11.0,,1.2734402781254574e+18,,0.0,0.0,,"RT @smbenlazar: INTERIM RESULTS FROM AN ONGOING PHASE 1/2 CLINICAL TRIAL OF TAGRAXOFUSP (SL-401), A CD123-DIRECTED THERAPY, IN PATIENTS WIT‚Ä¶",en,0.0,354.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,7.0,4.0,https://twitter.com/drwenbin_xiao/statuses/1273440278125457411,0.0,0.0,,0.0,0.0,0.0,4.0,7.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @smbenlazar: INTERIM RESULTS FROM AN ONGOING PHASE 1/2 CLINICAL TRIAL OF TAGRAXOFUSP (SL-401), A CD123-DIRECTED THERAPY, IN PATIENTS WIT‚Ä¶",true
ADCReview,"ADC Review/J. Antibody-drug Conjugates, an open access journal, brings together researchers, scientists and physicians involved in the growing field of ADCs.",,"Phoenix, AZ (USA)",,2020-06-18 18:30:00+00:00,ADC Review,http://twitter.com/,0.0,,1.2736844033617388e+18,,0.0,0.0,,Loncastuximab Tesirine Demonstrates an Overall High Response Rates in Pivotal Phase II Single-agent Trial‚Ä¶ https://t.co/XxsiedAkBH,en,0.0,905.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/ADCReview/statuses/1273684403361738770,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,Loncastuximab Tesirine Demonstrates an Overall High Response Rates in Pivotal Phase II Single-agent Trial‚Ä¶ https://t.co/XxsiedAkBH,true
DrESHAJ9,"a passionate medical oncologist, a spiritual seeker",,,,2020-06-18 09:26:16+00:00,EJ,http://twitter.com/,29.0,,1.273547570988499e+18,,0.0,0.0,,"RT @graham74GC: Checkmate 744 - BV+Nivo 1st relapse cHL, 5-30yoa. 
Maus-Korholz et al
44 standard risk pts
BV-Nivo 82% ORR, 59% CMR
11 pts‚Ä¶",en,0.0,315.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,21.0,8.0,https://twitter.com/DrESHAJ9/statuses/1273547570988498944,0.0,0.0,,0.0,0.0,0.0,8.0,21.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @graham74GC: Checkmate 744 - BV+Nivo 1st relapse cHL, 5-30yoa. 
Maus-Korholz et al
44 standard risk pts
BV-Nivo 82% ORR, 59% CMR
11 pts‚Ä¶",true
dwiseman78,Consultant Haematologist / Clinician Scientist at University of Manchester. Interest in MDS and CMML/Overlap syndromes,,,,2020-06-18 22:23:14+00:00,Dan Wiseman,http://twitter.com/,36.0,,1.2737431005156805e+18,,0.0,0.0,,"RT @MPN_Hub: CONGRESS | #EHA25Virtual | Updated phase I/II trial results of tagraxofusp, an anti-CD123, demonstrated its clinical efficacy‚Ä¶",en,0.0,123.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,26.0,10.0,https://twitter.com/dwiseman78/statuses/1273743100515680263,0.0,0.0,,0.0,0.0,0.0,10.0,26.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @MPN_Hub: CONGRESS | #EHA25Virtual | Updated phase I/II trial results of tagraxofusp, an anti-CD123, demonstrated its clinical efficacy‚Ä¶",false
nycdoc29,"ASCO, ASH, EHA & ESMO Member, Hem/Onc - 11 MD specialty private practice, former full time academic, traveller, foodie & out of necessity now a business person!",,"Garden City, NY",,2020-06-18 14:29:37+00:00,NYCDoc29,http://twitter.com/,29.0,,1.2736239077072937e+18,,0.0,0.0,,"RT @graham74GC: Checkmate 744 - BV+Nivo 1st relapse cHL, 5-30yoa. 
Maus-Korholz et al
44 standard risk pts
BV-Nivo 82% ORR, 59% CMR
11 pts‚Ä¶",en,0.0,664.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,21.0,8.0,https://twitter.com/nycdoc29/statuses/1273623907707293697,0.0,0.0,,0.0,0.0,0.0,8.0,21.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @graham74GC: Checkmate 744 - BV+Nivo 1st relapse cHL, 5-30yoa. 
Maus-Korholz et al
44 standard risk pts
BV-Nivo 82% ORR, 59% CMR
11 pts‚Ä¶",true
shameel_shafqat,22 | MS4üë®‚Äç‚öïÔ∏è @AKUGlobal | Class of 2021 | Aspiring Physician. Live in üá∏üá¶ but üáµüá∞ at heart ‚ù§,,,,2020-06-16 16:29:43+00:00,Shameel Shafqat,http://twitter.com/,38.0,,1.2729293580769403e+18,,0.0,0.0,,RT @TheLancetHaem: Selim Corbacioglu: the first-in-human #CRISPR gene editing to disrupt BCL11A in hematopoietic stem and progenitor cells.‚Ä¶,en,0.0,383.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,25.0,13.0,https://twitter.com/shameel_shafqat/statuses/1272929358076940289,0.0,0.0,,0.0,0.0,0.0,13.0,25.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @TheLancetHaem: Selim Corbacioglu: the first-in-human #CRISPR gene editing to disrupt BCL11A in hematopoietic stem and progenitor cells.‚Ä¶,true
graham74GC,Lymphoma specialist at Oxford Cancer and Haematology centre. Haematologist and clinical trialist. Chair of UK Hodgkin and T-cell study groups.,,Opinions are mine,,2020-06-18 08:12:04+00:00,Graham Collins,http://twitter.com/,8.0,,1.273528894126252e+18,,0.0,0.0,,"Checkmate 744 - BV+Nivo 1st relapse cHL, 5-30yoa. 
Maus-Korholz et al
44 standard risk pts
BV-Nivo 82% ORR, 59% CMR‚Ä¶ https://t.co/CUKksLXkvP",en,0.0,6091.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,8.0,https://twitter.com/graham74GC/statuses/1273528894126252032,0.0,0.0,,0.0,0.0,0.0,8.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"Checkmate 744 - BV+Nivo 1st relapse cHL, 5-30yoa. 
Maus-Korholz et al
44 standard risk pts
BV-Nivo 82% ORR, 59% CMR‚Ä¶ https://t.co/CUKksLXkvP",true
dr_emmyd,"Doctor. Mum. Londoner in Cambridge. Trying not to be middle aged, middle class and middle of the road.",,,,2020-03-19 00:02:19+00:00,Ems,http://twitter.com/,27.0,,1.2404283516444058e+18,,0.0,0.0,,"RT @thalassaemiaTIF: #TIF‚Äôs enriched Leaflet on the new #Covid_19 #Pandemic &amp; Haemoglobin Disorders is now online!üìñ

This material is a hel‚Ä¶",en,0.0,377.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,13.0,14.0,https://twitter.com/dr_emmyd/statuses/1240428351644405760,0.0,0.0,,0.0,0.0,0.0,14.0,13.0,False,False,False,False,True,Covid,0.0,0.0,1.0,"RT @thalassaemiaTIF: #TIF‚Äôs enriched Leaflet on the new #Covid_19 #Pandemic &amp; Haemoglobin Disorders is now online!üìñ

This material is a hel‚Ä¶",true
Sting64r,"Headmaster Emeritus at Hogwarts  4 young physicians since 1851-MACP,FRCP, committed to social justice-bringing hope 2children with chronic disease-Tweets my own",,Georgetown University,,2020-03-19 11:41:12+00:00,Stephen Mitchell,http://twitter.com/,2.0,,1.2406042323713147e+18,,0.0,0.0,,"SO GRATEFUL 4 our @GUMedicine team,OME,OSA,OSS,Fin&amp;Ops,
OSLAA,DML,TESS,FACS,IntNtl programs, for tireless Work and‚Ä¶ https://t.co/nvdiEPXhKz",en,0.0,2470.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/Sting64r/statuses/1240604232371314688,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,"SO GRATEFUL 4 our @GUMedicine team,OME,OSA,OSS,Fin&amp;Ops,
OSLAA,DML,TESS,FACS,IntNtl programs, for tireless Work and‚Ä¶ https://t.co/nvdiEPXhKz",true
docesr,"Haematologist (of the red cell variety). Lover of London, the NHS, food and walking. tweets are personal views, RT not necessarily endorsement or agreement",,"London, England",,2020-03-20 15:29:41+00:00,Elizabeth Rhodes,http://twitter.com/,52.0,,1.241024118042112e+18,,0.0,0.0,,RT @thalassaemiaTIF: Fear of #Covid_19 infection have dramatically reduced #BloodDonation in many countries &amp; the risk of blood supplies dr‚Ä¶,en,0.0,442.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,25.0,27.0,https://twitter.com/docesr/statuses/1241024118042112003,0.0,0.0,,0.0,0.0,0.0,27.0,25.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,RT @thalassaemiaTIF: Fear of #Covid_19 infection have dramatically reduced #BloodDonation in many countries &amp; the risk of blood supplies dr‚Ä¶,false
CAnaemiaNetwork,"We are a group of patients, carers, doctors, & scientists who are all interested in patients with #rare inherited #anaemia.  #haematology #blood",,"Oxford, England",,2020-03-21 07:00:10+00:00,@CongenitalAnaemia,http://twitter.com/,52.0,,1.241258283433943e+18,,0.0,0.0,,RT @thalassaemiaTIF: Fear of #Covid_19 infection have dramatically reduced #BloodDonation in many countries &amp; the risk of blood supplies dr‚Ä¶,en,0.0,163.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,25.0,27.0,https://twitter.com/CAnaemiaNetwork/statuses/1241258283433943040,0.0,0.0,,0.0,0.0,0.0,27.0,25.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,RT @thalassaemiaTIF: Fear of #Covid_19 infection have dramatically reduced #BloodDonation in many countries &amp; the risk of blood supplies dr‚Ä¶,true
CAnaemiaNetwork,"We are a group of patients, carers, doctors, & scientists who are all interested in patients with #rare inherited #anaemia.  #haematology #blood",,"Oxford, England",,2020-03-18 23:08:53+00:00,@CongenitalAnaemia,http://twitter.com/,27.0,,1.2404149027806495e+18,,0.0,0.0,,"RT @thalassaemiaTIF: #TIF‚Äôs enriched Leaflet on the new #Covid_19 #Pandemic &amp; Haemoglobin Disorders is now online!üìñ

This material is a hel‚Ä¶",en,0.0,163.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,13.0,14.0,https://twitter.com/CAnaemiaNetwork/statuses/1240414902780649477,0.0,0.0,,0.0,0.0,0.0,14.0,13.0,False,False,False,False,True,Covid,0.0,0.0,1.0,"RT @thalassaemiaTIF: #TIF‚Äôs enriched Leaflet on the new #Covid_19 #Pandemic &amp; Haemoglobin Disorders is now online!üìñ

This material is a hel‚Ä¶",true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-02-16 19:49:04+00:00,Oncology Tube,http://twitter.com/,0.0,,1.2291305947238728e+18,,0.0,0.0,,"Phase I Study of Duvelisib in CLL/SLL #ASH19 #ASH @DanaFarber: Jennifer Crombie, MD of @DanaFarber discusses a phas‚Ä¶ https://t.co/9aLAyFLJQ6",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1229130594723872768,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"Phase I Study of Duvelisib in CLL/SLL #ASH19 #ASH @DanaFarber: Jennifer Crombie, MD of @DanaFarber discusses a phas‚Ä¶ https://t.co/9aLAyFLJQ6",true
DrGoutomi,"MD , fellow in Pediatric hematology,oncology and bone marrow transplantation",,"Cardiff, Wales",,2020-02-20 09:26:23+00:00,Dr. Goutomi Chatterjee,http://twitter.com/,19.0,,1.230423441016152e+18,,0.0,0.0,,RT @satya_yadav: #VOD can progress rapidly to Multi organ failure . So early diagnosis and treatment can be life saving #TCTM20 #Cooke http‚Ä¶,en,0.0,120.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,15.0,4.0,https://twitter.com/DrGoutomi/statuses/1230423441016152065,0.0,0.0,,0.0,0.0,0.0,4.0,15.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @satya_yadav: #VOD can progress rapidly to Multi organ failure . So early diagnosis and treatment can be life saving #TCTM20 #Cooke http‚Ä¶,true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-02-20 13:48:08+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,0.0,,1.230489314993328e+18,,0.0,0.0,,"#TCTM20 Spellman: ongoing ph2 study of multiply HLA mismatched (4-7/8) with PTCy, Siro, MMF: study still young but‚Ä¶ https://t.co/uB4kuqlfIS",en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/hemedoc/statuses/1230489314993328131,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"#TCTM20 Spellman: ongoing ph2 study of multiply HLA mismatched (4-7/8) with PTCy, Siro, MMF: study still young but‚Ä¶ https://t.co/uB4kuqlfIS",true
michyong2,"Infectious diseases physician, CMV & viral infections, Clinician researcher, @NCICancer @PeterMacCC @TheRMH @TheDohertyInst",,"Melbourne, Victoria",,2020-02-20 16:31:40+00:00,Michelle Yong,http://twitter.com/,2.0,,1.2305304687072092e+18,,0.0,0.0,,@FranciscoMarty_ #TCTM20 Personalized infection risk in HSCT. Lots of personalized and humorous slides! Breath fung‚Ä¶ https://t.co/KeojG3ysv9,en,0.0,386.0,,,0.0,FranciscoMarty_,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/michyong2/statuses/1230530468707209216,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Side Effects,1.0,0.0,0.0,@FranciscoMarty_ #TCTM20 Personalized infection risk in HSCT. Lots of personalized and humorous slides! Breath fung‚Ä¶ https://t.co/KeojG3ysv9,false
AimeeTalleurMD,Physician Scientist | Pediatric BMT & Immunotherapy | Clinical Trial Development | Med-ed | Academics | Twin Mom | opinions=my own | @stjuderesearch,,"Memphis, TN",,2020-02-20 19:53:56+00:00,"Aimee Talleur, MD",http://twitter.com/,4.0,,1.2305813701766554e+18,,0.0,0.0,,Relapse after alloHCT = bad. 2nd transplant is a reasonable option for some patients @AkshaySharmaMD presenting the‚Ä¶ https://t.co/rEPvjprSsl,en,0.0,345.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,4.0,https://twitter.com/AimeeTalleurMD/statuses/1230581370176655360,0.0,0.0,,0.0,0.0,0.0,4.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,Relapse after alloHCT = bad. 2nd transplant is a reasonable option for some patients @AkshaySharmaMD presenting the‚Ä¶ https://t.co/rEPvjprSsl,true
dgermain21,MD-PhD. 2nd year Heme/Onc fellow focused on lymphoma and leukemia. Physician-scientist-in-training. Tweet/RT not medical advice or endorsement.,,"St. Louis, MO",,2020-02-20 01:37:52+00:00,David A. Russler-Germain,http://twitter.com/,10.0,,1.2303055381452431e+18,,0.0,0.0,,"RT @AML_Hub: CONGRESS | #TCTM20 | Bart L. Scott, @fredhutch, presents long-term FU from the BMT CTN 0901 (MAvRIC)  phase III trial of MAC v‚Ä¶",en,0.0,1612.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,6.0,https://twitter.com/dgermain21/statuses/1230305538145243139,0.0,0.0,,0.0,0.0,0.0,6.0,4.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"RT @AML_Hub: CONGRESS | #TCTM20 | Bart L. Scott, @fredhutch, presents long-term FU from the BMT CTN 0901 (MAvRIC)  phase III trial of MAC v‚Ä¶",true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-02-20 16:13:52+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,14.0,,1.2305259885823836e+18,,0.0,0.0,,#TCTM20 Christopher: mHC class II downregulation observed in 30-50% of AML relapses after alloHCT. May be reversibl‚Ä¶ https://t.co/nr2F18iVnx,en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,14.0,https://twitter.com/hemedoc/statuses/1230525988582383616,0.0,0.0,,0.0,0.0,0.0,14.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,#TCTM20 Christopher: mHC class II downregulation observed in 30-50% of AML relapses after alloHCT. May be reversibl‚Ä¶ https://t.co/nr2F18iVnx,true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-02-20 13:51:08+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,0.0,,1.2304900697415803e+18,,0.0,0.0,,#TCTM20 Spellman: another Ph2 using PTCY with 7/8 matches shows excellent 1 year OS https://t.co/3f2d408xSJ,en,0.0,4813.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/hemedoc/statuses/1230490069741580289,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,1.0,0.0,0.0,#TCTM20 Spellman: another Ph2 using PTCY with 7/8 matches shows excellent 1 year OS https://t.co/3f2d408xSJ,true
abhinav_deol,MD,,"Detroit, MI",,2020-02-20 15:46:19+00:00,Abhinav Deol,http://twitter.com/,0.0,,1.2305190563499213e+18,,0.0,0.0,,"#TCTM20 Dr. Minnie: Auto tranplant resets the ""immune"" thermostat and relapse is possibly mediated by T cell exhaus‚Ä¶ https://t.co/InYeM9r4a9",en,0.0,251.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/abhinav_deol/statuses/1230519056349921280,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"#TCTM20 Dr. Minnie: Auto tranplant resets the ""immune"" thermostat and relapse is possibly mediated by T cell exhaus‚Ä¶ https://t.co/InYeM9r4a9",true
adrianabello,"pediatrician, pediatric hematologyst, mother adribello@hotmail.com",,,,2020-02-21 13:11:06+00:00,Adriana Bello,http://twitter.com/,6.0,,1.23084238172715e+18,,0.0,0.0,,"RT @hemedoc: #TCTM20 Jagasia: abatacept gave PR in 44% in SR-cGVHD, reduction but not liberation from steroids. Phase 2 underway. https://t‚Ä¶",en,0.0,1968.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,3.0,https://twitter.com/adrianabello/statuses/1230842381727150080,0.0,0.0,,0.0,0.0,0.0,3.0,3.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @hemedoc: #TCTM20 Jagasia: abatacept gave PR in 44% in SR-cGVHD, reduction but not liberation from steroids. Phase 2 underway. https://t‚Ä¶",false
colwynpoole,"Social justice through health care access,  building transplant services in the public sector. MD, transfusion medicine. Views my own, RT not endorsement.",,"Johannesburg, South Africa",,2020-02-21 17:20:01+00:00,Colwyn Poole,http://twitter.com/,7.0,,1.230905022378107e+18,,0.0,0.0,,"RT @satya_yadav: Risk of therapy related MDS/leukemia post BMT 

Progressive Shortening of telomere length in stem cells over time post BMT‚Ä¶",en,0.0,197.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,2.0,https://twitter.com/colwynpoole/statuses/1230905022378106886,0.0,0.0,,0.0,0.0,0.0,2.0,5.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @satya_yadav: Risk of therapy related MDS/leukemia post BMT 

Progressive Shortening of telomere length in stem cells over time post BMT‚Ä¶",true
DrChrisHourigan,"Physician-Scientist, Acute Myeloid Leukemia Doctor, Human Immunologist, Laboratory PI, Measurable Residual Disease Advocate, Optimist.  Views are my own.",,"Washington, DC",,2020-07-25 14:46:35+00:00,Chris Hourigan,http://twitter.com/,11.0,,1.2870365290141983e+18,,0.0,0.0,,RT @VJHemOnc: VIDEO: Conditioning intensity and genomics: relapse after allogeneic #Transplant in #MDS w/ @DrChrisHourigan of @nih_nhlbi: h‚Ä¶,en,0.0,1169.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,7.0,4.0,https://twitter.com/DrChrisHourigan/statuses/1287036529014198273,0.0,0.0,,0.0,0.0,0.0,4.0,7.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @VJHemOnc: VIDEO: Conditioning intensity and genomics: relapse after allogeneic #Transplant in #MDS w/ @DrChrisHourigan of @nih_nhlbi: h‚Ä¶,true
DMadduri,"Multiple Myeloma physician at MountSinai, Icahn School of Medicine, New York; Associate Director of Cellular Therapy #cart #mm",,"Manhattan, NY",,2020-03-01 00:44:51+00:00,Deepu Madduri,http://twitter.com/,6.0,,1.2339160737680837e+18,,0.0,0.0,,"RT @HemOncToday: Cover Story: results of the phase 1b/phase 2 CARTITUDE-1 trial presented by Deepu Madduri, MD @DMadduri @IcahnMountSinai d‚Ä¶",en,0.0,594.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,2.0,https://twitter.com/DMadduri/statuses/1233916073768083461,0.0,0.0,,0.0,0.0,0.0,2.0,4.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @HemOncToday: Cover Story: results of the phase 1b/phase 2 CARTITUDE-1 trial presented by Deepu Madduri, MD @DMadduri @IcahnMountSinai d‚Ä¶",true
healing_genes,"We are scientists, doctors, researchers, nurses and others who focus on healing debilitating and, in many cases, life-threatening genetic-based diseases.",,"Baltimore, MD",,2020-02-26 01:19:53+00:00,Healing Genes,http://twitter.com/,2.0,,1.2324753361238303e+18,,0.0,0.0,,"RT @ASGCTherapy: Have you downloaded the #ASGCT20 app yet? You can view the preliminary meeting schedule, search for speakers and sessions,‚Ä¶",en,0.0,45.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,1.0,1.0,https://twitter.com/healing_genes/statuses/1232475336123830272,0.0,0.0,,0.0,0.0,0.0,1.0,1.0,False,False,False,False,True,Thought Leadership,0.0,0.0,1.0,"RT @ASGCTherapy: Have you downloaded the #ASGCT20 app yet? You can view the preliminary meeting schedule, search for speakers and sessions,‚Ä¶",true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-03-01 03:29:04+00:00,Oncology Tube,http://twitter.com/,0.0,,1.2339573991882383e+18,,0.0,0.0,,"Comparative Outcomes of Relapsed Follicular Lymphoma Patients #ASH19 @ClevelandClinic: Allison M. Winter, MD of‚Ä¶ https://t.co/7wLDL798MI",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1233957399188238336,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"Comparative Outcomes of Relapsed Follicular Lymphoma Patients #ASH19 @ClevelandClinic: Allison M. Winter, MD of‚Ä¶ https://t.co/7wLDL798MI",true
Areejmd,An oncologist with a passion to improve the quality of life and care of patients with hematologic malignancies #ASH #PallOnc #CIBMTR #ASBMT @MGHCancerCenter,,"Boston, MA",,2020-02-22 16:28:40+00:00,Areej El-Jawahri,http://twitter.com/,31.0,,1.2312544871777567e+18,,0.0,0.0,,RT @PennisiMartina: congratssss @RShouval on your young investigator award from @ASTCT ! All the best for you! #TCTM20,en,0.0,957.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,27.0,4.0,https://twitter.com/Areejmd/statuses/1231254487177756672,0.0,0.0,,0.0,0.0,0.0,4.0,27.0,False,False,False,False,True,Financial Performance,1.0,0.0,0.0,RT @PennisiMartina: congratssss @RShouval on your young investigator award from @ASTCT ! All the best for you! #TCTM20,false
abhinav_deol,MD,,"Detroit, MI",,2020-02-22 23:15:23+00:00,Abhinav Deol,http://twitter.com/,21.0,,1.2313568415332805e+18,,0.0,0.0,,RT @BldCancerDoc: üôèüôèüôè to incredible group of colleagues who do üëçüëçüëç volunteer work for @ASTCT #TCTM20,en,0.0,251.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,19.0,2.0,https://twitter.com/abhinav_deol/statuses/1231356841533280258,0.0,0.0,,0.0,0.0,0.0,2.0,19.0,False,False,False,False,True,Disease Advocacy,1.0,0.0,0.0,RT @BldCancerDoc: üôèüôèüôè to incredible group of colleagues who do üëçüëçüëç volunteer work for @ASTCT #TCTM20,true
JJ_boelens,"Physician-scientist | Chief, Stem Cell Transplant & Cellular Therapies, MSK Kids | Memorial Sloan Kettering Cancer Center | Traveling around üåç",,"New York, NY",,2020-02-22 22:46:49+00:00,Jaap J Boelens,http://twitter.com/,1.0,,1.231349653716816e+18,,0.0,0.0,,@jennifernsaultz @AkshaySharmaMD If we believe it is important not to loose ‚Äògeneral‚Äô CBT expertise: Urgent to need‚Ä¶ https://t.co/cxZcReplq5,en,0.0,1118.0,,,0.0,jennifernsaultz,1.2313130151627858e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/JJ_boelens/statuses/1231349653716815872,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Thought Leadership,0.0,0.0,1.0,@jennifernsaultz @AkshaySharmaMD If we believe it is important not to loose ‚Äògeneral‚Äô CBT expertise: Urgent to need‚Ä¶ https://t.co/cxZcReplq5,true
adrianabello,"pediatrician, pediatric hematologyst, mother adribello@hotmail.com",,,,2020-02-22 16:43:37+00:00,Adriana Bello,http://twitter.com/,11.0,,1.231258250617729e+18,,0.0,0.0,,"RT @hmgcoa2: #TCTM20 fascinating insight into the mechanisms of Neurotox post #CARTcells  characteristic MRI changes, IL6 not very high in‚Ä¶",en,0.0,1968.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,6.0,https://twitter.com/adrianabello/statuses/1231258250617729025,0.0,0.0,,0.0,0.0,0.0,6.0,5.0,False,False,False,False,True,Diagnostic Tools,1.0,0.0,0.0,"RT @hmgcoa2: #TCTM20 fascinating insight into the mechanisms of Neurotox post #CARTcells  characteristic MRI changes, IL6 not very high in‚Ä¶",true
ouholter,"Proud Oklahoma hematologist, wife, BMT physician, researcher, sooner, mom, loyal friend, thunder fan, and so proud of two amazing daughters! Tweets my own.",,"Oklahoma City, OK",,2020-02-22 18:29:51+00:00,J Holter Chakrabarty,http://twitter.com/,2.0,,1.231284987447726e+18,,0.0,0.0,,#TCTM20 I‚Äôm so proud of 1st year ID fellow Miranda McGhee coming to ‚Å¶@ASTCT‚Å© Meeting and presenting at Infection an‚Ä¶ https://t.co/1MSBmfG2IF,en,0.0,309.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/ouholter/statuses/1231284987447726080,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Side Effects,1.0,0.0,0.0,#TCTM20 I‚Äôm so proud of 1st year ID fellow Miranda McGhee coming to ‚Å¶@ASTCT‚Å© Meeting and presenting at Infection an‚Ä¶ https://t.co/1MSBmfG2IF,true
marrow,"Clinical Haematologist, marrow transplanter. President World Marrow Donor Association (WMDA). Editor-in-Chief Internal Medicine Journal.",,"Melbourne, Australia",,2020-02-22 21:14:48+00:00,Jeff Szer,http://twitter.com/,0.0,,1.2313264967756923e+18,,0.0,0.0,,"Dr Sharat Damodar from Bengaluru, India finishing the International Workshop with transplants for thalassaemia in I‚Ä¶ https://t.co/vT5FB5ETmm",en,0.0,2195.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/marrow/statuses/1231326496775692291,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,"Dr Sharat Damodar from Bengaluru, India finishing the International Workshop with transplants for thalassaemia in I‚Ä¶ https://t.co/vT5FB5ETmm",true
marrow,"Clinical Haematologist, marrow transplanter. President World Marrow Donor Association (WMDA). Editor-in-Chief Internal Medicine Journal.",,"Melbourne, Australia",,2020-02-22 20:39:49+00:00,Jeff Szer,http://twitter.com/,0.0,,1.231317694915453e+18,,0.0,0.0,,@carmembonf Presenting in Transplants for Famcomi anaemia in Curibita Brazil after successful collaboration.‚Ä¶ https://t.co/sE7q1O6jk1,en,0.0,2195.0,,,0.0,carmembonf,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/marrow/statuses/1231317694915452933,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,@carmembonf Presenting in Transplants for Famcomi anaemia in Curibita Brazil after successful collaboration.‚Ä¶ https://t.co/sE7q1O6jk1,false
ouholter,"Proud Oklahoma hematologist, wife, BMT physician, researcher, sooner, mom, loyal friend, thunder fan, and so proud of two amazing daughters! Tweets my own.",,"Oklahoma City, OK",,2020-02-22 16:41:30+00:00,J Holter Chakrabarty,http://twitter.com/,11.0,,1.2312577190064742e+18,,0.0,0.0,,"RT @hmgcoa2: #TCTM20 fascinating insight into the mechanisms of Neurotox post #CARTcells  characteristic MRI changes, IL6 not very high in‚Ä¶",en,0.0,309.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,6.0,https://twitter.com/ouholter/statuses/1231257719006474242,0.0,0.0,,0.0,0.0,0.0,6.0,5.0,False,False,False,False,True,Diagnostic Tools,1.0,0.0,0.0,"RT @hmgcoa2: #TCTM20 fascinating insight into the mechanisms of Neurotox post #CARTcells  characteristic MRI changes, IL6 not very high in‚Ä¶",true
EllenFraint,"Pediatric oncologist, stem cell transplant researcher, queer adoptive mom, activistüåàüß¨üö≤",,,,2020-02-22 13:36:23+00:00,Ellen Fraint,http://twitter.com/,7.0,,1.2312111335094804e+18,,0.0,0.0,,"If you‚Äôd like to hear about an exciting novel hematopoietic stem cell transplant model, come stop by my poster #384‚Ä¶ https://t.co/wTEZ4vR0RB",en,0.0,430.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,7.0,https://twitter.com/EllenFraint/statuses/1231211133509480453,0.0,0.0,,0.0,0.0,0.0,7.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"If you‚Äôd like to hear about an exciting novel hematopoietic stem cell transplant model, come stop by my poster #384‚Ä¶ https://t.co/wTEZ4vR0RB",true
ouholter,"Proud Oklahoma hematologist, wife, BMT physician, researcher, sooner, mom, loyal friend, thunder fan, and so proud of two amazing daughters! Tweets my own.",,"Oklahoma City, OK",,2020-02-22 17:31:35+00:00,J Holter Chakrabarty,http://twitter.com/,3.0,,1.231270322218918e+18,,0.0,0.0,,"‚Å¶@DrMiguelPerales, ‚Å¶@drkomanduri‚Å© and Dr. Marcie Riches along with Dr. Soyoung Kim and Naya He, MS in Infection and‚Ä¶ https://t.co/eybmxVeGON",en,0.0,309.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/ouholter/statuses/1231270322218917888,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"‚Å¶@DrMiguelPerales, ‚Å¶@drkomanduri‚Å© and Dr. Marcie Riches along with Dr. Soyoung Kim and Naya He, MS in Infection and‚Ä¶ https://t.co/eybmxVeGON",true
Kt10ab,MD üë©üèª‚Äç‚öïÔ∏è | ‚òïÔ∏è üê∂ üìö,,,,2020-08-27 20:56:35+00:00,Katherine Abifandi,http://twitter.com/,10.0,,1.2990884436880794e+18,,0.0,0.0,,"RT @CIBMTR: At the TCT Meetings, we shine a spotlight on innovative research in the field. Abstract submission is now open for #TCTM21. Sub‚Ä¶",en,0.0,88.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,4.0,https://twitter.com/Kt10ab/statuses/1299088443688079361,0.0,0.0,,0.0,0.0,0.0,4.0,6.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"RT @CIBMTR: At the TCT Meetings, we shine a spotlight on innovative research in the field. Abstract submission is now open for #TCTM21. Sub‚Ä¶",true
TAinaMDMPH,Sister.Daughter.Physician.PediatricAnesthesiologist.ClinicianEducator. Tweets are my own ‚ù§,,United States,,2020-08-27 16:55:23+00:00,"T.Aina, MD MPH",http://twitter.com/,1.0,,1.2990277453395927e+18,,0.0,0.0,,RT @Pedisedationdoc: Virtual Sickle Cell Disease fundraising brunch with live music from Karter James. #SickleTiniSaturday #SCDAA https://t‚Ä¶,en,0.0,150.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/TAinaMDMPH/statuses/1299027745339592704,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Disease Advocacy,0.0,0.0,1.0,RT @Pedisedationdoc: Virtual Sickle Cell Disease fundraising brunch with live music from Karter James. #SickleTiniSaturday #SCDAA https://t‚Ä¶,true
Pedisedationdoc,"Pediatric emergency medicne physician. Passion for family-centered, quality pain & sedation management/research. tweets are my own",,"Houston, TX",,2020-08-27 16:48:50+00:00,Corrie Chumpitazi MD MS FAAP FACEP,http://twitter.com/,1.0,,1.299026095711359e+18,,0.0,0.0,,Virtual Sickle Cell Disease fundraising brunch with live music from Karter James. #SickleTiniSaturday #SCDAA‚Ä¶ https://t.co/KOl4Zf44iJ,en,0.0,942.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/Pedisedationdoc/statuses/1299026095711358983,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Disease Advocacy,0.0,0.0,1.0,Virtual Sickle Cell Disease fundraising brunch with live music from Karter James. #SickleTiniSaturday #SCDAA‚Ä¶ https://t.co/KOl4Zf44iJ,false
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-03-05 01:08:05+00:00,Oncology Tube,http://twitter.com/,0.0,,1.2353714717042235e+18,,0.0,0.0,,Magenta Therapeutics to Present New Clinical and Preclinical Data at American Society of Hematology (ASH) Annual Me‚Ä¶ https://t.co/PtGR0SMlg9,en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1235371471704223744,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,Magenta Therapeutics to Present New Clinical and Preclinical Data at American Society of Hematology (ASH) Annual Me‚Ä¶ https://t.co/PtGR0SMlg9,true
sarah_glogowski,PGY3 AP/CP @BUMCpath. 2022 @hemepathUTSW. @Pathologists RFEC Chair. @theUSCAP Ambassador. @Texpathol. #NTSP Advisory Committee üê∂Mom #UltimateFrisbee #DND #INTJ,,"Dallas, TX",,2020-10-25 03:54:24+00:00,"Sarah Glogowski, DO",http://twitter.com/,16.0,,1.3202120866565202e+18,,0.0,0.0,,"RT @ASH_hematology: #ASH20 is right around the corner! Watch our video to see the unique features of our innovative, virtual platform. üñ•Ô∏èüì±üíª‚Ä¶",en,0.0,1506.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,11.0,5.0,https://twitter.com/sarah_glogowski/statuses/1320212086656520192,0.0,0.0,,0.0,0.0,0.0,5.0,11.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"RT @ASH_hematology: #ASH20 is right around the corner! Watch our video to see the unique features of our innovative, virtual platform. üñ•Ô∏èüì±üíª‚Ä¶",true
venkymd,Medical and Pediatric Oncologist. Global health student. #Kilpauk #PGI #AIIMS #StJude #cancerInstitute,,,,2020-11-06 12:44:37+00:00,Venkatraman Radhakrishnan (Venky),http://twitter.com/,22.0,,1.3246941725954458e+18,,0.0,0.0,,"RT @graham74GC: Rodday et al (HoLISTIC cosortium)
- &gt; 1000 pts in different trials with st III/IV cHL
- poor prog factors: Age &gt;50, stage I‚Ä¶",en,0.0,2842.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,17.0,5.0,https://twitter.com/venkymd/statuses/1324694172595445761,0.0,0.0,,0.0,0.0,0.0,5.0,17.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @graham74GC: Rodday et al (HoLISTIC cosortium)
- &gt; 1000 pts in different trials with st III/IV cHL
- poor prog factors: Age &gt;50, stage I‚Ä¶",true
MiGilbertson,"Husband / Dad. Haematologist with interest in Hodgkin and non-Hodgkin lymphoma, myeloma, CLL. Monash Health, Western Health. Views are my own.",,"Melbourne, Victoria",,2020-11-06 20:01:48+00:00,Michael Gilbertson,http://twitter.com/,22.0,,1.3248041947468636e+18,,0.0,0.0,,"RT @graham74GC: Rodday et al (HoLISTIC cosortium)
- &gt; 1000 pts in different trials with st III/IV cHL
- poor prog factors: Age &gt;50, stage I‚Ä¶",en,0.0,54.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,17.0,5.0,https://twitter.com/MiGilbertson/statuses/1324804194746863616,0.0,0.0,,0.0,0.0,0.0,5.0,17.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @graham74GC: Rodday et al (HoLISTIC cosortium)
- &gt; 1000 pts in different trials with st III/IV cHL
- poor prog factors: Age &gt;50, stage I‚Ä¶",true
humberto0927,"Blood cancer doctor/researcher, epidemiology MSc (c), focus on Multiple Myeloma and Hodgkin Lymphoma.",,Colombia,,2020-11-06 17:33:45+00:00,Humberto Martinez-Cordero,http://twitter.com/,2.0,,1.3247669386613268e+18,,0.0,0.0,,RT @mtmdphd: Severity of Sars-Cov-2 Infection in Patients with Hematologic Malignancies: A COVID-19 &amp; Cancer Consortium (CCC19) Registry An‚Ä¶,en,0.0,474.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,1.0,1.0,https://twitter.com/humberto0927/statuses/1324766938661326848,0.0,0.0,,0.0,0.0,0.0,1.0,1.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,RT @mtmdphd: Severity of Sars-Cov-2 Infection in Patients with Hematologic Malignancies: A COVID-19 &amp; Cancer Consortium (CCC19) Registry An‚Ä¶,true
ThiloZander,Medical Oncologist. Head of Lymphoma & Myeloma Service. Lucerne Cancer Center. Switzerland.,,"Lucerne, Switzerland",,2020-11-06 20:39:24+00:00,"Thilo J Zander, MD",http://twitter.com/,3.0,,1.324813657088426e+18,,0.0,0.0,,Abstract #3018. #ASH20 Pembrolizumab in relapsed #PCNSL ORR: 26% | PFS 2.6 months &gt; PD1 inhibition much less effect‚Ä¶ https://t.co/QHdHcvJ2OI,en,0.0,843.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/ThiloZander/statuses/1324813657088425984,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,Abstract #3018. #ASH20 Pembrolizumab in relapsed #PCNSL ORR: 26% | PFS 2.6 months &gt; PD1 inhibition much less effect‚Ä¶ https://t.co/QHdHcvJ2OI,false
biostockguru,Physician executive(MD CWRU;Rice/Jones);Healthcare focus Fund;Pharma advisor/KOL;Tweets NOT investment advice.Pls do your DD. Support https://t.co/97U34OldNG,,United States,,2020-11-06 12:09:06+00:00,biostockGuru,http://twitter.com/,0.0,,1.3246852345419776e+18,,0.0,0.0,,"PB2452 only reversal agent of #Brilinta $AZN

$PHAS 

PTLA ‚Äî&gt; $ALXN buyout for 1.5 Billion $

$PHAS market cap $96M‚Ä¶ https://t.co/2g4fwtOfub",en,0.0,14011.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/biostockguru/statuses/1324685234541977600,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,"PB2452 only reversal agent of #Brilinta $AZN

$PHAS 

PTLA ‚Äî&gt; $ALXN buyout for 1.5 Billion $

$PHAS market cap $96M‚Ä¶ https://t.co/2g4fwtOfub",true
KellyMi06345321,"Wife| Mother of 3| Sister| Daughter| Cook| Runner| RN BSN| Proud & Privileged to work for Abiomed as Dir, US Physician Programs| Tweets are my own",,"Delafield, WI",,2020-10-14 22:53:43+00:00,Kelly Miller,http://twitter.com/,8.0,,1.3165125398496952e+18,,0.0,0.0,,RT @ProtectedPCI: New data from PROTECT III is being presented at #TCTConnect as a part of the Best of Abstracts session by @BillONeillMD o‚Ä¶,en,0.0,301.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,3.0,https://twitter.com/KellyMi06345321/statuses/1316512539849695238,0.0,0.0,,0.0,0.0,0.0,3.0,5.0,False,False,False,False,True,Cost of Care,1.0,0.0,0.0,RT @ProtectedPCI: New data from PROTECT III is being presented at #TCTConnect as a part of the Best of Abstracts session by @BillONeillMD o‚Ä¶,true
MattPPlayer,Husband to Eloise. Christian. Haematologist. Interested in Global Haematology. Sports fan.,,Malawi,,2020-09-14 07:18:59+00:00,Matthew Player,http://twitter.com/,310.0,,1.3054056691395256e+18,,0.0,0.0,,RT @VincentRK: 4 key slides from my talk on ‚ÄúHow I Treat Newly Diagnosed Myeloma‚Äù at #ASHMHM20 @ASH_hematology meeting. @MayoCancerCare @Ma‚Ä¶,en,0.0,41.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,220.0,90.0,https://twitter.com/MattPPlayer/statuses/1305405669139525633,0.0,0.0,,0.0,0.0,0.0,90.0,220.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @VincentRK: 4 key slides from my talk on ‚ÄúHow I Treat Newly Diagnosed Myeloma‚Äù at #ASHMHM20 @ASH_hematology meeting. @MayoCancerCare @Ma‚Ä¶,true
AZarzourMD,Oncologist at @NorthwesternMed #WarrenvilleCancerCenter #CentralDuPageHospital @LurieCancer | @NorthwesternMed and @ClevelandClinic alum,,"Chicago, IL",,2020-09-14 04:09:29+00:00,Ahmad Zarzour,http://twitter.com/,310.0,,1.3053579799365796e+18,,0.0,0.0,,RT @VincentRK: 4 key slides from my talk on ‚ÄúHow I Treat Newly Diagnosed Myeloma‚Äù at #ASHMHM20 @ASH_hematology meeting. @MayoCancerCare @Ma‚Ä¶,en,0.0,207.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,220.0,90.0,https://twitter.com/AZarzourMD/statuses/1305357979936579585,0.0,0.0,,0.0,0.0,0.0,90.0,220.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @VincentRK: 4 key slides from my talk on ‚ÄúHow I Treat Newly Diagnosed Myeloma‚Äù at #ASHMHM20 @ASH_hematology meeting. @MayoCancerCare @Ma‚Ä¶,true
hematonews,"M√©dico Hemat√≥logo. Maestr√≠a y Doctorado en Ciencias. Profesor de Posgrado (UNAM). Apasionado del arte, cultura, literatura, novela, gadgets,cine, musica, France",,"√úT: 18.843385,-99.200819",,2020-09-14 04:35:04+00:00,Carlos M Murillo PhD,http://twitter.com/,310.0,,1.3053644174633615e+18,,0.0,0.0,,RT @VincentRK: 4 key slides from my talk on ‚ÄúHow I Treat Newly Diagnosed Myeloma‚Äù at #ASHMHM20 @ASH_hematology meeting. @MayoCancerCare @Ma‚Ä¶,en,0.0,898.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,220.0,90.0,https://twitter.com/hematonews/statuses/1305364417463361537,0.0,0.0,,0.0,0.0,0.0,90.0,220.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @VincentRK: 4 key slides from my talk on ‚ÄúHow I Treat Newly Diagnosed Myeloma‚Äù at #ASHMHM20 @ASH_hematology meeting. @MayoCancerCare @Ma‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-09-14 22:38:03+00:00,"Ritcha Saxena, MD",http://twitter.com/,310.0,,1.3056369611982395e+18,,0.0,0.0,,RT @VincentRK: 4 key slides from my talk on ‚ÄúHow I Treat Newly Diagnosed Myeloma‚Äù at #ASHMHM20 @ASH_hematology meeting. @MayoCancerCare @Ma‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,220.0,90.0,https://twitter.com/RitchaSaxena/statuses/1305636961198239746,0.0,0.0,,0.0,0.0,0.0,90.0,220.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @VincentRK: 4 key slides from my talk on ‚ÄúHow I Treat Newly Diagnosed Myeloma‚Äù at #ASHMHM20 @ASH_hematology meeting. @MayoCancerCare @Ma‚Ä¶,false
diegoah66,"Hematologist-Oncologist @UVMMedCenter, Assistant Professor of Medicine @UVMLarnerMed | üáµüá™üá∫üá∏",,"Burlington, VT",,2020-09-14 04:53:04+00:00,Diego Adrianzen-Herrera,http://twitter.com/,310.0,,1.305368947827581e+18,,0.0,0.0,,RT @VincentRK: 4 key slides from my talk on ‚ÄúHow I Treat Newly Diagnosed Myeloma‚Äù at #ASHMHM20 @ASH_hematology meeting. @MayoCancerCare @Ma‚Ä¶,en,0.0,187.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,220.0,90.0,https://twitter.com/diegoah66/statuses/1305368947827580928,0.0,0.0,,0.0,0.0,0.0,90.0,220.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @VincentRK: 4 key slides from my talk on ‚ÄúHow I Treat Newly Diagnosed Myeloma‚Äù at #ASHMHM20 @ASH_hematology meeting. @MayoCancerCare @Ma‚Ä¶,true
tmortiz,"Oncologist, former Harvard Med, Dana-Farber/MGH trainee. Franciscan Onc Medical Director of Clinical Trials",,"Indianapolis, IN",,2020-09-14 10:44:36+00:00,"Taylor Ortiz, MD",http://twitter.com/,310.0,,1.3054574156982313e+18,,0.0,0.0,,RT @VincentRK: 4 key slides from my talk on ‚ÄúHow I Treat Newly Diagnosed Myeloma‚Äù at #ASHMHM20 @ASH_hematology meeting. @MayoCancerCare @Ma‚Ä¶,en,0.0,86.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,220.0,90.0,https://twitter.com/tmortiz/statuses/1305457415698231296,0.0,0.0,,0.0,0.0,0.0,90.0,220.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @VincentRK: 4 key slides from my talk on ‚ÄúHow I Treat Newly Diagnosed Myeloma‚Äù at #ASHMHM20 @ASH_hematology meeting. @MayoCancerCare @Ma‚Ä¶,true
TxaviManCat,"Hematologist, MD, PhD. Hospital del Mar, IMIM, GRETNHE (Translational Research on Hematological Neoplasms Group).",,"El Clot, Barcelona",,2020-09-14 05:58:39+00:00,Xavier Calvo,http://twitter.com/,310.0,,1.3053854508913664e+18,,0.0,0.0,,RT @VincentRK: 4 key slides from my talk on ‚ÄúHow I Treat Newly Diagnosed Myeloma‚Äù at #ASHMHM20 @ASH_hematology meeting. @MayoCancerCare @Ma‚Ä¶,en,0.0,895.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,220.0,90.0,https://twitter.com/TxaviManCat/statuses/1305385450891366401,0.0,0.0,,0.0,0.0,0.0,90.0,220.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @VincentRK: 4 key slides from my talk on ‚ÄúHow I Treat Newly Diagnosed Myeloma‚Äù at #ASHMHM20 @ASH_hematology meeting. @MayoCancerCare @Ma‚Ä¶,true
venkymd,Medical and Pediatric Oncologist. Global health student. #Kilpauk #PGI #AIIMS #StJude #cancerInstitute,,,,2020-09-14 04:09:53+00:00,Venkatraman Radhakrishnan (Venky),http://twitter.com/,310.0,,1.3053580821431828e+18,,0.0,0.0,,RT @VincentRK: 4 key slides from my talk on ‚ÄúHow I Treat Newly Diagnosed Myeloma‚Äù at #ASHMHM20 @ASH_hematology meeting. @MayoCancerCare @Ma‚Ä¶,en,0.0,2842.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,220.0,90.0,https://twitter.com/venkymd/statuses/1305358082143182850,0.0,0.0,,0.0,0.0,0.0,90.0,220.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @VincentRK: 4 key slides from my talk on ‚ÄúHow I Treat Newly Diagnosed Myeloma‚Äù at #ASHMHM20 @ASH_hematology meeting. @MayoCancerCare @Ma‚Ä¶,true
olga45093932,"MD,PhD, hematologist of @NationalCancerInst of @oncohematologyDepart",,"Kiev, Ukraine",,2020-09-14 19:36:11+00:00,Olga,http://twitter.com/,310.0,,1.305591190352474e+18,,0.0,0.0,,RT @VincentRK: 4 key slides from my talk on ‚ÄúHow I Treat Newly Diagnosed Myeloma‚Äù at #ASHMHM20 @ASH_hematology meeting. @MayoCancerCare @Ma‚Ä¶,en,0.0,64.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,220.0,90.0,https://twitter.com/olga45093932/statuses/1305591190352474116,0.0,0.0,,0.0,0.0,0.0,90.0,220.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @VincentRK: 4 key slides from my talk on ‚ÄúHow I Treat Newly Diagnosed Myeloma‚Äù at #ASHMHM20 @ASH_hematology meeting. @MayoCancerCare @Ma‚Ä¶,true
DrPehlivan,Gaziantep √úniversitesi Kemik ƒ∞liƒüi Transplantasyon Merkezi Prof. Dr.,,Hayat devam ediyor...,,2020-09-14 04:02:47+00:00,Mustafa Pehlivan,http://twitter.com/,310.0,,1.305356295696978e+18,,0.0,0.0,,RT @VincentRK: 4 key slides from my talk on ‚ÄúHow I Treat Newly Diagnosed Myeloma‚Äù at #ASHMHM20 @ASH_hematology meeting. @MayoCancerCare @Ma‚Ä¶,en,0.0,1469.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,220.0,90.0,https://twitter.com/DrPehlivan/statuses/1305356295696977921,0.0,0.0,,0.0,0.0,0.0,90.0,220.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @VincentRK: 4 key slides from my talk on ‚ÄúHow I Treat Newly Diagnosed Myeloma‚Äù at #ASHMHM20 @ASH_hematology meeting. @MayoCancerCare @Ma‚Ä¶,false
VincentRK,"Professor, Mayo Clinic; Editor, Blood Cancer Journal; Oncologist; Health Costs; COVID threads @SurvivedCOVID Opinions=personal views https://t.co/TMq9vc5hZk",,"Rochester, MN, USA",,2020-09-14 02:57:01+00:00,Vincent Rajkumar,http://twitter.com/,90.0,,1.3053397432286167e+18,,0.0,0.0,,4 key slides from my talk on ‚ÄúHow I Treat Newly Diagnosed Myeloma‚Äù at #ASHMHM20 @ASH_hematology meeting.‚Ä¶ https://t.co/AQulPQHpiB,en,0.0,33589.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,90.0,https://twitter.com/VincentRK/statuses/1305339743228616704,0.0,0.0,,0.0,0.0,0.0,90.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,4 key slides from my talk on ‚ÄúHow I Treat Newly Diagnosed Myeloma‚Äù at #ASHMHM20 @ASH_hematology meeting.‚Ä¶ https://t.co/AQulPQHpiB,true
AKeyzner,"hematologist #BMT #leuksm physician ‚â†provider immigrant, opinions my own, likes‚â†endorsement",,,,2020-09-14 20:35:25+00:00,Alla Keyzner,http://twitter.com/,310.0,,1.3056060982258565e+18,,0.0,0.0,,RT @VincentRK: 4 key slides from my talk on ‚ÄúHow I Treat Newly Diagnosed Myeloma‚Äù at #ASHMHM20 @ASH_hematology meeting. @MayoCancerCare @Ma‚Ä¶,en,0.0,157.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,220.0,90.0,https://twitter.com/AKeyzner/statuses/1305606098225856513,0.0,0.0,,0.0,0.0,0.0,90.0,220.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @VincentRK: 4 key slides from my talk on ‚ÄúHow I Treat Newly Diagnosed Myeloma‚Äù at #ASHMHM20 @ASH_hematology meeting. @MayoCancerCare @Ma‚Ä¶,true
KardiologieHH,Interventional Cardiologist | Sch√∂n Klinik Hamburg Eilbek Germany | Husband ‚ù§Ô∏è| Father üëß üëß | #radialfirst |#DGKAmbassador | #AGIKAmbassador,,"Hamburg, Deutschland",,2020-10-14 18:04:11+00:00,Erik Rafflenbeul,http://twitter.com/,31.0,,1.3164396755953009e+18,,0.0,0.0,,"RT @DrSethdb: #TCTConnect #TCT2020 Abstracts out-all at once
RESTORE-EF investigators present high risk PCI supported with Impella #Protect‚Ä¶",en,0.0,1643.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,22.0,9.0,https://twitter.com/KardiologieHH/statuses/1316439675595300864,0.0,0.0,,0.0,0.0,0.0,9.0,22.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,"RT @DrSethdb: #TCTConnect #TCT2020 Abstracts out-all at once
RESTORE-EF investigators present high risk PCI supported with Impella #Protect‚Ä¶",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 20:12:35+00:00,"Ritcha Saxena, MD",http://twitter.com/,10.0,,1.3356785468288164e+18,,0.0,0.0,,RT @razan_mohty: Venetoclax + Gilteritinib for R/R FLT3-Mutated #AML in the Expansion Cohort of a Phase 1b Study by Dr Naval Daver - Nice r‚Ä¶,en,0.0,6875.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,4.0,https://twitter.com/RitchaSaxena/statuses/1335678546828816393,0.0,0.0,,0.0,0.0,0.0,4.0,6.0,False,False,False,False,True,Clinical Trials,1.0,0.0,0.0,RT @razan_mohty: Venetoclax + Gilteritinib for R/R FLT3-Mutated #AML in the Expansion Cohort of a Phase 1b Study by Dr Naval Daver - Nice r‚Ä¶,true
AlexSilverMSTP,MD/PhD student in Savona Lab at @VanderbiltMSTP | #ClonalHematopoiesis #DoubleDocs #HeForShe #BLM | @WilliamsCollege alum | he/him |Views are my own,,Vanderbilt Medical School,,2020-12-07 20:19:39+00:00,Alex Silver,http://twitter.com/,3.0,,1.3360427120852296e+18,,0.0,0.0,,RT @feldstej: 714 Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Hematopoietic Stem Cells in JAK2-Muta‚Ä¶,en,0.0,1480.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,2.0,1.0,https://twitter.com/AlexSilverMSTP/statuses/1336042712085229570,0.0,0.0,,0.0,0.0,0.0,1.0,2.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @feldstej: 714 Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Hematopoietic Stem Cells in JAK2-Muta‚Ä¶,true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-12-06 16:45:05+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,1.0,,1.3356263262255145e+18,,0.0,0.0,,"#ASH20 Donald: ‚ÄúPersistent health disparities leave us all diminished.‚Äù
#BLM #healthequity",en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/hemedoc/statuses/1335626326225514496,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,"#ASH20 Donald: ‚ÄúPersistent health disparities leave us all diminished.‚Äù
#BLM #healthequity",false
TaylorJ_MD,"Assistant Professor, UM Sylvester Comprehensive Cancer Center. Physician scientist studying the role of nuclear export and splicing in hematologic cancers.",,"Miami, FL",,2020-12-07 17:24:01+00:00,Taylor Lab UM,http://twitter.com/,0.0,,1.3359985114273792e+18,,0.0,0.0,,"XPO1 mutations, particularly E571K, are oncogenic, alter nuclear export signal recognition and predict preclinical‚Ä¶ https://t.co/NkLIzsrpRz",en,0.0,1781.0,,,0.0,TaylorJ_MD,1.335998504968151e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/TaylorJ_MD/statuses/1335998511427379200,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"XPO1 mutations, particularly E571K, are oncogenic, alter nuclear export signal recognition and predict preclinical‚Ä¶ https://t.co/NkLIzsrpRz",true
donlaz4u,"Medical Doctor| Public Health Specialist| CEO, @TalkHealth9ja| Founder, @TestrogenHub| Co-Founder @AfrYPoD | Producer, #TalkingHealthWithDrLaz| @MakeOurHospWork",,"Abuja, Nigeria",,2020-10-22 09:41:04+00:00,Laz Ude Eze,http://twitter.com/,58.0,,1.319212165463683e+18,,0.0,0.0,,"RT @accountlabng: Join us Friday, 24th April here @accountlabng for the April edition of #TIF as we discuss the #COVID19 pandemic 

Special‚Ä¶",en,0.0,7624.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,34.0,24.0,https://twitter.com/donlaz4u/statuses/1319212165463683077,0.0,0.0,,0.0,0.0,0.0,24.0,34.0,False,False,False,False,True,Covid,0.0,0.0,1.0,"RT @accountlabng: Join us Friday, 24th April here @accountlabng for the April edition of #TIF as we discuss the #COVID19 pandemic 

Special‚Ä¶",true
EladSharonMD,"#MedicalOncologist tweeting on #immunotherapy, #drugdevelopment, #COVID19 & #HealthEcon. #NCI #CancerMoonshot Adult Immunotherapy Co-Chair. Tweets are mine.",,"Washington, DC",,2020-12-06 18:04:30+00:00,Elad Sharon,http://twitter.com/,40.0,,1.335646311853351e+18,,0.0,0.0,,RT @Dr_AmerZeidan: Very proud of our effective partnership with @theNCI @NCICTEP_ClinRes @EladSharonMD and many collaborators to develop th‚Ä¶,en,0.0,2113.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,34.0,6.0,https://twitter.com/EladSharonMD/statuses/1335646311853350912,0.0,0.0,,0.0,0.0,0.0,6.0,34.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @Dr_AmerZeidan: Very proud of our effective partnership with @theNCI @NCICTEP_ClinRes @EladSharonMD and many collaborators to develop th‚Ä¶,true
haematognomist,"Internal Medicine PGY1 @BrighamMedRes MD @Penn ‰∏®Team Member @CPSolvers & @runthelistpod ‰∏®Leukemia Genomics & Med-Ed‰∏®Afro-Latinx, Pura Vida! üá∫üá∏üá®üá∑üáØüá≤",,"Boston, MA",,2020-12-06 23:13:29+00:00,H. Moses Murdock,http://twitter.com/,22.0,,1.3357240695437025e+18,,0.0,0.0,,RT @LuskinMarlise: Great work by @ErikaHaydu with @ColemanLindsley @DanaFarber #ASH2020,en,0.0,2619.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,20.0,2.0,https://twitter.com/haematognomist/statuses/1335724069543702528,0.0,0.0,,0.0,0.0,0.0,2.0,20.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @LuskinMarlise: Great work by @ErikaHaydu with @ColemanLindsley @DanaFarber #ASH2020,true
UjjaniC,CLL/Lymphoma oncologist at Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research Center/University of Washington,,"Seattle, WA",,2020-12-07 16:20:50+00:00,"Chaitra Ujjani, MD",http://twitter.com/,8.0,,1.3359826115717243e+18,,0.0,0.0,,So excited to finally present Ibrutinib + Venetoclax in Follicular #Lymphoma! ORR &gt; 80% at RP2D. Phase 2 currently‚Ä¶ https://t.co/y0EAqwEimZ,en,0.0,590.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,8.0,https://twitter.com/UjjaniC/statuses/1335982611571724289,0.0,0.0,,0.0,0.0,0.0,8.0,0.0,False,False,False,False,True,Clinical Trials,1.0,0.0,0.0,So excited to finally present Ibrutinib + Venetoclax in Follicular #Lymphoma! ORR &gt; 80% at RP2D. Phase 2 currently‚Ä¶ https://t.co/y0EAqwEimZ,true
A_Ivanovs,"Doctor (#Haematology; #NHS). Scientist (#HSC Biology). MD, MSc (Translational Biomedical Research), PhD (Experimental Haematology), MRCP(UK)",,Between Edinburgh and Glasgow,,2020-12-07 00:31:44+00:00,Andrejs Ivanovs,http://twitter.com/,51.0,,1.335743762992132e+18,,0.0,0.0,,RT @ProfMakris: Tranexamic acid did not reduce bleeding but increased central line occlusions in thrombocytopenic patients post-chemo. The‚Ä¶,en,0.0,194.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,40.0,11.0,https://twitter.com/A_Ivanovs/statuses/1335743762992132098,0.0,0.0,,0.0,0.0,0.0,11.0,40.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @ProfMakris: Tranexamic acid did not reduce bleeding but increased central line occlusions in thrombocytopenic patients post-chemo. The‚Ä¶,false
CanerSaygin,"Heme-Onc Fellow @UChicago | Alumni of @OhioStateIMRes, @CCLRI | #Leukemia, #MDS, #CHIP physician-scientist. Tweets=own opinions.",,"Chicago, IL",,2020-12-06 22:43:11+00:00,"Caner Saygin, MD",http://twitter.com/,0.0,,1.3357164432085074e+18,,0.0,0.0,,"Dr Ravandi presented phase 1 study of vibecotamab (XmAb14045), CD123 x CD3 bispecific antibody in R/R #AML pts. Res‚Ä¶ https://t.co/0QEdVV2Y14",en,0.0,743.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/CanerSaygin/statuses/1335716443208507395,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"Dr Ravandi presented phase 1 study of vibecotamab (XmAb14045), CD123 x CD3 bispecific antibody in R/R #AML pts. Res‚Ä¶ https://t.co/0QEdVV2Y14",true
PAMJ84,Ronin Haematologist,,Europe,,2020-12-07 19:12:29+00:00,P. A-M,http://twitter.com/,22.0,,1.3360258065948467e+18,,0.0,0.0,,"RT @tobyeyre82: AUTO3 bicistronic CART
Dual targeting CD19/CD22 
PD1i Pembro to reduce CAR-T exhaustion
Phase I/II
n=49
3 prior lines
2% G3‚Ä¶",en,0.0,110.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,18.0,4.0,https://twitter.com/PAMJ84/statuses/1336025806594846722,0.0,0.0,,0.0,0.0,0.0,4.0,18.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @tobyeyre82: AUTO3 bicistronic CART
Dual targeting CD19/CD22 
PD1i Pembro to reduce CAR-T exhaustion
Phase I/II
n=49
3 prior lines
2% G3‚Ä¶",true
graham74GC,Lymphoma specialist at Oxford Cancer and Haematology centre. Haematologist and clinical trialist. Chair of UK Hodgkin and T-cell study groups.,,Opinions are mine,,2020-12-06 17:43:40+00:00,Graham Collins,http://twitter.com/,4.0,,1.3356410681052406e+18,,0.0,0.0,,"Buske - mature FU of iNNOVATE
Ibr+R vs Plac+R in WM
- 45% pop 1L
- 54mo PFS 68% vs 25% (HR 0.25!)
- largely indep o‚Ä¶ https://t.co/rzeXF4OhtT",en,0.0,6091.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,4.0,https://twitter.com/graham74GC/statuses/1335641068105240579,0.0,0.0,,0.0,0.0,0.0,4.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"Buske - mature FU of iNNOVATE
Ibr+R vs Plac+R in WM
- 45% pop 1L
- 54mo PFS 68% vs 25% (HR 0.25!)
- largely indep o‚Ä¶ https://t.co/rzeXF4OhtT",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-07 18:35:50+00:00,Lisa Palacios,http://twitter.com/,2.0,,1.3360165842934088e+18,,0.0,0.0,,RT @MicheleNadeemB: More CLL #ASH20 NEWS tomorrow @PatientPower Join me with 3 leading CLL docs @MDAndersonNews @wwierda @WeillCornell @Nor‚Ä¶,en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,1.0,1.0,https://twitter.com/Lisa_Palacios/statuses/1336016584293408771,0.0,0.0,,0.0,0.0,0.0,1.0,1.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @MicheleNadeemB: More CLL #ASH20 NEWS tomorrow @PatientPower Join me with 3 leading CLL docs @MDAndersonNews @wwierda @WeillCornell @Nor‚Ä¶,true
JoeNFrost,"Postdoctoral immunologist @Drakesmith_Lab @MRC_HIU @MRC_WIMM @UniofOxford interested in how physiology and immunology interact, with a focus on iron homeostasis",,,,2020-12-06 23:00:49+00:00,Joe Frost,http://twitter.com/,25.0,,1.3357208842130842e+18,,0.0,0.0,,"RT @srpasricha: In time for #ASH20: our @TheLancet seminar on #irondeficiency. An update on the pathophysiology, epidemiology, diagnosis, f‚Ä¶",en,0.0,116.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,20.0,5.0,https://twitter.com/JoeNFrost/statuses/1335720884213084165,0.0,0.0,,0.0,0.0,0.0,5.0,20.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"RT @srpasricha: In time for #ASH20: our @TheLancet seminar on #irondeficiency. An update on the pathophysiology, epidemiology, diagnosis, f‚Ä¶",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-07 14:02:24+00:00,Lisa Palacios,http://twitter.com/,0.0,,1.3359477722442015e+18,,0.0,0.0,,"Tune in soon for Dr. Baran's presentation, 'Overcoming NOTCH1-Driven Chemoresistance in T-Cell Acute Lymphoblastic‚Ä¶ https://t.co/eXKXOeTQWg",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/Lisa_Palacios/statuses/1335947772244201474,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"Tune in soon for Dr. Baran's presentation, 'Overcoming NOTCH1-Driven Chemoresistance in T-Cell Acute Lymphoblastic‚Ä¶ https://t.co/eXKXOeTQWg",false
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-07 21:32:54+00:00,"Ritcha Saxena, MD",http://twitter.com/,6.0,,1.3360611462442803e+18,,0.0,0.0,,RT @feldstej: 3114 Myelodysplastic Syndromes (MDS) &amp; COVID-19: Clinical Experience from the US Epicenter of the Pandemic https://t.co/NCuX8‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,2.0,https://twitter.com/RitchaSaxena/statuses/1336061146244280320,0.0,0.0,,0.0,0.0,0.0,2.0,4.0,False,False,False,False,True,Covid,0.0,0.0,1.0,RT @feldstej: 3114 Myelodysplastic Syndromes (MDS) &amp; COVID-19: Clinical Experience from the US Epicenter of the Pandemic https://t.co/NCuX8‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 01:54:10+00:00,"Ritcha Saxena, MD",http://twitter.com/,24.0,,1.3354021187113e+18,,0.0,0.0,,RT @DanaFarberNews: A phase 1 trial found cytokine-induced memory-like NK cells exhibit expansion and long-term persistence after infusion‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,21.0,3.0,https://twitter.com/RitchaSaxena/statuses/1335402118711300096,0.0,0.0,,0.0,0.0,0.0,3.0,21.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @DanaFarberNews: A phase 1 trial found cytokine-induced memory-like NK cells exhibit expansion and long-term persistence after infusion‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 16:22:34+00:00,"Ritcha Saxena, MD",http://twitter.com/,13.0,,1.3356206585968804e+18,,0.0,0.0,,RT @AkshaySharmaMD: #ASH20 Richa Sharma from @StJudeResearch @marrowgenes lab #TBD #BMF https://t.co/TU4uUcXFWb,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,9.0,4.0,https://twitter.com/RitchaSaxena/statuses/1335620658596880386,0.0,0.0,,0.0,0.0,0.0,4.0,9.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @AkshaySharmaMD: #ASH20 Richa Sharma from @StJudeResearch @marrowgenes lab #TBD #BMF https://t.co/TU4uUcXFWb,true
drjgauthier,"MD, MSc, Assistant Professor @fredhutch @UW focused on #CARTcell #immunotherapy #tcellrx 
Interests also include #rstats #bmtsm #epitwitter #bayes",,"Seattle, WA",,2020-12-07 23:30:25+00:00,Jordan Gauthier,http://twitter.com/,38.0,,1.3360907178657382e+18,,0.0,0.0,,"RT @BCD_AACR: Dr Nikhil Munshi presents clinical data on BCMA loss in #myeloma #CAR_T relapse #ASH20. 
Read a related commentary, Dual Targ‚Ä¶",en,0.0,3295.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,30.0,8.0,https://twitter.com/drjgauthier/statuses/1336090717865738245,0.0,0.0,,0.0,0.0,0.0,8.0,30.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @BCD_AACR: Dr Nikhil Munshi presents clinical data on BCMA loss in #myeloma #CAR_T relapse #ASH20. 
Read a related commentary, Dual Targ‚Ä¶",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-07 02:40:24+00:00,"Ritcha Saxena, MD",http://twitter.com/,42.0,,1.3357761438075576e+18,,0.0,0.0,,RT @KenFigueroaLab: Congratulations to Dr Bhatnagar &amp; the OSU team for very important research into health disparities in AML presented at‚Ä¶,en,0.0,6875.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,32.0,10.0,https://twitter.com/RitchaSaxena/statuses/1335776143807557634,0.0,0.0,,0.0,0.0,0.0,10.0,32.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @KenFigueroaLab: Congratulations to Dr Bhatnagar &amp; the OSU team for very important research into health disparities in AML presented at‚Ä¶,true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-12-07 20:45:07+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,0.0,,1.33604911976525e+18,,0.0,0.0,,#ASH20 #leusm Stein (636): @LLSusa Prelim report from BEAT AML overall shows improved OS in those assigned to inves‚Ä¶ https://t.co/UZIzTEeRpR,en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/hemedoc/statuses/1336049119765250048,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Disease Advocacy,0.0,0.0,1.0,#ASH20 #leusm Stein (636): @LLSusa Prelim report from BEAT AML overall shows improved OS in those assigned to inves‚Ä¶ https://t.co/UZIzTEeRpR,false
emmamgroarke,"Haematologist in Bethesda. Irish trained üáÆüá™ Particular interests: #aplasticanemia, #telomeredisease, #CHIP, #MDS, #AML, #HSCT All comments my own.",,"Washington, DC",,2020-12-07 18:06:31+00:00,Emma M. Groarke,http://twitter.com/,9.0,,1.3360092067601654e+18,,0.0,0.0,,RT @AkshaySharmaMD: #ASH20 Very interesting concept by Dr Emily R Levy about #CRISPR #GeneEditing of #chemokine receptors as a novel strate‚Ä¶,en,0.0,130.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,8.0,1.0,https://twitter.com/emmamgroarke/statuses/1336009206760165377,0.0,0.0,,0.0,0.0,0.0,1.0,8.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @AkshaySharmaMD: #ASH20 Very interesting concept by Dr Emily R Levy about #CRISPR #GeneEditing of #chemokine receptors as a novel strate‚Ä¶,true
MalinHultcrantz,"MD PhD, Specialized in Multiple Myeloma. Memorial Sloan Kettering Cancer Center. Karolinska Institute. Tweets are my own.",,,,2020-12-06 19:37:43+00:00,Malin Hultcrantz MD PhD,http://twitter.com/,12.0,,1.335669771942105e+18,,0.0,0.0,,"RT @DrOlaLandgren: Excellent overview on immunotherapy in #myeloma . Strong talks by all presenters. Impressive, innovative translational w‚Ä¶",en,0.0,908.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,9.0,3.0,https://twitter.com/MalinHultcrantz/statuses/1335669771942105092,0.0,0.0,,0.0,0.0,0.0,3.0,9.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"RT @DrOlaLandgren: Excellent overview on immunotherapy in #myeloma . Strong talks by all presenters. Impressive, innovative translational w‚Ä¶",true
shalinhnaik,"Scientist @WEHI_research, part-time singer of the #Inflammatones, co-host of #AskTheDoctor and #ABCCatalyst on @ABCTV. Views are my own.",,"Melbourne, Victoria",,2020-12-06 22:48:17+00:00,Dr Shalin Naik,http://twitter.com/,185.0,,1.335717727290368e+18,,0.0,0.0,,"RT @AlejoFraticelli: Call to all stem cell hematologists and immunologists!!

My lab, Quantitative Stem Cell Dynamics (https://t.co/j0ocWZY‚Ä¶",en,0.0,2426.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,124.0,61.0,https://twitter.com/shalinhnaik/statuses/1335717727290368000,0.0,0.0,,0.0,0.0,0.0,61.0,124.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @AlejoFraticelli: Call to all stem cell hematologists and immunologists!!

My lab, Quantitative Stem Cell Dynamics (https://t.co/j0ocWZY‚Ä¶",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 21:23:06+00:00,"Ritcha Saxena, MD",http://twitter.com/,6.0,,1.335696289191891e+18,,0.0,0.0,,"RT @hemedoc: #ASH20 #leusm Bhatnagar: In analysis of @ALLIANCE_org studies blacks had worse OS, but no difference in early death, CR rate,‚Ä¶",en,0.0,6875.0,,,0.0,,,Negative,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,1.0,https://twitter.com/RitchaSaxena/statuses/1335696289191890949,0.0,0.0,,0.0,0.0,0.0,1.0,5.0,False,False,False,False,True,Collaboration,0.0,1.0,0.0,"RT @hemedoc: #ASH20 #leusm Bhatnagar: In analysis of @ALLIANCE_org studies blacks had worse OS, but no difference in early death, CR rate,‚Ä¶",true
christiplady,"Haematologist @northumbriaNHS, Executive Coach and Mentor, Director of Undergraduate Clinical Studies and programme lead for MMedEd @UoSMedicine",,Newcastle Upon Tyne,,2020-12-06 20:14:26+00:00,Chris Tiplady üíô,http://twitter.com/,26.0,,1.3356790115031736e+18,,0.0,0.0,,RT @ProfMakris: The Choosing Wisely program aims to reduce wastage and improve health care. It is amazing how much resource is wasted. Incr‚Ä¶,en,0.0,3295.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,20.0,6.0,https://twitter.com/christiplady/statuses/1335679011503173632,0.0,0.0,,0.0,0.0,0.0,6.0,20.0,False,False,False,False,True,Diagnosis Progression,1.0,0.0,0.0,RT @ProfMakris: The Choosing Wisely program aims to reduce wastage and improve health care. It is amazing how much resource is wasted. Incr‚Ä¶,true
dgermain21,MD-PhD. 2nd year Heme/Onc fellow focused on lymphoma and leukemia. Physician-scientist-in-training. Tweet/RT not medical advice or endorsement.,,"St. Louis, MO",,2020-12-06 22:17:37+00:00,David A. Russler-Germain,http://twitter.com/,43.0,,1.3357100119479378e+18,,0.0,0.0,,RT @MediHumdani: Pembro GVD: Outstanding data. Nearly 100% CR rates in relapsed classical HL @CMoskowitzMD #lymsm #ASH20,en,0.0,1612.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,32.0,11.0,https://twitter.com/dgermain21/statuses/1335710011947937795,0.0,0.0,,0.0,0.0,0.0,11.0,32.0,False,False,False,False,True,Diagnosis Progression,1.0,0.0,0.0,RT @MediHumdani: Pembro GVD: Outstanding data. Nearly 100% CR rates in relapsed classical HL @CMoskowitzMD #lymsm #ASH20,false
CanerSaygin,"Heme-Onc Fellow @UChicago | Alumni of @OhioStateIMRes, @CCLRI | #Leukemia, #MDS, #CHIP physician-scientist. Tweets=own opinions.",,"Chicago, IL",,2020-12-06 23:10:15+00:00,"Caner Saygin, MD",http://twitter.com/,218.0,,1.3357232573167247e+18,,0.0,0.0,,"RT @hemedoc: #ASH20 #leusm Wei: We are all excited to have new therapeutic options in AML, but the overall message I get from this money sl‚Ä¶",en,0.0,743.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,168.0,50.0,https://twitter.com/CanerSaygin/statuses/1335723257316724739,0.0,0.0,,0.0,0.0,0.0,50.0,168.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"RT @hemedoc: #ASH20 #leusm Wei: We are all excited to have new therapeutic options in AML, but the overall message I get from this money sl‚Ä¶",true
AGomez_MD,Hematologist-Oncologist |Stem Cell Transplant & Cellular Therapies | Assistant Professor @WeillCornell @nyphospital,,"New York, USA",,2020-12-06 19:06:08+00:00,Alexandra Gomez A.,http://twitter.com/,1.0,,1.335661823060816e+18,,0.0,0.0,,Very exciting work presented by Dr. Noa G. Holtzman &amp; @StevenPavletic. Phase I/II study of Baricitinib (oral jak1/2‚Ä¶ https://t.co/fh7EgXLSPb,en,0.0,1062.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/AGomez_MD/statuses/1335661823060815874,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Clinical Trials,1.0,0.0,0.0,Very exciting work presented by Dr. Noa G. Holtzman &amp; @StevenPavletic. Phase I/II study of Baricitinib (oral jak1/2‚Ä¶ https://t.co/fh7EgXLSPb,true
DrKussmanMD,Board Certified Pediatrician.Pediatric Hematology-Oncology Fellow interested in Bone Marrow Transplant and Cellular Therapy.Pediatric Cancer Survivor. Mom/wife.,,"Columbus, OH",,2020-12-08 20:52:51+00:00,Dr. Ashleigh Kussman,http://twitter.com/,2.0,,1.3364134527814164e+18,,0.0,0.0,,Because #COVID19 does not just cause an infection of the lungs... it also may cause blood clots and bleeding in add‚Ä¶ https://t.co/JQbneH83PV,en,0.0,2691.0,,,0.0,,,Negative,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/DrKussmanMD/statuses/1336413452781416451,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Disease Management,0.0,1.0,0.0,Because #COVID19 does not just cause an infection of the lungs... it also may cause blood clots and bleeding in add‚Ä¶ https://t.co/JQbneH83PV,true
Grilli15,Forensic Pathologist,,"Foggia,Italia",,2020-12-08 18:25:12+00:00,GiovanniMariaGrilli,http://twitter.com/,68.0,,1.3363762967425477e+18,,0.0,0.0,,RT @JanssenEMEA: What is CAR-T therapy? Watch this 3D VR video to learn more about how this innovative technology is being used to tackle #‚Ä¶,en,0.0,833.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,55.0,13.0,https://twitter.com/Grilli15/statuses/1336376296742547464,0.0,0.0,,0.0,0.0,0.0,13.0,55.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @JanssenEMEA: What is CAR-T therapy? Watch this 3D VR video to learn more about how this innovative technology is being used to tackle #‚Ä¶,true
TelehealthBot,Created by Doctor @KrittanawongMD. A bot that collects Tweets about medicine and medical innovation,,GJ 357 d,,2020-12-09 23:57:28+00:00,MedEd,http://twitter.com/,8.0,,1.3368223014012314e+18,,0.0,0.0,,RT @OncologyTimes: #ASH2020 Research Highlights on Acute Myeloid Leukemia: Venetoclax Added to Standard Treatments Shows Promise https://t.‚Ä¶,en,0.0,683.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,5.0,https://twitter.com/TelehealthBot/statuses/1336822301401231361,0.0,0.0,,0.0,0.0,0.0,5.0,3.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @OncologyTimes: #ASH2020 Research Highlights on Acute Myeloid Leukemia: Venetoclax Added to Standard Treatments Shows Promise https://t.‚Ä¶,true
ramya_ramaswami,"An oncologist caring for people living with HIV+cancer @theNCI|Trained in the üá¨üáß, from many cultures üá∏üá¨üáÆüá≥ now in üá∫üá∏ |Former @NEJM fellow |Views are mine",,"Washington, DC (for now)",,2020-12-07 22:43:42+00:00,Ramya Ramaswami,http://twitter.com/,14.0,,1.3360789628339528e+18,,0.0,0.0,,"RT @CwynKate: Great presentation @prp_diciaccio and mentorship by @nadahamad.
Fantastic international collaboration üá¶üá∫üá¨üáßüá®üá¶
n=197 Plasmablas‚Ä¶",en,0.0,1033.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,12.0,2.0,https://twitter.com/ramya_ramaswami/statuses/1336078962833952768,0.0,0.0,,0.0,0.0,0.0,2.0,12.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,"RT @CwynKate: Great presentation @prp_diciaccio and mentorship by @nadahamad.
Fantastic international collaboration üá¶üá∫üá¨üáßüá®üá¶
n=197 Plasmablas‚Ä¶",false
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-09 00:34:49+00:00,"Ritcha Saxena, MD",http://twitter.com/,8.0,,1.3364693123711263e+18,,0.0,0.0,,"RT @adctherapeutics: Attending #ASH20? Check out interim results from LOTIS 3, the Phase 1/2 trial of our lead investigational product in c‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,4.0,https://twitter.com/RitchaSaxena/statuses/1336469312371126278,0.0,0.0,,0.0,0.0,0.0,4.0,4.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @adctherapeutics: Attending #ASH20? Check out interim results from LOTIS 3, the Phase 1/2 trial of our lead investigational product in c‚Ä¶",true
Physns1stWatch,Physician's First Watch offers brief daily reviews of news that affects a physician's practice.,,"Waltham, MA",,2020-12-09 14:24:33+00:00,PhysiciansFirstWatch,http://twitter.com/,1.0,,1.3366781242858127e+18,,0.0,0.0,,News from #ASH20: Dr. Christopher Gibson talks with Joe Elia about new findings that show it might not be necessary‚Ä¶ https://t.co/vm3HxCkKpX,en,0.0,16507.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/Physns1stWatch/statuses/1336678124285812736,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,News from #ASH20: Dr. Christopher Gibson talks with Joe Elia about new findings that show it might not be necessary‚Ä¶ https://t.co/vm3HxCkKpX,true
Sanctiyague,"Hematopathologist, Molecular and Bone & Soft Tissue. Lymphoma research in my free time. Head of the Translational Hematopathology Lab. Ad Astra per Aspera.",,"Santander, Espa√±a",,2020-12-09 18:27:35+00:00,Santiago Montes Moreno,http://twitter.com/,38.0,,1.3367392852240712e+18,,0.0,0.0,,RT @sanamloghavi: major diagnostic pitfall 4 High-grade (double/triple hit) lymphoma with leukemic presentation is misclassifying as de nov‚Ä¶,en,0.0,320.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,29.0,9.0,https://twitter.com/Sanctiyague/statuses/1336739285224071170,0.0,0.0,,0.0,0.0,0.0,9.0,29.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @sanamloghavi: major diagnostic pitfall 4 High-grade (double/triple hit) lymphoma with leukemic presentation is misclassifying as de nov‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-09 00:31:14+00:00,"Ritcha Saxena, MD",http://twitter.com/,27.0,,1.3364684136785633e+18,,0.0,0.0,,"RT @MediHumdani: What I learnt from @SoniSmithMD transformed NHL talk? #ASH20 #lymsm 
-Biopsy üóùÔ∏è esp in POD24s 
-MYC can be acquire
-anthra‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,21.0,6.0,https://twitter.com/RitchaSaxena/statuses/1336468413678563339,0.0,0.0,,0.0,0.0,0.0,6.0,21.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"RT @MediHumdani: What I learnt from @SoniSmithMD transformed NHL talk? #ASH20 #lymsm 
-Biopsy üóùÔ∏è esp in POD24s 
-MYC can be acquire
-anthra‚Ä¶",true
DrABurke,"Mum, wife, haematologist, daughter, sister, friend - in no particular order! Personal account #carecantwait RTs do not equal endorsement",,,,2020-12-09 09:35:51+00:00,Aine Burke,http://twitter.com/,86.0,,1.3366054682198712e+18,,0.0,0.0,,RT @oconnn04: A big thank you to the clinical teams in the NCC and the Clinical research facility @stjamesdublin and the Irish participants‚Ä¶,en,0.0,911.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,73.0,13.0,https://twitter.com/DrABurke/statuses/1336605468219871232,0.0,0.0,,0.0,0.0,0.0,13.0,73.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @oconnn04: A big thank you to the clinical teams in the NCC and the Clinical research facility @stjamesdublin and the Irish participants‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-09 00:31:17+00:00,"Ritcha Saxena, MD",http://twitter.com/,25.0,,1.3364684259384934e+18,,0.0,0.0,,RT @AkshaySharmaMD: #ASH20 #PresidentialSymposium Dr Bronwen Shaw @CIBMTR shared the donation of bone marrow grafts all over the world whic‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,20.0,5.0,https://twitter.com/RitchaSaxena/statuses/1336468425938493447,0.0,0.0,,0.0,0.0,0.0,5.0,20.0,False,False,False,False,True,Charity,0.0,0.0,1.0,RT @AkshaySharmaMD: #ASH20 #PresidentialSymposium Dr Bronwen Shaw @CIBMTR shared the donation of bone marrow grafts all over the world whic‚Ä¶,false
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-09 00:19:26+00:00,"Ritcha Saxena, MD",http://twitter.com/,86.0,,1.336465443314348e+18,,0.0,0.0,,RT @oconnn04: A big thank you to the clinical teams in the NCC and the Clinical research facility @stjamesdublin and the Irish participants‚Ä¶,en,0.0,6875.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,73.0,13.0,https://twitter.com/RitchaSaxena/statuses/1336465443314348034,0.0,0.0,,0.0,0.0,0.0,13.0,73.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @oconnn04: A big thank you to the clinical teams in the NCC and the Clinical research facility @stjamesdublin and the Irish participants‚Ä¶,true
nchinyee,Palliative Care Physician at St. Michael‚Äôs Hospital @UnityHealthTO MSc Clin Epi (c) @IHPMEuoft,,"Toronto, Ontario",,2020-12-09 13:41:41+00:00,Nicolas Chin-Yee,http://twitter.com/,4.0,,1.3366673334405243e+18,,0.0,0.0,,"RT @BenChinYee: Also, early integration of specialty palliative care alongside curative intent treatment improves symptoms &amp; QoL #ASH2020 @‚Ä¶",en,0.0,268.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,1.0,https://twitter.com/nchinyee/statuses/1336667333440524290,0.0,0.0,,0.0,0.0,0.0,1.0,3.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @BenChinYee: Also, early integration of specialty palliative care alongside curative intent treatment improves symptoms &amp; QoL #ASH2020 @‚Ä¶",true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-12-09 19:05:00+00:00,Oncology Tube,http://twitter.com/,0.0,,1.3367487000439194e+18,,0.0,0.0,,"2191 Randomized Phase 2 Trial Joshua Zeidner, MD @LeukDocJZ @UNC_Lineberger #ASH20 #MDS #CMML #AML #cancer‚Ä¶ https://t.co/9nw92bLShS",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1336748700043919361,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"2191 Randomized Phase 2 Trial Joshua Zeidner, MD @LeukDocJZ @UNC_Lineberger #ASH20 #MDS #CMML #AML #cancer‚Ä¶ https://t.co/9nw92bLShS",true
nadahamad,"BMT, cellular therapies and clinical haematologist, clinical researcher, lymphoma doc, mother of 3, feminist and ANZTCT president. Opinions are my own.",,"Sydney, Australia",,2020-12-09 02:20:53+00:00,A/Prof Nada Hamad,http://twitter.com/,29.0,,1.3364960069013504e+18,,0.0,0.0,,RT @DrStevenDevine: Superb presentation by Dr Shaw at #ASH20 Presidential symposium. @BeTheMatch is working with her and other great invest‚Ä¶,en,0.0,346.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,22.0,7.0,https://twitter.com/nadahamad/statuses/1336496006901350400,0.0,0.0,,0.0,0.0,0.0,7.0,22.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @DrStevenDevine: Superb presentation by Dr Shaw at #ASH20 Presidential symposium. @BeTheMatch is working with her and other great invest‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 12:35:23+00:00,"Ritcha Saxena, MD",http://twitter.com/,2.0,,1.3355634887485071e+18,,0.0,0.0,,RT @feldstej: 2310 28-Day Metronomic Therapy for Relapsed Refractory Multiple Myeloma https://t.co/RxcGFPIwW2 #ASH20 #ASH2020 #ASHFromHome‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,1.0,1.0,https://twitter.com/RitchaSaxena/statuses/1335563488748507138,0.0,0.0,,0.0,0.0,0.0,1.0,1.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @feldstej: 2310 28-Day Metronomic Therapy for Relapsed Refractory Multiple Myeloma https://t.co/RxcGFPIwW2 #ASH20 #ASH2020 #ASHFromHome‚Ä¶,true
ThiloZander,Medical Oncologist. Head of Lymphoma & Myeloma Service. Lucerne Cancer Center. Switzerland.,,"Lucerne, Switzerland",,2020-12-06 08:42:30+00:00,"Thilo J Zander, MD",http://twitter.com/,4.0,,1.3355048804175176e+18,,0.0,0.0,,First day of #ASH20 three new targets that work in heavily pretreated relapsed and refractory #myeloma: BRAF (ORR 8‚Ä¶ https://t.co/T4qySEXN0f,en,0.0,843.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,4.0,https://twitter.com/ThiloZander/statuses/1335504880417517568,0.0,0.0,,0.0,0.0,0.0,4.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,First day of #ASH20 three new targets that work in heavily pretreated relapsed and refractory #myeloma: BRAF (ORR 8‚Ä¶ https://t.co/T4qySEXN0f,false
DrSStern,Consultant Haematologist. Interested in haemato-oncology in general and multiple myeloma in particular.,,,,2020-12-06 17:19:12+00:00,Simon Stern,http://twitter.com/,0.0,,1.3356349129641738e+18,,0.0,0.0,,A sad consequence of the pandemic has been the high number of myeloma patients we've seen presenting late with seve‚Ä¶ https://t.co/7s87GVUeNk,en,0.0,185.0,,,0.0,,,Negative,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/DrSStern/statuses/1335634912964173826,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Covid,0.0,1.0,0.0,A sad consequence of the pandemic has been the high number of myeloma patients we've seen presenting late with seve‚Ä¶ https://t.co/7s87GVUeNk,true
pembeoltulu,"Pathologist(Associate professor), Meram Faculty of Medicine, Konya/Turkey; I lv #hemepath, #dermpath üíóMarried and have 4 children, RT/Tw are not medical advice",,T√ºrkiye,,2020-12-06 21:56:44+00:00,"Pembe Oltulu, MD",http://twitter.com/,2.0,,1.3357047571057336e+18,,0.0,0.0,,RT @smbenlazar: Interim Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients (Pts) W‚Ä¶,en,0.0,8940.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/pembeoltulu/statuses/1335704757105733642,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @smbenlazar: Interim Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients (Pts) W‚Ä¶,true
SandyWong02111,UCSF Hematologist and BMT physician,,"San Francisco, CA",,2020-12-06 22:27:21+00:00,Sandy Wong,http://twitter.com/,3.0,,1.3357124588376433e+18,,0.0,0.0,,Proud of @SwethaKMD for her #ASH20 abstract 2352 on infection and CAR-T! 47 #MYELOMA pt tx with BCMA #CARTcell tx!‚Ä¶ https://t.co/RhyHGvroj0,en,0.0,759.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/SandyWong02111/statuses/1335712458837643264,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Side Effects,1.0,0.0,0.0,Proud of @SwethaKMD for her #ASH20 abstract 2352 on infection and CAR-T! 47 #MYELOMA pt tx with BCMA #CARTcell tx!‚Ä¶ https://t.co/RhyHGvroj0,true
jacklynsuarez19,Doctor of Pharmacy üíä,,,,2020-12-06 18:06:25+00:00,Jacklyn Suarez,http://twitter.com/,22.0,,1.335646794424828e+18,,0.0,0.0,,"RT @MM_Hub: Congress| #ASH20| @AlGarfall, @PennCancer, presented data on the phase I trial of teclistamab for R/R MM showing encouraging to‚Ä¶",en,0.0,5.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,14.0,8.0,https://twitter.com/jacklynsuarez19/statuses/1335646794424827904,0.0,0.0,,0.0,0.0,0.0,8.0,14.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @MM_Hub: Congress| #ASH20| @AlGarfall, @PennCancer, presented data on the phase I trial of teclistamab for R/R MM showing encouraging to‚Ä¶",true
AnnaSureda5,"Haematologist interested in lymphoid malignancies, stem cell transplantation and CART cells. #CART #BMT #lymphomas #immunotherapy #WomenInMedicine",,"Barcelona, Spain",,2020-12-06 15:37:45+00:00,Anna Sureda,http://twitter.com/,40.0,,1.3356093798324224e+18,,0.0,0.0,,RT @UrviShahMD: Another effective target for MM! First anti-GPRC5D Bispecific Ab (Talquetamab) Phase 1 presented by Dr. Ajai Chari. RP2D 40‚Ä¶,en,0.0,658.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,30.0,10.0,https://twitter.com/AnnaSureda5/statuses/1335609379832422400,0.0,0.0,,0.0,0.0,0.0,10.0,30.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @UrviShahMD: Another effective target for MM! First anti-GPRC5D Bispecific Ab (Talquetamab) Phase 1 presented by Dr. Ajai Chari. RP2D 40‚Ä¶,true
olga45093932,"MD,PhD, hematologist of @NationalCancerInst of @oncohematologyDepart",,"Kiev, Ukraine",,2020-12-06 07:21:56+00:00,Olga,http://twitter.com/,76.0,,1.3354846031469896e+18,,0.0,0.0,,"RT @Mohty_EBMT: Natural history of myeloma. More than ever, We need to optimize/succeed frontline and 1st relapse therapy because both phas‚Ä¶",en,0.0,64.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,56.0,20.0,https://twitter.com/olga45093932/statuses/1335484603146989568,0.0,0.0,,0.0,0.0,0.0,20.0,56.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @Mohty_EBMT: Natural history of myeloma. More than ever, We need to optimize/succeed frontline and 1st relapse therapy because both phas‚Ä¶",false
majorajay,"Hematology/oncology fellow. #lymsm & #mmsm outcomes researcher. Physician-publisher & founder of https://t.co/dPfLt8QVMr, @inTrainingDoc & @inHouseMag.",,"Chicago, IL",,2020-12-06 17:45:04+00:00,"Ajay Major, MD, MBA",http://twitter.com/,0.0,,1.3356414213075067e+18,,0.0,0.0,,Updated results of INNOVATE study in Waldenstrom macroglobulinemia. Saving this for future reference! #lymsm #ASH20‚Ä¶ https://t.co/cPEVvIOfnb,en,0.0,3518.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/majorajay/statuses/1335641421307506688,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,Updated results of INNOVATE study in Waldenstrom macroglobulinemia. Saving this for future reference! #lymsm #ASH20‚Ä¶ https://t.co/cPEVvIOfnb,true
majorajay,"Hematology/oncology fellow. #lymsm & #mmsm outcomes researcher. Physician-publisher & founder of https://t.co/dPfLt8QVMr, @inTrainingDoc & @inHouseMag.",,"Chicago, IL",,2020-12-06 22:47:24+00:00,"Ajay Major, MD, MBA",http://twitter.com/,4.0,,1.3357175077016904e+18,,0.0,0.0,,RT @MariaAmaya_27: Interesting study on CNS ppx during front-line therapy in aggressive Non-Hodgkin Lymphoma. Higher risk of CNS relapse de‚Ä¶,en,0.0,3518.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,1.0,https://twitter.com/majorajay/statuses/1335717507701690373,0.0,0.0,,0.0,0.0,0.0,1.0,3.0,False,False,False,False,True,Diagnosis Progression,1.0,0.0,0.0,RT @MariaAmaya_27: Interesting study on CNS ppx during front-line therapy in aggressive Non-Hodgkin Lymphoma. Higher risk of CNS relapse de‚Ä¶,true
johnde1MYELOMA,"myeloma survivor üêú, gastroenterologist, bicyclist, animal lover",,"Santa Fe, NM",,2020-12-06 14:10:51+00:00,John DeFlice,http://twitter.com/,0.0,,1.3355875131135631e+18,,0.0,0.0,,CartItude 1 (cilta-cel) CAR BCMA targeted phase 1b/2 with deep/durable responses with ORR 94.8% in heavily pretreat‚Ä¶ https://t.co/hYXHQXXb0X,en,0.0,218.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/johnde1MYELOMA/statuses/1335587513113563137,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,CartItude 1 (cilta-cel) CAR BCMA targeted phase 1b/2 with deep/durable responses with ORR 94.8% in heavily pretreat‚Ä¶ https://t.co/hYXHQXXb0X,true
majorajay,"Hematology/oncology fellow. #lymsm & #mmsm outcomes researcher. Physician-publisher & founder of https://t.co/dPfLt8QVMr, @inTrainingDoc & @inHouseMag.",,"Chicago, IL",,2020-12-06 18:36:11+00:00,"Ajay Major, MD, MBA",http://twitter.com/,11.0,,1.3356542844368937e+18,,0.0,0.0,,RT @SoniSmithMD: Very lucky to work with #ASH2020 Mentor recipient Dr Wendy Stock. The words of her mentees say it all! https://t.co/b7OJ4z‚Ä¶,en,0.0,3518.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,1.0,https://twitter.com/majorajay/statuses/1335654284436893698,0.0,0.0,,0.0,0.0,0.0,1.0,10.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @SoniSmithMD: Very lucky to work with #ASH2020 Mentor recipient Dr Wendy Stock. The words of her mentees say it all! https://t.co/b7OJ4z‚Ä¶,true
JoannaS_Yi,"Christ-loving disciple who loves music, crafts, and getting to be around kids as a pediatric oncologist and drug discovery scientist. Tweets are my own.",,,,2020-12-06 23:04:35+00:00,JoannaS_Yi,http://twitter.com/,3.0,,1.3357218302970634e+18,,0.0,0.0,,"A longer-acting asparaginase soon be available for ALL pts, based on the single agent phase 2 trial NOR-GRASPALL201‚Ä¶ https://t.co/ot094beSe8",en,0.0,163.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/JoannaS_Yi/statuses/1335721830297063424,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"A longer-acting asparaginase soon be available for ALL pts, based on the single agent phase 2 trial NOR-GRASPALL201‚Ä¶ https://t.co/ot094beSe8",true
HallekMichael,"Hematologist and oncologist at the University of Cologne, Germany. Tweets are my own & no medical advice.",,"Cologne, Germany",,2020-12-06 21:43:59+00:00,Michael Hallek,http://twitter.com/,0.0,,1.335701547846656e+18,,0.0,0.0,,"Peter Borchmann ‚Å¶@UKKoeln‚Å© Dept I Int Med reports promising first in human, phase I results with a bispecific CD20/‚Ä¶ https://t.co/dfw86u4gd0",en,0.0,4644.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/HallekMichael/statuses/1335701547846656002,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"Peter Borchmann ‚Å¶@UKKoeln‚Å© Dept I Int Med reports promising first in human, phase I results with a bispecific CD20/‚Ä¶ https://t.co/dfw86u4gd0",false
majorajay,"Hematology/oncology fellow. #lymsm & #mmsm outcomes researcher. Physician-publisher & founder of https://t.co/dPfLt8QVMr, @inTrainingDoc & @inHouseMag.",,"Chicago, IL",,2020-12-06 20:49:33+00:00,"Ajay Major, MD, MBA",http://twitter.com/,0.0,,1.3356878466785444e+18,,0.0,0.0,,"Interesting retrospective review of HRQoL in transplant-ineligible newly-diagnosed #myeloma patients, which showed‚Ä¶ https://t.co/ifVxO45qHz",en,0.0,3518.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/majorajay/statuses/1335687846678544385,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"Interesting retrospective review of HRQoL in transplant-ineligible newly-diagnosed #myeloma patients, which showed‚Ä¶ https://t.co/ifVxO45qHz",true
PAMJ84,Ronin Haematologist,,Europe,,2020-12-06 00:51:41+00:00,P. A-M,http://twitter.com/,15.0,,1.335386394471043e+18,,0.0,0.0,,"RT @Mohty_EBMT: Subcutaneous Daratumumab Plus Pomalidomide/Dexamethasone in Relapsed or Refractory Multiple Myeloma - The ASCO Post
#ASH20‚Ä¶",ro,0.0,110.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,12.0,3.0,https://twitter.com/PAMJ84/statuses/1335386394471043073,0.0,0.0,,0.0,0.0,0.0,3.0,12.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @Mohty_EBMT: Subcutaneous Daratumumab Plus Pomalidomide/Dexamethasone in Relapsed or Refractory Multiple Myeloma - The ASCO Post
#ASH20‚Ä¶",true
dgermain21,MD-PhD. 2nd year Heme/Onc fellow focused on lymphoma and leukemia. Physician-scientist-in-training. Tweet/RT not medical advice or endorsement.,,"St. Louis, MO",,2020-12-06 23:06:36+00:00,David A. Russler-Germain,http://twitter.com/,30.0,,1.335722336704729e+18,,0.0,0.0,,"RT @graham74GC: Neelapu: Axi-Cel in 1L DLBCL
- DHL / THL AND pos iPET (D4 or 5) after 2x R-chemo
- PS0-1, non-chemo bridging allowed after‚Ä¶",en,0.0,1612.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,26.0,4.0,https://twitter.com/dgermain21/statuses/1335722336704729090,0.0,0.0,,0.0,0.0,0.0,4.0,26.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @graham74GC: Neelapu: Axi-Cel in 1L DLBCL
- DHL / THL AND pos iPET (D4 or 5) after 2x R-chemo
- PS0-1, non-chemo bridging allowed after‚Ä¶",true
MDAndersonNews,"The official account of MD Anderson Cancer Center, a leader in cancer care, cancer research and the fight to #EndCancer. Appointments available: 1-877-632-6789.",,"Houston, TX",,2020-12-06 04:07:00+00:00,MD Anderson Cancer Center,http://twitter.com/,3.0,,1.3354355467981128e+18,,0.0,0.0,,"‚ÄúHaving new and specialized therapies like CAR T cells, new therapies that were invented here like CAR NK cells ‚Ä¶ c‚Ä¶ https://t.co/XwKjkFEZ49",en,0.0,114120.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/MDAndersonNews/statuses/1335435546798112768,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"‚ÄúHaving new and specialized therapies like CAR T cells, new therapies that were invented here like CAR NK cells ‚Ä¶ c‚Ä¶ https://t.co/XwKjkFEZ49",true
BroeckelmannPJ,"MD @UKKoeln & Physician Scientist Postdoc @MPIAGE. Hemato-Oncology. Lymphoma. Immunotherapies. DNA damage. Personal opinion, RT/like ‚â† endorsement.",,"Cologne, Germany",,2020-12-06 23:46:16+00:00,Paul Br√∂ckelmann,http://twitter.com/,45.0,,1.335732320008069e+18,,0.0,0.0,,RT @DrMiguelPerales: #ASH20 Abs 470 Impressive results in Phase II Study of Pembrolizumab Plus GVD As 2nd-Line Therapy for Rel/Ref Classica‚Ä¶,en,0.0,243.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,34.0,11.0,https://twitter.com/BroeckelmannPJ/statuses/1335732320008069122,0.0,0.0,,0.0,0.0,0.0,11.0,34.0,False,False,False,False,True,Clinical Trials,1.0,0.0,0.0,RT @DrMiguelPerales: #ASH20 Abs 470 Impressive results in Phase II Study of Pembrolizumab Plus GVD As 2nd-Line Therapy for Rel/Ref Classica‚Ä¶,true
majorajay,"Hematology/oncology fellow. #lymsm & #mmsm outcomes researcher. Physician-publisher & founder of https://t.co/dPfLt8QVMr, @inTrainingDoc & @inHouseMag.",,"Chicago, IL",,2020-12-06 22:42:29+00:00,"Ajay Major, MD, MBA",http://twitter.com/,0.0,,1.3357162672742113e+18,,0.0,0.0,,"@AlexandraRojek In short, CNS relapse rate between intrathecal versus intravenous prophylaxis was not significantly‚Ä¶ https://t.co/6ZydwRneYx",en,0.0,3518.0,,,0.0,majorajay,1.3357145148227215e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/majorajay/statuses/1335716267274211340,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"@AlexandraRojek In short, CNS relapse rate between intrathecal versus intravenous prophylaxis was not significantly‚Ä¶ https://t.co/6ZydwRneYx",false
MullallyLab,Physician-Scientist in MPN & myeloid malignancies @BrighamHeme @BrighamResearch @DanaFarber @broadinstitute #MPNsm Formerly @OslerResidency @UCDMedicine,,"Boston, MA",,2020-12-08 23:33:28+00:00,Mullally Lab,http://twitter.com/,0.0,,1.3364538740985774e+18,,0.0,0.0,,Next generation science needs next generation scientists! Congrats to @DebraVanEgeren (&amp; welcome to Twitter!)‚Ä¶ https://t.co/zI7xG82VJZ,en,0.0,1003.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/MullallyLab/statuses/1336453874098577410,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Long Term Benefits,1.0,0.0,0.0,Next generation science needs next generation scientists! Congrats to @DebraVanEgeren (&amp; welcome to Twitter!)‚Ä¶ https://t.co/zI7xG82VJZ,true
BMT_DrNemecek,"Pediatrician and Hematologist/ Oncologist. Director of Clinical Research, OHSU Knight Cancer Institute. Opinions in this platform are personal.",,"Oregon, USA",,2020-12-08 19:44:15+00:00,Eneida Nemecek,http://twitter.com/,52.0,,1.3363961908043735e+18,,0.0,0.0,,RT @BldCancerDoc: Did #ASH20 notice that üëá session has an awesome moderator and three üåüüåüüåü speakers - and all of them are women! #ASHKudos @‚Ä¶,en,0.0,419.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,45.0,7.0,https://twitter.com/BMT_DrNemecek/statuses/1336396190804373505,0.0,0.0,,0.0,0.0,0.0,7.0,45.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,RT @BldCancerDoc: Did #ASH20 notice that üëá session has an awesome moderator and three üåüüåüüåü speakers - and all of them are women! #ASHKudos @‚Ä¶,true
GlopesMd,"Cancer Doctor and Researcher, Faculty @SylvesterCancer @UnivMiami. Helping improve Cancer Control in LMICs. Editor-in-Chief JCO Global Oncology @ASCO",,"Miami, FL",,2020-12-08 23:44:59+00:00,gilberto lopes,http://twitter.com/,17.0,,1.3364567721655214e+18,,0.0,0.0,,RT @KenFigueroaLab: Congratulations!!! So proud to work with such a talented group of clinical and basic investigators at @SylvesterCancer‚Ä¶,en,0.0,31610.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,16.0,1.0,https://twitter.com/GlopesMd/statuses/1336456772165521409,0.0,0.0,,0.0,0.0,0.0,1.0,16.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @KenFigueroaLab: Congratulations!!! So proud to work with such a talented group of clinical and basic investigators at @SylvesterCancer‚Ä¶,true
Prasshmehta,"Medical Oncologist,Hematoncologist and bone marrow transplant physician,
DM(AIIMS, Delhi)
Program Director- Leukemia/BMT( Asian Institute of Medical Sciences)",,,,2020-12-08 17:35:16+00:00,Prashant Mehta,http://twitter.com/,8.0,,1.3363637306033684e+18,,0.0,0.0,,RT @AkshaySharmaMD: #ASH20 This offers an immense potential to not only diagnose but perhaps prevent #MPN decades before they develop. Cong‚Ä¶,en,0.0,1065.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,2.0,https://twitter.com/Prasshmehta/statuses/1336363730603368449,0.0,0.0,,0.0,0.0,0.0,2.0,6.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @AkshaySharmaMD: #ASH20 This offers an immense potential to not only diagnose but perhaps prevent #MPN decades before they develop. Cong‚Ä¶,true
Prasshmehta,"Medical Oncologist,Hematoncologist and bone marrow transplant physician,
DM(AIIMS, Delhi)
Program Director- Leukemia/BMT( Asian Institute of Medical Sciences)",,,,2020-12-08 17:39:49+00:00,Prashant Mehta,http://twitter.com/,194.0,,1.3363648752332063e+18,,0.0,0.0,,RT @VincentRK: #ASH20 special: Active myeloma drugs with their mechanism of action in one slide. Unapproved investigational drugs in blue f‚Ä¶,en,0.0,1065.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,147.0,47.0,https://twitter.com/Prasshmehta/statuses/1336364875233206272,0.0,0.0,,0.0,0.0,0.0,47.0,147.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,RT @VincentRK: #ASH20 special: Active myeloma drugs with their mechanism of action in one slide. Unapproved investigational drugs in blue f‚Ä¶,true
sheilsroc,Clinical Specialist Physiotherapist specialised in Haemophilia.,,Ireland,,2020-12-08 15:09:36+00:00,Sheila Roche,http://twitter.com/,86.0,,1.3363270733343457e+18,,0.0,0.0,,RT @oconnn04: A big thank you to the clinical teams in the NCC and the Clinical research facility @stjamesdublin and the Irish participants‚Ä¶,en,0.0,123.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,73.0,13.0,https://twitter.com/sheilsroc/statuses/1336327073334345739,0.0,0.0,,0.0,0.0,0.0,13.0,73.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @oconnn04: A big thank you to the clinical teams in the NCC and the Clinical research facility @stjamesdublin and the Irish participants‚Ä¶,false
johnde1MYELOMA,"myeloma survivor üêú, gastroenterologist, bicyclist, animal lover",,"Santa Fe, NM",,2020-12-08 12:16:34+00:00,John DeFlice,http://twitter.com/,0.0,,1.3362835258430136e+18,,0.0,0.0,,"Phase 2 HR SMM Rx KRd w/ R maintenance results MRD neg / CR  70%, 10% developed MM, Kazandjian, et al #mmsm‚Ä¶ https://t.co/uzPJW3AXpj",in,0.0,218.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/johnde1MYELOMA/statuses/1336283525843013632,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"Phase 2 HR SMM Rx KRd w/ R maintenance results MRD neg / CR  70%, 10% developed MM, Kazandjian, et al #mmsm‚Ä¶ https://t.co/uzPJW3AXpj",true
smaliske07,Husband. Father. Cancer Physician. @SanfordHealth #RogerMarisCancerCenter @UIowa @UIowaCancer @ASTCT @CIBMTR @BMTCTN #BMTsm #CARTcell #CellTherapy,,"Iowa City, IA",,2020-12-08 03:10:41+00:00,smaliske07,http://twitter.com/,30.0,,1.3361461513645834e+18,,0.0,0.0,,RT @DrOlaLandgren: Daratumumab + KRd &amp; Daratumumab + VRd = 2 most effective combos for newly diagnosed #myeloma in 2020/2021. Limit IV flui‚Ä¶,en,0.0,4.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,23.0,7.0,https://twitter.com/smaliske07/statuses/1336146151364583424,0.0,0.0,,0.0,0.0,0.0,7.0,23.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @DrOlaLandgren: Daratumumab + KRd &amp; Daratumumab + VRd = 2 most effective combos for newly diagnosed #myeloma in 2020/2021. Limit IV flui‚Ä¶,true
JohnPLeonardMD,"Doctor for lymphoma patients, researcher, collaborator, professor/senior associate dean @WeillCornell & @NYPhospital Tweets mine RT not=endorsement, he/him/his",,Weill Cornell Medicine,,2020-12-08 00:04:57+00:00,"John P. Leonard, MD",http://twitter.com/,0.0,,1.336099410103636e+18,,0.0,0.0,,Doesn‚Äôt get much better than watching mentees give a great presentation! #ASH20 https://t.co/VnqmToJwIc,en,0.0,6269.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/JohnPLeonardMD/statuses/1336099410103635969,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnosis Progression,1.0,0.0,0.0,Doesn‚Äôt get much better than watching mentees give a great presentation! #ASH20 https://t.co/VnqmToJwIc,true
MyMKaiser,"Haemato-oncologist and Myeloma researcher, working on trials, biomarkers, imaging. NOT a football manager",,"London, England",,2020-12-08 10:00:36+00:00,Martin Kaiser,http://twitter.com/,0.0,,1.3362493109131592e+18,,0.0,0.0,,Congratulations Angelo Belotti and team for exciting data on Diffusion-Weighted MRI in myeloma #ASH20. Great to see‚Ä¶ https://t.co/eWuBzsPUTg,en,0.0,705.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/MyMKaiser/statuses/1336249310913159170,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnostic Tools,1.0,0.0,0.0,Congratulations Angelo Belotti and team for exciting data on Diffusion-Weighted MRI in myeloma #ASH20. Great to see‚Ä¶ https://t.co/eWuBzsPUTg,true
NicholasShortMD,Leukemia Physician at MD Anderson Cancer Center. Clinical/translational research in AML and ALL.,,"Houston, TX",,2020-12-06 22:06:18+00:00,Nicholas Short MD,http://twitter.com/,19.0,,1.3357071612724593e+18,,0.0,0.0,,"RT @MDAndersonNews: ‚ÄúWe are very encouraged that every patient on the study achieved a complete remission and 97% achieved MRD negativity,‚Äù‚Ä¶",en,0.0,587.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,17.0,2.0,https://twitter.com/NicholasShortMD/statuses/1335707161272459268,0.0,0.0,,0.0,0.0,0.0,2.0,17.0,False,False,False,False,True,Diagnosis Progression,1.0,0.0,0.0,"RT @MDAndersonNews: ‚ÄúWe are very encouraged that every patient on the study achieved a complete remission and 97% achieved MRD negativity,‚Äù‚Ä¶",true
MDedgeHemOnc,MDedge Hematology & Oncology provides the most important and up to date information and news for oncologists. Now part of the Medscape Professional Network.,,"Rockville, MD, Parsippany, NJ",,2020-12-08 16:09:12+00:00,MDedge Hematology & Oncology,http://twitter.com/,0.0,,1.3363420715280097e+18,,0.0,0.0,,"Allogeneic transplant can lead to durable remissions in T-cell lymphoma, #ASH20 study finds.‚Ä¶ https://t.co/RnZj4WIazc",en,0.0,6726.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/MDedgeHemOnc/statuses/1336342071528009731,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"Allogeneic transplant can lead to durable remissions in T-cell lymphoma, #ASH20 study finds.‚Ä¶ https://t.co/RnZj4WIazc",false
FranciscoMarty_,"Infectious diseases doctor who specializes in treating transplant and cancer patients, work at @BrighamWomens and @DanaFarber, @harvardmed.",,"Boston, MA",,2020-12-06 01:32:13+00:00,"Francisco Marty, MD",http://twitter.com/,218.0,,1.3353965960502395e+18,,0.0,0.0,,"RT @hemedoc: #ASH20 #leusm Wei: We are all excited to have new therapeutic options in AML, but the overall message I get from this money sl‚Ä¶",en,0.0,9990.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,168.0,50.0,https://twitter.com/FranciscoMarty_/statuses/1335396596050239490,0.0,0.0,,0.0,0.0,0.0,50.0,168.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"RT @hemedoc: #ASH20 #leusm Wei: We are all excited to have new therapeutic options in AML, but the overall message I get from this money sl‚Ä¶",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 21:34:45+00:00,"Ritcha Saxena, MD",http://twitter.com/,14.0,,1.3356992225119355e+18,,0.0,0.0,,RT @Anand_88_Patel: Check out our #ASH20 talk on cytogenetics/outcomes of pts developing myeloid neoplasms after radiation therapy alone! T‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,4.0,https://twitter.com/RitchaSaxena/statuses/1335699222511935492,0.0,0.0,,0.0,0.0,0.0,4.0,10.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @Anand_88_Patel: Check out our #ASH20 talk on cytogenetics/outcomes of pts developing myeloid neoplasms after radiation therapy alone! T‚Ä¶,true
EduardoFlavioO1,"MD, Hematologist, Brasilia/Brasil, main interest in CLL, Lymphoma and MM; dad and husband; tweets are my own opinion",,"Bras√≠lia, Brasil",,2020-12-06 22:33:57+00:00,Eduardo Flavio Oliveira Ribeiro,http://twitter.com/,0.0,,1.3357141222232635e+18,,0.0,0.0,,Prophylactic HDMTX was not effective in preventing CNS relapse in DLBCL. There‚Äôs a trend for better systemic contro‚Ä¶ https://t.co/folOtMvNE0,en,0.0,545.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/EduardoFlavioO1/statuses/1335714122223263751,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,Prophylactic HDMTX was not effective in preventing CNS relapse in DLBCL. There‚Äôs a trend for better systemic contro‚Ä¶ https://t.co/folOtMvNE0,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 21:35:50+00:00,"Ritcha Saxena, MD",http://twitter.com/,8.0,,1.3356994953136783e+18,,0.0,0.0,,RT @CanerSaygin: Dr Lachowiez presenting data on FLAG-IDA + ven in both newly diagnosed and R/R pts. CRc is &gt;60% even in R/R setting and fM‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,4.0,https://twitter.com/RitchaSaxena/statuses/1335699495313678338,0.0,0.0,,0.0,0.0,0.0,4.0,4.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @CanerSaygin: Dr Lachowiez presenting data on FLAG-IDA + ven in both newly diagnosed and R/R pts. CRc is &gt;60% even in R/R setting and fM‚Ä¶,true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-12-06 16:56:10+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,1.0,,1.335629113378259e+18,,0.0,0.0,,"#ASH20 #leusm Bhatnagar: In analysis of @ALLIANCE_org studies blacks had worse OS, but no difference in early death‚Ä¶ https://t.co/WWC2dPHF03",en,0.0,4813.0,,,0.0,,,Negative,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/hemedoc/statuses/1335629113378258945,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Collaboration,0.0,1.0,0.0,"#ASH20 #leusm Bhatnagar: In analysis of @ALLIANCE_org studies blacks had worse OS, but no difference in early death‚Ä¶ https://t.co/WWC2dPHF03",true
NicoleKuderer,"Translational Oncologist (Biomarkers, Toxicities, Health Outcomes, Clinico-Genomic Big Data, @OncoAlert). Motto: ""Let's make a difference"". Tweets are my own.",,USA,,2020-12-06 18:55:34+00:00,Nicole Kuderer,http://twitter.com/,38.0,,1.3356591622445015e+18,,0.0,0.0,,"RT @fniainle: Prof @MiddeldorpS reminds us that optimal VTE prevention in hospital wasn‚Äôt perfectly answered even before the pandemic. 

Th‚Ä¶",en,0.0,6212.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,30.0,8.0,https://twitter.com/NicoleKuderer/statuses/1335659162244501504,0.0,0.0,,0.0,0.0,0.0,8.0,30.0,False,False,False,False,True,Covid,0.0,0.0,1.0,"RT @fniainle: Prof @MiddeldorpS reminds us that optimal VTE prevention in hospital wasn‚Äôt perfectly answered even before the pandemic. 

Th‚Ä¶",false
Jessica_Okosun,"CRUK-funded Clinician-Scientist at Barts Cancer Institute @QMBCI, Haematologist @BartsHospital. #Lymphoma, cancer #genomics, evolution, Big Data, technophile",,"London, England",,2020-12-06 17:01:25+00:00,Jessica Okosun,http://twitter.com/,0.0,,1.3356304354104525e+18,,0.0,0.0,,"Where to start #ASHkudos #ASH20 plenary - brilliant work, excellent speakers across the breadth of haematology. Thr‚Ä¶ https://t.co/p3yP789LJS",en,0.0,654.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/Jessica_Okosun/statuses/1335630435410452481,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,"Where to start #ASHkudos #ASH20 plenary - brilliant work, excellent speakers across the breadth of haematology. Thr‚Ä¶ https://t.co/p3yP789LJS",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 21:34:07+00:00,"Ritcha Saxena, MD",http://twitter.com/,69.0,,1.335699063916925e+18,,0.0,0.0,,RT @Anand_88_Patel: So happy to see Dr. Wendy Stock winning the @ash_hematology #ASH20 Mentor Award! Since I first met her during fellowshi‚Ä¶,en,0.0,6875.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,62.0,7.0,https://twitter.com/RitchaSaxena/statuses/1335699063916924933,0.0,0.0,,0.0,0.0,0.0,7.0,62.0,False,False,False,False,True,Financial Performance,1.0,0.0,0.0,RT @Anand_88_Patel: So happy to see Dr. Wendy Stock winning the @ash_hematology #ASH20 Mentor Award! Since I first met her during fellowshi‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 12:38:25+00:00,"Ritcha Saxena, MD",http://twitter.com/,14.0,,1.3355642495114363e+18,,0.0,0.0,,RT @VJHemOnc: The Advances in Diagnosis &amp; Management of #MyelodysplasticSyndromes Virtual #ASH20 Symposium is now available to watch on dem‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,4.0,https://twitter.com/RitchaSaxena/statuses/1335564249511436288,0.0,0.0,,0.0,0.0,0.0,4.0,10.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @VJHemOnc: The Advances in Diagnosis &amp; Management of #MyelodysplasticSyndromes Virtual #ASH20 Symposium is now available to watch on dem‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 20:16:12+00:00,"Ritcha Saxena, MD",http://twitter.com/,14.0,,1.3356794544635986e+18,,0.0,0.0,,"RT @kristenpettitmd: A gigantic #ASHKudos to Dr Stock! Her brilliance, enthusiasm, and ‚ù§Ô∏è for her job/patients/colleagues/mentees sold me o‚Ä¶",en,0.0,6875.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,12.0,2.0,https://twitter.com/RitchaSaxena/statuses/1335679454463598594,0.0,0.0,,0.0,0.0,0.0,2.0,12.0,False,False,False,False,True,Financial Performance,1.0,0.0,0.0,"RT @kristenpettitmd: A gigantic #ASHKudos to Dr Stock! Her brilliance, enthusiasm, and ‚ù§Ô∏è for her job/patients/colleagues/mentees sold me o‚Ä¶",true
graham74GC,Lymphoma specialist at Oxford Cancer and Haematology centre. Haematologist and clinical trialist. Chair of UK Hodgkin and T-cell study groups.,,Opinions are mine,,2020-12-06 21:31:30+00:00,Graham Collins,http://twitter.com/,2.0,,1.3356984034230395e+18,,0.0,0.0,,"Thoughts:
- v hard pt group, so great to see data
- BUT PS0-1 (well) &amp; only non-chemo bridging chemo post apheresis‚Ä¶ https://t.co/XfhUrfHMLE",en,0.0,6091.0,,,0.0,graham74GC,1.3356984010155868e+18,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/graham74GC/statuses/1335698403423039488,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"Thoughts:
- v hard pt group, so great to see data
- BUT PS0-1 (well) &amp; only non-chemo bridging chemo post apheresis‚Ä¶ https://t.co/XfhUrfHMLE",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 15:57:12+00:00,"Ritcha Saxena, MD",http://twitter.com/,6.0,,1.3356142763551826e+18,,0.0,0.0,,RT @CanerSaygin: Dr Huang showing preclinical data on synergistic combination of BET and MEK inhibitors in #AML. Switching gears in clinica‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,2.0,https://twitter.com/RitchaSaxena/statuses/1335614276355182597,0.0,0.0,,0.0,0.0,0.0,2.0,4.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @CanerSaygin: Dr Huang showing preclinical data on synergistic combination of BET and MEK inhibitors in #AML. Switching gears in clinica‚Ä¶,false
DrShaniJ,Pediatric heme/onc fellow @TexasChildrens| #SickleCell advocate & physician-scientist in training | @LurieChildrens @DukeMedSchool @UF Alum| Tweets 100% my own,,"Houston, TX",,2020-12-06 19:49:44+00:00,"Shani Johnson, MD",http://twitter.com/,0.0,,1.33567279454217e+18,,0.0,0.0,,"Although I‚Äôm doing #ASHFromHome, I‚Äôm still getting that afternoon fatigue. Do I take a quick 20 mins of shuteye on‚Ä¶ https://t.co/fZJk1M4yxp",en,0.0,430.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/DrShaniJ/statuses/1335672794542170112,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"Although I‚Äôm doing #ASHFromHome, I‚Äôm still getting that afternoon fatigue. Do I take a quick 20 mins of shuteye on‚Ä¶ https://t.co/fZJk1M4yxp",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 12:34:46+00:00,"Ritcha Saxena, MD",http://twitter.com/,31.0,,1.3355633312692265e+18,,0.0,0.0,,RT @Mohty_EBMT: Amazing twitter community at #ASH20 @Mohty_EBMT https://t.co/9dsa2DZZHc,en,0.0,6875.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,25.0,6.0,https://twitter.com/RitchaSaxena/statuses/1335563331269226503,0.0,0.0,,0.0,0.0,0.0,6.0,25.0,False,False,False,False,True,Disease Advocacy,1.0,0.0,0.0,RT @Mohty_EBMT: Amazing twitter community at #ASH20 @Mohty_EBMT https://t.co/9dsa2DZZHc,true
ValenBaezS,MD - UCV. Hematology/Oncology Fellow,,,,2020-12-06 16:08:53+00:00,Valentina Baez,http://twitter.com/,27.0,,1.3356172173172367e+18,,0.0,0.0,,RT @Lachelle_Dawn: Results of A-TREAT: randomized placebo-controlled study to evaluate the safety &amp; efficacy of TXA in preventing bleeding‚Ä¶,en,0.0,302.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,19.0,8.0,https://twitter.com/ValenBaezS/statuses/1335617217317236738,0.0,0.0,,0.0,0.0,0.0,8.0,19.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @Lachelle_Dawn: Results of A-TREAT: randomized placebo-controlled study to evaluate the safety &amp; efficacy of TXA in preventing bleeding‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 21:24:39+00:00,"Ritcha Saxena, MD",http://twitter.com/,3.0,,1.3356966824456645e+18,,0.0,0.0,,RT @gvhd_hub: CONGRESS | #ASH20 | Hannah Choe @ohiostate presents phase I GRAVITAS-119 trial data where JAKi itacitinib plus CNI as GvHD pr‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,1.0,2.0,https://twitter.com/RitchaSaxena/statuses/1335696682445664263,0.0,0.0,,0.0,0.0,0.0,2.0,1.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @gvhd_hub: CONGRESS | #ASH20 | Hannah Choe @ohiostate presents phase I GRAVITAS-119 trial data where JAKi itacitinib plus CNI as GvHD pr‚Ä¶,true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-12-06 22:06:12+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,2.0,,1.335707138639872e+18,,0.0,0.0,,#ASH20 #leusm Short: hCVAD+Blin in frontline for Ph neg B-ALL in age 14+. 4 cycles of chemo (2 for high risk) then‚Ä¶ https://t.co/YbeZ6JM6G8,en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/hemedoc/statuses/1335707138639872000,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,#ASH20 #leusm Short: hCVAD+Blin in frontline for Ph neg B-ALL in age 14+. 4 cycles of chemo (2 for high risk) then‚Ä¶ https://t.co/YbeZ6JM6G8,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 20:12:46+00:00,"Ritcha Saxena, MD",http://twitter.com/,36.0,,1.3356785924208804e+18,,0.0,0.0,,"RT @razan_mohty: FLAG-IDA-VEN in newly diagnosed and R/R #AML by Dr Curtis Lachowiez - high CR rate, higher in newly diagnosed - Acceptable‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,28.0,8.0,https://twitter.com/RitchaSaxena/statuses/1335678592420880384,0.0,0.0,,0.0,0.0,0.0,8.0,28.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"RT @razan_mohty: FLAG-IDA-VEN in newly diagnosed and R/R #AML by Dr Curtis Lachowiez - high CR rate, higher in newly diagnosed - Acceptable‚Ä¶",false
AndreaAnampaG,"Medstudent @UNMSM_ with OCD ‚Ä¢ @ASCO & @AMWAdoctors Social Media
@CPsolvers Team Member ‚Ä¢ #Globaloncology #WomenInMedicine #MedEd #SurvOnc üáµüá™ #IMG üåà she/ella",,"Lima, Peru",,2020-12-06 02:14:59+00:00,Andrea Anampa-Guzm√°n,http://twitter.com/,69.0,,1.3354073594815365e+18,,0.0,0.0,,RT @Anand_88_Patel: So happy to see Dr. Wendy Stock winning the @ash_hematology #ASH20 Mentor Award! Since I first met her during fellowshi‚Ä¶,en,0.0,1908.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,62.0,7.0,https://twitter.com/AndreaAnampaG/statuses/1335407359481536513,0.0,0.0,,0.0,0.0,0.0,7.0,62.0,False,False,False,False,True,Financial Performance,1.0,0.0,0.0,RT @Anand_88_Patel: So happy to see Dr. Wendy Stock winning the @ash_hematology #ASH20 Mentor Award! Since I first met her during fellowshi‚Ä¶,true
CBCIDocs,Thoughts and perspectives from the hematology and transplant physicians at Colorado Blood Cancer Institute @ColoradoBlood @SarahCannonDocs @PresStLukesDenv,,"Denver, CO",,2020-12-07 16:11:49+00:00,CBCI,http://twitter.com/,6.0,,1.3359803415556751e+18,,0.0,0.0,,RT @LukeMtjoy: Poster 1408 Schade: We know BiTes have activity in #myeloma but what about TriTACs? The good @schadeh reviews phase 1/2 HPN2‚Ä¶,en,0.0,782.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,1.0,https://twitter.com/CBCIDocs/statuses/1335980341555675136,0.0,0.0,,0.0,0.0,0.0,1.0,5.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @LukeMtjoy: Poster 1408 Schade: We know BiTes have activity in #myeloma but what about TriTACs? The good @schadeh reviews phase 1/2 HPN2‚Ä¶,true
SandyWong02111,UCSF Hematologist and BMT physician,,"San Francisco, CA",,2020-12-06 17:44:44+00:00,Sandy Wong,http://twitter.com/,29.0,,1.3356413377905172e+18,,0.0,0.0,,RT @MazieTsangMD: #ASH20 #ASHKudos to @UCSFCancer fellow @SwethaKMD who worked so hard on this phase 2 study of Dara + Aza + Dex (Darazadex‚Ä¶,en,0.0,759.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,22.0,7.0,https://twitter.com/SandyWong02111/statuses/1335641337790517248,0.0,0.0,,0.0,0.0,0.0,7.0,22.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @MazieTsangMD: #ASH20 #ASHKudos to @UCSFCancer fellow @SwethaKMD who worked so hard on this phase 2 study of Dara + Aza + Dex (Darazadex‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 16:20:24+00:00,"Ritcha Saxena, MD",http://twitter.com/,17.0,,1.3356201137399972e+18,,0.0,0.0,,"RT @PedsHemeDoc: #ASHKudos to all the plenary speakers at this year‚Äôs @ASH_hematology meeting! üëèüèª
Different vibe, same level of scientific‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,14.0,3.0,https://twitter.com/RitchaSaxena/statuses/1335620113739997184,0.0,0.0,,0.0,0.0,0.0,3.0,14.0,False,False,False,False,True,Thought Leadership,0.0,0.0,1.0,"RT @PedsHemeDoc: #ASHKudos to all the plenary speakers at this year‚Äôs @ASH_hematology meeting! üëèüèª
Different vibe, same level of scientific‚Ä¶",true
JerroldLevy,"Critical care physician in CTICU @DukeMedSchool, interested in coagulation, bleeding, inflammation-also oenophile and foody. Tweets are my own (‚â†medical advice)",,"Durham, North Carolina",,2020-12-06 16:12:06+00:00,"Jerrold Levy, MD",http://twitter.com/,27.0,,1.3356180273464238e+18,,0.0,0.0,,RT @Lachelle_Dawn: Results of A-TREAT: randomized placebo-controlled study to evaluate the safety &amp; efficacy of TXA in preventing bleeding‚Ä¶,en,0.0,1755.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,19.0,8.0,https://twitter.com/JerroldLevy/statuses/1335618027346423815,0.0,0.0,,0.0,0.0,0.0,8.0,19.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @Lachelle_Dawn: Results of A-TREAT: randomized placebo-controlled study to evaluate the safety &amp; efficacy of TXA in preventing bleeding‚Ä¶,true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-12-06 16:49:44+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,2.0,,1.3356274966544712e+18,,0.0,0.0,,#ASH20 #leusm Bhatnagar: Black pts w AML have higher mortality. This @ALLIANCE_org study sought to assess if this i‚Ä¶ https://t.co/6cz6SirqDF,en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/hemedoc/statuses/1335627496654471168,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,#ASH20 #leusm Bhatnagar: Black pts w AML have higher mortality. This @ALLIANCE_org study sought to assess if this i‚Ä¶ https://t.co/6cz6SirqDF,false
AndreaAnampaG,"Medstudent @UNMSM_ with OCD ‚Ä¢ @ASCO & @AMWAdoctors Social Media
@CPsolvers Team Member ‚Ä¢ #Globaloncology #WomenInMedicine #MedEd #SurvOnc üáµüá™ #IMG üåà she/ella",,"Lima, Peru",,2020-12-07 19:23:02+00:00,Andrea Anampa-Guzm√°n,http://twitter.com/,17.0,,1.3360284611572654e+18,,0.0,0.0,,RT @amarkelkar: The talk captures the philosophy @DrMMurphy uses when leading our @UFHealthCancer Fellowship Program (@HemeOncGators) &amp; the‚Ä¶,en,0.0,1908.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,15.0,2.0,https://twitter.com/AndreaAnampaG/statuses/1336028461157265409,0.0,0.0,,0.0,0.0,0.0,2.0,15.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @amarkelkar: The talk captures the philosophy @DrMMurphy uses when leading our @UFHealthCancer Fellowship Program (@HemeOncGators) &amp; the‚Ä¶,true
Rfonsi1,"Interim Executive Director, Mayo Clinic Cancer Center. Myeloma doctor. Visiting Healthcare Fellow @GoldwaterInst. Tweets-own/RT not an endorsement",,,,2020-12-07 15:16:57+00:00,Rafael Fonseca MD,http://twitter.com/,1.0,,1.3359665332526449e+18,,0.0,0.0,,Single arm Ph 2 Rx of High Risk (HR) SMM) with KRd followed by 2 yr Maint. We need to strike the balance between no‚Ä¶ https://t.co/1TTIP8AYqw,en,0.0,8301.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/Rfonsi1/statuses/1335966533252644865,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,Single arm Ph 2 Rx of High Risk (HR) SMM) with KRd followed by 2 yr Maint. We need to strike the balance between no‚Ä¶ https://t.co/1TTIP8AYqw,true
A_Ivanovs,"Doctor (#Haematology; #NHS). Scientist (#HSC Biology). MD, MSc (Translational Biomedical Research), PhD (Experimental Haematology), MRCP(UK)",,Between Edinburgh and Glasgow,,2020-12-07 22:08:58+00:00,Andrejs Ivanovs,http://twitter.com/,22.0,,1.3360702219547402e+18,,0.0,0.0,,"RT @tobyeyre82: AUTO3 bicistronic CART
Dual targeting CD19/CD22 
PD1i Pembro to reduce CAR-T exhaustion
Phase I/II
n=49
3 prior lines
2% G3‚Ä¶",en,0.0,194.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,18.0,4.0,https://twitter.com/A_Ivanovs/statuses/1336070221954740224,0.0,0.0,,0.0,0.0,0.0,4.0,18.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @tobyeyre82: AUTO3 bicistronic CART
Dual targeting CD19/CD22 
PD1i Pembro to reduce CAR-T exhaustion
Phase I/II
n=49
3 prior lines
2% G3‚Ä¶",true
nagakos93,"MD, PhD student at Semmelweis University, interested in Lymphoma research and haematology. #lymsm #liquidbiopsy",,"Budapest, Magyarorsz√°g",,2020-12-07 12:28:54+00:00,Nagy √Åkos,http://twitter.com/,0.0,,1.3359242437925847e+18,,0.0,0.0,,"#FL long survivors (&gt;110 months after immunochemoth (R-CHOP/R-CHOP-like/R-CVP/R-B) are enriched in MEF2B mutations,‚Ä¶ https://t.co/pANQaeDkVw",en,0.0,52.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/nagakos93/statuses/1335924243792584706,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"#FL long survivors (&gt;110 months after immunochemoth (R-CHOP/R-CHOP-like/R-CVP/R-B) are enriched in MEF2B mutations,‚Ä¶ https://t.co/pANQaeDkVw",true
MDedgeHemOnc,MDedge Hematology & Oncology provides the most important and up to date information and news for oncologists. Now part of the Medscape Professional Network.,,"Rockville, MD, Parsippany, NJ",,2020-12-07 21:03:01+00:00,MDedge Hematology & Oncology,http://twitter.com/,0.0,,1.336053623273345e+18,,0.0,0.0,,The largest-ever reported patient series of an allogeneic transplant can lead to durable remissions in T-cell lymph‚Ä¶ https://t.co/wsIe8cEFyX,en,0.0,6726.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/MDedgeHemOnc/statuses/1336053623273345025,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,The largest-ever reported patient series of an allogeneic transplant can lead to durable remissions in T-cell lymph‚Ä¶ https://t.co/wsIe8cEFyX,true
DrMonzrAlMalki,Hematopoietic Stem Cell Transplantation @cityofhope | Leukemia | clinical trails | personal views | Physician ‚â† Provider,,"Los Angeles, CA",,2020-12-07 07:16:50+00:00,"Monzr M. AlMalki, MD",http://twitter.com/,0.0,,1.3358457084196618e+18,,0.0,0.0,,@Dr_AmerZeidan @theNCI @NCICTEP_ClinRes @EladSharonMD Congratulations @Dr_AmerZeidan on your work and partnership with @theNCI #ASH2020,en,0.0,28.0,,,0.0,Dr_AmerZeidan,1.3356434267344036e+18,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/DrMonzrAlMalki/statuses/1335845708419661826,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,@Dr_AmerZeidan @theNCI @NCICTEP_ClinRes @EladSharonMD Congratulations @Dr_AmerZeidan on your work and partnership with @theNCI #ASH2020,false
KENNETHROMER,CEO of Myeloma New Zealand. Retired haematologist. Father of five children. An advocate for patients with blood cancers. Bit of a curmudgeon.Foodie.,,"Wellington City, New Zealand",,2020-12-07 00:53:27+00:00,haemdoc,http://twitter.com/,14.0,,1.3357492271383142e+18,,0.0,0.0,,"RT @DrOlaLandgren: Congrats to all success; #Janssen is pushing the envelope! Visionary medical, science-driven leadership. Delivery throug‚Ä¶",en,0.0,211.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,11.0,3.0,https://twitter.com/KENNETHROMER/statuses/1335749227138314240,0.0,0.0,,0.0,0.0,0.0,3.0,11.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,"RT @DrOlaLandgren: Congrats to all success; #Janssen is pushing the envelope! Visionary medical, science-driven leadership. Delivery throug‚Ä¶",true
MScordoMD,Hematologist & Oncologist / Hematopoietic Cell Transplantation & Cellular Therapy / Memorial Sloan Kettering Cancer Center,,,,2020-12-07 18:26:39+00:00,Michael Scordo,http://twitter.com/,0.0,,1.336014272711811e+18,,0.0,0.0,,"@drkomanduri @SylvesterCancer @MSKHemOncTrials Awesome work, Trent! It‚Äôs been a great collaboration with Trent,‚Ä¶ https://t.co/A3WVazr8wp",en,0.0,503.0,,,0.0,drkomanduri,1.3360062206967237e+18,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/MScordoMD/statuses/1336014272711811078,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,"@drkomanduri @SylvesterCancer @MSKHemOncTrials Awesome work, Trent! It‚Äôs been a great collaboration with Trent,‚Ä¶ https://t.co/A3WVazr8wp",true
KellySchoenbeck,"Hematology/Oncology Fellow @UCSFCancer | IM @ColumbiaMed | MD @OHSUSOM | hematology, myeloid malignancies #QOL #geriheme | tweets my own",,,,2020-12-07 22:05:30+00:00,Kelly Schoenbeck,http://twitter.com/,2.0,,1.3360693500510413e+18,,0.0,0.0,,"#ASH2020 #mdssm Abs 656 Aza+Ven higher risk MDS Phase 1b
üìåmedian age 70, IPSS-R high/v high 82%
üìåORR 79%, Med DoR 1‚Ä¶ https://t.co/tJfTqJqe6Q",en,0.0,48.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/KellySchoenbeck/statuses/1336069350051041280,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"#ASH2020 #mdssm Abs 656 Aza+Ven higher risk MDS Phase 1b
üìåmedian age 70, IPSS-R high/v high 82%
üìåORR 79%, Med DoR 1‚Ä¶ https://t.co/tJfTqJqe6Q",true
Areejmd,An oncologist with a passion to improve the quality of life and care of patients with hematologic malignancies #ASH #PallOnc #CIBMTR #ASBMT @MGHCancerCenter,,"Boston, MA",,2020-12-07 08:12:30+00:00,Areej El-Jawahri,http://twitter.com/,12.0,,1.3358597180662047e+18,,0.0,0.0,,RT @GabyHobbs: Impressive results from the phase I EXPLORER study by Dr. Gotlib #ASH2020 https://t.co/B2DvFb9IiV,en,0.0,957.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,2.0,https://twitter.com/Areejmd/statuses/1335859718066204674,0.0,0.0,,0.0,0.0,0.0,2.0,10.0,False,False,False,False,True,Clinical Trials,1.0,0.0,0.0,RT @GabyHobbs: Impressive results from the phase I EXPLORER study by Dr. Gotlib #ASH2020 https://t.co/B2DvFb9IiV,true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-07 21:45:06+00:00,Lisa Palacios,http://twitter.com/,6.0,,1.3360642138323067e+18,,0.0,0.0,,"RT @VJHemOnc: #Decitabine w/ #Venetoclax vs intensive chemotherapy in R/R #AML

For further discussion around this study watch out intervie‚Ä¶",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,1.0,https://twitter.com/Lisa_Palacios/statuses/1336064213832306689,0.0,0.0,,0.0,0.0,0.0,1.0,5.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @VJHemOnc: #Decitabine w/ #Venetoclax vs intensive chemotherapy in R/R #AML

For further discussion around this study watch out intervie‚Ä¶",true
SJKBio,"Medical Doctor - digital health, genomics, imaging, surgery, systems.",,Dublin,,2020-12-07 16:24:26+00:00,Stephen Kearney,http://twitter.com/,7.0,,1.3359835168578847e+18,,0.0,0.0,,"RT @AzizNazhaMD: The conclusions of Molecular landscape of Our #AI algorithm to predict MDS diagnosis from CBC and mutational data only, #A‚Ä¶",en,0.0,351.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,3.0,https://twitter.com/SJKBio/statuses/1335983516857884676,0.0,0.0,,0.0,0.0,0.0,3.0,4.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"RT @AzizNazhaMD: The conclusions of Molecular landscape of Our #AI algorithm to predict MDS diagnosis from CBC and mutational data only, #A‚Ä¶",false
kaufman_MMdoc,Myeloma/amyloid/plasma cell doctor @WinshipAtEmory #myeloma. #mmsm,,"Atlanta, GA",,2020-12-07 20:07:37+00:00,"Jonathan Kaufman, MD",http://twitter.com/,11.0,,1.336039683227312e+18,,0.0,0.0,,RT @OncLive: Daratumumab Combo Improved Response Rates for Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma @kaufman_MMdo‚Ä¶,en,0.0,1548.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,8.0,3.0,https://twitter.com/kaufman_MMdoc/statuses/1336039683227312129,0.0,0.0,,0.0,0.0,0.0,3.0,8.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @OncLive: Daratumumab Combo Improved Response Rates for Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma @kaufman_MMdo‚Ä¶,true
MediHumdani,"Director, BMT & Cellular Therapy Program @Froedtert & @MedicalCollege | Lymphoma | Clinical Trials | @CIBMTR | @BMTCTN | Personal views | Physician ‚â† Provider",,"Milwaukee, WI",,2020-12-07 20:11:09+00:00,Mehdi Hamadani,http://twitter.com/,1.0,,1.3360405738038843e+18,,0.0,0.0,,"Phase 1 Study of TTI-621, targeting CD47, in r/r hem malignancies #lymsm #ASH20  
N=200+; thrombocytopenia common‚Ä¶ https://t.co/WNSUqJec6q",en,0.0,4590.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/MediHumdani/statuses/1336040573803884545,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"Phase 1 Study of TTI-621, targeting CD47, in r/r hem malignancies #lymsm #ASH20  
N=200+; thrombocytopenia common‚Ä¶ https://t.co/WNSUqJec6q",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-07 00:53:44+00:00,"Ritcha Saxena, MD",http://twitter.com/,10.0,,1.335749298009596e+18,,0.0,0.0,,RT @hemedoc: #ASH20 #leusm Short: hCVAD+Blin in frontline for Ph neg B-ALL in age 14+. 4 cycles of chemo (2 for high risk) then Blin x 4 th‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,8.0,2.0,https://twitter.com/RitchaSaxena/statuses/1335749298009595911,0.0,0.0,,0.0,0.0,0.0,2.0,8.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @hemedoc: #ASH20 #leusm Short: hCVAD+Blin in frontline for Ph neg B-ALL in age 14+. 4 cycles of chemo (2 for high risk) then Blin x 4 th‚Ä¶,true
dbranderMD,translational oncologist at Duke Cancer Institute / director CLL & Lymphoma research program / views and tweets are my own,,,,2020-12-07 00:55:52+00:00,Danielle M. Brander,http://twitter.com/,5.0,,1.3357498337690214e+18,,0.0,0.0,,"RT @DukeHMCT: #ASH20 poster by @LindsayReinMD @DukeHMCT @dukemedicine @DukeCancer 

Phase I trial incorporating NK cells for patients w/ #C‚Ä¶",en,0.0,376.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,2.0,https://twitter.com/dbranderMD/statuses/1335749833769021440,0.0,0.0,,0.0,0.0,0.0,2.0,3.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @DukeHMCT: #ASH20 poster by @LindsayReinMD @DukeHMCT @dukemedicine @DukeCancer 

Phase I trial incorporating NK cells for patients w/ #C‚Ä¶",true
AndreaAnampaG,"Medstudent @UNMSM_ with OCD ‚Ä¢ @ASCO & @AMWAdoctors Social Media
@CPsolvers Team Member ‚Ä¢ #Globaloncology #WomenInMedicine #MedEd #SurvOnc üáµüá™ #IMG üåà she/ella",,"Lima, Peru",,2020-12-07 16:35:49+00:00,Andrea Anampa-Guzm√°n,http://twitter.com/,40.0,,1.3359863822385193e+18,,0.0,0.0,,RT @Anand_88_Patel: Here's our #ASH20 talk on a modified pediatric regimen in older adults for tx of ALL! Big thanks to Dr. Stock for her m‚Ä¶,en,0.0,1908.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,37.0,3.0,https://twitter.com/AndreaAnampaG/statuses/1335986382238519298,0.0,0.0,,0.0,0.0,0.0,3.0,37.0,False,False,False,False,True,Financial Performance,1.0,0.0,0.0,RT @Anand_88_Patel: Here's our #ASH20 talk on a modified pediatric regimen in older adults for tx of ALL! Big thanks to Dr. Stock for her m‚Ä¶,true
Gaurav_C42,"Hematopathologist @ACTREC_TMC, @TataMemorial. Love Instrumental, Coffee, Independent movies, Kajari and Freedom. Views=own",,,,2020-12-07 12:48:56+00:00,Gaurav Chatterjee,http://twitter.com/,13.0,,1.335929283517141e+18,,0.0,0.0,,RT @AML_Hub: CONGRESS | #ASH20 | Nikhil Patkar @nvpatkar investigated ‚Äúhotspot‚Äù panel of 35 mutated genes in AML plus FLT3-ITD PCR based NG‚Ä¶,en,0.0,167.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,8.0,5.0,https://twitter.com/Gaurav_C42/statuses/1335929283517140994,0.0,0.0,,0.0,0.0,0.0,5.0,8.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,RT @AML_Hub: CONGRESS | #ASH20 | Nikhil Patkar @nvpatkar investigated ‚Äúhotspot‚Äù panel of 35 mutated genes in AML plus FLT3-ITD PCR based NG‚Ä¶,false
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-07 00:56:30+00:00,"Ritcha Saxena, MD",http://twitter.com/,14.0,,1.3357499933035848e+18,,0.0,0.0,,"RT @SandyWong02111: Proud of @SwethaKMD for her #ASH20 abstract 2352 on infection and CAR-T! 47 #MYELOMA pt tx with BCMA #CARTcell tx!
@Tom‚Ä¶",en,0.0,6875.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,11.0,3.0,https://twitter.com/RitchaSaxena/statuses/1335749993303584772,0.0,0.0,,0.0,0.0,0.0,3.0,11.0,False,False,False,False,True,Side Effects,1.0,0.0,0.0,"RT @SandyWong02111: Proud of @SwethaKMD for her #ASH20 abstract 2352 on infection and CAR-T! 47 #MYELOMA pt tx with BCMA #CARTcell tx!
@Tom‚Ä¶",true
Vchang_lab,"Pediatric oncologist focusing on blood stem cells, aging and cancer susceptibility @ucla. Views are my own. she/her/hers. Personal account @v_e_e_e_e",,,,2020-12-07 21:44:09+00:00,"Vivian Y Chang, MD, MS",http://twitter.com/,1.0,,1.3360639768918508e+18,,0.0,0.0,,"After a quick trip to pickup lunch from the kitchen 10‚Äô away, I‚Äôm ready to learn about Genetic Testing for Heritabl‚Ä¶ https://t.co/OsXAYReE2U",en,0.0,464.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/Vchang_lab/statuses/1336063976891850753,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"After a quick trip to pickup lunch from the kitchen 10‚Äô away, I‚Äôm ready to learn about Genetic Testing for Heritabl‚Ä¶ https://t.co/OsXAYReE2U",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-07 14:03:38+00:00,Lisa Palacios,http://twitter.com/,0.0,,1.3359480847827515e+18,,0.0,0.0,,"Don't miss @wwierda's presentation, 'Transcend #CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in C‚Ä¶ https://t.co/KbtK6Uqp85",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/Lisa_Palacios/statuses/1335948084782751748,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"Don't miss @wwierda's presentation, 'Transcend #CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in C‚Ä¶ https://t.co/KbtK6Uqp85",true
LukeMtjoy,Hematologist and transplant physician at Colorado Blood Cancer Institute. Former hem/onc fellow @MayoClinic AZ. view and opinions are my own,,"Denver, CO",,2020-12-07 19:06:41+00:00,LukeMtjoy,http://twitter.com/,3.0,,1.336024350009434e+18,,0.0,0.0,,"RT @hemedoc: #ASH20 #leusm Garcia (584): MFC analysis of CSF at diagnosis of ALL in adults treated with hCVAD (n=92, 80% B-ALL). COG rules‚Ä¶",en,0.0,137.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,1.0,2.0,https://twitter.com/LukeMtjoy/statuses/1336024350009434113,0.0,0.0,,0.0,0.0,0.0,2.0,1.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"RT @hemedoc: #ASH20 #leusm Garcia (584): MFC analysis of CSF at diagnosis of ALL in adults treated with hCVAD (n=92, 80% B-ALL). COG rules‚Ä¶",true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-12-17 18:40:00+00:00,Oncology Tube,http://twitter.com/,0.0,,1.3396415110848717e+18,,0.0,0.0,,"Preliminary Results of a Phase 1 Dose Escalation Study Elizabeth Budde, MD Ph.D. @elizabeth_budde @cityofhope‚Ä¶ https://t.co/li9r56bmDp",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1339641511084871680,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"Preliminary Results of a Phase 1 Dose Escalation Study Elizabeth Budde, MD Ph.D. @elizabeth_budde @cityofhope‚Ä¶ https://t.co/li9r56bmDp",true
khouri_jack,Myeloma/BMT #hematologist #oncologist @ClevelandClinic Assistant Prof @CleClinicLCM @CWRUSOM | alum @TuftsMedSchool @Uni_Of_Balamand #mmsm #bmtsm,,"Cleveland, OH",,2020-12-07 22:01:48+00:00,"Jack Khouri, MD",http://twitter.com/,36.0,,1.3360684162607596e+18,,0.0,0.0,,"RT @ninashah33: Cyber IBER! Iber with dara dex or
BTZ dex with 35-50% ORR. I think this data useful to show us how to combine this new drug‚Ä¶",en,0.0,443.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,28.0,8.0,https://twitter.com/khouri_jack/statuses/1336068416260759552,0.0,0.0,,0.0,0.0,0.0,8.0,28.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @ninashah33: Cyber IBER! Iber with dara dex or
BTZ dex with 35-50% ORR. I think this data useful to show us how to combine this new drug‚Ä¶",false
dgermain21,MD-PhD. 2nd year Heme/Onc fellow focused on lymphoma and leukemia. Physician-scientist-in-training. Tweet/RT not medical advice or endorsement.,,"St. Louis, MO",,2020-12-07 17:10:09+00:00,David A. Russler-Germain,http://twitter.com/,47.0,,1.335995022316089e+18,,0.0,0.0,,RT @UjjaniC: So excited to finally present Ibrutinib + Venetoclax in Follicular #Lymphoma! ORR &gt; 80% at RP2D. Phase 2 currently accruing @S‚Ä¶,en,0.0,1612.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,39.0,8.0,https://twitter.com/dgermain21/statuses/1335995022316089350,0.0,0.0,,0.0,0.0,0.0,8.0,39.0,False,False,False,False,True,Clinical Trials,1.0,0.0,0.0,RT @UjjaniC: So excited to finally present Ibrutinib + Venetoclax in Follicular #Lymphoma! ORR &gt; 80% at RP2D. Phase 2 currently accruing @S‚Ä¶,true
CBCIDocs,Thoughts and perspectives from the hematology and transplant physicians at Colorado Blood Cancer Institute @ColoradoBlood @SarahCannonDocs @PresStLukesDenv,,"Denver, CO",,2020-12-17 16:57:54+00:00,CBCI,http://twitter.com/,68.0,,1.3396158170178068e+18,,0.0,0.0,,"RT @BMS_Myeloma_US: During #ASH20, learn why new treatment options are needed in triple-class exposed* multiple myeloma. #MMSM",en,0.0,782.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,55.0,13.0,https://twitter.com/CBCIDocs/statuses/1339615817017806850,0.0,0.0,,0.0,0.0,0.0,13.0,55.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @BMS_Myeloma_US: During #ASH20, learn why new treatment options are needed in triple-class exposed* multiple myeloma. #MMSM",true
jasaunders90,"Physician Associate in Haematology @G_ICEMD. Acute leukaemia, MDS and MPN. Faculty board @FPARCP. Often found in Bayern/Berlin. Pers√∂nliche Meinungen üá™üá∫üè≥Ô∏è‚Äçüåà",,London (he/him),,2020-12-18 07:43:42+00:00,Jamie Saunders,http://twitter.com/,26.0,,1.3398387354589637e+18,,0.0,0.0,,RT @Dr_AmerZeidan: One of the few bright spots of the pandemic year 2020 has been starting the new #MDSsm ‚ÄúMDS Sessions‚Äù series with @VJHem‚Ä¶,en,0.0,2666.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,21.0,5.0,https://twitter.com/jasaunders90/statuses/1339838735458963456,0.0,0.0,,0.0,0.0,0.0,5.0,21.0,False,False,False,False,True,Covid,0.0,0.0,1.0,RT @Dr_AmerZeidan: One of the few bright spots of the pandemic year 2020 has been starting the new #MDSsm ‚ÄúMDS Sessions‚Äù series with @VJHem‚Ä¶,true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-12-16 18:37:00+00:00,Oncology Tube,http://twitter.com/,0.0,,1.3392783682780774e+18,,0.0,0.0,,"180 Updated Phase 1 Results of Teclistamab, a BCMA x CD3 Bispecific Antibody Amrita Krishnan, MD, FACP‚Ä¶ https://t.co/vkCHCJteZw",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1339278368278077443,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"180 Updated Phase 1 Results of Teclistamab, a BCMA x CD3 Bispecific Antibody Amrita Krishnan, MD, FACP‚Ä¶ https://t.co/vkCHCJteZw",true
drjsporter,Licensed Psychologist | Sickle Cell Researcher @stjuderesearch | Alum @UVA @FloridaState @VCU @NUFeinbergMed | Tweets are my own.,,"Memphis, TN",,2020-12-04 17:28:19+00:00,"Dr. Jerlym Porter, PhD",http://twitter.com/,46.0,,1.3349124311523574e+18,,0.0,0.0,,"RT @acweyand: What often happens to the Black community by police is just as frequently happening to sickle cell patients in hospitals. 

I‚Ä¶",en,0.0,447.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,40.0,6.0,https://twitter.com/drjsporter/statuses/1334912431152357376,0.0,0.0,,0.0,0.0,0.0,6.0,40.0,False,False,False,False,True,Disease Advocacy,0.0,0.0,1.0,"RT @acweyand: What often happens to the Black community by police is just as frequently happening to sickle cell patients in hospitals. 

I‚Ä¶",true
AnnaSureda5,"Haematologist interested in lymphoid malignancies, stem cell transplantation and CART cells. #CART #BMT #lymphomas #immunotherapy #WomenInMedicine",,"Barcelona, Spain",,2020-12-04 14:11:18+00:00,Anna Sureda,http://twitter.com/,5.0,,1.3348628509600563e+18,,0.0,0.0,,"RT @TheEBMT: Get to know the #EBMT values üèÜ
Value 3/8 = Innovativeüßë‚Äçüî¨

The EBMT community embraces clinical research, basic science and edu‚Ä¶",en,0.0,658.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,1.0,https://twitter.com/AnnaSureda5/statuses/1334862850960056320,0.0,0.0,,0.0,0.0,0.0,1.0,4.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @TheEBMT: Get to know the #EBMT values üèÜ
Value 3/8 = Innovativeüßë‚Äçüî¨

The EBMT community embraces clinical research, basic science and edu‚Ä¶",false
drjaneholland,"MD PhD PgDipEd MRCS FAS Ex-Surgeon, Anatomist, Medical Educator, Mezzo, RYA Yachtmaster... RT not necessarily my views but things I found interesting",,"Dublin, Ireland",,2020-12-04 19:40:54+00:00,Jane Holland MD PhD MRCSI,http://twitter.com/,48.0,,1.3349457963583488e+18,,0.0,0.0,,"RT @acweyand: Women wait up to 15 years to be diagnosed with bleeding disorders!

In the meantime, women undergo hysterectomies, suffer fro‚Ä¶",en,0.0,1873.0,,,0.0,,,Negative,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,41.0,7.0,https://twitter.com/drjaneholland/statuses/1334945796358348805,0.0,0.0,,0.0,0.0,0.0,7.0,41.0,False,False,False,False,True,Diagnostic Tools,0.0,1.0,0.0,"RT @acweyand: Women wait up to 15 years to be diagnosed with bleeding disorders!

In the meantime, women undergo hysterectomies, suffer fro‚Ä¶",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-04 18:12:43+00:00,Lisa Palacios,http://twitter.com/,1.0,,1.3349236055206093e+18,,0.0,0.0,,RT @neurology_live: Join @GoToPER TODAY at the #ASH20 FSS for an opportunity to network with top minds in hematology and engage in expert d‚Ä¶,en,0.0,657.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/Lisa_Palacios/statuses/1334923605520609281,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @neurology_live: Join @GoToPER TODAY at the #ASH20 FSS for an opportunity to network with top minds in hematology and engage in expert d‚Ä¶,true
rosslevinemd,"Physician Scientist/MSKCC.  All views expressed here are my own & do not represent my employer. 

COI:https://t.co/yXttSKlaik",,,,2020-12-04 03:02:15+00:00,"Ross ""FollowtheScience"" Levine",http://twitter.com/,13.0,,1.3346944781170033e+18,,0.0,0.0,,RT @tchlon: Catching up on yesterday‚Äôs #ashmyeloidworkshop. Great talks by many of my fellow young investigators! Congratulations everyone!‚Ä¶,en,0.0,5307.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,12.0,1.0,https://twitter.com/rosslevinemd/statuses/1334694478117003264,0.0,0.0,,0.0,0.0,0.0,1.0,12.0,False,False,False,False,True,Financial Performance,1.0,0.0,0.0,RT @tchlon: Catching up on yesterday‚Äôs #ashmyeloidworkshop. Great talks by many of my fellow young investigators! Congratulations everyone!‚Ä¶,true
NazliDizman,MD & Researcher & Aspiring medical oncologist | @YaleIMed | Postdoc Fellow @CityofHope_GU | #WomenInMedicine | Tweets are my own | @ASCO FCOI https://t.co/2qasYPvDli,,"New Haven, CT",,2020-12-04 03:18:07+00:00,Nazli Dizman,http://twitter.com/,14.0,,1.3346984694795592e+18,,0.0,0.0,,"RT @MazieTsangMD: #ASH20 #GeriHeme
My mentor and collaborator @MelissaLoh21 moderating this interesting session with lots of great question‚Ä¶",en,0.0,2298.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,12.0,2.0,https://twitter.com/NazliDizman/statuses/1334698469479559168,0.0,0.0,,0.0,0.0,0.0,2.0,12.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,"RT @MazieTsangMD: #ASH20 #GeriHeme
My mentor and collaborator @MelissaLoh21 moderating this interesting session with lots of great question‚Ä¶",true
fniainle,"Haematologist, passionate about VTE. Co-director @ConwaySphere; Director https://t.co/csdWq9XJ57; RT not endorsement, views my own",,"Dublin City, Ireland",,2020-12-04 20:41:21+00:00,Fionnuala N√≠ √Åinle,http://twitter.com/,25.0,,1.334961007194681e+18,,0.0,0.0,,"RT @LaurenMerzMD: LOVED this talk from @sholzberg at #ASH20 on delivery, postpartum period, and health equity in women with bleeding disord‚Ä¶",en,0.0,2069.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,20.0,5.0,https://twitter.com/fniainle/statuses/1334961007194681344,0.0,0.0,,0.0,0.0,0.0,5.0,20.0,False,False,False,False,True,Financial Performance,1.0,0.0,0.0,"RT @LaurenMerzMD: LOVED this talk from @sholzberg at #ASH20 on delivery, postpartum period, and health equity in women with bleeding disord‚Ä¶",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-04 21:19:14+00:00,Lisa Palacios,http://twitter.com/,12.0,,1.33497054411511e+18,,0.0,0.0,,RT @doctorpemm: #ASH20 | Venetoclax w/Decitabine Versus Intensive Chemotherapy in AML : A Propensity Score Matched Analysis Stratified by R‚Ä¶,en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,8.0,4.0,https://twitter.com/Lisa_Palacios/statuses/1334970544115109888,0.0,0.0,,0.0,0.0,0.0,4.0,8.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @doctorpemm: #ASH20 | Venetoclax w/Decitabine Versus Intensive Chemotherapy in AML : A Propensity Score Matched Analysis Stratified by R‚Ä¶,false
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-12-29 20:50:03+00:00,Oncology Tube,http://twitter.com/,0.0,,1.3440228938401464e+18,,0.0,0.0,,"@TomSilver39 We had the pleasure of speaking with Dr. Arora - Phase 1 Study of Axatilimab (SNDX-6352) Mukta Arora,‚Ä¶ https://t.co/sjtDzN3zCh",en,0.0,14785.0,,,0.0,TomSilver39,1.3358091986264596e+18,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1344022893840146433,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,1.0,0.0,0.0,"@TomSilver39 We had the pleasure of speaking with Dr. Arora - Phase 1 Study of Axatilimab (SNDX-6352) Mukta Arora,‚Ä¶ https://t.co/sjtDzN3zCh",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-11-16 13:04:05+00:00,Lisa Palacios,http://twitter.com/,19.0,,1.3283229522161132e+18,,0.0,0.0,,"RT @doctorpemm: #ASH20 | A Multicenter Phase 1/2 Clinical Trial of Tagraxofusp, a #CD123-Targeted Therapy, in Patients with Poor-Risk Myelo‚Ä¶",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,15.0,4.0,https://twitter.com/Lisa_Palacios/statuses/1328322952216113154,0.0,0.0,,0.0,0.0,0.0,4.0,15.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @doctorpemm: #ASH20 | A Multicenter Phase 1/2 Clinical Trial of Tagraxofusp, a #CD123-Targeted Therapy, in Patients with Poor-Risk Myelo‚Ä¶",true
lepikurian,"Haematologist, researcher, biotech startup co-founder",,"Saint-Petersburg, Russia",,2020-11-09 06:20:15+00:00,Kirill Lepik M.D.,http://twitter.com/,113.0,,1.3256846102070108e+18,,0.0,0.0,,"RT @graham74GC: Puckrin et al
- retro study CNS relapse in DLBCL
- found CNS-IPI prognostic
- use of IV MTX proph NOT assoc with ‚¨áÔ∏è CNS rel‚Ä¶",en,0.0,89.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,86.0,27.0,https://twitter.com/lepikurian/statuses/1325684610207010816,0.0,0.0,,0.0,0.0,0.0,27.0,86.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @graham74GC: Puckrin et al
- retro study CNS relapse in DLBCL
- found CNS-IPI prognostic
- use of IV MTX proph NOT assoc with ‚¨áÔ∏è CNS rel‚Ä¶",true
shivshankar87,"Medical oncologist, Loves traveling, cooking & philosophy. Views personal.",,New Delhi,,2020-11-15 16:12:35+00:00,Shivashankara MS,http://twitter.com/,41.0,,1.3280080013539615e+18,,0.0,0.0,,"RT @VincentRK: #1 Talquetamab, novel bi specific antibody targeting GPRC5D (expressed on myeloma cells) &amp; CD3 shows activity in relapsed re‚Ä¶",en,0.0,164.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,29.0,12.0,https://twitter.com/shivshankar87/statuses/1328008001353961473,0.0,0.0,,0.0,0.0,0.0,12.0,29.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @VincentRK: #1 Talquetamab, novel bi specific antibody targeting GPRC5D (expressed on myeloma cells) &amp; CD3 shows activity in relapsed re‚Ä¶",true
szusmani,"Division Chief, Plasma Cell Disorders|Director, Clinical Research Hem Malignancies | Views are my own | RT not endorsement | Physician ‚â† Provider",,"Charlotte, NC",,2020-11-09 16:23:33+00:00,Saad Z. Usmani MD MBA FACP (he/his/him),http://twitter.com/,1.0,,1.325836432980779e+18,,0.0,0.0,,"5/7
TOP CLINICAL PHASE 2/3 RRMM #ASH20SU #ASH20 #mmsm
-Ixa-Kd IKEMA Update (https://t.co/MliR1Ry4XB)
-Dara-Pod APOL‚Ä¶ https://t.co/OvWjgbuyrV",tl,0.0,5512.0,,,0.0,szusmani,1.325836431705641e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/szusmani/statuses/1325836432980779011,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"5/7
TOP CLINICAL PHASE 2/3 RRMM #ASH20SU #ASH20 #mmsm
-Ixa-Kd IKEMA Update (https://t.co/MliR1Ry4XB)
-Dara-Pod APOL‚Ä¶ https://t.co/OvWjgbuyrV",true
venkymd,Medical and Pediatric Oncologist. Global health student. #Kilpauk #PGI #AIIMS #StJude #cancerInstitute,,,,2020-11-09 02:29:46+00:00,Venkatraman Radhakrishnan (Venky),http://twitter.com/,15.0,,1.3256266063212012e+18,,0.0,0.0,,RT @mtmdphd: Lack of Effectiveness of Intravenous High-Dose Methotrexate for Prevention of CNS Relapse in Patients with High-Risk DLBCL: A‚Ä¶,en,0.0,2842.0,,,0.0,,,Negative,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,5.0,https://twitter.com/venkymd/statuses/1325626606321201154,0.0,0.0,,0.0,0.0,0.0,5.0,10.0,False,False,False,False,True,Diagnosis Progression,0.0,1.0,0.0,RT @mtmdphd: Lack of Effectiveness of Intravenous High-Dose Methotrexate for Prevention of CNS Relapse in Patients with High-Risk DLBCL: A‚Ä¶,false
szusmani,"Division Chief, Plasma Cell Disorders|Director, Clinical Research Hem Malignancies | Views are my own | RT not endorsement | Physician ‚â† Provider",,"Charlotte, NC",,2020-11-09 16:23:32+00:00,Saad Z. Usmani MD MBA FACP (he/his/him),http://twitter.com/,1.0,,1.3258364305145403e+18,,0.0,0.0,,"3/7
TOP CLINICAL NON-CART PHASE 1 RRMM  #ASH20SU #ASH20 #mmsm
-Teclistamab (https://t.co/6VMtLsKbiP)
-MEDI2228 (‚Ä¶ https://t.co/qT9F5L228n",tl,0.0,5512.0,,,0.0,szusmani,1.325836429193261e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/szusmani/statuses/1325836430514540544,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"3/7
TOP CLINICAL NON-CART PHASE 1 RRMM  #ASH20SU #ASH20 #mmsm
-Teclistamab (https://t.co/6VMtLsKbiP)
-MEDI2228 (‚Ä¶ https://t.co/qT9F5L228n",true
majorajay,"Hematology/oncology fellow. #lymsm & #mmsm outcomes researcher. Physician-publisher & founder of https://t.co/dPfLt8QVMr, @inTrainingDoc & @inHouseMag.",,"Chicago, IL",,2020-11-09 15:00:00+00:00,"Ajay Major, MD, MBA",http://twitter.com/,2.0,,1.3258154087004815e+18,,0.0,0.0,,"I'm excited to present our phase I/II clinical trial at the upcoming @ASH_hematology #ASH20 conference, under the m‚Ä¶ https://t.co/QEAbX03imq",en,0.0,3518.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/majorajay/statuses/1325815408700481536,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Clinical Trials,1.0,0.0,0.0,"I'm excited to present our phase I/II clinical trial at the upcoming @ASH_hematology #ASH20 conference, under the m‚Ä¶ https://t.co/QEAbX03imq",true
szusmani,"Division Chief, Plasma Cell Disorders|Director, Clinical Research Hem Malignancies | Views are my own | RT not endorsement | Physician ‚â† Provider",,"Charlotte, NC",,2020-11-09 16:23:32+00:00,Saad Z. Usmani MD MBA FACP (he/his/him),http://twitter.com/,1.0,,1.325836431705641e+18,,0.0,0.0,,"4/7
TOP CLINICAL CART PHASE 1 RRMM #ASH20SU #ASH20 #mmsm
-Cilta-cel (https://t.co/RhqSaLn6v2)
-Anti-BCMA &amp; Anti-CD5‚Ä¶ https://t.co/HKnS9F8jbr",in,0.0,5512.0,,,0.0,szusmani,1.3258364305145403e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/szusmani/statuses/1325836431705640960,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"4/7
TOP CLINICAL CART PHASE 1 RRMM #ASH20SU #ASH20 #mmsm
-Cilta-cel (https://t.co/RhqSaLn6v2)
-Anti-BCMA &amp; Anti-CD5‚Ä¶ https://t.co/HKnS9F8jbr",true
venkymd,Medical and Pediatric Oncologist. Global health student. #Kilpauk #PGI #AIIMS #StJude #cancerInstitute,,,,2020-11-09 05:18:40+00:00,Venkatraman Radhakrishnan (Venky),http://twitter.com/,44.0,,1.3256691101396623e+18,,0.0,0.0,,RT @mtmdphd: Lack of Effectiveness of IV High-Dose Methotrexate for Prevention of CNS Relapse in High-Risk DLBCL: Retrospective Analysis fr‚Ä¶,en,0.0,2842.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,34.0,10.0,https://twitter.com/venkymd/statuses/1325669110139662339,0.0,0.0,,0.0,0.0,0.0,10.0,34.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @mtmdphd: Lack of Effectiveness of IV High-Dose Methotrexate for Prevention of CNS Relapse in High-Risk DLBCL: Retrospective Analysis fr‚Ä¶,true
AKeyzner,"hematologist #BMT #leuksm physician ‚â†provider immigrant, opinions my own, likes‚â†endorsement",,,,2020-11-09 14:15:45+00:00,Alla Keyzner,http://twitter.com/,44.0,,1.325804273964376e+18,,0.0,0.0,,RT @mtmdphd: Lack of Effectiveness of IV High-Dose Methotrexate for Prevention of CNS Relapse in High-Risk DLBCL: Retrospective Analysis fr‚Ä¶,en,0.0,157.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,34.0,10.0,https://twitter.com/AKeyzner/statuses/1325804273964376064,0.0,0.0,,0.0,0.0,0.0,10.0,34.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @mtmdphd: Lack of Effectiveness of IV High-Dose Methotrexate for Prevention of CNS Relapse in High-Risk DLBCL: Retrospective Analysis fr‚Ä¶,true
venkymd,Medical and Pediatric Oncologist. Global health student. #Kilpauk #PGI #AIIMS #StJude #cancerInstitute,,,,2020-11-09 01:35:58+00:00,Venkatraman Radhakrishnan (Venky),http://twitter.com/,113.0,,1.325613065698566e+18,,0.0,0.0,,"RT @graham74GC: Puckrin et al
- retro study CNS relapse in DLBCL
- found CNS-IPI prognostic
- use of IV MTX proph NOT assoc with ‚¨áÔ∏è CNS rel‚Ä¶",en,0.0,2842.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,86.0,27.0,https://twitter.com/venkymd/statuses/1325613065698566144,0.0,0.0,,0.0,0.0,0.0,27.0,86.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @graham74GC: Puckrin et al
- retro study CNS relapse in DLBCL
- found CNS-IPI prognostic
- use of IV MTX proph NOT assoc with ‚¨áÔ∏è CNS rel‚Ä¶",false
szusmani,"Division Chief, Plasma Cell Disorders|Director, Clinical Research Hem Malignancies | Views are my own | RT not endorsement | Physician ‚â† Provider",,"Charlotte, NC",,2020-11-09 16:23:33+00:00,Saad Z. Usmani MD MBA FACP (he/his/him),http://twitter.com/,2.0,,1.3258364342348595e+18,,0.0,0.0,,"6/7
TOP 5 CLINICAL PHASE 2/3 Newly Diagnosed #ASH20SU #ASH20 #mmsm
-GRIFFIN Update (https://t.co/UBT5mcwA7Y)
-EMN02‚Ä¶ https://t.co/I7mygDw3S3",en,0.0,5512.0,,,0.0,szusmani,1.325836432980779e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/szusmani/statuses/1325836434234859521,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"6/7
TOP 5 CLINICAL PHASE 2/3 Newly Diagnosed #ASH20SU #ASH20 #mmsm
-GRIFFIN Update (https://t.co/UBT5mcwA7Y)
-EMN02‚Ä¶ https://t.co/I7mygDw3S3",true
dgermain21,MD-PhD. 2nd year Heme/Onc fellow focused on lymphoma and leukemia. Physician-scientist-in-training. Tweet/RT not medical advice or endorsement.,,"St. Louis, MO",,2020-11-09 12:03:02+00:00,David A. Russler-Germain,http://twitter.com/,11.0,,1.3257708732242412e+18,,0.0,0.0,,"RT @CwynKate: Reminder that CNS relapse occurs early: 24% during/before the end of front line therapy
And median survival after CNS relapse‚Ä¶",en,0.0,1612.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,8.0,3.0,https://twitter.com/dgermain21/statuses/1325770873224241152,0.0,0.0,,0.0,0.0,0.0,3.0,8.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @CwynKate: Reminder that CNS relapse occurs early: 24% during/before the end of front line therapy
And median survival after CNS relapse‚Ä¶",true
DrBenParsons,"Hematologist and Oncologist at Gundersen Health System with a special interest in Hematologic malignancy, precision medicine and immunotherapy",,"La Crosse, WI",,2020-11-09 02:08:07+00:00,Dr. Benjamin Parsons,http://twitter.com/,44.0,,1.3256211585873388e+18,,0.0,0.0,,RT @mtmdphd: Lack of Effectiveness of IV High-Dose Methotrexate for Prevention of CNS Relapse in High-Risk DLBCL: Retrospective Analysis fr‚Ä¶,en,0.0,223.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,34.0,10.0,https://twitter.com/DrBenParsons/statuses/1325621158587338753,0.0,0.0,,0.0,0.0,0.0,10.0,34.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @mtmdphd: Lack of Effectiveness of IV High-Dose Methotrexate for Prevention of CNS Relapse in High-Risk DLBCL: Retrospective Analysis fr‚Ä¶,true
aditishasMD,Physician-scientist researching cures for AML & MDS. Addressing health disparities in cancer care. Tweets my own #leusm #mds,,"New York, NY",,2020-12-02 17:24:12+00:00,"Aditi Shastri, MD",http://twitter.com/,1.0,,1.334186620602491e+18,,0.0,0.0,,Thank you @DavidSteensma ! Congratulations to all the speakers at the #ASH2020 for a fantastic session in a pandemi‚Ä¶ https://t.co/PUqhuigmXG,en,0.0,723.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/aditishasMD/statuses/1334186620602490886,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,Thank you @DavidSteensma ! Congratulations to all the speakers at the #ASH2020 for a fantastic session in a pandemi‚Ä¶ https://t.co/PUqhuigmXG,true
Gritsman_lab,Physician-scientist investigating signaling and self-renewal in myeloid malignancies and hematopoietic stem cells. Tweets are my own.,,,,2020-12-02 01:30:34+00:00,Kira Gritsman,http://twitter.com/,56.0,,1.3339466277369528e+18,,0.0,0.0,,RT @juliamaxson: The myeloid development workshop is my favorite part of ASH! The line up of jr. faculty speakers tomorrow looks fantastic!‚Ä¶,en,0.0,701.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,52.0,4.0,https://twitter.com/Gritsman_lab/statuses/1333946627736952833,0.0,0.0,,0.0,0.0,0.0,4.0,52.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,RT @juliamaxson: The myeloid development workshop is my favorite part of ASH! The line up of jr. faculty speakers tomorrow looks fantastic!‚Ä¶,true
HowellJollyBody,"Physician Scientist @UChicagoMed. Belligerent patient. Collector of stories. Cancer Immunology & Leuk(a)emia üî¨üá¨üáßüá∫üá∏ (views not employers, she/her)",,"Chicago, IL",,2020-12-02 16:00:20+00:00,"Athalia Pyzer, MD PhD",http://twitter.com/,4.0,,1.3341655134847754e+18,,0.0,0.0,,"#ASH20 is here! #ASHaiku 

A year of pain, but
like stem cells we adapted
to our strange new niche‚Ä¶ https://t.co/cUKeNEMD68",en,0.0,1496.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,4.0,https://twitter.com/HowellJollyBody/statuses/1334165513484775426,0.0,0.0,,0.0,0.0,0.0,4.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"#ASH20 is here! #ASHaiku 

A year of pain, but
like stem cells we adapted
to our strange new niche‚Ä¶ https://t.co/cUKeNEMD68",false
JerroldLevy,"Critical care physician in CTICU @DukeMedSchool, interested in coagulation, bleeding, inflammation-also oenophile and foody. Tweets are my own (‚â†medical advice)",,"Durham, North Carolina",,2020-12-02 02:24:04+00:00,"Jerrold Levy, MD",http://twitter.com/,28.0,,1.3339600925307126e+18,,0.0,0.0,,"RT @connors_md: #ASH2020 starts for me tomorrow with scientific workshop on infectious disease and coagulation
#ASHaiku @connors_md @BloodD‚Ä¶",en,0.0,1755.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,27.0,1.0,https://twitter.com/JerroldLevy/statuses/1333960092530712577,0.0,0.0,,0.0,0.0,0.0,1.0,27.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"RT @connors_md: #ASH2020 starts for me tomorrow with scientific workshop on infectious disease and coagulation
#ASHaiku @connors_md @BloodD‚Ä¶",true
CanerSaygin,"Heme-Onc Fellow @UChicago | Alumni of @OhioStateIMRes, @CCLRI | #Leukemia, #MDS, #CHIP physician-scientist. Tweets=own opinions.",,"Chicago, IL",,2020-12-02 00:26:38+00:00,"Caner Saygin, MD",http://twitter.com/,56.0,,1.333930541096325e+18,,0.0,0.0,,RT @juliamaxson: The myeloid development workshop is my favorite part of ASH! The line up of jr. faculty speakers tomorrow looks fantastic!‚Ä¶,en,0.0,743.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,52.0,4.0,https://twitter.com/CanerSaygin/statuses/1333930541096325120,0.0,0.0,,0.0,0.0,0.0,4.0,52.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,RT @juliamaxson: The myeloid development workshop is my favorite part of ASH! The line up of jr. faculty speakers tomorrow looks fantastic!‚Ä¶,true
majorajay,"Hematology/oncology fellow. #lymsm & #mmsm outcomes researcher. Physician-publisher & founder of https://t.co/dPfLt8QVMr, @inTrainingDoc & @inHouseMag.",,"Chicago, IL",,2020-12-02 16:21:50+00:00,"Ajay Major, MD, MBA",http://twitter.com/,32.0,,1.3341709241831506e+18,,0.0,0.0,,"RT @HowellJollyBody: #ASH20 is here! #ASHaiku 

A year of pain, but
like stem cells we adapted
to our strange new niche

#ASHmyeloidworksho‚Ä¶",en,0.0,3518.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,28.0,4.0,https://twitter.com/majorajay/statuses/1334170924183150597,0.0,0.0,,0.0,0.0,0.0,4.0,28.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @HowellJollyBody: #ASH20 is here! #ASHaiku 

A year of pain, but
like stem cells we adapted
to our strange new niche

#ASHmyeloidworksho‚Ä¶",true
graham74GC,Lymphoma specialist at Oxford Cancer and Haematology centre. Haematologist and clinical trialist. Chair of UK Hodgkin and T-cell study groups.,,Opinions are mine,,2020-12-02 07:02:22+00:00,Graham Collins,http://twitter.com/,22.0,,1.334030130704953e+18,,0.0,0.0,,"RT @JohnPLeonardMD: Number 4 #LeonardList #ASH20 - Wang - 117 -  Non-covalent BTKi LOXO-305 in MCL &amp; B cell NHL - tox fatigue/diarrhea, ORR‚Ä¶",en,0.0,6091.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,17.0,5.0,https://twitter.com/graham74GC/statuses/1334030130704953344,0.0,0.0,,0.0,0.0,0.0,5.0,17.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"RT @JohnPLeonardMD: Number 4 #LeonardList #ASH20 - Wang - 117 -  Non-covalent BTKi LOXO-305 in MCL &amp; B cell NHL - tox fatigue/diarrhea, ORR‚Ä¶",true
sanamloghavi,Hematopathologist/Molecular Pathologist @mdandersonnews #endcancer #hemepath #mpnsm #lymsm #leusm #hemepathMDA Tweets are my own.,,"Houston, TX",,2020-12-02 17:02:15+00:00,"Sanam Loghavi, MD",http://twitter.com/,4.0,,1.3341810963602022e+18,,0.0,0.0,,Happy first day of #ASH20 to everyone except the person that did this BM ‚Äúcore biopsy‚Äù üòí  #thestruggleisreal https://t.co/pIh4KarkiN,en,0.0,4797.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,4.0,https://twitter.com/sanamloghavi/statuses/1334181096360202244,0.0,0.0,,0.0,0.0,0.0,4.0,0.0,False,False,False,False,True,Diagnostic Tools,1.0,0.0,0.0,Happy first day of #ASH20 to everyone except the person that did this BM ‚Äúcore biopsy‚Äù üòí  #thestruggleisreal https://t.co/pIh4KarkiN,true
chanyooncheah,Doctor for patients with lymphoma. Clinical researcher.,,"Perth, Western Australia",,2020-12-02 14:46:06+00:00,Chan Cheah,http://twitter.com/,22.0,,1.334146830087594e+18,,0.0,0.0,,"RT @JohnPLeonardMD: Number 4 #LeonardList #ASH20 - Wang - 117 -  Non-covalent BTKi LOXO-305 in MCL &amp; B cell NHL - tox fatigue/diarrhea, ORR‚Ä¶",en,0.0,1717.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,17.0,5.0,https://twitter.com/chanyooncheah/statuses/1334146830087593984,0.0,0.0,,0.0,0.0,0.0,5.0,17.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"RT @JohnPLeonardMD: Number 4 #LeonardList #ASH20 - Wang - 117 -  Non-covalent BTKi LOXO-305 in MCL &amp; B cell NHL - tox fatigue/diarrhea, ORR‚Ä¶",false
rosslevinemd,"Physician Scientist/MSKCC.  All views expressed here are my own & do not represent my employer. 

COI:https://t.co/yXttSKlaik",,,,2020-12-02 15:58:56+00:00,"Ross ""FollowtheScience"" Levine",http://twitter.com/,46.0,,1.3341651618679562e+18,,0.0,0.0,,RT @DavidSteensma: And so it begins! #ASH20 #ASHmyeloidworkshop with @rosslevinemd; @pietras_eric moderating first session: Drs Heather O'L‚Ä¶,en,0.0,5307.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,41.0,5.0,https://twitter.com/rosslevinemd/statuses/1334165161867956224,0.0,0.0,,0.0,0.0,0.0,5.0,41.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,RT @DavidSteensma: And so it begins! #ASH20 #ASHmyeloidworkshop with @rosslevinemd; @pietras_eric moderating first session: Drs Heather O'L‚Ä¶,true
drjgauthier,"MD, MSc, Assistant Professor @fredhutch @UW focused on #CARTcell #immunotherapy #tcellrx 
Interests also include #rstats #bmtsm #epitwitter #bayes",,"Seattle, WA",,2020-12-02 23:49:40+00:00,Jordan Gauthier,http://twitter.com/,7.0,,1.3342836227575398e+18,,0.0,0.0,,RT @SeattleCCA: Our 2020 SCCA at @ASH_hematology website is now live: https://t.co/BwxjB9x2BR View the schedule of our team of speakers and‚Ä¶,en,0.0,3295.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,2.0,https://twitter.com/drjgauthier/statuses/1334283622757539842,0.0,0.0,,0.0,0.0,0.0,2.0,5.0,False,False,False,False,True,Thought Leadership,0.0,0.0,1.0,RT @SeattleCCA: Our 2020 SCCA at @ASH_hematology website is now live: https://t.co/BwxjB9x2BR View the schedule of our team of speakers and‚Ä¶,true
gur_ola,#Cancer biologist. #Epigenetics lover. Mouse #leukemia doctor.,,"Gainesville, FL",,2020-12-02 17:06:22+00:00,Olga Guryanova,http://twitter.com/,46.0,,1.3341821292283863e+18,,0.0,0.0,,RT @DavidSteensma: And so it begins! #ASH20 #ASHmyeloidworkshop with @rosslevinemd; @pietras_eric moderating first session: Drs Heather O'L‚Ä¶,en,0.0,563.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,41.0,5.0,https://twitter.com/gur_ola/statuses/1334182129228386305,0.0,0.0,,0.0,0.0,0.0,5.0,41.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,RT @DavidSteensma: And so it begins! #ASH20 #ASHmyeloidworkshop with @rosslevinemd; @pietras_eric moderating first session: Drs Heather O'L‚Ä¶,true
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-10-14 14:50:04+00:00,Cardiovascular Research Foundation,http://twitter.com/,2.0,,1.3163908223640166e+18,,0.0,0.0,,Explore #MedTech #innovation in the #COVID19 era. Tune in at 11:00 AM ET for a special session examining current ch‚Ä¶ https://t.co/WR8CPbo6Yn,en,0.0,12239.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/crfheart/statuses/1316390822364016640,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,Explore #MedTech #innovation in the #COVID19 era. Tune in at 11:00 AM ET for a special session examining current ch‚Ä¶ https://t.co/WR8CPbo6Yn,true
kdjhaveri,"Nephrologist Educator, academic nephrologist, onconephrologist, cyclist üö¥‚Äç‚ôÄÔ∏è, runner üèÉ Editor in chief: ASN Kidney News",,"Great Neck, NY",,2020-12-02 23:05:32+00:00,Kenar Jhaveri,http://twitter.com/,194.0,,1.334272515972141e+18,,0.0,0.0,,RT @VincentRK: #ASH20 special: Active myeloma drugs with their mechanism of action in one slide. Unapproved investigational drugs in blue f‚Ä¶,en,0.0,5192.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,147.0,47.0,https://twitter.com/kdjhaveri/statuses/1334272515972141056,0.0,0.0,,0.0,0.0,0.0,47.0,147.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,RT @VincentRK: #ASH20 special: Active myeloma drugs with their mechanism of action in one slide. Unapproved investigational drugs in blue f‚Ä¶,true
VincentRK,"Professor, Mayo Clinic; Editor, Blood Cancer Journal; Oncologist; Health Costs; COVID threads @SurvivedCOVID Opinions=personal views https://t.co/TMq9vc5hZk",,"Rochester, MN, USA",,2020-12-02 23:42:43+00:00,Vincent Rajkumar,http://twitter.com/,0.0,,1.3342818773148017e+18,,0.0,0.0,,Data on some of the new drugs in this thread. #ASH20 https://t.co/zO6HRwXTBk,en,0.0,33590.0,,,0.0,VincentRK,1.3342724336883712e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/VincentRK/statuses/1334281877314801666,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,Data on some of the new drugs in this thread. #ASH20 https://t.co/zO6HRwXTBk,false
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-10-14 13:10:26+00:00,Cardiovascular Research Foundation,http://twitter.com/,17.0,,1.3163657512515912e+18,,0.0,0.0,,RT @JGrapsa: An innovative #TCTConnect #TCT2020 just started @TCTConference @crfheart @Drroxmehran @ajaykirtane There are 30+ social media‚Ä¶,en,0.0,12239.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,11.0,6.0,https://twitter.com/crfheart/statuses/1316365751251591168,0.0,0.0,,0.0,0.0,0.0,6.0,11.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @JGrapsa: An innovative #TCTConnect #TCT2020 just started @TCTConference @crfheart @Drroxmehran @ajaykirtane There are 30+ social media‚Ä¶,true
heartdoc45,Interventional Cardiologist at @CardioInstitute; Ochsner/Scripps trained; Pearl Jam enthusiast. Views expressed are my own. #RadialFirst,,"Lafayette, Louisiana",,2020-10-14 16:24:55+00:00,"David Homan, MD",http://twitter.com/,1.0,,1.3164146950253732e+18,,0.0,0.0,,Medtech #Innovation in the #COVID19 Era: Challenges and Emerging Opportunities live now at #TCTConnect with‚Ä¶ https://t.co/MzcriaFZrU,en,0.0,6040.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/heartdoc45/statuses/1316414695025373185,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,Medtech #Innovation in the #COVID19 Era: Challenges and Emerging Opportunities live now at #TCTConnect with‚Ä¶ https://t.co/MzcriaFZrU,true
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-10-14 13:08:28+00:00,Cardiovascular Research Foundation,http://twitter.com/,33.0,,1.3163652577581916e+18,,0.0,0.0,,"RT @JGrapsa: Inspiring the next generation, promoting innovation &amp; clinical excellence, @ACCinTouch together with @crfheart introduce Marti‚Ä¶",en,0.0,12239.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,23.0,10.0,https://twitter.com/crfheart/statuses/1316365257758191620,0.0,0.0,,0.0,0.0,0.0,10.0,23.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"RT @JGrapsa: Inspiring the next generation, promoting innovation &amp; clinical excellence, @ACCinTouch together with @crfheart introduce Marti‚Ä¶",true
jaygirimd,"Interventional cardiologist, cardiovascular outcomes & policy researcher, sports fan, @PennMedicine, @VAPhiladelphia, @PennLDI, tweets reflect only my opinions",,"Philadelphia, PA",,2020-10-14 12:43:35+00:00,Jay Giri,http://twitter.com/,13.0,,1.3163589921222574e+18,,0.0,0.0,,"RT @hect2701: ""Long-Term Outcomes After DES Implantation in Thrombotic Lesions: Pooled Analysis of 8 Randomized Controlled Trials""

#TCTCon‚Ä¶",en,0.0,2336.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,7.0,https://twitter.com/jaygirimd/statuses/1316358992122257409,0.0,0.0,,0.0,0.0,0.0,7.0,6.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @hect2701: ""Long-Term Outcomes After DES Implantation in Thrombotic Lesions: Pooled Analysis of 8 Randomized Controlled Trials""

#TCTCon‚Ä¶",true
rafavidalperez,#Cardi√≥logo #Cardiologist #somosCHUAC / Tesorero @secardiologia /#ACVC @escardio Board /Associate Editor #JACCCaseReports /#EHJDigital #SoMe / Tweets are my own,,Espa√±a,,2020-10-14 16:56:29+00:00,rafavidalperez,http://twitter.com/,34.0,,1.3164226379508244e+18,,0.0,0.0,,"RT @DFCapodanno: Dear speaker who is presenting COMPARE-CRUSH now, be aware that we are all with you, and feel your frustration as your sli‚Ä¶",en,0.0,11577.0,,,0.0,,,Negative,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,31.0,3.0,https://twitter.com/rafavidalperez/statuses/1316422637950824448,0.0,0.0,,0.0,0.0,0.0,3.0,31.0,False,False,False,False,True,Thought Leadership,0.0,1.0,0.0,"RT @DFCapodanno: Dear speaker who is presenting COMPARE-CRUSH now, be aware that we are all with you, and feel your frustration as your sli‚Ä¶",true
Hragy,"Cardiologist, National Heart Institute, Egypt ÿ±ÿ¨ÿßÿ° ÿπÿØŸÖ ÿßŸÑÿ™ŸàÿßÿµŸÑ ÿ®ÿ¥ÿ£ŸÜ ÿ¥ÿ§ŸàŸÜ ÿ∑ÿ®Ÿäÿ© ÿÆÿßÿµÿ© ÿπŸÑŸä ÿ™ŸàŸäÿ™ÿ±",,egypt,,2020-10-14 12:58:40+00:00,Hany Ragy,http://twitter.com/,13.0,,1.3163627879086162e+18,,0.0,0.0,,"RT @hect2701: ""Long-Term Outcomes After DES Implantation in Thrombotic Lesions: Pooled Analysis of 8 Randomized Controlled Trials""

#TCTCon‚Ä¶",en,0.0,31448.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,7.0,https://twitter.com/Hragy/statuses/1316362787908616194,0.0,0.0,,0.0,0.0,0.0,7.0,6.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @hect2701: ""Long-Term Outcomes After DES Implantation in Thrombotic Lesions: Pooled Analysis of 8 Randomized Controlled Trials""

#TCTCon‚Ä¶",false
JGrapsa,Consultant Cardiologist GSTT - Editor in chief #JACCcasereports -Secretary ESC council on VHD - Tweets are my own opinion#,,,,2020-10-14 12:51:48+00:00,Julia Grapsa,http://twitter.com/,6.0,,1.3163610618687447e+18,,0.0,0.0,,An innovative #TCTConnect #TCT2020 just started @TCTConference @crfheart @Drroxmehran @ajaykirtane There are 30+ so‚Ä¶ https://t.co/9wy5dhIyJ8,en,0.0,11060.0,,,0.0,JGrapsa,1.3163150884381368e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,6.0,https://twitter.com/JGrapsa/statuses/1316361061868744706,0.0,0.0,,0.0,0.0,0.0,6.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,An innovative #TCTConnect #TCT2020 just started @TCTConference @crfheart @Drroxmehran @ajaykirtane There are 30+ so‚Ä¶ https://t.co/9wy5dhIyJ8,true
heartdoc45,Interventional Cardiologist at @CardioInstitute; Ochsner/Scripps trained; Pearl Jam enthusiast. Views expressed are my own. #RadialFirst,,"Lafayette, Louisiana",,2020-10-14 11:28:01+00:00,"David Homan, MD",http://twitter.com/,6.0,,1.316339974791463e+18,,0.0,0.0,,"Quick reference for things to watch at today‚Äôs #TCTConnect

#TCT2020 #innovation https://t.co/eH8hTYNj0f",en,0.0,6040.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,6.0,https://twitter.com/heartdoc45/statuses/1316339974791462912,0.0,0.0,,0.0,0.0,0.0,6.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"Quick reference for things to watch at today‚Äôs #TCTConnect

#TCT2020 #innovation https://t.co/eH8hTYNj0f",true
ajaykirtane,"Practicing Cardiologist, Professor @ColumbiaMed
Researcher & advocate for thoughtful patient care; tweets‚â†endorsements nor med advice
https://t.co/YyilZMYayJ",,NewYork-Presbyterian & beyond,,2020-10-14 12:53:11+00:00,Ajay Kirtane MD SM,http://twitter.com/,17.0,,1.3163614088759583e+18,,0.0,0.0,,RT @JGrapsa: An innovative #TCTConnect #TCT2020 just started @TCTConference @crfheart @Drroxmehran @ajaykirtane There are 30+ social media‚Ä¶,en,0.0,17044.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,11.0,6.0,https://twitter.com/ajaykirtane/statuses/1316361408875958275,0.0,0.0,,0.0,0.0,0.0,6.0,11.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @JGrapsa: An innovative #TCTConnect #TCT2020 just started @TCTConference @crfheart @Drroxmehran @ajaykirtane There are 30+ social media‚Ä¶,true
heartdoc45,Interventional Cardiologist at @CardioInstitute; Ochsner/Scripps trained; Pearl Jam enthusiast. Views expressed are my own. #RadialFirst,,"Lafayette, Louisiana",,2020-10-14 11:32:14+00:00,"David Homan, MD",http://twitter.com/,10.0,,1.3163410391757332e+18,,0.0,0.0,,"RT @heartdoc45: TCT week is here!

Medtech #Innovation in the #COVID19 Era: Challenges and Emerging Opportunities at #TCT2020! Wednesday 11‚Ä¶",en,0.0,6040.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,7.0,3.0,https://twitter.com/heartdoc45/statuses/1316341039175733248,0.0,0.0,,0.0,0.0,0.0,3.0,7.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"RT @heartdoc45: TCT week is here!

Medtech #Innovation in the #COVID19 Era: Challenges and Emerging Opportunities at #TCT2020! Wednesday 11‚Ä¶",true
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-10-14 13:08:14+00:00,Cardiovascular Research Foundation,http://twitter.com/,21.0,,1.3163651955775652e+18,,0.0,0.0,,"RT @AGoldsweig: ‚Å¶‚Å¶@ajaykirtane‚Å©, ‚Å¶‚Å¶@Drroxmehran‚Å©, &amp; ‚Å¶@sahilparikhmd‚Å© introduce #TCTConnect.

Excited for this innovative meeting by ‚Å¶@crfhe‚Ä¶",en,0.0,12239.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,19.0,2.0,https://twitter.com/crfheart/statuses/1316365195577565185,0.0,0.0,,0.0,0.0,0.0,2.0,19.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"RT @AGoldsweig: ‚Å¶‚Å¶@ajaykirtane‚Å©, ‚Å¶‚Å¶@Drroxmehran‚Å©, &amp; ‚Å¶@sahilparikhmd‚Å© introduce #TCTConnect.

Excited for this innovative meeting by ‚Å¶@crfhe‚Ä¶",true
purviparwani,"Cardiologist, DirectorWomens‚ù§Ô∏è Clinic #LLUH, BOT @scmrorg ,tweets=myopinion #CardiacImaging #WomenCVhealth #wellness üßò‚Äç‚ôÄÔ∏è üå±",,"California, USA",,2020-10-14 14:38:26+00:00,Dr. Purvi Parwani,http://twitter.com/,33.0,,1.316387895557546e+18,,0.0,0.0,,"RT @JGrapsa: Inspiring the next generation, promoting innovation &amp; clinical excellence, @ACCinTouch together with @crfheart introduce Marti‚Ä¶",en,0.0,19397.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,23.0,10.0,https://twitter.com/purviparwani/statuses/1316387895557545984,0.0,0.0,,0.0,0.0,0.0,10.0,23.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"RT @JGrapsa: Inspiring the next generation, promoting innovation &amp; clinical excellence, @ACCinTouch together with @crfheart introduce Marti‚Ä¶",false
Rfonsi1,"Interim Executive Director, Mayo Clinic Cancer Center. Myeloma doctor. Visiting Healthcare Fellow @GoldwaterInst. Tweets-own/RT not an endorsement",,,,2020-11-29 19:03:41+00:00,Rafael Fonseca MD,http://twitter.com/,0.0,,1.333124492458041e+18,,0.0,0.0,,"A Phase 1, Talquetamab, (GPRC5D x CD3 Bispecific) in RRMM.137 pts (IV/SQ) Prior Rx 6. Rx neurotox in 7 (5%). ORR at‚Ä¶ https://t.co/9ZgTUJeEjl",ro,0.0,8301.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/Rfonsi1/statuses/1333124492458041345,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"A Phase 1, Talquetamab, (GPRC5D x CD3 Bispecific) in RRMM.137 pts (IV/SQ) Prior Rx 6. Rx neurotox in 7 (5%). ORR at‚Ä¶ https://t.co/9ZgTUJeEjl",true
Rfonsi1,"Interim Executive Director, Mayo Clinic Cancer Center. Myeloma doctor. Visiting Healthcare Fellow @GoldwaterInst. Tweets-own/RT not an endorsement",,,,2020-11-29 17:50:31+00:00,Rafael Fonseca MD,http://twitter.com/,0.0,,1.3331060758815212e+18,,0.0,0.0,,Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Mul‚Ä¶ https://t.co/uOUH8Apo05,en,0.0,8301.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/Rfonsi1/statuses/1333106075881521156,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Mul‚Ä¶ https://t.co/uOUH8Apo05,true
AvikDuttaSpeaks,"Postdoctoral Fellow at NIH/NICHD

Foodie Scientist Traveler Hematologist Immunologist Immunotherapy",,"Bethesda, Maryland",,2020-11-29 18:35:40+00:00,AvikDutta,http://twitter.com/,0.0,,1.333117439316521e+18,,0.0,0.0,,#ASH2020 The RNA Splicing Factor U2AF1 Controls Hematopoietic Stem Cell Survival and Function | Blood | American So‚Ä¶ https://t.co/xaWAANySnh,en,0.0,25.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/AvikDuttaSpeaks/statuses/1333117439316520969,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,#ASH2020 The RNA Splicing Factor U2AF1 Controls Hematopoietic Stem Cell Survival and Function | Blood | American So‚Ä¶ https://t.co/xaWAANySnh,true
Rfonsi1,"Interim Executive Director, Mayo Clinic Cancer Center. Myeloma doctor. Visiting Healthcare Fellow @GoldwaterInst. Tweets-own/RT not an endorsement",,,,2020-11-29 19:31:11+00:00,Rafael Fonseca MD,http://twitter.com/,4.0,,1.3331314129631642e+18,,0.0,0.0,,FIH Dual BCMA and CD19 Targeted Novel Platform Fast CAR-T Cell Therapy for Patients with Relapsed/Refractory Multip‚Ä¶ https://t.co/hHRRQJMzXX,en,0.0,8301.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,4.0,https://twitter.com/Rfonsi1/statuses/1333131412963164160,0.0,0.0,,0.0,0.0,0.0,4.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,FIH Dual BCMA and CD19 Targeted Novel Platform Fast CAR-T Cell Therapy for Patients with Relapsed/Refractory Multip‚Ä¶ https://t.co/hHRRQJMzXX,true
Rfonsi1,"Interim Executive Director, Mayo Clinic Cancer Center. Myeloma doctor. Visiting Healthcare Fellow @GoldwaterInst. Tweets-own/RT not an endorsement",,,,2020-11-29 18:42:11+00:00,Rafael Fonseca MD,http://twitter.com/,2.0,,1.333119081583559e+18,,0.0,0.0,,"CARTITUDE-1: Phase 1b/2 BCM CART Study in RRMM. 97 pts- med of 6 prior lines Rx. ORR 94.8%, sCR 55.7% . Med time to‚Ä¶ https://t.co/rctcDYZptu",en,0.0,8301.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/Rfonsi1/statuses/1333119081583558656,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"CARTITUDE-1: Phase 1b/2 BCM CART Study in RRMM. 97 pts- med of 6 prior lines Rx. ORR 94.8%, sCR 55.7% . Med time to‚Ä¶ https://t.co/rctcDYZptu",true
Rfonsi1,"Interim Executive Director, Mayo Clinic Cancer Center. Myeloma doctor. Visiting Healthcare Fellow @GoldwaterInst. Tweets-own/RT not an endorsement",,,,2020-11-29 17:24:52+00:00,Rafael Fonseca MD,http://twitter.com/,3.0,,1.3330996225505198e+18,,0.0,0.0,,Two-Year Follow-up of Investigator-Initiated Phase 1 Trials of the Safety and Efficacy of Fully Human Anti-Bcma CAR‚Ä¶ https://t.co/M2wXxOc2qa,en,0.0,8301.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/Rfonsi1/statuses/1333099622550519808,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,Two-Year Follow-up of Investigator-Initiated Phase 1 Trials of the Safety and Efficacy of Fully Human Anti-Bcma CAR‚Ä¶ https://t.co/M2wXxOc2qa,false
dgermain21,MD-PhD. 2nd year Heme/Onc fellow focused on lymphoma and leukemia. Physician-scientist-in-training. Tweet/RT not medical advice or endorsement.,,"St. Louis, MO",,2020-11-29 15:58:43+00:00,David A. Russler-Germain,http://twitter.com/,19.0,,1.333077940666585e+18,,0.0,0.0,,"RT @chadinabhan: Despite its retro nature, this study suggests no benefit from HD-MTX in #DLBCL patients w high-risk of CNS relapse/involve‚Ä¶",en,0.0,1612.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,15.0,4.0,https://twitter.com/dgermain21/statuses/1333077940666585091,0.0,0.0,,0.0,0.0,0.0,4.0,15.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @chadinabhan: Despite its retro nature, this study suggests no benefit from HD-MTX in #DLBCL patients w high-risk of CNS relapse/involve‚Ä¶",true
olga45093932,"MD,PhD, hematologist of @NationalCancerInst of @oncohematologyDepart",,"Kiev, Ukraine",,2020-11-09 10:27:55+00:00,Olga,http://twitter.com/,11.0,,1.325746934779437e+18,,0.0,0.0,,"RT @CwynKate: Reminder that CNS relapse occurs early: 24% during/before the end of front line therapy
And median survival after CNS relapse‚Ä¶",en,0.0,64.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,8.0,3.0,https://twitter.com/olga45093932/statuses/1325746934779437058,0.0,0.0,,0.0,0.0,0.0,3.0,8.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @CwynKate: Reminder that CNS relapse occurs early: 24% during/before the end of front line therapy
And median survival after CNS relapse‚Ä¶",true
Rfonsi1,"Interim Executive Director, Mayo Clinic Cancer Center. Myeloma doctor. Visiting Healthcare Fellow @GoldwaterInst. Tweets-own/RT not an endorsement",,,,2020-11-29 21:56:15+00:00,Rafael Fonseca MD,http://twitter.com/,7.0,,1.3331679192497723e+18,,0.0,0.0,,"Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial
Th‚Ä¶ https://t.co/eN5GfTDDA7",en,0.0,8301.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,7.0,https://twitter.com/Rfonsi1/statuses/1333167919249772544,0.0,0.0,,0.0,0.0,0.0,7.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial
Th‚Ä¶ https://t.co/eN5GfTDDA7",true
sarthak_s,"MD-PhD Candidate | Vanier & Killam Scholar @leadersinmed. @TEDx, @TED_Ed on wounds, scar, hair regeneration. Proud @UTSC '18 alum. Opinions mine, RT‚â†endorse.",,"Calgary, Alberta",,2020-11-12 03:46:56+00:00,Sarthak Sinha,http://twitter.com/,45.0,,1.3267331900908175e+18,,0.0,0.0,,RT @NBahlis: My lab in collaboration with Dr P Neri will be presenting @ASH_hematology #ASH20 exciting data on T cells scRNA &amp; scATAC seque‚Ä¶,en,0.0,3079.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,33.0,12.0,https://twitter.com/sarthak_s/statuses/1326733190090817537,0.0,0.0,,0.0,0.0,0.0,12.0,33.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @NBahlis: My lab in collaboration with Dr P Neri will be presenting @ASH_hematology #ASH20 exciting data on T cells scRNA &amp; scATAC seque‚Ä¶,true
SandyWong02111,UCSF Hematologist and BMT physician,,"San Francisco, CA",,2020-11-12 04:11:19+00:00,Sandy Wong,http://twitter.com/,45.0,,1.3267393273851003e+18,,0.0,0.0,,RT @NBahlis: My lab in collaboration with Dr P Neri will be presenting @ASH_hematology #ASH20 exciting data on T cells scRNA &amp; scATAC seque‚Ä¶,en,0.0,759.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,33.0,12.0,https://twitter.com/SandyWong02111/statuses/1326739327385100290,0.0,0.0,,0.0,0.0,0.0,12.0,33.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @NBahlis: My lab in collaboration with Dr P Neri will be presenting @ASH_hematology #ASH20 exciting data on T cells scRNA &amp; scATAC seque‚Ä¶,true
Rfonsi1,"Interim Executive Director, Mayo Clinic Cancer Center. Myeloma doctor. Visiting Healthcare Fellow @GoldwaterInst. Tweets-own/RT not an endorsement",,,,2020-11-29 19:20:57+00:00,Rafael Fonseca MD,http://twitter.com/,2.0,,1.3331288349131612e+18,,0.0,0.0,,"Phase 1- FcRH5 bispecific Ab. Totally biased as I am part of this, but love it, q3 weeks. CRS (38/51 pts, 75%), G1‚Ä¶ https://t.co/bN22OEBSdu",en,0.0,8301.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/Rfonsi1/statuses/1333128834913161216,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Clinical Trials,1.0,0.0,0.0,"Phase 1- FcRH5 bispecific Ab. Totally biased as I am part of this, but love it, q3 weeks. CRS (38/51 pts, 75%), G1‚Ä¶ https://t.co/bN22OEBSdu",false
bpiperdi,"thoracic medical oncologist, clinical researcher, a proud Dad, at Merck Research Labs, opinions and tweets are my own opinion.",,,,2020-11-14 14:45:20+00:00,Bilal Piperdi,http://twitter.com/,41.0,,1.327623655950586e+18,,0.0,0.0,,"RT @VincentRK: #1 Talquetamab, novel bi specific antibody targeting GPRC5D (expressed on myeloma cells) &amp; CD3 shows activity in relapsed re‚Ä¶",en,0.0,319.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,29.0,12.0,https://twitter.com/bpiperdi/statuses/1327623655950585858,0.0,0.0,,0.0,0.0,0.0,12.0,29.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @VincentRK: #1 Talquetamab, novel bi specific antibody targeting GPRC5D (expressed on myeloma cells) &amp; CD3 shows activity in relapsed re‚Ä¶",true
drng,A Doctor Doctor. As seen fleetingly on Netflix. Author of this Magnum Opus in @NatureComms üëâ https://t.co/luZqhBspBt,,Australia,,2020-11-14 04:57:34+00:00,Lord Blood,http://twitter.com/,23.0,,1.32747573902157e+18,,0.0,0.0,,RT @VincentRK: #4 Identification of a potential mechanism for frequent relapses after CAR-T therapy for myeloma: Bi allelic loss of BCMA lo‚Ä¶,en,0.0,2226.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,17.0,6.0,https://twitter.com/drng/statuses/1327475739021570048,0.0,0.0,,0.0,0.0,0.0,6.0,17.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @VincentRK: #4 Identification of a potential mechanism for frequent relapses after CAR-T therapy for myeloma: Bi allelic loss of BCMA lo‚Ä¶,true
TamarAzikuri,"üë©üèº‚Äç‚öïÔ∏è MD, Haematologist; Transfusion medicine specialist; Interest in HSCT. Proud @TheEBMT Young Ambassador 2020",,"Georgia, Tbilisi üìç",,2020-12-11 04:11:48+00:00,Tamar Azikuri,http://twitter.com/,30.0,,1.3372486934901678e+18,,0.0,0.0,,RT @COVID19nCCC: Severity of Sars-Cov-2 Infection in Pts w/ Hematologic Malignancies: A COVID-19 &amp; Cancer Consortium (#CCC19) Registry Anal‚Ä¶,en,0.0,174.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,21.0,9.0,https://twitter.com/TamarAzikuri/statuses/1337248693490167811,0.0,0.0,,0.0,0.0,0.0,9.0,21.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,RT @COVID19nCCC: Severity of Sars-Cov-2 Infection in Pts w/ Hematologic Malignancies: A COVID-19 &amp; Cancer Consortium (#CCC19) Registry Anal‚Ä¶,true
MedpageOnco,Breaking cancer + oncology news | Reports from all major oncology meetings | Peer-reviewed | Oncologist-trusted | Part of @MedPageToday,,,,2020-12-11 15:52:03+00:00,MedPage Oncology,http://twitter.com/,0.0,,1.3374249171936911e+18,,0.0,0.0,,This formulation met the primary endpoint of progression-free survival as part of combination therapy for relapsed‚Ä¶ https://t.co/mVN4IE4h2Q,en,0.0,443.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/MedpageOnco/statuses/1337424917193691137,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,This formulation met the primary endpoint of progression-free survival as part of combination therapy for relapsed‚Ä¶ https://t.co/mVN4IE4h2Q,true
prashkrishna,"Human, husband, son, father, doctor, pharmaceutical physician, scientist, cook... so far...",,"iPhone: 51.823280,-0.193998",,2020-12-11 08:45:34+00:00,Prash krishna,http://twitter.com/,76.0,,1.3373175908935188e+18,,0.0,0.0,,RT @NovartisCancer: We are committed to the pursuit of cutting-edge medicines and are working to transform what it means to live with blood‚Ä¶,en,0.0,24.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,67.0,9.0,https://twitter.com/prashkrishna/statuses/1337317590893518848,0.0,0.0,,0.0,0.0,0.0,9.0,67.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @NovartisCancer: We are committed to the pursuit of cutting-edge medicines and are working to transform what it means to live with blood‚Ä¶,true
CleClinicMD,"News and insights for physicians and clinical professionals from @ClevelandClinic. Research, case studies and CME opportunities.",,"Cleveland, Ohio, United States",,2020-12-11 22:11:17+00:00,Cleveland Clinic MD,http://twitter.com/,0.0,,1.337520356693844e+18,,0.0,0.0,,.@BrianBolwellMD discusses how reducing time to treatment for cancer patients became a vision for him: #ASH20,en,0.0,302311.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/CleClinicMD/statuses/1337520356693843969,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Thought Leadership,0.0,0.0,1.0,.@BrianBolwellMD discusses how reducing time to treatment for cancer patients became a vision for him: #ASH20,false
HallekMichael,"Hematologist and oncologist at the University of Cologne, Germany. Tweets are my own & no medical advice.",,"Cologne, Germany",,2020-12-11 15:22:24+00:00,Michael Hallek,http://twitter.com/,6.0,,1.337417458148397e+18,,0.0,0.0,,RT @lymphomahub: #ASH20 | Watch the @lymphomahub interview with Peter Borchmann about the results from the phase I study of a novel CD19/CD‚Ä¶,en,0.0,4644.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,3.0,https://twitter.com/HallekMichael/statuses/1337417458148397056,0.0,0.0,,0.0,0.0,0.0,3.0,3.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @lymphomahub: #ASH20 | Watch the @lymphomahub interview with Peter Borchmann about the results from the phase I study of a novel CD19/CD‚Ä¶,true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-11-19 21:38:53+00:00,Lisa Palacios,http://twitter.com/,9.0,,1.329539669449732e+18,,0.0,0.0,,"RT @DrAmitPatel: Phase I trial @TapKadia @doctorpemm: single infusion of #CK0801, #allogeneic #cord #blood expanded #Treg cellular therapy‚Ä¶",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,3.0,https://twitter.com/Lisa_Palacios/statuses/1329539669449732102,0.0,0.0,,0.0,0.0,0.0,3.0,6.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @DrAmitPatel: Phase I trial @TapKadia @doctorpemm: single infusion of #CK0801, #allogeneic #cord #blood expanded #Treg cellular therapy‚Ä¶",true
chanyooncheah,Doctor for patients with lymphoma. Clinical researcher.,,"Perth, Western Australia",,2020-12-12 10:17:13+00:00,Chan Cheah,http://twitter.com/,0.0,,1.3377030453212488e+18,,0.0,0.0,,"@DrChrisPFox Excellent summary and synthesis Chris. Well designed, collaborative adequately powered retrospective s‚Ä¶ https://t.co/wrzZGE59kJ",en,0.0,1717.0,,,0.0,DrChrisPFox,1.3374980598702326e+18,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/chanyooncheah/statuses/1337703045321248769,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,"@DrChrisPFox Excellent summary and synthesis Chris. Well designed, collaborative adequately powered retrospective s‚Ä¶ https://t.co/wrzZGE59kJ",true
DrMamaKai,"I'm an optimist, wife, football mom, and physician. #Twitternist on #MedTwitter Tweets my own, NOT medical advice #WomenInMedicine #YESiCanBeaDoctorToo",,"California, USA",,2020-12-12 15:21:51+00:00,"Kaishauna Guidry, MD",http://twitter.com/,1.0,,1.33777970857907e+18,,0.0,0.0,,"RT @medpagetoday: Patients with hematologic malignancies and #COVID19 seemed to be at a higher risk for severe infection and death, reporte‚Ä¶",en,0.0,1902.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/DrMamaKai/statuses/1337779708579069952,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"RT @medpagetoday: Patients with hematologic malignancies and #COVID19 seemed to be at a higher risk for severe infection and death, reporte‚Ä¶",true
DrESHAJ9,"a passionate medical oncologist, a spiritual seeker",,,,2020-12-12 15:29:49+00:00,EJ,http://twitter.com/,3.0,,1.3377817109481677e+18,,0.0,0.0,,"RT @OncLive: Anti-CD19 CAR T-cell therapy produces durable remission in approximately 40% of patients with  B-cell lymphomas, however strat‚Ä¶",en,0.0,315.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,2.0,1.0,https://twitter.com/DrESHAJ9/statuses/1337781710948167681,0.0,0.0,,0.0,0.0,0.0,1.0,2.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @OncLive: Anti-CD19 CAR T-cell therapy produces durable remission in approximately 40% of patients with  B-cell lymphomas, however strat‚Ä¶",true
Tamim80976890,"MD, M. Sc, Hematology, HSCT",,,,2020-12-12 11:25:39+00:00,Tamim,http://twitter.com/,29.0,,1.3377202660934246e+18,,0.0,0.0,,"RT @Mohty_EBMT: CAR-T cells jumping the lines in lymphoma #ASH20
Phase II ZUMA-12 Study Investigates First-Line Axicabtagene Ciloleucel for‚Ä¶",en,0.0,34.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,23.0,6.0,https://twitter.com/Tamim80976890/statuses/1337720266093424641,0.0,0.0,,0.0,0.0,0.0,6.0,23.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @Mohty_EBMT: CAR-T cells jumping the lines in lymphoma #ASH20
Phase II ZUMA-12 Study Investigates First-Line Axicabtagene Ciloleucel for‚Ä¶",false
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-11-19 21:00:42+00:00,"Ritcha Saxena, MD",http://twitter.com/,4.0,,1.3295300584957133e+18,,0.0,0.0,,RT @smbenlazar: Blockade of PD-1 Added to Standard Therapy to Target #MRD in #CML: a Phase II Study of Adding the Anti-PD-1 Pembrolizumab t‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,2.0,2.0,https://twitter.com/RitchaSaxena/statuses/1329530058495713282,0.0,0.0,,0.0,0.0,0.0,2.0,2.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @smbenlazar: Blockade of PD-1 Added to Standard Therapy to Target #MRD in #CML: a Phase II Study of Adding the Anti-PD-1 Pembrolizumab t‚Ä¶,true
oconnn04,"Haematologist, hiker and camper, Lyric FM fan, proud mother of three amazing daughters",,"Dublin City, Ireland",,2020-12-08 14:45:59+00:00,Niamh O'Connell,http://twitter.com/,13.0,,1.3363211273295913e+18,,0.0,0.0,,A big thank you to the clinical teams in the NCC and the Clinical research facility @stjamesdublin and the Irish pa‚Ä¶ https://t.co/WBXTEp7Ras,en,0.0,60.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,13.0,https://twitter.com/oconnn04/statuses/1336321127329591298,0.0,0.0,,0.0,0.0,0.0,13.0,0.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,A big thank you to the clinical teams in the NCC and the Clinical research facility @stjamesdublin and the Irish pa‚Ä¶ https://t.co/WBXTEp7Ras,true
Transplant_Doc,Stem Cell Transplant physician and clinical researcher at MD Anderson Cancer Center; special interest in myeloma. Opinions expressed are my own,,,,2020-12-08 03:11:18+00:00,Muzaffar Qazilbash,http://twitter.com/,16.0,,1.3361463081895977e+18,,0.0,0.0,,RT @akeithstewart: #ASH2020 Active drugs for sure but with Pom/Dex Belamaf &gt;51% grade 3 keratopathy and Selinexor &gt; 70% nausea not sure rol‚Ä¶,en,0.0,5455.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,15.0,1.0,https://twitter.com/Transplant_Doc/statuses/1336146308189597697,0.0,0.0,,0.0,0.0,0.0,1.0,15.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,RT @akeithstewart: #ASH2020 Active drugs for sure but with Pom/Dex Belamaf &gt;51% grade 3 keratopathy and Selinexor &gt; 70% nausea not sure rol‚Ä¶,true
LesokhinMD,I am an oncologist @sloan_kettering who specializes in immunotherapy and the treatment of multiple myeloma.  Tweets are mine.,,"New York, NY",,2020-12-08 00:37:07+00:00,AlexanderLesokhin MD,http://twitter.com/,30.0,,1.336107505538261e+18,,0.0,0.0,,RT @DrOlaLandgren: Daratumumab + KRd &amp; Daratumumab + VRd = 2 most effective combos for newly diagnosed #myeloma in 2020/2021. Limit IV flui‚Ä¶,en,0.0,3194.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,23.0,7.0,https://twitter.com/LesokhinMD/statuses/1336107505538260998,0.0,0.0,,0.0,0.0,0.0,7.0,23.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @DrOlaLandgren: Daratumumab + KRd &amp; Daratumumab + VRd = 2 most effective combos for newly diagnosed #myeloma in 2020/2021. Limit IV flui‚Ä¶,true
MediHumdani,"Director, BMT & Cellular Therapy Program @Froedtert & @MedicalCollege | Lymphoma | Clinical Trials | @CIBMTR | @BMTCTN | Personal views | Physician ‚â† Provider",,"Milwaukee, WI",,2020-12-08 17:56:29+00:00,Mehdi Hamadani,http://twitter.com/,6.0,,1.3363690687025766e+18,,0.0,0.0,,"What I learnt from @SoniSmithMD transformed NHL talk? #ASH20 #lymsm 
-Biopsy üóùÔ∏è esp in POD24s 
-MYC can be acquire‚Ä¶ https://t.co/tkSVVWQnRo",en,0.0,4590.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,6.0,https://twitter.com/MediHumdani/statuses/1336369068702576644,0.0,0.0,,0.0,0.0,0.0,6.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"What I learnt from @SoniSmithMD transformed NHL talk? #ASH20 #lymsm 
-Biopsy üóùÔ∏è esp in POD24s 
-MYC can be acquire‚Ä¶ https://t.co/tkSVVWQnRo",true
JerroldLevy,"Critical care physician in CTICU @DukeMedSchool, interested in coagulation, bleeding, inflammation-also oenophile and foody. Tweets are my own (‚â†medical advice)",,"Durham, North Carolina",,2020-12-08 04:23:23+00:00,"Jerrold Levy, MD",http://twitter.com/,22.0,,1.3361644467676365e+18,,0.0,0.0,,RT @fniainle: An outstanding multidisciplinary collaboration led by Dr @RosovskyRachel addressing a major clinical challenge in COVID-19 pa‚Ä¶,en,0.0,1755.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,20.0,2.0,https://twitter.com/JerroldLevy/statuses/1336164446767636481,0.0,0.0,,0.0,0.0,0.0,2.0,20.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @fniainle: An outstanding multidisciplinary collaboration led by Dr @RosovskyRachel addressing a major clinical challenge in COVID-19 pa‚Ä¶,false
szusmani,"Division Chief, Plasma Cell Disorders|Director, Clinical Research Hem Malignancies | Views are my own | RT not endorsement | Physician ‚â† Provider",,"Charlotte, NC",,2020-12-08 15:11:16+00:00,Saad Z. Usmani MD MBA FACP (he/his/him),http://twitter.com/,1.0,,1.3363274902817505e+18,,0.0,0.0,,"A big shoutout to all the @ASH_hematology staff, @StephanieLeeMD, Bill(@reednow) et al, the freeman crew for making‚Ä¶ https://t.co/Mm7UadD4A3",en,0.0,5512.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/szusmani/statuses/1336327490281750535,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Cost of Care,1.0,0.0,0.0,"A big shoutout to all the @ASH_hematology staff, @StephanieLeeMD, Bill(@reednow) et al, the freeman crew for making‚Ä¶ https://t.co/Mm7UadD4A3",true
johnde1MYELOMA,"myeloma survivor üêú, gastroenterologist, bicyclist, animal lover",,"Santa Fe, NM",,2020-12-08 12:37:12+00:00,John DeFlice,http://twitter.com/,0.0,,1.3362887201194803e+18,,0.0,0.0,,"Tourmaline Phase 3 NDMM transplant ineligible IRd vs placebo Rd, PFS trend w/ improved TTP/CR, Facon #mmsm #MYELOMA‚Ä¶ https://t.co/I9sjmdVPoT",en,0.0,218.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/johnde1MYELOMA/statuses/1336288720119480322,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"Tourmaline Phase 3 NDMM transplant ineligible IRd vs placebo Rd, PFS trend w/ improved TTP/CR, Facon #mmsm #MYELOMA‚Ä¶ https://t.co/I9sjmdVPoT",true
ShakiraG_MBBS,BC Geriatrician + Hematologist + Oncologist. Assistant Professor + Clinical Researcher UNC-CH #geriheme #gerionc #mmsm #BlackWomanInMedicine. Tweets=my views,,"North Carolina, USA",,2020-12-08 15:32:34+00:00,Dr. Shakira J Grant MBBS,http://twitter.com/,7.0,,1.3363328512691036e+18,,0.0,0.0,,#ASH20 @LundJenny et al.üëáüèæSEER-Medicare data analysis of OAs with #CLL: 28%: high comorbid burden (NCI comorbidity‚Ä¶ https://t.co/WcJQAhD7Jo,en,0.0,340.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,7.0,https://twitter.com/ShakiraG_MBBS/statuses/1336332851269103618,0.0,0.0,,0.0,0.0,0.0,7.0,0.0,False,False,False,False,True,Insurance Coverage,0.0,0.0,1.0,#ASH20 @LundJenny et al.üëáüèæSEER-Medicare data analysis of OAs with #CLL: 28%: high comorbid burden (NCI comorbidity‚Ä¶ https://t.co/WcJQAhD7Jo,true
mike_dickinson1,Clinical haematologist at Peter MacCallum Cancer Centre in Melbourne. Aggressive Lymphoma Lead. MDS/AML/myeloma.Early phase trials. Views are my own.,,Melbourne,,2020-12-05 00:51:46+00:00,Michael Dickinson,http://twitter.com/,4.0,,1.3350240268681994e+18,,0.0,0.0,,Did you miss the Scientific Workshop on Translational Molecular Diagnostics at #ash20 #ASH2020? Piers Blombery and‚Ä¶ https://t.co/S4v4SR9ZA5,en,0.0,921.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,4.0,https://twitter.com/mike_dickinson1/statuses/1335024026868199427,0.0,0.0,,0.0,0.0,0.0,4.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,Did you miss the Scientific Workshop on Translational Molecular Diagnostics at #ash20 #ASH2020? Piers Blombery and‚Ä¶ https://t.co/S4v4SR9ZA5,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-05 19:55:56+00:00,"Ritcha Saxena, MD",http://twitter.com/,2.0,,1.3353119662068982e+18,,0.0,0.0,,"RT @MDMagazine: ‚ÄúCPX-351 plus 7 days of #venetoclax is tolerable, with acceptable toxicities in patients with Relapsed/Refactroy #AML."" 

#‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/RitchaSaxena/statuses/1335311966206898181,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @MDMagazine: ‚ÄúCPX-351 plus 7 days of #venetoclax is tolerable, with acceptable toxicities in patients with Relapsed/Refactroy #AML."" 

#‚Ä¶",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-05 14:48:25+00:00,"Ritcha Saxena, MD",http://twitter.com/,9.0,,1.3352345759126075e+18,,0.0,0.0,,RT @PedsHemeDoc: This conversation with @drzsicklecell keeps getting better - we HAVE to normalize uncomfortable conversations &amp; get people‚Ä¶,en,0.0,6875.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,7.0,2.0,https://twitter.com/RitchaSaxena/statuses/1335234575912607744,0.0,0.0,,0.0,0.0,0.0,2.0,7.0,False,False,False,False,True,Diagnosis Progression,1.0,0.0,0.0,RT @PedsHemeDoc: This conversation with @drzsicklecell keeps getting better - we HAVE to normalize uncomfortable conversations &amp; get people‚Ä¶,false
AKeyzner,"hematologist #BMT #leuksm physician ‚â†provider immigrant, opinions my own, likes‚â†endorsement",,,,2020-12-05 16:57:41+00:00,Alla Keyzner,http://twitter.com/,0.0,,1.3352671094887793e+18,,0.0,0.0,,Use of Donors with DNMT3A-CH VAF&gt;0.01 associated with improved survival due to reduced risk of relapse in patients‚Ä¶ https://t.co/bFEjKGD9zM,en,0.0,157.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/AKeyzner/statuses/1335267109488779264,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,Use of Donors with DNMT3A-CH VAF&gt;0.01 associated with improved survival due to reduced risk of relapse in patients‚Ä¶ https://t.co/bFEjKGD9zM,true
cgfran01,"dad, physician, scientist, musician",,,,2020-12-05 14:54:48+00:00,cedric francois,http://twitter.com/,4.0,,1.3352361828846838e+18,,0.0,0.0,,RT @ApellisPharma: We are proud to share our latest scientific research in #PNH this year at the virtual #ASH2020. Learn more about Apellis‚Ä¶,en,0.0,510.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,1.0,https://twitter.com/cgfran01/statuses/1335236182884683776,0.0,0.0,,0.0,0.0,0.0,1.0,3.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @ApellisPharma: We are proud to share our latest scientific research in #PNH this year at the virtual #ASH2020. Learn more about Apellis‚Ä¶,true
fniainle,"Haematologist, passionate about VTE. Co-director @ConwaySphere; Director https://t.co/csdWq9XJ57; RT not endorsement, views my own",,"Dublin City, Ireland",,2020-12-05 20:20:57+00:00,Fionnuala N√≠ √Åinle,http://twitter.com/,17.0,,1.3353182630777364e+18,,0.0,0.0,,RT @joanne_britto: Excellent presentation by @leslieskeith at #ASH2020 on the lab aspects of diagnosis &amp; treatment of VTE in pregnancy. Key‚Ä¶,en,0.0,2069.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,15.0,2.0,https://twitter.com/fniainle/statuses/1335318263077736448,0.0,0.0,,0.0,0.0,0.0,2.0,15.0,False,False,False,False,True,Diagnostic Tools,1.0,0.0,0.0,RT @joanne_britto: Excellent presentation by @leslieskeith at #ASH2020 on the lab aspects of diagnosis &amp; treatment of VTE in pregnancy. Key‚Ä¶,true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 21:50:26+00:00,Lisa Palacios,http://twitter.com/,20.0,,1.3353407815115694e+18,,0.0,0.0,,"RT @doctorpemm: #ASH20 AML oral presentation session. Fantastic talk phase I, 2 arm study (Prior SCT vs no prior SCT) Dec+IPI in patients w‚Ä¶",en,0.0,657.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,14.0,6.0,https://twitter.com/Lisa_Palacios/statuses/1335340781511569417,0.0,0.0,,0.0,0.0,0.0,6.0,14.0,False,False,False,False,True,Clinical Trials,1.0,0.0,0.0,"RT @doctorpemm: #ASH20 AML oral presentation session. Fantastic talk phase I, 2 arm study (Prior SCT vs no prior SCT) Dec+IPI in patients w‚Ä¶",true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-12-05 23:43:30+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,3.0,,1.335369235279749e+18,,0.0,0.0,,"#ASH20 #leusm Tiong: NMP1mut MRD predicts risk of relapse, including post-HCT. ELN defined molecular persistence at‚Ä¶ https://t.co/cJVBmXBBsk",en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/hemedoc/statuses/1335369235279749122,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"#ASH20 #leusm Tiong: NMP1mut MRD predicts risk of relapse, including post-HCT. ELN defined molecular persistence at‚Ä¶ https://t.co/cJVBmXBBsk",true
mpdrc,Executive Director- Mays Cancer Center at UT Health San Antonio MD Anderson; (Views on Twitter are personal opinion),,"UT Health San Antonio ,TX, USA",,2020-12-05 15:21:16+00:00,"Ruben A. Mesa, MD",http://twitter.com/,4.0,,1.3352428435988234e+18,,0.0,0.0,,Excited for the upcoming start of First #ASHFromHome MPN Clinical Session : New Therapies and JAKi-Based Combinatio‚Ä¶ https://t.co/WaDlUWbi8n,en,0.0,3222.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,4.0,https://twitter.com/mpdrc/statuses/1335242843598823427,0.0,0.0,,0.0,0.0,0.0,4.0,0.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,Excited for the upcoming start of First #ASHFromHome MPN Clinical Session : New Therapies and JAKi-Based Combinatio‚Ä¶ https://t.co/WaDlUWbi8n,false
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 16:22:15+00:00,Lisa Palacios,http://twitter.com/,12.0,,1.3352581908717486e+18,,0.0,0.0,,RT @MarkGeyerMD: Musa Yilmaz of @LeukemiaMDA presents phase I/II study if quizartinib + 10d decitabine (DAC10) +/- ven in 22 unfit or R/R A‚Ä¶,en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,9.0,3.0,https://twitter.com/Lisa_Palacios/statuses/1335258190871748608,0.0,0.0,,0.0,0.0,0.0,3.0,9.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @MarkGeyerMD: Musa Yilmaz of @LeukemiaMDA presents phase I/II study if quizartinib + 10d decitabine (DAC10) +/- ven in 22 unfit or R/R A‚Ä¶,true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 20:47:24+00:00,Lisa Palacios,http://twitter.com/,19.0,,1.3353249178107945e+18,,0.0,0.0,,RT @CanerSaygin: Dr Kadia presented phase II data utilizing their MDACC backbone regimen in #AML. Venetoclax combined with cladribine + LDA‚Ä¶,en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,16.0,3.0,https://twitter.com/Lisa_Palacios/statuses/1335324917810794499,0.0,0.0,,0.0,0.0,0.0,3.0,16.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @CanerSaygin: Dr Kadia presented phase II data utilizing their MDACC backbone regimen in #AML. Venetoclax combined with cladribine + LDA‚Ä¶,true
CanerSaygin,"Heme-Onc Fellow @UChicago | Alumni of @OhioStateIMRes, @CCLRI | #Leukemia, #MDS, #CHIP physician-scientist. Tweets=own opinions.",,"Chicago, IL",,2020-12-05 16:42:29+00:00,"Caner Saygin, MD",http://twitter.com/,2.0,,1.3352632821863465e+18,,0.0,0.0,,Phase II data on CPX-351 + venetoclax in newly diagnosed and R/R AML (38% with TP53m) by Dr Kadia. This combo is qu‚Ä¶ https://t.co/6UCPZjsnoy,en,0.0,743.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/CanerSaygin/statuses/1335263282186346496,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,Phase II data on CPX-351 + venetoclax in newly diagnosed and R/R AML (38% with TP53m) by Dr Kadia. This combo is qu‚Ä¶ https://t.co/6UCPZjsnoy,true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-12-05 20:56:56+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,4.0,,1.33532731818983e+18,,0.0,0.0,,#ASH20 #bmtsm Zhang: Rapid turnaround (5-7day) CART (CD28 costim) for post-allo relapse in B-ALL. CR achieved in 28‚Ä¶ https://t.co/Di17yNQKAC,en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,4.0,https://twitter.com/hemedoc/statuses/1335327318189830144,0.0,0.0,,0.0,0.0,0.0,4.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,#ASH20 #bmtsm Zhang: Rapid turnaround (5-7day) CART (CD28 costim) for post-allo relapse in B-ALL. CR achieved in 28‚Ä¶ https://t.co/Di17yNQKAC,true
CanerSaygin,"Heme-Onc Fellow @UChicago | Alumni of @OhioStateIMRes, @CCLRI | #Leukemia, #MDS, #CHIP physician-scientist. Tweets=own opinions.",,"Chicago, IL",,2020-12-05 15:59:08+00:00,"Caner Saygin, MD",http://twitter.com/,3.0,,1.3352523735230792e+18,,0.0,0.0,,Dr Kadia presented phase II data utilizing their MDACC backbone regimen in #AML. Venetoclax combined with cladribin‚Ä¶ https://t.co/CRsOCAu24I,en,0.0,743.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/CanerSaygin/statuses/1335252373523079169,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,Dr Kadia presented phase II data utilizing their MDACC backbone regimen in #AML. Venetoclax combined with cladribin‚Ä¶ https://t.co/CRsOCAu24I,true
aditishasMD,Physician-scientist researching cures for AML & MDS. Addressing health disparities in cancer care. Tweets my own #leusm #mds,,"New York, NY",,2020-12-05 12:54:10+00:00,"Aditi Shastri, MD",http://twitter.com/,6.0,,1.33520582774195e+18,,0.0,0.0,,RT @HadidiSamer: You don‚Äôt want to miss this : how the pandemic has affected patients with hematologic malignancies with Dr Fauci and @Step‚Ä¶,en,0.0,723.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,1.0,https://twitter.com/aditishasMD/statuses/1335205827741949952,0.0,0.0,,0.0,0.0,0.0,1.0,5.0,False,False,False,False,True,Covid,0.0,0.0,1.0,RT @HadidiSamer: You don‚Äôt want to miss this : how the pandemic has affected patients with hematologic malignancies with Dr Fauci and @Step‚Ä¶,false
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 16:36:25+00:00,Lisa Palacios,http://twitter.com/,4.0,,1.3352617579175526e+18,,0.0,0.0,,RT @CPI_epigenetics: Dr. Srdan Verstovek of @MDAndersonNews is presenting results at 11:45 am ET from Arm 2 of our ongoing Phase 2 MANIFEST‚Ä¶,en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,1.0,https://twitter.com/Lisa_Palacios/statuses/1335261757917552645,0.0,0.0,,0.0,0.0,0.0,1.0,3.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @CPI_epigenetics: Dr. Srdan Verstovek of @MDAndersonNews is presenting results at 11:45 am ET from Arm 2 of our ongoing Phase 2 MANIFEST‚Ä¶,true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 19:31:59+00:00,Lisa Palacios,http://twitter.com/,2.0,,1.335305940707537e+18,,0.0,0.0,,"RT @MDMagazine: ‚ÄúCPX-351 plus 7 days of #venetoclax is tolerable, with acceptable toxicities in patients with Relapsed/Refactroy #AML."" 

#‚Ä¶",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/Lisa_Palacios/statuses/1335305940707536898,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @MDMagazine: ‚ÄúCPX-351 plus 7 days of #venetoclax is tolerable, with acceptable toxicities in patients with Relapsed/Refactroy #AML."" 

#‚Ä¶",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-05 17:09:52+00:00,"Ritcha Saxena, MD",http://twitter.com/,66.0,,1.3352701743379292e+18,,0.0,0.0,,RT @ActiniumPharma: Our 100% remission rate data will be live today at 3:00 PM ET during an oral presentation at #ASH2020. More details abo‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,55.0,11.0,https://twitter.com/RitchaSaxena/statuses/1335270174337929223,0.0,0.0,,0.0,0.0,0.0,11.0,55.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @ActiniumPharma: Our 100% remission rate data will be live today at 3:00 PM ET during an oral presentation at #ASH2020. More details abo‚Ä¶,true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-12-05 15:09:24+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,2.0,,1.335239860290945e+18,,0.0,0.0,,"#ASH20 Fauci: ""We have to be humble enough to say we don‚Äôt know [how long immunity will last from natural infection‚Ä¶ https://t.co/tETXR5pCPh",en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/hemedoc/statuses/1335239860290945029,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"#ASH20 Fauci: ""We have to be humble enough to say we don‚Äôt know [how long immunity will last from natural infection‚Ä¶ https://t.co/tETXR5pCPh",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-05 05:31:55+00:00,"Ritcha Saxena, MD",http://twitter.com/,19.0,,1.335094528144003e+18,,0.0,0.0,,RT @amarkelkar: Flying solo for the early phases of #ASH20 ... interesting early talks on #racism in medicine and infection/coagulation! My‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,18.0,1.0,https://twitter.com/RitchaSaxena/statuses/1335094528144003072,0.0,0.0,,0.0,0.0,0.0,1.0,18.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @amarkelkar: Flying solo for the early phases of #ASH20 ... interesting early talks on #racism in medicine and infection/coagulation! My‚Ä¶,true
graham74GC,Lymphoma specialist at Oxford Cancer and Haematology centre. Haematologist and clinical trialist. Chair of UK Hodgkin and T-cell study groups.,,Opinions are mine,,2020-12-05 15:59:32+00:00,Graham Collins,http://twitter.com/,6.0,,1.335252474509353e+18,,0.0,0.0,,"Ruan et al - CC486 (oral aza) + CHOP 1L PTCL
- 21 pts; 17 Tfh
- med 66y, 90% stage III/IV
- 10 had SCT
- No CHOP do‚Ä¶ https://t.co/oz7swmiwiL",en,0.0,6091.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,6.0,https://twitter.com/graham74GC/statuses/1335252474509352960,0.0,0.0,,0.0,0.0,0.0,6.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"Ruan et al - CC486 (oral aza) + CHOP 1L PTCL
- 21 pts; 17 Tfh
- med 66y, 90% stage III/IV
- 10 had SCT
- No CHOP do‚Ä¶ https://t.co/oz7swmiwiL",false
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-05 19:57:19+00:00,"Ritcha Saxena, MD",http://twitter.com/,10.0,,1.335312315776979e+18,,0.0,0.0,,RT @OncLive: Selinexor Shows Clinical Benefit Across Age Groups in Relapsed/Refractory DLBCL @JulesBordet @ASH_hematology  #ASH20 #lymsm ht‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,9.0,1.0,https://twitter.com/RitchaSaxena/statuses/1335312315776978947,0.0,0.0,,0.0,0.0,0.0,1.0,9.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @OncLive: Selinexor Shows Clinical Benefit Across Age Groups in Relapsed/Refractory DLBCL @JulesBordet @ASH_hematology  #ASH20 #lymsm ht‚Ä¶,true
CanerSaygin,"Heme-Onc Fellow @UChicago | Alumni of @OhioStateIMRes, @CCLRI | #Leukemia, #MDS, #CHIP physician-scientist. Tweets=own opinions.",,"Chicago, IL",,2020-12-05 16:15:05+00:00,"Caner Saygin, MD",http://twitter.com/,1.0,,1.3352563904080404e+18,,0.0,0.0,,Another feasibility phase I/II study from Dr Yilmaz showing quizartinib + 10d decitabine and venetoclax in newly di‚Ä¶ https://t.co/jyR0eGfUSj,en,0.0,743.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/CanerSaygin/statuses/1335256390408040451,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,Another feasibility phase I/II study from Dr Yilmaz showing quizartinib + 10d decitabine and venetoclax in newly di‚Ä¶ https://t.co/jyR0eGfUSj,true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 21:52:33+00:00,Lisa Palacios,http://twitter.com/,1.0,,1.3353413131814953e+18,,0.0,0.0,,RT @AlkaliDr: Preclinical data of targeting CD200 in AML. #ASH20 #leusm https://t.co/NA40OpufXM,en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/Lisa_Palacios/statuses/1335341313181495297,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @AlkaliDr: Preclinical data of targeting CD200 in AML. #ASH20 #leusm https://t.co/NA40OpufXM,true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 16:22:10+00:00,Lisa Palacios,http://twitter.com/,36.0,,1.335258172303536e+18,,0.0,0.0,,RT @razan_mohty: Data from @LeukemiaMDA on VEN with Cladribine/LDAC alternating with azacitidine in newly diagnosed older #AML by Dr @TapKa‚Ä¶,en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,27.0,9.0,https://twitter.com/Lisa_Palacios/statuses/1335258172303536128,0.0,0.0,,0.0,0.0,0.0,9.0,27.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @razan_mohty: Data from @LeukemiaMDA on VEN with Cladribine/LDAC alternating with azacitidine in newly diagnosed older #AML by Dr @TapKa‚Ä¶,true
DrESHAJ9,"a passionate medical oncologist, a spiritual seeker",,,,2020-12-05 06:19:14+00:00,EJ,http://twitter.com/,84.0,,1.3351064383482143e+18,,0.0,0.0,,"RT @hemedoc: #ASH20 #leusm Levis: I don‚Äôt know who needs to hear this, but there really is no role for intensive chemotherapy in TP53 mutat‚Ä¶",en,0.0,315.0,,,0.0,,,Negative,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,65.0,19.0,https://twitter.com/DrESHAJ9/statuses/1335106438348214273,0.0,0.0,,0.0,0.0,0.0,19.0,65.0,False,False,False,False,True,Innovation,0.0,1.0,0.0,"RT @hemedoc: #ASH20 #leusm Levis: I don‚Äôt know who needs to hear this, but there really is no role for intensive chemotherapy in TP53 mutat‚Ä¶",true
biostockguru,Physician executive(MD CWRU;Rice/Jones);Healthcare focus Fund;Pharma advisor/KOL;Tweets NOT investment advice.Pls do your DD. Support https://t.co/97U34OldNG,,United States,,2020-12-05 00:59:08+00:00,biostockGuru,http://twitter.com/,0.0,,1.335025880146432e+18,,0.0,0.0,,"$SRRA 

Likely a Santa Claus üéÖ December  
1st up is 
#ASH2020 update
&amp; then an
Investor event DEC16

Trading at $46‚Ä¶ https://t.co/7LQfJGmOuz",en,0.0,14012.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/biostockguru/statuses/1335025880146432000,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,"$SRRA 

Likely a Santa Claus üéÖ December  
1st up is 
#ASH2020 update
&amp; then an
Investor event DEC16

Trading at $46‚Ä¶ https://t.co/7LQfJGmOuz",false
MediHumdani,"Director, BMT & Cellular Therapy Program @Froedtert & @MedicalCollege | Lymphoma | Clinical Trials | @CIBMTR | @BMTCTN | Personal views | Physician ‚â† Provider",,"Milwaukee, WI",,2020-12-05 16:28:34+00:00,Mehdi Hamadani,http://twitter.com/,1.0,,1.3352597818089718e+18,,0.0,0.0,,RUX better than best supportive care in refractory cGVHD. Important for #alloHCT. Work need for patients with BOS a‚Ä¶ https://t.co/FHLozh0b7I,en,0.0,4590.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/MediHumdani/statuses/1335259781808971784,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RUX better than best supportive care in refractory cGVHD. Important for #alloHCT. Work need for patients with BOS a‚Ä¶ https://t.co/FHLozh0b7I,true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 19:47:28+00:00,Lisa Palacios,http://twitter.com/,14.0,,1.3353098360415437e+18,,0.0,0.0,,RT @mpdrc: Excited for the upcoming start of First #ASHFromHome MPN Clinical Session : New Therapies and JAKi-Based Combinations for Myelof‚Ä¶,en,0.0,657.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,4.0,https://twitter.com/Lisa_Palacios/statuses/1335309836041543684,0.0,0.0,,0.0,0.0,0.0,4.0,10.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @mpdrc: Excited for the upcoming start of First #ASHFromHome MPN Clinical Session : New Therapies and JAKi-Based Combinations for Myelof‚Ä¶,true
MediHumdani,"Director, BMT & Cellular Therapy Program @Froedtert & @MedicalCollege | Lymphoma | Clinical Trials | @CIBMTR | @BMTCTN | Personal views | Physician ‚â† Provider",,"Milwaukee, WI",,2020-12-05 16:53:35+00:00,Mehdi Hamadani,http://twitter.com/,2.0,,1.3352660792041226e+18,,0.0,0.0,,Very interesting data by @bpromd Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the‚Ä¶ https://t.co/rdBnRw5qta,en,0.0,4590.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/MediHumdani/statuses/1335266079204122631,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Diagnosis Progression,1.0,0.0,0.0,Very interesting data by @bpromd Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the‚Ä¶ https://t.co/rdBnRw5qta,true
ThiloZander,Medical Oncologist. Head of Lymphoma & Myeloma Service. Lucerne Cancer Center. Switzerland.,,"Lucerne, Switzerland",,2020-12-05 17:40:15+00:00,"Thilo J Zander, MD",http://twitter.com/,2.0,,1.335277821527257e+18,,0.0,0.0,,Efficacy of LOXO-305 in relapsed Mantle Cell Lymphoma. Responses seen in patients already treated with BTKi. Cool.‚Ä¶ https://t.co/tAU1sev3zM,en,0.0,843.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/ThiloZander/statuses/1335277821527257092,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,Efficacy of LOXO-305 in relapsed Mantle Cell Lymphoma. Responses seen in patients already treated with BTKi. Cool.‚Ä¶ https://t.co/tAU1sev3zM,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 21:35:18+00:00,"Ritcha Saxena, MD",http://twitter.com/,11.0,,1.3356993625807544e+18,,0.0,0.0,,RT @CanerSaygin: Dr Sallman presenting impressive phase I results of AZA + magrolimab in first-line #AML treatment. On-target anemia is mit‚Ä¶,en,0.0,6875.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,9.0,2.0,https://twitter.com/RitchaSaxena/statuses/1335699362580754439,0.0,0.0,,0.0,0.0,0.0,2.0,9.0,False,False,False,False,True,Clinical Trials,1.0,0.0,0.0,RT @CanerSaygin: Dr Sallman presenting impressive phase I results of AZA + magrolimab in first-line #AML treatment. On-target anemia is mit‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 21:33:33+00:00,"Ritcha Saxena, MD",http://twitter.com/,54.0,,1.3356989223423222e+18,,0.0,0.0,,RT @lauracmichaelis: Turkish eggs and a plenary session on stem cells- pretty nice way to start the day #ASHFromHome https://t.co/qqXiNC5aMb,en,0.0,6875.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,50.0,4.0,https://twitter.com/RitchaSaxena/statuses/1335698922342322179,0.0,0.0,,0.0,0.0,0.0,4.0,50.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @lauracmichaelis: Turkish eggs and a plenary session on stem cells- pretty nice way to start the day #ASHFromHome https://t.co/qqXiNC5aMb,false
SandyWong02111,UCSF Hematologist and BMT physician,,"San Francisco, CA",,2020-12-06 01:44:11+00:00,Sandy Wong,http://twitter.com/,27.0,,1.3353996052576584e+18,,0.0,0.0,,RT @ninashah33: The O.G. BiTE (but better): AMG-701 with extended half life‚Äî&gt; 36% ORR in early cohorts but 5/6 (86%) ORR in most recent dos‚Ä¶,en,0.0,759.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,16.0,11.0,https://twitter.com/SandyWong02111/statuses/1335399605257658368,0.0,0.0,,0.0,0.0,0.0,11.0,16.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @ninashah33: The O.G. BiTE (but better): AMG-701 with extended half life‚Äî&gt; 36% ORR in early cohorts but 5/6 (86%) ORR in most recent dos‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 12:35:20+00:00,"Ritcha Saxena, MD",http://twitter.com/,4.0,,1.3355634724033044e+18,,0.0,0.0,,RT @feldstej: 2573 Outcomes of COVID-19 Infection in Patients Receiving Ruxolitinib and Hypomethylating Agent Therapy https://t.co/PHo5iYKj‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,1.0,https://twitter.com/RitchaSaxena/statuses/1335563472403304449,0.0,0.0,,0.0,0.0,0.0,1.0,3.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,RT @feldstej: 2573 Outcomes of COVID-19 Infection in Patients Receiving Ruxolitinib and Hypomethylating Agent Therapy https://t.co/PHo5iYKj‚Ä¶,true
noriega_dr,"MD, PhD. Hematologist in CHUAC (A Coru√±a-Spain). Leukemia and Bone Marrow Transplantation. Tweets and opinions are mine.",,,,2020-12-06 18:27:13+00:00,Dr Victor Noriega,http://twitter.com/,10.0,,1.3356520307324928e+18,,0.0,0.0,,RT @razan_mohty: Venetoclax + Gilteritinib for R/R FLT3-Mutated #AML in the Expansion Cohort of a Phase 1b Study by Dr Naval Daver - Nice r‚Ä¶,en,0.0,959.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,4.0,https://twitter.com/noriega_dr/statuses/1335652030732492803,0.0,0.0,,0.0,0.0,0.0,4.0,6.0,False,False,False,False,True,Clinical Trials,1.0,0.0,0.0,RT @razan_mohty: Venetoclax + Gilteritinib for R/R FLT3-Mutated #AML in the Expansion Cohort of a Phase 1b Study by Dr Naval Daver - Nice r‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 21:15:58+00:00,"Ritcha Saxena, MD",http://twitter.com/,14.0,,1.3356944971629158e+18,,0.0,0.0,,"RT @DrOlaLandgren: Congrats to all success; #Janssen is pushing the envelope! Visionary medical, science-driven leadership. Delivery throug‚Ä¶",en,0.0,6875.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,11.0,3.0,https://twitter.com/RitchaSaxena/statuses/1335694497162915842,0.0,0.0,,0.0,0.0,0.0,3.0,11.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,"RT @DrOlaLandgren: Congrats to all success; #Janssen is pushing the envelope! Visionary medical, science-driven leadership. Delivery throug‚Ä¶",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 21:24:28+00:00,"Ritcha Saxena, MD",http://twitter.com/,4.0,,1.3356966331541873e+18,,0.0,0.0,,"RT @gvhd_hub: CONGRESS | #ASH20 | Mukta Arora, @umnmedschool, reported the data from the phase I study of axatilimab (SNDX-6352), a CSF-1R‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,1.0,https://twitter.com/RitchaSaxena/statuses/1335696633154187265,0.0,0.0,,0.0,0.0,0.0,1.0,3.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @gvhd_hub: CONGRESS | #ASH20 | Mukta Arora, @umnmedschool, reported the data from the phase I study of axatilimab (SNDX-6352), a CSF-1R‚Ä¶",true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-12-06 07:44:38+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,2.0,,1.3354903152941097e+18,,0.0,0.0,,#ASH20 #leusm Short: high rate of death in CR (64%) obsd in age 70+; protocol further changed to elim chemo in this‚Ä¶ https://t.co/Zza60FTau9,en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/hemedoc/statuses/1335490315294109696,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,#ASH20 #leusm Short: high rate of death in CR (64%) obsd in age 70+; protocol further changed to elim chemo in this‚Ä¶ https://t.co/Zza60FTau9,false
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 01:46:47+00:00,"Ritcha Saxena, MD",http://twitter.com/,15.0,,1.3354002627484754e+18,,0.0,0.0,,"RT @ASH_hematology: We are pleased to recognize @RepBillFoster at #ASH20 with the 2020 Public Service Award, recognizing his leadership on‚Ä¶",en,0.0,6875.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,14.0,1.0,https://twitter.com/RitchaSaxena/statuses/1335400262748475392,0.0,0.0,,0.0,0.0,0.0,1.0,14.0,False,False,False,False,True,Cost of Care,1.0,0.0,0.0,"RT @ASH_hematology: We are pleased to recognize @RepBillFoster at #ASH20 with the 2020 Public Service Award, recognizing his leadership on‚Ä¶",true
ThiloZander,Medical Oncologist. Head of Lymphoma & Myeloma Service. Lucerne Cancer Center. Switzerland.,,"Lucerne, Switzerland",,2020-12-06 13:08:28+00:00,"Thilo J Zander, MD",http://twitter.com/,40.0,,1.33557181128371e+18,,0.0,0.0,,RT @UrviShahMD: Another effective target for MM! First anti-GPRC5D Bispecific Ab (Talquetamab) Phase 1 presented by Dr. Ajai Chari. RP2D 40‚Ä¶,en,0.0,843.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,30.0,10.0,https://twitter.com/ThiloZander/statuses/1335571811283709953,0.0,0.0,,0.0,0.0,0.0,10.0,30.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @UrviShahMD: Another effective target for MM! First anti-GPRC5D Bispecific Ab (Talquetamab) Phase 1 presented by Dr. Ajai Chari. RP2D 40‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 15:59:12+00:00,"Ritcha Saxena, MD",http://twitter.com/,12.0,,1.3356147802378772e+18,,0.0,0.0,,RT @CanerSaygin: Phase II data on CPX-351 + venetoclax in newly diagnosed and R/R AML (38% with TP53m) by Dr Kadia. This combo is quite tox‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,2.0,https://twitter.com/RitchaSaxena/statuses/1335614780237877249,0.0,0.0,,0.0,0.0,0.0,2.0,10.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @CanerSaygin: Phase II data on CPX-351 + venetoclax in newly diagnosed and R/R AML (38% with TP53m) by Dr Kadia. This combo is quite tox‚Ä¶,true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-06 17:10:45+00:00,Lisa Palacios,http://twitter.com/,17.0,,1.3356327857600225e+18,,0.0,0.0,,"RT @OncLive: Allogeneic Off-the-Shelf UCART22 Product Shows Early Activity, Tolerability in CD22+ B-Cell Relapsed/Refractory ALL
@MDAnderso‚Ä¶",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,13.0,4.0,https://twitter.com/Lisa_Palacios/statuses/1335632785760022539,0.0,0.0,,0.0,0.0,0.0,4.0,13.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @OncLive: Allogeneic Off-the-Shelf UCART22 Product Shows Early Activity, Tolerability in CD22+ B-Cell Relapsed/Refractory ALL
@MDAnderso‚Ä¶",true
OdejideOreofe,Hematologic oncologist @danafarber and researcher in QOL and care for patients with blood cancers. Asst. Professor of Medicine @harvardmed | Tweets mine,,"Boston, MA",,2020-12-06 19:52:18+00:00,@Ore Odejide MD,http://twitter.com/,9.0,,1.3356734407543398e+18,,0.0,0.0,,RT @drlenawine: @npdcoalition @Jen_WilkesMD @hospitals4kids @CIDRAP_RDSP @AmerAcadPeds @PHEgov @PharmResponse @TheWRAPEM @PIPSQC @ASHPOffic‚Ä¶,en,0.0,90.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,7.0,2.0,https://twitter.com/OdejideOreofe/statuses/1335673440754339844,0.0,0.0,,0.0,0.0,0.0,2.0,7.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,RT @drlenawine: @npdcoalition @Jen_WilkesMD @hospitals4kids @CIDRAP_RDSP @AmerAcadPeds @PHEgov @PharmResponse @TheWRAPEM @PIPSQC @ASHPOffic‚Ä¶,true
LuskinMarlise,"Leukemia MD @DanaFarber | Caring for adults with leukemia, trying to make the options better | Asst. Prof of Medicine @harvardmed | Tweets my own",,"Boston, MA",,2020-12-06 16:29:10+00:00,"Marlise R. Luskin MD, MSCE",http://twitter.com/,2.0,,1.3356223210889585e+18,,0.0,0.0,,Great work by @ErikaHaydu with @ColemanLindsley @DanaFarber #ASH2020 https://t.co/9XJCsF5GfQ,en,0.0,301.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/LuskinMarlise/statuses/1335622321088958465,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,Great work by @ErikaHaydu with @ColemanLindsley @DanaFarber #ASH2020 https://t.co/9XJCsF5GfQ,false
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-06 18:41:30+00:00,Lisa Palacios,http://twitter.com/,4.0,,1.335655623371989e+18,,0.0,0.0,,RT @smbenlazar: Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induc‚Ä¶,en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,2.0,2.0,https://twitter.com/Lisa_Palacios/statuses/1335655623371988992,0.0,0.0,,0.0,0.0,0.0,2.0,2.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @smbenlazar: Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induc‚Ä¶,true
pembeoltulu,"Pathologist(Associate professor), Meram Faculty of Medicine, Konya/Turkey; I lv #hemepath, #dermpath üíóMarried and have 4 children, RT/Tw are not medical advice",,T√ºrkiye,,2020-12-06 21:43:28+00:00,"Pembe Oltulu, MD",http://twitter.com/,54.0,,1.3357014170430917e+18,,0.0,0.0,,RT @lauracmichaelis: Turkish eggs and a plenary session on stem cells- pretty nice way to start the day #ASHFromHome https://t.co/qqXiNC5aMb,en,0.0,8940.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,50.0,4.0,https://twitter.com/pembeoltulu/statuses/1335701417043091460,0.0,0.0,,0.0,0.0,0.0,4.0,50.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @lauracmichaelis: Turkish eggs and a plenary session on stem cells- pretty nice way to start the day #ASHFromHome https://t.co/qqXiNC5aMb,true
Lymphoma_Doc,"Director of Clinical Research, Section Chief of Aggressive Lymphomas at MD Anderson Cancer Center, CAR T-cell, dreamer and doer. Opinions are mine",,"Houston, TX",,2020-12-06 20:29:19+00:00,"Jason Westin, MD FACP",http://twitter.com/,4.0,,1.3356827566223647e+18,,0.0,0.0,,"Dr Olszewski presented data on Mosunetuzumab in 1L DLBCL elderly patients instead of chemo, median age 82y, 52% IPI‚Ä¶ https://t.co/UjSgcI37wa",en,0.0,5105.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,4.0,https://twitter.com/Lymphoma_Doc/statuses/1335682756622364672,0.0,0.0,,0.0,0.0,0.0,4.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"Dr Olszewski presented data on Mosunetuzumab in 1L DLBCL elderly patients instead of chemo, median age 82y, 52% IPI‚Ä¶ https://t.co/UjSgcI37wa",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 15:59:25+00:00,"Ritcha Saxena, MD",http://twitter.com/,5.0,,1.3356148354726912e+18,,0.0,0.0,,RT @CanerSaygin: AML clinical abstracts are live: Dr Keith Pratz presenting phase I data on the safety and feasibility of combining gilteri‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,1.0,https://twitter.com/RitchaSaxena/statuses/1335614835472691202,0.0,0.0,,0.0,0.0,0.0,1.0,4.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @CanerSaygin: AML clinical abstracts are live: Dr Keith Pratz presenting phase I data on the safety and feasibility of combining gilteri‚Ä¶,true
majorajay,"Hematology/oncology fellow. #lymsm & #mmsm outcomes researcher. Physician-publisher & founder of https://t.co/dPfLt8QVMr, @inTrainingDoc & @inHouseMag.",,"Chicago, IL",,2020-12-03 06:02:58+00:00,"Ajay Major, MD, MBA",http://twitter.com/,0.0,,1.334377570205307e+18,,0.0,0.0,,"With all this talk at #ASH20 about the possible role of plasma exchange for severe #COVID19 infection, check out th‚Ä¶ https://t.co/ossQzHgJo6",en,0.0,3518.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/majorajay/statuses/1334377570205306883,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"With all this talk at #ASH20 about the possible role of plasma exchange for severe #COVID19 infection, check out th‚Ä¶ https://t.co/ossQzHgJo6",true
JohannMorelle,"Physician-scientist and clinical nephrologist at Saint-Luc Academic Hospital and UCLouvain, Brussels, Belgium - kidney diseases and home dialysis techniques",,Belgique,,2020-12-03 09:06:28+00:00,Morelle Johann,http://twitter.com/,194.0,,1.334423749593084e+18,,0.0,0.0,,RT @VincentRK: #ASH20 special: Active myeloma drugs with their mechanism of action in one slide. Unapproved investigational drugs in blue f‚Ä¶,en,0.0,205.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,147.0,47.0,https://twitter.com/JohannMorelle/statuses/1334423749593083904,0.0,0.0,,0.0,0.0,0.0,47.0,147.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,RT @VincentRK: #ASH20 special: Active myeloma drugs with their mechanism of action in one slide. Unapproved investigational drugs in blue f‚Ä¶,false
SandyWong02111,UCSF Hematologist and BMT physician,,"San Francisco, CA",,2020-12-03 05:20:10+00:00,Sandy Wong,http://twitter.com/,194.0,,1.334366797127041e+18,,0.0,0.0,,RT @VincentRK: #ASH20 special: Active myeloma drugs with their mechanism of action in one slide. Unapproved investigational drugs in blue f‚Ä¶,en,0.0,759.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,147.0,47.0,https://twitter.com/SandyWong02111/statuses/1334366797127041025,0.0,0.0,,0.0,0.0,0.0,47.0,147.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,RT @VincentRK: #ASH20 special: Active myeloma drugs with their mechanism of action in one slide. Unapproved investigational drugs in blue f‚Ä¶,true
szusmani,"Division Chief, Plasma Cell Disorders|Director, Clinical Research Hem Malignancies | Views are my own | RT not endorsement | Physician ‚â† Provider",,"Charlotte, NC",,2020-12-03 16:05:07+00:00,Saad Z. Usmani MD MBA FACP (he/his/him),http://twitter.com/,6.0,,1.334529102691373e+18,,0.0,0.0,,RT @ASH_hematology: Don't miss the Scientific Workshops during #ASH20--or engaging with fellow attendees on Twitter about the innovative sc‚Ä¶,en,0.0,5512.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,1.0,https://twitter.com/szusmani/statuses/1334529102691373058,0.0,0.0,,0.0,0.0,0.0,1.0,5.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @ASH_hematology: Don't miss the Scientific Workshops during #ASH20--or engaging with fellow attendees on Twitter about the innovative sc‚Ä¶,true
Lachelle_Dawn,heme-onc fellow | physician-scientist | racial justice & health equity | views are mine | there will be typos | i tweet what i want | pronouns: she/her/hers,,"Boston, MA",,2020-12-03 20:14:42+00:00,Lachelle Dawn,http://twitter.com/,0.0,,1.3345919158834217e+18,,0.0,0.0,,"Here‚Äôs the ‚òïÔ∏è on virtual #ASH20 #ashapalooza  #ASHTrainee day

- still having fun
- speakers have been phenomenal
-‚Ä¶ https://t.co/zMSbIBAGX6",en,0.0,3338.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/Lachelle_Dawn/statuses/1334591915883421698,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,"Here‚Äôs the ‚òïÔ∏è on virtual #ASH20 #ashapalooza  #ASHTrainee day

- still having fun
- speakers have been phenomenal
-‚Ä¶ https://t.co/zMSbIBAGX6",true
Lachelle_Dawn,heme-onc fellow | physician-scientist | racial justice & health equity | views are mine | there will be typos | i tweet what i want | pronouns: she/her/hers,,"Boston, MA",,2020-12-03 20:17:42+00:00,Lachelle Dawn,http://twitter.com/,0.0,,1.3345926689077453e+18,,0.0,0.0,,"Thanks to all of the trainees, mentors and speakers who participated in #ashapalooza day 1!!!

It was a great day.‚Ä¶ https://t.co/FUgDj2idid",en,0.0,3338.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/Lachelle_Dawn/statuses/1334592668907745283,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,"Thanks to all of the trainees, mentors and speakers who participated in #ashapalooza day 1!!!

It was a great day.‚Ä¶ https://t.co/FUgDj2idid",true
mshadman,"Associate Professor,  Fred Hutchinson, U of Washington. Lymphoma/CLL oncologist.  Tweets are mine.",,"Seattle, WA",,2020-12-03 00:34:30+00:00,"Mazyar Shadman, MD MPH",http://twitter.com/,7.0,,1.3342949088410214e+18,,0.0,0.0,,RT @SeattleCCA: Our 2020 SCCA at @ASH_hematology website is now live: https://t.co/BwxjB9x2BR View the schedule of our team of speakers and‚Ä¶,en,0.0,927.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,2.0,https://twitter.com/mshadman/statuses/1334294908841021440,0.0,0.0,,0.0,0.0,0.0,2.0,5.0,False,False,False,False,True,Thought Leadership,0.0,0.0,1.0,RT @SeattleCCA: Our 2020 SCCA at @ASH_hematology website is now live: https://t.co/BwxjB9x2BR View the schedule of our team of speakers and‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-03 03:13:19+00:00,"Ritcha Saxena, MD",http://twitter.com/,194.0,,1.3343348759445422e+18,,0.0,0.0,,RT @VincentRK: #ASH20 special: Active myeloma drugs with their mechanism of action in one slide. Unapproved investigational drugs in blue f‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,147.0,47.0,https://twitter.com/RitchaSaxena/statuses/1334334875944542208,0.0,0.0,,0.0,0.0,0.0,47.0,147.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,RT @VincentRK: #ASH20 special: Active myeloma drugs with their mechanism of action in one slide. Unapproved investigational drugs in blue f‚Ä¶,false
SandyWong02111,UCSF Hematologist and BMT physician,,"San Francisco, CA",,2020-12-03 19:08:56+00:00,Sandy Wong,http://twitter.com/,6.0,,1.3345753621901312e+18,,0.0,0.0,,"RT @SLentzsch: #ASH20 Adaption of Next Generation Sequencing, Next Generation Flow Cytometry, and CyTOF: The big question ?Can we use MALDI‚Ä¶",en,0.0,759.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,3.0,https://twitter.com/SandyWong02111/statuses/1334575362190131201,0.0,0.0,,0.0,0.0,0.0,3.0,3.0,False,False,False,False,True,Long Term Benefits,0.0,0.0,1.0,"RT @SLentzsch: #ASH20 Adaption of Next Generation Sequencing, Next Generation Flow Cytometry, and CyTOF: The big question ?Can we use MALDI‚Ä¶",true
drjgauthier,"MD, MSc, Assistant Professor @fredhutch @UW focused on #CARTcell #immunotherapy #tcellrx 
Interests also include #rstats #bmtsm #epitwitter #bayes",,"Seattle, WA",,2020-12-03 22:13:57+00:00,Jordan Gauthier,http://twitter.com/,20.0,,1.3346219249413898e+18,,0.0,0.0,,"RT @SeattleCCA: Coming up at #ASH20: CAR-T Scientific Workshop with @drjgauthier, MD - ""Age, Performance Status, and Comorbidities in Relat‚Ä¶",en,0.0,3295.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,16.0,4.0,https://twitter.com/drjgauthier/statuses/1334621924941389824,0.0,0.0,,0.0,0.0,0.0,4.0,16.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,"RT @SeattleCCA: Coming up at #ASH20: CAR-T Scientific Workshop with @drjgauthier, MD - ""Age, Performance Status, and Comorbidities in Relat‚Ä¶",true
emmamgroarke,"Haematologist in Bethesda. Irish trained üáÆüá™ Particular interests: #aplasticanemia, #telomeredisease, #CHIP, #MDS, #AML, #HSCT All comments my own.",,"Washington, DC",,2020-12-03 23:39:21+00:00,Emma M. Groarke,http://twitter.com/,0.0,,1.3346434155317944e+18,,0.0,0.0,,Tune in this Saturday at 5pm EST for #ASH20 oral presentation that was a large #NIH collaboration ‚Äúsomatic mutation‚Ä¶ https://t.co/ucnoCmm9se,en,0.0,130.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/emmamgroarke/statuses/1334643415531794434,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,Tune in this Saturday at 5pm EST for #ASH20 oral presentation that was a large #NIH collaboration ‚Äúsomatic mutation‚Ä¶ https://t.co/ucnoCmm9se,true
rajshekharucms,Hem/Onc Physician/Clinical Researcher @ColumbiaCancer #MultipleMyeloma & #Amyloidosis. Asst. Prof of Medicine @ColumbiaMed #ClinicalTrials and Outcomes Research,,"New York, NY",,2020-12-03 20:32:41+00:00,Raj Chakraborty,http://twitter.com/,187.0,,1.3345964377833964e+18,,0.0,0.0,,"RT @VincentRK: One of the most common questions myeloma patients ask me is: Should I get a stem cell transplant, and if so when should I do‚Ä¶",en,0.0,1148.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,136.0,51.0,https://twitter.com/rajshekharucms/statuses/1334596437783396352,0.0,0.0,,0.0,0.0,0.0,51.0,136.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @VincentRK: One of the most common questions myeloma patients ask me is: Should I get a stem cell transplant, and if so when should I do‚Ä¶",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-03 18:20:49+00:00,Lisa Palacios,http://twitter.com/,21.0,,1.3345632558141235e+18,,0.0,0.0,,"RT @MDAndersonNews: Chemotherapy used to be the standard treatment option for mantle cell lymphoma. But what‚Äôs next? 

Our Dr. Michael Wang‚Ä¶",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,19.0,2.0,https://twitter.com/Lisa_Palacios/statuses/1334563255814123529,0.0,0.0,,0.0,0.0,0.0,2.0,19.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @MDAndersonNews: Chemotherapy used to be the standard treatment option for mantle cell lymphoma. But what‚Äôs next? 

Our Dr. Michael Wang‚Ä¶",true
EileenMBoyle,"MD,PhD, post-doctoral fellow, Myeloma Research Program, @nyulangone, opinions are my own.",,"New York, USA",,2020-12-03 22:19:03+00:00,Eileen M. Boyle,http://twitter.com/,20.0,,1.334623206716674e+18,,0.0,0.0,,"RT @SeattleCCA: Coming up at #ASH20: CAR-T Scientific Workshop with @drjgauthier, MD - ""Age, Performance Status, and Comorbidities in Relat‚Ä¶",en,0.0,112.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,16.0,4.0,https://twitter.com/EileenMBoyle/statuses/1334623206716674049,0.0,0.0,,0.0,0.0,0.0,4.0,16.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,"RT @SeattleCCA: Coming up at #ASH20: CAR-T Scientific Workshop with @drjgauthier, MD - ""Age, Performance Status, and Comorbidities in Relat‚Ä¶",false
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-03 23:51:01+00:00,"Ritcha Saxena, MD",http://twitter.com/,5.0,,1.3346463498921124e+18,,0.0,0.0,,"RT @feldstej: Flow Cytometric Measurement Issues for MRD and IP in MM; Adaption of Next Generation Sequencing, Next Generation Flow Cytomet‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,1.0,https://twitter.com/RitchaSaxena/statuses/1334646349892112393,0.0,0.0,,0.0,0.0,0.0,1.0,4.0,False,False,False,False,True,Long Term Benefits,0.0,0.0,1.0,"RT @feldstej: Flow Cytometric Measurement Issues for MRD and IP in MM; Adaption of Next Generation Sequencing, Next Generation Flow Cytomet‚Ä¶",true
dgermain21,MD-PhD. 2nd year Heme/Onc fellow focused on lymphoma and leukemia. Physician-scientist-in-training. Tweet/RT not medical advice or endorsement.,,"St. Louis, MO",,2020-12-03 22:30:02+00:00,David A. Russler-Germain,http://twitter.com/,187.0,,1.3346259715473367e+18,,0.0,0.0,,"RT @VincentRK: One of the most common questions myeloma patients ask me is: Should I get a stem cell transplant, and if so when should I do‚Ä¶",en,0.0,1612.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,136.0,51.0,https://twitter.com/dgermain21/statuses/1334625971547336707,0.0,0.0,,0.0,0.0,0.0,51.0,136.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @VincentRK: One of the most common questions myeloma patients ask me is: Should I get a stem cell transplant, and if so when should I do‚Ä¶",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-03 20:14:30+00:00,Lisa Palacios,http://twitter.com/,0.0,,1.3345918638068982e+18,,0.0,0.0,,"12/4 11a-2p PST #ASH20

Building New Management Models for NHL Care: Tumor Board Insights on Innovative Therapeutic‚Ä¶ https://t.co/85c9Dfg5d5",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/Lisa_Palacios/statuses/1334591863806898178,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"12/4 11a-2p PST #ASH20

Building New Management Models for NHL Care: Tumor Board Insights on Innovative Therapeutic‚Ä¶ https://t.co/85c9Dfg5d5",true
Jme_os,Research Lecturer Irish Centre for Vascular Biology | Royal College of Surgeons in Ireland | VWF Biology | Cancer-Coagulation crosstalk | COVID-coag |@RCSI_Irl,,"Dublin, Ireland",,2020-12-03 18:17:07+00:00,Jamie O' Sullivan,http://twitter.com/,2.0,,1.3345623249596826e+18,,0.0,0.0,,Evidence that patients really are at the core of everything we do #basicScience #clinicalScience #collaboration Wor‚Ä¶ https://t.co/qEfFagkMPS,en,0.0,673.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/Jme_os/statuses/1334562324959682562,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,Evidence that patients really are at the core of everything we do #basicScience #clinicalScience #collaboration Wor‚Ä¶ https://t.co/qEfFagkMPS,true
BenjaminGVincen,Physician-scientist @UNC_Lineberger Immunotherapy Group | Systems Tumor Immunology & Immunogenomics,,,,2020-12-03 22:14:19+00:00,Benjamin Vincent,http://twitter.com/,0.0,,1.3346220169394463e+18,,0.0,0.0,,...studying minor histocompatibility antigen specific T cell responses in human allogeneic stem cell transplant rec‚Ä¶ https://t.co/u7Vl92tHKS,en,0.0,584.0,,,0.0,BenjaminGVincen,1.3346220160921969e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/BenjaminGVincen/statuses/1334622016939446274,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,...studying minor histocompatibility antigen specific T cell responses in human allogeneic stem cell transplant rec‚Ä¶ https://t.co/u7Vl92tHKS,true
BaylisMedical,Leading developer of high-performance #cardiology devices that help physicians deliver life-changing therapies to patients. #CardioTwitter #MedTech,,"Toronto, Canada",,2020-10-01 15:38:22+00:00,Baylis Medical,http://twitter.com/,13.0,,1.3116919368064287e+18,,0.0,0.0,,Save the date: We will be part of  #TCTConnect from October 14-18 showcasing our innovative solutions to optimize l‚Ä¶ https://t.co/wYj3LJRFOw,en,0.0,2067.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,13.0,https://twitter.com/BaylisMedical/statuses/1311691936806428674,0.0,0.0,,0.0,0.0,0.0,13.0,0.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,Save the date: We will be part of  #TCTConnect from October 14-18 showcasing our innovative solutions to optimize l‚Ä¶ https://t.co/wYj3LJRFOw,false
medshronline,"MedShr -The App for Doctors, is a HIPAA & GMC compliant network for medical professionals to discuss clinical cases. MedShr now has over 1M members worldwide.",,"London, England",,2020-10-02 16:40:19+00:00,MedShr,http://twitter.com/,15.0,,1.3120699159234273e+18,,0.0,0.0,,"RT @crfheart: TCT‚Äôs Shark Tank is here again! Join us during #TCTConnect to watch 6 teams compete for the top innovation prize &amp; win $200,0‚Ä¶",en,0.0,8228.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,11.0,4.0,https://twitter.com/medshronline/statuses/1312069915923427330,0.0,0.0,,0.0,0.0,0.0,4.0,11.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"RT @crfheart: TCT‚Äôs Shark Tank is here again! Join us during #TCTConnect to watch 6 teams compete for the top innovation prize &amp; win $200,0‚Ä¶",true
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-10-02 16:31:27+00:00,Cardiovascular Research Foundation,http://twitter.com/,4.0,,1.3120676842893476e+18,,0.0,0.0,,TCT‚Äôs Shark Tank is here again! Join us during #TCTConnect to watch 6 teams compete for the top innovation prize &amp;‚Ä¶ https://t.co/gv8q8OwdxP,en,0.0,12239.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,4.0,https://twitter.com/crfheart/statuses/1312067684289347584,0.0,0.0,,0.0,0.0,0.0,4.0,0.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,TCT‚Äôs Shark Tank is here again! Join us during #TCTConnect to watch 6 teams compete for the top innovation prize &amp;‚Ä¶ https://t.co/gv8q8OwdxP,true
ehe_drepa,"Association de lutte contre la dr√©panocytose
Informer. Inciter au d√©pistage, au don du sang. Financer la recherche. Soulager les malades les plus d√©munis.",,France,,2020-10-26 14:31:05+00:00,Espoir Hope Elikia,http://twitter.com/,11.0,,1.3207347009404682e+18,,0.0,0.0,,RT @ERNEuroBloodNet: üì¢We are looking for the starting of #SCD Patients Educational Session at ASCAT 2020 organized by @ERNEuroBloodNet and‚Ä¶,en,0.0,15.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,6.0,https://twitter.com/ehe_drepa/statuses/1320734700940468225,0.0,0.0,,0.0,0.0,0.0,6.0,5.0,False,False,False,False,True,Patient Education,0.0,0.0,1.0,RT @ERNEuroBloodNet: üì¢We are looking for the starting of #SCD Patients Educational Session at ASCAT 2020 organized by @ERNEuroBloodNet and‚Ä¶,true
DLBHATTMD,"Dr. Deepak L. Bhatt, MD, MPH, is a Professor at Harvard and Executive Director of Interventional Cardiovascular Programs at Brigham and Women‚Äôs Hospital.",,"Boston, USA",,2020-11-03 17:58:50+00:00,Dr. Deepak L. Bhatt,http://twitter.com/,18.0,,1.323686084354736e+18,,0.0,0.0,,"RT @CardiologyToday: Compared with placebo, icosapent ethyl reduced first and total MACE in patients with prior PCI, according to results f‚Ä¶",en,0.0,16200.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,12.0,6.0,https://twitter.com/DLBHATTMD/statuses/1323686084354736129,0.0,0.0,,0.0,0.0,0.0,6.0,12.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @CardiologyToday: Compared with placebo, icosapent ethyl reduced first and total MACE in patients with prior PCI, according to results f‚Ä¶",true
MattPPlayer,Husband to Eloise. Christian. Haematologist. Interested in Global Haematology. Sports fan.,,Malawi,,2020-10-28 19:34:56+00:00,Matthew Player,http://twitter.com/,19.0,,1.3215359415137485e+18,,0.0,0.0,,"RT @TheLancetHaem: Dr  Marilyn J Telen presents promising results from the phase 1 trial of FT-4202, a pyruvate kinase R-activator, in pati‚Ä¶",en,0.0,41.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,13.0,6.0,https://twitter.com/MattPPlayer/statuses/1321535941513748482,0.0,0.0,,0.0,0.0,0.0,6.0,13.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @TheLancetHaem: Dr  Marilyn J Telen presents promising results from the phase 1 trial of FT-4202, a pyruvate kinase R-activator, in pati‚Ä¶",true
chanyooncheah,Doctor for patients with lymphoma. Clinical researcher.,,"Perth, Western Australia",,2020-11-05 00:41:12+00:00,Chan Cheah,http://twitter.com/,0.0,,1.3241497314764718e+18,,0.0,0.0,,Agree Toby great data for this agent (COI: we are both investigators) #CLLsm @loxooncology #ASH2020 https://t.co/vbs6MiD9gK,en,0.0,1717.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/chanyooncheah/statuses/1324149731476471808,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Financial Performance,1.0,0.0,0.0,Agree Toby great data for this agent (COI: we are both investigators) #CLLsm @loxooncology #ASH2020 https://t.co/vbs6MiD9gK,false
venkymd,Medical and Pediatric Oncologist. Global health student. #Kilpauk #PGI #AIIMS #StJude #cancerInstitute,,,,2020-11-05 13:10:39+00:00,Venkatraman Radhakrishnan (Venky),http://twitter.com/,22.0,,1.3243383367192822e+18,,0.0,0.0,,RT @mtmdphd: Severity of Sars-Cov-2 Infection in Pts w/ Hematologic Malignancies: A COVID-19 &amp; Cancer Consortium (#CCC19) Registry Analysis‚Ä¶,en,0.0,2842.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,12.0,https://twitter.com/venkymd/statuses/1324338336719282177,0.0,0.0,,0.0,0.0,0.0,12.0,10.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,RT @mtmdphd: Severity of Sars-Cov-2 Infection in Pts w/ Hematologic Malignancies: A COVID-19 &amp; Cancer Consortium (#CCC19) Registry Analysis‚Ä¶,true
e_morawa,Oncologist - Stem Cell Transplant - CAR T - CRISPR - Comments mine not CRISPR Tx,,United States,,2020-11-05 01:56:48+00:00,Ewelina Morawa,http://twitter.com/,51.0,,1.3241687571540337e+18,,0.0,0.0,,"RT @CRISPRTX: Today, $CRSP, in collaboration with @VertexPharma, announced the plenary presentation of new data for CTX001‚Ñ¢ at the upcoming‚Ä¶",en,0.0,18.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,41.0,10.0,https://twitter.com/e_morawa/statuses/1324168757154033664,0.0,0.0,,0.0,0.0,0.0,10.0,41.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,"RT @CRISPRTX: Today, $CRSP, in collaboration with @VertexPharma, announced the plenary presentation of new data for CTX001‚Ñ¢ at the upcoming‚Ä¶",true
RuthClifford5,"Consultant Haematologist, University Hospital Limerick, IRL. Special interests CLL, genomics, MPNs.",,,,2020-11-05 20:40:12+00:00,Ruth Clifford,http://twitter.com/,24.0,,1.3244514713756672e+18,,0.0,0.0,,"RT @tobyeyre82: 5y final results 
INNOVATE
Continued substantial PFS adv to #ibrutinib-R vs R. No OS diff

RAINBOW trial (CI R. Auer, Barts‚Ä¶",en,0.0,287.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,17.0,7.0,https://twitter.com/RuthClifford5/statuses/1324451471375667203,0.0,0.0,,0.0,0.0,0.0,7.0,17.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @tobyeyre82: 5y final results 
INNOVATE
Continued substantial PFS adv to #ibrutinib-R vs R. No OS diff

RAINBOW trial (CI R. Auer, Barts‚Ä¶",true
graham74GC,Lymphoma specialist at Oxford Cancer and Haematology centre. Haematologist and clinical trialist. Chair of UK Hodgkin and T-cell study groups.,,Opinions are mine,,2020-11-05 23:25:48+00:00,Graham Collins,http://twitter.com/,16.0,,1.3244931466134938e+18,,0.0,0.0,,"RT @CwynKate: Well done and much deserved @prp_diciaccio üëè and @nadahamad 
Fantastic international collaboration
n=197 Plasmablastic #lymph‚Ä¶",en,0.0,6091.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,12.0,4.0,https://twitter.com/graham74GC/statuses/1324493146613493761,0.0,0.0,,0.0,0.0,0.0,4.0,12.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,"RT @CwynKate: Well done and much deserved @prp_diciaccio üëè and @nadahamad 
Fantastic international collaboration
n=197 Plasmablastic #lymph‚Ä¶",true
chanyooncheah,Doctor for patients with lymphoma. Clinical researcher.,,"Perth, Western Australia",,2020-11-05 00:51:27+00:00,Chan Cheah,http://twitter.com/,0.0,,1.3241523142994944e+18,,0.0,0.0,,Look forward to presenting updated findings for this phase I trial @TGTherapeutics #lymSM #CLLsm #ASH2020 https://t.co/eHK2C6BBjn,en,0.0,1717.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/chanyooncheah/statuses/1324152314299494400,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,1.0,0.0,0.0,Look forward to presenting updated findings for this phase I trial @TGTherapeutics #lymSM #CLLsm #ASH2020 https://t.co/eHK2C6BBjn,true
aliciad3,Paediatric infections doctor @EvelinaLondon @GSTTnhs and epidemiologist @PHE_uk. #IPC #AntimicrobialStewardship #AntimicrobialResistance. Views my own.,,"London, England",,2020-10-27 17:30:43+00:00,Dr. Alicia,http://twitter.com/,7.0,,1.3211422947252183e+18,,0.0,0.0,,RT @TeamHaem: Excellent talk by Andrew Campbell at #ascatconference regarding Covid-19. Data on the effects of covid-19 infection in patien‚Ä¶,en,0.0,2673.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,4.0,https://twitter.com/aliciad3/statuses/1321142294725218304,0.0,0.0,,0.0,0.0,0.0,4.0,3.0,False,False,False,False,True,Side Effects,1.0,0.0,0.0,RT @TeamHaem: Excellent talk by Andrew Campbell at #ascatconference regarding Covid-19. Data on the effects of covid-19 infection in patien‚Ä¶,false
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-11-13 09:12:43+00:00,"Ritcha Saxena, MD",http://twitter.com/,26.0,,1.327177563706372e+18,,0.0,0.0,,RT @doctorpemm: #ASH20 || Our Multi-National group effort: Impact of #COVID19 Pandemic &amp; MPN: International Survey Results ‚û°Ô∏è led by Dr @Je‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,19.0,7.0,https://twitter.com/RitchaSaxena/statuses/1327177563706372098,0.0,0.0,,0.0,0.0,0.0,7.0,19.0,False,False,False,False,True,Covid,0.0,0.0,1.0,RT @doctorpemm: #ASH20 || Our Multi-National group effort: Impact of #COVID19 Pandemic &amp; MPN: International Survey Results ‚û°Ô∏è led by Dr @Je‚Ä¶,true
dr_wei_jiang,Haematologist | PhD Researcher | Humanist | Musician | Stem Cell Transplantation | Cellular Therapies | HSANZ/Leukaemia Foundation PhD Scholar,,"Sydney, New South Wales",,2020-10-27 02:21:35+00:00,Wei Jiang,http://twitter.com/,9.0,,1.3209135063218463e+18,,0.0,0.0,,RT @EmilyBlyth5: We are investigating the use of adoptively transferred #PRAME and #WT1 specific #Tcells in combo with pathogen specific T‚Ä¶,en,0.0,163.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,3.0,https://twitter.com/dr_wei_jiang/statuses/1320913506321846273,0.0,0.0,,0.0,0.0,0.0,3.0,6.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,RT @EmilyBlyth5: We are investigating the use of adoptively transferred #PRAME and #WT1 specific #Tcells in combo with pathogen specific T‚Ä¶,true
cvigilgonzales,Hematologist/Leukemia physician/researcher/ Lurie Cancer Center @northwesternmed,,"Chicago, IL",,2020-07-30 18:48:51+00:00,"Carlos E. Vigil, MD",http://twitter.com/,5.0,,1.2889094379069645e+18,,0.0,0.0,,"RT @AML_Hub: During #EHA25Virtual @Cluzeau91592213, @CHUdeNice, presented data from the GFM-APR trial that is investigating the safety &amp; ef‚Ä¶",en,0.0,266.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,2.0,https://twitter.com/cvigilgonzales/statuses/1288909437906964482,0.0,0.0,,0.0,0.0,0.0,2.0,3.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,"RT @AML_Hub: During #EHA25Virtual @Cluzeau91592213, @CHUdeNice, presented data from the GFM-APR trial that is investigating the safety &amp; ef‚Ä¶",true
CancerMedMDA,"Mission of largest MD Anderson division is to eliminate cancer via best, integrated patient care, research & education programs. Appts.available 877-632-6789.",,"Houston, TX",,2020-07-30 16:42:39+00:00,Cancer Medicine,http://twitter.com/,16.0,,1.2888776776346092e+18,,0.0,0.0,,RT @ecancer: #EHA25: Dr Elias Jabbour of @MDAndersonNews discusses the use of venetoclax plus navitoclax in relapsed/refractory ALL and lym‚Ä¶,en,0.0,6443.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,12.0,4.0,https://twitter.com/CancerMedMDA/statuses/1288877677634609154,0.0,0.0,,0.0,0.0,0.0,4.0,12.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @ecancer: #EHA25: Dr Elias Jabbour of @MDAndersonNews discusses the use of venetoclax plus navitoclax in relapsed/refractory ALL and lym‚Ä¶,true
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-10-18 11:00:46+00:00,Cardiovascular Research Foundation,http://twitter.com/,0.0,,1.3177826718719222e+18,,0.0,0.0,,Ready to enhance your learning during #TCTConnect with E-Satellite Programs? Watch dynamic educational programs hig‚Ä¶ https://t.co/UfbY2srgJf,en,0.0,12239.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/crfheart/statuses/1317782671871922176,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Disease Advocacy,1.0,0.0,0.0,Ready to enhance your learning during #TCTConnect with E-Satellite Programs? Watch dynamic educational programs hig‚Ä¶ https://t.co/UfbY2srgJf,true
CNCFCardio,"The Coll√®ge National des Cardiologues Fran√ßais (CNCF) is an apolitical professional association and independent trade union, representing cardiologists.",,13 rue NIEPCE-75014 PARIS-FRANCE,,2020-10-18 08:48:19+00:00,CNCFCardio,http://twitter.com/,12.0,,1.3177493385970975e+18,,0.0,0.0,,"RT @HeartFlow: New data from FORECAST RCT show the #HeartFlowAnalysis impact to cardiovascular treatment efficiency, number of diagnostic c‚Ä¶",en,0.0,3508.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,2.0,https://twitter.com/CNCFCardio/statuses/1317749338597097474,0.0,0.0,,0.0,0.0,0.0,2.0,10.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"RT @HeartFlow: New data from FORECAST RCT show the #HeartFlowAnalysis impact to cardiovascular treatment efficiency, number of diagnostic c‚Ä¶",false
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-11-23 21:35:10+00:00,Lisa Palacios,http://twitter.com/,11.0,,1.3309882873816883e+18,,0.0,0.0,,RT @doctorpemm: #ASH20 || Implications of #RAS Mutational Status in Subsets of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) a‚Ä¶,en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,8.0,3.0,https://twitter.com/Lisa_Palacios/statuses/1330988287381688327,0.0,0.0,,0.0,0.0,0.0,3.0,8.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @doctorpemm: #ASH20 || Implications of #RAS Mutational Status in Subsets of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) a‚Ä¶,true
humberto0927,"Blood cancer doctor/researcher, epidemiology MSc (c), focus on Multiple Myeloma and Hodgkin Lymphoma.",,Colombia,,2020-11-04 20:27:56+00:00,Humberto Martinez-Cordero,http://twitter.com/,22.0,,1.3240859957515264e+18,,0.0,0.0,,RT @mtmdphd: Severity of Sars-Cov-2 Infection in Pts w/ Hematologic Malignancies: A COVID-19 &amp; Cancer Consortium (#CCC19) Registry Analysis‚Ä¶,en,0.0,474.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,12.0,https://twitter.com/humberto0927/statuses/1324085995751526401,0.0,0.0,,0.0,0.0,0.0,12.0,10.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,RT @mtmdphd: Severity of Sars-Cov-2 Infection in Pts w/ Hematologic Malignancies: A COVID-19 &amp; Cancer Consortium (#CCC19) Registry Analysis‚Ä¶,true
DrMoritzWvB,heart valve specialist. minimally invasive & robotic heart surgeon. statistician. eliminating #SHD with cold steel & wires. repair that valve. #TAVR #TMVR #TTVR,,BRN üõ¨BOS üõ¨MKE üõ¨RDU üõ¨HOU,,2020-10-30 03:27:37+00:00,"Moritz ¬© Wyler von Ballmoos, MD, PhD",http://twitter.com/,2.0,,1.3220172869963162e+18,,0.0,0.0,,"Excited for this truly innovative, #TCT approach to #mitral valve disease &amp; the Gore TCR 20-02 EFS that‚Äôs coming! E‚Ä¶ https://t.co/4vHdvuqPNe",en,0.0,1196.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/DrMoritzWvB/statuses/1322017286996316162,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"Excited for this truly innovative, #TCT approach to #mitral valve disease &amp; the Gore TCR 20-02 EFS that‚Äôs coming! E‚Ä¶ https://t.co/4vHdvuqPNe",true
graham74GC,Lymphoma specialist at Oxford Cancer and Haematology centre. Haematologist and clinical trialist. Chair of UK Hodgkin and T-cell study groups.,,Opinions are mine,,2020-11-04 16:35:05+00:00,Graham Collins,http://twitter.com/,7.0,,1.3240273973233009e+18,,0.0,0.0,,"Phase II of cami-T (ADCT301) in R/R Hodgkin, Herrera et al
- Failed BV &amp; PD1i
- 47 pts in analysis (study ongoing)‚Ä¶ https://t.co/WAkDpb7ulz",en,0.0,6091.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,7.0,https://twitter.com/graham74GC/statuses/1324027397323300871,0.0,0.0,,0.0,0.0,0.0,7.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"Phase II of cami-T (ADCT301) in R/R Hodgkin, Herrera et al
- Failed BV &amp; PD1i
- 47 pts in analysis (study ongoing)‚Ä¶ https://t.co/WAkDpb7ulz",true
NBahlis,"Physician-scientist focused on multiple myeloma
Tweets are my own.",,,,2020-11-11 18:51:15+00:00,nizar jacques bahlis,http://twitter.com/,12.0,,1.3265983819138253e+18,,0.0,0.0,,My lab in collaboration with Dr P Neri will be presenting @ASH_hematology #ASH20 exciting data on T cells scRNA &amp; s‚Ä¶ https://t.co/6V63jFBTR5,en,0.0,436.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,12.0,https://twitter.com/NBahlis/statuses/1326598381913825285,0.0,0.0,,0.0,0.0,0.0,12.0,0.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,My lab in collaboration with Dr P Neri will be presenting @ASH_hematology #ASH20 exciting data on T cells scRNA &amp; s‚Ä¶ https://t.co/6V63jFBTR5,true
JPapatzimas,PhD in Medicinal Chemistry from @UCalgary. Postdoctoral Fellow in the @DanNomura group. Footy fanatic. Lover of all (big) dogs.,,"Calgary, Alberta",,2020-11-11 19:08:03+00:00,James Papatzimas,http://twitter.com/,45.0,,1.3266026068865434e+18,,0.0,0.0,,RT @NBahlis: My lab in collaboration with Dr P Neri will be presenting @ASH_hematology #ASH20 exciting data on T cells scRNA &amp; scATAC seque‚Ä¶,en,0.0,270.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,33.0,12.0,https://twitter.com/JPapatzimas/statuses/1326602606886543360,0.0,0.0,,0.0,0.0,0.0,12.0,33.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @NBahlis: My lab in collaboration with Dr P Neri will be presenting @ASH_hematology #ASH20 exciting data on T cells scRNA &amp; scATAC seque‚Ä¶,false
DrMoritzWvB,heart valve specialist. minimally invasive & robotic heart surgeon. statistician. eliminating #SHD with cold steel & wires. repair that valve. #TAVR #TMVR #TTVR,,BRN üõ¨BOS üõ¨MKE üõ¨RDU üõ¨HOU,,2020-10-30 03:06:19+00:00,"Moritz ¬© Wyler von Ballmoos, MD, PhD",http://twitter.com/,1.0,,1.3220119248890634e+18,,0.0,0.0,,"Congratulations, Alex! Welcome to @ISMICS, where #innovation &amp; the #evolution of #heartsurgery have had a home for‚Ä¶ https://t.co/541GY4arjY",en,0.0,1196.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/DrMoritzWvB/statuses/1322011924889063424,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"Congratulations, Alex! Welcome to @ISMICS, where #innovation &amp; the #evolution of #heartsurgery have had a home for‚Ä¶ https://t.co/541GY4arjY",true
SachinGoelMD,"Interventional Cardiologist, Houston Methodist Hospital, Structural Heart, #MitraClip #TAVR #LAA Closure #TMVR, Cleveland Clinic alum, opinions my own",,"Houston, TX",,2020-10-30 12:54:39+00:00,Sachin Goel,http://twitter.com/,7.0,,1.3221599840047923e+18,,0.0,0.0,,"RT @DrMoritzWvB: Excited for this truly innovative, #TCT approach to #mitral valve disease &amp; the Gore TCR 20-02 EFS that‚Äôs coming! Even mor‚Ä¶",en,0.0,2794.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,2.0,https://twitter.com/SachinGoelMD/statuses/1322159984004792326,0.0,0.0,,0.0,0.0,0.0,2.0,5.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"RT @DrMoritzWvB: Excited for this truly innovative, #TCT approach to #mitral valve disease &amp; the Gore TCR 20-02 EFS that‚Äôs coming! Even mor‚Ä¶",true
graham74GC,Lymphoma specialist at Oxford Cancer and Haematology centre. Haematologist and clinical trialist. Chair of UK Hodgkin and T-cell study groups.,,Opinions are mine,,2020-11-04 16:44:30+00:00,Graham Collins,http://twitter.com/,7.0,,1.3240297683382313e+18,,0.0,0.0,,"Nivo + BV post-ASCT consol, R/R HL
- Herrera et al
- 59 pts, PhII, high risk relapse
- 8 cycles max, prim EP PFS 18‚Ä¶ https://t.co/0XsBuu7c4l",en,0.0,6091.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,7.0,https://twitter.com/graham74GC/statuses/1324029768338231297,0.0,0.0,,0.0,0.0,0.0,7.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"Nivo + BV post-ASCT consol, R/R HL
- Herrera et al
- 59 pts, PhII, high risk relapse
- 8 cycles max, prim EP PFS 18‚Ä¶ https://t.co/0XsBuu7c4l",true
alxbenevides,"Cardiovascular surgeon, father, husband and a lover of life; in all its letters, sounds and colors.",,"Sao Paulo - Brazil ",,2020-10-30 10:52:51+00:00,Dr. Alex M. Benevidesüáßüá∑,http://twitter.com/,5.0,,1.3221293323750318e+18,,0.0,0.0,,"RT @DrMoritzWvB: Congratulations, Alex! Welcome to @ISMICS, where #innovation &amp; the #evolution of #heartsurgery have had a home for the pas‚Ä¶",en,0.0,2371.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,1.0,https://twitter.com/alxbenevides/statuses/1322129332375031809,0.0,0.0,,0.0,0.0,0.0,1.0,4.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"RT @DrMoritzWvB: Congratulations, Alex! Welcome to @ISMICS, where #innovation &amp; the #evolution of #heartsurgery have had a home for the pas‚Ä¶",true
drparagjasani,"Consultant Haematologist @RFL and @UCLH, special interest in CLL and Lymphoma. Own views",,UK,,2020-11-04 15:15:21+00:00,Dr Parag Jasani,http://twitter.com/,17.0,,1.3240073323979407e+18,,0.0,0.0,,"RT @tobyeyre82: Phase I trial
VLS-101 (ROR1 ADC) in R/R #mantle cell #lymphoma

All BTKi exposed
13/15 stopped due to PD 

Neutropenia &amp; PN‚Ä¶",en,0.0,60.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,7.0,https://twitter.com/drparagjasani/statuses/1324007332397940738,0.0,0.0,,0.0,0.0,0.0,7.0,10.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @tobyeyre82: Phase I trial
VLS-101 (ROR1 ADC) in R/R #mantle cell #lymphoma

All BTKi exposed
13/15 stopped due to PD 

Neutropenia &amp; PN‚Ä¶",true
lepikurian,"Haematologist, researcher, biotech startup co-founder",,"Saint-Petersburg, Russia",,2020-11-04 19:03:06+00:00,Kirill Lepik M.D.,http://twitter.com/,25.0,,1.3240646456536064e+18,,0.0,0.0,,"RT @graham74GC: Nivo + BV post-ASCT consol, R/R HL
- Herrera et al
- 59 pts, PhII, high risk relapse
- 8 cycles max, prim EP PFS 18mo post-‚Ä¶",en,0.0,89.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,18.0,7.0,https://twitter.com/lepikurian/statuses/1324064645653606402,0.0,0.0,,0.0,0.0,0.0,7.0,18.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @graham74GC: Nivo + BV post-ASCT consol, R/R HL
- Herrera et al
- 59 pts, PhII, high risk relapse
- 8 cycles max, prim EP PFS 18mo post-‚Ä¶",false
GermanBiotech,"Biotech Investor, Former Scientist, M.D., Tweets since October 2019",,Germany,,2020-11-04 19:03:42+00:00,German Biotech,http://twitter.com/,0.0,,1.324064797319725e+18,,0.0,0.0,,"$ATNM

For completeness: Lintuzumab-225Ac in Combination with Venetoclax in Relapsed/Refractory AML

I hope (and it‚Ä¶ https://t.co/ARgbl1m1Rk",en,0.0,837.0,,,0.0,GermanBiotech,1.3239636787991552e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/GermanBiotech/statuses/1324064797319725063,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"$ATNM

For completeness: Lintuzumab-225Ac in Combination with Venetoclax in Relapsed/Refractory AML

I hope (and it‚Ä¶ https://t.co/ARgbl1m1Rk",true
VincentRK,"Professor, Mayo Clinic; Editor, Blood Cancer Journal; Oncologist; Health Costs; COVID threads @SurvivedCOVID Opinions=personal views https://t.co/TMq9vc5hZk",,"Rochester, MN, USA",,2020-11-13 21:06:38+00:00,Vincent Rajkumar,http://twitter.com/,6.0,,1.3273572245665956e+18,,0.0,0.0,,#4 Identification of a potential mechanism for frequent relapses after CAR-T therapy for myeloma: Bi allelic loss o‚Ä¶ https://t.co/kYdcpZ7xSd,en,0.0,33590.0,,,0.0,VincentRK,1.327357222704255e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,6.0,https://twitter.com/VincentRK/statuses/1327357224566595585,0.0,0.0,,0.0,0.0,0.0,6.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,#4 Identification of a potential mechanism for frequent relapses after CAR-T therapy for myeloma: Bi allelic loss o‚Ä¶ https://t.co/kYdcpZ7xSd,true
HoratiuOlteanu,"Hematopathologist. Chair, @MayoClinicPath #Hemepath Myeloid Working Group. @UNLincoln alumnus and #Huskers enthusiast. Opinions are mine.",,"Rochester, MN",,2020-09-15 12:00:01+00:00,Horatiu Olteanu,http://twitter.com/,310.0,,1.3058387822609285e+18,,0.0,0.0,,RT @VincentRK: 4 key slides from my talk on ‚ÄúHow I Treat Newly Diagnosed Myeloma‚Äù at #ASHMHM20 @ASH_hematology meeting. @MayoCancerCare @Ma‚Ä¶,en,0.0,1622.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,220.0,90.0,https://twitter.com/HoratiuOlteanu/statuses/1305838782260928512,0.0,0.0,,0.0,0.0,0.0,90.0,220.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @VincentRK: 4 key slides from my talk on ‚ÄúHow I Treat Newly Diagnosed Myeloma‚Äù at #ASHMHM20 @ASH_hematology meeting. @MayoCancerCare @Ma‚Ä¶,true
JulioChavezMD,"Malignant Hematology at Moffitt Cancer Center, Lymphoma physician, Immunotherapy. Tweets are my own views",,"Tampa, FL",,2020-09-15 10:35:15+00:00,Julio Chavez,http://twitter.com/,44.0,,1.305817448797569e+18,,0.0,0.0,,"RT @EHA_Hematology: Today on #WorldLymphomaAwarenessDay, #EHA is joining @knowyournodes &amp; the global #lymphoma community in giving A World‚Ä¶",en,0.0,78.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,31.0,13.0,https://twitter.com/JulioChavezMD/statuses/1305817448797569024,0.0,0.0,,0.0,0.0,0.0,13.0,31.0,False,False,False,False,True,Disease Advocacy,0.0,0.0,1.0,"RT @EHA_Hematology: Today on #WorldLymphomaAwarenessDay, #EHA is joining @knowyournodes &amp; the global #lymphoma community in giving A World‚Ä¶",true
DrMCanales,"Hematologist MD, PhD #LaPazHospital4U, Head Hematology Clinic Unit @hematoLaPaz, Associate Professor of Medicine @UAM_Medicina, #hematology #lymphoma #bmtsm",,"Madrid, Spain",,2020-09-15 06:09:30+00:00,Miguel Canales,http://twitter.com/,44.0,,1.3057505722310203e+18,,0.0,0.0,,"RT @EHA_Hematology: Today on #WorldLymphomaAwarenessDay, #EHA is joining @knowyournodes &amp; the global #lymphoma community in giving A World‚Ä¶",en,0.0,1819.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,31.0,13.0,https://twitter.com/DrMCanales/statuses/1305750572231020545,0.0,0.0,,0.0,0.0,0.0,13.0,31.0,False,False,False,False,True,Disease Advocacy,0.0,0.0,1.0,"RT @EHA_Hematology: Today on #WorldLymphomaAwarenessDay, #EHA is joining @knowyournodes &amp; the global #lymphoma community in giving A World‚Ä¶",true
pb10_bmt,"MD, DM, Assistant Professor,
Clinical Hematology-Oncology, and Stem Cell Transplantation at DMC Ludhiana, Punjab.  Lifelong student!!",,"Punjab, India",,2020-09-15 02:21:46+00:00,Suvir Singh,http://twitter.com/,310.0,,1.3056932621207962e+18,,0.0,0.0,,RT @VincentRK: 4 key slides from my talk on ‚ÄúHow I Treat Newly Diagnosed Myeloma‚Äù at #ASHMHM20 @ASH_hematology meeting. @MayoCancerCare @Ma‚Ä¶,en,0.0,919.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,220.0,90.0,https://twitter.com/pb10_bmt/statuses/1305693262120796160,0.0,0.0,,0.0,0.0,0.0,90.0,220.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @VincentRK: 4 key slides from my talk on ‚ÄúHow I Treat Newly Diagnosed Myeloma‚Äù at #ASHMHM20 @ASH_hematology meeting. @MayoCancerCare @Ma‚Ä¶,false
BroeckelmannPJ,"MD @UKKoeln & Physician Scientist Postdoc @MPIAGE. Hemato-Oncology. Lymphoma. Immunotherapies. DNA damage. Personal opinion, RT/like ‚â† endorsement.",,"Cologne, Germany",,2020-09-15 06:40:06+00:00,Paul Br√∂ckelmann,http://twitter.com/,44.0,,1.3057582725326848e+18,,0.0,0.0,,"RT @EHA_Hematology: Today on #WorldLymphomaAwarenessDay, #EHA is joining @knowyournodes &amp; the global #lymphoma community in giving A World‚Ä¶",en,0.0,243.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,31.0,13.0,https://twitter.com/BroeckelmannPJ/statuses/1305758272532684800,0.0,0.0,,0.0,0.0,0.0,13.0,31.0,False,False,False,False,True,Disease Advocacy,0.0,0.0,1.0,"RT @EHA_Hematology: Today on #WorldLymphomaAwarenessDay, #EHA is joining @knowyournodes &amp; the global #lymphoma community in giving A World‚Ä¶",true
Hammad2286,"MBBS, FCPS Med, Resident Clinical Haem
#physician #internalmedicine #hemepath #pocus",,,,2020-09-15 14:26:33+00:00,Hammad,http://twitter.com/,310.0,,1.3058756583761756e+18,,0.0,0.0,,RT @VincentRK: 4 key slides from my talk on ‚ÄúHow I Treat Newly Diagnosed Myeloma‚Äù at #ASHMHM20 @ASH_hematology meeting. @MayoCancerCare @Ma‚Ä¶,en,0.0,106.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,220.0,90.0,https://twitter.com/Hammad2286/statuses/1305875658376175621,0.0,0.0,,0.0,0.0,0.0,90.0,220.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @VincentRK: 4 key slides from my talk on ‚ÄúHow I Treat Newly Diagnosed Myeloma‚Äù at #ASHMHM20 @ASH_hematology meeting. @MayoCancerCare @Ma‚Ä¶,true
shoukry58,TELEMEDICNE DOCTOR . SENIOR CONSULTANT OF INTEGRATIVE DERMATOLOGY & INTEGRATIVE ANDROLOGY,,EGYPT,,2020-09-15 03:57:20+00:00,SHOUKRY SAKR,http://twitter.com/,163.0,,1.30571730995746e+18,,0.0,0.0,,"RT @pppapin: Hard to keep track of everything right now, but it appears recent designated #TD21 (formerly Invest #97L) just west of the Cap‚Ä¶",en,0.0,74.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,144.0,19.0,https://twitter.com/shoukry58/statuses/1305717309957459969,0.0,0.0,,0.0,0.0,0.0,19.0,144.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,"RT @pppapin: Hard to keep track of everything right now, but it appears recent designated #TD21 (formerly Invest #97L) just west of the Cap‚Ä¶",true
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-10-12 23:21:56+00:00,Cardiovascular Research Foundation,http://twitter.com/,16.0,,1.3157948650835515e+18,,0.0,0.0,,"Follow our #TCTConnect Social Media Ambassadors! With their vast experience and expertise, they‚Äôll help you get a u‚Ä¶ https://t.co/fBtfGQ4CMY",en,0.0,12239.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,16.0,https://twitter.com/crfheart/statuses/1315794865083551744,0.0,0.0,,0.0,0.0,0.0,16.0,0.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,"Follow our #TCTConnect Social Media Ambassadors! With their vast experience and expertise, they‚Äôll help you get a u‚Ä¶ https://t.co/fBtfGQ4CMY",true
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-10-12 12:12:00+00:00,Cardiovascular Research Foundation,http://twitter.com/,21.0,,1.3156262705421722e+18,,0.0,0.0,,"RT @heartdoc45: TCT week is here! TCT week is here!

Mastering Bifurcation PCI #Innovation session at #TCT2020 Wednesday at 0700 EST

Free‚Ä¶",en,0.0,12239.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,15.0,6.0,https://twitter.com/crfheart/statuses/1315626270542172161,0.0,0.0,,0.0,0.0,0.0,6.0,15.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @heartdoc45: TCT week is here! TCT week is here!

Mastering Bifurcation PCI #Innovation session at #TCT2020 Wednesday at 0700 EST

Free‚Ä¶",true
chadialraies,Heart doctor @DMC_Heals Clinician researcher educator #CHIP #PAD #RadialFirst - Founder: https://t.co/CRHKx6HNVb Pub: https://t.co/h3aHzr1oGU -Tweet=my opinion,,"Detroit, MI",,2020-10-12 23:19:24+00:00,"M Chadi Alraies, MD FACC",http://twitter.com/,21.0,,1.3157942278555894e+18,,0.0,0.0,,"RT @heartdoc45: TCT week is here! TCT week is here!

Mastering Bifurcation PCI #Innovation session at #TCT2020 Wednesday at 0700 EST

Free‚Ä¶",en,0.0,21439.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,15.0,6.0,https://twitter.com/chadialraies/statuses/1315794227855589376,0.0,0.0,,0.0,0.0,0.0,6.0,15.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @heartdoc45: TCT week is here! TCT week is here!

Mastering Bifurcation PCI #Innovation session at #TCT2020 Wednesday at 0700 EST

Free‚Ä¶",false
heartdoc45,Interventional Cardiologist at @CardioInstitute; Ochsner/Scripps trained; Pearl Jam enthusiast. Views expressed are my own. #RadialFirst,,"Lafayette, Louisiana",,2020-10-04 14:02:16+00:00,"David Homan, MD",http://twitter.com/,0.0,,1.3127549161721938e+18,,0.0,0.0,,"@bostonsci is sponsoring an #Innovation session at #TCT2020 titled ""Contemporary Tools &amp; Techniques for Complete Re‚Ä¶ https://t.co/iMSDNE1r3d",en,0.0,6040.0,,,0.0,bostonsci,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/heartdoc45/statuses/1312754916172193794,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"@bostonsci is sponsoring an #Innovation session at #TCT2020 titled ""Contemporary Tools &amp; Techniques for Complete Re‚Ä¶ https://t.co/iMSDNE1r3d",true
BSCCardiology,Boston Scientific Cardiology. We invite physicians in the U.S. to learn about our cardiology & electrophysiology therapies and devices. https://t.co/yQRZwwXVRr,,"St Paul, MN",,2020-10-06 22:00:37+00:00,BostonSci Cardiology,http://twitter.com/,4.0,,1.3136000743756677e+18,,0.0,0.0,,Mark your #TCTConnect calendar for the Symposium: WATCHMAN‚Ñ¢ FLX: Elevating LAAC Therapy Through Innovation &amp; Clinic‚Ä¶ https://t.co/Y3P6mPpAH2,en,0.0,23588.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,4.0,https://twitter.com/BSCCardiology/statuses/1313600074375667713,0.0,0.0,,0.0,0.0,0.0,4.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,Mark your #TCTConnect calendar for the Symposium: WATCHMAN‚Ñ¢ FLX: Elevating LAAC Therapy Through Innovation &amp; Clinic‚Ä¶ https://t.co/Y3P6mPpAH2,true
M_Pompeu_Sa_MD,"MD, MSc, PhD | PGY-6 Cardiovascular Surgery Resident | Associate Editor, @ESC_Journals #EHJCaseReports | Passionate about foreign languages...",,"Recife, Brasilien",,2020-10-22 12:30:01+00:00,Michel Pompeu S√°,http://twitter.com/,32.0,,1.3192546842726482e+18,,0.0,0.0,,"RT @Argenscore: CARDIAC CLASSIFICATION: ‚ÄúAORTIC STENOSIS-DISEASE‚Äù
@PhilGenereuxMD et al.

1661 p from the PARTNER TRIAL

#TCT2020 #TCTConne‚Ä¶",en,0.0,1075.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,23.0,9.0,https://twitter.com/M_Pompeu_Sa_MD/statuses/1319254684272648192,0.0,0.0,,0.0,0.0,0.0,9.0,23.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,"RT @Argenscore: CARDIAC CLASSIFICATION: ‚ÄúAORTIC STENOSIS-DISEASE‚Äù
@PhilGenereuxMD et al.

1661 p from the PARTNER TRIAL

#TCT2020 #TCTConne‚Ä¶",true
JerroldLevy,"Critical care physician in CTICU @DukeMedSchool, interested in coagulation, bleeding, inflammation-also oenophile and foody. Tweets are my own (‚â†medical advice)",,"Durham, North Carolina",,2020-10-21 14:59:12+00:00,"Jerrold Levy, MD",http://twitter.com/,67.0,,1.3189298368119767e+18,,0.0,0.0,,RT @ASH_hematology: @NIAIDNews Director Dr. Anthony Fauci is the #ASH20 keynote speaker! Join ASH President @StephanieLeeMD &amp; Dr. Fauci as‚Ä¶,en,0.0,1755.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,49.0,18.0,https://twitter.com/JerroldLevy/statuses/1318929836811976704,0.0,0.0,,0.0,0.0,0.0,18.0,49.0,False,False,False,False,True,Thought Leadership,0.0,0.0,1.0,RT @ASH_hematology: @NIAIDNews Director Dr. Anthony Fauci is the #ASH20 keynote speaker! Join ASH President @StephanieLeeMD &amp; Dr. Fauci as‚Ä¶,true
drjgauthier,"MD, MSc, Assistant Professor @fredhutch @UW focused on #CARTcell #immunotherapy #tcellrx 
Interests also include #rstats #bmtsm #epitwitter #bayes",,"Seattle, WA",,2020-08-30 14:56:58+00:00,Jordan Gauthier,http://twitter.com/,37.0,,1.3000851085195182e+18,,0.0,0.0,,"RT @DrMiguelPerales: #EBMT20 #EBMT20virtual CD34+ Allo HCT, &lt; GVHD, no increase in relapse, Better CRFS - Waiting for results of @BMTCTN 13‚Ä¶",en,0.0,3295.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,27.0,10.0,https://twitter.com/drjgauthier/statuses/1300085108519518208,0.0,0.0,,0.0,0.0,0.0,10.0,27.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @DrMiguelPerales: #EBMT20 #EBMT20virtual CD34+ Allo HCT, &lt; GVHD, no increase in relapse, Better CRFS - Waiting for results of @BMTCTN 13‚Ä¶",true
HemOncWomenDocs,Worldwide network of 1400+ women heme/onc subspecialty physicians #medonc #surgonc #pallonc #radonc #gynonc #PHOdocs #HOWPG #wolfpack #SheForShe #TimesUpHC,,,,2020-10-21 14:10:50+00:00,Hematology & Oncology Women Physician Group,http://twitter.com/,29.0,,1.3189176676344832e+18,,0.0,0.0,,RT @seethal_jacobmd: How excited am I about #ASH20?! Dr. Fauci is the keynote speaker!,en,0.0,3531.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,25.0,4.0,https://twitter.com/HemOncWomenDocs/statuses/1318917667634483200,0.0,0.0,,0.0,0.0,0.0,4.0,25.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,RT @seethal_jacobmd: How excited am I about #ASH20?! Dr. Fauci is the keynote speaker!,false
HemOncWomenDocs,Worldwide network of 1400+ women heme/onc subspecialty physicians #medonc #surgonc #pallonc #radonc #gynonc #PHOdocs #HOWPG #wolfpack #SheForShe #TimesUpHC,,,,2020-10-21 14:10:39+00:00,Hematology & Oncology Women Physician Group,http://twitter.com/,67.0,,1.3189176207798804e+18,,0.0,0.0,,RT @ASH_hematology: @NIAIDNews Director Dr. Anthony Fauci is the #ASH20 keynote speaker! Join ASH President @StephanieLeeMD &amp; Dr. Fauci as‚Ä¶,en,0.0,3531.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,49.0,18.0,https://twitter.com/HemOncWomenDocs/statuses/1318917620779880448,0.0,0.0,,0.0,0.0,0.0,18.0,49.0,False,False,False,False,True,Thought Leadership,0.0,0.0,1.0,RT @ASH_hematology: @NIAIDNews Director Dr. Anthony Fauci is the #ASH20 keynote speaker! Join ASH President @StephanieLeeMD &amp; Dr. Fauci as‚Ä¶,true
MatthewChungMD,Structural/Interventional Cardiologist @VirginiaCardio. Via @MedicineUVA Med School | @IMResidencyDuke | @WUSTLmed Cards/IC | @DukeCardiology Structural Heart,,"Richmond, VA",,2020-10-17 03:10:47+00:00,Matthew J. Chung,http://twitter.com/,24.0,,1.3173020091381883e+18,,0.0,0.0,,RT @hahn_rt: New Technology: MitraClip G4 and PASCAL https://t.co/Rv2B0hhjS9 #TCTConnect #TCT2020 @ACCinTouch @ASE360 @TCTMD #echofirst @PS‚Ä¶,en,0.0,332.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,16.0,8.0,https://twitter.com/MatthewChungMD/statuses/1317302009138188288,0.0,0.0,,0.0,0.0,0.0,8.0,16.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @hahn_rt: New Technology: MitraClip G4 and PASCAL https://t.co/Rv2B0hhjS9 #TCTConnect #TCT2020 @ACCinTouch @ASE360 @TCTMD #echofirst @PS‚Ä¶,true
VijayKunadian,Academic Interventional Cardiologist | Heart Disease Researcher @UniofNewcastle @NewcastleHosps | Views here are my own opinion & thinking üòä,,"Newcastle Upon Tyne, England",,2020-10-17 17:24:58+00:00,Vijay Kunadian,http://twitter.com/,35.0,,1.3175169706575012e+18,,0.0,0.0,,"RT @Drroxmehran: Long-term (5y) data from #PARTNER-2 registry (n=365) showed comparable clinical outcomes between ViV and Native TAVR pts,‚Ä¶",en,0.0,3389.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,25.0,10.0,https://twitter.com/VijayKunadian/statuses/1317516970657501186,0.0,0.0,,0.0,0.0,0.0,10.0,25.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,"RT @Drroxmehran: Long-term (5y) data from #PARTNER-2 registry (n=365) showed comparable clinical outcomes between ViV and Native TAVR pts,‚Ä¶",true
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-10-17 11:00:50+00:00,Cardiovascular Research Foundation,http://twitter.com/,1.0,,1.317420298585727e+18,,0.0,0.0,,Ready to enhance your learning during #TCTConnect with E-Satellite Programs? Watch dynamic educational programs hig‚Ä¶ https://t.co/vjxGzlXIff,en,0.0,12239.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/crfheart/statuses/1317420298585726976,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Disease Advocacy,1.0,0.0,0.0,Ready to enhance your learning during #TCTConnect with E-Satellite Programs? Watch dynamic educational programs hig‚Ä¶ https://t.co/vjxGzlXIff,true
chadialraies,Heart doctor @DMC_Heals Clinician researcher educator #CHIP #PAD #RadialFirst - Founder: https://t.co/CRHKx6HNVb Pub: https://t.co/h3aHzr1oGU -Tweet=my opinion,,"Detroit, MI",,2020-10-17 11:31:25+00:00,"M Chadi Alraies, MD FACC",http://twitter.com/,1.0,,1.3174279945799025e+18,,0.0,0.0,,RT @crfheart: Ready to enhance your learning during #TCTConnect with E-Satellite Programs? Watch dynamic educational programs highlighting‚Ä¶,en,0.0,21439.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/chadialraies/statuses/1317427994579902464,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Disease Advocacy,1.0,0.0,0.0,RT @crfheart: Ready to enhance your learning during #TCTConnect with E-Satellite Programs? Watch dynamic educational programs highlighting‚Ä¶,true
BSCCardiology,Boston Scientific Cardiology. We invite physicians in the U.S. to learn about our cardiology & electrophysiology therapies and devices. https://t.co/yQRZwwXVRr,,"St Paul, MN",,2020-10-15 18:30:26+00:00,BostonSci Cardiology,http://twitter.com/,1.0,,1.3168086679084485e+18,,0.0,0.0,,Attend the #TCTConnect Symposium TODAY at 3 pm EST - WATCHMAN‚Ñ¢ FLX: Elevating LAAC Therapy Through Innovation &amp; Cli‚Ä¶ https://t.co/N6rn3mBBaU,en,0.0,23588.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/BSCCardiology/statuses/1316808667908448257,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,Attend the #TCTConnect Symposium TODAY at 3 pm EST - WATCHMAN‚Ñ¢ FLX: Elevating LAAC Therapy Through Innovation &amp; Cli‚Ä¶ https://t.co/N6rn3mBBaU,false
pcalvachi1,"MD,MSc - Masters‚Äô student @HarvardDBMI, Postdoc fellow @BWH, @Harvardmed -Producer and Host @MioCardioPod üéô- Latina üá®üá¥",,"Boston, MA",,2020-10-15 13:47:09+00:00,Paola Calvachi,http://twitter.com/,39.0,,1.3167373774450524e+18,,0.0,0.0,,RT @jgranadacrf: Innovation Shark-Tank #TCTConnect starts today (11:00-AM EST @ Innovation Channel). 3 technologies will present today and‚Ä¶,en,0.0,275.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,23.0,16.0,https://twitter.com/pcalvachi1/statuses/1316737377445052416,0.0,0.0,,0.0,0.0,0.0,16.0,23.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @jgranadacrf: Innovation Shark-Tank #TCTConnect starts today (11:00-AM EST @ Innovation Channel). 3 technologies will present today and‚Ä¶,true
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-10-15 11:01:14+00:00,Cardiovascular Research Foundation,http://twitter.com/,0.0,,1.3166956247844577e+18,,0.0,0.0,,Ready to enhance your learning during #TCTConnect with E-Satellite Programs? Watch dynamic educational programs hig‚Ä¶ https://t.co/yFBtlex24B,en,0.0,12239.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/crfheart/statuses/1316695624784457728,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Disease Advocacy,1.0,0.0,0.0,Ready to enhance your learning during #TCTConnect with E-Satellite Programs? Watch dynamic educational programs hig‚Ä¶ https://t.co/yFBtlex24B,true
sbrugaletta,"üáÆüáπInterventional Cardiologist at @HospitalClinic & @Barnaclinic, Associate prof @UniBarcelona, Editor-in-chief @pcronline, #SoMe Editor @eurointerventio",,"Barcellona, Spagna",,2020-10-15 15:52:36+00:00,Salvatore Brugaletta,http://twitter.com/,8.0,,1.3167689488352911e+18,,0.0,0.0,,Filter in TAVI is not more effective but safe. should we use it in specific subgroup of patients? #TAVR #TCTConnect‚Ä¶ https://t.co/0XVw7CCG4y,en,0.0,6753.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,8.0,https://twitter.com/sbrugaletta/statuses/1316768948835291137,0.0,0.0,,0.0,0.0,0.0,8.0,0.0,False,False,False,False,True,Drug Comparisons,0.0,0.0,1.0,Filter in TAVI is not more effective but safe. should we use it in specific subgroup of patients? #TAVR #TCTConnect‚Ä¶ https://t.co/0XVw7CCG4y,true
heartdoc45,Interventional Cardiologist at @CardioInstitute; Ochsner/Scripps trained; Pearl Jam enthusiast. Views expressed are my own. #RadialFirst,,"Lafayette, Louisiana",,2020-10-15 17:56:00+00:00,"David Homan, MD",http://twitter.com/,0.0,,1.3168000033907384e+18,,0.0,0.0,,#Innovation Trends in MedTech II: Vascular Therapies going on now. The SoundBite device caught my eye. Interesting‚Ä¶ https://t.co/tjaspfCwrX,en,0.0,6040.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/heartdoc45/statuses/1316800003390738433,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,#Innovation Trends in MedTech II: Vascular Therapies going on now. The SoundBite device caught my eye. Interesting‚Ä¶ https://t.co/tjaspfCwrX,true
ShaziaTHussain1,Interventional Cardiologist. Mother of 3 teenage boys  ! DIY enthusiast. In search of an authentic life. Tweets my own.,,Leicester England,,2020-10-15 14:52:23+00:00,Shazia T Hussain,http://twitter.com/,61.0,,1.3167537940934615e+18,,0.0,0.0,,RT @heartdoc45: Loving the current live case at #TCTConnect! Challenging calcified PCI with Impella support. Excellent panel and @DrBillLom‚Ä¶,en,0.0,1181.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,51.0,10.0,https://twitter.com/ShaziaTHussain1/statuses/1316753794093461511,0.0,0.0,,0.0,0.0,0.0,10.0,51.0,False,False,False,False,True,Cost of Care,1.0,0.0,0.0,RT @heartdoc45: Loving the current live case at #TCTConnect! Challenging calcified PCI with Impella support. Excellent panel and @DrBillLom‚Ä¶,true
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-10-15 14:45:05+00:00,Cardiovascular Research Foundation,http://twitter.com/,1.0,,1.3167519575503995e+18,,0.0,0.0,,Step into the #TCT2020 Shark Tank! Tune in at 11:00 AM ET to watch the first 3 teams compete for the top innovation‚Ä¶ https://t.co/uctSAzYJFU,en,0.0,12239.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/crfheart/statuses/1316751957550399488,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,Step into the #TCT2020 Shark Tank! Tune in at 11:00 AM ET to watch the first 3 teams compete for the top innovation‚Ä¶ https://t.co/uctSAzYJFU,false
BSCCardiology,Boston Scientific Cardiology. We invite physicians in the U.S. to learn about our cardiology & electrophysiology therapies and devices. https://t.co/yQRZwwXVRr,,"St Paul, MN",,2020-10-15 20:00:38+00:00,BostonSci Cardiology,http://twitter.com/,3.0,,1.3168313666260623e+18,,0.0,0.0,,Join us on #TCTConnect for an FDA-Approved WATCHMAN FLX‚Ñ¢ #LAAC live case ‚Äì happening now!  #TCT2020 https://t.co/0o3R44nt7U,en,0.0,23588.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/BSCCardiology/statuses/1316831366626062341,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,Join us on #TCTConnect for an FDA-Approved WATCHMAN FLX‚Ñ¢ #LAAC live case ‚Äì happening now!  #TCT2020 https://t.co/0o3R44nt7U,true
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-10-15 16:30:27+00:00,Cardiovascular Research Foundation,http://twitter.com/,1.0,,1.3167784727154975e+18,,0.0,0.0,,Next up on at 1:00 PM ET on the #TCTConnect Innovation Channel: A session on the latest trends in #MedTech for‚Ä¶ https://t.co/w95XVOWXjb,en,0.0,12239.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/crfheart/statuses/1316778472715497474,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,Next up on at 1:00 PM ET on the #TCTConnect Innovation Channel: A session on the latest trends in #MedTech for‚Ä¶ https://t.co/w95XVOWXjb,true
AkhilGulati,Interventional Cardiologist @ Beaumont Michigan Heart Group. Northwestern alum. Husband to @govani. Detroiter always.,,"Michigan, USA",,2020-10-15 16:46:56+00:00,Akhil Gulati MD,http://twitter.com/,61.0,,1.3167826233190892e+18,,0.0,0.0,,RT @heartdoc45: Loving the current live case at #TCTConnect! Challenging calcified PCI with Impella support. Excellent panel and @DrBillLom‚Ä¶,en,0.0,688.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,51.0,10.0,https://twitter.com/AkhilGulati/statuses/1316782623319089152,0.0,0.0,,0.0,0.0,0.0,10.0,51.0,False,False,False,False,True,Cost of Care,1.0,0.0,0.0,RT @heartdoc45: Loving the current live case at #TCTConnect! Challenging calcified PCI with Impella support. Excellent panel and @DrBillLom‚Ä¶,true
JGrapsa,Consultant Cardiologist GSTT - Editor in chief #JACCcasereports -Secretary ESC council on VHD - Tweets are my own opinion#,,,,2020-10-15 08:11:33+00:00,Julia Grapsa,http://twitter.com/,6.0,,1.316652921338069e+18,,0.0,0.0,,RT @fischman_david: 5 Things to Watch for on Thurs @TCTConference #TCTConnect #TCT2020 My favorite ‚ÄúShark Tank‚Äù where innovation comes to t‚Ä¶,en,0.0,11060.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,1.0,https://twitter.com/JGrapsa/statuses/1316652921338068992,0.0,0.0,,0.0,0.0,0.0,1.0,5.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @fischman_david: 5 Things to Watch for on Thurs @TCTConference #TCTConnect #TCT2020 My favorite ‚ÄúShark Tank‚Äù where innovation comes to t‚Ä¶,true
NavinKapur4,Interventional Heart Failure Specialist; Physician-Scientist,,,,2020-10-15 17:38:38+00:00,Navin Kapur,http://twitter.com/,39.0,,1.3167956347212063e+18,,0.0,0.0,,RT @jgranadacrf: Innovation Shark-Tank #TCTConnect starts today (11:00-AM EST @ Innovation Channel). 3 technologies will present today and‚Ä¶,en,0.0,1408.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,23.0,16.0,https://twitter.com/NavinKapur4/statuses/1316795634721206272,0.0,0.0,,0.0,0.0,0.0,16.0,23.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @jgranadacrf: Innovation Shark-Tank #TCTConnect starts today (11:00-AM EST @ Innovation Channel). 3 technologies will present today and‚Ä¶,true
OPreventzaMD,"Cardiac Surgeon, Prof. Surg with Tenure , Baylor College of Medicine , President Elect of ISEVS, WTS Adult Cardiac Surg representative . Leadership, HC Policy",,"Houston, TX",,2020-10-15 01:56:45+00:00,Ourania Preventza,http://twitter.com/,33.0,,1.3165586015998034e+18,,0.0,0.0,,"RT @JGrapsa: Inspiring the next generation, promoting innovation &amp; clinical excellence, @ACCinTouch together with @crfheart introduce Marti‚Ä¶",en,0.0,2276.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,23.0,10.0,https://twitter.com/OPreventzaMD/statuses/1316558601599803392,0.0,0.0,,0.0,0.0,0.0,10.0,23.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"RT @JGrapsa: Inspiring the next generation, promoting innovation &amp; clinical excellence, @ACCinTouch together with @crfheart introduce Marti‚Ä¶",false
ajaykirtane,"Practicing Cardiologist, Professor @ColumbiaMed
Researcher & advocate for thoughtful patient care; tweets‚â†endorsements nor med advice
https://t.co/YyilZMYayJ",,NewYork-Presbyterian & beyond,,2020-10-15 16:49:51+00:00,Ajay Kirtane MD SM,http://twitter.com/,39.0,,1.3167833573431378e+18,,0.0,0.0,,RT @jgranadacrf: Innovation Shark-Tank #TCTConnect starts today (11:00-AM EST @ Innovation Channel). 3 technologies will present today and‚Ä¶,en,0.0,17044.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,23.0,16.0,https://twitter.com/ajaykirtane/statuses/1316783357343137794,0.0,0.0,,0.0,0.0,0.0,16.0,23.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @jgranadacrf: Innovation Shark-Tank #TCTConnect starts today (11:00-AM EST @ Innovation Channel). 3 technologies will present today and‚Ä¶,true
Hragy,"Cardiologist, National Heart Institute, Egypt ÿ±ÿ¨ÿßÿ° ÿπÿØŸÖ ÿßŸÑÿ™ŸàÿßÿµŸÑ ÿ®ÿ¥ÿ£ŸÜ ÿ¥ÿ§ŸàŸÜ ÿ∑ÿ®Ÿäÿ© ÿÆÿßÿµÿ© ÿπŸÑŸä ÿ™ŸàŸäÿ™ÿ±",,egypt,,2020-10-15 06:07:24+00:00,Hany Ragy,http://twitter.com/,17.0,,1.316621680366809e+18,,0.0,0.0,,"RT @TCTConference: Day 2 of #TCTConnect features live cases, late-breaking trials, and the #TCT2020 Shark Tank #Innovation competition. Joi‚Ä¶",en,0.0,31448.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,12.0,5.0,https://twitter.com/Hragy/statuses/1316621680366809088,0.0,0.0,,0.0,0.0,0.0,5.0,12.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @TCTConference: Day 2 of #TCTConnect features live cases, late-breaking trials, and the #TCT2020 Shark Tank #Innovation competition. Joi‚Ä¶",true
aymanka,"interventional cardiologist ( ex SCAI BOT ,ex Washington Hospital Center ) runner , diver , NFL . lucky to be in a profession that keeps you learning !",,,,2020-10-15 11:18:39+00:00,Ayman Magd,http://twitter.com/,17.0,,1.3167000077441024e+18,,0.0,0.0,,"RT @TCTConference: Day 2 of #TCTConnect features live cases, late-breaking trials, and the #TCT2020 Shark Tank #Innovation competition. Joi‚Ä¶",en,0.0,3854.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,12.0,5.0,https://twitter.com/aymanka/statuses/1316700007744102400,0.0,0.0,,0.0,0.0,0.0,5.0,12.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @TCTConference: Day 2 of #TCTConnect features live cases, late-breaking trials, and the #TCT2020 Shark Tank #Innovation competition. Joi‚Ä¶",true
heartdoc45,Interventional Cardiologist at @CardioInstitute; Ochsner/Scripps trained; Pearl Jam enthusiast. Views expressed are my own. #RadialFirst,,"Lafayette, Louisiana",,2020-10-15 12:55:33+00:00,"David Homan, MD",http://twitter.com/,3.0,,1.316724393792467e+18,,0.0,0.0,,Great #Innovation session happening now at #TCTConnect re: Managing Calcified CAD with @KateKearney4 @cathjockey72‚Ä¶ https://t.co/5ipDe4RH4p,en,0.0,6040.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/heartdoc45/statuses/1316724393792466944,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,Great #Innovation session happening now at #TCTConnect re: Managing Calcified CAD with @KateKearney4 @cathjockey72‚Ä¶ https://t.co/5ipDe4RH4p,true
aymanka,"interventional cardiologist ( ex SCAI BOT ,ex Washington Hospital Center ) runner , diver , NFL . lucky to be in a profession that keeps you learning !",,,,2020-10-15 11:11:50+00:00,Ayman Magd,http://twitter.com/,26.0,,1.316698291871142e+18,,0.0,0.0,,RT @mmamas1973: #TCTConnect if you missed the LBT session can see livestream below @CardioIAN @billgogas @GiuseppeGalati_ @gbiondizoccai @h‚Ä¶,en,0.0,3854.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,18.0,8.0,https://twitter.com/aymanka/statuses/1316698291871141889,0.0,0.0,,0.0,0.0,0.0,8.0,18.0,False,False,False,False,True,Disease Management,0.0,0.0,1.0,RT @mmamas1973: #TCTConnect if you missed the LBT session can see livestream below @CardioIAN @billgogas @GiuseppeGalati_ @gbiondizoccai @h‚Ä¶,true
ajaykirtane,"Practicing Cardiologist, Professor @ColumbiaMed
Researcher & advocate for thoughtful patient care; tweets‚â†endorsements nor med advice
https://t.co/YyilZMYayJ",,NewYork-Presbyterian & beyond,,2020-10-15 01:01:18+00:00,Ajay Kirtane MD SM,http://twitter.com/,17.0,,1.316544647557251e+18,,0.0,0.0,,"RT @TCTConference: Day 2 of #TCTConnect features live cases, late-breaking trials, and the #TCT2020 Shark Tank #Innovation competition. Joi‚Ä¶",en,0.0,17044.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,12.0,5.0,https://twitter.com/ajaykirtane/statuses/1316544647557251073,0.0,0.0,,0.0,0.0,0.0,5.0,12.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @TCTConference: Day 2 of #TCTConnect features live cases, late-breaking trials, and the #TCT2020 Shark Tank #Innovation competition. Joi‚Ä¶",false
Hragy,"Cardiologist, National Heart Institute, Egypt ÿ±ÿ¨ÿßÿ° ÿπÿØŸÖ ÿßŸÑÿ™ŸàÿßÿµŸÑ ÿ®ÿ¥ÿ£ŸÜ ÿ¥ÿ§ŸàŸÜ ÿ∑ÿ®Ÿäÿ© ÿÆÿßÿµÿ© ÿπŸÑŸä ÿ™ŸàŸäÿ™ÿ±",,egypt,,2020-10-15 16:59:31+00:00,Hany Ragy,http://twitter.com/,0.0,,1.3167857890328986e+18,,0.0,0.0,,"#TCTConnect Xience90/28 conclusion 
My take : it‚Äôs good to know you can stop DAPT early with a leading stent, but t‚Ä¶ https://t.co/x7uxoE0T0J",en,0.0,31448.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/Hragy/statuses/1316785789032898560,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"#TCTConnect Xience90/28 conclusion 
My take : it‚Äôs good to know you can stop DAPT early with a leading stent, but t‚Ä¶ https://t.co/x7uxoE0T0J",true
Ortega_Paz,Interventional Cardiology Fellow @hospitalclinic | Postdoctoral researcher @idibaps | Social Media Team @eurointerventio | Editorial Team @PCRonline #EAPCI,,"Barcelona, Catalu√±a",,2020-10-15 16:02:51+00:00,Luis Ortega Paz,http://twitter.com/,22.0,,1.3167715278372209e+18,,0.0,0.0,,RT @sbrugaletta: Filter in TAVI is not more effective but safe. should we use it in specific subgroup of patients? #TAVR #TCTConnect @PCRon‚Ä¶,en,0.0,3089.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,14.0,8.0,https://twitter.com/Ortega_Paz/statuses/1316771527837220867,0.0,0.0,,0.0,0.0,0.0,8.0,14.0,False,False,False,False,True,Drug Comparisons,0.0,0.0,1.0,RT @sbrugaletta: Filter in TAVI is not more effective but safe. should we use it in specific subgroup of patients? #TAVR #TCTConnect @PCRon‚Ä¶,true
ajaykirtane,"Practicing Cardiologist, Professor @ColumbiaMed
Researcher & advocate for thoughtful patient care; tweets‚â†endorsements nor med advice
https://t.co/YyilZMYayJ",,NewYork-Presbyterian & beyond,,2020-10-15 16:50:18+00:00,Ajay Kirtane MD SM,http://twitter.com/,4.0,,1.316783470010491e+18,,0.0,0.0,,RT @chadialraies: #CADIII Presented meeting safety and efficacy endpoints congratulations the investigators - one more novel technology to‚Ä¶,en,0.0,17044.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,1.0,https://twitter.com/ajaykirtane/statuses/1316783470010490880,0.0,0.0,,0.0,0.0,0.0,1.0,3.0,False,False,False,False,True,Financial Performance,1.0,0.0,0.0,RT @chadialraies: #CADIII Presented meeting safety and efficacy endpoints congratulations the investigators - one more novel technology to‚Ä¶,true
aitawi1,Cardiologist. Proud Lebanese American. God above all. Better to die on your feet than live on your knees.,,United States,,2020-10-15 19:01:20+00:00,Wissam Gharib,http://twitter.com/,3.0,,1.3168164466729943e+18,,0.0,0.0,,RT @BSCCardiology: Attend the #TCTConnect Symposium TODAY at 3 pm EST - WATCHMAN‚Ñ¢ FLX: Elevating LAAC Therapy Through Innovation &amp; Clinical‚Ä¶,en,0.0,126.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,2.0,1.0,https://twitter.com/aitawi1/statuses/1316816446672994307,0.0,0.0,,0.0,0.0,0.0,1.0,2.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @BSCCardiology: Attend the #TCTConnect Symposium TODAY at 3 pm EST - WATCHMAN‚Ñ¢ FLX: Elevating LAAC Therapy Through Innovation &amp; Clinical‚Ä¶,true
reflowmedical,"We design and develop medical devices for treating cardiovascular disease, working with physicians on innovative solutions for improved patient outcomes.",,"San Clemente, CA",,2020-10-15 18:19:05+00:00,ReflowMedical,http://twitter.com/,1.0,,1.3168058121535775e+18,,0.0,0.0,,Big thanks to @Mustapja for representing in the Innovation Session! Temporary Spur Stent System clinical trial NCT0‚Ä¶ https://t.co/26Uz1jhK8U,en,0.0,283.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/reflowmedical/statuses/1316805812153577477,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,Big thanks to @Mustapja for representing in the Innovation Session! Temporary Spur Stent System clinical trial NCT0‚Ä¶ https://t.co/26Uz1jhK8U,true
Babar_Basir,"Interventional Cardiologist, #CTO #CHIP #MCS, Clinician & Researcher, #NationalCSI PI, Director of Acute MCS",,"Detroit, MI",,2020-10-20 02:05:28+00:00,Babar Basir,http://twitter.com/,43.0,,1.31837273420902e+18,,0.0,0.0,,"RT @AGoldsweig: @Babar_Basir, @BillONeillMD, &amp; @Mike_Hacala lead the virtual #NCSI investigators meeting after #TCT2020. 

So exciting to s‚Ä¶",en,0.0,6352.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,37.0,6.0,https://twitter.com/Babar_Basir/statuses/1318372734209019905,0.0,0.0,,0.0,0.0,0.0,6.0,37.0,False,False,False,False,True,Financial Performance,1.0,0.0,0.0,"RT @AGoldsweig: @Babar_Basir, @BillONeillMD, &amp; @Mike_Hacala lead the virtual #NCSI investigators meeting after #TCT2020. 

So exciting to s‚Ä¶",false
Transplant_Doc,Stem Cell Transplant physician and clinical researcher at MD Anderson Cancer Center; special interest in myeloma. Opinions expressed are my own,,,,2020-08-31 04:38:14+00:00,Muzaffar Qazilbash,http://twitter.com/,0.0,,1.3002917864396268e+18,,0.0,0.0,,The latest The Stem Cell Transplant Daily! https://t.co/LwSj67XOoE Thanks to @DrMiguelPerales @BldCancerDoc #ebmt20 #ebmt20virtual,en,0.0,5455.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/Transplant_Doc/statuses/1300291786439626752,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,The latest The Stem Cell Transplant Daily! https://t.co/LwSj67XOoE Thanks to @DrMiguelPerales @BldCancerDoc #ebmt20 #ebmt20virtual,true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-02-13 20:14:04+00:00,Oncology Tube,http://twitter.com/,0.0,,1.2280497239588086e+18,,0.0,0.0,,"Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American‚Ä¶ https://t.co/5bvrxTcR34",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1228049723958808576,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American‚Ä¶ https://t.co/5bvrxTcR34",true
DrMDavids,"Hematologist/oncologist, CLL researcher, director of #lymphoma clinical research @DanaFarber, faculty @harvardmed. Tweets are my own & not medical advice.",,"Boston, USA",,2020-12-03 13:24:07+00:00,"Matthew Davids, MD, MMSc",http://twitter.com/,46.0,,1.3344885870653194e+18,,0.0,0.0,,RT @anthonymatomd: Great collaboration planned between our centers. Meeting of three great friends at ASH 2019 will be virtual at #ASH2020‚Ä¶,en,0.0,2195.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,44.0,2.0,https://twitter.com/DrMDavids/statuses/1334488587065319424,0.0,0.0,,0.0,0.0,0.0,2.0,44.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @anthonymatomd: Great collaboration planned between our centers. Meeting of three great friends at ASH 2019 will be virtual at #ASH2020‚Ä¶,true
elimanasanch,Myeloma physician. Opinions are mine.,,"Houston, TX",,2020-12-09 13:24:26+00:00,Elisabet Manasanch,http://twitter.com/,49.0,,1.336662993350832e+18,,0.0,0.0,,"RT @michaelwangmd: We have an ongoing CAR T cell  trial for relapsed mantle cell lymphoma, this trial is open for enrollment. Good data wil‚Ä¶",en,0.0,280.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,39.0,10.0,https://twitter.com/elimanasanch/statuses/1336662993350832129,0.0,0.0,,0.0,0.0,0.0,10.0,39.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @michaelwangmd: We have an ongoing CAR T cell  trial for relapsed mantle cell lymphoma, this trial is open for enrollment. Good data wil‚Ä¶",true
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-09-23 12:09:26+00:00,Cardiovascular Research Foundation,http://twitter.com/,0.0,,1.3087402548710318e+18,,0.0,0.0,,Tune in to #TCTConnect to watch the TCT Shark Tank #Innovation Competition. #TCT2020 Register or FREE now!‚Ä¶ https://t.co/us3AzOswZn,en,0.0,12239.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/crfheart/statuses/1308740254871031808,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,Tune in to #TCTConnect to watch the TCT Shark Tank #Innovation Competition. #TCT2020 Register or FREE now!‚Ä¶ https://t.co/us3AzOswZn,true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-01-28 01:30:04+00:00,Oncology Tube,http://twitter.com/,0.0,,1.2219686506696786e+18,,0.0,0.0,,Magenta Therapeutics to Present New Clinical and Preclinical Data at American Society of Hematology (ASH) Annual Me‚Ä¶ https://t.co/SDUk6uvwXt,en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1221968650669678592,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,Magenta Therapeutics to Present New Clinical and Preclinical Data at American Society of Hematology (ASH) Annual Me‚Ä¶ https://t.co/SDUk6uvwXt,false
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-01-19 16:50:04+00:00,Oncology Tube,http://twitter.com/,0.0,,1.2189386853216666e+18,,0.0,0.0,,Verastem Oncology Presents Phase 2 PRIMO Study Data Evaluating Duvelisib in Relapsed or Refractory Peripheral T-Cel‚Ä¶ https://t.co/g0qMMQr6jb,en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1218938685321666560,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,Verastem Oncology Presents Phase 2 PRIMO Study Data Evaluating Duvelisib in Relapsed or Refractory Peripheral T-Cel‚Ä¶ https://t.co/g0qMMQr6jb,true
Adrianapordios,"Physician, Master in Public Health & Epidemiology, Hematology and Medical Affairs. Opinions are my own",,,,2020-01-28 01:40:24+00:00,Adriana Aguilar,http://twitter.com/,14.0,,1.2219712517088092e+18,,0.0,0.0,,RT @ASHClinicalNews: The @US_FDA and @ASH_hematology partnered to bring hematologists practical information about newly approved agents dur‚Ä¶,en,0.0,456.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,9.0,5.0,https://twitter.com/Adrianapordios/statuses/1221971251708809223,0.0,0.0,,0.0,0.0,0.0,5.0,9.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,RT @ASHClinicalNews: The @US_FDA and @ASH_hematology partnered to bring hematologists practical information about newly approved agents dur‚Ä¶,true
docdeepika,"Pediatrician, Public Health Specialist & Clinical Scientist. A rare breed focusing on complete lifecourse approach & Health Systems with a scientific lens",,India,,2020-10-07 13:31:14+00:00,Dr. Deepika Saraf,http://twitter.com/,111.0,,1.3138342682551665e+18,,0.0,0.0,,RT @nvpatkar: Thrilled to know that we will be presenting @India_Alliance funded research on #AMLMRD using error corrected #NGS as oral pre‚Ä¶,en,0.0,504.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,102.0,9.0,https://twitter.com/docdeepika/statuses/1313834268255166464,0.0,0.0,,0.0,0.0,0.0,9.0,102.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @nvpatkar: Thrilled to know that we will be presenting @India_Alliance funded research on #AMLMRD using error corrected #NGS as oral pre‚Ä¶,true
hematologymd,Hematologist/Stem cell transplanter/Oncologist/Palliative care proponent via @mayoclinic @uconnhealth #BMTsm #leusm #gvhdsm #CARTcell #immunoonc. RT‚â† endorse,,"Rhode Island, USA",,2020-10-16 20:16:41+00:00,Kapil Meleveedu,http://twitter.com/,9.0,,1.3171977937490944e+18,,0.0,0.0,,RT @aljurf100: .Hematology/Oncology &amp; Stem Cell Rx. Very comprehensive 13 reviews about HSCT in SCD | Proceedings of the European Society f‚Ä¶,en,0.0,227.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,5.0,https://twitter.com/hematologymd/statuses/1317197793749094408,0.0,0.0,,0.0,0.0,0.0,5.0,4.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @aljurf100: .Hematology/Oncology &amp; Stem Cell Rx. Very comprehensive 13 reviews about HSCT in SCD | Proceedings of the European Society f‚Ä¶,true
_VaibhavAgrawal,"Blood and Marrow Transplantation and Cellular Therapy Fellow @StanfordMed | MD, MBA, MJ, MSHA | @Stanford @StanfordHealth",,,,2020-10-16 20:32:41+00:00,Vaibhav Agrawal,http://twitter.com/,9.0,,1.317201822449193e+18,,0.0,0.0,,RT @aljurf100: .Hematology/Oncology &amp; Stem Cell Rx. Very comprehensive 13 reviews about HSCT in SCD | Proceedings of the European Society f‚Ä¶,en,0.0,233.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,5.0,https://twitter.com/_VaibhavAgrawal/statuses/1317201822449192960,0.0,0.0,,0.0,0.0,0.0,5.0,4.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @aljurf100: .Hematology/Oncology &amp; Stem Cell Rx. Very comprehensive 13 reviews about HSCT in SCD | Proceedings of the European Society f‚Ä¶,true
Brbhealth,"Psychotherapist| #ACT| focus on grief, illness, cancer| anxiety| Couples|husband| Dad| Celtics ‚òòÔ∏è fan| Simpson‚Äôs fan| and have OCD @smithcollegessw",,"Charlottesville, VA",,2020-10-16 23:52:44+00:00,"Jesse Dice, LCSW",http://twitter.com/,62.0,,1.3172521682740716e+18,,0.0,0.0,,"RT @andreharris89: I can finally share that tonight, I was awarded the Community Health Worker P.O.W.E.R. Award at the SCDAA 48th Annual Vi‚Ä¶",en,0.0,2260.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,59.0,3.0,https://twitter.com/Brbhealth/statuses/1317252168274071553,0.0,0.0,,0.0,0.0,0.0,3.0,59.0,False,False,False,False,True,Disease Advocacy,1.0,0.0,0.0,"RT @andreharris89: I can finally share that tonight, I was awarded the Community Health Worker P.O.W.E.R. Award at the SCDAA 48th Annual Vi‚Ä¶",false
ptptrish,"clinical psychologist, singer/songwriter, wife, mother, grandmother, mil, sister, aunt, cape cod/fire island lover. #impeachedforever #putamaskonit",,NY,,2020-10-24 05:00:20+00:00,drptptrish,http://twitter.com/,125.0,,1.319866291226878e+18,,0.0,0.0,,RT @ASH_hematology: Hematologists are conducting cutting-edge research to fight the pandemic. Register now for the all-virtual ASH annual m‚Ä¶,en,0.0,1779.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,94.0,31.0,https://twitter.com/ptptrish/statuses/1319866291226877953,0.0,0.0,,0.0,0.0,0.0,31.0,94.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @ASH_hematology: Hematologists are conducting cutting-edge research to fight the pandemic. Register now for the all-virtual ASH annual m‚Ä¶,true
gforbes,Family Physician at Jane and Finch. Codeswitcher.,,,,2020-10-17 00:03:00+00:00,gforbes,http://twitter.com/,62.0,,1.317254748354105e+18,,0.0,0.0,,"RT @andreharris89: I can finally share that tonight, I was awarded the Community Health Worker P.O.W.E.R. Award at the SCDAA 48th Annual Vi‚Ä¶",en,0.0,1854.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,59.0,3.0,https://twitter.com/gforbes/statuses/1317254748354105344,0.0,0.0,,0.0,0.0,0.0,3.0,59.0,False,False,False,False,True,Disease Advocacy,1.0,0.0,0.0,"RT @andreharris89: I can finally share that tonight, I was awarded the Community Health Worker P.O.W.E.R. Award at the SCDAA 48th Annual Vi‚Ä¶",true
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-10-07 23:30:05+00:00,Cardiovascular Research Foundation,http://twitter.com/,0.0,,1.3139849756210422e+18,,0.0,0.0,,"The #TCTConnect Innovation &amp; E-Training Channel features the #FDA Town Hall, TCT Shark Tank Competition, as well as‚Ä¶ https://t.co/QqH99G8jpH",en,0.0,12239.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/crfheart/statuses/1313984975621042178,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"The #TCTConnect Innovation &amp; E-Training Channel features the #FDA Town Hall, TCT Shark Tank Competition, as well as‚Ä¶ https://t.co/QqH99G8jpH",true
BSCCardiology,Boston Scientific Cardiology. We invite physicians in the U.S. to learn about our cardiology & electrophysiology therapies and devices. https://t.co/yQRZwwXVRr,,"St Paul, MN",,2020-10-05 13:02:09+00:00,BostonSci Cardiology,http://twitter.com/,1.0,,1.3131021773517496e+18,,0.0,0.0,,"Working in solidarity with physicians, patients and industry to transform lives. Join us at #TCTConnect for access‚Ä¶ https://t.co/yVaW64YKdj",en,0.0,23588.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/BSCCardiology/statuses/1313102177351749632,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,"Working in solidarity with physicians, patients and industry to transform lives. Join us at #TCTConnect for access‚Ä¶ https://t.co/yVaW64YKdj",true
HirotWatanabeMD,"Interventional Cardiologist, SHD, Papa of twins, living in Kyoto, Japan",,Kyoto,,2020-10-08 21:50:44+00:00,Hirotoshi Watanabe,http://twitter.com/,3.0,,1.3143223602421105e+18,,0.0,0.0,,RT @TCTConference: The World Connect &amp; E-Satellite channel gives you access to global experts &amp; thought-provoking educational programs on n‚Ä¶,en,0.0,193.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,1.0,2.0,https://twitter.com/HirotWatanabeMD/statuses/1314322360242110471,0.0,0.0,,0.0,0.0,0.0,2.0,1.0,False,False,False,False,True,Disease Advocacy,1.0,0.0,0.0,RT @TCTConference: The World Connect &amp; E-Satellite channel gives you access to global experts &amp; thought-provoking educational programs on n‚Ä¶,true
ClinOncNews,"An independent source of unbiased, accurate, reliable news and in-depth expert analysis on issues oncologists and hematologist/oncologists care about most.",,New York City,,2020-10-05 17:15:13+00:00,ClinicalOncologyNews,http://twitter.com/,0.0,,1.313165860090114e+18,,0.0,0.0,,New treatment options for acute myeloid #leukemia are pushing out old standards. https://t.co/BOBlHYjaLu @ASCO‚Ä¶ https://t.co/s35v4MgaVH,en,0.0,3172.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/ClinOncNews/statuses/1313165860090114049,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,New treatment options for acute myeloid #leukemia are pushing out old standards. https://t.co/BOBlHYjaLu @ASCO‚Ä¶ https://t.co/s35v4MgaVH,false
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-10-08 16:30:47+00:00,Cardiovascular Research Foundation,http://twitter.com/,2.0,,1.314241842410553e+18,,0.0,0.0,,The World Connect &amp; E-Satellite channel gives you access to global experts &amp; thought-provoking educational programs‚Ä¶ https://t.co/kSu0yY7vJu,en,0.0,12239.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/crfheart/statuses/1314241842410553344,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Disease Advocacy,1.0,0.0,0.0,The World Connect &amp; E-Satellite channel gives you access to global experts &amp; thought-provoking educational programs‚Ä¶ https://t.co/kSu0yY7vJu,true
cardioPCImom,"Interventional Cardiologist, advocate #CardioObstetrics, #WIC, mother to precocious 6yr old, tweets are my own",,"Gainesville, FL",,2020-10-12 12:11:55+00:00,Ki Park,http://twitter.com/,21.0,,1.3156262484130284e+18,,0.0,0.0,,"RT @heartdoc45: TCT week is here! TCT week is here!

Mastering Bifurcation PCI #Innovation session at #TCT2020 Wednesday at 0700 EST

Free‚Ä¶",en,0.0,4511.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,15.0,6.0,https://twitter.com/cardioPCImom/statuses/1315626248413028355,0.0,0.0,,0.0,0.0,0.0,6.0,15.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @heartdoc45: TCT week is here! TCT week is here!

Mastering Bifurcation PCI #Innovation session at #TCT2020 Wednesday at 0700 EST

Free‚Ä¶",true
heartdoc45,Interventional Cardiologist at @CardioInstitute; Ochsner/Scripps trained; Pearl Jam enthusiast. Views expressed are my own. #RadialFirst,,"Lafayette, Louisiana",,2020-10-12 11:46:02+00:00,"David Homan, MD",http://twitter.com/,6.0,,1.3156197333671483e+18,,0.0,0.0,,"TCT week is here! TCT week is here!

Mastering Bifurcation PCI #Innovation session at #TCT2020 Wednesday at 0700 ES‚Ä¶ https://t.co/QHjFPJfT6U",en,0.0,6040.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,6.0,https://twitter.com/heartdoc45/statuses/1315619733367148544,0.0,0.0,,0.0,0.0,0.0,6.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"TCT week is here! TCT week is here!

Mastering Bifurcation PCI #Innovation session at #TCT2020 Wednesday at 0700 ES‚Ä¶ https://t.co/QHjFPJfT6U",true
marcelocane,Cardiologista Intervencionista. Procape UPE,,"-8.051032,-34.891461",,2020-10-12 16:22:08+00:00,Marcelo Canejo,http://twitter.com/,21.0,,1.3156892184930796e+18,,0.0,0.0,,"RT @heartdoc45: TCT week is here! TCT week is here!

Mastering Bifurcation PCI #Innovation session at #TCT2020 Wednesday at 0700 EST

Free‚Ä¶",en,0.0,51.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,15.0,6.0,https://twitter.com/marcelocane/statuses/1315689218493079553,0.0,0.0,,0.0,0.0,0.0,6.0,15.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @heartdoc45: TCT week is here! TCT week is here!

Mastering Bifurcation PCI #Innovation session at #TCT2020 Wednesday at 0700 EST

Free‚Ä¶",true
heartdoc45,Interventional Cardiologist at @CardioInstitute; Ochsner/Scripps trained; Pearl Jam enthusiast. Views expressed are my own. #RadialFirst,,"Lafayette, Louisiana",,2020-10-12 19:46:35+00:00,"David Homan, MD",http://twitter.com/,3.0,,1.3157406688836037e+18,,0.0,0.0,,"TCT week is here!

Medtech #Innovation in the #COVID19 Era: Challenges and Emerging Opportunities at #TCT2020! Wedn‚Ä¶ https://t.co/N8arRJVmDV",en,0.0,6040.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/heartdoc45/statuses/1315740668883603457,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"TCT week is here!

Medtech #Innovation in the #COVID19 Era: Challenges and Emerging Opportunities at #TCT2020! Wedn‚Ä¶ https://t.co/N8arRJVmDV",true
mughal381,Interventional Pediatric Cardiologist RavianÿåPMCianÿå proud Pakistani.üíö,,Pakistan,,2020-10-18 01:28:36+00:00,Dr Mughal,http://twitter.com/,68.0,,1.3176386808031478e+18,,0.0,0.0,,RT @mmamas1973: #VIVPartner trial #TCTConnect fascinating presentation around valve in valve treatment of failing #SAVR with #TAVR - this i‚Ä¶,en,0.0,1047.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,49.0,19.0,https://twitter.com/mughal381/statuses/1317638680803147776,0.0,0.0,,0.0,0.0,0.0,19.0,49.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @mmamas1973: #VIVPartner trial #TCTConnect fascinating presentation around valve in valve treatment of failing #SAVR with #TAVR - this i‚Ä¶,false
Pooh_Velagapudi,Cardiologist; Associate PD-Cardiology Fellowship @UNMC; Chair #ACCEarlyCareer section; SoMe editor @JACCJournals; #Education #HRPCI #SHD; EDMüé∂; Opinions my own,,United States,,2020-10-18 15:21:19+00:00,Poonam Velagapudi,http://twitter.com/,9.0,,1.317848238691668e+18,,0.0,0.0,,"#VOYAGERPAD #LBCT #TCT2020 #TCTConnect: Long-term Safety of DCBs in Peripheral Artery Revascularization: 

üåüNo asso‚Ä¶ https://t.co/MrIH6Y0nJ2",en,0.0,8841.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,9.0,https://twitter.com/Pooh_Velagapudi/statuses/1317848238691667970,0.0,0.0,,0.0,0.0,0.0,9.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"#VOYAGERPAD #LBCT #TCT2020 #TCTConnect: Long-term Safety of DCBs in Peripheral Artery Revascularization: 

üåüNo asso‚Ä¶ https://t.co/MrIH6Y0nJ2",true
DrDamluji,Interventional Cardiologist | Structural Heart @InovaHealth | Assistant Professor @JohnsHopkins | Memento Vivere,,"Washington, DC",,2020-10-14 17:46:15+00:00,"Abdulla A Damluji, MD, PhD, MPH",http://twitter.com/,0.0,,1.3164351620963738e+18,,0.0,0.0,,"Half Moon @Medtronic: Next generation Transcatheter mitral valve! 

#TCTConnect https://t.co/IWhBpyzZpN",en,0.0,5908.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/DrDamluji/statuses/1316435162096373783,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Long Term Benefits,0.0,0.0,1.0,"Half Moon @Medtronic: Next generation Transcatheter mitral valve! 

#TCTConnect https://t.co/IWhBpyzZpN",true
care4urheart2,"Interventional Cardiologist, rotaablater, TAVI man, CRT implanter, High on OCT,dreamer, loves traveling, music, fascinated by geopolitics,entrepreneur.",,"Mumbai, India",,2020-10-18 08:06:25+00:00,Ankur Phatarpekar,http://twitter.com/,11.0,,1.3177387958406226e+18,,0.0,0.0,,RT @GiorgioMedranda: PARTNER 2: TAVR for Failed TAVR Safe and Efficacious at 5 Years. #TCTConnect #CRTOnline #TAVR #PARTNERTrial https://t.‚Ä¶,en,0.0,922.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,7.0,4.0,https://twitter.com/care4urheart2/statuses/1317738795840622592,0.0,0.0,,0.0,0.0,0.0,4.0,7.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,RT @GiorgioMedranda: PARTNER 2: TAVR for Failed TAVR Safe and Efficacious at 5 Years. #TCTConnect #CRTOnline #TAVR #PARTNERTrial https://t.‚Ä¶,true
hect2701,"Professor of Medicine, Georgetown University. Cardiology, Interventional Cardiologist, Cardiovascular Imaging. Opinions are my own and RT are not endorsements.",,"Washington, DC",,2020-10-14 13:17:00+00:00,Prof. Hector M. Garcia-Garcia,http://twitter.com/,2.0,,1.3163674022595543e+18,,0.0,0.0,,"#TCTConnect #TCT2020 @crfheart, @tctconference @TCTMD 

""The fatal impact of bleeding &amp; MI persisted beyond 1 yr. A‚Ä¶ https://t.co/DzQMbQNppw",en,0.0,3101.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/hect2701/statuses/1316367402259554305,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"#TCTConnect #TCT2020 @crfheart, @tctconference @TCTMD 

""The fatal impact of bleeding &amp; MI persisted beyond 1 yr. A‚Ä¶ https://t.co/DzQMbQNppw",true
gbiondizoccai,"Academic interventional cardiologist, data scientist, & medical writer/reviewer/editor.
All opinions own, (re)tweets/likes not endorsements nor medical advice.",,"Rome, Italy",,2020-10-14 16:01:44+00:00,Giuseppe Biondi-Zoccai,http://twitter.com/,37.0,,1.3164088590875812e+18,,0.0,0.0,,"RT @DFCapodanno: PROSPECT-ABSORB: ""trend for benefit (p=0.12) on lesion-based MACEs"". Interesting hypothesis for a new trial of capping vul‚Ä¶",en,0.0,1321.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,35.0,2.0,https://twitter.com/gbiondizoccai/statuses/1316408859087581184,0.0,0.0,,0.0,0.0,0.0,2.0,35.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @DFCapodanno: PROSPECT-ABSORB: ""trend for benefit (p=0.12) on lesion-based MACEs"". Interesting hypothesis for a new trial of capping vul‚Ä¶",true
DrAmirKaki,"Interventional Cardiologist. Director of Mechanical Circulatory Support and Complex PCI, St. John‚Äôs Hospital.  Associate Professor of Medicine Wayne State SOM",,"Detroit, MI",,2020-10-14 12:52:53+00:00,"Amir Kaki, MD",http://twitter.com/,18.0,,1.3163613349430272e+18,,0.0,0.0,,RT @crfheart: This morning‚Äôs #TCTConnect Japan session tackles controversies in cardiogenic shock. Tune in at 8:00 AM ET #TCT2020 @BillONei‚Ä¶,en,0.0,8128.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,12.0,6.0,https://twitter.com/DrAmirKaki/statuses/1316361334943027200,0.0,0.0,,0.0,0.0,0.0,6.0,12.0,False,False,False,False,True,Cost of Care,0.0,0.0,1.0,RT @crfheart: This morning‚Äôs #TCTConnect Japan session tackles controversies in cardiogenic shock. Tune in at 8:00 AM ET #TCT2020 @BillONei‚Ä¶,false
GiuseppeGalati_,MD #HeartFailure & #Cardiomyopathies #Cardiologist @SanRaffaeleMi ‚Ä¢ Medical MSc in #HF by @anmco @escardio #PCHF‚Ä¢ #IFC #HFA_ESC St. Group #Cardiomyopathies üá™üá∫,,"Milan , Italy üáÆüáπ",,2020-10-14 16:49:47+00:00,Giuseppe Galati,http://twitter.com/,26.0,,1.316420950376751e+18,,0.0,0.0,,RT @mmamas1973: #TCTConnect if you missed the LBT session can see livestream below @CardioIAN @billgogas @GiuseppeGalati_ @gbiondizoccai @h‚Ä¶,en,0.0,5413.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,18.0,8.0,https://twitter.com/GiuseppeGalati_/statuses/1316420950376751104,0.0,0.0,,0.0,0.0,0.0,8.0,18.0,False,False,False,False,True,Disease Management,0.0,0.0,1.0,RT @mmamas1973: #TCTConnect if you missed the LBT session can see livestream below @CardioIAN @billgogas @GiuseppeGalati_ @gbiondizoccai @h‚Ä¶,true
Pooh_Velagapudi,Cardiologist; Associate PD-Cardiology Fellowship @UNMC; Chair #ACCEarlyCareer section; SoMe editor @JACCJournals; #Education #HRPCI #SHD; EDMüé∂; Opinions my own,,United States,,2020-10-14 14:01:21+00:00,Poonam Velagapudi,http://twitter.com/,33.0,,1.3163785644812206e+18,,0.0,0.0,,"RT @JGrapsa: Inspiring the next generation, promoting innovation &amp; clinical excellence, @ACCinTouch together with @crfheart introduce Marti‚Ä¶",en,0.0,8841.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,23.0,10.0,https://twitter.com/Pooh_Velagapudi/statuses/1316378564481220609,0.0,0.0,,0.0,0.0,0.0,10.0,23.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"RT @JGrapsa: Inspiring the next generation, promoting innovation &amp; clinical excellence, @ACCinTouch together with @crfheart introduce Marti‚Ä¶",true
DFCapodanno,"Interventional Cardiologist | University of Catania, Italy | Editor @EuroInterventio",,"Catania, Sicily",,2020-10-14 15:59:34+00:00,Davide Capodanno,http://twitter.com/,2.0,,1.3164083138532065e+18,,0.0,0.0,,"PROSPECT-ABSORB: ""trend for benefit (p=0.12) on lesion-based MACEs"". Interesting hypothesis for a new trial of capp‚Ä¶ https://t.co/IBxcUy9mjr",en,0.0,5313.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/DFCapodanno/statuses/1316408313853206528,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"PROSPECT-ABSORB: ""trend for benefit (p=0.12) on lesion-based MACEs"". Interesting hypothesis for a new trial of capp‚Ä¶ https://t.co/IBxcUy9mjr",true
Hragy,"Cardiologist, National Heart Institute, Egypt ÿ±ÿ¨ÿßÿ° ÿπÿØŸÖ ÿßŸÑÿ™ŸàÿßÿµŸÑ ÿ®ÿ¥ÿ£ŸÜ ÿ¥ÿ§ŸàŸÜ ÿ∑ÿ®Ÿäÿ© ÿÆÿßÿµÿ© ÿπŸÑŸä ÿ™ŸàŸäÿ™ÿ±",,egypt,,2020-10-14 15:35:28+00:00,Hany Ragy,http://twitter.com/,0.0,,1.3164022495354962e+18,,0.0,0.0,,"Again all events clustered in TCFA group! Soon we may be diagnosing this less invasively ...
#TCTConnect  #COMBINE(‚Ä¶ https://t.co/GkqUOa3tUU",en,0.0,31448.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/Hragy/statuses/1316402249535496200,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"Again all events clustered in TCFA group! Soon we may be diagnosing this less invasively ...
#TCTConnect  #COMBINE(‚Ä¶ https://t.co/GkqUOa3tUU",true
chadialraies,Heart doctor @DMC_Heals Clinician researcher educator #CHIP #PAD #RadialFirst - Founder: https://t.co/CRHKx6HNVb Pub: https://t.co/h3aHzr1oGU -Tweet=my opinion,,"Detroit, MI",,2020-10-14 16:54:41+00:00,"M Chadi Alraies, MD FACC",http://twitter.com/,17.0,,1.3164221839467807e+18,,0.0,0.0,,"RT @ACCinTouch: Unique registry collaboration between @SCAI, Canadian Association of Interventional Cardiology &amp; #ACCIC aims to improve out‚Ä¶",en,0.0,21439.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,11.0,6.0,https://twitter.com/chadialraies/statuses/1316422183946780673,0.0,0.0,,0.0,0.0,0.0,6.0,11.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,"RT @ACCinTouch: Unique registry collaboration between @SCAI, Canadian Association of Interventional Cardiology &amp; #ACCIC aims to improve out‚Ä¶",true
mughal381,Interventional Pediatric Cardiologist RavianÿåPMCianÿå proud Pakistani.üíö,,Pakistan,,2020-10-16 00:58:56+00:00,Dr Mughal,http://twitter.com/,11.0,,1.3169064384810555e+18,,0.0,0.0,,"RT @crfheart: Have you been following our #TCTConnect ambassadors? With their vast experience and expertise, they‚Äôll help you get a unique‚Ä¶",en,0.0,1047.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,5.0,https://twitter.com/mughal381/statuses/1316906438481055745,0.0,0.0,,0.0,0.0,0.0,5.0,6.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,"RT @crfheart: Have you been following our #TCTConnect ambassadors? With their vast experience and expertise, they‚Äôll help you get a unique‚Ä¶",false
hvanspall,"Associate Professor, Cardiologist, Scientist @MacDeptMed @HEI_McMaster. Alumnus @HarvardHSPH @UofTMedicine #HeartFailure #RCTs #Implementation #DigitalHealth",,,,2020-10-16 13:09:39+00:00,"Harriette Van Spall, MD MPH",http://twitter.com/,33.0,,1.3170903305802342e+18,,0.0,0.0,,RT @mmamas1973: #TCTConnect join us in the innovation and e-training centre at 10am EST for discussions around SDD and #RadialFirst with Ma‚Ä¶,en,0.0,9079.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,21.0,12.0,https://twitter.com/hvanspall/statuses/1317090330580234241,0.0,0.0,,0.0,0.0,0.0,12.0,21.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @mmamas1973: #TCTConnect join us in the innovation and e-training centre at 10am EST for discussions around SDD and #RadialFirst with Ma‚Ä¶,true
minhaskh,Interventional Cardiologist Tweets ‚â† Medical Advice.,,USA,,2020-10-16 16:35:57+00:00,"Khalid Minhas, MD",http://twitter.com/,89.0,,1.317142245578072e+18,,0.0,0.0,,RT @GreggWStone: FORECAST late breaking trial at #TCT2020. 1300 pts with chest pain at out-pt clinics rand to FFRCT vs usual diagnostic eva‚Ä¶,en,0.0,4394.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,61.0,28.0,https://twitter.com/minhaskh/statuses/1317142245578072064,0.0,0.0,,0.0,0.0,0.0,28.0,61.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @GreggWStone: FORECAST late breaking trial at #TCT2020. 1300 pts with chest pain at out-pt clinics rand to FFRCT vs usual diagnostic eva‚Ä¶,true
DrDerekConnolly,Consultant Inteventional Cardiologist Birmingham City and Priory Hospitals,,Birmingham & Sandwell UK,,2020-10-16 18:36:44+00:00,Dr Derek Connolly,http://twitter.com/,89.0,,1.317172642496e+18,,0.0,0.0,,RT @GreggWStone: FORECAST late breaking trial at #TCT2020. 1300 pts with chest pain at out-pt clinics rand to FFRCT vs usual diagnostic eva‚Ä¶,en,0.0,2181.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,61.0,28.0,https://twitter.com/DrDerekConnolly/statuses/1317172642496000000,0.0,0.0,,0.0,0.0,0.0,28.0,61.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @GreggWStone: FORECAST late breaking trial at #TCT2020. 1300 pts with chest pain at out-pt clinics rand to FFRCT vs usual diagnostic eva‚Ä¶,true
ajaykirtane,"Practicing Cardiologist, Professor @ColumbiaMed
Researcher & advocate for thoughtful patient care; tweets‚â†endorsements nor med advice
https://t.co/YyilZMYayJ",,NewYork-Presbyterian & beyond,,2020-10-16 01:29:22+00:00,Ajay Kirtane MD SM,http://twitter.com/,8.0,,1.3169140972550267e+18,,0.0,0.0,,"RT @crfheart: Have you been following our #TCTConnect ambassadors? With their vast experience and expertise, they‚Äôll help you get a unique‚Ä¶",en,0.0,17044.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,4.0,https://twitter.com/ajaykirtane/statuses/1316914097255026690,0.0,0.0,,0.0,0.0,0.0,4.0,4.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,"RT @crfheart: Have you been following our #TCTConnect ambassadors? With their vast experience and expertise, they‚Äôll help you get a unique‚Ä¶",true
OuzounianMD,"Cardiac and Aortic surgeon - Peter Munk Cardiac Centre; Fellowship Director - Toronto General Hospital; Associate Professor of Surgery, University of Toronto",,"Toronto ",,2020-10-18 03:19:17+00:00,Maral Ouzounian,http://twitter.com/,68.0,,1.317666532458193e+18,,0.0,0.0,,RT @mmamas1973: #VIVPartner trial #TCTConnect fascinating presentation around valve in valve treatment of failing #SAVR with #TAVR - this i‚Ä¶,en,0.0,4249.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,49.0,19.0,https://twitter.com/OuzounianMD/statuses/1317666532458192896,0.0,0.0,,0.0,0.0,0.0,19.0,49.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @mmamas1973: #VIVPartner trial #TCTConnect fascinating presentation around valve in valve treatment of failing #SAVR with #TAVR - this i‚Ä¶,true
CardioSurgPost,üëâüèª A virtual Cardiac Surgery diary ‚ù§Ô∏èüî™ üëâüèª Bringing together cardiovascular physicians and showing cases! ‚ù§Ô∏èüìö,,,,2020-10-18 09:53:55+00:00,CardioSurgeryPost,http://twitter.com/,68.0,,1.3177658487533732e+18,,0.0,0.0,,RT @mmamas1973: #VIVPartner trial #TCTConnect fascinating presentation around valve in valve treatment of failing #SAVR with #TAVR - this i‚Ä¶,en,0.0,320.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,49.0,19.0,https://twitter.com/CardioSurgPost/statuses/1317765848753373185,0.0,0.0,,0.0,0.0,0.0,19.0,49.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @mmamas1973: #VIVPartner trial #TCTConnect fascinating presentation around valve in valve treatment of failing #SAVR with #TAVR - this i‚Ä¶,false
NishithChandra,"#Cardiologist, Passionate about coronary#OCT, Sky Diver, Bungee Jumping
Director #Interventional Cardiologist at N. Delhi's Fortis Escorts #Heart Inst.#INDIA",,New Delhi,,2020-10-16 04:27:13+00:00,ùîªùï£ ‚Ñïùïöùï§ùïôùïöùï•ùïô ‚ÑÇùïôùïíùïüùïïùï£ùïí,http://twitter.com/,6.0,,1.3169588530749809e+18,,0.0,0.0,,Those missed yesterday's SharkTank ! #TCTConnect #TCT2020 A remarkable Innovation ‚û°Ô∏èNatural Vascular Scaffolding.Di‚Ä¶ https://t.co/h7NbNRJDWR,en,0.0,1780.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,6.0,https://twitter.com/NishithChandra/statuses/1316958853074980864,0.0,0.0,,0.0,0.0,0.0,6.0,0.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,Those missed yesterday's SharkTank ! #TCTConnect #TCT2020 A remarkable Innovation ‚û°Ô∏èNatural Vascular Scaffolding.Di‚Ä¶ https://t.co/h7NbNRJDWR,true
mathur_a,"#Interventional #cardiologist, ExUAB, ExAIIMS, Sports enthusiast, In sync with the world. #Carotid stenting #TAVR #Structural Heart #Endovascular Interventions",,"New Delhi, India",,2020-10-16 04:17:33+00:00,Atul Mathur,http://twitter.com/,8.0,,1.3169564237634314e+18,,0.0,0.0,,"RT @crfheart: Have you been following our #TCTConnect ambassadors? With their vast experience and expertise, they‚Äôll help you get a unique‚Ä¶",en,0.0,458.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,4.0,https://twitter.com/mathur_a/statuses/1316956423763431424,0.0,0.0,,0.0,0.0,0.0,4.0,4.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,"RT @crfheart: Have you been following our #TCTConnect ambassadors? With their vast experience and expertise, they‚Äôll help you get a unique‚Ä¶",true
ziadalinyc,"Interventional Cardiologist & Vascular Biologist @Columbia @nyphospital. Clinical Trialist @CRFheart. Son, Brother, Husband, Dad everywhere.",,"New York, NY",,2020-10-16 01:45:16+00:00,Ziad Ali,http://twitter.com/,18.0,,1.3169180983315784e+18,,0.0,0.0,,"RT @crfheart: Have you been following our #TCTConnect ambassadors? With their vast experience and expertise, they‚Äôll help you get a unique‚Ä¶",en,0.0,3676.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,11.0,7.0,https://twitter.com/ziadalinyc/statuses/1316918098331578369,0.0,0.0,,0.0,0.0,0.0,7.0,11.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,"RT @crfheart: Have you been following our #TCTConnect ambassadors? With their vast experience and expertise, they‚Äôll help you get a unique‚Ä¶",true
Hragy,"Cardiologist, National Heart Institute, Egypt ÿ±ÿ¨ÿßÿ° ÿπÿØŸÖ ÿßŸÑÿ™ŸàÿßÿµŸÑ ÿ®ÿ¥ÿ£ŸÜ ÿ¥ÿ§ŸàŸÜ ÿ∑ÿ®Ÿäÿ© ÿÆÿßÿµÿ© ÿπŸÑŸä ÿ™ŸàŸäÿ™ÿ±",,egypt,,2020-10-16 13:21:35+00:00,Hany Ragy,http://twitter.com/,33.0,,1.3170933323010867e+18,,0.0,0.0,,RT @mmamas1973: #TCTConnect join us in the innovation and e-training centre at 10am EST for discussions around SDD and #RadialFirst with Ma‚Ä¶,en,0.0,31448.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,21.0,12.0,https://twitter.com/Hragy/statuses/1317093332301086720,0.0,0.0,,0.0,0.0,0.0,12.0,21.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @mmamas1973: #TCTConnect join us in the innovation and e-training centre at 10am EST for discussions around SDD and #RadialFirst with Ma‚Ä¶,true
aymanka,"interventional cardiologist ( ex SCAI BOT ,ex Washington Hospital Center ) runner , diver , NFL . lucky to be in a profession that keeps you learning !",,,,2020-10-16 16:19:41+00:00,Ayman Magd,http://twitter.com/,89.0,,1.3171381524406804e+18,,0.0,0.0,,RT @GreggWStone: FORECAST late breaking trial at #TCT2020. 1300 pts with chest pain at out-pt clinics rand to FFRCT vs usual diagnostic eva‚Ä¶,en,0.0,3854.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,61.0,28.0,https://twitter.com/aymanka/statuses/1317138152440680449,0.0,0.0,,0.0,0.0,0.0,28.0,61.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @GreggWStone: FORECAST late breaking trial at #TCT2020. 1300 pts with chest pain at out-pt clinics rand to FFRCT vs usual diagnostic eva‚Ä¶,true
rabonour1,myeloma doctor,,USA,,2020-12-05 18:02:43+00:00,Rafat Abonour,http://twitter.com/,0.0,,1.3352834731296315e+18,,0.0,0.0,,#ASH20 if the pandemic occurred 10 years ago would we have an ASH meeting? No. Congratulations #ASH20 on great meeting,en,0.0,1225.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/rabonour1/statuses/1335283473129631744,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Covid,1.0,0.0,0.0,#ASH20 if the pandemic occurred 10 years ago would we have an ASH meeting? No. Congratulations #ASH20 on great meeting,false
alexisphero,"Cardiac surgeon, MD-PhD I fix hearts for living.üíñ I gave my heart to @anatarahes Tweets are for information & are not medical advice or views of my employer.",,"Waikoloa Village, HI",,2020-09-29 06:07:10+00:00,Alex,http://twitter.com/,22.0,,1.3108234154404536e+18,,0.0,0.0,,RT @crfheart: Want a front-row seat to #innovation? Join us next month at #TCTConnect! Registration is FREE: https://t.co/KWSbMwmu0f #TCT20‚Ä¶,en,0.0,97.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,12.0,10.0,https://twitter.com/alexisphero/statuses/1310823415440453632,0.0,0.0,,0.0,0.0,0.0,10.0,12.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @crfheart: Want a front-row seat to #innovation? Join us next month at #TCTConnect! Registration is FREE: https://t.co/KWSbMwmu0f #TCT20‚Ä¶,true
julefranve,"Oncologist, cancer research. Lymphoma, Myeloma. INEN, Lima, Peru. Tweets are my own.",,"Lima, Peru",,2020-09-19 06:59:15+00:00,"Jule Vasquez, MD",http://twitter.com/,15.0,,1.3072126411994276e+18,,0.0,0.0,,"RT @ASTCT: Abstract submissions for #TCTM21 are now open! Share your original research, and help us pioneer new areas of investigation for‚Ä¶",en,0.0,155.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,8.0,7.0,https://twitter.com/julefranve/statuses/1307212641199427584,0.0,0.0,,0.0,0.0,0.0,7.0,8.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @ASTCT: Abstract submissions for #TCTM21 are now open! Share your original research, and help us pioneer new areas of investigation for‚Ä¶",true
blood_doctor_,"Consultant Hematologist and Hemato-oncologist
Shalby Hospitals, Ahmedabad",,‡§≠‡§æ‡§∞‡§§,,2020-09-19 03:29:56+00:00,Abha Dubey,http://twitter.com/,310.0,,1.30715996779998e+18,,0.0,0.0,,RT @VincentRK: 4 key slides from my talk on ‚ÄúHow I Treat Newly Diagnosed Myeloma‚Äù at #ASHMHM20 @ASH_hematology meeting. @MayoCancerCare @Ma‚Ä¶,en,0.0,31.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,220.0,90.0,https://twitter.com/blood_doctor_/statuses/1307159967799980032,0.0,0.0,,0.0,0.0,0.0,90.0,220.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @VincentRK: 4 key slides from my talk on ‚ÄúHow I Treat Newly Diagnosed Myeloma‚Äù at #ASHMHM20 @ASH_hematology meeting. @MayoCancerCare @Ma‚Ä¶,true
MariaSantos_bio,Doctora en Biolog√≠a (@usal) y futura fil√≥loga. Traductora m√©dica y cient√≠fica EN-ES. | PhD in Biology. Medical & scientific translator EN-ES.,,"Salamanca, Espa√±a",,2020-09-22 07:04:59+00:00,Mar√≠a Santos Vicente,http://twitter.com/,31.0,,1.3083012496792084e+18,,0.0,0.0,,"RT @EHA_Hematology: Today, on #WorldCMLDay20, #EHA is joining, @cmlnet &amp; the global #CML community in raising awareness of the needs of chr‚Ä¶",en,0.0,39.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,20.0,11.0,https://twitter.com/MariaSantos_bio/statuses/1308301249679208454,0.0,0.0,,0.0,0.0,0.0,11.0,20.0,False,False,False,False,True,Disease Advocacy,0.0,0.0,1.0,"RT @EHA_Hematology: Today, on #WorldCMLDay20, #EHA is joining, @cmlnet &amp; the global #CML community in raising awareness of the needs of chr‚Ä¶",true
TrevorBaglin,"Venture Partner Medicxi. Founder of XO1, SuperX, Apcintex, previously Consultant Haematologist Cambridge University Hospitals, UK.",,Cambridge UK,,2020-09-01 19:58:13+00:00,Trevor Baglin,http://twitter.com/,22.0,,1.3008856938461716e+18,,0.0,0.0,,RT @JHuntingtonUCam: #ApcinteX is pleased to report dosing today of the first patient in Ph2 of its ongoing clinical trial #hemophilia Mont‚Ä¶,en,0.0,401.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,18.0,4.0,https://twitter.com/TrevorBaglin/statuses/1300885693846171651,0.0,0.0,,0.0,0.0,0.0,4.0,18.0,False,False,False,False,True,Clinical Trials,1.0,0.0,0.0,RT @JHuntingtonUCam: #ApcinteX is pleased to report dosing today of the first patient in Ph2 of its ongoing clinical trial #hemophilia Mont‚Ä¶,true
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-10-18 13:01:24+00:00,Cardiovascular Research Foundation,http://twitter.com/,1.0,,1.3178130290824192e+18,,0.0,0.0,,Take a break from world-class education to network and engage with industry partners at our Engagement Hub during‚Ä¶ https://t.co/RYtjpYKgEu,en,0.0,12239.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/crfheart/statuses/1317813029082419201,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,Take a break from world-class education to network and engage with industry partners at our Engagement Hub during‚Ä¶ https://t.co/RYtjpYKgEu,false
cesardegali,"Doctorado en Biotecnolog√≠a. Licenciado en Bioqu√≠mica y en Ciencias Qu√≠micas. Apasionado de la ciencia. Ecologista, submarinista y lector.",,,,2020-09-03 09:54:19+00:00,C√©sar del Rio Merino,http://twitter.com/,37.0,,1.3014584945839675e+18,,0.0,0.0,,"RT @DrMiguelPerales: #EBMT20 #EBMT20virtual CD34+ Allo HCT, &lt; GVHD, no increase in relapse, Better CRFS - Waiting for results of @BMTCTN 13‚Ä¶",en,0.0,29.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,27.0,10.0,https://twitter.com/cesardegali/statuses/1301458494583967745,0.0,0.0,,0.0,0.0,0.0,10.0,27.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @DrMiguelPerales: #EBMT20 #EBMT20virtual CD34+ Allo HCT, &lt; GVHD, no increase in relapse, Better CRFS - Waiting for results of @BMTCTN 13‚Ä¶",true
GautschiOliver,Oncologist https://t.co/21aVUEtXwo | Assoc Professor @unibern | @etop_eu @myESMO @IASLC @sakk_ch,,"Luzern, Schweiz",,2020-10-11 21:01:24+00:00,Oliver Gautschi,http://twitter.com/,10.0,,1.3153971086321132e+18,,0.0,0.0,,Honored to present LIBRETTO-001 results at the #DGHO2020 conference on behalf of the whole trial team (oral abstrac‚Ä¶ https://t.co/p2udp2zmRu,en,0.0,1573.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,10.0,https://twitter.com/GautschiOliver/statuses/1315397108632113152,0.0,0.0,,0.0,0.0,0.0,10.0,0.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,Honored to present LIBRETTO-001 results at the #DGHO2020 conference on behalf of the whole trial team (oral abstrac‚Ä¶ https://t.co/p2udp2zmRu,true
trnsltnl,Lung Cancer researcher and physician | Translational research aficionado | Tweets are my own and do NOT reflect the opinion of my employers,,"Cologne, Germany",,2020-10-11 21:52:14+00:00,Matthias Scheffler,http://twitter.com/,31.0,,1.3154099012382228e+18,,0.0,0.0,,RT @GautschiOliver: Honored to present LIBRETTO-001 results at the #DGHO2020 conference on behalf of the whole trial team (oral abstract 87‚Ä¶,en,0.0,903.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,21.0,10.0,https://twitter.com/trnsltnl/statuses/1315409901238222850,0.0,0.0,,0.0,0.0,0.0,10.0,21.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @GautschiOliver: Honored to present LIBRETTO-001 results at the #DGHO2020 conference on behalf of the whole trial team (oral abstract 87‚Ä¶,true
VivekSubbiah,"Oncologist | Associate Prof | Executive Director-Research, MD Anderson Cancer Network | Medical Director, Clinical Center for Targeted Therapy. Tweets = my own.",,"Houston, TX",,2020-10-11 21:38:57+00:00,"Vivek Subbiah, MD",http://twitter.com/,31.0,,1.3154065587009413e+18,,0.0,0.0,,RT @GautschiOliver: Honored to present LIBRETTO-001 results at the #DGHO2020 conference on behalf of the whole trial team (oral abstract 87‚Ä¶,en,0.0,8354.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,21.0,10.0,https://twitter.com/VivekSubbiah/statuses/1315406558700941315,0.0,0.0,,0.0,0.0,0.0,10.0,21.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @GautschiOliver: Honored to present LIBRETTO-001 results at the #DGHO2020 conference on behalf of the whole trial team (oral abstract 87‚Ä¶,true
Hragy,"Cardiologist, National Heart Institute, Egypt ÿ±ÿ¨ÿßÿ° ÿπÿØŸÖ ÿßŸÑÿ™ŸàÿßÿµŸÑ ÿ®ÿ¥ÿ£ŸÜ ÿ¥ÿ§ŸàŸÜ ÿ∑ÿ®Ÿäÿ© ÿÆÿßÿµÿ© ÿπŸÑŸä ÿ™ŸàŸäÿ™ÿ±",,egypt,,2020-10-16 04:05:06+00:00,Hany Ragy,http://twitter.com/,11.0,,1.3169532889784074e+18,,0.0,0.0,,"RT @crfheart: Have you been following our #TCTConnect ambassadors? With their vast experience and expertise, they‚Äôll help you get a unique‚Ä¶",en,0.0,31448.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,5.0,https://twitter.com/Hragy/statuses/1316953288978407424,0.0,0.0,,0.0,0.0,0.0,5.0,6.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,"RT @crfheart: Have you been following our #TCTConnect ambassadors? With their vast experience and expertise, they‚Äôll help you get a unique‚Ä¶",true
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-10-11 00:27:56+00:00,Cardiovascular Research Foundation,http://twitter.com/,11.0,,1.315086698645205e+18,,0.0,0.0,,RT @AnkitaGore1: Unexpected benefit of the pandemic - conferences for FREE at our fingertips! With no coordinating days off or need for tra‚Ä¶,en,0.0,12239.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,9.0,2.0,https://twitter.com/crfheart/statuses/1315086698645204994,0.0,0.0,,0.0,0.0,0.0,2.0,9.0,False,False,False,False,True,Covid,0.0,0.0,1.0,RT @AnkitaGore1: Unexpected benefit of the pandemic - conferences for FREE at our fingertips! With no coordinating days off or need for tra‚Ä¶,false
GlopesMd,"Cancer Doctor and Researcher, Faculty @SylvesterCancer @UnivMiami. Helping improve Cancer Control in LMICs. Editor-in-Chief JCO Global Oncology @ASCO",,"Miami, FL",,2020-10-11 21:37:20+00:00,gilberto lopes,http://twitter.com/,31.0,,1.3154061531621417e+18,,0.0,0.0,,RT @GautschiOliver: Honored to present LIBRETTO-001 results at the #DGHO2020 conference on behalf of the whole trial team (oral abstract 87‚Ä¶,en,0.0,31610.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,21.0,10.0,https://twitter.com/GlopesMd/statuses/1315406153162141696,0.0,0.0,,0.0,0.0,0.0,10.0,21.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @GautschiOliver: Honored to present LIBRETTO-001 results at the #DGHO2020 conference on behalf of the whole trial team (oral abstract 87‚Ä¶,true
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-10-16 19:57:27+00:00,Cardiovascular Research Foundation,http://twitter.com/,17.0,,1.3171929560345846e+18,,0.0,0.0,,RT @AKassier: Very much enjoyed watching #RenalDenervation #livecase while holding this cutting edge technology in my hand @TimAFischellMD‚Ä¶,en,0.0,12239.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,15.0,2.0,https://twitter.com/crfheart/statuses/1317192956034584583,0.0,0.0,,0.0,0.0,0.0,2.0,15.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @AKassier: Very much enjoyed watching #RenalDenervation #livecase while holding this cutting edge technology in my hand @TimAFischellMD‚Ä¶,true
GreggWStone,"Interventional cardiologist, trialist, innovator, provocateur, educator, husband, father, friend",,New York and the world,,2020-10-16 15:13:46+00:00,Gregg W. Stone MD,http://twitter.com/,28.0,,1.3171215631671624e+18,,0.0,0.0,,FORECAST late breaking trial at #TCT2020. 1300 pts with chest pain at out-pt clinics rand to FFRCT vs usual diagnos‚Ä¶ https://t.co/iel1OrqZ8V,en,0.0,18925.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,28.0,https://twitter.com/GreggWStone/statuses/1317121563167162368,0.0,0.0,,0.0,0.0,0.0,28.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,FORECAST late breaking trial at #TCT2020. 1300 pts with chest pain at out-pt clinics rand to FFRCT vs usual diagnos‚Ä¶ https://t.co/iel1OrqZ8V,true
arek_pietrasik,"Invasive cardiologist, MD, PhD",,"Warszawa, Polska",,2020-10-16 20:21:08+00:00,Arek Pietrasik,http://twitter.com/,89.0,,1.317198917356933e+18,,0.0,0.0,,RT @GreggWStone: FORECAST late breaking trial at #TCT2020. 1300 pts with chest pain at out-pt clinics rand to FFRCT vs usual diagnostic eva‚Ä¶,en,0.0,207.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,61.0,28.0,https://twitter.com/arek_pietrasik/statuses/1317198917356933121,0.0,0.0,,0.0,0.0,0.0,28.0,61.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @GreggWStone: FORECAST late breaking trial at #TCT2020. 1300 pts with chest pain at out-pt clinics rand to FFRCT vs usual diagnostic eva‚Ä¶,true
purviparwani,"Cardiologist, DirectorWomens‚ù§Ô∏è Clinic #LLUH, BOT @scmrorg ,tweets=myopinion #CardiacImaging #WomenCVhealth #wellness üßò‚Äç‚ôÄÔ∏è üå±",,"California, USA",,2020-10-16 01:58:48+00:00,Dr. Purvi Parwani,http://twitter.com/,11.0,,1.3169215030034022e+18,,0.0,0.0,,"RT @crfheart: Have you been following our #TCTConnect ambassadors? With their vast experience and expertise, they‚Äôll help you get a unique‚Ä¶",en,0.0,19397.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,7.0,4.0,https://twitter.com/purviparwani/statuses/1316921503003402243,0.0,0.0,,0.0,0.0,0.0,4.0,7.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,"RT @crfheart: Have you been following our #TCTConnect ambassadors? With their vast experience and expertise, they‚Äôll help you get a unique‚Ä¶",true
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-10-16 00:51:11+00:00,Cardiovascular Research Foundation,http://twitter.com/,7.0,,1.316904489857749e+18,,0.0,0.0,,"Have you been following our #TCTConnect ambassadors? With their vast experience and expertise, they‚Äôll help you get‚Ä¶ https://t.co/Jk3pS6hhha",en,0.0,12239.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,7.0,https://twitter.com/crfheart/statuses/1316904489857748994,0.0,0.0,,0.0,0.0,0.0,7.0,0.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,"Have you been following our #TCTConnect ambassadors? With their vast experience and expertise, they‚Äôll help you get‚Ä¶ https://t.co/Jk3pS6hhha",false
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-10-16 00:56:46+00:00,Cardiovascular Research Foundation,http://twitter.com/,4.0,,1.316905892999213e+18,,0.0,0.0,,"Have you been following our #TCTConnect ambassadors? With their vast experience and expertise, they‚Äôll help you get‚Ä¶ https://t.co/lOXh7Z2nz3",en,0.0,12239.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,4.0,https://twitter.com/crfheart/statuses/1316905892999213058,0.0,0.0,,0.0,0.0,0.0,4.0,0.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,"Have you been following our #TCTConnect ambassadors? With their vast experience and expertise, they‚Äôll help you get‚Ä¶ https://t.co/lOXh7Z2nz3",true
gbiondizoccai,"Academic interventional cardiologist, data scientist, & medical writer/reviewer/editor.
All opinions own, (re)tweets/likes not endorsements nor medical advice.",,"Rome, Italy",,2020-10-11 09:16:44+00:00,Giuseppe Biondi-Zoccai,http://twitter.com/,18.0,,1.3152197754595574e+18,,0.0,0.0,,RT @PradeepYadavMD: So looking forward! #TCT2020 #TCTConnect Incredible effort by @crfheart and all participating sites/speakers. Watch out‚Ä¶,en,0.0,1322.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,13.0,5.0,https://twitter.com/gbiondizoccai/statuses/1315219775459557376,0.0,0.0,,0.0,0.0,0.0,5.0,13.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,RT @PradeepYadavMD: So looking forward! #TCT2020 #TCTConnect Incredible effort by @crfheart and all participating sites/speakers. Watch out‚Ä¶,true
cvigilgonzales,Hematologist/Leukemia physician/researcher/ Lurie Cancer Center @northwesternmed,,"Chicago, IL",,2020-08-13 00:49:55+00:00,"Carlos E. Vigil, MD",http://twitter.com/,77.0,,1.293711347163771e+18,,0.0,0.0,,"RT @LeukemiaMDA: Combination therapy significantly improves survival outcomes for patients w/ acute myeloid #leukemia | 
Lead investigator‚Ä¶",en,0.0,266.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,62.0,15.0,https://twitter.com/cvigilgonzales/statuses/1293711347163770881,0.0,0.0,,0.0,0.0,0.0,15.0,62.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,"RT @LeukemiaMDA: Combination therapy significantly improves survival outcomes for patients w/ acute myeloid #leukemia | 
Lead investigator‚Ä¶",true
dgermain21,MD-PhD. 2nd year Heme/Onc fellow focused on lymphoma and leukemia. Physician-scientist-in-training. Tweet/RT not medical advice or endorsement.,,"St. Louis, MO",,2020-08-13 22:14:06+00:00,David A. Russler-Germain,http://twitter.com/,10.0,,1.294034521877295e+18,,0.0,0.0,,"RT @lymphomahub: Did you miss the @lymphomahub interview with Emanuele Zucca, Institute of Oncology Research, Bellinzona, about chemotherap‚Ä¶",en,0.0,1612.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,8.0,2.0,https://twitter.com/dgermain21/statuses/1294034521877295108,0.0,0.0,,0.0,0.0,0.0,2.0,8.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @lymphomahub: Did you miss the @lymphomahub interview with Emanuele Zucca, Institute of Oncology Research, Bellinzona, about chemotherap‚Ä¶",true
TapKadia,"Tapan Kadia, MD 
- Leukemia Doc at MD Anderson Cancer Center 
 Leukemia, clinical/translational research.  Views, posts and opinions shared are my own.",,"Houston, TX",,2020-08-13 02:55:56+00:00,Tapan Kadia,http://twitter.com/,78.0,,1.2937430574778163e+18,,0.0,0.0,,"RT @LeukemiaMDA: Combination therapy significantly improves survival outcomes for patients w/ acute myeloid #leukemia | 
Lead investigator‚Ä¶",en,0.0,2499.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,63.0,15.0,https://twitter.com/TapKadia/statuses/1293743057477816320,0.0,0.0,,0.0,0.0,0.0,15.0,63.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,"RT @LeukemiaMDA: Combination therapy significantly improves survival outcomes for patients w/ acute myeloid #leukemia | 
Lead investigator‚Ä¶",true
amit_sud,"Haematologist and Academic Lecturer. #Genetics #Epidemiology #Cancer.
@HoulstonLab_ICR @ICR_London @royalmarsdenNHS.
üß¨üî¥üî¨üíªüö¥üèΩ‚Äç‚ôÇÔ∏èü•Åüíôüá¨üáßüá™üá∫üå±üåàüåç",,London,,2020-08-13 07:26:23+00:00,Amit Sud,http://twitter.com/,78.0,,1.293811118650151e+18,,0.0,0.0,,"RT @LeukemiaMDA: Combination therapy significantly improves survival outcomes for patients w/ acute myeloid #leukemia | 
Lead investigator‚Ä¶",en,0.0,449.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,63.0,15.0,https://twitter.com/amit_sud/statuses/1293811118650150913,0.0,0.0,,0.0,0.0,0.0,15.0,63.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,"RT @LeukemiaMDA: Combination therapy significantly improves survival outcomes for patients w/ acute myeloid #leukemia | 
Lead investigator‚Ä¶",false
acctravassos,"m√©dica, pediatra, endocrinologista, nas horas vagas adoro escrever, ver filmes e s√©ries, cozinhar e ficar com a fam√≠lia!",,Sao Paulo,,2020-08-13 03:12:46+00:00,Ana Travassos,http://twitter.com/,78.0,,1.2937472972270264e+18,,0.0,0.0,,"RT @LeukemiaMDA: Combination therapy significantly improves survival outcomes for patients w/ acute myeloid #leukemia | 
Lead investigator‚Ä¶",en,0.0,83.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,63.0,15.0,https://twitter.com/acctravassos/statuses/1293747297227026433,0.0,0.0,,0.0,0.0,0.0,15.0,63.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,"RT @LeukemiaMDA: Combination therapy significantly improves survival outcomes for patients w/ acute myeloid #leukemia | 
Lead investigator‚Ä¶",true
ZubairAfzalMD,Hematology/Medical Oncology fellow at NCCC@Dartmouth-Hitchcock| Physician views| Physician ‚â† Provider.,,"Hanover, NH",,2020-08-12 22:38:22+00:00,Zubair Afzal,http://twitter.com/,7.0,,1.2936782403646628e+18,,0.0,0.0,,RT @ASHClinicalNews: Adding isatuximab to carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory #my‚Ä¶,en,0.0,53.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,2.0,https://twitter.com/ZubairAfzalMD/statuses/1293678240364662784,0.0,0.0,,0.0,0.0,0.0,2.0,5.0,False,False,False,False,True,Diagnosis Progression,1.0,0.0,0.0,RT @ASHClinicalNews: Adding isatuximab to carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory #my‚Ä¶,true
garciamanero,"Leukemia physician and Professor of Medicine and Chief of Section of MDS at MD Anderson Cancer Center. Leukemia, maybe some other stuff. All my own opinion.",,Houston,,2020-08-12 23:07:09+00:00,G Garcia-Manero,http://twitter.com/,78.0,,1.2936854844058747e+18,,0.0,0.0,,"RT @LeukemiaMDA: Combination therapy significantly improves survival outcomes for patients w/ acute myeloid #leukemia | 
Lead investigator‚Ä¶",en,0.0,3150.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,63.0,15.0,https://twitter.com/garciamanero/statuses/1293685484405874688,0.0,0.0,,0.0,0.0,0.0,15.0,63.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,"RT @LeukemiaMDA: Combination therapy significantly improves survival outcomes for patients w/ acute myeloid #leukemia | 
Lead investigator‚Ä¶",true
jorgeglezmarqu4,e-MD. Healthcare passionate. Soccer dummy.,,M√©x,,2020-08-12 23:25:51+00:00,jorge gonzalez marquez,http://twitter.com/,78.0,,1.2936901902639882e+18,,0.0,0.0,,"RT @LeukemiaMDA: Combination therapy significantly improves survival outcomes for patients w/ acute myeloid #leukemia | 
Lead investigator‚Ä¶",en,0.0,87.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,63.0,15.0,https://twitter.com/jorgeglezmarqu4/statuses/1293690190263988225,0.0,0.0,,0.0,0.0,0.0,15.0,63.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,"RT @LeukemiaMDA: Combination therapy significantly improves survival outcomes for patients w/ acute myeloid #leukemia | 
Lead investigator‚Ä¶",true
ValerieTheCNL,"Nurse Administrator at MD Anderson Cancer Center, selfie queen. @ me, I love to chat! All tweets are my own, RT does not = endorsement.",,"Houston, TX",,2020-08-12 23:43:15+00:00,Valerie Counts,http://twitter.com/,78.0,,1.293694568798384e+18,,0.0,0.0,,"RT @LeukemiaMDA: Combination therapy significantly improves survival outcomes for patients w/ acute myeloid #leukemia | 
Lead investigator‚Ä¶",en,0.0,178.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,63.0,15.0,https://twitter.com/ValerieTheCNL/statuses/1293694568798384129,0.0,0.0,,0.0,0.0,0.0,15.0,63.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,"RT @LeukemiaMDA: Combination therapy significantly improves survival outcomes for patients w/ acute myeloid #leukemia | 
Lead investigator‚Ä¶",true
allydprice,Physician Assistant at MD Anderson Cancer Center Dept of Leukemia. Spin instructor at Revolution Studio. Tweets are my own.,,"Houston, TX",,2020-08-12 23:50:30+00:00,"Allyson, PA-C",http://twitter.com/,78.0,,1.29369639159697e+18,,0.0,0.0,,"RT @LeukemiaMDA: Combination therapy significantly improves survival outcomes for patients w/ acute myeloid #leukemia | 
Lead investigator‚Ä¶",en,0.0,510.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,63.0,15.0,https://twitter.com/allydprice/statuses/1293696391596969985,0.0,0.0,,0.0,0.0,0.0,15.0,63.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,"RT @LeukemiaMDA: Combination therapy significantly improves survival outcomes for patients w/ acute myeloid #leukemia | 
Lead investigator‚Ä¶",false
cardioPCImom,"Interventional Cardiologist, advocate #CardioObstetrics, #WIC, mother to precocious 6yr old, tweets are my own",,"Gainesville, FL",,2020-10-12 19:47:52+00:00,Ki Park,http://twitter.com/,10.0,,1.315740991593341e+18,,0.0,0.0,,"RT @heartdoc45: TCT week is here!

Medtech #Innovation in the #COVID19 Era: Challenges and Emerging Opportunities at #TCT2020! Wednesday 11‚Ä¶",en,0.0,4511.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,7.0,3.0,https://twitter.com/cardioPCImom/statuses/1315740991593340933,0.0,0.0,,0.0,0.0,0.0,3.0,7.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"RT @heartdoc45: TCT week is here!

Medtech #Innovation in the #COVID19 Era: Challenges and Emerging Opportunities at #TCT2020! Wednesday 11‚Ä¶",true
GoranEBC,"Interventional cardiologist; researcher; professor; trialist
#Bifurcation #LeftMain #EuropeanBifurcationClub #EuroPCR #EAPCI @PCRonline All opinions my own.",,"Belgrade, Republic of Serbia",,2020-10-12 11:49:11+00:00,"Goran Stankovic, MD, PhD",http://twitter.com/,21.0,,1.3156205259144233e+18,,0.0,0.0,,"RT @heartdoc45: TCT week is here! TCT week is here!

Mastering Bifurcation PCI #Innovation session at #TCT2020 Wednesday at 0700 EST

Free‚Ä¶",en,0.0,3114.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,15.0,6.0,https://twitter.com/GoranEBC/statuses/1315620525914423296,0.0,0.0,,0.0,0.0,0.0,6.0,15.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @heartdoc45: TCT week is here! TCT week is here!

Mastering Bifurcation PCI #Innovation session at #TCT2020 Wednesday at 0700 EST

Free‚Ä¶",true
PavanCheruvuMD,"CEO of Sio Gene Therapies. Father, physician and entrepreneur passionate about building great teams and accelerating cutting-edge science into the clinic.",,"New York, USA",,2020-01-21 22:56:16+00:00,"Pavan Cheruvu, M.D.",http://twitter.com/,1.0,,1.2197556218070098e+18,,0.0,0.0,,"RT @axovant: We applaud the Alliance for Regenerative Medicine, #ARM, for spearheading efforts assessing the impact of advanced therapies o‚Ä¶",en,0.0,128.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/PavanCheruvuMD/statuses/1219755621807009795,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"RT @axovant: We applaud the Alliance for Regenerative Medicine, #ARM, for spearheading efforts assessing the impact of advanced therapies o‚Ä¶",true
erodcauCCV,"Padre, esposo, hijo,hermano, amigo, m√©dico, cirujano, doctor, futbolista...MD, PhD, FETCS",,"Sevilla, Espa√±a",,2020-10-18 09:33:40+00:00,Emiliano Rodr√≠guez,http://twitter.com/,68.0,,1.31776075006942e+18,,0.0,0.0,,RT @mmamas1973: #VIVPartner trial #TCTConnect fascinating presentation around valve in valve treatment of failing #SAVR with #TAVR - this i‚Ä¶,en,0.0,549.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,49.0,19.0,https://twitter.com/erodcauCCV/statuses/1317760750069420033,0.0,0.0,,0.0,0.0,0.0,19.0,49.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @mmamas1973: #VIVPartner trial #TCTConnect fascinating presentation around valve in valve treatment of failing #SAVR with #TAVR - this i‚Ä¶,true
heartdoc45,Interventional Cardiologist at @CardioInstitute; Ochsner/Scripps trained; Pearl Jam enthusiast. Views expressed are my own. #RadialFirst,,"Lafayette, Louisiana",,2020-10-03 14:42:20+00:00,"David Homan, MD",http://twitter.com/,8.0,,1.3124026111449866e+18,,0.0,0.0,,"#TCT2020 free registration is open!

Register here: https://t.co/tJi0CzEQR5

On the #Innovation front, my partner‚Ä¶ https://t.co/1UTLorulJt",en,0.0,6040.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,8.0,https://twitter.com/heartdoc45/statuses/1312402611144986626,0.0,0.0,,0.0,0.0,0.0,8.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"#TCT2020 free registration is open!

Register here: https://t.co/tJi0CzEQR5

On the #Innovation front, my partner‚Ä¶ https://t.co/1UTLorulJt",true
pomyers,"Cardiovascular surgeon, Associate editor @CTSNet, Secretary @EBCTS, interested in clinical research. (opinions my own & retweets aren‚Äôt endorsement)",,"Geneva, Switzerland",,2020-10-22 12:59:25+00:00,Patrick Myers,http://twitter.com/,32.0,,1.319262079992406e+18,,0.0,0.0,,"RT @Argenscore: CARDIAC CLASSIFICATION: ‚ÄúAORTIC STENOSIS-DISEASE‚Äù
@PhilGenereuxMD et al.

1661 p from the PARTNER TRIAL

#TCT2020 #TCTConne‚Ä¶",en,0.0,2389.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,23.0,9.0,https://twitter.com/pomyers/statuses/1319262079992406017,0.0,0.0,,0.0,0.0,0.0,9.0,23.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,"RT @Argenscore: CARDIAC CLASSIFICATION: ‚ÄúAORTIC STENOSIS-DISEASE‚Äù
@PhilGenereuxMD et al.

1661 p from the PARTNER TRIAL

#TCT2020 #TCTConne‚Ä¶",false
GBisleri,"Cardiac Surgeon, Minimally Invasive/Structural Heart/Arrhythmia Surgery. Associate Professor, @uoftcvsurgery @uoftmedicine @unityhealthto. Entrepreneur.",,"Toronto, Ontario",,2020-10-22 14:07:16+00:00,"Gianluigi Bisleri, MD",http://twitter.com/,32.0,,1.3192791566647788e+18,,0.0,0.0,,"RT @Argenscore: CARDIAC CLASSIFICATION: ‚ÄúAORTIC STENOSIS-DISEASE‚Äù
@PhilGenereuxMD et al.

1661 p from the PARTNER TRIAL

#TCT2020 #TCTConne‚Ä¶",en,0.0,929.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,23.0,9.0,https://twitter.com/GBisleri/statuses/1319279156664778760,0.0,0.0,,0.0,0.0,0.0,9.0,23.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,"RT @Argenscore: CARDIAC CLASSIFICATION: ‚ÄúAORTIC STENOSIS-DISEASE‚Äù
@PhilGenereuxMD et al.

1661 p from the PARTNER TRIAL

#TCT2020 #TCTConne‚Ä¶",true
adityadoc1,"Interventional Cardiologist,Loma Linda Univ, Early Career Chair CAACC #SoMe Editor#ACCIC, #CHIP #WarOnShock #TAVR #PAD #MountSinai,NY trained. Tweets=my opinion",,"Loma Linda, CA",,2020-10-22 03:31:34+00:00,Aditya Bharadwaj,http://twitter.com/,43.0,,1.3191191766618317e+18,,0.0,0.0,,"RT @AGoldsweig: @Babar_Basir, @BillONeillMD, &amp; @Mike_Hacala lead the virtual #NCSI investigators meeting after #TCT2020. 

So exciting to s‚Ä¶",en,0.0,3591.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,37.0,6.0,https://twitter.com/adityadoc1/statuses/1319119176661831681,0.0,0.0,,0.0,0.0,0.0,6.0,37.0,False,False,False,False,True,Financial Performance,1.0,0.0,0.0,"RT @AGoldsweig: @Babar_Basir, @BillONeillMD, &amp; @Mike_Hacala lead the virtual #NCSI investigators meeting after #TCT2020. 

So exciting to s‚Ä¶",true
FMDTsosglobi,F√©d√©ration nationale des associations de malades touch√©s par la dr√©panocytose et thalass√©mie French Federation for Sickle Cell Disease and Thalassemia patients,,,,2020-10-28 18:46:18+00:00,F√©d√©ration SOS Globi,http://twitter.com/,5.0,,1.321523705093251e+18,,0.0,0.0,,Day 3 of #ASCAT2020 we are happy to be involved in the SCD Patient's Educational Session organized by‚Ä¶ https://t.co/JzpsKymSEH,en,0.0,294.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,5.0,https://twitter.com/FMDTsosglobi/statuses/1321523705093251074,0.0,0.0,,0.0,0.0,0.0,5.0,0.0,False,False,False,False,True,Patient Education,1.0,0.0,0.0,Day 3 of #ASCAT2020 we are happy to be involved in the SCD Patient's Educational Session organized by‚Ä¶ https://t.co/JzpsKymSEH,true
chadialraies,Heart doctor @DMC_Heals Clinician researcher educator #CHIP #PAD #RadialFirst - Founder: https://t.co/CRHKx6HNVb Pub: https://t.co/h3aHzr1oGU -Tweet=my opinion,,"Detroit, MI",,2020-10-16 01:24:23+00:00,"M Chadi Alraies, MD FACC",http://twitter.com/,18.0,,1.3169128431119974e+18,,0.0,0.0,,"RT @crfheart: Have you been following our #TCTConnect ambassadors? With their vast experience and expertise, they‚Äôll help you get a unique‚Ä¶",en,0.0,21439.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,11.0,7.0,https://twitter.com/chadialraies/statuses/1316912843111997440,0.0,0.0,,0.0,0.0,0.0,7.0,11.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,"RT @crfheart: Have you been following our #TCTConnect ambassadors? With their vast experience and expertise, they‚Äôll help you get a unique‚Ä¶",true
BSCCardiology,Boston Scientific Cardiology. We invite physicians in the U.S. to learn about our cardiology & electrophysiology therapies and devices. https://t.co/yQRZwwXVRr,,"St Paul, MN",,2020-10-16 17:45:00+00:00,BostonSci Cardiology,http://twitter.com/,1.0,,1.317159622713643e+18,,0.0,0.0,,Boston Scientific‚Äôs partnership with @SiemensHealth provides innovative offerings to accelerate your cardiovascular‚Ä¶ https://t.co/7VO7JQVxTJ,en,0.0,23588.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/BSCCardiology/statuses/1317159622713643008,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,Boston Scientific‚Äôs partnership with @SiemensHealth provides innovative offerings to accelerate your cardiovascular‚Ä¶ https://t.co/7VO7JQVxTJ,true
gbiondizoccai,"Academic interventional cardiologist, data scientist, & medical writer/reviewer/editor.
All opinions own, (re)tweets/likes not endorsements nor medical advice.",,"Rome, Italy",,2020-10-16 13:17:03+00:00,Giuseppe Biondi-Zoccai,http://twitter.com/,33.0,,1.3170921904269883e+18,,0.0,0.0,,RT @mmamas1973: #TCTConnect join us in the innovation and e-training centre at 10am EST for discussions around SDD and #RadialFirst with Ma‚Ä¶,en,0.0,1321.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,21.0,12.0,https://twitter.com/gbiondizoccai/statuses/1317092190426988544,0.0,0.0,,0.0,0.0,0.0,12.0,21.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @mmamas1973: #TCTConnect join us in the innovation and e-training centre at 10am EST for discussions around SDD and #RadialFirst with Ma‚Ä¶,false
NishithChandra,"#Cardiologist, Passionate about coronary#OCT, Sky Diver, Bungee Jumping
Director #Interventional Cardiologist at N. Delhi's Fortis Escorts #Heart Inst.#INDIA",,New Delhi,,2020-10-16 01:52:40+00:00,ùîªùï£ ‚Ñïùïöùï§ùïôùïöùï•ùïô ‚ÑÇùïôùïíùïüùïïùï£ùïí,http://twitter.com/,11.0,,1.316919961412096e+18,,0.0,0.0,,"RT @crfheart: Have you been following our #TCTConnect ambassadors? With their vast experience and expertise, they‚Äôll help you get a unique‚Ä¶",en,0.0,1780.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,5.0,https://twitter.com/NishithChandra/statuses/1316919961412096013,0.0,0.0,,0.0,0.0,0.0,5.0,6.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,"RT @crfheart: Have you been following our #TCTConnect ambassadors? With their vast experience and expertise, they‚Äôll help you get a unique‚Ä¶",true
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-10-16 16:05:07+00:00,Cardiovascular Research Foundation,http://twitter.com/,22.0,,1.3171344864596132e+18,,0.0,0.0,,RT @NishithChandra: Those missed yesterday's SharkTank ! #TCTConnect #TCT2020 A remarkable Innovation ‚û°Ô∏èNatural Vascular Scaffolding.Dilate‚Ä¶,en,0.0,12239.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,16.0,6.0,https://twitter.com/crfheart/statuses/1317134486459613184,0.0,0.0,,0.0,0.0,0.0,6.0,16.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @NishithChandra: Those missed yesterday's SharkTank ! #TCTConnect #TCT2020 A remarkable Innovation ‚û°Ô∏èNatural Vascular Scaffolding.Dilate‚Ä¶,true
garciamanero,"Leukemia physician and Professor of Medicine and Chief of Section of MDS at MD Anderson Cancer Center. Leukemia, maybe some other stuff. All my own opinion.",,Houston,,2020-07-31 01:30:21+00:00,G Garcia-Manero,http://twitter.com/,16.0,,1.2890104775829545e+18,,0.0,0.0,,RT @ecancer: #EHA25: Dr Elias Jabbour of @MDAndersonNews discusses the use of venetoclax plus navitoclax in relapsed/refractory ALL and lym‚Ä¶,en,0.0,3150.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,12.0,4.0,https://twitter.com/garciamanero/statuses/1289010477582954496,0.0,0.0,,0.0,0.0,0.0,4.0,12.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @ecancer: #EHA25: Dr Elias Jabbour of @MDAndersonNews discusses the use of venetoclax plus navitoclax in relapsed/refractory ALL and lym‚Ä¶,true
cgfran01,"dad, physician, scientist, musician",,,,2020-11-05 14:56:12+00:00,cedric francois,http://twitter.com/,16.0,,1.3243649016960983e+18,,0.0,0.0,,"RT @ApellisPharma: Today, we announced that eight abstracts highlighting our #PNH scientific research were accepted at the virtual @ASH_hem‚Ä¶",en,0.0,510.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,9.0,7.0,https://twitter.com/cgfran01/statuses/1324364901696098304,0.0,0.0,,0.0,0.0,0.0,7.0,9.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @ApellisPharma: Today, we announced that eight abstracts highlighting our #PNH scientific research were accepted at the virtual @ASH_hem‚Ä¶",true
dgermain21,MD-PhD. 2nd year Heme/Onc fellow focused on lymphoma and leukemia. Physician-scientist-in-training. Tweet/RT not medical advice or endorsement.,,"St. Louis, MO",,2020-11-20 01:06:26+00:00,David A. Russler-Germain,http://twitter.com/,55.0,,1.329591902648361e+18,,0.0,0.0,,RT @MediHumdani: Phase 1 Study of Lonca-T CD19 ADC in R/R B-Cell NHL | @BloodJournal  | ORR in DLBCL ~45% (active pre / post #CART) @ccarlo‚Ä¶,en,0.0,1612.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,42.0,13.0,https://twitter.com/dgermain21/statuses/1329591902648360963,0.0,0.0,,0.0,0.0,0.0,13.0,42.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @MediHumdani: Phase 1 Study of Lonca-T CD19 ADC in R/R B-Cell NHL | @BloodJournal  | ORR in DLBCL ~45% (active pre / post #CART) @ccarlo‚Ä¶,true
Areejmd,An oncologist with a passion to improve the quality of life and care of patients with hematologic malignancies #ASH #PallOnc #CIBMTR #ASBMT @MGHCancerCenter,,"Boston, MA",,2020-11-20 22:33:25+00:00,Areej El-Jawahri,http://twitter.com/,14.0,,1.3299157791610798e+18,,0.0,0.0,,"RT @Jmarksloan: Survival after autoSCT unaffected by HTLV status.  AlloSCT OS  worse in HTLV+ pts, partly due to higher non-relapse mortali‚Ä¶",en,0.0,957.0,,,0.0,,,Negative,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,9.0,5.0,https://twitter.com/Areejmd/statuses/1329915779161079809,0.0,0.0,,0.0,0.0,0.0,5.0,9.0,False,False,False,False,True,Diagnosis Progression,0.0,1.0,0.0,"RT @Jmarksloan: Survival after autoSCT unaffected by HTLV status.  AlloSCT OS  worse in HTLV+ pts, partly due to higher non-relapse mortali‚Ä¶",false
sairah__ahmed,"Lymphoma/Cellular Therapy & SCT at MD Anderson Cancer Center, opinions/tweets shared= my own.",,"Houston, TX",,2020-11-20 23:46:22+00:00,Sairah Ahmed MD,http://twitter.com/,55.0,,1.3299341383344538e+18,,0.0,0.0,,RT @MediHumdani: Phase 1 Study of Lonca-T CD19 ADC in R/R B-Cell NHL | @BloodJournal  | ORR in DLBCL ~45% (active pre / post #CART) @ccarlo‚Ä¶,en,0.0,491.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,42.0,13.0,https://twitter.com/sairah__ahmed/statuses/1329934138334453763,0.0,0.0,,0.0,0.0,0.0,13.0,42.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @MediHumdani: Phase 1 Study of Lonca-T CD19 ADC in R/R B-Cell NHL | @BloodJournal  | ORR in DLBCL ~45% (active pre / post #CART) @ccarlo‚Ä¶,true
DitaGratzinger,"Comments are my personal opinions and do not represent official statements on behalf of Stanford.
Associate Professor, Hematopathologist",,"Stanford, CA",,2020-11-20 21:01:05+00:00,"Dita Gratzinger, MD, PhD",http://twitter.com/,14.0,,1.3298925460135895e+18,,0.0,0.0,,"RT @Jmarksloan: Survival after autoSCT unaffected by HTLV status.  AlloSCT OS  worse in HTLV+ pts, partly due to higher non-relapse mortali‚Ä¶",en,0.0,1348.0,,,0.0,,,Negative,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,9.0,5.0,https://twitter.com/DitaGratzinger/statuses/1329892546013589504,0.0,0.0,,0.0,0.0,0.0,5.0,9.0,False,False,False,False,True,Diagnosis Progression,0.0,1.0,0.0,"RT @Jmarksloan: Survival after autoSCT unaffected by HTLV status.  AlloSCT OS  worse in HTLV+ pts, partly due to higher non-relapse mortali‚Ä¶",true
AnandPheresisMD,"Transfusion Med MD & Platelet Immunologist; Physician, Mayo Clinic; Co-Founder & Chief Science Officer, Retham Technologies; Opinions my own; Not medical advice",,"Rochester, MN",,2020-11-20 01:18:57+00:00,Anand Padmanabhan,http://twitter.com/,2.0,,1.3295950528432087e+18,,0.0,0.0,,"RT @mayocliniclabs: ""The risks associated with delayed diagnosis and misdiagnosis of heparin-induced thrombocytopenia can be high."" Learn m‚Ä¶",en,0.0,120.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,1.0,1.0,https://twitter.com/AnandPheresisMD/statuses/1329595052843208704,0.0,0.0,,0.0,0.0,0.0,1.0,1.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"RT @mayocliniclabs: ""The risks associated with delayed diagnosis and misdiagnosis of heparin-induced thrombocytopenia can be high."" Learn m‚Ä¶",true
drjgauthier,"MD, MSc, Assistant Professor @fredhutch @UW focused on #CARTcell #immunotherapy #tcellrx 
Interests also include #rstats #bmtsm #epitwitter #bayes",,"Seattle, WA",,2020-11-20 01:07:38+00:00,Jordan Gauthier,http://twitter.com/,55.0,,1.3295922049023508e+18,,0.0,0.0,,RT @MediHumdani: Phase 1 Study of Lonca-T CD19 ADC in R/R B-Cell NHL | @BloodJournal  | ORR in DLBCL ~45% (active pre / post #CART) @ccarlo‚Ä¶,en,0.0,3295.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,42.0,13.0,https://twitter.com/drjgauthier/statuses/1329592204902350848,0.0,0.0,,0.0,0.0,0.0,13.0,42.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @MediHumdani: Phase 1 Study of Lonca-T CD19 ADC in R/R B-Cell NHL | @BloodJournal  | ORR in DLBCL ~45% (active pre / post #CART) @ccarlo‚Ä¶,true
MediHumdani,"Director, BMT & Cellular Therapy Program @Froedtert & @MedicalCollege | Lymphoma | Clinical Trials | @CIBMTR | @BMTCTN | Personal views | Physician ‚â† Provider",,"Milwaukee, WI",,2020-11-20 01:05:00+00:00,Mehdi Hamadani,http://twitter.com/,13.0,,1.3295915424037642e+18,,0.0,0.0,,Phase 1 Study of Lonca-T CD19 ADC in R/R B-Cell NHL | @BloodJournal  | ORR in DLBCL ~45% (active pre / post #CART)‚Ä¶ https://t.co/OGVRLM8B6F,en,0.0,4590.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,13.0,https://twitter.com/MediHumdani/statuses/1329591542403764224,0.0,0.0,,0.0,0.0,0.0,13.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,Phase 1 Study of Lonca-T CD19 ADC in R/R B-Cell NHL | @BloodJournal  | ORR in DLBCL ~45% (active pre / post #CART)‚Ä¶ https://t.co/OGVRLM8B6F,true
NavinKapur4,Interventional Heart Failure Specialist; Physician-Scientist,,,,2020-10-20 23:20:36+00:00,Navin Kapur,http://twitter.com/,3.0,,1.3186936333784064e+18,,0.0,0.0,,RT @TCTConference: Step into the #TCT2020 Shark Tank! Tune in at 11:00 AM ET to watch the first 3 teams compete for the top innovation priz‚Ä¶,en,0.0,1408.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,2.0,1.0,https://twitter.com/NavinKapur4/statuses/1318693633378406402,0.0,0.0,,0.0,0.0,0.0,1.0,2.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @TCTConference: Step into the #TCT2020 Shark Tank! Tune in at 11:00 AM ET to watch the first 3 teams compete for the top innovation priz‚Ä¶,false
tomleblancMD,"#Patientexperience & cancer outcomes researcher, #leukemia & #palliative care doc. Improving #QOL #decisionmaking #hapc in #hematology. Tweets mine ‚â† med advice",,"Durham, NC",,2020-10-26 20:07:42+00:00,"Thomas LeBlanc, MD, MA, MHS, FAAHPM",http://twitter.com/,0.0,,1.3208194133822874e+18,,0.0,0.0,,@doctorpemm @sanamloghavi @MrinalPatnaik @Transplant_Doc @LeukemiaMDA @sanjayvdesai happy birthday @doctorpemm!  Ho‚Ä¶ https://t.co/REKXkarpCc,en,0.0,4390.0,,,0.0,doctorpemm,1.32080004924117e+18,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/tomleblancMD/statuses/1320819413382287361,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnostic Tools,1.0,0.0,0.0,@doctorpemm @sanamloghavi @MrinalPatnaik @Transplant_Doc @LeukemiaMDA @sanjayvdesai happy birthday @doctorpemm!  Ho‚Ä¶ https://t.co/REKXkarpCc,true
DrAnkushG,"Professor of Medicine & Interventional Cardiologist, #Radial First #CTO #CHIP # BMV #CardioTwitter drankushgupta@gmail.com",,"New Delhi, India",,2020-10-16 13:04:43+00:00,Ankush Gupta,http://twitter.com/,22.0,,1.317089087325565e+18,,0.0,0.0,,RT @NishithChandra: Those missed yesterday's SharkTank ! #TCTConnect #TCT2020 A remarkable Innovation ‚û°Ô∏èNatural Vascular Scaffolding.Dilate‚Ä¶,en,0.0,1156.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,16.0,6.0,https://twitter.com/DrAnkushG/statuses/1317089087325564930,0.0,0.0,,0.0,0.0,0.0,6.0,16.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @NishithChandra: Those missed yesterday's SharkTank ! #TCTConnect #TCT2020 A remarkable Innovation ‚û°Ô∏èNatural Vascular Scaffolding.Dilate‚Ä¶,true
Drroxmehran,"Interventional cardiologist, Professor of Medicine @mountsinaiNYC, trialist, outcomes researcher, wife and mother; opinions my own #ACCBOT @womenas1",,"Manhattan, NY",,2020-10-16 14:44:28+00:00,Roxana Mehran,http://twitter.com/,10.0,,1.317114192462336e+18,,0.0,0.0,,RT @crfheart: Step into the #TCT2020 Shark Tank! Tune in at 11:00 AM ET to watch the next 3 teams compete for the top innovation prize at #‚Ä¶,en,0.0,9783.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,7.0,3.0,https://twitter.com/Drroxmehran/statuses/1317114192462336000,0.0,0.0,,0.0,0.0,0.0,3.0,7.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @crfheart: Step into the #TCT2020 Shark Tank! Tune in at 11:00 AM ET to watch the next 3 teams compete for the top innovation prize at #‚Ä¶,true
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-10-14 15:30:28+00:00,Cardiovascular Research Foundation,http://twitter.com/,1.0,,1.316400990514557e+18,,0.0,0.0,,Leading experts take on current controversies in #TAVR in the next #TCTConnect Middle East session at 12:00 PM ET‚Ä¶ https://t.co/coDvw9TSsC,en,0.0,12239.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/crfheart/statuses/1316400990514556929,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,Leading experts take on current controversies in #TAVR in the next #TCTConnect Middle East session at 12:00 PM ET‚Ä¶ https://t.co/coDvw9TSsC,true
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-09-21 14:29:08+00:00,Cardiovascular Research Foundation,http://twitter.com/,41.0,,1.3080506333254492e+18,,0.0,0.0,,"RT @mryburns: Busy day filming for #TCTConnect #tct2020 Innovative, elegantly performed hybrid #ViV #TMVR ‚Äî Very honored to be a part of th‚Ä¶",en,0.0,12239.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,33.0,8.0,https://twitter.com/crfheart/statuses/1308050633325449216,0.0,0.0,,0.0,0.0,0.0,8.0,33.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"RT @mryburns: Busy day filming for #TCTConnect #tct2020 Innovative, elegantly performed hybrid #ViV #TMVR ‚Äî Very honored to be a part of th‚Ä¶",true
Drroxmehran,"Interventional cardiologist, Professor of Medicine @mountsinaiNYC, trialist, outcomes researcher, wife and mother; opinions my own #ACCBOT @womenas1",,"Manhattan, NY",,2020-09-25 00:10:01+00:00,Roxana Mehran,http://twitter.com/,22.0,,1.3092839822075863e+18,,0.0,0.0,,RT @crfheart: Want a front-row seat to #innovation? Join us next month at #TCTConnect! Registration is FREE: https://t.co/KWSbMwmu0f #TCT20‚Ä¶,en,0.0,9783.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,12.0,10.0,https://twitter.com/Drroxmehran/statuses/1309283982207586305,0.0,0.0,,0.0,0.0,0.0,10.0,12.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @crfheart: Want a front-row seat to #innovation? Join us next month at #TCTConnect! Registration is FREE: https://t.co/KWSbMwmu0f #TCT20‚Ä¶,false
sahilparikhmd,"Interventional Cardiologist, Vascular Medicine, Clinician Educator and Clinical Researcher, Husband/Father, Friend. My views only; not medical advice.",,"New York, NY",,2020-09-25 02:09:02+00:00,"Sahil A. Parikh, MD",http://twitter.com/,13.0,,1.309313933136855e+18,,0.0,0.0,,RT @TCTConference: Experience #innovation in action at #TCTConnect! Register now for FREE: https://t.co/kHX7qNvGJj #TCT2020 #interventional‚Ä¶,en,0.0,1410.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,8.0,5.0,https://twitter.com/sahilparikhmd/statuses/1309313933136855040,0.0,0.0,,0.0,0.0,0.0,5.0,8.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @TCTConference: Experience #innovation in action at #TCTConnect! Register now for FREE: https://t.co/kHX7qNvGJj #TCT2020 #interventional‚Ä¶,true
majorajay,"Hematology/oncology fellow. #lymsm & #mmsm outcomes researcher. Physician-publisher & founder of https://t.co/dPfLt8QVMr, @inTrainingDoc & @inHouseMag.",,"Chicago, IL",,2020-10-20 22:27:03+00:00,"Ajay Major, MD, MBA",http://twitter.com/,1.0,,1.318680154969936e+18,,0.0,0.0,,"Did everyone see that the @ASH_hematology #ASH20 annual meeting keynote speaker is going to be Dr. Fauci?!

This is‚Ä¶ https://t.co/Bdy7JSrXIw",en,0.0,3518.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/majorajay/statuses/1318680154969935883,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Thought Leadership,0.0,0.0,1.0,"Did everyone see that the @ASH_hematology #ASH20 annual meeting keynote speaker is going to be Dr. Fauci?!

This is‚Ä¶ https://t.co/Bdy7JSrXIw",true
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-09-25 00:24:52+00:00,Cardiovascular Research Foundation,http://twitter.com/,4.0,,1.3092877186529116e+18,,0.0,0.0,,RT @TCTConference: Tune in to #TCTConnect to watch the TCT Shark Tank #Innovation Competition. #TCT2020 Register for FREE now! https://t.co‚Ä¶,en,0.0,12239.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,1.0,https://twitter.com/crfheart/statuses/1309287718652911616,0.0,0.0,,0.0,0.0,0.0,1.0,3.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @TCTConference: Tune in to #TCTConnect to watch the TCT Shark Tank #Innovation Competition. #TCT2020 Register for FREE now! https://t.co‚Ä¶,true
Kfarooqi,"Pediatric cardiologist,3D printing, echo, fetal,CMR, CCT, AR/VR @Kidsatcolumbia @SCCT #futureleaders,@journalCCT #SoMe Editor, @scmr #SoMe subcommittee",,"New York, NY",,2020-09-25 03:20:34+00:00,Dr. Kanwal M Farooqi,http://twitter.com/,22.0,,1.309331934573736e+18,,0.0,0.0,,RT @crfheart: Want a front-row seat to #innovation? Join us next month at #TCTConnect! Registration is FREE: https://t.co/KWSbMwmu0f #TCT20‚Ä¶,en,0.0,1980.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,12.0,10.0,https://twitter.com/Kfarooqi/statuses/1309331934573735936,0.0,0.0,,0.0,0.0,0.0,10.0,12.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @crfheart: Want a front-row seat to #innovation? Join us next month at #TCTConnect! Registration is FREE: https://t.co/KWSbMwmu0f #TCT20‚Ä¶,true
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-09-25 00:00:39+00:00,Cardiovascular Research Foundation,http://twitter.com/,10.0,,1.3092816275085517e+18,,0.0,0.0,,Want a front-row seat to #innovation? Join us next month at #TCTConnect! Registration is FREE:‚Ä¶ https://t.co/78ZR0yqHuN,en,0.0,12239.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,10.0,https://twitter.com/crfheart/statuses/1309281627508551688,0.0,0.0,,0.0,0.0,0.0,10.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,Want a front-row seat to #innovation? Join us next month at #TCTConnect! Registration is FREE:‚Ä¶ https://t.co/78ZR0yqHuN,true
AnkitaGore1,IM Resident Physician @StonyBrookMed | @ColumbiaBME and @RWJMS alum | Biomedical Engineer | #DesignThinking #HealthcareInnovation,,"New York, USA",,2020-09-25 01:59:12+00:00,"Ankita Gore, MD",http://twitter.com/,13.0,,1.3093114605359473e+18,,0.0,0.0,,RT @TCTConference: Experience #innovation in action at #TCTConnect! Register now for FREE: https://t.co/kHX7qNvGJj #TCT2020 #interventional‚Ä¶,en,0.0,137.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,8.0,5.0,https://twitter.com/AnkitaGore1/statuses/1309311460535947264,0.0,0.0,,0.0,0.0,0.0,5.0,8.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @TCTConference: Experience #innovation in action at #TCTConnect! Register now for FREE: https://t.co/kHX7qNvGJj #TCT2020 #interventional‚Ä¶,false
mshadman,"Associate Professor,  Fred Hutchinson, U of Washington. Lymphoma/CLL oncologist.  Tweets are mine.",,"Seattle, WA",,2020-10-21 01:34:05+00:00,"Mazyar Shadman, MD MPH",http://twitter.com/,67.0,,1.3187272244936827e+18,,0.0,0.0,,RT @ASH_hematology: @NIAIDNews Director Dr. Anthony Fauci is the #ASH20 keynote speaker! Join ASH President @StephanieLeeMD &amp; Dr. Fauci as‚Ä¶,en,0.0,927.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,49.0,18.0,https://twitter.com/mshadman/statuses/1318727224493682688,0.0,0.0,,0.0,0.0,0.0,18.0,49.0,False,False,False,False,True,Thought Leadership,0.0,0.0,1.0,RT @ASH_hematology: @NIAIDNews Director Dr. Anthony Fauci is the #ASH20 keynote speaker! Join ASH President @StephanieLeeMD &amp; Dr. Fauci as‚Ä¶,true
PradeepYadavMD,"Interventional Cardiologist, Structural Heart Disease, Tweets are my own opinion",,"Atlanta, USA",,2020-10-10 16:27:26+00:00,Pradeep Yadav,http://twitter.com/,5.0,,1.314965776118448e+18,,0.0,0.0,,So looking forward! #TCT2020 #TCTConnect Incredible effort by @crfheart and all participating sites/speakers. Watch‚Ä¶ https://t.co/genmuipVv7,en,0.0,3149.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,5.0,https://twitter.com/PradeepYadavMD/statuses/1314965776118448130,0.0,0.0,,0.0,0.0,0.0,5.0,0.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,So looking forward! #TCT2020 #TCTConnect Incredible effort by @crfheart and all participating sites/speakers. Watch‚Ä¶ https://t.co/genmuipVv7,true
AnkitaGore1,IM Resident Physician @StonyBrookMed | @ColumbiaBME and @RWJMS alum | Biomedical Engineer | #DesignThinking #HealthcareInnovation,,"New York, USA",,2020-10-10 21:56:15+00:00,"Ankita Gore, MD",http://twitter.com/,2.0,,1.3150485263558533e+18,,0.0,0.0,,Unexpected benefit of the pandemic - conferences for FREE at our fingertips! With no coordinating days off or need‚Ä¶ https://t.co/U9d0ceM0TY,en,0.0,137.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/AnkitaGore1/statuses/1315048526355853313,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Covid,0.0,0.0,1.0,Unexpected benefit of the pandemic - conferences for FREE at our fingertips! With no coordinating days off or need‚Ä¶ https://t.co/U9d0ceM0TY,true
ClinOncNews,"An independent source of unbiased, accurate, reliable news and in-depth expert analysis on issues oncologists and hematologist/oncologists care about most.",,New York City,,2020-10-10 15:15:10+00:00,ClinicalOncologyNews,http://twitter.com/,1.0,,1.3149475894402458e+18,,0.0,0.0,,New treatment options for acute myeloid #leukemia are pushing out old standards. https://t.co/BOBlHYjaLu @ASCO‚Ä¶ https://t.co/PHcC0MSE5X,en,0.0,3172.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/ClinOncNews/statuses/1314947589440245762,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,New treatment options for acute myeloid #leukemia are pushing out old standards. https://t.co/BOBlHYjaLu @ASCO‚Ä¶ https://t.co/PHcC0MSE5X,true
DrTomWaggoner,"Dr. Thomas E. Waggoner, DO, FACC, FSCAI, FSVM, RPVI; Director #StructuralHeart Program, Director Cardiovascular Research @TweetPimaHeart @tmcaznews #TAVR",,,,2020-10-10 21:58:10+00:00,Thomas Waggoner,http://twitter.com/,10.0,,1.3150490092920832e+18,,0.0,0.0,,RT @BSCCardiology: Mark your #TCTConnect calendar for the Symposium: WATCHMAN‚Ñ¢ FLX: Elevating LAAC Therapy Through Innovation &amp; Clinical Sc‚Ä¶,en,0.0,546.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,4.0,https://twitter.com/DrTomWaggoner/statuses/1315049009292083200,0.0,0.0,,0.0,0.0,0.0,4.0,6.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @BSCCardiology: Mark your #TCTConnect calendar for the Symposium: WATCHMAN‚Ñ¢ FLX: Elevating LAAC Therapy Through Innovation &amp; Clinical Sc‚Ä¶,true
BSCCardiology,Boston Scientific Cardiology. We invite physicians in the U.S. to learn about our cardiology & electrophysiology therapies and devices. https://t.co/yQRZwwXVRr,,"St Paul, MN",,2020-10-09 20:04:31+00:00,BostonSci Cardiology,http://twitter.com/,0.0,,1.3146580180391567e+18,,0.0,0.0,,Mark your #TCTConnect calendar for the Symposium: WATCHMAN‚Ñ¢ FLX: Elevating LAAC Therapy Through Innovation &amp; Clinic‚Ä¶ https://t.co/WW7yI17gcY,en,0.0,23588.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/BSCCardiology/statuses/1314658018039156736,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,Mark your #TCTConnect calendar for the Symposium: WATCHMAN‚Ñ¢ FLX: Elevating LAAC Therapy Through Innovation &amp; Clinic‚Ä¶ https://t.co/WW7yI17gcY,false
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-10-10 19:45:46+00:00,Cardiovascular Research Foundation,http://twitter.com/,18.0,,1.315015688579285e+18,,0.0,0.0,,RT @PradeepYadavMD: So looking forward! #TCT2020 #TCTConnect Incredible effort by @crfheart and all participating sites/speakers. Watch out‚Ä¶,en,0.0,12239.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,13.0,5.0,https://twitter.com/crfheart/statuses/1315015688579284992,0.0,0.0,,0.0,0.0,0.0,5.0,13.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,RT @PradeepYadavMD: So looking forward! #TCT2020 #TCTConnect Incredible effort by @crfheart and all participating sites/speakers. Watch out‚Ä¶,true
UjjwalRastogiMD,‚ñ™Ô∏èInterventional/Endovascular Cardiologist ‚ñ™Ô∏è@ACCinTouch committee ‚ñ™Ô∏è@MountSinaiNYC alumnus‚ñ™Ô∏è#CHIP #CLI #RadialFirst #SafeFemoral #PAD #PVD ‚ñ™Ô∏èTweets/RT ‚â† Advice,,"Kanpur, India / New York, USA",,2020-10-09 17:40:59+00:00,"Ujjwal Rastogi, MD",http://twitter.com/,12.0,,1.3146218992767754e+18,,0.0,0.0,,"RT @heartdoc45: Sirolimus-Coated Balloon: What the FUTURE holds for PAD #Innovation session at #TCT2020

Free registration for TCT: https:/‚Ä¶",en,0.0,1517.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,2.0,https://twitter.com/UjjwalRastogiMD/statuses/1314621899276775427,0.0,0.0,,0.0,0.0,0.0,2.0,10.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @heartdoc45: Sirolimus-Coated Balloon: What the FUTURE holds for PAD #Innovation session at #TCT2020

Free registration for TCT: https:/‚Ä¶",true
BSCCardiology,Boston Scientific Cardiology. We invite physicians in the U.S. to learn about our cardiology & electrophysiology therapies and devices. https://t.co/yQRZwwXVRr,,"St Paul, MN",,2020-10-09 19:49:47+00:00,BostonSci Cardiology,http://twitter.com/,2.0,,1.314654309678801e+18,,0.0,0.0,,"Working in solidarity with physicians, patients and industry to transform lives. Join us at #TCTConnect for access‚Ä¶ https://t.co/pHN518kxYd",en,0.0,23588.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/BSCCardiology/statuses/1314654309678800897,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,"Working in solidarity with physicians, patients and industry to transform lives. Join us at #TCTConnect for access‚Ä¶ https://t.co/pHN518kxYd",true
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-10-09 17:18:51+00:00,Cardiovascular Research Foundation,http://twitter.com/,12.0,,1.3146163261581926e+18,,0.0,0.0,,"RT @heartdoc45: Sirolimus-Coated Balloon: What the FUTURE holds for PAD #Innovation session at #TCT2020

Free registration for TCT: https:/‚Ä¶",en,0.0,12239.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,2.0,https://twitter.com/crfheart/statuses/1314616326158192640,0.0,0.0,,0.0,0.0,0.0,2.0,10.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @heartdoc45: Sirolimus-Coated Balloon: What the FUTURE holds for PAD #Innovation session at #TCT2020

Free registration for TCT: https:/‚Ä¶",true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-01-18 02:53:03+00:00,Oncology Tube,http://twitter.com/,0.0,,1.2183656555246592e+18,,0.0,0.0,,"Phase 2 Study of Luspatercept Commonly Asked Questions #ASH19 @CleClinicMD: Aaron Gerds, MD of @CleClinicMD discuss‚Ä¶ https://t.co/kpVkElhvz0",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1218365655524659200,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"Phase 2 Study of Luspatercept Commonly Asked Questions #ASH19 @CleClinicMD: Aaron Gerds, MD of @CleClinicMD discuss‚Ä¶ https://t.co/kpVkElhvz0",true
heartdoc45,Interventional Cardiologist at @CardioInstitute; Ochsner/Scripps trained; Pearl Jam enthusiast. Views expressed are my own. #RadialFirst,,"Lafayette, Louisiana",,2020-10-09 15:45:11+00:00,"David Homan, MD",http://twitter.com/,2.0,,1.3145927561662095e+18,,0.0,0.0,,"Sirolimus-Coated Balloon: What the FUTURE holds for PAD #Innovation session at #TCT2020

Free registration for TCT:‚Ä¶ https://t.co/aZ7g9CVrZd",en,0.0,6040.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/heartdoc45/statuses/1314592756166209536,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"Sirolimus-Coated Balloon: What the FUTURE holds for PAD #Innovation session at #TCT2020

Free registration for TCT:‚Ä¶ https://t.co/aZ7g9CVrZd",false
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-01-18 15:01:03+00:00,Oncology Tube,http://twitter.com/,0.0,,1.2185488626688287e+18,,0.0,0.0,,"Phase II Study of Oral Rigosertib #ASH19 @MountSinaiNYC: Shyamala Navada, MD of @MountSinaiNYC discusses the phase‚Ä¶ https://t.co/VEJ0sZBg9y",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1218548862668828672,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"Phase II Study of Oral Rigosertib #ASH19 @MountSinaiNYC: Shyamala Navada, MD of @MountSinaiNYC discusses the phase‚Ä¶ https://t.co/VEJ0sZBg9y",true
CardioInstitute,"Cardiovascular Institute of the South is a team of more than 900 & 60 physicians providing advanced cardiovascular care across Louisiana, Mississippi & beyond.",,"Louisiana, USA; MS",,2020-10-03 14:55:50+00:00,Cardiovascular Institute of the South,http://twitter.com/,18.0,,1.312406009357443e+18,,0.0,0.0,,"RT @heartdoc45: #TCT2020 free registration is open!

Register here: https://t.co/tJi0CzEQR5

On the #Innovation front, my partner @ALodha_m‚Ä¶",en,0.0,2611.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,8.0,https://twitter.com/CardioInstitute/statuses/1312406009357443072,0.0,0.0,,0.0,0.0,0.0,8.0,10.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @heartdoc45: #TCT2020 free registration is open!

Register here: https://t.co/tJi0CzEQR5

On the #Innovation front, my partner @ALodha_m‚Ä¶",true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-01-29 18:51:04+00:00,Oncology Tube,http://twitter.com/,0.0,,1.222593018198278e+18,,0.0,0.0,,Phase I Study Evaluating NKTR-255 in MM and NHL #ASH #ASH19 @DanaFarber: Nikhil Munshi of @DanaFarber discusses the‚Ä¶ https://t.co/M3nNblrWhF,en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1222593018198278145,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,Phase I Study Evaluating NKTR-255 in MM and NHL #ASH #ASH19 @DanaFarber: Nikhil Munshi of @DanaFarber discusses the‚Ä¶ https://t.co/M3nNblrWhF,true
sahilparikhmd,"Interventional Cardiologist, Vascular Medicine, Clinician Educator and Clinical Researcher, Husband/Father, Friend. My views only; not medical advice.",,"New York, NY",,2020-10-03 01:34:41+00:00,"Sahil A. Parikh, MD",http://twitter.com/,9.0,,1.3122043948389335e+18,,0.0,0.0,,RT @TCTConference: TCT‚Äôs Shark Tank is here again! Join us during #TCTConnect to watch 6 teams compete for the top innovation prize &amp; win $‚Ä¶,en,0.0,1410.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,3.0,https://twitter.com/sahilparikhmd/statuses/1312204394838933504,0.0,0.0,,0.0,0.0,0.0,3.0,6.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @TCTConference: TCT‚Äôs Shark Tank is here again! Join us during #TCTConnect to watch 6 teams compete for the top innovation prize &amp; win $‚Ä¶,true
HSrinagesh,MD/MSCR. PGY-1 at Stanford Internal Medicine by way of Icahn School of Medicine at Mount Sinai and Williams College.,,"Manhattan, NY",,2020-01-29 22:14:40+00:00,Hrishi Srinagesh,http://twitter.com/,10.0,,1.2226442529513144e+18,,0.0,0.0,,RT @viracoreurofins: Will you be attending #TCTM20? Drs. James Ferrara &amp; Ryotaro Nakamura will be presenting ‚ÄúGVHD Diagnostics: Using the M‚Ä¶,en,0.0,117.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,4.0,https://twitter.com/HSrinagesh/statuses/1222644252951314434,0.0,0.0,,0.0,0.0,0.0,4.0,6.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @viracoreurofins: Will you be attending #TCTM20? Drs. James Ferrara &amp; Ryotaro Nakamura will be presenting ‚ÄúGVHD Diagnostics: Using the M‚Ä¶,true
davidhenrymd,"Practicing MD Hematologist Oncologist 
Vice Chair Dept of Medicine Pennsylvania Hospital Blood&Cancer host Research-supportive care @MDedgeTweets @MDedgeHemeOnc",,"Philadelphia, PA",,2020-01-18 14:00:09+00:00,David Henry,http://twitter.com/,0.0,,1.2185335364640645e+18,,0.0,0.0,,"Study from #ASH19 investigates how to predict TTP relapse in pregnancy, authors suggest following ADAMSTS13 level a‚Ä¶ https://t.co/pc0YDMsRNF",en,0.0,1771.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/davidhenrymd/statuses/1218533536464064513,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"Study from #ASH19 investigates how to predict TTP relapse in pregnancy, authors suggest following ADAMSTS13 level a‚Ä¶ https://t.co/pc0YDMsRNF",false
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-01-18 02:23:03+00:00,Oncology Tube,http://twitter.com/,0.0,,1.2183581059703972e+18,,0.0,0.0,,"Therapy for Secondary and Relapsed/ Refractory AML #ASH19 @RoswellPark: Eunice Wang, MD of @RoswellPark discusses c‚Ä¶ https://t.co/aZez9RjVDN",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1218358105970397184,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"Therapy for Secondary and Relapsed/ Refractory AML #ASH19 @RoswellPark: Eunice Wang, MD of @RoswellPark discusses c‚Ä¶ https://t.co/aZez9RjVDN",true
docsaw,"Professor, Interventional Cardiologist, Vancouver General Hospital, UBC. Associate Editor #JACCINT. My own tweets #SCAD, #vanscad, #canscad, #LAAC, #LAAO, #FMD",,"Vancouver, BC, Canada",,2020-01-31 15:28:44+00:00,Jacqueline Saw,http://twitter.com/,37.0,,1.2232668719040348e+18,,0.0,0.0,,"RT @DeeDeeWangMD: Honored to be a part of 2020 @TCTConference PDC. Behind the scenes session planning, will be innovative #TCT2020 @crfhear‚Ä¶",en,0.0,2520.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,30.0,7.0,https://twitter.com/docsaw/statuses/1223266871904034817,0.0,0.0,,0.0,0.0,0.0,7.0,30.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"RT @DeeDeeWangMD: Honored to be a part of 2020 @TCTConference PDC. Behind the scenes session planning, will be innovative #TCT2020 @crfhear‚Ä¶",true
abhinav_deol,MD,,"Detroit, MI",,2020-02-20 16:11:27+00:00,Abhinav Deol,http://twitter.com/,1.0,,1.230525379108053e+18,,0.0,0.0,,"#TCTM20 Dr. Christopher: down regulation of MHC II  genes on AML cell may lead to relapse, which may be fixed with‚Ä¶ https://t.co/Yfuqd5hlVv",en,0.0,251.0,,,0.0,abhinav_deol,1.2305242467718636e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/abhinav_deol/statuses/1230525379108052992,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"#TCTM20 Dr. Christopher: down regulation of MHC II  genes on AML cell may lead to relapse, which may be fixed with‚Ä¶ https://t.co/Yfuqd5hlVv",true
abhinav_deol,MD,,"Detroit, MI",,2020-02-20 15:57:13+00:00,Abhinav Deol,http://twitter.com/,1.0,,1.2305217969585316e+18,,0.0,0.0,,#TCTM20  Dr. Minnie: Plasma cells inhibit alloreactive T cells leading to inhibition of GVM --&gt;  poor post allo tra‚Ä¶ https://t.co/lHWvTG7VPP,en,0.0,251.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/abhinav_deol/statuses/1230521796958531584,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,#TCTM20  Dr. Minnie: Plasma cells inhibit alloreactive T cells leading to inhibition of GVM --&gt;  poor post allo tra‚Ä¶ https://t.co/lHWvTG7VPP,true
NinaOrfali,Myeloid / BMT Physician @stjamesdublin @tcddublin,,"Dublin City, Ireland",,2020-02-20 23:28:47+00:00,Nina Orfali,http://twitter.com/,2.0,,1.2306354413947986e+18,,0.0,0.0,,"#TCTM20 science: #Autophagy in gut and liver protective of #GVHD related mortality in murine models..........
Clini‚Ä¶ https://t.co/QSjudAkmsu",en,0.0,257.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/NinaOrfali/statuses/1230635441394798592,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"#TCTM20 science: #Autophagy in gut and liver protective of #GVHD related mortality in murine models..........
Clini‚Ä¶ https://t.co/QSjudAkmsu",true
ollidufva,"MD, PhD student @helsinkiuni. Genomics, CRISPR screens & drug discovery in cancer immunotherapy & hematology",,"Helsinki, Suomi",,2020-02-20 18:26:59+00:00,Olli Dufva,http://twitter.com/,5.0,,1.2305594892684083e+18,,0.0,0.0,,RT @hemedoc: #TCTM20 Vago: non-genomic mechanisms of relapse include epigenetic silencing of MHC-II expression https://t.co/haqlQglFLT,ro,0.0,640.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,1.0,https://twitter.com/ollidufva/statuses/1230559489268408320,0.0,0.0,,0.0,0.0,0.0,1.0,4.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @hemedoc: #TCTM20 Vago: non-genomic mechanisms of relapse include epigenetic silencing of MHC-II expression https://t.co/haqlQglFLT,false
drjgauthier,"MD, MSc, Assistant Professor @fredhutch @UW focused on #CARTcell #immunotherapy #tcellrx 
Interests also include #rstats #bmtsm #epitwitter #bayes",,"Seattle, WA",,2020-02-20 16:43:01+00:00,Jordan Gauthier,http://twitter.com/,11.0,,1.2305333244157174e+18,,0.0,0.0,,"RT @hemedoc: #TCTM20 Vago: genomic and non-genomic mechanisms of HLA loss in AML relapse. Genomic: Loss if heterozygosity, operative mostly‚Ä¶",en,0.0,3295.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,8.0,3.0,https://twitter.com/drjgauthier/statuses/1230533324415717376,0.0,0.0,,0.0,0.0,0.0,3.0,8.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @hemedoc: #TCTM20 Vago: genomic and non-genomic mechanisms of HLA loss in AML relapse. Genomic: Loss if heterozygosity, operative mostly‚Ä¶",true
drjgauthier,"MD, MSc, Assistant Professor @fredhutch @UW focused on #CARTcell #immunotherapy #tcellrx 
Interests also include #rstats #bmtsm #epitwitter #bayes",,"Seattle, WA",,2020-02-20 05:27:41+00:00,Jordan Gauthier,http://twitter.com/,46.0,,1.2303633727192023e+18,,0.0,0.0,,RT @MDonatoBMT: üëâüèªDr. Riddell ‚Å¶@fredhutch‚Å© #CART BCMA+ gamma secretase inhibitor ‚¨áÔ∏è‚¨áÔ∏èrelapse. Great worküôåüèª #TCTM20 #TCT2020 https://t.co/qu‚Ä¶,en,0.0,3295.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,32.0,14.0,https://twitter.com/drjgauthier/statuses/1230363372719202304,0.0,0.0,,0.0,0.0,0.0,14.0,32.0,False,False,False,False,True,Diagnosis Progression,1.0,0.0,0.0,RT @MDonatoBMT: üëâüèªDr. Riddell ‚Å¶@fredhutch‚Å© #CART BCMA+ gamma secretase inhibitor ‚¨áÔ∏è‚¨áÔ∏èrelapse. Great worküôåüèª #TCTM20 #TCT2020 https://t.co/qu‚Ä¶,true
romeerizwan,Physician-Scientist @DanaFarber @HarvardMed researching NK cell immunology / Gene manipulation / Synthetic biology / Stem cell transplan. Tweets my own opinion.,,"Boston, MA",,2020-02-20 12:50:46+00:00,Rizwan Romee,http://twitter.com/,19.0,,1.2304748758082396e+18,,0.0,0.0,,"RT @hemedoc: #TCTM20 Scott: MAC outcomes not affected by NGS positivity prior to alloHCT, but has large impact on relapse after RIC. https:‚Ä¶",en,0.0,2701.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,9.0,https://twitter.com/romeerizwan/statuses/1230474875808239617,0.0,0.0,,0.0,0.0,0.0,9.0,10.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @hemedoc: #TCTM20 Scott: MAC outcomes not affected by NGS positivity prior to alloHCT, but has large impact on relapse after RIC. https:‚Ä¶",true
michyong2,"Infectious diseases physician, CMV & viral infections, Clinician researcher, @NCICancer @PeterMacCC @TheRMH @TheDohertyInst",,"Melbourne, Victoria",,2020-02-20 15:22:41+00:00,Michelle Yong,http://twitter.com/,47.0,,1.2305131085081723e+18,,0.0,0.0,,"RT @FranciscoMarty_: Hope to see many of you at #TCTM20 Thursday 20 Feb 10:30 am for a amazing session on #Infection after #Transplant, whe‚Ä¶",en,0.0,386.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,37.0,10.0,https://twitter.com/michyong2/statuses/1230513108508172297,0.0,0.0,,0.0,0.0,0.0,10.0,37.0,False,False,False,False,True,Side Effects,1.0,0.0,0.0,"RT @FranciscoMarty_: Hope to see many of you at #TCTM20 Thursday 20 Feb 10:30 am for a amazing session on #Infection after #Transplant, whe‚Ä¶",true
Yasmyneee,A girl w/ strong opinions trying to become a doctor. BLM | ACAB | Füå∏ck ICE! | She/Her,,,,2020-01-08 19:15:03+00:00,Black women are beautiful but let me refocus,http://twitter.com/,38.0,,1.2149889070512865e+18,,0.0,0.0,,RT @Medscape: Lymphoma is now curable but its pricey. üí≤ üí≤ #ASH19 #lymsm https://t.co/1jJi5rKLD4,en,0.0,370.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,23.0,15.0,https://twitter.com/Yasmyneee/statuses/1214988907051286528,0.0,0.0,,0.0,0.0,0.0,15.0,23.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @Medscape: Lymphoma is now curable but its pricey. üí≤ üí≤ #ASH19 #lymsm https://t.co/1jJi5rKLD4,true
adrianabello,"pediatrician, pediatric hematologyst, mother adribello@hotmail.com",,,,2020-02-05 18:39:01+00:00,Adriana Bello,http://twitter.com/,3.0,,1.2251266971184538e+18,,0.0,0.0,,RT @PeerView: Learn best practices to prevent #CMV infection ‚Äì February 20 symposium at #TCTM20 #PeerView https://t.co/gggK0zouC0,en,0.0,1968.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,2.0,1.0,https://twitter.com/adrianabello/statuses/1225126697118453761,0.0,0.0,,0.0,0.0,0.0,1.0,2.0,False,False,False,False,True,Disease Management,0.0,0.0,1.0,RT @PeerView: Learn best practices to prevent #CMV infection ‚Äì February 20 symposium at #TCTM20 #PeerView https://t.co/gggK0zouC0,false
YoramPuiusMD,"Transplant Infectious Diseases Physician #TxID, Montefiore Medical Center @montefiorenyc @MontefioreID @EinsteinMed | Maintains https://t.co/A52XHbwkYC",,,,2020-02-05 02:18:53+00:00,"Yoram Puius, MD, PhD",http://twitter.com/,72.0,,1.2248800413493043e+18,,0.0,0.0,,"RT @7eyeblink: Anti infective prophylaxis EBMT recommendations after CAR-T Cell infusion, now in #CART20 #CART2020 #CARTMeeting https://t.c‚Ä¶",en,0.0,486.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,50.0,22.0,https://twitter.com/YoramPuiusMD/statuses/1224880041349304321,0.0,0.0,,0.0,0.0,0.0,22.0,50.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"RT @7eyeblink: Anti infective prophylaxis EBMT recommendations after CAR-T Cell infusion, now in #CART20 #CART2020 #CARTMeeting https://t.c‚Ä¶",true
TischCancer,"Official account of The Tisch Cancer Institute @MountSinaiNYC. Committed to cancer prevention, detection, treatment & research. Appointments:  1-844-MD CANCER",,"New York, NY",,2020-01-14 16:25:34+00:00,The Tisch Cancer Institute,http://twitter.com/,127.0,,1.2171205842759148e+18,,0.0,0.0,,RT @theNCI: Immunotherapy drug improves outcomes for some children with relapsed leukemia https://t.co/pYKzkITSRC #blinatumomab #ASH19 #imm‚Ä¶,en,0.0,1789.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,84.0,43.0,https://twitter.com/TischCancer/statuses/1217120584275914752,0.0,0.0,,0.0,0.0,0.0,43.0,84.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @theNCI: Immunotherapy drug improves outcomes for some children with relapsed leukemia https://t.co/pYKzkITSRC #blinatumomab #ASH19 #imm‚Ä¶,true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-01-01 23:37:32+00:00,Oncology Tube,http://twitter.com/,2.0,,1.212518249201406e+18,,0.0,0.0,,"Phase 2 CAPTIVATE Trial: What's Next? #ASH19 #ASH @PeterMacCC: Con Tam, MD of @PeterMacCC discusses the phase 2 CAP‚Ä¶ https://t.co/48YROpdMza",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/oncologytube/statuses/1212518249201405952,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"Phase 2 CAPTIVATE Trial: What's Next? #ASH19 #ASH @PeterMacCC: Con Tam, MD of @PeterMacCC discusses the phase 2 CAP‚Ä¶ https://t.co/48YROpdMza",true
davidhenrymd,"Practicing MD Hematologist Oncologist 
Vice Chair Dept of Medicine Pennsylvania Hospital Blood&Cancer host Research-supportive care @MDedgeTweets @MDedgeHemeOnc",,"Philadelphia, PA",,2020-01-14 13:26:04+00:00,David Henry,http://twitter.com/,0.0,,1.2170754087404626e+18,,0.0,0.0,,From #ASH19: A phase 2 study of luspatercept in pts w/ myelofibrosis associated anemia revealed very good response‚Ä¶ https://t.co/DAGsW1GUZy,en,0.0,1771.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/davidhenrymd/statuses/1217075408740462593,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,1.0,0.0,0.0,From #ASH19: A phase 2 study of luspatercept in pts w/ myelofibrosis associated anemia revealed very good response‚Ä¶ https://t.co/DAGsW1GUZy,true
jetertseng,"General Pediatrician @ Jia-An Mother and Child Clinic, Taiwan. Interested about pediatric hematology/oncology, neonatology, neurology and allergy",,Taiwain,,2020-01-12 11:23:49+00:00,jetertseng,http://twitter.com/,32.0,,1.2163198671852913e+18,,0.0,0.0,,RT @StJudeResearch: Study shows Venetoclax chemo combination is well-tolerated and effective in kids and young adults with relapsed or refr‚Ä¶,en,0.0,4.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,23.0,9.0,https://twitter.com/jetertseng/statuses/1216319867185291264,0.0,0.0,,0.0,0.0,0.0,9.0,23.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @StJudeResearch: Study shows Venetoclax chemo combination is well-tolerated and effective in kids and young adults with relapsed or refr‚Ä¶,true
SarahCannonDocs,Fighting Cancer Together. Find out the latest news directly from Sarah Cannon physicians.,,"Nashville, TN",,2020-01-22 19:05:55+00:00,Sarah Cannon Docs,http://twitter.com/,3.0,,1.2200600384730565e+18,,0.0,0.0,,"RT @oncologytube: Phase 1 Clinical Study (CRB-402) of bb21217 #ASH19 @BerdejaJesus: Jesus Berdeja, MD @BerdejaJesus of Sarah Cannon Center‚Ä¶",en,0.0,2504.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,1.0,2.0,https://twitter.com/SarahCannonDocs/statuses/1220060038473056256,0.0,0.0,,0.0,0.0,0.0,2.0,1.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @oncologytube: Phase 1 Clinical Study (CRB-402) of bb21217 #ASH19 @BerdejaJesus: Jesus Berdeja, MD @BerdejaJesus of Sarah Cannon Center‚Ä¶",false
Jessica_Okosun,"CRUK-funded Clinician-Scientist at Barts Cancer Institute @QMBCI, Haematologist @BartsHospital. #Lymphoma, cancer #genomics, evolution, Big Data, technophile",,"London, England",,2020-01-16 18:18:43+00:00,Jessica Okosun,http://twitter.com/,6.0,,1.2178738352881582e+18,,0.0,0.0,,RT @lymphoma_connec: Missed our Experts Knowledge Share on #chemotherapy-free treatment approaches in #lymphoma at #ASH19? #lymsm #MedEd‚Ä¶,en,0.0,654.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,2.0,4.0,https://twitter.com/Jessica_Okosun/statuses/1217873835288158209,0.0,0.0,,0.0,0.0,0.0,4.0,2.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @lymphoma_connec: Missed our Experts Knowledge Share on #chemotherapy-free treatment approaches in #lymphoma at #ASH19? #lymsm #MedEd‚Ä¶,true
GI_OncologyHub,"We follow and re-tweet as many medical oncologists, researchers and biomedical journals as possible to keep you connected. Mostly GI and Immune focused.",,,,2020-01-15 11:38:20+00:00,GI Oncology Re-Tweeter,http://twitter.com/,127.0,,1.2174106840964792e+18,,0.0,0.0,,RT @theNCI: Immunotherapy drug improves outcomes for some children with relapsed leukemia https://t.co/pYKzkITSRC #blinatumomab #ASH19 #imm‚Ä¶,en,0.0,116.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,84.0,43.0,https://twitter.com/GI_OncologyHub/statuses/1217410684096479232,0.0,0.0,,0.0,0.0,0.0,43.0,84.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @theNCI: Immunotherapy drug improves outcomes for some children with relapsed leukemia https://t.co/pYKzkITSRC #blinatumomab #ASH19 #imm‚Ä¶,true
MooHosny,Physician,,Egypt,,2020-01-14 22:39:49+00:00,Mohamed Hosny,http://twitter.com/,127.0,,1.2172147657240535e+18,,0.0,0.0,,RT @theNCI: Immunotherapy drug improves outcomes for some children with relapsed leukemia https://t.co/pYKzkITSRC #blinatumomab #ASH19 #imm‚Ä¶,en,0.0,1345.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,84.0,43.0,https://twitter.com/MooHosny/statuses/1217214765724053504,0.0,0.0,,0.0,0.0,0.0,43.0,84.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @theNCI: Immunotherapy drug improves outcomes for some children with relapsed leukemia https://t.co/pYKzkITSRC #blinatumomab #ASH19 #imm‚Ä¶,true
Dr_ask_dr_ask,Surgeonüî¨Autopsy‚ö∞üî™Anatomy Neurologyüé©Neuro-Bio-QuantumüíÜGenetic Biomarkerist of Cancersüî¨Cyberknife‚öõDarwinistüåçEpicureis,,Turkey,,2020-01-14 12:52:47+00:00,SCIENTISTüî¨üíäüíâ,http://twitter.com/,127.0,,1.2170670338521047e+18,,0.0,0.0,,RT @theNCI: Immunotherapy drug improves outcomes for some children with relapsed leukemia https://t.co/pYKzkITSRC #blinatumomab #ASH19 #imm‚Ä¶,en,0.0,68.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,84.0,43.0,https://twitter.com/Dr_ask_dr_ask/statuses/1217067033852104704,0.0,0.0,,0.0,0.0,0.0,43.0,84.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @theNCI: Immunotherapy drug improves outcomes for some children with relapsed leukemia https://t.co/pYKzkITSRC #blinatumomab #ASH19 #imm‚Ä¶,true
sminaev2015,Professor of pediatric surgery #sminaev #SurgTweeting #pediatric #surgery #healthtech #digitalhealth #ILookLikeASurgeon #Health,,,,2020-01-15 12:05:52+00:00,Sergey Minaev,http://twitter.com/,127.0,,1.2174176162198692e+18,,0.0,0.0,,RT @theNCI: Immunotherapy drug improves outcomes for some children with relapsed leukemia https://t.co/pYKzkITSRC #blinatumomab #ASH19 #imm‚Ä¶,en,0.0,28119.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,84.0,43.0,https://twitter.com/sminaev2015/statuses/1217417616219869186,0.0,0.0,,0.0,0.0,0.0,43.0,84.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @theNCI: Immunotherapy drug improves outcomes for some children with relapsed leukemia https://t.co/pYKzkITSRC #blinatumomab #ASH19 #imm‚Ä¶,true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-01-30 16:21:04+00:00,Oncology Tube,http://twitter.com/,0.0,,1.2229176554572186e+18,,0.0,0.0,,"New PreClinical Data for its IL-15 Agonist, NKTR-255 #ASH19 #ASH: Loui Madakamutil, PhD of Nektar Therapeutics disc‚Ä¶ https://t.co/xwG160C8C0",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1222917655457218560,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"New PreClinical Data for its IL-15 Agonist, NKTR-255 #ASH19 #ASH: Loui Madakamutil, PhD of Nektar Therapeutics disc‚Ä¶ https://t.co/xwG160C8C0",false
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-01-05 21:41:05+00:00,Oncology Tube,http://twitter.com/,0.0,,1.213938492201263e+18,,0.0,0.0,,"MAIA Study Update #ASH19: Nizar Bahlis, MD of University of Calgary discusses patients with newly diagnosed multipl‚Ä¶ https://t.co/2wE904DrnK",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1213938492201263105,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"MAIA Study Update #ASH19: Nizar Bahlis, MD of University of Calgary discusses patients with newly diagnosed multipl‚Ä¶ https://t.co/2wE904DrnK",true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-01-23 22:58:33+00:00,Oncology Tube,http://twitter.com/,0.0,,1.220480971402666e+18,,0.0,0.0,,"Phase 2 CAPTIVATE clinical trial in CLL #ASH19 #ASH @PeterMacCC: Con Tam, MD of @PeterMacCC discusses the phase 2 C‚Ä¶ https://t.co/BdQSIzZKX5",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1220480971402665984,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"Phase 2 CAPTIVATE clinical trial in CLL #ASH19 #ASH @PeterMacCC: Con Tam, MD of @PeterMacCC discusses the phase 2 C‚Ä¶ https://t.co/BdQSIzZKX5",true
profnickhw,"Coaching Psychologist and Professor of Behavioural Medicine. Specialising in psychosocial oncology, health behaviour and CBS. Views expressed are my own.",,Chester UK,,2020-03-23 15:13:06+00:00,Nick HulbertWilliams,http://twitter.com/,37.0,,1.2421071062260283e+18,,0.0,0.0,,RT @christheeagle1: The reality of the speed of global change created by #coronavirus! If life had gone to plan I would have been speaking‚Ä¶,en,0.0,1361.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,27.0,10.0,https://twitter.com/profnickhw/statuses/1242107106226028547,0.0,0.0,,0.0,0.0,0.0,10.0,27.0,False,False,False,False,True,Covid,0.0,0.0,1.0,RT @christheeagle1: The reality of the speed of global change created by #coronavirus! If life had gone to plan I would have been speaking‚Ä¶,true
G23Mld,"MD, PhD, MPH, Univ. Chair, Emerging Diseases Dept. of Human Sciences - ‚ÄòRatio vero nequaquam ex auctoritate‚Äô - BLOCCO I TROLL",,"Roma, Lazio",,2020-07-13 11:55:13+00:00,Ilnomevabenecos√¨,http://twitter.com/,467.0,,1.2826447502192517e+18,,0.0,0.0,,"RT @NovartisCancer: What are you most concerned about for your #sicklecell patients during the current COVID-19 pandemic?

Learn more about‚Ä¶",en,0.0,2871.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,392.0,75.0,https://twitter.com/G23Mld/statuses/1282644750219251712,0.0,0.0,,0.0,0.0,0.0,75.0,392.0,False,False,False,False,True,Covid,0.0,0.0,1.0,"RT @NovartisCancer: What are you most concerned about for your #sicklecell patients during the current COVID-19 pandemic?

Learn more about‚Ä¶",true
Kasia_HP,Physician pursuing #medtech #innovation and patient access. Medical affairs and market access leader. #scicom #healthtech,,"Las Vegas, NV",,2020-10-09 12:10:33+00:00,KasiaHP,http://twitter.com/,12.0,,1.3145387425694884e+18,,0.0,0.0,,RT @terumobct: We're looking forward to the @alliancerm Cell &amp; Gene Therapy Meeting on the Mesa! The virtual meeting is Oct. 12-16. We are‚Ä¶,en,0.0,8197.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,8.0,4.0,https://twitter.com/Kasia_HP/statuses/1314538742569488384,0.0,0.0,,0.0,0.0,0.0,4.0,8.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @terumobct: We're looking forward to the @alliancerm Cell &amp; Gene Therapy Meeting on the Mesa! The virtual meeting is Oct. 12-16. We are‚Ä¶,true
CBCIDocs,Thoughts and perspectives from the hematology and transplant physicians at Colorado Blood Cancer Institute @ColoradoBlood @SarahCannonDocs @PresStLukesDenv,,"Denver, CO",,2020-07-07 12:07:18+00:00,CBCI,http://twitter.com/,73.0,,1.2804734624656916e+18,,0.0,0.0,,RT @DavidSteensma: Lots of folks tweeting &amp; sending me DMs after @ASH_hematology #ASH2020 email for invited faculty/speakers went out yeste‚Ä¶,en,0.0,782.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,56.0,17.0,https://twitter.com/CBCIDocs/statuses/1280473462465691649,0.0,0.0,,0.0,0.0,0.0,17.0,56.0,False,False,False,False,True,Thought Leadership,0.0,0.0,1.0,RT @DavidSteensma: Lots of folks tweeting &amp; sending me DMs after @ASH_hematology #ASH2020 email for invited faculty/speakers went out yeste‚Ä¶,false
docbmt,Haematologist @KingsCollegeNHS @myeloidkings #StemcellTransplantation #GVHD #MedicalMycology #loveToNetwork #BloodCancerResearch,,"London, England",,2020-07-07 12:01:03+00:00,Varun Mehra,http://twitter.com/,73.0,,1.2804718919087432e+18,,0.0,0.0,,RT @DavidSteensma: Lots of folks tweeting &amp; sending me DMs after @ASH_hematology #ASH2020 email for invited faculty/speakers went out yeste‚Ä¶,en,0.0,95.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,56.0,17.0,https://twitter.com/docbmt/statuses/1280471891908743175,0.0,0.0,,0.0,0.0,0.0,17.0,56.0,False,False,False,False,True,Thought Leadership,0.0,0.0,1.0,RT @DavidSteensma: Lots of folks tweeting &amp; sending me DMs after @ASH_hematology #ASH2020 email for invited faculty/speakers went out yeste‚Ä¶,true
nadahamad,"BMT, cellular therapies and clinical haematologist, clinical researcher, lymphoma doc, mother of 3, feminist and ANZTCT president. Opinions are my own.",,"Sydney, Australia",,2020-07-07 11:56:26+00:00,A/Prof Nada Hamad,http://twitter.com/,73.0,,1.280470731025838e+18,,0.0,0.0,,RT @DavidSteensma: Lots of folks tweeting &amp; sending me DMs after @ASH_hematology #ASH2020 email for invited faculty/speakers went out yeste‚Ä¶,en,0.0,346.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,56.0,17.0,https://twitter.com/nadahamad/statuses/1280470731025838082,0.0,0.0,,0.0,0.0,0.0,17.0,56.0,False,False,False,False,True,Thought Leadership,0.0,0.0,1.0,RT @DavidSteensma: Lots of folks tweeting &amp; sending me DMs after @ASH_hematology #ASH2020 email for invited faculty/speakers went out yeste‚Ä¶,true
UrviShahMD,Oncologist and researcher on Myeloma service @sloan_kettering. Interested in nutrition for cancer and immune therapies. Views are my own,,"New York, NY",,2020-07-07 17:46:51+00:00,Urvi Shah,http://twitter.com/,73.0,,1.2805589140865434e+18,,0.0,0.0,,RT @DavidSteensma: Lots of folks tweeting &amp; sending me DMs after @ASH_hematology #ASH2020 email for invited faculty/speakers went out yeste‚Ä¶,en,0.0,1227.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,56.0,17.0,https://twitter.com/UrviShahMD/statuses/1280558914086543362,0.0,0.0,,0.0,0.0,0.0,17.0,56.0,False,False,False,False,True,Thought Leadership,0.0,0.0,1.0,RT @DavidSteensma: Lots of folks tweeting &amp; sending me DMs after @ASH_hematology #ASH2020 email for invited faculty/speakers went out yeste‚Ä¶,true
IowaMSTP,"Steven Lentz is the Director of the University of Iowa Medical Scientist Training Program (MSTP), an integrated MD/PhD training program. Tweets are my own.",,Iowa City,,2020-07-07 12:58:40+00:00,Iowa MSTP Director,http://twitter.com/,73.0,,1.280486390946562e+18,,0.0,0.0,,RT @DavidSteensma: Lots of folks tweeting &amp; sending me DMs after @ASH_hematology #ASH2020 email for invited faculty/speakers went out yeste‚Ä¶,en,0.0,860.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,56.0,17.0,https://twitter.com/IowaMSTP/statuses/1280486390946562048,0.0,0.0,,0.0,0.0,0.0,17.0,56.0,False,False,False,False,True,Thought Leadership,0.0,0.0,1.0,RT @DavidSteensma: Lots of folks tweeting &amp; sending me DMs after @ASH_hematology #ASH2020 email for invited faculty/speakers went out yeste‚Ä¶,true
DrESHAJ9,"a passionate medical oncologist, a spiritual seeker",,,,2020-07-10 15:07:58+00:00,EJ,http://twitter.com/,5.0,,1.2816060934083994e+18,,0.0,0.0,,"RT @ASCOPost: Arnon P. Kater, MD, PhD, on CLL: Efficacy of Venetoclax in Relapsed or Refractory Disease https://t.co/lt02vICFI2 #leusm #hem‚Ä¶",en,0.0,315.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,2.0,3.0,https://twitter.com/DrESHAJ9/statuses/1281606093408399360,0.0,0.0,,0.0,0.0,0.0,3.0,2.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @ASCOPost: Arnon P. Kater, MD, PhD, on CLL: Efficacy of Venetoclax in Relapsed or Refractory Disease https://t.co/lt02vICFI2 #leusm #hem‚Ä¶",true
NicoleCruzMD,Hematologist @WeillCornell | #AcuteMyeloidLeukemia | HSP70 and AML metabolism researcher |#physicianscientist | From PR to NYC in pursuit of my dreams,,"New York, NY",,2020-07-08 02:43:33+00:00,"Nicole M Cruz, MD üáµüá∑",http://twitter.com/,73.0,,1.2806939806494392e+18,,0.0,0.0,,RT @DavidSteensma: Lots of folks tweeting &amp; sending me DMs after @ASH_hematology #ASH2020 email for invited faculty/speakers went out yeste‚Ä¶,en,0.0,1128.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,56.0,17.0,https://twitter.com/NicoleCruzMD/statuses/1280693980649439234,0.0,0.0,,0.0,0.0,0.0,17.0,56.0,False,False,False,False,True,Thought Leadership,0.0,0.0,1.0,RT @DavidSteensma: Lots of folks tweeting &amp; sending me DMs after @ASH_hematology #ASH2020 email for invited faculty/speakers went out yeste‚Ä¶,false
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-03-13 17:27:18+00:00,Cardiovascular Research Foundation,http://twitter.com/,8.0,,1.2385170014228767e+18,,0.0,0.0,,"Due to the #COVID19 pandemic, CRF has decided to cancel #CRFFellows2020 to ensure the health &amp; safety of all attend‚Ä¶ https://t.co/2sV8yi5pqr",en,0.0,12239.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,8.0,https://twitter.com/crfheart/statuses/1238517001422876672,0.0,0.0,,0.0,0.0,0.0,8.0,0.0,False,False,False,False,True,Covid,0.0,0.0,1.0,"Due to the #COVID19 pandemic, CRF has decided to cancel #CRFFellows2020 to ensure the health &amp; safety of all attend‚Ä¶ https://t.co/2sV8yi5pqr",true
ajaykirtane,"Practicing Cardiologist, Professor @ColumbiaMed
Researcher & advocate for thoughtful patient care; tweets‚â†endorsements nor med advice
https://t.co/YyilZMYayJ",,NewYork-Presbyterian & beyond,,2020-03-13 17:27:45+00:00,Ajay Kirtane MD SM,http://twitter.com/,15.0,,1.2385171141991342e+18,,0.0,0.0,,"RT @crfheart: Due to the #COVID19 pandemic, CRF has decided to cancel #CRFFellows2020 to ensure the health &amp; safety of all attendees. We ar‚Ä¶",en,0.0,17044.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,7.0,8.0,https://twitter.com/ajaykirtane/statuses/1238517114199134208,0.0,0.0,,0.0,0.0,0.0,8.0,7.0,False,False,False,False,True,Covid,0.0,0.0,1.0,"RT @crfheart: Due to the #COVID19 pandemic, CRF has decided to cancel #CRFFellows2020 to ensure the health &amp; safety of all attendees. We ar‚Ä¶",true
BollamRajesh4,"Oncologist & Hematologist ( Tata memorial hospital)

Working in Yashoda hospital Secunderabad",,"Hyderabad, India",,2020-01-02 07:05:17+00:00,Dr Rajesh Bollam - Cancer Specialist in Hyderabad,http://twitter.com/,6.0,,1.2126309275636408e+18,,0.0,0.0,,"RT @TheLancetHaem: Nathan H Fowler‚ÄîPhase 1-2 trial of Lenalidomide Plus Obinutuzumab in r/r indolent NHL: at 17 months follow-up, 24mo PFS‚Ä¶",en,0.0,955.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,2.0,4.0,https://twitter.com/BollamRajesh4/statuses/1212630927563640832,0.0,0.0,,0.0,0.0,0.0,4.0,2.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @TheLancetHaem: Nathan H Fowler‚ÄîPhase 1-2 trial of Lenalidomide Plus Obinutuzumab in r/r indolent NHL: at 17 months follow-up, 24mo PFS‚Ä¶",true
dgermain21,MD-PhD. 2nd year Heme/Onc fellow focused on lymphoma and leukemia. Physician-scientist-in-training. Tweet/RT not medical advice or endorsement.,,"St. Louis, MO",,2020-05-18 11:24:18+00:00,David A. Russler-Germain,http://twitter.com/,28.0,,1.2623432505281618e+18,,0.0,0.0,,"RT @graham74GC: Phillips et al - @NCRI_partners INCA trial
‚Ä¢ randomised trial in anthracycline unfit DLBCL 1L (1st ever?)
‚Ä¢ RGCVP v R-CVP+i‚Ä¶",en,0.0,1612.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,20.0,8.0,https://twitter.com/dgermain21/statuses/1262343250528161792,0.0,0.0,,0.0,0.0,0.0,8.0,20.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,"RT @graham74GC: Phillips et al - @NCRI_partners INCA trial
‚Ä¢ randomised trial in anthracycline unfit DLBCL 1L (1st ever?)
‚Ä¢ RGCVP v R-CVP+i‚Ä¶",true
drnborges,Doctor @MadeinHEENE ‚Ä¢ Haematology ‚Ä¢ Committee @Young_EHA,,"Newcastle Upon Tyne, England",,2020-07-24 06:31:56+00:00,Nuno Borges,http://twitter.com/,18.0,,1.286549658186199e+18,,0.0,0.0,,RT @EHA_Hematology: This year's @young_eha Research Meeting (YERM) at #EHA25Virtual covered topics like: normal hematopoiesis &amp; stem cell b‚Ä¶,en,0.0,644.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,13.0,5.0,https://twitter.com/drnborges/statuses/1286549658186199040,0.0,0.0,,0.0,0.0,0.0,5.0,13.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @EHA_Hematology: This year's @young_eha Research Meeting (YERM) at #EHA25Virtual covered topics like: normal hematopoiesis &amp; stem cell b‚Ä¶,true
MediHumdani,"Director, BMT & Cellular Therapy Program @Froedtert & @MedicalCollege | Lymphoma | Clinical Trials | @CIBMTR | @BMTCTN | Personal views | Physician ‚â† Provider",,"Milwaukee, WI",,2020-07-24 00:59:02+00:00,Mehdi Hamadani,http://twitter.com/,4.0,,1.2864658824876892e+18,,0.0,0.0,,Congrats @drzsicklecell for leading @ASH_hematology New Daily in #ASH20 and also makes me really proud to see fourt‚Ä¶ https://t.co/HYJybXav1r,en,0.0,4590.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,4.0,https://twitter.com/MediHumdani/statuses/1286465882487689216,0.0,0.0,,0.0,0.0,0.0,4.0,0.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,Congrats @drzsicklecell for leading @ASH_hematology New Daily in #ASH20 and also makes me really proud to see fourt‚Ä¶ https://t.co/HYJybXav1r,false
drnborges,Doctor @MadeinHEENE ‚Ä¢ Haematology ‚Ä¢ Committee @Young_EHA,,"Newcastle Upon Tyne, England",,2020-06-02 06:56:46+00:00,Nuno Borges,http://twitter.com/,23.0,,1.2677117411123405e+18,,0.0,0.0,,"RT @young_eha: #EHA25 #countdown #9DaysToGo 
This year's congress is packed with amazing sessions and outstanding speakers! ü§© Remember to c‚Ä¶",en,0.0,644.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,15.0,8.0,https://twitter.com/drnborges/statuses/1267711741112340481,0.0,0.0,,0.0,0.0,0.0,8.0,15.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,"RT @young_eha: #EHA25 #countdown #9DaysToGo 
This year's congress is packed with amazing sessions and outstanding speakers! ü§© Remember to c‚Ä¶",true
mabeky,Leukemia Department Administrator at MD Anderson Cancer Center,,"Houston, TX",,2020-08-21 01:15:11+00:00,M. Silverstein,http://twitter.com/,78.0,,1.2966168068079862e+18,,0.0,0.0,,"RT @LeukemiaMDA: Combination therapy significantly improves survival outcomes for patients w/ acute myeloid #leukemia | 
Lead investigator‚Ä¶",en,0.0,206.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,63.0,15.0,https://twitter.com/mabeky/statuses/1296616806807986178,0.0,0.0,,0.0,0.0,0.0,15.0,63.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,"RT @LeukemiaMDA: Combination therapy significantly improves survival outcomes for patients w/ acute myeloid #leukemia | 
Lead investigator‚Ä¶",true
alba_maiques,"Postdoctoral scientist @Idibaps. Interest TF, epigenetics & leukemia.Twin mum. Member @young_eha. Founder maiques_factory.  #womeninSTEM #creativity #mentoring",,"Barcelona, Espa√±a",,2020-06-02 10:01:06+00:00,Alba Maiques-Diaz,http://twitter.com/,23.0,,1.2677581303955784e+18,,0.0,0.0,,"RT @young_eha: #EHA25 #countdown #9DaysToGo 
This year's congress is packed with amazing sessions and outstanding speakers! ü§© Remember to c‚Ä¶",en,0.0,482.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,15.0,8.0,https://twitter.com/alba_maiques/statuses/1267758130395578368,0.0,0.0,,0.0,0.0,0.0,8.0,15.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,"RT @young_eha: #EHA25 #countdown #9DaysToGo 
This year's congress is packed with amazing sessions and outstanding speakers! ü§© Remember to c‚Ä¶",true
Alvudena,"MD, PhD
Hematologist at Hospital Universitario de Salamanca",,,,2020-06-02 11:06:49+00:00,Almudena Navarro,http://twitter.com/,23.0,,1.267774666082566e+18,,0.0,0.0,,"RT @young_eha: #EHA25 #countdown #9DaysToGo 
This year's congress is packed with amazing sessions and outstanding speakers! ü§© Remember to c‚Ä¶",en,0.0,88.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,15.0,8.0,https://twitter.com/Alvudena/statuses/1267774666082566144,0.0,0.0,,0.0,0.0,0.0,8.0,15.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,"RT @young_eha: #EHA25 #countdown #9DaysToGo 
This year's congress is packed with amazing sessions and outstanding speakers! ü§© Remember to c‚Ä¶",true
healing_genes,"We are scientists, doctors, researchers, nurses and others who focus on healing debilitating and, in many cases, life-threatening genetic-based diseases.",,"Baltimore, MD",,2020-05-06 20:34:22+00:00,Healing Genes,http://twitter.com/,10.0,,1.258133023746384e+18,,0.0,0.0,,RT @ASGCTherapy: Did you know that #ASGCT20 will feature a number of policy-focused symposia that include governmental speakers and topics?‚Ä¶,en,0.0,45.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,7.0,3.0,https://twitter.com/healing_genes/statuses/1258133023746383875,0.0,0.0,,0.0,0.0,0.0,3.0,7.0,False,False,False,False,True,Thought Leadership,0.0,0.0,1.0,RT @ASGCTherapy: Did you know that #ASGCT20 will feature a number of policy-focused symposia that include governmental speakers and topics?‚Ä¶,true
AnnalisaRugger1,"Hematologist, HCT and cellular therapy physician scientist,  secretary of CTIWP-EBMT, Eurocord",,,,2020-05-06 12:48:11+00:00,Annalisa Ruggeri,http://twitter.com/,62.0,,1.258015705812865e+18,,0.0,0.0,,"RT @TheEBMT: In light of the global #COVID-19 pandemic and its extensive worldwide impact, @TheEBMT decided to hold #EBMT20 Annnual Meeting‚Ä¶",en,0.0,139.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,39.0,23.0,https://twitter.com/AnnalisaRugger1/statuses/1258015705812865025,0.0,0.0,,0.0,0.0,0.0,23.0,39.0,False,False,False,False,True,Covid,0.0,0.0,1.0,"RT @TheEBMT: In light of the global #COVID-19 pandemic and its extensive worldwide impact, @TheEBMT decided to hold #EBMT20 Annnual Meeting‚Ä¶",false
chano_py,Sola Gracia. Medico Hematologo. Donante de √≥rganos. #DonaenVida. #HSCT Dr in #Paraguay. Patient Advocacy Co-Chair at #WBMT. Secretary at @LABMT2,,Paraguay,,2020-05-06 20:12:12+00:00,Cristobal Frutos,http://twitter.com/,62.0,,1.258127444630016e+18,,0.0,0.0,,"RT @TheEBMT: In light of the global #COVID-19 pandemic and its extensive worldwide impact, @TheEBMT decided to hold #EBMT20 Annnual Meeting‚Ä¶",en,0.0,903.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,39.0,23.0,https://twitter.com/chano_py/statuses/1258127444630016000,0.0,0.0,,0.0,0.0,0.0,23.0,39.0,False,False,False,False,True,Covid,0.0,0.0,1.0,"RT @TheEBMT: In light of the global #COVID-19 pandemic and its extensive worldwide impact, @TheEBMT decided to hold #EBMT20 Annnual Meeting‚Ä¶",true
haemyisu,"Haematology doctor and PhD student @powrie_lab, University of Oxford. Wellcome Trust clinical research fellow. Interested in #Tregs #microbiome #GVHD",,"Oxford, UK",,2020-05-06 18:20:18+00:00,Yisu Gu,http://twitter.com/,62.0,,1.2580992828104704e+18,,0.0,0.0,,"RT @TheEBMT: In light of the global #COVID-19 pandemic and its extensive worldwide impact, @TheEBMT decided to hold #EBMT20 Annnual Meeting‚Ä¶",en,0.0,203.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,39.0,23.0,https://twitter.com/haemyisu/statuses/1258099282810470400,0.0,0.0,,0.0,0.0,0.0,23.0,39.0,False,False,False,False,True,Covid,0.0,0.0,1.0,"RT @TheEBMT: In light of the global #COVID-19 pandemic and its extensive worldwide impact, @TheEBMT decided to hold #EBMT20 Annnual Meeting‚Ä¶",true
jasaunders90,"Physician Associate in Haematology @G_ICEMD. Acute leukaemia, MDS and MPN. Faculty board @FPARCP. Often found in Bayern/Berlin. Pers√∂nliche Meinungen üá™üá∫üè≥Ô∏è‚Äçüåà",,London (he/him),,2020-05-06 17:22:14+00:00,Jamie Saunders,http://twitter.com/,62.0,,1.2580846699937587e+18,,0.0,0.0,,"RT @TheEBMT: In light of the global #COVID-19 pandemic and its extensive worldwide impact, @TheEBMT decided to hold #EBMT20 Annnual Meeting‚Ä¶",en,0.0,2666.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,39.0,23.0,https://twitter.com/jasaunders90/statuses/1258084669993758724,0.0,0.0,,0.0,0.0,0.0,23.0,39.0,False,False,False,False,True,Covid,0.0,0.0,1.0,"RT @TheEBMT: In light of the global #COVID-19 pandemic and its extensive worldwide impact, @TheEBMT decided to hold #EBMT20 Annnual Meeting‚Ä¶",true
alba_maiques,"Postdoctoral scientist @Idibaps. Interest TF, epigenetics & leukemia.Twin mum. Member @young_eha. Founder maiques_factory.  #womeninSTEM #creativity #mentoring",,"Barcelona, Espa√±a",,2020-03-26 20:30:21+00:00,Alba Maiques-Diaz,http://twitter.com/,35.0,,1.243274111314428e+18,,0.0,0.0,,"RT @EHA_Hematology: #EHA is committed to provide useful advice to #hematologists facing the COVID-19 pandemic. For more information, please‚Ä¶",en,0.0,482.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,21.0,14.0,https://twitter.com/alba_maiques/statuses/1243274111314427905,0.0,0.0,,0.0,0.0,0.0,14.0,21.0,False,False,False,False,True,Covid,1.0,0.0,0.0,"RT @EHA_Hematology: #EHA is committed to provide useful advice to #hematologists facing the COVID-19 pandemic. For more information, please‚Ä¶",true
truogs,"social commentator, Man U fan, Doctor",,"Enugu, Nigeria",,2020-04-24 15:47:51+00:00,ogochukwu forchu,http://twitter.com/,58.0,,1.2537122656998892e+18,,0.0,0.0,,"RT @accountlabng: Join us Friday, 24th April here @accountlabng for the April edition of #TIF as we discuss the #COVID19 pandemic 

Special‚Ä¶",en,0.0,264.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,34.0,24.0,https://twitter.com/truogs/statuses/1253712265699889153,0.0,0.0,,0.0,0.0,0.0,24.0,34.0,False,False,False,False,True,Covid,0.0,0.0,1.0,"RT @accountlabng: Join us Friday, 24th April here @accountlabng for the April edition of #TIF as we discuss the #COVID19 pandemic 

Special‚Ä¶",true
LukeMtjoy,Hematologist and transplant physician at Colorado Blood Cancer Institute. Former hem/onc fellow @MayoClinic AZ. view and opinions are my own,,"Denver, CO",,2020-02-21 22:30:18+00:00,LukeMtjoy,http://twitter.com/,10.0,,1.2309831088973414e+18,,0.0,0.0,,RT @AkshaySharmaMD: #TCTM20 Popat from @MDAndersonNews You can still give fractionated myeloablative chemotherapy and reduce toxicity but n‚Ä¶,en,0.0,137.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,5.0,https://twitter.com/LukeMtjoy/statuses/1230983108897341440,0.0,0.0,,0.0,0.0,0.0,5.0,5.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @AkshaySharmaMD: #TCTM20 Popat from @MDAndersonNews You can still give fractionated myeloablative chemotherapy and reduce toxicity but n‚Ä¶,false
MedpageOnco,Breaking cancer + oncology news | Reports from all major oncology meetings | Peer-reviewed | Oncologist-trusted | Part of @MedPageToday,,,,2020-02-26 20:05:01+00:00,MedPage Oncology,http://twitter.com/,2.0,,1.232758488759251e+18,,0.0,0.0,,This treatment led to a high rate of allogeneic hematopoietic stem cell transplant in older patients with relapsed/‚Ä¶ https://t.co/16XaME1Hoy,en,0.0,443.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/MedpageOnco/statuses/1232758488759250946,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,This treatment led to a high rate of allogeneic hematopoietic stem cell transplant in older patients with relapsed/‚Ä¶ https://t.co/16XaME1Hoy,true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-02-22 18:42:48+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,2.0,,1.2312882439179346e+18,,0.0,0.0,,#TCTM20 Foran: non-randomized data show support for Aza maint after allo (tho the data are not strong). A pilot stu‚Ä¶ https://t.co/TvsKsksoqB,en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/hemedoc/statuses/1231288243917934594,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Disease Advocacy,0.0,0.0,1.0,#TCTM20 Foran: non-randomized data show support for Aza maint after allo (tho the data are not strong). A pilot stu‚Ä¶ https://t.co/TvsKsksoqB,true
hiendliu1,"Hematologist/Oncologist | Blood & Marrow Transplant | Medical Director, Apheresis Program @ Moffitt Cancer Center | Opinions my own",,"Tampa, FL",,2020-02-22 22:06:03+00:00,"Hien D. Liu, MD",http://twitter.com/,2.0,,1.2313393927169843e+18,,0.0,0.0,,impressive data presented by Dr. John DiPersio on stem cell mobilization using Mgta-145 in Combination with Plerixa‚Ä¶ https://t.co/msElQ3yFr2,en,0.0,874.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/hiendliu1/statuses/1231339392716984329,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,impressive data presented by Dr. John DiPersio on stem cell mobilization using Mgta-145 in Combination with Plerixa‚Ä¶ https://t.co/msElQ3yFr2,true
DrFabLucas,#physicianscientist #pathology #hematology @BWH @HarvardMed #FlowCytometry #rigor #reproducibility. Open doors for others to walk through. Never stop moving.,,United States,,2020-05-12 10:53:50+00:00,Fabienne McClanahan Lucas (she/her/hers),http://twitter.com/,20.0,,1.2601612555554324e+18,,0.0,0.0,,"RT @EHA_Hematology: #EHA25Virtual will take place on Jun 11-21! What can you expect? 

‚û°Ô∏èJun 11 ‚Äì 14:  invited speakers, abstract presenter‚Ä¶",en,0.0,441.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,14.0,6.0,https://twitter.com/DrFabLucas/statuses/1260161255555432448,0.0,0.0,,0.0,0.0,0.0,6.0,14.0,False,False,False,False,True,Thought Leadership,0.0,0.0,1.0,"RT @EHA_Hematology: #EHA25Virtual will take place on Jun 11-21! What can you expect? 

‚û°Ô∏èJun 11 ‚Äì 14:  invited speakers, abstract presenter‚Ä¶",true
drnborges,Doctor @MadeinHEENE ‚Ä¢ Haematology ‚Ä¢ Committee @Young_EHA,,"Newcastle Upon Tyne, England",,2020-03-27 12:40:01+00:00,Nuno Borges,http://twitter.com/,35.0,,1.2435181345454162e+18,,0.0,0.0,,"RT @EHA_Hematology: #EHA is committed to provide useful advice to #hematologists facing the COVID-19 pandemic. For more information, please‚Ä¶",en,0.0,644.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,21.0,14.0,https://twitter.com/drnborges/statuses/1243518134545416199,0.0,0.0,,0.0,0.0,0.0,14.0,21.0,False,False,False,False,True,Covid,1.0,0.0,0.0,"RT @EHA_Hematology: #EHA is committed to provide useful advice to #hematologists facing the COVID-19 pandemic. For more information, please‚Ä¶",true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-04-08 20:07:03+00:00,Oncology Tube,http://twitter.com/,0.0,,1.2479792894100316e+18,,0.0,0.0,,Venetoclax-Rituximab (VenR) in Relapsed Refractory (R R) CLL How This Affects Clinicians #ASH19 #ASH‚Ä¶ https://t.co/VNfFPp7MiT,en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1247979289410031616,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,Venetoclax-Rituximab (VenR) in Relapsed Refractory (R R) CLL How This Affects Clinicians #ASH19 #ASH‚Ä¶ https://t.co/VNfFPp7MiT,false
EduardoFlavioO1,"MD, Hematologist, Brasilia/Brasil, main interest in CLL, Lymphoma and MM; dad and husband; tweets are my own opinion",,"Bras√≠lia, Brasil",,2020-06-13 01:06:43+00:00,Eduardo Flavio Oliveira Ribeiro,http://twitter.com/,0.0,,1.271609912217477e+18,,0.0,0.0,,"OAsiS phase I/II trial, analysis of cohort C (MCL untreated) wt Obino, Ven plus Ibrutinib. FUP14m, no ASCT, n=15, t‚Ä¶ https://t.co/WHPtxxj6RQ",en,0.0,545.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/EduardoFlavioO1/statuses/1271609912217477120,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"OAsiS phase I/II trial, analysis of cohort C (MCL untreated) wt Obino, Ven plus Ibrutinib. FUP14m, no ASCT, n=15, t‚Ä¶ https://t.co/WHPtxxj6RQ",true
kwackergibs,"Lymphoma Nurse Clinician at The Christie, Manchester. Doctoral student. Own views.",,"Manchester, England",,2020-06-13 16:22:47+00:00,Jane Gibson,http://twitter.com/,17.0,,1.2718404507192033e+18,,0.0,0.0,,"RT @tobyeyre82: INCA trial highlighting the clear need for regimens with improved tolerability in elderly #DLBCL 

Very high non-relapse mo‚Ä¶",en,0.0,266.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,13.0,4.0,https://twitter.com/kwackergibs/statuses/1271840450719203328,0.0,0.0,,0.0,0.0,0.0,4.0,13.0,False,False,False,False,True,Diagnosis Progression,1.0,0.0,0.0,"RT @tobyeyre82: INCA trial highlighting the clear need for regimens with improved tolerability in elderly #DLBCL 

Very high non-relapse mo‚Ä¶",true
pammckay123,"Haematologist specialising in Lymphoma at #BeatsonCancerCentre. Spend the rest of my time on running, chocolate and my family",,"Glasgow, Scotland",,2020-06-13 21:07:13+00:00,Pam McKay,http://twitter.com/,13.0,,1.2719120279724155e+18,,0.0,0.0,,"RT @tobyeyre82: #Loncastuximab terisine 
phase II R/R #DLBCL
n=145
anti-CD19 ADC
150ug/kg C1-2-&gt;75ug/kg
3 lines
58% ref last Rx
ORR 48% CR‚Ä¶",en,0.0,109.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,8.0,5.0,https://twitter.com/pammckay123/statuses/1271912027972415490,0.0,0.0,,0.0,0.0,0.0,5.0,8.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @tobyeyre82: #Loncastuximab terisine 
phase II R/R #DLBCL
n=145
anti-CD19 ADC
150ug/kg C1-2-&gt;75ug/kg
3 lines
58% ref last Rx
ORR 48% CR‚Ä¶",true
chano_py,Sola Gracia. Medico Hematologo. Donante de √≥rganos. #DonaenVida. #HSCT Dr in #Paraguay. Patient Advocacy Co-Chair at #WBMT. Secretary at @LABMT2,,Paraguay,,2020-06-13 15:22:06+00:00,Cristobal Frutos,http://twitter.com/,2.0,,1.271825178973127e+18,,0.0,0.0,,Very interesting abstract by @NIH @DrChrisHourigan on conditioning intensity and genomics impact on relapse after‚Ä¶ https://t.co/U6bMyipaPW,en,0.0,903.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/chano_py/statuses/1271825178973126658,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Diagnosis Progression,1.0,0.0,0.0,Very interesting abstract by @NIH @DrChrisHourigan on conditioning intensity and genomics impact on relapse after‚Ä¶ https://t.co/U6bMyipaPW,true
shameel_shafqat,22 | MS4üë®‚Äç‚öïÔ∏è @AKUGlobal | Class of 2021 | Aspiring Physician. Live in üá∏üá¶ but üáµüá∞ at heart ‚ù§,,,,2020-06-13 12:15:25+00:00,Shameel Shafqat,http://twitter.com/,0.0,,1.2717781976680694e+18,,0.0,0.0,,"#DigitalMedicine and #ArtificialIntelligence are the future! We have been forced to innovate, and restructure healt‚Ä¶ https://t.co/Rj8YJ1PTLr",en,0.0,383.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/shameel_shafqat/statuses/1271778197668069382,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"#DigitalMedicine and #ArtificialIntelligence are the future! We have been forced to innovate, and restructure healt‚Ä¶ https://t.co/Rj8YJ1PTLr",true
EduardoFlavioO1,"MD, Hematologist, Brasilia/Brasil, main interest in CLL, Lymphoma and MM; dad and husband; tweets are my own opinion",,"Bras√≠lia, Brasil",,2020-06-13 19:37:56+00:00,Eduardo Flavio Oliveira Ribeiro,http://twitter.com/,4.0,,1.2718895613548954e+18,,0.0,0.0,,"CLL educational program. Sooner than expected, we‚Äôll move from FISH and Sanger for NGS tools, in order to better qu‚Ä¶ https://t.co/sBpMQoqdkX",en,0.0,545.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,4.0,https://twitter.com/EduardoFlavioO1/statuses/1271889561354895365,0.0,0.0,,0.0,0.0,0.0,4.0,0.0,False,False,False,False,True,Disease Advocacy,0.0,0.0,1.0,"CLL educational program. Sooner than expected, we‚Äôll move from FISH and Sanger for NGS tools, in order to better qu‚Ä¶ https://t.co/sBpMQoqdkX",false
DrChrisHourigan,"Physician-Scientist, Acute Myeloid Leukemia Doctor, Human Immunologist, Laboratory PI, Measurable Residual Disease Advocate, Optimist.  Views are my own.",,"Washington, DC",,2020-06-13 16:43:19+00:00,Chris Hourigan,http://twitter.com/,18.0,,1.2718456173635625e+18,,0.0,0.0,,RT @chano_py: Very interesting abstract by @NIH @DrChrisHourigan on conditioning intensity and genomics impact on relapse after #AlloSCT fo‚Ä¶,en,0.0,1169.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,16.0,2.0,https://twitter.com/DrChrisHourigan/statuses/1271845617363562498,0.0,0.0,,0.0,0.0,0.0,2.0,16.0,False,False,False,False,True,Diagnosis Progression,1.0,0.0,0.0,RT @chano_py: Very interesting abstract by @NIH @DrChrisHourigan on conditioning intensity and genomics impact on relapse after #AlloSCT fo‚Ä¶,true
dokter_onkologi,"Sebelas Maret University Lecturer. Internist,hematology&medical oncology. MD from Faculty of medicine UGM. Internal medicine from FKUI RSCM. member of ESMO&ASCO",,"Yogyakarta, Solo, Jakarta",,2020-06-13 01:26:10+00:00,dr Jati Sp.PD,http://twitter.com/,6.0,,1.2716148106737009e+18,,0.0,0.0,,RT @EduardoFlavioO1: More about PMBL from Educational Program. Here are the take home messages. #EHA2020 #EHA25Virtual https://t.co/s9kpOqC‚Ä¶,en,0.0,8594.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,1.0,https://twitter.com/dokter_onkologi/statuses/1271614810673700865,0.0,0.0,,0.0,0.0,0.0,1.0,5.0,False,False,False,False,True,Disease Advocacy,0.0,0.0,1.0,RT @EduardoFlavioO1: More about PMBL from Educational Program. Here are the take home messages. #EHA2020 #EHA25Virtual https://t.co/s9kpOqC‚Ä¶,true
nycdoc29,"ASCO, ASH, EHA & ESMO Member, Hem/Onc - 11 MD specialty private practice, former full time academic, traveller, foodie & out of necessity now a business person!",,"Garden City, NY",,2020-06-13 16:39:56+00:00,NYCDoc29,http://twitter.com/,92.0,,1.2718447669013176e+18,,0.0,0.0,,RT @DocHutchings: Pleased to present the final results from the dose escalation part of the Phase 1/2 study of epcoritamab in r/r B-NHL at‚Ä¶,en,0.0,664.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,69.0,23.0,https://twitter.com/nycdoc29/statuses/1271844766901317633,0.0,0.0,,0.0,0.0,0.0,23.0,69.0,False,False,False,False,True,Clinical Trials,1.0,0.0,0.0,RT @DocHutchings: Pleased to present the final results from the dose escalation part of the Phase 1/2 study of epcoritamab in r/r B-NHL at‚Ä¶,true
nycdoc29,"ASCO, ASH, EHA & ESMO Member, Hem/Onc - 11 MD specialty private practice, former full time academic, traveller, foodie & out of necessity now a business person!",,"Garden City, NY",,2020-06-13 22:19:04+00:00,NYCDoc29,http://twitter.com/,37.0,,1.2719301098224722e+18,,0.0,0.0,,"RT @tobyeyre82: #acalabrutinib in 1L #CLL 
phase II trial
n=99
53m median fup
14 d/c to date: 6 AEs (4 SPM, 2 infection), 3 PD
Tox profile:‚Ä¶",en,0.0,664.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,28.0,9.0,https://twitter.com/nycdoc29/statuses/1271930109822472193,0.0,0.0,,0.0,0.0,0.0,9.0,28.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @tobyeyre82: #acalabrutinib in 1L #CLL 
phase II trial
n=99
53m median fup
14 d/c to date: 6 AEs (4 SPM, 2 infection), 3 PD
Tox profile:‚Ä¶",true
EduardoFlavioO1,"MD, Hematologist, Brasilia/Brasil, main interest in CLL, Lymphoma and MM; dad and husband; tweets are my own opinion",,"Bras√≠lia, Brasil",,2020-06-13 18:39:03+00:00,Eduardo Flavio Oliveira Ribeiro,http://twitter.com/,1.0,,1.2718747409621074e+18,,0.0,0.0,,CLL educational program: how to improve personalized therapy using molecular profile and patterns of individual dru‚Ä¶ https://t.co/LOHVjV0rwr,en,0.0,545.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/EduardoFlavioO1/statuses/1271874740962107393,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Disease Advocacy,0.0,0.0,1.0,CLL educational program: how to improve personalized therapy using molecular profile and patterns of individual dru‚Ä¶ https://t.co/LOHVjV0rwr,true
GeydsonHemato,"MD, MSc Brazilian Hematologist in Aracaju SE Brazil. University Hospital of Sergipe Hematology Service All Tweets are my own. Instagram: @hematonaweb",,"Aracaju, Brasil",,2020-06-13 11:04:03+00:00,"Geydson Cruz MD, MSc",http://twitter.com/,11.0,,1.2717602368194724e+18,,0.0,0.0,,RT @TheLancetHaem: Total body irradiation remains the conditioning regimen of choice compared with chemo-based conditioning for children wi‚Ä¶,en,0.0,101.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,7.0,4.0,https://twitter.com/GeydsonHemato/statuses/1271760236819472386,0.0,0.0,,0.0,0.0,0.0,4.0,7.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @TheLancetHaem: Total body irradiation remains the conditioning regimen of choice compared with chemo-based conditioning for children wi‚Ä¶,false
dokter_onkologi,"Sebelas Maret University Lecturer. Internist,hematology&medical oncology. MD from Faculty of medicine UGM. Internal medicine from FKUI RSCM. member of ESMO&ASCO",,"Yogyakarta, Solo, Jakarta",,2020-06-13 01:26:56+00:00,dr Jati Sp.PD,http://twitter.com/,10.0,,1.2716149999500493e+18,,0.0,0.0,,RT @EduardoFlavioO1: Unfolder Trial PMBL(subgroup): RCHOP 21 or 14 +/- RTx. RCHOP21 similar to 14. RT benefit more chemosensitive tumors. E‚Ä¶,en,0.0,8594.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,7.0,3.0,https://twitter.com/dokter_onkologi/statuses/1271614999950049280,0.0,0.0,,0.0,0.0,0.0,3.0,7.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @EduardoFlavioO1: Unfolder Trial PMBL(subgroup): RCHOP 21 or 14 +/- RTx. RCHOP21 similar to 14. RT benefit more chemosensitive tumors. E‚Ä¶,true
chano_py,Sola Gracia. Medico Hematologo. Donante de √≥rganos. #DonaenVida. #HSCT Dr in #Paraguay. Patient Advocacy Co-Chair at #WBMT. Secretary at @LABMT2,,Paraguay,,2020-06-13 21:27:52+00:00,Cristobal Frutos,http://twitter.com/,7.0,,1.271917226036269e+18,,0.0,0.0,,"RT @Care4Access: . @jmikhaelmd: ""That first #remission is important because at every new #TreatmentLine, #myeloma #MM #patients die, especi‚Ä¶",en,0.0,903.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,4.0,https://twitter.com/chano_py/statuses/1271917226036269057,0.0,0.0,,0.0,0.0,0.0,4.0,3.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @Care4Access: . @jmikhaelmd: ""That first #remission is important because at every new #TreatmentLine, #myeloma #MM #patients die, especi‚Ä¶",true
ADCReview,"ADC Review/J. Antibody-drug Conjugates, an open access journal, brings together researchers, scientists and physicians involved in the growing field of ADCs.",,"Phoenix, AZ (USA)",,2020-06-13 04:25:39+00:00,ADC Review,http://twitter.com/,0.0,,1.2716599783575675e+18,,0.0,0.0,,Loncastuximab Tesirine Demonstrates an Overall High Response Rates in Pivotal Phase II Single-agent Trial‚Ä¶ https://t.co/MeZjAf7NIU,en,0.0,905.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/ADCReview/statuses/1271659978357567489,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,Loncastuximab Tesirine Demonstrates an Overall High Response Rates in Pivotal Phase II Single-agent Trial‚Ä¶ https://t.co/MeZjAf7NIU,true
dwiseman78,Consultant Haematologist / Clinician Scientist at University of Manchester. Interest in MDS and CMML/Overlap syndromes,,,,2020-06-13 17:38:25+00:00,Dan Wiseman,http://twitter.com/,97.0,,1.2718594840723333e+18,,0.0,0.0,,"RT @NovartisCancer: What is the role of TIM-3 in MDS/AML? How does it work? Let‚Äôs discuss with Dr Amer Zeidan, Prof Francesco Buccisano, an‚Ä¶",en,0.0,123.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,77.0,20.0,https://twitter.com/dwiseman78/statuses/1271859484072333312,0.0,0.0,,0.0,0.0,0.0,20.0,77.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,"RT @NovartisCancer: What is the role of TIM-3 in MDS/AML? How does it work? Let‚Äôs discuss with Dr Amer Zeidan, Prof Francesco Buccisano, an‚Ä¶",true
drlouisemason,"Physician, enhanced by biotechnology",,"Cambridge, MA",,2020-05-14 19:56:13+00:00,Louise Mason,http://twitter.com/,10.0,,1.2610225268780196e+18,,0.0,0.0,,RT @avrobio: Today we announced new preclinical data from our  #genetherapy program for #Pompe disease. See the details in our release: htt‚Ä¶,en,0.0,1110.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,5.0,https://twitter.com/drlouisemason/statuses/1261022526878019584,0.0,0.0,,0.0,0.0,0.0,5.0,5.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @avrobio: Today we announced new preclinical data from our  #genetherapy program for #Pompe disease. See the details in our release: htt‚Ä¶,true
alex_jares,"Husband, MD/PhD trainee @StonyBrookMed | MS4 applying to psychiatry ‚îÇ researcher ‚îÇ gene + cell therapies | @Yale College, @NIH alum ‚îÇ views=mine (he/him/his)",,"New York, USA",,2020-05-14 20:57:58+00:00,"Alex Jares, Ph.D.",http://twitter.com/,1.0,,1.2610380676972257e+18,,0.0,0.0,,The new @ASGCTherapy logo is like a biomedical version of the ‚Äúworm‚Äù NASA logo. I like it. #ASGCT20 https://t.co/jmTID722JY,en,0.0,489.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/alex_jares/statuses/1261038067697225728,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,The new @ASGCTherapy logo is like a biomedical version of the ‚Äúworm‚Äù NASA logo. I like it. #ASGCT20 https://t.co/jmTID722JY,false
diegoah66,"Hematologist-Oncologist @UVMMedCenter, Assistant Professor of Medicine @UVMLarnerMed | üáµüá™üá∫üá∏",,"Burlington, VT",,2020-05-19 01:44:57+00:00,Diego Adrianzen-Herrera,http://twitter.com/,61.0,,1.2625598370717368e+18,,0.0,0.0,,RT @Dr_AmerZeidan: Choose your favorite agent! The MDS Revolution is coming..@aamdsif @LLSResearch @HeretoHelpMDS @MDSFoundation @EHA_Hemat‚Ä¶,en,0.0,187.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,51.0,10.0,https://twitter.com/diegoah66/statuses/1262559837071736832,0.0,0.0,,0.0,0.0,0.0,10.0,51.0,False,False,False,False,True,Disease Advocacy,1.0,0.0,0.0,RT @Dr_AmerZeidan: Choose your favorite agent! The MDS Revolution is coming..@aamdsif @LLSResearch @HeretoHelpMDS @MDSFoundation @EHA_Hemat‚Ä¶,true
EladSharonMD,"#MedicalOncologist tweeting on #immunotherapy, #drugdevelopment, #COVID19 & #HealthEcon. #NCI #CancerMoonshot Adult Immunotherapy Co-Chair. Tweets are mine.",,"Washington, DC",,2020-05-19 02:05:20+00:00,Elad Sharon,http://twitter.com/,61.0,,1.2625649698722652e+18,,0.0,0.0,,RT @Dr_AmerZeidan: Choose your favorite agent! The MDS Revolution is coming..@aamdsif @LLSResearch @HeretoHelpMDS @MDSFoundation @EHA_Hemat‚Ä¶,en,0.0,2113.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,51.0,10.0,https://twitter.com/EladSharonMD/statuses/1262564969872265217,0.0,0.0,,0.0,0.0,0.0,10.0,51.0,False,False,False,False,True,Disease Advocacy,1.0,0.0,0.0,RT @Dr_AmerZeidan: Choose your favorite agent! The MDS Revolution is coming..@aamdsif @LLSResearch @HeretoHelpMDS @MDSFoundation @EHA_Hemat‚Ä¶,true
sahilparikhmd,"Interventional Cardiologist, Vascular Medicine, Clinician Educator and Clinical Researcher, Husband/Father, Friend. My views only; not medical advice.",,"New York, NY",,2020-03-04 06:52:28+00:00,"Sahil A. Parikh, MD",http://twitter.com/,25.0,,1.2350957497481257e+18,,0.0,0.0,,"RT @TCTConference: Submit your science for the chance to present at #TCT2020! The call for abstracts, challenging cases, innovation and the‚Ä¶",en,0.0,1410.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,13.0,12.0,https://twitter.com/sahilparikhmd/statuses/1235095749748125696,0.0,0.0,,0.0,0.0,0.0,12.0,13.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @TCTConference: Submit your science for the chance to present at #TCT2020! The call for abstracts, challenging cases, innovation and the‚Ä¶",true
ajaykirtane,"Practicing Cardiologist, Professor @ColumbiaMed
Researcher & advocate for thoughtful patient care; tweets‚â†endorsements nor med advice
https://t.co/YyilZMYayJ",,NewYork-Presbyterian & beyond,,2020-03-04 10:13:44+00:00,Ajay Kirtane MD SM,http://twitter.com/,25.0,,1.2351464007632036e+18,,0.0,0.0,,"RT @TCTConference: Submit your science for the chance to present at #TCT2020! The call for abstracts, challenging cases, innovation and the‚Ä¶",en,0.0,17044.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,13.0,12.0,https://twitter.com/ajaykirtane/statuses/1235146400763203585,0.0,0.0,,0.0,0.0,0.0,12.0,13.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @TCTConference: Submit your science for the chance to present at #TCT2020! The call for abstracts, challenging cases, innovation and the‚Ä¶",true
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-03-04 03:00:09+00:00,Cardiovascular Research Foundation,http://twitter.com/,1.0,,1.235037284463829e+18,,0.0,0.0,,"Submit your science for the chance to present at #TCT2020! The call for abstracts, challenging cases, innovation an‚Ä¶ https://t.co/rldUgrN6uZ",en,0.0,12239.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/crfheart/statuses/1235037284463828992,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"Submit your science for the chance to present at #TCT2020! The call for abstracts, challenging cases, innovation an‚Ä¶ https://t.co/rldUgrN6uZ",true
dlwagner13,Physician & science enthusiast @ChariteBerlin // previously: @CAGTHouston // Genome Editing and Immunology // 50% of @immunoboys,,"Berlin, Germany",,2020-05-14 21:40:15+00:00,Dimitrios L. Wagner,http://twitter.com/,5.0,,1.2610487046661325e+18,,0.0,0.0,,RT @alex_jares: The new @ASGCTherapy logo is like a biomedical version of the ‚Äúworm‚Äù NASA logo. I like it. #ASGCT20 https://t.co/jmTID722JY,en,0.0,532.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,1.0,https://twitter.com/dlwagner13/statuses/1261048704666132481,0.0,0.0,,0.0,0.0,0.0,1.0,4.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @alex_jares: The new @ASGCTherapy logo is like a biomedical version of the ‚Äúworm‚Äù NASA logo. I like it. #ASGCT20 https://t.co/jmTID722JY,false
ApcpResp,The Association of Paediatric Chartered Physiotherapists Respiratory Committee focuses on the management of children with acute & chronic respiratory conditions,,UK,,2020-07-18 19:53:38+00:00,APCPResp,http://twitter.com/,467.0,,1.284577085550461e+18,,0.0,0.0,,"RT @NovartisCancer: What are you most concerned about for your #sicklecell patients during the current COVID-19 pandemic?

Learn more about‚Ä¶",en,0.0,445.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,392.0,75.0,https://twitter.com/ApcpResp/statuses/1284577085550460934,0.0,0.0,,0.0,0.0,0.0,75.0,392.0,False,False,False,False,True,Covid,0.0,0.0,1.0,"RT @NovartisCancer: What are you most concerned about for your #sicklecell patients during the current COVID-19 pandemic?

Learn more about‚Ä¶",true
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-06-25 17:01:07+00:00,Cardiovascular Research Foundation,http://twitter.com/,1.0,,1.276198752651563e+18,,0.0,0.0,,"Deadline is next week! ‚è±Ô∏èüìÖ Don't miss the chance to share your innovative technologies at #TCTConnect. 

Submit to‚Ä¶ https://t.co/7NY1Nw0O3Z",en,0.0,12239.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/crfheart/statuses/1276198752651563011,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"Deadline is next week! ‚è±Ô∏èüìÖ Don't miss the chance to share your innovative technologies at #TCTConnect. 

Submit to‚Ä¶ https://t.co/7NY1Nw0O3Z",true
TaylorJ_MD,"Assistant Professor, UM Sylvester Comprehensive Cancer Center. Physician scientist studying the role of nuclear export and splicing in hematologic cancers.",,"Miami, FL",,2020-06-15 18:09:36+00:00,Taylor Lab UM,http://twitter.com/,2.0,,1.27259210697719e+18,,0.0,0.0,,"Been seeing these survival curves posted, first off- congrats to all investigators &amp; everyone involved!  However, n‚Ä¶ https://t.co/urxFojpUHq",en,0.0,1781.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/TaylorJ_MD/statuses/1272592106977189892,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Financial Performance,1.0,0.0,0.0,"Been seeing these survival curves posted, first off- congrats to all investigators &amp; everyone involved!  However, n‚Ä¶ https://t.co/urxFojpUHq",true
ADCReview,"ADC Review/J. Antibody-drug Conjugates, an open access journal, brings together researchers, scientists and physicians involved in the growing field of ADCs.",,"Phoenix, AZ (USA)",,2020-06-15 18:30:00+00:00,ADC Review,http://twitter.com/,0.0,,1.2725972405324472e+18,,0.0,0.0,,Loncastuximab Tesirine Demonstrates an Overall High Response Rates in Pivotal Phase II Single-agent Trial‚Ä¶ https://t.co/PxLHx0fZd9,en,0.0,905.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/ADCReview/statuses/1272597240532447232,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,Loncastuximab Tesirine Demonstrates an Overall High Response Rates in Pivotal Phase II Single-agent Trial‚Ä¶ https://t.co/PxLHx0fZd9,true
md_wentrejo,Mexicanüá≤üáΩ|Doctor üë©üèª‚Äç‚öïÔ∏è@anahuac |World Thrombosis Day supporter ‚ù§Ô∏èüíô#WTDay19 #DVT #SAFp #APS #Thrombophilia #G20210A |Opinions are my ownüí¨‚úçüèº,,M√©xico,,2020-06-15 16:45:08+00:00,"Wendy Trejo MD., MSc.",http://twitter.com/,64.0,,1.272570851779584e+18,,0.0,0.0,,"RT @EHA_Hematology: On-demand content at #EHA25Virtual is now available: Explore the invited speaker program, oral abstract and e-poster pr‚Ä¶",en,0.0,432.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,45.0,19.0,https://twitter.com/md_wentrejo/statuses/1272570851779584000,0.0,0.0,,0.0,0.0,0.0,19.0,45.0,False,False,False,False,True,Thought Leadership,0.0,0.0,1.0,"RT @EHA_Hematology: On-demand content at #EHA25Virtual is now available: Explore the invited speaker program, oral abstract and e-poster pr‚Ä¶",true
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-10-14 13:02:44+00:00,Cardiovascular Research Foundation,http://twitter.com/,0.0,,1.3163638143638938e+18,,0.0,0.0,,Take a break from world-class education to network and engage with industry partners at our Engagement Hub during‚Ä¶ https://t.co/XeKGuw6IU3,en,0.0,12239.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/crfheart/statuses/1316363814363893764,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,Take a break from world-class education to network and engage with industry partners at our Engagement Hub during‚Ä¶ https://t.co/XeKGuw6IU3,false
SejlaHodzic4,Physician - scientist working as Global Medical Director of malignant hematology @novartisüí°Tweets are my own üí°,,"New Jersey, USA",,2020-12-30 15:32:00+00:00,"Sejla Hodzic, MD MMSc",http://twitter.com/,8.0,,1.344305241966207e+18,,0.0,0.0,,"RT @AML_Hub: Congress| #ASH20| Jorge Sierra, @HospitalSantPau, discussed results of the phase 3a of midostaurin in adults with newly-diagno‚Ä¶",en,0.0,18.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,7.0,1.0,https://twitter.com/SejlaHodzic4/statuses/1344305241966206976,0.0,0.0,,0.0,0.0,0.0,1.0,7.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"RT @AML_Hub: Congress| #ASH20| Jorge Sierra, @HospitalSantPau, discussed results of the phase 3a of midostaurin in adults with newly-diagno‚Ä¶",true
MedpageOnco,Breaking cancer + oncology news | Reports from all major oncology meetings | Peer-reviewed | Oncologist-trusted | Part of @MedPageToday,,,,2020-12-30 00:26:00+00:00,MedPage Oncology,http://twitter.com/,2.0,,1.3440772416853197e+18,,0.0,0.0,,"In this #video, @VPrasadMDMPH, MD, @AaronGoodman33, MD, and @Abdallah81MD, MD, discuss how autologous stem cell tra‚Ä¶ https://t.co/FADOgIg8ap",en,0.0,443.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/MedpageOnco/statuses/1344077241685319684,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"In this #video, @VPrasadMDMPH, MD, @AaronGoodman33, MD, and @Abdallah81MD, MD, discuss how autologous stem cell tra‚Ä¶ https://t.co/FADOgIg8ap",true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-12-30 22:15:44+00:00,Oncology Tube,http://twitter.com/,0.0,,1.3444068453439488e+18,,0.0,0.0,,"LBA-4 Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study Andreas Hochhaus, MD‚Ä¶ https://t.co/CQMziIGNRk",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1344406845343948801,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"LBA-4 Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study Andreas Hochhaus, MD‚Ä¶ https://t.co/CQMziIGNRk",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-24 15:24:57+00:00,"Ritcha Saxena, MD",http://twitter.com/,33.0,,1.3421291414460293e+18,,0.0,0.0,,"RT @ASH_hematology: ASH Foundation Chair Gary Schiller, MD, running for this year's run/walk, which supports our new Research Restart Award‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,31.0,2.0,https://twitter.com/RitchaSaxena/statuses/1342129141446029313,0.0,0.0,,0.0,0.0,0.0,2.0,31.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @ASH_hematology: ASH Foundation Chair Gary Schiller, MD, running for this year's run/walk, which supports our new Research Restart Award‚Ä¶",true
SurvivingMD,Hematologist and oncologist and Professor of Clinical Medicine at City of Hope. Author of Surviving American Medicine. https://t.co/ZVx56FNk6v,,"Los Angeles, California",,2020-12-10 22:50:03+00:00,Dr. Cary Presant,http://twitter.com/,0.0,,1.3371677244396298e+18,,0.0,0.0,,The #ASH2020 meeting showed new treatments for #leukemia and #lymphoma. A new #CAR-T treatment in #CLL patients who‚Ä¶ https://t.co/2boqTBsAj3,en,0.0,549.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/SurvivingMD/statuses/1337167724439629827,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,The #ASH2020 meeting showed new treatments for #leukemia and #lymphoma. A new #CAR-T treatment in #CLL patients who‚Ä¶ https://t.co/2boqTBsAj3,true
FranciscoMarty_,"Infectious diseases doctor who specializes in treating transplant and cancer patients, work at @BrighamWomens and @DanaFarber, @harvardmed.",,"Boston, MA",,2020-12-04 22:31:38+00:00,"Francisco Marty, MD",http://twitter.com/,14.0,,1.334988763911557e+18,,0.0,0.0,,"RT @DanaFarberNews: TODAY: Dana-Farber's Corey Cutler, MD (@DrCCutler), to present results from a new clinical trial studying donor stem ce‚Ä¶",en,0.0,9991.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,12.0,2.0,https://twitter.com/FranciscoMarty_/statuses/1334988763911557121,0.0,0.0,,0.0,0.0,0.0,2.0,12.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @DanaFarberNews: TODAY: Dana-Farber's Corey Cutler, MD (@DrCCutler), to present results from a new clinical trial studying donor stem ce‚Ä¶",false
VincentRK,"Professor, Mayo Clinic; Editor, Blood Cancer Journal; Oncologist; Health Costs; COVID threads @SurvivedCOVID Opinions=personal views https://t.co/TMq9vc5hZk",,"Rochester, MN, USA",,2020-12-02 23:03:59+00:00,Vincent Rajkumar,http://twitter.com/,47.0,,1.3342721270134497e+18,,0.0,0.0,,#ASH20 special: Active myeloma drugs with their mechanism of action in one slide. Unapproved investigational drugs‚Ä¶ https://t.co/XuWrRuyG9A,en,0.0,33590.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,47.0,https://twitter.com/VincentRK/statuses/1334272127013449730,0.0,0.0,,0.0,0.0,0.0,47.0,0.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,#ASH20 special: Active myeloma drugs with their mechanism of action in one slide. Unapproved investigational drugs‚Ä¶ https://t.co/XuWrRuyG9A,true
smherbrich,Postdoctoral fellow at @MDAndersonNews. Budding immunologist. Bioinformatics journeyman. Stray animal collector. Tweets (and misspelled words) are mine.,,"Houston, TX",,2020-12-02 18:52:54+00:00,Shelley Herbrich,http://twitter.com/,32.0,,1.334208941115515e+18,,0.0,0.0,,"RT @HowellJollyBody: #ASH20 is here! #ASHaiku 

A year of pain, but
like stem cells we adapted
to our strange new niche

#ASHmyeloidworksho‚Ä¶",en,0.0,138.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,28.0,4.0,https://twitter.com/smherbrich/statuses/1334208941115514881,0.0,0.0,,0.0,0.0,0.0,4.0,28.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @HowellJollyBody: #ASH20 is here! #ASHaiku 

A year of pain, but
like stem cells we adapted
to our strange new niche

#ASHmyeloidworksho‚Ä¶",true
JerroldLevy,"Critical care physician in CTICU @DukeMedSchool, interested in coagulation, bleeding, inflammation-also oenophile and foody. Tweets are my own (‚â†medical advice)",,"Durham, North Carolina",,2020-12-02 15:30:47+00:00,"Jerrold Levy, MD",http://twitter.com/,17.0,,1.3341580768496312e+18,,0.0,0.0,,RT @aswolberg: Great start to #ASH20 with this session on infection and coagulation! https://t.co/pXotemz0zo,en,0.0,1755.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,15.0,2.0,https://twitter.com/JerroldLevy/statuses/1334158076849631234,0.0,0.0,,0.0,0.0,0.0,2.0,15.0,False,False,False,False,True,Side Effects,1.0,0.0,0.0,RT @aswolberg: Great start to #ASH20 with this session on infection and coagulation! https://t.co/pXotemz0zo,true
DachiRashid2,"Senior Medical Research and Consultancy, C.E.O.Dachi Group of Companies, Beekeeping Research and Apicuture Consultancy, Medical Psychologist,Bio-Pharmacetical",,"Dar es Salaam, Tanzania",,2020-12-02 15:50:36+00:00,Dachi Rashidi,http://twitter.com/,20.0,,1.334163063289901e+18,,0.0,0.0,,RT @AdvCellTherapy: Bristol Myers Squibb‚Äôs vision is to fulfill the potential of #celltherapy research. Learn more about our approach and o‚Ä¶,en,0.0,1308.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,14.0,6.0,https://twitter.com/DachiRashid2/statuses/1334163063289901057,0.0,0.0,,0.0,0.0,0.0,6.0,14.0,False,False,False,False,True,Thought Leadership,0.0,0.0,1.0,RT @AdvCellTherapy: Bristol Myers Squibb‚Äôs vision is to fulfill the potential of #celltherapy research. Learn more about our approach and o‚Ä¶,true
VincentRK,"Professor, Mayo Clinic; Editor, Blood Cancer Journal; Oncologist; Health Costs; COVID threads @SurvivedCOVID Opinions=personal views https://t.co/TMq9vc5hZk",,"Rochester, MN, USA",,2020-12-02 23:05:12+00:00,Vincent Rajkumar,http://twitter.com/,0.0,,1.3342724336883712e+18,,0.0,0.0,,I don‚Äôt think next year I can keep all of this in one slide. A lot of data on the new drugs in blue font are being‚Ä¶ https://t.co/0J6nigEqKN,en,0.0,33590.0,,,0.0,VincentRK,1.3342721270134497e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/VincentRK/statuses/1334272433688371200,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,I don‚Äôt think next year I can keep all of this in one slide. A lot of data on the new drugs in blue font are being‚Ä¶ https://t.co/0J6nigEqKN,true
TischCancer,"Official account of The Tisch Cancer Institute @MountSinaiNYC. Committed to cancer prevention, detection, treatment & research. Appointments:  1-844-MD CANCER",,"New York, NY",,2020-12-04 23:31:12+00:00,The Tisch Cancer Institute,http://twitter.com/,2.0,,1.3350037546645135e+18,,0.0,0.0,,".@DMadduri will present tomorrow at #ASH20 on preliminary phase 1b/2 data from CARTITUDE-1 
https://t.co/0PVzzXaW2N‚Ä¶ https://t.co/EvKIyn3fOZ",en,0.0,1789.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/TischCancer/statuses/1335003754664513536,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,".@DMadduri will present tomorrow at #ASH20 on preliminary phase 1b/2 data from CARTITUDE-1 
https://t.co/0PVzzXaW2N‚Ä¶ https://t.co/EvKIyn3fOZ",false
abhinav_deol,MD,,"Detroit, MI",,2020-12-04 19:18:24+00:00,Abhinav Deol,http://twitter.com/,0.0,,1.3349401345261036e+18,,0.0,0.0,,As in post CART relapses post Biab may be mediated by loss of CD 20 expression and change in microenviornment #ASH20 https://t.co/20l8G754mB,en,0.0,251.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/abhinav_deol/statuses/1334940134526103552,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,As in post CART relapses post Biab may be mediated by loss of CD 20 expression and change in microenviornment #ASH20 https://t.co/20l8G754mB,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-04 22:07:12+00:00,"Ritcha Saxena, MD",http://twitter.com/,30.0,,1.3349826114758203e+18,,0.0,0.0,,"RT @ASH_hematology: Studies to be presented at #ASH20 examine Disparities in Health Care: Diversity, Equity, and Inclusion (#DEI). Read mor‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,24.0,6.0,https://twitter.com/RitchaSaxena/statuses/1334982611475820544,0.0,0.0,,0.0,0.0,0.0,6.0,24.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,"RT @ASH_hematology: Studies to be presented at #ASH20 examine Disparities in Health Care: Diversity, Equity, and Inclusion (#DEI). Read mor‚Ä¶",true
AlbaRMeira,"Postdoctoral Researcher at @MRC_WIMM @UniofOxford @CR_UK . Molecular and computational biologist, #singlecell genomics. @ComunidadCERU #SRUKCancer Committee",,"Oxford, England",,2020-12-10 02:46:23+00:00,Alba Meira,http://twitter.com/,185.0,,1.3368648099801948e+18,,0.0,0.0,,"RT @AlejoFraticelli: Call to all stem cell hematologists and immunologists!!

My lab, Quantitative Stem Cell Dynamics (https://t.co/j0ocWZY‚Ä¶",en,0.0,417.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,124.0,61.0,https://twitter.com/AlbaRMeira/statuses/1336864809980194817,0.0,0.0,,0.0,0.0,0.0,61.0,124.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @AlejoFraticelli: Call to all stem cell hematologists and immunologists!!

My lab, Quantitative Stem Cell Dynamics (https://t.co/j0ocWZY‚Ä¶",true
HKlepinMD,Geriatric oncologist,,,,2020-12-10 21:48:08+00:00,Heidi Klepin,http://twitter.com/,11.0,,1.3371521428980613e+18,,0.0,0.0,,RT @ShakiraG_MBBS: #ASH20 #hematology + #aging Poster Walk No:2628 Dr. Charity Oyedeji @DukeHealth üëáused physical+cognitive function measur‚Ä¶,en,0.0,902.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,9.0,2.0,https://twitter.com/HKlepinMD/statuses/1337152142898061314,0.0,0.0,,0.0,0.0,0.0,2.0,9.0,False,False,False,False,True,Disease Advocacy,0.0,0.0,1.0,RT @ShakiraG_MBBS: #ASH20 #hematology + #aging Poster Walk No:2628 Dr. Charity Oyedeji @DukeHealth üëáused physical+cognitive function measur‚Ä¶,true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-10 17:57:22+00:00,Lisa Palacios,http://twitter.com/,1.0,,1.3370940683006157e+18,,0.0,0.0,,Combination of chemotherapy and blinatumomab improves survival for patients with B-cell acute lymphoblastic‚Ä¶ https://t.co/KQDonuFRNd,en,0.0,657.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/Lisa_Palacios/statuses/1337094068300615682,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,Combination of chemotherapy and blinatumomab improves survival for patients with B-cell acute lymphoblastic‚Ä¶ https://t.co/KQDonuFRNd,true
DrMJoyner,"Physiologist & anesthesiologist Interested in human performance, views my own. He/him/his",,,,2020-12-10 21:28:16+00:00,Michael Joyner,http://twitter.com/,8.0,,1.3371471443487662e+18,,0.0,0.0,,RT @mtmdphd: A National Collaborative Multicenter Phase II Study for Potential Safety Efficacy of Convalescent Plasma to Treat Severe COVID‚Ä¶,en,0.0,13041.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,3.0,https://twitter.com/DrMJoyner/statuses/1337147144348766213,0.0,0.0,,0.0,0.0,0.0,3.0,5.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @mtmdphd: A National Collaborative Multicenter Phase II Study for Potential Safety Efficacy of Convalescent Plasma to Treat Severe COVID‚Ä¶,false
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-10 03:23:51+00:00,"Ritcha Saxena, MD",http://twitter.com/,46.0,,1.3368742408643748e+18,,0.0,0.0,,"RT @RitchaSaxena: So proud to have the honor of being the top influencer in #ASH20, a wonderful community of loving colleagues &amp; brilliant‚Ä¶",en,0.0,6875.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,33.0,13.0,https://twitter.com/RitchaSaxena/statuses/1336874240864374785,0.0,0.0,,0.0,0.0,0.0,13.0,33.0,False,False,False,False,True,Disease Advocacy,1.0,0.0,0.0,"RT @RitchaSaxena: So proud to have the honor of being the top influencer in #ASH20, a wonderful community of loving colleagues &amp; brilliant‚Ä¶",true
MedpageOnco,Breaking cancer + oncology news | Reports from all major oncology meetings | Peer-reviewed | Oncologist-trusted | Part of @MedPageToday,,,,2020-12-10 21:08:02+00:00,MedPage Oncology,http://twitter.com/,0.0,,1.337142051893293e+18,,0.0,0.0,,"Patients with hematologic malignancies and #COVID19 seemed to be at a higher risk for severe infection and death, r‚Ä¶ https://t.co/SIwo1XMkWj",en,0.0,443.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/MedpageOnco/statuses/1337142051893293056,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"Patients with hematologic malignancies and #COVID19 seemed to be at a higher risk for severe infection and death, r‚Ä¶ https://t.co/SIwo1XMkWj",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-10 17:44:03+00:00,Lisa Palacios,http://twitter.com/,4.0,,1.337090715382329e+18,,0.0,0.0,,"RT @oncologytube: A Randomized Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Nicholas J. Short, MD @NicholasShortMD @MDAnderso‚Ä¶",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,2.0,2.0,https://twitter.com/Lisa_Palacios/statuses/1337090715382329346,0.0,0.0,,0.0,0.0,0.0,2.0,2.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @oncologytube: A Randomized Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Nicholas J. Short, MD @NicholasShortMD @MDAnderso‚Ä¶",true
medox1234,interventional cardiologist,,"Muscat, Oman",,2020-10-15 08:51:09+00:00,Ahmed M. El Said,http://twitter.com/,75.0,,1.3166628877929925e+18,,0.0,0.0,,RT @TomJFord: 48M Recurrent NSTEMI without obstructive disease. Men can also have MINOCA. Invasive functional testing provides a diagnosis!‚Ä¶,en,0.0,941.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,62.0,13.0,https://twitter.com/medox1234/statuses/1316662887792992261,0.0,0.0,,0.0,0.0,0.0,13.0,62.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @TomJFord: 48M Recurrent NSTEMI without obstructive disease. Men can also have MINOCA. Invasive functional testing provides a diagnosis!‚Ä¶,true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-12-10 17:42:00+00:00,Oncology Tube,http://twitter.com/,2.0,,1.3370901998896947e+18,,0.0,0.0,,"A Randomized Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Nicholas J. Short, MD @NicholasShortMD‚Ä¶ https://t.co/2qEKhUpqsp",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/oncologytube/statuses/1337090199889694723,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"A Randomized Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Nicholas J. Short, MD @NicholasShortMD‚Ä¶ https://t.co/2qEKhUpqsp",true
2Scottish,Vascular cardiologist|Platelet biologist|PE. Information is my opinion based on an academic interest in cardiac/vascular care-not my employer.,,"Cleveland, OH",,2020-10-15 09:39:43+00:00,Scott Cameron üè¥Û†ÅßÛ†Å¢Û†Å≥Û†Å£Û†Å¥Û†Åøü©∫üìüüî¨üß´üß¨,http://twitter.com/,75.0,,1.3166751090888786e+18,,0.0,0.0,,RT @TomJFord: 48M Recurrent NSTEMI without obstructive disease. Men can also have MINOCA. Invasive functional testing provides a diagnosis!‚Ä¶,en,0.0,1047.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,62.0,13.0,https://twitter.com/2Scottish/statuses/1316675109088878592,0.0,0.0,,0.0,0.0,0.0,13.0,62.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @TomJFord: 48M Recurrent NSTEMI without obstructive disease. Men can also have MINOCA. Invasive functional testing provides a diagnosis!‚Ä¶,false
Hragy,"Cardiologist, National Heart Institute, Egypt ÿ±ÿ¨ÿßÿ° ÿπÿØŸÖ ÿßŸÑÿ™ŸàÿßÿµŸÑ ÿ®ÿ¥ÿ£ŸÜ ÿ¥ÿ§ŸàŸÜ ÿ∑ÿ®Ÿäÿ© ÿÆÿßÿµÿ© ÿπŸÑŸä ÿ™ŸàŸäÿ™ÿ±",,egypt,,2020-10-15 19:45:20+00:00,Hany Ragy,http://twitter.com/,0.0,,1.3168275198202143e+18,,0.0,0.0,,"#TCTConnect 900 abstracts presented to TCT2020 , each graded by 10 referees ...even in the year of the pandemic! Ku‚Ä¶ https://t.co/xJlH2CAwKG",en,0.0,31448.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/Hragy/statuses/1316827519820214274,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Covid,0.0,0.0,1.0,"#TCTConnect 900 abstracts presented to TCT2020 , each graded by 10 referees ...even in the year of the pandemic! Ku‚Ä¶ https://t.co/xJlH2CAwKG",true
Hragy,"Cardiologist, National Heart Institute, Egypt ÿ±ÿ¨ÿßÿ° ÿπÿØŸÖ ÿßŸÑÿ™ŸàÿßÿµŸÑ ÿ®ÿ¥ÿ£ŸÜ ÿ¥ÿ§ŸàŸÜ ÿ∑ÿ®Ÿäÿ© ÿÆÿßÿµÿ© ÿπŸÑŸä ÿ™ŸàŸäÿ™ÿ±",,egypt,,2020-10-17 20:53:07+00:00,Hany Ragy,http://twitter.com/,21.0,,1.3175693538737644e+18,,0.0,0.0,,RT @heartdoc45: #TCTConnect highlighting use of @csi360 for calcified RCA #cto #innovation @crfheart https://t.co/UwV7NOFML4,en,0.0,31448.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,16.0,5.0,https://twitter.com/Hragy/statuses/1317569353873764353,0.0,0.0,,0.0,0.0,0.0,5.0,16.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @heartdoc45: #TCTConnect highlighting use of @csi360 for calcified RCA #cto #innovation @crfheart https://t.co/UwV7NOFML4,true
HuangJustyn,"Sydney Cardiologist. Ctca,Cmr,Echo,Toe interests.",,"Maroubra, Sydney",,2020-10-17 19:24:20+00:00,Justyn Huang,http://twitter.com/,75.0,,1.3175470109798687e+18,,0.0,0.0,,RT @TomJFord: 48M Recurrent NSTEMI without obstructive disease. Men can also have MINOCA. Invasive functional testing provides a diagnosis!‚Ä¶,en,0.0,147.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,62.0,13.0,https://twitter.com/HuangJustyn/statuses/1317547010979868673,0.0,0.0,,0.0,0.0,0.0,13.0,62.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @TomJFord: 48M Recurrent NSTEMI without obstructive disease. Men can also have MINOCA. Invasive functional testing provides a diagnosis!‚Ä¶,true
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-10-17 13:01:44+00:00,Cardiovascular Research Foundation,http://twitter.com/,1.0,,1.3174507248259973e+18,,0.0,0.0,,Take a break from world-class education to network and engage with industry partners at our Engagement Hub during‚Ä¶ https://t.co/QQp8iMbANj,en,0.0,12239.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/crfheart/statuses/1317450724825997312,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,Take a break from world-class education to network and engage with industry partners at our Engagement Hub during‚Ä¶ https://t.co/QQp8iMbANj,true
Pooh_Velagapudi,Cardiologist; Associate PD-Cardiology Fellowship @UNMC; Chair #ACCEarlyCareer section; SoMe editor @JACCJournals; #Education #HRPCI #SHD; EDMüé∂; Opinions my own,,United States,,2020-10-17 17:26:09+00:00,Poonam Velagapudi,http://twitter.com/,68.0,,1.317517266888647e+18,,0.0,0.0,,RT @mmamas1973: #VIVPartner trial #TCTConnect fascinating presentation around valve in valve treatment of failing #SAVR with #TAVR - this i‚Ä¶,en,0.0,8841.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,49.0,19.0,https://twitter.com/Pooh_Velagapudi/statuses/1317517266888646659,0.0,0.0,,0.0,0.0,0.0,19.0,49.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @mmamas1973: #VIVPartner trial #TCTConnect fascinating presentation around valve in valve treatment of failing #SAVR with #TAVR - this i‚Ä¶,true
medox1234,interventional cardiologist,,"Muscat, Oman",,2020-10-17 18:31:21+00:00,Ahmed M. El Said,http://twitter.com/,35.0,,1.3175336771617137e+18,,0.0,0.0,,"RT @Drroxmehran: Long-term (5y) data from #PARTNER-2 registry (n=365) showed comparable clinical outcomes between ViV and Native TAVR pts,‚Ä¶",en,0.0,941.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,25.0,10.0,https://twitter.com/medox1234/statuses/1317533677161713664,0.0,0.0,,0.0,0.0,0.0,10.0,25.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,"RT @Drroxmehran: Long-term (5y) data from #PARTNER-2 registry (n=365) showed comparable clinical outcomes between ViV and Native TAVR pts,‚Ä¶",false
vonBardelebenRS,"Head of Heart Valve Center Mainz, Senior Interventional Cardiologist, coEditor in Chief EchocardiographyJ, #HFA #EAPCI #ACHD #EMAH #EACVI CPC #ESC_Ambassador",,"Mainz, Deutschland",,2020-10-17 20:49:33+00:00,Ralph Stephan von Bardeleben,http://twitter.com/,68.0,,1.317568456401838e+18,,0.0,0.0,,RT @mmamas1973: #VIVPartner trial #TCTConnect fascinating presentation around valve in valve treatment of failing #SAVR with #TAVR - this i‚Ä¶,en,0.0,877.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,49.0,19.0,https://twitter.com/vonBardelebenRS/statuses/1317568456401838081,0.0,0.0,,0.0,0.0,0.0,19.0,49.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @mmamas1973: #VIVPartner trial #TCTConnect fascinating presentation around valve in valve treatment of failing #SAVR with #TAVR - this i‚Ä¶,true
hvanspall,"Associate Professor, Cardiologist, Scientist @MacDeptMed @HEI_McMaster. Alumnus @HarvardHSPH @UofTMedicine #HeartFailure #RCTs #Implementation #DigitalHealth",,,,2020-10-17 17:39:55+00:00,"Harriette Van Spall, MD MPH",http://twitter.com/,68.0,,1.317520732981703e+18,,0.0,0.0,,RT @mmamas1973: #VIVPartner trial #TCTConnect fascinating presentation around valve in valve treatment of failing #SAVR with #TAVR - this i‚Ä¶,en,0.0,9080.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,49.0,19.0,https://twitter.com/hvanspall/statuses/1317520732981702658,0.0,0.0,,0.0,0.0,0.0,19.0,49.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @mmamas1973: #VIVPartner trial #TCTConnect fascinating presentation around valve in valve treatment of failing #SAVR with #TAVR - this i‚Ä¶,true
CBCIDocs,Thoughts and perspectives from the hematology and transplant physicians at Colorado Blood Cancer Institute @ColoradoBlood @SarahCannonDocs @PresStLukesDenv,,"Denver, CO",,2020-10-21 15:00:51+00:00,CBCI,http://twitter.com/,67.0,,1.318930252702339e+18,,0.0,0.0,,RT @ASH_hematology: @NIAIDNews Director Dr. Anthony Fauci is the #ASH20 keynote speaker! Join ASH President @StephanieLeeMD &amp; Dr. Fauci as‚Ä¶,en,0.0,782.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,49.0,18.0,https://twitter.com/CBCIDocs/statuses/1318930252702339077,0.0,0.0,,0.0,0.0,0.0,18.0,49.0,False,False,False,False,True,Thought Leadership,0.0,0.0,1.0,RT @ASH_hematology: @NIAIDNews Director Dr. Anthony Fauci is the #ASH20 keynote speaker! Join ASH President @StephanieLeeMD &amp; Dr. Fauci as‚Ä¶,true
Obisht,"Consultant interventional Cardiologist - Helios Clinic Erfurt-Germany
#CHIP #PCI #Rotablation #CTO #LM  #TAVI #LAAO #MitraClip #TriClip #Impella #ECMOüá©üá™üá™üá¨",,Germany,,2020-10-25 02:16:59+00:00,Osama Bisht,http://twitter.com/,89.0,,1.3201875690999685e+18,,0.0,0.0,,RT @GreggWStone: FORECAST late breaking trial at #TCT2020. 1300 pts with chest pain at out-pt clinics rand to FFRCT vs usual diagnostic eva‚Ä¶,en,0.0,1171.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,61.0,28.0,https://twitter.com/Obisht/statuses/1320187569099968516,0.0,0.0,,0.0,0.0,0.0,28.0,61.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @GreggWStone: FORECAST late breaking trial at #TCT2020. 1300 pts with chest pain at out-pt clinics rand to FFRCT vs usual diagnostic eva‚Ä¶,true
heartdoc45,Interventional Cardiologist at @CardioInstitute; Ochsner/Scripps trained; Pearl Jam enthusiast. Views expressed are my own. #RadialFirst,,"Lafayette, Louisiana",,2020-10-17 13:34:35+00:00,"David Homan, MD",http://twitter.com/,5.0,,1.3174589920677396e+18,,0.0,0.0,,#TCTConnect highlighting use of @csi360 for calcified RCA #cto #innovation @crfheart https://t.co/UwV7NOFML4,en,0.0,6040.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,5.0,https://twitter.com/heartdoc45/statuses/1317458992067739649,0.0,0.0,,0.0,0.0,0.0,5.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,#TCTConnect highlighting use of @csi360 for calcified RCA #cto #innovation @crfheart https://t.co/UwV7NOFML4,true
dr_m_ohamad,"Minimal invasive and structural Cardiac surgeon @kfshrc_j, alumi of @mcgillu, @uoft and @queensu ÿßÿ≥ÿ™ÿ¥ÿßÿ±Ÿä ÿ¨ÿ±ÿßÿ≠ÿ© ÿßŸÑŸÇŸÑÿ® ŸÅŸä ŸÖÿ≥ÿ™ÿ¥ŸÅŸâ ÿßŸÑŸÖŸÑŸÉ ŸÅŸäÿµŸÑ ÿßŸÑÿ™ÿÆÿµÿµŸä ÿ®ÿ¨ÿØŸá",,Montreal-Makkah-Jeddah-toronto,,2020-10-22 12:22:30+00:00,"Mohammad Alrefai, MD,MSc, FRCSC",http://twitter.com/,32.0,,1.3192527926667182e+18,,0.0,0.0,,"RT @Argenscore: CARDIAC CLASSIFICATION: ‚ÄúAORTIC STENOSIS-DISEASE‚Äù
@PhilGenereuxMD et al.

1661 p from the PARTNER TRIAL

#TCT2020 #TCTConne‚Ä¶",en,0.0,735.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,23.0,9.0,https://twitter.com/dr_m_ohamad/statuses/1319252792666718208,0.0,0.0,,0.0,0.0,0.0,9.0,23.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,"RT @Argenscore: CARDIAC CLASSIFICATION: ‚ÄúAORTIC STENOSIS-DISEASE‚Äù
@PhilGenereuxMD et al.

1661 p from the PARTNER TRIAL

#TCT2020 #TCTConne‚Ä¶",false
purviparwani,"Cardiologist, DirectorWomens‚ù§Ô∏è Clinic #LLUH, BOT @scmrorg ,tweets=myopinion #CardiacImaging #WomenCVhealth #wellness üßò‚Äç‚ôÄÔ∏è üå±",,"California, USA",,2020-10-15 04:00:57+00:00,Dr. Purvi Parwani,http://twitter.com/,75.0,,1.3165898555482194e+18,,0.0,0.0,,RT @TomJFord: 48M Recurrent NSTEMI without obstructive disease. Men can also have MINOCA. Invasive functional testing provides a diagnosis!‚Ä¶,en,0.0,19397.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,62.0,13.0,https://twitter.com/purviparwani/statuses/1316589855548219399,0.0,0.0,,0.0,0.0,0.0,13.0,62.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @TomJFord: 48M Recurrent NSTEMI without obstructive disease. Men can also have MINOCA. Invasive functional testing provides a diagnosis!‚Ä¶,true
ziadalinyc,"Interventional Cardiologist & Vascular Biologist @Columbia @nyphospital. Clinical Trialist @CRFheart. Son, Brother, Husband, Dad everywhere.",,"New York, NY",,2020-10-13 04:21:30+00:00,Ziad Ali,http://twitter.com/,61.0,,1.315870252069249e+18,,0.0,0.0,,"RT @crfheart: Follow our #TCTConnect Social Media Ambassadors! With their vast experience and expertise, they‚Äôll help you get a unique pers‚Ä¶",en,0.0,3676.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,45.0,16.0,https://twitter.com/ziadalinyc/statuses/1315870252069249024,0.0,0.0,,0.0,0.0,0.0,16.0,45.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,"RT @crfheart: Follow our #TCTConnect Social Media Ambassadors! With their vast experience and expertise, they‚Äôll help you get a unique pers‚Ä¶",true
AndreaAnampaG,"Medstudent @UNMSM_ with OCD ‚Ä¢ @ASCO & @AMWAdoctors Social Media
@CPsolvers Team Member ‚Ä¢ #Globaloncology #WomenInMedicine #MedEd #SurvOnc üáµüá™ #IMG üåà she/ella",,"Lima, Peru",,2020-12-05 21:45:14+00:00,Andrea Anampa-Guzm√°n,http://twitter.com/,29.0,,1.3353394746629448e+18,,0.0,0.0,,RT @PTMcGann: @DrSickleStrong is always an incredible speaker but this #ASH20 talk is a must watch. He carefully and clearly describes the‚Ä¶,en,0.0,1908.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,21.0,8.0,https://twitter.com/AndreaAnampaG/statuses/1335339474662944771,0.0,0.0,,0.0,0.0,0.0,8.0,21.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,RT @PTMcGann: @DrSickleStrong is always an incredible speaker but this #ASH20 talk is a must watch. He carefully and clearly describes the‚Ä¶,true
rositadeolivop1,#surgical pathologist #pathology #hemepath #UNAM #Oaxaca #HGM_OD SSA @ampatologia @SOLAHP_ORG @ColegioOaxaca @FEDPATMEX1,,"Oaxaca, M√©xico",,2020-12-05 23:57:22+00:00,Rosalinda Pe√±aloza,http://twitter.com/,10.0,,1.335372727801287e+18,,0.0,0.0,,"RT @Fer_martinmoro: üî¨ Strategies for aggressive T-Cell lymphomas:
- Challenging diagnosis for pathologists and clinicians
- Initial treatme‚Ä¶",en,0.0,1920.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,7.0,3.0,https://twitter.com/rositadeolivop1/statuses/1335372727801286659,0.0,0.0,,0.0,0.0,0.0,3.0,7.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"RT @Fer_martinmoro: üî¨ Strategies for aggressive T-Cell lymphomas:
- Challenging diagnosis for pathologists and clinicians
- Initial treatme‚Ä¶",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 15:37:47+00:00,Lisa Palacios,http://twitter.com/,5.0,,1.3352469997345874e+18,,0.0,0.0,,RT @sierraoncology: We‚Äôre presenting new data at #ASH20 showing the potential of our treatment in development to provide survival benefits‚Ä¶,en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,2.0,https://twitter.com/Lisa_Palacios/statuses/1335246999734587393,0.0,0.0,,0.0,0.0,0.0,2.0,3.0,False,False,False,False,True,Drug Discovery,0.0,0.0,1.0,RT @sierraoncology: We‚Äôre presenting new data at #ASH20 showing the potential of our treatment in development to provide survival benefits‚Ä¶,true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 22:55:42+00:00,Lisa Palacios,http://twitter.com/,7.0,,1.3353572057223946e+18,,0.0,0.0,,"RT @VJHemOnc: Highlights from #MPNsm new therapies &amp; JAKi based combinations for #Myelofibrosis orals at #ASH20

Navitoclax + ruxolitinib i‚Ä¶",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,4.0,https://twitter.com/Lisa_Palacios/statuses/1335357205722394625,0.0,0.0,,0.0,0.0,0.0,4.0,3.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @VJHemOnc: Highlights from #MPNsm new therapies &amp; JAKi based combinations for #Myelofibrosis orals at #ASH20

Navitoclax + ruxolitinib i‚Ä¶",false
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 19:45:26+00:00,Lisa Palacios,http://twitter.com/,8.0,,1.3353093251627172e+18,,0.0,0.0,,"RT @OncLive: Navitoclax/Ruxolitinib Combo Improves Spleen Volume, Symptoms in Relapsed/Refractory Myelofibrosis @doctorpemm @MDAndersonNews‚Ä¶",ro,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,3.0,https://twitter.com/Lisa_Palacios/statuses/1335309325162717188,0.0,0.0,,0.0,0.0,0.0,3.0,5.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @OncLive: Navitoclax/Ruxolitinib Combo Improves Spleen Volume, Symptoms in Relapsed/Refractory Myelofibrosis @doctorpemm @MDAndersonNews‚Ä¶",true
fniainle,"Haematologist, passionate about VTE. Co-director @ConwaySphere; Director https://t.co/csdWq9XJ57; RT not endorsement, views my own",,"Dublin City, Ireland",,2020-12-05 21:05:09+00:00,Fionnuala N√≠ √Åinle,http://twitter.com/,21.0,,1.3353293848913428e+18,,0.0,0.0,,"RT @IMYanXu: Dr. Wee Shian Chan from @BCWomensHosp discusses the diagnostic yield of pregnancy-associated #PE across trimesters, and differ‚Ä¶",en,0.0,2069.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,18.0,3.0,https://twitter.com/fniainle/statuses/1335329384891342849,0.0,0.0,,0.0,0.0,0.0,3.0,18.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"RT @IMYanXu: Dr. Wee Shian Chan from @BCWomensHosp discusses the diagnostic yield of pregnancy-associated #PE across trimesters, and differ‚Ä¶",true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-12-05 22:24:37+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,5.0,,1.3353493840876544e+18,,0.0,0.0,,#ASH20 #leusm Stahl: Molecular predictors of AML MRD eradication after chemo and HCT. Based on genomic profiling 21‚Ä¶ https://t.co/SL2KwMshc5,en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,5.0,https://twitter.com/hemedoc/statuses/1335349384087654400,0.0,0.0,,0.0,0.0,0.0,5.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,#ASH20 #leusm Stahl: Molecular predictors of AML MRD eradication after chemo and HCT. Based on genomic profiling 21‚Ä¶ https://t.co/SL2KwMshc5,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-05 19:55:04+00:00,"Ritcha Saxena, MD",http://twitter.com/,49.0,,1.335311750233731e+18,,0.0,0.0,,"RT @Lymphoma_Doc: My annual complaint at ASH: CR is complete response, it is not complete remission. 
Response is categorical, remission is‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,45.0,4.0,https://twitter.com/RitchaSaxena/statuses/1335311750233731074,0.0,0.0,,0.0,0.0,0.0,4.0,45.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @Lymphoma_Doc: My annual complaint at ASH: CR is complete response, it is not complete remission. 
Response is categorical, remission is‚Ä¶",true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-12-05 23:52:05+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,1.0,,1.3353713953336402e+18,,0.0,0.0,,#ASH20 #leusm Tiong: Most received 3-4Cy chemo. 16% never become neg (threshold 2%) and directly progress from MRD+‚Ä¶ https://t.co/EAKNVC83qL,en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/hemedoc/statuses/1335371395333640192,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,#ASH20 #leusm Tiong: Most received 3-4Cy chemo. 16% never become neg (threshold 2%) and directly progress from MRD+‚Ä¶ https://t.co/EAKNVC83qL,true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 17:42:21+00:00,Lisa Palacios,http://twitter.com/,8.0,,1.335278348541563e+18,,0.0,0.0,,"RT @tobyeyre82: .@michaelwangmd et al
#loxo-305 in R/R NHL phase I/II
No DLTs or MTD reached
3 prior lines - high risk pts
Post BTKi ORR in‚Ä¶",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,3.0,https://twitter.com/Lisa_Palacios/statuses/1335278348541562880,0.0,0.0,,0.0,0.0,0.0,3.0,5.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @tobyeyre82: .@michaelwangmd et al
#loxo-305 in R/R NHL phase I/II
No DLTs or MTD reached
3 prior lines - high risk pts
Post BTKi ORR in‚Ä¶",false
ShuchiGulati,GU Oncologist/ Phase1/ CAT/ clinical trialist/ mom of 3/ learning to create a balance. Tweets are my own,,University of Cincinnati,,2020-12-05 22:49:25+00:00,Shuchi Gulati MD MSc FACP,http://twitter.com/,24.0,,1.3353556248807956e+18,,0.0,0.0,,RT @RosovskyRachel: Grateful for opportunity to work with CCC19 thrombosis team on this important topic. Tune #ASH20 Abst 204 today; 12 pm‚Ä¶,en,0.0,658.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,19.0,5.0,https://twitter.com/ShuchiGulati/statuses/1335355624880795649,0.0,0.0,,0.0,0.0,0.0,5.0,19.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @RosovskyRachel: Grateful for opportunity to work with CCC19 thrombosis team on this important topic. Tune #ASH20 Abst 204 today; 12 pm‚Ä¶,true
graham74GC,Lymphoma specialist at Oxford Cancer and Haematology centre. Haematologist and clinical trialist. Chair of UK Hodgkin and T-cell study groups.,,Opinions are mine,,2020-12-05 19:06:33+00:00,Graham Collins,http://twitter.com/,3.0,,1.3352995393858478e+18,,0.0,0.0,,"Jerkeman et al - Ven/Len/R in rel MCL
- When MRD neg, 3 more months then stop (interesting)
- Ph1 - len 15mg &amp; ven‚Ä¶ https://t.co/7YcqfjZAAb",en,0.0,6091.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/graham74GC/statuses/1335299539385847811,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"Jerkeman et al - Ven/Len/R in rel MCL
- When MRD neg, 3 more months then stop (interesting)
- Ph1 - len 15mg &amp; ven‚Ä¶ https://t.co/7YcqfjZAAb",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 21:13:09+00:00,Lisa Palacios,http://twitter.com/,4.0,,1.3353313996378565e+18,,0.0,0.0,,RT @MarkGeyerMD: @NitinJainMD from @LeukemiaMDA discusses initial results from phase 1 UCART22 study (uses TALEN to disrupt TRAC and CD52 g‚Ä¶,en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,1.0,https://twitter.com/Lisa_Palacios/statuses/1335331399637856258,0.0,0.0,,0.0,0.0,0.0,1.0,3.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @MarkGeyerMD: @NitinJainMD from @LeukemiaMDA discusses initial results from phase 1 UCART22 study (uses TALEN to disrupt TRAC and CD52 g‚Ä¶,true
majorajay,"Hematology/oncology fellow. #lymsm & #mmsm outcomes researcher. Physician-publisher & founder of https://t.co/dPfLt8QVMr, @inTrainingDoc & @inHouseMag.",,"Chicago, IL",,2020-12-04 20:55:04+00:00,"Ajay Major, MD, MBA",http://twitter.com/,1.0,,1.3349644593837425e+18,,0.0,0.0,,Saving these slides on general approach to diagnosis and treatment of #amyloidosis. #ASH20 #ASH20AM #myeloma #mmsm https://t.co/nU4nrdBtZ2,en,0.0,3518.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/majorajay/statuses/1334964459383742467,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,Saving these slides on general approach to diagnosis and treatment of #amyloidosis. #ASH20 #ASH20AM #myeloma #mmsm https://t.co/nU4nrdBtZ2,true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-12-05 05:41:07+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,19.0,,1.3350968464447283e+18,,0.0,0.0,,"#ASH20 #leusm Levis: I don‚Äôt know who needs to hear this, but there really is no role for intensive chemotherapy in‚Ä¶ https://t.co/SHveo4ZtIl",en,0.0,4813.0,,,0.0,,,Negative,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,19.0,https://twitter.com/hemedoc/statuses/1335096846444728320,0.0,0.0,,0.0,0.0,0.0,19.0,0.0,False,False,False,False,True,Innovation,0.0,1.0,0.0,"#ASH20 #leusm Levis: I don‚Äôt know who needs to hear this, but there really is no role for intensive chemotherapy in‚Ä¶ https://t.co/SHveo4ZtIl",true
CanerSaygin,"Heme-Onc Fellow @UChicago | Alumni of @OhioStateIMRes, @CCLRI | #Leukemia, #MDS, #CHIP physician-scientist. Tweets=own opinions.",,"Chicago, IL",,2020-12-05 18:44:07+00:00,"Caner Saygin, MD",http://twitter.com/,7.0,,1.335293892170756e+18,,0.0,0.0,,Dr Wang presenting phase I data on 12 R/R #AML pts treated with Menin-KMT2A (MLL) Inhibitor KO-539. May be promisin‚Ä¶ https://t.co/eDxxBoCXkE,en,0.0,743.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,7.0,https://twitter.com/CanerSaygin/statuses/1335293892170756097,0.0,0.0,,0.0,0.0,0.0,7.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,Dr Wang presenting phase I data on 12 R/R #AML pts treated with Menin-KMT2A (MLL) Inhibitor KO-539. May be promisin‚Ä¶ https://t.co/eDxxBoCXkE,false
aorticsurgeon,"üá®üá¶ Vascular Surgeon and Lead of #VascularTeam @RoyalFreeNHS ...views are my own, as evidence-based as possible & biased to finding a solution 4 aortic disease",,"England, United Kingdom",,2020-10-16 23:51:47+00:00,Tara Mastracci,http://twitter.com/,9.0,,1.317251925969146e+18,,0.0,0.0,,RT @callumlittle6: Could Optical Ultrasound help us detect sidebranches during complex endovascular procedures? Check out our abstract (TCT‚Ä¶,en,0.0,2416.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,7.0,2.0,https://twitter.com/aorticsurgeon/statuses/1317251925969145857,0.0,0.0,,0.0,0.0,0.0,2.0,7.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @callumlittle6: Could Optical Ultrasound help us detect sidebranches during complex endovascular procedures? Check out our abstract (TCT‚Ä¶,true
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-12-04 00:30:14+00:00,Cardiovascular Research Foundation,http://twitter.com/,6.0,,1.334656219911512e+18,,0.0,0.0,,"Watch #TCTConnect on demand‚Äîany time, any place‚Äîthrough Oct. 18, 2021. 

Stream 110+ hours of educational programmi‚Ä¶ https://t.co/gClgk2LLQ7",en,0.0,12239.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,6.0,https://twitter.com/crfheart/statuses/1334656219911512065,0.0,0.0,,0.0,0.0,0.0,6.0,0.0,False,False,False,False,True,Disease Advocacy,0.0,0.0,1.0,"Watch #TCTConnect on demand‚Äîany time, any place‚Äîthrough Oct. 18, 2021. 

Stream 110+ hours of educational programmi‚Ä¶ https://t.co/gClgk2LLQ7",true
VincentRK,"Professor, Mayo Clinic; Editor, Blood Cancer Journal; Oncologist; Health Costs; COVID threads @SurvivedCOVID Opinions=personal views https://t.co/TMq9vc5hZk",,"Rochester, MN, USA",,2020-12-04 13:31:42+00:00,Vincent Rajkumar,http://twitter.com/,194.0,,1.3348528818166784e+18,,0.0,0.0,,RT @VincentRK: #ASH20 special: Active myeloma drugs with their mechanism of action in one slide. Unapproved investigational drugs in blue f‚Ä¶,en,0.0,33590.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,147.0,47.0,https://twitter.com/VincentRK/statuses/1334852881816678400,0.0,0.0,,0.0,0.0,0.0,47.0,147.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,RT @VincentRK: #ASH20 special: Active myeloma drugs with their mechanism of action in one slide. Unapproved investigational drugs in blue f‚Ä¶,true
AdityaMandawat,"Dad. Intv Cardiologist at #ChattanoogaHeart. Duke Cards, Brigham & Women‚Äôs IM, CWRU SOM, Georgia Tech Engineering. Passionate about high quality care.",,"Chattanooga, TN",,2020-10-16 15:46:19+00:00,"Aditya Mandawat, MD",http://twitter.com/,89.0,,1.3171297574321234e+18,,0.0,0.0,,RT @GreggWStone: FORECAST late breaking trial at #TCT2020. 1300 pts with chest pain at out-pt clinics rand to FFRCT vs usual diagnostic eva‚Ä¶,en,0.0,1632.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,61.0,28.0,https://twitter.com/AdityaMandawat/statuses/1317129757432123393,0.0,0.0,,0.0,0.0,0.0,28.0,61.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @GreggWStone: FORECAST late breaking trial at #TCT2020. 1300 pts with chest pain at out-pt clinics rand to FFRCT vs usual diagnostic eva‚Ä¶,true
AJuradoRoman,"Interventional Cardiologist, MD, PhD in myocardial infarction. ComplexPCI. CTO. Intracoronary imaging and phisiology",,,,2020-10-16 18:54:09+00:00,Alfonso Jurado Rom√°n,http://twitter.com/,9.0,,1.317177026269401e+18,,0.0,0.0,,RT @jgranadacrf: Innovation Shark-Tank II @ #TCTConnect today (11:00-AM EST @ Innovation Channel). The LAST 3 technologies presenting today‚Ä¶,en,0.0,2103.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,7.0,2.0,https://twitter.com/AJuradoRoman/statuses/1317177026269401088,0.0,0.0,,0.0,0.0,0.0,2.0,7.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @jgranadacrf: Innovation Shark-Tank II @ #TCTConnect today (11:00-AM EST @ Innovation Channel). The LAST 3 technologies presenting today‚Ä¶,true
tiffchenMD,"Cardiologist ‚ù§Ô∏è, multimodality SHD imager (echo/CMR/CT) üì∏üß≤, 3D enthusiast @PennCardiology ‚Ä¢ Ex @UWCardiology @BrownMedicine ‚Ä¢ @MIT nerd ü§ì ‚Ä¢ Tweets = mine",,"Philadelphia, PA",,2020-10-17 13:12:04+00:00,Tiffany Chen,http://twitter.com/,24.0,,1.3174533252274053e+18,,0.0,0.0,,RT @hahn_rt: New Technology: MitraClip G4 and PASCAL https://t.co/Rv2B0hhjS9 #TCTConnect #TCT2020 @ACCinTouch @ASE360 @TCTMD #echofirst @PS‚Ä¶,en,0.0,1823.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,16.0,8.0,https://twitter.com/tiffchenMD/statuses/1317453325227405313,0.0,0.0,,0.0,0.0,0.0,8.0,16.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @hahn_rt: New Technology: MitraClip G4 and PASCAL https://t.co/Rv2B0hhjS9 #TCTConnect #TCT2020 @ACCinTouch @ASE360 @TCTMD #echofirst @PS‚Ä¶,false
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-10-14 23:00:44+00:00,Cardiovascular Research Foundation,http://twitter.com/,5.0,,1.3165143033909494e+18,,0.0,0.0,,"Day 2 of #TCTConnect features live cases, late-breaking trials, and the #TCT2020 Shark Tank #Innovation competition‚Ä¶ https://t.co/TFSVUkCK4w",en,0.0,12239.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,5.0,https://twitter.com/crfheart/statuses/1316514303390949376,0.0,0.0,,0.0,0.0,0.0,5.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"Day 2 of #TCTConnect features live cases, late-breaking trials, and the #TCT2020 Shark Tank #Innovation competition‚Ä¶ https://t.co/TFSVUkCK4w",true
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-10-16 11:01:40+00:00,Cardiovascular Research Foundation,http://twitter.com/,0.0,,1.3170581201416356e+18,,0.0,0.0,,Ready to enhance your learning during #TCTConnect with E-Satellite Programs? Watch dynamic educational programs hig‚Ä¶ https://t.co/m5cfOyYM3Q,en,0.0,12239.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/crfheart/statuses/1317058120141635585,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Disease Advocacy,1.0,0.0,0.0,Ready to enhance your learning during #TCTConnect with E-Satellite Programs? Watch dynamic educational programs hig‚Ä¶ https://t.co/m5cfOyYM3Q,true
chadialraies,Heart doctor @DMC_Heals Clinician researcher educator #CHIP #PAD #RadialFirst - Founder: https://t.co/CRHKx6HNVb Pub: https://t.co/h3aHzr1oGU -Tweet=my opinion,,"Detroit, MI",,2020-10-17 13:02:07+00:00,"M Chadi Alraies, MD FACC",http://twitter.com/,2.0,,1.317450822914105e+18,,0.0,0.0,,RT @crfheart: Take a break from world-class education to network and engage with industry partners at our Engagement Hub during #TCTConnect‚Ä¶,en,0.0,21440.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,1.0,1.0,https://twitter.com/chadialraies/statuses/1317450822914105346,0.0,0.0,,0.0,0.0,0.0,1.0,1.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,RT @crfheart: Take a break from world-class education to network and engage with industry partners at our Engagement Hub during #TCTConnect‚Ä¶,true
hect2701,"Professor of Medicine, Georgetown University. Cardiology, Interventional Cardiologist, Cardiovascular Imaging. Opinions are my own and RT are not endorsements.",,"Washington, DC",,2020-10-14 11:48:17+00:00,Prof. Hector M. Garcia-Garcia,http://twitter.com/,4.0,,1.316345075312583e+18,,0.0,0.0,,"""Base Camp to Everest Summit: Rapid Ascent of Artificial Intelligence Algorithms for STEMI Diagnosis""
#TCTConnect‚Ä¶ https://t.co/s7fPvsFJzG",en,0.0,3101.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,4.0,https://twitter.com/hect2701/statuses/1316345075312582657,0.0,0.0,,0.0,0.0,0.0,4.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"""Base Camp to Everest Summit: Rapid Ascent of Artificial Intelligence Algorithms for STEMI Diagnosis""
#TCTConnect‚Ä¶ https://t.co/s7fPvsFJzG",true
Drroxmehran,"Interventional cardiologist, Professor of Medicine @mountsinaiNYC, trialist, outcomes researcher, wife and mother; opinions my own #ACCBOT @womenas1",,"Manhattan, NY",,2020-10-17 21:30:22+00:00,Roxana Mehran,http://twitter.com/,11.0,,1.3175787285921014e+18,,0.0,0.0,,RT @JAMACardio: In 30 minutes at #TCT2020: Assoc Editor @Drroxmehran presents The Need of a Dedicated DES to Treat Diabetes in the Innovati‚Ä¶,en,0.0,9783.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,5.0,https://twitter.com/Drroxmehran/statuses/1317578728592101377,0.0,0.0,,0.0,0.0,0.0,5.0,6.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @JAMACardio: In 30 minutes at #TCT2020: Assoc Editor @Drroxmehran presents The Need of a Dedicated DES to Treat Diabetes in the Innovati‚Ä¶,true
FlorianZauner,Interventional Fellow. Cardiologist. Intensivist. PCI. Structural Heart. Eager to lern. Husband. Dad of 2 daughters.,,"Landshut, Deutschland",,2020-10-17 22:00:09+00:00,Florian Zauner,http://twitter.com/,68.0,,1.3175862232932557e+18,,0.0,0.0,,RT @mmamas1973: #VIVPartner trial #TCTConnect fascinating presentation around valve in valve treatment of failing #SAVR with #TAVR - this i‚Ä¶,en,0.0,76.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,49.0,19.0,https://twitter.com/FlorianZauner/statuses/1317586223293255680,0.0,0.0,,0.0,0.0,0.0,19.0,49.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @mmamas1973: #VIVPartner trial #TCTConnect fascinating presentation around valve in valve treatment of failing #SAVR with #TAVR - this i‚Ä¶,false
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-10-14 11:01:20+00:00,Cardiovascular Research Foundation,http://twitter.com/,0.0,,1.3163332600587878e+18,,0.0,0.0,,Ready to enhance your learning during #TCTConnect with E-Satellite Programs? Watch dynamic educational programs hig‚Ä¶ https://t.co/5ydqYoKS1p,en,0.0,12239.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/crfheart/statuses/1316333260058787846,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Disease Advocacy,1.0,0.0,0.0,Ready to enhance your learning during #TCTConnect with E-Satellite Programs? Watch dynamic educational programs hig‚Ä¶ https://t.co/5ydqYoKS1p,true
Hragy,"Cardiologist, National Heart Institute, Egypt ÿ±ÿ¨ÿßÿ° ÿπÿØŸÖ ÿßŸÑÿ™ŸàÿßÿµŸÑ ÿ®ÿ¥ÿ£ŸÜ ÿ¥ÿ§ŸàŸÜ ÿ∑ÿ®Ÿäÿ© ÿÆÿßÿµÿ© ÿπŸÑŸä ÿ™ŸàŸäÿ™ÿ±",,egypt,,2020-10-14 17:32:00+00:00,Hany Ragy,http://twitter.com/,4.0,,1.316431577698775e+18,,0.0,0.0,,RT @TCTConference: Take a break from world-class education to network and engage with industry partners at our Engagement Hub during #TCTCo‚Ä¶,en,0.0,31448.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,1.0,https://twitter.com/Hragy/statuses/1316431577698775040,0.0,0.0,,0.0,0.0,0.0,1.0,3.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,RT @TCTConference: Take a break from world-class education to network and engage with industry partners at our Engagement Hub during #TCTCo‚Ä¶,true
gbiondizoccai,"Academic interventional cardiologist, data scientist, & medical writer/reviewer/editor.
All opinions own, (re)tweets/likes not endorsements nor medical advice.",,"Rome, Italy",,2020-10-14 16:54:15+00:00,Giuseppe Biondi-Zoccai,http://twitter.com/,34.0,,1.316422075322708e+18,,0.0,0.0,,"RT @DFCapodanno: Dear speaker who is presenting COMPARE-CRUSH now, be aware that we are all with you, and feel your frustration as your sli‚Ä¶",en,0.0,1321.0,,,0.0,,,Negative,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,31.0,3.0,https://twitter.com/gbiondizoccai/statuses/1316422075322707969,0.0,0.0,,0.0,0.0,0.0,3.0,31.0,False,False,False,False,True,Thought Leadership,0.0,1.0,0.0,"RT @DFCapodanno: Dear speaker who is presenting COMPARE-CRUSH now, be aware that we are all with you, and feel your frustration as your sli‚Ä¶",true
purviparwani,"Cardiologist, DirectorWomens‚ù§Ô∏è Clinic #LLUH, BOT @scmrorg ,tweets=myopinion #CardiacImaging #WomenCVhealth #wellness üßò‚Äç‚ôÄÔ∏è üå±",,"California, USA",,2020-10-14 14:40:22+00:00,Dr. Purvi Parwani,http://twitter.com/,17.0,,1.3163883818451558e+18,,0.0,0.0,,RT @JGrapsa: An innovative #TCTConnect #TCT2020 just started @TCTConference @crfheart @Drroxmehran @ajaykirtane There are 30+ social media‚Ä¶,en,0.0,19397.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,11.0,6.0,https://twitter.com/purviparwani/statuses/1316388381845155845,0.0,0.0,,0.0,0.0,0.0,6.0,11.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @JGrapsa: An innovative #TCTConnect #TCT2020 just started @TCTConference @crfheart @Drroxmehran @ajaykirtane There are 30+ social media‚Ä¶,true
BartoszHudzik,"Assoc. Prof. of Cardiology #Medical Univ.of Silesia, Senior Cardiologist #SilesianCenterforHeartDisease, #JACCCaseReports Editorial Consultant #thrombosis #AFib",,Polska,,2020-10-14 23:37:25+00:00,Bartosz Hudzik MD PhD FESC FACC,http://twitter.com/,33.0,,1.316523534265594e+18,,0.0,0.0,,"RT @JGrapsa: Inspiring the next generation, promoting innovation &amp; clinical excellence, @ACCinTouch together with @crfheart introduce Marti‚Ä¶",en,0.0,317.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,23.0,10.0,https://twitter.com/BartoszHudzik/statuses/1316523534265593857,0.0,0.0,,0.0,0.0,0.0,10.0,23.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"RT @JGrapsa: Inspiring the next generation, promoting innovation &amp; clinical excellence, @ACCinTouch together with @crfheart introduce Marti‚Ä¶",true
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-10-14 17:02:11+00:00,Cardiovascular Research Foundation,http://twitter.com/,0.0,,1.3164240713542164e+18,,0.0,0.0,,Curious about the latest innovation trends in #MedTech? Watch our session #structuralheart and interventional‚Ä¶ https://t.co/yJbqYXkcxF,en,0.0,12239.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/crfheart/statuses/1316424071354216451,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,Curious about the latest innovation trends in #MedTech? Watch our session #structuralheart and interventional‚Ä¶ https://t.co/yJbqYXkcxF,false
SVRaoMD,Cardiologist @DukeCardiology @vadurham; Editor-In-Chief @CircIntv; Exec Committee @SCAI; No non-research RWI since March 2018; Tweets my own and ‚â† med advice,,,,2020-10-14 14:27:13+00:00,Sunil V. Rao,http://twitter.com/,10.0,,1.3163850722583142e+18,,0.0,0.0,,RT @ZeroTLR: Controversies in Cardiogenic Shock @BurkhoffMd @BillONeillMD  @SVRaoMD  #TCT2020 #TCTConnect  World Connect   Mechanical suppo‚Ä¶,en,0.0,17947.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,7.0,3.0,https://twitter.com/SVRaoMD/statuses/1316385072258314240,0.0,0.0,,0.0,0.0,0.0,3.0,7.0,False,False,False,False,True,Cost of Care,0.0,0.0,1.0,RT @ZeroTLR: Controversies in Cardiogenic Shock @BurkhoffMd @BillONeillMD  @SVRaoMD  #TCT2020 #TCTConnect  World Connect   Mechanical suppo‚Ä¶,true
KardiologieHH,Interventional Cardiologist | Sch√∂n Klinik Hamburg Eilbek Germany | Husband ‚ù§Ô∏è| Father üëß üëß | #radialfirst |#DGKAmbassador | #AGIKAmbassador,,"Hamburg, Deutschland",,2020-10-14 19:34:14+00:00,Erik Rafflenbeul,http://twitter.com/,26.0,,1.3164623357588726e+18,,0.0,0.0,,RT @DrSethdb: Controversies in Cardiogenic Shock at #TCTConnect with @BillONeillMD putting in perspective on evolving data on Impella in AM‚Ä¶,en,0.0,1643.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,18.0,8.0,https://twitter.com/KardiologieHH/statuses/1316462335758872576,0.0,0.0,,0.0,0.0,0.0,8.0,18.0,False,False,False,False,True,Cost of Care,0.0,0.0,1.0,RT @DrSethdb: Controversies in Cardiogenic Shock at #TCTConnect with @BillONeillMD putting in perspective on evolving data on Impella in AM‚Ä¶,true
heartdoc45,Interventional Cardiologist at @CardioInstitute; Ochsner/Scripps trained; Pearl Jam enthusiast. Views expressed are my own. #RadialFirst,,"Lafayette, Louisiana",,2020-10-14 18:07:58+00:00,"David Homan, MD",http://twitter.com/,17.0,,1.3164406284783045e+18,,0.0,0.0,,RT @JGrapsa: An innovative #TCTConnect #TCT2020 just started @TCTConference @crfheart @Drroxmehran @ajaykirtane There are 30+ social media‚Ä¶,en,0.0,6040.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,11.0,6.0,https://twitter.com/heartdoc45/statuses/1316440628478304256,0.0,0.0,,0.0,0.0,0.0,6.0,11.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @JGrapsa: An innovative #TCTConnect #TCT2020 just started @TCTConference @crfheart @Drroxmehran @ajaykirtane There are 30+ social media‚Ä¶,true
JGrapsa,Consultant Cardiologist GSTT - Editor in chief #JACCcasereports -Secretary ESC council on VHD - Tweets are my own opinion#,,,,2020-10-14 13:02:16+00:00,Julia Grapsa,http://twitter.com/,10.0,,1.3163636950233702e+18,,0.0,0.0,,"Inspiring the next generation, promoting innovation &amp; clinical excellence, @ACCinTouch together with @crfheart intr‚Ä¶ https://t.co/PTnuODhV3z",en,0.0,11060.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,10.0,https://twitter.com/JGrapsa/statuses/1316363695023370240,0.0,0.0,,0.0,0.0,0.0,10.0,0.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"Inspiring the next generation, promoting innovation &amp; clinical excellence, @ACCinTouch together with @crfheart intr‚Ä¶ https://t.co/PTnuODhV3z",true
Drroxmehran,"Interventional cardiologist, Professor of Medicine @mountsinaiNYC, trialist, outcomes researcher, wife and mother; opinions my own #ACCBOT @womenas1",,"Manhattan, NY",,2020-10-14 13:38:53+00:00,Roxana Mehran,http://twitter.com/,17.0,,1.316372911113089e+18,,0.0,0.0,,RT @JGrapsa: An innovative #TCTConnect #TCT2020 just started @TCTConference @crfheart @Drroxmehran @ajaykirtane There are 30+ social media‚Ä¶,en,0.0,9783.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,11.0,6.0,https://twitter.com/Drroxmehran/statuses/1316372911113089025,0.0,0.0,,0.0,0.0,0.0,6.0,11.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @JGrapsa: An innovative #TCTConnect #TCT2020 just started @TCTConference @crfheart @Drroxmehran @ajaykirtane There are 30+ social media‚Ä¶,true
jaygirimd,"Interventional cardiologist, cardiovascular outcomes & policy researcher, sports fan, @PennMedicine, @VAPhiladelphia, @PennLDI, tweets reflect only my opinions",,"Philadelphia, PA",,2020-10-14 17:43:34+00:00,Jay Giri,http://twitter.com/,15.0,,1.3164344874090865e+18,,0.0,0.0,,"RT @Drroxmehran: #NACMI: In the North American #COVID-19 STEMI registry, #COVID+ pts had worse prognosis compared with pts under investigat‚Ä¶",en,0.0,2336.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,12.0,3.0,https://twitter.com/jaygirimd/statuses/1316434487409086465,0.0,0.0,,0.0,0.0,0.0,3.0,12.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,"RT @Drroxmehran: #NACMI: In the North American #COVID-19 STEMI registry, #COVID+ pts had worse prognosis compared with pts under investigat‚Ä¶",false
hvanspall,"Associate Professor, Cardiologist, Scientist @MacDeptMed @HEI_McMaster. Alumnus @HarvardHSPH @UofTMedicine #HeartFailure #RCTs #Implementation #DigitalHealth",,,,2020-10-14 16:50:40+00:00,"Harriette Van Spall, MD MPH",http://twitter.com/,26.0,,1.3164211752333883e+18,,0.0,0.0,,RT @mmamas1973: #TCTConnect if you missed the LBT session can see livestream below @CardioIAN @billgogas @GiuseppeGalati_ @gbiondizoccai @h‚Ä¶,en,0.0,9080.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,18.0,8.0,https://twitter.com/hvanspall/statuses/1316421175233388545,0.0,0.0,,0.0,0.0,0.0,8.0,18.0,False,False,False,False,True,Disease Management,0.0,0.0,1.0,RT @mmamas1973: #TCTConnect if you missed the LBT session can see livestream below @CardioIAN @billgogas @GiuseppeGalati_ @gbiondizoccai @h‚Ä¶,true
Drroxmehran,"Interventional cardiologist, Professor of Medicine @mountsinaiNYC, trialist, outcomes researcher, wife and mother; opinions my own #ACCBOT @womenas1",,"Manhattan, NY",,2020-10-14 13:38:27+00:00,Roxana Mehran,http://twitter.com/,33.0,,1.3163728011341742e+18,,0.0,0.0,,"RT @JGrapsa: Inspiring the next generation, promoting innovation &amp; clinical excellence, @ACCinTouch together with @crfheart introduce Marti‚Ä¶",en,0.0,9783.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,23.0,10.0,https://twitter.com/Drroxmehran/statuses/1316372801134174209,0.0,0.0,,0.0,0.0,0.0,10.0,23.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"RT @JGrapsa: Inspiring the next generation, promoting innovation &amp; clinical excellence, @ACCinTouch together with @crfheart introduce Marti‚Ä¶",true
cesardegali,"Doctorado en Biotecnolog√≠a. Licenciado en Bioqu√≠mica y en Ciencias Qu√≠micas. Apasionado de la ciencia. Ecologista, submarinista y lector.",,,,2020-09-03 09:55:16+00:00,C√©sar del Rio Merino,http://twitter.com/,14.0,,1.301458733860561e+18,,0.0,0.0,,"RT @DrMiguelPerales: #EBMT20 Comparative data between CD34 selected allo-HCT vs unmodified.  Same relapse rate, less GVHD, better CRFS @BMT‚Ä¶",en,0.0,29.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,12.0,2.0,https://twitter.com/cesardegali/statuses/1301458733860560896,0.0,0.0,,0.0,0.0,0.0,2.0,12.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @DrMiguelPerales: #EBMT20 Comparative data between CD34 selected allo-HCT vs unmodified.  Same relapse rate, less GVHD, better CRFS @BMT‚Ä¶",true
medox1234,interventional cardiologist,,"Muscat, Oman",,2020-10-16 15:03:36+00:00,Ahmed M. El Said,http://twitter.com/,10.0,,1.3171190069234606e+18,,0.0,0.0,,"RT @Argenscore: #TAVR IN LOW-RISK PATIENTS: 

McCarthy #TCT2020 #TCTConnect

Dr. Kaul: @kaulcsmc

‚ÄúThe QUANTUM of EVIDENCE is INSUFFICIENT‚Ä¶",en,0.0,941.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,5.0,https://twitter.com/medox1234/statuses/1317119006923460610,0.0,0.0,,0.0,0.0,0.0,5.0,5.0,False,False,False,False,True,Insurance Coverage,0.0,0.0,1.0,"RT @Argenscore: #TAVR IN LOW-RISK PATIENTS: 

McCarthy #TCT2020 #TCTConnect

Dr. Kaul: @kaulcsmc

‚ÄúThe QUANTUM of EVIDENCE is INSUFFICIENT‚Ä¶",true
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-10-16 14:40:03+00:00,Cardiovascular Research Foundation,http://twitter.com/,3.0,,1.317113080116138e+18,,0.0,0.0,,Step into the #TCT2020 Shark Tank! Tune in at 11:00 AM ET to watch the next 3 teams compete for the top innovation‚Ä¶ https://t.co/HCCNqeTVFP,en,0.0,12239.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/crfheart/statuses/1317113080116137984,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,Step into the #TCT2020 Shark Tank! Tune in at 11:00 AM ET to watch the next 3 teams compete for the top innovation‚Ä¶ https://t.co/HCCNqeTVFP,true
aymanka,"interventional cardiologist ( ex SCAI BOT ,ex Washington Hospital Center ) runner , diver , NFL . lucky to be in a profession that keeps you learning !",,,,2020-10-16 17:06:43+00:00,Ayman Magd,http://twitter.com/,33.0,,1.3171499879445176e+18,,0.0,0.0,,RT @mmamas1973: #TCTConnect join us in the innovation and e-training centre at 10am EST for discussions around SDD and #RadialFirst with Ma‚Ä¶,en,0.0,3854.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,21.0,12.0,https://twitter.com/aymanka/statuses/1317149987944517635,0.0,0.0,,0.0,0.0,0.0,12.0,21.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @mmamas1973: #TCTConnect join us in the innovation and e-training centre at 10am EST for discussions around SDD and #RadialFirst with Ma‚Ä¶,false
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-10-16 01:47:59+00:00,Cardiovascular Research Foundation,http://twitter.com/,14.0,,1.3169187809504666e+18,,0.0,0.0,,"RT @AnastasiaSMihai: üåüüåüüåüüåüüåüsessions scheduled #TCT2020 ‚ÄºÔ∏è
 
üìçLive Cases! 
üìç#LBCT &amp; #Science (my‚ù§Ô∏è)
üìç TCTü¶àtank innovations
üìç FDA Town Hall‚ô®Ô∏èT‚Ä¶",en,0.0,12239.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,8.0,6.0,https://twitter.com/crfheart/statuses/1316918780950466561,0.0,0.0,,0.0,0.0,0.0,6.0,8.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @AnastasiaSMihai: üåüüåüüåüüåüüåüsessions scheduled #TCT2020 ‚ÄºÔ∏è
 
üìçLive Cases! 
üìç#LBCT &amp; #Science (my‚ù§Ô∏è)
üìç TCTü¶àtank innovations
üìç FDA Town Hall‚ô®Ô∏èT‚Ä¶",true
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-10-16 00:55:11+00:00,Cardiovascular Research Foundation,http://twitter.com/,4.0,,1.31690549462852e+18,,0.0,0.0,,"Have you been following our #TCTConnect ambassadors? With their vast experience and expertise, they‚Äôll help you get‚Ä¶ https://t.co/oDuOyXYFEs",en,0.0,12239.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,4.0,https://twitter.com/crfheart/statuses/1316905494628519937,0.0,0.0,,0.0,0.0,0.0,4.0,0.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,"Have you been following our #TCTConnect ambassadors? With their vast experience and expertise, they‚Äôll help you get‚Ä¶ https://t.co/oDuOyXYFEs",true
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-10-16 00:57:36+00:00,Cardiovascular Research Foundation,http://twitter.com/,5.0,,1.3169061013681152e+18,,0.0,0.0,,"Have you been following our #TCTConnect ambassadors? With their vast experience and expertise, they‚Äôll help you get‚Ä¶ https://t.co/GStCEieylP",en,0.0,12239.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,5.0,https://twitter.com/crfheart/statuses/1316906101368115201,0.0,0.0,,0.0,0.0,0.0,5.0,0.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,"Have you been following our #TCTConnect ambassadors? With their vast experience and expertise, they‚Äôll help you get‚Ä¶ https://t.co/GStCEieylP",true
medshronline,"MedShr -The App for Doctors, is a HIPAA & GMC compliant network for medical professionals to discuss clinical cases. MedShr now has over 1M members worldwide.",,"London, England",,2020-10-16 10:19:58+00:00,MedShr,http://twitter.com/,18.0,,1.3170476261734195e+18,,0.0,0.0,,"RT @crfheart: Have you been following our #TCTConnect ambassadors? With their vast experience and expertise, they‚Äôll help you get a unique‚Ä¶",en,0.0,8228.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,11.0,7.0,https://twitter.com/medshronline/statuses/1317047626173419522,0.0,0.0,,0.0,0.0,0.0,7.0,11.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,"RT @crfheart: Have you been following our #TCTConnect ambassadors? With their vast experience and expertise, they‚Äôll help you get a unique‚Ä¶",true
pash22,"Public Hlth Dr,interested in evid-based health services commissioning,clinical leadership & hlth policy.My views are my own,RTs are no endorsements",,United Kingdom,,2020-10-16 15:40:16+00:00,Ash Paul,http://twitter.com/,10.0,,1.3171282314730783e+18,,0.0,0.0,,"RT @Argenscore: #TAVR IN LOW-RISK PATIENTS: 

McCarthy #TCT2020 #TCTConnect

Dr. Kaul: @kaulcsmc

‚ÄúThe QUANTUM of EVIDENCE is INSUFFICIENT‚Ä¶",en,0.0,26941.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,5.0,https://twitter.com/pash22/statuses/1317128231473078273,0.0,0.0,,0.0,0.0,0.0,5.0,5.0,False,False,False,False,True,Insurance Coverage,0.0,0.0,1.0,"RT @Argenscore: #TAVR IN LOW-RISK PATIENTS: 

McCarthy #TCT2020 #TCTConnect

Dr. Kaul: @kaulcsmc

‚ÄúThe QUANTUM of EVIDENCE is INSUFFICIENT‚Ä¶",true
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-10-16 00:54:04+00:00,Cardiovascular Research Foundation,http://twitter.com/,1.0,,1.3169052131613164e+18,,0.0,0.0,,"Have you been following our #TCTConnect ambassadors? With their vast experience and expertise, they‚Äôll help you get‚Ä¶ https://t.co/WDo4zScgpf",en,0.0,12239.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/crfheart/statuses/1316905213161316362,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,"Have you been following our #TCTConnect ambassadors? With their vast experience and expertise, they‚Äôll help you get‚Ä¶ https://t.co/WDo4zScgpf",false
MDAndersonNews,"The official account of MD Anderson Cancer Center, a leader in cancer care, cancer research and the fight to #EndCancer. Appointments available: 1-877-632-6789.",,"Houston, TX",,2020-12-08 11:24:00+00:00,MD Anderson Cancer Center,http://twitter.com/,1.0,,1.3362702995585393e+18,,0.0,0.0,,"Presented by our Dr. William Wierda at #ASH20, results from Phase II CAPTIVATE study show that venetoclax plus ibru‚Ä¶ https://t.co/5Szrab8CgB",en,0.0,114120.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/MDAndersonNews/statuses/1336270299558539264,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"Presented by our Dr. William Wierda at #ASH20, results from Phase II CAPTIVATE study show that venetoclax plus ibru‚Ä¶ https://t.co/5Szrab8CgB",true
MDMagazine,Clinical News for Connected Physicians. Everything you need to enhance your clinical approach to improving patient care.,,United States,,2020-12-08 16:50:22+00:00,HCPLive,http://twitter.com/,0.0,,1.3363524306493153e+18,,0.0,0.0,,New data from #ASH20 indicates that #lintuzumab Ac225 plus CLAG-M chemotherapy has an acceptable safety profile for‚Ä¶ https://t.co/JLIFNovdDt,en,0.0,7073.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/MDMagazine/statuses/1336352430649315328,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,New data from #ASH20 indicates that #lintuzumab Ac225 plus CLAG-M chemotherapy has an acceptable safety profile for‚Ä¶ https://t.co/JLIFNovdDt,true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-08 14:35:03+00:00,Lisa Palacios,http://twitter.com/,11.0,,1.3363183768687206e+18,,0.0,0.0,,"RT @MDAndersonNews: When Trena Robertson faced a multiple myeloma recurrence after a stem cell transplant, our Dr. Krina Patel offered her‚Ä¶",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,1.0,https://twitter.com/Lisa_Palacios/statuses/1336318376868720640,0.0,0.0,,0.0,0.0,0.0,1.0,10.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @MDAndersonNews: When Trena Robertson faced a multiple myeloma recurrence after a stem cell transplant, our Dr. Krina Patel offered her‚Ä¶",true
AzizNazhaMD,"Practice Manager at Amazon Web Services, Physician, #Programmer, #DataScientist, interested in the Digital Transformation of Healthcare",,Cleveland Clinic,,2020-12-08 17:00:04+00:00,Aziz Nazha,http://twitter.com/,0.0,,1.3363548727535985e+18,,0.0,0.0,,"Our #AI, #ML, #MachineLearning model that can predict response to chemotherapy using blood counts, #ASH2020 
Doximi‚Ä¶ https://t.co/KEM1crv0kj",en,0.0,2087.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/AzizNazhaMD/statuses/1336354872753598465,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"Our #AI, #ML, #MachineLearning model that can predict response to chemotherapy using blood counts, #ASH2020 
Doximi‚Ä¶ https://t.co/KEM1crv0kj",true
KellySchoenbeck,"Hematology/Oncology Fellow @UCSFCancer | IM @ColumbiaMed | MD @OHSUSOM | hematology, myeloid malignancies #QOL #geriheme | tweets my own",,,,2020-12-08 20:16:03+00:00,Kelly Schoenbeck,http://twitter.com/,15.0,,1.336404194245296e+18,,0.0,0.0,,RT @ShakiraG_MBBS: #ASH20 @LundJenny et al.üëáüèæSEER-Medicare data analysis of OAs with #CLL: 28%: high comorbid burden (NCI comorbidity index‚Ä¶,en,0.0,48.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,8.0,7.0,https://twitter.com/KellySchoenbeck/statuses/1336404194245296129,0.0,0.0,,0.0,0.0,0.0,7.0,8.0,False,False,False,False,True,Insurance Coverage,0.0,0.0,1.0,RT @ShakiraG_MBBS: #ASH20 @LundJenny et al.üëáüèæSEER-Medicare data analysis of OAs with #CLL: 28%: high comorbid burden (NCI comorbidity index‚Ä¶,true
MDMagazine,Clinical News for Connected Physicians. Everything you need to enhance your clinical approach to improving patient care.,,United States,,2020-12-08 13:30:00+00:00,HCPLive,http://twitter.com/,0.0,,1.3363020079849925e+18,,0.0,0.0,,"#ICYMI: 

New findings from a #sicklecell study indicate that increased systolic pressure from light exercise may h‚Ä¶ https://t.co/SEzRaZk3ky",en,0.0,7073.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/MDMagazine/statuses/1336302007984992256,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"#ICYMI: 

New findings from a #sicklecell study indicate that increased systolic pressure from light exercise may h‚Ä¶ https://t.co/SEzRaZk3ky",false
makil_melvin,Doctor of Pharmacy and Masters in Business Administration Graduate working as a Medical Science Liaison within the Malignant Hematology Space. Opinions are mine,,New Jersey,,2020-12-08 15:21:44+00:00,"Melvin Makil, PharmD MBA",http://twitter.com/,1.0,,1.336330127366443e+18,,0.0,0.0,,Anyone else believe #ASH2020 brought a sense of excitement and re-charge that we needed? Bring on innovation and research. #hemepath,en,0.0,87.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/makil_melvin/statuses/1336330127366443012,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,Anyone else believe #ASH2020 brought a sense of excitement and re-charge that we needed? Bring on innovation and research. #hemepath,true
MDMagazine,Clinical News for Connected Physicians. Everything you need to enhance your clinical approach to improving patient care.,,United States,,2020-12-08 22:42:56+00:00,HCPLive,http://twitter.com/,0.0,,1.3364411568178586e+18,,0.0,0.0,,Findings suggest that neurocognitive screening measures for adult #sicklecell patients have inherent educational bi‚Ä¶ https://t.co/OiWiuxJxXO,en,0.0,7073.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/MDMagazine/statuses/1336441156817858562,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Patient Education,0.0,0.0,1.0,Findings suggest that neurocognitive screening measures for adult #sicklecell patients have inherent educational bi‚Ä¶ https://t.co/OiWiuxJxXO,true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-12-08 21:30:00+00:00,Oncology Tube,http://twitter.com/,0.0,,1.3364228040282644e+18,,0.0,0.0,,"Phase 1 Results of Teclistamab, BCMA Alfred L. Garfall, MD, MS @AlGarfall @PennMedNews #ASH20 #BCMA #RRMM #Cancer‚Ä¶ https://t.co/ENF8w1XNpO",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1336422804028264456,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"Phase 1 Results of Teclistamab, BCMA Alfred L. Garfall, MD, MS @AlGarfall @PennMedNews #ASH20 #BCMA #RRMM #Cancer‚Ä¶ https://t.co/ENF8w1XNpO",true
dgermain21,MD-PhD. 2nd year Heme/Onc fellow focused on lymphoma and leukemia. Physician-scientist-in-training. Tweet/RT not medical advice or endorsement.,,"St. Louis, MO",,2020-12-08 23:42:43+00:00,David A. Russler-Germain,http://twitter.com/,46.0,,1.33645620062029e+18,,0.0,0.0,,RT @JohnPLeonardMD: Cancer-associated mutations can be present as long as 50 years prior to diagnosis.... #ASH20 Researchers Trace the Orig‚Ä¶,en,0.0,1612.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,42.0,4.0,https://twitter.com/dgermain21/statuses/1336456200620290052,0.0,0.0,,0.0,0.0,0.0,4.0,42.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @JohnPLeonardMD: Cancer-associated mutations can be present as long as 50 years prior to diagnosis.... #ASH20 Researchers Trace the Orig‚Ä¶,true
emmamgroarke,"Haematologist in Bethesda. Irish trained üáÆüá™ Particular interests: #aplasticanemia, #telomeredisease, #CHIP, #MDS, #AML, #HSCT All comments my own.",,"Washington, DC",,2020-12-08 15:27:50+00:00,Emma M. Groarke,http://twitter.com/,218.0,,1.3363316601161974e+18,,0.0,0.0,,"RT @hemedoc: #ASH20 #leusm Wei: We are all excited to have new therapeutic options in AML, but the overall message I get from this money sl‚Ä¶",en,0.0,130.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,168.0,50.0,https://twitter.com/emmamgroarke/statuses/1336331660116197389,0.0,0.0,,0.0,0.0,0.0,50.0,168.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"RT @hemedoc: #ASH20 #leusm Wei: We are all excited to have new therapeutic options in AML, but the overall message I get from this money sl‚Ä¶",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-05 02:14:32+00:00,"Ritcha Saxena, MD",http://twitter.com/,9.0,,1.3350448568598118e+18,,0.0,0.0,,RT @DanaFarberNews: #ASH20 News: Donor stem cell transplant shown to improve survival in older patients with #MDS: https://t.co/rjdqBns8VQ‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,7.0,2.0,https://twitter.com/RitchaSaxena/statuses/1335044856859811840,0.0,0.0,,0.0,0.0,0.0,2.0,7.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @DanaFarberNews: #ASH20 News: Donor stem cell transplant shown to improve survival in older patients with #MDS: https://t.co/rjdqBns8VQ‚Ä¶,false
nixon786,Physician investing in Biotech. Not an investment advise or recommendation to buy & sell. Please do your own DD.,,NYC,,2020-12-05 17:43:50+00:00,nixon786,http://twitter.com/,18.0,,1.335278722728026e+18,,0.0,0.0,,RT @AuclairDan: Interesting early data presented by Roman Shapiro at #ASH20 from a Phase I study using memory-like #NK cells ‚Å¶@romeerizwan‚Å©‚Ä¶,en,0.0,1082.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,14.0,4.0,https://twitter.com/nixon786/statuses/1335278722728026120,0.0,0.0,,0.0,0.0,0.0,4.0,14.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @AuclairDan: Interesting early data presented by Roman Shapiro at #ASH20 from a Phase I study using memory-like #NK cells ‚Å¶@romeerizwan‚Å©‚Ä¶,true
EbonyJHilton_MD,"Associate Prof of Anesthesiology ‚ñ™Ô∏èCritical Care Physician ‚ñ™Ô∏è Author ‚ñ™Ô∏è Inventor ‚ñ™Ô∏è Medical Director, @GOODSTOCK_LLC",,"Charlottesville, VA",,2020-12-05 00:28:37+00:00,"Ebony Jade Hilton, MD",http://twitter.com/,37.0,,1.3350182032280863e+18,,0.0,0.0,,RT @acweyand: So important to work with our #Transgender patients and engage in shared decision making to ensure they can proceed with thei‚Ä¶,en,0.0,19205.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,32.0,5.0,https://twitter.com/EbonyJHilton_MD/statuses/1335018203228086275,0.0,0.0,,0.0,0.0,0.0,5.0,32.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @acweyand: So important to work with our #Transgender patients and engage in shared decision making to ensure they can proceed with thei‚Ä¶,true
RichardBurwick,"Maternal Fetal Medicine @CedarsSinai | Dad, husband, doctor, researcher | Interested in #Complement #Preeclampsia #HELLP #aHUS #COVID19 | Global Health üá®üá¥",,Los Angeles,,2020-12-05 20:43:14+00:00,"Richard Burwick, MD, MPH",http://twitter.com/,10.0,,1.3353238715583447e+18,,0.0,0.0,,"RT @aHUSAllianceAct: Thrombotic microangiopathy &amp; #complement figure in multiple presentations for #ASH20. Noting here: #genetics, C3 &amp; CFH‚Ä¶",en,0.0,278.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,8.0,2.0,https://twitter.com/RichardBurwick/statuses/1335323871558344705,0.0,0.0,,0.0,0.0,0.0,2.0,8.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,"RT @aHUSAllianceAct: Thrombotic microangiopathy &amp; #complement figure in multiple presentations for #ASH20. Noting here: #genetics, C3 &amp; CFH‚Ä¶",true
pdmanas30,Pathologist and physician-scientist. Medical Director @ Amgen leading CDx/Biomarker Strategy. #MolPath #precisiononcology #liquidbiopsy #LungCa #AI T/RT my own,,,,2020-12-05 21:18:21+00:00,"Partha Das, MBBS, MD",http://twitter.com/,10.0,,1.3353327065157796e+18,,0.0,0.0,,"RT @AmgenOncology: Are you registered for #ASH20? Join us for the latest @Amgen oral presentation, #181, on the Phase 1 first-in-human stud‚Ä¶",en,0.0,39.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,4.0,https://twitter.com/pdmanas30/statuses/1335332706515779590,0.0,0.0,,0.0,0.0,0.0,4.0,6.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @AmgenOncology: Are you registered for #ASH20? Join us for the latest @Amgen oral presentation, #181, on the Phase 1 first-in-human stud‚Ä¶",true
crowley_maeve,Cork based haematologist,,"Cork, Ireland ",,2020-12-05 18:07:34+00:00,Maeve Crowley,http://twitter.com/,3.0,,1.3352846941418373e+18,,0.0,0.0,,"Great session by ‚Å¶@fniainle‚Å©,‚Å¶@Erik_Klok_MD‚Å© and ‚Å¶@WeeShianChan‚Å© regarding diagnostic and prognostic models in vte‚Ä¶ https://t.co/PZ39Dxmpp3",en,0.0,173.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/crowley_maeve/statuses/1335284694141837316,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Diagnostic Tools,1.0,0.0,0.0,"Great session by ‚Å¶@fniainle‚Å©,‚Å¶@Erik_Klok_MD‚Å© and ‚Å¶@WeeShianChan‚Å© regarding diagnostic and prognostic models in vte‚Ä¶ https://t.co/PZ39Dxmpp3",true
diegoah66,"Hematologist-Oncologist @UVMMedCenter, Assistant Professor of Medicine @UVMLarnerMed | üáµüá™üá∫üá∏",,"Burlington, VT",,2020-12-05 07:47:17+00:00,Diego Adrianzen-Herrera,http://twitter.com/,218.0,,1.3351285942810788e+18,,0.0,0.0,,"RT @hemedoc: #ASH20 #leusm Wei: We are all excited to have new therapeutic options in AML, but the overall message I get from this money sl‚Ä¶",en,0.0,187.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,168.0,50.0,https://twitter.com/diegoah66/statuses/1335128594281078786,0.0,0.0,,0.0,0.0,0.0,50.0,168.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"RT @hemedoc: #ASH20 #leusm Wei: We are all excited to have new therapeutic options in AML, but the overall message I get from this money sl‚Ä¶",false
jenweiying,Haematologist working on https://t.co/fiMAwrCDXt - #FOAMed for students and trainees. Collaborators welcome. Tweets are my own opinion and not medical advice.,,Singapore,,2020-12-05 03:00:58+00:00,Wei Ying Jen,http://twitter.com/,47.0,,1.3350565419137925e+18,,0.0,0.0,,RT @MrinalPatnaik: Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes| Join me at #ASH2020 as I discuss gen‚Ä¶,en,0.0,251.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,40.0,7.0,https://twitter.com/jenweiying/statuses/1335056541913792512,0.0,0.0,,0.0,0.0,0.0,7.0,40.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @MrinalPatnaik: Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes| Join me at #ASH2020 as I discuss gen‚Ä¶,true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 14:04:04+00:00,Lisa Palacios,http://twitter.com/,2.0,,1.3352234171429765e+18,,0.0,0.0,,RT @feldstej: 32 High-Dimensional Single-Cell Proteomic Analysis Reveals Therapeutic Vulnerabilities in Relapsed/Refractory AML By Concomit‚Ä¶,en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/Lisa_Palacios/statuses/1335223417142976513,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @feldstej: 32 High-Dimensional Single-Cell Proteomic Analysis Reveals Therapeutic Vulnerabilities in Relapsed/Refractory AML By Concomit‚Ä¶,true
Mikeypod50,"Podiatrist, now part-time, but still enjoying caring for patients. Father of 4, ""Baba"" to 7. Philly sports fan (sigh) for too many years",,,,2020-12-05 21:33:01+00:00,(((Michael Katz))),http://twitter.com/,6.0,,1.3353363982834852e+18,,0.0,0.0,,RT @NorthTxMSG: Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with RRMM: Correlation o‚Ä¶,en,0.0,81.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,1.0,https://twitter.com/Mikeypod50/statuses/1335336398283485184,0.0,0.0,,0.0,0.0,0.0,1.0,5.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @NorthTxMSG: Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with RRMM: Correlation o‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-05 18:20:48+00:00,"Ritcha Saxena, MD",http://twitter.com/,3.0,,1.3352880240416645e+18,,0.0,0.0,,"RT @amarkelkar: i.e. It's not yet clear that #COVID19 long-haulers are unique to this particular infection, and may have been more identifi‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,2.0,1.0,https://twitter.com/RitchaSaxena/statuses/1335288024041664519,0.0,0.0,,0.0,0.0,0.0,1.0,2.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"RT @amarkelkar: i.e. It's not yet clear that #COVID19 long-haulers are unique to this particular infection, and may have been more identifi‚Ä¶",true
LohiOlli,"MD, PhD, Chief of Pediatric Hematology & Oncology Division, Tampere University Hospital, Finland. Translational research on ALL biology. @TampereUniMET",,"Tampere, Suomi",,2020-12-05 21:25:34+00:00,Olli Lohi,http://twitter.com/,7.0,,1.335334522976686e+18,,0.0,0.0,,RT @TheLancetHaem: #ASH20 Erica Brivio: phase 2 results of the ITCC-059 trial of inotuzumab ozogamicin in pediatric CD22-positive r/r ALL #‚Ä¶,en,0.0,460.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,4.0,https://twitter.com/LohiOlli/statuses/1335334522976686082,0.0,0.0,,0.0,0.0,0.0,4.0,3.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @TheLancetHaem: #ASH20 Erica Brivio: phase 2 results of the ITCC-059 trial of inotuzumab ozogamicin in pediatric CD22-positive r/r ALL #‚Ä¶,true
chanyooncheah,Doctor for patients with lymphoma. Clinical researcher.,,"Perth, Western Australia",,2020-12-05 17:00:18+00:00,Chan Cheah,http://twitter.com/,0.0,,1.335267768279552e+18,,0.0,0.0,,"@bpromd does a great job presenting the PRIMO trial of duvelisib in relapsed/refractory PTCL. 
- ORR 52% in expansi‚Ä¶ https://t.co/8agapuziRR",en,0.0,1717.0,,,0.0,bpromd,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/chanyooncheah/statuses/1335267768279552002,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnosis Progression,1.0,0.0,0.0,"@bpromd does a great job presenting the PRIMO trial of duvelisib in relapsed/refractory PTCL. 
- ORR 52% in expansi‚Ä¶ https://t.co/8agapuziRR",false
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 20:47:27+00:00,Lisa Palacios,http://twitter.com/,24.0,,1.3353249311864545e+18,,0.0,0.0,,RT @CanerSaygin: Dr Wang presenting phase I data on 12 R/R #AML pts treated with Menin-KMT2A (MLL) Inhibitor KO-539. May be promising for M‚Ä¶,en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,17.0,7.0,https://twitter.com/Lisa_Palacios/statuses/1335324931186454530,0.0,0.0,,0.0,0.0,0.0,7.0,17.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @CanerSaygin: Dr Wang presenting phase I data on 12 R/R #AML pts treated with Menin-KMT2A (MLL) Inhibitor KO-539. May be promising for M‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-05 17:24:06+00:00,"Ritcha Saxena, MD",http://twitter.com/,25.0,,1.335273758635004e+18,,0.0,0.0,,"RT @vangalenlab: Coming up! Signaling and Development #ASHmyeloidworkshop with Teresa Bowman on R-loops @Bowmaniacs_Lab, Grant Rowe on Lin2‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,23.0,2.0,https://twitter.com/RitchaSaxena/statuses/1335273758635003904,0.0,0.0,,0.0,0.0,0.0,2.0,23.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,"RT @vangalenlab: Coming up! Signaling and Development #ASHmyeloidworkshop with Teresa Bowman on R-loops @Bowmaniacs_Lab, Grant Rowe on Lin2‚Ä¶",true
gjmccaughan,"Haematologist interested in plasma cell disorders Zamasa Foundation Myeloma Fellow, Kinghorn Cancer Centre, St Vincent‚Äôs Hospital, Sydney",,,,2020-12-08 05:49:08+00:00,Georgia McCaughan,http://twitter.com/,0.0,,1.3361860282734592e+18,,0.0,0.0,,CAEL-101 Phase II #ASH20 - impressive renal responses including 1 pt without sustained haem response; only 1/8 card‚Ä¶ https://t.co/uUN6KPLmHN,en,0.0,528.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/gjmccaughan/statuses/1336186028273459200,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,CAEL-101 Phase II #ASH20 - impressive renal responses including 1 pt without sustained haem response; only 1/8 card‚Ä¶ https://t.co/uUN6KPLmHN,true
RolandBWalter,"Physician-Scientist at Fred Hutchinson Cancer Research Center/University of Washington, focus on clinical/translational research in acute myeloid leukemia (AML)",,"Seattle, WA, USA",,2020-12-08 03:41:57+00:00,"Roland B. Walter, MD PhD MS",http://twitter.com/,3.0,,1.3361540207847424e+18,,0.0,0.0,,Important data presented by @groboz from QUAZAR-001 showing CC-486 benefit in MRDneg and MRDpos remission. MRD resp‚Ä¶ https://t.co/msyZS29EyZ,en,0.0,222.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/RolandBWalter/statuses/1336154020784742402,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,Important data presented by @groboz from QUAZAR-001 showing CC-486 benefit in MRDneg and MRDpos remission. MRD resp‚Ä¶ https://t.co/msyZS29EyZ,true
MalinHultcrantz,"MD PhD, Specialized in Multiple Myeloma. Memorial Sloan Kettering Cancer Center. Karolinska Institute. Tweets are my own.",,,,2020-12-08 09:11:24+00:00,Malin Hultcrantz MD PhD,http://twitter.com/,27.0,,1.3362369291851817e+18,,0.0,0.0,,RT @UrviShahMD: We studied the risk of preceding diabetes on individual lymphoproliferative diagnoses in a Swedish case control study. Risk‚Ä¶,en,0.0,908.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,19.0,8.0,https://twitter.com/MalinHultcrantz/statuses/1336236929185181697,0.0,0.0,,0.0,0.0,0.0,8.0,19.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @UrviShahMD: We studied the risk of preceding diabetes on individual lymphoproliferative diagnoses in a Swedish case control study. Risk‚Ä¶,true
Transplant_Doc,Stem Cell Transplant physician and clinical researcher at MD Anderson Cancer Center; special interest in myeloma. Opinions expressed are my own,,,,2020-12-08 03:05:50+00:00,Muzaffar Qazilbash,http://twitter.com/,36.0,,1.336144929635119e+18,,0.0,0.0,,"RT @ninashah33: Cyber IBER! Iber with dara dex or
BTZ dex with 35-50% ORR. I think this data useful to show us how to combine this new drug‚Ä¶",en,0.0,5455.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,28.0,8.0,https://twitter.com/Transplant_Doc/statuses/1336144929635119106,0.0,0.0,,0.0,0.0,0.0,8.0,28.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @ninashah33: Cyber IBER! Iber with dara dex or
BTZ dex with 35-50% ORR. I think this data useful to show us how to combine this new drug‚Ä¶",false
DrGavinL,"Londoner (city boy at heart) - specialist physician in haemostasis (@gsttnhs), PhD in gene therapy (UCL), plays piano. Fair weather runner. Views my own.",,"London, England",,2020-12-08 22:38:31+00:00,Gavin Ling,http://twitter.com/,0.0,,1.3364400439935017e+18,,0.0,0.0,,XTEND-1 - BIVV001 in Phase 3 trials is what we should be waiting for in #hemophilia. Once weekly dosing of FVIII in‚Ä¶ https://t.co/bHbu1o0rV8,en,0.0,101.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/DrGavinL/statuses/1336440043993501697,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,XTEND-1 - BIVV001 in Phase 3 trials is what we should be waiting for in #hemophilia. Once weekly dosing of FVIII in‚Ä¶ https://t.co/bHbu1o0rV8,true
bagalbp,"Hemato-oncologist, Tata Memorial Center",,Mumbai,,2020-12-08 12:26:23+00:00,Bhausaheb Bagal,http://twitter.com/,27.0,,1.336285998448169e+18,,0.0,0.0,,RT @BldCancerDoc: Benefit of virtual #ASH20 is greater engagement from #LMIC #LIC colleagues - puts innovations into sobering perspective;‚Ä¶,en,0.0,1110.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,22.0,5.0,https://twitter.com/bagalbp/statuses/1336285998448168960,0.0,0.0,,0.0,0.0,0.0,5.0,22.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @BldCancerDoc: Benefit of virtual #ASH20 is greater engagement from #LMIC #LIC colleagues - puts innovations into sobering perspective;‚Ä¶,true
ShakiraG_MBBS,BC Geriatrician + Hematologist + Oncologist. Assistant Professor + Clinical Researcher UNC-CH #geriheme #gerionc #mmsm #BlackWomanInMedicine. Tweets=my views,,"North Carolina, USA",,2020-12-08 16:42:50+00:00,Dr. Shakira J Grant MBBS,http://twitter.com/,1.0,,1.3363505371349688e+18,,0.0,0.0,,#ASH20 excellent qualitative study by Dr. Charity Oyedejiüëá@DukeHealth examining barriers and facilitators of Advanc‚Ä¶ https://t.co/ioE0uPwIU3,en,0.0,340.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/ShakiraG_MBBS/statuses/1336350537134968837,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Disease Advocacy,1.0,0.0,0.0,#ASH20 excellent qualitative study by Dr. Charity Oyedejiüëá@DukeHealth examining barriers and facilitators of Advanc‚Ä¶ https://t.co/ioE0uPwIU3,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-05 20:36:09+00:00,"Ritcha Saxena, MD",http://twitter.com/,3.0,,1.3353220886898196e+18,,0.0,0.0,,RT @feldstej: Hematologic Aspects of the Pandemic: Advancing the Study of COVID-19 https://t.co/EY1ZQugH3e #ASH20 #ASH2020 #ASHCOVID #ASHFr‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,1.0,2.0,https://twitter.com/RitchaSaxena/statuses/1335322088689819653,0.0,0.0,,0.0,0.0,0.0,2.0,1.0,False,False,False,False,True,Covid,0.0,0.0,1.0,RT @feldstej: Hematologic Aspects of the Pandemic: Advancing the Study of COVID-19 https://t.co/EY1ZQugH3e #ASH20 #ASH2020 #ASHCOVID #ASHFr‚Ä¶,true
UrviShahMD,Oncologist and researcher on Myeloma service @sloan_kettering. Interested in nutrition for cancer and immune therapies. Views are my own,,"New York, NY",,2020-12-05 18:48:24+00:00,Urvi Shah,http://twitter.com/,1.0,,1.3352949718014444e+18,,0.0,0.0,,"LUMMICAR study 2 - CT053 N=20, ORR 94%, no gr3-5 CRS, Phase 2 dose will likely be 250-300M cells @myelomaMD #ASH20‚Ä¶ https://t.co/7uO8k4wBOH",en,0.0,1227.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/UrviShahMD/statuses/1335294971801444359,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"LUMMICAR study 2 - CT053 N=20, ORR 94%, no gr3-5 CRS, Phase 2 dose will likely be 250-300M cells @myelomaMD #ASH20‚Ä¶ https://t.co/7uO8k4wBOH",true
szusmani,"Division Chief, Plasma Cell Disorders|Director, Clinical Research Hem Malignancies | Views are my own | RT not endorsement | Physician ‚â† Provider",,"Charlotte, NC",,2020-12-05 15:12:30+00:00,Saad Z. Usmani MD MBA FACP (he/his/him),http://twitter.com/,6.0,,1.3352406400163758e+18,,0.0,0.0,,"RT @agarwalonc: Duration of immunity of natural infection of coronaviruses measured in months... not years and decades... 
Dr Fauci at #ASH‚Ä¶",en,0.0,5512.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,1.0,https://twitter.com/szusmani/statuses/1335240640016375808,0.0,0.0,,0.0,0.0,0.0,1.0,5.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"RT @agarwalonc: Duration of immunity of natural infection of coronaviruses measured in months... not years and decades... 
Dr Fauci at #ASH‚Ä¶",false
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 18:12:48+00:00,Lisa Palacios,http://twitter.com/,7.0,,1.3352860139801846e+18,,0.0,0.0,,RT @EduardoFlavioO1: Ibrutinib+Ven in #CLL 1st line (Captivate) and RR setting (TAP Clarity) showing long term remissions and sustained res‚Ä¶,en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,3.0,https://twitter.com/Lisa_Palacios/statuses/1335286013980184576,0.0,0.0,,0.0,0.0,0.0,3.0,4.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @EduardoFlavioO1: Ibrutinib+Ven in #CLL 1st line (Captivate) and RR setting (TAP Clarity) showing long term remissions and sustained res‚Ä¶,true
dgermain21,MD-PhD. 2nd year Heme/Onc fellow focused on lymphoma and leukemia. Physician-scientist-in-training. Tweet/RT not medical advice or endorsement.,,"St. Louis, MO",,2020-12-08 22:10:09+00:00,David A. Russler-Germain,http://twitter.com/,27.0,,1.3364329089664983e+18,,0.0,0.0,,"RT @MediHumdani: What I learnt from @SoniSmithMD transformed NHL talk? #ASH20 #lymsm 
-Biopsy üóùÔ∏è esp in POD24s 
-MYC can be acquire
-anthra‚Ä¶",en,0.0,1612.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,21.0,6.0,https://twitter.com/dgermain21/statuses/1336432908966498306,0.0,0.0,,0.0,0.0,0.0,6.0,21.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"RT @MediHumdani: What I learnt from @SoniSmithMD transformed NHL talk? #ASH20 #lymsm 
-Biopsy üóùÔ∏è esp in POD24s 
-MYC can be acquire
-anthra‚Ä¶",true
dgermain21,MD-PhD. 2nd year Heme/Onc fellow focused on lymphoma and leukemia. Physician-scientist-in-training. Tweet/RT not medical advice or endorsement.,,"St. Louis, MO",,2020-12-08 00:19:22+00:00,David A. Russler-Germain,http://twitter.com/,23.0,,1.3361030382940897e+18,,0.0,0.0,,"RT @lymphomahub: CONGRESS | #ASH20 | Caron Jacobson, @DanaFarberNews, presents results from the initial analysis of the phase II ZUMA-5 tri‚Ä¶",en,0.0,1612.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,17.0,6.0,https://twitter.com/dgermain21/statuses/1336103038294089729,0.0,0.0,,0.0,0.0,0.0,6.0,17.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @lymphomahub: CONGRESS | #ASH20 | Caron Jacobson, @DanaFarberNews, presents results from the initial analysis of the phase II ZUMA-5 tri‚Ä¶",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 16:55:20+00:00,Lisa Palacios,http://twitter.com/,6.0,,1.335266515726295e+18,,0.0,0.0,,"RT @MPN_Hub: CONGRESS | #ASH20 | Srdan Verstovsek, @MDAndersonNews, @LeukemiaMDA, results from phase II MANIFEST study, investigating CPI-0‚Ä¶",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,1.0,https://twitter.com/Lisa_Palacios/statuses/1335266515726295040,0.0,0.0,,0.0,0.0,0.0,1.0,5.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @MPN_Hub: CONGRESS | #ASH20 | Srdan Verstovsek, @MDAndersonNews, @LeukemiaMDA, results from phase II MANIFEST study, investigating CPI-0‚Ä¶",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-05 05:38:44+00:00,"Ritcha Saxena, MD",http://twitter.com/,37.0,,1.335096246231511e+18,,0.0,0.0,,RT @acweyand: So important to work with our #Transgender patients and engage in shared decision making to ensure they can proceed with thei‚Ä¶,en,0.0,6875.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,32.0,5.0,https://twitter.com/RitchaSaxena/statuses/1335096246231511040,0.0,0.0,,0.0,0.0,0.0,5.0,32.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @acweyand: So important to work with our #Transgender patients and engage in shared decision making to ensure they can proceed with thei‚Ä¶,true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-12-08 15:35:40+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,0.0,,1.3363336337123164e+18,,0.0,0.0,,#ASH20 #mpnsm Bradbury (LBA2): First-line corticosteroids (CS) for ITP assoc w 20% long-term remission. FLIGHT tria‚Ä¶ https://t.co/Tf1JnnmNMM,en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/hemedoc/statuses/1336333633712316422,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,#ASH20 #mpnsm Bradbury (LBA2): First-line corticosteroids (CS) for ITP assoc w 20% long-term remission. FLIGHT tria‚Ä¶ https://t.co/Tf1JnnmNMM,false
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-05 19:56:10+00:00,"Ritcha Saxena, MD",http://twitter.com/,21.0,,1.3353120265126175e+18,,0.0,0.0,,RT @UjjaniC: #ASH president @StephanieLeeMD from @SeattleCCA @fredhutch leading an amazing chat on #COVID19 with Dr. Fauci. #ASH20 #ASH2020‚Ä¶,en,0.0,6875.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,15.0,6.0,https://twitter.com/RitchaSaxena/statuses/1335312026512617479,0.0,0.0,,0.0,0.0,0.0,6.0,15.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @UjjaniC: #ASH president @StephanieLeeMD from @SeattleCCA @fredhutch leading an amazing chat on #COVID19 with Dr. Fauci. #ASH20 #ASH2020‚Ä¶,true
MDedgeHemOnc,MDedge Hematology & Oncology provides the most important and up to date information and news for oncologists. Now part of the Medscape Professional Network.,,"Rockville, MD, Parsippany, NJ",,2020-12-08 19:59:18+00:00,MDedge Hematology & Oncology,http://twitter.com/,0.0,,1.3363999769104916e+18,,0.0,0.0,,Reach 3 Trial: New findings show that ruxolitinib was superior to standard therapy in reducing symptoms of #cGVHD.‚Ä¶ https://t.co/1l5fW9NIzK,en,0.0,6726.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/MDedgeHemOnc/statuses/1336399976910491650,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,Reach 3 Trial: New findings show that ruxolitinib was superior to standard therapy in reducing symptoms of #cGVHD.‚Ä¶ https://t.co/1l5fW9NIzK,true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 14:03:17+00:00,Lisa Palacios,http://twitter.com/,1.0,,1.3352232189872087e+18,,0.0,0.0,,RT @feldstej: 1092 Distinct Prognostic Effects of TP53 Mutations in Newly Diagnosed Versus R-R pts with B-ALL Treated with Mini-Hcvd-Inotuz‚Ä¶,en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/Lisa_Palacios/statuses/1335223218987208707,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @feldstej: 1092 Distinct Prognostic Effects of TP53 Mutations in Newly Diagnosed Versus R-R pts with B-ALL Treated with Mini-Hcvd-Inotuz‚Ä¶,true
andrewlipskymd,"Assistant Professor @ColumbiaMed
Hematologist-Oncologist @ColumbiaCancer @nyphospital
Specializing in CLL #CancerGenomics",,,,2020-12-05 23:06:44+00:00,Andrew Lipsky,http://twitter.com/,2.0,,1.3353599841970463e+18,,0.0,0.0,,Excited to present our work on subclonal BTK resistance in #CLL at #ASH20. An honor and a privilege to work with‚Ä¶ https://t.co/LEAtN9zEqo,en,0.0,131.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/andrewlipskymd/statuses/1335359984197046272,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,Excited to present our work on subclonal BTK resistance in #CLL at #ASH20. An honor and a privilege to work with‚Ä¶ https://t.co/LEAtN9zEqo,true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-08 14:34:38+00:00,Lisa Palacios,http://twitter.com/,7.0,,1.336318272875139e+18,,0.0,0.0,,"RT @MDAndersonNews: Presented by our Dr. William Wierda at #ASH20, results from Phase II CAPTIVATE study show that venetoclax plus ibrutini‚Ä¶",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,1.0,https://twitter.com/Lisa_Palacios/statuses/1336318272875139072,0.0,0.0,,0.0,0.0,0.0,1.0,6.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @MDAndersonNews: Presented by our Dr. William Wierda at #ASH20, results from Phase II CAPTIVATE study show that venetoclax plus ibrutini‚Ä¶",true
Adrianapordios,"Physician, Master in Public Health & Epidemiology, Hematology and Medical Affairs. Opinions are my own",,,,2020-12-05 18:39:19+00:00,Adriana Aguilar,http://twitter.com/,48.0,,1.3352926875667087e+18,,0.0,0.0,,RT @anthonymatomd: New publication! Our strategies for treatment of relapsed #CLL after venetoclax. Algorithm included! Identification of e‚Ä¶,en,0.0,456.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,35.0,13.0,https://twitter.com/Adrianapordios/statuses/1335292687566708738,0.0,0.0,,0.0,0.0,0.0,13.0,35.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @anthonymatomd: New publication! Our strategies for treatment of relapsed #CLL after venetoclax. Algorithm included! Identification of e‚Ä¶,false
abhinav_deol,MD,,"Detroit, MI",,2020-12-05 15:18:04+00:00,Abhinav Deol,http://twitter.com/,0.0,,1.3352420381246956e+18,,0.0,0.0,,#ASH20  Dr. Fauci: there potentially may be 2 distinct reasons for some pts to have long term effects after infecti‚Ä¶ https://t.co/U0P5xWQ5Y2,en,0.0,251.0,,,0.0,abhinav_deol,1.335237925450158e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/abhinav_deol/statuses/1335242038124695560,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,#ASH20  Dr. Fauci: there potentially may be 2 distinct reasons for some pts to have long term effects after infecti‚Ä¶ https://t.co/U0P5xWQ5Y2,true
CanerSaygin,"Heme-Onc Fellow @UChicago | Alumni of @OhioStateIMRes, @CCLRI | #Leukemia, #MDS, #CHIP physician-scientist. Tweets=own opinions.",,"Chicago, IL",,2020-12-05 18:14:05+00:00,"Caner Saygin, MD",http://twitter.com/,2.0,,1.3352863343705702e+18,,0.0,0.0,,Dr Huang showing preclinical data on synergistic combination of BET and MEK inhibitors in #AML. Switching gears in‚Ä¶ https://t.co/lkYrIjizaZ,en,0.0,743.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/CanerSaygin/statuses/1335286334370570241,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,Dr Huang showing preclinical data on synergistic combination of BET and MEK inhibitors in #AML. Switching gears in‚Ä¶ https://t.co/lkYrIjizaZ,true
rajshekharucms,Hem/Onc Physician/Clinical Researcher @ColumbiaCancer #MultipleMyeloma & #Amyloidosis. Asst. Prof of Medicine @ColumbiaMed #ClinicalTrials and Outcomes Research,,"New York, NY",,2020-12-05 21:14:00+00:00,Raj Chakraborty,http://twitter.com/,27.0,,1.335331615254438e+18,,0.0,0.0,,RT @ninashah33: The O.G. BiTE (but better): AMG-701 with extended half life‚Äî&gt; 36% ORR in early cohorts but 5/6 (86%) ORR in most recent dos‚Ä¶,en,0.0,1148.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,16.0,11.0,https://twitter.com/rajshekharucms/statuses/1335331615254437895,0.0,0.0,,0.0,0.0,0.0,11.0,16.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @ninashah33: The O.G. BiTE (but better): AMG-701 with extended half life‚Äî&gt; 36% ORR in early cohorts but 5/6 (86%) ORR in most recent dos‚Ä¶,true
MDMagazine,Clinical News for Connected Physicians. Everything you need to enhance your clinical approach to improving patient care.,,United States,,2020-12-05 19:15:00+00:00,HCPLive,http://twitter.com/,2.0,,1.335301665122095e+18,,0.0,0.0,,"‚ÄúCPX-351 plus 7 days of #venetoclax is tolerable, with acceptable toxicities in patients with Relapsed/Refactroy‚Ä¶ https://t.co/E2mfb73ElA",en,0.0,7073.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/MDMagazine/statuses/1335301665122095112,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"‚ÄúCPX-351 plus 7 days of #venetoclax is tolerable, with acceptable toxicities in patients with Relapsed/Refactroy‚Ä¶ https://t.co/E2mfb73ElA",true
khouri_jack,Myeloma/BMT #hematologist #oncologist @ClevelandClinic Assistant Prof @CleClinicLCM @CWRUSOM | alum @TuftsMedSchool @Uni_Of_Balamand #mmsm #bmtsm,,"Cleveland, OH",,2020-12-05 18:15:12+00:00,"Jack Khouri, MD",http://twitter.com/,53.0,,1.3352866168233615e+18,,0.0,0.0,,RT @ninashah33: Bb2121: everything you wanted to know but were too afraid to ask: Ide-cel phase 1 long term FU‚Äî&gt; DOR 2y in responders and O‚Ä¶,en,0.0,443.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,41.0,12.0,https://twitter.com/khouri_jack/statuses/1335286616823361537,0.0,0.0,,0.0,0.0,0.0,12.0,41.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @ninashah33: Bb2121: everything you wanted to know but were too afraid to ask: Ide-cel phase 1 long term FU‚Äî&gt; DOR 2y in responders and O‚Ä¶,true
DrESHAJ9,"a passionate medical oncologist, a spiritual seeker",,,,2020-12-05 06:22:02+00:00,EJ,http://twitter.com/,7.0,,1.335107140843815e+18,,0.0,0.0,,"RT @hemedoc: #ASH20 #leusm Wei: median OS in AML patients refractory or relapsed after HMA/Ven is very poor, here 2.4 mos. https://t.co/FKR‚Ä¶",en,0.0,315.0,,,0.0,,,Negative,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,1.0,https://twitter.com/DrESHAJ9/statuses/1335107140843814913,0.0,0.0,,0.0,0.0,0.0,1.0,6.0,False,False,False,False,True,Diagnosis Progression,0.0,1.0,0.0,"RT @hemedoc: #ASH20 #leusm Wei: median OS in AML patients refractory or relapsed after HMA/Ven is very poor, here 2.4 mos. https://t.co/FKR‚Ä¶",false
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-12-05 04:40:59+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,50.0,,1.3350817113951928e+18,,0.0,0.0,,"#ASH20 #leusm Wei: We are all excited to have new therapeutic options in AML, but the overall message I get from th‚Ä¶ https://t.co/fch6v0Q22l",en,0.0,4813.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,50.0,https://twitter.com/hemedoc/statuses/1335081711395192832,0.0,0.0,,0.0,0.0,0.0,50.0,0.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"#ASH20 #leusm Wei: We are all excited to have new therapeutic options in AML, but the overall message I get from th‚Ä¶ https://t.co/fch6v0Q22l",true
mariglesiascoma,"G-I #pathologist, teacher and Mum, #GIPath",,,,2020-12-05 17:41:12+00:00,Mar Iglesias,http://twitter.com/,49.0,,1.335278058610307e+18,,0.0,0.0,,RT @gretnhe: Dr. Calvo team referenced for their contributions to MDS diagnosis and classification at MDS symposium #ASH20 @TxaviManCat @ho‚Ä¶,en,0.0,462.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,38.0,11.0,https://twitter.com/mariglesiascoma/statuses/1335278058610307076,0.0,0.0,,0.0,0.0,0.0,11.0,38.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @gretnhe: Dr. Calvo team referenced for their contributions to MDS diagnosis and classification at MDS symposium #ASH20 @TxaviManCat @ho‚Ä¶,true
GlopesMd,"Cancer Doctor and Researcher, Faculty @SylvesterCancer @UnivMiami. Helping improve Cancer Control in LMICs. Editor-in-Chief JCO Global Oncology @ASCO",,"Miami, FL",,2020-12-06 17:07:31+00:00,gilberto lopes,http://twitter.com/,42.0,,1.3356319703369728e+18,,0.0,0.0,,RT @KenFigueroaLab: Congratulations to Dr Bhatnagar &amp; the OSU team for very important research into health disparities in AML presented at‚Ä¶,en,0.0,31610.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,32.0,10.0,https://twitter.com/GlopesMd/statuses/1335631970336972800,0.0,0.0,,0.0,0.0,0.0,10.0,32.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @KenFigueroaLab: Congratulations to Dr Bhatnagar &amp; the OSU team for very important research into health disparities in AML presented at‚Ä¶,true
fniainle,"Haematologist, passionate about VTE. Co-director @ConwaySphere; Director https://t.co/csdWq9XJ57; RT not endorsement, views my own",,"Dublin City, Ireland",,2020-12-06 18:24:57+00:00,Fionnuala N√≠ √Åinle,http://twitter.com/,27.0,,1.3356514600134943e+18,,0.0,0.0,,RT @VeronicaFlood18: Kudos to @james_paulad for highlighting the struggle women with bleeding disorders endure while seeking a diagnosis #A‚Ä¶,en,0.0,2069.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,24.0,3.0,https://twitter.com/fniainle/statuses/1335651460013494273,0.0,0.0,,0.0,0.0,0.0,3.0,24.0,False,False,False,False,True,Diagnostic Tools,1.0,0.0,0.0,RT @VeronicaFlood18: Kudos to @james_paulad for highlighting the struggle women with bleeding disorders endure while seeking a diagnosis #A‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 21:27:25+00:00,"Ritcha Saxena, MD",http://twitter.com/,20.0,,1.3356973793586094e+18,,0.0,0.0,,"RT @gvhd_hub: CONGRESS | #ASH20 | @DrCCutler, @DanaFarber, reported the top-line results from the ROCKstar phase 2 trial of belumosudil for‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,16.0,4.0,https://twitter.com/RitchaSaxena/statuses/1335697379358609412,0.0,0.0,,0.0,0.0,0.0,4.0,16.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @gvhd_hub: CONGRESS | #ASH20 | @DrCCutler, @DanaFarber, reported the top-line results from the ROCKstar phase 2 trial of belumosudil for‚Ä¶",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 21:37:40+00:00,"Ritcha Saxena, MD",http://twitter.com/,73.0,,1.3356999551561275e+18,,0.0,0.0,,"RT @MPaiMD: @MaryCushmanMD There‚Äôs a lot of novelty at #ASH20 this year - negative trials, featuring more speakers of historically excluded‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,60.0,13.0,https://twitter.com/RitchaSaxena/statuses/1335699955156127744,0.0,0.0,,0.0,0.0,0.0,13.0,60.0,False,False,False,False,True,Thought Leadership,0.0,0.0,1.0,"RT @MPaiMD: @MaryCushmanMD There‚Äôs a lot of novelty at #ASH20 this year - negative trials, featuring more speakers of historically excluded‚Ä¶",false
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 16:10:54+00:00,"Ritcha Saxena, MD",http://twitter.com/,8.0,,1.335617721686487e+18,,0.0,0.0,,"RT @MM_Hub: CONGRESS | #ASH20 | DW-MRI and MRD assessments may be complementary prognostic tools in #MM after ASCT. Angelo Belotti, Spedali‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,3.0,https://twitter.com/RitchaSaxena/statuses/1335617721686487041,0.0,0.0,,0.0,0.0,0.0,3.0,5.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"RT @MM_Hub: CONGRESS | #ASH20 | DW-MRI and MRD assessments may be complementary prognostic tools in #MM after ASCT. Angelo Belotti, Spedali‚Ä¶",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-06 18:39:24+00:00,Lisa Palacios,http://twitter.com/,8.0,,1.335655093392257e+18,,0.0,0.0,,RT @CanerSaygin: Dr Lachowiez presenting data on FLAG-IDA + ven in both newly diagnosed and R/R pts. CRc is &gt;60% even in R/R setting and fM‚Ä¶,en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,4.0,https://twitter.com/Lisa_Palacios/statuses/1335655093392257026,0.0,0.0,,0.0,0.0,0.0,4.0,4.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @CanerSaygin: Dr Lachowiez presenting data on FLAG-IDA + ven in both newly diagnosed and R/R pts. CRc is &gt;60% even in R/R setting and fM‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 20:27:53+00:00,"Ritcha Saxena, MD",http://twitter.com/,10.0,,1.3356823972292155e+18,,0.0,0.0,,"RT @DanaFarber: #ASH20 News: Donor stem cell transplant shown to improve survival in older patients with #MDS. Dana-Farber's Corey Cutler,‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,7.0,3.0,https://twitter.com/RitchaSaxena/statuses/1335682397229215746,0.0,0.0,,0.0,0.0,0.0,3.0,7.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @DanaFarber: #ASH20 News: Donor stem cell transplant shown to improve survival in older patients with #MDS. Dana-Farber's Corey Cutler,‚Ä¶",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 15:56:51+00:00,"Ritcha Saxena, MD",http://twitter.com/,16.0,,1.3356141889458913e+18,,0.0,0.0,,RT @CanerSaygin: Dr Abedin presenting phase I data on combination of lintuzumab (radiolabeled anti-CD33) with CLAG-M in R/R #AML pts (n= 15‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,13.0,3.0,https://twitter.com/RitchaSaxena/statuses/1335614188945891331,0.0,0.0,,0.0,0.0,0.0,3.0,13.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @CanerSaygin: Dr Abedin presenting phase I data on combination of lintuzumab (radiolabeled anti-CD33) with CLAG-M in R/R #AML pts (n= 15‚Ä¶,true
drlenawine,Physician-scientist & stem cell transplanter @UCSFcancer focused on #disparities in #ChildhoodCancer & working toward #healthequity. #PHODocs #tweetiatrician,,"San Francisco, CA",,2020-12-06 16:06:21+00:00,"Lena Winestone, MD MSHP",http://twitter.com/,2.0,,1.3356165771572224e+18,,0.0,0.0,,@npdcoalition @Jen_WilkesMD @hospitals4kids @CIDRAP_RDSP @AmerAcadPeds @PHEgov @PharmResponse @TheWRAPEM @PIPSQC‚Ä¶ https://t.co/cWgmVBvYhB,en,0.0,361.0,,,0.0,npdcoalition,1.3352363040663634e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/drlenawine/statuses/1335616577157222402,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,@npdcoalition @Jen_WilkesMD @hospitals4kids @CIDRAP_RDSP @AmerAcadPeds @PHEgov @PharmResponse @TheWRAPEM @PIPSQC‚Ä¶ https://t.co/cWgmVBvYhB,true
CraigMoskMD,"Physician in Chief, @SylvesterCancer @UMiamihealth #Lymphoma #Cancerdoc #Golfer #hodgkin",,"Miami, FL",,2020-12-06 20:59:48+00:00,"Craig Moskowitz, MD",http://twitter.com/,2.0,,1.3356904255507292e+18,,0.0,0.0,,"Amazing session on 4 different bispecifics and CR rates mirror CART cells, let‚Äôs hope remission duration will be prolonged as well #ASH20",en,0.0,757.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/CraigMoskMD/statuses/1335690425550729216,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Diagnosis Progression,1.0,0.0,0.0,"Amazing session on 4 different bispecifics and CR rates mirror CART cells, let‚Äôs hope remission duration will be prolonged as well #ASH20",false
BrentonMar,Pediatric Oncologist.  Medical Director at Blueprint Medicines. Translating genomics into new therapies in cancer patients.,,Boston,,2020-12-06 19:21:55+00:00,Brenton Mar,http://twitter.com/,7.0,,1.3356657933638246e+18,,0.0,0.0,,"RT @MPN_Hub: CONGRESS | #ASH20 | Jason Gotlib, @StanfordMed, presents  data from phase I EXPLORER study in pts with advanced #mastocytosis:‚Ä¶",en,0.0,220.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,1.0,https://twitter.com/BrentonMar/statuses/1335665793363824641,0.0,0.0,,0.0,0.0,0.0,1.0,6.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @MPN_Hub: CONGRESS | #ASH20 | Jason Gotlib, @StanfordMed, presents  data from phase I EXPLORER study in pts with advanced #mastocytosis:‚Ä¶",true
HKlepinMD,Geriatric oncologist,,,,2020-12-06 16:16:07+00:00,Heidi Klepin,http://twitter.com/,15.0,,1.3356190372802847e+18,,0.0,0.0,,RT @ShakiraG_MBBS: #ASH20 highlighting today's oral abstracts by members of the #geriheme @myCARG research communityüëáJoin session: 905. Out‚Ä¶,en,0.0,902.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,5.0,https://twitter.com/HKlepinMD/statuses/1335619037280284686,0.0,0.0,,0.0,0.0,0.0,5.0,10.0,False,False,False,False,True,Disease Advocacy,0.0,0.0,1.0,RT @ShakiraG_MBBS: #ASH20 highlighting today's oral abstracts by members of the #geriheme @myCARG research communityüëáJoin session: 905. Out‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 21:21:45+00:00,"Ritcha Saxena, MD",http://twitter.com/,4.0,,1.3356959515084186e+18,,0.0,0.0,,"RT @hemedoc: #ASH20 #bmtsm Choe: 10-13% overall gr2-4 aGVHD, ~44% cGVHD. 1yr GRFS 28% wo ATG (n=40), 61% w ATG (n=23). 1yr OS 74-83%. Infec‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,1.0,https://twitter.com/RitchaSaxena/statuses/1335695951508418561,0.0,0.0,,0.0,0.0,0.0,1.0,3.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"RT @hemedoc: #ASH20 #bmtsm Choe: 10-13% overall gr2-4 aGVHD, ~44% cGVHD. 1yr GRFS 28% wo ATG (n=40), 61% w ATG (n=23). 1yr OS 74-83%. Infec‚Ä¶",true
fniainle,"Haematologist, passionate about VTE. Co-director @ConwaySphere; Director https://t.co/csdWq9XJ57; RT not endorsement, views my own",,"Dublin City, Ireland",,2020-12-06 01:06:41+00:00,Fionnuala N√≠ √Åinle,http://twitter.com/,4.0,,1.3353901689588408e+18,,0.0,0.0,,Thank you Dr @GeorgeGoshuaMD- the credit goes to the investigators who have delivered practice-changing studies for‚Ä¶ https://t.co/xieSs4f0Wr,en,0.0,2069.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,4.0,https://twitter.com/fniainle/statuses/1335390168958840832,0.0,0.0,,0.0,0.0,0.0,4.0,0.0,False,False,False,False,True,Financial Performance,1.0,0.0,0.0,Thank you Dr @GeorgeGoshuaMD- the credit goes to the investigators who have delivered practice-changing studies for‚Ä¶ https://t.co/xieSs4f0Wr,true
mike_dickinson1,Clinical haematologist at Peter MacCallum Cancer Centre in Melbourne. Aggressive Lymphoma Lead. MDS/AML/myeloma.Early phase trials. Views are my own.,,Melbourne,,2020-12-06 22:10:02+00:00,Michael Dickinson,http://twitter.com/,1.0,,1.3357081016437924e+18,,0.0,0.0,,High dose methotrexate for DLBCL with high risk of CNS relapse? Apparently not. 900 patient chart review .‚Ä¶ https://t.co/ve2iAIVPjT,en,0.0,921.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/mike_dickinson1/statuses/1335708101643792384,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,High dose methotrexate for DLBCL with high risk of CNS relapse? Apparently not. 900 patient chart review .‚Ä¶ https://t.co/ve2iAIVPjT,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 21:09:06+00:00,"Ritcha Saxena, MD",http://twitter.com/,22.0,,1.3356927683588383e+18,,0.0,0.0,,RT @DrMiguelPerales: Another busy day for @sloan_kettering investigators at #ASH20 @DrMvandenBrink @sgiraltbmtdoc @gilles_salles @MartinTal‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,18.0,4.0,https://twitter.com/RitchaSaxena/statuses/1335692768358838277,0.0,0.0,,0.0,0.0,0.0,4.0,18.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,RT @DrMiguelPerales: Another busy day for @sloan_kettering investigators at #ASH20 @DrMvandenBrink @sgiraltbmtdoc @gilles_salles @MartinTal‚Ä¶,false
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 21:17:35+00:00,"Ritcha Saxena, MD",http://twitter.com/,14.0,,1.3356949044969677e+18,,0.0,0.0,,RT @DrOlaLandgren: Huge step forward. Science is driving innovation. Great for patients! #mmsm #ASH20 https://t.co/Vjbyf4Uo3l,en,0.0,6875.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,12.0,2.0,https://twitter.com/RitchaSaxena/statuses/1335694904496967688,0.0,0.0,,0.0,0.0,0.0,2.0,12.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @DrOlaLandgren: Huge step forward. Science is driving innovation. Great for patients! #mmsm #ASH20 https://t.co/Vjbyf4Uo3l,true
bloodgenes,"Pediatric Hematologist/Oncologist, Geneticist, Stem Cell Biologist - @DFBC_PedCare, @BostonChildrens, @DanaFarber & @broadinstitute",,"Boston, MA",,2020-12-06 17:06:37+00:00,Vijay Sankaran,http://twitter.com/,25.0,,1.3356317465289275e+18,,0.0,0.0,,RT @DrMiguelPerales: #ASH20 Important study on #healthequity in AML - Worse outcomes in young black patients though responses rates were sa‚Ä¶,en,0.0,4057.0,,,0.0,,,Negative,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,15.0,10.0,https://twitter.com/bloodgenes/statuses/1335631746528927745,0.0,0.0,,0.0,0.0,0.0,10.0,15.0,False,False,False,False,True,Financial Performance,0.0,1.0,0.0,RT @DrMiguelPerales: #ASH20 Important study on #healthequity in AML - Worse outcomes in young black patients though responses rates were sa‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 16:31:42+00:00,"Ritcha Saxena, MD",http://twitter.com/,129.0,,1.335622956035281e+18,,0.0,0.0,,"RT @JanssenEMEA: 4 in 100,000 people may be diagnosed with #CLL in their lifetime, so it's important to know the symptoms. #VictoriesOverCa‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,95.0,34.0,https://twitter.com/RitchaSaxena/statuses/1335622956035280896,0.0,0.0,,0.0,0.0,0.0,34.0,95.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"RT @JanssenEMEA: 4 in 100,000 people may be diagnosed with #CLL in their lifetime, so it's important to know the symptoms. #VictoriesOverCa‚Ä¶",true
MDAndersonNews,"The official account of MD Anderson Cancer Center, a leader in cancer care, cancer research and the fight to #EndCancer. Appointments available: 1-877-632-6789.",,"Houston, TX",,2020-12-06 22:05:52+00:00,MD Anderson Cancer Center,http://twitter.com/,2.0,,1.335707052711293e+18,,0.0,0.0,,‚ÄúWe are very encouraged that every patient on the study achieved a complete remission and 97% achieved MRD negativi‚Ä¶ https://t.co/M93jTfgUdf,en,0.0,114120.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/MDAndersonNews/statuses/1335707052711292932,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Diagnosis Progression,1.0,0.0,0.0,‚ÄúWe are very encouraged that every patient on the study achieved a complete remission and 97% achieved MRD negativi‚Ä¶ https://t.co/M93jTfgUdf,true
tanyawildes,"Hematologist/oncologist/geriatrician, studying the intersection of Myeloma & other cancers with Aging. Woman of faith/wife of Mr Doctor Wildes/Mom.",,,,2020-12-06 21:02:08+00:00,Tanya Wildes MD,http://twitter.com/,11.0,,1.3356910165071913e+18,,0.0,0.0,,RT @ShakiraG_MBBS: #ASH20 Dr. @HiraSMian and colleagues identified high symptom burden among transplant-ineligible adults with newly diagno‚Ä¶,en,0.0,2800.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,8.0,3.0,https://twitter.com/tanyawildes/statuses/1335691016507191297,0.0,0.0,,0.0,0.0,0.0,3.0,8.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @ShakiraG_MBBS: #ASH20 Dr. @HiraSMian and colleagues identified high symptom burden among transplant-ineligible adults with newly diagno‚Ä¶,true
graham74GC,Lymphoma specialist at Oxford Cancer and Haematology centre. Haematologist and clinical trialist. Chair of UK Hodgkin and T-cell study groups.,,Opinions are mine,,2020-12-06 15:36:53+00:00,Graham Collins,http://twitter.com/,6.0,,1.335609164203176e+18,,0.0,0.0,,"Gernsheimer et al - TREAT-A 
Tranexamic acid v plac, haem malig pts, chemo +/- SCT
- Prim EP: WHO G2 bld events
- N‚Ä¶ https://t.co/9Xcyupmght",en,0.0,6091.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,6.0,https://twitter.com/graham74GC/statuses/1335609164203175939,0.0,0.0,,0.0,0.0,0.0,6.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"Gernsheimer et al - TREAT-A 
Tranexamic acid v plac, haem malig pts, chemo +/- SCT
- Prim EP: WHO G2 bld events
- N‚Ä¶ https://t.co/9Xcyupmght",false
JohnPLeonardMD,"Doctor for lymphoma patients, researcher, collaborator, professor/senior associate dean @WeillCornell & @NYPhospital Tweets mine RT not=endorsement, he/him/his",,Weill Cornell Medicine,,2020-12-06 20:36:07+00:00,"John P. Leonard, MD",http://twitter.com/,0.0,,1.3356844671014134e+18,,0.0,0.0,,Would be good to know time from diagnosis to treatment - as per @MaurerStats this is a big factor and potentially a‚Ä¶ https://t.co/ap6UyjubOM,en,0.0,6269.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/JohnPLeonardMD/statuses/1335684467101413384,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnostic Tools,1.0,0.0,0.0,Would be good to know time from diagnosis to treatment - as per @MaurerStats this is a big factor and potentially a‚Ä¶ https://t.co/ap6UyjubOM,true
chano_py,Sola Gracia. Medico Hematologo. Donante de √≥rganos. #DonaenVida. #HSCT Dr in #Paraguay. Patient Advocacy Co-Chair at #WBMT. Secretary at @LABMT2,,Paraguay,,2020-12-06 21:45:56+00:00,Cristobal Frutos,http://twitter.com/,0.0,,1.3357020357029435e+18,,0.0,0.0,,Gilterinib + 7+3 ‚û°Ô∏è IDAC (and HSTC at any time) ‚û°Ô∏è maintenance for #NDAML.. Phase 1.. Nice results on the FLT3+ coh‚Ä¶ https://t.co/zFN4qufr5L,en,0.0,903.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/chano_py/statuses/1335702035702943744,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,1.0,0.0,0.0,Gilterinib + 7+3 ‚û°Ô∏è IDAC (and HSTC at any time) ‚û°Ô∏è maintenance for #NDAML.. Phase 1.. Nice results on the FLT3+ coh‚Ä¶ https://t.co/zFN4qufr5L,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 21:23:14+00:00,"Ritcha Saxena, MD",http://twitter.com/,8.0,,1.335696324155609e+18,,0.0,0.0,,RT @hemedoc: #ASH20 #leusm Bhatnagar: Black pts w AML have higher mortality. This @ALLIANCE_org study sought to assess if this is due to bi‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,2.0,https://twitter.com/RitchaSaxena/statuses/1335696324155609093,0.0,0.0,,0.0,0.0,0.0,2.0,6.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,RT @hemedoc: #ASH20 #leusm Bhatnagar: Black pts w AML have higher mortality. This @ALLIANCE_org study sought to assess if this is due to bi‚Ä¶,true
CanerSaygin,"Heme-Onc Fellow @UChicago | Alumni of @OhioStateIMRes, @CCLRI | #Leukemia, #MDS, #CHIP physician-scientist. Tweets=own opinions.",,"Chicago, IL",,2020-12-06 22:29:05+00:00,"Caner Saygin, MD",http://twitter.com/,0.0,,1.335712897041916e+18,,0.0,0.0,,Dr Wang is presenting data comparing subq vs iv infusion cytarabine in induction therapy of newly diagnosed #AML. T‚Ä¶ https://t.co/JZymD4EciE,en,0.0,743.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/CanerSaygin/statuses/1335712897041915906,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,Dr Wang is presenting data comparing subq vs iv infusion cytarabine in induction therapy of newly diagnosed #AML. T‚Ä¶ https://t.co/JZymD4EciE,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 23:47:48+00:00,"Ritcha Saxena, MD",http://twitter.com/,9.0,,1.3357327052129526e+18,,0.0,0.0,,"RT @ASH_hematology: Studies to be presented at #ASH20 examine Hematologic Aspects of the Pandemic: Advancing the Study of #COVID19. 

Read‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,4.0,https://twitter.com/RitchaSaxena/statuses/1335732705212952580,0.0,0.0,,0.0,0.0,0.0,4.0,5.0,False,False,False,False,True,Covid,0.0,0.0,1.0,"RT @ASH_hematology: Studies to be presented at #ASH20 examine Hematologic Aspects of the Pandemic: Advancing the Study of #COVID19. 

Read‚Ä¶",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 01:47:04+00:00,"Ritcha Saxena, MD",http://twitter.com/,118.0,,1.3354003318160794e+18,,0.0,0.0,,"RT @ASH_hematology: Wendy Stock, MD, of @UChicago, with the 2020 ASH Mentor Award for contributing to the professional development of #hema‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,105.0,13.0,https://twitter.com/RitchaSaxena/statuses/1335400331816079360,0.0,0.0,,0.0,0.0,0.0,13.0,105.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,"RT @ASH_hematology: Wendy Stock, MD, of @UChicago, with the 2020 ASH Mentor Award for contributing to the professional development of #hema‚Ä¶",false
MediHumdani,"Director, BMT & Cellular Therapy Program @Froedtert & @MedicalCollege | Lymphoma | Clinical Trials | @CIBMTR | @BMTCTN | Personal views | Physician ‚â† Provider",,"Milwaukee, WI",,2020-12-06 22:09:46+00:00,Mehdi Hamadani,http://twitter.com/,11.0,,1.3357080331675853e+18,,0.0,0.0,,Pembro GVD: Outstanding data. Nearly 100% CR rates in relapsed classical HL @CMoskowitzMD #lymsm #ASH20,en,0.0,4590.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,11.0,https://twitter.com/MediHumdani/statuses/1335708033167585288,0.0,0.0,,0.0,0.0,0.0,11.0,0.0,False,False,False,False,True,Diagnosis Progression,1.0,0.0,0.0,Pembro GVD: Outstanding data. Nearly 100% CR rates in relapsed classical HL @CMoskowitzMD #lymsm #ASH20,true
tanyawildes,"Hematologist/oncologist/geriatrician, studying the intersection of Myeloma & other cancers with Aging. Woman of faith/wife of Mr Doctor Wildes/Mom.",,,,2020-12-06 16:16:05+00:00,Tanya Wildes MD,http://twitter.com/,15.0,,1.3356190294579077e+18,,0.0,0.0,,RT @ShakiraG_MBBS: #ASH20 highlighting today's oral abstracts by members of the #geriheme @myCARG research communityüëáJoin session: 905. Out‚Ä¶,en,0.0,2800.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,5.0,https://twitter.com/tanyawildes/statuses/1335619029457907719,0.0,0.0,,0.0,0.0,0.0,5.0,10.0,False,False,False,False,True,Disease Advocacy,0.0,0.0,1.0,RT @ShakiraG_MBBS: #ASH20 highlighting today's oral abstracts by members of the #geriheme @myCARG research communityüëáJoin session: 905. Out‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 16:02:31+00:00,"Ritcha Saxena, MD",http://twitter.com/,17.0,,1.3356156118551183e+18,,0.0,0.0,,"RT @hemedoc: #ASH20 #leusm Tiong: NMP1mut MRD predicts risk of relapse, including post-HCT. ELN defined molecular persistence at low copy n‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,14.0,3.0,https://twitter.com/RitchaSaxena/statuses/1335615611855118337,0.0,0.0,,0.0,0.0,0.0,3.0,14.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @hemedoc: #ASH20 #leusm Tiong: NMP1mut MRD predicts risk of relapse, including post-HCT. ELN defined molecular persistence at low copy n‚Ä¶",true
UjjaniC,CLL/Lymphoma oncologist at Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research Center/University of Washington,,"Seattle, WA",,2020-12-06 00:43:39+00:00,"Chaitra Ujjani, MD",http://twitter.com/,21.0,,1.335384374989058e+18,,0.0,0.0,,"RT @SeattleCCA: Today at #ASH20: Poster session with Ryan C. Lynch, MD (2nd author) - ""1632 Severity of Sars-Cov-2 Infection in Patients wi‚Ä¶",en,0.0,590.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,17.0,4.0,https://twitter.com/UjjaniC/statuses/1335384374989058050,0.0,0.0,,0.0,0.0,0.0,4.0,17.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"RT @SeattleCCA: Today at #ASH20: Poster session with Ryan C. Lynch, MD (2nd author) - ""1632 Severity of Sars-Cov-2 Infection in Patients wi‚Ä¶",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 21:46:17+00:00,"Ritcha Saxena, MD",http://twitter.com/,17.0,,1.335702126186668e+18,,0.0,0.0,,RT @YaleCancer: New research led by Dr. George Goshua .@classicalheme &amp; Dr. Alfred Lee at virtual #ASH20 shows caplacizumab is not cost-eff‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,13.0,4.0,https://twitter.com/RitchaSaxena/statuses/1335702126186668033,0.0,0.0,,0.0,0.0,0.0,4.0,13.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @YaleCancer: New research led by Dr. George Goshua .@classicalheme &amp; Dr. Alfred Lee at virtual #ASH20 shows caplacizumab is not cost-eff‚Ä¶,true
szusmani,"Division Chief, Plasma Cell Disorders|Director, Clinical Research Hem Malignancies | Views are my own | RT not endorsement | Physician ‚â† Provider",,"Charlotte, NC",,2020-12-06 20:30:44+00:00,Saad Z. Usmani MD MBA FACP (he/his/him),http://twitter.com/,2.0,,1.3356831129033196e+18,,0.0,0.0,,"Impressed with the DPomCyD data, albeit phase II #ASH20 #mmsm @ResearchMyeloma https://t.co/FzMRot7YvQ",en,0.0,5512.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/szusmani/statuses/1335683112903319552,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Clinical Trials,1.0,0.0,0.0,"Impressed with the DPomCyD data, albeit phase II #ASH20 #mmsm @ResearchMyeloma https://t.co/FzMRot7YvQ",false
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 16:01:01+00:00,"Ritcha Saxena, MD",http://twitter.com/,15.0,,1.335615236217385e+18,,0.0,0.0,,RT @hemedoc: #ASH20 #leusm Stahl: Molecular predictors of AML MRD eradication after chemo and HCT. Based on genomic profiling 215 patients‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,5.0,https://twitter.com/RitchaSaxena/statuses/1335615236217384960,0.0,0.0,,0.0,0.0,0.0,5.0,10.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @hemedoc: #ASH20 #leusm Stahl: Molecular predictors of AML MRD eradication after chemo and HCT. Based on genomic profiling 215 patients‚Ä¶,true
DrChrisHourigan,"Physician-Scientist, Acute Myeloid Leukemia Doctor, Human Immunologist, Laboratory PI, Measurable Residual Disease Advocate, Optimist.  Views are my own.",,"Washington, DC",,2020-12-06 16:46:27+00:00,Chris Hourigan,http://twitter.com/,10.0,,1.335626669705425e+18,,0.0,0.0,,"RT @hemedoc: #ASH20 Donald: ‚ÄúPersistent health disparities leave us all diminished.‚Äù
#BLM #healthequity",en,0.0,1169.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,9.0,1.0,https://twitter.com/DrChrisHourigan/statuses/1335626669705424897,0.0,0.0,,0.0,0.0,0.0,1.0,9.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,"RT @hemedoc: #ASH20 Donald: ‚ÄúPersistent health disparities leave us all diminished.‚Äù
#BLM #healthequity",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 21:32:54+00:00,"Ritcha Saxena, MD",http://twitter.com/,20.0,,1.3356987572378255e+18,,0.0,0.0,,"RT @ASHCollab: #ASH20 Press Release: Certain People with Blood Cancers and COVID-19 Infection Vulnerable to Severe Illness, Death https://t‚Ä¶",en,0.0,6875.0,,,0.0,,,Negative,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,14.0,6.0,https://twitter.com/RitchaSaxena/statuses/1335698757237825537,0.0,0.0,,0.0,0.0,0.0,6.0,14.0,False,False,False,False,True,Side Effects,0.0,1.0,0.0,"RT @ASHCollab: #ASH20 Press Release: Certain People with Blood Cancers and COVID-19 Infection Vulnerable to Severe Illness, Death https://t‚Ä¶",true
Lachelle_Dawn,heme-onc fellow | physician-scientist | racial justice & health equity | views are mine | there will be typos | i tweet what i want | pronouns: she/her/hers,,"Boston, MA",,2020-12-06 17:56:27+00:00,Lachelle Dawn,http://twitter.com/,73.0,,1.3356442852874772e+18,,0.0,0.0,,"RT @MPaiMD: @MaryCushmanMD There‚Äôs a lot of novelty at #ASH20 this year - negative trials, featuring more speakers of historically excluded‚Ä¶",en,0.0,3338.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,60.0,13.0,https://twitter.com/Lachelle_Dawn/statuses/1335644285287477249,0.0,0.0,,0.0,0.0,0.0,13.0,60.0,False,False,False,False,True,Thought Leadership,0.0,0.0,1.0,"RT @MPaiMD: @MaryCushmanMD There‚Äôs a lot of novelty at #ASH20 this year - negative trials, featuring more speakers of historically excluded‚Ä¶",true
NitinJainMD,Leukemia Physician at MD Anderson Cancer Center | #Leukemia #CLL #ALL | Med School #AIIMS | Tweets are my own thoughts and opinions,,"Houston, Texas",,2020-12-06 17:05:46+00:00,Nitin Jain,http://twitter.com/,17.0,,1.335631529708499e+18,,0.0,0.0,,"RT @OncLive: Allogeneic Off-the-Shelf UCART22 Product Shows Early Activity, Tolerability in CD22+ B-Cell Relapsed/Refractory ALL
@MDAnderso‚Ä¶",en,0.0,2259.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,13.0,4.0,https://twitter.com/NitinJainMD/statuses/1335631529708498946,0.0,0.0,,0.0,0.0,0.0,4.0,13.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @OncLive: Allogeneic Off-the-Shelf UCART22 Product Shows Early Activity, Tolerability in CD22+ B-Cell Relapsed/Refractory ALL
@MDAnderso‚Ä¶",true
hkazemi83,Hematologist-Oncologist,,"New Jersey, USA",,2020-12-06 01:41:14+00:00,M. Hossein Kazemi,http://twitter.com/,84.0,,1.3353988626730926e+18,,0.0,0.0,,"RT @hemedoc: #ASH20 #leusm Levis: I don‚Äôt know who needs to hear this, but there really is no role for intensive chemotherapy in TP53 mutat‚Ä¶",en,0.0,184.0,,,0.0,,,Negative,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,65.0,19.0,https://twitter.com/hkazemi83/statuses/1335398862673092608,0.0,0.0,,0.0,0.0,0.0,19.0,65.0,False,False,False,False,True,Innovation,0.0,1.0,0.0,"RT @hemedoc: #ASH20 #leusm Levis: I don‚Äôt know who needs to hear this, but there really is no role for intensive chemotherapy in TP53 mutat‚Ä¶",false
abhinav_deol,MD,,"Detroit, MI",,2020-12-08 18:38:17+00:00,Abhinav Deol,http://twitter.com/,0.0,,1.3363795890614725e+18,,0.0,0.0,,#ASH20 iRBC and iPlatelets derived from pluripotent stem cells to overcome issues with compromised blood donor supp‚Ä¶ https://t.co/o4NTqru2Uk,en,0.0,251.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/abhinav_deol/statuses/1336379589061472262,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,#ASH20 iRBC and iPlatelets derived from pluripotent stem cells to overcome issues with compromised blood donor supp‚Ä¶ https://t.co/o4NTqru2Uk,true
TaylorJ_MD,"Assistant Professor, UM Sylvester Comprehensive Cancer Center. Physician scientist studying the role of nuclear export and splicing in hematologic cancers.",,"Miami, FL",,2020-12-08 15:45:46+00:00,Taylor Lab UM,http://twitter.com/,0.0,,1.336336174709756e+18,,0.0,0.0,,Late-breaking abstract just presented at #ASH20! First-in-class STAMP inhibitor for #CML! Congrats to all investiga‚Ä¶ https://t.co/BbGPSPbst1,en,0.0,1781.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/TaylorJ_MD/statuses/1336336174709755904,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Financial Performance,1.0,0.0,0.0,Late-breaking abstract just presented at #ASH20! First-in-class STAMP inhibitor for #CML! Congrats to all investiga‚Ä¶ https://t.co/BbGPSPbst1,true
abhinav_deol,MD,,"Detroit, MI",,2020-12-08 17:46:19+00:00,Abhinav Deol,http://twitter.com/,1.0,,1.336366511527768e+18,,0.0,0.0,,"#ASH20 Pluripotent stem cells to generate T cell, a novel way to generate off the shelf cellular therapy in the fut‚Ä¶ https://t.co/9lvJ46h6g6",en,0.0,251.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/abhinav_deol/statuses/1336366511527768067,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"#ASH20 Pluripotent stem cells to generate T cell, a novel way to generate off the shelf cellular therapy in the fut‚Ä¶ https://t.co/9lvJ46h6g6",true
MDedgeHemOnc,MDedge Hematology & Oncology provides the most important and up to date information and news for oncologists. Now part of the Medscape Professional Network.,,"Rockville, MD, Parsippany, NJ",,2020-12-08 00:11:00+00:00,MDedge Hematology & Oncology,http://twitter.com/,1.0,,1.3361009343640412e+18,,0.0,0.0,,A new study compared tranexamic acid to placebo and found no significant differences in terms of the number of blee‚Ä¶ https://t.co/cbVakPOZPy,en,0.0,6726.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/MDedgeHemOnc/statuses/1336100934364041219,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,A new study compared tranexamic acid to placebo and found no significant differences in terms of the number of blee‚Ä¶ https://t.co/cbVakPOZPy,true
DrMDavids,"Hematologist/oncologist, CLL researcher, director of #lymphoma clinical research @DanaFarber, faculty @harvardmed. Tweets are my own & not medical advice.",,"Boston, USA",,2020-12-07 16:29:57+00:00,"Matthew Davids, MD, MMSc",http://twitter.com/,47.0,,1.335984903767421e+18,,0.0,0.0,,RT @UjjaniC: So excited to finally present Ibrutinib + Venetoclax in Follicular #Lymphoma! ORR &gt; 80% at RP2D. Phase 2 currently accruing @S‚Ä¶,en,0.0,2195.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,39.0,8.0,https://twitter.com/DrMDavids/statuses/1335984903767420931,0.0,0.0,,0.0,0.0,0.0,8.0,39.0,False,False,False,False,True,Clinical Trials,1.0,0.0,0.0,RT @UjjaniC: So excited to finally present Ibrutinib + Venetoclax in Follicular #Lymphoma! ORR &gt; 80% at RP2D. Phase 2 currently accruing @S‚Ä¶,true
KirovDoc,"MD, Ph.D., Hematologist at Kirov Research Institute of Hematology and Blood transfusion",,Russia,,2020-12-08 18:14:44+00:00,Alexander Luchinin,http://twitter.com/,7.0,,1.33637366325223e+18,,0.0,0.0,,RT @MM_Hub: #ASH20 | Suzanne Trudel also presented a summary of pom-based triplets results in relapsed/refractory #myeloma according to pre‚Ä¶,en,0.0,27.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,2.0,https://twitter.com/KirovDoc/statuses/1336373663252230147,0.0,0.0,,0.0,0.0,0.0,2.0,5.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @MM_Hub: #ASH20 | Suzanne Trudel also presented a summary of pom-based triplets results in relapsed/refractory #myeloma according to pre‚Ä¶,false
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-07 04:03:08+00:00,"Ritcha Saxena, MD",http://twitter.com/,40.0,,1.3357969645087744e+18,,0.0,0.0,,RT @RahmaWarsameMD: Promising results from phase 1 VSV-IFNb-NIS in pts with relapsed refractory hem malignancies. Strongest signal in TCL.‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,30.0,10.0,https://twitter.com/RitchaSaxena/statuses/1335796964508774411,0.0,0.0,,0.0,0.0,0.0,10.0,30.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @RahmaWarsameMD: Promising results from phase 1 VSV-IFNb-NIS in pts with relapsed refractory hem malignancies. Strongest signal in TCL.‚Ä¶,true
fniainle,"Haematologist, passionate about VTE. Co-director @ConwaySphere; Director https://t.co/csdWq9XJ57; RT not endorsement, views my own",,"Dublin City, Ireland",,2020-12-06 18:25:37+00:00,Fionnuala N√≠ √Åinle,http://twitter.com/,27.0,,1.335651624442794e+18,,0.0,0.0,,RT @Lachelle_Dawn: Results of A-TREAT: randomized placebo-controlled study to evaluate the safety &amp; efficacy of TXA in preventing bleeding‚Ä¶,en,0.0,2069.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,19.0,8.0,https://twitter.com/fniainle/statuses/1335651624442793991,0.0,0.0,,0.0,0.0,0.0,8.0,19.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @Lachelle_Dawn: Results of A-TREAT: randomized placebo-controlled study to evaluate the safety &amp; efficacy of TXA in preventing bleeding‚Ä¶,true
LakshmiKoulmane,"Associate Professor of Pathology, Staff Pathologist at Hematology and clinical Pathology laboratory, Kasturba Medical College and Hospital, Manipal. MAHE",,"Karnataka, India",,2020-12-07 15:49:10+00:00,Sindhura Lakshmi,http://twitter.com/,13.0,,1.3359746412658278e+18,,0.0,0.0,,RT @AML_Hub: CONGRESS | #ASH20 | Nikhil Patkar @nvpatkar investigated ‚Äúhotspot‚Äù panel of 35 mutated genes in AML plus FLT3-ITD PCR based NG‚Ä¶,en,0.0,642.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,8.0,5.0,https://twitter.com/LakshmiKoulmane/statuses/1335974641265827840,0.0,0.0,,0.0,0.0,0.0,5.0,8.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,RT @AML_Hub: CONGRESS | #ASH20 | Nikhil Patkar @nvpatkar investigated ‚Äúhotspot‚Äù panel of 35 mutated genes in AML plus FLT3-ITD PCR based NG‚Ä¶,true
YaleCancer,Yale Cancer Center is a collaboration between renowned cancer researchers and physicians at Yale University and Smilow Cancer Hospital.,,"New Haven, Connecticut",,2020-12-06 20:06:08+00:00,Yale Cancer Center,http://twitter.com/,4.0,,1.335676921636647e+18,,0.0,0.0,,New research led by Dr. George Goshua .@classicalheme &amp; Dr. Alfred Lee at virtual #ASH20 shows caplacizumab is not‚Ä¶ https://t.co/7uTkjHnNRC,en,0.0,9957.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,4.0,https://twitter.com/YaleCancer/statuses/1335676921636646912,0.0,0.0,,0.0,0.0,0.0,4.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,New research led by Dr. George Goshua .@classicalheme &amp; Dr. Alfred Lee at virtual #ASH20 shows caplacizumab is not‚Ä¶ https://t.co/7uTkjHnNRC,true
KirovDoc,"MD, Ph.D., Hematologist at Kirov Research Institute of Hematology and Blood transfusion",,Russia,,2020-12-07 04:28:12+00:00,Alexander Luchinin,http://twitter.com/,9.0,,1.335803270951002e+18,,0.0,0.0,,"RT @MM_Hub: CONGRESS | #ASH20 | Michael Sebag, @cusm_muhc, discussed phase II data of DARA, weekly low-dose dex, and cyclophosphamide ¬± Pom‚Ä¶",en,0.0,27.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,3.0,https://twitter.com/KirovDoc/statuses/1335803270951002113,0.0,0.0,,0.0,0.0,0.0,3.0,6.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @MM_Hub: CONGRESS | #ASH20 | Michael Sebag, @cusm_muhc, discussed phase II data of DARA, weekly low-dose dex, and cyclophosphamide ¬± Pom‚Ä¶",true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-12-06 21:10:43+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,3.0,,1.3356931763554714e+18,,0.0,0.0,,"#ASH20 #leusm Sasaki: IZKF1del can be subtyped by site of deletion, which lead to either haploinsufficiency or domi‚Ä¶ https://t.co/hbRNIfdtDT",en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/hemedoc/statuses/1335693176355471363,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Insurance Coverage,0.0,0.0,1.0,"#ASH20 #leusm Sasaki: IZKF1del can be subtyped by site of deletion, which lead to either haploinsufficiency or domi‚Ä¶ https://t.co/hbRNIfdtDT",false
LeukDocJZ,Oncologist | Associate Prof of Med @UNC_Lineberger | Clinical Trialist- #AML & #MDS | Alum of Osler Residency & Hopkins Oncology | Diehard NYG fan| Views my own,,"Chapel Hill, NC",,2020-12-06 17:26:31+00:00,Joshua Zeidner MD,http://twitter.com/,0.0,,1.3356367523132948e+18,,0.0,0.0,,Fantastic &amp; illuminating plenary session. #ASHkudos to Dr. Bhavana Bhatnagar &amp; colleagues at Ohio State &amp; Alliance‚Ä¶ https://t.co/akWLkJVoLv,en,0.0,710.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/LeukDocJZ/statuses/1335636752313294851,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,Fantastic &amp; illuminating plenary session. #ASHkudos to Dr. Bhavana Bhatnagar &amp; colleagues at Ohio State &amp; Alliance‚Ä¶ https://t.co/akWLkJVoLv,true
rajshekharucms,Hem/Onc Physician/Clinical Researcher @ColumbiaCancer #MultipleMyeloma & #Amyloidosis. Asst. Prof of Medicine @ColumbiaMed #ClinicalTrials and Outcomes Research,,"New York, NY",,2020-12-07 22:08:08+00:00,Raj Chakraborty,http://twitter.com/,1.0,,1.33607001386265e+18,,0.0,0.0,,"Increasing data on circulating plasma cells in #MultipleMyeloma: A valuable tool for risk assessment at diagnosis,‚Ä¶ https://t.co/2Pa4bc7F45",en,0.0,1148.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/rajshekharucms/statuses/1336070013862649856,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"Increasing data on circulating plasma cells in #MultipleMyeloma: A valuable tool for risk assessment at diagnosis,‚Ä¶ https://t.co/2Pa4bc7F45",true
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-10-16 22:23:24+00:00,Cardiovascular Research Foundation,http://twitter.com/,9.0,,1.3172296861503365e+18,,0.0,0.0,,"RT @MHIF_Heart: MHIF Live Case at #TCTConnect: 10/17 at 3pm CT, observe a unique case leveraging expertise across imaging, minimally invasi‚Ä¶",en,0.0,12239.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,7.0,2.0,https://twitter.com/crfheart/statuses/1317229686150336512,0.0,0.0,,0.0,0.0,0.0,2.0,7.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,"RT @MHIF_Heart: MHIF Live Case at #TCTConnect: 10/17 at 3pm CT, observe a unique case leveraging expertise across imaging, minimally invasi‚Ä¶",true
Rfonsi1,"Interim Executive Director, Mayo Clinic Cancer Center. Myeloma doctor. Visiting Healthcare Fellow @GoldwaterInst. Tweets-own/RT not an endorsement",,,,2020-12-07 22:56:38+00:00,Rafael Fonseca MD,http://twitter.com/,0.0,,1.33608221817156e+18,,0.0,0.0,,A Phase 3 trial has been started. It is a must-have to know what the contribution is but congratulations to the tea‚Ä¶ https://t.co/3WN48kSCh3,en,0.0,8301.0,,,0.0,Rfonsi1,1.3360822137465285e+18,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/Rfonsi1/statuses/1336082218171559936,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,FDA Approval,1.0,0.0,0.0,A Phase 3 trial has been started. It is a must-have to know what the contribution is but congratulations to the tea‚Ä¶ https://t.co/3WN48kSCh3,true
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-10-16 00:52:35+00:00,Cardiovascular Research Foundation,http://twitter.com/,5.0,,1.3169048402918236e+18,,0.0,0.0,,"Have you been following our #TCTConnect ambassadors? With their vast experience and expertise, they‚Äôll help you get‚Ä¶ https://t.co/y3QubwW27C",en,0.0,12239.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,5.0,https://twitter.com/crfheart/statuses/1316904840291823618,0.0,0.0,,0.0,0.0,0.0,5.0,0.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,"Have you been following our #TCTConnect ambassadors? With their vast experience and expertise, they‚Äôll help you get‚Ä¶ https://t.co/y3QubwW27C",true
drskharlamov,"Physician, General and Interventional Cardiologist | CV imaging, biomedical engineering, nanomedicine | NOTHING IS IMPOSSIBLE!",,"Rotterdam, Nederland üá≥üá± ",,2020-10-16 15:31:51+00:00,John ‚ÄúAlex‚Äù Kharlamov MD FESC FACC FEACVI üá∫üá∏üá≥üá±,http://twitter.com/,89.0,,1.3171261166379213e+18,,0.0,0.0,,RT @GreggWStone: FORECAST late breaking trial at #TCT2020. 1300 pts with chest pain at out-pt clinics rand to FFRCT vs usual diagnostic eva‚Ä¶,en,0.0,1651.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,61.0,28.0,https://twitter.com/drskharlamov/statuses/1317126116637921282,0.0,0.0,,0.0,0.0,0.0,28.0,61.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @GreggWStone: FORECAST late breaking trial at #TCT2020. 1300 pts with chest pain at out-pt clinics rand to FFRCT vs usual diagnostic eva‚Ä¶,false
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-10-16 00:58:33+00:00,Cardiovascular Research Foundation,http://twitter.com/,2.0,,1.316906341655548e+18,,0.0,0.0,,"Have you been following our #TCTConnect ambassadors? With their vast experience and expertise, they‚Äôll help you get‚Ä¶ https://t.co/jFr76lBgXt",en,0.0,12239.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/crfheart/statuses/1316906341655547905,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,"Have you been following our #TCTConnect ambassadors? With their vast experience and expertise, they‚Äôll help you get‚Ä¶ https://t.co/jFr76lBgXt",true
aymanka,"interventional cardiologist ( ex SCAI BOT ,ex Washington Hospital Center ) runner , diver , NFL . lucky to be in a profession that keeps you learning !",,,,2020-10-16 14:50:58+00:00,Ayman Magd,http://twitter.com/,10.0,,1.3171158249232015e+18,,0.0,0.0,,RT @crfheart: Step into the #TCT2020 Shark Tank! Tune in at 11:00 AM ET to watch the next 3 teams compete for the top innovation prize at #‚Ä¶,en,0.0,3854.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,7.0,3.0,https://twitter.com/aymanka/statuses/1317115824923201536,0.0,0.0,,0.0,0.0,0.0,3.0,7.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @crfheart: Step into the #TCT2020 Shark Tank! Tune in at 11:00 AM ET to watch the next 3 teams compete for the top innovation prize at #‚Ä¶,true
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-10-16 13:03:13+00:00,Cardiovascular Research Foundation,http://twitter.com/,0.0,,1.3170887100774154e+18,,0.0,0.0,,Take a break from world-class education to network and engage with industry partners at our Engagement Hub during‚Ä¶ https://t.co/5J6RWtvhMG,en,0.0,12239.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/crfheart/statuses/1317088710077415426,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,Take a break from world-class education to network and engage with industry partners at our Engagement Hub during‚Ä¶ https://t.co/5J6RWtvhMG,true
sajannarayanan,Senior Interventional Cardiologist.. STEMI care specialist...working on FFR/iFR ...imaging enthusiast,,"Kochi, India",,2020-10-16 15:24:16+00:00,sajannarayanan,http://twitter.com/,89.0,,1.317124208330117e+18,,0.0,0.0,,RT @GreggWStone: FORECAST late breaking trial at #TCT2020. 1300 pts with chest pain at out-pt clinics rand to FFRCT vs usual diagnostic eva‚Ä¶,en,0.0,700.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,61.0,28.0,https://twitter.com/sajannarayanan/statuses/1317124208330117120,0.0,0.0,,0.0,0.0,0.0,28.0,61.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @GreggWStone: FORECAST late breaking trial at #TCT2020. 1300 pts with chest pain at out-pt clinics rand to FFRCT vs usual diagnostic eva‚Ä¶,true
mughal381,Interventional Pediatric Cardiologist RavianÿåPMCianÿå proud Pakistani.üíö,,Pakistan,,2020-10-16 07:25:55+00:00,Dr Mughal,http://twitter.com/,22.0,,1.3170038253335716e+18,,0.0,0.0,,RT @NishithChandra: Those missed yesterday's SharkTank ! #TCTConnect #TCT2020 A remarkable Innovation ‚û°Ô∏èNatural Vascular Scaffolding.Dilate‚Ä¶,en,0.0,1047.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,16.0,6.0,https://twitter.com/mughal381/statuses/1317003825333571585,0.0,0.0,,0.0,0.0,0.0,6.0,16.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @NishithChandra: Those missed yesterday's SharkTank ! #TCTConnect #TCT2020 A remarkable Innovation ‚û°Ô∏èNatural Vascular Scaffolding.Dilate‚Ä¶,true
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-10-16 16:45:04+00:00,Cardiovascular Research Foundation,http://twitter.com/,2.0,,1.3171445425592607e+18,,0.0,0.0,,"Congratulations to @onsight_medical! Winner of the #TCTConnect Shark Tank Innovation Competition and $200,000 provi‚Ä¶ https://t.co/jlGHONcsmM",en,0.0,12239.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/crfheart/statuses/1317144542559260672,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"Congratulations to @onsight_medical! Winner of the #TCTConnect Shark Tank Innovation Competition and $200,000 provi‚Ä¶ https://t.co/jlGHONcsmM",false
DrBModi,Interventional Cardiologist / PhD in Coronary Physiology / Long Suffering Aston Villa fan / Cricket Enthusiast,,"London, England",,2020-10-16 18:52:15+00:00,Bhavik Modi,http://twitter.com/,89.0,,1.317176549402153e+18,,0.0,0.0,,RT @GreggWStone: FORECAST late breaking trial at #TCT2020. 1300 pts with chest pain at out-pt clinics rand to FFRCT vs usual diagnostic eva‚Ä¶,en,0.0,425.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,61.0,28.0,https://twitter.com/DrBModi/statuses/1317176549402152962,0.0,0.0,,0.0,0.0,0.0,28.0,61.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @GreggWStone: FORECAST late breaking trial at #TCT2020. 1300 pts with chest pain at out-pt clinics rand to FFRCT vs usual diagnostic eva‚Ä¶,true
atunuguntla1,"Interventional Cardiologist, CHI Health Nebraska Heart, Lincoln, NE. Tweets = My Opinion & not medical advice #StructuralHeart #RadialFirst #ACCWIC",,"Nebraska, USA",,2020-10-16 01:43:03+00:00,"Anuradha Tunuguntla, MD, FACC, FSCAI",http://twitter.com/,14.0,,1.3169175422215004e+18,,0.0,0.0,,"RT @AnastasiaSMihai: üåüüåüüåüüåüüåüsessions scheduled #TCT2020 ‚ÄºÔ∏è
 
üìçLive Cases! 
üìç#LBCT &amp; #Science (my‚ù§Ô∏è)
üìç TCTü¶àtank innovations
üìç FDA Town Hall‚ô®Ô∏èT‚Ä¶",en,0.0,3619.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,8.0,6.0,https://twitter.com/atunuguntla1/statuses/1316917542221500418,0.0,0.0,,0.0,0.0,0.0,6.0,8.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @AnastasiaSMihai: üåüüåüüåüüåüüåüsessions scheduled #TCT2020 ‚ÄºÔ∏è
 
üìçLive Cases! 
üìç#LBCT &amp; #Science (my‚ù§Ô∏è)
üìç TCTü¶àtank innovations
üìç FDA Town Hall‚ô®Ô∏èT‚Ä¶",true
AntoniousAttall,"interventional cardiologist, Medical director of PERT @Ascension St. John, Detroit, MI #imagefirst #precisionpci #radialfirst #CHIP #IVUS #CTO #FordTrained",,"Roseville, MI",,2020-10-16 02:21:55+00:00,"Antonious Attallah, MD, FACC, FSCAI",http://twitter.com/,22.0,,1.316927319819387e+18,,0.0,0.0,,RT @heartdoc45: Great #Innovation session happening now at #TCTConnect re: Managing Calcified CAD with @KateKearney4 @cathjockey72 Robert R‚Ä¶,en,0.0,5114.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,19.0,3.0,https://twitter.com/AntoniousAttall/statuses/1316927319819386885,0.0,0.0,,0.0,0.0,0.0,3.0,19.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @heartdoc45: Great #Innovation session happening now at #TCTConnect re: Managing Calcified CAD with @KateKearney4 @cathjockey72 Robert R‚Ä¶,true
lamelaspablo,Interventional cardiologist @ICBAonline üá¶üá∑ Assistant Professor at Health Research Methods @HEI_McMaster üá®üá¶ Birthplace of Evidence-Based Medicine,,"Buenos Aires, Argentina",,2020-10-16 15:33:17+00:00,Pablo Lamelas üá¶üá∑üá®üá¶,http://twitter.com/,89.0,,1.317126476786e+18,,0.0,0.0,,RT @GreggWStone: FORECAST late breaking trial at #TCT2020. 1300 pts with chest pain at out-pt clinics rand to FFRCT vs usual diagnostic eva‚Ä¶,en,0.0,7465.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,61.0,28.0,https://twitter.com/lamelaspablo/statuses/1317126476785999872,0.0,0.0,,0.0,0.0,0.0,28.0,61.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @GreggWStone: FORECAST late breaking trial at #TCT2020. 1300 pts with chest pain at out-pt clinics rand to FFRCT vs usual diagnostic eva‚Ä¶,true
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-10-16 16:40:03+00:00,Cardiovascular Research Foundation,http://twitter.com/,0.0,,1.3171432786351104e+18,,0.0,0.0,,Up next at 12:50 PM ET on the #TCTConnect Innovation Channel: A session on the latest trends in MedTech for‚Ä¶ https://t.co/chouafhhFp,en,0.0,12239.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/crfheart/statuses/1317143278635110401,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,Up next at 12:50 PM ET on the #TCTConnect Innovation Channel: A session on the latest trends in MedTech for‚Ä¶ https://t.co/chouafhhFp,true
gbiondizoccai,"Academic interventional cardiologist, data scientist, & medical writer/reviewer/editor.
All opinions own, (re)tweets/likes not endorsements nor medical advice.",,"Rome, Italy",,2020-10-16 10:30:26+00:00,Giuseppe Biondi-Zoccai,http://twitter.com/,22.0,,1.3170502606031954e+18,,0.0,0.0,,RT @sbrugaletta: Filter in TAVI is not more effective but safe. should we use it in specific subgroup of patients? #TAVR #TCTConnect @PCRon‚Ä¶,en,0.0,1321.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,14.0,8.0,https://twitter.com/gbiondizoccai/statuses/1317050260603195392,0.0,0.0,,0.0,0.0,0.0,8.0,14.0,False,False,False,False,True,Drug Comparisons,0.0,0.0,1.0,RT @sbrugaletta: Filter in TAVI is not more effective but safe. should we use it in specific subgroup of patients? #TAVR #TCTConnect @PCRon‚Ä¶,false
IamSpurs,Consultant Interventional Cardiologist | Editor @Heart_BMJ | Editor @OUPMedicine | R&D Comm @BCIS_uk | Alumnus @KingsCardio | COYS @SpursOfficial | Views my own,,By Your Bedside,,2020-10-16 11:14:07+00:00,Aung Myat MD üíô,http://twitter.com/,0.0,,1.3170612537356e+18,,0.0,0.0,,"Forecast will be the death of diagnostic angiography.

You heard it here first folks!!

#TCTConnect #TCT2020",en,0.0,3380.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/IamSpurs/statuses/1317061253735600128,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"Forecast will be the death of diagnostic angiography.

You heard it here first folks!!

#TCTConnect #TCT2020",true
VijayKunadian,Academic Interventional Cardiologist | Heart Disease Researcher @UniofNewcastle @NewcastleHosps | Views here are my own opinion & thinking üòä,,"Newcastle Upon Tyne, England",,2020-10-16 15:14:18+00:00,Vijay Kunadian,http://twitter.com/,89.0,,1.317121699209511e+18,,0.0,0.0,,RT @GreggWStone: FORECAST late breaking trial at #TCT2020. 1300 pts with chest pain at out-pt clinics rand to FFRCT vs usual diagnostic eva‚Ä¶,en,0.0,3389.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,61.0,28.0,https://twitter.com/VijayKunadian/statuses/1317121699209510913,0.0,0.0,,0.0,0.0,0.0,28.0,61.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @GreggWStone: FORECAST late breaking trial at #TCT2020. 1300 pts with chest pain at out-pt clinics rand to FFRCT vs usual diagnostic eva‚Ä¶,true
heartdoc45,Interventional Cardiologist at @CardioInstitute; Ochsner/Scripps trained; Pearl Jam enthusiast. Views expressed are my own. #RadialFirst,,"Lafayette, Louisiana",,2020-10-16 23:00:38+00:00,"David Homan, MD",http://twitter.com/,89.0,,1.3172390552313897e+18,,0.0,0.0,,RT @GreggWStone: FORECAST late breaking trial at #TCT2020. 1300 pts with chest pain at out-pt clinics rand to FFRCT vs usual diagnostic eva‚Ä¶,en,0.0,6040.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,61.0,28.0,https://twitter.com/heartdoc45/statuses/1317239055231389696,0.0,0.0,,0.0,0.0,0.0,28.0,61.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @GreggWStone: FORECAST late breaking trial at #TCT2020. 1300 pts with chest pain at out-pt clinics rand to FFRCT vs usual diagnostic eva‚Ä¶,true
medox1234,interventional cardiologist,,"Muscat, Oman",,2020-10-16 17:10:09+00:00,Ahmed M. El Said,http://twitter.com/,89.0,,1.3171508519249224e+18,,0.0,0.0,,RT @GreggWStone: FORECAST late breaking trial at #TCT2020. 1300 pts with chest pain at out-pt clinics rand to FFRCT vs usual diagnostic eva‚Ä¶,en,0.0,941.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,61.0,28.0,https://twitter.com/medox1234/statuses/1317150851924922368,0.0,0.0,,0.0,0.0,0.0,28.0,61.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @GreggWStone: FORECAST late breaking trial at #TCT2020. 1300 pts with chest pain at out-pt clinics rand to FFRCT vs usual diagnostic eva‚Ä¶,true
cardioPCImom,"Interventional Cardiologist, advocate #CardioObstetrics, #WIC, mother to precocious 6yr old, tweets are my own",,"Gainesville, FL",,2020-10-16 02:05:30+00:00,Ki Park,http://twitter.com/,14.0,,1.3169231905438515e+18,,0.0,0.0,,"RT @AnastasiaSMihai: üåüüåüüåüüåüüåüsessions scheduled #TCT2020 ‚ÄºÔ∏è
 
üìçLive Cases! 
üìç#LBCT &amp; #Science (my‚ù§Ô∏è)
üìç TCTü¶àtank innovations
üìç FDA Town Hall‚ô®Ô∏èT‚Ä¶",en,0.0,4510.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,8.0,6.0,https://twitter.com/cardioPCImom/statuses/1316923190543851520,0.0,0.0,,0.0,0.0,0.0,6.0,8.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @AnastasiaSMihai: üåüüåüüåüüåüüåüsessions scheduled #TCT2020 ‚ÄºÔ∏è
 
üìçLive Cases! 
üìç#LBCT &amp; #Science (my‚ù§Ô∏è)
üìç TCTü¶àtank innovations
üìç FDA Town Hall‚ô®Ô∏èT‚Ä¶",true
NadeenFaza,"Asst Professor, Cardiologist/ Interventional Imager @HMethodistCV l Asst PD @HMHCardioFellow l  #JACCCaseReports & @DeBakeyCVedu editorial team l Tweets=my own.",,"Houston, Texas ",,2020-10-16 00:54:31+00:00,"Nadeen N. Faza, M.D.",http://twitter.com/,11.0,,1.3169053257910067e+18,,0.0,0.0,,"RT @crfheart: Have you been following our #TCTConnect ambassadors? With their vast experience and expertise, they‚Äôll help you get a unique‚Ä¶",en,0.0,5480.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,5.0,https://twitter.com/NadeenFaza/statuses/1316905325791006720,0.0,0.0,,0.0,0.0,0.0,5.0,6.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,"RT @crfheart: Have you been following our #TCTConnect ambassadors? With their vast experience and expertise, they‚Äôll help you get a unique‚Ä¶",false
RezaEmaminia,"Cardiologist, Echocardiographer, Director of Advanced Cardiac Imaging, Inova Heart and Vascular Institute @InovaHeart. @UMiamiMedicine @ColumbiaMed Alumni.",,"Fairfax, VA",,2020-10-13 01:19:06+00:00,Abbas (Reza) Emaminia,http://twitter.com/,61.0,,1.3158243489225482e+18,,0.0,0.0,,"RT @crfheart: Follow our #TCTConnect Social Media Ambassadors! With their vast experience and expertise, they‚Äôll help you get a unique pers‚Ä¶",en,0.0,4310.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,45.0,16.0,https://twitter.com/RezaEmaminia/statuses/1315824348922548224,0.0,0.0,,0.0,0.0,0.0,16.0,45.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,"RT @crfheart: Follow our #TCTConnect Social Media Ambassadors! With their vast experience and expertise, they‚Äôll help you get a unique pers‚Ä¶",true
Hragy,"Cardiologist, National Heart Institute, Egypt ÿ±ÿ¨ÿßÿ° ÿπÿØŸÖ ÿßŸÑÿ™ŸàÿßÿµŸÑ ÿ®ÿ¥ÿ£ŸÜ ÿ¥ÿ§ŸàŸÜ ÿ∑ÿ®Ÿäÿ© ÿÆÿßÿµÿ© ÿπŸÑŸä ÿ™ŸàŸäÿ™ÿ±",,egypt,,2020-10-13 05:19:49+00:00,Hany Ragy,http://twitter.com/,61.0,,1.3158849291384668e+18,,0.0,0.0,,"RT @crfheart: Follow our #TCTConnect Social Media Ambassadors! With their vast experience and expertise, they‚Äôll help you get a unique pers‚Ä¶",en,0.0,31448.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,45.0,16.0,https://twitter.com/Hragy/statuses/1315884929138466816,0.0,0.0,,0.0,0.0,0.0,16.0,45.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,"RT @crfheart: Follow our #TCTConnect Social Media Ambassadors! With their vast experience and expertise, they‚Äôll help you get a unique pers‚Ä¶",true
adityadoc1,"Interventional Cardiologist,Loma Linda Univ, Early Career Chair CAACC #SoMe Editor#ACCIC, #CHIP #WarOnShock #TAVR #PAD #MountSinai,NY trained. Tweets=my opinion",,"Loma Linda, CA",,2020-10-19 19:31:31+00:00,Aditya Bharadwaj,http://twitter.com/,68.0,,1.3182735907902136e+18,,0.0,0.0,,RT @mmamas1973: #VIVPartner trial #TCTConnect fascinating presentation around valve in valve treatment of failing #SAVR with #TAVR - this i‚Ä¶,en,0.0,3591.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,49.0,19.0,https://twitter.com/adityadoc1/statuses/1318273590790213633,0.0,0.0,,0.0,0.0,0.0,19.0,49.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @mmamas1973: #VIVPartner trial #TCTConnect fascinating presentation around valve in valve treatment of failing #SAVR with #TAVR - this i‚Ä¶,true
FabienPraz,"Interventional cardiologist at Bern University Hospital, Switzerland, passionate about multimodality imaging",,"Berne, Suisse",,2020-10-17 08:50:11+00:00,Fabien Praz,http://twitter.com/,24.0,,1.3173874180986511e+18,,0.0,0.0,,RT @hahn_rt: New Technology: MitraClip G4 and PASCAL https://t.co/Rv2B0hhjS9 #TCTConnect #TCT2020 @ACCinTouch @ASE360 @TCTMD #echofirst @PS‚Ä¶,en,0.0,763.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,16.0,8.0,https://twitter.com/FabienPraz/statuses/1317387418098651136,0.0,0.0,,0.0,0.0,0.0,8.0,16.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @hahn_rt: New Technology: MitraClip G4 and PASCAL https://t.co/Rv2B0hhjS9 #TCTConnect #TCT2020 @ACCinTouch @ASE360 @TCTMD #echofirst @PS‚Ä¶,true
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-10-17 13:29:37+00:00,Cardiovascular Research Foundation,http://twitter.com/,5.0,,1.3174577407306957e+18,,0.0,0.0,,RT @suheildhanse: Amazing innovation! Nothing but the best at #TCTConnect #TCT2020 https://t.co/ldUCSjNJgn,en,0.0,12239.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,1.0,https://twitter.com/crfheart/statuses/1317457740730695684,0.0,0.0,,0.0,0.0,0.0,1.0,4.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @suheildhanse: Amazing innovation! Nothing but the best at #TCTConnect #TCT2020 https://t.co/ldUCSjNJgn,true
suheildhanse,"Interventional Cardiologist, 
Assistant Prof., MGM Medical College, Navi Mumbai, 
#Manipal Alum 
#Cardiotwitter 
#Radialfirst 
üáÆüá≥üáßüá≠",,"Navi Mumbai, India",,2020-10-17 05:50:10+00:00,Suheil Dhanse,http://twitter.com/,1.0,,1.317342117174403e+18,,0.0,0.0,,Amazing innovation! Nothing but the best at #TCTConnect #TCT2020 https://t.co/ldUCSjNJgn,en,0.0,709.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/suheildhanse/statuses/1317342117174403074,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,Amazing innovation! Nothing but the best at #TCTConnect #TCT2020 https://t.co/ldUCSjNJgn,false
chadialraies,Heart doctor @DMC_Heals Clinician researcher educator #CHIP #PAD #RadialFirst - Founder: https://t.co/CRHKx6HNVb Pub: https://t.co/h3aHzr1oGU -Tweet=my opinion,,"Detroit, MI",,2020-10-17 13:02:10+00:00,"M Chadi Alraies, MD FACC",http://twitter.com/,3.0,,1.3174508333872046e+18,,0.0,0.0,,RT @TCTConference: Take a break from world-class education to network and engage with industry partners at our Engagement Hub during #TCTCo‚Ä¶,en,0.0,21440.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,2.0,1.0,https://twitter.com/chadialraies/statuses/1317450833387204609,0.0,0.0,,0.0,0.0,0.0,1.0,2.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,RT @TCTConference: Take a break from world-class education to network and engage with industry partners at our Engagement Hub during #TCTCo‚Ä¶,true
KellyMi06345321,"Wife| Mother of 3| Sister| Daughter| Cook| Runner| RN BSN| Proud & Privileged to work for Abiomed as Dir, US Physician Programs| Tweets are my own",,"Delafield, WI",,2020-10-20 09:13:42+00:00,Kelly Miller,http://twitter.com/,43.0,,1.3184805013012562e+18,,0.0,0.0,,"RT @AGoldsweig: @Babar_Basir, @BillONeillMD, &amp; @Mike_Hacala lead the virtual #NCSI investigators meeting after #TCT2020. 

So exciting to s‚Ä¶",en,0.0,301.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,37.0,6.0,https://twitter.com/KellyMi06345321/statuses/1318480501301256194,0.0,0.0,,0.0,0.0,0.0,6.0,37.0,False,False,False,False,True,Financial Performance,1.0,0.0,0.0,"RT @AGoldsweig: @Babar_Basir, @BillONeillMD, &amp; @Mike_Hacala lead the virtual #NCSI investigators meeting after #TCT2020. 

So exciting to s‚Ä¶",true
CBCIDocs,Thoughts and perspectives from the hematology and transplant physicians at Colorado Blood Cancer Institute @ColoradoBlood @SarahCannonDocs @PresStLukesDenv,,"Denver, CO",,2020-10-23 16:34:40+00:00,CBCI,http://twitter.com/,16.0,,1.319678639051518e+18,,0.0,0.0,,"RT @ASH_hematology: #ASH20 is right around the corner! Watch our video to see the unique features of our innovative, virtual platform. üñ•Ô∏èüì±üíª‚Ä¶",en,0.0,782.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,11.0,5.0,https://twitter.com/CBCIDocs/statuses/1319678639051517953,0.0,0.0,,0.0,0.0,0.0,5.0,11.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"RT @ASH_hematology: #ASH20 is right around the corner! Watch our video to see the unique features of our innovative, virtual platform. üñ•Ô∏èüì±üíª‚Ä¶",true
erodcauCCV,"Padre, esposo, hijo,hermano, amigo, m√©dico, cirujano, doctor, futbolista...MD, PhD, FETCS",,"Sevilla, Espa√±a",,2020-10-17 07:51:00+00:00,Emiliano Rodr√≠guez,http://twitter.com/,4.0,,1.317372525685461e+18,,0.0,0.0,,"RT @Argenscore: MEDICARE TAVR PATIENTS
Mentias et al.
142825 patients
Follow up: 297 days.

INCIDENCE OF ACUTE CORONARY SYNDROME AFTER TAVR‚Ä¶",en,0.0,549.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,1.0,https://twitter.com/erodcauCCV/statuses/1317372525685460992,0.0,0.0,,0.0,0.0,0.0,1.0,3.0,False,False,False,False,True,Insurance Coverage,0.0,0.0,1.0,"RT @Argenscore: MEDICARE TAVR PATIENTS
Mentias et al.
142825 patients
Follow up: 297 days.

INCIDENCE OF ACUTE CORONARY SYNDROME AFTER TAVR‚Ä¶",true
gbiondizoccai,"Academic interventional cardiologist, data scientist, & medical writer/reviewer/editor.
All opinions own, (re)tweets/likes not endorsements nor medical advice.",,"Rome, Italy",,2020-10-15 14:16:19+00:00,Giuseppe Biondi-Zoccai,http://twitter.com/,61.0,,1.3167447177371034e+18,,0.0,0.0,,RT @heartdoc45: Loving the current live case at #TCTConnect! Challenging calcified PCI with Impella support. Excellent panel and @DrBillLom‚Ä¶,en,0.0,1321.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,51.0,10.0,https://twitter.com/gbiondizoccai/statuses/1316744717737103366,0.0,0.0,,0.0,0.0,0.0,10.0,51.0,False,False,False,False,True,Cost of Care,1.0,0.0,0.0,RT @heartdoc45: Loving the current live case at #TCTConnect! Challenging calcified PCI with Impella support. Excellent panel and @DrBillLom‚Ä¶,true
VijayKunadian,Academic Interventional Cardiologist | Heart Disease Researcher @UniofNewcastle @NewcastleHosps | Views here are my own opinion & thinking üòä,,"Newcastle Upon Tyne, England",,2020-10-15 16:12:11+00:00,Vijay Kunadian,http://twitter.com/,0.0,,1.3167738791305871e+18,,0.0,0.0,,Many congratulations to all investigators in the 3 great structural studies &amp; the curiosity &amp; progress in valvular‚Ä¶ https://t.co/bUSOR7pKAU,en,0.0,3389.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/VijayKunadian/statuses/1316773879130587137,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Financial Performance,1.0,0.0,0.0,Many congratulations to all investigators in the 3 great structural studies &amp; the curiosity &amp; progress in valvular‚Ä¶ https://t.co/bUSOR7pKAU,false
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-10-15 13:02:21+00:00,Cardiovascular Research Foundation,http://twitter.com/,1.0,,1.3167261023212298e+18,,0.0,0.0,,Take a break from world-class education to network and engage with industry partners at our Engagement Hub during‚Ä¶ https://t.co/CB0dkyn5QF,en,0.0,12239.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/crfheart/statuses/1316726102321229824,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,Take a break from world-class education to network and engage with industry partners at our Engagement Hub during‚Ä¶ https://t.co/CB0dkyn5QF,true
Hragy,"Cardiologist, National Heart Institute, Egypt ÿ±ÿ¨ÿßÿ° ÿπÿØŸÖ ÿßŸÑÿ™ŸàÿßÿµŸÑ ÿ®ÿ¥ÿ£ŸÜ ÿ¥ÿ§ŸàŸÜ ÿ∑ÿ®Ÿäÿ© ÿÆÿßÿµÿ© ÿπŸÑŸä ÿ™ŸàŸäÿ™ÿ±",,egypt,,2020-10-15 20:04:37+00:00,Hany Ragy,http://twitter.com/,0.0,,1.3168323719001334e+18,,0.0,0.0,,"Father and Son team Bill and Brian O‚ÄôNeill from Henry Ford and a Watchman Flex live case, after their other planned‚Ä¶ https://t.co/31sOeJw9Ze",en,0.0,31448.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/Hragy/statuses/1316832371900133387,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Cost of Care,0.0,0.0,1.0,"Father and Son team Bill and Brian O‚ÄôNeill from Henry Ford and a Watchman Flex live case, after their other planned‚Ä¶ https://t.co/31sOeJw9Ze",true
seyi_dr,"MD MPH FACC FSCAI. Interventional Cardiologist. Inova Fairfax, Sentara, MWH. alum @Johnshopkins @columbiamed etc. Global health enthusiast. tweets= my opinion.",,"Virginia, USA",,2020-10-15 12:02:42+00:00,Seyi Bolorunduro MD MPH,http://twitter.com/,36.0,,1.316711091997741e+18,,0.0,0.0,,RT @ajaykirtane: Really excited moderating with Bill Lombardi two GREAT coronary cases from @DKarmpaliotis and @KAlaswadMD in the main aren‚Ä¶,en,0.0,1505.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,35.0,1.0,https://twitter.com/seyi_dr/statuses/1316711091997741057,0.0,0.0,,0.0,0.0,0.0,1.0,35.0,False,False,False,False,True,Cost of Care,1.0,0.0,0.0,RT @ajaykirtane: Really excited moderating with Bill Lombardi two GREAT coronary cases from @DKarmpaliotis and @KAlaswadMD in the main aren‚Ä¶,true
TharushaGunawa4,Cardiologist. @Heart_BMJ Digital Media Intern. Thaththa to Lily and Eran and husband to Jo. Hobbies: Cultivating mass/memes. he/him.,,"Norwich, England",,2020-10-15 07:41:25+00:00,Tharusha Gunawardena,http://twitter.com/,75.0,,1.3166453406579794e+18,,0.0,0.0,,RT @TomJFord: 48M Recurrent NSTEMI without obstructive disease. Men can also have MINOCA. Invasive functional testing provides a diagnosis!‚Ä¶,en,0.0,1975.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,62.0,13.0,https://twitter.com/TharushaGunawa4/statuses/1316645340657979392,0.0,0.0,,0.0,0.0,0.0,13.0,62.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @TomJFord: 48M Recurrent NSTEMI without obstructive disease. Men can also have MINOCA. Invasive functional testing provides a diagnosis!‚Ä¶,true
ajaykirtane,"Practicing Cardiologist, Professor @ColumbiaMed
Researcher & advocate for thoughtful patient care; tweets‚â†endorsements nor med advice
https://t.co/YyilZMYayJ",,NewYork-Presbyterian & beyond,,2020-10-15 11:24:26+00:00,Ajay Kirtane MD SM,http://twitter.com/,1.0,,1.3167014615486095e+18,,0.0,0.0,,Really excited moderating with Bill Lombardi two GREAT coronary cases from @DKarmpaliotis and @KAlaswadMD in the ma‚Ä¶ https://t.co/UJhhS5G9pO,en,0.0,17044.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/ajaykirtane/statuses/1316701461548609536,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Cost of Care,1.0,0.0,0.0,Really excited moderating with Bill Lombardi two GREAT coronary cases from @DKarmpaliotis and @KAlaswadMD in the ma‚Ä¶ https://t.co/UJhhS5G9pO,true
iWhoob,"üá∏üá¶ Intern, Proud CVT ü´Ä, and future interventional cardiologist, a gamer who also loves movies, TV, and books. P.S. my colleagues call me Grandpa üë®üèª‚Äçü¶≥",,"Cath lab,Saudi Arabia, Riyadh ",,2020-10-15 08:56:39+00:00,Abdulwahab Al-Sarhan,http://twitter.com/,75.0,,1.3166642715400192e+18,,0.0,0.0,,RT @TomJFord: 48M Recurrent NSTEMI without obstructive disease. Men can also have MINOCA. Invasive functional testing provides a diagnosis!‚Ä¶,en,0.0,896.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,62.0,13.0,https://twitter.com/iWhoob/statuses/1316664271540019201,0.0,0.0,,0.0,0.0,0.0,13.0,62.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @TomJFord: 48M Recurrent NSTEMI without obstructive disease. Men can also have MINOCA. Invasive functional testing provides a diagnosis!‚Ä¶,false
kevinmb01,MD - Internal Medicine  - Chess Player,,,,2020-12-05 22:56:03+00:00,Kevin Mora Ba√±os,http://twitter.com/,76.0,,1.3353572951281418e+18,,0.0,0.0,,"RT @Mohty_EBMT: Natural history of myeloma. More than ever, We need to optimize/succeed frontline and 1st relapse therapy because both phas‚Ä¶",en,0.0,931.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,56.0,20.0,https://twitter.com/kevinmb01/statuses/1335357295128141830,0.0,0.0,,0.0,0.0,0.0,20.0,56.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @Mohty_EBMT: Natural history of myeloma. More than ever, We need to optimize/succeed frontline and 1st relapse therapy because both phas‚Ä¶",true
heartdoc45,Interventional Cardiologist at @CardioInstitute; Ochsner/Scripps trained; Pearl Jam enthusiast. Views expressed are my own. #RadialFirst,,"Lafayette, Louisiana",,2020-10-13 02:19:18+00:00,"David Homan, MD",http://twitter.com/,61.0,,1.3158395003130757e+18,,0.0,0.0,,"RT @crfheart: Follow our #TCTConnect Social Media Ambassadors! With their vast experience and expertise, they‚Äôll help you get a unique pers‚Ä¶",en,0.0,6040.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,45.0,16.0,https://twitter.com/heartdoc45/statuses/1315839500313075713,0.0,0.0,,0.0,0.0,0.0,16.0,45.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,"RT @crfheart: Follow our #TCTConnect Social Media Ambassadors! With their vast experience and expertise, they‚Äôll help you get a unique pers‚Ä¶",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 23:32:48+00:00,Lisa Palacios,http://twitter.com/,12.0,,1.3353665418235494e+18,,0.0,0.0,,RT @OncLive: First-in-Human Trial Demonstrates Clinical Activity with ROR1-Directed ADC in MCL and DLBCL @MDAndersonNews @michaelwangmd #ly‚Ä¶,en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,2.0,https://twitter.com/Lisa_Palacios/statuses/1335366541823549447,0.0,0.0,,0.0,0.0,0.0,2.0,10.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @OncLive: First-in-Human Trial Demonstrates Clinical Activity with ROR1-Directed ADC in MCL and DLBCL @MDAndersonNews @michaelwangmd #ly‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-05 18:45:50+00:00,"Ritcha Saxena, MD",http://twitter.com/,53.0,,1.3352943246202757e+18,,0.0,0.0,,RT @ninashah33: Bb2121: everything you wanted to know but were too afraid to ask: Ide-cel phase 1 long term FU‚Äî&gt; DOR 2y in responders and O‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,41.0,12.0,https://twitter.com/RitchaSaxena/statuses/1335294324620275712,0.0,0.0,,0.0,0.0,0.0,12.0,41.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @ninashah33: Bb2121: everything you wanted to know but were too afraid to ask: Ide-cel phase 1 long term FU‚Äî&gt; DOR 2y in responders and O‚Ä¶,true
DevikaDasMD,"Section Chief,Thoracic Oncologist ü´Å Assoc Fellowship PD,Co-created @HOJournalclub #lcsm #QI #Safety #Mentor #ally üåà#womeninmedicine #Equity My tweets=My views",,"Birmingham AL  ",,2020-12-05 20:22:57+00:00,"Devika Das, MD, MSHQS üò∑",http://twitter.com/,8.0,,1.3353187673882665e+18,,0.0,0.0,,"RT @GeorgeGoshuaMD: An #ASH20 #healthequity highlight in ""non-malignant"" hematology. #healthequity requires affordable access to effective‚Ä¶",en,0.0,4281.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,2.0,https://twitter.com/DevikaDasMD/statuses/1335318767388266503,0.0,0.0,,0.0,0.0,0.0,2.0,6.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,"RT @GeorgeGoshuaMD: An #ASH20 #healthequity highlight in ""non-malignant"" hematology. #healthequity requires affordable access to effective‚Ä¶",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-08 14:34:47+00:00,Lisa Palacios,http://twitter.com/,14.0,,1.3363183121255014e+18,,0.0,0.0,,"RT @MDAndersonNews: Resulting in a 100% complete response rate and an 80% two-year survival rate, the chemotherapy and monoclonal antibody‚Ä¶",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,4.0,https://twitter.com/Lisa_Palacios/statuses/1336318312125501440,0.0,0.0,,0.0,0.0,0.0,4.0,10.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @MDAndersonNews: Resulting in a 100% complete response rate and an 80% two-year survival rate, the chemotherapy and monoclonal antibody‚Ä¶",false
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-05 19:03:28+00:00,"Ritcha Saxena, MD",http://twitter.com/,18.0,,1.335298761824891e+18,,0.0,0.0,,"RT @Elena_Kum: Excited to present the work of our community of practice at #ASH2020, part of a collaborative effort to improve stem cell do‚Ä¶",en,0.0,6875.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,16.0,2.0,https://twitter.com/RitchaSaxena/statuses/1335298761824890884,0.0,0.0,,0.0,0.0,0.0,2.0,16.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"RT @Elena_Kum: Excited to present the work of our community of practice at #ASH2020, part of a collaborative effort to improve stem cell do‚Ä¶",true
gjmccaughan,"Haematologist interested in plasma cell disorders Zamasa Foundation Myeloma Fellow, Kinghorn Cancer Centre, St Vincent‚Äôs Hospital, Sydney",,,,2020-12-08 03:18:03+00:00,Georgia McCaughan,http://twitter.com/,4.0,,1.3361480039129702e+18,,0.0,0.0,,"Real world analysis of 2787 European pts with AL amyloidosis: 2 cohorts 2004-2010 and 2011-2018 #ASH20.
16% Stage I‚Ä¶ https://t.co/VTAAFJ61h4",en,0.0,528.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,4.0,https://twitter.com/gjmccaughan/statuses/1336148003912970243,0.0,0.0,,0.0,0.0,0.0,4.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"Real world analysis of 2787 European pts with AL amyloidosis: 2 cohorts 2004-2010 and 2011-2018 #ASH20.
16% Stage I‚Ä¶ https://t.co/VTAAFJ61h4",true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-12-05 20:15:20+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,0.0,,1.3353168504738324e+18,,0.0,0.0,,"In discussion, speaker mentions that it takes 5 days to meet release criteria, so patients could get LD chemo durin‚Ä¶ https://t.co/UUrrB4Lx2M",en,0.0,4813.0,,,0.0,hemedoc,1.3353161901057188e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/hemedoc/statuses/1335316850473832449,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"In discussion, speaker mentions that it takes 5 days to meet release criteria, so patients could get LD chemo durin‚Ä¶ https://t.co/UUrrB4Lx2M",true
ovanoekelen,PhD student in Parekh lab @ Mount Sinai NYC studying myeloma immunology - Belgian MD - wannabe hem/onc - bioinformatics üáπüá©üá∫üá∏üá™üá∫üè≥Ô∏è‚Äçüåà,,"New York, USA",,2020-12-05 00:32:00+00:00,Oliver Van Oekelen,http://twitter.com/,2.0,,1.3350190545459855e+18,,0.0,0.0,,Love how clearly @SagarLonialMD presents the options for first relapse. Agree 100% with using the potential synergy‚Ä¶ https://t.co/tqvr3cRETp,en,0.0,352.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/ovanoekelen/statuses/1335019054545985536,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Diagnosis Progression,1.0,0.0,0.0,Love how clearly @SagarLonialMD presents the options for first relapse. Agree 100% with using the potential synergy‚Ä¶ https://t.co/tqvr3cRETp,true
sairah__ahmed,"Lymphoma/Cellular Therapy & SCT at MD Anderson Cancer Center, opinions/tweets shared= my own.",,"Houston, TX",,2020-12-05 23:21:55+00:00,Sairah Ahmed MD,http://twitter.com/,84.0,,1.3353638029095936e+18,,0.0,0.0,,"RT @hemedoc: #ASH20 #leusm Levis: I don‚Äôt know who needs to hear this, but there really is no role for intensive chemotherapy in TP53 mutat‚Ä¶",en,0.0,491.0,,,0.0,,,Negative,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,65.0,19.0,https://twitter.com/sairah__ahmed/statuses/1335363802909593605,0.0,0.0,,0.0,0.0,0.0,19.0,65.0,False,False,False,False,True,Innovation,0.0,1.0,0.0,"RT @hemedoc: #ASH20 #leusm Levis: I don‚Äôt know who needs to hear this, but there really is no role for intensive chemotherapy in TP53 mutat‚Ä¶",true
Transplant_Doc,Stem Cell Transplant physician and clinical researcher at MD Anderson Cancer Center; special interest in myeloma. Opinions expressed are my own,,,,2020-12-08 03:17:31+00:00,Muzaffar Qazilbash,http://twitter.com/,27.0,,1.3361478713730785e+18,,0.0,0.0,,"RT @VincentRK: #ASH20 IFM 2009 trial results presented by @PerrotAurore 

On intent to treat basis early and delayed stem cell transplantat‚Ä¶",en,0.0,5455.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,23.0,4.0,https://twitter.com/Transplant_Doc/statuses/1336147871373078528,0.0,0.0,,0.0,0.0,0.0,4.0,23.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @VincentRK: #ASH20 IFM 2009 trial results presented by @PerrotAurore 

On intent to treat basis early and delayed stem cell transplantat‚Ä¶",false
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-05 20:36:58+00:00,"Ritcha Saxena, MD",http://twitter.com/,1.0,,1.33532229388356e+18,,0.0,0.0,,RT @feldstej: CHIPing Away at the Hematopoietic Stem Cell Niche https://t.co/JZ8JuXjt5D #ASH20 #ASH2020 #ASHFromHome #ASHTogether #ASHKudos‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/RitchaSaxena/statuses/1335322293883559938,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @feldstej: CHIPing Away at the Hematopoietic Stem Cell Niche https://t.co/JZ8JuXjt5D #ASH20 #ASH2020 #ASHFromHome #ASHTogether #ASHKudos‚Ä¶,true
weldeiry,Physician-Scientist; Translational Oncologist; Associate Dean @BrownMedicine Pubs https://t.co/LBFw6qi3zW Cancer Center Director @BrownUCancer https://t.co/6eeywx4qdG,,Pennsylvania,,2020-12-05 20:41:24+00:00,"Wafik S. El-Deiry, MD, PhD, FACP",http://twitter.com/,24.0,,1.335323409773949e+18,,0.0,0.0,,RT @DanaFarberNews: A phase 1 trial found cytokine-induced memory-like NK cells exhibit expansion and long-term persistence after infusion‚Ä¶,en,0.0,8168.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,21.0,3.0,https://twitter.com/weldeiry/statuses/1335323409773948929,0.0,0.0,,0.0,0.0,0.0,3.0,21.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @DanaFarberNews: A phase 1 trial found cytokine-induced memory-like NK cells exhibit expansion and long-term persistence after infusion‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-05 18:20:32+00:00,"Ritcha Saxena, MD",http://twitter.com/,4.0,,1.3352879586272993e+18,,0.0,0.0,,"RT @amarkelkar: Phase II Trial of Cladribine/LDAC+Venetoclax in Older Adults presented by Dr.@TapKadia.
-Median OS not yet reached
-1-year‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,2.0,2.0,https://twitter.com/RitchaSaxena/statuses/1335287958627299332,0.0,0.0,,0.0,0.0,0.0,2.0,2.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @amarkelkar: Phase II Trial of Cladribine/LDAC+Venetoclax in Older Adults presented by Dr.@TapKadia.
-Median OS not yet reached
-1-year‚Ä¶",true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-12-05 20:38:13+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,2.0,,1.3353226090098442e+18,,0.0,0.0,,"#ASH20 #bmtsm Zhang: 37 recipients of donor-derived anti-CD19 donors, 28 after post-allo relapse. 4/24 have relapse‚Ä¶ https://t.co/o5g03EHbbZ",en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/hemedoc/statuses/1335322609009844224,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"#ASH20 #bmtsm Zhang: 37 recipients of donor-derived anti-CD19 donors, 28 after post-allo relapse. 4/24 have relapse‚Ä¶ https://t.co/o5g03EHbbZ",true
csernatamayo_md,"Med Onc Fellow in Bethesda, MD; Former Fellow @MSHSGeriPalCare; Research Alum @sloan_kettering; MD @Rutgers_NJMS; BS @Cornell; HS @hchs4diversity üá®üá¥üè≥Ô∏è‚Äçüåàüá∫üá∏",,"Washington, DC",,2020-12-05 15:00:46+00:00,"Cristian Serna Tamayo, MD",http://twitter.com/,0.0,,1.3352376876877005e+18,,0.0,0.0,,Who's ready for the fireside chat with Dr. Fauci re: the effects the SARS-CoV2 infection has had on hematologic con‚Ä¶ https://t.co/MCLAMgDAjA,en,0.0,502.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/csernatamayo_md/statuses/1335237687687700483,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,Who's ready for the fireside chat with Dr. Fauci re: the effects the SARS-CoV2 infection has had on hematologic con‚Ä¶ https://t.co/MCLAMgDAjA,true
AndreaAnampaG,"Medstudent @UNMSM_ with OCD ‚Ä¢ @ASCO & @AMWAdoctors Social Media
@CPsolvers Team Member ‚Ä¢ #Globaloncology #WomenInMedicine #MedEd #SurvOnc üáµüá™ #IMG üåà she/ella",,"Lima, Peru",,2020-12-05 01:18:01+00:00,Andrea Anampa-Guzm√°n,http://twitter.com/,37.0,,1.3350306320623163e+18,,0.0,0.0,,RT @acweyand: So important to work with our #Transgender patients and engage in shared decision making to ensure they can proceed with thei‚Ä¶,en,0.0,1908.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,32.0,5.0,https://twitter.com/AndreaAnampaG/statuses/1335030632062316545,0.0,0.0,,0.0,0.0,0.0,5.0,32.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @acweyand: So important to work with our #Transgender patients and engage in shared decision making to ensure they can proceed with thei‚Ä¶,false
HoratiuOlteanu,"Hematopathologist. Chair, @MayoClinicPath #Hemepath Myeloid Working Group. @UNLincoln alumnus and #Huskers enthusiast. Opinions are mine.",,"Rochester, MN",,2020-12-05 17:00:33+00:00,Horatiu Olteanu,http://twitter.com/,47.0,,1.335267831127085e+18,,0.0,0.0,,RT @MrinalPatnaik: Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes| Join me at #ASH2020 as I discuss gen‚Ä¶,en,0.0,1622.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,40.0,7.0,https://twitter.com/HoratiuOlteanu/statuses/1335267831127085056,0.0,0.0,,0.0,0.0,0.0,7.0,40.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @MrinalPatnaik: Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes| Join me at #ASH2020 as I discuss gen‚Ä¶,true
EghtedarAli,Oncologist & bone marrow transplant physician working at Colorado Blood Cancer Center in Denver since 2015,,,,2020-12-05 22:24:39+00:00,Ali Eghtedar,http://twitter.com/,2.0,,1.3353493918095237e+18,,0.0,0.0,,Strong data by MDACC BMT group: randomized phase III study of clofarabine plus Flu/Bu conditioning vs Flu/Bu in AML‚Ä¶ https://t.co/1eGT92BuvQ,en,0.0,50.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/EghtedarAli/statuses/1335349391809523719,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,Strong data by MDACC BMT group: randomized phase III study of clofarabine plus Flu/Bu conditioning vs Flu/Bu in AML‚Ä¶ https://t.co/1eGT92BuvQ,true
fniainle,"Haematologist, passionate about VTE. Co-director @ConwaySphere; Director https://t.co/csdWq9XJ57; RT not endorsement, views my own",,"Dublin City, Ireland",,2020-12-05 18:19:27+00:00,Fionnuala N√≠ √Åinle,http://twitter.com/,25.0,,1.3352876880108708e+18,,0.0,0.0,,"RT @crowley_maeve: Great session by ‚Å¶@fniainle‚Å©,‚Å¶@Erik_Klok_MD‚Å© and ‚Å¶@WeeShianChan‚Å© regarding diagnostic and prognostic models in vte manag‚Ä¶",en,0.0,2069.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,22.0,3.0,https://twitter.com/fniainle/statuses/1335287688010870785,0.0,0.0,,0.0,0.0,0.0,3.0,22.0,False,False,False,False,True,Diagnostic Tools,1.0,0.0,0.0,"RT @crowley_maeve: Great session by ‚Å¶@fniainle‚Å©,‚Å¶@Erik_Klok_MD‚Å© and ‚Å¶@WeeShianChan‚Å© regarding diagnostic and prognostic models in vte manag‚Ä¶",true
NBahlis,"Physician-scientist focused on multiple myeloma
Tweets are my own.",,,,2020-12-05 21:22:44+00:00,nizar jacques bahlis,http://twitter.com/,0.0,,1.3353338095757394e+18,,0.0,0.0,,@HJChoMDPhD1 @ASH_hematology @theMMRF One of the side effects of this virtual #ASH20 is weight gain instead of loos‚Ä¶ https://t.co/cmyAqyldjO,en,0.0,436.0,,,0.0,HJChoMDPhD1,1.335331585701372e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/NBahlis/statuses/1335333809575739392,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,@HJChoMDPhD1 @ASH_hematology @theMMRF One of the side effects of this virtual #ASH20 is weight gain instead of loos‚Ä¶ https://t.co/cmyAqyldjO,true
AndreaAnampaG,"Medstudent @UNMSM_ with OCD ‚Ä¢ @ASCO & @AMWAdoctors Social Media
@CPsolvers Team Member ‚Ä¢ #Globaloncology #WomenInMedicine #MedEd #SurvOnc üáµüá™ #IMG üåà she/ella",,"Lima, Peru",,2020-12-05 21:30:38+00:00,Andrea Anampa-Guzm√°n,http://twitter.com/,20.0,,1.335335799945093e+18,,0.0,0.0,,"RT @doctorpemm: #ASH20 AML oral presentation session. Fantastic talk phase I, 2 arm study (Prior SCT vs no prior SCT) Dec+IPI in patients w‚Ä¶",en,0.0,1908.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,14.0,6.0,https://twitter.com/AndreaAnampaG/statuses/1335335799945093121,0.0,0.0,,0.0,0.0,0.0,6.0,14.0,False,False,False,False,True,Clinical Trials,1.0,0.0,0.0,"RT @doctorpemm: #ASH20 AML oral presentation session. Fantastic talk phase I, 2 arm study (Prior SCT vs no prior SCT) Dec+IPI in patients w‚Ä¶",true
drjsporter,Licensed Psychologist | Sickle Cell Researcher @stjuderesearch | Alum @UVA @FloridaState @VCU @NUFeinbergMed | Tweets are my own.,,"Memphis, TN",,2020-12-05 15:43:10+00:00,"Dr. Jerlym Porter, PhD",http://twitter.com/,23.0,,1.3352483578041713e+18,,0.0,0.0,,"RT @BPitel12: If we‚Äôre going to really crush this pandemic, it will be with global and equitable efforts.  This was a fabulous discussion!‚Ä¶",en,0.0,447.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,19.0,4.0,https://twitter.com/drjsporter/statuses/1335248357804171265,0.0,0.0,,0.0,0.0,0.0,4.0,19.0,False,False,False,False,True,Covid,1.0,0.0,0.0,"RT @BPitel12: If we‚Äôre going to really crush this pandemic, it will be with global and equitable efforts.  This was a fabulous discussion!‚Ä¶",false
Lachelle_Dawn,heme-onc fellow | physician-scientist | racial justice & health equity | views are mine | there will be typos | i tweet what i want | pronouns: she/her/hers,,"Boston, MA",,2020-12-05 19:59:50+00:00,Lachelle Dawn,http://twitter.com/,0.0,,1.3353129466841948e+18,,0.0,0.0,,"Ok this is happening now :) 

#RaceAndScience #DiversityandInclusion 
#Innovation
#ASH20 https://t.co/9SehmxPKIZ",en,0.0,3338.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/Lachelle_Dawn/statuses/1335312946684194816,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"Ok this is happening now :) 

#RaceAndScience #DiversityandInclusion 
#Innovation
#ASH20 https://t.co/9SehmxPKIZ",true
ouholter,"Proud Oklahoma hematologist, wife, BMT physician, researcher, sooner, mom, loyal friend, thunder fan, and so proud of two amazing daughters! Tweets my own.",,"Oklahoma City, OK",,2020-12-05 19:24:13+00:00,J Holter Chakrabarty,http://twitter.com/,2.0,,1.335303984412758e+18,,0.0,0.0,,RT @TaniaJain11: A forward-looking #MPN oral abstract session #ASH20 - super-exciting to see these drugs move forward. I‚Äôm just going to th‚Ä¶,en,0.0,309.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,1.0,1.0,https://twitter.com/ouholter/statuses/1335303984412758018,0.0,0.0,,0.0,0.0,0.0,1.0,1.0,False,False,False,False,True,Thought Leadership,0.0,0.0,1.0,RT @TaniaJain11: A forward-looking #MPN oral abstract session #ASH20 - super-exciting to see these drugs move forward. I‚Äôm just going to th‚Ä¶,true
AmitKulkarniMD,"Assistant Professor, Hematology & Oncology, @UMNCancer | Thoracic Oncologist | Translational research, Microbiome, Clinical trials | No FCOI",,"Minneapolis, MN",,2020-12-05 19:02:43+00:00,Amit Kulkarni,http://twitter.com/,24.0,,1.3352985760590848e+18,,0.0,0.0,,RT @RosovskyRachel: Grateful for opportunity to work with CCC19 thrombosis team on this important topic. Tune #ASH20 Abst 204 today; 12 pm‚Ä¶,en,0.0,867.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,19.0,5.0,https://twitter.com/AmitKulkarniMD/statuses/1335298576059084802,0.0,0.0,,0.0,0.0,0.0,5.0,19.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @RosovskyRachel: Grateful for opportunity to work with CCC19 thrombosis team on this important topic. Tune #ASH20 Abst 204 today; 12 pm‚Ä¶,true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 13:01:21+00:00,Lisa Palacios,http://twitter.com/,45.0,,1.3352076352898294e+18,,0.0,0.0,,"RT @ppisters: Through teamwork and pioneering research, @MDAndersonNews experts are committed to improving outcomes for patients with blood‚Ä¶",en,0.0,657.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,39.0,6.0,https://twitter.com/Lisa_Palacios/statuses/1335207635289829377,0.0,0.0,,0.0,0.0,0.0,6.0,39.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"RT @ppisters: Through teamwork and pioneering research, @MDAndersonNews experts are committed to improving outcomes for patients with blood‚Ä¶",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 20:54:41+00:00,Lisa Palacios,http://twitter.com/,7.0,,1.3353267508097434e+18,,0.0,0.0,,RT @SaudiLeukemia: CPX-351 + Ven : Phase II study . Dr Tapan Kadia from @MDAndersonNews MDACC.  #ASH20  #ASH2020 https://t.co/Aou1OOAwKs,en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,4.0,https://twitter.com/Lisa_Palacios/statuses/1335326750809743361,0.0,0.0,,0.0,0.0,0.0,4.0,3.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @SaudiLeukemia: CPX-351 + Ven : Phase II study . Dr Tapan Kadia from @MDAndersonNews MDACC.  #ASH20  #ASH2020 https://t.co/Aou1OOAwKs,true
LemaistreFred,"SVP and Physician in Chief Hematology, Sarah Cannon; past President of @FACTunmc and @ASTCT. @TexasMSD Thoughts and ideas are my own.",,"Nashville, TN",,2020-12-05 20:51:11+00:00,Fred LeMaistre,http://twitter.com/,23.0,,1.3353258729083412e+18,,0.0,0.0,,RT @BldCancerDoc: Years of multi-center effort by a large number of investigators/research staff and grateful to hundreds of patients - and‚Ä¶,en,0.0,1163.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,20.0,3.0,https://twitter.com/LemaistreFred/statuses/1335325872908341254,0.0,0.0,,0.0,0.0,0.0,3.0,20.0,False,False,False,False,True,Financial Performance,1.0,0.0,0.0,RT @BldCancerDoc: Years of multi-center effort by a large number of investigators/research staff and grateful to hundreds of patients - and‚Ä¶,false
LesokhinMD,I am an oncologist @sloan_kettering who specializes in immunotherapy and the treatment of multiple myeloma.  Tweets are mine.,,"New York, NY",,2020-12-05 16:00:01+00:00,AlexanderLesokhin MD,http://twitter.com/,62.0,,1.33525259635388e+18,,0.0,0.0,,"RT @DrMiguelPerales: Busy day today for @sloan_kettering investigators at @ASH_hematology #ASH20 Check out the schedule for talks, oral pre‚Ä¶",en,0.0,3194.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,50.0,12.0,https://twitter.com/LesokhinMD/statuses/1335252596353880065,0.0,0.0,,0.0,0.0,0.0,12.0,50.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,"RT @DrMiguelPerales: Busy day today for @sloan_kettering investigators at @ASH_hematology #ASH20 Check out the schedule for talks, oral pre‚Ä¶",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 15:46:24+00:00,Lisa Palacios,http://twitter.com/,18.0,,1.3352491705302426e+18,,0.0,0.0,,RT @doctorpemm: #ASH20 MPN oral session. Outstanding talk by Dr Kristen Pettit @kristenpettitmd #LSD1 inhibitor ph2 clinical trial #IMG7289‚Ä¶,en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,15.0,3.0,https://twitter.com/Lisa_Palacios/statuses/1335249170530242563,0.0,0.0,,0.0,0.0,0.0,3.0,15.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @doctorpemm: #ASH20 MPN oral session. Outstanding talk by Dr Kristen Pettit @kristenpettitmd #LSD1 inhibitor ph2 clinical trial #IMG7289‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-05 19:54:31+00:00,"Ritcha Saxena, MD",http://twitter.com/,2.0,,1.3353116105592586e+18,,0.0,0.0,,RT @majorajay: The YEARS algorithm leads to a large proportion of patients avoiding chest imaging to diagnose PE. LMWH is the best option f‚Ä¶,en,0.0,6875.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,1.0,1.0,https://twitter.com/RitchaSaxena/statuses/1335311610559258633,0.0,0.0,,0.0,0.0,0.0,1.0,1.0,False,False,False,False,True,Diagnostic Tools,1.0,0.0,0.0,RT @majorajay: The YEARS algorithm leads to a large proportion of patients avoiding chest imaging to diagnose PE. LMWH is the best option f‚Ä¶,true
LukeMtjoy,Hematologist and transplant physician at Colorado Blood Cancer Institute. Former hem/onc fellow @MayoClinic AZ. view and opinions are my own,,"Denver, CO",,2020-12-05 22:15:29+00:00,LukeMtjoy,http://twitter.com/,1.0,,1.3353470865653924e+18,,0.0,0.0,,Now this is really interesting. Dec10Ven compared to intensive chemo. Dec10Ven looks better. Need a true randomized‚Ä¶ https://t.co/KaBAeEQeYz,en,0.0,137.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/LukeMtjoy/statuses/1335347086565392385,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,Now this is really interesting. Dec10Ven compared to intensive chemo. Dec10Ven looks better. Need a true randomized‚Ä¶ https://t.co/KaBAeEQeYz,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-05 18:23:19+00:00,"Ritcha Saxena, MD",http://twitter.com/,4.0,,1.3352886592313057e+18,,0.0,0.0,,RT @RahulBanerjeeMD: I will say - the classical music playing at ASH leading up to plenary sessions sounds MUCH more - allegro - when it's‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,1.0,https://twitter.com/RitchaSaxena/statuses/1335288659231305737,0.0,0.0,,0.0,0.0,0.0,1.0,3.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @RahulBanerjeeMD: I will say - the classical music playing at ASH leading up to plenary sessions sounds MUCH more - allegro - when it's‚Ä¶,true
Vchang_lab,"Pediatric oncologist focusing on blood stem cells, aging and cancer susceptibility @ucla. Views are my own. she/her/hers. Personal account @v_e_e_e_e",,,,2020-12-05 16:00:04+00:00,"Vivian Y Chang, MD, MS",http://twitter.com/,0.0,,1.3352526105598405e+18,,0.0,0.0,,Learning about the extrinsic regulation of hematopoietic stem cell emergence and homeostasis. Great discussions!‚Ä¶ https://t.co/6PMlvCPeyD,en,0.0,464.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/Vchang_lab/statuses/1335252610559840257,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,Learning about the extrinsic regulation of hematopoietic stem cell emergence and homeostasis. Great discussions!‚Ä¶ https://t.co/6PMlvCPeyD,false
bloodgenes,"Pediatric Hematologist/Oncologist, Geneticist, Stem Cell Biologist - @DFBC_PedCare, @BostonChildrens, @DanaFarber & @broadinstitute",,"Boston, MA",,2020-12-05 15:07:11+00:00,Vijay Sankaran,http://twitter.com/,0.0,,1.3352393002633175e+18,,0.0,0.0,,Such valuable insights on the #COVID19 pandemic from Dr. Fauci at #ASH20! https://t.co/Fq96HtEZqA,en,0.0,4057.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/bloodgenes/statuses/1335239300263317505,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Covid,0.0,0.0,1.0,Such valuable insights on the #COVID19 pandemic from Dr. Fauci at #ASH20! https://t.co/Fq96HtEZqA,true
mshadman,"Associate Professor,  Fred Hutchinson, U of Washington. Lymphoma/CLL oncologist.  Tweets are mine.",,"Seattle, WA",,2020-12-05 19:00:01+00:00,"Mazyar Shadman, MD MPH",http://twitter.com/,21.0,,1.3352978937505587e+18,,0.0,0.0,,RT @UjjaniC: #ASH president @StephanieLeeMD from @SeattleCCA @fredhutch leading an amazing chat on #COVID19 with Dr. Fauci. #ASH20 #ASH2020‚Ä¶,en,0.0,927.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,15.0,6.0,https://twitter.com/mshadman/statuses/1335297893750558720,0.0,0.0,,0.0,0.0,0.0,6.0,15.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @UjjaniC: #ASH president @StephanieLeeMD from @SeattleCCA @fredhutch leading an amazing chat on #COVID19 with Dr. Fauci. #ASH20 #ASH2020‚Ä¶,true
CanerSaygin,"Heme-Onc Fellow @UChicago | Alumni of @OhioStateIMRes, @CCLRI | #Leukemia, #MDS, #CHIP physician-scientist. Tweets=own opinions.",,"Chicago, IL",,2020-12-05 15:41:29+00:00,"Caner Saygin, MD",http://twitter.com/,1.0,,1.3352479322500014e+18,,0.0,0.0,,AML clinical abstracts are live: Dr Keith Pratz presenting phase I data on the safety and feasibility of combining‚Ä¶ https://t.co/wd6dBuKsbe,en,0.0,743.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/CanerSaygin/statuses/1335247932250001408,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,AML clinical abstracts are live: Dr Keith Pratz presenting phase I data on the safety and feasibility of combining‚Ä¶ https://t.co/wd6dBuKsbe,true
DrDanPersky,"#lymphoma and #CLL specialist, Assoc Dir of Clinical Investigations @UAZCancer. Tweets are my own. Physician ‚â† Provider.",,"Tucson, AZ",,2020-12-05 22:31:02+00:00,"Daniel Persky, MD",http://twitter.com/,21.0,,1.3353510005430843e+18,,0.0,0.0,,"RT @Jessica_Okosun: #ASH20 1108 Quivoron et al - Genetic profiles of relapsed, refractory #DLBCL 
- enriched in TP53 &amp; epigenetic muts echo‚Ä¶",en,0.0,349.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,16.0,5.0,https://twitter.com/DrDanPersky/statuses/1335351000543084547,0.0,0.0,,0.0,0.0,0.0,5.0,16.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @Jessica_Okosun: #ASH20 1108 Quivoron et al - Genetic profiles of relapsed, refractory #DLBCL 
- enriched in TP53 &amp; epigenetic muts echo‚Ä¶",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 17:42:41+00:00,Lisa Palacios,http://twitter.com/,7.0,,1.3352784325367194e+18,,0.0,0.0,,RT @ThiloZander: Efficacy of LOXO-305 in relapsed Mantle Cell Lymphoma. Responses seen in patients already treated with BTKi. Cool. Congrat‚Ä¶,en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,2.0,https://twitter.com/Lisa_Palacios/statuses/1335278432536719366,0.0,0.0,,0.0,0.0,0.0,2.0,5.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @ThiloZander: Efficacy of LOXO-305 in relapsed Mantle Cell Lymphoma. Responses seen in patients already treated with BTKi. Cool. Congrat‚Ä¶,true
PAMJ84,Ronin Haematologist,,Europe,,2020-12-05 20:28:26+00:00,P. A-M,http://twitter.com/,24.0,,1.3353201467941317e+18,,0.0,0.0,,RT @VincentRK: Myeloma Future State: New drugs bring challenges and opportunities. We could very well have triple-class refractoriness in 1‚Ä¶,en,0.0,110.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,18.0,6.0,https://twitter.com/PAMJ84/statuses/1335320146794131460,0.0,0.0,,0.0,0.0,0.0,6.0,18.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @VincentRK: Myeloma Future State: New drugs bring challenges and opportunities. We could very well have triple-class refractoriness in 1‚Ä¶,false
HendrikPoeck,"Physician scientist, Stem cell transplantation, Immuno-Oncology, Microbiome @ University Hospital Regensburg",,Germany,,2020-12-05 18:15:53+00:00,"Hendrik Poeck, MD",http://twitter.com/,0.0,,1.3352867872085156e+18,,0.0,0.0,,Fantastic session today on Challenges in Cell Therapy: Relapse and Toxicities #ASH20,en,0.0,47.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/HendrikPoeck/statuses/1335286787208515584,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnosis Progression,1.0,0.0,0.0,Fantastic session today on Challenges in Cell Therapy: Relapse and Toxicities #ASH20,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-05 19:55:41+00:00,"Ritcha Saxena, MD",http://twitter.com/,8.0,,1.335311905297232e+18,,0.0,0.0,,"RT @OncLive: Navitoclax/Ruxolitinib Combo Improves Spleen Volume, Symptoms in Relapsed/Refractory Myelofibrosis @doctorpemm @MDAndersonNews‚Ä¶",ro,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,3.0,https://twitter.com/RitchaSaxena/statuses/1335311905297231873,0.0,0.0,,0.0,0.0,0.0,3.0,5.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @OncLive: Navitoclax/Ruxolitinib Combo Improves Spleen Volume, Symptoms in Relapsed/Refractory Myelofibrosis @doctorpemm @MDAndersonNews‚Ä¶",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 23:31:46+00:00,Lisa Palacios,http://twitter.com/,9.0,,1.3353662849476772e+18,,0.0,0.0,,"RT @VJHemOnc: Highlights from #MPNsm new therapies &amp; JAKi based combinations for #Myelofibrosis orals at #ASH20

Srdan Verstovesk presented‚Ä¶",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,3.0,https://twitter.com/Lisa_Palacios/statuses/1335366284947677184,0.0,0.0,,0.0,0.0,0.0,3.0,6.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @VJHemOnc: Highlights from #MPNsm new therapies &amp; JAKi based combinations for #Myelofibrosis orals at #ASH20

Srdan Verstovesk presented‚Ä¶",true
CanerSaygin,"Heme-Onc Fellow @UChicago | Alumni of @OhioStateIMRes, @CCLRI | #Leukemia, #MDS, #CHIP physician-scientist. Tweets=own opinions.",,"Chicago, IL",,2020-12-05 20:12:32+00:00,"Caner Saygin, MD",http://twitter.com/,3.0,,1.3353161442873098e+18,,0.0,0.0,,Dr Abedin presenting phase I data on combination of lintuzumab (radiolabeled anti-CD33) with CLAG-M in R/R #AML pts‚Ä¶ https://t.co/zqPt0DuY8V,en,0.0,743.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/CanerSaygin/statuses/1335316144287309827,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,Dr Abedin presenting phase I data on combination of lintuzumab (radiolabeled anti-CD33) with CLAG-M in R/R #AML pts‚Ä¶ https://t.co/zqPt0DuY8V,true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 23:01:28+00:00,Lisa Palacios,http://twitter.com/,4.0,,1.3353586563014533e+18,,0.0,0.0,,"RT @EghtedarAli: Strong data by MDACC BMT group: randomized phase III study of clofarabine plus Flu/Bu conditioning vs Flu/Bu in AML/MDS
#A‚Ä¶",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,2.0,2.0,https://twitter.com/Lisa_Palacios/statuses/1335358656301453314,0.0,0.0,,0.0,0.0,0.0,2.0,2.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"RT @EghtedarAli: Strong data by MDACC BMT group: randomized phase III study of clofarabine plus Flu/Bu conditioning vs Flu/Bu in AML/MDS
#A‚Ä¶",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 16:43:54+00:00,Lisa Palacios,http://twitter.com/,12.0,,1.3352636388951368e+18,,0.0,0.0,,RT @CanerSaygin: Phase II data on CPX-351 + venetoclax in newly diagnosed and R/R AML (38% with TP53m) by Dr Kadia. This combo is quite tox‚Ä¶,en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,2.0,https://twitter.com/Lisa_Palacios/statuses/1335263638895136769,0.0,0.0,,0.0,0.0,0.0,2.0,10.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @CanerSaygin: Phase II data on CPX-351 + venetoclax in newly diagnosed and R/R AML (38% with TP53m) by Dr Kadia. This combo is quite tox‚Ä¶,false
noriega_dr,"MD, PhD. Hematologist in CHUAC (A Coru√±a-Spain). Leukemia and Bone Marrow Transplantation. Tweets and opinions are mine.",,,,2020-12-05 16:08:50+00:00,Dr Victor Noriega,http://twitter.com/,36.0,,1.3352548150189875e+18,,0.0,0.0,,RT @razan_mohty: Data from @LeukemiaMDA on VEN with Cladribine/LDAC alternating with azacitidine in newly diagnosed older #AML by Dr @TapKa‚Ä¶,en,0.0,959.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,27.0,9.0,https://twitter.com/noriega_dr/statuses/1335254815018987520,0.0,0.0,,0.0,0.0,0.0,9.0,27.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @razan_mohty: Data from @LeukemiaMDA on VEN with Cladribine/LDAC alternating with azacitidine in newly diagnosed older #AML by Dr @TapKa‚Ä¶,true
pattymondello,"Advanced oncology fellow, Physician-Scientist, lymphoma researcher @sloan_kettering working on #lymphoma",,"Manhattan, NY",,2020-12-06 16:05:37+00:00,"Patrizia Mondello, MD, PhD, MSc",http://twitter.com/,22.0,,1.3356163921550664e+18,,0.0,0.0,,RT @DrMiguelPerales: Another busy day for @sloan_kettering investigators at #ASH20 @DrMvandenBrink @sgiraltbmtdoc @gilles_salles @MartinTal‚Ä¶,en,0.0,206.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,18.0,4.0,https://twitter.com/pattymondello/statuses/1335616392155066374,0.0,0.0,,0.0,0.0,0.0,4.0,18.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,RT @DrMiguelPerales: Another busy day for @sloan_kettering investigators at #ASH20 @DrMvandenBrink @sgiraltbmtdoc @gilles_salles @MartinTal‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 21:33:14+00:00,"Ritcha Saxena, MD",http://twitter.com/,85.0,,1.3356988425583534e+18,,0.0,0.0,,RT @ASH_hematology: Calling all #ASH20 attendees: Use our featured hashtags to be üåü featured üåü on the Community Collage of the virtual meet‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,69.0,16.0,https://twitter.com/RitchaSaxena/statuses/1335698842558353408,0.0,0.0,,0.0,0.0,0.0,16.0,69.0,False,False,False,False,True,Disease Advocacy,0.0,0.0,1.0,RT @ASH_hematology: Calling all #ASH20 attendees: Use our featured hashtags to be üåü featured üåü on the Community Collage of the virtual meet‚Ä¶,true
Daniel_DT15,DC | @uprrp ‚Äò19 üêîüáµüá∑| NIH IRTA Postbac | Aspiring physician | Opinions my own | he/him/el,,,,2020-12-06 22:23:01+00:00,Daniel,http://twitter.com/,185.0,,1.3357113688052982e+18,,0.0,0.0,,"RT @AlejoFraticelli: Call to all stem cell hematologists and immunologists!!

My lab, Quantitative Stem Cell Dynamics (https://t.co/j0ocWZY‚Ä¶",en,0.0,211.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,124.0,61.0,https://twitter.com/Daniel_DT15/statuses/1335711368805298180,0.0,0.0,,0.0,0.0,0.0,61.0,124.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @AlejoFraticelli: Call to all stem cell hematologists and immunologists!!

My lab, Quantitative Stem Cell Dynamics (https://t.co/j0ocWZY‚Ä¶",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-06 21:48:37+00:00,Lisa Palacios,http://twitter.com/,85.0,,1.335702710851674e+18,,0.0,0.0,,RT @ASH_hematology: Calling all #ASH20 attendees: Use our featured hashtags to be üåü featured üåü on the Community Collage of the virtual meet‚Ä¶,en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,69.0,16.0,https://twitter.com/Lisa_Palacios/statuses/1335702710851674112,0.0,0.0,,0.0,0.0,0.0,16.0,69.0,False,False,False,False,True,Disease Advocacy,0.0,0.0,1.0,RT @ASH_hematology: Calling all #ASH20 attendees: Use our featured hashtags to be üåü featured üåü on the Community Collage of the virtual meet‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 20:13:46+00:00,"Ritcha Saxena, MD",http://twitter.com/,29.0,,1.335678841096954e+18,,0.0,0.0,,"RT @felrassi: Memories from ASH5k in 2016, Missing my mentor and big brother Hanna Jean Khoury with his infectious passion for ASH @MArella‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,24.0,5.0,https://twitter.com/RitchaSaxena/statuses/1335678841096953863,0.0,0.0,,0.0,0.0,0.0,5.0,24.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"RT @felrassi: Memories from ASH5k in 2016, Missing my mentor and big brother Hanna Jean Khoury with his infectious passion for ASH @MArella‚Ä¶",false
olga45093932,"MD,PhD, hematologist of @NationalCancerInst of @oncohematologyDepart",,"Kiev, Ukraine",,2020-12-06 07:25:45+00:00,Olga,http://twitter.com/,39.0,,1.3354855669854618e+18,,0.0,0.0,,"RT @DrRaulCordoba: Despite not attending in-person @ASH_hematology Annual Meeting #ASH20 due to the #COVID„Éº19 pandemic, the entire #hematol‚Ä¶",en,0.0,64.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,38.0,1.0,https://twitter.com/olga45093932/statuses/1335485566985461761,0.0,0.0,,0.0,0.0,0.0,1.0,38.0,False,False,False,False,True,Covid,0.0,0.0,1.0,"RT @DrRaulCordoba: Despite not attending in-person @ASH_hematology Annual Meeting #ASH20 due to the #COVID„Éº19 pandemic, the entire #hematol‚Ä¶",true
KellySchoenbeck,"Hematology/Oncology Fellow @UCSFCancer | IM @ColumbiaMed | MD @OHSUSOM | hematology, myeloid malignancies #QOL #geriheme | tweets my own",,,,2020-12-07 02:20:12+00:00,Kelly Schoenbeck,http://twitter.com/,9.0,,1.3357710602270351e+18,,0.0,0.0,,"RT @MazieTsangMD: #ASH20 #GeriHeme @UCSFCancer fellow poster:

@vekennedy Abstract 1526

**Useful for older patients with AML or chemo resi‚Ä¶",en,0.0,48.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,8.0,1.0,https://twitter.com/KellySchoenbeck/statuses/1335771060227035141,0.0,0.0,,0.0,0.0,0.0,1.0,8.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @MazieTsangMD: #ASH20 #GeriHeme @UCSFCancer fellow poster:

@vekennedy Abstract 1526

**Useful for older patients with AML or chemo resi‚Ä¶",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 12:41:41+00:00,"Ritcha Saxena, MD",http://twitter.com/,13.0,,1.335565072496812e+18,,0.0,0.0,,RT @anthonymatomd: Chemotherapy free pathways in #CLL! Newest review on this topic. Algorithms included. Approaches for relapsed #CLL after‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,9.0,4.0,https://twitter.com/RitchaSaxena/statuses/1335565072496812032,0.0,0.0,,0.0,0.0,0.0,4.0,9.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @anthonymatomd: Chemotherapy free pathways in #CLL! Newest review on this topic. Algorithms included. Approaches for relapsed #CLL after‚Ä¶,true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-12-07 21:07:54+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,1.0,,1.3360548543308964e+18,,0.0,0.0,,"#ASH20 #leusm Maiti (637): Non-randomized comparison of 10d Decitabine+Venetoclax vs intensive chemo (CLIA, CIA, or‚Ä¶ https://t.co/xn4Ov1kr8t",en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/hemedoc/statuses/1336054854330896386,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"#ASH20 #leusm Maiti (637): Non-randomized comparison of 10d Decitabine+Venetoclax vs intensive chemo (CLIA, CIA, or‚Ä¶ https://t.co/xn4Ov1kr8t",true
AzizNazhaMD,"Practice Manager at Amazon Web Services, Physician, #Programmer, #DataScientist, interested in the Digital Transformation of Healthcare",,Cleveland Clinic,,2020-12-07 15:41:33+00:00,Aziz Nazha,http://twitter.com/,0.0,,1.3359727259874222e+18,,0.0,0.0,,"Come join us, our personalized model to improve the diagnosis of MDS will be presented at #ASH20, #ASH2020 in 15 mi‚Ä¶ https://t.co/9vknvwrgcL",en,0.0,2087.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/AzizNazhaMD/statuses/1335972725987422209,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnostic Tools,1.0,0.0,0.0,"Come join us, our personalized model to improve the diagnosis of MDS will be presented at #ASH20, #ASH2020 in 15 mi‚Ä¶ https://t.co/9vknvwrgcL",true
DrTonyLetai,"Physician-scientist @DanaFarber. Professor of Medicine @harvardmed. President, Society for Functional Precision Medicine. You probably should be BH3 profiling.",,"Boston, MA",,2020-12-07 23:32:40+00:00,Anthony Letai MD PhD,http://twitter.com/,26.0,,1.3360912843401503e+18,,0.0,0.0,,"RT @DanaFarberNews: Little is known about #mentalhealth disorders among patients with hematologic malignancies, but new research is underwa‚Ä¶",en,0.0,1809.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,18.0,8.0,https://twitter.com/DrTonyLetai/statuses/1336091284340150284,0.0,0.0,,0.0,0.0,0.0,8.0,18.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @DanaFarberNews: Little is known about #mentalhealth disorders among patients with hematologic malignancies, but new research is underwa‚Ä¶",false
felrassi,Adult hematologist and sickle cell doctor @emorymedicine @winshipatemory @gradyhealth @slusom @AUBAlumni https://t.co/q6mGxISoAq,,"Georgia, USA",,2020-12-06 15:31:53+00:00,"Fuad El Rassi, MD",http://twitter.com/,5.0,,1.3356079061301535e+18,,0.0,0.0,,"Memories from ASH5k in 2016, Missing my mentor and big brother Hanna Jean Khoury with his infectious passion for AS‚Ä¶ https://t.co/qhBMmCtf3i",en,0.0,227.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,5.0,https://twitter.com/felrassi/statuses/1335607906130153472,0.0,0.0,,0.0,0.0,0.0,5.0,0.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"Memories from ASH5k in 2016, Missing my mentor and big brother Hanna Jean Khoury with his infectious passion for AS‚Ä¶ https://t.co/qhBMmCtf3i",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-07 21:32:31+00:00,"Ritcha Saxena, MD",http://twitter.com/,3.0,,1.336061050744148e+18,,0.0,0.0,,RT @feldstej: E. Donnall Thomas Lecture and Prize #ASH20 Quiescence and and Cell Metabolism in Hematopoietic Stem Cells https://t.co/Ei2RbH‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,2.0,1.0,https://twitter.com/RitchaSaxena/statuses/1336061050744147968,0.0,0.0,,0.0,0.0,0.0,1.0,2.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @feldstej: E. Donnall Thomas Lecture and Prize #ASH20 Quiescence and and Cell Metabolism in Hematopoietic Stem Cells https://t.co/Ei2RbH‚Ä¶,true
AlannaChurch_MD,"Your friendly neighborhood molecular and pediatric pathologist, caring for children with cancer @bostonchildrens @DFBC_PedCare @harvardmed üá®üá¶ üá∫üá∏",,"Boston, MA",,2020-12-07 18:53:59+00:00,"Alanna Church, MD",http://twitter.com/,11.0,,1.3360211507368632e+18,,0.0,0.0,,"RT @JonMarronMD: Please join us this afternoon for a live Q&amp;A at 1:30 PST (4:30 EST) about our #ASH20 education session ""Genetic Testing fo‚Ä¶",en,0.0,187.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,7.0,4.0,https://twitter.com/AlannaChurch_MD/statuses/1336021150736863234,0.0,0.0,,0.0,0.0,0.0,4.0,7.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @JonMarronMD: Please join us this afternoon for a live Q&amp;A at 1:30 PST (4:30 EST) about our #ASH20 education session ""Genetic Testing fo‚Ä¶",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-07 04:04:02+00:00,"Ritcha Saxena, MD",http://twitter.com/,27.0,,1.3357971898435748e+18,,0.0,0.0,,RT @ninashah33: The O.G. BiTE (but better): AMG-701 with extended half life‚Äî&gt; 36% ORR in early cohorts but 5/6 (86%) ORR in most recent dos‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,16.0,11.0,https://twitter.com/RitchaSaxena/statuses/1335797189843574792,0.0,0.0,,0.0,0.0,0.0,11.0,16.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @ninashah33: The O.G. BiTE (but better): AMG-701 with extended half life‚Äî&gt; 36% ORR in early cohorts but 5/6 (86%) ORR in most recent dos‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-07 00:53:24+00:00,"Ritcha Saxena, MD",http://twitter.com/,4.0,,1.3357492149078712e+18,,0.0,0.0,,RT @hemedoc: #ASH20 #leusm Rubnitz: Interesting high rate of CR in ETP-ALL (5/7). BH3 profiling being investigated for correlation with res‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,1.0,https://twitter.com/RitchaSaxena/statuses/1335749214907871235,0.0,0.0,,0.0,0.0,0.0,1.0,3.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,RT @hemedoc: #ASH20 #leusm Rubnitz: Interesting high rate of CR in ETP-ALL (5/7). BH3 profiling being investigated for correlation with res‚Ä¶,true
MDMagazine,Clinical News for Connected Physicians. Everything you need to enhance your clinical approach to improving patient care.,,United States,,2020-12-07 15:40:00+00:00,HCPLive,http://twitter.com/,0.0,,1.3359723338911416e+18,,0.0,0.0,,"A look at CTX001, the gene therapy being investigated for curative #SickleCell and thalassemia effects.

#ASH2020 

https://t.co/AfWZGKIbci",en,0.0,7073.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/MDMagazine/statuses/1335972333891141632,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,"A look at CTX001, the gene therapy being investigated for curative #SickleCell and thalassemia effects.

#ASH2020 

https://t.co/AfWZGKIbci",false
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-07 15:12:40+00:00,Lisa Palacios,http://twitter.com/,3.0,,1.3359654552075674e+18,,0.0,0.0,,"RT @ImmuneOnc: Today Dr. Courtney DiNardo from @LeukemiaMDA presents poster (Abstract #2867) of Phase 1 trial of IO-202, a first-in-class a‚Ä¶",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,2.0,1.0,https://twitter.com/Lisa_Palacios/statuses/1335965455207567361,0.0,0.0,,0.0,0.0,0.0,1.0,2.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @ImmuneOnc: Today Dr. Courtney DiNardo from @LeukemiaMDA presents poster (Abstract #2867) of Phase 1 trial of IO-202, a first-in-class a‚Ä¶",true
AzizNazhaMD,"Practice Manager at Amazon Web Services, Physician, #Programmer, #DataScientist, interested in the Digital Transformation of Healthcare",,Cleveland Clinic,,2020-12-07 20:11:07+00:00,Aziz Nazha,http://twitter.com/,0.0,,1.3360405655201628e+18,,0.0,0.0,,Thanks for the great collaborations around the world to complete our #AI model that predict response or resistance‚Ä¶ https://t.co/EW72y3fB6q,en,0.0,2087.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/AzizNazhaMD/statuses/1336040565520162816,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,Thanks for the great collaborations around the world to complete our #AI model that predict response or resistance‚Ä¶ https://t.co/EW72y3fB6q,true
MDAndersonNews,"The official account of MD Anderson Cancer Center, a leader in cancer care, cancer research and the fight to #EndCancer. Appointments available: 1-877-632-6789.",,"Houston, TX",,2020-12-07 15:59:02+00:00,MD Anderson Cancer Center,http://twitter.com/,5.0,,1.3359771230524744e+18,,0.0,0.0,,Results of the ZUMA-12 clinical trial may allow some patients with newly diagnosed aggressive B-cell lymphoma to sk‚Ä¶ https://t.co/zseqgUd5lr,en,0.0,114120.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,5.0,https://twitter.com/MDAndersonNews/statuses/1335977123052474372,0.0,0.0,,0.0,0.0,0.0,5.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,Results of the ZUMA-12 clinical trial may allow some patients with newly diagnosed aggressive B-cell lymphoma to sk‚Ä¶ https://t.co/zseqgUd5lr,true
AzizNazhaMD,"Practice Manager at Amazon Web Services, Physician, #Programmer, #DataScientist, interested in the Digital Transformation of Healthcare",,Cleveland Clinic,,2020-12-07 19:15:06+00:00,Aziz Nazha,http://twitter.com/,6.0,,1.3360264665937592e+18,,0.0,0.0,,"Today, we will present at #ASH20 a great international collaboration that uses state of the art #MachineLearning,‚Ä¶ https://t.co/IumcJpF7Ml",en,0.0,2087.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,6.0,https://twitter.com/AzizNazhaMD/statuses/1336026466593759233,0.0,0.0,,0.0,0.0,0.0,6.0,0.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,"Today, we will present at #ASH20 a great international collaboration that uses state of the art #MachineLearning,‚Ä¶ https://t.co/IumcJpF7Ml",true
EmilyT18210760,"Haematologist in the NE of England, with a developing interest in Myeloma.",,,,2020-12-07 07:09:22+00:00,EMRT,http://twitter.com/,17.0,,1.3358438294302925e+18,,0.0,0.0,,RT @profghjackson: 4 cycles of KRD cannot match a stem cell transplant in terms of sustained MRD -ve rates. Data from the forte study shows‚Ä¶,en,0.0,116.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,15.0,2.0,https://twitter.com/EmilyT18210760/statuses/1335843829430292481,0.0,0.0,,0.0,0.0,0.0,2.0,15.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @profghjackson: 4 cycles of KRD cannot match a stem cell transplant in terms of sustained MRD -ve rates. Data from the forte study shows‚Ä¶,true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-12-07 21:14:39+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,3.0,,1.3360565509898076e+18,,0.0,0.0,,#ASH20 #leusm Maiti (637): ORR 59% DAC/Ven vs 31% IC. MRD neg CR 54 vs 69% (NS). Relapse similar 41-44%. EFS 5.7 vs‚Ä¶ https://t.co/VGz0HMCbTq,en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/hemedoc/statuses/1336056550989807616,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,#ASH20 #leusm Maiti (637): ORR 59% DAC/Ven vs 31% IC. MRD neg CR 54 vs 69% (NS). Relapse similar 41-44%. EFS 5.7 vs‚Ä¶ https://t.co/VGz0HMCbTq,false
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-07 15:31:57+00:00,Lisa Palacios,http://twitter.com/,2.0,,1.3359703098124616e+18,,0.0,0.0,,RT @VJHemOnc: #MPNs updates from #ASH20: @bose_prithviraj of @MDAndersonNews discussed the Phase II study of #Sotatercept for #Anemia of #M‚Ä¶,en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,1.0,1.0,https://twitter.com/Lisa_Palacios/statuses/1335970309812461568,0.0,0.0,,0.0,0.0,0.0,1.0,1.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @VJHemOnc: #MPNs updates from #ASH20: @bose_prithviraj of @MDAndersonNews discussed the Phase II study of #Sotatercept for #Anemia of #M‚Ä¶,true
AndreaAnampaG,"Medstudent @UNMSM_ with OCD ‚Ä¢ @ASCO & @AMWAdoctors Social Media
@CPsolvers Team Member ‚Ä¢ #Globaloncology #WomenInMedicine #MedEd #SurvOnc üáµüá™ #IMG üåà she/ella",,"Lima, Peru",,2020-12-07 18:58:56+00:00,Andrea Anampa-Guzm√°n,http://twitter.com/,20.0,,1.336022399863681e+18,,0.0,0.0,,"RT @VincentRK: #ASH20 Here are some superstars from @MayoClinic @MayoCancerCare posting cutting edge information

Myeloma 
@Rfonsi1 
@myelo‚Ä¶",en,0.0,1908.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,15.0,5.0,https://twitter.com/AndreaAnampaG/statuses/1336022399863681032,0.0,0.0,,0.0,0.0,0.0,5.0,15.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @VincentRK: #ASH20 Here are some superstars from @MayoClinic @MayoCancerCare posting cutting edge information

Myeloma 
@Rfonsi1 
@myelo‚Ä¶",true
AzizNazhaMD,"Practice Manager at Amazon Web Services, Physician, #Programmer, #DataScientist, interested in the Digital Transformation of Healthcare",,Cleveland Clinic,,2020-12-07 16:17:17+00:00,Aziz Nazha,http://twitter.com/,0.0,,1.3359817173965906e+18,,0.0,0.0,,"Our #AI algorithm to predict MDS diagnosis, #ASH20, #ASH2020, #ML, #ArtificialIntelligence, #DataScience,‚Ä¶ https://t.co/7gj8BFQeKP",fr,0.0,2087.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/AzizNazhaMD/statuses/1335981717396590598,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"Our #AI algorithm to predict MDS diagnosis, #ASH20, #ASH2020, #ML, #ArtificialIntelligence, #DataScience,‚Ä¶ https://t.co/7gj8BFQeKP",true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-12-07 20:56:26+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,2.0,,1.336051967144022e+18,,0.0,0.0,,"#ASH20 #leusm Stein (636): 22% differentiation syndrome w Ena, 17% Ena+Aza. CR 37% w Ena monotx, 18% w Ena+Aza, but‚Ä¶ https://t.co/NElUNgmPCM",en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/hemedoc/statuses/1336051967144022016,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"#ASH20 #leusm Stein (636): 22% differentiation syndrome w Ena, 17% Ena+Aza. CR 37% w Ena monotx, 18% w Ena+Aza, but‚Ä¶ https://t.co/NElUNgmPCM",true
AnnaSureda5,"Haematologist interested in lymphoid malignancies, stem cell transplantation and CART cells. #CART #BMT #lymphomas #immunotherapy #WomenInMedicine",,"Barcelona, Spain",,2020-12-07 06:40:28+00:00,Anna Sureda,http://twitter.com/,34.0,,1.3358365556304814e+18,,0.0,0.0,,RT @DrRaulCordoba: #ASH20 Impact of #SARSCoV2 infection on 491 hematological patients: the #ECOVIDEHE multicenter study in Spain üá™üá∏. Advanc‚Ä¶,en,0.0,658.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,23.0,11.0,https://twitter.com/AnnaSureda5/statuses/1335836555630481408,0.0,0.0,,0.0,0.0,0.0,11.0,23.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,RT @DrRaulCordoba: #ASH20 Impact of #SARSCoV2 infection on 491 hematological patients: the #ECOVIDEHE multicenter study in Spain üá™üá∏. Advanc‚Ä¶,true
SJKBio,"Medical Doctor - digital health, genomics, imaging, surgery, systems.",,Dublin,,2020-12-07 16:24:00+00:00,Stephen Kearney,http://twitter.com/,7.0,,1.3359834094501478e+18,,0.0,0.0,,"RT @AzizNazhaMD: Molecular landscape of Our #AI algorithm to predict MDS diagnosis from CBC and mutational data only, #ASH20, #ASH2020, #ML‚Ä¶",en,0.0,351.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,3.0,https://twitter.com/SJKBio/statuses/1335983409450147842,0.0,0.0,,0.0,0.0,0.0,3.0,4.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"RT @AzizNazhaMD: Molecular landscape of Our #AI algorithm to predict MDS diagnosis from CBC and mutational data only, #ASH20, #ASH2020, #ML‚Ä¶",false
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-07 16:05:47+00:00,Lisa Palacios,http://twitter.com/,20.0,,1.3359788257301545e+18,,0.0,0.0,,RT @MDAndersonNews: Results of the ZUMA-12 clinical trial may allow some patients with newly diagnosed aggressive B-cell lymphoma to skip c‚Ä¶,en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,15.0,5.0,https://twitter.com/Lisa_Palacios/statuses/1335978825730154501,0.0,0.0,,0.0,0.0,0.0,5.0,15.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @MDAndersonNews: Results of the ZUMA-12 clinical trial may allow some patients with newly diagnosed aggressive B-cell lymphoma to skip c‚Ä¶,true
ChusGC,"Dr.  #cencia
‚ô•: @ele_nyka 
üè†: @L12EleJe 
üé§: 
@CuentaEsperant
@UnaVagaIdea 
@CaucazicRanita 
N√∫m. S√∫per3: 114937
Pol√≠tica 
üöÖüöå 
Idiomas 
#Esperanto 
#LaMancha",,Barcelona / La Mancha,,2020-12-07 07:05:18+00:00,ChuS ‚Äî Democr√†cia‚ùó (üéóÔ∏è),http://twitter.com/,185.0,,1.3358428080543416e+18,,0.0,0.0,,"RT @AlejoFraticelli: Call to all stem cell hematologists and immunologists!!

My lab, Quantitative Stem Cell Dynamics (https://t.co/j0ocWZY‚Ä¶",en,0.0,1227.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,124.0,61.0,https://twitter.com/ChusGC/statuses/1335842808054341641,0.0,0.0,,0.0,0.0,0.0,61.0,124.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @AlejoFraticelli: Call to all stem cell hematologists and immunologists!!

My lab, Quantitative Stem Cell Dynamics (https://t.co/j0ocWZY‚Ä¶",true
emmamgroarke,"Haematologist in Bethesda. Irish trained üáÆüá™ Particular interests: #aplasticanemia, #telomeredisease, #CHIP, #MDS, #AML, #HSCT All comments my own.",,"Washington, DC",,2020-12-07 17:53:46+00:00,Emma M. Groarke,http://twitter.com/,5.0,,1.336005997505155e+18,,0.0,0.0,,"RT @miljko: ViPOR phase 1b/2 response data on all patients (aggressive + indolent BCL) from @MelanicjMD, @RoschewskiMD and others at @NCICC‚Ä¶",en,0.0,130.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,2.0,https://twitter.com/emmamgroarke/statuses/1336005997505155072,0.0,0.0,,0.0,0.0,0.0,2.0,3.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @miljko: ViPOR phase 1b/2 response data on all patients (aggressive + indolent BCL) from @MelanicjMD, @RoschewskiMD and others at @NCICC‚Ä¶",true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-12-08 20:42:42+00:00,Oncology Tube,http://twitter.com/,0.0,,1.3364108988821627e+18,,0.0,0.0,,"A Phase 1, First-in-Human Study of Talquetamab Ajai Chari, MD, Ph.D. @IcahnMountSinai #ASH20 #MultipleMyeloma‚Ä¶ https://t.co/ujyjNXtb6l",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1336410898882162688,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"A Phase 1, First-in-Human Study of Talquetamab Ajai Chari, MD, Ph.D. @IcahnMountSinai #ASH20 #MultipleMyeloma‚Ä¶ https://t.co/ujyjNXtb6l",true
SethRotz,Pediatric Hematologist/Oncologist/BMT @Cleveland Clinic Children's; opinions my own,,"Cleveland, OH",,2020-12-08 22:44:49+00:00,seth rotz,http://twitter.com/,29.0,,1.3364416331313357e+18,,0.0,0.0,,RT @DrStevenDevine: Superb presentation by Dr Shaw at #ASH20 Presidential symposium. @BeTheMatch is working with her and other great invest‚Ä¶,en,0.0,416.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,22.0,7.0,https://twitter.com/SethRotz/statuses/1336441633131335684,0.0,0.0,,0.0,0.0,0.0,7.0,22.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @DrStevenDevine: Superb presentation by Dr Shaw at #ASH20 Presidential symposium. @BeTheMatch is working with her and other great invest‚Ä¶,true
MDAndersonNews,"The official account of MD Anderson Cancer Center, a leader in cancer care, cancer research and the fight to #EndCancer. Appointments available: 1-877-632-6789.",,"Houston, TX",,2020-12-08 04:03:01+00:00,MD Anderson Cancer Center,http://twitter.com/,4.0,,1.3361593216720036e+18,,0.0,0.0,,"Resulting in a 100% complete response rate and an 80% two-year survival rate, the chemotherapy and monoclonal antib‚Ä¶ https://t.co/jCJlRFuH4B",en,0.0,114120.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,4.0,https://twitter.com/MDAndersonNews/statuses/1336159321672003584,0.0,0.0,,0.0,0.0,0.0,4.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"Resulting in a 100% complete response rate and an 80% two-year survival rate, the chemotherapy and monoclonal antib‚Ä¶ https://t.co/jCJlRFuH4B",false
JohnPLeonardMD,"Doctor for lymphoma patients, researcher, collaborator, professor/senior associate dean @WeillCornell & @NYPhospital Tweets mine RT not=endorsement, he/him/his",,Weill Cornell Medicine,,2020-12-08 15:58:28+00:00,"John P. Leonard, MD",http://twitter.com/,4.0,,1.3363393697250263e+18,,0.0,0.0,,Cancer-associated mutations can be present as long as 50 years prior to diagnosis.... #ASH20 Researchers Trace the‚Ä¶ https://t.co/2lWXrTGmmw,en,0.0,6269.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,4.0,https://twitter.com/JohnPLeonardMD/statuses/1336339369725026305,0.0,0.0,,0.0,0.0,0.0,4.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,Cancer-associated mutations can be present as long as 50 years prior to diagnosis.... #ASH20 Researchers Trace the‚Ä¶ https://t.co/2lWXrTGmmw,true
BMT_DrNemecek,"Pediatrician and Hematologist/ Oncologist. Director of Clinical Research, OHSU Knight Cancer Institute. Opinions in this platform are personal.",,"Oregon, USA",,2020-12-08 20:47:42+00:00,Eneida Nemecek,http://twitter.com/,29.0,,1.3364121593083085e+18,,0.0,0.0,,RT @DrStevenDevine: Superb presentation by Dr Shaw at #ASH20 Presidential symposium. @BeTheMatch is working with her and other great invest‚Ä¶,en,0.0,419.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,22.0,7.0,https://twitter.com/BMT_DrNemecek/statuses/1336412159308308485,0.0,0.0,,0.0,0.0,0.0,7.0,22.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @DrStevenDevine: Superb presentation by Dr Shaw at #ASH20 Presidential symposium. @BeTheMatch is working with her and other great invest‚Ä¶,true
AnnaSureda5,"Haematologist interested in lymphoid malignancies, stem cell transplantation and CART cells. #CART #BMT #lymphomas #immunotherapy #WomenInMedicine",,"Barcelona, Spain",,2020-12-08 05:57:15+00:00,Anna Sureda,http://twitter.com/,23.0,,1.336188069893038e+18,,0.0,0.0,,RT @MediHumdani: Dr. Jasmin Zain presenting Phase I Study of Yttrium-90 Labeled ANTI-CD25 (aTac) Monoclonal Antibody PLUS BEAM for Autologo‚Ä¶,en,0.0,658.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,19.0,4.0,https://twitter.com/AnnaSureda5/statuses/1336188069893038082,0.0,0.0,,0.0,0.0,0.0,4.0,19.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @MediHumdani: Dr. Jasmin Zain presenting Phase I Study of Yttrium-90 Labeled ANTI-CD25 (aTac) Monoclonal Antibody PLUS BEAM for Autologo‚Ä¶,true
Pooh_Velagapudi,Cardiologist; Associate PD-Cardiology Fellowship @UNMC; Chair #ACCEarlyCareer section; SoMe editor @JACCJournals; #Education #HRPCI #SHD; EDMüé∂; Opinions my own,,United States,,2020-10-14 14:25:25+00:00,Poonam Velagapudi,http://twitter.com/,0.0,,1.316384621945401e+18,,0.0,0.0,,"THIS was the BEST part of the case- Ajay wiring that diag! Awesome! üëèüëè 

#TeamWork #ACCEarlyCareer #ACCFIT‚Ä¶ https://t.co/2At3o1zI6V",en,0.0,8841.0,,,0.0,Pooh_Velagapudi,1.3163700573883228e+18,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/Pooh_Velagapudi/statuses/1316384621945401345,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Disease Advocacy,1.0,0.0,0.0,"THIS was the BEST part of the case- Ajay wiring that diag! Awesome! üëèüëè 

#TeamWork #ACCEarlyCareer #ACCFIT‚Ä¶ https://t.co/2At3o1zI6V",true
Drroxmehran,"Interventional cardiologist, Professor of Medicine @mountsinaiNYC, trialist, outcomes researcher, wife and mother; opinions my own #ACCBOT @womenas1",,"Manhattan, NY",,2020-10-14 19:45:48+00:00,Roxana Mehran,http://twitter.com/,5.0,,1.3164652466897306e+18,,0.0,0.0,,RT @crfheart: The #TCTConnect FDA Town Hall kicks off its opening session at 4:00 PM ET. Learn more about the FDA vision from Dr. Jeffrey S‚Ä¶,en,0.0,9783.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,1.0,https://twitter.com/Drroxmehran/statuses/1316465246689730567,0.0,0.0,,0.0,0.0,0.0,1.0,4.0,False,False,False,False,True,Thought Leadership,0.0,0.0,1.0,RT @crfheart: The #TCTConnect FDA Town Hall kicks off its opening session at 4:00 PM ET. Learn more about the FDA vision from Dr. Jeffrey S‚Ä¶,true
andrea_avilab,"MD, Sports medicine/PhD Cardiac Rehabilitation in KULeuven/ Profesora Medicina del deporte Universidad Nacional de Colombia/Universidad El Bosque",,"Bogot√°, D.C., Colombia",,2020-10-14 17:14:37+00:00,andrea avila,http://twitter.com/,17.0,,1.3164272022763315e+18,,0.0,0.0,,"RT @ACCinTouch: Unique registry collaboration between @SCAI, Canadian Association of Interventional Cardiology &amp; #ACCIC aims to improve out‚Ä¶",en,0.0,249.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,11.0,6.0,https://twitter.com/andrea_avilab/statuses/1316427202276331522,0.0,0.0,,0.0,0.0,0.0,6.0,11.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,"RT @ACCinTouch: Unique registry collaboration between @SCAI, Canadian Association of Interventional Cardiology &amp; #ACCIC aims to improve out‚Ä¶",false
DFCapodanno,"Interventional Cardiologist | University of Catania, Italy | Editor @EuroInterventio",,"Catania, Sicily",,2020-10-14 16:52:57+00:00,Davide Capodanno,http://twitter.com/,3.0,,1.316421749282689e+18,,0.0,0.0,,"Dear speaker who is presenting COMPARE-CRUSH now, be aware that we are all with you, and feel your frustration as y‚Ä¶ https://t.co/G9JfdUbgX7",en,0.0,5313.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/DFCapodanno/statuses/1316421749282689024,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Thought Leadership,0.0,0.0,1.0,"Dear speaker who is presenting COMPARE-CRUSH now, be aware that we are all with you, and feel your frustration as y‚Ä¶ https://t.co/G9JfdUbgX7",true
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-10-14 19:40:04+00:00,Cardiovascular Research Foundation,http://twitter.com/,1.0,,1.316463803371065e+18,,0.0,0.0,,The #TCTConnect FDA Town Hall kicks off its opening session at 4:00 PM ET. Learn more about the FDA vision from Dr.‚Ä¶ https://t.co/ZUmqIkqoKr,en,0.0,12239.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/crfheart/statuses/1316463803371065345,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Thought Leadership,0.0,0.0,1.0,The #TCTConnect FDA Town Hall kicks off its opening session at 4:00 PM ET. Learn more about the FDA vision from Dr.‚Ä¶ https://t.co/ZUmqIkqoKr,true
CoronaryDoc,Cardiologist & Scientist ‚Ä¢ Dad ‚Ä¢ Husband of A Stroke Survivor Hero ‚Ä¢ @EmoryHeart Trained ‚Ä¢ #FAHA ‚Ä¢ Assoc Editor #EHJCaseReports ‚Ä¢ #SoMe Editor @Open_HeartBMJ,,"Atlanta, GA",,2020-10-14 22:47:54+00:00,Parham Eshtehardi MD,http://twitter.com/,75.0,,1.3165110751233024e+18,,0.0,0.0,,RT @TomJFord: 48M Recurrent NSTEMI without obstructive disease. Men can also have MINOCA. Invasive functional testing provides a diagnosis!‚Ä¶,en,0.0,2610.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,62.0,13.0,https://twitter.com/CoronaryDoc/statuses/1316511075123302400,0.0,0.0,,0.0,0.0,0.0,13.0,62.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @TomJFord: 48M Recurrent NSTEMI without obstructive disease. Men can also have MINOCA. Invasive functional testing provides a diagnosis!‚Ä¶,true
medox1234,interventional cardiologist,,"Muscat, Oman",,2020-10-14 14:38:46+00:00,Ahmed M. El Said,http://twitter.com/,5.0,,1.3163879809494958e+18,,0.0,0.0,,"RT @hect2701: #TCTConnect #TCT2020 @crfheart, @tctconference @TCTMD 

""The fatal impact of bleeding &amp; MI persisted beyond 1 yr. Additional‚Ä¶",en,0.0,941.0,,,0.0,,,Negative,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,2.0,https://twitter.com/medox1234/statuses/1316387980949495810,0.0,0.0,,0.0,0.0,0.0,2.0,3.0,False,False,False,False,True,Diagnosis Progression,0.0,1.0,0.0,"RT @hect2701: #TCTConnect #TCT2020 @crfheart, @tctconference @TCTMD 

""The fatal impact of bleeding &amp; MI persisted beyond 1 yr. Additional‚Ä¶",true
turilrh,"Interventional Cardiologist and Assistant Professor Cardiology MTI, LRH, Peshawar, KP, Pakistan",,,,2020-10-14 17:10:25+00:00,jabar,http://twitter.com/,26.0,,1.3164261437220209e+18,,0.0,0.0,,RT @mmamas1973: #TCTConnect if you missed the LBT session can see livestream below @CardioIAN @billgogas @GiuseppeGalati_ @gbiondizoccai @h‚Ä¶,en,0.0,999.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,18.0,8.0,https://twitter.com/turilrh/statuses/1316426143722020864,0.0,0.0,,0.0,0.0,0.0,8.0,18.0,False,False,False,False,True,Disease Management,0.0,0.0,1.0,RT @mmamas1973: #TCTConnect if you missed the LBT session can see livestream below @CardioIAN @billgogas @GiuseppeGalati_ @gbiondizoccai @h‚Ä¶,true
hect2701,"Professor of Medicine, Georgetown University. Cardiology, Interventional Cardiologist, Cardiovascular Imaging. Opinions are my own and RT are not endorsements.",,"Washington, DC",,2020-10-14 12:42:38+00:00,Prof. Hector M. Garcia-Garcia,http://twitter.com/,7.0,,1.3163587555299574e+18,,0.0,0.0,,"""Long-Term Outcomes After DES Implantation in Thrombotic Lesions: Pooled Analysis of 8 Randomized Controlled Trials‚Ä¶ https://t.co/ONhqiopdwZ",en,0.0,3101.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,7.0,https://twitter.com/hect2701/statuses/1316358755529957377,0.0,0.0,,0.0,0.0,0.0,7.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"""Long-Term Outcomes After DES Implantation in Thrombotic Lesions: Pooled Analysis of 8 Randomized Controlled Trials‚Ä¶ https://t.co/ONhqiopdwZ",false
JohnPLeonardMD,"Doctor for lymphoma patients, researcher, collaborator, professor/senior associate dean @WeillCornell & @NYPhospital Tweets mine RT not=endorsement, he/him/his",,Weill Cornell Medicine,,2020-12-04 23:08:27+00:00,"John P. Leonard, MD",http://twitter.com/,8.0,,1.3349980265790095e+18,,0.0,0.0,,RT @WCMLymphoma: The #ASH20 Annual Meeting is underway. Stay tuned for exciting #lymphoma #research updates from our team and see what Dr.‚Ä¶,en,0.0,6269.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,2.0,https://twitter.com/JohnPLeonardMD/statuses/1334998026579009541,0.0,0.0,,0.0,0.0,0.0,2.0,6.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @WCMLymphoma: The #ASH20 Annual Meeting is underway. Stay tuned for exciting #lymphoma #research updates from our team and see what Dr.‚Ä¶,true
johnde1MYELOMA,"myeloma survivor üêú, gastroenterologist, bicyclist, animal lover",,"Santa Fe, NM",,2020-12-04 17:06:16+00:00,John DeFlice,http://twitter.com/,30.0,,1.334906882050298e+18,,0.0,0.0,,RT @IMFsupport: Who to follow for #ASH20?  #Myeloma Patients / #IMFASH20 support group leaders: @JackMAiello @blondie1746 @NorthTxMSG @Myel‚Ä¶,en,0.0,218.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,21.0,9.0,https://twitter.com/johnde1MYELOMA/statuses/1334906882050297857,0.0,0.0,,0.0,0.0,0.0,9.0,21.0,False,False,False,False,True,Disease Advocacy,0.0,0.0,1.0,RT @IMFsupport: Who to follow for #ASH20?  #Myeloma Patients / #IMFASH20 support group leaders: @JackMAiello @blondie1746 @NorthTxMSG @Myel‚Ä¶,true
majorajay,"Hematology/oncology fellow. #lymsm & #mmsm outcomes researcher. Physician-publisher & founder of https://t.co/dPfLt8QVMr, @inTrainingDoc & @inHouseMag.",,"Chicago, IL",,2020-12-04 21:42:50+00:00,"Ajay Major, MD, MBA",http://twitter.com/,1.0,,1.334976480326148e+18,,0.0,0.0,,Two algorithms from #ASH20 #myeloma session in the first relapse setting. #mmsm #ASH20AM https://t.co/91dHU3ZymP,en,0.0,3518.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/majorajay/statuses/1334976480326148110,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,Two algorithms from #ASH20 #myeloma session in the first relapse setting. #mmsm #ASH20AM https://t.co/91dHU3ZymP,true
Jeni_woods_OT,"Oncology Occupational Therapist. Chair of RCOT SS Major Health Conditions. Interests- geriatric oncology, frailty,dementia, change & leadership Views my own",,"North West, England",,2020-12-04 17:30:24+00:00,Jeni Woods,http://twitter.com/,68.0,,1.33491295251277e+18,,0.0,0.0,,RT @JanssenEMEA: What is CAR-T therapy? Watch this 3D VR video to learn more about how this innovative technology is being used to tackle #‚Ä¶,en,0.0,949.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,55.0,13.0,https://twitter.com/Jeni_woods_OT/statuses/1334912952512770048,0.0,0.0,,0.0,0.0,0.0,13.0,55.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @JanssenEMEA: What is CAR-T therapy? Watch this 3D VR video to learn more about how this innovative technology is being used to tackle #‚Ä¶,true
majorajay,"Hematology/oncology fellow. #lymsm & #mmsm outcomes researcher. Physician-publisher & founder of https://t.co/dPfLt8QVMr, @inTrainingDoc & @inHouseMag.",,"Chicago, IL",,2020-12-04 21:40:55+00:00,"Ajay Major, MD, MBA",http://twitter.com/,1.0,,1.33497599961276e+18,,0.0,0.0,,Two different algorithms for newly-diagnosed #myeloma from the #ASH20 session. #mmsm https://t.co/5qhReCVDw9,en,0.0,3518.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/majorajay/statuses/1334975999612760065,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,Two different algorithms for newly-diagnosed #myeloma from the #ASH20 session. #mmsm https://t.co/5qhReCVDw9,true
johnde1MYELOMA,"myeloma survivor üêú, gastroenterologist, bicyclist, animal lover",,"Santa Fe, NM",,2020-12-04 21:47:35+00:00,John DeFlice,http://twitter.com/,0.0,,1.3349776753419264e+18,,0.0,0.0,,Options for second or higher relapses in MM. #mmsm  #myeloma #ASH20 #IMFASH20 https://t.co/5acGX3zzIC,en,0.0,218.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/johnde1MYELOMA/statuses/1334977675341926400,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,Options for second or higher relapses in MM. #mmsm  #myeloma #ASH20 #IMFASH20 https://t.co/5acGX3zzIC,false
pdmanas30,Pathologist and physician-scientist. Medical Director @ Amgen leading CDx/Biomarker Strategy. #MolPath #precisiononcology #liquidbiopsy #LungCa #AI T/RT my own,,,,2020-12-04 20:34:52+00:00,"Partha Das, MBBS, MD",http://twitter.com/,5.0,,1.3349593769147392e+18,,0.0,0.0,,RT @AmgenOncology: Half-Life Extended (HLE) BiTE¬Æ technology has a longer half-life than a traditional BiTE¬Æ molecule. Learn more about thi‚Ä¶,en,0.0,39.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,2.0,https://twitter.com/pdmanas30/statuses/1334959376914739200,0.0,0.0,,0.0,0.0,0.0,2.0,3.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @AmgenOncology: Half-Life Extended (HLE) BiTE¬Æ technology has a longer half-life than a traditional BiTE¬Æ molecule. Learn more about thi‚Ä¶,true
kapiroto,Attending physician on stem cell transplantation at Barretos Cancer Hospital,,"Barretos, Brasil",,2020-12-04 01:31:56+00:00,Carlos Sabaini,http://twitter.com/,194.0,,1.3346717487306424e+18,,0.0,0.0,,RT @VincentRK: #ASH20 special: Active myeloma drugs with their mechanism of action in one slide. Unapproved investigational drugs in blue f‚Ä¶,en,0.0,35.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,147.0,47.0,https://twitter.com/kapiroto/statuses/1334671748730642432,0.0,0.0,,0.0,0.0,0.0,47.0,147.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,RT @VincentRK: #ASH20 special: Active myeloma drugs with their mechanism of action in one slide. Unapproved investigational drugs in blue f‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-04 22:05:02+00:00,"Ritcha Saxena, MD",http://twitter.com/,4.0,,1.3349820673404027e+18,,0.0,0.0,,RT @majorajay: Two algorithms from #ASH20 #myeloma session in the first relapse setting. #mmsm #ASH20AM https://t.co/91dHU3ZymP,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,1.0,https://twitter.com/RitchaSaxena/statuses/1334982067340402689,0.0,0.0,,0.0,0.0,0.0,1.0,3.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @majorajay: Two algorithms from #ASH20 #myeloma session in the first relapse setting. #mmsm #ASH20AM https://t.co/91dHU3ZymP,true
VincentRK,"Professor, Mayo Clinic; Editor, Blood Cancer Journal; Oncologist; Health Costs; COVID threads @SurvivedCOVID Opinions=personal views https://t.co/TMq9vc5hZk",,"Rochester, MN, USA",,2020-12-04 15:06:32+00:00,Vincent Rajkumar,http://twitter.com/,3.0,,1.3348767472596623e+18,,0.0,0.0,,"12. Phase I results of TNB-383B, a BCMA/CD3 Bispecific Antibody, in Relapsed/Refractory Myeloma. #ASH20‚Ä¶ https://t.co/O4ZsgGcGOW",en,0.0,33590.0,,,0.0,VincentRK,1.3348757469013647e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/VincentRK/statuses/1334876747259662337,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"12. Phase I results of TNB-383B, a BCMA/CD3 Bispecific Antibody, in Relapsed/Refractory Myeloma. #ASH20‚Ä¶ https://t.co/O4ZsgGcGOW",true
majorajay,"Hematology/oncology fellow. #lymsm & #mmsm outcomes researcher. Physician-publisher & founder of https://t.co/dPfLt8QVMr, @inTrainingDoc & @inHouseMag.",,"Chicago, IL",,2020-12-04 20:25:38+00:00,"Ajay Major, MD, MBA",http://twitter.com/,4.0,,1.3349570521128878e+18,,0.0,0.0,,Extremely important slides from #ASH20 @IMFmyeloma session on evidence regarding 1st relapse after lenalidomide the‚Ä¶ https://t.co/Ioks5tepfA,en,0.0,3518.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,4.0,https://twitter.com/majorajay/statuses/1334957052112887809,0.0,0.0,,0.0,0.0,0.0,4.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,Extremely important slides from #ASH20 @IMFmyeloma session on evidence regarding 1st relapse after lenalidomide the‚Ä¶ https://t.co/Ioks5tepfA,true
VincentRK,"Professor, Mayo Clinic; Editor, Blood Cancer Journal; Oncologist; Health Costs; COVID threads @SurvivedCOVID Opinions=personal views https://t.co/TMq9vc5hZk",,"Rochester, MN, USA",,2020-12-04 14:59:02+00:00,Vincent Rajkumar,http://twitter.com/,0.0,,1.3348748628637327e+18,,0.0,0.0,,"6. CA-4948, IRAK4 inhibitor: phase I results in mantle cell lymphoma. #ASH20 https://t.co/o8ATzVk8Sq",en,0.0,33590.0,,,0.0,VincentRK,1.3348748618822533e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/VincentRK/statuses/1334874862863732743,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"6. CA-4948, IRAK4 inhibitor: phase I results in mantle cell lymphoma. #ASH20 https://t.co/o8ATzVk8Sq",false
majorajay,"Hematology/oncology fellow. #lymsm & #mmsm outcomes researcher. Physician-publisher & founder of https://t.co/dPfLt8QVMr, @inTrainingDoc & @inHouseMag.",,"Chicago, IL",,2020-12-04 20:14:00+00:00,"Ajay Major, MD, MBA",http://twitter.com/,7.0,,1.334954127688917e+18,,0.0,0.0,,RT @MyelomaValarie: Dr. Philippe Moreau presents on the current clinical trials for newly diagnosed transplant ineligible #MYELOMA #ASH20 #‚Ä¶,en,0.0,3518.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,3.0,https://twitter.com/majorajay/statuses/1334954127688916997,0.0,0.0,,0.0,0.0,0.0,3.0,4.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @MyelomaValarie: Dr. Philippe Moreau presents on the current clinical trials for newly diagnosed transplant ineligible #MYELOMA #ASH20 #‚Ä¶,true
majorajay,"Hematology/oncology fellow. #lymsm & #mmsm outcomes researcher. Physician-publisher & founder of https://t.co/dPfLt8QVMr, @inTrainingDoc & @inHouseMag.",,"Chicago, IL",,2020-12-04 20:31:07+00:00,"Ajay Major, MD, MBA",http://twitter.com/,0.0,,1.3349584348280996e+18,,0.0,0.0,,"Harrowing data at #ASH20 on ~20% mortality in transplant patients (auto and allo) with #COVID19 infection, with inf‚Ä¶ https://t.co/cKmUYPx7vf",en,0.0,3518.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/majorajay/statuses/1334958434828099591,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"Harrowing data at #ASH20 on ~20% mortality in transplant patients (auto and allo) with #COVID19 infection, with inf‚Ä¶ https://t.co/cKmUYPx7vf",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-04 20:04:23+00:00,"Ritcha Saxena, MD",http://twitter.com/,187.0,,1.3349517039725486e+18,,0.0,0.0,,"RT @VincentRK: One of the most common questions myeloma patients ask me is: Should I get a stem cell transplant, and if so when should I do‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,136.0,51.0,https://twitter.com/RitchaSaxena/statuses/1334951703972548609,0.0,0.0,,0.0,0.0,0.0,51.0,136.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @VincentRK: One of the most common questions myeloma patients ask me is: Should I get a stem cell transplant, and if so when should I do‚Ä¶",true
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-10-15 14:34:30+00:00,Cardiovascular Research Foundation,http://twitter.com/,61.0,,1.3167492931397018e+18,,0.0,0.0,,RT @heartdoc45: Loving the current live case at #TCTConnect! Challenging calcified PCI with Impella support. Excellent panel and @DrBillLom‚Ä¶,en,0.0,12239.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,51.0,10.0,https://twitter.com/crfheart/statuses/1316749293139701761,0.0,0.0,,0.0,0.0,0.0,10.0,51.0,False,False,False,False,True,Cost of Care,1.0,0.0,0.0,RT @heartdoc45: Loving the current live case at #TCTConnect! Challenging calcified PCI with Impella support. Excellent panel and @DrBillLom‚Ä¶,true
MDBeni,Cardiologist/Echocardiographer @Cardiotweets83 üòé ü´Ä#Echofirst #POCUS,,M√©xico,,2020-10-15 05:32:28+00:00,Ben Valderr√°bano,http://twitter.com/,75.0,,1.316612886169555e+18,,0.0,0.0,,RT @TomJFord: 48M Recurrent NSTEMI without obstructive disease. Men can also have MINOCA. Invasive functional testing provides a diagnosis!‚Ä¶,en,0.0,671.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,62.0,13.0,https://twitter.com/MDBeni/statuses/1316612886169554947,0.0,0.0,,0.0,0.0,0.0,13.0,62.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @TomJFord: 48M Recurrent NSTEMI without obstructive disease. Men can also have MINOCA. Invasive functional testing provides a diagnosis!‚Ä¶,true
medshronline,"MedShr -The App for Doctors, is a HIPAA & GMC compliant network for medical professionals to discuss clinical cases. MedShr now has over 1M members worldwide.",,"London, England",,2020-10-15 14:12:07+00:00,MedShr,http://twitter.com/,61.0,,1.316743659996545e+18,,0.0,0.0,,RT @heartdoc45: Loving the current live case at #TCTConnect! Challenging calcified PCI with Impella support. Excellent panel and @DrBillLom‚Ä¶,en,0.0,8228.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,51.0,10.0,https://twitter.com/medshronline/statuses/1316743659996545024,0.0,0.0,,0.0,0.0,0.0,10.0,51.0,False,False,False,False,True,Cost of Care,1.0,0.0,0.0,RT @heartdoc45: Loving the current live case at #TCTConnect! Challenging calcified PCI with Impella support. Excellent panel and @DrBillLom‚Ä¶,false
chadialraies,Heart doctor @DMC_Heals Clinician researcher educator #CHIP #PAD #RadialFirst - Founder: https://t.co/CRHKx6HNVb Pub: https://t.co/h3aHzr1oGU -Tweet=my opinion,,"Detroit, MI",,2020-10-15 16:47:27+00:00,"M Chadi Alraies, MD FACC",http://twitter.com/,1.0,,1.3167827519038218e+18,,0.0,0.0,,#CADIII Presented meeting safety and efficacy endpoints congratulations the investigators - one more novel technolo‚Ä¶ https://t.co/JWIOn6zO3i,en,0.0,21440.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/chadialraies/statuses/1316782751903821824,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Financial Performance,1.0,0.0,0.0,#CADIII Presented meeting safety and efficacy endpoints congratulations the investigators - one more novel technolo‚Ä¶ https://t.co/JWIOn6zO3i,true
AusamiAbbas,Cardiothoracic Radiologist,,,,2020-10-17 15:46:59+00:00,abb,http://twitter.com/,89.0,,1.317492311425753e+18,,0.0,0.0,,RT @GreggWStone: FORECAST late breaking trial at #TCT2020. 1300 pts with chest pain at out-pt clinics rand to FFRCT vs usual diagnostic eva‚Ä¶,en,0.0,223.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,61.0,28.0,https://twitter.com/AusamiAbbas/statuses/1317492311425753088,0.0,0.0,,0.0,0.0,0.0,28.0,61.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @GreggWStone: FORECAST late breaking trial at #TCT2020. 1300 pts with chest pain at out-pt clinics rand to FFRCT vs usual diagnostic eva‚Ä¶,true
mughal381,Interventional Pediatric Cardiologist RavianÿåPMCianÿå proud Pakistani.üíö,,Pakistan,,2020-10-17 08:49:51+00:00,Dr Mughal,http://twitter.com/,24.0,,1.3173873366872433e+18,,0.0,0.0,,RT @hahn_rt: New Technology: MitraClip G4 and PASCAL https://t.co/Rv2B0hhjS9 #TCTConnect #TCT2020 @ACCinTouch @ASE360 @TCTMD #echofirst @PS‚Ä¶,en,0.0,1047.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,16.0,8.0,https://twitter.com/mughal381/statuses/1317387336687243264,0.0,0.0,,0.0,0.0,0.0,8.0,16.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @hahn_rt: New Technology: MitraClip G4 and PASCAL https://t.co/Rv2B0hhjS9 #TCTConnect #TCT2020 @ACCinTouch @ASE360 @TCTMD #echofirst @PS‚Ä¶,true
UrviShahMD,Oncologist and researcher on Myeloma service @sloan_kettering. Interested in nutrition for cancer and immune therapies. Views are my own,,"New York, NY",,2020-12-05 21:05:31+00:00,Urvi Shah,http://twitter.com/,19.0,,1.3353294762517094e+18,,0.0,0.0,,"RT @ninashah33: Ready for MEDI! MEDI2228 BCMA ADC: 66% ORR at MTD, 60% photophobia ‚Äî&gt; would like to understand how this qualitatively compa‚Ä¶",en,0.0,1227.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,14.0,5.0,https://twitter.com/UrviShahMD/statuses/1335329476251709443,0.0,0.0,,0.0,0.0,0.0,5.0,14.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @ninashah33: Ready for MEDI! MEDI2228 BCMA ADC: 66% ORR at MTD, 60% photophobia ‚Äî&gt; would like to understand how this qualitatively compa‚Ä¶",true
DrHMahmudMD,"IM Physician/Medical Doctor, Patient care, Clinical Research; Tweets are mine.",,United States,,2020-10-17 00:45:05+00:00,"Hossen Mahmud, MD",http://twitter.com/,39.0,,1.3172653424277627e+18,,0.0,0.0,,RT @jgranadacrf: Innovation Shark-Tank #TCTConnect starts today (11:00-AM EST @ Innovation Channel). 3 technologies will present today and‚Ä¶,en,0.0,98.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,23.0,16.0,https://twitter.com/DrHMahmudMD/statuses/1317265342427762692,0.0,0.0,,0.0,0.0,0.0,16.0,23.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @jgranadacrf: Innovation Shark-Tank #TCTConnect starts today (11:00-AM EST @ Innovation Channel). 3 technologies will present today and‚Ä¶,true
CanerSaygin,"Heme-Onc Fellow @UChicago | Alumni of @OhioStateIMRes, @CCLRI | #Leukemia, #MDS, #CHIP physician-scientist. Tweets=own opinions.",,"Chicago, IL",,2020-12-05 17:59:31+00:00,"Caner Saygin, MD",http://twitter.com/,2.0,,1.3352826680665334e+18,,0.0,0.0,,Dr deBotton presenting interesting data on combined SY-1425 (RARA agonist) + Aza in newly diagnosed unfit #AML pts.‚Ä¶ https://t.co/BFjHGtW0fp,en,0.0,743.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/CanerSaygin/statuses/1335282668066533376,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,Dr deBotton presenting interesting data on combined SY-1425 (RARA agonist) + Aza in newly diagnosed unfit #AML pts.‚Ä¶ https://t.co/BFjHGtW0fp,false
CarinHagberg,"Chief Academic Officer; Professor and Division Head, Division of Anesthesiology and Critical Care, MD Anderson Cancer Center. Tweets are my own.",,"Houston, TX",,2020-12-05 21:34:36+00:00,"Carin Hagberg, MD",http://twitter.com/,45.0,,1.3353367969101947e+18,,0.0,0.0,,"RT @ppisters: Through teamwork and pioneering research, @MDAndersonNews experts are committed to improving outcomes for patients with blood‚Ä¶",en,0.0,1506.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,39.0,6.0,https://twitter.com/CarinHagberg/statuses/1335336796910194688,0.0,0.0,,0.0,0.0,0.0,6.0,39.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"RT @ppisters: Through teamwork and pioneering research, @MDAndersonNews experts are committed to improving outcomes for patients with blood‚Ä¶",true
sairah__ahmed,"Lymphoma/Cellular Therapy & SCT at MD Anderson Cancer Center, opinions/tweets shared= my own.",,"Houston, TX",,2020-12-05 23:17:40+00:00,Sairah Ahmed MD,http://twitter.com/,218.0,,1.3353627345573765e+18,,0.0,0.0,,"RT @hemedoc: #ASH20 #leusm Wei: We are all excited to have new therapeutic options in AML, but the overall message I get from this money sl‚Ä¶",en,0.0,491.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,168.0,50.0,https://twitter.com/sairah__ahmed/statuses/1335362734557376512,0.0,0.0,,0.0,0.0,0.0,50.0,168.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"RT @hemedoc: #ASH20 #leusm Wei: We are all excited to have new therapeutic options in AML, but the overall message I get from this money sl‚Ä¶",true
glimelius,"Lymphoma researcher, MD, oncologist in Sweden. #Hodgkin #MCL. Nordic MCL group member. I also love reading and gymnastics.",,"Uppsala, Sverige",,2020-12-05 11:56:19+00:00,Ingrid Glimelius,http://twitter.com/,0.0,,1.3351912685200425e+18,,0.0,0.0,,#MCL a disease most common in males and as many as 44% have comorbidities at diagnose. Clearly a clinical challenge‚Ä¶ https://t.co/xZ2Jv1wEuY,en,0.0,186.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/glimelius/statuses/1335191268520042496,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,#MCL a disease most common in males and as many as 44% have comorbidities at diagnose. Clearly a clinical challenge‚Ä¶ https://t.co/xZ2Jv1wEuY,true
HKlepinMD,Geriatric oncologist,,,,2020-12-05 22:08:27+00:00,Heidi Klepin,http://twitter.com/,29.0,,1.3353453161371525e+18,,0.0,0.0,,RT @PTMcGann: @DrSickleStrong is always an incredible speaker but this #ASH20 talk is a must watch. He carefully and clearly describes the‚Ä¶,en,0.0,902.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,21.0,8.0,https://twitter.com/HKlepinMD/statuses/1335345316137152513,0.0,0.0,,0.0,0.0,0.0,8.0,21.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,RT @PTMcGann: @DrSickleStrong is always an incredible speaker but this #ASH20 talk is a must watch. He carefully and clearly describes the‚Ä¶,true
DrGarethMorgan1,"Clinician researcher and committed myeloma doctor using genetics to understand and cure myeloma, amyloid and Waldenstrom.",,"NYU Langone, Manhattan, NYC",,2020-12-05 23:30:18+00:00,Dr. Gareth Morgan,http://twitter.com/,0.0,,1.3353659160754545e+18,,0.0,0.0,,Congratulations to Ben Buelow for moving it from inception to preclinical and now to clinical efficacy #mmsm #ASH20 https://t.co/K7RLP1m605,en,0.0,630.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/DrGarethMorgan1/statuses/1335365916075454465,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,1.0,0.0,0.0,Congratulations to Ben Buelow for moving it from inception to preclinical and now to clinical efficacy #mmsm #ASH20 https://t.co/K7RLP1m605,true
biostockguru,Physician executive(MD CWRU;Rice/Jones);Healthcare focus Fund;Pharma advisor/KOL;Tweets NOT investment advice.Pls do your DD. Support https://t.co/97U34OldNG,,United States,,2020-12-05 20:01:34+00:00,biostockGuru,http://twitter.com/,52.0,,1.3353133861547786e+18,,0.0,0.0,,"RT @GantosJ: $APTO #ASH20 Poster - A Phase 1a/b Dose Escalation Study of the MYC Repressor APTO-253 in Patients with R/R AML or HR-MDS 
htt‚Ä¶",en,0.0,14021.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,45.0,7.0,https://twitter.com/biostockguru/statuses/1335313386154778624,0.0,0.0,,0.0,0.0,0.0,7.0,45.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @GantosJ: $APTO #ASH20 Poster - A Phase 1a/b Dose Escalation Study of the MYC Repressor APTO-253 in Patients with R/R AML or HR-MDS 
htt‚Ä¶",false
HindRafei,Hematology and Oncology Fellow at MD Anderson Cancer Center. #NKcellRx #immunoRx #immunology  Tweets are my own.,,"Houston, TX",,2020-12-05 13:45:49+00:00,Hind Rafei,http://twitter.com/,45.0,,1.335218822828204e+18,,0.0,0.0,,"RT @ppisters: Through teamwork and pioneering research, @MDAndersonNews experts are committed to improving outcomes for patients with blood‚Ä¶",en,0.0,935.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,39.0,6.0,https://twitter.com/HindRafei/statuses/1335218822828204032,0.0,0.0,,0.0,0.0,0.0,6.0,39.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"RT @ppisters: Through teamwork and pioneering research, @MDAndersonNews experts are committed to improving outcomes for patients with blood‚Ä¶",true
LiaPalomba,oncologist @sloankettering lymphoma expert immunotherapy CAR T cells Waldenstrom‚Äôs macroglobulinemia,,New York City,,2020-12-05 15:13:00+00:00,Lia Palomba,http://twitter.com/,62.0,,1.335240766021636e+18,,0.0,0.0,,"RT @DrMiguelPerales: Busy day today for @sloan_kettering investigators at @ASH_hematology #ASH20 Check out the schedule for talks, oral pre‚Ä¶",en,0.0,956.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,50.0,12.0,https://twitter.com/LiaPalomba/statuses/1335240766021636097,0.0,0.0,,0.0,0.0,0.0,12.0,50.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,"RT @DrMiguelPerales: Busy day today for @sloan_kettering investigators at @ASH_hematology #ASH20 Check out the schedule for talks, oral pre‚Ä¶",true
UrviShahMD,Oncologist and researcher on Myeloma service @sloan_kettering. Interested in nutrition for cancer and immune therapies. Views are my own,,"New York, NY",,2020-12-05 18:27:13+00:00,Urvi Shah,http://twitter.com/,23.0,,1.3352896418727977e+18,,0.0,0.0,,"RT @DrOlaLandgren: Agreed! CR = not complete remission. CR = complete response; a categorical treatment response (typically, based on older‚Ä¶",en,0.0,1227.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,20.0,3.0,https://twitter.com/UrviShahMD/statuses/1335289641872797696,0.0,0.0,,0.0,0.0,0.0,3.0,20.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @DrOlaLandgren: Agreed! CR = not complete remission. CR = complete response; a categorical treatment response (typically, based on older‚Ä¶",true
Vchang_lab,"Pediatric oncologist focusing on blood stem cells, aging and cancer susceptibility @ucla. Views are my own. she/her/hers. Personal account @v_e_e_e_e",,,,2020-12-05 15:07:49+00:00,"Vivian Y Chang, MD, MS",http://twitter.com/,0.0,,1.335239458052948e+18,,0.0,0.0,,Total stan over here... thank you Dr Fauci for your service and leadership. #COVID19 #pandemic @ASH_hematology‚Ä¶ https://t.co/vBIJ8hYwPu,en,0.0,464.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/Vchang_lab/statuses/1335239458052947969,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Covid,1.0,0.0,0.0,Total stan over here... thank you Dr Fauci for your service and leadership. #COVID19 #pandemic @ASH_hematology‚Ä¶ https://t.co/vBIJ8hYwPu,true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 17:49:05+00:00,Lisa Palacios,http://twitter.com/,6.0,,1.335280043963142e+18,,0.0,0.0,,RT @lymphomahub: CONGRESS | #ASH20 | @michaelwangmd shows results of Phase 1/2 BRUIN study using selective BTKi LOXO-305 in heavily pre-tre‚Ä¶,en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,2.0,https://twitter.com/Lisa_Palacios/statuses/1335280043963142152,0.0,0.0,,0.0,0.0,0.0,2.0,4.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @lymphomahub: CONGRESS | #ASH20 | @michaelwangmd shows results of Phase 1/2 BRUIN study using selective BTKi LOXO-305 in heavily pre-tre‚Ä¶,true
dgermain21,MD-PhD. 2nd year Heme/Onc fellow focused on lymphoma and leukemia. Physician-scientist-in-training. Tweet/RT not medical advice or endorsement.,,"St. Louis, MO",,2020-12-05 13:40:45+00:00,David A. Russler-Germain,http://twitter.com/,13.0,,1.3352175501127967e+18,,0.0,0.0,,RT @anthonymatomd: Chemotherapy free pathways in #CLL! Newest review on this topic. Algorithms included. Approaches for relapsed #CLL after‚Ä¶,en,0.0,1612.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,9.0,4.0,https://twitter.com/dgermain21/statuses/1335217550112796673,0.0,0.0,,0.0,0.0,0.0,4.0,9.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @anthonymatomd: Chemotherapy free pathways in #CLL! Newest review on this topic. Algorithms included. Approaches for relapsed #CLL after‚Ä¶,false
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-12-05 05:05:14+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,1.0,,1.3350878143214428e+18,,0.0,0.0,,"#ASH20 #leusm Wei: median OS in AML patients refractory or relapsed after HMA/Ven is very poor, here 2.4 mos. https://t.co/FKR63Mldtl",en,0.0,4813.0,,,0.0,,,Negative,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/hemedoc/statuses/1335087814321442816,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,1.0,0.0,"#ASH20 #leusm Wei: median OS in AML patients refractory or relapsed after HMA/Ven is very poor, here 2.4 mos. https://t.co/FKR63Mldtl",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-05 02:14:22+00:00,"Ritcha Saxena, MD",http://twitter.com/,10.0,,1.3350448168671273e+18,,0.0,0.0,,"RT @DanaFarber: #ASH20 News: Donor stem cell transplant shown to improve survival in older patients with #MDS. Dana-Farber's Corey Cutler,‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,7.0,3.0,https://twitter.com/RitchaSaxena/statuses/1335044816867127298,0.0,0.0,,0.0,0.0,0.0,3.0,7.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @DanaFarber: #ASH20 News: Donor stem cell transplant shown to improve survival in older patients with #MDS. Dana-Farber's Corey Cutler,‚Ä¶",true
SandyWong02111,UCSF Hematologist and BMT physician,,"San Francisco, CA",,2020-12-05 18:45:06+00:00,Sandy Wong,http://twitter.com/,53.0,,1.3352941421050634e+18,,0.0,0.0,,RT @ninashah33: Bb2121: everything you wanted to know but were too afraid to ask: Ide-cel phase 1 long term FU‚Äî&gt; DOR 2y in responders and O‚Ä¶,en,0.0,759.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,41.0,12.0,https://twitter.com/SandyWong02111/statuses/1335294142105063429,0.0,0.0,,0.0,0.0,0.0,12.0,41.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @ninashah33: Bb2121: everything you wanted to know but were too afraid to ask: Ide-cel phase 1 long term FU‚Äî&gt; DOR 2y in responders and O‚Ä¶,true
mpdrc,Executive Director- Mays Cancer Center at UT Health San Antonio MD Anderson; (Views on Twitter are personal opinion),,"UT Health San Antonio ,TX, USA",,2020-12-05 23:11:12+00:00,"Ruben A. Mesa, MD",http://twitter.com/,9.0,,1.3353611086564844e+18,,0.0,0.0,,"RT @VJHemOnc: Highlights from #MPNsm new therapies &amp; JAKi based combinations for #Myelofibrosis orals at #ASH20

Srdan Verstovesk presented‚Ä¶",en,0.0,3222.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,3.0,https://twitter.com/mpdrc/statuses/1335361108656484352,0.0,0.0,,0.0,0.0,0.0,3.0,6.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @VJHemOnc: Highlights from #MPNsm new therapies &amp; JAKi based combinations for #Myelofibrosis orals at #ASH20

Srdan Verstovesk presented‚Ä¶",true
NicoleKuderer,"Translational Oncologist (Biomarkers, Toxicities, Health Outcomes, Clinico-Genomic Big Data, @OncoAlert). Motto: ""Let's make a difference"". Tweets are my own.",,USA,,2020-12-05 21:46:36+00:00,Nicole Kuderer,http://twitter.com/,24.0,,1.3353398185915597e+18,,0.0,0.0,,RT @RosovskyRachel: Grateful for opportunity to work with CCC19 thrombosis team on this important topic. Tune #ASH20 Abst 204 today; 12 pm‚Ä¶,en,0.0,6212.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,19.0,5.0,https://twitter.com/NicoleKuderer/statuses/1335339818591559680,0.0,0.0,,0.0,0.0,0.0,5.0,19.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @RosovskyRachel: Grateful for opportunity to work with CCC19 thrombosis team on this important topic. Tune #ASH20 Abst 204 today; 12 pm‚Ä¶,true
CanerSaygin,"Heme-Onc Fellow @UChicago | Alumni of @OhioStateIMRes, @CCLRI | #Leukemia, #MDS, #CHIP physician-scientist. Tweets=own opinions.",,"Chicago, IL",,2020-12-05 19:22:52+00:00,"Caner Saygin, MD",http://twitter.com/,6.0,,1.3353036449468334e+18,,0.0,0.0,,"RT @UCHemOncFellows: And our fellows have had a chance to contribute to #ASH20 educational manuscripts as well!

@CanerSaygin on therapies‚Ä¶",en,0.0,743.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,2.0,https://twitter.com/CanerSaygin/statuses/1335303644946833409,0.0,0.0,,0.0,0.0,0.0,2.0,4.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"RT @UCHemOncFellows: And our fellows have had a chance to contribute to #ASH20 educational manuscripts as well!

@CanerSaygin on therapies‚Ä¶",false
DrMDavids,"Hematologist/oncologist, CLL researcher, director of #lymphoma clinical research @DanaFarber, faculty @harvardmed. Tweets are my own & not medical advice.",,"Boston, USA",,2020-12-05 22:06:21+00:00,"Matthew Davids, MD, MMSc",http://twitter.com/,20.0,,1.3353447859771187e+18,,0.0,0.0,,"RT @doctorpemm: #ASH20 AML oral presentation session. Fantastic talk phase I, 2 arm study (Prior SCT vs no prior SCT) Dec+IPI in patients w‚Ä¶",en,0.0,2195.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,14.0,6.0,https://twitter.com/DrMDavids/statuses/1335344785977118720,0.0,0.0,,0.0,0.0,0.0,6.0,14.0,False,False,False,False,True,Clinical Trials,1.0,0.0,0.0,"RT @doctorpemm: #ASH20 AML oral presentation session. Fantastic talk phase I, 2 arm study (Prior SCT vs no prior SCT) Dec+IPI in patients w‚Ä¶",true
mpndoc,Physician-scientist. Myeloproliferative neoplasms. Genomics. Mass cytometry. #mpnsm. #CyTOF. #multipleximaging.,,"St. Louis, MO",,2020-12-05 01:35:03+00:00,Stephen Oh,http://twitter.com/,4.0,,1.3350349220132495e+18,,0.0,0.0,,#ASH20 #mpnsm community rest up tonight and get ready for a MPN clinical oral session in the AM (moderated by mysel‚Ä¶ https://t.co/LtzAc3S3bZ,en,0.0,1079.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,4.0,https://twitter.com/mpndoc/statuses/1335034922013249536,0.0,0.0,,0.0,0.0,0.0,4.0,0.0,False,False,False,False,True,Disease Advocacy,0.0,0.0,1.0,#ASH20 #mpnsm community rest up tonight and get ready for a MPN clinical oral session in the AM (moderated by mysel‚Ä¶ https://t.co/LtzAc3S3bZ,true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-12-05 16:24:02+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,1.0,,1.335258641054589e+18,,0.0,0.0,,"#ASH20 #bmtsm Zeiser: Also, importantly, trend toward more fungal infections with Rux (11.5% vs 5.7%), but no diff‚Ä¶ https://t.co/YJgvmrYV9Y",en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/hemedoc/statuses/1335258641054588930,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"#ASH20 #bmtsm Zeiser: Also, importantly, trend toward more fungal infections with Rux (11.5% vs 5.7%), but no diff‚Ä¶ https://t.co/YJgvmrYV9Y",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 22:54:13+00:00,Lisa Palacios,http://twitter.com/,3.0,,1.3353568315443077e+18,,0.0,0.0,,RT @drsangeetmd: üëâüèº Can Ven be added to intensive chemo - Seems to be Yes - Trial being led by @DrHKantarjian @TapKadia @garciamanero @musa‚Ä¶,en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,1.0,2.0,https://twitter.com/Lisa_Palacios/statuses/1335356831544307712,0.0,0.0,,0.0,0.0,0.0,2.0,1.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @drsangeetmd: üëâüèº Can Ven be added to intensive chemo - Seems to be Yes - Trial being led by @DrHKantarjian @TapKadia @garciamanero @musa‚Ä¶,true
DrShaniJ,Pediatric heme/onc fellow @TexasChildrens| #SickleCell advocate & physician-scientist in training | @LurieChildrens @DukeMedSchool @UF Alum| Tweets 100% my own,,"Houston, TX",,2020-12-05 20:33:30+00:00,"Shani Johnson, MD",http://twitter.com/,29.0,,1.3353214229111237e+18,,0.0,0.0,,RT @PTMcGann: @DrSickleStrong is always an incredible speaker but this #ASH20 talk is a must watch. He carefully and clearly describes the‚Ä¶,en,0.0,430.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,21.0,8.0,https://twitter.com/DrShaniJ/statuses/1335321422911123457,0.0,0.0,,0.0,0.0,0.0,8.0,21.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,RT @PTMcGann: @DrSickleStrong is always an incredible speaker but this #ASH20 talk is a must watch. He carefully and clearly describes the‚Ä¶,true
drjgauthier,"MD, MSc, Assistant Professor @fredhutch @UW focused on #CARTcell #immunotherapy #tcellrx 
Interests also include #rstats #bmtsm #epitwitter #bayes",,"Seattle, WA",,2020-12-05 15:59:05+00:00,Jordan Gauthier,http://twitter.com/,21.0,,1.335252361745318e+18,,0.0,0.0,,RT @UjjaniC: #ASH president @StephanieLeeMD from @SeattleCCA @fredhutch leading an amazing chat on #COVID19 with Dr. Fauci. #ASH20 #ASH2020‚Ä¶,en,0.0,3295.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,15.0,6.0,https://twitter.com/drjgauthier/statuses/1335252361745317888,0.0,0.0,,0.0,0.0,0.0,6.0,15.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @UjjaniC: #ASH president @StephanieLeeMD from @SeattleCCA @fredhutch leading an amazing chat on #COVID19 with Dr. Fauci. #ASH20 #ASH2020‚Ä¶,false
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 16:27:05+00:00,Lisa Palacios,http://twitter.com/,4.0,,1.3352594093548052e+18,,0.0,0.0,,"RT @amarkelkar: Phase II Trial of Cladribine/LDAC+Venetoclax in Older Adults presented by Dr.@TapKadia.
-Median OS not yet reached
-1-year‚Ä¶",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,2.0,2.0,https://twitter.com/Lisa_Palacios/statuses/1335259409354805250,0.0,0.0,,0.0,0.0,0.0,2.0,2.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @amarkelkar: Phase II Trial of Cladribine/LDAC+Venetoclax in Older Adults presented by Dr.@TapKadia.
-Median OS not yet reached
-1-year‚Ä¶",true
Lymphoma_Doc,"Director of Clinical Research, Section Chief of Aggressive Lymphomas at MD Anderson Cancer Center, CAR T-cell, dreamer and doer. Opinions are mine",,"Houston, TX",,2020-12-05 16:42:43+00:00,"Jason Westin, MD FACP",http://twitter.com/,4.0,,1.3352633442830336e+18,,0.0,0.0,,"My annual complaint at ASH: CR is complete response, it is not complete remission. 
Response is categorical, remiss‚Ä¶ https://t.co/k0uu4JfjJM",en,0.0,5105.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,4.0,https://twitter.com/Lymphoma_Doc/statuses/1335263344283033600,0.0,0.0,,0.0,0.0,0.0,4.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"My annual complaint at ASH: CR is complete response, it is not complete remission. 
Response is categorical, remiss‚Ä¶ https://t.co/k0uu4JfjJM",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 20:21:55+00:00,Lisa Palacios,http://twitter.com/,18.0,,1.3353185059363144e+18,,0.0,0.0,,RT @doctorpemm: #ASH20 Nice talk by Dr Sameem Abedin Ph I #Lintuzumab #Ac225 + #CLAGM in patients with R/R AML N=15 #radioImmunoChemotherap‚Ä¶,en,0.0,657.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,16.0,2.0,https://twitter.com/Lisa_Palacios/statuses/1335318505936314368,0.0,0.0,,0.0,0.0,0.0,2.0,16.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @doctorpemm: #ASH20 Nice talk by Dr Sameem Abedin Ph I #Lintuzumab #Ac225 + #CLAGM in patients with R/R AML N=15 #radioImmunoChemotherap‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-05 05:33:07+00:00,"Ritcha Saxena, MD",http://twitter.com/,27.0,,1.335094832344277e+18,,0.0,0.0,,RT @mpndoc: #ASH20 #mpnsm community rest up tonight and get ready for a MPN clinical oral session in the AM (moderated by myself and Lucia‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,23.0,4.0,https://twitter.com/RitchaSaxena/statuses/1335094832344276992,0.0,0.0,,0.0,0.0,0.0,4.0,23.0,False,False,False,False,True,Disease Advocacy,0.0,0.0,1.0,RT @mpndoc: #ASH20 #mpnsm community rest up tonight and get ready for a MPN clinical oral session in the AM (moderated by myself and Lucia‚Ä¶,true
JerroldLevy,"Critical care physician in CTICU @DukeMedSchool, interested in coagulation, bleeding, inflammation-also oenophile and foody. Tweets are my own (‚â†medical advice)",,"Durham, North Carolina",,2020-12-05 14:37:44+00:00,"Jerrold Levy, MD",http://twitter.com/,25.0,,1.3352318905682125e+18,,0.0,0.0,,"RT @LaurenMerzMD: LOVED this talk from @sholzberg at #ASH20 on delivery, postpartum period, and health equity in women with bleeding disord‚Ä¶",en,0.0,1755.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,20.0,5.0,https://twitter.com/JerroldLevy/statuses/1335231890568212484,0.0,0.0,,0.0,0.0,0.0,5.0,20.0,False,False,False,False,True,Financial Performance,1.0,0.0,0.0,"RT @LaurenMerzMD: LOVED this talk from @sholzberg at #ASH20 on delivery, postpartum period, and health equity in women with bleeding disord‚Ä¶",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 17:43:01+00:00,Lisa Palacios,http://twitter.com/,3.0,,1.335278517085479e+18,,0.0,0.0,,RT @MarkGeyerMD: @wwierda presents on pts achieving MRD-undetectable (MRDu) on CAPTIVATE (phase 2 study of IBR/VEN x1 yr fixed) -&gt; at 1 yr‚Ä¶,en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,2.0,1.0,https://twitter.com/Lisa_Palacios/statuses/1335278517085478924,0.0,0.0,,0.0,0.0,0.0,1.0,2.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @MarkGeyerMD: @wwierda presents on pts achieving MRD-undetectable (MRDu) on CAPTIVATE (phase 2 study of IBR/VEN x1 yr fixed) -&gt; at 1 yr‚Ä¶,false
fniainle,"Haematologist, passionate about VTE. Co-director @ConwaySphere; Director https://t.co/csdWq9XJ57; RT not endorsement, views my own",,"Dublin City, Ireland",,2020-12-05 18:22:05+00:00,Fionnuala N√≠ √Åinle,http://twitter.com/,18.0,,1.3352883504927252e+18,,0.0,0.0,,RT @AggieLeeMD: Brilliant Q&amp;A session on diagnostic and prognostic models in VTE management ready for prime time chaired by @fniainle #ASHK‚Ä¶,en,0.0,2069.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,15.0,3.0,https://twitter.com/fniainle/statuses/1335288350492725249,0.0,0.0,,0.0,0.0,0.0,3.0,15.0,False,False,False,False,True,Diagnostic Tools,1.0,0.0,0.0,RT @AggieLeeMD: Brilliant Q&amp;A session on diagnostic and prognostic models in VTE management ready for prime time chaired by @fniainle #ASHK‚Ä¶,true
UrviShahMD,Oncologist and researcher on Myeloma service @sloan_kettering. Interested in nutrition for cancer and immune therapies. Views are my own,,"New York, NY",,2020-12-05 17:27:24+00:00,Urvi Shah,http://twitter.com/,62.0,,1.335274585831379e+18,,0.0,0.0,,"RT @DrMiguelPerales: Busy day today for @sloan_kettering investigators at @ASH_hematology #ASH20 Check out the schedule for talks, oral pre‚Ä¶",en,0.0,1227.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,50.0,12.0,https://twitter.com/UrviShahMD/statuses/1335274585831378948,0.0,0.0,,0.0,0.0,0.0,12.0,50.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,"RT @DrMiguelPerales: Busy day today for @sloan_kettering investigators at @ASH_hematology #ASH20 Check out the schedule for talks, oral pre‚Ä¶",true
KirovDoc,"MD, Ph.D., Hematologist at Kirov Research Institute of Hematology and Blood transfusion",,Russia,,2020-12-06 11:34:34+00:00,Alexander Luchinin,http://twitter.com/,16.0,,1.335548181439017e+18,,0.0,0.0,,RT @theMMRF: Talquetamab: 1st in class off-the-shelf GPRC5D X CD3 bispecific antibody. Phase 1 study of 102 pts with IV dosing and 55 pts w‚Ä¶,en,0.0,27.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,13.0,3.0,https://twitter.com/KirovDoc/statuses/1335548181439016960,0.0,0.0,,0.0,0.0,0.0,3.0,13.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @theMMRF: Talquetamab: 1st in class off-the-shelf GPRC5D X CD3 bispecific antibody. Phase 1 study of 102 pts with IV dosing and 55 pts w‚Ä¶,true
AmaHemonc,Hematologist and Oncologist proudly serving the people of TX Panhandle. The views/opinions = personal and don‚Äôt reflect Texas Oncology or US Oncology,,"Amarillo, TX",,2020-12-06 17:47:08+00:00,#HemOnc#AMA,http://twitter.com/,0.0,,1.3356419419340431e+18,,0.0,0.0,,Another interesting phase1b study antiCD47 Magrolimabwith Aza in unfit AML patients #ASH20 .Look forward for phase 3 Ven+AZA vs Magrolimab,en,0.0,8.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/AmaHemonc/statuses/1335641941934043136,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,Another interesting phase1b study antiCD47 Magrolimabwith Aza in unfit AML patients #ASH20 .Look forward for phase 3 Ven+AZA vs Magrolimab,true
EileenMBoyle,"MD,PhD, post-doctoral fellow, Myeloma Research Program, @nyulangone, opinions are my own.",,"New York, USA",,2020-12-06 22:53:19+00:00,Eileen M. Boyle,http://twitter.com/,0.0,,1.3357189965539492e+18,,0.0,0.0,,Kudos to Dr Maclachlan et al @MSKCC for her abstract presented today. Innovative and unbiaised way of identifying c‚Ä¶ https://t.co/IZZ3sOGeyb,en,0.0,112.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/EileenMBoyle/statuses/1335718996553949187,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,Kudos to Dr Maclachlan et al @MSKCC for her abstract presented today. Innovative and unbiaised way of identifying c‚Ä¶ https://t.co/IZZ3sOGeyb,true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-06 18:39:49+00:00,Lisa Palacios,http://twitter.com/,36.0,,1.335655199936045e+18,,0.0,0.0,,"RT @razan_mohty: FLAG-IDA-VEN in newly diagnosed and R/R #AML by Dr Curtis Lachowiez - high CR rate, higher in newly diagnosed - Acceptable‚Ä¶",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,28.0,8.0,https://twitter.com/Lisa_Palacios/statuses/1335655199936045056,0.0,0.0,,0.0,0.0,0.0,8.0,28.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"RT @razan_mohty: FLAG-IDA-VEN in newly diagnosed and R/R #AML by Dr Curtis Lachowiez - high CR rate, higher in newly diagnosed - Acceptable‚Ä¶",false
UrviShahMD,Oncologist and researcher on Myeloma service @sloan_kettering. Interested in nutrition for cancer and immune therapies. Views are my own,,"New York, NY",,2020-12-06 18:24:07+00:00,Urvi Shah,http://twitter.com/,24.0,,1.3356512476475802e+18,,0.0,0.0,,RT @MalinHultcrantz: Great news! The first 10 patients treated with CRISPR edited stem cells (CTX001) are transfusion independent and and v‚Ä¶,en,0.0,1227.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,19.0,5.0,https://twitter.com/UrviShahMD/statuses/1335651247647580169,0.0,0.0,,0.0,0.0,0.0,5.0,19.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @MalinHultcrantz: Great news! The first 10 patients treated with CRISPR edited stem cells (CTX001) are transfusion independent and and v‚Ä¶,true
dgermain21,MD-PhD. 2nd year Heme/Onc fellow focused on lymphoma and leukemia. Physician-scientist-in-training. Tweet/RT not medical advice or endorsement.,,"St. Louis, MO",,2020-12-06 23:30:35+00:00,David A. Russler-Germain,http://twitter.com/,23.0,,1.3357283724382003e+18,,0.0,0.0,,"RT @lymphomahub: CONGRESS | #ASH20 |@DocHutchings, @Rigshospitalet, presents the data from a phase I/II study evaluating the SC bispecific‚Ä¶",en,0.0,1612.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,18.0,5.0,https://twitter.com/dgermain21/statuses/1335728372438200321,0.0,0.0,,0.0,0.0,0.0,5.0,18.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @lymphomahub: CONGRESS | #ASH20 |@DocHutchings, @Rigshospitalet, presents the data from a phase I/II study evaluating the SC bispecific‚Ä¶",true
Rfonsi1,"Interim Executive Director, Mayo Clinic Cancer Center. Myeloma doctor. Visiting Healthcare Fellow @GoldwaterInst. Tweets-own/RT not an endorsement",,,,2020-12-06 23:58:26+00:00,Rafael Fonseca MD,http://twitter.com/,2.0,,1.3357353826719089e+18,,0.0,0.0,,Symptom Burden in Transplant Ineligible Patients with Newly Diagnosed MM: A Population-Based Study of Patient-Repor‚Ä¶ https://t.co/IBIvVnaIOB,en,0.0,8301.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/Rfonsi1/statuses/1335735382671908865,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,Symptom Burden in Transplant Ineligible Patients with Newly Diagnosed MM: A Population-Based Study of Patient-Repor‚Ä¶ https://t.co/IBIvVnaIOB,true
StefanoLuminari,"Medical oncologist/hematologist , lymphomaniac, bike rider, chair of the Indolent Lymphoma committee of FIL @filinf.it  @unimore.it @irccs_re.it",,,,2020-12-06 22:12:26+00:00,"Stefano Luminari, MD",http://twitter.com/,0.0,,1.3357087045498552e+18,,0.0,0.0,,No progressions after pembro-gvd in rr HL by moskowitz et al #ASH2020 small phase II study but results used to take‚Ä¶ https://t.co/ltxM3qhqHb,en,0.0,2250.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/StefanoLuminari/statuses/1335708704549855236,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,No progressions after pembro-gvd in rr HL by moskowitz et al #ASH2020 small phase II study but results used to take‚Ä¶ https://t.co/ltxM3qhqHb,true
CanerSaygin,"Heme-Onc Fellow @UChicago | Alumni of @OhioStateIMRes, @CCLRI | #Leukemia, #MDS, #CHIP physician-scientist. Tweets=own opinions.",,"Chicago, IL",,2020-12-06 17:43:39+00:00,"Caner Saygin, MD",http://twitter.com/,2.0,,1.3356410644940308e+18,,0.0,0.0,,Dr Sallman presenting impressive phase I results of AZA + magrolimab in first-line #AML treatment. On-target anemia‚Ä¶ https://t.co/HpM2wwKwjl,en,0.0,743.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/CanerSaygin/statuses/1335641064494030850,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Clinical Trials,1.0,0.0,0.0,Dr Sallman presenting impressive phase I results of AZA + magrolimab in first-line #AML treatment. On-target anemia‚Ä¶ https://t.co/HpM2wwKwjl,true
Physns1stWatch,Physician's First Watch offers brief daily reviews of news that affects a physician's practice.,,"Waltham, MA",,2020-12-06 02:15:56+00:00,PhysiciansFirstWatch,http://twitter.com/,2.0,,1.335407597583741e+18,,0.0,0.0,,News from #ASH2020: Dr. Haydar Frangoul talks about his team's work in developing a novel way to treat transfusion-‚Ä¶ https://t.co/dh3Ldgnptg,en,0.0,16507.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/Physns1stWatch/statuses/1335407597583740929,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,News from #ASH2020: Dr. Haydar Frangoul talks about his team's work in developing a novel way to treat transfusion-‚Ä¶ https://t.co/dh3Ldgnptg,false
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 20:15:17+00:00,"Ritcha Saxena, MD",http://twitter.com/,12.0,,1.335679223638405e+18,,0.0,0.0,,RT @GabyHobbs: Impressive results from the phase I EXPLORER study by Dr. Gotlib #ASH2020 https://t.co/B2DvFb9IiV,en,0.0,6875.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,2.0,https://twitter.com/RitchaSaxena/statuses/1335679223638405122,0.0,0.0,,0.0,0.0,0.0,2.0,10.0,False,False,False,False,True,Clinical Trials,1.0,0.0,0.0,RT @GabyHobbs: Impressive results from the phase I EXPLORER study by Dr. Gotlib #ASH2020 https://t.co/B2DvFb9IiV,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 15:59:20+00:00,"Ritcha Saxena, MD",http://twitter.com/,3.0,,1.335614810722087e+18,,0.0,0.0,,RT @CanerSaygin: Another feasibility phase I/II study from Dr Yilmaz showing quizartinib + 10d decitabine and venetoclax in newly diagnosed‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,2.0,1.0,https://twitter.com/RitchaSaxena/statuses/1335614810722086913,0.0,0.0,,0.0,0.0,0.0,1.0,2.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @CanerSaygin: Another feasibility phase I/II study from Dr Yilmaz showing quizartinib + 10d decitabine and venetoclax in newly diagnosed‚Ä¶,true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-06 22:03:30+00:00,Lisa Palacios,http://twitter.com/,6.0,,1.335706459577987e+18,,0.0,0.0,,"RT @hemedoc: #ASH20 #leusm Sasaki: IZKF1del can be subtyped by site of deletion, which lead to either haploinsufficiency or dominant negati‚Ä¶",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,3.0,https://twitter.com/Lisa_Palacios/statuses/1335706459577987084,0.0,0.0,,0.0,0.0,0.0,3.0,3.0,False,False,False,False,True,Insurance Coverage,0.0,0.0,1.0,"RT @hemedoc: #ASH20 #leusm Sasaki: IZKF1del can be subtyped by site of deletion, which lead to either haploinsufficiency or dominant negati‚Ä¶",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-06 18:30:26+00:00,Lisa Palacios,http://twitter.com/,10.0,,1.3356528394362675e+18,,0.0,0.0,,RT @razan_mohty: Venetoclax + Gilteritinib for R/R FLT3-Mutated #AML in the Expansion Cohort of a Phase 1b Study by Dr Naval Daver - Nice r‚Ä¶,en,0.0,657.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,4.0,https://twitter.com/Lisa_Palacios/statuses/1335652839436267520,0.0,0.0,,0.0,0.0,0.0,4.0,6.0,False,False,False,False,True,Clinical Trials,1.0,0.0,0.0,RT @razan_mohty: Venetoclax + Gilteritinib for R/R FLT3-Mutated #AML in the Expansion Cohort of a Phase 1b Study by Dr Naval Daver - Nice r‚Ä¶,true
RaajitRampal,"Physician-Scientist, focused on #MPN and #AML  @sloan_kettering #MPNSM",,"New York, NY",,2020-12-06 23:10:33+00:00,"Raajit Rampal, M.D.Ph.D.",http://twitter.com/,3.0,,1.33572333244928e+18,,0.0,0.0,,We‚Äôve been focusing on introducing new treatments at ASH thus far. Now we have data on the prospect of  INF discont‚Ä¶ https://t.co/L4pEmlg8Uy,en,0.0,607.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/RaajitRampal/statuses/1335723332449280001,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,We‚Äôve been focusing on introducing new treatments at ASH thus far. Now we have data on the prospect of  INF discont‚Ä¶ https://t.co/L4pEmlg8Uy,true
AzizNazhaMD,"Practice Manager at Amazon Web Services, Physician, #Programmer, #DataScientist, interested in the Digital Transformation of Healthcare",,Cleveland Clinic,,2020-12-07 16:21:56+00:00,Aziz Nazha,http://twitter.com/,0.0,,1.33598288992265e+18,,0.0,0.0,,"Our personalized prediction using explainable #AI,  Our #AI algorithm to predict MDS diagnosis from CBC and mutatio‚Ä¶ https://t.co/loYtW8uxZd",en,0.0,2087.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/AzizNazhaMD/statuses/1335982889922650115,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"Our personalized prediction using explainable #AI,  Our #AI algorithm to predict MDS diagnosis from CBC and mutatio‚Ä¶ https://t.co/loYtW8uxZd",false
TheUSONetwork,The US Oncology Network is one of the nation‚Äôs largest networks of community-based oncology physicians dedicated to advancing cancer care in America.,,"The Woodlands, Texas",,2020-12-07 05:10:01+00:00,US Oncology Network,http://twitter.com/,0.0,,1.335813795911e+18,,0.0,0.0,,TUNE IN #ASH20 (12/6 12:15 p.m. et.): ‚ÄúSingle-Agent Mosunetuzumab Is a Promising Safe and Efficacious Chemotherapy-‚Ä¶ https://t.co/3LXX7rqU0g,en,0.0,6914.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/TheUSONetwork/statuses/1335813795911000066,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,TUNE IN #ASH20 (12/6 12:15 p.m. et.): ‚ÄúSingle-Agent Mosunetuzumab Is a Promising Safe and Efficacious Chemotherapy-‚Ä¶ https://t.co/3LXX7rqU0g,true
KirovDoc,"MD, Ph.D., Hematologist at Kirov Research Institute of Hematology and Blood transfusion",,Russia,,2020-12-07 04:31:46+00:00,Alexander Luchinin,http://twitter.com/,22.0,,1.3358041695302574e+18,,0.0,0.0,,"RT @MM_Hub: CONGRESS | #ASH20 |Maria-Victoria Mateos, @mvmateos, presented results of phase II GEM-KyCyDex trial, showing the addition of C‚Ä¶",en,0.0,27.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,12.0,10.0,https://twitter.com/KirovDoc/statuses/1335804169530257409,0.0,0.0,,0.0,0.0,0.0,10.0,12.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @MM_Hub: CONGRESS | #ASH20 |Maria-Victoria Mateos, @mvmateos, presented results of phase II GEM-KyCyDex trial, showing the addition of C‚Ä¶",true
Lachelle_Dawn,heme-onc fellow | physician-scientist | racial justice & health equity | views are mine | there will be typos | i tweet what i want | pronouns: she/her/hers,,"Boston, MA",,2020-12-07 01:01:16+00:00,Lachelle Dawn,http://twitter.com/,0.0,,1.335751192832512e+18,,0.0,0.0,,#ASHKudos to @UDurani for this wonderful effort to characterize the impact of the pandemic on hematology training.‚Ä¶ https://t.co/XB9G2P29FS,en,0.0,3338.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/Lachelle_Dawn/statuses/1335751192832512001,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Covid,1.0,0.0,0.0,#ASHKudos to @UDurani for this wonderful effort to characterize the impact of the pandemic on hematology training.‚Ä¶ https://t.co/XB9G2P29FS,true
bloodgenes,"Pediatric Hematologist/Oncologist, Geneticist, Stem Cell Biologist - @DFBC_PedCare, @BostonChildrens, @DanaFarber & @broadinstitute",,"Boston, MA",,2020-12-07 16:31:27+00:00,Vijay Sankaran,http://twitter.com/,12.0,,1.3359852832678707e+18,,0.0,0.0,,"RT @JoannaS_Yi: A longer-acting asparaginase soon be available for ALL pts, based on the single agent phase 2 trial NOR-GRASPALL2016 (NCT03‚Ä¶",en,0.0,4057.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,9.0,3.0,https://twitter.com/bloodgenes/statuses/1335985283267870722,0.0,0.0,,0.0,0.0,0.0,3.0,9.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @JoannaS_Yi: A longer-acting asparaginase soon be available for ALL pts, based on the single agent phase 2 trial NOR-GRASPALL2016 (NCT03‚Ä¶",true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-12-07 18:14:05+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,0.0,,1.3360111109991834e+18,,0.0,0.0,,"#ASH20 #leusm Garcia (584): In MVA, the only variable predicting CSF relapse was MFC pos CSF at diagnosis. 3yr cumu‚Ä¶ https://t.co/gdvfT6xoz7",en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/hemedoc/statuses/1336011110999183360,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"#ASH20 #leusm Garcia (584): In MVA, the only variable predicting CSF relapse was MFC pos CSF at diagnosis. 3yr cumu‚Ä¶ https://t.co/gdvfT6xoz7",true
AzizNazhaMD,"Practice Manager at Amazon Web Services, Physician, #Programmer, #DataScientist, interested in the Digital Transformation of Healthcare",,Cleveland Clinic,,2020-12-07 23:37:49+00:00,Aziz Nazha,http://twitter.com/,20.0,,1.3360925818606797e+18,,0.0,0.0,,RT @Dr_AmerZeidan: Nice data from IMerge study updating on activity of imetelstat in lower risk #MDSsm from the phase 2 part of study with‚Ä¶,en,0.0,2087.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,14.0,6.0,https://twitter.com/AzizNazhaMD/statuses/1336092581860679680,0.0,0.0,,0.0,0.0,0.0,6.0,14.0,False,False,False,False,True,Clinical Trials,1.0,0.0,0.0,RT @Dr_AmerZeidan: Nice data from IMerge study updating on activity of imetelstat in lower risk #MDSsm from the phase 2 part of study with‚Ä¶,false
CBCIDocs,Thoughts and perspectives from the hematology and transplant physicians at Colorado Blood Cancer Institute @ColoradoBlood @SarahCannonDocs @PresStLukesDenv,,"Denver, CO",,2020-12-07 03:11:01+00:00,CBCI,http://twitter.com/,4.0,,1.3357838469360763e+18,,0.0,0.0,,"RT @EghtedarAli: Strong data by MDACC BMT group: randomized phase III study of clofarabine plus Flu/Bu conditioning vs Flu/Bu in AML/MDS
#A‚Ä¶",en,0.0,782.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,2.0,2.0,https://twitter.com/CBCIDocs/statuses/1335783846936076289,0.0,0.0,,0.0,0.0,0.0,2.0,2.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"RT @EghtedarAli: Strong data by MDACC BMT group: randomized phase III study of clofarabine plus Flu/Bu conditioning vs Flu/Bu in AML/MDS
#A‚Ä¶",true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-12-07 18:05:51+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,2.0,,1.3360090413199196e+18,,0.0,0.0,,"#ASH20 #leusm Garcia (584): MFC analysis of CSF at diagnosis of ALL in adults treated with hCVAD (n=92, 80% B-ALL).‚Ä¶ https://t.co/OZ5H2qNpyY",en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/hemedoc/statuses/1336009041319919616,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"#ASH20 #leusm Garcia (584): MFC analysis of CSF at diagnosis of ALL in adults treated with hCVAD (n=92, 80% B-ALL).‚Ä¶ https://t.co/OZ5H2qNpyY",true
chanyooncheah,Doctor for patients with lymphoma. Clinical researcher.,,"Perth, Western Australia",,2020-12-07 23:00:27+00:00,Chan Cheah,http://twitter.com/,0.0,,1.336083177937326e+18,,0.0,0.0,,@nadahamad @prp_diciaccio @SnowdomeAU Congrats @prp_diciaccio @nadahamad and all #australasianlymphomaalliance coll‚Ä¶ https://t.co/KNMFjr37oW,en,0.0,1717.0,,,0.0,nadahamad,1.3360716993940193e+18,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/chanyooncheah/statuses/1336083177937326082,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,@nadahamad @prp_diciaccio @SnowdomeAU Congrats @prp_diciaccio @nadahamad and all #australasianlymphomaalliance coll‚Ä¶ https://t.co/KNMFjr37oW,true
MariaAmaya_27,"Physician Scientist, University of Colorado | MDS, AML | Tweets are my own | üáªüá™",,"Denver, CO",,2020-12-07 13:48:14+00:00,"Maria Amaya, MD PhD",http://twitter.com/,13.0,,1.3359442075974492e+18,,0.0,0.0,,"RT @AML_Hub: Congress| #ASH20| @DanPollyea, @uchealth, presented data from an ongoing phase III study that showed higher response rates, lo‚Ä¶",en,0.0,430.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,3.0,https://twitter.com/MariaAmaya_27/statuses/1335944207597449218,0.0,0.0,,0.0,0.0,0.0,3.0,10.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"RT @AML_Hub: Congress| #ASH20| @DanPollyea, @uchealth, presented data from an ongoing phase III study that showed higher response rates, lo‚Ä¶",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-07 00:45:15+00:00,"Ritcha Saxena, MD",http://twitter.com/,13.0,,1.335747162622333e+18,,0.0,0.0,,RT @AuclairDan: Great work reported by Alissa Visram at #ASH20 on immune profiling of aggressive #myeloma relapsers ‚Å¶@Taxkourel‚Å© #mmsm http‚Ä¶,en,0.0,6875.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,9.0,4.0,https://twitter.com/RitchaSaxena/statuses/1335747162622332928,0.0,0.0,,0.0,0.0,0.0,4.0,9.0,False,False,False,False,True,Diagnosis Progression,1.0,0.0,0.0,RT @AuclairDan: Great work reported by Alissa Visram at #ASH20 on immune profiling of aggressive #myeloma relapsers ‚Å¶@Taxkourel‚Å© #mmsm http‚Ä¶,true
SarahCannonDocs,Fighting Cancer Together. Find out the latest news directly from Sarah Cannon physicians.,,"Nashville, TN",,2020-12-07 18:20:07+00:00,Sarah Cannon Docs,http://twitter.com/,8.0,,1.3360126286243717e+18,,0.0,0.0,,"RT @HCAhealthcare: New research is showing promising results for the treatment of sickle cell disease. @SarahCannonDocs, the Cancer Institu‚Ä¶",en,0.0,2504.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,2.0,https://twitter.com/SarahCannonDocs/statuses/1336012628624371712,0.0,0.0,,0.0,0.0,0.0,2.0,6.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @HCAhealthcare: New research is showing promising results for the treatment of sickle cell disease. @SarahCannonDocs, the Cancer Institu‚Ä¶",false
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-07 17:52:41+00:00,Lisa Palacios,http://twitter.com/,12.0,,1.3360057257646735e+18,,0.0,0.0,,RT @doctorpemm: #ASH20 Outstanding presentation from Dr Emily R Levy on #CRISPR gene üß¨ editing of #chemokine receptors as a novel strategy‚Ä¶,en,0.0,657.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,9.0,3.0,https://twitter.com/Lisa_Palacios/statuses/1336005725764673536,0.0,0.0,,0.0,0.0,0.0,3.0,9.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @doctorpemm: #ASH20 Outstanding presentation from Dr Emily R Levy on #CRISPR gene üß¨ editing of #chemokine receptors as a novel strategy‚Ä¶,true
MDAndersonNews,"The official account of MD Anderson Cancer Center, a leader in cancer care, cancer research and the fight to #EndCancer. Appointments available: 1-877-632-6789.",,"Houston, TX",,2020-12-07 15:35:57+00:00,MD Anderson Cancer Center,http://twitter.com/,17.0,,1.335971314335699e+18,,0.0,0.0,,"RT @OncLive: Allogeneic Off-the-Shelf UCART22 Product Shows Early Activity, Tolerability in CD22+ B-Cell Relapsed/Refractory ALL
@MDAnderso‚Ä¶",en,0.0,114120.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,13.0,4.0,https://twitter.com/MDAndersonNews/statuses/1335971314335698944,0.0,0.0,,0.0,0.0,0.0,4.0,13.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @OncLive: Allogeneic Off-the-Shelf UCART22 Product Shows Early Activity, Tolerability in CD22+ B-Cell Relapsed/Refractory ALL
@MDAnderso‚Ä¶",true
Grilli15,Forensic Pathologist,,"Foggia,Italia",,2020-12-07 19:31:18+00:00,GiovanniMariaGrilli,http://twitter.com/,76.0,,1.3360305422575903e+18,,0.0,0.0,,RT @NovartisCancer: We are committed to the pursuit of cutting-edge medicines and are working to transform what it means to live with blood‚Ä¶,en,0.0,833.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,67.0,9.0,https://twitter.com/Grilli15/statuses/1336030542257590278,0.0,0.0,,0.0,0.0,0.0,9.0,67.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @NovartisCancer: We are committed to the pursuit of cutting-edge medicines and are working to transform what it means to live with blood‚Ä¶,true
CBCIDocs,Thoughts and perspectives from the hematology and transplant physicians at Colorado Blood Cancer Institute @ColoradoBlood @SarahCannonDocs @PresStLukesDenv,,"Denver, CO",,2020-12-07 03:11:06+00:00,CBCI,http://twitter.com/,3.0,,1.3357838669555343e+18,,0.0,0.0,,RT @LukeMtjoy: Now this is really interesting. Dec10Ven compared to intensive chemo. Dec10Ven looks better. Need a true randomized trial...‚Ä¶,en,0.0,782.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,2.0,1.0,https://twitter.com/CBCIDocs/statuses/1335783866955534336,0.0,0.0,,0.0,0.0,0.0,1.0,2.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @LukeMtjoy: Now this is really interesting. Dec10Ven compared to intensive chemo. Dec10Ven looks better. Need a true randomized trial...‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-07 03:58:42+00:00,"Ritcha Saxena, MD",http://twitter.com/,6.0,,1.3357958492223035e+18,,0.0,0.0,,"RT @gjmccaughan: In first collaboration between @ALLGtrials #AMWG and Asian Myeloma Network, #@HangQuach1 presents at #ASH20 Phase II study‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,2.0,https://twitter.com/RitchaSaxena/statuses/1335795849222303749,0.0,0.0,,0.0,0.0,0.0,2.0,4.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @gjmccaughan: In first collaboration between @ALLGtrials #AMWG and Asian Myeloma Network, #@HangQuach1 presents at #ASH20 Phase II study‚Ä¶",true
AzizNazhaMD,"Practice Manager at Amazon Web Services, Physician, #Programmer, #DataScientist, interested in the Digital Transformation of Healthcare",,Cleveland Clinic,,2020-12-07 18:15:02+00:00,Aziz Nazha,http://twitter.com/,3.0,,1.336011351249072e+18,,0.0,0.0,,Paper: A Personalized Clinical-Decision Tool to Improve the Diagnostic Accuracy of Myelodysplastic Syndromes‚Ä¶ https://t.co/xN0rVqBYyA,en,0.0,2087.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/AzizNazhaMD/statuses/1336011351249072131,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Diagnostic Tools,1.0,0.0,0.0,Paper: A Personalized Clinical-Decision Tool to Improve the Diagnostic Accuracy of Myelodysplastic Syndromes‚Ä¶ https://t.co/xN0rVqBYyA,false
kazisaj1,"Haematologist, MSc Clin Ed candidate @EdiUni. #MedEd #MedTwitter #WIMStrongerTogether",,,,2020-12-07 12:59:38+00:00,Sajida Kazi,http://twitter.com/,30.0,,1.3359319770782884e+18,,0.0,0.0,,"RT @DrMMurphy: Today‚Äôs the day! Join us for some thoughtful discussion on #leadership - leading yourSELF, leading others &amp; leading organiza‚Ä¶",en,0.0,226.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,26.0,4.0,https://twitter.com/kazisaj1/statuses/1335931977078288384,0.0,0.0,,0.0,0.0,0.0,4.0,26.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"RT @DrMMurphy: Today‚Äôs the day! Join us for some thoughtful discussion on #leadership - leading yourSELF, leading others &amp; leading organiza‚Ä¶",true
AzizNazhaMD,"Practice Manager at Amazon Web Services, Physician, #Programmer, #DataScientist, interested in the Digital Transformation of Healthcare",,Cleveland Clinic,,2020-12-07 16:25:13+00:00,Aziz Nazha,http://twitter.com/,0.0,,1.3359837139272458e+18,,0.0,0.0,,Thanks to all the collaborators around the globe for their contribution to our work. Molecular landscape of Our #AI‚Ä¶ https://t.co/MAB4mvN1Qb,en,0.0,2087.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/AzizNazhaMD/statuses/1335983713927245826,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,Thanks to all the collaborators around the globe for their contribution to our work. Molecular landscape of Our #AI‚Ä¶ https://t.co/MAB4mvN1Qb,true
LohiOlli,"MD, PhD, Chief of Pediatric Hematology & Oncology Division, Tampere University Hospital, Finland. Translational research on ALL biology. @TampereUniMET",,"Tampere, Suomi",,2020-12-07 07:33:16+00:00,Olli Lohi,http://twitter.com/,12.0,,1.3358498452114596e+18,,0.0,0.0,,"RT @JoannaS_Yi: A longer-acting asparaginase soon be available for ALL pts, based on the single agent phase 2 trial NOR-GRASPALL2016 (NCT03‚Ä¶",en,0.0,460.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,9.0,3.0,https://twitter.com/LohiOlli/statuses/1335849845211459584,0.0,0.0,,0.0,0.0,0.0,3.0,9.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @JoannaS_Yi: A longer-acting asparaginase soon be available for ALL pts, based on the single agent phase 2 trial NOR-GRASPALL2016 (NCT03‚Ä¶",true
andrewcowanmd,"Myeloma/plasma cell disorders MD, Immunotherapy/transplant attending, UW/SCCA/Fred Hutch, Seattle WA",,"Seattle, WA",,2020-12-07 19:44:39+00:00,Andrew Cowan,http://twitter.com/,0.0,,1.3360339034552934e+18,,0.0,0.0,,Our collaboration with @winsoncheung examining comparative outcomes in MM in Alberta vs SEER Medicare highlighted h‚Ä¶ https://t.co/0yq5EWdjK5,en,0.0,553.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/andrewcowanmd/statuses/1336033903455293441,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,Our collaboration with @winsoncheung examining comparative outcomes in MM in Alberta vs SEER Medicare highlighted h‚Ä¶ https://t.co/0yq5EWdjK5,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-07 04:01:23+00:00,"Ritcha Saxena, MD",http://twitter.com/,10.0,,1.335796520399106e+18,,0.0,0.0,,RT @AuclairDan: Paper 2295 - Lilly Wong at #ASH20 on PK/PD results from Phase I of novel CELMoD CC-92480 in relapse #myeloma. Very interest‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,4.0,https://twitter.com/RitchaSaxena/statuses/1335796520399106049,0.0,0.0,,0.0,0.0,0.0,4.0,6.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @AuclairDan: Paper 2295 - Lilly Wong at #ASH20 on PK/PD results from Phase I of novel CELMoD CC-92480 in relapse #myeloma. Very interest‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-07 04:04:20+00:00,"Ritcha Saxena, MD",http://twitter.com/,7.0,,1.3357972663854162e+18,,0.0,0.0,,RT @rajshekharucms: Low concordance between Bone Marrow MRD (10-5) and whole body DW-MRI in #Myeloma ‚û°Ô∏è demonstrates importance of incorpor‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,2.0,https://twitter.com/RitchaSaxena/statuses/1335797266385416192,0.0,0.0,,0.0,0.0,0.0,2.0,5.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @rajshekharucms: Low concordance between Bone Marrow MRD (10-5) and whole body DW-MRI in #Myeloma ‚û°Ô∏è demonstrates importance of incorpor‚Ä¶,false
majorajay,"Hematology/oncology fellow. #lymsm & #mmsm outcomes researcher. Physician-publisher & founder of https://t.co/dPfLt8QVMr, @inTrainingDoc & @inHouseMag.",,"Chicago, IL",,2020-12-05 03:03:17+00:00,"Ajay Major, MD, MBA",http://twitter.com/,30.0,,1.3350571245488947e+18,,0.0,0.0,,"RT @VPrasadMDMPH: Agree with Bernie #ASH20 
We analyzed the benefit of new leukemia drugs here:
https://t.co/shpfPoghcW https://t.co/MzZHCa‚Ä¶",en,0.0,3518.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,22.0,8.0,https://twitter.com/majorajay/statuses/1335057124548894728,0.0,0.0,,0.0,0.0,0.0,8.0,22.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @VPrasadMDMPH: Agree with Bernie #ASH20 
We analyzed the benefit of new leukemia drugs here:
https://t.co/shpfPoghcW https://t.co/MzZHCa‚Ä¶",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-05 19:53:41+00:00,"Ritcha Saxena, MD",http://twitter.com/,7.0,,1.3353114017332795e+18,,0.0,0.0,,RT @EduardoFlavioO1: Ibrutinib+Ven in #CLL 1st line (Captivate) and RR setting (TAP Clarity) showing long term remissions and sustained res‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,3.0,https://twitter.com/RitchaSaxena/statuses/1335311401733279746,0.0,0.0,,0.0,0.0,0.0,3.0,4.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @EduardoFlavioO1: Ibrutinib+Ven in #CLL 1st line (Captivate) and RR setting (TAP Clarity) showing long term remissions and sustained res‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-05 19:55:31+00:00,"Ritcha Saxena, MD",http://twitter.com/,14.0,,1.3353118624900751e+18,,0.0,0.0,,RT @mpdrc: Excited for the upcoming start of First #ASHFromHome MPN Clinical Session : New Therapies and JAKi-Based Combinations for Myelof‚Ä¶,en,0.0,6875.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,4.0,https://twitter.com/RitchaSaxena/statuses/1335311862490075138,0.0,0.0,,0.0,0.0,0.0,4.0,10.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @mpdrc: Excited for the upcoming start of First #ASHFromHome MPN Clinical Session : New Therapies and JAKi-Based Combinations for Myelof‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-05 20:36:26+00:00,"Ritcha Saxena, MD",http://twitter.com/,2.0,,1.3353221602195128e+18,,0.0,0.0,,RT @feldstej: Advances in Diagnosis and Management of Myelodysplastic Syndromes https://t.co/3kZ3mo60gz #ASH20 #ASH2020 #ASHFromHome #ASHTo‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/RitchaSaxena/statuses/1335322160219512833,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @feldstej: Advances in Diagnosis and Management of Myelodysplastic Syndromes https://t.co/3kZ3mo60gz #ASH20 #ASH2020 #ASHFromHome #ASHTo‚Ä¶,true
johnde1MYELOMA,"myeloma survivor üêú, gastroenterologist, bicyclist, animal lover",,"Santa Fe, NM",,2020-12-05 22:55:48+00:00,John DeFlice,http://twitter.com/,0.0,,1.3353572334004347e+18,,0.0,0.0,,"BISPECIFIC TNB-383B  BCMA/CD3 redirecting human ab phase 1 in RRMM with being well tolerated and ORR of 52%, Rodrig‚Ä¶ https://t.co/G0imr7A1Yi",en,0.0,218.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/johnde1MYELOMA/statuses/1335357233400434689,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"BISPECIFIC TNB-383B  BCMA/CD3 redirecting human ab phase 1 in RRMM with being well tolerated and ORR of 52%, Rodrig‚Ä¶ https://t.co/G0imr7A1Yi",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 12:29:42+00:00,Lisa Palacios,http://twitter.com/,27.0,,1.3351996671859794e+18,,0.0,0.0,,RT @mpndoc: #ASH20 #mpnsm community rest up tonight and get ready for a MPN clinical oral session in the AM (moderated by myself and Lucia‚Ä¶,en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,23.0,4.0,https://twitter.com/Lisa_Palacios/statuses/1335199667185979393,0.0,0.0,,0.0,0.0,0.0,4.0,23.0,False,False,False,False,True,Disease Advocacy,0.0,0.0,1.0,RT @mpndoc: #ASH20 #mpnsm community rest up tonight and get ready for a MPN clinical oral session in the AM (moderated by myself and Lucia‚Ä¶,false
chanyooncheah,Doctor for patients with lymphoma. Clinical researcher.,,"Perth, Western Australia",,2020-12-06 17:42:39+00:00,Chan Cheah,http://twitter.com/,0.0,,1.335640814102311e+18,,0.0,0.0,,Dr Buske kicks off the indolent B-cell lymphoma session with the final results of the iNNOVATE study in Waldenstrom‚Ä¶ https://t.co/oW04TZMYGE,en,0.0,1717.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/chanyooncheah/statuses/1335640814102310913,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,Dr Buske kicks off the indolent B-cell lymphoma session with the final results of the iNNOVATE study in Waldenstrom‚Ä¶ https://t.co/oW04TZMYGE,true
MDAndersonNews,"The official account of MD Anderson Cancer Center, a leader in cancer care, cancer research and the fight to #EndCancer. Appointments available: 1-877-632-6789.",,"Houston, TX",,2020-12-06 04:45:00+00:00,MD Anderson Cancer Center,http://twitter.com/,4.0,,1.3354451118288486e+18,,0.0,0.0,,"Based on initial findings of the Phase I/II study in BPDCN, the FDA granted breakthrough therapy designation to IMG‚Ä¶ https://t.co/oAdF8nMN1u",en,0.0,114120.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,4.0,https://twitter.com/MDAndersonNews/statuses/1335445111828848640,0.0,0.0,,0.0,0.0,0.0,4.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"Based on initial findings of the Phase I/II study in BPDCN, the FDA granted breakthrough therapy designation to IMG‚Ä¶ https://t.co/oAdF8nMN1u",true
pb10_bmt,"MD, DM, Assistant Professor,
Clinical Hematology-Oncology, and Stem Cell Transplantation at DMC Ludhiana, Punjab.  Lifelong student!!",,"Punjab, India",,2020-12-03 05:03:20+00:00,Suvir Singh,http://twitter.com/,194.0,,1.3343625626793e+18,,0.0,0.0,,RT @VincentRK: #ASH20 special: Active myeloma drugs with their mechanism of action in one slide. Unapproved investigational drugs in blue f‚Ä¶,en,0.0,919.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,147.0,47.0,https://twitter.com/pb10_bmt/statuses/1334362562679300098,0.0,0.0,,0.0,0.0,0.0,47.0,147.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,RT @VincentRK: #ASH20 special: Active myeloma drugs with their mechanism of action in one slide. Unapproved investigational drugs in blue f‚Ä¶,true
ShakiraG_MBBS,BC Geriatrician + Hematologist + Oncologist. Assistant Professor + Clinical Researcher UNC-CH #geriheme #gerionc #mmsm #BlackWomanInMedicine. Tweets=my views,,"North Carolina, USA",,2020-12-03 22:09:37+00:00,Dr. Shakira J Grant MBBS,http://twitter.com/,3.0,,1.334620833847812e+18,,0.0,0.0,,"#ASH2020 join the #geriheme #GeriHeme, #gerihem #gerionc community online now‚¨áÔ∏è to learn about the exciting advance‚Ä¶ https://t.co/5qZ5Yv1GDS",en,0.0,340.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/ShakiraG_MBBS/statuses/1334620833847812096,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Disease Advocacy,1.0,0.0,0.0,"#ASH2020 join the #geriheme #GeriHeme, #gerihem #gerionc community online now‚¨áÔ∏è to learn about the exciting advance‚Ä¶ https://t.co/5qZ5Yv1GDS",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 12:35:29+00:00,"Ritcha Saxena, MD",http://twitter.com/,23.0,,1.3355635136081551e+18,,0.0,0.0,,"RT @PennMedNews: Today‚Äôs #ASH20 plenary features research from a team that includes Kojo Elenitoba-Johnson, MD, director of Penn‚Äôs Center f‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,17.0,6.0,https://twitter.com/RitchaSaxena/statuses/1335563513608155137,0.0,0.0,,0.0,0.0,0.0,6.0,17.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,"RT @PennMedNews: Today‚Äôs #ASH20 plenary features research from a team that includes Kojo Elenitoba-Johnson, MD, director of Penn‚Äôs Center f‚Ä¶",true
alegozzetti,"MD,PhD, Associate Professor of Hematology , University of Siena,Policlinico le Scotte, Italy",,"Siena, Toscana",,2020-12-06 22:41:14+00:00,ALESSANDRO Gozzetti,http://twitter.com/,1.0,,1.3357159538968084e+18,,0.0,0.0,,"RT @VJHemOnc: #ASH20: @alegozzetti discussed the effect of #Daratumumab on MRD in #Myeloma measured by next generation flow

Watch his inte‚Ä¶",en,0.0,17.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/alegozzetti/statuses/1335715953896808448,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Long Term Benefits,0.0,0.0,1.0,"RT @VJHemOnc: #ASH20: @alegozzetti discussed the effect of #Daratumumab on MRD in #Myeloma measured by next generation flow

Watch his inte‚Ä¶",false
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 03:48:15+00:00,"Ritcha Saxena, MD",http://twitter.com/,65.0,,1.335430829279994e+18,,0.0,0.0,,RT @Jme_os: Excited to present at the scientific workshop on infection and coagulation tomorrow at #ASH20 #haemostasis #covid19 #malaria ü©∏‚Ä¶,en,0.0,6875.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,62.0,3.0,https://twitter.com/RitchaSaxena/statuses/1335430829279993857,0.0,0.0,,0.0,0.0,0.0,3.0,62.0,False,False,False,False,True,Side Effects,1.0,0.0,0.0,RT @Jme_os: Excited to present at the scientific workshop on infection and coagulation tomorrow at #ASH20 #haemostasis #covid19 #malaria ü©∏‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 16:31:36+00:00,"Ritcha Saxena, MD",http://twitter.com/,24.0,,1.3356229330756485e+18,,0.0,0.0,,"RT @JanssenEMEA: #Amyloidosis can remain undiagnosed for several years, resulting in poor outcomes. At #ASH20 we're showcasing our latest r‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,20.0,4.0,https://twitter.com/RitchaSaxena/statuses/1335622933075648513,0.0,0.0,,0.0,0.0,0.0,4.0,20.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"RT @JanssenEMEA: #Amyloidosis can remain undiagnosed for several years, resulting in poor outcomes. At #ASH20 we're showcasing our latest r‚Ä¶",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 16:10:32+00:00,"Ritcha Saxena, MD",http://twitter.com/,22.0,,1.3356176292062904e+18,,0.0,0.0,,"RT @MM_Hub: Congress| #ASH20| @AlGarfall, @PennCancer, presented data on the phase I trial of teclistamab for R/R MM showing encouraging to‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,14.0,8.0,https://twitter.com/RitchaSaxena/statuses/1335617629206290438,0.0,0.0,,0.0,0.0,0.0,8.0,14.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @MM_Hub: Congress| #ASH20| @AlGarfall, @PennCancer, presented data on the phase I trial of teclistamab for R/R MM showing encouraging to‚Ä¶",true
CanerSaygin,"Heme-Onc Fellow @UChicago | Alumni of @OhioStateIMRes, @CCLRI | #Leukemia, #MDS, #CHIP physician-scientist. Tweets=own opinions.",,"Chicago, IL",,2020-12-06 22:14:55+00:00,"Caner Saygin, MD",http://twitter.com/,0.0,,1.3357093316988805e+18,,0.0,0.0,,Dr Rollig showed us once again that double induction at CR1 in newly diagnosed #AML pts does not confer additional‚Ä¶ https://t.co/zsXNbWmmvz,en,0.0,743.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/CanerSaygin/statuses/1335709331698880514,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,Dr Rollig showed us once again that double induction at CR1 in newly diagnosed #AML pts does not confer additional‚Ä¶ https://t.co/zsXNbWmmvz,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 16:27:32+00:00,"Ritcha Saxena, MD",http://twitter.com/,88.0,,1.3356219075263242e+18,,0.0,0.0,,RT @DavidSteensma: #ASH20 Plenary Session this morning. I feel a little badly for this year's speakers/introducers. Walking from green room‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,83.0,5.0,https://twitter.com/RitchaSaxena/statuses/1335621907526324224,0.0,0.0,,0.0,0.0,0.0,5.0,83.0,False,False,False,False,True,Thought Leadership,0.0,0.0,1.0,RT @DavidSteensma: #ASH20 Plenary Session this morning. I feel a little badly for this year's speakers/introducers. Walking from green room‚Ä¶,true
Margybargy,"Retired psychotherapist, rapidly turning into her mother, deeply annoyed by injustice and stupidity.",,London UK,,2020-12-06 19:27:04+00:00,Margybargy,http://twitter.com/,68.0,,1.3356670911611576e+18,,0.0,0.0,,RT @JanssenEMEA: What is CAR-T therapy? Watch this 3D VR video to learn more about how this innovative technology is being used to tackle #‚Ä¶,en,0.0,2175.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,55.0,13.0,https://twitter.com/Margybargy/statuses/1335667091161157634,0.0,0.0,,0.0,0.0,0.0,13.0,55.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @JanssenEMEA: What is CAR-T therapy? Watch this 3D VR video to learn more about how this innovative technology is being used to tackle #‚Ä¶,false
JerroldLevy,"Critical care physician in CTICU @DukeMedSchool, interested in coagulation, bleeding, inflammation-also oenophile and foody. Tweets are my own (‚â†medical advice)",,"Durham, North Carolina",,2020-12-06 17:55:17+00:00,"Jerrold Levy, MD",http://twitter.com/,29.0,,1.335643993636475e+18,,0.0,0.0,,RT @AyeshaNZia: A call for collaboration from @MiddeldorpS #COVID19 Thrombosis AC trials #ASH20 https://t.co/RDTmrMp76D,en,0.0,1755.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,23.0,6.0,https://twitter.com/JerroldLevy/statuses/1335643993636474887,0.0,0.0,,0.0,0.0,0.0,6.0,23.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,RT @AyeshaNZia: A call for collaboration from @MiddeldorpS #COVID19 Thrombosis AC trials #ASH20 https://t.co/RDTmrMp76D,true
JudithTrotman1,Kiwi-Australian mother of 6. Haematologist. Passions: clinical trials research as integral to quality medical care; gender equality; All Blacks. Opinions my own,,"Sydney, New South Wales",,2020-12-07 20:26:36+00:00,Judith Trotman,http://twitter.com/,57.0,,1.3360444597676524e+18,,0.0,0.0,,"RT @tobyeyre82: .@anthonymatomd et al
LOXO-305
170 R/R #CLL pts
phase I/II
non-covalent reversible BTKi
3 prior lines, 4 in prior BTKi
v hi‚Ä¶",en,0.0,1612.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,52.0,5.0,https://twitter.com/JudithTrotman1/statuses/1336044459767652352,0.0,0.0,,0.0,0.0,0.0,5.0,52.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @tobyeyre82: .@anthonymatomd et al
LOXO-305
170 R/R #CLL pts
phase I/II
non-covalent reversible BTKi
3 prior lines, 4 in prior BTKi
v hi‚Ä¶",true
ShakiraG_MBBS,BC Geriatrician + Hematologist + Oncologist. Assistant Professor + Clinical Researcher UNC-CH #geriheme #gerionc #mmsm #BlackWomanInMedicine. Tweets=my views,,"North Carolina, USA",,2020-12-07 22:07:43+00:00,Dr. Shakira J Grant MBBS,http://twitter.com/,0.0,,1.336069905754411e+18,,0.0,0.0,,#ASH20 Dr @DiMengyang presents data from an analysis of a Medicare-OASIS linked datasetüëá for OAs with DLBCL: severe‚Ä¶ https://t.co/ZYpjen8N3f,en,0.0,340.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/ShakiraG_MBBS/statuses/1336069905754411011,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Insurance Coverage,0.0,0.0,1.0,#ASH20 Dr @DiMengyang presents data from an analysis of a Medicare-OASIS linked datasetüëá for OAs with DLBCL: severe‚Ä¶ https://t.co/ZYpjen8N3f,true
AzizNazhaMD,"Practice Manager at Amazon Web Services, Physician, #Programmer, #DataScientist, interested in the Digital Transformation of Healthcare",,Cleveland Clinic,,2020-12-07 16:24:15+00:00,Aziz Nazha,http://twitter.com/,3.0,,1.3359834689253786e+18,,0.0,0.0,,The conclusions of Molecular landscape of Our #AI algorithm to predict MDS diagnosis from CBC and mutational data o‚Ä¶ https://t.co/EA46kauNg1,en,0.0,2087.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/AzizNazhaMD/statuses/1335983468925378560,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,The conclusions of Molecular landscape of Our #AI algorithm to predict MDS diagnosis from CBC and mutational data o‚Ä¶ https://t.co/EA46kauNg1,true
AnnaSureda5,"Haematologist interested in lymphoid malignancies, stem cell transplantation and CART cells. #CART #BMT #lymphomas #immunotherapy #WomenInMedicine",,"Barcelona, Spain",,2020-12-07 06:36:19+00:00,Anna Sureda,http://twitter.com/,43.0,,1.3358355127797924e+18,,0.0,0.0,,RT @MediHumdani: Pembro GVD: Outstanding data. Nearly 100% CR rates in relapsed classical HL @CMoskowitzMD #lymsm #ASH20,en,0.0,658.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,32.0,11.0,https://twitter.com/AnnaSureda5/statuses/1335835512779792384,0.0,0.0,,0.0,0.0,0.0,11.0,32.0,False,False,False,False,True,Diagnosis Progression,1.0,0.0,0.0,RT @MediHumdani: Pembro GVD: Outstanding data. Nearly 100% CR rates in relapsed classical HL @CMoskowitzMD #lymsm #ASH20,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-07 21:32:36+00:00,"Ritcha Saxena, MD",http://twitter.com/,11.0,,1.336061069001945e+18,,0.0,0.0,,RT @andreahgreif: Dr Stein @sloan_kettering presents data from @LLSusa #beataml study showing strong results for enasidenib in older newly‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,8.0,3.0,https://twitter.com/RitchaSaxena/statuses/1336061069001945091,0.0,0.0,,0.0,0.0,0.0,3.0,8.0,False,False,False,False,True,Disease Advocacy,0.0,0.0,1.0,RT @andreahgreif: Dr Stein @sloan_kettering presents data from @LLSusa #beataml study showing strong results for enasidenib in older newly‚Ä¶,false
YaleCancer,Yale Cancer Center is a collaboration between renowned cancer researchers and physicians at Yale University and Smilow Cancer Hospital.,,"New Haven, Connecticut",,2020-12-07 16:13:51+00:00,Yale Cancer Center,http://twitter.com/,0.0,,1.3359808545695457e+18,,0.0,0.0,,"Tune in to virtual #ASH20 today at Noon. @YaleCancer Dr. Thomas Prebet reports on ""Risk Groups in a Phase 3 Study o‚Ä¶ https://t.co/dRPeg7bbYs",en,0.0,9957.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/YaleCancer/statuses/1335980854569545731,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"Tune in to virtual #ASH20 today at Noon. @YaleCancer Dr. Thomas Prebet reports on ""Risk Groups in a Phase 3 Study o‚Ä¶ https://t.co/dRPeg7bbYs",true
DocHutchings,Haemato-oncologist. Clinical researcher. Mostly lymphoma and phase 1 haematology studies.,,,,2020-12-06 22:36:44+00:00,Martin Hutchings,http://twitter.com/,23.0,,1.3357148213005148e+18,,0.0,0.0,,"RT @lymphomahub: CONGRESS | #ASH20 |@DocHutchings, @Rigshospitalet, presents the data from a phase I/II study evaluating the SC bispecific‚Ä¶",en,0.0,284.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,18.0,5.0,https://twitter.com/DocHutchings/statuses/1335714821300514818,0.0,0.0,,0.0,0.0,0.0,5.0,18.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @lymphomahub: CONGRESS | #ASH20 |@DocHutchings, @Rigshospitalet, presents the data from a phase I/II study evaluating the SC bispecific‚Ä¶",true
pb10_bmt,"MD, DM, Assistant Professor,
Clinical Hematology-Oncology, and Stem Cell Transplantation at DMC Ludhiana, Punjab.  Lifelong student!!",,"Punjab, India",,2020-12-05 07:10:00+00:00,Suvir Singh,http://twitter.com/,0.0,,1.3351192123820155e+18,,0.0,0.0,,Higher stage and frailty associated with higher infection risk in new patients with MM treated with novel agents.‚Ä¶ https://t.co/8aHVXYhZ7d,en,0.0,919.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/pb10_bmt/statuses/1335119212382015489,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,Higher stage and frailty associated with higher infection risk in new patients with MM treated with novel agents.‚Ä¶ https://t.co/8aHVXYhZ7d,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 16:11:32+00:00,"Ritcha Saxena, MD",http://twitter.com/,7.0,,1.3356178817662935e+18,,0.0,0.0,,RT @SaudiLeukemia: CPX-351 + Ven : Phase II study . Dr Tapan Kadia from @MDAndersonNews MDACC.  #ASH20  #ASH2020 https://t.co/Aou1OOAwKs,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,4.0,https://twitter.com/RitchaSaxena/statuses/1335617881766293504,0.0,0.0,,0.0,0.0,0.0,4.0,3.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @SaudiLeukemia: CPX-351 + Ven : Phase II study . Dr Tapan Kadia from @MDAndersonNews MDACC.  #ASH20  #ASH2020 https://t.co/Aou1OOAwKs,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 21:20:33+00:00,"Ritcha Saxena, MD",http://twitter.com/,6.0,,1.335695649195651e+18,,0.0,0.0,,"RT @hemedoc: #ASH20 #leusm Sasaki: IZKF1del can be subtyped by site of deletion, which lead to either haploinsufficiency or dominant negati‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,3.0,https://twitter.com/RitchaSaxena/statuses/1335695649195651077,0.0,0.0,,0.0,0.0,0.0,3.0,3.0,False,False,False,False,True,Insurance Coverage,0.0,0.0,1.0,"RT @hemedoc: #ASH20 #leusm Sasaki: IZKF1del can be subtyped by site of deletion, which lead to either haploinsufficiency or dominant negati‚Ä¶",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 21:09:13+00:00,"Ritcha Saxena, MD",http://twitter.com/,62.0,,1.3356927961629614e+18,,0.0,0.0,,"RT @DrMiguelPerales: Busy day today for @sloan_kettering investigators at @ASH_hematology #ASH20 Check out the schedule for talks, oral pre‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,50.0,12.0,https://twitter.com/RitchaSaxena/statuses/1335692796162961408,0.0,0.0,,0.0,0.0,0.0,12.0,50.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,"RT @DrMiguelPerales: Busy day today for @sloan_kettering investigators at @ASH_hematology #ASH20 Check out the schedule for talks, oral pre‚Ä¶",false
DrSStern,Consultant Haematologist. Interested in haemato-oncology in general and multiple myeloma in particular.,,,,2020-12-05 18:11:11+00:00,Simon Stern,http://twitter.com/,0.0,,1.3352856043645297e+18,,0.0,0.0,,Superb review of the treatment of AL amyloidosis by Giovanni Palladini in the #ASH20 educational programme. #mmsm https://t.co/yG6dfa4ROF,en,0.0,185.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/DrSStern/statuses/1335285604364529668,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Disease Advocacy,1.0,0.0,0.0,Superb review of the treatment of AL amyloidosis by Giovanni Palladini in the #ASH20 educational programme. #mmsm https://t.co/yG6dfa4ROF,true
jason_wollmuth,"Interventional cardiologist, CTO/CHIP operator, avid Oregon Duck fan, husband, father",,"Lake Oswego, OR",,2020-10-15 01:52:22+00:00,Jason Wollmuth,http://twitter.com/,31.0,,1.3165574972437012e+18,,0.0,0.0,,"RT @DrSethdb: #TCTConnect #TCT2020 Abstracts out-all at once
RESTORE-EF investigators present high risk PCI supported with Impella #Protect‚Ä¶",en,0.0,2255.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,22.0,9.0,https://twitter.com/jason_wollmuth/statuses/1316557497243701254,0.0,0.0,,0.0,0.0,0.0,9.0,22.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,"RT @DrSethdb: #TCTConnect #TCT2020 Abstracts out-all at once
RESTORE-EF investigators present high risk PCI supported with Impella #Protect‚Ä¶",true
JuanAlderuccio,Hematologist-Oncologist | Lymphoma Physician @SylvesterCancer | University of Miami,,"Miami, FL",,2020-11-08 18:19:37+00:00,Juan P. Alderuccio,http://twitter.com/,8.0,,1.325503254877397e+18,,0.0,0.0,,"RT @CwynKate: Prognosis/Outcomes in #HIV-#Burkitt #lymphoma:US and UK Collaborative Analysis n=249
Med CD4 217
CODOX-M 60%/DA-EPOCH 25% (+R‚Ä¶",en,0.0,83.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,2.0,https://twitter.com/JuanAlderuccio/statuses/1325503254877396998,0.0,0.0,,0.0,0.0,0.0,2.0,6.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,"RT @CwynKate: Prognosis/Outcomes in #HIV-#Burkitt #lymphoma:US and UK Collaborative Analysis n=249
Med CD4 217
CODOX-M 60%/DA-EPOCH 25% (+R‚Ä¶",true
BroeckelmannPJ,"MD @UKKoeln & Physician Scientist Postdoc @MPIAGE. Hemato-Oncology. Lymphoma. Immunotherapies. DNA damage. Personal opinion, RT/like ‚â† endorsement.",,"Cologne, Germany",,2020-11-22 06:35:28+00:00,Paul Br√∂ckelmann,http://twitter.com/,71.0,,1.3303994805422694e+18,,0.0,0.0,,"RT @graham74GC: Mehta-Shah et al 
12 academic centres, retrospec study allogeneic Tx for PTCL
- 508 pts med 51y
- mostly relapsed, most RIC‚Ä¶",en,0.0,243.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,59.0,12.0,https://twitter.com/BroeckelmannPJ/statuses/1330399480542269441,0.0,0.0,,0.0,0.0,0.0,12.0,59.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @graham74GC: Mehta-Shah et al 
12 academic centres, retrospec study allogeneic Tx for PTCL
- 508 pts med 51y
- mostly relapsed, most RIC‚Ä¶",true
UrviShahMD,Oncologist and researcher on Myeloma service @sloan_kettering. Interested in nutrition for cancer and immune therapies. Views are my own,,"New York, NY",,2020-11-22 20:42:43+00:00,Urvi Shah,http://twitter.com/,0.0,,1.3306126988082463e+18,,0.0,0.0,,DREAMM-2 phase 2 study was published by @SagarLonialMD et al. in Lancet Oncol 2019. We will see 1 year outcomes at‚Ä¶ https://t.co/np1POJdgbt,en,0.0,1227.0,,,0.0,UrviShahMD,1.330612694387454e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/UrviShahMD/statuses/1330612698808246283,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,DREAMM-2 phase 2 study was published by @SagarLonialMD et al. in Lancet Oncol 2019. We will see 1 year outcomes at‚Ä¶ https://t.co/np1POJdgbt,true
UrviShahMD,Oncologist and researcher on Myeloma service @sloan_kettering. Interested in nutrition for cancer and immune therapies. Views are my own,,"New York, NY",,2020-11-22 20:03:22+00:00,Urvi Shah,http://twitter.com/,1.0,,1.3306027972267172e+18,,0.0,0.0,,"AMG-701 - Updates @ASH_hematology by Harrison et al. @SLentzsch Phase 1 study, 75 patients, ORR 36% at 3-12mg dose,‚Ä¶ https://t.co/kuacuDGmmm",en,0.0,1227.0,,,0.0,UrviShahMD,1.3306027953308918e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/UrviShahMD/statuses/1330602797226717189,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"AMG-701 - Updates @ASH_hematology by Harrison et al. @SLentzsch Phase 1 study, 75 patients, ORR 36% at 3-12mg dose,‚Ä¶ https://t.co/kuacuDGmmm",false
UrviShahMD,Oncologist and researcher on Myeloma service @sloan_kettering. Interested in nutrition for cancer and immune therapies. Views are my own,,"New York, NY",,2020-11-22 20:42:45+00:00,Urvi Shah,http://twitter.com/,0.0,,1.3306127054142218e+18,,0.0,0.0,,"Belamaf Pom Dex - phase 1 part 1, 35 patients, ORR 86%, Trudel et al. to be presented at #ASH20 Promising efficacy‚Ä¶ https://t.co/LoJfmQipBM",en,0.0,1227.0,,,0.0,UrviShahMD,1.3306127032961516e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/UrviShahMD/statuses/1330612705414221826,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"Belamaf Pom Dex - phase 1 part 1, 35 patients, ORR 86%, Trudel et al. to be presented at #ASH20 Promising efficacy‚Ä¶ https://t.co/LoJfmQipBM",true
UrviShahMD,Oncologist and researcher on Myeloma service @sloan_kettering. Interested in nutrition for cancer and immune therapies. Views are my own,,"New York, NY",,2020-11-22 20:42:46+00:00,Urvi Shah,http://twitter.com/,0.0,,1.3306127087781233e+18,,0.0,0.0,,"MEDI2228 Another BCMA ADC with less corneal toxicity - 82 patients, MTD 0.14 mg/kg q3w, ORR 61%, mDOR NR, photophob‚Ä¶ https://t.co/OZq2yS9UXJ",en,0.0,1227.0,,,0.0,UrviShahMD,1.3306127054142218e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/UrviShahMD/statuses/1330612708778123279,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"MEDI2228 Another BCMA ADC with less corneal toxicity - 82 patients, MTD 0.14 mg/kg q3w, ORR 61%, mDOR NR, photophob‚Ä¶ https://t.co/OZq2yS9UXJ",true
MDAndersonNews,"The official account of MD Anderson Cancer Center, a leader in cancer care, cancer research and the fight to #EndCancer. Appointments available: 1-877-632-6789.",,"Houston, TX",,2020-11-22 17:53:01+00:00,MD Anderson Cancer Center,http://twitter.com/,5.0,,1.330569993189208e+18,,0.0,0.0,,"When multiple myeloma relapsed after chemotherapy, a stem cell transplant and targeted therapy, Beth Norris is back‚Ä¶ https://t.co/OlOsDYIi5H",en,0.0,114120.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,5.0,https://twitter.com/MDAndersonNews/statuses/1330569993189208064,0.0,0.0,,0.0,0.0,0.0,5.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"When multiple myeloma relapsed after chemotherapy, a stem cell transplant and targeted therapy, Beth Norris is back‚Ä¶ https://t.co/OlOsDYIi5H",true
TapKadia,"Tapan Kadia, MD 
- Leukemia Doc at MD Anderson Cancer Center 
 Leukemia, clinical/translational research.  Views, posts and opinions shared are my own.",,"Houston, TX",,2020-11-22 22:51:24+00:00,Tapan Kadia,http://twitter.com/,11.0,,1.3306450841451151e+18,,0.0,0.0,,RT @doctorpemm: #ASH20 || Implications of #RAS Mutational Status in Subsets of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) a‚Ä¶,en,0.0,2499.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,8.0,3.0,https://twitter.com/TapKadia/statuses/1330645084145115139,0.0,0.0,,0.0,0.0,0.0,3.0,8.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @doctorpemm: #ASH20 || Implications of #RAS Mutational Status in Subsets of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) a‚Ä¶,true
UrviShahMD,Oncologist and researcher on Myeloma service @sloan_kettering. Interested in nutrition for cancer and immune therapies. Views are my own,,"New York, NY",,2020-11-22 20:03:27+00:00,Urvi Shah,http://twitter.com/,0.0,,1.3306028164952924e+18,,0.0,0.0,,"Talquetamab - first GPRC5D bispecific, phase 1, 137 patients, IV ORR 78%, SC ORR 67%, CRS 47%, NT 5%. Another very‚Ä¶ https://t.co/B8dxOww09E",en,0.0,1227.0,,,0.0,UrviShahMD,1.3306028123723612e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/UrviShahMD/statuses/1330602816495292421,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"Talquetamab - first GPRC5D bispecific, phase 1, 137 patients, IV ORR 78%, SC ORR 67%, CRS 47%, NT 5%. Another very‚Ä¶ https://t.co/B8dxOww09E",true
UrviShahMD,Oncologist and researcher on Myeloma service @sloan_kettering. Interested in nutrition for cancer and immune therapies. Views are my own,,"New York, NY",,2020-11-22 20:03:28+00:00,Urvi Shah,http://twitter.com/,0.0,,1.330602821335593e+18,,0.0,0.0,,BCFR4350A - FcRH5 bispecific. Phase 1 study ORR 52% at all dose levels. More data to be presented at #ASH20‚Ä¶ https://t.co/IqTM7ev4uY,en,0.0,1227.0,,,0.0,UrviShahMD,1.3306028164952924e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/UrviShahMD/statuses/1330602821335592969,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,BCFR4350A - FcRH5 bispecific. Phase 1 study ORR 52% at all dose levels. More data to be presented at #ASH20‚Ä¶ https://t.co/IqTM7ev4uY,false
Transplant_Doc,Stem Cell Transplant physician and clinical researcher at MD Anderson Cancer Center; special interest in myeloma. Opinions expressed are my own,,,,2020-11-10 18:48:49+00:00,Muzaffar Qazilbash,http://twitter.com/,12.0,,1.3262353788654633e+18,,0.0,0.0,,"RT @szusmani: 6/7
TOP 5 CLINICAL PHASE 2/3 Newly Diagnosed #ASH20SU #ASH20 #mmsm
-GRIFFIN Update (https://t.co/UBT5mcwA7Y)
-EMN02/HO95 Upda‚Ä¶",en,0.0,5455.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,2.0,https://twitter.com/Transplant_Doc/statuses/1326235378865463296,0.0,0.0,,0.0,0.0,0.0,2.0,10.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @szusmani: 6/7
TOP 5 CLINICAL PHASE 2/3 Newly Diagnosed #ASH20SU #ASH20 #mmsm
-GRIFFIN Update (https://t.co/UBT5mcwA7Y)
-EMN02/HO95 Upda‚Ä¶",true
drabhijeetkumar,"Lymphoma oncologist  at U of Arizona.  Car guy with no enthusiast cars. Stick shift Taco driver and most importantly, Dad.",,"Arizona, USA",,2020-11-10 14:37:53+00:00,Abhijeet Kumar,http://twitter.com/,113.0,,1.3261722285772104e+18,,0.0,0.0,,"RT @graham74GC: Puckrin et al
- retro study CNS relapse in DLBCL
- found CNS-IPI prognostic
- use of IV MTX proph NOT assoc with ‚¨áÔ∏è CNS rel‚Ä¶",en,0.0,108.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,86.0,27.0,https://twitter.com/drabhijeetkumar/statuses/1326172228577210368,0.0,0.0,,0.0,0.0,0.0,27.0,86.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @graham74GC: Puckrin et al
- retro study CNS relapse in DLBCL
- found CNS-IPI prognostic
- use of IV MTX proph NOT assoc with ‚¨áÔ∏è CNS rel‚Ä¶",true
DrRajivsankar,"Consultant Cardiologist @LivHospitals Researcher @NIHRResearch @LiverpoolCCS, #heartfailure #LFC #YNWA #renalcancer survivor All views my own.RT‚â†endorsement",,"Liverpool, England",,2020-11-27 12:22:22+00:00,Dr.Rajiv Sankaranarayanan ‚Äú #VaccinesWork ‚Äú,http://twitter.com/,14.0,,1.3322987192161526e+18,,0.0,0.0,,"RT @CJWhelan18: There may be freezing fog in ol‚Äô London Town but things are hotting üî•up for day 2 #BSH2020VISION Great speakers, great sess‚Ä¶",en,0.0,2124.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,12.0,2.0,https://twitter.com/DrRajivsankar/statuses/1332298719216152577,0.0,0.0,,0.0,0.0,0.0,2.0,12.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,"RT @CJWhelan18: There may be freezing fog in ol‚Äô London Town but things are hotting üî•up for day 2 #BSH2020VISION Great speakers, great sess‚Ä¶",true
JohnPLeonardMD,"Doctor for lymphoma patients, researcher, collaborator, professor/senior associate dean @WeillCornell & @NYPhospital Tweets mine RT not=endorsement, he/him/his",,Weill Cornell Medicine,,2020-11-27 18:03:14+00:00,"John P. Leonard, MD",http://twitter.com/,0.0,,1.33238450188911e+18,,0.0,0.0,,"Number 8 #LeonardList #ASH20 - 121 - Wang - VLS-101, anti-ROR1 ADC ph 1 trial, toxicities cytopenias, alopecia, neu‚Ä¶ https://t.co/8VKg6nvgCY",en,0.0,6269.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/JohnPLeonardMD/statuses/1332384501889110018,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"Number 8 #LeonardList #ASH20 - 121 - Wang - VLS-101, anti-ROR1 ADC ph 1 trial, toxicities cytopenias, alopecia, neu‚Ä¶ https://t.co/8VKg6nvgCY",true
noriega_dr,"MD, PhD. Hematologist in CHUAC (A Coru√±a-Spain). Leukemia and Bone Marrow Transplantation. Tweets and opinions are mine.",,,,2020-11-10 11:41:24+00:00,Dr Victor Noriega,http://twitter.com/,37.0,,1.3261278160905134e+18,,0.0,0.0,,"RT @DrMiguelPerales: #EBMT20 #EBMT20virtual CD34+ Allo HCT, &lt; GVHD, no increase in relapse, Better CRFS - Waiting for results of @BMTCTN 13‚Ä¶",en,0.0,959.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,27.0,10.0,https://twitter.com/noriega_dr/statuses/1326127816090513408,0.0,0.0,,0.0,0.0,0.0,10.0,27.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @DrMiguelPerales: #EBMT20 #EBMT20virtual CD34+ Allo HCT, &lt; GVHD, no increase in relapse, Better CRFS - Waiting for results of @BMTCTN 13‚Ä¶",true
CJWhelan18,Cardiologist and Proud Mum üíï,,"London, England",,2020-11-27 08:46:23+00:00,Carol Whelan,http://twitter.com/,2.0,,1.3322443670803497e+18,,0.0,0.0,,"There may be freezing fog in ol‚Äô London Town but things are hotting üî•up for day 2 #BSH2020VISION Great speakers, gr‚Ä¶ https://t.co/kp6yLQXCdd",en,0.0,309.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/CJWhelan18/statuses/1332244367080349700,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Thought Leadership,0.0,0.0,1.0,"There may be freezing fog in ol‚Äô London Town but things are hotting üî•up for day 2 #BSH2020VISION Great speakers, gr‚Ä¶ https://t.co/kp6yLQXCdd",false
AnandPheresisMD,"Transfusion Med MD & Platelet Immunologist; Physician, Mayo Clinic; Co-Founder & Chief Science Officer, Retham Technologies; Opinions my own; Not medical advice",,"Rochester, MN",,2020-11-27 18:42:48+00:00,Anand Padmanabhan,http://twitter.com/,1.0,,1.3323944595233792e+18,,0.0,0.0,,Colleagues‚ÄîMayo Clinic is organizing a symposium at #ASH20 on Thrombosis and Hemostasis and speakers will cover a n‚Ä¶ https://t.co/qIPW4Gwb5z,en,0.0,120.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/AnandPheresisMD/statuses/1332394459523379202,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Thought Leadership,0.0,0.0,1.0,Colleagues‚ÄîMayo Clinic is organizing a symposium at #ASH20 on Thrombosis and Hemostasis and speakers will cover a n‚Ä¶ https://t.co/qIPW4Gwb5z,true
DrRajivsankar,"Consultant Cardiologist @LivHospitals Researcher @NIHRResearch @LiverpoolCCS, #heartfailure #LFC #YNWA #renalcancer survivor All views my own.RT‚â†endorsement",,"Liverpool, England",,2020-11-27 17:08:27+00:00,Dr.Rajiv Sankaranarayanan ‚Äú #VaccinesWork ‚Äú,http://twitter.com/,90.0,,1.3323707140291584e+18,,0.0,0.0,,RT @BSHNurseForum: Huge congratulations to Jayne Masters the winner of the inaugural Lynda Blue Award! @MastersJayne is a leading voice in‚Ä¶,en,0.0,2124.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,81.0,9.0,https://twitter.com/DrRajivsankar/statuses/1332370714029158401,0.0,0.0,,0.0,0.0,0.0,9.0,81.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @BSHNurseForum: Huge congratulations to Jayne Masters the winner of the inaugural Lynda Blue Award! @MastersJayne is a leading voice in‚Ä¶,true
Transplant_Doc,Stem Cell Transplant physician and clinical researcher at MD Anderson Cancer Center; special interest in myeloma. Opinions expressed are my own,,,,2020-11-27 13:11:40+00:00,Muzaffar Qazilbash,http://twitter.com/,59.0,,1.3323111274061087e+18,,0.0,0.0,,RT @MediHumdani: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 shows early signal of activity in Relapsed/Refractory #Myelom‚Ä¶,en,0.0,5455.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,46.0,13.0,https://twitter.com/Transplant_Doc/statuses/1332311127406108672,0.0,0.0,,0.0,0.0,0.0,13.0,46.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @MediHumdani: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 shows early signal of activity in Relapsed/Refractory #Myelom‚Ä¶,true
AnnaSureda5,"Haematologist interested in lymphoid malignancies, stem cell transplantation and CART cells. #CART #BMT #lymphomas #immunotherapy #WomenInMedicine",,"Barcelona, Spain",,2020-11-27 06:39:10+00:00,Anna Sureda,http://twitter.com/,59.0,,1.3322123491561267e+18,,0.0,0.0,,RT @MediHumdani: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 shows early signal of activity in Relapsed/Refractory #Myelom‚Ä¶,en,0.0,658.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,46.0,13.0,https://twitter.com/AnnaSureda5/statuses/1332212349156126720,0.0,0.0,,0.0,0.0,0.0,13.0,46.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @MediHumdani: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 shows early signal of activity in Relapsed/Refractory #Myelom‚Ä¶,true
BotCardiology,"Created by Doctor @KrittanawongMD. A bot that collects Tweets about cardiology, medicine and new science",,Kepler-452b,,2020-11-27 16:47:35+00:00,Cardiology Bot,http://twitter.com/,4.0,,1.3323654653819576e+18,,0.0,0.0,,RT @PoppyBrooks1: This üëáüèª Fantastic case studies demonstrating this point from Dr Will Petchey #BSH2020VISION #nephrologistslikediuretics #‚Ä¶,en,0.0,328.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,1.0,https://twitter.com/BotCardiology/statuses/1332365465381957634,0.0,0.0,,0.0,0.0,0.0,1.0,3.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @PoppyBrooks1: This üëáüèª Fantastic case studies demonstrating this point from Dr Will Petchey #BSH2020VISION #nephrologistslikediuretics #‚Ä¶,true
JoeKhouryMD,Professor & Executive Director at MD Anderson Cancer Center. Pathology & Lab Medicine. Dedicated to fighting cancer. Tweets my own.,,"Houston, TX",,2020-11-16 01:19:49+00:00,"Joseph D. Khoury, MD, FCAP",http://twitter.com/,19.0,,1.328145719128191e+18,,0.0,0.0,,"RT @doctorpemm: #ASH20 | A Multicenter Phase 1/2 Clinical Trial of Tagraxofusp, a #CD123-Targeted Therapy, in Patients with Poor-Risk Myelo‚Ä¶",en,0.0,2869.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,15.0,4.0,https://twitter.com/JoeKhouryMD/statuses/1328145719128190979,0.0,0.0,,0.0,0.0,0.0,4.0,15.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @doctorpemm: #ASH20 | A Multicenter Phase 1/2 Clinical Trial of Tagraxofusp, a #CD123-Targeted Therapy, in Patients with Poor-Risk Myelo‚Ä¶",false
drjgauthier,"MD, MSc, Assistant Professor @fredhutch @UW focused on #CARTcell #immunotherapy #tcellrx 
Interests also include #rstats #bmtsm #epitwitter #bayes",,"Seattle, WA",,2020-12-10 15:37:52+00:00,Jordan Gauthier,http://twitter.com/,2.0,,1.337058963720966e+18,,0.0,0.0,,#ASH20 #ASHPosterwalk Dr. Noelle Frey introducing Dr. Federico Simonetta's preclinical work on in vivo molecular im‚Ä¶ https://t.co/A6jT85PYtT,en,0.0,3295.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/drjgauthier/statuses/1337058963720966144,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,#ASH20 #ASHPosterwalk Dr. Noelle Frey introducing Dr. Federico Simonetta's preclinical work on in vivo molecular im‚Ä¶ https://t.co/A6jT85PYtT,true
LoriLeslieMD,"Lymphoma/CLL oncologist at John Theurer Cancer Center in Hackensack, NJ.",,"Hackensack, NJ",,2020-12-10 02:14:06+00:00,Lori Leslie,http://twitter.com/,47.0,,1.3368566878698332e+18,,0.0,0.0,,RT @UjjaniC: So excited to finally present Ibrutinib + Venetoclax in Follicular #Lymphoma! ORR &gt; 80% at RP2D. Phase 2 currently accruing @S‚Ä¶,en,0.0,355.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,39.0,8.0,https://twitter.com/LoriLeslieMD/statuses/1336856687869833218,0.0,0.0,,0.0,0.0,0.0,8.0,39.0,False,False,False,False,True,Clinical Trials,1.0,0.0,0.0,RT @UjjaniC: So excited to finally present Ibrutinib + Venetoclax in Follicular #Lymphoma! ORR &gt; 80% at RP2D. Phase 2 currently accruing @S‚Ä¶,true
MedpageOnco,Breaking cancer + oncology news | Reports from all major oncology meetings | Peer-reviewed | Oncologist-trusted | Part of @MedPageToday,,,,2020-12-10 00:28:01+00:00,MedPage Oncology,http://twitter.com/,0.0,,1.336829992626434e+18,,0.0,0.0,,"An investigational tyrosine kinase inhibitor, #asciminib, doubled the major molecular response rate in previously t‚Ä¶ https://t.co/ntmdk14B66",en,0.0,443.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/MedpageOnco/statuses/1336829992626434052,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,"An investigational tyrosine kinase inhibitor, #asciminib, doubled the major molecular response rate in previously t‚Ä¶ https://t.co/ntmdk14B66",true
biostockguru,Physician executive(MD CWRU;Rice/Jones);Healthcare focus Fund;Pharma advisor/KOL;Tweets NOT investment advice.Pls do your DD. Support https://t.co/97U34OldNG,,United States,,2020-12-10 13:55:00+00:00,biostockGuru,http://twitter.com/,6.0,,1.33703307575928e+18,,0.0,0.0,,"RT @funstocks1: $ONCT If they get CAR-T in clinic, I think $JNJ or $ABBV will buy them. CAR-T at current stage alone support the current va‚Ä¶",en,0.0,14021.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,1.0,https://twitter.com/biostockguru/statuses/1337033075759280128,0.0,0.0,,0.0,0.0,0.0,1.0,5.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @funstocks1: $ONCT If they get CAR-T in clinic, I think $JNJ or $ABBV will buy them. CAR-T at current stage alone support the current va‚Ä¶",true
drjgauthier,"MD, MSc, Assistant Professor @fredhutch @UW focused on #CARTcell #immunotherapy #tcellrx 
Interests also include #rstats #bmtsm #epitwitter #bayes",,"Seattle, WA",,2020-12-10 15:20:35+00:00,Jordan Gauthier,http://twitter.com/,0.0,,1.337054613804114e+18,,0.0,0.0,,#ASH20 #ASHposterwalk Dr. Peter Hillmen presenting the impressive results of the PEGASUS phase III trial: pegcetaco‚Ä¶ https://t.co/91yKp9f5is,en,0.0,3295.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/drjgauthier/statuses/1337054613804113921,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,FDA Approval,1.0,0.0,0.0,#ASH20 #ASHposterwalk Dr. Peter Hillmen presenting the impressive results of the PEGASUS phase III trial: pegcetaco‚Ä¶ https://t.co/91yKp9f5is,true
cardiacpolymath,Cardiologist (General/ICC/STRUCTURAL). @SCAI #ELM chair. @wolfson_cam alumni. Use FP's making cardiomyocytes great again. @steelershockey fan. Dad/Husband/Son,,"Manchester, England",,2020-12-10 13:44:29+00:00,Matt Daniels MD PhD,http://twitter.com/,185.0,,1.3370304297324667e+18,,0.0,0.0,,"RT @AlejoFraticelli: Call to all stem cell hematologists and immunologists!!

My lab, Quantitative Stem Cell Dynamics (https://t.co/j0ocWZY‚Ä¶",en,0.0,1701.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,124.0,61.0,https://twitter.com/cardiacpolymath/statuses/1337030429732466688,0.0,0.0,,0.0,0.0,0.0,61.0,124.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @AlejoFraticelli: Call to all stem cell hematologists and immunologists!!

My lab, Quantitative Stem Cell Dynamics (https://t.co/j0ocWZY‚Ä¶",false
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-10 17:52:35+00:00,Lisa Palacios,http://twitter.com/,0.0,,1.3370928645395538e+18,,0.0,0.0,,Venetoclax plus ibrutinib may induce treatment-free remission in patients with #CLL https://t.co/t6hpsJCYoa  | Will‚Ä¶ https://t.co/VMJMeDSX7Q,en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/Lisa_Palacios/statuses/1337092864539553795,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,Venetoclax plus ibrutinib may induce treatment-free remission in patients with #CLL https://t.co/t6hpsJCYoa  | Will‚Ä¶ https://t.co/VMJMeDSX7Q,true
drjgauthier,"MD, MSc, Assistant Professor @fredhutch @UW focused on #CARTcell #immunotherapy #tcellrx 
Interests also include #rstats #bmtsm #epitwitter #bayes",,"Seattle, WA",,2020-12-10 15:56:30+00:00,Jordan Gauthier,http://twitter.com/,3.0,,1.3370636498029322e+18,,0.0,0.0,,#ASH20 #ASHPosterwalk Dr. Jie Wang presenting preclinical work evaluating CAR T cells targeting T-Cell Receptor VŒ≤‚Ä¶ https://t.co/UlHY7YKupq,en,0.0,3295.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/drjgauthier/statuses/1337063649802932228,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,#ASH20 #ASHPosterwalk Dr. Jie Wang presenting preclinical work evaluating CAR T cells targeting T-Cell Receptor VŒ≤‚Ä¶ https://t.co/UlHY7YKupq,true
WilliamDale_MD,"Dad/Doctor/Scholar/Exec Producer
#GeriOnc #SupportiveCare,
City of Hope
 https://t.co/eX3ulsGvFG",,"City of Hope, wdale@coh.org",,2020-12-10 22:10:09+00:00,"William Dale, MD, PhD",http://twitter.com/,11.0,,1.3371576827849933e+18,,0.0,0.0,,RT @ShakiraG_MBBS: #ASH20 #hematology + #aging Poster Walk No:2628 Dr. Charity Oyedeji @DukeHealth üëáused physical+cognitive function measur‚Ä¶,en,0.0,5551.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,9.0,2.0,https://twitter.com/WilliamDale_MD/statuses/1337157682784993280,0.0,0.0,,0.0,0.0,0.0,2.0,9.0,False,False,False,False,True,Disease Advocacy,0.0,0.0,1.0,RT @ShakiraG_MBBS: #ASH20 #hematology + #aging Poster Walk No:2628 Dr. Charity Oyedeji @DukeHealth üëáused physical+cognitive function measur‚Ä¶,true
yusufhameed,"Anesthesiologist, Pain Management Fellowship, Entrepreneur, Angel Investor.  Aetho, Vireo Labs, C'reer, Enviroflight (now Intrexon/Precigen).",,"Savannah, GA",,2020-12-10 20:42:30+00:00,"Yusuf Hameed, MD",http://twitter.com/,0.0,,1.3371356255399936e+18,,0.0,0.0,,"Amazing what volume can do for a stock like $SGMO, and other undervalued stocks like $PROG and $NMTR will be much h‚Ä¶ https://t.co/651u5sWuo9",en,0.0,1138.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/yusufhameed/statuses/1337135625539993600,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Financial Performance,1.0,0.0,0.0,"Amazing what volume can do for a stock like $SGMO, and other undervalued stocks like $PROG and $NMTR will be much h‚Ä¶ https://t.co/651u5sWuo9",true
DrTonyLetai,"Physician-scientist @DanaFarber. Professor of Medicine @harvardmed. President, Society for Functional Precision Medicine. You probably should be BH3 profiling.",,"Boston, MA",,2020-12-10 14:30:38+00:00,Anthony Letai MD PhD,http://twitter.com/,8.0,,1.3370420434875228e+18,,0.0,0.0,,RT @OncologyTimes: #ASH2020 Research Highlights on Acute Myeloid Leukemia: Venetoclax Added to Standard Treatments Shows Promise https://t.‚Ä¶,en,0.0,1809.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,5.0,https://twitter.com/DrTonyLetai/statuses/1337042043487522826,0.0,0.0,,0.0,0.0,0.0,5.0,3.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @OncologyTimes: #ASH2020 Research Highlights on Acute Myeloid Leukemia: Venetoclax Added to Standard Treatments Shows Promise https://t.‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-10 03:07:14+00:00,"Ritcha Saxena, MD",http://twitter.com/,13.0,,1.336870056744153e+18,,0.0,0.0,,"So proud to have the honor of being the top influencer in #ASH20, a wonderful community of loving colleagues &amp; bril‚Ä¶ https://t.co/DkHGbNtSMd",en,0.0,6875.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,13.0,https://twitter.com/RitchaSaxena/statuses/1336870056744153090,0.0,0.0,,0.0,0.0,0.0,13.0,0.0,False,False,False,False,True,Disease Advocacy,1.0,0.0,0.0,"So proud to have the honor of being the top influencer in #ASH20, a wonderful community of loving colleagues &amp; bril‚Ä¶ https://t.co/DkHGbNtSMd",false
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-10 17:44:08+00:00,Lisa Palacios,http://twitter.com/,25.0,,1.3370907359134966e+18,,0.0,0.0,,RT @DanielleHammo20: What does Spock have to do with @LabMelnick? Find out in my piece about this visionary scientist and person. Thanks to‚Ä¶,en,0.0,657.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,20.0,5.0,https://twitter.com/Lisa_Palacios/statuses/1337090735913496578,0.0,0.0,,0.0,0.0,0.0,5.0,20.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,RT @DanielleHammo20: What does Spock have to do with @LabMelnick? Find out in my piece about this visionary scientist and person. Thanks to‚Ä¶,true
ShakiraG_MBBS,BC Geriatrician + Hematologist + Oncologist. Assistant Professor + Clinical Researcher UNC-CH #geriheme #gerionc #mmsm #BlackWomanInMedicine. Tweets=my views,,"North Carolina, USA",,2020-12-10 16:14:39+00:00,Dr. Shakira J Grant MBBS,http://twitter.com/,2.0,,1.3370682167832617e+18,,0.0,0.0,,#ASH20 #hematology + #aging Poster Walk No:2628 Dr. Charity Oyedeji @DukeHealth üëáused physical+cognitive function m‚Ä¶ https://t.co/tTkeTlwyZf,en,0.0,340.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/ShakiraG_MBBS/statuses/1337068216783261696,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Disease Advocacy,0.0,0.0,1.0,#ASH20 #hematology + #aging Poster Walk No:2628 Dr. Charity Oyedeji @DukeHealth üëáused physical+cognitive function m‚Ä¶ https://t.co/tTkeTlwyZf,true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-12-17 18:20:00+00:00,Oncology Tube,http://twitter.com/,0.0,,1.339636478025093e+18,,0.0,0.0,,"Phase 1 Study of Axatilimab (SNDX-6352) Mukta Arora, MD  @UMNews @UMNreasearch #ASH20 #cGVHD #GvHD #Cancer‚Ä¶ https://t.co/T157l9KcYA",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1339636478025093120,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"Phase 1 Study of Axatilimab (SNDX-6352) Mukta Arora, MD  @UMNews @UMNreasearch #ASH20 #cGVHD #GvHD #Cancer‚Ä¶ https://t.co/T157l9KcYA",true
MDedgeHemOnc,MDedge Hematology & Oncology provides the most important and up to date information and news for oncologists. Now part of the Medscape Professional Network.,,"Rockville, MD, Parsippany, NJ",,2020-12-16 15:01:00+00:00,MDedge Hematology & Oncology,http://twitter.com/,0.0,,1.3392240127911813e+18,,0.0,0.0,,News from #ASH20: Phase 1 study of synthetic T-cell receptor and antigen receptor shows efficacy in treating CD19+‚Ä¶ https://t.co/0psKARZn1F,en,0.0,6726.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/MDedgeHemOnc/statuses/1339224012791181313,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,News from #ASH20: Phase 1 study of synthetic T-cell receptor and antigen receptor shows efficacy in treating CD19+‚Ä¶ https://t.co/0psKARZn1F,true
CellworksLife,"Cellworks is a world leader in Precision Medicine. We help physicians & payors navigate to efficacious cost effective treatments in a transparent, timely manner",,"San Jose, CA",,2020-12-16 11:30:08+00:00,CellworksLife,http://twitter.com/,1.0,,1.3391709448420762e+18,,0.0,0.0,,"Predicting Resistance to the Combination of ATO and ATRA in APL Patients with PML-Rara Fusions, Using a Computation‚Ä¶ https://t.co/ChvsMdRF1G",en,0.0,144.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/CellworksLife/statuses/1339170944842076166,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"Predicting Resistance to the Combination of ATO and ATRA in APL Patients with PML-Rara Fusions, Using a Computation‚Ä¶ https://t.co/ChvsMdRF1G",true
biostockguru,Physician executive(MD CWRU;Rice/Jones);Healthcare focus Fund;Pharma advisor/KOL;Tweets NOT investment advice.Pls do your DD. Support https://t.co/97U34OldNG,,United States,,2020-12-06 01:22:57+00:00,biostockGuru,http://twitter.com/,1.0,,1.335394263228543e+18,,0.0,0.0,,"#CART Making a BIG splash at #ASH2020 

Meanwhile 

$XBIO CAR-T pipeline 

Partnered with Takeda
5M Market cap; 
(-‚Ä¶ https://t.co/SOQ6uY4NIF",en,0.0,14021.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/biostockguru/statuses/1335394263228542976,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,"#CART Making a BIG splash at #ASH2020 

Meanwhile 

$XBIO CAR-T pipeline 

Partnered with Takeda
5M Market cap; 
(-‚Ä¶ https://t.co/SOQ6uY4NIF",false
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 15:56:47+00:00,"Ritcha Saxena, MD",http://twitter.com/,9.0,,1.3356141688845353e+18,,0.0,0.0,,RT @CanerSaygin: Dr Floisand presenting data on WT-1 and PRAME dendritic cell vaccine in #AML pts as a post-remission strategy. High mutati‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,3.0,https://twitter.com/RitchaSaxena/statuses/1335614168884535299,0.0,0.0,,0.0,0.0,0.0,3.0,6.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @CanerSaygin: Dr Floisand presenting data on WT-1 and PRAME dendritic cell vaccine in #AML pts as a post-remission strategy. High mutati‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 12:45:24+00:00,"Ritcha Saxena, MD",http://twitter.com/,30.0,,1.3355660078014177e+18,,0.0,0.0,,"RT @VincentRK: From #ASH17: Editors working with Blood, Leukemia, BCJ, and BMT trading secrets about proverbial Reviewer 2... #ASH20 #throw‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,26.0,4.0,https://twitter.com/RitchaSaxena/statuses/1335566007801417731,0.0,0.0,,0.0,0.0,0.0,4.0,26.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,"RT @VincentRK: From #ASH17: Editors working with Blood, Leukemia, BCJ, and BMT trading secrets about proverbial Reviewer 2... #ASH20 #throw‚Ä¶",true
JohnPLeonardMD,"Doctor for lymphoma patients, researcher, collaborator, professor/senior associate dean @WeillCornell & @NYPhospital Tweets mine RT not=endorsement, he/him/his",,Weill Cornell Medicine,,2020-12-06 17:32:21+00:00,"John P. Leonard, MD",http://twitter.com/,1.0,,1.3356382204539249e+18,,0.0,0.0,,Great study and plenary talk!  Proud to collaborate with this #lymphoma team @WeillCornell @nyphospital #ASH20 https://t.co/oDSVV1a60R,en,0.0,6269.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/JohnPLeonardMD/statuses/1335638220453924866,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,Great study and plenary talk!  Proud to collaborate with this #lymphoma team @WeillCornell @nyphospital #ASH20 https://t.co/oDSVV1a60R,true
segol60,"physician-scientist, interested in #innovation #research in #pharma #healthcare #healthliteracy and #ehealth",,Barcelona Spain,,2020-12-06 03:39:37+00:00,Eduard Centeno,http://twitter.com/,129.0,,1.3354286558294098e+18,,0.0,0.0,,"RT @JanssenEMEA: 4 in 100,000 people may be diagnosed with #CLL in their lifetime, so it's important to know the symptoms. #VictoriesOverCa‚Ä¶",en,0.0,213.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,95.0,34.0,https://twitter.com/segol60/statuses/1335428655829409794,0.0,0.0,,0.0,0.0,0.0,34.0,95.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"RT @JanssenEMEA: 4 in 100,000 people may be diagnosed with #CLL in their lifetime, so it's important to know the symptoms. #VictoriesOverCa‚Ä¶",true
KirovDoc,"MD, Ph.D., Hematologist at Kirov Research Institute of Hematology and Blood transfusion",,Russia,,2020-12-06 06:25:38+00:00,Alexander Luchinin,http://twitter.com/,22.0,,1.3354704361094597e+18,,0.0,0.0,,"RT @MM_Hub: Congress| #ASH20| @AlGarfall, @PennCancer, presented data on the phase I trial of teclistamab for R/R MM showing encouraging to‚Ä¶",en,0.0,27.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,14.0,8.0,https://twitter.com/KirovDoc/statuses/1335470436109459457,0.0,0.0,,0.0,0.0,0.0,8.0,14.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @MM_Hub: Congress| #ASH20| @AlGarfall, @PennCancer, presented data on the phase I trial of teclistamab for R/R MM showing encouraging to‚Ä¶",true
TelehealthBot,Created by Doctor @KrittanawongMD. A bot that collects Tweets about medicine and medical innovation,,GJ 357 d,,2020-12-06 17:28:57+00:00,MedEd,http://twitter.com/,36.0,,1.3356373664557998e+18,,0.0,0.0,,"RT @AAcosta_MedMD: #ASH20 #ASHTrainee #MedTwitter 

Don‚Äôt forget to check out our team‚Äôs poster (#1675) on complement-mediated TMA relapse‚Ä¶",en,0.0,683.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,29.0,7.0,https://twitter.com/TelehealthBot/statuses/1335637366455799809,0.0,0.0,,0.0,0.0,0.0,7.0,29.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @AAcosta_MedMD: #ASH20 #ASHTrainee #MedTwitter 

Don‚Äôt forget to check out our team‚Äôs poster (#1675) on complement-mediated TMA relapse‚Ä¶",false
majorajay,"Hematology/oncology fellow. #lymsm & #mmsm outcomes researcher. Physician-publisher & founder of https://t.co/dPfLt8QVMr, @inTrainingDoc & @inHouseMag.",,"Chicago, IL",,2020-12-06 15:33:53+00:00,"Ajay Major, MD, MBA",http://twitter.com/,3.0,,1.3356084058730578e+18,,0.0,0.0,,"&gt;3000 patients screened for A-TREAT, 330 included. No difference in bleeding outcomes for TXA vs placebo, and signi‚Ä¶ https://t.co/o6IJ8kTdcr",en,0.0,3518.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/majorajay/statuses/1335608405873057792,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"&gt;3000 patients screened for A-TREAT, 330 included. No difference in bleeding outcomes for TXA vs placebo, and signi‚Ä¶ https://t.co/o6IJ8kTdcr",true
SoniSmithMD,"Lymphoma doctor, University of Chicago, love cooking and family. Views and opinions my own.",,"Chicago, IL",,2020-12-06 18:35:08+00:00,Soni Smith MD,http://twitter.com/,1.0,,1.3356540204180357e+18,,0.0,0.0,,Very lucky to work with #ASH2020 Mentor recipient Dr Wendy Stock. The words of her mentees say it all! https://t.co/b7OJ4zB056,en,0.0,1106.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/SoniSmithMD/statuses/1335654020418035712,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,Very lucky to work with #ASH2020 Mentor recipient Dr Wendy Stock. The words of her mentees say it all! https://t.co/b7OJ4zB056,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 04:03:20+00:00,"Ritcha Saxena, MD",http://twitter.com/,5.0,,1.3354346257752596e+18,,0.0,0.0,,"RT @_TanyaBondar_: Great Firechat with Dr. Fauci at #ASH20! Dr. Stephanie Lee asked whether patients receiving a transplant, chemo- or  imm‚Ä¶",en,0.0,6875.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,2.0,https://twitter.com/RitchaSaxena/statuses/1335434625775259648,0.0,0.0,,0.0,0.0,0.0,2.0,3.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"RT @_TanyaBondar_: Great Firechat with Dr. Fauci at #ASH20! Dr. Stephanie Lee asked whether patients receiving a transplant, chemo- or  imm‚Ä¶",true
majorajay,"Hematology/oncology fellow. #lymsm & #mmsm outcomes researcher. Physician-publisher & founder of https://t.co/dPfLt8QVMr, @inTrainingDoc & @inHouseMag.",,"Chicago, IL",,2020-12-06 14:02:35+00:00,"Ajay Major, MD, MBA",http://twitter.com/,14.0,,1.3355854330031022e+18,,0.0,0.0,,RT @PurveySneha: #ASH20 DAY 1 Take home point for community oncology @BMTCTN 1102 trial @DrCCutler- Consider referral to transplant center‚Ä¶,en,0.0,3518.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,11.0,3.0,https://twitter.com/majorajay/statuses/1335585433003102210,0.0,0.0,,0.0,0.0,0.0,3.0,11.0,False,False,False,False,True,Disease Advocacy,0.0,0.0,1.0,RT @PurveySneha: #ASH20 DAY 1 Take home point for community oncology @BMTCTN 1102 trial @DrCCutler- Consider referral to transplant center‚Ä¶,true
dgermain21,MD-PhD. 2nd year Heme/Onc fellow focused on lymphoma and leukemia. Physician-scientist-in-training. Tweet/RT not medical advice or endorsement.,,"St. Louis, MO",,2020-12-09 23:02:52+00:00,David A. Russler-Germain,http://twitter.com/,38.0,,1.3368085616036536e+18,,0.0,0.0,,RT @sanamloghavi: major diagnostic pitfall 4 High-grade (double/triple hit) lymphoma with leukemic presentation is misclassifying as de nov‚Ä¶,en,0.0,1612.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,29.0,9.0,https://twitter.com/dgermain21/statuses/1336808561603653636,0.0,0.0,,0.0,0.0,0.0,9.0,29.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @sanamloghavi: major diagnostic pitfall 4 High-grade (double/triple hit) lymphoma with leukemic presentation is misclassifying as de nov‚Ä¶,true
majorajay,"Hematology/oncology fellow. #lymsm & #mmsm outcomes researcher. Physician-publisher & founder of https://t.co/dPfLt8QVMr, @inTrainingDoc & @inHouseMag.",,"Chicago, IL",,2020-12-06 17:07:13+00:00,"Ajay Major, MD, MBA",http://twitter.com/,0.0,,1.3356318967269376e+18,,0.0,0.0,,"We always reach to 'biology' first, with the access and equity issues being a second thought. ""There may be socioec‚Ä¶ https://t.co/TYrnZkgZY9",en,0.0,3518.0,,,0.0,majorajay,1.3356311068430254e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/majorajay/statuses/1335631896726937606,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,"We always reach to 'biology' first, with the access and equity issues being a second thought. ""There may be socioec‚Ä¶ https://t.co/TYrnZkgZY9",false
majorajay,"Hematology/oncology fellow. #lymsm & #mmsm outcomes researcher. Physician-publisher & founder of https://t.co/dPfLt8QVMr, @inTrainingDoc & @inHouseMag.",,"Chicago, IL",,2020-12-06 22:25:46+00:00,"Ajay Major, MD, MBA",http://twitter.com/,0.0,,1.3357120610415985e+18,,0.0,0.0,,"In a retrospective study in Alberta, high-dose methotrexate did not reduce risk of CNS relapse in DLBCL, but there‚Ä¶ https://t.co/szzPTTzLOv",en,0.0,3518.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/majorajay/statuses/1335712061041598469,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"In a retrospective study in Alberta, high-dose methotrexate did not reduce risk of CNS relapse in DLBCL, but there‚Ä¶ https://t.co/szzPTTzLOv",true
majorajay,"Hematology/oncology fellow. #lymsm & #mmsm outcomes researcher. Physician-publisher & founder of https://t.co/dPfLt8QVMr, @inTrainingDoc & @inHouseMag.",,"Chicago, IL",,2020-12-06 15:42:49+00:00,"Ajay Major, MD, MBA",http://twitter.com/,0.0,,1.3356106557061407e+18,,0.0,0.0,,"The Q&amp;A after the A-TREAT presentation: the speaker said her researcher coordinators ""swore they know who was on pl‚Ä¶ https://t.co/fky08OBO9A",en,0.0,3518.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/majorajay/statuses/1335610655706140673,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Thought Leadership,0.0,0.0,1.0,"The Q&amp;A after the A-TREAT presentation: the speaker said her researcher coordinators ""swore they know who was on pl‚Ä¶ https://t.co/fky08OBO9A",true
dgermain21,MD-PhD. 2nd year Heme/Onc fellow focused on lymphoma and leukemia. Physician-scientist-in-training. Tweet/RT not medical advice or endorsement.,,"St. Louis, MO",,2020-12-06 15:05:39+00:00,David A. Russler-Germain,http://twitter.com/,45.0,,1.3356013041278853e+18,,0.0,0.0,,RT @DrMiguelPerales: #ASH20 Abs 470 Impressive results in Phase II Study of Pembrolizumab Plus GVD As 2nd-Line Therapy for Rel/Ref Classica‚Ä¶,en,0.0,1612.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,34.0,11.0,https://twitter.com/dgermain21/statuses/1335601304127885314,0.0,0.0,,0.0,0.0,0.0,11.0,34.0,False,False,False,False,True,Clinical Trials,1.0,0.0,0.0,RT @DrMiguelPerales: #ASH20 Abs 470 Impressive results in Phase II Study of Pembrolizumab Plus GVD As 2nd-Line Therapy for Rel/Ref Classica‚Ä¶,true
Lymphoma_Doc,"Director of Clinical Research, Section Chief of Aggressive Lymphomas at MD Anderson Cancer Center, CAR T-cell, dreamer and doer. Opinions are mine",,"Houston, TX",,2020-12-09 22:28:58+00:00,"Jason Westin, MD FACP",http://twitter.com/,38.0,,1.3368000308591534e+18,,0.0,0.0,,RT @sanamloghavi: major diagnostic pitfall 4 High-grade (double/triple hit) lymphoma with leukemic presentation is misclassifying as de nov‚Ä¶,en,0.0,5105.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,29.0,9.0,https://twitter.com/Lymphoma_Doc/statuses/1336800030859153410,0.0,0.0,,0.0,0.0,0.0,9.0,29.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @sanamloghavi: major diagnostic pitfall 4 High-grade (double/triple hit) lymphoma with leukemic presentation is misclassifying as de nov‚Ä¶,true
majorajay,"Hematology/oncology fellow. #lymsm & #mmsm outcomes researcher. Physician-publisher & founder of https://t.co/dPfLt8QVMr, @inTrainingDoc & @inHouseMag.",,"Chicago, IL",,2020-12-06 20:41:14+00:00,"Ajay Major, MD, MBA",http://twitter.com/,0.0,,1.3356857530247332e+18,,0.0,0.0,,@JohnPLeonardMD A little patient-reported outcomes work can help with that! #ASH20,en,0.0,3518.0,,,0.0,JohnPLeonardMD,1.3356855850093322e+18,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/majorajay/statuses/1335685753024733184,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,@JohnPLeonardMD A little patient-reported outcomes work can help with that! #ASH20,true
noriega_dr,"MD, PhD. Hematologist in CHUAC (A Coru√±a-Spain). Leukemia and Bone Marrow Transplantation. Tweets and opinions are mine.",,,,2020-12-06 16:58:32+00:00,Dr Victor Noriega,http://twitter.com/,0.0,,1.3356297093470085e+18,,0.0,0.0,,#ASH20 #Plenary Poor Treatment Outcomes of Young (&lt;60 Years) African American Patients (Pts) Diagnosed with Acute M‚Ä¶ https://t.co/V8788ijdoV,en,0.0,959.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/noriega_dr/statuses/1335629709347008513,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,#ASH20 #Plenary Poor Treatment Outcomes of Young (&lt;60 Years) African American Patients (Pts) Diagnosed with Acute M‚Ä¶ https://t.co/V8788ijdoV,false
drjgauthier,"MD, MSc, Assistant Professor @fredhutch @UW focused on #CARTcell #immunotherapy #tcellrx 
Interests also include #rstats #bmtsm #epitwitter #bayes",,"Seattle, WA",,2020-12-06 22:54:00+00:00,Jordan Gauthier,http://twitter.com/,15.0,,1.3357191654165463e+18,,0.0,0.0,,"RT @fredhutch: Dr. Elizabeth Krakow to present ""Phase I Study of Adoptive Immunotherapy with HA-1-Specific CD8+ and CD4+ Memory T Cells for‚Ä¶",en,0.0,3295.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,13.0,2.0,https://twitter.com/drjgauthier/statuses/1335719165416546305,0.0,0.0,,0.0,0.0,0.0,2.0,13.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @fredhutch: Dr. Elizabeth Krakow to present ""Phase I Study of Adoptive Immunotherapy with HA-1-Specific CD8+ and CD4+ Memory T Cells for‚Ä¶",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 21:14:59+00:00,"Ritcha Saxena, MD",http://twitter.com/,8.0,,1.335694249669636e+18,,0.0,0.0,,RT @DrOlaLandgren: @GretchenTap @DrPaulyDeSantis Immuno-PET is not yet available as standard of care. We will open a new phase 2 study for‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,2.0,https://twitter.com/RitchaSaxena/statuses/1335694249669636097,0.0,0.0,,0.0,0.0,0.0,2.0,6.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @DrOlaLandgren: @GretchenTap @DrPaulyDeSantis Immuno-PET is not yet available as standard of care. We will open a new phase 2 study for‚Ä¶,true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-06 17:14:36+00:00,Lisa Palacios,http://twitter.com/,6.0,,1.3356337538682675e+18,,0.0,0.0,,RT @HemOncToday: NEWS from #ASH20 - Venetoclax + ibrutinib may induce treatment-free remission in patients with chronic lymphocytic leukemi‚Ä¶,en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,2.0,https://twitter.com/Lisa_Palacios/statuses/1335633753868267533,0.0,0.0,,0.0,0.0,0.0,2.0,4.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @HemOncToday: NEWS from #ASH20 - Venetoclax + ibrutinib may induce treatment-free remission in patients with chronic lymphocytic leukemi‚Ä¶,true
majorajay,"Hematology/oncology fellow. #lymsm & #mmsm outcomes researcher. Physician-publisher & founder of https://t.co/dPfLt8QVMr, @inTrainingDoc & @inHouseMag.",,"Chicago, IL",,2020-12-06 21:57:58+00:00,"Ajay Major, MD, MBA",http://twitter.com/,2.0,,1.3357050667586888e+18,,0.0,0.0,,Saving this slide with the diagnostic criteria for POEMS syndrome. #ASH20 #ASH20AM #mmsm https://t.co/AO4NWa1hOR,en,0.0,3518.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/majorajay/statuses/1335705066758688768,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,Saving this slide with the diagnostic criteria for POEMS syndrome. #ASH20 #ASH20AM #mmsm https://t.co/AO4NWa1hOR,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 12:30:48+00:00,"Ritcha Saxena, MD",http://twitter.com/,8.0,,1.335562333054247e+18,,0.0,0.0,,RT @WCMLymphoma: The #ASH20 Annual Meeting is underway. Stay tuned for exciting #lymphoma #research updates from our team and see what Dr.‚Ä¶,en,0.0,6875.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,2.0,https://twitter.com/RitchaSaxena/statuses/1335562333054246912,0.0,0.0,,0.0,0.0,0.0,2.0,6.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @WCMLymphoma: The #ASH20 Annual Meeting is underway. Stay tuned for exciting #lymphoma #research updates from our team and see what Dr.‚Ä¶,true
JohnPLeonardMD,"Doctor for lymphoma patients, researcher, collaborator, professor/senior associate dean @WeillCornell & @NYPhospital Tweets mine RT not=endorsement, he/him/his",,Weill Cornell Medicine,,2020-12-06 20:40:33+00:00,"John P. Leonard, MD",http://twitter.com/,2.0,,1.3356855850093322e+18,,0.0,0.0,,So the CAR-T debate of which works better/is less toxic is now going to be rivaled by the bispecific antibody debat‚Ä¶ https://t.co/Rhq1pIuxve,en,0.0,6269.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/JohnPLeonardMD/statuses/1335685585009332224,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Drug Comparisons,0.0,0.0,1.0,So the CAR-T debate of which works better/is less toxic is now going to be rivaled by the bispecific antibody debat‚Ä¶ https://t.co/Rhq1pIuxve,false
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 12:45:59+00:00,"Ritcha Saxena, MD",http://twitter.com/,20.0,,1.335566156447568e+18,,0.0,0.0,,"RT @MDAndersonNews: Based on initial findings of the Phase I/II study in BPDCN, the FDA granted breakthrough therapy designation to IMGN632‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,16.0,4.0,https://twitter.com/RitchaSaxena/statuses/1335566156447567873,0.0,0.0,,0.0,0.0,0.0,4.0,16.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @MDAndersonNews: Based on initial findings of the Phase I/II study in BPDCN, the FDA granted breakthrough therapy designation to IMGN632‚Ä¶",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 16:04:24+00:00,"Ritcha Saxena, MD",http://twitter.com/,3.0,,1.335616089166934e+18,,0.0,0.0,,"RT @SeattleCCA: Coming up at #ASH20: Education program with Michael Linenberger, MD - ""Updates on the Diagnosis and Management of the Most‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,2.0,1.0,https://twitter.com/RitchaSaxena/statuses/1335616089166934019,0.0,0.0,,0.0,0.0,0.0,1.0,2.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"RT @SeattleCCA: Coming up at #ASH20: Education program with Michael Linenberger, MD - ""Updates on the Diagnosis and Management of the Most‚Ä¶",true
FunchainMD,"Melanoma and high risk skin cancer medical oncologist. Studying hereditary and somatic genomics. CA explant in OH. (IO!) Sports fan, geek, and mommy.",,"Cleveland, OH",,2020-12-06 03:07:00+00:00,Pauline Funchain,http://twitter.com/,19.0,,1.3354204502189138e+18,,0.0,0.0,,"RT @khouri_jack: Intriguing data from the phase 2 BIRMA trial, combined BRAF/MEK inhibition: 80% response rates in RR #myeloma patients wit‚Ä¶",en,0.0,1530.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,15.0,4.0,https://twitter.com/FunchainMD/statuses/1335420450218913792,0.0,0.0,,0.0,0.0,0.0,4.0,15.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @khouri_jack: Intriguing data from the phase 2 BIRMA trial, combined BRAF/MEK inhibition: 80% response rates in RR #myeloma patients wit‚Ä¶",true
majorajay,"Hematology/oncology fellow. #lymsm & #mmsm outcomes researcher. Physician-publisher & founder of https://t.co/dPfLt8QVMr, @inTrainingDoc & @inHouseMag.",,"Chicago, IL",,2020-12-06 14:06:34+00:00,"Ajay Major, MD, MBA",http://twitter.com/,2.0,,1.3355864327994e+18,,0.0,0.0,,RT @HadidiSamer: Practical recommendations to treat MM during COVID-19 pandemic by Sr Mateos @ASH_hematology #ASH20 https://t.co/zu9SQt4cav,en,0.0,3518.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,1.0,1.0,https://twitter.com/majorajay/statuses/1335586432799399938,0.0,0.0,,0.0,0.0,0.0,1.0,1.0,False,False,False,False,True,Covid,0.0,0.0,1.0,RT @HadidiSamer: Practical recommendations to treat MM during COVID-19 pandemic by Sr Mateos @ASH_hematology #ASH20 https://t.co/zu9SQt4cav,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 23:54:55+00:00,"Ritcha Saxena, MD",http://twitter.com/,310.0,,1.3357344973971415e+18,,0.0,0.0,,RT @VincentRK: 4 key slides from my talk on ‚ÄúHow I Treat Newly Diagnosed Myeloma‚Äù at #ASHMHM20 @ASH_hematology meeting. @MayoCancerCare @Ma‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,220.0,90.0,https://twitter.com/RitchaSaxena/statuses/1335734497397141505,0.0,0.0,,0.0,0.0,0.0,90.0,220.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @VincentRK: 4 key slides from my talk on ‚ÄúHow I Treat Newly Diagnosed Myeloma‚Äù at #ASHMHM20 @ASH_hematology meeting. @MayoCancerCare @Ma‚Ä¶,true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-06 22:30:10+00:00,Lisa Palacios,http://twitter.com/,1.0,,1.335713170011398e+18,,0.0,0.0,,RT @VJHemOnc: @NicholasShortMD of @LeukemiaMDA talked on the results from a Phase II study of #Blinatumomab following hyper-CVAD in B-cell‚Ä¶,en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/Lisa_Palacios/statuses/1335713170011398145,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @VJHemOnc: @NicholasShortMD of @LeukemiaMDA talked on the results from a Phase II study of #Blinatumomab following hyper-CVAD in B-cell‚Ä¶,false
sairah__ahmed,"Lymphoma/Cellular Therapy & SCT at MD Anderson Cancer Center, opinions/tweets shared= my own.",,"Houston, TX",,2020-12-06 16:49:17+00:00,Sairah Ahmed MD,http://twitter.com/,9.0,,1.3356273827330703e+18,,0.0,0.0,,RT @Rfonsi1: FIH Dual BCMA and CD19 Targeted Novel Platform Fast CAR-T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma.‚Ä¶,en,0.0,491.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,4.0,https://twitter.com/sairah__ahmed/statuses/1335627382733070341,0.0,0.0,,0.0,0.0,0.0,4.0,5.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @Rfonsi1: FIH Dual BCMA and CD19 Targeted Novel Platform Fast CAR-T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma.‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 21:25:08+00:00,"Ritcha Saxena, MD",http://twitter.com/,12.0,,1.3356968045082952e+18,,0.0,0.0,,"RT @MoffittNews: Magrolimab plus chemotherapy found effective in acute myeloid leukemia patients, especially those with TP53 mutation. Dr.‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,2.0,https://twitter.com/RitchaSaxena/statuses/1335696804508295171,0.0,0.0,,0.0,0.0,0.0,2.0,10.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @MoffittNews: Magrolimab plus chemotherapy found effective in acute myeloid leukemia patients, especially those with TP53 mutation. Dr.‚Ä¶",true
graham74GC,Lymphoma specialist at Oxford Cancer and Haematology centre. Haematologist and clinical trialist. Chair of UK Hodgkin and T-cell study groups.,,Opinions are mine,,2020-12-06 21:31:29+00:00,Graham Collins,http://twitter.com/,4.0,,1.3356984010155868e+18,,0.0,0.0,,"Neelapu: Axi-Cel in 1L DLBCL
- DHL / THL AND pos iPET (D4 or 5) after 2x R-chemo
- PS0-1, non-chemo bridging allowe‚Ä¶ https://t.co/Gafj89DGZF",en,0.0,6092.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,4.0,https://twitter.com/graham74GC/statuses/1335698401015586818,0.0,0.0,,0.0,0.0,0.0,4.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"Neelapu: Axi-Cel in 1L DLBCL
- DHL / THL AND pos iPET (D4 or 5) after 2x R-chemo
- PS0-1, non-chemo bridging allowe‚Ä¶ https://t.co/Gafj89DGZF",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 21:25:24+00:00,"Ritcha Saxena, MD",http://twitter.com/,3.0,,1.3356968691047588e+18,,0.0,0.0,,RT @MoffittNews: Can follicular lymphoma patients who relapse after CAR T therapy be retreated with the genetically modified immune cells?‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,2.0,1.0,https://twitter.com/RitchaSaxena/statuses/1335696869104758786,0.0,0.0,,0.0,0.0,0.0,1.0,2.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @MoffittNews: Can follicular lymphoma patients who relapse after CAR T therapy be retreated with the genetically modified immune cells?‚Ä¶,true
BroeckelmannPJ,"MD @UKKoeln & Physician Scientist Postdoc @MPIAGE. Hemato-Oncology. Lymphoma. Immunotherapies. DNA damage. Personal opinion, RT/like ‚â† endorsement.",,"Cologne, Germany",,2020-12-06 16:55:33+00:00,Paul Br√∂ckelmann,http://twitter.com/,0.0,,1.3356289604666573e+18,,0.0,0.0,,Excited to share updated data of the GHSG phase II NIVAHL trial investigating sequential and concomitant Nivo + AVD‚Ä¶ https://t.co/WaCFH51owb,en,0.0,243.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/BroeckelmannPJ/statuses/1335628960466657281,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,1.0,0.0,0.0,Excited to share updated data of the GHSG phase II NIVAHL trial investigating sequential and concomitant Nivo + AVD‚Ä¶ https://t.co/WaCFH51owb,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 16:16:47+00:00,"Ritcha Saxena, MD",http://twitter.com/,10.0,,1.3356192053040865e+18,,0.0,0.0,,RT @HemOncToday: NEWS from @ASH_hematology #ASH20 - Results from phase 2 ZUMA-5 trial show axi-cel CAR-T #CellTherapy confers durable clini‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,5.0,https://twitter.com/RitchaSaxena/statuses/1335619205304086528,0.0,0.0,,0.0,0.0,0.0,5.0,5.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @HemOncToday: NEWS from @ASH_hematology #ASH20 - Results from phase 2 ZUMA-5 trial show axi-cel CAR-T #CellTherapy confers durable clini‚Ä¶,false
DrRakeshPopat,Haematologist @uclh & associate professor @ucl. Vice-chair UK Myeloma Research Alliance. Interests: multiple myeloma & clinical trials. All views are my own.,,"London, England",,2020-12-06 21:28:09+00:00,Rakesh Popat,http://twitter.com/,0.0,,1.3356975608797143e+18,,0.0,0.0,,"Oral low dose cyclophosphamide performing well with novel agents for relapsed myeloma at #ASH20 ! 
Nice data adding‚Ä¶ https://t.co/aLWZMLe2hq",en,0.0,506.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/DrRakeshPopat/statuses/1335697560879714304,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnosis Progression,1.0,0.0,0.0,"Oral low dose cyclophosphamide performing well with novel agents for relapsed myeloma at #ASH20 ! 
Nice data adding‚Ä¶ https://t.co/aLWZMLe2hq",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-06 23:42:45+00:00,Lisa Palacios,http://twitter.com/,12.0,,1.3357314346198917e+18,,0.0,0.0,,RT @VJHemOnc: Marina Konopleva of @MDAndersonNews at #ASH20: #Venetoclax &amp; #Azacitadine in intensive chemotherapy-ineligible FLT3-mutated #‚Ä¶,en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,2.0,https://twitter.com/Lisa_Palacios/statuses/1335731434619891713,0.0,0.0,,0.0,0.0,0.0,2.0,10.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @VJHemOnc: Marina Konopleva of @MDAndersonNews at #ASH20: #Venetoclax &amp; #Azacitadine in intensive chemotherapy-ineligible FLT3-mutated #‚Ä¶,true
rajshekharucms,Hem/Onc Physician/Clinical Researcher @ColumbiaCancer #MultipleMyeloma & #Amyloidosis. Asst. Prof of Medicine @ColumbiaMed #ClinicalTrials and Outcomes Research,,"New York, NY",,2020-12-06 02:44:28+00:00,Raj Chakraborty,http://twitter.com/,45.0,,1.3354147790291886e+18,,0.0,0.0,,"RT @BiostatGirl: Symptoms improve after Autologous Stem Cell Transplant in pts w/ Multiple Myeloma. High symptoms associated w/ male sex, h‚Ä¶",en,0.0,1148.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,30.0,15.0,https://twitter.com/rajshekharucms/statuses/1335414779029188608,0.0,0.0,,0.0,0.0,0.0,15.0,30.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @BiostatGirl: Symptoms improve after Autologous Stem Cell Transplant in pts w/ Multiple Myeloma. High symptoms associated w/ male sex, h‚Ä¶",true
dr_supreetkaur,Hematologist/ Oncologist at University of Texas at San Antonio | Passionate about lymphoma | Believes in hope and chocolate therapy!,,,,2020-12-06 22:58:17+00:00,Supreet Kaur,http://twitter.com/,0.0,,1.3357202435247227e+18,,0.0,0.0,,"Moskowitz et al - Phase 2 second line Pembro + GVD for R/R cHL
95% achieved CR and proceeded to ASCT 
No progressio‚Ä¶ https://t.co/m0s4NW7JOk",en,0.0,51.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/dr_supreetkaur/statuses/1335720243524722690,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"Moskowitz et al - Phase 2 second line Pembro + GVD for R/R cHL
95% achieved CR and proceeded to ASCT 
No progressio‚Ä¶ https://t.co/m0s4NW7JOk",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-06 05:19:16+00:00,Lisa Palacios,http://twitter.com/,20.0,,1.335453732688044e+18,,0.0,0.0,,"RT @MDAndersonNews: Based on initial findings of the Phase I/II study in BPDCN, the FDA granted breakthrough therapy designation to IMGN632‚Ä¶",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,16.0,4.0,https://twitter.com/Lisa_Palacios/statuses/1335453732688044033,0.0,0.0,,0.0,0.0,0.0,4.0,16.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @MDAndersonNews: Based on initial findings of the Phase I/II study in BPDCN, the FDA granted breakthrough therapy designation to IMGN632‚Ä¶",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 21:15:36+00:00,"Ritcha Saxena, MD",http://twitter.com/,12.0,,1.3356944053202534e+18,,0.0,0.0,,"RT @DrOlaLandgren: Excellent overview on immunotherapy in #myeloma . Strong talks by all presenters. Impressive, innovative translational w‚Ä¶",en,0.0,6875.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,9.0,3.0,https://twitter.com/RitchaSaxena/statuses/1335694405320253440,0.0,0.0,,0.0,0.0,0.0,3.0,9.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"RT @DrOlaLandgren: Excellent overview on immunotherapy in #myeloma . Strong talks by all presenters. Impressive, innovative translational w‚Ä¶",false
smaliske07,Husband. Father. Cancer Physician. @SanfordHealth #RogerMarisCancerCenter @UIowa @UIowaCancer @ASTCT @CIBMTR @BMTCTN #BMTsm #CARTcell #CellTherapy,,"Iowa City, IA",,2020-12-06 12:25:32+00:00,smaliske07,http://twitter.com/,187.0,,1.335561007360598e+18,,0.0,0.0,,"RT @VincentRK: One of the most common questions myeloma patients ask me is: Should I get a stem cell transplant, and if so when should I do‚Ä¶",en,0.0,4.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,136.0,51.0,https://twitter.com/smaliske07/statuses/1335561007360598016,0.0,0.0,,0.0,0.0,0.0,51.0,136.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @VincentRK: One of the most common questions myeloma patients ask me is: Should I get a stem cell transplant, and if so when should I do‚Ä¶",true
bloodgenes,"Pediatric Hematologist/Oncologist, Geneticist, Stem Cell Biologist - @DFBC_PedCare, @BostonChildrens, @DanaFarber & @broadinstitute",,"Boston, MA",,2020-12-07 15:37:53+00:00,Vijay Sankaran,http://twitter.com/,24.0,,1.3359718019066511e+18,,0.0,0.0,,"RT @acweyand: Preventing scurvy isn‚Äôt the only thing Vitamin C is good for!  

Data showing ascorbic acid in combination with chemotherapy‚Ä¶",en,0.0,4057.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,23.0,1.0,https://twitter.com/bloodgenes/statuses/1335971801906651136,0.0,0.0,,0.0,0.0,0.0,1.0,23.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @acweyand: Preventing scurvy isn‚Äôt the only thing Vitamin C is good for!  

Data showing ascorbic acid in combination with chemotherapy‚Ä¶",true
majorajay,"Hematology/oncology fellow. #lymsm & #mmsm outcomes researcher. Physician-publisher & founder of https://t.co/dPfLt8QVMr, @inTrainingDoc & @inHouseMag.",,"Chicago, IL",,2020-12-06 00:05:35+00:00,"Ajay Major, MD, MBA",http://twitter.com/,0.0,,1.3353747947920548e+18,,0.0,0.0,,"I am privileged to have worked with Dr. Wendy Stock, this year's #ASH20 Mentor Award winner. Congratulations, Dr. S‚Ä¶ https://t.co/Qcn8jccquW",en,0.0,3518.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/majorajay/statuses/1335374794792054785,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,"I am privileged to have worked with Dr. Wendy Stock, this year's #ASH20 Mentor Award winner. Congratulations, Dr. S‚Ä¶ https://t.co/Qcn8jccquW",true
UrviShahMD,Oncologist and researcher on Myeloma service @sloan_kettering. Interested in nutrition for cancer and immune therapies. Views are my own,,"New York, NY",,2020-12-07 01:19:58+00:00,Urvi Shah,http://twitter.com/,8.0,,1.3357558989926605e+18,,0.0,0.0,,We studied the risk of preceding diabetes on individual lymphoproliferative diagnoses in a Swedish case control stu‚Ä¶ https://t.co/ayH61pvo1c,en,0.0,1227.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,8.0,https://twitter.com/UrviShahMD/statuses/1335755898992660486,0.0,0.0,,0.0,0.0,0.0,8.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,We studied the risk of preceding diabetes on individual lymphoproliferative diagnoses in a Swedish case control stu‚Ä¶ https://t.co/ayH61pvo1c,true
dgermain21,MD-PhD. 2nd year Heme/Onc fellow focused on lymphoma and leukemia. Physician-scientist-in-training. Tweet/RT not medical advice or endorsement.,,"St. Louis, MO",,2020-12-06 01:18:52+00:00,David A. Russler-Germain,http://twitter.com/,18.0,,1.335393235842298e+18,,0.0,0.0,,"RT @tobyeyre82: .@michaelwangmd et al
VLS-101 in R/R #MCL + #DLBCL
anti-ROR1 MMAE-ADC monotx data
phase I trial
MTD 2.5mg/kg
neutropenia +‚Ä¶",en,0.0,1612.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,14.0,4.0,https://twitter.com/dgermain21/statuses/1335393235842297857,0.0,0.0,,0.0,0.0,0.0,4.0,14.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @tobyeyre82: .@michaelwangmd et al
VLS-101 in R/R #MCL + #DLBCL
anti-ROR1 MMAE-ADC monotx data
phase I trial
MTD 2.5mg/kg
neutropenia +‚Ä¶",true
DrArunCMC,"Hematopathologist, Molecular Hematologist and Flow Cytometrist. CMC Vellore.",,"Vellore, India",,2020-12-06 03:05:30+00:00,Arun Kumar Arunachalam,http://twitter.com/,24.0,,1.3354200719512576e+18,,0.0,0.0,,RT @DrMiguelPerales: #ASH20 #273 Molecular Predictors and Effectiveness of Measurable Residual Disease (MRD) Eradication with Chemotherapy‚Ä¶,en,0.0,332.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,19.0,5.0,https://twitter.com/DrArunCMC/statuses/1335420071951257600,0.0,0.0,,0.0,0.0,0.0,5.0,19.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @DrMiguelPerales: #ASH20 #273 Molecular Predictors and Effectiveness of Measurable Residual Disease (MRD) Eradication with Chemotherapy‚Ä¶,false
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 16:31:53+00:00,"Ritcha Saxena, MD",http://twitter.com/,40.0,,1.3356230027807908e+18,,0.0,0.0,,RT @JanssenEMEA: Raising awareness of the symptoms of multiple myeloma is vital to support early diagnosis. #ASH20 #ASHFromHome #VictoriesO‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,34.0,6.0,https://twitter.com/RitchaSaxena/statuses/1335623002780790785,0.0,0.0,,0.0,0.0,0.0,6.0,34.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @JanssenEMEA: Raising awareness of the symptoms of multiple myeloma is vital to support early diagnosis. #ASH20 #ASHFromHome #VictoriesO‚Ä¶,true
Mikeypod50,"Podiatrist, now part-time, but still enjoying caring for patients. Father of 4, ""Baba"" to 7. Philly sports fan (sigh) for too many years",,,,2020-12-05 17:30:56+00:00,(((Michael Katz))),http://twitter.com/,68.0,,1.335275477645357e+18,,0.0,0.0,,"RT @BMS_Myeloma_US: During #ASH20, learn why new treatment options are needed in triple-class exposed* multiple myeloma. #MMSM",en,0.0,81.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,55.0,13.0,https://twitter.com/Mikeypod50/statuses/1335275477645357066,0.0,0.0,,0.0,0.0,0.0,13.0,55.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @BMS_Myeloma_US: During #ASH20, learn why new treatment options are needed in triple-class exposed* multiple myeloma. #MMSM",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-05 20:36:18+00:00,"Ritcha Saxena, MD",http://twitter.com/,1.0,,1.335322123603153e+18,,0.0,0.0,,RT @feldstej: 1404 Effect of Intravenous Immunoglobulin on Infections in Multiple Myeloma (MM) Patients Receiving Daratumumab https://t.co/‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/RitchaSaxena/statuses/1335322123603152903,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Disease Management,0.0,0.0,1.0,RT @feldstej: 1404 Effect of Intravenous Immunoglobulin on Infections in Multiple Myeloma (MM) Patients Receiving Daratumumab https://t.co/‚Ä¶,true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 16:43:05+00:00,Lisa Palacios,http://twitter.com/,1.0,,1.3352634354294415e+18,,0.0,0.0,,RT @afinch7: Common theme when combining venetoclax with intensive chemo ‚û°Ô∏è prolonged myelosuppresion &amp; INFECTION.  We see it with FlaV-Ida‚Ä¶,en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/Lisa_Palacios/statuses/1335263435429441536,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @afinch7: Common theme when combining venetoclax with intensive chemo ‚û°Ô∏è prolonged myelosuppresion &amp; INFECTION.  We see it with FlaV-Ida‚Ä¶,true
VPrasadMDMPH,"Associate Prof, Physician, Epidemiology @ucsf_epibiostat, Podcast @Plenary_Session, Author: Malignant (2020); Ending Medical Reversal (2015); Views my own",,"San Francisco, Ca",,2020-12-05 02:53:46+00:00,Vinay Prasad MD MPH,http://twitter.com/,8.0,,1.3350547310314455e+18,,0.0,0.0,,"Agree with Bernie #ASH20 
We analyzed the benefit of new leukemia drugs here:
https://t.co/shpfPoghcW‚Ä¶ https://t.co/xeFzdquPkX",en,0.0,63817.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,8.0,https://twitter.com/VPrasadMDMPH/statuses/1335054731031445505,0.0,0.0,,0.0,0.0,0.0,8.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"Agree with Bernie #ASH20 
We analyzed the benefit of new leukemia drugs here:
https://t.co/shpfPoghcW‚Ä¶ https://t.co/xeFzdquPkX",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-05 19:54:52+00:00,"Ritcha Saxena, MD",http://twitter.com/,1.0,,1.3353116992939827e+18,,0.0,0.0,,RT @majorajay: Dr. Pro @bpromd et al. presenting the Phase II PRIMO results for duvelisib in R/R PTCL. ORR at 75 mg bid dose was 52% (36% C‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/RitchaSaxena/statuses/1335311699293982721,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @majorajay: Dr. Pro @bpromd et al. presenting the Phase II PRIMO results for duvelisib in R/R PTCL. ORR at 75 mg bid dose was 52% (36% C‚Ä¶,false
UrviShahMD,Oncologist and researcher on Myeloma service @sloan_kettering. Interested in nutrition for cancer and immune therapies. Views are my own,,"New York, NY",,2020-12-05 20:26:48+00:00,Urvi Shah,http://twitter.com/,15.0,,1.335319733265195e+18,,0.0,0.0,,"RT @DrMiguelPerales: #ASH20 CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, #BCMA #CARTcells in R/R #myeloma @DMadduri #mmsm Im‚Ä¶",en,0.0,1227.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,13.0,2.0,https://twitter.com/UrviShahMD/statuses/1335319733265195008,0.0,0.0,,0.0,0.0,0.0,2.0,13.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @DrMiguelPerales: #ASH20 CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, #BCMA #CARTcells in R/R #myeloma @DMadduri #mmsm Im‚Ä¶",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 21:51:15+00:00,Lisa Palacios,http://twitter.com/,4.0,,1.3353409874937897e+18,,0.0,0.0,,"RT @VJHemOnc: Highlights from newly diagnosed #AMLsm novel combination therapy orals at #ASH20 

@musayilmaz54 @MDAndersonNews: In FLT3-ITD‚Ä¶",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,2.0,2.0,https://twitter.com/Lisa_Palacios/statuses/1335340987493789700,0.0,0.0,,0.0,0.0,0.0,2.0,2.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"RT @VJHemOnc: Highlights from newly diagnosed #AMLsm novel combination therapy orals at #ASH20 

@musayilmaz54 @MDAndersonNews: In FLT3-ITD‚Ä¶",true
mav_jav,"Human,fighter,survivor. Passionate about helping and healing.Histopathologist",,"The Capital, Kuwait",,2020-12-05 19:55:21+00:00,Mawish javed,http://twitter.com/,16.0,,1.3353118213272412e+18,,0.0,0.0,,"RT @VincentRK: 11. Phase 1 results of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed/Refractory Myeloma. 61% response rate in heav‚Ä¶",en,0.0,956.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,6.0,https://twitter.com/mav_jav/statuses/1335311821327241219,0.0,0.0,,0.0,0.0,0.0,6.0,10.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @VincentRK: 11. Phase 1 results of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed/Refractory Myeloma. 61% response rate in heav‚Ä¶",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-05 02:09:26+00:00,"Ritcha Saxena, MD",http://twitter.com/,46.0,,1.3350435737593037e+18,,0.0,0.0,,RT @BldCancerDoc: #ASH20 @CleClinicMD #CleClinicCancer is hiring faculty for #Leukemia #MDS program - come work with ü§©üòé colleagues @Carrawa‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,39.0,7.0,https://twitter.com/RitchaSaxena/statuses/1335043573759303681,0.0,0.0,,0.0,0.0,0.0,7.0,39.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,RT @BldCancerDoc: #ASH20 @CleClinicMD #CleClinicCancer is hiring faculty for #Leukemia #MDS program - come work with ü§©üòé colleagues @Carrawa‚Ä¶,true
Transplant_Doc,Stem Cell Transplant physician and clinical researcher at MD Anderson Cancer Center; special interest in myeloma. Opinions expressed are my own,,,,2020-12-05 02:30:08+00:00,Muzaffar Qazilbash,http://twitter.com/,187.0,,1.335048782300541e+18,,0.0,0.0,,"RT @VincentRK: One of the most common questions myeloma patients ask me is: Should I get a stem cell transplant, and if so when should I do‚Ä¶",en,0.0,5455.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,136.0,51.0,https://twitter.com/Transplant_Doc/statuses/1335048782300540930,0.0,0.0,,0.0,0.0,0.0,51.0,136.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @VincentRK: One of the most common questions myeloma patients ask me is: Should I get a stem cell transplant, and if so when should I do‚Ä¶",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 15:29:41+00:00,Lisa Palacios,http://twitter.com/,11.0,,1.335244964691927e+18,,0.0,0.0,,"RT @amarkelkar: ""Anyone who doesn't think we need to be working on a universal coronavirus vaccine isn't paying attention"" - Dr. Anthony Fa‚Ä¶",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,8.0,3.0,https://twitter.com/Lisa_Palacios/statuses/1335244964691927041,0.0,0.0,,0.0,0.0,0.0,3.0,8.0,False,False,False,False,True,Covid,0.0,0.0,1.0,"RT @amarkelkar: ""Anyone who doesn't think we need to be working on a universal coronavirus vaccine isn't paying attention"" - Dr. Anthony Fa‚Ä¶",false
BCD_AACR,Follow Blood Cancer Discovery for high-impact articles on pace-setting advances of researchers and physician-scientists working globally. Published by @AACR.,,,,2020-12-05 16:15:04+00:00,Blood Cancer Discovery,http://twitter.com/,0.0,,1.3352563836635996e+18,,0.0,0.0,,ICYMI: COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City‚Äî A Cohort Study‚Ä¶ https://t.co/n0FiDYic0l,en,0.0,1332.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/BCD_AACR/statuses/1335256383663599619,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,ICYMI: COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City‚Äî A Cohort Study‚Ä¶ https://t.co/n0FiDYic0l,true
majorajay,"Hematology/oncology fellow. #lymsm & #mmsm outcomes researcher. Physician-publisher & founder of https://t.co/dPfLt8QVMr, @inTrainingDoc & @inHouseMag.",,"Chicago, IL",,2020-12-05 00:59:02+00:00,"Ajay Major, MD, MBA",http://twitter.com/,0.0,,1.3350258551233536e+18,,0.0,0.0,,"Logged into the #ASH20 hemophilia A session tonight, with some exciting discussion about new therapies in the pipel‚Ä¶ https://t.co/W8Tr9Wy2o7",en,0.0,3518.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/majorajay/statuses/1335025855123353604,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"Logged into the #ASH20 hemophilia A session tonight, with some exciting discussion about new therapies in the pipel‚Ä¶ https://t.co/W8Tr9Wy2o7",true
2Scottish,Vascular cardiologist|Platelet biologist|PE. Information is my opinion based on an academic interest in cardiac/vascular care-not my employer.,,"Cleveland, OH",,2020-12-05 14:31:47+00:00,Scott Cameron üè¥Û†ÅßÛ†Å¢Û†Å≥Û†Å£Û†Å¥Û†Åøü©∫üìüüî¨üß´üß¨,http://twitter.com/,17.0,,1.3352303904040632e+18,,0.0,0.0,,RT @ProfMakris: Interesting question to Dr Dong Chen at #ASH20. What platelet conditions need electron microscopy for diagnosis? He feels i‚Ä¶,en,0.0,1047.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,11.0,6.0,https://twitter.com/2Scottish/statuses/1335230390404063240,0.0,0.0,,0.0,0.0,0.0,6.0,11.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @ProfMakris: Interesting question to Dr Dong Chen at #ASH20. What platelet conditions need electron microscopy for diagnosis? He feels i‚Ä¶,true
AndreaAnampaG,"Medstudent @UNMSM_ with OCD ‚Ä¢ @ASCO & @AMWAdoctors Social Media
@CPsolvers Team Member ‚Ä¢ #Globaloncology #WomenInMedicine #MedEd #SurvOnc üáµüá™ #IMG üåà she/ella",,"Lima, Peru",,2020-12-05 23:50:38+00:00,Andrea Anampa-Guzm√°n,http://twitter.com/,30.0,,1.3353710294143713e+18,,0.0,0.0,,RT @DrMiguelPerales: #ASH20 Frontline Sequential Immunochemotherapy Plus Lenalidomide for Mantle Cell Lymphoma Incorporating MRD Evaluation‚Ä¶,en,0.0,1908.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,24.0,6.0,https://twitter.com/AndreaAnampaG/statuses/1335371029414371334,0.0,0.0,,0.0,0.0,0.0,6.0,24.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @DrMiguelPerales: #ASH20 Frontline Sequential Immunochemotherapy Plus Lenalidomide for Mantle Cell Lymphoma Incorporating MRD Evaluation‚Ä¶,true
khouri_jack,Myeloma/BMT #hematologist #oncologist @ClevelandClinic Assistant Prof @CleClinicLCM @CWRUSOM | alum @TuftsMedSchool @Uni_Of_Balamand #mmsm #bmtsm,,"Cleveland, OH",,2020-12-05 23:29:05+00:00,"Jack Khouri, MD",http://twitter.com/,4.0,,1.3353656066784256e+18,,0.0,0.0,,"Intriguing data from the phase 2 BIRMA trial, combined BRAF/MEK inhibition: 80% response rates in RR #myeloma patie‚Ä¶ https://t.co/sTFnxur0Hv",en,0.0,443.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,4.0,https://twitter.com/khouri_jack/statuses/1335365606678425603,0.0,0.0,,0.0,0.0,0.0,4.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"Intriguing data from the phase 2 BIRMA trial, combined BRAF/MEK inhibition: 80% response rates in RR #myeloma patie‚Ä¶ https://t.co/sTFnxur0Hv",true
ovanoekelen,PhD student in Parekh lab @ Mount Sinai NYC studying myeloma immunology - Belgian MD - wannabe hem/onc - bioinformatics üáπüá©üá∫üá∏üá™üá∫üè≥Ô∏è‚Äçüåà,,"New York, USA",,2020-12-05 15:24:04+00:00,Oliver Van Oekelen,http://twitter.com/,2.0,,1.3352435487158518e+18,,0.0,0.0,,"""Let's not forget that we have CRUSHED multiple infectious disease outbreaks with vaccines. There is no reason why‚Ä¶ https://t.co/ovkpEsVVK4",en,0.0,352.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/ovanoekelen/statuses/1335243548715851783,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"""Let's not forget that we have CRUSHED multiple infectious disease outbreaks with vaccines. There is no reason why‚Ä¶ https://t.co/ovkpEsVVK4",false
Vchang_lab,"Pediatric oncologist focusing on blood stem cells, aging and cancer susceptibility @ucla. Views are my own. she/her/hers. Personal account @v_e_e_e_e",,,,2020-12-05 15:27:36+00:00,"Vivian Y Chang, MD, MS",http://twitter.com/,0.0,,1.335244438201766e+18,,0.0,0.0,,Fauci says we really need to start working on a universal #coronavirus vaccine. #ASH20,en,0.0,464.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/Vchang_lab/statuses/1335244438201765890,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Covid,0.0,0.0,1.0,Fauci says we really need to start working on a universal #coronavirus vaccine. #ASH20,true
szusmani,"Division Chief, Plasma Cell Disorders|Director, Clinical Research Hem Malignancies | Views are my own | RT not endorsement | Physician ‚â† Provider",,"Charlotte, NC",,2020-12-05 22:02:44+00:00,Saad Z. Usmani MD MBA FACP (he/his/him),http://twitter.com/,22.0,,1.335343877759361e+18,,0.0,0.0,,"RT @MM_Hub: Congress| #ASH20| @AlGarfall, @PennCancer, presented data on the phase I trial of teclistamab for R/R MM showing encouraging to‚Ä¶",en,0.0,5512.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,14.0,8.0,https://twitter.com/szusmani/statuses/1335343877759361025,0.0,0.0,,0.0,0.0,0.0,8.0,14.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @MM_Hub: Congress| #ASH20| @AlGarfall, @PennCancer, presented data on the phase I trial of teclistamab for R/R MM showing encouraging to‚Ä¶",true
majorajay,"Hematology/oncology fellow. #lymsm & #mmsm outcomes researcher. Physician-publisher & founder of https://t.co/dPfLt8QVMr, @inTrainingDoc & @inHouseMag.",,"Chicago, IL",,2020-12-05 17:18:25+00:00,"Ajay Major, MD, MBA",http://twitter.com/,1.0,,1.3352723247870198e+18,,0.0,0.0,,The YEARS algorithm leads to a large proportion of patients avoiding chest imaging to diagnose PE. LMWH is the best‚Ä¶ https://t.co/HmNIZsMTKS,en,0.0,3518.0,,,0.0,majorajay,1.335271132333822e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/majorajay/statuses/1335272324787019776,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,The YEARS algorithm leads to a large proportion of patients avoiding chest imaging to diagnose PE. LMWH is the best‚Ä¶ https://t.co/HmNIZsMTKS,true
dgermain21,MD-PhD. 2nd year Heme/Onc fellow focused on lymphoma and leukemia. Physician-scientist-in-training. Tweet/RT not medical advice or endorsement.,,"St. Louis, MO",,2020-12-05 03:30:52+00:00,David A. Russler-Germain,http://twitter.com/,30.0,,1.3350640679129784e+18,,0.0,0.0,,"RT @VPrasadMDMPH: Agree with Bernie #ASH20 
We analyzed the benefit of new leukemia drugs here:
https://t.co/shpfPoghcW https://t.co/FZL43h‚Ä¶",en,0.0,1612.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,22.0,8.0,https://twitter.com/dgermain21/statuses/1335064067912978439,0.0,0.0,,0.0,0.0,0.0,8.0,22.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @VPrasadMDMPH: Agree with Bernie #ASH20 
We analyzed the benefit of new leukemia drugs here:
https://t.co/shpfPoghcW https://t.co/FZL43h‚Ä¶",true
UrviShahMD,Oncologist and researcher on Myeloma service @sloan_kettering. Interested in nutrition for cancer and immune therapies. Views are my own,,"New York, NY",,2020-12-05 22:21:34+00:00,Urvi Shah,http://twitter.com/,10.0,,1.3353486179939738e+18,,0.0,0.0,,Another effective target for MM! First anti-GPRC5D Bispecific Ab (Talquetamab) Phase 1 presented by Dr. Ajai Chari.‚Ä¶ https://t.co/td1dSRZSmf,en,0.0,1227.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,10.0,https://twitter.com/UrviShahMD/statuses/1335348617993973761,0.0,0.0,,0.0,0.0,0.0,10.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,Another effective target for MM! First anti-GPRC5D Bispecific Ab (Talquetamab) Phase 1 presented by Dr. Ajai Chari.‚Ä¶ https://t.co/td1dSRZSmf,true
khouri_jack,Myeloma/BMT #hematologist #oncologist @ClevelandClinic Assistant Prof @CleClinicLCM @CWRUSOM | alum @TuftsMedSchool @Uni_Of_Balamand #mmsm #bmtsm,,"Cleveland, OH",,2020-12-05 02:25:10+00:00,"Jack Khouri, MD",http://twitter.com/,187.0,,1.3350475341133865e+18,,0.0,0.0,,"RT @VincentRK: One of the most common questions myeloma patients ask me is: Should I get a stem cell transplant, and if so when should I do‚Ä¶",en,0.0,443.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,136.0,51.0,https://twitter.com/khouri_jack/statuses/1335047534113386498,0.0,0.0,,0.0,0.0,0.0,51.0,136.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @VincentRK: One of the most common questions myeloma patients ask me is: Should I get a stem cell transplant, and if so when should I do‚Ä¶",false
UrviShahMD,Oncologist and researcher on Myeloma service @sloan_kettering. Interested in nutrition for cancer and immune therapies. Views are my own,,"New York, NY",,2020-12-05 20:26:43+00:00,Urvi Shah,http://twitter.com/,9.0,,1.335319713849729e+18,,0.0,0.0,,"RT @DrMiguelPerales: #ASH20 CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, #BCMA #CARTcells in R/R #myeloma @DMadduri #mmsm Im‚Ä¶",en,0.0,1227.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,3.0,https://twitter.com/UrviShahMD/statuses/1335319713849729026,0.0,0.0,,0.0,0.0,0.0,3.0,6.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @DrMiguelPerales: #ASH20 CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, #BCMA #CARTcells in R/R #myeloma @DMadduri #mmsm Im‚Ä¶",true
johnde1MYELOMA,"myeloma survivor üêú, gastroenterologist, bicyclist, animal lover",,"Santa Fe, NM",,2020-12-05 18:57:41+00:00,John DeFlice,http://twitter.com/,1.0,,1.3352973068752036e+18,,0.0,0.0,,"CAR P-BCMA-101 using piggyBac system with low toxicity and significant efficacy in phase 1/2 study, Costello, et al‚Ä¶ https://t.co/WhGdGSI6gc",en,0.0,218.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/johnde1MYELOMA/statuses/1335297306875203584,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"CAR P-BCMA-101 using piggyBac system with low toxicity and significant efficacy in phase 1/2 study, Costello, et al‚Ä¶ https://t.co/WhGdGSI6gc",true
johnde1MYELOMA,"myeloma survivor üêú, gastroenterologist, bicyclist, animal lover",,"Santa Fe, NM",,2020-12-05 22:15:32+00:00,John DeFlice,http://twitter.com/,0.0,,1.3353470989049733e+18,,0.0,0.0,,"BISPECIFIC Talquetamab GPRC50/CD3 ab with a manageable safety profile in phase 1 1st in human RRMM, Chari,et al‚Ä¶ https://t.co/65FgOiEqwy",ro,0.0,218.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/johnde1MYELOMA/statuses/1335347098904973312,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"BISPECIFIC Talquetamab GPRC50/CD3 ab with a manageable safety profile in phase 1 1st in human RRMM, Chari,et al‚Ä¶ https://t.co/65FgOiEqwy",true
UrviShahMD,Oncologist and researcher on Myeloma service @sloan_kettering. Interested in nutrition for cancer and immune therapies. Views are my own,,"New York, NY",,2020-12-05 23:31:55+00:00,Urvi Shah,http://twitter.com/,19.0,,1.335366321677144e+18,,0.0,0.0,,"RT @khouri_jack: Intriguing data from the phase 2 BIRMA trial, combined BRAF/MEK inhibition: 80% response rates in RR #myeloma patients wit‚Ä¶",en,0.0,1227.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,15.0,4.0,https://twitter.com/UrviShahMD/statuses/1335366321677144067,0.0,0.0,,0.0,0.0,0.0,4.0,15.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @khouri_jack: Intriguing data from the phase 2 BIRMA trial, combined BRAF/MEK inhibition: 80% response rates in RR #myeloma patients wit‚Ä¶",true
majorajay,"Hematology/oncology fellow. #lymsm & #mmsm outcomes researcher. Physician-publisher & founder of https://t.co/dPfLt8QVMr, @inTrainingDoc & @inHouseMag.",,"Chicago, IL",,2020-12-05 16:56:50+00:00,"Ajay Major, MD, MBA",http://twitter.com/,1.0,,1.335266895516332e+18,,0.0,0.0,,Dr. Pro @bpromd et al. presenting the Phase II PRIMO results for duvelisib in R/R PTCL. ORR at 75 mg bid dose was 5‚Ä¶ https://t.co/dmV0TbXGKB,en,0.0,3518.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/majorajay/statuses/1335266895516332032,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,Dr. Pro @bpromd et al. presenting the Phase II PRIMO results for duvelisib in R/R PTCL. ORR at 75 mg bid dose was 5‚Ä¶ https://t.co/dmV0TbXGKB,true
HKlepinMD,Geriatric oncologist,,,,2020-12-05 17:56:18+00:00,Heidi Klepin,http://twitter.com/,45.0,,1.3352818595976438e+18,,0.0,0.0,,"RT @BiostatGirl: Symptoms improve after Autologous Stem Cell Transplant in pts w/ Multiple Myeloma. High symptoms associated w/ male sex, h‚Ä¶",en,0.0,902.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,30.0,15.0,https://twitter.com/HKlepinMD/statuses/1335281859597643777,0.0,0.0,,0.0,0.0,0.0,15.0,30.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @BiostatGirl: Symptoms improve after Autologous Stem Cell Transplant in pts w/ Multiple Myeloma. High symptoms associated w/ male sex, h‚Ä¶",false
SKamath_MD,"GI #Oncologist @ClevelandClinic | @USNews contributor | @NorthwesternMed, @ColumbiaPS, @CWRU alum | Advocate for under-advocated #cancers | Tweets my own",,"Cleveland, OH",,2020-12-05 15:02:19+00:00,Suneel Kamath MD,http://twitter.com/,46.0,,1.3352380742012027e+18,,0.0,0.0,,RT @BldCancerDoc: #ASH20 @CleClinicMD #CleClinicCancer is hiring faculty for #Leukemia #MDS program - come work with ü§©üòé colleagues @Carrawa‚Ä¶,en,0.0,1406.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,39.0,7.0,https://twitter.com/SKamath_MD/statuses/1335238074201202690,0.0,0.0,,0.0,0.0,0.0,7.0,39.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,RT @BldCancerDoc: #ASH20 @CleClinicMD #CleClinicCancer is hiring faculty for #Leukemia #MDS program - come work with ü§©üòé colleagues @Carrawa‚Ä¶,true
AustralasianLy1,We are a community of researchers & doctors with a dedicated interest in Lymphoma.  Working to improve outcomes for Lymphoma patients.,,,,2020-12-04 00:54:03+00:00,Australasian Lymphoma Alliance,http://twitter.com/,0.0,,1.3346622144819528e+18,,0.0,0.0,,Congratulations to all the Australasian Lymphoma Alliance members presenting at #ASH2020 next week.  The time diffe‚Ä¶ https://t.co/frtivYTmRm,en,0.0,31.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/AustralasianLy1/statuses/1334662214481952772,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,Congratulations to all the Australasian Lymphoma Alliance members presenting at #ASH2020 next week.  The time diffe‚Ä¶ https://t.co/frtivYTmRm,true
tomleblancMD,"#Patientexperience & cancer outcomes researcher, #leukemia & #palliative care doc. Improving #QOL #decisionmaking #hapc in #hematology. Tweets mine ‚â† med advice",,"Durham, NC",,2020-12-04 19:20:09+00:00,"Thomas LeBlanc, MD, MA, MHS, FAAHPM",http://twitter.com/,7.0,,1.3349405724156314e+18,,0.0,0.0,,"Great discussion of cutting edge #AML treatment paradigms from a fantastic group of experts, including @DukeCancer‚Ä¶ https://t.co/EdgACrcVzr",en,0.0,4390.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,7.0,https://twitter.com/tomleblancMD/statuses/1334940572415631363,0.0,0.0,,0.0,0.0,0.0,7.0,0.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"Great discussion of cutting edge #AML treatment paradigms from a fantastic group of experts, including @DukeCancer‚Ä¶ https://t.co/EdgACrcVzr",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-04 19:26:43+00:00,Lisa Palacios,http://twitter.com/,18.0,,1.334942226485547e+18,,0.0,0.0,,"RT @tomleblancMD: Great discussion of cutting edge #AML treatment paradigms from a fantastic group of experts, including @DukeCancer leukem‚Ä¶",en,0.0,657.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,11.0,7.0,https://twitter.com/Lisa_Palacios/statuses/1334942226485547009,0.0,0.0,,0.0,0.0,0.0,7.0,11.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"RT @tomleblancMD: Great discussion of cutting edge #AML treatment paradigms from a fantastic group of experts, including @DukeCancer leukem‚Ä¶",true
DrVikasAsati,Dr Vikas Asati is medical oncologist at Indore MP India. He did MBBS and MD Medicine from MGM Medical College Indore & DM from kidwai cancer institute Bengaluru,,"Indore, India",,2020-12-04 06:22:06+00:00,"Dr Vikas Asati, Indore, Medical Oncologist",http://twitter.com/,187.0,,1.3347447705271992e+18,,0.0,0.0,,"RT @VincentRK: One of the most common questions myeloma patients ask me is: Should I get a stem cell transplant, and if so when should I do‚Ä¶",en,0.0,318.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,136.0,51.0,https://twitter.com/DrVikasAsati/statuses/1334744770527199237,0.0,0.0,,0.0,0.0,0.0,51.0,136.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @VincentRK: One of the most common questions myeloma patients ask me is: Should I get a stem cell transplant, and if so when should I do‚Ä¶",true
VincentRK,"Professor, Mayo Clinic; Editor, Blood Cancer Journal; Oncologist; Health Costs; COVID threads @SurvivedCOVID Opinions=personal views https://t.co/TMq9vc5hZk",,"Rochester, MN, USA",,2020-12-04 14:59:05+00:00,Vincent Rajkumar,http://twitter.com/,2.0,,1.3348748743687168e+18,,0.0,0.0,,10. ÔøºLummicar-2: A Phase 1b/2 BCMA CAR T trial results in Patients with Relapsed and/or Refractory Myeloma. #ASH20‚Ä¶ https://t.co/swKm8Vsn9K,en,0.0,33590.0,,,0.0,VincentRK,1.3348748725148262e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/VincentRK/statuses/1334874874368716801,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,10. ÔøºLummicar-2: A Phase 1b/2 BCMA CAR T trial results in Patients with Relapsed and/or Refractory Myeloma. #ASH20‚Ä¶ https://t.co/swKm8Vsn9K,false
VincentRK,"Professor, Mayo Clinic; Editor, Blood Cancer Journal; Oncologist; Health Costs; COVID threads @SurvivedCOVID Opinions=personal views https://t.co/TMq9vc5hZk",,"Rochester, MN, USA",,2020-12-04 15:02:33+00:00,Vincent Rajkumar,http://twitter.com/,6.0,,1.3348757469013647e+18,,0.0,0.0,,"11. Phase 1 results of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed/Refractory Myeloma. 61% response rat‚Ä¶ https://t.co/NDPVKo13sl",en,0.0,33590.0,,,0.0,VincentRK,1.3348748743687168e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,6.0,https://twitter.com/VincentRK/statuses/1334875746901364739,0.0,0.0,,0.0,0.0,0.0,6.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"11. Phase 1 results of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed/Refractory Myeloma. 61% response rat‚Ä¶ https://t.co/NDPVKo13sl",true
VincentRK,"Professor, Mayo Clinic; Editor, Blood Cancer Journal; Oncologist; Health Costs; COVID threads @SurvivedCOVID Opinions=personal views https://t.co/TMq9vc5hZk",,"Rochester, MN, USA",,2020-12-04 18:46:17+00:00,Vincent Rajkumar,http://twitter.com/,14.0,,1.3349320491997637e+18,,0.0,0.0,,RT @NorthTxMSG: This was Dr. @VincentRK 2019 #myaloma treatment algorithm. With the introduction of a couple new drugs to the approved list‚Ä¶,en,0.0,33590.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,11.0,3.0,https://twitter.com/VincentRK/statuses/1334932049199763459,0.0,0.0,,0.0,0.0,0.0,3.0,11.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @NorthTxMSG: This was Dr. @VincentRK 2019 #myaloma treatment algorithm. With the introduction of a couple new drugs to the approved list‚Ä¶,true
Dr_Curley,"üò∑ Medical Oncologist/Hematologist @ArizonaCCC 
opinions=my own",,"Scottsdale, AZ",,2020-12-04 22:12:03+00:00,"Brendan Curley DO, MPH",http://twitter.com/,4.0,,1.3349838326934036e+18,,0.0,0.0,,RT @MyelomaValarie: Proposed algorithm to determine treatment in #myeloma at diagnosis #ASH20 #mmsm #IMFASH20 https://t.co/ARV7bK06eQ,en,0.0,615.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,1.0,https://twitter.com/Dr_Curley/statuses/1334983832693403648,0.0,0.0,,0.0,0.0,0.0,1.0,3.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @MyelomaValarie: Proposed algorithm to determine treatment in #myeloma at diagnosis #ASH20 #mmsm #IMFASH20 https://t.co/ARV7bK06eQ,true
VincentRK,"Professor, Mayo Clinic; Editor, Blood Cancer Journal; Oncologist; Health Costs; COVID threads @SurvivedCOVID Opinions=personal views https://t.co/TMq9vc5hZk",,"Rochester, MN, USA",,2020-12-04 13:31:49+00:00,Vincent Rajkumar,http://twitter.com/,187.0,,1.3348529146329375e+18,,0.0,0.0,,"RT @VincentRK: One of the most common questions myeloma patients ask me is: Should I get a stem cell transplant, and if so when should I do‚Ä¶",en,0.0,33590.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,136.0,51.0,https://twitter.com/VincentRK/statuses/1334852914632937472,0.0,0.0,,0.0,0.0,0.0,51.0,136.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @VincentRK: One of the most common questions myeloma patients ask me is: Should I get a stem cell transplant, and if so when should I do‚Ä¶",true
CJWhelan18,Cardiologist and Proud Mum üíï,,"London, England",,2020-11-26 20:31:25+00:00,Carol Whelan,http://twitter.com/,1.0,,1.3320594043599217e+18,,0.0,0.0,,Great presentations from our Early Investigators this evening. #HFresearch #BSH2020VISION Who is the winner? It was‚Ä¶ https://t.co/adqyc962Ej,en,0.0,309.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/CJWhelan18/statuses/1332059404359921665,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Financial Performance,1.0,0.0,0.0,Great presentations from our Early Investigators this evening. #HFresearch #BSH2020VISION Who is the winner? It was‚Ä¶ https://t.co/adqyc962Ej,true
BotCardiology,"Created by Doctor @KrittanawongMD. A bot that collects Tweets about cardiology, medicine and new science",,Kepler-452b,,2020-12-04 00:43:50+00:00,Cardiology Bot,http://twitter.com/,17.0,,1.3346596442797097e+18,,0.0,0.0,,"RT @crfheart: Watch #TCTConnect on demand‚Äîany time, any place‚Äîthrough Oct. 18, 2021. 

Stream 110+ hours of educational programming at your‚Ä¶",en,0.0,328.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,11.0,6.0,https://twitter.com/BotCardiology/statuses/1334659644279709700,0.0,0.0,,0.0,0.0,0.0,6.0,11.0,False,False,False,False,True,Disease Advocacy,0.0,0.0,1.0,"RT @crfheart: Watch #TCTConnect on demand‚Äîany time, any place‚Äîthrough Oct. 18, 2021. 

Stream 110+ hours of educational programming at your‚Ä¶",false
ajaykirtane,"Practicing Cardiologist, Professor @ColumbiaMed
Researcher & advocate for thoughtful patient care; tweets‚â†endorsements nor med advice
https://t.co/YyilZMYayJ",,NewYork-Presbyterian & beyond,,2020-12-04 05:05:04+00:00,Ajay Kirtane MD SM,http://twitter.com/,17.0,,1.334725385767035e+18,,0.0,0.0,,"RT @crfheart: Watch #TCTConnect on demand‚Äîany time, any place‚Äîthrough Oct. 18, 2021. 

Stream 110+ hours of educational programming at your‚Ä¶",en,0.0,17044.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,11.0,6.0,https://twitter.com/ajaykirtane/statuses/1334725385767034880,0.0,0.0,,0.0,0.0,0.0,6.0,11.0,False,False,False,False,True,Disease Advocacy,0.0,0.0,1.0,"RT @crfheart: Watch #TCTConnect on demand‚Äîany time, any place‚Äîthrough Oct. 18, 2021. 

Stream 110+ hours of educational programming at your‚Ä¶",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-03 23:52:16+00:00,"Ritcha Saxena, MD",http://twitter.com/,7.0,,1.33464666596216e+18,,0.0,0.0,,RT @TheBethesdaLabs: Join #NHLBI‚Äôs Dr. Cynthia Dunbar‚Äôs live Q&amp;A and panel discussion: ‚ÄúCHIPing Away at the Hematopoietic Stem Cell Niche‚Äù‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,2.0,https://twitter.com/RitchaSaxena/statuses/1334646665962160130,0.0,0.0,,0.0,0.0,0.0,2.0,5.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @TheBethesdaLabs: Join #NHLBI‚Äôs Dr. Cynthia Dunbar‚Äôs live Q&amp;A and panel discussion: ‚ÄúCHIPing Away at the Hematopoietic Stem Cell Niche‚Äù‚Ä¶,true
gjmccaughan,"Haematologist interested in plasma cell disorders Zamasa Foundation Myeloma Fellow, Kinghorn Cancer Centre, St Vincent‚Äôs Hospital, Sydney",,,,2020-12-03 22:10:54+00:00,Georgia McCaughan,http://twitter.com/,187.0,,1.33462115651976e+18,,0.0,0.0,,"RT @VincentRK: One of the most common questions myeloma patients ask me is: Should I get a stem cell transplant, and if so when should I do‚Ä¶",en,0.0,528.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,136.0,51.0,https://twitter.com/gjmccaughan/statuses/1334621156519759872,0.0,0.0,,0.0,0.0,0.0,51.0,136.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @VincentRK: One of the most common questions myeloma patients ask me is: Should I get a stem cell transplant, and if so when should I do‚Ä¶",true
gjmccaughan,"Haematologist interested in plasma cell disorders Zamasa Foundation Myeloma Fellow, Kinghorn Cancer Centre, St Vincent‚Äôs Hospital, Sydney",,,,2020-12-03 03:38:04+00:00,Georgia McCaughan,http://twitter.com/,194.0,,1.3343411029297605e+18,,0.0,0.0,,RT @VincentRK: #ASH20 special: Active myeloma drugs with their mechanism of action in one slide. Unapproved investigational drugs in blue f‚Ä¶,en,0.0,528.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,147.0,47.0,https://twitter.com/gjmccaughan/statuses/1334341102929760257,0.0,0.0,,0.0,0.0,0.0,47.0,147.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,RT @VincentRK: #ASH20 special: Active myeloma drugs with their mechanism of action in one slide. Unapproved investigational drugs in blue f‚Ä¶,true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-03 21:15:00+00:00,Lisa Palacios,http://twitter.com/,1.0,,1.3346070881991885e+18,,0.0,0.0,,"12/4 3-6p PST #ASH20

Adopting New Approaches for Relapsed/Refractory Follicular #Lymphoma | Loretta J. Nastoupil,‚Ä¶ https://t.co/hGRxGkpdbY",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/Lisa_Palacios/statuses/1334607088199188480,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"12/4 3-6p PST #ASH20

Adopting New Approaches for Relapsed/Refractory Follicular #Lymphoma | Loretta J. Nastoupil,‚Ä¶ https://t.co/hGRxGkpdbY",true
DrCSWilliam,Family Medicine & Lifestyle Medicine Physician in #westpalmbeach Founder of @LaVieMDOfficial #CannabisMedicine Health & Wellness Advocate,,"Florida, USA",,2020-12-03 16:00:23+00:00,"Dr. Claudia William MD, MScHAL ü©∫üíä",http://twitter.com/,16.0,,1.3345279134635827e+18,,0.0,0.0,,"RT @acweyand: Anyone interested in hemostasis and thrombosis, check üëáüèΩout

Amazing opportunity to work with @nih_nhlbi funded, #HeForShe me‚Ä¶",en,0.0,7879.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,14.0,2.0,https://twitter.com/DrCSWilliam/statuses/1334527913463582720,0.0,0.0,,0.0,0.0,0.0,2.0,14.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,"RT @acweyand: Anyone interested in hemostasis and thrombosis, check üëáüèΩout

Amazing opportunity to work with @nih_nhlbi funded, #HeForShe me‚Ä¶",false
Jme_os,Research Lecturer Irish Centre for Vascular Biology | Royal College of Surgeons in Ireland | VWF Biology | Cancer-Coagulation crosstalk | COVID-coag |@RCSI_Irl,,"Dublin, Ireland",,2020-12-03 13:15:07+00:00,Jamie O' Sullivan,http://twitter.com/,2.0,,1.3344863208408474e+18,,0.0,0.0,,Join us for #ASH2020 workshop on the interplay between Coagulation &amp; Malignancy. Great lineup of speakers discussin‚Ä¶ https://t.co/yySt2WnqQz,en,0.0,673.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/Jme_os/statuses/1334486320840847363,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,Join us for #ASH2020 workshop on the interplay between Coagulation &amp; Malignancy. Great lineup of speakers discussin‚Ä¶ https://t.co/yySt2WnqQz,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-03 19:08:29+00:00,"Ritcha Saxena, MD",http://twitter.com/,6.0,,1.3345752490614497e+18,,0.0,0.0,,"RT @SLentzsch: #ASH20 Adaption of Next Generation Sequencing, Next Generation Flow Cytometry, and CyTOF: The big question ?Can we use MALDI‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,3.0,https://twitter.com/RitchaSaxena/statuses/1334575249061449729,0.0,0.0,,0.0,0.0,0.0,3.0,3.0,False,False,False,False,True,Long Term Benefits,0.0,0.0,1.0,"RT @SLentzsch: #ASH20 Adaption of Next Generation Sequencing, Next Generation Flow Cytometry, and CyTOF: The big question ?Can we use MALDI‚Ä¶",true
DrHelenOram,"Haematologist, Cyclist, Medical Educator, Assessment, üè¥Û†ÅßÛ†Å¢Û†Å≥Û†Å£Û†Å¥Û†Åø#paediatrichaematology #TYAhaem #transition #genomics #bioinformatics #MedEd",,"Scotland to London via NL&TX ",,2020-12-03 17:15:57+00:00,Helen Oram,http://twitter.com/,0.0,,1.334546929385091e+18,,0.0,0.0,,Such an interesting pipeline- screening for germline mutations leading to a predisposition to haematological malign‚Ä¶ https://t.co/YtevCQ8XfT,en,0.0,407.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/DrHelenOram/statuses/1334546929385091075,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,Such an interesting pipeline- screening for germline mutations leading to a predisposition to haematological malign‚Ä¶ https://t.co/YtevCQ8XfT,true
EileenMBoyle,"MD,PhD, post-doctoral fellow, Myeloma Research Program, @nyulangone, opinions are my own.",,"New York, USA",,2020-12-03 19:29:58+00:00,Eileen M. Boyle,http://twitter.com/,0.0,,1.3345806575242732e+18,,0.0,0.0,,"Exciting session, great topic, amaizing speakers. Aging workshop at #ASH2020 https://t.co/48Klz66qZ0",en,0.0,112.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/EileenMBoyle/statuses/1334580657524273159,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,"Exciting session, great topic, amaizing speakers. Aging workshop at #ASH2020 https://t.co/48Klz66qZ0",true
sujithonco,"Medical Oncologist( Thoracic, Neuro, Hemat, Musculoskeletal) l Apollo Proton Cancer Center l Global Oncology l Palliative Care l Grateful to All Lifeüôèüèº",,"Chennai, India",,2020-12-03 22:50:33+00:00,Sujith Mullapally,http://twitter.com/,194.0,,1.3346311333093868e+18,,0.0,0.0,,RT @VincentRK: #ASH20 special: Active myeloma drugs with their mechanism of action in one slide. Unapproved investigational drugs in blue f‚Ä¶,en,0.0,495.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,147.0,47.0,https://twitter.com/sujithonco/statuses/1334631133309386753,0.0,0.0,,0.0,0.0,0.0,47.0,147.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,RT @VincentRK: #ASH20 special: Active myeloma drugs with their mechanism of action in one slide. Unapproved investigational drugs in blue f‚Ä¶,true
VincentRK,"Professor, Mayo Clinic; Editor, Blood Cancer Journal; Oncologist; Health Costs; COVID threads @SurvivedCOVID Opinions=personal views https://t.co/TMq9vc5hZk",,"Rochester, MN, USA",,2020-12-03 15:32:53+00:00,Vincent Rajkumar,http://twitter.com/,51.0,,1.334520990898991e+18,,0.0,0.0,,"One of the most common questions myeloma patients ask me is: Should I get a stem cell transplant, and if so when sh‚Ä¶ https://t.co/s07zierZOL",en,0.0,33590.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,51.0,https://twitter.com/VincentRK/statuses/1334520990898991110,0.0,0.0,,0.0,0.0,0.0,51.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"One of the most common questions myeloma patients ask me is: Should I get a stem cell transplant, and if so when sh‚Ä¶ https://t.co/s07zierZOL",false
rajshekharucms,Hem/Onc Physician/Clinical Researcher @ColumbiaCancer #MultipleMyeloma & #Amyloidosis. Asst. Prof of Medicine @ColumbiaMed #ClinicalTrials and Outcomes Research,,"New York, NY",,2020-12-03 14:58:27+00:00,Raj Chakraborty,http://twitter.com/,194.0,,1.3345123283149414e+18,,0.0,0.0,,RT @VincentRK: #ASH20 special: Active myeloma drugs with their mechanism of action in one slide. Unapproved investigational drugs in blue f‚Ä¶,en,0.0,1148.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,147.0,47.0,https://twitter.com/rajshekharucms/statuses/1334512328314941444,0.0,0.0,,0.0,0.0,0.0,47.0,147.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,RT @VincentRK: #ASH20 special: Active myeloma drugs with their mechanism of action in one slide. Unapproved investigational drugs in blue f‚Ä¶,true
Jessica_Okosun,"CRUK-funded Clinician-Scientist at Barts Cancer Institute @QMBCI, Haematologist @BartsHospital. #Lymphoma, cancer #genomics, evolution, Big Data, technophile",,"London, England",,2020-12-05 21:29:34+00:00,Jessica Okosun,http://twitter.com/,0.0,,1.335335528632365e+18,,0.0,0.0,,Listening to a great session on Emerging Diagnostic Tools and Techniques #ASH20. From machine learning to report bl‚Ä¶ https://t.co/CHsw5ZPrBg,en,0.0,654.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/Jessica_Okosun/statuses/1335335528632365056,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnostic Tools,1.0,0.0,0.0,Listening to a great session on Emerging Diagnostic Tools and Techniques #ASH20. From machine learning to report bl‚Ä¶ https://t.co/CHsw5ZPrBg,true
Vchang_lab,"Pediatric oncologist focusing on blood stem cells, aging and cancer susceptibility @ucla. Views are my own. she/her/hers. Personal account @v_e_e_e_e",,,,2020-12-05 15:32:08+00:00,"Vivian Y Chang, MD, MS",http://twitter.com/,0.0,,1.3352455782261678e+18,,0.0,0.0,,No time to rest for the weary. Let‚Äôs all do our part to end this #pandemic so that Dr Fauci (and all of us!!!!) can‚Ä¶ https://t.co/2wd7yOiepd,en,0.0,464.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/Vchang_lab/statuses/1335245578226167809,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Covid,0.0,0.0,1.0,No time to rest for the weary. Let‚Äôs all do our part to end this #pandemic so that Dr Fauci (and all of us!!!!) can‚Ä¶ https://t.co/2wd7yOiepd,true
SandyWong02111,UCSF Hematologist and BMT physician,,"San Francisco, CA",,2020-12-07 21:58:05+00:00,Sandy Wong,http://twitter.com/,36.0,,1.3360674839255e+18,,0.0,0.0,,"RT @ninashah33: Cyber IBER! Iber with dara dex or
BTZ dex with 35-50% ORR. I think this data useful to show us how to combine this new drug‚Ä¶",en,0.0,759.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,28.0,8.0,https://twitter.com/SandyWong02111/statuses/1336067483925499904,0.0,0.0,,0.0,0.0,0.0,8.0,28.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @ninashah33: Cyber IBER! Iber with dara dex or
BTZ dex with 35-50% ORR. I think this data useful to show us how to combine this new drug‚Ä¶",true
majorajay,"Hematology/oncology fellow. #lymsm & #mmsm outcomes researcher. Physician-publisher & founder of https://t.co/dPfLt8QVMr, @inTrainingDoc & @inHouseMag.",,"Chicago, IL",,2020-12-05 15:28:54+00:00,"Ajay Major, MD, MBA",http://twitter.com/,8.0,,1.3352447675218698e+18,,0.0,0.0,,"RT @microbialkrysta: ""We've had 3 coronavirus pandemics - we need to be thinking about a universal coronavirus vaccine... and all the aspec‚Ä¶",en,0.0,3518.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,3.0,https://twitter.com/majorajay/statuses/1335244767521869824,0.0,0.0,,0.0,0.0,0.0,3.0,5.0,False,False,False,False,True,Covid,0.0,0.0,1.0,"RT @microbialkrysta: ""We've had 3 coronavirus pandemics - we need to be thinking about a universal coronavirus vaccine... and all the aspec‚Ä¶",true
nadahamad,"BMT, cellular therapies and clinical haematologist, clinical researcher, lymphoma doc, mother of 3, feminist and ANZTCT president. Opinions are my own.",,"Sydney, Australia",,2020-12-07 22:14:50+00:00,A/Prof Nada Hamad,http://twitter.com/,0.0,,1.3360716993940193e+18,,0.0,0.0,,#ASH20 #lymsm Our own rising star @prp_diciaccio presenting our amazing ALA international collaboration üá¶üá∫üá≥üáøüá¨üáßüá®üá¶ on‚Ä¶ https://t.co/3G2h1fXOAX,en,0.0,346.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/nadahamad/statuses/1336071699394019329,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,#ASH20 #lymsm Our own rising star @prp_diciaccio presenting our amazing ALA international collaboration üá¶üá∫üá≥üáøüá¨üáßüá®üá¶ on‚Ä¶ https://t.co/3G2h1fXOAX,false
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-05 18:20:44+00:00,"Ritcha Saxena, MD",http://twitter.com/,11.0,,1.3352880096930284e+18,,0.0,0.0,,"RT @amarkelkar: ""Anyone who doesn't think we need to be working on a universal coronavirus vaccine isn't paying attention"" - Dr. Anthony Fa‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,8.0,3.0,https://twitter.com/RitchaSaxena/statuses/1335288009693028352,0.0,0.0,,0.0,0.0,0.0,3.0,8.0,False,False,False,False,True,Covid,0.0,0.0,1.0,"RT @amarkelkar: ""Anyone who doesn't think we need to be working on a universal coronavirus vaccine isn't paying attention"" - Dr. Anthony Fa‚Ä¶",true
archibhat3,"MD, PDCC (Nephropath), Assistant Professor and Consultant Pathologist. Special interests - Renal and Pulmonary pathology.",,"Mangalore, India",,2020-12-07 16:12:31+00:00,Archana bhat,http://twitter.com/,13.0,,1.3359805172089078e+18,,0.0,0.0,,RT @AML_Hub: CONGRESS | #ASH20 | Nikhil Patkar @nvpatkar investigated ‚Äúhotspot‚Äù panel of 35 mutated genes in AML plus FLT3-ITD PCR based NG‚Ä¶,en,0.0,672.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,8.0,5.0,https://twitter.com/archibhat3/statuses/1335980517208907776,0.0,0.0,,0.0,0.0,0.0,5.0,8.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,RT @AML_Hub: CONGRESS | #ASH20 | Nikhil Patkar @nvpatkar investigated ‚Äúhotspot‚Äù panel of 35 mutated genes in AML plus FLT3-ITD PCR based NG‚Ä¶,true
nadahamad,"BMT, cellular therapies and clinical haematologist, clinical researcher, lymphoma doc, mother of 3, feminist and ANZTCT president. Opinions are my own.",,"Sydney, Australia",,2020-12-07 01:52:43+00:00,A/Prof Nada Hamad,http://twitter.com/,1.0,,1.3357641403971953e+18,,0.0,0.0,,#ASH20 We are getting better at cGVHD prevention but still need better treatments. REACH3 is a taste of the renaiss‚Ä¶ https://t.co/NvrX0QQa2g,en,0.0,346.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/nadahamad/statuses/1335764140397195264,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Diagnosis Progression,1.0,0.0,0.0,#ASH20 We are getting better at cGVHD prevention but still need better treatments. REACH3 is a taste of the renaiss‚Ä¶ https://t.co/NvrX0QQa2g,true
AzizNazhaMD,"Practice Manager at Amazon Web Services, Physician, #Programmer, #DataScientist, interested in the Digital Transformation of Healthcare",,Cleveland Clinic,,2020-12-07 16:19:43+00:00,Aziz Nazha,http://twitter.com/,3.0,,1.3359823306121585e+18,,0.0,0.0,,"Molecular landscape of Our #AI algorithm to predict MDS diagnosis from CBC and mutational data only, #ASH20,‚Ä¶ https://t.co/nLwyRrIZTB",en,0.0,2087.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/AzizNazhaMD/statuses/1335982330612158468,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"Molecular landscape of Our #AI algorithm to predict MDS diagnosis from CBC and mutational data only, #ASH20,‚Ä¶ https://t.co/nLwyRrIZTB",true
VincentRK,"Professor, Mayo Clinic; Editor, Blood Cancer Journal; Oncologist; Health Costs; COVID threads @SurvivedCOVID Opinions=personal views https://t.co/TMq9vc5hZk",,"Rochester, MN, USA",,2020-12-05 20:10:48+00:00,Vincent Rajkumar,http://twitter.com/,6.0,,1.3353157091744276e+18,,0.0,0.0,,Myeloma Future State: New drugs bring challenges and opportunities. We could very well have triple-class refractori‚Ä¶ https://t.co/utu8l2wEbg,en,0.0,33590.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,6.0,https://twitter.com/VincentRK/statuses/1335315709174427648,0.0,0.0,,0.0,0.0,0.0,6.0,0.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,Myeloma Future State: New drugs bring challenges and opportunities. We could very well have triple-class refractori‚Ä¶ https://t.co/utu8l2wEbg,true
humberto0927,"Blood cancer doctor/researcher, epidemiology MSc (c), focus on Multiple Myeloma and Hodgkin Lymphoma.",,Colombia,,2020-12-05 13:43:58+00:00,Humberto Martinez-Cordero,http://twitter.com/,0.0,,1.335218358460031e+18,,0.0,0.0,,There are three main types of blood cancer. Virtual #ASH20 attendees: Which type do you most commonly diagnose?,en,0.0,474.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/humberto0927/statuses/1335218358460030979,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,There are three main types of blood cancer. Virtual #ASH20 attendees: Which type do you most commonly diagnose?,false
fniainle,"Haematologist, passionate about VTE. Co-director @ConwaySphere; Director https://t.co/csdWq9XJ57; RT not endorsement, views my own",,"Dublin City, Ireland",,2020-12-07 20:10:12+00:00,Fionnuala N√≠ √Åinle,http://twitter.com/,2.0,,1.3360403311801836e+18,,0.0,0.0,,An outstanding multidisciplinary collaboration led by Dr @RosovskyRachel addressing a major clinical challenge in C‚Ä¶ https://t.co/iqFxK4gXaX,en,0.0,2069.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/fniainle/statuses/1336040331180183552,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,An outstanding multidisciplinary collaboration led by Dr @RosovskyRachel addressing a major clinical challenge in C‚Ä¶ https://t.co/iqFxK4gXaX,true
UjjaniC,CLL/Lymphoma oncologist at Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research Center/University of Washington,,"Seattle, WA",,2020-12-05 15:16:06+00:00,"Chaitra Ujjani, MD",http://twitter.com/,6.0,,1.3352415455076923e+18,,0.0,0.0,,#ASH president @StephanieLeeMD from @SeattleCCA @fredhutch leading an amazing chat on #COVID19 with Dr. Fauci.‚Ä¶ https://t.co/H9C8n9zCct,en,0.0,590.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,6.0,https://twitter.com/UjjaniC/statuses/1335241545507692545,0.0,0.0,,0.0,0.0,0.0,6.0,0.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,#ASH president @StephanieLeeMD from @SeattleCCA @fredhutch leading an amazing chat on #COVID19 with Dr. Fauci.‚Ä¶ https://t.co/H9C8n9zCct,true
majorajay,"Hematology/oncology fellow. #lymsm & #mmsm outcomes researcher. Physician-publisher & founder of https://t.co/dPfLt8QVMr, @inTrainingDoc & @inHouseMag.",,"Chicago, IL",,2020-12-05 18:03:52+00:00,"Ajay Major, MD, MBA",http://twitter.com/,7.0,,1.3352837639332209e+18,,0.0,0.0,,RT @EduardoFlavioO1: Ibrutinib+Ven in #CLL 1st line (Captivate) and RR setting (TAP Clarity) showing long term remissions and sustained res‚Ä¶,en,0.0,3518.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,3.0,https://twitter.com/majorajay/statuses/1335283763933220864,0.0,0.0,,0.0,0.0,0.0,3.0,4.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @EduardoFlavioO1: Ibrutinib+Ven in #CLL 1st line (Captivate) and RR setting (TAP Clarity) showing long term remissions and sustained res‚Ä¶,true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-07 21:44:39+00:00,Lisa Palacios,http://twitter.com/,1.0,,1.336064103350145e+18,,0.0,0.0,,"RT @hemedoc: #ASH20 #leusm Maiti (637): Non-randomized comparison of 10d Decitabine+Venetoclax vs intensive chemo (CLIA, CIA, or FIA); all‚Ä¶",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/Lisa_Palacios/statuses/1336064103350145026,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @hemedoc: #ASH20 #leusm Maiti (637): Non-randomized comparison of 10d Decitabine+Venetoclax vs intensive chemo (CLIA, CIA, or FIA); all‚Ä¶",true
fniainle,"Haematologist, passionate about VTE. Co-director @ConwaySphere; Director https://t.co/csdWq9XJ57; RT not endorsement, views my own",,"Dublin City, Ireland",,2020-12-06 17:59:37+00:00,Fionnuala N√≠ √Åinle,http://twitter.com/,29.0,,1.3356450849314693e+18,,0.0,0.0,,RT @AyeshaNZia: A call for collaboration from @MiddeldorpS #COVID19 Thrombosis AC trials #ASH20 https://t.co/RDTmrMp76D,en,0.0,2069.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,23.0,6.0,https://twitter.com/fniainle/statuses/1335645084931469316,0.0,0.0,,0.0,0.0,0.0,6.0,23.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,RT @AyeshaNZia: A call for collaboration from @MiddeldorpS #COVID19 Thrombosis AC trials #ASH20 https://t.co/RDTmrMp76D,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 21:16:32+00:00,"Ritcha Saxena, MD",http://twitter.com/,5.0,,1.3356946377098568e+18,,0.0,0.0,,"RT @MAWJNJ: Congratulations Dr Buske in presenting the updated data from the iNNOVATE study #ASH20. Thank you to Dr Treon, @thanosdimop and‚Ä¶",en,0.0,6875.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,1.0,https://twitter.com/RitchaSaxena/statuses/1335694637709856770,0.0,0.0,,0.0,0.0,0.0,1.0,4.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"RT @MAWJNJ: Congratulations Dr Buske in presenting the updated data from the iNNOVATE study #ASH20. Thank you to Dr Treon, @thanosdimop and‚Ä¶",false
rishi_puram,Physician Scientist | Hematology Oncology Fellow @DanaFarber @BroadInstitute | Internal Medicine @MGH ‚Äò18 | MD/PhD '16 @HarvardMed @mit_hst | Alum '08 @MIT,,"Boston, MA",,2020-12-06 00:20:17+00:00,Rishi Puram,http://twitter.com/,22.0,,1.335378493794816e+18,,0.0,0.0,,RT @DanaFarberNews: #ASH20 News: Study reveals surprising benefit of DNMT3A clonal hematopoiesis in allogeneic stem cell or bone marrow tra‚Ä¶,en,0.0,193.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,18.0,4.0,https://twitter.com/rishi_puram/statuses/1335378493794816005,0.0,0.0,,0.0,0.0,0.0,4.0,18.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @DanaFarberNews: #ASH20 News: Study reveals surprising benefit of DNMT3A clonal hematopoiesis in allogeneic stem cell or bone marrow tra‚Ä¶,true
nadahamad,"BMT, cellular therapies and clinical haematologist, clinical researcher, lymphoma doc, mother of 3, feminist and ANZTCT president. Opinions are my own.",,"Sydney, Australia",,2020-12-07 01:56:32+00:00,A/Prof Nada Hamad,http://twitter.com/,0.0,,1.3357651014926172e+18,,0.0,0.0,,"#ASH20 is killing it with the female representation amongst moderators this year! #genderequityinmedicne 
Thank you‚Ä¶ https://t.co/XGvA3R7cgv",en,0.0,346.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/nadahamad/statuses/1335765101492617216,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Financial Performance,1.0,0.0,0.0,"#ASH20 is killing it with the female representation amongst moderators this year! #genderequityinmedicne 
Thank you‚Ä¶ https://t.co/XGvA3R7cgv",true
youssefsorour,Consultant Haematologist - @barnshospital and @sheffieldhosp. Y&H RTC Chair @yhrtc . #transfusion #lymphoma #CLL #myeloma. Views are my own. Retweet = look.,,"Sheffield, Uk",,2020-12-07 20:16:21+00:00,Youssef Sorour,http://twitter.com/,187.0,,1.3360418817095311e+18,,0.0,0.0,,"RT @VincentRK: One of the most common questions myeloma patients ask me is: Should I get a stem cell transplant, and if so when should I do‚Ä¶",en,0.0,350.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,136.0,51.0,https://twitter.com/youssefsorour/statuses/1336041881709531139,0.0,0.0,,0.0,0.0,0.0,51.0,136.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @VincentRK: One of the most common questions myeloma patients ask me is: Should I get a stem cell transplant, and if so when should I do‚Ä¶",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-07 02:39:46+00:00,"Ritcha Saxena, MD",http://twitter.com/,68.0,,1.3357759819954954e+18,,0.0,0.0,,RT @JohnPLeonardMD: So the CAR-T debate of which works better/is less toxic is now going to be rivaled by the bispecific antibody debate of‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,66.0,2.0,https://twitter.com/RitchaSaxena/statuses/1335775981995495425,0.0,0.0,,0.0,0.0,0.0,2.0,66.0,False,False,False,False,True,Drug Comparisons,0.0,0.0,1.0,RT @JohnPLeonardMD: So the CAR-T debate of which works better/is less toxic is now going to be rivaled by the bispecific antibody debate of‚Ä¶,true
majorajay,"Hematology/oncology fellow. #lymsm & #mmsm outcomes researcher. Physician-publisher & founder of https://t.co/dPfLt8QVMr, @inTrainingDoc & @inHouseMag.",,"Chicago, IL",,2020-12-07 04:33:05+00:00,"Ajay Major, MD, MBA",http://twitter.com/,0.0,,1.3358045015724155e+18,,0.0,0.0,,"I'm presenting an upcoming case of mistaken diagnosis at an upcoming lymphoma rounds, and I need a good title idea.‚Ä¶ https://t.co/mzKwCVjwYP",en,0.0,3518.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/majorajay/statuses/1335804501572415489,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"I'm presenting an upcoming case of mistaken diagnosis at an upcoming lymphoma rounds, and I need a good title idea.‚Ä¶ https://t.co/mzKwCVjwYP",true
roverome,Hematologist Oncologist,,"Barrington, IL",,2020-12-07 01:07:13+00:00,Roberto C.  Montoya,http://twitter.com/,43.0,,1.3357526927072338e+18,,0.0,0.0,,RT @MediHumdani: Pembro GVD: Outstanding data. Nearly 100% CR rates in relapsed classical HL @CMoskowitzMD #lymsm #ASH20,en,0.0,291.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,32.0,11.0,https://twitter.com/roverome/statuses/1335752692707233793,0.0,0.0,,0.0,0.0,0.0,11.0,32.0,False,False,False,False,True,Diagnosis Progression,1.0,0.0,0.0,RT @MediHumdani: Pembro GVD: Outstanding data. Nearly 100% CR rates in relapsed classical HL @CMoskowitzMD #lymsm #ASH20,false
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-07 21:44:28+00:00,Lisa Palacios,http://twitter.com/,8.0,,1.336064057531642e+18,,0.0,0.0,,RT @hemedoc: #ASH20 #leusm Maiti (637): ORR 59% DAC/Ven vs 31% IC. MRD neg CR 54 vs 69% (NS). Relapse similar 41-44%. EFS 5.7 vs 1.7mo favo‚Ä¶,en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,3.0,https://twitter.com/Lisa_Palacios/statuses/1336064057531641858,0.0,0.0,,0.0,0.0,0.0,3.0,5.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @hemedoc: #ASH20 #leusm Maiti (637): ORR 59% DAC/Ven vs 31% IC. MRD neg CR 54 vs 69% (NS). Relapse similar 41-44%. EFS 5.7 vs 1.7mo favo‚Ä¶,true
DrGavinL,"Londoner (city boy at heart) - specialist physician in haemostasis (@gsttnhs), PhD in gene therapy (UCL), plays piano. Fair weather runner. Views my own.",,"London, England",,2020-12-07 11:44:54+00:00,Gavin Ling,http://twitter.com/,0.0,,1.3359131704987116e+18,,0.0,0.0,,"Presentation by @KathleenFreson: great to see the power of genomics and how through collaboration, new pathological‚Ä¶ https://t.co/ycN8jbuPFp",en,0.0,101.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/DrGavinL/statuses/1335913170498711552,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,"Presentation by @KathleenFreson: great to see the power of genomics and how through collaboration, new pathological‚Ä¶ https://t.co/ycN8jbuPFp",true
genperisi,"Genetics & Applied Genomicsüî¨
Molecular OncologistüîéItaliana/Turca
Tweets are not medical advice. Views mine. Ispra - Istanbulüö©
METU/ GBF / UCLA / UMIST",,Italia,,2020-12-07 12:10:34+00:00,Dr. Birep Ayg√ºn,http://twitter.com/,17.0,,1.335919630720897e+18,,0.0,0.0,,RT @MDAndersonNews: A chemotherapy and monoclonal antibody combination offers new option for a high-risk form of ALL known as Philadelphia‚Ä¶,en,0.0,10241.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,12.0,5.0,https://twitter.com/genperisi/statuses/1335919630720897025,0.0,0.0,,0.0,0.0,0.0,5.0,12.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @MDAndersonNews: A chemotherapy and monoclonal antibody combination offers new option for a high-risk form of ALL known as Philadelphia‚Ä¶,true
rajshekharucms,Hem/Onc Physician/Clinical Researcher @ColumbiaCancer #MultipleMyeloma & #Amyloidosis. Asst. Prof of Medicine @ColumbiaMed #ClinicalTrials and Outcomes Research,,"New York, NY",,2020-12-07 21:49:24+00:00,Raj Chakraborty,http://twitter.com/,2.0,,1.336065299154489e+18,,0.0,0.0,,Great summary of efficacy for key regimens at 1st relapse in #MultipleMyeloma #mmsm #ASH20 https://t.co/EWaeSgmViO,en,0.0,1148.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/rajshekharucms/statuses/1336065299154489345,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Diagnosis Progression,1.0,0.0,0.0,Great summary of efficacy for key regimens at 1st relapse in #MultipleMyeloma #mmsm #ASH20 https://t.co/EWaeSgmViO,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-07 02:38:58+00:00,"Ritcha Saxena, MD",http://twitter.com/,8.0,,1.3357757800649482e+18,,0.0,0.0,,"RT @CwynKate: Prognosis/Outcomes in #HIV-#Burkitt #lymphoma:US and UK Collaborative Analysis n=249
Med CD4 217
CODOX-M 60%/DA-EPOCH 25% (+R‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,2.0,https://twitter.com/RitchaSaxena/statuses/1335775780064948225,0.0,0.0,,0.0,0.0,0.0,2.0,6.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,"RT @CwynKate: Prognosis/Outcomes in #HIV-#Burkitt #lymphoma:US and UK Collaborative Analysis n=249
Med CD4 217
CODOX-M 60%/DA-EPOCH 25% (+R‚Ä¶",true
Anil_Prasad1234,"M.B.B.S, DA, (DNB), Intensivist and Anaesthesiologist..",,"Chennai, India",,2020-12-07 02:12:11+00:00,Anil Prasad,http://twitter.com/,51.0,,1.3357690396295332e+18,,0.0,0.0,,RT @ProfMakris: Tranexamic acid did not reduce bleeding but increased central line occlusions in thrombocytopenic patients post-chemo. The‚Ä¶,en,0.0,269.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,40.0,11.0,https://twitter.com/Anil_Prasad1234/statuses/1335769039629533184,0.0,0.0,,0.0,0.0,0.0,11.0,40.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @ProfMakris: Tranexamic acid did not reduce bleeding but increased central line occlusions in thrombocytopenic patients post-chemo. The‚Ä¶,false
graham74GC,Lymphoma specialist at Oxford Cancer and Haematology centre. Haematologist and clinical trialist. Chair of UK Hodgkin and T-cell study groups.,,Opinions are mine,,2020-12-07 10:58:45+00:00,Graham Collins,http://twitter.com/,3.0,,1.3359015551119606e+18,,0.0,0.0,,"Herrera et al - BV+Nivo consol high risk ASCT #Hodgkin
- Aethera risk + BSx at relapse, &gt;1 line salvage prior ASCT‚Ä¶ https://t.co/yQJLVTXVuy",en,0.0,6091.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/graham74GC/statuses/1335901555111960579,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"Herrera et al - BV+Nivo consol high risk ASCT #Hodgkin
- Aethera risk + BSx at relapse, &gt;1 line salvage prior ASCT‚Ä¶ https://t.co/yQJLVTXVuy",true
DrWuRadOnc,"Physician Scientist, MD/PhD, Radiation Oncologist #RadOnc, Making a fuss about FUS #TheFussAboutFUS, Keeping Up With Columbia RadOnc #KUWCRO [tweets=mine]",,"New York, NY",,2020-12-07 12:29:23+00:00,Cheng-Chia Wu,http://twitter.com/,7.0,,1.3359243642025042e+18,,0.0,0.0,,RT @JustinekahnMD: Addressing the survival gap in #AYA #hodgkinlymphoma through development of collaborative clinical trials @COGorg @SWOG‚Ä¶,en,0.0,298.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,2.0,https://twitter.com/DrWuRadOnc/statuses/1335924364202504194,0.0,0.0,,0.0,0.0,0.0,2.0,5.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,RT @JustinekahnMD: Addressing the survival gap in #AYA #hodgkinlymphoma through development of collaborative clinical trials @COGorg @SWOG‚Ä¶,true
gmcrotty,Blood doctor (consultant haematologist). https://t.co/eod4cQFZ7Z Past President of IHCA. Personal views. Retweets are not endorsements. #QI,,"Tullamore, Co Offaly",,2020-12-07 00:10:35+00:00,Gerard Crotty #CareCantWait,http://twitter.com/,51.0,,1.3357384376605204e+18,,0.0,0.0,,RT @ProfMakris: Tranexamic acid did not reduce bleeding but increased central line occlusions in thrombocytopenic patients post-chemo. The‚Ä¶,en,0.0,27278.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,40.0,11.0,https://twitter.com/gmcrotty/statuses/1335738437660520456,0.0,0.0,,0.0,0.0,0.0,11.0,40.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @ProfMakris: Tranexamic acid did not reduce bleeding but increased central line occlusions in thrombocytopenic patients post-chemo. The‚Ä¶,true
miljko,Hematologist/oncologist. Views are my own. #RWRI 14 attendee. @ Hemato-onkolog. MFUB 2002-2008. üéô https://t.co/xzLsKCsirz üñã https://t.co/NBAgn0OFhh * https://t.co/xD3CELCeVW,,DC,,2020-12-07 13:39:39+00:00,Milo≈° Miljkoviƒá,http://twitter.com/,2.0,,1.3359420471114506e+18,,0.0,0.0,,"#ASH20 Abstract 598: Phase 1b/2 study of ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) in R‚Ä¶ https://t.co/mzklza7Cbu",en,0.0,2422.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/miljko/statuses/1335942047111450628,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"#ASH20 Abstract 598: Phase 1b/2 study of ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) in R‚Ä¶ https://t.co/mzklza7Cbu",true
MediHumdani,"Director, BMT & Cellular Therapy Program @Froedtert & @MedicalCollege | Lymphoma | Clinical Trials | @CIBMTR | @BMTCTN | Personal views | Physician ‚â† Provider",,"Milwaukee, WI",,2020-12-07 17:53:16+00:00,Mehdi Hamadani,http://twitter.com/,4.0,,1.3360058733243963e+18,,0.0,0.0,,Dr. Jasmin Zain presenting Phase I Study of Yttrium-90 Labeled ANTI-CD25 (aTac) Monoclonal Antibody PLUS BEAM for A‚Ä¶ https://t.co/47yhYoLfPg,en,0.0,4590.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,4.0,https://twitter.com/MediHumdani/statuses/1336005873324396546,0.0,0.0,,0.0,0.0,0.0,4.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,Dr. Jasmin Zain presenting Phase I Study of Yttrium-90 Labeled ANTI-CD25 (aTac) Monoclonal Antibody PLUS BEAM for A‚Ä¶ https://t.co/47yhYoLfPg,true
TaylorJ_MD,"Assistant Professor, UM Sylvester Comprehensive Cancer Center. Physician scientist studying the role of nuclear export and splicing in hematologic cancers.",,"Miami, FL",,2020-12-07 16:17:53+00:00,Taylor Lab UM,http://twitter.com/,1.0,,1.3359818674561024e+18,,0.0,0.0,,Nice work Anthony and all! Important work for our patients with #CLL #leusm #ASH20 @sloan_kettering @SylvesterCancer https://t.co/9OCThjRAEZ,en,0.0,1781.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/TaylorJ_MD/statuses/1335981867456102402,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,Nice work Anthony and all! Important work for our patients with #CLL #leusm #ASH20 @sloan_kettering @SylvesterCancer https://t.co/9OCThjRAEZ,false
miljko,Hematologist/oncologist. Views are my own. #RWRI 14 attendee. @ Hemato-onkolog. MFUB 2002-2008. üéô https://t.co/xzLsKCsirz üñã https://t.co/NBAgn0OFhh * https://t.co/xD3CELCeVW,,DC,,2020-12-07 17:33:13+00:00,Milo≈° Miljkoviƒá,http://twitter.com/,2.0,,1.3360008266875576e+18,,0.0,0.0,,"ViPOR phase 1b/2 response data on all patients (aggressive + indolent BCL) from @MelanicjMD, @RoschewskiMD and othe‚Ä¶ https://t.co/6pkG84EaNd",en,0.0,2422.0,,,0.0,miljko,1.3359420471114506e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/miljko/statuses/1336000826687557634,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"ViPOR phase 1b/2 response data on all patients (aggressive + indolent BCL) from @MelanicjMD, @RoschewskiMD and othe‚Ä¶ https://t.co/6pkG84EaNd",true
VincentRK,"Professor, Mayo Clinic; Editor, Blood Cancer Journal; Oncologist; Health Costs; COVID threads @SurvivedCOVID Opinions=personal views https://t.co/TMq9vc5hZk",,"Rochester, MN, USA",,2020-12-07 15:07:24+00:00,Vincent Rajkumar,http://twitter.com/,5.0,,1.3359641329951662e+18,,0.0,0.0,,"#ASH20 Here are some superstars from @MayoClinic @MayoCancerCare posting cutting edge information

Myeloma‚Ä¶ https://t.co/8VUXDj3BWP",en,0.0,33590.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,5.0,https://twitter.com/VincentRK/statuses/1335964132995166210,0.0,0.0,,0.0,0.0,0.0,5.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"#ASH20 Here are some superstars from @MayoClinic @MayoCancerCare posting cutting edge information

Myeloma‚Ä¶ https://t.co/8VUXDj3BWP",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-07 17:57:20+00:00,Lisa Palacios,http://twitter.com/,7.0,,1.3360068970198671e+18,,0.0,0.0,,"RT @VJHemOnc: @VJHemOnc had a great chat w/ @Daver_Leukemia @LeukemiaMDA around the Phase Ib trial of #Magrolimab +azacitidine in  #AML

Ca‚Ä¶",en,0.0,657.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,2.0,https://twitter.com/Lisa_Palacios/statuses/1336006897019867139,0.0,0.0,,0.0,0.0,0.0,2.0,5.0,False,False,False,False,True,FDA Approval,1.0,0.0,0.0,"RT @VJHemOnc: @VJHemOnc had a great chat w/ @Daver_Leukemia @LeukemiaMDA around the Phase Ib trial of #Magrolimab +azacitidine in  #AML

Ca‚Ä¶",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-07 00:52:06+00:00,"Ritcha Saxena, MD",http://twitter.com/,10.0,,1.3357488896983122e+18,,0.0,0.0,,"RT @Fer_martinmoro: üî¨ Strategies for aggressive T-Cell lymphomas:
- Challenging diagnosis for pathologists and clinicians
- Initial treatme‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,7.0,3.0,https://twitter.com/RitchaSaxena/statuses/1335748889698312195,0.0,0.0,,0.0,0.0,0.0,3.0,7.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"RT @Fer_martinmoro: üî¨ Strategies for aggressive T-Cell lymphomas:
- Challenging diagnosis for pathologists and clinicians
- Initial treatme‚Ä¶",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-07 15:20:52+00:00,Lisa Palacios,http://twitter.com/,0.0,,1.33596751806276e+18,,0.0,0.0,,"Tune in now:
William Wierda, MD, PhD, @wwierda, ""Transcend #CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (li‚Ä¶ https://t.co/rM9Wr8o893",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/Lisa_Palacios/statuses/1335967518062759938,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"Tune in now:
William Wierda, MD, PhD, @wwierda, ""Transcend #CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (li‚Ä¶ https://t.co/rM9Wr8o893",true
AzizNazhaMD,"Practice Manager at Amazon Web Services, Physician, #Programmer, #DataScientist, interested in the Digital Transformation of Healthcare",,Cleveland Clinic,,2020-12-07 16:18:51+00:00,Aziz Nazha,http://twitter.com/,1.0,,1.3359821106293023e+18,,0.0,0.0,,"The clinical characteristics of our #AI algorithm to predict MDS diagnosis, #ASH20, #ASH2020, #ML,‚Ä¶ https://t.co/owIqfpEDzT",en,0.0,2087.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/AzizNazhaMD/statuses/1335982110629302278,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"The clinical characteristics of our #AI algorithm to predict MDS diagnosis, #ASH20, #ASH2020, #ML,‚Ä¶ https://t.co/owIqfpEDzT",false
SarahCannonDocs,Fighting Cancer Together. Find out the latest news directly from Sarah Cannon physicians.,,"Nashville, TN",,2020-12-07 23:03:58+00:00,Sarah Cannon Docs,http://twitter.com/,0.0,,1.3360840642778276e+18,,0.0,0.0,,"Although #ASH20 is coming to a close, our cutting-edge research is happening all year long. Learn more about the Sa‚Ä¶ https://t.co/Z777reTL9u",en,0.0,2504.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/SarahCannonDocs/statuses/1336084064277827585,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"Although #ASH20 is coming to a close, our cutting-edge research is happening all year long. Learn more about the Sa‚Ä¶ https://t.co/Z777reTL9u",true
DrTonyLetai,"Physician-scientist @DanaFarber. Professor of Medicine @harvardmed. President, Society for Functional Precision Medicine. You probably should be BH3 profiling.",,"Boston, MA",,2020-12-07 22:14:12+00:00,Anthony Letai MD PhD,http://twitter.com/,12.0,,1.3360715375484723e+18,,0.0,0.0,,RT @DanaFarberNews: New research presented at #ASH20 finds #CARTcell therapy has meaningfully impacted patients with advanced indolent non-‚Ä¶,en,0.0,1809.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,8.0,4.0,https://twitter.com/DrTonyLetai/statuses/1336071537548472321,0.0,0.0,,0.0,0.0,0.0,4.0,8.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @DanaFarberNews: New research presented at #ASH20 finds #CARTcell therapy has meaningfully impacted patients with advanced indolent non-‚Ä¶,true
MDAndersonNews,"The official account of MD Anderson Cancer Center, a leader in cancer care, cancer research and the fight to #EndCancer. Appointments available: 1-877-632-6789.",,"Houston, TX",,2020-12-07 11:59:01+00:00,MD Anderson Cancer Center,http://twitter.com/,5.0,,1.33591672322091e+18,,0.0,0.0,,A chemotherapy and monoclonal antibody combination offers new option for a high-risk form of ALL known as Philadelp‚Ä¶ https://t.co/BCx0g5xMJi,en,0.0,114120.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,5.0,https://twitter.com/MDAndersonNews/statuses/1335916723220910083,0.0,0.0,,0.0,0.0,0.0,5.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,A chemotherapy and monoclonal antibody combination offers new option for a high-risk form of ALL known as Philadelp‚Ä¶ https://t.co/BCx0g5xMJi,true
rajshekharucms,Hem/Onc Physician/Clinical Researcher @ColumbiaCancer #MultipleMyeloma & #Amyloidosis. Asst. Prof of Medicine @ColumbiaMed #ClinicalTrials and Outcomes Research,,"New York, NY",,2020-12-07 23:51:46+00:00,Raj Chakraborty,http://twitter.com/,1.0,,1.336096092031742e+18,,0.0,0.0,,Hard to not use quadruplets in newly diagnosed #MultipleMyeloma any more #mmsm #ASH20 https://t.co/D2bAkuGhRx,en,0.0,1148.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/rajshekharucms/statuses/1336096092031741953,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,Hard to not use quadruplets in newly diagnosed #MultipleMyeloma any more #mmsm #ASH20 https://t.co/D2bAkuGhRx,true
Rfonsi1,"Interim Executive Director, Mayo Clinic Cancer Center. Myeloma doctor. Visiting Healthcare Fellow @GoldwaterInst. Tweets-own/RT not an endorsement",,,,2020-12-07 17:21:09+00:00,Rafael Fonseca MD,http://twitter.com/,20.0,,1.335997792116863e+18,,0.0,0.0,,"RT @VincentRK: #ASH20 Here are some superstars from @MayoClinic @MayoCancerCare posting cutting edge information

Myeloma 
@Rfonsi1 
@myelo‚Ä¶",en,0.0,8301.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,15.0,5.0,https://twitter.com/Rfonsi1/statuses/1335997792116862976,0.0,0.0,,0.0,0.0,0.0,5.0,15.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @VincentRK: #ASH20 Here are some superstars from @MayoClinic @MayoCancerCare posting cutting edge information

Myeloma 
@Rfonsi1 
@myelo‚Ä¶",true
TaylorJ_MD,"Assistant Professor, UM Sylvester Comprehensive Cancer Center. Physician scientist studying the role of nuclear export and splicing in hematologic cancers.",,"Miami, FL",,2020-12-07 17:24:05+00:00,Taylor Lab UM,http://twitter.com/,0.0,,1.3359985294461665e+18,,0.0,0.0,,"Finally, combo is being moved forward to Phase 1 study in R/R #CLL and Richter's transformation. Hopefully open ear‚Ä¶ https://t.co/ESgMYHkq8Y",en,0.0,1781.0,,,0.0,TaylorJ_MD,1.335998523892908e+18,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/TaylorJ_MD/statuses/1335998529446166528,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,1.0,0.0,0.0,"Finally, combo is being moved forward to Phase 1 study in R/R #CLL and Richter's transformation. Hopefully open ear‚Ä¶ https://t.co/ESgMYHkq8Y",false
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-12-07 17:38:37+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,1.0,,1.3360021878229115e+18,,0.0,0.0,,"#ASH20 #leusm Short (583): Overall CIR 8% if NGS MRD neg, 27% if only neg by MFC. No relapses in mini-hCVD cohort.‚Ä¶ https://t.co/tGgG67GMc1",en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/hemedoc/statuses/1336002187822911488,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"#ASH20 #leusm Short (583): Overall CIR 8% if NGS MRD neg, 27% if only neg by MFC. No relapses in mini-hCVD cohort.‚Ä¶ https://t.co/tGgG67GMc1",true
AndreaAnampaG,"Medstudent @UNMSM_ with OCD ‚Ä¢ @ASCO & @AMWAdoctors Social Media
@CPsolvers Team Member ‚Ä¢ #Globaloncology #WomenInMedicine #MedEd #SurvOnc üáµüá™ #IMG üåà she/ella",,"Lima, Peru",,2020-12-07 01:43:05+00:00,Andrea Anampa-Guzm√°n,http://twitter.com/,0.0,,1.3357617181197066e+18,,0.0,0.0,,@AnaVManana @XimeJordan @MazieTsangMD They keep on getting better and better #ASH20,en,0.0,1908.0,,,0.0,AnaVManana,1.335761417123758e+18,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/AndreaAnampaG/statuses/1335761718119706624,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnosis Progression,1.0,0.0,0.0,@AnaVManana @XimeJordan @MazieTsangMD They keep on getting better and better #ASH20,true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-07 13:53:29+00:00,Lisa Palacios,http://twitter.com/,17.0,,1.3359455276246098e+18,,0.0,0.0,,RT @MDAndersonNews: A chemotherapy and monoclonal antibody combination offers new option for a high-risk form of ALL known as Philadelphia‚Ä¶,en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,12.0,5.0,https://twitter.com/Lisa_Palacios/statuses/1335945527624609792,0.0,0.0,,0.0,0.0,0.0,5.0,12.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @MDAndersonNews: A chemotherapy and monoclonal antibody combination offers new option for a high-risk form of ALL known as Philadelphia‚Ä¶,true
MDMagazine,Clinical News for Connected Physicians. Everything you need to enhance your clinical approach to improving patient care.,,United States,,2020-12-07 16:40:00+00:00,HCPLive,http://twitter.com/,0.0,,1.335987433406681e+18,,0.0,0.0,,From #ASH2020: Empiric use of antiplatelets or anticoagulants at #COVID19 diagnosis is not conducive to improved pa‚Ä¶ https://t.co/x4YG13GvfW,en,0.0,7073.0,,,0.0,,,Negative,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/MDMagazine/statuses/1335987433406681108,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,1.0,0.0,From #ASH2020: Empiric use of antiplatelets or anticoagulants at #COVID19 diagnosis is not conducive to improved pa‚Ä¶ https://t.co/x4YG13GvfW,true
pb10_bmt,"MD, DM, Assistant Professor,
Clinical Hematology-Oncology, and Stem Cell Transplantation at DMC Ludhiana, Punjab.  Lifelong student!!",,"Punjab, India",,2020-12-03 16:45:00+00:00,Suvir Singh,http://twitter.com/,187.0,,1.3345391425421558e+18,,0.0,0.0,,"RT @VincentRK: One of the most common questions myeloma patients ask me is: Should I get a stem cell transplant, and if so when should I do‚Ä¶",en,0.0,919.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,136.0,51.0,https://twitter.com/pb10_bmt/statuses/1334539142542155778,0.0,0.0,,0.0,0.0,0.0,51.0,136.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @VincentRK: One of the most common questions myeloma patients ask me is: Should I get a stem cell transplant, and if so when should I do‚Ä¶",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-07 02:39:29+00:00,"Ritcha Saxena, MD",http://twitter.com/,11.0,,1.3357759109355315e+18,,0.0,0.0,,RT @SylvesterCancer: Now at #ASH20:  Poster (#2092) by @SylvesterCancer research  team on a TFR1-Targeted Doxorubicin Nanocarrier for DLBCL‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,9.0,2.0,https://twitter.com/RitchaSaxena/statuses/1335775910935531522,0.0,0.0,,0.0,0.0,0.0,2.0,9.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,RT @SylvesterCancer: Now at #ASH20:  Poster (#2092) by @SylvesterCancer research  team on a TFR1-Targeted Doxorubicin Nanocarrier for DLBCL‚Ä¶,false
khouri_jack,Myeloma/BMT #hematologist #oncologist @ClevelandClinic Assistant Prof @CleClinicLCM @CWRUSOM | alum @TuftsMedSchool @Uni_Of_Balamand #mmsm #bmtsm,,"Cleveland, OH",,2020-12-07 22:15:04+00:00,"Jack Khouri, MD",http://twitter.com/,21.0,,1.336071756474425e+18,,0.0,0.0,,RT @SLentzsch: #724 Niels Van De Donk showed Phase 1 data: IBER (CC-220)/ DEX/ DARA or BORT in RRMM‚û°Ô∏èORR 42% Iber/Dex/Dara and 61% IBER/DEX‚Ä¶,en,0.0,443.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,14.0,7.0,https://twitter.com/khouri_jack/statuses/1336071756474425345,0.0,0.0,,0.0,0.0,0.0,7.0,14.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @SLentzsch: #724 Niels Van De Donk showed Phase 1 data: IBER (CC-220)/ DEX/ DARA or BORT in RRMM‚û°Ô∏èORR 42% Iber/Dex/Dara and 61% IBER/DEX‚Ä¶,true
AnandPheresisMD,"Transfusion Med MD & Platelet Immunologist; Physician, Mayo Clinic; Co-Founder & Chief Science Officer, Retham Technologies; Opinions my own; Not medical advice",,"Rochester, MN",,2020-12-03 13:39:44+00:00,Anand Padmanabhan,http://twitter.com/,13.0,,1.3344925194978632e+18,,0.0,0.0,,"RT @drzsicklecell: Bringing his expertise in #TransfusionMedicine and #Thrombosis, @AnandPheresisMD (@MayoClinic) has a keen eye when it co‚Ä¶",en,0.0,120.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,9.0,4.0,https://twitter.com/AnandPheresisMD/statuses/1334492519497863170,0.0,0.0,,0.0,0.0,0.0,4.0,9.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,"RT @drzsicklecell: Bringing his expertise in #TransfusionMedicine and #Thrombosis, @AnandPheresisMD (@MayoClinic) has a keen eye when it co‚Ä¶",true
Haytham_Samy,BMT and cell therapy physician @KUcancercenter,,"Kansas city, USA",,2020-12-03 18:57:49+00:00,Haitham Abdelhakim,http://twitter.com/,187.0,,1.3345725643126907e+18,,0.0,0.0,,"RT @VincentRK: One of the most common questions myeloma patients ask me is: Should I get a stem cell transplant, and if so when should I do‚Ä¶",en,0.0,358.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,136.0,51.0,https://twitter.com/Haytham_Samy/statuses/1334572564312690690,0.0,0.0,,0.0,0.0,0.0,51.0,136.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @VincentRK: One of the most common questions myeloma patients ask me is: Should I get a stem cell transplant, and if so when should I do‚Ä¶",true
szusmani,"Division Chief, Plasma Cell Disorders|Director, Clinical Research Hem Malignancies | Views are my own | RT not endorsement | Physician ‚â† Provider",,"Charlotte, NC",,2020-12-03 00:22:08+00:00,Saad Z. Usmani MD MBA FACP (he/his/him),http://twitter.com/,194.0,,1.3342917953127752e+18,,0.0,0.0,,RT @VincentRK: #ASH20 special: Active myeloma drugs with their mechanism of action in one slide. Unapproved investigational drugs in blue f‚Ä¶,en,0.0,5512.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,147.0,47.0,https://twitter.com/szusmani/statuses/1334291795312775168,0.0,0.0,,0.0,0.0,0.0,47.0,147.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,RT @VincentRK: #ASH20 special: Active myeloma drugs with their mechanism of action in one slide. Unapproved investigational drugs in blue f‚Ä¶,true
emmamgroarke,"Haematologist in Bethesda. Irish trained üáÆüá™ Particular interests: #aplasticanemia, #telomeredisease, #CHIP, #MDS, #AML, #HSCT All comments my own.",,"Washington, DC",,2020-12-03 20:52:46+00:00,Emma M. Groarke,http://twitter.com/,7.0,,1.3346014931907625e+18,,0.0,0.0,,RT @TheBethesdaLabs: Join #NHLBI‚Äôs Dr. Cynthia Dunbar‚Äôs live Q&amp;A and panel discussion: ‚ÄúCHIPing Away at the Hematopoietic Stem Cell Niche‚Äù‚Ä¶,en,0.0,130.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,2.0,https://twitter.com/emmamgroarke/statuses/1334601493190762497,0.0,0.0,,0.0,0.0,0.0,2.0,5.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @TheBethesdaLabs: Join #NHLBI‚Äôs Dr. Cynthia Dunbar‚Äôs live Q&amp;A and panel discussion: ‚ÄúCHIPing Away at the Hematopoietic Stem Cell Niche‚Äù‚Ä¶,true
diegoah66,"Hematologist-Oncologist @UVMMedCenter, Assistant Professor of Medicine @UVMLarnerMed | üáµüá™üá∫üá∏",,"Burlington, VT",,2020-12-03 01:18:40+00:00,Diego Adrianzen-Herrera,http://twitter.com/,194.0,,1.3343060218802954e+18,,0.0,0.0,,RT @VincentRK: #ASH20 special: Active myeloma drugs with their mechanism of action in one slide. Unapproved investigational drugs in blue f‚Ä¶,en,0.0,187.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,147.0,47.0,https://twitter.com/diegoah66/statuses/1334306021880295424,0.0,0.0,,0.0,0.0,0.0,47.0,147.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,RT @VincentRK: #ASH20 special: Active myeloma drugs with their mechanism of action in one slide. Unapproved investigational drugs in blue f‚Ä¶,false
MDAndersonNews,"The official account of MD Anderson Cancer Center, a leader in cancer care, cancer research and the fight to #EndCancer. Appointments available: 1-877-632-6789.",,"Houston, TX",,2020-12-03 18:18:01+00:00,MD Anderson Cancer Center,http://twitter.com/,2.0,,1.334562551162671e+18,,0.0,0.0,,"Chemotherapy used to be the standard treatment option for mantle cell lymphoma. But what‚Äôs next? 

Our Dr. Michael‚Ä¶ https://t.co/MF9AetHetb",en,0.0,114120.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/MDAndersonNews/statuses/1334562551162671110,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"Chemotherapy used to be the standard treatment option for mantle cell lymphoma. But what‚Äôs next? 

Our Dr. Michael‚Ä¶ https://t.co/MF9AetHetb",true
sortoutbleeding,"Coagulation haematologist with a passion for bleeding disorders and women's health.

Advocate for better health for all. 

All views expressed are my own.",,Irish Centre for Vascular Biol,,2020-12-09 19:42:36+00:00,Michelle Lavin,http://twitter.com/,86.0,,1.3367581637905736e+18,,0.0,0.0,,RT @oconnn04: A big thank you to the clinical teams in the NCC and the Clinical research facility @stjamesdublin and the Irish participants‚Ä¶,en,0.0,1136.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,73.0,13.0,https://twitter.com/sortoutbleeding/statuses/1336758163790573580,0.0,0.0,,0.0,0.0,0.0,13.0,73.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @oconnn04: A big thank you to the clinical teams in the NCC and the Clinical research facility @stjamesdublin and the Irish participants‚Ä¶,true
GlopesMd,"Cancer Doctor and Researcher, Faculty @SylvesterCancer @UnivMiami. Helping improve Cancer Control in LMICs. Editor-in-Chief JCO Global Oncology @ASCO",,"Miami, FL",,2020-12-28 16:54:18+00:00,gilberto lopes,http://twitter.com/,22.0,,1.3436011771377295e+18,,0.0,0.0,,RT @COVID19nCCC: Severity of Sars-Cov-2 Infection in Pts w/ Hematologic Malignancies: A COVID-19 &amp; Cancer Consortium (#CCC19) Registry Anal‚Ä¶,en,0.0,31610.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,14.0,8.0,https://twitter.com/GlopesMd/statuses/1343601177137729537,0.0,0.0,,0.0,0.0,0.0,8.0,14.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,RT @COVID19nCCC: Severity of Sars-Cov-2 Infection in Pts w/ Hematologic Malignancies: A COVID-19 &amp; Cancer Consortium (#CCC19) Registry Anal‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-09 00:22:34+00:00,"Ritcha Saxena, MD",http://twitter.com/,7.0,,1.3364662329508454e+18,,0.0,0.0,,"RT @VJHemOnc: At the #BestOfASH session the phase 1 study of #Talquetamab in R/R #Myeloma was highlighted

For more on this bispecific anti‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,1.0,https://twitter.com/RitchaSaxena/statuses/1336466232950845443,0.0,0.0,,0.0,0.0,0.0,1.0,6.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @VJHemOnc: At the #BestOfASH session the phase 1 study of #Talquetamab in R/R #Myeloma was highlighted

For more on this bispecific anti‚Ä¶",true
MDedgeHemOnc,MDedge Hematology & Oncology provides the most important and up to date information and news for oncologists. Now part of the Medscape Professional Network.,,"Rockville, MD, Parsippany, NJ",,2020-12-23 15:16:00+00:00,MDedge Hematology & Oncology,http://twitter.com/,1.0,,1.3417645024513477e+18,,0.0,0.0,,Blinatumomab shows superiority to HC3 chemotherapy among children with ALL in a phase 3 trial.‚Ä¶ https://t.co/6rvynrgwGO,en,0.0,6723.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/MDedgeHemOnc/statuses/1341764502451347459,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,Blinatumomab shows superiority to HC3 chemotherapy among children with ALL in a phase 3 trial.‚Ä¶ https://t.co/6rvynrgwGO,true
TelehealthBot,Created by Doctor @KrittanawongMD. A bot that collects Tweets about medicine and medical innovation,,GJ 357 d,,2020-12-23 22:48:57+00:00,MedEd,http://twitter.com/,1.0,,1.3418784888239675e+18,,0.0,0.0,,RT @OncologyTimes: #ASH2020 Updates: New Treatments that Offer Hope for Patients with Multiple Myeloma https://t.co/E6xrZ83GfP #medtwitter‚Ä¶,en,0.0,683.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/TelehealthBot/statuses/1341878488823967746,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @OncologyTimes: #ASH2020 Updates: New Treatments that Offer Hope for Patients with Multiple Myeloma https://t.co/E6xrZ83GfP #medtwitter‚Ä¶,false
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-24 15:25:05+00:00,"Ritcha Saxena, MD",http://twitter.com/,2.0,,1.342129173662466e+18,,0.0,0.0,,RT @ASH_hematology: Learn more about donating to the ASH Foundation: https://t.co/f3krYFDMVK #ASH20 #IWalkForASH #IRunForASH,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,1.0,1.0,https://twitter.com/RitchaSaxena/statuses/1342129173662466049,0.0,0.0,,0.0,0.0,0.0,1.0,1.0,False,False,False,False,True,Charity,0.0,0.0,1.0,RT @ASH_hematology: Learn more about donating to the ASH Foundation: https://t.co/f3krYFDMVK #ASH20 #IWalkForASH #IRunForASH,true
CleClinicMD,"News and insights for physicians and clinical professionals from @ClevelandClinic. Research, case studies and CME opportunities.",,"Cleveland, Ohio, United States",,2020-12-01 03:24:11+00:00,Cleveland Clinic MD,http://twitter.com/,0.0,,1.3336128341781504e+18,,0.0,0.0,,"A 27-year-old woman with stomach pain, nausea and diarrhea associated with COVID-19 presented after developing liver failure: #ASH20",en,0.0,302311.0,,,0.0,,,Negative,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/CleClinicMD/statuses/1333612834178150405,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Side Effects,0.0,1.0,0.0,"A 27-year-old woman with stomach pain, nausea and diarrhea associated with COVID-19 presented after developing liver failure: #ASH20",true
jenweiying,Haematologist working on https://t.co/fiMAwrCDXt - #FOAMed for students and trainees. Collaborators welcome. Tweets are my own opinion and not medical advice.,,Singapore,,2020-12-01 23:31:44+00:00,Wei Ying Jen,http://twitter.com/,14.0,,1.3339167232552755e+18,,0.0,0.0,,RT @mtmdphd: Lack of Effectiveness of IV High-Dose Methotrexate for Prevention of CNS Relapse in High-Risk DLBCL: Retrospective Analysis fr‚Ä¶,en,0.0,251.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,11.0,3.0,https://twitter.com/jenweiying/statuses/1333916723255275520,0.0,0.0,,0.0,0.0,0.0,3.0,11.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @mtmdphd: Lack of Effectiveness of IV High-Dose Methotrexate for Prevention of CNS Relapse in High-Risk DLBCL: Retrospective Analysis fr‚Ä¶,true
JerroldLevy,"Critical care physician in CTICU @DukeMedSchool, interested in coagulation, bleeding, inflammation-also oenophile and foody. Tweets are my own (‚â†medical advice)",,"Durham, North Carolina",,2020-12-01 15:23:11+00:00,"Jerrold Levy, MD",http://twitter.com/,1.0,,1.3337937756976087e+18,,0.0,0.0,,"Infection response
Immunohemostasis
Panel on 12/2

#ASH2020 #ASHaiku @connors_md @BloodDoc2 

10a EST https://t.co/lYgoKO4qzB",es,0.0,1755.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/JerroldLevy/statuses/1333793775697608711,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"Infection response
Immunohemostasis
Panel on 12/2

#ASH2020 #ASHaiku @connors_md @BloodDoc2 

10a EST https://t.co/lYgoKO4qzB",true
CleClinicMD,"News and insights for physicians and clinical professionals from @ClevelandClinic. Research, case studies and CME opportunities.",,"Cleveland, Ohio, United States",,2020-12-01 03:24:55+00:00,Cleveland Clinic MD,http://twitter.com/,0.0,,1.333613018538791e+18,,0.0,0.0,,New research shows the monoclonal antibody daratumumab is a safe and effective treatment for amyloid light-chain amyloidosis: #ASH20,en,0.0,302311.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/CleClinicMD/statuses/1333613018538790913,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,New research shows the monoclonal antibody daratumumab is a safe and effective treatment for amyloid light-chain amyloidosis: #ASH20,true
CleClinicMD,"News and insights for physicians and clinical professionals from @ClevelandClinic. Research, case studies and CME opportunities.",,"Cleveland, Ohio, United States",,2020-12-01 03:25:03+00:00,Cleveland Clinic MD,http://twitter.com/,0.0,,1.333613051128533e+18,,0.0,0.0,,A 61-year-old woman presented for evaluation of multiple episodes of bruising and other clues that led to a rare cancer diagnosis: #ASH20,en,0.0,302311.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/CleClinicMD/statuses/1333613051128532992,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,A 61-year-old woman presented for evaluation of multiple episodes of bruising and other clues that led to a rare cancer diagnosis: #ASH20,false
SandyWong02111,UCSF Hematologist and BMT physician,,"San Francisco, CA",,2020-12-01 06:00:05+00:00,Sandy Wong,http://twitter.com/,41.0,,1.3336520672571802e+18,,0.0,0.0,,"RT @VincentRK: #1 Talquetamab, novel bi specific antibody targeting GPRC5D (expressed on myeloma cells) &amp; CD3 shows activity in relapsed re‚Ä¶",en,0.0,759.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,29.0,12.0,https://twitter.com/SandyWong02111/statuses/1333652067257180160,0.0,0.0,,0.0,0.0,0.0,12.0,29.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @VincentRK: #1 Talquetamab, novel bi specific antibody targeting GPRC5D (expressed on myeloma cells) &amp; CD3 shows activity in relapsed re‚Ä¶",true
AnnaSureda5,"Haematologist interested in lymphoid malignancies, stem cell transplantation and CART cells. #CART #BMT #lymphomas #immunotherapy #WomenInMedicine",,"Barcelona, Spain",,2020-12-01 04:01:55+00:00,Anna Sureda,http://twitter.com/,92.0,,1.333622327788118e+18,,0.0,0.0,,RT @DocHutchings: Pleased to present the final results from the dose escalation part of the Phase 1/2 study of epcoritamab in r/r B-NHL at‚Ä¶,en,0.0,658.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,69.0,23.0,https://twitter.com/AnnaSureda5/statuses/1333622327788118018,0.0,0.0,,0.0,0.0,0.0,23.0,69.0,False,False,False,False,True,Clinical Trials,1.0,0.0,0.0,RT @DocHutchings: Pleased to present the final results from the dose escalation part of the Phase 1/2 study of epcoritamab in r/r B-NHL at‚Ä¶,true
JohnPLeonardMD,"Doctor for lymphoma patients, researcher, collaborator, professor/senior associate dean @WeillCornell & @NYPhospital Tweets mine RT not=endorsement, he/him/his",,Weill Cornell Medicine,,2020-12-01 14:38:55+00:00,"John P. Leonard, MD",http://twitter.com/,5.0,,1.333782634694996e+18,,0.0,0.0,,"Number 4 #LeonardList #ASH20 - Wang - 117 -  Non-covalent BTKi LOXO-305 in MCL &amp; B cell NHL - tox fatigue/diarrhea,‚Ä¶ https://t.co/sWy5aC4nbh",en,0.0,6269.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,5.0,https://twitter.com/JohnPLeonardMD/statuses/1333782634694995969,0.0,0.0,,0.0,0.0,0.0,5.0,0.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"Number 4 #LeonardList #ASH20 - Wang - 117 -  Non-covalent BTKi LOXO-305 in MCL &amp; B cell NHL - tox fatigue/diarrhea,‚Ä¶ https://t.co/sWy5aC4nbh",true
SandyWong02111,UCSF Hematologist and BMT physician,,"San Francisco, CA",,2020-12-01 05:59:39+00:00,Sandy Wong,http://twitter.com/,23.0,,1.33365195674991e+18,,0.0,0.0,,RT @VincentRK: #4 Identification of a potential mechanism for frequent relapses after CAR-T therapy for myeloma: Bi allelic loss of BCMA lo‚Ä¶,en,0.0,759.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,17.0,6.0,https://twitter.com/SandyWong02111/statuses/1333651956749910017,0.0,0.0,,0.0,0.0,0.0,6.0,17.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @VincentRK: #4 Identification of a potential mechanism for frequent relapses after CAR-T therapy for myeloma: Bi allelic loss of BCMA lo‚Ä¶,true
myelomatips,"Hematologist/Oncologist, Physician-scientist with focus on myeloma. Tweets are my own.",,,,2020-12-01 15:00:59+00:00,"Cesar Rodriguez, MD (Myelomatips.com)",http://twitter.com/,27.0,,1.3337881884022825e+18,,0.0,0.0,,RT @WakeCancer: Dr. Cesar Rodriguez will share results from a Phase 1 clinical study of TNB-383B in treating multiple myeloma patients who‚Ä¶,en,0.0,536.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,22.0,5.0,https://twitter.com/myelomatips/statuses/1333788188402282496,0.0,0.0,,0.0,0.0,0.0,5.0,22.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @WakeCancer: Dr. Cesar Rodriguez will share results from a Phase 1 clinical study of TNB-383B in treating multiple myeloma patients who‚Ä¶,true
Jme_os,Research Lecturer Irish Centre for Vascular Biology | Royal College of Surgeons in Ireland | VWF Biology | Cancer-Coagulation crosstalk | COVID-coag |@RCSI_Irl,,"Dublin, Ireland",,2020-12-01 22:12:02+00:00,Jamie O' Sullivan,http://twitter.com/,3.0,,1.33389666440337e+18,,0.0,0.0,,Excited to present at the scientific workshop on infection and coagulation tomorrow at #ASH20 #haemostasis #covid19‚Ä¶ https://t.co/mQH8x9v1rU,en,0.0,673.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/Jme_os/statuses/1333896664403369985,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Side Effects,1.0,0.0,0.0,Excited to present at the scientific workshop on infection and coagulation tomorrow at #ASH20 #haemostasis #covid19‚Ä¶ https://t.co/mQH8x9v1rU,false
aditishasMD,Physician-scientist researching cures for AML & MDS. Addressing health disparities in cancer care. Tweets my own #leusm #mds,,"New York, NY",,2020-11-30 16:54:45+00:00,"Aditi Shastri, MD",http://twitter.com/,0.0,,1.333454429450875e+18,,0.0,0.0,,"Dr.Shafia Rehman, PI Dr.Sica will present on clinical prognostic factors in newly diagnosed ATLL in our cohort‚Ä¶ https://t.co/2cPiUZz1C5",en,0.0,723.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/aditishasMD/statuses/1333454429450874880,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"Dr.Shafia Rehman, PI Dr.Sica will present on clinical prognostic factors in newly diagnosed ATLL in our cohort‚Ä¶ https://t.co/2cPiUZz1C5",true
rajshekharucms,Hem/Onc Physician/Clinical Researcher @ColumbiaCancer #MultipleMyeloma & #Amyloidosis. Asst. Prof of Medicine @ColumbiaMed #ClinicalTrials and Outcomes Research,,"New York, NY",,2020-11-30 22:03:05+00:00,Raj Chakraborty,http://twitter.com/,37.0,,1.333532026180227e+18,,0.0,0.0,,"RT @Rfonsi1: Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial
This remains‚Ä¶",en,0.0,1148.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,30.0,7.0,https://twitter.com/rajshekharucms/statuses/1333532026180227072,0.0,0.0,,0.0,0.0,0.0,7.0,30.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"RT @Rfonsi1: Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial
This remains‚Ä¶",true
KENNETHROMER,CEO of Myeloma New Zealand. Retired haematologist. Father of five children. An advocate for patients with blood cancers. Bit of a curmudgeon.Foodie.,,"Wellington City, New Zealand",,2020-11-30 03:06:23+00:00,haemdoc,http://twitter.com/,37.0,,1.3332459678107402e+18,,0.0,0.0,,"RT @Rfonsi1: Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial
This remains‚Ä¶",en,0.0,211.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,30.0,7.0,https://twitter.com/KENNETHROMER/statuses/1333245967810740224,0.0,0.0,,0.0,0.0,0.0,7.0,30.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"RT @Rfonsi1: Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial
This remains‚Ä¶",true
bagalbp,"Hemato-oncologist, Tata Memorial Center",,Mumbai,,2020-11-30 06:49:28+00:00,Bhausaheb Bagal,http://twitter.com/,71.0,,1.3333021076220436e+18,,0.0,0.0,,RT @nvpatkar: #ASH20 Molecular Measurable Residual Disease Detection in Acute Myeloid Leukemia Using Error Corrected Next Generation Sequen‚Ä¶,en,0.0,1110.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,62.0,9.0,https://twitter.com/bagalbp/statuses/1333302107622043648,0.0,0.0,,0.0,0.0,0.0,9.0,62.0,False,False,False,False,True,Long Term Benefits,0.0,0.0,1.0,RT @nvpatkar: #ASH20 Molecular Measurable Residual Disease Detection in Acute Myeloid Leukemia Using Error Corrected Next Generation Sequen‚Ä¶,true
Swathiprabhu5,"MD Pathology and #Oncopath fellow from #RCC Trivandrum. Thinker, traveller, believes in living life to the fullestüáÆüá≥",,"Chandigarh, India",,2020-11-30 09:43:20+00:00,"Swathi Prabhu, MD",http://twitter.com/,71.0,,1.333345862697644e+18,,0.0,0.0,,RT @nvpatkar: #ASH20 Molecular Measurable Residual Disease Detection in Acute Myeloid Leukemia Using Error Corrected Next Generation Sequen‚Ä¶,en,0.0,2095.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,62.0,9.0,https://twitter.com/Swathiprabhu5/statuses/1333345862697644033,0.0,0.0,,0.0,0.0,0.0,9.0,62.0,False,False,False,False,True,Long Term Benefits,0.0,0.0,1.0,RT @nvpatkar: #ASH20 Molecular Measurable Residual Disease Detection in Acute Myeloid Leukemia Using Error Corrected Next Generation Sequen‚Ä¶,true
LakshmiKoulmane,"Associate Professor of Pathology, Staff Pathologist at Hematology and clinical Pathology laboratory, Kasturba Medical College and Hospital, Manipal. MAHE",,"Karnataka, India",,2020-11-30 08:30:06+00:00,Sindhura Lakshmi,http://twitter.com/,71.0,,1.3333274334795694e+18,,0.0,0.0,,RT @nvpatkar: #ASH20 Molecular Measurable Residual Disease Detection in Acute Myeloid Leukemia Using Error Corrected Next Generation Sequen‚Ä¶,en,0.0,642.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,62.0,9.0,https://twitter.com/LakshmiKoulmane/statuses/1333327433479569409,0.0,0.0,,0.0,0.0,0.0,9.0,62.0,False,False,False,False,True,Long Term Benefits,0.0,0.0,1.0,RT @nvpatkar: #ASH20 Molecular Measurable Residual Disease Detection in Acute Myeloid Leukemia Using Error Corrected Next Generation Sequen‚Ä¶,false
CellworksLife,"Cellworks is a world leader in Precision Medicine. We help physicians & payors navigate to efficacious cost effective treatments in a transparent, timely manner",,"San Jose, CA",,2020-12-27 16:30:08+00:00,CellworksLife,http://twitter.com/,3.0,,1.3432327083198587e+18,,0.0,0.0,,Monosomy 7 and Co-Occurrent Genomic Aberrations Determine Chemotherapy Response in Acute Myeloid Leukemia (AML) Pat‚Ä¶ https://t.co/BxfSZWopdC,en,0.0,144.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/CellworksLife/statuses/1343232708319858690,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,Monosomy 7 and Co-Occurrent Genomic Aberrations Determine Chemotherapy Response in Acute Myeloid Leukemia (AML) Pat‚Ä¶ https://t.co/BxfSZWopdC,true
olga45093932,"MD,PhD, hematologist of @NationalCancerInst of @oncohematologyDepart",,"Kiev, Ukraine",,2020-12-28 19:49:50+00:00,Olga,http://twitter.com/,40.0,,1.3436453509644575e+18,,0.0,0.0,,RT @RahmaWarsameMD: Promising results from phase 1 VSV-IFNb-NIS in pts with relapsed refractory hem malignancies. Strongest signal in TCL.‚Ä¶,en,0.0,64.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,30.0,10.0,https://twitter.com/olga45093932/statuses/1343645350964457472,0.0,0.0,,0.0,0.0,0.0,10.0,30.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @RahmaWarsameMD: Promising results from phase 1 VSV-IFNb-NIS in pts with relapsed refractory hem malignancies. Strongest signal in TCL.‚Ä¶,true
AnnaSureda5,"Haematologist interested in lymphoid malignancies, stem cell transplantation and CART cells. #CART #BMT #lymphomas #immunotherapy #WomenInMedicine",,"Barcelona, Spain",,2020-12-27 09:00:16+00:00,Anna Sureda,http://twitter.com/,17.0,,1.3431194942276362e+18,,0.0,0.0,,"RT @VJHemOnc: #Flotetuzumab for primary induction failure &amp; early relapse #AML w/ John DiPersio of @WUSTLmed: https://t.co/cCPSDSRMOv

#ASH‚Ä¶",en,0.0,658.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,14.0,3.0,https://twitter.com/AnnaSureda5/statuses/1343119494227636224,0.0,0.0,,0.0,0.0,0.0,3.0,14.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @VJHemOnc: #Flotetuzumab for primary induction failure &amp; early relapse #AML w/ John DiPersio of @WUSTLmed: https://t.co/cCPSDSRMOv

#ASH‚Ä¶",true
BCMDeptMedicine,"The official Twitter account of @BCMHouston Department of Medicine, where we advance future medicine, educate future doctors and provide compassionate care.",,"Houston, TX",,2020-12-28 14:59:46+00:00,BCM Department of Medicine,http://twitter.com/,25.0,,1.343572356862767e+18,,0.0,0.0,,"RT @HadidiSamer: QUAZAR just published @NEJM. Maintenance oral AZA resulted in ~10 months longer OS in AML patients in first remission, res‚Ä¶",en,0.0,1272.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,20.0,5.0,https://twitter.com/BCMDeptMedicine/statuses/1343572356862767109,0.0,0.0,,0.0,0.0,0.0,5.0,20.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @HadidiSamer: QUAZAR just published @NEJM. Maintenance oral AZA resulted in ~10 months longer OS in AML patients in first remission, res‚Ä¶",true
lepikurian,"Haematologist, researcher, biotech startup co-founder",,"Saint-Petersburg, Russia",,2020-12-28 05:49:46+00:00,Kirill Lepik M.D.,http://twitter.com/,45.0,,1.3434339420625306e+18,,0.0,0.0,,RT @DrMiguelPerales: #ASH20 Abs 470 Impressive results in Phase II Study of Pembrolizumab Plus GVD As 2nd-Line Therapy for Rel/Ref Classica‚Ä¶,en,0.0,89.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,34.0,11.0,https://twitter.com/lepikurian/statuses/1343433942062530561,0.0,0.0,,0.0,0.0,0.0,11.0,34.0,False,False,False,False,True,Clinical Trials,1.0,0.0,0.0,RT @DrMiguelPerales: #ASH20 Abs 470 Impressive results in Phase II Study of Pembrolizumab Plus GVD As 2nd-Line Therapy for Rel/Ref Classica‚Ä¶,true
AnnaSureda5,"Haematologist interested in lymphoid malignancies, stem cell transplantation and CART cells. #CART #BMT #lymphomas #immunotherapy #WomenInMedicine",,"Barcelona, Spain",,2020-12-28 16:56:45+00:00,Anna Sureda,http://twitter.com/,22.0,,1.343601795885658e+18,,0.0,0.0,,RT @COVID19nCCC: Severity of Sars-Cov-2 Infection in Pts w/ Hematologic Malignancies: A COVID-19 &amp; Cancer Consortium (#CCC19) Registry Anal‚Ä¶,en,0.0,658.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,14.0,8.0,https://twitter.com/AnnaSureda5/statuses/1343601795885658114,0.0,0.0,,0.0,0.0,0.0,8.0,14.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,RT @COVID19nCCC: Severity of Sars-Cov-2 Infection in Pts w/ Hematologic Malignancies: A COVID-19 &amp; Cancer Consortium (#CCC19) Registry Anal‚Ä¶,false
Lungsolutions,Interventional Pulmonologist #RiseforPearl #WiIP #PhysicianRise #thewhiteribbonproject Founder&President of Lung Health Services/Mother/Speaker/Tweets r my own,,"Doylestown ",,2020-12-28 23:46:39+00:00,"Nina Maouelainin, DO, FCCP, MBA",http://twitter.com/,22.0,,1.343704948119376e+18,,0.0,0.0,,RT @COVID19nCCC: Severity of Sars-Cov-2 Infection in Pts w/ Hematologic Malignancies: A COVID-19 &amp; Cancer Consortium (#CCC19) Registry Anal‚Ä¶,en,0.0,1102.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,14.0,8.0,https://twitter.com/Lungsolutions/statuses/1343704948119375872,0.0,0.0,,0.0,0.0,0.0,8.0,14.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,RT @COVID19nCCC: Severity of Sars-Cov-2 Infection in Pts w/ Hematologic Malignancies: A COVID-19 &amp; Cancer Consortium (#CCC19) Registry Anal‚Ä¶,true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-12-15 19:17:00+00:00,Oncology Tube,http://twitter.com/,0.0,,1.338926046729605e+18,,0.0,0.0,,"The ECHELON-2 Trial: 5-year Results of a Randomized, Double-Blind, Phase 3 Study Miles Prince, MD @MilesPrince4‚Ä¶ https://t.co/9Ti7zyWRXP",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1338926046729605128,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"The ECHELON-2 Trial: 5-year Results of a Randomized, Double-Blind, Phase 3 Study Miles Prince, MD @MilesPrince4‚Ä¶ https://t.co/9Ti7zyWRXP",true
olga45093932,"MD,PhD, hematologist of @NationalCancerInst of @oncohematologyDepart",,"Kiev, Ukraine",,2020-12-28 19:51:27+00:00,Olga,http://twitter.com/,24.0,,1.3436457586382193e+18,,0.0,0.0,,RT @VincentRK: Myeloma Future State: New drugs bring challenges and opportunities. We could very well have triple-class refractoriness in 1‚Ä¶,en,0.0,64.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,18.0,6.0,https://twitter.com/olga45093932/statuses/1343645758638219270,0.0,0.0,,0.0,0.0,0.0,6.0,18.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @VincentRK: Myeloma Future State: New drugs bring challenges and opportunities. We could very well have triple-class refractoriness in 1‚Ä¶,true
dgermain21,MD-PhD. 2nd year Heme/Onc fellow focused on lymphoma and leukemia. Physician-scientist-in-training. Tweet/RT not medical advice or endorsement.,,"St. Louis, MO",,2020-12-15 15:00:50+00:00,David A. Russler-Germain,http://twitter.com/,48.0,,1.338861582852313e+18,,0.0,0.0,,"RT @graham74GC: #CollinsConclusions -Hodgkin
PD1i powers on
‚Ä¢ Pembro+GVD v active 1L relapse
- 94% CR in 34 eval pts: wow!
‚Ä¢ QoL superior f‚Ä¶",en,0.0,1612.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,40.0,8.0,https://twitter.com/dgermain21/statuses/1338861582852313088,0.0,0.0,,0.0,0.0,0.0,8.0,40.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @graham74GC: #CollinsConclusions -Hodgkin
PD1i powers on
‚Ä¢ Pembro+GVD v active 1L relapse
- 94% CR in 34 eval pts: wow!
‚Ä¢ QoL superior f‚Ä¶",true
graham74GC,Lymphoma specialist at Oxford Cancer and Haematology centre. Haematologist and clinical trialist. Chair of UK Hodgkin and T-cell study groups.,,Opinions are mine,,2020-12-15 14:58:08+00:00,Graham Collins,http://twitter.com/,8.0,,1.3388609002712883e+18,,0.0,0.0,,"#CollinsConclusions -Hodgkin
PD1i powers on
‚Ä¢ Pembro+GVD v active 1L relapse
- 94% CR in 34 eval pts: wow!
‚Ä¢ QoL su‚Ä¶ https://t.co/smMi4xtAhs",en,0.0,6091.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,8.0,https://twitter.com/graham74GC/statuses/1338860900271288320,0.0,0.0,,0.0,0.0,0.0,8.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"#CollinsConclusions -Hodgkin
PD1i powers on
‚Ä¢ Pembro+GVD v active 1L relapse
- 94% CR in 34 eval pts: wow!
‚Ä¢ QoL su‚Ä¶ https://t.co/smMi4xtAhs",true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-12-15 20:27:00+00:00,Oncology Tube,http://twitter.com/,0.0,,1.3389436626595226e+18,,0.0,0.0,,"Update of MANIFEST Phase 2 Study John Mascarenhas, MD @TischCancer @IcahnMountSinai #ASH20 #Myelofibrosis #Cancer‚Ä¶ https://t.co/77gZQvTTBR",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1338943662659522560,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"Update of MANIFEST Phase 2 Study John Mascarenhas, MD @TischCancer @IcahnMountSinai #ASH20 #Myelofibrosis #Cancer‚Ä¶ https://t.co/77gZQvTTBR",false
nick6886,"Haematologist, QUB, previous Chief Clinical Fellow L/BMT BC, current Clinical Lymphoma Fellow BC Cancer Agency, Vancouver. All views my own.",,"Vancouver, British Columbia",,2020-12-15 17:47:47+00:00,Nicholas Cunningham,http://twitter.com/,48.0,,1.3389035951025723e+18,,0.0,0.0,,"RT @graham74GC: #CollinsConclusions -Hodgkin
PD1i powers on
‚Ä¢ Pembro+GVD v active 1L relapse
- 94% CR in 34 eval pts: wow!
‚Ä¢ QoL superior f‚Ä¶",en,0.0,147.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,40.0,8.0,https://twitter.com/nick6886/statuses/1338903595102572545,0.0,0.0,,0.0,0.0,0.0,8.0,40.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @graham74GC: #CollinsConclusions -Hodgkin
PD1i powers on
‚Ä¢ Pembro+GVD v active 1L relapse
- 94% CR in 34 eval pts: wow!
‚Ä¢ QoL superior f‚Ä¶",true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-12-17 18:00:00+00:00,Oncology Tube,http://twitter.com/,0.0,,1.3396314465380065e+18,,0.0,0.0,,"Primary Efficacy and Safety Results from a Phase 1 Trial Andreas Hochhaus, MD @AndreasHochhaus @UniJena #ASH20‚Ä¶ https://t.co/W1h7FqYUNN",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1339631446538006529,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"Primary Efficacy and Safety Results from a Phase 1 Trial Andreas Hochhaus, MD @AndreasHochhaus @UniJena #ASH20‚Ä¶ https://t.co/W1h7FqYUNN",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-16 02:47:18+00:00,Lisa Palacios,http://twitter.com/,6.0,,1.3390393692614246e+18,,0.0,0.0,,"RT @OncLive: Findings on ponatinib in CP-CML were from the pivotal, phase 2, single-arm PACE trial, and the interim analysis of the multice‚Ä¶",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,1.0,https://twitter.com/Lisa_Palacios/statuses/1339039369261424640,0.0,0.0,,0.0,0.0,0.0,1.0,5.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @OncLive: Findings on ponatinib in CP-CML were from the pivotal, phase 2, single-arm PACE trial, and the interim analysis of the multice‚Ä¶",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-15 00:41:32+00:00,Lisa Palacios,http://twitter.com/,0.0,,1.3386453323648328e+18,,0.0,0.0,,"#ASH20: William Wierda, MD, PhD, @wwierda of @MDAndersonNews @LeukemiaMDA Discusses Phase 2 CAPTIVATE Study Data |‚Ä¶ https://t.co/Vy7tmHw8by",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/Lisa_Palacios/statuses/1338645332364832769,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"#ASH20: William Wierda, MD, PhD, @wwierda of @MDAndersonNews @LeukemiaMDA Discusses Phase 2 CAPTIVATE Study Data |‚Ä¶ https://t.co/Vy7tmHw8by",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-14 16:46:34+00:00,Lisa Palacios,http://twitter.com/,2.0,,1.3385258034291794e+18,,0.0,0.0,,"#ASH20 #MPN Daily Wrap-Up: New Research and Early Detection | Naveen Pemmaraju, MD, @doctorpemm of @MDAndersonNews‚Ä¶ https://t.co/Gxrz5sUFda",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/Lisa_Palacios/statuses/1338525803429179392,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"#ASH20 #MPN Daily Wrap-Up: New Research and Early Detection | Naveen Pemmaraju, MD, @doctorpemm of @MDAndersonNews‚Ä¶ https://t.co/Gxrz5sUFda",true
PAMJ84,Ronin Haematologist,,Europe,,2020-12-16 11:56:45+00:00,P. A-M,http://twitter.com/,7.0,,1.3391776414092124e+18,,0.0,0.0,,RT @MedscapeOnc: The investigational drug asciminibmay could become the new kid on the block for the treatment r/r CML. https://t.co/ynFYSV‚Ä¶,en,0.0,110.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,3.0,https://twitter.com/PAMJ84/statuses/1339177641409212419,0.0,0.0,,0.0,0.0,0.0,3.0,4.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,RT @MedscapeOnc: The investigational drug asciminibmay could become the new kid on the block for the treatment r/r CML. https://t.co/ynFYSV‚Ä¶,false
MDedgePediatric,MDedge Pediatrics is the leading news source for pediatricians. Now part of the Medscape Professional Network.,,"Rockville, MD",,2020-12-14 01:06:00+00:00,MDedge Pediatrics,http://twitter.com/,0.0,,1.3382891026183004e+18,,0.0,0.0,,Treating kids with B-cell non-#Hodgkin lymphomas under pediatric protocols have better outcomes.‚Ä¶ https://t.co/mRi8qz1Pel,en,0.0,3609.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/MDedgePediatric/statuses/1338289102618300418,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,Treating kids with B-cell non-#Hodgkin lymphomas under pediatric protocols have better outcomes.‚Ä¶ https://t.co/mRi8qz1Pel,true
diegoah66,"Hematologist-Oncologist @UVMMedCenter, Assistant Professor of Medicine @UVMLarnerMed | üáµüá™üá∫üá∏",,"Burlington, VT",,2020-12-14 17:02:29+00:00,Diego Adrianzen-Herrera,http://twitter.com/,6.0,,1.338529807819305e+18,,0.0,0.0,,RT @mtmdphd: Severity of Sars-Cov-2 Infection in Patients with Hematologic Malignancies: A COVID-19 and Cancer Consortium (#CCC19) Registry‚Ä¶,en,0.0,187.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,3.0,https://twitter.com/diegoah66/statuses/1338529807819304961,0.0,0.0,,0.0,0.0,0.0,3.0,3.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,RT @mtmdphd: Severity of Sars-Cov-2 Infection in Patients with Hematologic Malignancies: A COVID-19 and Cancer Consortium (#CCC19) Registry‚Ä¶,true
milena_mate,"MD  who adores  labs .,  has  a  yellow  one .",,,,2020-12-14 18:07:42+00:00,Dr. Mil√©na  M√°t√©,http://twitter.com/,5.0,,1.338546217974952e+18,,0.0,0.0,,RT @MedscapeOnc: ZUMA-5 results show impressive responses with CAR T cell therapy in patients with refractory/relapsed indolent non-Hodgkin‚Ä¶,en,0.0,680.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,2.0,https://twitter.com/milena_mate/statuses/1338546217974951940,0.0,0.0,,0.0,0.0,0.0,2.0,3.0,False,False,False,False,True,Diagnosis Progression,1.0,0.0,0.0,RT @MedscapeOnc: ZUMA-5 results show impressive responses with CAR T cell therapy in patients with refractory/relapsed indolent non-Hodgkin‚Ä¶,true
MedpageOnco,Breaking cancer + oncology news | Reports from all major oncology meetings | Peer-reviewed | Oncologist-trusted | Part of @MedPageToday,,,,2020-12-31 23:37:00+00:00,MedPage Oncology,http://twitter.com/,1.0,,1.34478968676676e+18,,0.0,0.0,,"In this #video, @DMadduri, MD, discusses the findings and implications of her study into the investigational treatm‚Ä¶ https://t.co/uu6tT3j4sM",en,0.0,443.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/MedpageOnco/statuses/1344789686766759941,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,"In this #video, @DMadduri, MD, discusses the findings and implications of her study into the investigational treatm‚Ä¶ https://t.co/uu6tT3j4sM",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-04 17:38:33+00:00,"Ritcha Saxena, MD",http://twitter.com/,46.0,,1.3349150069835284e+18,,0.0,0.0,,"RT @acweyand: What often happens to the Black community by police is just as frequently happening to sickle cell patients in hospitals. 

I‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,40.0,6.0,https://twitter.com/RitchaSaxena/statuses/1334915006983528450,0.0,0.0,,0.0,0.0,0.0,6.0,40.0,False,False,False,False,True,Disease Advocacy,0.0,0.0,1.0,"RT @acweyand: What often happens to the Black community by police is just as frequently happening to sickle cell patients in hospitals. 

I‚Ä¶",true
fniainle,"Haematologist, passionate about VTE. Co-director @ConwaySphere; Director https://t.co/csdWq9XJ57; RT not endorsement, views my own",,"Dublin City, Ireland",,2020-12-04 15:53:33+00:00,Fionnuala N√≠ √Åinle,http://twitter.com/,1.0,,1.3348885832835686e+18,,0.0,0.0,,There's Dr @leslieskeith addressing the role of the laboratory in the diagnosis and management of #PregnancyVTE. Wh‚Ä¶ https://t.co/EY1cf7ywAa,en,0.0,2069.0,,,0.0,fniainle,1.3348316815980585e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/fniainle/statuses/1334888583283568642,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,There's Dr @leslieskeith addressing the role of the laboratory in the diagnosis and management of #PregnancyVTE. Wh‚Ä¶ https://t.co/EY1cf7ywAa,false
sahilparikhmd,"Interventional Cardiologist, Vascular Medicine, Clinician Educator and Clinical Researcher, Husband/Father, Friend. My views only; not medical advice.",,"New York, NY",,2020-12-04 01:44:58+00:00,"Sahil A. Parikh, MD",http://twitter.com/,17.0,,1.3346750279591772e+18,,0.0,0.0,,"RT @crfheart: Watch #TCTConnect on demand‚Äîany time, any place‚Äîthrough Oct. 18, 2021. 

Stream 110+ hours of educational programming at your‚Ä¶",en,0.0,1410.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,11.0,6.0,https://twitter.com/sahilparikhmd/statuses/1334675027959177222,0.0,0.0,,0.0,0.0,0.0,6.0,11.0,False,False,False,False,True,Disease Advocacy,0.0,0.0,1.0,"RT @crfheart: Watch #TCTConnect on demand‚Äîany time, any place‚Äîthrough Oct. 18, 2021. 

Stream 110+ hours of educational programming at your‚Ä¶",true
TxaviManCat,"Hematologist, MD, PhD. Hospital del Mar, IMIM, GRETNHE (Translational Research on Hematological Neoplasms Group).",,"El Clot, Barcelona",,2020-12-04 19:31:36+00:00,Xavier Calvo,http://twitter.com/,49.0,,1.3349434575305482e+18,,0.0,0.0,,RT @gretnhe: Dr. Calvo team referenced for their contributions to MDS diagnosis and classification at MDS symposium #ASH20 @TxaviManCat @ho‚Ä¶,en,0.0,895.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,38.0,11.0,https://twitter.com/TxaviManCat/statuses/1334943457530548224,0.0,0.0,,0.0,0.0,0.0,11.0,38.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @gretnhe: Dr. Calvo team referenced for their contributions to MDS diagnosis and classification at MDS symposium #ASH20 @TxaviManCat @ho‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-04 17:37:30+00:00,"Ritcha Saxena, MD",http://twitter.com/,16.0,,1.3349147407878308e+18,,0.0,0.0,,"RT @smbenlazar: How I Think, How I Treat in the New Age of #AML Care: Personal Perspectives on New Evidence and Innovative Therapeutics  #A‚Ä¶",en,0.0,6875.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,12.0,4.0,https://twitter.com/RitchaSaxena/statuses/1334914740787830784,0.0,0.0,,0.0,0.0,0.0,4.0,12.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"RT @smbenlazar: How I Think, How I Treat in the New Age of #AML Care: Personal Perspectives on New Evidence and Innovative Therapeutics  #A‚Ä¶",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-04 20:06:07+00:00,"Ritcha Saxena, MD",http://twitter.com/,49.0,,1.3349521439634924e+18,,0.0,0.0,,RT @gretnhe: Dr. Calvo team referenced for their contributions to MDS diagnosis and classification at MDS symposium #ASH20 @TxaviManCat @ho‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,38.0,11.0,https://twitter.com/RitchaSaxena/statuses/1334952143963492354,0.0,0.0,,0.0,0.0,0.0,11.0,38.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @gretnhe: Dr. Calvo team referenced for their contributions to MDS diagnosis and classification at MDS symposium #ASH20 @TxaviManCat @ho‚Ä¶,true
VincentRK,"Professor, Mayo Clinic; Editor, Blood Cancer Journal; Oncologist; Health Costs; COVID threads @SurvivedCOVID Opinions=personal views https://t.co/TMq9vc5hZk",,"Rochester, MN, USA",,2020-12-04 14:59:03+00:00,Vincent Rajkumar,http://twitter.com/,1.0,,1.3348748664414495e+18,,0.0,0.0,,"7. Phase III trial results of ixazomib, len, dex (IRd) vs placebo, len, dex (Rd) in newly diagnosed myeloma. #ASH20‚Ä¶ https://t.co/CtM7OCcFd6",en,0.0,33590.0,,,0.0,VincentRK,1.3348748628637327e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/VincentRK/statuses/1334874866441449473,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"7. Phase III trial results of ixazomib, len, dex (IRd) vs placebo, len, dex (Rd) in newly diagnosed myeloma. #ASH20‚Ä¶ https://t.co/CtM7OCcFd6",true
ChowdaryStalin,Medical Oncologist at NIMS,,,,2020-12-04 10:27:02+00:00,Stalin Chowdary Bala,http://twitter.com/,187.0,,1.3348064108659958e+18,,0.0,0.0,,"RT @VincentRK: One of the most common questions myeloma patients ask me is: Should I get a stem cell transplant, and if so when should I do‚Ä¶",en,0.0,53.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,136.0,51.0,https://twitter.com/ChowdaryStalin/statuses/1334806410865995777,0.0,0.0,,0.0,0.0,0.0,51.0,136.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @VincentRK: One of the most common questions myeloma patients ask me is: Should I get a stem cell transplant, and if so when should I do‚Ä¶",false
islamsadek18,"physician, drug development & clinical research, Karate Champion, former Egypt national team player , Karate coach & Refree",,,,2020-11-26 19:33:05+00:00,Dr. Islam Sadek,http://twitter.com/,20.0,,1.332044725424185e+18,,0.0,0.0,,"RT @Dr_AmerZeidan: In this episode, we dig deep into diagnostic challenges and common misconceptions we encounter. We talk about the use of‚Ä¶",en,0.0,167.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,14.0,6.0,https://twitter.com/islamsadek18/statuses/1332044725424185350,0.0,0.0,,0.0,0.0,0.0,6.0,14.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"RT @Dr_AmerZeidan: In this episode, we dig deep into diagnostic challenges and common misconceptions we encounter. We talk about the use of‚Ä¶",true
BotCardiology,"Created by Doctor @KrittanawongMD. A bot that collects Tweets about cardiology, medicine and new science",,Kepler-452b,,2020-12-04 02:43:39+00:00,Cardiology Bot,http://twitter.com/,1.0,,1.3346897962839163e+18,,0.0,0.0,,"RT @TCTConference: Watch #TCTConnect on demand‚Äîany time, any place‚Äîthrough Oct. 18, 2021. 

Stream 110+ hours of educational programming at‚Ä¶",en,0.0,328.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/BotCardiology/statuses/1334689796283916291,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Disease Advocacy,0.0,0.0,1.0,"RT @TCTConference: Watch #TCTConnect on demand‚Äîany time, any place‚Äîthrough Oct. 18, 2021. 

Stream 110+ hours of educational programming at‚Ä¶",true
MediHumdani,"Director, BMT & Cellular Therapy Program @Froedtert & @MedicalCollege | Lymphoma | Clinical Trials | @CIBMTR | @BMTCTN | Personal views | Physician ‚â† Provider",,"Milwaukee, WI",,2020-11-26 23:35:36+00:00,Mehdi Hamadani,http://twitter.com/,13.0,,1.332105757689606e+18,,0.0,0.0,,An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 shows early signal of activity in Relapsed/Refractory‚Ä¶ https://t.co/ksfF2XwGVI,en,0.0,4590.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,13.0,https://twitter.com/MediHumdani/statuses/1332105757689606145,0.0,0.0,,0.0,0.0,0.0,13.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 shows early signal of activity in Relapsed/Refractory‚Ä¶ https://t.co/ksfF2XwGVI,true
gretnhe,"Hematologists, biologists, dermatologists and technicians who work together to transfer research to patients.",,"Barcelona, Espanya",,2020-12-08 17:54:11+00:00,Grup de Recerca Translacional Hematologia_GRETNHE,http://twitter.com/,40.0,,1.3363684927953592e+18,,0.0,0.0,,RT @ant_salar: Look at Abstract 2920 #ASH2020: different outcome in FL according to mTOR complex mutations and type of immunochemo. Nice jo‚Ä¶,en,0.0,172.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,32.0,8.0,https://twitter.com/gretnhe/statuses/1336368492795359241,0.0,0.0,,0.0,0.0,0.0,8.0,32.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @ant_salar: Look at Abstract 2920 #ASH2020: different outcome in FL according to mTOR complex mutations and type of immunochemo. Nice jo‚Ä¶,true
TxaviManCat,"Hematologist, MD, PhD. Hospital del Mar, IMIM, GRETNHE (Translational Research on Hematological Neoplasms Group).",,"El Clot, Barcelona",,2020-12-08 11:02:07+00:00,Xavier Calvo,http://twitter.com/,40.0,,1.3362647892664115e+18,,0.0,0.0,,RT @ant_salar: Look at Abstract 2920 #ASH2020: different outcome in FL according to mTOR complex mutations and type of immunochemo. Nice jo‚Ä¶,en,0.0,895.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,32.0,8.0,https://twitter.com/TxaviManCat/statuses/1336264789266411520,0.0,0.0,,0.0,0.0,0.0,8.0,32.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @ant_salar: Look at Abstract 2920 #ASH2020: different outcome in FL according to mTOR complex mutations and type of immunochemo. Nice jo‚Ä¶,true
CanerSaygin,"Heme-Onc Fellow @UChicago | Alumni of @OhioStateIMRes, @CCLRI | #Leukemia, #MDS, #CHIP physician-scientist. Tweets=own opinions.",,"Chicago, IL",,2020-12-06 18:00:48+00:00,"Caner Saygin, MD",http://twitter.com/,0.0,,1.3356453820811878e+18,,0.0,0.0,,Dr Aldoss showing early-phase data on Flotetuzumab (CD3xCD123) in primary refractory and early relapse #AML pts. It‚Ä¶ https://t.co/kM8E7c4uv8,en,0.0,743.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/CanerSaygin/statuses/1335645382081187842,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,Dr Aldoss showing early-phase data on Flotetuzumab (CD3xCD123) in primary refractory and early relapse #AML pts. It‚Ä¶ https://t.co/kM8E7c4uv8,false
juelmer,M.D. Pathologist.,,"Dominican Rep. & Florida, USA",,2020-12-08 14:59:26+00:00,juelmer,http://twitter.com/,3.0,,1.3363245146369516e+18,,0.0,0.0,,RT @GBT_news: Real-world experience data presented today at #ASH20 on the use of our FDA-approved medicine for treating #sicklecell disease‚Ä¶,en,0.0,199.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,2.0,1.0,https://twitter.com/juelmer/statuses/1336324514636951555,0.0,0.0,,0.0,0.0,0.0,1.0,2.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,RT @GBT_news: Real-world experience data presented today at #ASH20 on the use of our FDA-approved medicine for treating #sicklecell disease‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 01:52:43+00:00,"Ritcha Saxena, MD",http://twitter.com/,22.0,,1.3354017541255455e+18,,0.0,0.0,,RT @DanaFarberNews: #ASH20 News: Study reveals surprising benefit of DNMT3A clonal hematopoiesis in allogeneic stem cell or bone marrow tra‚Ä¶,en,0.0,6875.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,18.0,4.0,https://twitter.com/RitchaSaxena/statuses/1335401754125545474,0.0,0.0,,0.0,0.0,0.0,4.0,18.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @DanaFarberNews: #ASH20 News: Study reveals surprising benefit of DNMT3A clonal hematopoiesis in allogeneic stem cell or bone marrow tra‚Ä¶,true
Rfonsi1,"Interim Executive Director, Mayo Clinic Cancer Center. Myeloma doctor. Visiting Healthcare Fellow @GoldwaterInst. Tweets-own/RT not an endorsement",,,,2020-12-06 18:27:25+00:00,Rafael Fonseca MD,http://twitter.com/,53.0,,1.3356520772724e+18,,0.0,0.0,,RT @ninashah33: Bb2121: everything you wanted to know but were too afraid to ask: Ide-cel phase 1 long term FU‚Äî&gt; DOR 2y in responders and O‚Ä¶,en,0.0,8301.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,41.0,12.0,https://twitter.com/Rfonsi1/statuses/1335652077272399878,0.0,0.0,,0.0,0.0,0.0,12.0,41.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @ninashah33: Bb2121: everything you wanted to know but were too afraid to ask: Ide-cel phase 1 long term FU‚Äî&gt; DOR 2y in responders and O‚Ä¶,true
DrChrisHourigan,"Physician-Scientist, Acute Myeloid Leukemia Doctor, Human Immunologist, Laboratory PI, Measurable Residual Disease Advocate, Optimist.  Views are my own.",,"Washington, DC",,2020-12-08 14:57:28+00:00,Chris Hourigan,http://twitter.com/,26.0,,1.3363240194700124e+18,,0.0,0.0,,RT @RolandBWalter: Important data presented by @groboz from QUAZAR-001 showing CC-486 benefit in MRDneg and MRDpos remission. MRD response‚Ä¶,en,0.0,1169.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,23.0,3.0,https://twitter.com/DrChrisHourigan/statuses/1336324019470012417,0.0,0.0,,0.0,0.0,0.0,3.0,23.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @RolandBWalter: Important data presented by @groboz from QUAZAR-001 showing CC-486 benefit in MRDneg and MRDpos remission. MRD response‚Ä¶,true
ShakiraG_MBBS,BC Geriatrician + Hematologist + Oncologist. Assistant Professor + Clinical Researcher UNC-CH #geriheme #gerionc #mmsm #BlackWomanInMedicine. Tweets=my views,,"North Carolina, USA",,2020-12-06 16:15:28+00:00,Dr. Shakira J Grant MBBS,http://twitter.com/,5.0,,1.3356188718399775e+18,,0.0,0.0,,#ASH20 highlighting today's oral abstracts by members of the #geriheme @myCARG research communityüëáJoin session: 905‚Ä¶ https://t.co/XLwm14tgwf,en,0.0,340.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,5.0,https://twitter.com/ShakiraG_MBBS/statuses/1335618871839977475,0.0,0.0,,0.0,0.0,0.0,5.0,0.0,False,False,False,False,True,Disease Advocacy,0.0,0.0,1.0,#ASH20 highlighting today's oral abstracts by members of the #geriheme @myCARG research communityüëáJoin session: 905‚Ä¶ https://t.co/XLwm14tgwf,true
khouri_jack,Myeloma/BMT #hematologist #oncologist @ClevelandClinic Assistant Prof @CleClinicLCM @CWRUSOM | alum @TuftsMedSchool @Uni_Of_Balamand #mmsm #bmtsm,,"Cleveland, OH",,2020-12-06 01:48:44+00:00,"Jack Khouri, MD",http://twitter.com/,27.0,,1.3354007541574085e+18,,0.0,0.0,,RT @ninashah33: The O.G. BiTE (but better): AMG-701 with extended half life‚Äî&gt; 36% ORR in early cohorts but 5/6 (86%) ORR in most recent dos‚Ä¶,en,0.0,443.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,16.0,11.0,https://twitter.com/khouri_jack/statuses/1335400754157408256,0.0,0.0,,0.0,0.0,0.0,11.0,16.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @ninashah33: The O.G. BiTE (but better): AMG-701 with extended half life‚Äî&gt; 36% ORR in early cohorts but 5/6 (86%) ORR in most recent dos‚Ä¶,false
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-06 23:39:02+00:00,Lisa Palacios,http://twitter.com/,7.0,,1.3357304990300324e+18,,0.0,0.0,,"RT @AML_Hub: Congress| #ASH20| Farhad Ravandi, @LeukemiaMDA, presented data on a phase 1 study of vibecotamab that demonstrated a tolerable‚Ä¶",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,2.0,https://twitter.com/Lisa_Palacios/statuses/1335730499030032385,0.0,0.0,,0.0,0.0,0.0,2.0,5.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @AML_Hub: Congress| #ASH20| Farhad Ravandi, @LeukemiaMDA, presented data on a phase 1 study of vibecotamab that demonstrated a tolerable‚Ä¶",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 16:02:27+00:00,"Ritcha Saxena, MD",http://twitter.com/,5.0,,1.3356155961642107e+18,,0.0,0.0,,"RT @hemedoc: #ASH20 #leusm Tiong: Most received 3-4Cy chemo. 16% never become neg (threshold 2%) and directly progress from MRD+, 39% molec‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,1.0,https://twitter.com/RitchaSaxena/statuses/1335615596164210701,0.0,0.0,,0.0,0.0,0.0,1.0,4.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @hemedoc: #ASH20 #leusm Tiong: Most received 3-4Cy chemo. 16% never become neg (threshold 2%) and directly progress from MRD+, 39% molec‚Ä¶",true
NicoleKuderer,"Translational Oncologist (Biomarkers, Toxicities, Health Outcomes, Clinico-Genomic Big Data, @OncoAlert). Motto: ""Let's make a difference"". Tweets are my own.",,USA,,2020-12-06 01:23:07+00:00,Nicole Kuderer,http://twitter.com/,218.0,,1.3353943056917135e+18,,0.0,0.0,,"RT @hemedoc: #ASH20 #leusm Wei: We are all excited to have new therapeutic options in AML, but the overall message I get from this money sl‚Ä¶",en,0.0,6212.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,168.0,50.0,https://twitter.com/NicoleKuderer/statuses/1335394305691713538,0.0,0.0,,0.0,0.0,0.0,50.0,168.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"RT @hemedoc: #ASH20 #leusm Wei: We are all excited to have new therapeutic options in AML, but the overall message I get from this money sl‚Ä¶",true
khouri_jack,Myeloma/BMT #hematologist #oncologist @ClevelandClinic Assistant Prof @CleClinicLCM @CWRUSOM | alum @TuftsMedSchool @Uni_Of_Balamand #mmsm #bmtsm,,"Cleveland, OH",,2020-12-06 00:47:10+00:00,"Jack Khouri, MD",http://twitter.com/,19.0,,1.335385257097433e+18,,0.0,0.0,,"RT @ninashah33: Ready for MEDI! MEDI2228 BCMA ADC: 66% ORR at MTD, 60% photophobia ‚Äî&gt; would like to understand how this qualitatively compa‚Ä¶",en,0.0,443.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,14.0,5.0,https://twitter.com/khouri_jack/statuses/1335385257097433089,0.0,0.0,,0.0,0.0,0.0,5.0,14.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @ninashah33: Ready for MEDI! MEDI2228 BCMA ADC: 66% ORR at MTD, 60% photophobia ‚Äî&gt; would like to understand how this qualitatively compa‚Ä¶",true
pembeoltulu,"Pathologist(Associate professor), Meram Faculty of Medicine, Konya/Turkey; I lv #hemepath, #dermpath üíóMarried and have 4 children, RT/Tw are not medical advice",,T√ºrkiye,,2020-12-06 21:41:51+00:00,"Pembe Oltulu, MD",http://twitter.com/,8.0,,1.3357010110344763e+18,,0.0,0.0,,RT @CanerSaygin: Dr Lachowiez presenting data on FLAG-IDA + ven in both newly diagnosed and R/R pts. CRc is &gt;60% even in R/R setting and fM‚Ä¶,en,0.0,8940.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,4.0,https://twitter.com/pembeoltulu/statuses/1335701011034476544,0.0,0.0,,0.0,0.0,0.0,4.0,4.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @CanerSaygin: Dr Lachowiez presenting data on FLAG-IDA + ven in both newly diagnosed and R/R pts. CRc is &gt;60% even in R/R setting and fM‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 20:27:07+00:00,"Ritcha Saxena, MD",http://twitter.com/,1.0,,1.3356822030749e+18,,0.0,0.0,,RT @feldstej: 382 Mosaic Mutagenesis In Vivo Reveals Mutant Blood Stem Cells Intrinsically Resistant to Inflammatory Mediators in Clonal He‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/RitchaSaxena/statuses/1335682203074899973,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @feldstej: 382 Mosaic Mutagenesis In Vivo Reveals Mutant Blood Stem Cells Intrinsically Resistant to Inflammatory Mediators in Clonal He‚Ä¶,false
dgermain21,MD-PhD. 2nd year Heme/Onc fellow focused on lymphoma and leukemia. Physician-scientist-in-training. Tweet/RT not medical advice or endorsement.,,"St. Louis, MO",,2020-12-06 20:23:29+00:00,David A. Russler-Germain,http://twitter.com/,18.0,,1.3356812896141353e+18,,0.0,0.0,,"RT @lymphomahub: CONGRESS | #ASH20 | Rajat Bannerji, @RutgersCancer, presents the results from a phase I study investigating the CD20xCD3 b‚Ä¶",en,0.0,1612.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,14.0,4.0,https://twitter.com/dgermain21/statuses/1335681289614135298,0.0,0.0,,0.0,0.0,0.0,4.0,14.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @lymphomahub: CONGRESS | #ASH20 | Rajat Bannerji, @RutgersCancer, presents the results from a phase I study investigating the CD20xCD3 b‚Ä¶",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 16:28:32+00:00,"Ritcha Saxena, MD",http://twitter.com/,6.0,,1.3356221593398272e+18,,0.0,0.0,,"RT @LisaHicksMD: On now, report from the ASH RC COVID and hem malignancy registry, presented by Dr. Bill Wood at #ASH2020.  Age is a major‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,2.0,https://twitter.com/RitchaSaxena/statuses/1335622159339827202,0.0,0.0,,0.0,0.0,0.0,2.0,4.0,False,False,False,False,True,Cost of Care,0.0,0.0,1.0,"RT @LisaHicksMD: On now, report from the ASH RC COVID and hem malignancy registry, presented by Dr. Bill Wood at #ASH2020.  Age is a major‚Ä¶",true
olga45093932,"MD,PhD, hematologist of @NationalCancerInst of @oncohematologyDepart",,"Kiev, Ukraine",,2020-12-06 07:33:09+00:00,Olga,http://twitter.com/,218.0,,1.3354874255864177e+18,,0.0,0.0,,"RT @hemedoc: #ASH20 #leusm Wei: We are all excited to have new therapeutic options in AML, but the overall message I get from this money sl‚Ä¶",en,0.0,64.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,168.0,50.0,https://twitter.com/olga45093932/statuses/1335487425586417665,0.0,0.0,,0.0,0.0,0.0,50.0,168.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"RT @hemedoc: #ASH20 #leusm Wei: We are all excited to have new therapeutic options in AML, but the overall message I get from this money sl‚Ä¶",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 16:01:56+00:00,"Ritcha Saxena, MD",http://twitter.com/,5.0,,1.335615468548272e+18,,0.0,0.0,,RT @hemedoc: #ASH20 #leusm Short: high rate of death in CR (64%) obsd in age 70+; protocol further changed to elim chemo in this grp (now j‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,2.0,https://twitter.com/RitchaSaxena/statuses/1335615468548272128,0.0,0.0,,0.0,0.0,0.0,2.0,3.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @hemedoc: #ASH20 #leusm Short: high rate of death in CR (64%) obsd in age 70+; protocol further changed to elim chemo in this grp (now j‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 12:35:26+00:00,"Ritcha Saxena, MD",http://twitter.com/,12.0,,1.3355635008114156e+18,,0.0,0.0,,RT @DrRaulCordoba: #ASH20 Very high case fatality rate in both cohorts of patients with #CLL and #COVID„Éº19 analyzed: 30-34% https://t.co/4Z‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,9.0,3.0,https://twitter.com/RitchaSaxena/statuses/1335563500811415552,0.0,0.0,,0.0,0.0,0.0,3.0,9.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @DrRaulCordoba: #ASH20 Very high case fatality rate in both cohorts of patients with #CLL and #COVID„Éº19 analyzed: 30-34% https://t.co/4Z‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 16:02:10+00:00,"Ritcha Saxena, MD",http://twitter.com/,6.0,,1.335615525326639e+18,,0.0,0.0,,RT @hemedoc: #ASH20 #leusm Stelljes: Treatment of ALL in older pts historically assoc with poor outcomes. GMALL investigated use of Inotuzu‚Ä¶,en,0.0,6875.0,,,0.0,,,Negative,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,1.0,https://twitter.com/RitchaSaxena/statuses/1335615525326639105,0.0,0.0,,0.0,0.0,0.0,1.0,5.0,False,False,False,False,True,Financial Performance,0.0,1.0,0.0,RT @hemedoc: #ASH20 #leusm Stelljes: Treatment of ALL in older pts historically assoc with poor outcomes. GMALL investigated use of Inotuzu‚Ä¶,false
Joshuawolf,"Pediatrician, Infectious Diseases Physician and Researcher. Focus on infections in kids with cancer @StJudeResearch. Views are my own.",,"Memphis, TN",,2020-12-06 18:38:40+00:00,Josh Wolf,http://twitter.com/,13.0,,1.3356549118544568e+18,,0.0,0.0,,RT @AkshaySharmaMD: #ASH20 Richa Sharma from @StJudeResearch @marrowgenes lab #TBD #BMF https://t.co/TU4uUcXFWb,en,0.0,877.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,9.0,4.0,https://twitter.com/Joshuawolf/statuses/1335654911854456835,0.0,0.0,,0.0,0.0,0.0,4.0,9.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @AkshaySharmaMD: #ASH20 Richa Sharma from @StJudeResearch @marrowgenes lab #TBD #BMF https://t.co/TU4uUcXFWb,true
NBahlis,"Physician-scientist focused on multiple myeloma
Tweets are my own.",,,,2020-12-06 22:44:20+00:00,nizar jacques bahlis,http://twitter.com/,0.0,,1.3357167334919332e+18,,0.0,0.0,,"@SagarLonialMD Agree MM014 trial Len refractory in immediate last line mPFS 22 months, given it is a phase 2 update‚Ä¶ https://t.co/VZbb7lbSfh",en,0.0,436.0,,,0.0,SagarLonialMD,1.3357080165916467e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/NBahlis/statuses/1335716733491933184,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"@SagarLonialMD Agree MM014 trial Len refractory in immediate last line mPFS 22 months, given it is a phase 2 update‚Ä¶ https://t.co/VZbb7lbSfh",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 21:31:00+00:00,"Ritcha Saxena, MD",http://twitter.com/,7.0,,1.3356982786844836e+18,,0.0,0.0,,RT @DrMiguelPerales: Biology/preclinical data support JAK1 inhibition for GVHD ppx -  GRAVITAS-119 tested itacitanib for GVHD ppx with RIC‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,3.0,https://twitter.com/RitchaSaxena/statuses/1335698278684483584,0.0,0.0,,0.0,0.0,0.0,3.0,4.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @DrMiguelPerales: Biology/preclinical data support JAK1 inhibition for GVHD ppx -  GRAVITAS-119 tested itacitanib for GVHD ppx with RIC‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 21:12:43+00:00,"Ritcha Saxena, MD",http://twitter.com/,23.0,,1.335693677344256e+18,,0.0,0.0,,"RT @Mohty_EBMT: #ASH20 day 2: I have 2 general thoughts!
- Advances are not only about new drugs !
- Is there a regimen that cannot/shouldn‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,20.0,3.0,https://twitter.com/RitchaSaxena/statuses/1335693677344256007,0.0,0.0,,0.0,0.0,0.0,3.0,20.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @Mohty_EBMT: #ASH20 day 2: I have 2 general thoughts!
- Advances are not only about new drugs !
- Is there a regimen that cannot/shouldn‚Ä¶",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 16:26:48+00:00,"Ritcha Saxena, MD",http://twitter.com/,30.0,,1.335621724780585e+18,,0.0,0.0,,"RT @ASHClinicalNews: We spoke with Wendy Stock, 2020 @ASH_hematology Mentor Award recipient for clinical medicine, about the joy of cultiva‚Ä¶",en,0.0,6875.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,25.0,5.0,https://twitter.com/RitchaSaxena/statuses/1335621724780584960,0.0,0.0,,0.0,0.0,0.0,5.0,25.0,False,False,False,False,True,Financial Performance,1.0,0.0,0.0,"RT @ASHClinicalNews: We spoke with Wendy Stock, 2020 @ASH_hematology Mentor Award recipient for clinical medicine, about the joy of cultiva‚Ä¶",true
pkmadridista,"Pathologist, sports fan, madridista since 2003 interested in diplomacy",,,,2020-12-06 04:00:26+00:00,Pinakin (yes I am the Pathokin guy on insta),http://twitter.com/,48.0,,1.3354338944226714e+18,,0.0,0.0,,RT @_TanyaBondar_: Did you know an average human accumulates a million coding mutations in the blood stem cell pool by age 50? #ASH20: insi‚Ä¶,en,0.0,1400.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,42.0,6.0,https://twitter.com/pkmadridista/statuses/1335433894422671360,0.0,0.0,,0.0,0.0,0.0,6.0,42.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @_TanyaBondar_: Did you know an average human accumulates a million coding mutations in the blood stem cell pool by age 50? #ASH20: insi‚Ä¶,false
jenweiying,Haematologist working on https://t.co/fiMAwrCDXt - #FOAMed for students and trainees. Collaborators welcome. Tweets are my own opinion and not medical advice.,,Singapore,,2020-12-06 05:05:32+00:00,Wei Ying Jen,http://twitter.com/,218.0,,1.335450278376575e+18,,0.0,0.0,,"RT @hemedoc: #ASH20 #leusm Wei: We are all excited to have new therapeutic options in AML, but the overall message I get from this money sl‚Ä¶",en,0.0,251.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,168.0,50.0,https://twitter.com/jenweiying/statuses/1335450278376574976,0.0,0.0,,0.0,0.0,0.0,50.0,168.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"RT @hemedoc: #ASH20 #leusm Wei: We are all excited to have new therapeutic options in AML, but the overall message I get from this money sl‚Ä¶",true
LeukDocJZ,Oncologist | Associate Prof of Med @UNC_Lineberger | Clinical Trialist- #AML & #MDS | Alum of Osler Residency & Hopkins Oncology | Diehard NYG fan| Views my own,,"Chapel Hill, NC",,2020-12-06 02:42:25+00:00,Joshua Zeidner MD,http://twitter.com/,1.0,,1.3354142619133583e+18,,0.0,0.0,,"Check out results of our Biomarker-driven phase II exploratory cohort of Alvocidib, Cytarabine and Mitoxantrone in‚Ä¶ https://t.co/u7RSFZIQNc",en,0.0,710.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/LeukDocJZ/statuses/1335414261913358337,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"Check out results of our Biomarker-driven phase II exploratory cohort of Alvocidib, Cytarabine and Mitoxantrone in‚Ä¶ https://t.co/u7RSFZIQNc",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 16:34:46+00:00,"Ritcha Saxena, MD",http://twitter.com/,17.0,,1.3356237304925637e+18,,0.0,0.0,,"RT @PTMcGann: Catching up on abstract presentations from yesterday.

Super cool Gazelle instrument is designed to diagnose #anemia, #malari‚Ä¶",en,0.0,6875.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,13.0,4.0,https://twitter.com/RitchaSaxena/statuses/1335623730492563459,0.0,0.0,,0.0,0.0,0.0,4.0,13.0,False,False,False,False,True,Diagnostic Tools,1.0,0.0,0.0,"RT @PTMcGann: Catching up on abstract presentations from yesterday.

Super cool Gazelle instrument is designed to diagnose #anemia, #malari‚Ä¶",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 23:40:50+00:00,"Ritcha Saxena, MD",http://twitter.com/,185.0,,1.3357309535080243e+18,,0.0,0.0,,"RT @AlejoFraticelli: Call to all stem cell hematologists and immunologists!!

My lab, Quantitative Stem Cell Dynamics (https://t.co/j0ocWZY‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,124.0,61.0,https://twitter.com/RitchaSaxena/statuses/1335730953508024325,0.0,0.0,,0.0,0.0,0.0,61.0,124.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @AlejoFraticelli: Call to all stem cell hematologists and immunologists!!

My lab, Quantitative Stem Cell Dynamics (https://t.co/j0ocWZY‚Ä¶",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-06 21:57:38+00:00,Lisa Palacios,http://twitter.com/,11.0,,1.335704982054703e+18,,0.0,0.0,,"RT @lymphomahub: CONGRESS | #ASH20 | Sattva S. Neelapu, @MDAndersonNews, outlines the results from the interim analysis of the phase II ZUM‚Ä¶",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,9.0,2.0,https://twitter.com/Lisa_Palacios/statuses/1335704982054703107,0.0,0.0,,0.0,0.0,0.0,2.0,9.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @lymphomahub: CONGRESS | #ASH20 | Sattva S. Neelapu, @MDAndersonNews, outlines the results from the interim analysis of the phase II ZUM‚Ä¶",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 15:56:57+00:00,"Ritcha Saxena, MD",http://twitter.com/,6.0,,1.3356142136796815e+18,,0.0,0.0,,"RT @UCHemOncFellows: And our fellows have had a chance to contribute to #ASH20 educational manuscripts as well!

@CanerSaygin on therapies‚Ä¶",en,0.0,6875.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,2.0,https://twitter.com/RitchaSaxena/statuses/1335614213679681538,0.0,0.0,,0.0,0.0,0.0,2.0,4.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"RT @UCHemOncFellows: And our fellows have had a chance to contribute to #ASH20 educational manuscripts as well!

@CanerSaygin on therapies‚Ä¶",false
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 20:23:04+00:00,"Ritcha Saxena, MD",http://twitter.com/,3.0,,1.3356811821686497e+18,,0.0,0.0,,RT @feldstej: 388 Characteristics and Prognostic Effects of IDH Mutations across the Age Spectrum in AML: A Collaborative Analysis from COG‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/RitchaSaxena/statuses/1335681182168649731,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,RT @feldstej: 388 Characteristics and Prognostic Effects of IDH Mutations across the Age Spectrum in AML: A Collaborative Analysis from COG‚Ä¶,true
CanerSaygin,"Heme-Onc Fellow @UChicago | Alumni of @OhioStateIMRes, @CCLRI | #Leukemia, #MDS, #CHIP physician-scientist. Tweets=own opinions.",,"Chicago, IL",,2020-12-06 04:11:58+00:00,"Caner Saygin, MD",http://twitter.com/,2.0,,1.335436796797313e+18,,0.0,0.0,,"I am so happy to see Dr Stock receiving #ASH20 Mentor Award. She is an outstanding physician, scientist, teacher, m‚Ä¶ https://t.co/tCIuzT3EfV",en,0.0,743.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/CanerSaygin/statuses/1335436796797313024,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Financial Performance,1.0,0.0,0.0,"I am so happy to see Dr Stock receiving #ASH20 Mentor Award. She is an outstanding physician, scientist, teacher, m‚Ä¶ https://t.co/tCIuzT3EfV",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 21:29:41+00:00,"Ritcha Saxena, MD",http://twitter.com/,8.0,,1.3356979475819438e+18,,0.0,0.0,,"RT @SeattleCCA: Coming up at #ASH20: Oral presentation with @stephanieleemd, MD, MPH - ""358 Phase 1 Study of Axatilimab (SNDX-6352), a CSF-‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,3.0,https://twitter.com/RitchaSaxena/statuses/1335697947581943819,0.0,0.0,,0.0,0.0,0.0,3.0,5.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @SeattleCCA: Coming up at #ASH20: Oral presentation with @stephanieleemd, MD, MPH - ""358 Phase 1 Study of Axatilimab (SNDX-6352), a CSF-‚Ä¶",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 01:47:23+00:00,"Ritcha Saxena, MD",http://twitter.com/,12.0,,1.33540041060617e+18,,0.0,0.0,,RT @ASH_hematology: Dr. Andrew Roberts¬†will now present the¬†Ham-Wasserman Lecture¬†on Therapeutic Development and Current Uses of BCL-2 Inhi‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,11.0,1.0,https://twitter.com/RitchaSaxena/statuses/1335400410606170114,0.0,0.0,,0.0,0.0,0.0,1.0,11.0,False,False,False,False,True,Drug Discovery,0.0,0.0,1.0,RT @ASH_hematology: Dr. Andrew Roberts¬†will now present the¬†Ham-Wasserman Lecture¬†on Therapeutic Development and Current Uses of BCL-2 Inhi‚Ä¶,true
AndreaAnampaG,"Medstudent @UNMSM_ with OCD ‚Ä¢ @ASCO & @AMWAdoctors Social Media
@CPsolvers Team Member ‚Ä¢ #Globaloncology #WomenInMedicine #MedEd #SurvOnc üáµüá™ #IMG üåà she/ella",,"Lima, Peru",,2020-12-06 18:05:30+00:00,Andrea Anampa-Guzm√°n,http://twitter.com/,0.0,,1.3356465636543816e+18,,0.0,0.0,,"Quality of Life after Diagnosis in Survivors of Aggressive Lymphomas by Dr. Robert  M. Kraft

#survivorship‚Ä¶ https://t.co/iBeaIWEfD8",en,0.0,1908.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/AndreaAnampaG/statuses/1335646563654381569,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"Quality of Life after Diagnosis in Survivors of Aggressive Lymphomas by Dr. Robert  M. Kraft

#survivorship‚Ä¶ https://t.co/iBeaIWEfD8",true
kyleLogan1997,XULA 21‚Äô Hampton MS med science 23‚Äô | sports analytics enthusiast | former collegiate runner| patient transporter| future MDüöëhablo espa√±ol üá™üá∏üáµüá¶,,"Hampton, VA",,2020-12-06 22:32:55+00:00,"Kyle Logan, EMT",http://twitter.com/,17.0,,1.335713863061418e+18,,0.0,0.0,,"RT @OncLive: Allogeneic Off-the-Shelf UCART22 Product Shows Early Activity, Tolerability in CD22+ B-Cell Relapsed/Refractory ALL
@MDAnderso‚Ä¶",en,0.0,478.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,13.0,4.0,https://twitter.com/kyleLogan1997/statuses/1335713863061417991,0.0,0.0,,0.0,0.0,0.0,4.0,13.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @OncLive: Allogeneic Off-the-Shelf UCART22 Product Shows Early Activity, Tolerability in CD22+ B-Cell Relapsed/Refractory ALL
@MDAnderso‚Ä¶",false
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 15:55:11+00:00,"Ritcha Saxena, MD",http://twitter.com/,84.0,,1.3356137698887516e+18,,0.0,0.0,,"RT @hemedoc: #ASH20 #leusm Levis: I don‚Äôt know who needs to hear this, but there really is no role for intensive chemotherapy in TP53 mutat‚Ä¶",en,0.0,6875.0,,,0.0,,,Negative,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,65.0,19.0,https://twitter.com/RitchaSaxena/statuses/1335613769888751618,0.0,0.0,,0.0,0.0,0.0,19.0,65.0,False,False,False,False,True,Innovation,0.0,1.0,0.0,"RT @hemedoc: #ASH20 #leusm Levis: I don‚Äôt know who needs to hear this, but there really is no role for intensive chemotherapy in TP53 mutat‚Ä¶",true
MalinHultcrantz,"MD PhD, Specialized in Multiple Myeloma. Memorial Sloan Kettering Cancer Center. Karolinska Institute. Tweets are my own.",,,,2020-12-06 18:22:45+00:00,Malin Hultcrantz MD PhD,http://twitter.com/,5.0,,1.3356509058579415e+18,,0.0,0.0,,Great news! The first 10 patients treated with CRISPR edited stem cells (CTX001) are transfusion independent and an‚Ä¶ https://t.co/u44EWNZBLn,en,0.0,908.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,5.0,https://twitter.com/MalinHultcrantz/statuses/1335650905857941505,0.0,0.0,,0.0,0.0,0.0,5.0,0.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,Great news! The first 10 patients treated with CRISPR edited stem cells (CTX001) are transfusion independent and an‚Ä¶ https://t.co/u44EWNZBLn,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 16:04:12+00:00,"Ritcha Saxena, MD",http://twitter.com/,21.0,,1.3356160384535224e+18,,0.0,0.0,,"RT @SeattleCCA: Today at #ASH20: Poster session with Ryan C. Lynch, MD (2nd author) - ""1632 Severity of Sars-Cov-2 Infection in Patients wi‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,17.0,4.0,https://twitter.com/RitchaSaxena/statuses/1335616038453522433,0.0,0.0,,0.0,0.0,0.0,4.0,17.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"RT @SeattleCCA: Today at #ASH20: Poster session with Ryan C. Lynch, MD (2nd author) - ""1632 Severity of Sars-Cov-2 Infection in Patients wi‚Ä¶",true
tanyawildes,"Hematologist/oncologist/geriatrician, studying the intersection of Myeloma & other cancers with Aging. Woman of faith/wife of Mr Doctor Wildes/Mom.",,,,2020-12-06 20:49:36+00:00,Tanya Wildes MD,http://twitter.com/,40.0,,1.335687860326953e+18,,0.0,0.0,,RT @RahmaWarsameMD: Promising results from phase 1 VSV-IFNb-NIS in pts with relapsed refractory hem malignancies. Strongest signal in TCL.‚Ä¶,en,0.0,2800.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,30.0,10.0,https://twitter.com/tanyawildes/statuses/1335687860326952967,0.0,0.0,,0.0,0.0,0.0,10.0,30.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @RahmaWarsameMD: Promising results from phase 1 VSV-IFNb-NIS in pts with relapsed refractory hem malignancies. Strongest signal in TCL.‚Ä¶,true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-12-06 22:42:42+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,1.0,,1.3357163211541217e+18,,0.0,0.0,,#ASH20 #leusm Rubnitz: Interesting high rate of CR in ETP-ALL (5/7). BH3 profiling being investigated for correlati‚Ä¶ https://t.co/xadTkNpxyN,en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/hemedoc/statuses/1335716321154121729,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,#ASH20 #leusm Rubnitz: Interesting high rate of CR in ETP-ALL (5/7). BH3 profiling being investigated for correlati‚Ä¶ https://t.co/xadTkNpxyN,true
drdavidoconnor,"CRUK-funded Clinician-Scientist @uclcancer, Paediatric Haematologist @GreatOrmondSt. Researching childhood leukaemia.",,"London, England",,2020-12-06 20:31:21+00:00,David O'Connor,http://twitter.com/,1.0,,1.3356832683314913e+18,,0.0,0.0,,A typically passionate talk from @drbobphillips on improving symptoms in children undergoing cancer treatment. Who‚Ä¶ https://t.co/9Iq6e2xtB8,en,0.0,318.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/drdavidoconnor/statuses/1335683268331491328,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,A typically passionate talk from @drbobphillips on improving symptoms in children undergoing cancer treatment. Who‚Ä¶ https://t.co/9Iq6e2xtB8,false
diegoah66,"Hematologist-Oncologist @UVMMedCenter, Assistant Professor of Medicine @UVMLarnerMed | üáµüá™üá∫üá∏",,"Burlington, VT",,2020-12-06 17:48:27+00:00,Diego Adrianzen-Herrera,http://twitter.com/,0.0,,1.3356422714888602e+18,,0.0,0.0,,Phase 1b results First-in-Class Anti-CD47 Antibody Magrolimab + Azacitidine in AML Patients. Promising results in T‚Ä¶ https://t.co/GeD69suDUh,en,0.0,187.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/diegoah66/statuses/1335642271488860164,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,Phase 1b results First-in-Class Anti-CD47 Antibody Magrolimab + Azacitidine in AML Patients. Promising results in T‚Ä¶ https://t.co/GeD69suDUh,true
drjgauthier,"MD, MSc, Assistant Professor @fredhutch @UW focused on #CARTcell #immunotherapy #tcellrx 
Interests also include #rstats #bmtsm #epitwitter #bayes",,"Seattle, WA",,2020-12-06 18:12:30+00:00,Jordan Gauthier,http://twitter.com/,5.0,,1.3356483254715884e+18,,0.0,0.0,,"#ASH20 355 Dr. Pidala @MoffittNews 
Preclinical and Phase I Trial Results of Biological and Clinical Impact of JAK2‚Ä¶ https://t.co/yqo5d94ulv",en,0.0,3295.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,5.0,https://twitter.com/drjgauthier/statuses/1335648325471588353,0.0,0.0,,0.0,0.0,0.0,5.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"#ASH20 355 Dr. Pidala @MoffittNews 
Preclinical and Phase I Trial Results of Biological and Clinical Impact of JAK2‚Ä¶ https://t.co/yqo5d94ulv",true
Dr_Daniel_Molin,Oncologist at Uppsala university hospital. Chair of the Swedish lymphoma group (SLG) and the Swedish Hodgkin lymphoma group.,,Uppsala,,2020-12-06 08:19:20+00:00,Daniel Molin,http://twitter.com/,0.0,,1.3354990479064474e+18,,0.0,0.0,,PD-1 inhibitors are the best that happened for cHL patients since combination chemo and RT. BV next in line. Now le‚Ä¶ https://t.co/HBnbUNpMuZ,en,0.0,193.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/Dr_Daniel_Molin/statuses/1335499047906447362,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,PD-1 inhibitors are the best that happened for cHL patients since combination chemo and RT. BV next in line. Now le‚Ä¶ https://t.co/HBnbUNpMuZ,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 23:51:58+00:00,"Ritcha Saxena, MD",http://twitter.com/,38.0,,1.335733754648793e+18,,0.0,0.0,,RT @jjkiladjian: Happy to show large superiority of #ropeginterferon vs standard treatment to eradicate JAK2 mutant cells in selected patie‚Ä¶,en,0.0,6875.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,31.0,7.0,https://twitter.com/RitchaSaxena/statuses/1335733754648793088,0.0,0.0,,0.0,0.0,0.0,7.0,31.0,False,False,False,False,True,Clinical Trials,1.0,0.0,0.0,RT @jjkiladjian: Happy to show large superiority of #ropeginterferon vs standard treatment to eradicate JAK2 mutant cells in selected patie‚Ä¶,true
MattPPlayer,Husband to Eloise. Christian. Haematologist. Interested in Global Haematology. Sports fan.,,Malawi,,2020-12-06 15:20:25+00:00,Matthew Player,http://twitter.com/,2.0,,1.335605020163707e+18,,0.0,0.0,,RT @TheLancetHaem: #ASH20 Manuela Albisetti presents results of the phase 2-3 DIVERSITY trial showing non-inferiority of dabigatran vs SOC‚Ä¶,en,0.0,41.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,1.0,1.0,https://twitter.com/MattPPlayer/statuses/1335605020163706880,0.0,0.0,,0.0,0.0,0.0,1.0,1.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @TheLancetHaem: #ASH20 Manuela Albisetti presents results of the phase 2-3 DIVERSITY trial showing non-inferiority of dabigatran vs SOC‚Ä¶,true
drjsporter,Licensed Psychologist | Sickle Cell Researcher @stjuderesearch | Alum @UVA @FloridaState @VCU @NUFeinbergMed | Tweets are my own.,,"Memphis, TN",,2020-12-06 14:09:41+00:00,"Dr. Jerlym Porter, PhD",http://twitter.com/,13.0,,1.335587216702255e+18,,0.0,0.0,,RT @AkshaySharmaMD: #ASH20 Richa Sharma from @StJudeResearch @marrowgenes lab #TBD #BMF,en,0.0,447.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,9.0,4.0,https://twitter.com/drjsporter/statuses/1335587216702255106,0.0,0.0,,0.0,0.0,0.0,4.0,9.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @AkshaySharmaMD: #ASH20 Richa Sharma from @StJudeResearch @marrowgenes lab #TBD #BMF,false
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 21:17:13+00:00,"Ritcha Saxena, MD",http://twitter.com/,6.0,,1.3356948097097236e+18,,0.0,0.0,,"RT @MAWJNJ: Great job by Dr Chari @IcahnMountSinai in presenting the first results from the Phase 1 #talquetamab study #ASH20 #janssen 

ht‚Ä¶",en,0.0,6875.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,2.0,https://twitter.com/RitchaSaxena/statuses/1335694809709723648,0.0,0.0,,0.0,0.0,0.0,2.0,4.0,False,False,False,False,True,Clinical Trials,1.0,0.0,0.0,"RT @MAWJNJ: Great job by Dr Chari @IcahnMountSinai in presenting the first results from the Phase 1 #talquetamab study #ASH20 #janssen 

ht‚Ä¶",true
graham74GC,Lymphoma specialist at Oxford Cancer and Haematology centre. Haematologist and clinical trialist. Chair of UK Hodgkin and T-cell study groups.,,Opinions are mine,,2020-12-06 23:03:46+00:00,Graham Collins,http://twitter.com/,0.0,,1.335721624146948e+18,,0.0,0.0,,"Thoughts:
- incredibly good CMR
- no relapses is v promising
- rather than just adding pembro Mx, I do wish a rando‚Ä¶ https://t.co/xT7zML4K3P",en,0.0,6091.0,,,0.0,graham74GC,1.3357216216555233e+18,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/graham74GC/statuses/1335721624146948097,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnosis Progression,1.0,0.0,0.0,"Thoughts:
- incredibly good CMR
- no relapses is v promising
- rather than just adding pembro Mx, I do wish a rando‚Ä¶ https://t.co/xT7zML4K3P",true
Lachelle_Dawn,heme-onc fellow | physician-scientist | racial justice & health equity | views are mine | there will be typos | i tweet what i want | pronouns: she/her/hers,,"Boston, MA",,2020-12-06 15:37:36+00:00,Lachelle Dawn,http://twitter.com/,8.0,,1.3356093419242824e+18,,0.0,0.0,,Results of A-TREAT: randomized placebo-controlled study to evaluate the safety &amp; efficacy of TXA in preventing blee‚Ä¶ https://t.co/O8I1JiiZoo,en,0.0,3338.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,8.0,https://twitter.com/Lachelle_Dawn/statuses/1335609341924282368,0.0,0.0,,0.0,0.0,0.0,8.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,Results of A-TREAT: randomized placebo-controlled study to evaluate the safety &amp; efficacy of TXA in preventing blee‚Ä¶ https://t.co/O8I1JiiZoo,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 01:18:57+00:00,"Ritcha Saxena, MD",http://twitter.com/,3.0,,1.335393258348929e+18,,0.0,0.0,,RT @drsangeetmd: üëâüèº Can Ven be added to intensive chemo - Seems to be Yes - Trial being led by @DrHKantarjian @TapKadia @garciamanero @musa‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,1.0,2.0,https://twitter.com/RitchaSaxena/statuses/1335393258348929024,0.0,0.0,,0.0,0.0,0.0,2.0,1.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @drsangeetmd: üëâüèº Can Ven be added to intensive chemo - Seems to be Yes - Trial being led by @DrHKantarjian @TapKadia @garciamanero @musa‚Ä¶,true
CanerSaygin,"Heme-Onc Fellow @UChicago | Alumni of @OhioStateIMRes, @CCLRI | #Leukemia, #MDS, #CHIP physician-scientist. Tweets=own opinions.",,"Chicago, IL",,2020-12-06 18:13:04+00:00,"Caner Saygin, MD",http://twitter.com/,4.0,,1.3356484669834158e+18,,0.0,0.0,,Dr Lachowiez presenting data on FLAG-IDA + ven in both newly diagnosed and R/R pts. CRc is &gt;60% even in R/R setting‚Ä¶ https://t.co/gA6dKUlby8,en,0.0,743.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,4.0,https://twitter.com/CanerSaygin/statuses/1335648466983415809,0.0,0.0,,0.0,0.0,0.0,4.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,Dr Lachowiez presenting data on FLAG-IDA + ven in both newly diagnosed and R/R pts. CRc is &gt;60% even in R/R setting‚Ä¶ https://t.co/gA6dKUlby8,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 15:57:16+00:00,"Ritcha Saxena, MD",http://twitter.com/,8.0,,1.335614292805247e+18,,0.0,0.0,,RT @CanerSaygin: Dr deBotton presenting interesting data on combined SY-1425 (RARA agonist) + Aza in newly diagnosed unfit #AML pts. RARA o‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,2.0,https://twitter.com/RitchaSaxena/statuses/1335614292805246981,0.0,0.0,,0.0,0.0,0.0,2.0,6.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @CanerSaygin: Dr deBotton presenting interesting data on combined SY-1425 (RARA agonist) + Aza in newly diagnosed unfit #AML pts. RARA o‚Ä¶,false
KlausMetzelerMD,"Physician-scientist, leukemia geneticist, amateur photographer",,"Leipzig, Germany",,2020-12-06 18:44:28+00:00,Klaus Metzeler,http://twitter.com/,0.0,,1.335656368515199e+18,,0.0,0.0,,"Lots of exciting new AML regimens in Phase 2 @ #ASH20 - Magrolimab/Aza, Ven/Gilteritinib, Flotetuzumab... 
People a‚Ä¶ https://t.co/EMS098VcuH",en,0.0,736.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/KlausMetzelerMD/statuses/1335656368515198976,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,1.0,0.0,0.0,"Lots of exciting new AML regimens in Phase 2 @ #ASH20 - Magrolimab/Aza, Ven/Gilteritinib, Flotetuzumab... 
People a‚Ä¶ https://t.co/EMS098VcuH",true
DrChrisHourigan,"Physician-Scientist, Acute Myeloid Leukemia Doctor, Human Immunologist, Laboratory PI, Measurable Residual Disease Advocate, Optimist.  Views are my own.",,"Washington, DC",,2020-12-06 23:03:54+00:00,Chris Hourigan,http://twitter.com/,218.0,,1.3357216595217695e+18,,0.0,0.0,,"RT @hemedoc: #ASH20 #leusm Wei: We are all excited to have new therapeutic options in AML, but the overall message I get from this money sl‚Ä¶",en,0.0,1169.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,168.0,50.0,https://twitter.com/DrChrisHourigan/statuses/1335721659521769476,0.0,0.0,,0.0,0.0,0.0,50.0,168.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"RT @hemedoc: #ASH20 #leusm Wei: We are all excited to have new therapeutic options in AML, but the overall message I get from this money sl‚Ä¶",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-06 12:50:07+00:00,Lisa Palacios,http://twitter.com/,5.0,,1.335567194986582e+18,,0.0,0.0,,RT @hemedoc: #ASH20 #leusm Short: high rate of death in CR (64%) obsd in age 70+; protocol further changed to elim chemo in this grp (now j‚Ä¶,en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,2.0,https://twitter.com/Lisa_Palacios/statuses/1335567194986582017,0.0,0.0,,0.0,0.0,0.0,2.0,3.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @hemedoc: #ASH20 #leusm Short: high rate of death in CR (64%) obsd in age 70+; protocol further changed to elim chemo in this grp (now j‚Ä¶,true
GlopesMd,"Cancer Doctor and Researcher, Faculty @SylvesterCancer @UnivMiami. Helping improve Cancer Control in LMICs. Editor-in-Chief JCO Global Oncology @ASCO",,"Miami, FL",,2020-12-06 17:07:57+00:00,gilberto lopes,http://twitter.com/,11.0,,1.3356320789275156e+18,,0.0,0.0,,RT @SylvesterCancer: Now at #ASH20:  Poster (#2092) by @SylvesterCancer research  team on a TFR1-Targeted Doxorubicin Nanocarrier for DLBCL‚Ä¶,en,0.0,31610.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,9.0,2.0,https://twitter.com/GlopesMd/statuses/1335632078927515649,0.0,0.0,,0.0,0.0,0.0,2.0,9.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,RT @SylvesterCancer: Now at #ASH20:  Poster (#2092) by @SylvesterCancer research  team on a TFR1-Targeted Doxorubicin Nanocarrier for DLBCL‚Ä¶,true
glimelius,"Lymphoma researcher, MD, oncologist in Sweden. #Hodgkin #MCL. Nordic MCL group member. I also love reading and gymnastics.",,"Uppsala, Sverige",,2020-12-06 22:16:05+00:00,Ingrid Glimelius,http://twitter.com/,0.0,,1.3357096249813934e+18,,0.0,0.0,,Impressive chart review looking into CNS relapse risk in #DLBCL Methotrexate do not see to be the full solution‚¨áÔ∏è‚Ä¶ https://t.co/Dp3Kkayrac,en,0.0,186.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/glimelius/statuses/1335709624981393416,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,Impressive chart review looking into CNS relapse risk in #DLBCL Methotrexate do not see to be the full solution‚¨áÔ∏è‚Ä¶ https://t.co/Dp3Kkayrac,true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-06 22:29:51+00:00,Lisa Palacios,http://twitter.com/,19.0,,1.3357130889229353e+18,,0.0,0.0,,"RT @MDAndersonNews: ‚ÄúWe are very encouraged that every patient on the study achieved a complete remission and 97% achieved MRD negativity,‚Äù‚Ä¶",en,0.0,657.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,17.0,2.0,https://twitter.com/Lisa_Palacios/statuses/1335713088922935298,0.0,0.0,,0.0,0.0,0.0,2.0,17.0,False,False,False,False,True,Diagnosis Progression,1.0,0.0,0.0,"RT @MDAndersonNews: ‚ÄúWe are very encouraged that every patient on the study achieved a complete remission and 97% achieved MRD negativity,‚Äù‚Ä¶",false
VincentRK,"Professor, Mayo Clinic; Editor, Blood Cancer Journal; Oncologist; Health Costs; COVID threads @SurvivedCOVID Opinions=personal views https://t.co/TMq9vc5hZk",,"Rochester, MN, USA",,2020-12-06 22:30:57+00:00,Vincent Rajkumar,http://twitter.com/,40.0,,1.3357133661202596e+18,,0.0,0.0,,RT @RahmaWarsameMD: Promising results from phase 1 VSV-IFNb-NIS in pts with relapsed refractory hem malignancies. Strongest signal in TCL.‚Ä¶,en,0.0,33590.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,30.0,10.0,https://twitter.com/VincentRK/statuses/1335713366120259586,0.0,0.0,,0.0,0.0,0.0,10.0,30.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @RahmaWarsameMD: Promising results from phase 1 VSV-IFNb-NIS in pts with relapsed refractory hem malignancies. Strongest signal in TCL.‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 16:08:14+00:00,"Ritcha Saxena, MD",http://twitter.com/,6.0,,1.335617053131223e+18,,0.0,0.0,,"RT @SeattleCCA: Coming up at #ASH20: Scientific program with Aude G. Chapuis, MD - ""Challenges in #CellTherapy: Relapse and Toxicities"" htt‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,1.0,https://twitter.com/RitchaSaxena/statuses/1335617053131223042,0.0,0.0,,0.0,0.0,0.0,1.0,5.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @SeattleCCA: Coming up at #ASH20: Scientific program with Aude G. Chapuis, MD - ""Challenges in #CellTherapy: Relapse and Toxicities"" htt‚Ä¶",true
Areejmd,An oncologist with a passion to improve the quality of life and care of patients with hematologic malignancies #ASH #PallOnc #CIBMTR #ASBMT @MGHCancerCenter,,"Boston, MA",,2020-12-06 01:47:46+00:00,Areej El-Jawahri,http://twitter.com/,84.0,,1.3354005108960911e+18,,0.0,0.0,,"RT @hemedoc: #ASH20 #leusm Levis: I don‚Äôt know who needs to hear this, but there really is no role for intensive chemotherapy in TP53 mutat‚Ä¶",en,0.0,957.0,,,0.0,,,Negative,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,65.0,19.0,https://twitter.com/Areejmd/statuses/1335400510896091136,0.0,0.0,,0.0,0.0,0.0,19.0,65.0,False,False,False,False,True,Innovation,0.0,1.0,0.0,"RT @hemedoc: #ASH20 #leusm Levis: I don‚Äôt know who needs to hear this, but there really is no role for intensive chemotherapy in TP53 mutat‚Ä¶",true
EduardoFlavioO1,"MD, Hematologist, Brasilia/Brasil, main interest in CLL, Lymphoma and MM; dad and husband; tweets are my own opinion",,"Bras√≠lia, Brasil",,2020-12-06 13:17:55+00:00,Eduardo Flavio Oliveira Ribeiro,http://twitter.com/,0.0,,1.3355741905865564e+18,,0.0,0.0,,#ASH20 Educational Program. Fantastic analysis on different outcomes comparing references centers and private hospi‚Ä¶ https://t.co/krk7fePBkl,en,0.0,545.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/EduardoFlavioO1/statuses/1335574190586556417,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Disease Advocacy,1.0,0.0,0.0,#ASH20 Educational Program. Fantastic analysis on different outcomes comparing references centers and private hospi‚Ä¶ https://t.co/krk7fePBkl,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 23:56:03+00:00,"Ritcha Saxena, MD",http://twitter.com/,6.0,,1.3357347803784397e+18,,0.0,0.0,,"RT @BrunoPaiva_UNAV: Undetectable #MRD is prognostic in elderly #AML patients treated with semi-intensive chemo or HMA, but significant met‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,3.0,https://twitter.com/RitchaSaxena/statuses/1335734780378439680,0.0,0.0,,0.0,0.0,0.0,3.0,3.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @BrunoPaiva_UNAV: Undetectable #MRD is prognostic in elderly #AML patients treated with semi-intensive chemo or HMA, but significant met‚Ä¶",true
HollenhorstM,"Physician-Scientist, Hematologist, Transfusion Medicine Specialist @StanfordPath @Stanford_ChEMH @CarolynBertozzi l Alum @BrighamWomens @HarvardMed @MIT_HST",,"Stanford, CA",,2020-12-06 23:03:40+00:00,"Marie Hollenhorst, MD, PhD",http://twitter.com/,0.0,,1.3357215978737336e+18,,0.0,0.0,,"Wow, this was beautiful, poignant, and inspirational. @bobmass is a masterful speaker who demonstrates through his‚Ä¶ https://t.co/7Jqj8UE1CO",en,0.0,409.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/HollenhorstM/statuses/1335721597873733632,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,"Wow, this was beautiful, poignant, and inspirational. @bobmass is a masterful speaker who demonstrates through his‚Ä¶ https://t.co/7Jqj8UE1CO",false
NicoleKuderer,"Translational Oncologist (Biomarkers, Toxicities, Health Outcomes, Clinico-Genomic Big Data, @OncoAlert). Motto: ""Let's make a difference"". Tweets are my own.",,USA,,2020-12-06 18:49:46+00:00,Nicole Kuderer,http://twitter.com/,73.0,,1.335657701490053e+18,,0.0,0.0,,"RT @MPaiMD: @MaryCushmanMD There‚Äôs a lot of novelty at #ASH20 this year - negative trials, featuring more speakers of historically excluded‚Ä¶",en,0.0,6212.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,60.0,13.0,https://twitter.com/NicoleKuderer/statuses/1335657701490053120,0.0,0.0,,0.0,0.0,0.0,13.0,60.0,False,False,False,False,True,Thought Leadership,0.0,0.0,1.0,"RT @MPaiMD: @MaryCushmanMD There‚Äôs a lot of novelty at #ASH20 this year - negative trials, featuring more speakers of historically excluded‚Ä¶",true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-12-06 07:01:20+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,1.0,,1.335479420954366e+18,,0.0,0.0,,#ASH20 #leusm Stelljes: Treatment of ALL in older pts historically assoc with poor outcomes. GMALL investigated use‚Ä¶ https://t.co/CdxMnUL8NV,en,0.0,4813.0,,,0.0,,,Negative,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/hemedoc/statuses/1335479420954365953,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Financial Performance,0.0,1.0,0.0,#ASH20 #leusm Stelljes: Treatment of ALL in older pts historically assoc with poor outcomes. GMALL investigated use‚Ä¶ https://t.co/CdxMnUL8NV,true
szusmani,"Division Chief, Plasma Cell Disorders|Director, Clinical Research Hem Malignancies | Views are my own | RT not endorsement | Physician ‚â† Provider",,"Charlotte, NC",,2020-12-06 00:48:53+00:00,Saad Z. Usmani MD MBA FACP (he/his/him),http://twitter.com/,0.0,,1.335385688674607e+18,,0.0,0.0,,"Absolutely, it‚Äôs been fantastic working with Ben (https://t.co/bqF9PfUoYg), I like the less frequent dosing and low‚Ä¶ https://t.co/iO832kKLDg",en,0.0,5512.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/szusmani/statuses/1335385688674607107,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,"Absolutely, it‚Äôs been fantastic working with Ben (https://t.co/bqF9PfUoYg), I like the less frequent dosing and low‚Ä¶ https://t.co/iO832kKLDg",true
AndreaAnampaG,"Medstudent @UNMSM_ with OCD ‚Ä¢ @ASCO & @AMWAdoctors Social Media
@CPsolvers Team Member ‚Ä¢ #Globaloncology #WomenInMedicine #MedEd #SurvOnc üáµüá™ #IMG üåà she/ella",,"Lima, Peru",,2020-12-06 19:19:07+00:00,Andrea Anampa-Guzm√°n,http://twitter.com/,14.0,,1.3356650892660122e+18,,0.0,0.0,,RT @Anand_88_Patel: Check out our #ASH20 talk on cytogenetics/outcomes of pts developing myeloid neoplasms after radiation therapy alone! T‚Ä¶,en,0.0,1908.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,4.0,https://twitter.com/AndreaAnampaG/statuses/1335665089266012161,0.0,0.0,,0.0,0.0,0.0,4.0,10.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @Anand_88_Patel: Check out our #ASH20 talk on cytogenetics/outcomes of pts developing myeloid neoplasms after radiation therapy alone! T‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 21:17:06+00:00,"Ritcha Saxena, MD",http://twitter.com/,6.0,,1.335694782157484e+18,,0.0,0.0,,RT @MAWJNJ: Great to see @ASCOPost interview @thanosdimop on the #APOLLO Phase 3 study being presented at #ASH20. Looking forward to it bei‚Ä¶,en,0.0,6875.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,2.0,https://twitter.com/RitchaSaxena/statuses/1335694782157484034,0.0,0.0,,0.0,0.0,0.0,2.0,4.0,False,False,False,False,True,FDA Approval,1.0,0.0,0.0,RT @MAWJNJ: Great to see @ASCOPost interview @thanosdimop on the #APOLLO Phase 3 study being presented at #ASH20. Looking forward to it bei‚Ä¶,true
EladSharonMD,"#MedicalOncologist tweeting on #immunotherapy, #drugdevelopment, #COVID19 & #HealthEcon. #NCI #CancerMoonshot Adult Immunotherapy Co-Chair. Tweets are mine.",,"Washington, DC",,2020-12-06 01:19:40+00:00,Elad Sharon,http://twitter.com/,218.0,,1.33539343810841e+18,,0.0,0.0,,"RT @hemedoc: #ASH20 #leusm Wei: We are all excited to have new therapeutic options in AML, but the overall message I get from this money sl‚Ä¶",en,0.0,2113.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,168.0,50.0,https://twitter.com/EladSharonMD/statuses/1335393438108409856,0.0,0.0,,0.0,0.0,0.0,50.0,168.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"RT @hemedoc: #ASH20 #leusm Wei: We are all excited to have new therapeutic options in AML, but the overall message I get from this money sl‚Ä¶",false
AKeyzner,"hematologist #BMT #leuksm physician ‚â†provider immigrant, opinions my own, likes‚â†endorsement",,,,2020-12-06 18:22:11+00:00,Alla Keyzner,http://twitter.com/,17.0,,1.3356507623540283e+18,,0.0,0.0,,"RT @drjgauthier: #ASH20 355 Dr. Pidala @MoffittNews 
Preclinical and Phase I Trial Results of Biological and Clinical Impact of JAK2 (pacri‚Ä¶",en,0.0,157.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,12.0,5.0,https://twitter.com/AKeyzner/statuses/1335650762354028545,0.0,0.0,,0.0,0.0,0.0,5.0,12.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @drjgauthier: #ASH20 355 Dr. Pidala @MoffittNews 
Preclinical and Phase I Trial Results of Biological and Clinical Impact of JAK2 (pacri‚Ä¶",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 03:46:42+00:00,"Ritcha Saxena, MD",http://twitter.com/,48.0,,1.3354304376955904e+18,,0.0,0.0,,RT @_TanyaBondar_: Did you know an average human accumulates a million coding mutations in the blood stem cell pool by age 50? #ASH20: insi‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,42.0,6.0,https://twitter.com/RitchaSaxena/statuses/1335430437695590400,0.0,0.0,,0.0,0.0,0.0,6.0,42.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @_TanyaBondar_: Did you know an average human accumulates a million coding mutations in the blood stem cell pool by age 50? #ASH20: insi‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 21:31:03+00:00,"Ritcha Saxena, MD",http://twitter.com/,24.0,,1.3356982933226086e+18,,0.0,0.0,,RT @DrMiguelPerales: Biology/preclinical data support JAK1 inhibition for GVHD ppx -  we tested this in clinical trial of itacitanib and sh‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,19.0,5.0,https://twitter.com/RitchaSaxena/statuses/1335698293322608640,0.0,0.0,,0.0,0.0,0.0,5.0,19.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @DrMiguelPerales: Biology/preclinical data support JAK1 inhibition for GVHD ppx -  we tested this in clinical trial of itacitanib and sh‚Ä¶,true
MDedgeHemOnc,MDedge Hematology & Oncology provides the most important and up to date information and news for oncologists. Now part of the Medscape Professional Network.,,"Rockville, MD, Parsippany, NJ",,2020-12-07 14:09:12+00:00,MDedge Hematology & Oncology,http://twitter.com/,0.0,,1.3359494825178153e+18,,0.0,0.0,,"Allogeneic transplant can lead to durable remissions in T-cell lymphoma, #ASH20 study finds.‚Ä¶ https://t.co/1sFLwwfwCj",en,0.0,6726.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/MDedgeHemOnc/statuses/1335949482517815297,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"Allogeneic transplant can lead to durable remissions in T-cell lymphoma, #ASH20 study finds.‚Ä¶ https://t.co/1sFLwwfwCj",true
DrTiffanyL,"Former Saipan pediatrician, Current Peds hem/onc enthusiast with interest in med ed (and now a PD @ UCSF), QI & safety, hemostasis/thrombosis. Tweets are my own",,"San Francisco, CA",,2020-12-07 16:11:51+00:00,Tiffany (Lin) Lucas,http://twitter.com/,0.0,,1.3359803491558113e+18,,0.0,0.0,,Results of the phase 2 #fitusiran (siRNA against antithrombin) in 34 adult mod/sev hem A and B patients - monthly s‚Ä¶ https://t.co/2BgSqEVZlG,en,0.0,602.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/DrTiffanyL/statuses/1335980349155811330,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,Results of the phase 2 #fitusiran (siRNA against antithrombin) in 34 adult mod/sev hem A and B patients - monthly s‚Ä¶ https://t.co/2BgSqEVZlG,true
genperisi,"Genetics & Applied Genomicsüî¨
Molecular OncologistüîéItaliana/Turca
Tweets are not medical advice. Views mine. Ispra - Istanbulüö©
METU/ GBF / UCLA / UMIST",,Italia,,2020-12-07 22:11:37+00:00,Dr. Birep Ayg√ºn,http://twitter.com/,36.0,,1.336070886739284e+18,,0.0,0.0,,"RT @AAcosta_MedMD: #ASH20 #ASHTrainee #MedTwitter 

Don‚Äôt forget to check out our team‚Äôs poster (#1675) on complement-mediated TMA relapse‚Ä¶",en,0.0,10241.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,29.0,7.0,https://twitter.com/genperisi/statuses/1336070886739283973,0.0,0.0,,0.0,0.0,0.0,7.0,29.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @AAcosta_MedMD: #ASH20 #ASHTrainee #MedTwitter 

Don‚Äôt forget to check out our team‚Äôs poster (#1675) on complement-mediated TMA relapse‚Ä¶",false
BrentonMar,Pediatric Oncologist.  Medical Director at Blueprint Medicines. Translating genomics into new therapies in cancer patients.,,Boston,,2020-12-07 15:30:29+00:00,Brenton Mar,http://twitter.com/,11.0,,1.3359699398832415e+18,,0.0,0.0,,"RT @BlueprintMeds: At #ASH20, we‚Äôre presenting data highlighting our efforts to understand the disease burden, accelerate the diagnosis and‚Ä¶",en,0.0,220.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,8.0,3.0,https://twitter.com/BrentonMar/statuses/1335969939883241475,0.0,0.0,,0.0,0.0,0.0,3.0,8.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"RT @BlueprintMeds: At #ASH20, we‚Äôre presenting data highlighting our efforts to understand the disease burden, accelerate the diagnosis and‚Ä¶",true
miljko,Hematologist/oncologist. Views are my own. #RWRI 14 attendee. @ Hemato-onkolog. MFUB 2002-2008. üéô https://t.co/xzLsKCsirz üñã https://t.co/NBAgn0OFhh * https://t.co/xD3CELCeVW,,DC,,2020-12-07 13:33:51+00:00,Milo≈° Miljkoviƒá,http://twitter.com/,0.0,,1.3359405879760937e+18,,0.0,0.0,,"#ASH20 Abstract 2071: Phase 1 Study of subQ rhIL-15 and i.v. alemtuzumab for R/R CD52+ TCL
‚úì IL-15 x 2 weeks follow‚Ä¶ https://t.co/wcsHXMehjm",en,0.0,2422.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/miljko/statuses/1335940587976093697,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"#ASH20 Abstract 2071: Phase 1 Study of subQ rhIL-15 and i.v. alemtuzumab for R/R CD52+ TCL
‚úì IL-15 x 2 weeks follow‚Ä¶ https://t.co/wcsHXMehjm",true
AzizNazhaMD,"Practice Manager at Amazon Web Services, Physician, #Programmer, #DataScientist, interested in the Digital Transformation of Healthcare",,Cleveland Clinic,,2020-12-07 15:00:03+00:00,Aziz Nazha,http://twitter.com/,0.0,,1.335962283017638e+18,,0.0,0.0,,We will presenting our Phase I/II Trial of CPX-351 + Palbociclib in Patients with Acute Myeloid Leukemia‚Ä¶ https://t.co/mE0FvRnIdW,en,0.0,2087.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/AzizNazhaMD/statuses/1335962283017637888,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,We will presenting our Phase I/II Trial of CPX-351 + Palbociclib in Patients with Acute Myeloid Leukemia‚Ä¶ https://t.co/mE0FvRnIdW,true
FranciscoMarty_,"Infectious diseases doctor who specializes in treating transplant and cancer patients, work at @BrighamWomens and @DanaFarber, @harvardmed.",,"Boston, MA",,2020-12-07 12:46:27+00:00,"Francisco Marty, MD",http://twitter.com/,21.0,,1.3359286610992947e+18,,0.0,0.0,,RT @DrMiguelPerales: Congrats ‚Å¶@bwoodmd‚Å© ‚Å¶@LisaHicksMD‚Å© for leading this effort. Outcomes of patients with hematologic malignancies and #CO‚Ä¶,en,0.0,9991.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,14.0,7.0,https://twitter.com/FranciscoMarty_/statuses/1335928661099294722,0.0,0.0,,0.0,0.0,0.0,7.0,14.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @DrMiguelPerales: Congrats ‚Å¶@bwoodmd‚Å© ‚Å¶@LisaHicksMD‚Å© for leading this effort. Outcomes of patients with hematologic malignancies and #CO‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-07 04:01:56+00:00,"Ritcha Saxena, MD",http://twitter.com/,24.0,,1.3357966628082278e+18,,0.0,0.0,,RT @MalinHultcrantz: Great news! The first 10 patients treated with CRISPR edited stem cells (CTX001) are transfusion independent and and v‚Ä¶,en,0.0,6875.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,19.0,5.0,https://twitter.com/RitchaSaxena/statuses/1335796662808227840,0.0,0.0,,0.0,0.0,0.0,5.0,19.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @MalinHultcrantz: Great news! The first 10 patients treated with CRISPR edited stem cells (CTX001) are transfusion independent and and v‚Ä¶,true
VincentRK,"Professor, Mayo Clinic; Editor, Blood Cancer Journal; Oncologist; Health Costs; COVID threads @SurvivedCOVID Opinions=personal views https://t.co/TMq9vc5hZk",,"Rochester, MN, USA",,2020-12-07 20:00:59+00:00,Vincent Rajkumar,http://twitter.com/,4.0,,1.3360380149093622e+18,,0.0,0.0,,"#ASH20 IFM 2009 trial results presented by @PerrotAurore 

On intent to treat basis early and delayed stem cell tra‚Ä¶ https://t.co/XuED169Dty",en,0.0,33590.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,4.0,https://twitter.com/VincentRK/statuses/1336038014909362177,0.0,0.0,,0.0,0.0,0.0,4.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"#ASH20 IFM 2009 trial results presented by @PerrotAurore 

On intent to treat basis early and delayed stem cell tra‚Ä¶ https://t.co/XuED169Dty",false
GlopesMd,"Cancer Doctor and Researcher, Faculty @SylvesterCancer @UnivMiami. Helping improve Cancer Control in LMICs. Editor-in-Chief JCO Global Oncology @ASCO",,"Miami, FL",,2020-12-05 10:57:02+00:00,gilberto lopes,http://twitter.com/,30.0,,1.33517634946039e+18,,0.0,0.0,,RT @COVID19nCCC: Severity of Sars-Cov-2 Infection in Pts w/ Hematologic Malignancies: A COVID-19 &amp; Cancer Consortium (#CCC19) Registry Anal‚Ä¶,en,0.0,31610.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,21.0,9.0,https://twitter.com/GlopesMd/statuses/1335176349460389888,0.0,0.0,,0.0,0.0,0.0,9.0,21.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,RT @COVID19nCCC: Severity of Sars-Cov-2 Infection in Pts w/ Hematologic Malignancies: A COVID-19 &amp; Cancer Consortium (#CCC19) Registry Anal‚Ä¶,true
kirkizlar,"MD, Hematology, Trakya University Med Faculty",,"Edirne, T√ºrkiye",,2020-11-08 21:02:33+00:00,Onur Kirkizlar,http://twitter.com/,15.0,,1.3255442588462817e+18,,0.0,0.0,,RT @mtmdphd: Lack of Effectiveness of Intravenous High-Dose Methotrexate for Prevention of CNS Relapse in Patients with High-Risk DLBCL: A‚Ä¶,en,0.0,58.0,,,0.0,,,Negative,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,5.0,https://twitter.com/kirkizlar/statuses/1325544258846281732,0.0,0.0,,0.0,0.0,0.0,5.0,10.0,False,False,False,False,True,Diagnosis Progression,0.0,1.0,0.0,RT @mtmdphd: Lack of Effectiveness of Intravenous High-Dose Methotrexate for Prevention of CNS Relapse in Patients with High-Risk DLBCL: A‚Ä¶,true
pash22,"Public Hlth Dr,interested in evid-based health services commissioning,clinical leadership & hlth policy.My views are my own,RTs are no endorsements",,United Kingdom,,2020-11-08 21:48:49+00:00,Ash Paul,http://twitter.com/,113.0,,1.325555901340799e+18,,0.0,0.0,,"RT @graham74GC: Puckrin et al
- retro study CNS relapse in DLBCL
- found CNS-IPI prognostic
- use of IV MTX proph NOT assoc with ‚¨áÔ∏è CNS rel‚Ä¶",en,0.0,26941.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,86.0,27.0,https://twitter.com/pash22/statuses/1325555901340798978,0.0,0.0,,0.0,0.0,0.0,27.0,86.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @graham74GC: Puckrin et al
- retro study CNS relapse in DLBCL
- found CNS-IPI prognostic
- use of IV MTX proph NOT assoc with ‚¨áÔ∏è CNS rel‚Ä¶",true
bryony_ross,"Haematologist: NSW Pathology, Calvary Mater Newcastle and The Children‚Äôs Hospital at Westmead.",,"Newcastle, New South Wales",,2020-11-08 22:21:02+00:00,Bryony Ross,http://twitter.com/,113.0,,1.3255640083263283e+18,,0.0,0.0,,"RT @graham74GC: Puckrin et al
- retro study CNS relapse in DLBCL
- found CNS-IPI prognostic
- use of IV MTX proph NOT assoc with ‚¨áÔ∏è CNS rel‚Ä¶",en,0.0,194.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,86.0,27.0,https://twitter.com/bryony_ross/statuses/1325564008326328320,0.0,0.0,,0.0,0.0,0.0,27.0,86.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @graham74GC: Puckrin et al
- retro study CNS relapse in DLBCL
- found CNS-IPI prognostic
- use of IV MTX proph NOT assoc with ‚¨áÔ∏è CNS rel‚Ä¶",true
graham74GC,Lymphoma specialist at Oxford Cancer and Haematology centre. Haematologist and clinical trialist. Chair of UK Hodgkin and T-cell study groups.,,Opinions are mine,,2020-11-08 20:20:39+00:00,Graham Collins,http://twitter.com/,8.0,,1.3255337151000044e+18,,0.0,0.0,,"Zinzani et al - QoL in Keynote-204
- trial was BV v Pembro in R/R cHL
- PFS adv for Pembro seen
- here, fatigue &amp; p‚Ä¶ https://t.co/XYaE6XiaRN",en,0.0,6091.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,8.0,https://twitter.com/graham74GC/statuses/1325533715100004352,0.0,0.0,,0.0,0.0,0.0,8.0,0.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"Zinzani et al - QoL in Keynote-204
- trial was BV v Pembro in R/R cHL
- PFS adv for Pembro seen
- here, fatigue &amp; p‚Ä¶ https://t.co/XYaE6XiaRN",true
kirkizlar,"MD, Hematology, Trakya University Med Faculty",,"Edirne, T√ºrkiye",,2020-11-08 21:02:25+00:00,Onur Kirkizlar,http://twitter.com/,39.0,,1.3255442254217994e+18,,0.0,0.0,,"RT @graham74GC: Zinzani et al - QoL in Keynote-204
- trial was BV v Pembro in R/R cHL
- PFS adv for Pembro seen
- here, fatigue &amp; pain QoL‚Ä¶",en,0.0,58.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,31.0,8.0,https://twitter.com/kirkizlar/statuses/1325544225421799425,0.0,0.0,,0.0,0.0,0.0,8.0,31.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"RT @graham74GC: Zinzani et al - QoL in Keynote-204
- trial was BV v Pembro in R/R cHL
- PFS adv for Pembro seen
- here, fatigue &amp; pain QoL‚Ä¶",false
BroeckelmannPJ,"MD @UKKoeln & Physician Scientist Postdoc @MPIAGE. Hemato-Oncology. Lymphoma. Immunotherapies. DNA damage. Personal opinion, RT/like ‚â† endorsement.",,"Cologne, Germany",,2020-11-08 20:31:25+00:00,Paul Br√∂ckelmann,http://twitter.com/,39.0,,1.3255364263023163e+18,,0.0,0.0,,"RT @graham74GC: Zinzani et al - QoL in Keynote-204
- trial was BV v Pembro in R/R cHL
- PFS adv for Pembro seen
- here, fatigue &amp; pain QoL‚Ä¶",en,0.0,243.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,31.0,8.0,https://twitter.com/BroeckelmannPJ/statuses/1325536426302316545,0.0,0.0,,0.0,0.0,0.0,8.0,31.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"RT @graham74GC: Zinzani et al - QoL in Keynote-204
- trial was BV v Pembro in R/R cHL
- PFS adv for Pembro seen
- here, fatigue &amp; pain QoL‚Ä¶",true
mabeky,Leukemia Department Administrator at MD Anderson Cancer Center,,"Houston, TX",,2020-11-08 06:17:09+00:00,M. Silverstein,http://twitter.com/,29.0,,1.3253214420204954e+18,,0.0,0.0,,RT @doctorpemm: #ASH20 | @TapKadia et al Ph2 #CPX351 + #Venetoclax in patients with AML  https://t.co/VI8yGHWyoz | #leusm @DrKTakahashi @do‚Ä¶,en,0.0,206.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,22.0,7.0,https://twitter.com/mabeky/statuses/1325321442020495362,0.0,0.0,,0.0,0.0,0.0,7.0,22.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @doctorpemm: #ASH20 | @TapKadia et al Ph2 #CPX351 + #Venetoclax in patients with AML  https://t.co/VI8yGHWyoz | #leusm @DrKTakahashi @do‚Ä¶,true
graham74GC,Lymphoma specialist at Oxford Cancer and Haematology centre. Haematologist and clinical trialist. Chair of UK Hodgkin and T-cell study groups.,,Opinions are mine,,2020-11-08 20:30:17+00:00,Graham Collins,http://twitter.com/,27.0,,1.3255361381368422e+18,,0.0,0.0,,"Puckrin et al
- retro study CNS relapse in DLBCL
- found CNS-IPI prognostic
- use of IV MTX proph NOT assoc with ‚¨áÔ∏è‚Ä¶ https://t.co/6lQ2qW7gDB",en,0.0,6091.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,27.0,https://twitter.com/graham74GC/statuses/1325536138136842243,0.0,0.0,,0.0,0.0,0.0,27.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"Puckrin et al
- retro study CNS relapse in DLBCL
- found CNS-IPI prognostic
- use of IV MTX proph NOT assoc with ‚¨áÔ∏è‚Ä¶ https://t.co/6lQ2qW7gDB",true
farrell_katrina,"Haematologist. PhD. Defender of the NHS. Left leaning. Pro-independence. Beauty is truth, truth beauty. Views are my own. You have been warned...",,,,2020-11-08 20:51:50+00:00,Dr Katrina Farrell,http://twitter.com/,113.0,,1.3255415632090276e+18,,0.0,0.0,,"RT @graham74GC: Puckrin et al
- retro study CNS relapse in DLBCL
- found CNS-IPI prognostic
- use of IV MTX proph NOT assoc with ‚¨áÔ∏è CNS rel‚Ä¶",en,0.0,3353.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,86.0,27.0,https://twitter.com/farrell_katrina/statuses/1325541563209027587,0.0,0.0,,0.0,0.0,0.0,27.0,86.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @graham74GC: Puckrin et al
- retro study CNS relapse in DLBCL
- found CNS-IPI prognostic
- use of IV MTX proph NOT assoc with ‚¨áÔ∏è CNS rel‚Ä¶",true
graham74GC,Lymphoma specialist at Oxford Cancer and Haematology centre. Haematologist and clinical trialist. Chair of UK Hodgkin and T-cell study groups.,,Opinions are mine,,2020-11-21 22:50:21+00:00,Graham Collins,http://twitter.com/,12.0,,1.3302824288255631e+18,,0.0,0.0,,"Mehta-Shah et al 
12 academic centres, retrospec study allogeneic Tx for PTCL
- 508 pts med 51y
- mostly relapsed,‚Ä¶ https://t.co/D2DeygMq70",en,0.0,6091.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,12.0,https://twitter.com/graham74GC/statuses/1330282428825563140,0.0,0.0,,0.0,0.0,0.0,12.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"Mehta-Shah et al 
12 academic centres, retrospec study allogeneic Tx for PTCL
- 508 pts med 51y
- mostly relapsed,‚Ä¶ https://t.co/D2DeygMq70",true
dgermain21,MD-PhD. 2nd year Heme/Onc fellow focused on lymphoma and leukemia. Physician-scientist-in-training. Tweet/RT not medical advice or endorsement.,,"St. Louis, MO",,2020-11-21 23:29:01+00:00,David A. Russler-Germain,http://twitter.com/,71.0,,1.3302921600134922e+18,,0.0,0.0,,"RT @graham74GC: Mehta-Shah et al 
12 academic centres, retrospec study allogeneic Tx for PTCL
- 508 pts med 51y
- mostly relapsed, most RIC‚Ä¶",en,0.0,1612.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,59.0,12.0,https://twitter.com/dgermain21/statuses/1330292160013492227,0.0,0.0,,0.0,0.0,0.0,12.0,59.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @graham74GC: Mehta-Shah et al 
12 academic centres, retrospec study allogeneic Tx for PTCL
- 508 pts med 51y
- mostly relapsed, most RIC‚Ä¶",false
JohnPLeonardMD,"Doctor for lymphoma patients, researcher, collaborator, professor/senior associate dean @WeillCornell & @NYPhospital Tweets mine RT not=endorsement, he/him/his",,Weill Cornell Medicine,,2020-11-28 13:12:40+00:00,"John P. Leonard, MD",http://twitter.com/,0.0,,1.3326737665943716e+18,,0.0,0.0,,Number 7 #LeonardList #ASH20 - Chihara - Ph 1 trial data on pts with blood cancer - low rates of rx-attributed gr 5‚Ä¶ https://t.co/6Gc1Qr2nKp,en,0.0,6269.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/JohnPLeonardMD/statuses/1332673766594371585,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,Number 7 #LeonardList #ASH20 - Chihara - Ph 1 trial data on pts with blood cancer - low rates of rx-attributed gr 5‚Ä¶ https://t.co/6Gc1Qr2nKp,true
APSHOorg,"We are advanced practitioners in oncology: nurse practitioners, physician assistants, clinical nurse specialists, advanced degree nurses, and pharmacists.",,"Lawrenceville, NJ",,2020-12-22 20:01:45+00:00,APSHO,http://twitter.com/,0.0,,1.341474026351448e+18,,0.0,0.0,,"APSHO Board President Sandra Kurtin, PhD, ANP-C, AOCN discusses Long-Term Side Effects Among Patients With Primary‚Ä¶ https://t.co/w5hbUQWtLw",en,0.0,663.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/APSHOorg/statuses/1341474026351448069,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"APSHO Board President Sandra Kurtin, PhD, ANP-C, AOCN discusses Long-Term Side Effects Among Patients With Primary‚Ä¶ https://t.co/w5hbUQWtLw",true
chanyooncheah,Doctor for patients with lymphoma. Clinical researcher.,,"Perth, Western Australia",,2020-12-22 15:19:11+00:00,Chan Cheah,http://twitter.com/,0.0,,1.3414029124304443e+18,,0.0,0.0,,"@VJHemOnc interview discussing phase I data on TG-1701 from #ASH20 #CLLsm #lymSM 
@LinearClinical‚Ä¶ https://t.co/0iIwNuAUrp",en,0.0,1717.0,,,0.0,VJHemOnc,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/chanyooncheah/statuses/1341402912430444546,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"@VJHemOnc interview discussing phase I data on TG-1701 from #ASH20 #CLLsm #lymSM 
@LinearClinical‚Ä¶ https://t.co/0iIwNuAUrp",true
KirovDoc,"MD, Ph.D., Hematologist at Kirov Research Institute of Hematology and Blood transfusion",,Russia,,2020-12-23 05:04:18+00:00,Alexander Luchinin,http://twitter.com/,9.0,,1.341610563114287e+18,,0.0,0.0,,RT @MM_Hub: The addition of SC daratumumab to pomalidomide + dexamethasone improves PFS for patients with relapsed/refractory #myeloma. Rea‚Ä¶,en,0.0,27.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,3.0,https://twitter.com/KirovDoc/statuses/1341610563114287104,0.0,0.0,,0.0,0.0,0.0,3.0,6.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @MM_Hub: The addition of SC daratumumab to pomalidomide + dexamethasone improves PFS for patients with relapsed/refractory #myeloma. Rea‚Ä¶,true
alexjsternberg,Haematologist. Composer. Immposter.,,,,2020-12-05 15:21:44+00:00,Alex Sternberg,http://twitter.com/,0.0,,1.3352429631365038e+18,,0.0,0.0,,Dr Fauci recommends patients receiving chemo for blood cancer should be vaccinated against Covid 19 #ASH20,en,0.0,59.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/alexjsternberg/statuses/1335242963136503809,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,Dr Fauci recommends patients receiving chemo for blood cancer should be vaccinated against Covid 19 #ASH20,true
MDedgeHemOnc,MDedge Hematology & Oncology provides the most important and up to date information and news for oncologists. Now part of the Medscape Professional Network.,,"Rockville, MD, Parsippany, NJ",,2020-12-22 02:13:01+00:00,MDedge Hematology & Oncology,http://twitter.com/,0.0,,1.341205067454681e+18,,0.0,0.0,,A new study compared tranexamic acid to placebo and found no significant differences in terms of the number of blee‚Ä¶ https://t.co/uHZNdsemKh,en,0.0,6726.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/MDedgeHemOnc/statuses/1341205067454681088,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,A new study compared tranexamic acid to placebo and found no significant differences in terms of the number of blee‚Ä¶ https://t.co/uHZNdsemKh,false
johnde1MYELOMA,"myeloma survivor üêú, gastroenterologist, bicyclist, animal lover",,"Santa Fe, NM",,2020-12-05 22:38:13+00:00,John DeFlice,http://twitter.com/,0.0,,1.3353528059770348e+18,,0.0,0.0,,BISPECIFIC BFCR4350A FcRH5/CD3 ab phase 1 in heavily pretreated RRMM w/ hi risk cytogenetics showing deep/durable r‚Ä¶ https://t.co/IxEysjJ5UR,en,0.0,218.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/johnde1MYELOMA/statuses/1335352805977034753,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,BISPECIFIC BFCR4350A FcRH5/CD3 ab phase 1 in heavily pretreated RRMM w/ hi risk cytogenetics showing deep/durable r‚Ä¶ https://t.co/IxEysjJ5UR,true
johnde1MYELOMA,"myeloma survivor üêú, gastroenterologist, bicyclist, animal lover",,"Santa Fe, NM",,2020-12-05 21:14:44+00:00,John DeFlice,http://twitter.com/,0.0,,1.335331799778566e+18,,0.0,0.0,,"Anti-BCMA Bite phase 1 AMG 701 in heavily pretreated RRMM with 83 % ORR with manageable safety profile(CRS), Harris‚Ä¶ https://t.co/nEZkGgbYv4",en,0.0,218.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/johnde1MYELOMA/statuses/1335331799778566144,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"Anti-BCMA Bite phase 1 AMG 701 in heavily pretreated RRMM with 83 % ORR with manageable safety profile(CRS), Harris‚Ä¶ https://t.co/nEZkGgbYv4",true
johnde1MYELOMA,"myeloma survivor üêú, gastroenterologist, bicyclist, animal lover",,"Santa Fe, NM",,2020-12-05 22:23:41+00:00,John DeFlice,http://twitter.com/,0.0,,1.3353491515512463e+18,,0.0,0.0,,BISPECIFIC REGN5458 BCMA/CD3 ab 1st in human phase 1 in heavily pretreated RRMM with acceptable safety profile and‚Ä¶ https://t.co/BYnVWyiOkF,en,0.0,218.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/johnde1MYELOMA/statuses/1335349151551246336,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,BISPECIFIC REGN5458 BCMA/CD3 ab 1st in human phase 1 in heavily pretreated RRMM with acceptable safety profile and‚Ä¶ https://t.co/BYnVWyiOkF,true
UrviShahMD,Oncologist and researcher on Myeloma service @sloan_kettering. Interested in nutrition for cancer and immune therapies. Views are my own,,"New York, NY",,2020-12-05 21:49:14+00:00,Urvi Shah,http://twitter.com/,1.0,,1.3353404791944684e+18,,0.0,0.0,,Subcutaneous Daratumumab Plus Pomalidomide/Dexamethasone in Relapsed or Refractory Multiple Myeloma - The ASCO Post‚Ä¶ https://t.co/ZBaiwA2LZL,ro,0.0,1227.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/UrviShahMD/statuses/1335340479194468365,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,Subcutaneous Daratumumab Plus Pomalidomide/Dexamethasone in Relapsed or Refractory Multiple Myeloma - The ASCO Post‚Ä¶ https://t.co/ZBaiwA2LZL,true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 21:54:01+00:00,Lisa Palacios,http://twitter.com/,6.0,,1.335341685145031e+18,,0.0,0.0,,"RT @VJHemOnc: Highlights from newly diagnosed #AMLsm novel combination therapy orals at #ASH20 

@TapKadia @MDAndersonNews: Venetoclax+ cla‚Ä¶",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,1.0,https://twitter.com/Lisa_Palacios/statuses/1335341685145030658,0.0,0.0,,0.0,0.0,0.0,1.0,5.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"RT @VJHemOnc: Highlights from newly diagnosed #AMLsm novel combination therapy orals at #ASH20 

@TapKadia @MDAndersonNews: Venetoclax+ cla‚Ä¶",true
ThiloZander,Medical Oncologist. Head of Lymphoma & Myeloma Service. Lucerne Cancer Center. Switzerland.,,"Lucerne, Switzerland",,2020-12-05 16:27:40+00:00,"Thilo J Zander, MD",http://twitter.com/,1.0,,1.3352595557947187e+18,,0.0,0.0,,Impressive data from Huang et al.: Mitoxantrone Hydrochloride Liposome in Patients with Relapsed or Refractory Peri‚Ä¶ https://t.co/0Pg51mTN5t,en,0.0,843.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/ThiloZander/statuses/1335259555794718725,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,Impressive data from Huang et al.: Mitoxantrone Hydrochloride Liposome in Patients with Relapsed or Refractory Peri‚Ä¶ https://t.co/0Pg51mTN5t,false
mav_jav,"Human,fighter,survivor. Passionate about helping and healing.Histopathologist",,"The Capital, Kuwait",,2020-12-05 19:55:28+00:00,Mawish javed,http://twitter.com/,8.0,,1.335311851190694e+18,,0.0,0.0,,"RT @VincentRK: 12. Phase I results of TNB-383B, a BCMA/CD3 Bispecific Antibody, in Relapsed/Refractory Myeloma. #ASH20 @MayoMyeloma @myelom‚Ä¶",en,0.0,956.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,3.0,https://twitter.com/mav_jav/statuses/1335311851190693889,0.0,0.0,,0.0,0.0,0.0,3.0,5.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @VincentRK: 12. Phase I results of TNB-383B, a BCMA/CD3 Bispecific Antibody, in Relapsed/Refractory Myeloma. #ASH20 @MayoMyeloma @myelom‚Ä¶",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-05 20:34:26+00:00,"Ritcha Saxena, MD",http://twitter.com/,45.0,,1.3353216541976863e+18,,0.0,0.0,,"RT @BiostatGirl: Symptoms improve after Autologous Stem Cell Transplant in pts w/ Multiple Myeloma. High symptoms associated w/ male sex, h‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,30.0,15.0,https://twitter.com/RitchaSaxena/statuses/1335321654197686282,0.0,0.0,,0.0,0.0,0.0,15.0,30.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @BiostatGirl: Symptoms improve after Autologous Stem Cell Transplant in pts w/ Multiple Myeloma. High symptoms associated w/ male sex, h‚Ä¶",true
chanyooncheah,Doctor for patients with lymphoma. Clinical researcher.,,"Perth, Western Australia",,2020-12-05 16:12:41+00:00,Chan Cheah,http://twitter.com/,2.0,,1.3352557857947525e+18,,0.0,0.0,,"Mehta Shah et al
huge dataset describing allogeneic stem cell transplantation in PTCL #ASH20 
#lymSM 
particularly‚Ä¶ https://t.co/0x32N0DZK2",en,0.0,1717.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/chanyooncheah/statuses/1335255785794752513,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"Mehta Shah et al
huge dataset describing allogeneic stem cell transplantation in PTCL #ASH20 
#lymSM 
particularly‚Ä¶ https://t.co/0x32N0DZK2",true
khouri_jack,Myeloma/BMT #hematologist #oncologist @ClevelandClinic Assistant Prof @CleClinicLCM @CWRUSOM | alum @TuftsMedSchool @Uni_Of_Balamand #mmsm #bmtsm,,"Cleveland, OH",,2020-12-05 23:31:07+00:00,"Jack Khouri, MD",http://twitter.com/,15.0,,1.3353661199270134e+18,,0.0,0.0,,"RT @Mohty_EBMT: Subcutaneous Daratumumab Plus Pomalidomide/Dexamethasone in Relapsed or Refractory Multiple Myeloma - The ASCO Post
#ASH20‚Ä¶",ro,0.0,443.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,12.0,3.0,https://twitter.com/khouri_jack/statuses/1335366119927013380,0.0,0.0,,0.0,0.0,0.0,3.0,12.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @Mohty_EBMT: Subcutaneous Daratumumab Plus Pomalidomide/Dexamethasone in Relapsed or Refractory Multiple Myeloma - The ASCO Post
#ASH20‚Ä¶",true
tanyawildes,"Hematologist/oncologist/geriatrician, studying the intersection of Myeloma & other cancers with Aging. Woman of faith/wife of Mr Doctor Wildes/Mom.",,,,2020-12-05 18:17:56+00:00,Tanya Wildes MD,http://twitter.com/,45.0,,1.3352873039216558e+18,,0.0,0.0,,"RT @BiostatGirl: Symptoms improve after Autologous Stem Cell Transplant in pts w/ Multiple Myeloma. High symptoms associated w/ male sex, h‚Ä¶",en,0.0,2800.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,30.0,15.0,https://twitter.com/tanyawildes/statuses/1335287303921655810,0.0,0.0,,0.0,0.0,0.0,15.0,30.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @BiostatGirl: Symptoms improve after Autologous Stem Cell Transplant in pts w/ Multiple Myeloma. High symptoms associated w/ male sex, h‚Ä¶",true
majorajay,"Hematology/oncology fellow. #lymsm & #mmsm outcomes researcher. Physician-publisher & founder of https://t.co/dPfLt8QVMr, @inTrainingDoc & @inHouseMag.",,"Chicago, IL",,2020-12-05 16:43:04+00:00,"Ajay Major, MD, MBA",http://twitter.com/,49.0,,1.3352634291547628e+18,,0.0,0.0,,"RT @Lymphoma_Doc: My annual complaint at ASH: CR is complete response, it is not complete remission. 
Response is categorical, remission is‚Ä¶",en,0.0,3518.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,45.0,4.0,https://twitter.com/majorajay/statuses/1335263429154762758,0.0,0.0,,0.0,0.0,0.0,4.0,45.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @Lymphoma_Doc: My annual complaint at ASH: CR is complete response, it is not complete remission. 
Response is categorical, remission is‚Ä¶",false
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 21:24:43+00:00,"Ritcha Saxena, MD",http://twitter.com/,6.0,,1.3356966982875505e+18,,0.0,0.0,,"RT @gvhd_hub: CONGRESS | #ASH20 | Joseh Pidala, @MoffittNews, presents results of phase I/II trial in which pacritinib /sirolimus / tacroli‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,1.0,https://twitter.com/RitchaSaxena/statuses/1335696698287550464,0.0,0.0,,0.0,0.0,0.0,1.0,5.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @gvhd_hub: CONGRESS | #ASH20 | Joseh Pidala, @MoffittNews, presents results of phase I/II trial in which pacritinib /sirolimus / tacroli‚Ä¶",true
tarekmd91,MD @AUB_Lebanon | #multiplemyeloma #mmsm @DanaFarber | Medicine Resident @IcahnMountSinai @DOMSinaiNYC | Future @SinaiHemeOnc Fellow @TischCancer | üá±üáßüá∫üá∏,,"New York, NY",,2020-12-05 19:47:13+00:00,"Tarek Mouhieddine, MD",http://twitter.com/,76.0,,1.335309775337304e+18,,0.0,0.0,,"RT @Mohty_EBMT: Natural history of myeloma. More than ever, We need to optimize/succeed frontline and 1st relapse therapy because both phas‚Ä¶",en,0.0,958.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,56.0,20.0,https://twitter.com/tarekmd91/statuses/1335309775337304069,0.0,0.0,,0.0,0.0,0.0,20.0,56.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @Mohty_EBMT: Natural history of myeloma. More than ever, We need to optimize/succeed frontline and 1st relapse therapy because both phas‚Ä¶",true
IreneGhobrial,Physician-scientist in multiple myeloma at @DanaFarber/@BrighamWomens Hematologic Oncology Treatment Center. Tweets are my own & not medical advice. #mmsm,,"Boston, MA",,2020-12-06 02:18:03+00:00,Irene Ghobrial,http://twitter.com/,16.0,,1.3354081284316897e+18,,0.0,0.0,,RT @AuclairDan: Cool work presented this morning at #ASH20 using single-cell multi-omics work coming out of the collaboration between @land‚Ä¶,en,0.0,3965.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,15.0,1.0,https://twitter.com/IreneGhobrial/statuses/1335408128431689730,0.0,0.0,,0.0,0.0,0.0,1.0,15.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @AuclairDan: Cool work presented this morning at #ASH20 using single-cell multi-omics work coming out of the collaboration between @land‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 20:21:45+00:00,"Ritcha Saxena, MD",http://twitter.com/,25.0,,1.3356808517539635e+18,,0.0,0.0,,RT @DrMiguelPerales: #ASH20 Important study on #healthequity in AML - Worse outcomes in young black patients though responses rates were sa‚Ä¶,en,0.0,6875.0,,,0.0,,,Negative,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,15.0,10.0,https://twitter.com/RitchaSaxena/statuses/1335680851753963523,0.0,0.0,,0.0,0.0,0.0,10.0,15.0,False,False,False,False,True,Financial Performance,0.0,1.0,0.0,RT @DrMiguelPerales: #ASH20 Important study on #healthequity in AML - Worse outcomes in young black patients though responses rates were sa‚Ä¶,true
tarekmd91,MD @AUB_Lebanon | #multiplemyeloma #mmsm @DanaFarber | Medicine Resident @IcahnMountSinai @DOMSinaiNYC | Future @SinaiHemeOnc Fellow @TischCancer | üá±üáßüá∫üá∏,,"New York, NY",,2020-12-05 00:31:01+00:00,"Tarek Mouhieddine, MD",http://twitter.com/,15.0,,1.3350188077615145e+18,,0.0,0.0,,RT @MyelomaTeacher: Dr. San Miguel asks should we treat biochemical relapse?  I want to know the answer to this question. Why wait?  #ASH20‚Ä¶,en,0.0,958.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,9.0,6.0,https://twitter.com/tarekmd91/statuses/1335018807761514498,0.0,0.0,,0.0,0.0,0.0,6.0,9.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @MyelomaTeacher: Dr. San Miguel asks should we treat biochemical relapse?  I want to know the answer to this question. Why wait?  #ASH20‚Ä¶,true
majorajay,"Hematology/oncology fellow. #lymsm & #mmsm outcomes researcher. Physician-publisher & founder of https://t.co/dPfLt8QVMr, @inTrainingDoc & @inHouseMag.",,"Chicago, IL",,2020-12-06 00:06:39+00:00,"Ajay Major, MD, MBA",http://twitter.com/,69.0,,1.3353750605976904e+18,,0.0,0.0,,RT @Anand_88_Patel: So happy to see Dr. Wendy Stock winning the @ash_hematology #ASH20 Mentor Award! Since I first met her during fellowshi‚Ä¶,en,0.0,3518.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,62.0,7.0,https://twitter.com/majorajay/statuses/1335375060597690368,0.0,0.0,,0.0,0.0,0.0,7.0,62.0,False,False,False,False,True,Financial Performance,1.0,0.0,0.0,RT @Anand_88_Patel: So happy to see Dr. Wendy Stock winning the @ash_hematology #ASH20 Mentor Award! Since I first met her during fellowshi‚Ä¶,false
johnde1MYELOMA,"myeloma survivor üêú, gastroenterologist, bicyclist, animal lover",,"Santa Fe, NM",,2020-12-05 20:58:01+00:00,John DeFlice,http://twitter.com/,1.0,,1.3353275897920184e+18,,0.0,0.0,,BISPECIFIC phase 1 study Teclistamab-BCMC/CD3 ab in RRMM with deep/durable response with manageable safety profile‚Ä¶ https://t.co/rKSJ3uEfgZ,en,0.0,218.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/johnde1MYELOMA/statuses/1335327589792018432,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,BISPECIFIC phase 1 study Teclistamab-BCMC/CD3 ab in RRMM with deep/durable response with manageable safety profile‚Ä¶ https://t.co/rKSJ3uEfgZ,true
FranciscoMarty_,"Infectious diseases doctor who specializes in treating transplant and cancer patients, work at @BrighamWomens and @DanaFarber, @harvardmed.",,"Boston, MA",,2020-12-06 19:51:56+00:00,"Francisco Marty, MD",http://twitter.com/,14.0,,1.3356733497337487e+18,,0.0,0.0,,RT @DanaFarberNews: The ROCKstar Study investigates belumosudil for cGVHD after 2 + prior lines of therapy. Tune in to hear from Corey Cutl‚Ä¶,en,0.0,9991.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,13.0,1.0,https://twitter.com/FranciscoMarty_/statuses/1335673349733748737,0.0,0.0,,0.0,0.0,0.0,1.0,13.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,RT @DanaFarberNews: The ROCKstar Study investigates belumosudil for cGVHD after 2 + prior lines of therapy. Tune in to hear from Corey Cutl‚Ä¶,true
MarcosAPBorges2,Vascular Ultrasonography - Author - Angiology and Vascular Surgery - Vascular Access for Hemodialysis Surgeon,,"Bras√≠lia-DF, Brazil",,2020-12-06 11:58:06+00:00,"Marcos A. P. Borges, MD üáßüá∑",http://twitter.com/,17.0,,1.335554104790315e+18,,0.0,0.0,,RT @ProfMakris: Interesting question to Dr Dong Chen at #ASH20. What platelet conditions need electron microscopy for diagnosis? He feels i‚Ä¶,en,0.0,536.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,11.0,6.0,https://twitter.com/MarcosAPBorges2/statuses/1335554104790315008,0.0,0.0,,0.0,0.0,0.0,6.0,11.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @ProfMakris: Interesting question to Dr Dong Chen at #ASH20. What platelet conditions need electron microscopy for diagnosis? He feels i‚Ä¶,true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-06 05:20:32+00:00,Lisa Palacios,http://twitter.com/,16.0,,1.3354540524324045e+18,,0.0,0.0,,"RT @MDAndersonNews: ‚ÄúHaving new and specialized therapies like CAR T cells, new therapies that were invented here like CAR NK cells ‚Ä¶ creat‚Ä¶",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,13.0,3.0,https://twitter.com/Lisa_Palacios/statuses/1335454052432404483,0.0,0.0,,0.0,0.0,0.0,3.0,13.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @MDAndersonNews: ‚ÄúHaving new and specialized therapies like CAR T cells, new therapies that were invented here like CAR NK cells ‚Ä¶ creat‚Ä¶",true
fniainle,"Haematologist, passionate about VTE. Co-director @ConwaySphere; Director https://t.co/csdWq9XJ57; RT not endorsement, views my own",,"Dublin City, Ireland",,2020-12-06 18:15:46+00:00,Fionnuala N√≠ √Åinle,http://twitter.com/,1.0,,1.335649146301272e+18,,0.0,0.0,,Huge #ASHkudos to Dr Helen Chu on leading this cross-sectional community-based surveillance study of homeless shelt‚Ä¶ https://t.co/lcdfeZkEx1,en,0.0,2069.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/fniainle/statuses/1335649146301272077,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,Huge #ASHkudos to Dr Helen Chu on leading this cross-sectional community-based surveillance study of homeless shelt‚Ä¶ https://t.co/lcdfeZkEx1,true
farrell_katrina,"Haematologist. PhD. Defender of the NHS. Left leaning. Pro-independence. Beauty is truth, truth beauty. Views are my own. You have been warned...",,,,2020-12-05 20:35:04+00:00,Dr Katrina Farrell,http://twitter.com/,1.0,,1.3353218172848128e+18,,0.0,0.0,,PET scan better than bone marrow biopsy at detecting BM involvement in diffuse large B cell lymphoma. In‚Ä¶ https://t.co/WCN3qJQfBT,en,0.0,3353.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/farrell_katrina/statuses/1335321817284812807,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,PET scan better than bone marrow biopsy at detecting BM involvement in diffuse large B cell lymphoma. In‚Ä¶ https://t.co/WCN3qJQfBT,false
AzizNazhaMD,"Practice Manager at Amazon Web Services, Physician, #Programmer, #DataScientist, interested in the Digital Transformation of Healthcare",,Cleveland Clinic,,2020-12-07 16:17:51+00:00,Aziz Nazha,http://twitter.com/,0.0,,1.3359818600239186e+18,,0.0,0.0,,"Our #AI algorithm to predict MDS diagnosis, #ASH20, #ASH2020, #ML, #ArtificialIntelligence, #DataScience,‚Ä¶ https://t.co/SoMr7hKhw4",fr,0.0,2087.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/AzizNazhaMD/statuses/1335981860023918592,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"Our #AI algorithm to predict MDS diagnosis, #ASH20, #ASH2020, #ML, #ArtificialIntelligence, #DataScience,‚Ä¶ https://t.co/SoMr7hKhw4",true
akbar_romana,Haematologist,,,,2020-12-06 08:59:58+00:00,Dr Romana Akbar,http://twitter.com/,10.0,,1.3355092754022482e+18,,0.0,0.0,,"RT @ThiloZander: First day of #ASH20 three new targets that work in heavily pretreated relapsed and refractory #myeloma: BRAF (ORR 80%), Fc‚Ä¶",en,0.0,121.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,4.0,https://twitter.com/akbar_romana/statuses/1335509275402248196,0.0,0.0,,0.0,0.0,0.0,4.0,6.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @ThiloZander: First day of #ASH20 three new targets that work in heavily pretreated relapsed and refractory #myeloma: BRAF (ORR 80%), Fc‚Ä¶",true
DrKateLurain,Viral oncologist | Advocate for people living with HIV | Associate PD | Loving life @theNCI | #HIVonc | She/Her | My tweets are my own,,"Washington, DC",,2020-12-07 21:33:02+00:00,Kate Lurain,http://twitter.com/,7.0,,1.3360611782132408e+18,,0.0,0.0,,"RT @miljko: #ASH20 Abstract 598: Phase 1b/2 study of ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) in R/R BCL, 9am‚Ä¶",en,0.0,955.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,2.0,https://twitter.com/DrKateLurain/statuses/1336061178213240833,0.0,0.0,,0.0,0.0,0.0,2.0,5.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @miljko: #ASH20 Abstract 598: Phase 1b/2 study of ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) in R/R BCL, 9am‚Ä¶",true
JWatch,Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.,,"Waltham, MA",,2020-12-06 21:00:00+00:00,NEJM Journal Watch,http://twitter.com/,3.0,,1.3356904772621765e+18,,0.0,0.0,,#ASH2020 news from @NEJMGroup: Dr. Terry Gernsheimer discusses her team's research on the prophylactic use of trane‚Ä¶ https://t.co/qMPVc5Tonk,en,0.0,39079.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/JWatch/statuses/1335690477262176256,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,#ASH2020 news from @NEJMGroup: Dr. Terry Gernsheimer discusses her team's research on the prophylactic use of trane‚Ä¶ https://t.co/qMPVc5Tonk,true
AndreaAnampaG,"Medstudent @UNMSM_ with OCD ‚Ä¢ @ASCO & @AMWAdoctors Social Media
@CPsolvers Team Member ‚Ä¢ #Globaloncology #WomenInMedicine #MedEd #SurvOnc üáµüá™ #IMG üåà she/ella",,"Lima, Peru",,2020-12-07 22:05:28+00:00,Andrea Anampa-Guzm√°n,http://twitter.com/,36.0,,1.3360693423924388e+18,,0.0,0.0,,"RT @AAcosta_MedMD: #ASH20 #ASHTrainee #MedTwitter 

Don‚Äôt forget to check out our team‚Äôs poster (#1675) on complement-mediated TMA relapse‚Ä¶",en,0.0,1908.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,29.0,7.0,https://twitter.com/AndreaAnampaG/statuses/1336069342392438784,0.0,0.0,,0.0,0.0,0.0,7.0,29.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @AAcosta_MedMD: #ASH20 #ASHTrainee #MedTwitter 

Don‚Äôt forget to check out our team‚Äôs poster (#1675) on complement-mediated TMA relapse‚Ä¶",true
felrassi,Adult hematologist and sickle cell doctor @emorymedicine @winshipatemory @gradyhealth @slusom @AUBAlumni https://t.co/q6mGxISoAq,,"Georgia, USA",,2020-12-06 01:15:13+00:00,"Fuad El Rassi, MD",http://twitter.com/,29.0,,1.3353923162914202e+18,,0.0,0.0,,RT @PTMcGann: @DrSickleStrong is always an incredible speaker but this #ASH20 talk is a must watch. He carefully and clearly describes the‚Ä¶,en,0.0,227.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,21.0,8.0,https://twitter.com/felrassi/statuses/1335392316291420160,0.0,0.0,,0.0,0.0,0.0,8.0,21.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,RT @PTMcGann: @DrSickleStrong is always an incredible speaker but this #ASH20 talk is a must watch. He carefully and clearly describes the‚Ä¶,false
GruppSteve,"#CARTCell expert, bone marrow transplanter, pediatric oncologist, husband to my vastly better half. All opinions my own, not an investor. RT not=endorsementüåäüåä",,"Philadelphia, PA",,2020-12-06 12:45:29+00:00,Stephan Grupp MD PhD,http://twitter.com/,69.0,,1.335566027149767e+18,,0.0,0.0,,RT @Anand_88_Patel: So happy to see Dr. Wendy Stock winning the @ash_hematology #ASH20 Mentor Award! Since I first met her during fellowshi‚Ä¶,en,0.0,2534.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,62.0,7.0,https://twitter.com/GruppSteve/statuses/1335566027149766657,0.0,0.0,,0.0,0.0,0.0,7.0,62.0,False,False,False,False,True,Financial Performance,1.0,0.0,0.0,RT @Anand_88_Patel: So happy to see Dr. Wendy Stock winning the @ash_hematology #ASH20 Mentor Award! Since I first met her during fellowshi‚Ä¶,true
nadahamad,"BMT, cellular therapies and clinical haematologist, clinical researcher, lymphoma doc, mother of 3, feminist and ANZTCT president. Opinions are my own.",,"Sydney, Australia",,2020-12-07 22:50:37+00:00,A/Prof Nada Hamad,http://twitter.com/,20.0,,1.3360807037384172e+18,,0.0,0.0,,RT @BldCancerDoc: Our #CleClinicCancer @CleClinicMD hem-onc fellowship graduates are on üî•üî•üî• at #ASH20 - üëèüëèüëè @sagarpatel on leading this @CI‚Ä¶,en,0.0,346.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,17.0,3.0,https://twitter.com/nadahamad/statuses/1336080703738417153,0.0,0.0,,0.0,0.0,0.0,3.0,17.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @BldCancerDoc: Our #CleClinicCancer @CleClinicMD hem-onc fellowship graduates are on üî•üî•üî• at #ASH20 - üëèüëèüëè @sagarpatel on leading this @CI‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 12:33:37+00:00,"Ritcha Saxena, MD",http://twitter.com/,36.0,,1.3355630423404298e+18,,0.0,0.0,,RT @razan_mohty: Data from @LeukemiaMDA on VEN with Cladribine/LDAC alternating with azacitidine in newly diagnosed older #AML by Dr @TapKa‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,27.0,9.0,https://twitter.com/RitchaSaxena/statuses/1335563042340429824,0.0,0.0,,0.0,0.0,0.0,9.0,27.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @razan_mohty: Data from @LeukemiaMDA on VEN with Cladribine/LDAC alternating with azacitidine in newly diagnosed older #AML by Dr @TapKa‚Ä¶,true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-07 18:40:34+00:00,Lisa Palacios,http://twitter.com/,1.0,,1.3360177755344773e+18,,0.0,0.0,,"RT @hemedoc: #ASH20 #leusm Short (583): Overall CIR 8% if NGS MRD neg, 27% if only neg by MFC. No relapses in mini-hCVD cohort. When lookin‚Ä¶",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/Lisa_Palacios/statuses/1336017775534477315,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @hemedoc: #ASH20 #leusm Short (583): Overall CIR 8% if NGS MRD neg, 27% if only neg by MFC. No relapses in mini-hCVD cohort. When lookin‚Ä¶",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 01:53:47+00:00,"Ritcha Saxena, MD",http://twitter.com/,24.0,,1.335402024343638e+18,,0.0,0.0,,RT @DanaFarberNews: #ASH20 News: Dana-Farber researchers find promise in adding novel oral drug venetoclax to standard treatments in high-r‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,19.0,5.0,https://twitter.com/RitchaSaxena/statuses/1335402024343638017,0.0,0.0,,0.0,0.0,0.0,5.0,19.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @DanaFarberNews: #ASH20 News: Dana-Farber researchers find promise in adding novel oral drug venetoclax to standard treatments in high-r‚Ä¶,true
rajshekharucms,Hem/Onc Physician/Clinical Researcher @ColumbiaCancer #MultipleMyeloma & #Amyloidosis. Asst. Prof of Medicine @ColumbiaMed #ClinicalTrials and Outcomes Research,,"New York, NY",,2020-12-05 18:40:56+00:00,Raj Chakraborty,http://twitter.com/,2.0,,1.3352930909915832e+18,,0.0,0.0,,Low concordance between Bone Marrow MRD (10-5) and whole body DW-MRI in #Myeloma ‚û°Ô∏è demonstrates importance of inco‚Ä¶ https://t.co/03jYbXVdjr,en,0.0,1148.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/rajshekharucms/statuses/1335293090991583232,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,Low concordance between Bone Marrow MRD (10-5) and whole body DW-MRI in #Myeloma ‚û°Ô∏è demonstrates importance of inco‚Ä¶ https://t.co/03jYbXVdjr,false
hfrangoul,Pediatric Hematologist-Oncologist  |  Medical Director of Pediatric Transplant  |  Sarah Cannon Research Institute,,"Nashville, TN",,2020-12-06 03:08:28+00:00,Haydar Frangoul,http://twitter.com/,6.0,,1.3354208177069875e+18,,0.0,0.0,,RT @Physns1stWatch: News from #ASH2020: Dr. Haydar Frangoul talks about his team's work in developing a novel way to treat transfusion-depe‚Ä¶,en,0.0,32.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,2.0,https://twitter.com/hfrangoul/statuses/1335420817706987525,0.0,0.0,,0.0,0.0,0.0,2.0,4.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,RT @Physns1stWatch: News from #ASH2020: Dr. Haydar Frangoul talks about his team's work in developing a novel way to treat transfusion-depe‚Ä¶,true
AndreaAnampaG,"Medstudent @UNMSM_ with OCD ‚Ä¢ @ASCO & @AMWAdoctors Social Media
@CPsolvers Team Member ‚Ä¢ #Globaloncology #WomenInMedicine #MedEd #SurvOnc üáµüá™ #IMG üåà she/ella",,"Lima, Peru",,2020-12-06 20:58:56+00:00,Andrea Anampa-Guzm√°n,http://twitter.com/,40.0,,1.3356902100934902e+18,,0.0,0.0,,RT @RahmaWarsameMD: Promising results from phase 1 VSV-IFNb-NIS in pts with relapsed refractory hem malignancies. Strongest signal in TCL.‚Ä¶,en,0.0,1908.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,30.0,10.0,https://twitter.com/AndreaAnampaG/statuses/1335690210093490176,0.0,0.0,,0.0,0.0,0.0,10.0,30.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @RahmaWarsameMD: Promising results from phase 1 VSV-IFNb-NIS in pts with relapsed refractory hem malignancies. Strongest signal in TCL.‚Ä¶,true
graham74GC,Lymphoma specialist at Oxford Cancer and Haematology centre. Haematologist and clinical trialist. Chair of UK Hodgkin and T-cell study groups.,,Opinions are mine,,2020-12-06 17:00:36+00:00,Graham Collins,http://twitter.com/,31.0,,1.335630229163946e+18,,0.0,0.0,,RT @Mohty_EBMT: Amazing twitter community at #ASH20 @Mohty_EBMT https://t.co/9dsa2DZZHc,en,0.0,6091.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,25.0,6.0,https://twitter.com/graham74GC/statuses/1335630229163945987,0.0,0.0,,0.0,0.0,0.0,6.0,25.0,False,False,False,False,True,Disease Advocacy,1.0,0.0,0.0,RT @Mohty_EBMT: Amazing twitter community at #ASH20 @Mohty_EBMT https://t.co/9dsa2DZZHc,true
SarahCannonDocs,Fighting Cancer Together. Find out the latest news directly from Sarah Cannon physicians.,,"Nashville, TN",,2020-12-07 18:05:09+00:00,Sarah Cannon Docs,http://twitter.com/,9.0,,1.3360088650586112e+18,,0.0,0.0,,"RT @lymphomahub: CONGRESS | #ASH20 | Aravind Ramakrishnan, @SarahCannonDocs, presents the results from the phase I Alexander study evaluati‚Ä¶",en,0.0,2504.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,3.0,https://twitter.com/SarahCannonDocs/statuses/1336008865058611203,0.0,0.0,,0.0,0.0,0.0,3.0,6.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @lymphomahub: CONGRESS | #ASH20 | Aravind Ramakrishnan, @SarahCannonDocs, presents the results from the phase I Alexander study evaluati‚Ä¶",true
CaptainAV,"blood doctor #researcher finding new treatments for #SickleCell #Thalassemia #PKdeficiency #G6PD #PNH #aHUS #TMA #CDA #HS #HE/#HPP, also @MSF Tweets are my own",,,,2020-12-06 20:30:24+00:00,Kevin Kuo,http://twitter.com/,1.0,,1.335683030711722e+18,,0.0,0.0,,More #KT and validation studies to come! Please PM me or @stephanie_forte if you wish to #collaborate with us!‚Ä¶ https://t.co/qXzhAJ0JHg,en,0.0,274.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/CaptainAV/statuses/1335683030711721984,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,More #KT and validation studies to come! Please PM me or @stephanie_forte if you wish to #collaborate with us!‚Ä¶ https://t.co/qXzhAJ0JHg,true
rajshekharucms,Hem/Onc Physician/Clinical Researcher @ColumbiaCancer #MultipleMyeloma & #Amyloidosis. Asst. Prof of Medicine @ColumbiaMed #ClinicalTrials and Outcomes Research,,"New York, NY",,2020-12-07 23:51:57+00:00,Raj Chakraborty,http://twitter.com/,3.0,,1.3360961390037852e+18,,0.0,0.0,,RT @AuclairDan: Jason Valent at #ASH20 providing an update on ongoing Phase II trial of CAEL-101 in AL Amyloidosis #mmsm https://t.co/Hsb6n‚Ä¶,en,0.0,1148.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,2.0,1.0,https://twitter.com/rajshekharucms/statuses/1336096139003785220,0.0,0.0,,0.0,0.0,0.0,1.0,2.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @AuclairDan: Jason Valent at #ASH20 providing an update on ongoing Phase II trial of CAEL-101 in AL Amyloidosis #mmsm https://t.co/Hsb6n‚Ä¶,false
sghmd,hematologist and bleeding-heart optimist üåÑ | clinical/translational #GVHD physician scientist | powerlifter üèãÔ∏è‚Äç‚ôÄÔ∏è | personal views |  physician ‚â† provider,,location:  in my head,,2020-12-07 22:55:01+00:00,Shernan Holtan MD,http://twitter.com/,0.0,,1.3360818093277225e+18,,0.0,0.0,,‚ÄúImproving Symptom Control for Children with Hematological Malignancies‚Äù by @drbobphillips is a major #ASH20 gem üíé!‚Ä¶ https://t.co/q65jln6zv3,en,0.0,1463.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/sghmd/statuses/1336081809327722498,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,‚ÄúImproving Symptom Control for Children with Hematological Malignancies‚Äù by @drbobphillips is a major #ASH20 gem üíé!‚Ä¶ https://t.co/q65jln6zv3,true
RuthClifford5,"Consultant Haematologist, University Hospital Limerick, IRL. Special interests CLL, genomics, MPNs.",,,,2020-12-06 13:26:25+00:00,Ruth Clifford,http://twitter.com/,25.0,,1.3355763283981066e+18,,0.0,0.0,,"RT @crowley_maeve: Great session by ‚Å¶@fniainle‚Å©,‚Å¶@Erik_Klok_MD‚Å© and ‚Å¶@WeeShianChan‚Å© regarding diagnostic and prognostic models in vte manag‚Ä¶",en,0.0,287.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,22.0,3.0,https://twitter.com/RuthClifford5/statuses/1335576328398106625,0.0,0.0,,0.0,0.0,0.0,3.0,22.0,False,False,False,False,True,Diagnostic Tools,1.0,0.0,0.0,"RT @crowley_maeve: Great session by ‚Å¶@fniainle‚Å©,‚Å¶@Erik_Klok_MD‚Å© and ‚Å¶@WeeShianChan‚Å© regarding diagnostic and prognostic models in vte manag‚Ä¶",true
MDedgeHemOnc,MDedge Hematology & Oncology provides the most important and up to date information and news for oncologists. Now part of the Medscape Professional Network.,,"Rockville, MD, Parsippany, NJ",,2020-12-07 12:09:27+00:00,MDedge Hematology & Oncology,http://twitter.com/,1.0,,1.3359193487000945e+18,,0.0,0.0,,Overall mortality was 28% for the first 250 patients entered into the ASH Research Collaborative COVID-19 Registry‚Ä¶ https://t.co/D6quLFs4bl,en,0.0,6726.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/MDedgeHemOnc/statuses/1335919348700094466,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,Overall mortality was 28% for the first 250 patients entered into the ASH Research Collaborative COVID-19 Registry‚Ä¶ https://t.co/D6quLFs4bl,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 23:52:51+00:00,"Ritcha Saxena, MD",http://twitter.com/,4.0,,1.3357339775634885e+18,,0.0,0.0,,RT @TaniaJain11: #ASH20 #Diversity #Equity #Inclusion This is where ASH and our work goes beyond Science ! congratulations to @BhavanaBhatn‚Ä¶,en,0.0,6875.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,1.0,https://twitter.com/RitchaSaxena/statuses/1335733977563488256,0.0,0.0,,0.0,0.0,0.0,1.0,3.0,False,False,False,False,True,Financial Performance,1.0,0.0,0.0,RT @TaniaJain11: #ASH20 #Diversity #Equity #Inclusion This is where ASH and our work goes beyond Science ! congratulations to @BhavanaBhatn‚Ä¶,true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-07 17:54:24+00:00,Lisa Palacios,http://twitter.com/,11.0,,1.3360061563896422e+18,,0.0,0.0,,"RT @AML_Hub: Congress| #ASH20| @DanielleHammo20, @LeukemiaMDA, investigated response patterns and MRD in patients with IDH-mutated AML trea‚Ä¶",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,9.0,2.0,https://twitter.com/Lisa_Palacios/statuses/1336006156389642240,0.0,0.0,,0.0,0.0,0.0,2.0,9.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,"RT @AML_Hub: Congress| #ASH20| @DanielleHammo20, @LeukemiaMDA, investigated response patterns and MRD in patients with IDH-mutated AML trea‚Ä¶",true
alshamsi2000,ÿ±ÿ¶Ÿäÿ≥ ÿ¨ŸÖÿπŸäÿ© ÿßŸÑÿ•ŸÖÿßÿ±ÿßÿ™ ŸÑŸÑÿ£Ÿàÿ±ÿßŸÖ President of the Emirates oncology Society - ÿßŸÑÿ®Ÿàÿ±ÿØ üá¨üáßüá®üá¶üá∫üá∏ ÿåŸÖÿØŸäÿ± ŸÖÿπŸáÿØ ÿ®ÿ±ÿ¨ŸäŸÑ ŸÑŸÑÿ£Ÿàÿ±ÿßŸÖ Director of BCI - MD Anderson Alumni- üá¶üá™,,Abu Dhabi,,2020-12-05 12:10:29+00:00,üü¢Dr.Humaid Al-Shamsi üá¶üá™,http://twitter.com/,30.0,,1.3351948327389143e+18,,0.0,0.0,,RT @COVID19nCCC: Severity of Sars-Cov-2 Infection in Pts w/ Hematologic Malignancies: A COVID-19 &amp; Cancer Consortium (#CCC19) Registry Anal‚Ä¶,en,0.0,11527.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,21.0,9.0,https://twitter.com/alshamsi2000/statuses/1335194832738914305,0.0,0.0,,0.0,0.0,0.0,9.0,21.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,RT @COVID19nCCC: Severity of Sars-Cov-2 Infection in Pts w/ Hematologic Malignancies: A COVID-19 &amp; Cancer Consortium (#CCC19) Registry Anal‚Ä¶,false
brave_is_now,Psychotherapist/Advocate surviving & thriving with CLL as third cancer #CLLStrong #braveisnow #formygirls #momwithcancer #greatfulfor2day contact@braveisnow.com,,"NYC-MA  ",,2020-12-16 15:58:11+00:00,Brave Is Now¬Æ,http://twitter.com/,2.0,,1.3392384003527762e+18,,0.0,0.0,,"RT @PatientPower: NEW FROM #ASH20: Leading #CLL experts, Dr. Allan (@WeillCornell), Dr. Barrientos (@NorthwellHealth) &amp; @wwierda (@Leukemia‚Ä¶",en,0.0,241.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/brave_is_now/statuses/1339238400352776195,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @PatientPower: NEW FROM #ASH20: Leading #CLL experts, Dr. Allan (@WeillCornell), Dr. Barrientos (@NorthwellHealth) &amp; @wwierda (@Leukemia‚Ä¶",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-16 15:24:26+00:00,Lisa Palacios,http://twitter.com/,2.0,,1.3392299101293158e+18,,0.0,0.0,,"RT @PatientPower: NEW FROM #ASH20: Leading #CLL experts, Dr. Allan (@WeillCornell), Dr. Barrientos (@NorthwellHealth) &amp; @wwierda (@Leukemia‚Ä¶",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/Lisa_Palacios/statuses/1339229910129315840,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @PatientPower: NEW FROM #ASH20: Leading #CLL experts, Dr. Allan (@WeillCornell), Dr. Barrientos (@NorthwellHealth) &amp; @wwierda (@Leukemia‚Ä¶",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-16 21:40:56+00:00,Lisa Palacios,http://twitter.com/,5.0,,1.3393246567723295e+18,,0.0,0.0,,"RT @PatientPower: NEW FROM #ASH20: Phase 2 Study Combining Navitoclax and Ruxolitinib Sees Promising Results

Dr. Srdan Verstovsek, from @L‚Ä¶",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,2.0,https://twitter.com/Lisa_Palacios/statuses/1339324656772329473,0.0,0.0,,0.0,0.0,0.0,2.0,3.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @PatientPower: NEW FROM #ASH20: Phase 2 Study Combining Navitoclax and Ruxolitinib Sees Promising Results

Dr. Srdan Verstovsek, from @L‚Ä¶",true
EladSharonMD,"#MedicalOncologist tweeting on #immunotherapy, #drugdevelopment, #COVID19 & #HealthEcon. #NCI #CancerMoonshot Adult Immunotherapy Co-Chair. Tweets are mine.",,"Washington, DC",,2020-12-18 03:52:43+00:00,Elad Sharon,http://twitter.com/,26.0,,1.3397806060461834e+18,,0.0,0.0,,RT @Dr_AmerZeidan: One of the few bright spots of the pandemic year 2020 has been starting the new #MDSsm ‚ÄúMDS Sessions‚Äù series with @VJHem‚Ä¶,en,0.0,2113.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,21.0,5.0,https://twitter.com/EladSharonMD/statuses/1339780606046183425,0.0,0.0,,0.0,0.0,0.0,5.0,21.0,False,False,False,False,True,Covid,0.0,0.0,1.0,RT @Dr_AmerZeidan: One of the few bright spots of the pandemic year 2020 has been starting the new #MDSsm ‚ÄúMDS Sessions‚Äù series with @VJHem‚Ä¶,true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-12-18 14:38:00+00:00,Oncology Tube,http://twitter.com/,1.0,,1.339942997723472e+18,,0.0,0.0,,"Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib Tycel J. Phillips, MD @UMRogelCancer @UMich #ASH20‚Ä¶ https://t.co/u7TJm5PWRR",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/oncologytube/statuses/1339942997723471873,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib Tycel J. Phillips, MD @UMRogelCancer @UMich #ASH20‚Ä¶ https://t.co/u7TJm5PWRR",true
lepikurian,"Haematologist, researcher, biotech startup co-founder",,"Saint-Petersburg, Russia",,2020-12-17 00:37:03+00:00,Kirill Lepik M.D.,http://twitter.com/,48.0,,1.339368978855174e+18,,0.0,0.0,,"RT @graham74GC: #CollinsConclusions -Hodgkin
PD1i powers on
‚Ä¢ Pembro+GVD v active 1L relapse
- 94% CR in 34 eval pts: wow!
‚Ä¢ QoL superior f‚Ä¶",en,0.0,89.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,40.0,8.0,https://twitter.com/lepikurian/statuses/1339368978855174144,0.0,0.0,,0.0,0.0,0.0,8.0,40.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @graham74GC: #CollinsConclusions -Hodgkin
PD1i powers on
‚Ä¢ Pembro+GVD v active 1L relapse
- 94% CR in 34 eval pts: wow!
‚Ä¢ QoL superior f‚Ä¶",false
MDedgeHemOnc,MDedge Hematology & Oncology provides the most important and up to date information and news for oncologists. Now part of the Medscape Professional Network.,,"Rockville, MD, Parsippany, NJ",,2020-12-18 02:13:01+00:00,MDedge Hematology & Oncology,http://twitter.com/,1.0,,1.3397555175902904e+18,,0.0,0.0,,"Allogeneic transplant can lead to durable remissions in T-cell lymphoma, #ASH20 study finds.‚Ä¶ https://t.co/dtU8EoimDq",en,0.0,6726.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/MDedgeHemOnc/statuses/1339755517590290432,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"Allogeneic transplant can lead to durable remissions in T-cell lymphoma, #ASH20 study finds.‚Ä¶ https://t.co/dtU8EoimDq",true
CellworksLife,"Cellworks is a world leader in Precision Medicine. We help physicians & payors navigate to efficacious cost effective treatments in a transparent, timely manner",,"San Jose, CA",,2020-12-18 06:17:21+00:00,CellworksLife,http://twitter.com/,2.0,,1.339817004266492e+18,,0.0,0.0,,"RT @CellworksLife: Predicting Resistance to the Combination of ATO and ATRA in APL Patients with PML-Rara Fusions, Using a Computational Bi‚Ä¶",en,0.0,144.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,1.0,1.0,https://twitter.com/CellworksLife/statuses/1339817004266491904,0.0,0.0,,0.0,0.0,0.0,1.0,1.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"RT @CellworksLife: Predicting Resistance to the Combination of ATO and ATRA in APL Patients with PML-Rara Fusions, Using a Computational Bi‚Ä¶",true
CphtStoke,"CPHT Stoke trains local people to be Solution Focused Hypnotherapists. Its a fun, practical & fully accredited 10 month course that leads to 2 qualifications.",,,,2020-11-30 10:16:52+00:00,CPHT Stoke,http://twitter.com/,0.0,,1.3333542994396529e+18,,0.0,0.0,,"Jenny, one of the tutors of CPHT Stoke, helping to raise awareness of local charity, 'A child of mine' by doing a 2‚Ä¶ https://t.co/rUU8OaJcd1",en,0.0,5.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/CphtStoke/statuses/1333354299439652866,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Disease Advocacy,1.0,0.0,0.0,"Jenny, one of the tutors of CPHT Stoke, helping to raise awareness of local charity, 'A child of mine' by doing a 2‚Ä¶ https://t.co/rUU8OaJcd1",true
BurgosLopezLuz,Co-founder of Colectivo Bambula   (she/her/hers) Doctoral Student| Neag School of Education| UConn| H.E. Professional| #QPOC #BlackLivesMatter üáµüá∑,,"Hartford, CT",,2020-11-18 16:56:08+00:00,Luz Burgos-L√≥pez,http://twitter.com/,0.0,,1.3291061259801354e+18,,0.0,0.0,,"So, we are centering whiteness once again in equity and racial justice work in higher education.  Neoliberalism  an‚Ä¶ https://t.co/Unh7qBNav9",en,0.0,431.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/BurgosLopezLuz/statuses/1329106125980135425,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,"So, we are centering whiteness once again in equity and racial justice work in higher education.  Neoliberalism  an‚Ä¶ https://t.co/Unh7qBNav9",true
CleClinicMD,"News and insights for physicians and clinical professionals from @ClevelandClinic. Research, case studies and CME opportunities.",,"Cleveland, Ohio, United States",,2020-12-01 03:23:59+00:00,Cleveland Clinic MD,http://twitter.com/,1.0,,1.333612785129939e+18,,0.0,0.0,,New discoveries could open the door to a new generation of genetics-based diagnosis in Leukemia: #ASH20,en,0.0,302311.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/CleClinicMD/statuses/1333612785129938946,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,New discoveries could open the door to a new generation of genetics-based diagnosis in Leukemia: #ASH20,true
majorajay,"Hematology/oncology fellow. #lymsm & #mmsm outcomes researcher. Physician-publisher & founder of https://t.co/dPfLt8QVMr, @inTrainingDoc & @inHouseMag.",,"Chicago, IL",,2020-11-17 18:53:00+00:00,"Ajay Major, MD, MBA",http://twitter.com/,0.0,,1.328773147206824e+18,,0.0,0.0,,"Thanks for the mention, @UCHemOncFellows! I'm stoked for @ASH_hematology #ASH20 this year -- can't wait to connect‚Ä¶ https://t.co/a5PUfEYvsj",en,0.0,3518.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/majorajay/statuses/1328773147206823939,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"Thanks for the mention, @UCHemOncFellows! I'm stoked for @ASH_hematology #ASH20 this year -- can't wait to connect‚Ä¶ https://t.co/a5PUfEYvsj",false
DrESHAJ9,"a passionate medical oncologist, a spiritual seeker",,,,2020-11-17 15:16:54+00:00,EJ,http://twitter.com/,37.0,,1.328718766075642e+18,,0.0,0.0,,"RT @DrMiguelPerales: #EBMT20 #EBMT20virtual CD34+ Allo HCT, &lt; GVHD, no increase in relapse, Better CRFS - Waiting for results of @BMTCTN 13‚Ä¶",en,0.0,315.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,27.0,10.0,https://twitter.com/DrESHAJ9/statuses/1328718766075641858,0.0,0.0,,0.0,0.0,0.0,10.0,27.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @DrMiguelPerales: #EBMT20 #EBMT20virtual CD34+ Allo HCT, &lt; GVHD, no increase in relapse, Better CRFS - Waiting for results of @BMTCTN 13‚Ä¶",true
majorajay,"Hematology/oncology fellow. #lymsm & #mmsm outcomes researcher. Physician-publisher & founder of https://t.co/dPfLt8QVMr, @inTrainingDoc & @inHouseMag.",,"Chicago, IL",,2020-12-03 16:29:47+00:00,"Ajay Major, MD, MBA",http://twitter.com/,0.0,,1.3345353115908751e+18,,0.0,0.0,,It's also an issue of equity: trainees without the financial means to travel should have access to all of the educa‚Ä¶ https://t.co/bgwcB9Jl1l,en,0.0,3518.0,,,0.0,majorajay,1.3345347066086728e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/majorajay/statuses/1334535311590875137,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,It's also an issue of equity: trainees without the financial means to travel should have access to all of the educa‚Ä¶ https://t.co/bgwcB9Jl1l,true
AimeeTalleurMD,Physician Scientist | Pediatric BMT & Immunotherapy | Clinical Trial Development | Med-ed | Academics | Twin Mom | opinions=my own | @stjuderesearch,,"Memphis, TN",,2020-12-03 16:45:15+00:00,"Aimee Talleur, MD",http://twitter.com/,0.0,,1.3345392057253317e+18,,0.0,0.0,,key take-aways: be humble. be patient. be persistent. collaborations are a good thing. thank you @DrAlexisThompsn ! #ASH20,en,0.0,345.0,,,0.0,AimeeTalleurMD,1.334536525535703e+18,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/AimeeTalleurMD/statuses/1334539205725331458,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,key take-aways: be humble. be patient. be persistent. collaborations are a good thing. thank you @DrAlexisThompsn ! #ASH20,true
HKlepinMD,Geriatric oncologist,,,,2020-12-03 22:14:44+00:00,Heidi Klepin,http://twitter.com/,16.0,,1.3346221198928404e+18,,0.0,0.0,,"RT @ShakiraG_MBBS: #ASH2020 join the #geriheme #GeriHeme, #gerihem #gerionc community online now‚¨áÔ∏è to learn about the exciting advances in‚Ä¶",en,0.0,902.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,13.0,3.0,https://twitter.com/HKlepinMD/statuses/1334622119892840452,0.0,0.0,,0.0,0.0,0.0,3.0,13.0,False,False,False,False,True,Disease Advocacy,1.0,0.0,0.0,"RT @ShakiraG_MBBS: #ASH2020 join the #geriheme #GeriHeme, #gerihem #gerionc community online now‚¨áÔ∏è to learn about the exciting advances in‚Ä¶",true
AndreaAnampaG,"Medstudent @UNMSM_ with OCD ‚Ä¢ @ASCO & @AMWAdoctors Social Media
@CPsolvers Team Member ‚Ä¢ #Globaloncology #WomenInMedicine #MedEd #SurvOnc üáµüá™ #IMG üåà she/ella",,"Lima, Peru",,2020-12-04 15:53:52+00:00,Andrea Anampa-Guzm√°n,http://twitter.com/,18.0,,1.334888662924923e+18,,0.0,0.0,,RT @vasconez_w: Make sure to join the pre-conference CME on ‚ÄúAn optimized approach to Sickle Cell Disease Care in the New Era of Treatment‚Äù‚Ä¶,en,0.0,1908.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,14.0,4.0,https://twitter.com/AndreaAnampaG/statuses/1334888662924922881,0.0,0.0,,0.0,0.0,0.0,4.0,14.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @vasconez_w: Make sure to join the pre-conference CME on ‚ÄúAn optimized approach to Sickle Cell Disease Care in the New Era of Treatment‚Äù‚Ä¶,true
NBahlis,"Physician-scientist focused on multiple myeloma
Tweets are my own.",,,,2020-12-04 16:34:42+00:00,nizar jacques bahlis,http://twitter.com/,12.0,,1.3348989363691397e+18,,0.0,0.0,,RT @AuclairDan: ‚Å¶@HJChoMDPhD1‚Å© on triplets vs Dara-containing quads. Quads showing benefit in the relapse setting but not yet upfront. Inte‚Ä¶,en,0.0,436.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,8.0,4.0,https://twitter.com/NBahlis/statuses/1334898936369139712,0.0,0.0,,0.0,0.0,0.0,4.0,8.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @AuclairDan: ‚Å¶@HJChoMDPhD1‚Å© on triplets vs Dara-containing quads. Quads showing benefit in the relapse setting but not yet upfront. Inte‚Ä¶,false
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-04 16:40:29+00:00,Lisa Palacios,http://twitter.com/,16.0,,1.334900393025925e+18,,0.0,0.0,,"RT @smbenlazar: How I Think, How I Treat in the New Age of #AML Care: Personal Perspectives on New Evidence and Innovative Therapeutics  #A‚Ä¶",en,0.0,657.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,12.0,4.0,https://twitter.com/Lisa_Palacios/statuses/1334900393025925120,0.0,0.0,,0.0,0.0,0.0,4.0,12.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"RT @smbenlazar: How I Think, How I Treat in the New Age of #AML Care: Personal Perspectives on New Evidence and Innovative Therapeutics  #A‚Ä¶",true
VincentRK,"Professor, Mayo Clinic; Editor, Blood Cancer Journal; Oncologist; Health Costs; COVID threads @SurvivedCOVID Opinions=personal views https://t.co/TMq9vc5hZk",,"Rochester, MN, USA",,2020-12-04 14:59:00+00:00,Vincent Rajkumar,http://twitter.com/,0.0,,1.3348748548484055e+18,,0.0,0.0,,"3. In patients needing Auto transplant for relapsed DLBCL, interestingly the GCB type had poorer outcome compared t‚Ä¶ https://t.co/nvJ2tmTTGI",en,0.0,33590.0,,,0.0,VincentRK,1.334874849467097e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/VincentRK/statuses/1334874854848405504,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"3. In patients needing Auto transplant for relapsed DLBCL, interestingly the GCB type had poorer outcome compared t‚Ä¶ https://t.co/nvJ2tmTTGI",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-04 00:00:14+00:00,"Ritcha Saxena, MD",http://twitter.com/,32.0,,1.3346486709569577e+18,,0.0,0.0,,RT @pietras_eric: Geared up for #ASHmyeloidworkshop great lineup! Stem Cell session has cutting edge science from @DesaiLabCWRU @BeermanHSC‚Ä¶,en,0.0,6875.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,28.0,4.0,https://twitter.com/RitchaSaxena/statuses/1334648670956957704,0.0,0.0,,0.0,0.0,0.0,4.0,28.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,RT @pietras_eric: Geared up for #ASHmyeloidworkshop great lineup! Stem Cell session has cutting edge science from @DesaiLabCWRU @BeermanHSC‚Ä¶,true
gretnhe,"Hematologists, biologists, dermatologists and technicians who work together to transfer research to patients.",,"Barcelona, Espanya",,2020-12-04 19:06:09+00:00,Grup de Recerca Translacional Hematologia_GRETNHE,http://twitter.com/,11.0,,1.3349370511715328e+18,,0.0,0.0,,Dr. Calvo team referenced for their contributions to MDS diagnosis and classification at MDS symposium #ASH20‚Ä¶ https://t.co/LnhoL6uNDr,en,0.0,172.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,11.0,https://twitter.com/gretnhe/statuses/1334937051171532806,0.0,0.0,,0.0,0.0,0.0,11.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,Dr. Calvo team referenced for their contributions to MDS diagnosis and classification at MDS symposium #ASH20‚Ä¶ https://t.co/LnhoL6uNDr,true
TelehealthBot,Created by Doctor @KrittanawongMD. A bot that collects Tweets about medicine and medical innovation,,GJ 357 d,,2020-12-09 19:12:15+00:00,MedEd,http://twitter.com/,2.0,,1.3367505240377958e+18,,0.0,0.0,,RT @OncologyTimes: #ASH2020 Highlight: New Treatment for Achieving Hodgkin #Lymphoma Remission https://t.co/swfOKrjsCw #cancertreatment #me‚Ä¶,en,0.0,683.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,1.0,1.0,https://twitter.com/TelehealthBot/statuses/1336750524037795842,0.0,0.0,,0.0,0.0,0.0,1.0,1.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @OncologyTimes: #ASH2020 Highlight: New Treatment for Achieving Hodgkin #Lymphoma Remission https://t.co/swfOKrjsCw #cancertreatment #me‚Ä¶,true
sanamloghavi,Hematopathologist/Molecular Pathologist @mdandersonnews #endcancer #hemepath #mpnsm #lymsm #leusm #hemepathMDA Tweets are my own.,,"Houston, TX",,2020-12-09 14:45:57+00:00,"Sanam Loghavi, MD",http://twitter.com/,9.0,,1.336683510002815e+18,,0.0,0.0,,major diagnostic pitfall 4 High-grade (double/triple hit) lymphoma with leukemic presentation is misclassifying as‚Ä¶ https://t.co/CRF8EciVvY,en,0.0,4797.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,9.0,https://twitter.com/sanamloghavi/statuses/1336683510002814976,0.0,0.0,,0.0,0.0,0.0,9.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,major diagnostic pitfall 4 High-grade (double/triple hit) lymphoma with leukemic presentation is misclassifying as‚Ä¶ https://t.co/CRF8EciVvY,false
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-09 00:31:31+00:00,"Ritcha Saxena, MD",http://twitter.com/,52.0,,1.3364684838954148e+18,,0.0,0.0,,RT @BldCancerDoc: Did #ASH20 notice that üëá session has an awesome moderator and three üåüüåüüåü speakers - and all of them are women! #ASHKudos @‚Ä¶,en,0.0,6875.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,45.0,7.0,https://twitter.com/RitchaSaxena/statuses/1336468483895414786,0.0,0.0,,0.0,0.0,0.0,7.0,45.0,False,False,False,False,True,Thought Leadership,1.0,0.0,0.0,RT @BldCancerDoc: Did #ASH20 notice that üëá session has an awesome moderator and three üåüüåüüåü speakers - and all of them are women! #ASHKudos @‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-09 00:22:51+00:00,"Ritcha Saxena, MD",http://twitter.com/,5.0,,1.3364663003364762e+18,,0.0,0.0,,"RT @VJHemOnc: The VJSessions: Register for the post-ASH roundtable discussions with leading experts!

Don‚Äôt miss our #MDSsm session üëâhttps:‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,1.0,https://twitter.com/RitchaSaxena/statuses/1336466300336476160,0.0,0.0,,0.0,0.0,0.0,1.0,4.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @VJHemOnc: The VJSessions: Register for the post-ASH roundtable discussions with leading experts!

Don‚Äôt miss our #MDSsm session üëâhttps:‚Ä¶",true
JWatch,Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.,,"Waltham, MA",,2020-12-09 15:52:59+00:00,NEJM Journal Watch,http://twitter.com/,3.0,,1.3367003772746506e+18,,0.0,0.0,,RT @Physns1stWatch: News from #ASH20: Dr. Christopher Gibson talks with Joe Elia about new findings that show it might not be necessary to‚Ä¶,en,0.0,39079.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,2.0,1.0,https://twitter.com/JWatch/statuses/1336700377274650624,0.0,0.0,,0.0,0.0,0.0,1.0,2.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @Physns1stWatch: News from #ASH20: Dr. Christopher Gibson talks with Joe Elia about new findings that show it might not be necessary to‚Ä¶,true
dnair78,"Surgeon, mother, Aquarian,  fledgling dancer...",,,,2020-12-09 03:12:50+00:00,Deepa,http://twitter.com/,20.0,,1.3365090808698266e+18,,0.0,0.0,,RT @DrMMurphy: This clarity can be hard to find in a loud world that likes to tell you what you ‚Äúshould‚Äù be. Invest in the time to figure t‚Ä¶,en,0.0,307.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,18.0,2.0,https://twitter.com/dnair78/statuses/1336509080869826562,0.0,0.0,,0.0,0.0,0.0,2.0,18.0,False,False,False,False,True,Financial Performance,1.0,0.0,0.0,RT @DrMMurphy: This clarity can be hard to find in a loud world that likes to tell you what you ‚Äúshould‚Äù be. Invest in the time to figure t‚Ä¶,true
rositadeolivop1,#surgical pathologist #pathology #hemepath #UNAM #Oaxaca #HGM_OD SSA @ampatologia @SOLAHP_ORG @ColegioOaxaca @FEDPATMEX1,,"Oaxaca, M√©xico",,2020-12-09 16:45:13+00:00,Rosalinda Pe√±aloza,http://twitter.com/,38.0,,1.3367135227897037e+18,,0.0,0.0,,RT @sanamloghavi: major diagnostic pitfall 4 High-grade (double/triple hit) lymphoma with leukemic presentation is misclassifying as de nov‚Ä¶,en,0.0,1920.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,29.0,9.0,https://twitter.com/rositadeolivop1/statuses/1336713522789703682,0.0,0.0,,0.0,0.0,0.0,9.0,29.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @sanamloghavi: major diagnostic pitfall 4 High-grade (double/triple hit) lymphoma with leukemic presentation is misclassifying as de nov‚Ä¶,true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-12-09 18:45:00+00:00,Oncology Tube,http://twitter.com/,0.0,,1.3367436671811338e+18,,0.0,0.0,,"Long-Term Efficacy and Safety Results from a Phase 2 Study Michael Wang, MD @michaelwangmd @MDAndersonnews #ASH20‚Ä¶ https://t.co/ykyk7qeJKc",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1336743667181133825,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"Long-Term Efficacy and Safety Results from a Phase 2 Study Michael Wang, MD @michaelwangmd @MDAndersonnews #ASH20‚Ä¶ https://t.co/ykyk7qeJKc",false
KellySchoenbeck,"Hematology/Oncology Fellow @UCSFCancer | IM @ColumbiaMed | MD @OHSUSOM | hematology, myeloid malignancies #QOL #geriheme | tweets my own",,,,2020-12-07 02:23:20+00:00,Kelly Schoenbeck,http://twitter.com/,29.0,,1.3357718470240256e+18,,0.0,0.0,,RT @MazieTsangMD: #ASH20 #ASHKudos to @UCSFCancer fellow @SwethaKMD who worked so hard on this phase 2 study of Dara + Aza + Dex (Darazadex‚Ä¶,en,0.0,48.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,22.0,7.0,https://twitter.com/KellySchoenbeck/statuses/1335771847024025600,0.0,0.0,,0.0,0.0,0.0,7.0,22.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @MazieTsangMD: #ASH20 #ASHKudos to @UCSFCancer fellow @SwethaKMD who worked so hard on this phase 2 study of Dara + Aza + Dex (Darazadex‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-07 00:56:25+00:00,"Ritcha Saxena, MD",http://twitter.com/,29.0,,1.3357499738755643e+18,,0.0,0.0,,RT @MazieTsangMD: #ASH20 #ASHKudos to @UCSFCancer fellow @SwethaKMD who worked so hard on this phase 2 study of Dara + Aza + Dex (Darazadex‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,22.0,7.0,https://twitter.com/RitchaSaxena/statuses/1335749973875564545,0.0,0.0,,0.0,0.0,0.0,7.0,22.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @MazieTsangMD: #ASH20 #ASHKudos to @UCSFCancer fellow @SwethaKMD who worked so hard on this phase 2 study of Dara + Aza + Dex (Darazadex‚Ä¶,true
gjmccaughan,"Haematologist interested in plasma cell disorders Zamasa Foundation Myeloma Fellow, Kinghorn Cancer Centre, St Vincent‚Äôs Hospital, Sydney",,,,2020-12-07 03:13:50+00:00,Georgia McCaughan,http://twitter.com/,2.0,,1.335784558017409e+18,,0.0,0.0,,"In first collaboration between @ALLGtrials #AMWG and Asian Myeloma Network, #@HangQuach1 presents at #ASH20 Phase I‚Ä¶ https://t.co/eXiLSgEdgU",en,0.0,528.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/gjmccaughan/statuses/1335784558017409024,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"In first collaboration between @ALLGtrials #AMWG and Asian Myeloma Network, #@HangQuach1 presents at #ASH20 Phase I‚Ä¶ https://t.co/eXiLSgEdgU",true
drng,A Doctor Doctor. As seen fleetingly on Netflix. Author of this Magnum Opus in @NatureComms üëâ https://t.co/luZqhBspBt,,Australia,,2020-12-07 05:55:19+00:00,Lord Blood,http://twitter.com/,25.0,,1.3358251933993288e+18,,0.0,0.0,,"RT @srpasricha: In time for #ASH20: our @TheLancet seminar on #irondeficiency. An update on the pathophysiology, epidemiology, diagnosis, f‚Ä¶",en,0.0,2226.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,20.0,5.0,https://twitter.com/drng/statuses/1335825193399328774,0.0,0.0,,0.0,0.0,0.0,5.0,20.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"RT @srpasricha: In time for #ASH20: our @TheLancet seminar on #irondeficiency. An update on the pathophysiology, epidemiology, diagnosis, f‚Ä¶",true
BCD_AACR,Follow Blood Cancer Discovery for high-impact articles on pace-setting advances of researchers and physician-scientists working globally. Published by @AACR.,,,,2020-12-07 22:15:05+00:00,Blood Cancer Discovery,http://twitter.com/,8.0,,1.3360717592090993e+18,,0.0,0.0,,"Dr Nikhil Munshi presents clinical data on BCMA loss in #myeloma #CAR_T relapse #ASH20. 
Read a related commentary,‚Ä¶ https://t.co/DyBIBYN65t",en,0.0,1332.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,8.0,https://twitter.com/BCD_AACR/statuses/1336071759209099266,0.0,0.0,,0.0,0.0,0.0,8.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"Dr Nikhil Munshi presents clinical data on BCMA loss in #myeloma #CAR_T relapse #ASH20. 
Read a related commentary,‚Ä¶ https://t.co/DyBIBYN65t",true
MDAndersonNews,"The official account of MD Anderson Cancer Center, a leader in cancer care, cancer research and the fight to #EndCancer. Appointments available: 1-877-632-6789.",,"Houston, TX",,2020-12-07 17:01:10+00:00,MD Anderson Cancer Center,http://twitter.com/,1.0,,1.3359927621021164e+18,,0.0,0.0,,"When Trena Robertson faced a multiple myeloma recurrence after a stem cell transplant, our Dr. Krina Patel offered‚Ä¶ https://t.co/jM9wkGFvtz",en,0.0,114120.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/MDAndersonNews/statuses/1335992762102116360,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"When Trena Robertson faced a multiple myeloma recurrence after a stem cell transplant, our Dr. Krina Patel offered‚Ä¶ https://t.co/jM9wkGFvtz",false
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-12-07 20:49:48+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,1.0,,1.3360502996607713e+18,,0.0,0.0,,#ASH20 #leusm Stein (636): @LLSusa BEAT AML substudy of Enasidenib + Aza (for non-responders to IDHi monotx) in age‚Ä¶ https://t.co/gI0ckWefxw,en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/hemedoc/statuses/1336050299660771328,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Disease Advocacy,0.0,0.0,1.0,#ASH20 #leusm Stein (636): @LLSusa BEAT AML substudy of Enasidenib + Aza (for non-responders to IDHi monotx) in age‚Ä¶ https://t.co/gI0ckWefxw,true
nadahamad,"BMT, cellular therapies and clinical haematologist, clinical researcher, lymphoma doc, mother of 3, feminist and ANZTCT president. Opinions are my own.",,"Sydney, Australia",,2020-12-07 22:31:07+00:00,A/Prof Nada Hamad,http://twitter.com/,14.0,,1.3360757942384312e+18,,0.0,0.0,,"RT @CwynKate: Great presentation @prp_diciaccio and mentorship by @nadahamad.
Fantastic international collaboration üá¶üá∫üá¨üáßüá®üá¶
n=197 Plasmablas‚Ä¶",en,0.0,346.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,12.0,2.0,https://twitter.com/nadahamad/statuses/1336075794238431233,0.0,0.0,,0.0,0.0,0.0,2.0,12.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,"RT @CwynKate: Great presentation @prp_diciaccio and mentorship by @nadahamad.
Fantastic international collaboration üá¶üá∫üá¨üáßüá®üá¶
n=197 Plasmablas‚Ä¶",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-07 00:48:37+00:00,"Ritcha Saxena, MD",http://twitter.com/,34.0,,1.3357480106476298e+18,,0.0,0.0,,RT @DrRaulCordoba: #ASH20 Impact of #SARSCoV2 infection on 491 hematological patients: the #ECOVIDEHE multicenter study in Spain üá™üá∏. Advanc‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,23.0,11.0,https://twitter.com/RitchaSaxena/statuses/1335748010647629835,0.0,0.0,,0.0,0.0,0.0,11.0,23.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,RT @DrRaulCordoba: #ASH20 Impact of #SARSCoV2 infection on 491 hematological patients: the #ECOVIDEHE multicenter study in Spain üá™üá∏. Advanc‚Ä¶,true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-07 21:42:32+00:00,Lisa Palacios,http://twitter.com/,10.0,,1.3360635692223898e+18,,0.0,0.0,,RT @razan_mohty: Ten-Day Decitabine with Venetoclax Versus Intensive Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia =&gt; ORR h‚Ä¶,en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,4.0,https://twitter.com/Lisa_Palacios/statuses/1336063569222389761,0.0,0.0,,0.0,0.0,0.0,4.0,6.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @razan_mohty: Ten-Day Decitabine with Venetoclax Versus Intensive Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia =&gt; ORR h‚Ä¶,true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 15:29:59+00:00,Lisa Palacios,http://twitter.com/,8.0,,1.3352450374253486e+18,,0.0,0.0,,"RT @microbialkrysta: ""We've had 3 coronavirus pandemics - we need to be thinking about a universal coronavirus vaccine... and all the aspec‚Ä¶",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,3.0,https://twitter.com/Lisa_Palacios/statuses/1335245037425348615,0.0,0.0,,0.0,0.0,0.0,3.0,5.0,False,False,False,False,True,Covid,0.0,0.0,1.0,"RT @microbialkrysta: ""We've had 3 coronavirus pandemics - we need to be thinking about a universal coronavirus vaccine... and all the aspec‚Ä¶",true
dgermain21,MD-PhD. 2nd year Heme/Onc fellow focused on lymphoma and leukemia. Physician-scientist-in-training. Tweet/RT not medical advice or endorsement.,,"St. Louis, MO",,2020-12-05 20:04:20+00:00,David A. Russler-Germain,http://twitter.com/,21.0,,1.3353140800186655e+18,,0.0,0.0,,"RT @Jessica_Okosun: #ASH20 1108 Quivoron et al - Genetic profiles of relapsed, refractory #DLBCL 
- enriched in TP53 &amp; epigenetic muts echo‚Ä¶",en,0.0,1612.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,16.0,5.0,https://twitter.com/dgermain21/statuses/1335314080018665475,0.0,0.0,,0.0,0.0,0.0,5.0,16.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @Jessica_Okosun: #ASH20 1108 Quivoron et al - Genetic profiles of relapsed, refractory #DLBCL 
- enriched in TP53 &amp; epigenetic muts echo‚Ä¶",false
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 15:28:41+00:00,Lisa Palacios,http://twitter.com/,4.0,,1.335244711943164e+18,,0.0,0.0,,"RT @PedsHemeDoc: ""We have to have equitable distribution of the vaccine"" - Fauci

SO IMPORTANT!!

It's a global pandemic, everyone needs an‚Ä¶",en,0.0,657.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,1.0,https://twitter.com/Lisa_Palacios/statuses/1335244711943163904,0.0,0.0,,0.0,0.0,0.0,1.0,3.0,False,False,False,False,True,Covid,1.0,0.0,0.0,"RT @PedsHemeDoc: ""We have to have equitable distribution of the vaccine"" - Fauci

SO IMPORTANT!!

It's a global pandemic, everyone needs an‚Ä¶",true
Jessica_Okosun,"CRUK-funded Clinician-Scientist at Barts Cancer Institute @QMBCI, Haematologist @BartsHospital. #Lymphoma, cancer #genomics, evolution, Big Data, technophile",,"London, England",,2020-12-05 19:58:13+00:00,Jessica Okosun,http://twitter.com/,5.0,,1.335312541749293e+18,,0.0,0.0,,"#ASH20 1108 Quivoron et al - Genetic profiles of relapsed, refractory #DLBCL 
- enriched in TP53 &amp; epigenetic muts‚Ä¶ https://t.co/QiKzGv5zB6",en,0.0,654.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,5.0,https://twitter.com/Jessica_Okosun/statuses/1335312541749293059,0.0,0.0,,0.0,0.0,0.0,5.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"#ASH20 1108 Quivoron et al - Genetic profiles of relapsed, refractory #DLBCL 
- enriched in TP53 &amp; epigenetic muts‚Ä¶ https://t.co/QiKzGv5zB6",true
CanerSaygin,"Heme-Onc Fellow @UChicago | Alumni of @OhioStateIMRes, @CCLRI | #Leukemia, #MDS, #CHIP physician-scientist. Tweets=own opinions.",,"Chicago, IL",,2020-12-05 20:28:25+00:00,"Caner Saygin, MD",http://twitter.com/,3.0,,1.3353201398525583e+18,,0.0,0.0,,Dr Floisand presenting data on WT-1 and PRAME dendritic cell vaccine in #AML pts as a post-remission strategy. High‚Ä¶ https://t.co/piZihY5bYA,en,0.0,743.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/CanerSaygin/statuses/1335320139852558336,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,Dr Floisand presenting data on WT-1 and PRAME dendritic cell vaccine in #AML pts as a post-remission strategy. High‚Ä¶ https://t.co/piZihY5bYA,true
GwynDaviesMD,"Heme-Onc at the Juravinski Cancer Centre. MD, MPH in Epidemiology. Assistant Professor at McMaster. Runner and outdoor enthusiast!",,"Hamilton, Ontario",,2020-12-05 15:44:28+00:00,Gwynivere Davies,http://twitter.com/,1.0,,1.335248681986044e+18,,0.0,0.0,,"SO excited for Dr. Fauci! ‚ÄúOur patients on chemo/post transplant were excluded from these trials, but what would yo‚Ä¶ https://t.co/k47zWzr4R2",en,0.0,94.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/GwynDaviesMD/statuses/1335248681986043910,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Innovation,1.0,0.0,0.0,"SO excited for Dr. Fauci! ‚ÄúOur patients on chemo/post transplant were excluded from these trials, but what would yo‚Ä¶ https://t.co/k47zWzr4R2",true
NazliDizman,MD & Researcher & Aspiring medical oncologist | @YaleIMed | Postdoc Fellow @CityofHope_GU | #WomenInMedicine | Tweets are my own | @ASCO FCOI https://t.co/2qasYPvDli,,"New Haven, CT",,2020-12-05 23:39:17+00:00,Nazli Dizman,http://twitter.com/,17.0,,1.335368175291142e+18,,0.0,0.0,,RT @DevikaDasMD: Multi institutional collaboration looking at fellow and program director perspective on #covid19 on various aspects of onc‚Ä¶,en,0.0,2298.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,14.0,3.0,https://twitter.com/NazliDizman/statuses/1335368175291142145,0.0,0.0,,0.0,0.0,0.0,3.0,14.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,RT @DevikaDasMD: Multi institutional collaboration looking at fellow and program director perspective on #covid19 on various aspects of onc‚Ä¶,true
VincentRK,"Professor, Mayo Clinic; Editor, Blood Cancer Journal; Oncologist; Health Costs; COVID threads @SurvivedCOVID Opinions=personal views https://t.co/TMq9vc5hZk",,"Rochester, MN, USA",,2020-12-05 20:25:03+00:00,Vincent Rajkumar,http://twitter.com/,4.0,,1.3353192926996685e+18,,0.0,0.0,,"From #ASH17: Editors working with Blood, Leukemia, BCJ, and BMT trading secrets about proverbial Reviewer 2...‚Ä¶ https://t.co/zmAk8OToQC",en,0.0,33590.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,4.0,https://twitter.com/VincentRK/statuses/1335319292699668481,0.0,0.0,,0.0,0.0,0.0,4.0,0.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,"From #ASH17: Editors working with Blood, Leukemia, BCJ, and BMT trading secrets about proverbial Reviewer 2...‚Ä¶ https://t.co/zmAk8OToQC",false
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-12-05 15:15:59+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,0.0,,1.3352415159588168e+18,,0.0,0.0,,#ASH20 Fauci: ‚ÄúI want to clarify something that is inadvertently leading to some misunderstanding‚Ä¶‚Äù Need to disting‚Ä¶ https://t.co/3kpHxuGp3d,en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/hemedoc/statuses/1335241515958816769,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,#ASH20 Fauci: ‚ÄúI want to clarify something that is inadvertently leading to some misunderstanding‚Ä¶‚Äù Need to disting‚Ä¶ https://t.co/3kpHxuGp3d,true
DevikaDasMD,"Section Chief,Thoracic Oncologist ü´Å Assoc Fellowship PD,Co-created @HOJournalclub #lcsm #QI #Safety #Mentor #ally üåà#womeninmedicine #Equity My tweets=My views",,"Birmingham AL  ",,2020-12-05 19:05:02+00:00,"Devika Das, MD, MSHQS üò∑",http://twitter.com/,3.0,,1.3352991573644984e+18,,0.0,0.0,,Multi institutional collaboration looking at fellow and program director perspective on #covid19 on various aspects‚Ä¶ https://t.co/7PZl7LzFnQ,en,0.0,4281.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/DevikaDasMD/statuses/1335299157364498432,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,Multi institutional collaboration looking at fellow and program director perspective on #covid19 on various aspects‚Ä¶ https://t.co/7PZl7LzFnQ,true
EduardoFlavioO1,"MD, Hematologist, Brasilia/Brasil, main interest in CLL, Lymphoma and MM; dad and husband; tweets are my own opinion",,"Bras√≠lia, Brasil",,2020-12-05 18:03:00+00:00,Eduardo Flavio Oliveira Ribeiro,http://twitter.com/,3.0,,1.3352835444873093e+18,,0.0,0.0,,Ibrutinib+Ven in #CLL 1st line (Captivate) and RR setting (TAP Clarity) showing long term remissions and sustained‚Ä¶ https://t.co/AdQwWF5M3s,en,0.0,545.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/EduardoFlavioO1/statuses/1335283544487309313,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,Ibrutinib+Ven in #CLL 1st line (Captivate) and RR setting (TAP Clarity) showing long term remissions and sustained‚Ä¶ https://t.co/AdQwWF5M3s,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-05 14:42:03+00:00,"Ritcha Saxena, MD",http://twitter.com/,4.0,,1.3352329744434504e+18,,0.0,0.0,,RT @DrAmitPatel: @DrCCutler reports @BMTCTN 1102 trial; #allogeneic #stem cell #transplant improves 3-year #OS (47.4% vs. 16.0%) and #LFS (‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,2.0,2.0,https://twitter.com/RitchaSaxena/statuses/1335232974443450368,0.0,0.0,,0.0,0.0,0.0,2.0,2.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,RT @DrAmitPatel: @DrCCutler reports @BMTCTN 1102 trial; #allogeneic #stem cell #transplant improves 3-year #OS (47.4% vs. 16.0%) and #LFS (‚Ä¶,true
TelehealthBot,Created by Doctor @KrittanawongMD. A bot that collects Tweets about medicine and medical innovation,,GJ 357 d,,2020-12-05 19:58:36+00:00,MedEd,http://twitter.com/,25.0,,1.335312640118231e+18,,0.0,0.0,,"RT @AMarshallMD: üôåüèº Proud to lead our @ASH_hematology @ASCO collaboration ‚ÄúImpact of #COVID ü¶†on Heme-Onc Prog Directors‚Äù 
üëèüèæ Great work @An‚Ä¶",en,0.0,683.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,20.0,5.0,https://twitter.com/TelehealthBot/statuses/1335312640118231042,0.0,0.0,,0.0,0.0,0.0,5.0,20.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,"RT @AMarshallMD: üôåüèº Proud to lead our @ASH_hematology @ASCO collaboration ‚ÄúImpact of #COVID ü¶†on Heme-Onc Prog Directors‚Äù 
üëèüèæ Great work @An‚Ä¶",true
majorajay,"Hematology/oncology fellow. #lymsm & #mmsm outcomes researcher. Physician-publisher & founder of https://t.co/dPfLt8QVMr, @inTrainingDoc & @inHouseMag.",,"Chicago, IL",,2020-12-05 22:28:41+00:00,"Ajay Major, MD, MBA",http://twitter.com/,0.0,,1.335350408114475e+18,,0.0,0.0,,Great #survivorship talk using SEER-Medicare data to compare hospitalizations for older NHL patients to matched non‚Ä¶ https://t.co/qfkGQfRU8V,en,0.0,3518.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/majorajay/statuses/1335350408114475009,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Insurance Coverage,0.0,0.0,1.0,Great #survivorship talk using SEER-Medicare data to compare hospitalizations for older NHL patients to matched non‚Ä¶ https://t.co/qfkGQfRU8V,false
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-09 00:34:35+00:00,"Ritcha Saxena, MD",http://twitter.com/,3.0,,1.3364692551145925e+18,,0.0,0.0,,RT @adctherapeutics: Updated preliminary data from the pivotal Phase 2 trial of our CD25-targeted #antibodydrugconjugate in #Hodgkinlymphom‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,2.0,1.0,https://twitter.com/RitchaSaxena/statuses/1336469255114592261,0.0,0.0,,0.0,0.0,0.0,1.0,2.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @adctherapeutics: Updated preliminary data from the pivotal Phase 2 trial of our CD25-targeted #antibodydrugconjugate in #Hodgkinlymphom‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-09 00:24:05+00:00,"Ritcha Saxena, MD",http://twitter.com/,7.0,,1.336466613575557e+18,,0.0,0.0,,RT @feldstej: 726 Selinexor in Combination with Pomalidomide and Dexamethasone (SPd) for Treatment of Patients with Relapsed Refractory Mul‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,2.0,https://twitter.com/RitchaSaxena/statuses/1336466613575557120,0.0,0.0,,0.0,0.0,0.0,2.0,5.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @feldstej: 726 Selinexor in Combination with Pomalidomide and Dexamethasone (SPd) for Treatment of Patients with Relapsed Refractory Mul‚Ä¶,true
HKlepinMD,Geriatric oncologist,,,,2020-12-09 01:49:43+00:00,Heidi Klepin,http://twitter.com/,7.0,,1.3364881610867548e+18,,0.0,0.0,,RT @ShakiraG_MBBS: #ASH20 excellent qualitative study by Dr. Charity Oyedejiüëá@DukeHealth examining barriers and facilitators of Advance Car‚Ä¶,en,0.0,902.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,1.0,https://twitter.com/HKlepinMD/statuses/1336488161086754822,0.0,0.0,,0.0,0.0,0.0,1.0,6.0,False,False,False,False,True,Disease Advocacy,1.0,0.0,0.0,RT @ShakiraG_MBBS: #ASH20 excellent qualitative study by Dr. Charity Oyedejiüëá@DukeHealth examining barriers and facilitators of Advance Car‚Ä¶,true
kishorganorkar,"Proud Indian üáÆüá≥
First&Last- Human,
Forever- Student, 
Professionally- Doctor üë®üèª‚Äç‚öïüè•
PartTime- Artist,Traveller,Explorer,etc
‚Ä¢Unsolved Mystery for Myself",,Hiwarkhed (Orange City),,2020-12-09 16:55:55+00:00,Kishor Ganorkar,http://twitter.com/,2.0,,1.336716216723882e+18,,0.0,0.0,,"RT @OncologyTimes: Our new issue is now LIVE! Read it now for updates on proton therapy amid #COVID19, RNA nanoparticles for chemo, and mor‚Ä¶",en,0.0,108.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,1.0,1.0,https://twitter.com/kishorganorkar/statuses/1336716216723881990,0.0,0.0,,0.0,0.0,0.0,1.0,1.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @OncologyTimes: Our new issue is now LIVE! Read it now for updates on proton therapy amid #COVID19, RNA nanoparticles for chemo, and mor‚Ä¶",true
NicholasShortMD,Leukemia Physician at MD Anderson Cancer Center. Clinical/translational research in AML and ALL.,,"Houston, TX",,2020-12-09 00:41:58+00:00,Nicholas Short MD,http://twitter.com/,26.0,,1.3364711132751503e+18,,0.0,0.0,,RT @RolandBWalter: Important data presented by @groboz from QUAZAR-001 showing CC-486 benefit in MRDneg and MRDpos remission. MRD response‚Ä¶,en,0.0,587.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,23.0,3.0,https://twitter.com/NicholasShortMD/statuses/1336471113275150336,0.0,0.0,,0.0,0.0,0.0,3.0,23.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @RolandBWalter: Important data presented by @groboz from QUAZAR-001 showing CC-486 benefit in MRDneg and MRDpos remission. MRD response‚Ä¶,true
biostockguru,Physician executive(MD CWRU;Rice/Jones);Healthcare focus Fund;Pharma advisor/KOL;Tweets NOT investment advice.Pls do your DD. Support https://t.co/97U34OldNG,,United States,,2020-12-09 23:32:19+00:00,biostockGuru,http://twitter.com/,0.0,,1.33681597310652e+18,,0.0,0.0,,"$ONCT Only difference is that was before the 2.4Billion $$ $MRK buyout and the ‚Äúwow‚Äù #ROR1 #ASH20 data

This seems‚Ä¶ https://t.co/0nRGLPwbiy",en,0.0,14022.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/biostockguru/statuses/1336815973106520064,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Cost of Care,0.0,0.0,1.0,"$ONCT Only difference is that was before the 2.4Billion $$ $MRK buyout and the ‚Äúwow‚Äù #ROR1 #ASH20 data

This seems‚Ä¶ https://t.co/0nRGLPwbiy",false
ChinRoza,"Onco-Hematology Fellowship at Poali Calmette institut, Marseille,France. Medical Oncologist, Department Oncology, Khmer Soviet Friendship Hospital, CAMBODIA.",,"Marseille, France",,2020-12-09 18:44:08+00:00,Roza CHIN,http://twitter.com/,187.0,,1.3367434479154258e+18,,0.0,0.0,,"RT @VincentRK: One of the most common questions myeloma patients ask me is: Should I get a stem cell transplant, and if so when should I do‚Ä¶",en,0.0,36.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,136.0,51.0,https://twitter.com/ChinRoza/statuses/1336743447915425794,0.0,0.0,,0.0,0.0,0.0,51.0,136.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,"RT @VincentRK: One of the most common questions myeloma patients ask me is: Should I get a stem cell transplant, and if so when should I do‚Ä¶",true
MDedgeHemOnc,MDedge Hematology & Oncology provides the most important and up to date information and news for oncologists. Now part of the Medscape Professional Network.,,"Rockville, MD, Parsippany, NJ",,2020-12-09 14:33:39+00:00,MDedge Hematology & Oncology,http://twitter.com/,0.0,,1.336680412064723e+18,,0.0,0.0,,#ASH20: Hodgkin lymphoma is the most common cancer diagnosed in adolescents.,en,0.0,6726.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/MDedgeHemOnc/statuses/1336680412064722945,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,#ASH20: Hodgkin lymphoma is the most common cancer diagnosed in adolescents.,true
MDMagazine,Clinical News for Connected Physicians. Everything you need to enhance your clinical approach to improving patient care.,,United States,,2020-12-09 13:34:00+00:00,HCPLive,http://twitter.com/,0.0,,1.336665401019646e+18,,0.0,0.0,,"#ICYMI: 

New data demonstrates #lintuzumab Ac225 used in combination with CLAG-M is safe in patients with relapsed‚Ä¶ https://t.co/mvHcBimX2u",en,0.0,7073.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/MDMagazine/statuses/1336665401019645952,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"#ICYMI: 

New data demonstrates #lintuzumab Ac225 used in combination with CLAG-M is safe in patients with relapsed‚Ä¶ https://t.co/mvHcBimX2u",true
HKlepinMD,Geriatric oncologist,,,,2020-12-09 02:49:11+00:00,Heidi Klepin,http://twitter.com/,15.0,,1.3365031289512837e+18,,0.0,0.0,,RT @ShakiraG_MBBS: #ASH20 @LundJenny et al.üëáüèæSEER-Medicare data analysis of OAs with #CLL: 28%: high comorbid burden (NCI comorbidity index‚Ä¶,en,0.0,902.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,8.0,7.0,https://twitter.com/HKlepinMD/statuses/1336503128951283713,0.0,0.0,,0.0,0.0,0.0,7.0,8.0,False,False,False,False,True,Insurance Coverage,0.0,0.0,1.0,RT @ShakiraG_MBBS: #ASH20 @LundJenny et al.üëáüèæSEER-Medicare data analysis of OAs with #CLL: 28%: high comorbid burden (NCI comorbidity index‚Ä¶,true
SandyWong02111,UCSF Hematologist and BMT physician,,"San Francisco, CA",,2020-12-09 00:39:43+00:00,Sandy Wong,http://twitter.com/,3.0,,1.3364705454376264e+18,,0.0,0.0,,"RT @ESmithMDPhD: Important POC @LesokhinMD. While serial BCMA-targeted therapy will work for most (if relapse is not too aggressive), bette‚Ä¶",en,0.0,759.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,2.0,1.0,https://twitter.com/SandyWong02111/statuses/1336470545437626368,0.0,0.0,,0.0,0.0,0.0,1.0,2.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @ESmithMDPhD: Important POC @LesokhinMD. While serial BCMA-targeted therapy will work for most (if relapse is not too aggressive), bette‚Ä¶",true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-12-09 18:25:00+00:00,Oncology Tube,http://twitter.com/,0.0,,1.3367386334292296e+18,,0.0,0.0,,"A Phase 2, Open-Label Study - Safety, Tolerability and Efficacy of Cael-101 in AL Amyloidosis Pts Jason Valent, MD‚Ä¶ https://t.co/cGoJOchdRz",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1336738633429229575,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"A Phase 2, Open-Label Study - Safety, Tolerability and Efficacy of Cael-101 in AL Amyloidosis Pts Jason Valent, MD‚Ä¶ https://t.co/cGoJOchdRz",false
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-09 00:34:39+00:00,"Ritcha Saxena, MD",http://twitter.com/,5.0,,1.3364692720260792e+18,,0.0,0.0,,RT @adctherapeutics: Updated preliminary data from the pivotal Phase 2 trial of our CD25-targeted #antibodydrugconjugate in #Hodgkinlymphom‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,2.0,https://twitter.com/RitchaSaxena/statuses/1336469272026079236,0.0,0.0,,0.0,0.0,0.0,2.0,3.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,RT @adctherapeutics: Updated preliminary data from the pivotal Phase 2 trial of our CD25-targeted #antibodydrugconjugate in #Hodgkinlymphom‚Ä¶,true
MedpageOnco,Breaking cancer + oncology news | Reports from all major oncology meetings | Peer-reviewed | Oncologist-trusted | Part of @MedPageToday,,,,2020-12-09 21:09:02+00:00,MedPage Oncology,http://twitter.com/,0.0,,1.3367799131107082e+18,,0.0,0.0,,A chemotherapy-free investigational combination reduced the risk of disease progression or death for patients with‚Ä¶ https://t.co/ZsiCqTkRKF,en,0.0,443.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/MedpageOnco/statuses/1336779913110708235,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Innovation,0.0,0.0,1.0,A chemotherapy-free investigational combination reduced the risk of disease progression or death for patients with‚Ä¶ https://t.co/ZsiCqTkRKF,true
nihardesai7,"#Hematology fellow (DM) @SGPGI ¬∞ MD Internal Med || LTMC Sion ¬∞ @pinkfloyd fan ¬∞ Wildlife #photographer ¬∞ Drummer ¬∞ #Bombay boy ¬∞
Here for #MedTwitter",,"SGPGI Campus, Lucknow",,2020-12-09 03:34:12+00:00,ùó°ùó∂ùóµùóÆùóø ùóóùó≤ùòÄùóÆùó∂ ùó†ùóó,http://twitter.com/,0.0,,1.3365144574852014e+18,,0.0,0.0,,"Yeah , stage 2 it is üòÇ

@PanktiMehta24 @sujeethemat #ASH20 https://t.co/aHarTRGe9d",en,0.0,1025.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/nihardesai7/statuses/1336514457485201408,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"Yeah , stage 2 it is üòÇ

@PanktiMehta24 @sujeethemat #ASH20 https://t.co/aHarTRGe9d",true
nadahamad,"BMT, cellular therapies and clinical haematologist, clinical researcher, lymphoma doc, mother of 3, feminist and ANZTCT president. Opinions are my own.",,"Sydney, Australia",,2020-12-09 00:19:24+00:00,A/Prof Nada Hamad,http://twitter.com/,20.0,,1.3364654362804388e+18,,0.0,0.0,,RT @Fer_martinmoro: ASCEMBL phase 3 trial - Asceminib (STAMP inh) (n=157) vs bosutinib (n=76) in CML after failure to ‚â•2 TKIs. Congrats to‚Ä¶,en,0.0,346.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,14.0,6.0,https://twitter.com/nadahamad/statuses/1336465436280438785,0.0,0.0,,0.0,0.0,0.0,6.0,14.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,RT @Fer_martinmoro: ASCEMBL phase 3 trial - Asceminib (STAMP inh) (n=157) vs bosutinib (n=76) in CML after failure to ‚â•2 TKIs. Congrats to‚Ä¶,true
diegoah66,"Hematologist-Oncologist @UVMMedCenter, Assistant Professor of Medicine @UVMLarnerMed | üáµüá™üá∫üá∏",,"Burlington, VT",,2020-12-06 18:05:49+00:00,Diego Adrianzen-Herrera,http://twitter.com/,1.0,,1.3356466425114706e+18,,0.0,0.0,,Glad this #healthequity study exploring racial disparities in AML presented at #ASH20 plenary session. Good call to‚Ä¶ https://t.co/T5oHWbJ3dl,en,0.0,187.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/diegoah66/statuses/1335646642511470592,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Financial Performance,1.0,0.0,0.0,Glad this #healthequity study exploring racial disparities in AML presented at #ASH20 plenary session. Good call to‚Ä¶ https://t.co/T5oHWbJ3dl,true
JerroldLevy,"Critical care physician in CTICU @DukeMedSchool, interested in coagulation, bleeding, inflammation-also oenophile and foody. Tweets are my own (‚â†medical advice)",,"Durham, North Carolina",,2020-12-06 17:57:44+00:00,"Jerrold Levy, MD",http://twitter.com/,4.0,,1.3356446069234934e+18,,0.0,0.0,,Pandemics now and then #COVID19 #ASH20 by Dr @HelenChuMD https://t.co/Y568KDPhXf,en,0.0,1755.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,4.0,https://twitter.com/JerroldLevy/statuses/1335644606923493377,0.0,0.0,,0.0,0.0,0.0,4.0,0.0,False,False,False,False,True,Covid,0.0,0.0,1.0,Pandemics now and then #COVID19 #ASH20 by Dr @HelenChuMD https://t.co/Y568KDPhXf,false
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-01-17 17:28:08+00:00,Oncology Tube,http://twitter.com/,0.0,,1.218223493222785e+18,,0.0,0.0,,"MANIFEST, a Phase 2 Study of CPI-0610 @MountSinaiNYC #ASH #ASH19: John Mascarenhas, MD of @MountSinaiNYC discusses‚Ä¶ https://t.co/VsYH6AjjRy",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1218223493222785026,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"MANIFEST, a Phase 2 Study of CPI-0610 @MountSinaiNYC #ASH #ASH19: John Mascarenhas, MD of @MountSinaiNYC discusses‚Ä¶ https://t.co/VsYH6AjjRy",true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-02-04 15:43:04+00:00,Oncology Tube,http://twitter.com/,0.0,,1.2247200305515602e+18,,0.0,0.0,,Dose Optimization Portion of the Phase 2 PRIMO Study in Relapsed or Refractory PTCL #ASH19 @sloan_kettering: Steven‚Ä¶ https://t.co/gVtI92tVdk,en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1224720030551560192,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,Dose Optimization Portion of the Phase 2 PRIMO Study in Relapsed or Refractory PTCL #ASH19 @sloan_kettering: Steven‚Ä¶ https://t.co/gVtI92tVdk,true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-02-21 12:45:50+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,1.0,,1.2308360219249009e+18,,0.0,0.0,,"#TCTM20 Schroeder: IL22 protects intestinal stem cells, 70% ORR at day 28 in newly diagnosed gut GVHD https://t.co/2OtItgRsyA",en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/hemedoc/statuses/1230836021924900870,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"#TCTM20 Schroeder: IL22 protects intestinal stem cells, 70% ORR at day 28 in newly diagnosed gut GVHD https://t.co/2OtItgRsyA",true
MediHumdani,"Director, BMT & Cellular Therapy Program @Froedtert & @MedicalCollege | Lymphoma | Clinical Trials | @CIBMTR | @BMTCTN | Personal views | Physician ‚â† Provider",,"Milwaukee, WI",,2020-02-21 12:29:13+00:00,Mehdi Hamadani,http://twitter.com/,1.0,,1.2308318435509248e+18,,0.0,0.0,,Commitment early AM @BMTCTN 1703/1801 investigator meeting. @sghmd @DrMiguelPerales leading updates and discussion.‚Ä¶ https://t.co/1bLNqMyS8I,en,0.0,4590.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/MediHumdani/statuses/1230831843550924801,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,Commitment early AM @BMTCTN 1703/1801 investigator meeting. @sghmd @DrMiguelPerales leading updates and discussion.‚Ä¶ https://t.co/1bLNqMyS8I,true
LabWaggoner,Research lab of Dr. Stephen Waggoner at Cincinnati Children's Hospital Medical Center,,"Cincinnati, OH",,2020-02-21 03:01:53+00:00,Waggoner Lab,http://twitter.com/,9.0,,1.230689069191045e+18,,0.0,0.0,,RT @PurveySneha: #TCTM20 @romeerizwan great talk- #NK cells- targeting relapse after haplo with men-like NK cells phase 1a/b https://t.co/m‚Ä¶,en,0.0,1587.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,7.0,2.0,https://twitter.com/LabWaggoner/statuses/1230689069191045120,0.0,0.0,,0.0,0.0,0.0,2.0,7.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @PurveySneha: #TCTM20 @romeerizwan great talk- #NK cells- targeting relapse after haplo with men-like NK cells phase 1a/b https://t.co/m‚Ä¶,true
szusmani,"Division Chief, Plasma Cell Disorders|Director, Clinical Research Hem Malignancies | Views are my own | RT not endorsement | Physician ‚â† Provider",,"Charlotte, NC",,2020-01-30 22:45:33+00:00,Saad Z. Usmani MD MBA FACP (he/his/him),http://twitter.com/,2.0,,1.223014415273988e+18,,0.0,0.0,,Best of #ASH19 updates in newly diagnosed #mmsm being presented by @manisha_bhutani @LevineCancer @OncLive ‚Äî adding‚Ä¶ https://t.co/xXBwIW8VzP,en,0.0,5512.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/szusmani/statuses/1223014415273988096,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Disease Management,0.0,0.0,1.0,Best of #ASH19 updates in newly diagnosed #mmsm being presented by @manisha_bhutani @LevineCancer @OncLive ‚Äî adding‚Ä¶ https://t.co/xXBwIW8VzP,false
abhinav_deol,MD,,"Detroit, MI",,2020-02-20 16:06:57+00:00,Abhinav Deol,http://twitter.com/,3.0,,1.2305242467718636e+18,,0.0,0.0,,#TCTM20 Dr. Christopher: no reccureent mutations associted with relapse in AML post transplant or chemo https://t.co/4NsrAIadYy,en,0.0,251.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/abhinav_deol/statuses/1230524246771863556,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,#TCTM20 Dr. Christopher: no reccureent mutations associted with relapse in AML post transplant or chemo https://t.co/4NsrAIadYy,true
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-06-30 16:01:26+00:00,Cardiovascular Research Foundation,http://twitter.com/,2.0,,1.2779956703775007e+18,,0.0,0.0,,Calling all innovators! Do you have a novel technology for the diagnosis or treatment of heart disease? Submit to t‚Ä¶ https://t.co/r8t7pwxro0,en,0.0,12239.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/crfheart/statuses/1277995670377500672,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,Calling all innovators! Do you have a novel technology for the diagnosis or treatment of heart disease? Submit to t‚Ä¶ https://t.co/r8t7pwxro0,true
ElmerEdward1,"I am a physician, Lives in Bergen,Norway .
Favourite field : Cardiology and general surgery 
Sport : Cricket  Cricket Cricket !!!
Music : All kind of music",,,,2020-04-17 12:30:41+00:00,Elmer Edward,http://twitter.com/,29.0,,1.2511259319362232e+18,,0.0,0.0,,RT @EHA_Hematology: üì¢ CALLING ALL RESEARCHERS! #EHA has launched a new research grant - the COVID-19 in Hematology research grant. The call‚Ä¶,en,0.0,41.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,16.0,13.0,https://twitter.com/ElmerEdward1/statuses/1251125931936223232,0.0,0.0,,0.0,0.0,0.0,13.0,16.0,False,False,False,False,True,Research Funding,0.0,0.0,1.0,RT @EHA_Hematology: üì¢ CALLING ALL RESEARCHERS! #EHA has launched a new research grant - the COVID-19 in Hematology research grant. The call‚Ä¶,true
mpdrc,Executive Director- Mays Cancer Center at UT Health San Antonio MD Anderson; (Views on Twitter are personal opinion),,"UT Health San Antonio ,TX, USA",,2020-06-19 14:32:25+00:00,"Ruben A. Mesa, MD",http://twitter.com/,1.0,,1.2739870031856148e+18,,0.0,0.0,,Excited watching #EHA25Virtual this morning! Looking forward to the upcoming Live QA session on new therapies in MP‚Ä¶ https://t.co/VWrCeXkRHr,en,0.0,3222.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/mpdrc/statuses/1273987003185614849,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Research Funding,1.0,0.0,0.0,Excited watching #EHA25Virtual this morning! Looking forward to the upcoming Live QA session on new therapies in MP‚Ä¶ https://t.co/VWrCeXkRHr,true
DaniEinthoven,"MD PhD, Haematologist and chess player. BMT consultant @ King‚Äôs College Hospital in London üá¨üáß

EBMT Young Ambassador 2021.",,,,2020-06-15 19:08:19+00:00,Daniele Avenoso,http://twitter.com/,20.0,,1.272606885150163e+18,,0.0,0.0,,RT @young_eha: New therapeutic options for AML patients unfit for intensive chemo nicely summarized by Courtney Di Nardo from @LeukemiaMDA‚Ä¶,en,0.0,223.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,16.0,4.0,https://twitter.com/DaniEinthoven/statuses/1272606885150162945,0.0,0.0,,0.0,0.0,0.0,4.0,16.0,False,False,False,False,True,Research Funding,1.0,0.0,0.0,RT @young_eha: New therapeutic options for AML patients unfit for intensive chemo nicely summarized by Courtney Di Nardo from @LeukemiaMDA‚Ä¶,true
dgermain21,MD-PhD. 2nd year Heme/Onc fellow focused on lymphoma and leukemia. Physician-scientist-in-training. Tweet/RT not medical advice or endorsement.,,"St. Louis, MO",,2020-06-12 18:58:55+00:00,David A. Russler-Germain,http://twitter.com/,92.0,,1.2715173539149128e+18,,0.0,0.0,,RT @DocHutchings: Pleased to present the final results from the dose escalation part of the Phase 1/2 study of epcoritamab in r/r B-NHL at‚Ä¶,en,0.0,1612.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,69.0,23.0,https://twitter.com/dgermain21/statuses/1271517353914912770,0.0,0.0,,0.0,0.0,0.0,23.0,69.0,False,False,False,False,True,FDA Approval,1.0,0.0,0.0,RT @DocHutchings: Pleased to present the final results from the dose escalation part of the Phase 1/2 study of epcoritamab in r/r B-NHL at‚Ä¶,false
DrESHAJ9,"a passionate medical oncologist, a spiritual seeker",,,,2020-06-16 16:02:45+00:00,EJ,http://twitter.com/,92.0,,1.272922571994919e+18,,0.0,0.0,,RT @DocHutchings: Pleased to present the final results from the dose escalation part of the Phase 1/2 study of epcoritamab in r/r B-NHL at‚Ä¶,en,0.0,315.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,69.0,23.0,https://twitter.com/DrESHAJ9/statuses/1272922571994918913,0.0,0.0,,0.0,0.0,0.0,23.0,69.0,False,False,False,False,True,FDA Approval,1.0,0.0,0.0,RT @DocHutchings: Pleased to present the final results from the dose escalation part of the Phase 1/2 study of epcoritamab in r/r B-NHL at‚Ä¶,true
mpdrc,Executive Director- Mays Cancer Center at UT Health San Antonio MD Anderson; (Views on Twitter are personal opinion),,"UT Health San Antonio ,TX, USA",,2020-06-14 17:20:08+00:00,"Ruben A. Mesa, MD",http://twitter.com/,24.0,,1.2722172709080023e+18,,0.0,0.0,,RT @MPN_Hub: CONGRESS | #EHA25Virtual | T Barbui presented the LOW-PV phase II trial conducted by FROM Foundation @FormazioneHPG23. Ropeg-I‚Ä¶,en,0.0,3222.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,17.0,7.0,https://twitter.com/mpdrc/statuses/1272217270908002306,0.0,0.0,,0.0,0.0,0.0,7.0,17.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,RT @MPN_Hub: CONGRESS | #EHA25Virtual | T Barbui presented the LOW-PV phase II trial conducted by FROM Foundation @FormazioneHPG23. Ropeg-I‚Ä¶,true
EladSharonMD,"#MedicalOncologist tweeting on #immunotherapy, #drugdevelopment, #COVID19 & #HealthEcon. #NCI #CancerMoonshot Adult Immunotherapy Co-Chair. Tweets are mine.",,"Washington, DC",,2020-06-17 18:21:12+00:00,Elad Sharon,http://twitter.com/,15.0,,1.2733198003962225e+18,,0.0,0.0,,RT @Dr_AmerZeidan: My commentary on our first in human Phase 1 study of the protein degrader CC-90009 in refractory/relapsed aml that we pr‚Ä¶,en,0.0,2113.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,12.0,3.0,https://twitter.com/EladSharonMD/statuses/1273319800396222466,0.0,0.0,,0.0,0.0,0.0,3.0,12.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,RT @Dr_AmerZeidan: My commentary on our first in human Phase 1 study of the protein degrader CC-90009 in refractory/relapsed aml that we pr‚Ä¶,true
justinburkhard1,30. Twin. Physician Assistant and biotech enthusiast. 10 years of rec trading. My tweets are not investment advice. co Ceo/founder High Tides,,"Palm City, FL",,2020-08-11 16:55:57+00:00,Justin Burkhardt,http://twitter.com/,41.0,,1.29322968131618e+18,,0.0,0.0,,"RT @JD4myfab4: Market cap comparison: 

$FTSV $5BILLION $GILD buyout

$ALXO $1.6BILLION MC

$TRIL $700MILLION 

While better monotherapy PR‚Ä¶",en,0.0,361.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,32.0,9.0,https://twitter.com/justinburkhard1/statuses/1293229681316179968,0.0,0.0,,0.0,0.0,0.0,9.0,32.0,False,False,False,False,True,Cost of Care,0.0,0.0,1.0,"RT @JD4myfab4: Market cap comparison: 

$FTSV $5BILLION $GILD buyout

$ALXO $1.6BILLION MC

$TRIL $700MILLION 

While better monotherapy PR‚Ä¶",true
DocHutchings,Haemato-oncologist. Clinical researcher. Mostly lymphoma and phase 1 haematology studies.,,,,2020-06-12 12:42:55+00:00,Martin Hutchings,http://twitter.com/,23.0,,1.2714227286046597e+18,,0.0,0.0,,Pleased to present the final results from the dose escalation part of the Phase 1/2 study of epcoritamab in r/r B-N‚Ä¶ https://t.co/u8FeSt88tN,en,0.0,284.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,23.0,https://twitter.com/DocHutchings/statuses/1271422728604659717,0.0,0.0,,0.0,0.0,0.0,23.0,0.0,False,False,False,False,True,FDA Approval,1.0,0.0,0.0,Pleased to present the final results from the dose escalation part of the Phase 1/2 study of epcoritamab in r/r B-N‚Ä¶ https://t.co/u8FeSt88tN,true
adrianabello,"pediatrician, pediatric hematologyst, mother adribello@hotmail.com",,,,2020-06-12 17:06:36+00:00,Adriana Bello,http://twitter.com/,92.0,,1.2714890888650793e+18,,0.0,0.0,,RT @DocHutchings: Pleased to present the final results from the dose escalation part of the Phase 1/2 study of epcoritamab in r/r B-NHL at‚Ä¶,en,0.0,1968.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,69.0,23.0,https://twitter.com/adrianabello/statuses/1271489088865079298,0.0,0.0,,0.0,0.0,0.0,23.0,69.0,False,False,False,False,True,FDA Approval,1.0,0.0,0.0,RT @DocHutchings: Pleased to present the final results from the dose escalation part of the Phase 1/2 study of epcoritamab in r/r B-NHL at‚Ä¶,false
nycdoc29,"ASCO, ASH, EHA & ESMO Member, Hem/Onc - 11 MD specialty private practice, former full time academic, traveller, foodie & out of necessity now a business person!",,"Garden City, NY",,2020-06-13 14:16:39+00:00,NYCDoc29,http://twitter.com/,12.0,,1.2718087085117727e+18,,0.0,0.0,,"RT @lymphoma_connec: Herbaux et al present a primary analysis of a phase 2 trial from @LysaLymphoma at #EHA25Virtual 
#Atezolizumab + #obin‚Ä¶",en,0.0,664.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,6.0,https://twitter.com/nycdoc29/statuses/1271808708511772672,0.0,0.0,,0.0,0.0,0.0,6.0,6.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"RT @lymphoma_connec: Herbaux et al present a primary analysis of a phase 2 trial from @LysaLymphoma at #EHA25Virtual 
#Atezolizumab + #obin‚Ä¶",true
DrJonnys,Consultant General Surgery . former doctor at (CAF)üëÆüèª‚Äç‚ôÇÔ∏è / Anatomist. #umanitoba #uwinnipeg @Harvard,,"Winnipeg, Manitoba",,2020-02-19 14:55:56+00:00,ùê∑ùëü. ùêΩùëú‚Ñéùëõùëõùë¶ ùëÜùë°ùëíùë§ùëéùëüùë°‚Å¶üá®üá¶‚Å©üåàüçÅ,http://twitter.com/,38.0,,1.230143987220144e+18,,0.0,0.0,,"RT @satya_yadav: #Mackall : If one CAR crashes then buy a new one ! 

If leukemia relapses after CD19 #CART cell therapy then CD22 CART cel‚Ä¶",en,0.0,5805.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,29.0,9.0,https://twitter.com/DrJonnys/statuses/1230143987220144129,0.0,0.0,,0.0,0.0,0.0,9.0,29.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"RT @satya_yadav: #Mackall : If one CAR crashes then buy a new one ! 

If leukemia relapses after CD19 #CART cell therapy then CD22 CART cel‚Ä¶",true
chano_py,Sola Gracia. Medico Hematologo. Donante de √≥rganos. #DonaenVida. #HSCT Dr in #Paraguay. Patient Advocacy Co-Chair at #WBMT. Secretary at @LABMT2,,Paraguay,,2020-02-19 18:43:18+00:00,Cristobal Frutos,http://twitter.com/,38.0,,1.2302012077776443e+18,,0.0,0.0,,"RT @satya_yadav: #Mackall : If one CAR crashes then buy a new one ! 

If leukemia relapses after CD19 #CART cell therapy then CD22 CART cel‚Ä¶",en,0.0,903.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,29.0,9.0,https://twitter.com/chano_py/statuses/1230201207777644550,0.0,0.0,,0.0,0.0,0.0,9.0,29.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"RT @satya_yadav: #Mackall : If one CAR crashes then buy a new one ! 

If leukemia relapses after CD19 #CART cell therapy then CD22 CART cel‚Ä¶",true
HawazenAlsaedi,Pediatric Hematology and Oncology & Stem cell transplant physician,,,,2020-02-19 15:54:17+00:00,Hawazen Alsaedi,http://twitter.com/,38.0,,1.230158673995092e+18,,0.0,0.0,,"RT @satya_yadav: #Mackall : If one CAR crashes then buy a new one ! 

If leukemia relapses after CD19 #CART cell therapy then CD22 CART cel‚Ä¶",en,0.0,76.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,29.0,9.0,https://twitter.com/HawazenAlsaedi/statuses/1230158673995091968,0.0,0.0,,0.0,0.0,0.0,9.0,29.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"RT @satya_yadav: #Mackall : If one CAR crashes then buy a new one ! 

If leukemia relapses after CD19 #CART cell therapy then CD22 CART cel‚Ä¶",true
marrow,"Clinical Haematologist, marrow transplanter. President World Marrow Donor Association (WMDA). Editor-in-Chief Internal Medicine Journal.",,"Melbourne, Australia",,2020-02-19 15:49:28+00:00,Jeff Szer,http://twitter.com/,38.0,,1.2301574619292385e+18,,0.0,0.0,,"RT @satya_yadav: #Mackall : If one CAR crashes then buy a new one ! 

If leukemia relapses after CD19 #CART cell therapy then CD22 CART cel‚Ä¶",en,0.0,2195.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,29.0,9.0,https://twitter.com/marrow/statuses/1230157461929238529,0.0,0.0,,0.0,0.0,0.0,9.0,29.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"RT @satya_yadav: #Mackall : If one CAR crashes then buy a new one ! 

If leukemia relapses after CD19 #CART cell therapy then CD22 CART cel‚Ä¶",true
abhinav_deol,MD,,"Detroit, MI",,2020-02-19 16:27:50+00:00,Abhinav Deol,http://twitter.com/,5.0,,1.2301671158581412e+18,,0.0,0.0,,#TCTM20  $ 20-30 billion is what is the expected cost of oncology care by 2031 for Medicare pts alone  ....... https://t.co/X0aRsHToFE,en,0.0,251.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,5.0,https://twitter.com/abhinav_deol/statuses/1230167115858141184,0.0,0.0,,0.0,0.0,0.0,5.0,0.0,False,False,False,False,True,Insurance Coverage,0.0,0.0,1.0,#TCTM20  $ 20-30 billion is what is the expected cost of oncology care by 2031 for Medicare pts alone  ....... https://t.co/X0aRsHToFE,false
cesardegali,"Doctorado en Biotecnolog√≠a. Licenciado en Bioqu√≠mica y en Ciencias Qu√≠micas. Apasionado de la ciencia. Ecologista, submarinista y lector.",,,,2020-03-01 21:06:39+00:00,C√©sar del Rio Merino,http://twitter.com/,11.0,,1.234223550451589e+18,,0.0,0.0,,"RT @DrRenatoCunha: Dr. Lunnig - Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel‚Ä¶",en,0.0,29.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,7.0,4.0,https://twitter.com/cesardegali/statuses/1234223550451589120,0.0,0.0,,0.0,0.0,0.0,4.0,7.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"RT @DrRenatoCunha: Dr. Lunnig - Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel‚Ä¶",true
FranciscoMarty_,"Infectious diseases doctor who specializes in treating transplant and cancer patients, work at @BrighamWomens and @DanaFarber, @harvardmed.",,"Boston, MA",,2020-02-23 20:13:52+00:00,"Francisco Marty, MD",http://twitter.com/,9.0,,1.2316735490872156e+18,,0.0,0.0,,"RT @hemedoc: #TCTM20 Taplitz: community respiratory virus infections by day +180 after Haplo/PTCy, Sib/PTCy, and Sib/CNI. Higher risk with‚Ä¶",en,0.0,9990.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,7.0,2.0,https://twitter.com/FranciscoMarty_/statuses/1231673549087215617,0.0,0.0,,0.0,0.0,0.0,2.0,7.0,False,False,False,False,True,Disease Advocacy,0.0,0.0,1.0,"RT @hemedoc: #TCTM20 Taplitz: community respiratory virus infections by day +180 after Haplo/PTCy, Sib/PTCy, and Sib/CNI. Higher risk with‚Ä¶",true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-02-23 16:23:56+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,2.0,,1.2316156868516782e+18,,0.0,0.0,,"#TCTM20 Taplitz: community respiratory virus infections by day +180 after Haplo/PTCy, Sib/PTCy, and Sib/CNI. Higher‚Ä¶ https://t.co/b5lNow3335",en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/hemedoc/statuses/1231615686851678208,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Disease Advocacy,0.0,0.0,1.0,"#TCTM20 Taplitz: community respiratory virus infections by day +180 after Haplo/PTCy, Sib/PTCy, and Sib/CNI. Higher‚Ä¶ https://t.co/b5lNow3335",true
Transplant_Doc,Stem Cell Transplant physician and clinical researcher at MD Anderson Cancer Center; special interest in myeloma. Opinions expressed are my own,,,,2020-02-23 18:55:07+00:00,Muzaffar Qazilbash,http://twitter.com/,12.0,,1.231653730942161e+18,,0.0,0.0,,RT @hemedoc: #TCTM20 Cutler: median followup of 5mos for all surviving patients. KD025 very well tolerated. No increase in infection risk.‚Ä¶,en,0.0,5455.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,6.0,https://twitter.com/Transplant_Doc/statuses/1231653730942160896,0.0,0.0,,0.0,0.0,0.0,6.0,6.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,RT @hemedoc: #TCTM20 Cutler: median followup of 5mos for all surviving patients. KD025 very well tolerated. No increase in infection risk.‚Ä¶,true
DrZackDeFilipp,BMT physician and researcher @MGHCancerCenter / Opinions are my own. #bmtsm #leusm #cancer,,"Boston, MA",,2020-02-23 17:32:33+00:00,Zachariah DeFilipp,http://twitter.com/,12.0,,1.2316329540630487e+18,,0.0,0.0,,RT @hemedoc: #TCTM20 Cutler: median followup of 5mos for all surviving patients. KD025 very well tolerated. No increase in infection risk.‚Ä¶,en,0.0,547.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,6.0,https://twitter.com/DrZackDeFilipp/statuses/1231632954063048710,0.0,0.0,,0.0,0.0,0.0,6.0,6.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,RT @hemedoc: #TCTM20 Cutler: median followup of 5mos for all surviving patients. KD025 very well tolerated. No increase in infection risk.‚Ä¶,true
MichaelDJain,Oncologist @moffittnews. Lymphoma CAR T/BMT. üá®üá¶ in Florida (does not miss the cold).,,"Tampa, FL",,2020-02-23 20:46:08+00:00,Michael Jain,http://twitter.com/,14.0,,1.231681670761386e+18,,0.0,0.0,,RT @marrow: Jeremy Abramson from Boston presenting the TRANSCEND phase 1 study of liso-cel (lisocaptagene maraleucel) in lymphoma patients.‚Ä¶,en,0.0,212.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,9.0,5.0,https://twitter.com/MichaelDJain/statuses/1231681670761385984,0.0,0.0,,0.0,0.0,0.0,5.0,9.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,RT @marrow: Jeremy Abramson from Boston presenting the TRANSCEND phase 1 study of liso-cel (lisocaptagene maraleucel) in lymphoma patients.‚Ä¶,false
marrow,"Clinical Haematologist, marrow transplanter. President World Marrow Donor Association (WMDA). Editor-in-Chief Internal Medicine Journal.",,"Melbourne, Australia",,2020-02-23 17:59:40+00:00,Jeff Szer,http://twitter.com/,5.0,,1.2316397792525435e+18,,0.0,0.0,,Jeremy Abramson from Boston presenting the TRANSCEND phase 1 study of liso-cel (lisocaptagene maraleucel) in lympho‚Ä¶ https://t.co/nwytbL1yu2,en,0.0,2195.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,5.0,https://twitter.com/marrow/statuses/1231639779252543491,0.0,0.0,,0.0,0.0,0.0,5.0,0.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,Jeremy Abramson from Boston presenting the TRANSCEND phase 1 study of liso-cel (lisocaptagene maraleucel) in lympho‚Ä¶ https://t.co/nwytbL1yu2,true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-03-02 01:44:04+00:00,Oncology Tube,http://twitter.com/,0.0,,1.234293361206448e+18,,0.0,0.0,,"Phase 2 Study of Luspatercept Commonly Asked Questions #ASH19 @CleClinicMD: Aaron Gerds, MD of @CleClinicMD discuss‚Ä¶ https://t.co/zGLX79tY0T",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1234293361206448128,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"Phase 2 Study of Luspatercept Commonly Asked Questions #ASH19 @CleClinicMD: Aaron Gerds, MD of @CleClinicMD discuss‚Ä¶ https://t.co/zGLX79tY0T",true
MedInContext,"Medical Advisor, Molecular Oncologist, Healthcare Consultant, Cancer Patient Friend",,United States,,2020-02-19 14:39:56+00:00,Susanne Max Radke,http://twitter.com/,0.0,,1.2301399634523832e+18,,0.0,0.0,,"First day at #TCTM20
Looking forward to listening to new research and networking with scientists. https://t.co/rkfZJ7B6ET",en,0.0,358.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/MedInContext/statuses/1230139963452383234,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,"First day at #TCTM20
Looking forward to listening to new research and networking with scientists. https://t.co/rkfZJ7B6ET",true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-02-21 18:08:25+00:00,Oncology Tube,http://twitter.com/,20.0,,1.230917203102335e+18,,0.0,0.0,,RT @sagarpatel: Upcoming trial comparing ruxolitinib vs alloHCT based on available donor status @PeerView #MPNsm #BMTsm #TCTM20 https://t.c‚Ä¶,en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,12.0,8.0,https://twitter.com/oncologytube/statuses/1230917203102334976,0.0,0.0,,0.0,0.0,0.0,8.0,12.0,False,False,False,False,True,Research Funding,0.0,0.0,1.0,RT @sagarpatel: Upcoming trial comparing ruxolitinib vs alloHCT based on available donor status @PeerView #MPNsm #BMTsm #TCTM20 https://t.c‚Ä¶,true
FranciscoMarty_,"Infectious diseases doctor who specializes in treating transplant and cancer patients, work at @BrighamWomens and @DanaFarber, @harvardmed.",,"Boston, MA",,2020-02-23 20:12:05+00:00,"Francisco Marty, MD",http://twitter.com/,12.0,,1.23167310072875e+18,,0.0,0.0,,RT @hemedoc: #TCTM20 Cutler: median followup of 5mos for all surviving patients. KD025 very well tolerated. No increase in infection risk.‚Ä¶,en,0.0,9990.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,6.0,https://twitter.com/FranciscoMarty_/statuses/1231673100728750081,0.0,0.0,,0.0,0.0,0.0,6.0,6.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,RT @hemedoc: #TCTM20 Cutler: median followup of 5mos for all surviving patients. KD025 very well tolerated. No increase in infection risk.‚Ä¶,true
marrow,"Clinical Haematologist, marrow transplanter. President World Marrow Donor Association (WMDA). Editor-in-Chief Internal Medicine Journal.",,"Melbourne, Australia",,2020-02-23 15:13:52+00:00,Jeff Szer,http://twitter.com/,49.0,,1.231598052613509e+18,,0.0,0.0,,RT @DrMiguelPerales: Important @CIBMTR study presented yesterday by Javier Bolanos-Meade &amp; Bronwen Shaw reporting multicenter phase 2 trial‚Ä¶,en,0.0,2195.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,35.0,14.0,https://twitter.com/marrow/statuses/1231598052613509120,0.0,0.0,,0.0,0.0,0.0,14.0,35.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,RT @DrMiguelPerales: Important @CIBMTR study presented yesterday by Javier Bolanos-Meade &amp; Bronwen Shaw reporting multicenter phase 2 trial‚Ä¶,false
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-01-03 22:47:32+00:00,Oncology Tube,http://twitter.com/,0.0,,1.2132304400954204e+18,,0.0,0.0,,"A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia #ASH19 @CleClinicMD: Aaron Gerds,‚Ä¶ https://t.co/KpqeaefnxX",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1213230440095420416,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia #ASH19 @CleClinicMD: Aaron Gerds,‚Ä¶ https://t.co/KpqeaefnxX",true
KristinCanavera,Pediatric Psychologist in #childhood cancer and #PedsICU critical illness @stjuderesearch; studying Bioethics @Loyolabioethics. Thoughts are my own.,,"Memphis, TN",,2020-01-13 05:31:30+00:00,"Dr. Kristin Canavera, PhD",http://twitter.com/,32.0,,1.2165935912268472e+18,,0.0,0.0,,RT @StJudeResearch: Study shows Venetoclax chemo combination is well-tolerated and effective in kids and young adults with relapsed or refr‚Ä¶,en,0.0,196.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,23.0,9.0,https://twitter.com/KristinCanavera/statuses/1216593591226847233,0.0,0.0,,0.0,0.0,0.0,9.0,23.0,False,False,False,False,True,Diagnosis Progression,1.0,0.0,0.0,RT @StJudeResearch: Study shows Venetoclax chemo combination is well-tolerated and effective in kids and young adults with relapsed or refr‚Ä¶,true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-01-15 05:57:02+00:00,Oncology Tube,http://twitter.com/,0.0,,1.2173247961128591e+18,,0.0,0.0,,"MANIFEST, a Phase 2 Study of CPI-0610 @MountSinaiNYC #ASH #ASH19: John Mascarenhas, MD of @MountSinaiNYC discusses‚Ä¶ https://t.co/h1DAxwVVNd",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1217324796112859136,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"MANIFEST, a Phase 2 Study of CPI-0610 @MountSinaiNYC #ASH #ASH19: John Mascarenhas, MD of @MountSinaiNYC discusses‚Ä¶ https://t.co/h1DAxwVVNd",true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-01-28 05:46:02+00:00,Oncology Tube,http://twitter.com/,1.0,,1.222033069810438e+18,,0.0,0.0,,"Phase 2 study of Frontline Brentuximab Vedotin #ASH19 @TheUSONetwork: Christopher Yasenchak, MD of @TheUSONetwork d‚Ä¶ https://t.co/u9aKasEUPQ",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/oncologytube/statuses/1222033069810438144,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"Phase 2 study of Frontline Brentuximab Vedotin #ASH19 @TheUSONetwork: Christopher Yasenchak, MD of @TheUSONetwork d‚Ä¶ https://t.co/u9aKasEUPQ",true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-01-23 04:19:04+00:00,Oncology Tube,http://twitter.com/,0.0,,1.220199241718481e+18,,0.0,0.0,,"A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia #ASH19 @CleClinicMD: Aaron Gerds,‚Ä¶ https://t.co/iYTADZrm1I",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1220199241718480896,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia #ASH19 @CleClinicMD: Aaron Gerds,‚Ä¶ https://t.co/iYTADZrm1I",true
Adrianapordios,"Physician, Master in Public Health & Epidemiology, Hematology and Medical Affairs. Opinions are my own",,,,2020-01-22 02:20:07+00:00,Adriana Aguilar,http://twitter.com/,12.0,,1.2198069214288814e+18,,0.0,0.0,,"RT @AGP_hematology: FLAG-based regimens have an important role in the treatment of patients with newly diagnosed AML, and in the relapsed/r‚Ä¶",en,0.0,456.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,8.0,4.0,https://twitter.com/Adrianapordios/statuses/1219806921428881408,0.0,0.0,,0.0,0.0,0.0,4.0,8.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @AGP_hematology: FLAG-based regimens have an important role in the treatment of patients with newly diagnosed AML, and in the relapsed/r‚Ä¶",false
mabeky,Leukemia Department Administrator at MD Anderson Cancer Center,,"Houston, TX",,2020-01-21 23:01:10+00:00,M. Silverstein,http://twitter.com/,12.0,,1.2197568552089723e+18,,0.0,0.0,,"RT @AGP_hematology: FLAG-based regimens have an important role in the treatment of patients with newly diagnosed AML, and in the relapsed/r‚Ä¶",en,0.0,206.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,8.0,4.0,https://twitter.com/mabeky/statuses/1219756855208972288,0.0,0.0,,0.0,0.0,0.0,4.0,8.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @AGP_hematology: FLAG-based regimens have an important role in the treatment of patients with newly diagnosed AML, and in the relapsed/r‚Ä¶",true
KargerHCP,@KargerPublisher is a globally active publishing house in health sciences. Healthcare caters to the needs of doctors in clinics/private practice & specialists.,,"Basel, Switzerland",,2020-11-25 07:37:26+00:00,Karger Healthcare Professionals,http://twitter.com/,22.0,,1.3315022372863631e+18,,0.0,0.0,,"RT @ASHClinicalNews: When Virtual Becomes the Reality: Bill Reed, @ASH_hematology‚Äôs Chief Event Strategy Officer gives a behind-the-scenes‚Ä¶",en,0.0,426.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,15.0,7.0,https://twitter.com/KargerHCP/statuses/1331502237286363137,0.0,0.0,,0.0,0.0,0.0,7.0,15.0,False,False,False,False,True,Cost of Care,0.0,0.0,1.0,"RT @ASHClinicalNews: When Virtual Becomes the Reality: Bill Reed, @ASH_hematology‚Äôs Chief Event Strategy Officer gives a behind-the-scenes‚Ä¶",true
LukeMtjoy,Hematologist and transplant physician at Colorado Blood Cancer Institute. Former hem/onc fellow @MayoClinic AZ. view and opinions are my own,,"Denver, CO",,2020-06-14 15:58:33+00:00,LukeMtjoy,http://twitter.com/,92.0,,1.2721967395506872e+18,,0.0,0.0,,RT @DocHutchings: Pleased to present the final results from the dose escalation part of the Phase 1/2 study of epcoritamab in r/r B-NHL at‚Ä¶,en,0.0,137.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,69.0,23.0,https://twitter.com/LukeMtjoy/statuses/1272196739550687233,0.0,0.0,,0.0,0.0,0.0,23.0,69.0,False,False,False,False,True,FDA Approval,1.0,0.0,0.0,RT @DocHutchings: Pleased to present the final results from the dose escalation part of the Phase 1/2 study of epcoritamab in r/r B-NHL at‚Ä¶,true
docesr,"Haematologist (of the red cell variety). Lover of London, the NHS, food and walking. tweets are personal views, RT not necessarily endorsement or agreement",,"London, England",,2020-03-20 15:29:41+00:00,Elizabeth Rhodes,http://twitter.com/,52.0,,1.241024118042112e+18,,0.0,0.0,,RT @thalassaemiaTIF: Fear of #Covid_19 infection have dramatically reduced #BloodDonation in many countries &amp; the risk of blood supplies dr‚Ä¶,en,0.0,442.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,25.0,27.0,https://twitter.com/docesr/statuses/1241024118042112003,0.0,0.0,,0.0,0.0,0.0,27.0,25.0,False,False,False,False,True,Charity,0.0,0.0,1.0,RT @thalassaemiaTIF: Fear of #Covid_19 infection have dramatically reduced #BloodDonation in many countries &amp; the risk of blood supplies dr‚Ä¶,true
CAnaemiaNetwork,"We are a group of patients, carers, doctors, & scientists who are all interested in patients with #rare inherited #anaemia.  #haematology #blood",,"Oxford, England",,2020-03-21 07:00:10+00:00,@CongenitalAnaemia,http://twitter.com/,52.0,,1.241258283433943e+18,,0.0,0.0,,RT @thalassaemiaTIF: Fear of #Covid_19 infection have dramatically reduced #BloodDonation in many countries &amp; the risk of blood supplies dr‚Ä¶,en,0.0,163.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,25.0,27.0,https://twitter.com/CAnaemiaNetwork/statuses/1241258283433943040,0.0,0.0,,0.0,0.0,0.0,27.0,25.0,False,False,False,False,True,Charity,0.0,0.0,1.0,RT @thalassaemiaTIF: Fear of #Covid_19 infection have dramatically reduced #BloodDonation in many countries &amp; the risk of blood supplies dr‚Ä¶,true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-02-16 19:49:04+00:00,Oncology Tube,http://twitter.com/,0.0,,1.2291305947238728e+18,,0.0,0.0,,"Phase I Study of Duvelisib in CLL/SLL #ASH19 #ASH @DanaFarber: Jennifer Crombie, MD of @DanaFarber discusses a phas‚Ä¶ https://t.co/9aLAyFLJQ6",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1229130594723872768,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"Phase I Study of Duvelisib in CLL/SLL #ASH19 #ASH @DanaFarber: Jennifer Crombie, MD of @DanaFarber discusses a phas‚Ä¶ https://t.co/9aLAyFLJQ6",false
TAinaMDMPH,Sister.Daughter.Physician.PediatricAnesthesiologist.ClinicianEducator. Tweets are my own ‚ù§,,United States,,2020-08-27 16:55:23+00:00,"T.Aina, MD MPH",http://twitter.com/,1.0,,1.2990277453395927e+18,,0.0,0.0,,RT @Pedisedationdoc: Virtual Sickle Cell Disease fundraising brunch with live music from Karter James. #SickleTiniSaturday #SCDAA https://t‚Ä¶,en,0.0,150.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/TAinaMDMPH/statuses/1299027745339592704,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,RT @Pedisedationdoc: Virtual Sickle Cell Disease fundraising brunch with live music from Karter James. #SickleTiniSaturday #SCDAA https://t‚Ä¶,true
Pedisedationdoc,"Pediatric emergency medicne physician. Passion for family-centered, quality pain & sedation management/research. tweets are my own",,"Houston, TX",,2020-08-27 16:48:50+00:00,Corrie Chumpitazi MD MS FAAP FACEP,http://twitter.com/,1.0,,1.299026095711359e+18,,0.0,0.0,,Virtual Sickle Cell Disease fundraising brunch with live music from Karter James. #SickleTiniSaturday #SCDAA‚Ä¶ https://t.co/KOl4Zf44iJ,en,0.0,942.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/Pedisedationdoc/statuses/1299026095711358983,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,Virtual Sickle Cell Disease fundraising brunch with live music from Karter James. #SickleTiniSaturday #SCDAA‚Ä¶ https://t.co/KOl4Zf44iJ,true
biostockguru,Physician executive(MD CWRU;Rice/Jones);Healthcare focus Fund;Pharma advisor/KOL;Tweets NOT investment advice.Pls do your DD. Support https://t.co/97U34OldNG,,United States,,2020-11-06 12:09:06+00:00,biostockGuru,http://twitter.com/,0.0,,1.3246852345419776e+18,,0.0,0.0,,"PB2452 only reversal agent of #Brilinta $AZN

$PHAS 

PTLA ‚Äî&gt; $ALXN buyout for 1.5 Billion $

$PHAS market cap $96M‚Ä¶ https://t.co/2g4fwtOfub",en,0.0,14011.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/biostockguru/statuses/1324685234541977600,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Cost of Care,0.0,0.0,1.0,"PB2452 only reversal agent of #Brilinta $AZN

$PHAS 

PTLA ‚Äî&gt; $ALXN buyout for 1.5 Billion $

$PHAS market cap $96M‚Ä¶ https://t.co/2g4fwtOfub",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 20:12:35+00:00,"Ritcha Saxena, MD",http://twitter.com/,10.0,,1.3356785468288164e+18,,0.0,0.0,,RT @razan_mohty: Venetoclax + Gilteritinib for R/R FLT3-Mutated #AML in the Expansion Cohort of a Phase 1b Study by Dr Naval Daver - Nice r‚Ä¶,en,0.0,6875.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,4.0,https://twitter.com/RitchaSaxena/statuses/1335678546828816393,0.0,0.0,,0.0,0.0,0.0,4.0,6.0,False,False,False,False,True,FDA Approval,1.0,0.0,0.0,RT @razan_mohty: Venetoclax + Gilteritinib for R/R FLT3-Mutated #AML in the Expansion Cohort of a Phase 1b Study by Dr Naval Daver - Nice r‚Ä¶,true
CanerSaygin,"Heme-Onc Fellow @UChicago | Alumni of @OhioStateIMRes, @CCLRI | #Leukemia, #MDS, #CHIP physician-scientist. Tweets=own opinions.",,"Chicago, IL",,2020-12-06 22:43:11+00:00,"Caner Saygin, MD",http://twitter.com/,0.0,,1.3357164432085074e+18,,0.0,0.0,,"Dr Ravandi presented phase 1 study of vibecotamab (XmAb14045), CD123 x CD3 bispecific antibody in R/R #AML pts. Res‚Ä¶ https://t.co/0QEdVV2Y14",en,0.0,743.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/CanerSaygin/statuses/1335716443208507395,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"Dr Ravandi presented phase 1 study of vibecotamab (XmAb14045), CD123 x CD3 bispecific antibody in R/R #AML pts. Res‚Ä¶ https://t.co/0QEdVV2Y14",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 01:54:10+00:00,"Ritcha Saxena, MD",http://twitter.com/,24.0,,1.3354021187113e+18,,0.0,0.0,,RT @DanaFarberNews: A phase 1 trial found cytokine-induced memory-like NK cells exhibit expansion and long-term persistence after infusion‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,21.0,3.0,https://twitter.com/RitchaSaxena/statuses/1335402118711300096,0.0,0.0,,0.0,0.0,0.0,3.0,21.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,RT @DanaFarberNews: A phase 1 trial found cytokine-induced memory-like NK cells exhibit expansion and long-term persistence after infusion‚Ä¶,false
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 16:22:34+00:00,"Ritcha Saxena, MD",http://twitter.com/,13.0,,1.3356206585968804e+18,,0.0,0.0,,RT @AkshaySharmaMD: #ASH20 Richa Sharma from @StJudeResearch @marrowgenes lab #TBD #BMF https://t.co/TU4uUcXFWb,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,9.0,4.0,https://twitter.com/RitchaSaxena/statuses/1335620658596880386,0.0,0.0,,0.0,0.0,0.0,4.0,9.0,False,False,False,False,True,Research Funding,0.0,0.0,1.0,RT @AkshaySharmaMD: #ASH20 Richa Sharma from @StJudeResearch @marrowgenes lab #TBD #BMF https://t.co/TU4uUcXFWb,true
CanerSaygin,"Heme-Onc Fellow @UChicago | Alumni of @OhioStateIMRes, @CCLRI | #Leukemia, #MDS, #CHIP physician-scientist. Tweets=own opinions.",,"Chicago, IL",,2020-12-06 23:10:15+00:00,"Caner Saygin, MD",http://twitter.com/,218.0,,1.3357232573167247e+18,,0.0,0.0,,"RT @hemedoc: #ASH20 #leusm Wei: We are all excited to have new therapeutic options in AML, but the overall message I get from this money sl‚Ä¶",en,0.0,743.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,168.0,50.0,https://twitter.com/CanerSaygin/statuses/1335723257316724739,0.0,0.0,,0.0,0.0,0.0,50.0,168.0,False,False,False,False,True,Research Funding,1.0,0.0,0.0,"RT @hemedoc: #ASH20 #leusm Wei: We are all excited to have new therapeutic options in AML, but the overall message I get from this money sl‚Ä¶",true
DrKussmanMD,Board Certified Pediatrician.Pediatric Hematology-Oncology Fellow interested in Bone Marrow Transplant and Cellular Therapy.Pediatric Cancer Survivor. Mom/wife.,,"Columbus, OH",,2020-12-08 20:52:51+00:00,Dr. Ashleigh Kussman,http://twitter.com/,2.0,,1.3364134527814164e+18,,0.0,0.0,,Because #COVID19 does not just cause an infection of the lungs... it also may cause blood clots and bleeding in add‚Ä¶ https://t.co/JQbneH83PV,en,0.0,2691.0,,,0.0,,,Negative,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/DrKussmanMD/statuses/1336413452781416451,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Side Effects,0.0,1.0,0.0,Because #COVID19 does not just cause an infection of the lungs... it also may cause blood clots and bleeding in add‚Ä¶ https://t.co/JQbneH83PV,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-09 00:34:49+00:00,"Ritcha Saxena, MD",http://twitter.com/,8.0,,1.3364693123711263e+18,,0.0,0.0,,"RT @adctherapeutics: Attending #ASH20? Check out interim results from LOTIS 3, the Phase 1/2 trial of our lead investigational product in c‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,4.0,https://twitter.com/RitchaSaxena/statuses/1336469312371126278,0.0,0.0,,0.0,0.0,0.0,4.0,4.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"RT @adctherapeutics: Attending #ASH20? Check out interim results from LOTIS 3, the Phase 1/2 trial of our lead investigational product in c‚Ä¶",true
Physns1stWatch,Physician's First Watch offers brief daily reviews of news that affects a physician's practice.,,"Waltham, MA",,2020-12-09 14:24:33+00:00,PhysiciansFirstWatch,http://twitter.com/,1.0,,1.3366781242858127e+18,,0.0,0.0,,News from #ASH20: Dr. Christopher Gibson talks with Joe Elia about new findings that show it might not be necessary‚Ä¶ https://t.co/vm3HxCkKpX,en,0.0,16507.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/Physns1stWatch/statuses/1336678124285812736,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Research Funding,0.0,0.0,1.0,News from #ASH20: Dr. Christopher Gibson talks with Joe Elia about new findings that show it might not be necessary‚Ä¶ https://t.co/vm3HxCkKpX,true
DrABurke,"Mum, wife, haematologist, daughter, sister, friend - in no particular order! Personal account #carecantwait RTs do not equal endorsement",,,,2020-12-09 09:35:51+00:00,Aine Burke,http://twitter.com/,86.0,,1.3366054682198712e+18,,0.0,0.0,,RT @oconnn04: A big thank you to the clinical teams in the NCC and the Clinical research facility @stjamesdublin and the Irish participants‚Ä¶,en,0.0,911.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,73.0,13.0,https://twitter.com/DrABurke/statuses/1336605468219871232,0.0,0.0,,0.0,0.0,0.0,13.0,73.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @oconnn04: A big thank you to the clinical teams in the NCC and the Clinical research facility @stjamesdublin and the Irish participants‚Ä¶,false
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-09 00:19:26+00:00,"Ritcha Saxena, MD",http://twitter.com/,86.0,,1.336465443314348e+18,,0.0,0.0,,RT @oconnn04: A big thank you to the clinical teams in the NCC and the Clinical research facility @stjamesdublin and the Irish participants‚Ä¶,en,0.0,6875.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,73.0,13.0,https://twitter.com/RitchaSaxena/statuses/1336465443314348034,0.0,0.0,,0.0,0.0,0.0,13.0,73.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @oconnn04: A big thank you to the clinical teams in the NCC and the Clinical research facility @stjamesdublin and the Irish participants‚Ä¶,true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-12-09 19:05:00+00:00,Oncology Tube,http://twitter.com/,0.0,,1.3367487000439194e+18,,0.0,0.0,,"2191 Randomized Phase 2 Trial Joshua Zeidner, MD @LeukDocJZ @UNC_Lineberger #ASH20 #MDS #CMML #AML #cancer‚Ä¶ https://t.co/9nw92bLShS",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1336748700043919361,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"2191 Randomized Phase 2 Trial Joshua Zeidner, MD @LeukDocJZ @UNC_Lineberger #ASH20 #MDS #CMML #AML #cancer‚Ä¶ https://t.co/9nw92bLShS",true
nadahamad,"BMT, cellular therapies and clinical haematologist, clinical researcher, lymphoma doc, mother of 3, feminist and ANZTCT president. Opinions are my own.",,"Sydney, Australia",,2020-12-09 02:20:53+00:00,A/Prof Nada Hamad,http://twitter.com/,29.0,,1.3364960069013504e+18,,0.0,0.0,,RT @DrStevenDevine: Superb presentation by Dr Shaw at #ASH20 Presidential symposium. @BeTheMatch is working with her and other great invest‚Ä¶,en,0.0,346.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,22.0,7.0,https://twitter.com/nadahamad/statuses/1336496006901350400,0.0,0.0,,0.0,0.0,0.0,7.0,22.0,False,False,False,False,True,Financial Performance,1.0,0.0,0.0,RT @DrStevenDevine: Superb presentation by Dr Shaw at #ASH20 Presidential symposium. @BeTheMatch is working with her and other great invest‚Ä¶,true
pembeoltulu,"Pathologist(Associate professor), Meram Faculty of Medicine, Konya/Turkey; I lv #hemepath, #dermpath üíóMarried and have 4 children, RT/Tw are not medical advice",,T√ºrkiye,,2020-12-06 21:56:44+00:00,"Pembe Oltulu, MD",http://twitter.com/,2.0,,1.3357047571057336e+18,,0.0,0.0,,RT @smbenlazar: Interim Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients (Pts) W‚Ä¶,en,0.0,8940.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/pembeoltulu/statuses/1335704757105733642,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,RT @smbenlazar: Interim Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients (Pts) W‚Ä¶,true
jacklynsuarez19,Doctor of Pharmacy üíä,,,,2020-12-06 18:06:25+00:00,Jacklyn Suarez,http://twitter.com/,22.0,,1.335646794424828e+18,,0.0,0.0,,"RT @MM_Hub: Congress| #ASH20| @AlGarfall, @PennCancer, presented data on the phase I trial of teclistamab for R/R MM showing encouraging to‚Ä¶",en,0.0,5.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,14.0,8.0,https://twitter.com/jacklynsuarez19/statuses/1335646794424827904,0.0,0.0,,0.0,0.0,0.0,8.0,14.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"RT @MM_Hub: Congress| #ASH20| @AlGarfall, @PennCancer, presented data on the phase I trial of teclistamab for R/R MM showing encouraging to‚Ä¶",true
majorajay,"Hematology/oncology fellow. #lymsm & #mmsm outcomes researcher. Physician-publisher & founder of https://t.co/dPfLt8QVMr, @inTrainingDoc & @inHouseMag.",,"Chicago, IL",,2020-12-06 18:36:11+00:00,"Ajay Major, MD, MBA",http://twitter.com/,11.0,,1.3356542844368937e+18,,0.0,0.0,,RT @SoniSmithMD: Very lucky to work with #ASH2020 Mentor recipient Dr Wendy Stock. The words of her mentees say it all! https://t.co/b7OJ4z‚Ä¶,en,0.0,3518.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,1.0,https://twitter.com/majorajay/statuses/1335654284436893698,0.0,0.0,,0.0,0.0,0.0,1.0,10.0,False,False,False,False,True,Financial Performance,1.0,0.0,0.0,RT @SoniSmithMD: Very lucky to work with #ASH2020 Mentor recipient Dr Wendy Stock. The words of her mentees say it all! https://t.co/b7OJ4z‚Ä¶,false
JoannaS_Yi,"Christ-loving disciple who loves music, crafts, and getting to be around kids as a pediatric oncologist and drug discovery scientist. Tweets are my own.",,,,2020-12-06 23:04:35+00:00,JoannaS_Yi,http://twitter.com/,3.0,,1.3357218302970634e+18,,0.0,0.0,,"A longer-acting asparaginase soon be available for ALL pts, based on the single agent phase 2 trial NOR-GRASPALL201‚Ä¶ https://t.co/ot094beSe8",en,0.0,163.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/JoannaS_Yi/statuses/1335721830297063424,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"A longer-acting asparaginase soon be available for ALL pts, based on the single agent phase 2 trial NOR-GRASPALL201‚Ä¶ https://t.co/ot094beSe8",true
MDAndersonNews,"The official account of MD Anderson Cancer Center, a leader in cancer care, cancer research and the fight to #EndCancer. Appointments available: 1-877-632-6789.",,"Houston, TX",,2020-12-06 04:07:00+00:00,MD Anderson Cancer Center,http://twitter.com/,3.0,,1.3354355467981128e+18,,0.0,0.0,,"‚ÄúHaving new and specialized therapies like CAR T cells, new therapies that were invented here like CAR NK cells ‚Ä¶ c‚Ä¶ https://t.co/XwKjkFEZ49",en,0.0,114120.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/MDAndersonNews/statuses/1335435546798112768,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Research Funding,0.0,0.0,1.0,"‚ÄúHaving new and specialized therapies like CAR T cells, new therapies that were invented here like CAR NK cells ‚Ä¶ c‚Ä¶ https://t.co/XwKjkFEZ49",true
BroeckelmannPJ,"MD @UKKoeln & Physician Scientist Postdoc @MPIAGE. Hemato-Oncology. Lymphoma. Immunotherapies. DNA damage. Personal opinion, RT/like ‚â† endorsement.",,"Cologne, Germany",,2020-12-06 23:46:16+00:00,Paul Br√∂ckelmann,http://twitter.com/,45.0,,1.335732320008069e+18,,0.0,0.0,,RT @DrMiguelPerales: #ASH20 Abs 470 Impressive results in Phase II Study of Pembrolizumab Plus GVD As 2nd-Line Therapy for Rel/Ref Classica‚Ä¶,en,0.0,243.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,34.0,11.0,https://twitter.com/BroeckelmannPJ/statuses/1335732320008069122,0.0,0.0,,0.0,0.0,0.0,11.0,34.0,False,False,False,False,True,FDA Approval,1.0,0.0,0.0,RT @DrMiguelPerales: #ASH20 Abs 470 Impressive results in Phase II Study of Pembrolizumab Plus GVD As 2nd-Line Therapy for Rel/Ref Classica‚Ä¶,true
GlopesMd,"Cancer Doctor and Researcher, Faculty @SylvesterCancer @UnivMiami. Helping improve Cancer Control in LMICs. Editor-in-Chief JCO Global Oncology @ASCO",,"Miami, FL",,2020-12-08 23:44:59+00:00,gilberto lopes,http://twitter.com/,17.0,,1.3364567721655214e+18,,0.0,0.0,,RT @KenFigueroaLab: Congratulations!!! So proud to work with such a talented group of clinical and basic investigators at @SylvesterCancer‚Ä¶,en,0.0,31610.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,16.0,1.0,https://twitter.com/GlopesMd/statuses/1336456772165521409,0.0,0.0,,0.0,0.0,0.0,1.0,16.0,False,False,False,False,True,Financial Performance,1.0,0.0,0.0,RT @KenFigueroaLab: Congratulations!!! So proud to work with such a talented group of clinical and basic investigators at @SylvesterCancer‚Ä¶,true
sheilsroc,Clinical Specialist Physiotherapist specialised in Haemophilia.,,Ireland,,2020-12-08 15:09:36+00:00,Sheila Roche,http://twitter.com/,86.0,,1.3363270733343457e+18,,0.0,0.0,,RT @oconnn04: A big thank you to the clinical teams in the NCC and the Clinical research facility @stjamesdublin and the Irish participants‚Ä¶,en,0.0,123.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,73.0,13.0,https://twitter.com/sheilsroc/statuses/1336327073334345739,0.0,0.0,,0.0,0.0,0.0,13.0,73.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @oconnn04: A big thank you to the clinical teams in the NCC and the Clinical research facility @stjamesdublin and the Irish participants‚Ä¶,true
FranciscoMarty_,"Infectious diseases doctor who specializes in treating transplant and cancer patients, work at @BrighamWomens and @DanaFarber, @harvardmed.",,"Boston, MA",,2020-12-06 01:32:13+00:00,"Francisco Marty, MD",http://twitter.com/,218.0,,1.3353965960502395e+18,,0.0,0.0,,"RT @hemedoc: #ASH20 #leusm Wei: We are all excited to have new therapeutic options in AML, but the overall message I get from this money sl‚Ä¶",en,0.0,9990.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,168.0,50.0,https://twitter.com/FranciscoMarty_/statuses/1335396596050239490,0.0,0.0,,0.0,0.0,0.0,50.0,168.0,False,False,False,False,True,Research Funding,1.0,0.0,0.0,"RT @hemedoc: #ASH20 #leusm Wei: We are all excited to have new therapeutic options in AML, but the overall message I get from this money sl‚Ä¶",false
SandyWong02111,UCSF Hematologist and BMT physician,,"San Francisco, CA",,2020-12-06 17:44:44+00:00,Sandy Wong,http://twitter.com/,29.0,,1.3356413377905172e+18,,0.0,0.0,,RT @MazieTsangMD: #ASH20 #ASHKudos to @UCSFCancer fellow @SwethaKMD who worked so hard on this phase 2 study of Dara + Aza + Dex (Darazadex‚Ä¶,en,0.0,759.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,22.0,7.0,https://twitter.com/SandyWong02111/statuses/1335641337790517248,0.0,0.0,,0.0,0.0,0.0,7.0,22.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,RT @MazieTsangMD: #ASH20 #ASHKudos to @UCSFCancer fellow @SwethaKMD who worked so hard on this phase 2 study of Dara + Aza + Dex (Darazadex‚Ä¶,true
MediHumdani,"Director, BMT & Cellular Therapy Program @Froedtert & @MedicalCollege | Lymphoma | Clinical Trials | @CIBMTR | @BMTCTN | Personal views | Physician ‚â† Provider",,"Milwaukee, WI",,2020-12-07 20:11:09+00:00,Mehdi Hamadani,http://twitter.com/,1.0,,1.3360405738038843e+18,,0.0,0.0,,"Phase 1 Study of TTI-621, targeting CD47, in r/r hem malignancies #lymsm #ASH20  
N=200+; thrombocytopenia common‚Ä¶ https://t.co/WNSUqJec6q",en,0.0,4590.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/MediHumdani/statuses/1336040573803884545,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"Phase 1 Study of TTI-621, targeting CD47, in r/r hem malignancies #lymsm #ASH20  
N=200+; thrombocytopenia common‚Ä¶ https://t.co/WNSUqJec6q",true
dbranderMD,translational oncologist at Duke Cancer Institute / director CLL & Lymphoma research program / views and tweets are my own,,,,2020-12-07 00:55:52+00:00,Danielle M. Brander,http://twitter.com/,5.0,,1.3357498337690214e+18,,0.0,0.0,,"RT @DukeHMCT: #ASH20 poster by @LindsayReinMD @DukeHMCT @dukemedicine @DukeCancer 

Phase I trial incorporating NK cells for patients w/ #C‚Ä¶",en,0.0,376.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,2.0,https://twitter.com/dbranderMD/statuses/1335749833769021440,0.0,0.0,,0.0,0.0,0.0,2.0,3.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"RT @DukeHMCT: #ASH20 poster by @LindsayReinMD @DukeHMCT @dukemedicine @DukeCancer 

Phase I trial incorporating NK cells for patients w/ #C‚Ä¶",true
khouri_jack,Myeloma/BMT #hematologist #oncologist @ClevelandClinic Assistant Prof @CleClinicLCM @CWRUSOM | alum @TuftsMedSchool @Uni_Of_Balamand #mmsm #bmtsm,,"Cleveland, OH",,2020-12-07 22:01:48+00:00,"Jack Khouri, MD",http://twitter.com/,36.0,,1.3360684162607596e+18,,0.0,0.0,,"RT @ninashah33: Cyber IBER! Iber with dara dex or
BTZ dex with 35-50% ORR. I think this data useful to show us how to combine this new drug‚Ä¶",en,0.0,443.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,28.0,8.0,https://twitter.com/khouri_jack/statuses/1336068416260759552,0.0,0.0,,0.0,0.0,0.0,8.0,28.0,False,False,False,False,True,Research Funding,0.0,0.0,1.0,"RT @ninashah33: Cyber IBER! Iber with dara dex or
BTZ dex with 35-50% ORR. I think this data useful to show us how to combine this new drug‚Ä¶",true
CBCIDocs,Thoughts and perspectives from the hematology and transplant physicians at Colorado Blood Cancer Institute @ColoradoBlood @SarahCannonDocs @PresStLukesDenv,,"Denver, CO",,2020-12-17 16:57:54+00:00,CBCI,http://twitter.com/,68.0,,1.3396158170178068e+18,,0.0,0.0,,"RT @BMS_Myeloma_US: During #ASH20, learn why new treatment options are needed in triple-class exposed* multiple myeloma. #MMSM",en,0.0,782.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,55.0,13.0,https://twitter.com/CBCIDocs/statuses/1339615817017806850,0.0,0.0,,0.0,0.0,0.0,13.0,55.0,False,False,False,False,True,Drug Discovery,0.0,0.0,1.0,"RT @BMS_Myeloma_US: During #ASH20, learn why new treatment options are needed in triple-class exposed* multiple myeloma. #MMSM",true
AnnaSureda5,"Haematologist interested in lymphoid malignancies, stem cell transplantation and CART cells. #CART #BMT #lymphomas #immunotherapy #WomenInMedicine",,"Barcelona, Spain",,2020-12-04 14:11:18+00:00,Anna Sureda,http://twitter.com/,5.0,,1.3348628509600563e+18,,0.0,0.0,,"RT @TheEBMT: Get to know the #EBMT values üèÜ
Value 3/8 = Innovativeüßë‚Äçüî¨

The EBMT community embraces clinical research, basic science and edu‚Ä¶",en,0.0,658.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,1.0,https://twitter.com/AnnaSureda5/statuses/1334862850960056320,0.0,0.0,,0.0,0.0,0.0,1.0,4.0,False,False,False,False,True,Disease Advocacy,0.0,0.0,1.0,"RT @TheEBMT: Get to know the #EBMT values üèÜ
Value 3/8 = Innovativeüßë‚Äçüî¨

The EBMT community embraces clinical research, basic science and edu‚Ä¶",false
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-12-29 20:50:03+00:00,Oncology Tube,http://twitter.com/,0.0,,1.3440228938401464e+18,,0.0,0.0,,"@TomSilver39 We had the pleasure of speaking with Dr. Arora - Phase 1 Study of Axatilimab (SNDX-6352) Mukta Arora,‚Ä¶ https://t.co/sjtDzN3zCh",en,0.0,14785.0,,,0.0,TomSilver39,1.3358091986264596e+18,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1344022893840146433,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,FDA Approval,1.0,0.0,0.0,"@TomSilver39 We had the pleasure of speaking with Dr. Arora - Phase 1 Study of Axatilimab (SNDX-6352) Mukta Arora,‚Ä¶ https://t.co/sjtDzN3zCh",true
szusmani,"Division Chief, Plasma Cell Disorders|Director, Clinical Research Hem Malignancies | Views are my own | RT not endorsement | Physician ‚â† Provider",,"Charlotte, NC",,2020-11-09 16:23:33+00:00,Saad Z. Usmani MD MBA FACP (he/his/him),http://twitter.com/,2.0,,1.3258364342348595e+18,,0.0,0.0,,"6/7
TOP 5 CLINICAL PHASE 2/3 Newly Diagnosed #ASH20SU #ASH20 #mmsm
-GRIFFIN Update (https://t.co/UBT5mcwA7Y)
-EMN02‚Ä¶ https://t.co/I7mygDw3S3",en,0.0,5512.0,,,0.0,szusmani,1.325836432980779e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/szusmani/statuses/1325836434234859521,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"6/7
TOP 5 CLINICAL PHASE 2/3 Newly Diagnosed #ASH20SU #ASH20 #mmsm
-GRIFFIN Update (https://t.co/UBT5mcwA7Y)
-EMN02‚Ä¶ https://t.co/I7mygDw3S3",true
VincentRK,"Professor, Mayo Clinic; Editor, Blood Cancer Journal; Oncologist; Health Costs; COVID threads @SurvivedCOVID Opinions=personal views https://t.co/TMq9vc5hZk",,"Rochester, MN, USA",,2020-12-02 23:42:43+00:00,Vincent Rajkumar,http://twitter.com/,0.0,,1.3342818773148017e+18,,0.0,0.0,,Data on some of the new drugs in this thread. #ASH20 https://t.co/zO6HRwXTBk,en,0.0,33590.0,,,0.0,VincentRK,1.3342724336883712e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/VincentRK/statuses/1334281877314801666,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Research Funding,0.0,0.0,1.0,Data on some of the new drugs in this thread. #ASH20 https://t.co/zO6HRwXTBk,true
crfheart,CRF is a nonprofit dedicated to helping doctors improve survival and quality of life for people suffering from heart disease.,,"New York, NY",,2020-10-14 13:08:28+00:00,Cardiovascular Research Foundation,http://twitter.com/,33.0,,1.3163652577581916e+18,,0.0,0.0,,"RT @JGrapsa: Inspiring the next generation, promoting innovation &amp; clinical excellence, @ACCinTouch together with @crfheart introduce Marti‚Ä¶",en,0.0,12239.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,23.0,10.0,https://twitter.com/crfheart/statuses/1316365257758191620,0.0,0.0,,0.0,0.0,0.0,10.0,23.0,False,False,False,False,True,Long Term Benefits,1.0,0.0,0.0,"RT @JGrapsa: Inspiring the next generation, promoting innovation &amp; clinical excellence, @ACCinTouch together with @crfheart introduce Marti‚Ä¶",true
purviparwani,"Cardiologist, DirectorWomens‚ù§Ô∏è Clinic #LLUH, BOT @scmrorg ,tweets=myopinion #CardiacImaging #WomenCVhealth #wellness üßò‚Äç‚ôÄÔ∏è üå±",,"California, USA",,2020-10-14 14:38:26+00:00,Dr. Purvi Parwani,http://twitter.com/,33.0,,1.316387895557546e+18,,0.0,0.0,,"RT @JGrapsa: Inspiring the next generation, promoting innovation &amp; clinical excellence, @ACCinTouch together with @crfheart introduce Marti‚Ä¶",en,0.0,19397.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,23.0,10.0,https://twitter.com/purviparwani/statuses/1316387895557545984,0.0,0.0,,0.0,0.0,0.0,10.0,23.0,False,False,False,False,True,Long Term Benefits,1.0,0.0,0.0,"RT @JGrapsa: Inspiring the next generation, promoting innovation &amp; clinical excellence, @ACCinTouch together with @crfheart introduce Marti‚Ä¶",true
Rfonsi1,"Interim Executive Director, Mayo Clinic Cancer Center. Myeloma doctor. Visiting Healthcare Fellow @GoldwaterInst. Tweets-own/RT not an endorsement",,,,2020-11-29 17:50:31+00:00,Rafael Fonseca MD,http://twitter.com/,0.0,,1.3331060758815212e+18,,0.0,0.0,,Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Mul‚Ä¶ https://t.co/uOUH8Apo05,en,0.0,8301.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/Rfonsi1/statuses/1333106075881521156,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Mul‚Ä¶ https://t.co/uOUH8Apo05,false
Rfonsi1,"Interim Executive Director, Mayo Clinic Cancer Center. Myeloma doctor. Visiting Healthcare Fellow @GoldwaterInst. Tweets-own/RT not an endorsement",,,,2020-11-29 17:24:52+00:00,Rafael Fonseca MD,http://twitter.com/,3.0,,1.3330996225505198e+18,,0.0,0.0,,Two-Year Follow-up of Investigator-Initiated Phase 1 Trials of the Safety and Efficacy of Fully Human Anti-Bcma CAR‚Ä¶ https://t.co/M2wXxOc2qa,en,0.0,8301.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/Rfonsi1/statuses/1333099622550519808,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,Two-Year Follow-up of Investigator-Initiated Phase 1 Trials of the Safety and Efficacy of Fully Human Anti-Bcma CAR‚Ä¶ https://t.co/M2wXxOc2qa,true
HallekMichael,"Hematologist and oncologist at the University of Cologne, Germany. Tweets are my own & no medical advice.",,"Cologne, Germany",,2020-12-11 15:22:24+00:00,Michael Hallek,http://twitter.com/,6.0,,1.337417458148397e+18,,0.0,0.0,,RT @lymphomahub: #ASH20 | Watch the @lymphomahub interview with Peter Borchmann about the results from the phase I study of a novel CD19/CD‚Ä¶,en,0.0,4644.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,3.0,https://twitter.com/HallekMichael/statuses/1337417458148397056,0.0,0.0,,0.0,0.0,0.0,3.0,3.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,RT @lymphomahub: #ASH20 | Watch the @lymphomahub interview with Peter Borchmann about the results from the phase I study of a novel CD19/CD‚Ä¶,true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-11-19 21:38:53+00:00,Lisa Palacios,http://twitter.com/,9.0,,1.329539669449732e+18,,0.0,0.0,,"RT @DrAmitPatel: Phase I trial @TapKadia @doctorpemm: single infusion of #CK0801, #allogeneic #cord #blood expanded #Treg cellular therapy‚Ä¶",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,3.0,https://twitter.com/Lisa_Palacios/statuses/1329539669449732102,0.0,0.0,,0.0,0.0,0.0,3.0,6.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"RT @DrAmitPatel: Phase I trial @TapKadia @doctorpemm: single infusion of #CK0801, #allogeneic #cord #blood expanded #Treg cellular therapy‚Ä¶",true
Tamim80976890,"MD, M. Sc, Hematology, HSCT",,,,2020-12-12 11:25:39+00:00,Tamim,http://twitter.com/,29.0,,1.3377202660934246e+18,,0.0,0.0,,"RT @Mohty_EBMT: CAR-T cells jumping the lines in lymphoma #ASH20
Phase II ZUMA-12 Study Investigates First-Line Axicabtagene Ciloleucel for‚Ä¶",en,0.0,34.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,23.0,6.0,https://twitter.com/Tamim80976890/statuses/1337720266093424641,0.0,0.0,,0.0,0.0,0.0,6.0,23.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,"RT @Mohty_EBMT: CAR-T cells jumping the lines in lymphoma #ASH20
Phase II ZUMA-12 Study Investigates First-Line Axicabtagene Ciloleucel for‚Ä¶",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-11-19 21:00:42+00:00,"Ritcha Saxena, MD",http://twitter.com/,4.0,,1.3295300584957133e+18,,0.0,0.0,,RT @smbenlazar: Blockade of PD-1 Added to Standard Therapy to Target #MRD in #CML: a Phase II Study of Adding the Anti-PD-1 Pembrolizumab t‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,2.0,2.0,https://twitter.com/RitchaSaxena/statuses/1329530058495713282,0.0,0.0,,0.0,0.0,0.0,2.0,2.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,RT @smbenlazar: Blockade of PD-1 Added to Standard Therapy to Target #MRD in #CML: a Phase II Study of Adding the Anti-PD-1 Pembrolizumab t‚Ä¶,true
oconnn04,"Haematologist, hiker and camper, Lyric FM fan, proud mother of three amazing daughters",,"Dublin City, Ireland",,2020-12-08 14:45:59+00:00,Niamh O'Connell,http://twitter.com/,13.0,,1.3363211273295913e+18,,0.0,0.0,,A big thank you to the clinical teams in the NCC and the Clinical research facility @stjamesdublin and the Irish pa‚Ä¶ https://t.co/WBXTEp7Ras,en,0.0,60.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,13.0,https://twitter.com/oconnn04/statuses/1336321127329591298,0.0,0.0,,0.0,0.0,0.0,13.0,0.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,A big thank you to the clinical teams in the NCC and the Clinical research facility @stjamesdublin and the Irish pa‚Ä¶ https://t.co/WBXTEp7Ras,false
cgfran01,"dad, physician, scientist, musician",,,,2020-12-05 14:54:48+00:00,cedric francois,http://twitter.com/,4.0,,1.3352361828846838e+18,,0.0,0.0,,RT @ApellisPharma: We are proud to share our latest scientific research in #PNH this year at the virtual #ASH2020. Learn more about Apellis‚Ä¶,en,0.0,510.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,1.0,https://twitter.com/cgfran01/statuses/1335236182884683776,0.0,0.0,,0.0,0.0,0.0,1.0,3.0,False,False,False,False,True,Research Funding,1.0,0.0,0.0,RT @ApellisPharma: We are proud to share our latest scientific research in #PNH this year at the virtual #ASH2020. Learn more about Apellis‚Ä¶,true
mpdrc,Executive Director- Mays Cancer Center at UT Health San Antonio MD Anderson; (Views on Twitter are personal opinion),,"UT Health San Antonio ,TX, USA",,2020-12-05 15:21:16+00:00,"Ruben A. Mesa, MD",http://twitter.com/,4.0,,1.3352428435988234e+18,,0.0,0.0,,Excited for the upcoming start of First #ASHFromHome MPN Clinical Session : New Therapies and JAKi-Based Combinatio‚Ä¶ https://t.co/WaDlUWbi8n,en,0.0,3222.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,4.0,https://twitter.com/mpdrc/statuses/1335242843598823427,0.0,0.0,,0.0,0.0,0.0,4.0,0.0,False,False,False,False,True,Research Funding,1.0,0.0,0.0,Excited for the upcoming start of First #ASHFromHome MPN Clinical Session : New Therapies and JAKi-Based Combinatio‚Ä¶ https://t.co/WaDlUWbi8n,true
CanerSaygin,"Heme-Onc Fellow @UChicago | Alumni of @OhioStateIMRes, @CCLRI | #Leukemia, #MDS, #CHIP physician-scientist. Tweets=own opinions.",,"Chicago, IL",,2020-12-05 16:42:29+00:00,"Caner Saygin, MD",http://twitter.com/,2.0,,1.3352632821863465e+18,,0.0,0.0,,Phase II data on CPX-351 + venetoclax in newly diagnosed and R/R AML (38% with TP53m) by Dr Kadia. This combo is qu‚Ä¶ https://t.co/6UCPZjsnoy,en,0.0,743.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/CanerSaygin/statuses/1335263282186346496,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,Phase II data on CPX-351 + venetoclax in newly diagnosed and R/R AML (38% with TP53m) by Dr Kadia. This combo is qu‚Ä¶ https://t.co/6UCPZjsnoy,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-05 05:31:55+00:00,"Ritcha Saxena, MD",http://twitter.com/,19.0,,1.335094528144003e+18,,0.0,0.0,,RT @amarkelkar: Flying solo for the early phases of #ASH20 ... interesting early talks on #racism in medicine and infection/coagulation! My‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,18.0,1.0,https://twitter.com/RitchaSaxena/statuses/1335094528144003072,0.0,0.0,,0.0,0.0,0.0,1.0,18.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,RT @amarkelkar: Flying solo for the early phases of #ASH20 ... interesting early talks on #racism in medicine and infection/coagulation! My‚Ä¶,true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 19:47:28+00:00,Lisa Palacios,http://twitter.com/,14.0,,1.3353098360415437e+18,,0.0,0.0,,RT @mpdrc: Excited for the upcoming start of First #ASHFromHome MPN Clinical Session : New Therapies and JAKi-Based Combinations for Myelof‚Ä¶,en,0.0,657.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,4.0,https://twitter.com/Lisa_Palacios/statuses/1335309836041543684,0.0,0.0,,0.0,0.0,0.0,4.0,10.0,False,False,False,False,True,Research Funding,1.0,0.0,0.0,RT @mpdrc: Excited for the upcoming start of First #ASHFromHome MPN Clinical Session : New Therapies and JAKi-Based Combinations for Myelof‚Ä¶,true
noriega_dr,"MD, PhD. Hematologist in CHUAC (A Coru√±a-Spain). Leukemia and Bone Marrow Transplantation. Tweets and opinions are mine.",,,,2020-12-06 18:27:13+00:00,Dr Victor Noriega,http://twitter.com/,10.0,,1.3356520307324928e+18,,0.0,0.0,,RT @razan_mohty: Venetoclax + Gilteritinib for R/R FLT3-Mutated #AML in the Expansion Cohort of a Phase 1b Study by Dr Naval Daver - Nice r‚Ä¶,en,0.0,959.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,4.0,https://twitter.com/noriega_dr/statuses/1335652030732492803,0.0,0.0,,0.0,0.0,0.0,4.0,6.0,False,False,False,False,True,FDA Approval,1.0,0.0,0.0,RT @razan_mohty: Venetoclax + Gilteritinib for R/R FLT3-Mutated #AML in the Expansion Cohort of a Phase 1b Study by Dr Naval Daver - Nice r‚Ä¶,false
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 21:24:28+00:00,"Ritcha Saxena, MD",http://twitter.com/,4.0,,1.3356966331541873e+18,,0.0,0.0,,"RT @gvhd_hub: CONGRESS | #ASH20 | Mukta Arora, @umnmedschool, reported the data from the phase I study of axatilimab (SNDX-6352), a CSF-1R‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,1.0,https://twitter.com/RitchaSaxena/statuses/1335696633154187265,0.0,0.0,,0.0,0.0,0.0,1.0,3.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"RT @gvhd_hub: CONGRESS | #ASH20 | Mukta Arora, @umnmedschool, reported the data from the phase I study of axatilimab (SNDX-6352), a CSF-1R‚Ä¶",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 15:59:12+00:00,"Ritcha Saxena, MD",http://twitter.com/,12.0,,1.3356147802378772e+18,,0.0,0.0,,RT @CanerSaygin: Phase II data on CPX-351 + venetoclax in newly diagnosed and R/R AML (38% with TP53m) by Dr Kadia. This combo is quite tox‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,2.0,https://twitter.com/RitchaSaxena/statuses/1335614780237877249,0.0,0.0,,0.0,0.0,0.0,2.0,10.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @CanerSaygin: Phase II data on CPX-351 + venetoclax in newly diagnosed and R/R AML (38% with TP53m) by Dr Kadia. This combo is quite tox‚Ä¶,true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-03 18:20:49+00:00,Lisa Palacios,http://twitter.com/,21.0,,1.3345632558141235e+18,,0.0,0.0,,"RT @MDAndersonNews: Chemotherapy used to be the standard treatment option for mantle cell lymphoma. But what‚Äôs next? 

Our Dr. Michael Wang‚Ä¶",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,19.0,2.0,https://twitter.com/Lisa_Palacios/statuses/1334563255814123529,0.0,0.0,,0.0,0.0,0.0,2.0,19.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"RT @MDAndersonNews: Chemotherapy used to be the standard treatment option for mantle cell lymphoma. But what‚Äôs next? 

Our Dr. Michael Wang‚Ä¶",true
MattPPlayer,Husband to Eloise. Christian. Haematologist. Interested in Global Haematology. Sports fan.,,Malawi,,2020-10-28 19:34:56+00:00,Matthew Player,http://twitter.com/,19.0,,1.3215359415137485e+18,,0.0,0.0,,"RT @TheLancetHaem: Dr  Marilyn J Telen presents promising results from the phase 1 trial of FT-4202, a pyruvate kinase R-activator, in pati‚Ä¶",en,0.0,41.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,13.0,6.0,https://twitter.com/MattPPlayer/statuses/1321535941513748482,0.0,0.0,,0.0,0.0,0.0,6.0,13.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"RT @TheLancetHaem: Dr  Marilyn J Telen presents promising results from the phase 1 trial of FT-4202, a pyruvate kinase R-activator, in pati‚Ä¶",true
chanyooncheah,Doctor for patients with lymphoma. Clinical researcher.,,"Perth, Western Australia",,2020-11-05 00:51:27+00:00,Chan Cheah,http://twitter.com/,0.0,,1.3241523142994944e+18,,0.0,0.0,,Look forward to presenting updated findings for this phase I trial @TGTherapeutics #lymSM #CLLsm #ASH2020 https://t.co/eHK2C6BBjn,en,0.0,1717.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/chanyooncheah/statuses/1324152314299494400,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,FDA Approval,1.0,0.0,0.0,Look forward to presenting updated findings for this phase I trial @TGTherapeutics #lymSM #CLLsm #ASH2020 https://t.co/eHK2C6BBjn,true
drparagjasani,"Consultant Haematologist @RFL and @UCLH, special interest in CLL and Lymphoma. Own views",,UK,,2020-11-04 15:15:21+00:00,Dr Parag Jasani,http://twitter.com/,17.0,,1.3240073323979407e+18,,0.0,0.0,,"RT @tobyeyre82: Phase I trial
VLS-101 (ROR1 ADC) in R/R #mantle cell #lymphoma

All BTKi exposed
13/15 stopped due to PD 

Neutropenia &amp; PN‚Ä¶",en,0.0,60.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,7.0,https://twitter.com/drparagjasani/statuses/1324007332397940738,0.0,0.0,,0.0,0.0,0.0,7.0,10.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"RT @tobyeyre82: Phase I trial
VLS-101 (ROR1 ADC) in R/R #mantle cell #lymphoma

All BTKi exposed
13/15 stopped due to PD 

Neutropenia &amp; PN‚Ä¶",false
OPreventzaMD,"Cardiac Surgeon, Prof. Surg with Tenure , Baylor College of Medicine , President Elect of ISEVS, WTS Adult Cardiac Surg representative . Leadership, HC Policy",,"Houston, TX",,2020-10-15 01:56:45+00:00,Ourania Preventza,http://twitter.com/,33.0,,1.3165586015998034e+18,,0.0,0.0,,"RT @JGrapsa: Inspiring the next generation, promoting innovation &amp; clinical excellence, @ACCinTouch together with @crfheart introduce Marti‚Ä¶",en,0.0,2276.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,23.0,10.0,https://twitter.com/OPreventzaMD/statuses/1316558601599803392,0.0,0.0,,0.0,0.0,0.0,10.0,23.0,False,False,False,False,True,Long Term Benefits,1.0,0.0,0.0,"RT @JGrapsa: Inspiring the next generation, promoting innovation &amp; clinical excellence, @ACCinTouch together with @crfheart introduce Marti‚Ä¶",true
aymanka,"interventional cardiologist ( ex SCAI BOT ,ex Washington Hospital Center ) runner , diver , NFL . lucky to be in a profession that keeps you learning !",,,,2020-10-15 11:11:50+00:00,Ayman Magd,http://twitter.com/,26.0,,1.316698291871142e+18,,0.0,0.0,,RT @mmamas1973: #TCTConnect if you missed the LBT session can see livestream below @CardioIAN @billgogas @GiuseppeGalati_ @gbiondizoccai @h‚Ä¶,en,0.0,3854.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,18.0,8.0,https://twitter.com/aymanka/statuses/1316698291871141889,0.0,0.0,,0.0,0.0,0.0,8.0,18.0,False,False,False,False,True,Cost of Care,0.0,0.0,1.0,RT @mmamas1973: #TCTConnect if you missed the LBT session can see livestream below @CardioIAN @billgogas @GiuseppeGalati_ @gbiondizoccai @h‚Ä¶,true
Babar_Basir,"Interventional Cardiologist, #CTO #CHIP #MCS, Clinician & Researcher, #NationalCSI PI, Director of Acute MCS",,"Detroit, MI",,2020-10-20 02:05:28+00:00,Babar Basir,http://twitter.com/,43.0,,1.31837273420902e+18,,0.0,0.0,,"RT @AGoldsweig: @Babar_Basir, @BillONeillMD, &amp; @Mike_Hacala lead the virtual #NCSI investigators meeting after #TCT2020. 

So exciting to s‚Ä¶",en,0.0,6352.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,37.0,6.0,https://twitter.com/Babar_Basir/statuses/1318372734209019905,0.0,0.0,,0.0,0.0,0.0,6.0,37.0,False,False,False,False,True,Cost of Care,1.0,0.0,0.0,"RT @AGoldsweig: @Babar_Basir, @BillONeillMD, &amp; @Mike_Hacala lead the virtual #NCSI investigators meeting after #TCT2020. 

So exciting to s‚Ä¶",true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-01-19 16:50:04+00:00,Oncology Tube,http://twitter.com/,0.0,,1.2189386853216666e+18,,0.0,0.0,,Verastem Oncology Presents Phase 2 PRIMO Study Data Evaluating Duvelisib in Relapsed or Refractory Peripheral T-Cel‚Ä¶ https://t.co/g0qMMQr6jb,en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1218938685321666560,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,Verastem Oncology Presents Phase 2 PRIMO Study Data Evaluating Duvelisib in Relapsed or Refractory Peripheral T-Cel‚Ä¶ https://t.co/g0qMMQr6jb,true
ptptrish,"clinical psychologist, singer/songwriter, wife, mother, grandmother, mil, sister, aunt, cape cod/fire island lover. #impeachedforever #putamaskonit",,NY,,2020-10-24 05:00:20+00:00,drptptrish,http://twitter.com/,125.0,,1.319866291226878e+18,,0.0,0.0,,RT @ASH_hematology: Hematologists are conducting cutting-edge research to fight the pandemic. Register now for the all-virtual ASH annual m‚Ä¶,en,0.0,1779.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,94.0,31.0,https://twitter.com/ptptrish/statuses/1319866291226877953,0.0,0.0,,0.0,0.0,0.0,31.0,94.0,False,False,False,False,True,Covid,0.0,0.0,1.0,RT @ASH_hematology: Hematologists are conducting cutting-edge research to fight the pandemic. Register now for the all-virtual ASH annual m‚Ä¶,true
ClinOncNews,"An independent source of unbiased, accurate, reliable news and in-depth expert analysis on issues oncologists and hematologist/oncologists care about most.",,New York City,,2020-10-05 17:15:13+00:00,ClinicalOncologyNews,http://twitter.com/,0.0,,1.313165860090114e+18,,0.0,0.0,,New treatment options for acute myeloid #leukemia are pushing out old standards. https://t.co/BOBlHYjaLu @ASCO‚Ä¶ https://t.co/s35v4MgaVH,en,0.0,3172.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/ClinOncNews/statuses/1313165860090114049,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Drug Discovery,0.0,0.0,1.0,New treatment options for acute myeloid #leukemia are pushing out old standards. https://t.co/BOBlHYjaLu @ASCO‚Ä¶ https://t.co/s35v4MgaVH,false
gbiondizoccai,"Academic interventional cardiologist, data scientist, & medical writer/reviewer/editor.
All opinions own, (re)tweets/likes not endorsements nor medical advice.",,"Rome, Italy",,2020-10-14 16:01:44+00:00,Giuseppe Biondi-Zoccai,http://twitter.com/,37.0,,1.3164088590875812e+18,,0.0,0.0,,"RT @DFCapodanno: PROSPECT-ABSORB: ""trend for benefit (p=0.12) on lesion-based MACEs"". Interesting hypothesis for a new trial of capping vul‚Ä¶",en,0.0,1321.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,35.0,2.0,https://twitter.com/gbiondizoccai/statuses/1316408859087581184,0.0,0.0,,0.0,0.0,0.0,2.0,35.0,False,False,False,False,True,Research Funding,0.0,0.0,1.0,"RT @DFCapodanno: PROSPECT-ABSORB: ""trend for benefit (p=0.12) on lesion-based MACEs"". Interesting hypothesis for a new trial of capping vul‚Ä¶",true
GiuseppeGalati_,MD #HeartFailure & #Cardiomyopathies #Cardiologist @SanRaffaeleMi ‚Ä¢ Medical MSc in #HF by @anmco @escardio #PCHF‚Ä¢ #IFC #HFA_ESC St. Group #Cardiomyopathies üá™üá∫,,"Milan , Italy üáÆüáπ",,2020-10-14 16:49:47+00:00,Giuseppe Galati,http://twitter.com/,26.0,,1.316420950376751e+18,,0.0,0.0,,RT @mmamas1973: #TCTConnect if you missed the LBT session can see livestream below @CardioIAN @billgogas @GiuseppeGalati_ @gbiondizoccai @h‚Ä¶,en,0.0,5413.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,18.0,8.0,https://twitter.com/GiuseppeGalati_/statuses/1316420950376751104,0.0,0.0,,0.0,0.0,0.0,8.0,18.0,False,False,False,False,True,Cost of Care,0.0,0.0,1.0,RT @mmamas1973: #TCTConnect if you missed the LBT session can see livestream below @CardioIAN @billgogas @GiuseppeGalati_ @gbiondizoccai @h‚Ä¶,true
Pooh_Velagapudi,Cardiologist; Associate PD-Cardiology Fellowship @UNMC; Chair #ACCEarlyCareer section; SoMe editor @JACCJournals; #Education #HRPCI #SHD; EDMüé∂; Opinions my own,,United States,,2020-10-14 14:01:21+00:00,Poonam Velagapudi,http://twitter.com/,33.0,,1.3163785644812206e+18,,0.0,0.0,,"RT @JGrapsa: Inspiring the next generation, promoting innovation &amp; clinical excellence, @ACCinTouch together with @crfheart introduce Marti‚Ä¶",en,0.0,8841.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,23.0,10.0,https://twitter.com/Pooh_Velagapudi/statuses/1316378564481220609,0.0,0.0,,0.0,0.0,0.0,10.0,23.0,False,False,False,False,True,Long Term Benefits,1.0,0.0,0.0,"RT @JGrapsa: Inspiring the next generation, promoting innovation &amp; clinical excellence, @ACCinTouch together with @crfheart introduce Marti‚Ä¶",true
DFCapodanno,"Interventional Cardiologist | University of Catania, Italy | Editor @EuroInterventio",,"Catania, Sicily",,2020-10-14 15:59:34+00:00,Davide Capodanno,http://twitter.com/,2.0,,1.3164083138532065e+18,,0.0,0.0,,"PROSPECT-ABSORB: ""trend for benefit (p=0.12) on lesion-based MACEs"". Interesting hypothesis for a new trial of capp‚Ä¶ https://t.co/IBxcUy9mjr",en,0.0,5313.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/DFCapodanno/statuses/1316408313853206528,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Research Funding,0.0,0.0,1.0,"PROSPECT-ABSORB: ""trend for benefit (p=0.12) on lesion-based MACEs"". Interesting hypothesis for a new trial of capp‚Ä¶ https://t.co/IBxcUy9mjr",true
julefranve,"Oncologist, cancer research. Lymphoma, Myeloma. INEN, Lima, Peru. Tweets are my own.",,"Lima, Peru",,2020-09-19 06:59:15+00:00,"Jule Vasquez, MD",http://twitter.com/,15.0,,1.3072126411994276e+18,,0.0,0.0,,"RT @ASTCT: Abstract submissions for #TCTM21 are now open! Share your original research, and help us pioneer new areas of investigation for‚Ä¶",en,0.0,155.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,8.0,7.0,https://twitter.com/julefranve/statuses/1307212641199427584,0.0,0.0,,0.0,0.0,0.0,7.0,8.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,"RT @ASTCT: Abstract submissions for #TCTM21 are now open! Share your original research, and help us pioneer new areas of investigation for‚Ä¶",true
PavanCheruvuMD,"CEO of Sio Gene Therapies. Father, physician and entrepreneur passionate about building great teams and accelerating cutting-edge science into the clinic.",,"New York, USA",,2020-01-21 22:56:16+00:00,"Pavan Cheruvu, M.D.",http://twitter.com/,1.0,,1.2197556218070098e+18,,0.0,0.0,,"RT @axovant: We applaud the Alliance for Regenerative Medicine, #ARM, for spearheading efforts assessing the impact of advanced therapies o‚Ä¶",en,0.0,128.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/PavanCheruvuMD/statuses/1219755621807009795,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,"RT @axovant: We applaud the Alliance for Regenerative Medicine, #ARM, for spearheading efforts assessing the impact of advanced therapies o‚Ä¶",false
adityadoc1,"Interventional Cardiologist,Loma Linda Univ, Early Career Chair CAACC #SoMe Editor#ACCIC, #CHIP #WarOnShock #TAVR #PAD #MountSinai,NY trained. Tweets=my opinion",,"Loma Linda, CA",,2020-10-22 03:31:34+00:00,Aditya Bharadwaj,http://twitter.com/,43.0,,1.3191191766618317e+18,,0.0,0.0,,"RT @AGoldsweig: @Babar_Basir, @BillONeillMD, &amp; @Mike_Hacala lead the virtual #NCSI investigators meeting after #TCT2020. 

So exciting to s‚Ä¶",en,0.0,3591.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,37.0,6.0,https://twitter.com/adityadoc1/statuses/1319119176661831681,0.0,0.0,,0.0,0.0,0.0,6.0,37.0,False,False,False,False,True,Cost of Care,1.0,0.0,0.0,"RT @AGoldsweig: @Babar_Basir, @BillONeillMD, &amp; @Mike_Hacala lead the virtual #NCSI investigators meeting after #TCT2020. 

So exciting to s‚Ä¶",true
cgfran01,"dad, physician, scientist, musician",,,,2020-11-05 14:56:12+00:00,cedric francois,http://twitter.com/,16.0,,1.3243649016960983e+18,,0.0,0.0,,"RT @ApellisPharma: Today, we announced that eight abstracts highlighting our #PNH scientific research were accepted at the virtual @ASH_hem‚Ä¶",en,0.0,510.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,9.0,7.0,https://twitter.com/cgfran01/statuses/1324364901696098304,0.0,0.0,,0.0,0.0,0.0,7.0,9.0,False,False,False,False,True,Research Funding,0.0,0.0,1.0,"RT @ApellisPharma: Today, we announced that eight abstracts highlighting our #PNH scientific research were accepted at the virtual @ASH_hem‚Ä¶",true
dgermain21,MD-PhD. 2nd year Heme/Onc fellow focused on lymphoma and leukemia. Physician-scientist-in-training. Tweet/RT not medical advice or endorsement.,,"St. Louis, MO",,2020-11-20 01:06:26+00:00,David A. Russler-Germain,http://twitter.com/,55.0,,1.329591902648361e+18,,0.0,0.0,,RT @MediHumdani: Phase 1 Study of Lonca-T CD19 ADC in R/R B-Cell NHL | @BloodJournal  | ORR in DLBCL ~45% (active pre / post #CART) @ccarlo‚Ä¶,en,0.0,1612.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,42.0,13.0,https://twitter.com/dgermain21/statuses/1329591902648360963,0.0,0.0,,0.0,0.0,0.0,13.0,42.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,RT @MediHumdani: Phase 1 Study of Lonca-T CD19 ADC in R/R B-Cell NHL | @BloodJournal  | ORR in DLBCL ~45% (active pre / post #CART) @ccarlo‚Ä¶,true
sairah__ahmed,"Lymphoma/Cellular Therapy & SCT at MD Anderson Cancer Center, opinions/tweets shared= my own.",,"Houston, TX",,2020-11-20 23:46:22+00:00,Sairah Ahmed MD,http://twitter.com/,55.0,,1.3299341383344538e+18,,0.0,0.0,,RT @MediHumdani: Phase 1 Study of Lonca-T CD19 ADC in R/R B-Cell NHL | @BloodJournal  | ORR in DLBCL ~45% (active pre / post #CART) @ccarlo‚Ä¶,en,0.0,491.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,42.0,13.0,https://twitter.com/sairah__ahmed/statuses/1329934138334453763,0.0,0.0,,0.0,0.0,0.0,13.0,42.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,RT @MediHumdani: Phase 1 Study of Lonca-T CD19 ADC in R/R B-Cell NHL | @BloodJournal  | ORR in DLBCL ~45% (active pre / post #CART) @ccarlo‚Ä¶,true
drjgauthier,"MD, MSc, Assistant Professor @fredhutch @UW focused on #CARTcell #immunotherapy #tcellrx 
Interests also include #rstats #bmtsm #epitwitter #bayes",,"Seattle, WA",,2020-11-20 01:07:38+00:00,Jordan Gauthier,http://twitter.com/,55.0,,1.3295922049023508e+18,,0.0,0.0,,RT @MediHumdani: Phase 1 Study of Lonca-T CD19 ADC in R/R B-Cell NHL | @BloodJournal  | ORR in DLBCL ~45% (active pre / post #CART) @ccarlo‚Ä¶,en,0.0,3295.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,42.0,13.0,https://twitter.com/drjgauthier/statuses/1329592204902350848,0.0,0.0,,0.0,0.0,0.0,13.0,42.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,RT @MediHumdani: Phase 1 Study of Lonca-T CD19 ADC in R/R B-Cell NHL | @BloodJournal  | ORR in DLBCL ~45% (active pre / post #CART) @ccarlo‚Ä¶,true
MediHumdani,"Director, BMT & Cellular Therapy Program @Froedtert & @MedicalCollege | Lymphoma | Clinical Trials | @CIBMTR | @BMTCTN | Personal views | Physician ‚â† Provider",,"Milwaukee, WI",,2020-11-20 01:05:00+00:00,Mehdi Hamadani,http://twitter.com/,13.0,,1.3295915424037642e+18,,0.0,0.0,,Phase 1 Study of Lonca-T CD19 ADC in R/R B-Cell NHL | @BloodJournal  | ORR in DLBCL ~45% (active pre / post #CART)‚Ä¶ https://t.co/OGVRLM8B6F,en,0.0,4590.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,13.0,https://twitter.com/MediHumdani/statuses/1329591542403764224,0.0,0.0,,0.0,0.0,0.0,13.0,0.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,Phase 1 Study of Lonca-T CD19 ADC in R/R B-Cell NHL | @BloodJournal  | ORR in DLBCL ~45% (active pre / post #CART)‚Ä¶ https://t.co/OGVRLM8B6F,false
ClinOncNews,"An independent source of unbiased, accurate, reliable news and in-depth expert analysis on issues oncologists and hematologist/oncologists care about most.",,New York City,,2020-10-10 15:15:10+00:00,ClinicalOncologyNews,http://twitter.com/,1.0,,1.3149475894402458e+18,,0.0,0.0,,New treatment options for acute myeloid #leukemia are pushing out old standards. https://t.co/BOBlHYjaLu @ASCO‚Ä¶ https://t.co/PHcC0MSE5X,en,0.0,3172.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/ClinOncNews/statuses/1314947589440245762,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Drug Discovery,0.0,0.0,1.0,New treatment options for acute myeloid #leukemia are pushing out old standards. https://t.co/BOBlHYjaLu @ASCO‚Ä¶ https://t.co/PHcC0MSE5X,true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-01-18 02:53:03+00:00,Oncology Tube,http://twitter.com/,0.0,,1.2183656555246592e+18,,0.0,0.0,,"Phase 2 Study of Luspatercept Commonly Asked Questions #ASH19 @CleClinicMD: Aaron Gerds, MD of @CleClinicMD discuss‚Ä¶ https://t.co/kpVkElhvz0",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1218365655524659200,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"Phase 2 Study of Luspatercept Commonly Asked Questions #ASH19 @CleClinicMD: Aaron Gerds, MD of @CleClinicMD discuss‚Ä¶ https://t.co/kpVkElhvz0",true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-01-18 15:01:03+00:00,Oncology Tube,http://twitter.com/,0.0,,1.2185488626688287e+18,,0.0,0.0,,"Phase II Study of Oral Rigosertib #ASH19 @MountSinaiNYC: Shyamala Navada, MD of @MountSinaiNYC discusses the phase‚Ä¶ https://t.co/VEJ0sZBg9y",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1218548862668828672,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"Phase II Study of Oral Rigosertib #ASH19 @MountSinaiNYC: Shyamala Navada, MD of @MountSinaiNYC discusses the phase‚Ä¶ https://t.co/VEJ0sZBg9y",true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-01-29 18:51:04+00:00,Oncology Tube,http://twitter.com/,0.0,,1.222593018198278e+18,,0.0,0.0,,Phase I Study Evaluating NKTR-255 in MM and NHL #ASH #ASH19 @DanaFarber: Nikhil Munshi of @DanaFarber discusses the‚Ä¶ https://t.co/M3nNblrWhF,en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1222593018198278145,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,Phase I Study Evaluating NKTR-255 in MM and NHL #ASH #ASH19 @DanaFarber: Nikhil Munshi of @DanaFarber discusses the‚Ä¶ https://t.co/M3nNblrWhF,true
davidhenrymd,"Practicing MD Hematologist Oncologist 
Vice Chair Dept of Medicine Pennsylvania Hospital Blood&Cancer host Research-supportive care @MDedgeTweets @MDedgeHemeOnc",,"Philadelphia, PA",,2020-01-18 14:00:09+00:00,David Henry,http://twitter.com/,0.0,,1.2185335364640645e+18,,0.0,0.0,,"Study from #ASH19 investigates how to predict TTP relapse in pregnancy, authors suggest following ADAMSTS13 level a‚Ä¶ https://t.co/pc0YDMsRNF",en,0.0,1771.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/davidhenrymd/statuses/1218533536464064513,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,"Study from #ASH19 investigates how to predict TTP relapse in pregnancy, authors suggest following ADAMSTS13 level a‚Ä¶ https://t.co/pc0YDMsRNF",true
adrianabello,"pediatrician, pediatric hematologyst, mother adribello@hotmail.com",,,,2020-02-05 18:39:01+00:00,Adriana Bello,http://twitter.com/,3.0,,1.2251266971184538e+18,,0.0,0.0,,RT @PeerView: Learn best practices to prevent #CMV infection ‚Äì February 20 symposium at #TCTM20 #PeerView https://t.co/gggK0zouC0,en,0.0,1968.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,2.0,1.0,https://twitter.com/adrianabello/statuses/1225126697118453761,0.0,0.0,,0.0,0.0,0.0,1.0,2.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,RT @PeerView: Learn best practices to prevent #CMV infection ‚Äì February 20 symposium at #TCTM20 #PeerView https://t.co/gggK0zouC0,false
davidhenrymd,"Practicing MD Hematologist Oncologist 
Vice Chair Dept of Medicine Pennsylvania Hospital Blood&Cancer host Research-supportive care @MDedgeTweets @MDedgeHemeOnc",,"Philadelphia, PA",,2020-01-14 13:26:04+00:00,David Henry,http://twitter.com/,0.0,,1.2170754087404626e+18,,0.0,0.0,,From #ASH19: A phase 2 study of luspatercept in pts w/ myelofibrosis associated anemia revealed very good response‚Ä¶ https://t.co/DAGsW1GUZy,en,0.0,1771.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/davidhenrymd/statuses/1217075408740462593,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,FDA Approval,1.0,0.0,0.0,From #ASH19: A phase 2 study of luspatercept in pts w/ myelofibrosis associated anemia revealed very good response‚Ä¶ https://t.co/DAGsW1GUZy,true
jetertseng,"General Pediatrician @ Jia-An Mother and Child Clinic, Taiwan. Interested about pediatric hematology/oncology, neonatology, neurology and allergy",,Taiwain,,2020-01-12 11:23:49+00:00,jetertseng,http://twitter.com/,32.0,,1.2163198671852913e+18,,0.0,0.0,,RT @StJudeResearch: Study shows Venetoclax chemo combination is well-tolerated and effective in kids and young adults with relapsed or refr‚Ä¶,en,0.0,4.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,23.0,9.0,https://twitter.com/jetertseng/statuses/1216319867185291264,0.0,0.0,,0.0,0.0,0.0,9.0,23.0,False,False,False,False,True,Diagnosis Progression,1.0,0.0,0.0,RT @StJudeResearch: Study shows Venetoclax chemo combination is well-tolerated and effective in kids and young adults with relapsed or refr‚Ä¶,true
BollamRajesh4,"Oncologist & Hematologist ( Tata memorial hospital)

Working in Yashoda hospital Secunderabad",,"Hyderabad, India",,2020-01-02 07:05:17+00:00,Dr Rajesh Bollam - Cancer Specialist in Hyderabad,http://twitter.com/,6.0,,1.2126309275636408e+18,,0.0,0.0,,"RT @TheLancetHaem: Nathan H Fowler‚ÄîPhase 1-2 trial of Lenalidomide Plus Obinutuzumab in r/r indolent NHL: at 17 months follow-up, 24mo PFS‚Ä¶",en,0.0,955.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,2.0,4.0,https://twitter.com/BollamRajesh4/statuses/1212630927563640832,0.0,0.0,,0.0,0.0,0.0,4.0,2.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"RT @TheLancetHaem: Nathan H Fowler‚ÄîPhase 1-2 trial of Lenalidomide Plus Obinutuzumab in r/r indolent NHL: at 17 months follow-up, 24mo PFS‚Ä¶",true
MedpageOnco,Breaking cancer + oncology news | Reports from all major oncology meetings | Peer-reviewed | Oncologist-trusted | Part of @MedPageToday,,,,2020-02-26 20:05:01+00:00,MedPage Oncology,http://twitter.com/,2.0,,1.232758488759251e+18,,0.0,0.0,,This treatment led to a high rate of allogeneic hematopoietic stem cell transplant in older patients with relapsed/‚Ä¶ https://t.co/16XaME1Hoy,en,0.0,443.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/MedpageOnco/statuses/1232758488759250946,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,This treatment led to a high rate of allogeneic hematopoietic stem cell transplant in older patients with relapsed/‚Ä¶ https://t.co/16XaME1Hoy,true
nycdoc29,"ASCO, ASH, EHA & ESMO Member, Hem/Onc - 11 MD specialty private practice, former full time academic, traveller, foodie & out of necessity now a business person!",,"Garden City, NY",,2020-06-13 16:39:56+00:00,NYCDoc29,http://twitter.com/,92.0,,1.2718447669013176e+18,,0.0,0.0,,RT @DocHutchings: Pleased to present the final results from the dose escalation part of the Phase 1/2 study of epcoritamab in r/r B-NHL at‚Ä¶,en,0.0,664.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,69.0,23.0,https://twitter.com/nycdoc29/statuses/1271844766901317633,0.0,0.0,,0.0,0.0,0.0,23.0,69.0,False,False,False,False,True,FDA Approval,1.0,0.0,0.0,RT @DocHutchings: Pleased to present the final results from the dose escalation part of the Phase 1/2 study of epcoritamab in r/r B-NHL at‚Ä¶,true
nycdoc29,"ASCO, ASH, EHA & ESMO Member, Hem/Onc - 11 MD specialty private practice, former full time academic, traveller, foodie & out of necessity now a business person!",,"Garden City, NY",,2020-06-13 22:19:04+00:00,NYCDoc29,http://twitter.com/,37.0,,1.2719301098224722e+18,,0.0,0.0,,"RT @tobyeyre82: #acalabrutinib in 1L #CLL 
phase II trial
n=99
53m median fup
14 d/c to date: 6 AEs (4 SPM, 2 infection), 3 PD
Tox profile:‚Ä¶",en,0.0,664.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,28.0,9.0,https://twitter.com/nycdoc29/statuses/1271930109822472193,0.0,0.0,,0.0,0.0,0.0,9.0,28.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"RT @tobyeyre82: #acalabrutinib in 1L #CLL 
phase II trial
n=99
53m median fup
14 d/c to date: 6 AEs (4 SPM, 2 infection), 3 PD
Tox profile:‚Ä¶",false
chano_py,Sola Gracia. Medico Hematologo. Donante de √≥rganos. #DonaenVida. #HSCT Dr in #Paraguay. Patient Advocacy Co-Chair at #WBMT. Secretary at @LABMT2,,Paraguay,,2020-06-13 21:27:52+00:00,Cristobal Frutos,http://twitter.com/,7.0,,1.271917226036269e+18,,0.0,0.0,,"RT @Care4Access: . @jmikhaelmd: ""That first #remission is important because at every new #TreatmentLine, #myeloma #MM #patients die, especi‚Ä¶",en,0.0,903.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,4.0,https://twitter.com/chano_py/statuses/1271917226036269057,0.0,0.0,,0.0,0.0,0.0,4.0,3.0,False,False,False,False,True,Drug Discovery,0.0,0.0,1.0,"RT @Care4Access: . @jmikhaelmd: ""That first #remission is important because at every new #TreatmentLine, #myeloma #MM #patients die, especi‚Ä¶",true
alex_jares,"Husband, MD/PhD trainee @StonyBrookMed | MS4 applying to psychiatry ‚îÇ researcher ‚îÇ gene + cell therapies | @Yale College, @NIH alum ‚îÇ views=mine (he/him/his)",,"New York, USA",,2020-05-14 20:57:58+00:00,"Alex Jares, Ph.D.",http://twitter.com/,1.0,,1.2610380676972257e+18,,0.0,0.0,,The new @ASGCTherapy logo is like a biomedical version of the ‚Äúworm‚Äù NASA logo. I like it. #ASGCT20 https://t.co/jmTID722JY,en,0.0,489.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/alex_jares/statuses/1261038067697225728,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Research Funding,0.0,0.0,1.0,The new @ASGCTherapy logo is like a biomedical version of the ‚Äúworm‚Äù NASA logo. I like it. #ASGCT20 https://t.co/jmTID722JY,true
dlwagner13,Physician & science enthusiast @ChariteBerlin // previously: @CAGTHouston // Genome Editing and Immunology // 50% of @immunoboys,,"Berlin, Germany",,2020-05-14 21:40:15+00:00,Dimitrios L. Wagner,http://twitter.com/,5.0,,1.2610487046661325e+18,,0.0,0.0,,RT @alex_jares: The new @ASGCTherapy logo is like a biomedical version of the ‚Äúworm‚Äù NASA logo. I like it. #ASGCT20 https://t.co/jmTID722JY,en,0.0,532.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,1.0,https://twitter.com/dlwagner13/statuses/1261048704666132481,0.0,0.0,,0.0,0.0,0.0,1.0,4.0,False,False,False,False,True,Research Funding,0.0,0.0,1.0,RT @alex_jares: The new @ASGCTherapy logo is like a biomedical version of the ‚Äúworm‚Äù NASA logo. I like it. #ASGCT20 https://t.co/jmTID722JY,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-24 15:24:57+00:00,"Ritcha Saxena, MD",http://twitter.com/,33.0,,1.3421291414460293e+18,,0.0,0.0,,"RT @ASH_hematology: ASH Foundation Chair Gary Schiller, MD, running for this year's run/walk, which supports our new Research Restart Award‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,31.0,2.0,https://twitter.com/RitchaSaxena/statuses/1342129141446029313,0.0,0.0,,0.0,0.0,0.0,2.0,31.0,False,False,False,False,True,Research Funding,0.0,0.0,1.0,"RT @ASH_hematology: ASH Foundation Chair Gary Schiller, MD, running for this year's run/walk, which supports our new Research Restart Award‚Ä¶",true
SurvivingMD,Hematologist and oncologist and Professor of Clinical Medicine at City of Hope. Author of Surviving American Medicine. https://t.co/ZVx56FNk6v,,"Los Angeles, California",,2020-12-10 22:50:03+00:00,Dr. Cary Presant,http://twitter.com/,0.0,,1.3371677244396298e+18,,0.0,0.0,,The #ASH2020 meeting showed new treatments for #leukemia and #lymphoma. A new #CAR-T treatment in #CLL patients who‚Ä¶ https://t.co/2boqTBsAj3,en,0.0,549.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/SurvivingMD/statuses/1337167724439629827,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Drug Discovery,0.0,0.0,1.0,The #ASH2020 meeting showed new treatments for #leukemia and #lymphoma. A new #CAR-T treatment in #CLL patients who‚Ä¶ https://t.co/2boqTBsAj3,true
FranciscoMarty_,"Infectious diseases doctor who specializes in treating transplant and cancer patients, work at @BrighamWomens and @DanaFarber, @harvardmed.",,"Boston, MA",,2020-12-04 22:31:38+00:00,"Francisco Marty, MD",http://twitter.com/,14.0,,1.334988763911557e+18,,0.0,0.0,,"RT @DanaFarberNews: TODAY: Dana-Farber's Corey Cutler, MD (@DrCCutler), to present results from a new clinical trial studying donor stem ce‚Ä¶",en,0.0,9991.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,12.0,2.0,https://twitter.com/FranciscoMarty_/statuses/1334988763911557121,0.0,0.0,,0.0,0.0,0.0,2.0,12.0,False,False,False,False,True,Research Funding,0.0,0.0,1.0,"RT @DanaFarberNews: TODAY: Dana-Farber's Corey Cutler, MD (@DrCCutler), to present results from a new clinical trial studying donor stem ce‚Ä¶",false
VincentRK,"Professor, Mayo Clinic; Editor, Blood Cancer Journal; Oncologist; Health Costs; COVID threads @SurvivedCOVID Opinions=personal views https://t.co/TMq9vc5hZk",,"Rochester, MN, USA",,2020-12-02 23:05:12+00:00,Vincent Rajkumar,http://twitter.com/,0.0,,1.3342724336883712e+18,,0.0,0.0,,I don‚Äôt think next year I can keep all of this in one slide. A lot of data on the new drugs in blue font are being‚Ä¶ https://t.co/0J6nigEqKN,en,0.0,33590.0,,,0.0,VincentRK,1.3342721270134497e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/VincentRK/statuses/1334272433688371200,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Research Funding,0.0,0.0,1.0,I don‚Äôt think next year I can keep all of this in one slide. A lot of data on the new drugs in blue font are being‚Ä¶ https://t.co/0J6nigEqKN,true
HKlepinMD,Geriatric oncologist,,,,2020-12-10 21:48:08+00:00,Heidi Klepin,http://twitter.com/,11.0,,1.3371521428980613e+18,,0.0,0.0,,RT @ShakiraG_MBBS: #ASH20 #hematology + #aging Poster Walk No:2628 Dr. Charity Oyedeji @DukeHealth üëáused physical+cognitive function measur‚Ä¶,en,0.0,902.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,9.0,2.0,https://twitter.com/HKlepinMD/statuses/1337152142898061314,0.0,0.0,,0.0,0.0,0.0,2.0,9.0,False,False,False,False,True,Charity,0.0,0.0,1.0,RT @ShakiraG_MBBS: #ASH20 #hematology + #aging Poster Walk No:2628 Dr. Charity Oyedeji @DukeHealth üëáused physical+cognitive function measur‚Ä¶,true
DrMJoyner,"Physiologist & anesthesiologist Interested in human performance, views my own. He/him/his",,,,2020-12-10 21:28:16+00:00,Michael Joyner,http://twitter.com/,8.0,,1.3371471443487662e+18,,0.0,0.0,,RT @mtmdphd: A National Collaborative Multicenter Phase II Study for Potential Safety Efficacy of Convalescent Plasma to Treat Severe COVID‚Ä¶,en,0.0,13041.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,3.0,https://twitter.com/DrMJoyner/statuses/1337147144348766213,0.0,0.0,,0.0,0.0,0.0,3.0,5.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,RT @mtmdphd: A National Collaborative Multicenter Phase II Study for Potential Safety Efficacy of Convalescent Plasma to Treat Severe COVID‚Ä¶,true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-10 17:44:03+00:00,Lisa Palacios,http://twitter.com/,4.0,,1.337090715382329e+18,,0.0,0.0,,"RT @oncologytube: A Randomized Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Nicholas J. Short, MD @NicholasShortMD @MDAnderso‚Ä¶",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,2.0,2.0,https://twitter.com/Lisa_Palacios/statuses/1337090715382329346,0.0,0.0,,0.0,0.0,0.0,2.0,2.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"RT @oncologytube: A Randomized Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Nicholas J. Short, MD @NicholasShortMD @MDAnderso‚Ä¶",true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-12-10 17:42:00+00:00,Oncology Tube,http://twitter.com/,2.0,,1.3370901998896947e+18,,0.0,0.0,,"A Randomized Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Nicholas J. Short, MD @NicholasShortMD‚Ä¶ https://t.co/2qEKhUpqsp",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/oncologytube/statuses/1337090199889694723,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"A Randomized Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Nicholas J. Short, MD @NicholasShortMD‚Ä¶ https://t.co/2qEKhUpqsp",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 22:55:42+00:00,Lisa Palacios,http://twitter.com/,7.0,,1.3353572057223946e+18,,0.0,0.0,,"RT @VJHemOnc: Highlights from #MPNsm new therapies &amp; JAKi based combinations for #Myelofibrosis orals at #ASH20

Navitoclax + ruxolitinib i‚Ä¶",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,4.0,https://twitter.com/Lisa_Palacios/statuses/1335357205722394625,0.0,0.0,,0.0,0.0,0.0,4.0,3.0,False,False,False,False,True,Research Funding,0.0,0.0,1.0,"RT @VJHemOnc: Highlights from #MPNsm new therapies &amp; JAKi based combinations for #Myelofibrosis orals at #ASH20

Navitoclax + ruxolitinib i‚Ä¶",false
BartoszHudzik,"Assoc. Prof. of Cardiology #Medical Univ.of Silesia, Senior Cardiologist #SilesianCenterforHeartDisease, #JACCCaseReports Editorial Consultant #thrombosis #AFib",,Polska,,2020-10-14 23:37:25+00:00,Bartosz Hudzik MD PhD FESC FACC,http://twitter.com/,33.0,,1.316523534265594e+18,,0.0,0.0,,"RT @JGrapsa: Inspiring the next generation, promoting innovation &amp; clinical excellence, @ACCinTouch together with @crfheart introduce Marti‚Ä¶",en,0.0,317.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,23.0,10.0,https://twitter.com/BartoszHudzik/statuses/1316523534265593857,0.0,0.0,,0.0,0.0,0.0,10.0,23.0,False,False,False,False,True,Long Term Benefits,1.0,0.0,0.0,"RT @JGrapsa: Inspiring the next generation, promoting innovation &amp; clinical excellence, @ACCinTouch together with @crfheart introduce Marti‚Ä¶",true
JGrapsa,Consultant Cardiologist GSTT - Editor in chief #JACCcasereports -Secretary ESC council on VHD - Tweets are my own opinion#,,,,2020-10-14 13:02:16+00:00,Julia Grapsa,http://twitter.com/,10.0,,1.3163636950233702e+18,,0.0,0.0,,"Inspiring the next generation, promoting innovation &amp; clinical excellence, @ACCinTouch together with @crfheart intr‚Ä¶ https://t.co/PTnuODhV3z",en,0.0,11060.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,10.0,https://twitter.com/JGrapsa/statuses/1316363695023370240,0.0,0.0,,0.0,0.0,0.0,10.0,0.0,False,False,False,False,True,Long Term Benefits,1.0,0.0,0.0,"Inspiring the next generation, promoting innovation &amp; clinical excellence, @ACCinTouch together with @crfheart intr‚Ä¶ https://t.co/PTnuODhV3z",true
hvanspall,"Associate Professor, Cardiologist, Scientist @MacDeptMed @HEI_McMaster. Alumnus @HarvardHSPH @UofTMedicine #HeartFailure #RCTs #Implementation #DigitalHealth",,,,2020-10-14 16:50:40+00:00,"Harriette Van Spall, MD MPH",http://twitter.com/,26.0,,1.3164211752333883e+18,,0.0,0.0,,RT @mmamas1973: #TCTConnect if you missed the LBT session can see livestream below @CardioIAN @billgogas @GiuseppeGalati_ @gbiondizoccai @h‚Ä¶,en,0.0,9080.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,18.0,8.0,https://twitter.com/hvanspall/statuses/1316421175233388545,0.0,0.0,,0.0,0.0,0.0,8.0,18.0,False,False,False,False,True,Cost of Care,0.0,0.0,1.0,RT @mmamas1973: #TCTConnect if you missed the LBT session can see livestream below @CardioIAN @billgogas @GiuseppeGalati_ @gbiondizoccai @h‚Ä¶,true
Drroxmehran,"Interventional cardiologist, Professor of Medicine @mountsinaiNYC, trialist, outcomes researcher, wife and mother; opinions my own #ACCBOT @womenas1",,"Manhattan, NY",,2020-10-14 13:38:27+00:00,Roxana Mehran,http://twitter.com/,33.0,,1.3163728011341742e+18,,0.0,0.0,,"RT @JGrapsa: Inspiring the next generation, promoting innovation &amp; clinical excellence, @ACCinTouch together with @crfheart introduce Marti‚Ä¶",en,0.0,9783.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,23.0,10.0,https://twitter.com/Drroxmehran/statuses/1316372801134174209,0.0,0.0,,0.0,0.0,0.0,10.0,23.0,False,False,False,False,True,Long Term Benefits,1.0,0.0,0.0,"RT @JGrapsa: Inspiring the next generation, promoting innovation &amp; clinical excellence, @ACCinTouch together with @crfheart introduce Marti‚Ä¶",true
AzizNazhaMD,"Practice Manager at Amazon Web Services, Physician, #Programmer, #DataScientist, interested in the Digital Transformation of Healthcare",,Cleveland Clinic,,2020-12-08 17:00:04+00:00,Aziz Nazha,http://twitter.com/,0.0,,1.3363548727535985e+18,,0.0,0.0,,"Our #AI, #ML, #MachineLearning model that can predict response to chemotherapy using blood counts, #ASH2020 
Doximi‚Ä¶ https://t.co/KEM1crv0kj",en,0.0,2087.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/AzizNazhaMD/statuses/1336354872753598465,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"Our #AI, #ML, #MachineLearning model that can predict response to chemotherapy using blood counts, #ASH2020 
Doximi‚Ä¶ https://t.co/KEM1crv0kj",true
MDMagazine,Clinical News for Connected Physicians. Everything you need to enhance your clinical approach to improving patient care.,,United States,,2020-12-08 13:30:00+00:00,HCPLive,http://twitter.com/,0.0,,1.3363020079849925e+18,,0.0,0.0,,"#ICYMI: 

New findings from a #sicklecell study indicate that increased systolic pressure from light exercise may h‚Ä¶ https://t.co/SEzRaZk3ky",en,0.0,7073.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/MDMagazine/statuses/1336302007984992256,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Research Funding,0.0,0.0,1.0,"#ICYMI: 

New findings from a #sicklecell study indicate that increased systolic pressure from light exercise may h‚Ä¶ https://t.co/SEzRaZk3ky",false
emmamgroarke,"Haematologist in Bethesda. Irish trained üáÆüá™ Particular interests: #aplasticanemia, #telomeredisease, #CHIP, #MDS, #AML, #HSCT All comments my own.",,"Washington, DC",,2020-12-08 15:27:50+00:00,Emma M. Groarke,http://twitter.com/,218.0,,1.3363316601161974e+18,,0.0,0.0,,"RT @hemedoc: #ASH20 #leusm Wei: We are all excited to have new therapeutic options in AML, but the overall message I get from this money sl‚Ä¶",en,0.0,130.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,168.0,50.0,https://twitter.com/emmamgroarke/statuses/1336331660116197389,0.0,0.0,,0.0,0.0,0.0,50.0,168.0,False,False,False,False,True,Research Funding,1.0,0.0,0.0,"RT @hemedoc: #ASH20 #leusm Wei: We are all excited to have new therapeutic options in AML, but the overall message I get from this money sl‚Ä¶",true
nixon786,Physician investing in Biotech. Not an investment advise or recommendation to buy & sell. Please do your own DD.,,NYC,,2020-12-05 17:43:50+00:00,nixon786,http://twitter.com/,18.0,,1.335278722728026e+18,,0.0,0.0,,RT @AuclairDan: Interesting early data presented by Roman Shapiro at #ASH20 from a Phase I study using memory-like #NK cells ‚Å¶@romeerizwan‚Å©‚Ä¶,en,0.0,1082.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,14.0,4.0,https://twitter.com/nixon786/statuses/1335278722728026120,0.0,0.0,,0.0,0.0,0.0,4.0,14.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,RT @AuclairDan: Interesting early data presented by Roman Shapiro at #ASH20 from a Phase I study using memory-like #NK cells ‚Å¶@romeerizwan‚Å©‚Ä¶,true
diegoah66,"Hematologist-Oncologist @UVMMedCenter, Assistant Professor of Medicine @UVMLarnerMed | üáµüá™üá∫üá∏",,"Burlington, VT",,2020-12-05 07:47:17+00:00,Diego Adrianzen-Herrera,http://twitter.com/,218.0,,1.3351285942810788e+18,,0.0,0.0,,"RT @hemedoc: #ASH20 #leusm Wei: We are all excited to have new therapeutic options in AML, but the overall message I get from this money sl‚Ä¶",en,0.0,187.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,168.0,50.0,https://twitter.com/diegoah66/statuses/1335128594281078786,0.0,0.0,,0.0,0.0,0.0,50.0,168.0,False,False,False,False,True,Research Funding,1.0,0.0,0.0,"RT @hemedoc: #ASH20 #leusm Wei: We are all excited to have new therapeutic options in AML, but the overall message I get from this money sl‚Ä¶",true
Transplant_Doc,Stem Cell Transplant physician and clinical researcher at MD Anderson Cancer Center; special interest in myeloma. Opinions expressed are my own,,,,2020-12-08 03:05:50+00:00,Muzaffar Qazilbash,http://twitter.com/,36.0,,1.336144929635119e+18,,0.0,0.0,,"RT @ninashah33: Cyber IBER! Iber with dara dex or
BTZ dex with 35-50% ORR. I think this data useful to show us how to combine this new drug‚Ä¶",en,0.0,5455.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,28.0,8.0,https://twitter.com/Transplant_Doc/statuses/1336144929635119106,0.0,0.0,,0.0,0.0,0.0,8.0,28.0,False,False,False,False,True,Research Funding,0.0,0.0,1.0,"RT @ninashah33: Cyber IBER! Iber with dara dex or
BTZ dex with 35-50% ORR. I think this data useful to show us how to combine this new drug‚Ä¶",true
ShakiraG_MBBS,BC Geriatrician + Hematologist + Oncologist. Assistant Professor + Clinical Researcher UNC-CH #geriheme #gerionc #mmsm #BlackWomanInMedicine. Tweets=my views,,"North Carolina, USA",,2020-12-08 16:42:50+00:00,Dr. Shakira J Grant MBBS,http://twitter.com/,1.0,,1.3363505371349688e+18,,0.0,0.0,,#ASH20 excellent qualitative study by Dr. Charity Oyedejiüëá@DukeHealth examining barriers and facilitators of Advanc‚Ä¶ https://t.co/ioE0uPwIU3,en,0.0,340.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/ShakiraG_MBBS/statuses/1336350537134968837,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Charity,1.0,0.0,0.0,#ASH20 excellent qualitative study by Dr. Charity Oyedejiüëá@DukeHealth examining barriers and facilitators of Advanc‚Ä¶ https://t.co/ioE0uPwIU3,true
szusmani,"Division Chief, Plasma Cell Disorders|Director, Clinical Research Hem Malignancies | Views are my own | RT not endorsement | Physician ‚â† Provider",,"Charlotte, NC",,2020-12-05 15:12:30+00:00,Saad Z. Usmani MD MBA FACP (he/his/him),http://twitter.com/,6.0,,1.3352406400163758e+18,,0.0,0.0,,"RT @agarwalonc: Duration of immunity of natural infection of coronaviruses measured in months... not years and decades... 
Dr Fauci at #ASH‚Ä¶",en,0.0,5512.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,1.0,https://twitter.com/szusmani/statuses/1335240640016375808,0.0,0.0,,0.0,0.0,0.0,1.0,5.0,False,False,False,False,True,Covid,0.0,0.0,1.0,"RT @agarwalonc: Duration of immunity of natural infection of coronaviruses measured in months... not years and decades... 
Dr Fauci at #ASH‚Ä¶",false
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 16:55:20+00:00,Lisa Palacios,http://twitter.com/,6.0,,1.335266515726295e+18,,0.0,0.0,,"RT @MPN_Hub: CONGRESS | #ASH20 | Srdan Verstovsek, @MDAndersonNews, @LeukemiaMDA, results from phase II MANIFEST study, investigating CPI-0‚Ä¶",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,1.0,https://twitter.com/Lisa_Palacios/statuses/1335266515726295040,0.0,0.0,,0.0,0.0,0.0,1.0,5.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,"RT @MPN_Hub: CONGRESS | #ASH20 | Srdan Verstovsek, @MDAndersonNews, @LeukemiaMDA, results from phase II MANIFEST study, investigating CPI-0‚Ä¶",true
MDedgeHemOnc,MDedge Hematology & Oncology provides the most important and up to date information and news for oncologists. Now part of the Medscape Professional Network.,,"Rockville, MD, Parsippany, NJ",,2020-12-08 19:59:18+00:00,MDedge Hematology & Oncology,http://twitter.com/,0.0,,1.3363999769104916e+18,,0.0,0.0,,Reach 3 Trial: New findings show that ruxolitinib was superior to standard therapy in reducing symptoms of #cGVHD.‚Ä¶ https://t.co/1l5fW9NIzK,en,0.0,6726.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/MDedgeHemOnc/statuses/1336399976910491650,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Research Funding,0.0,0.0,1.0,Reach 3 Trial: New findings show that ruxolitinib was superior to standard therapy in reducing symptoms of #cGVHD.‚Ä¶ https://t.co/1l5fW9NIzK,true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-12-05 04:40:59+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,50.0,,1.3350817113951928e+18,,0.0,0.0,,"#ASH20 #leusm Wei: We are all excited to have new therapeutic options in AML, but the overall message I get from th‚Ä¶ https://t.co/fch6v0Q22l",en,0.0,4813.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,50.0,https://twitter.com/hemedoc/statuses/1335081711395192832,0.0,0.0,,0.0,0.0,0.0,50.0,0.0,False,False,False,False,True,Research Funding,1.0,0.0,0.0,"#ASH20 #leusm Wei: We are all excited to have new therapeutic options in AML, but the overall message I get from th‚Ä¶ https://t.co/fch6v0Q22l",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 21:27:25+00:00,"Ritcha Saxena, MD",http://twitter.com/,20.0,,1.3356973793586094e+18,,0.0,0.0,,"RT @gvhd_hub: CONGRESS | #ASH20 | @DrCCutler, @DanaFarber, reported the top-line results from the ROCKstar phase 2 trial of belumosudil for‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,16.0,4.0,https://twitter.com/RitchaSaxena/statuses/1335697379358609412,0.0,0.0,,0.0,0.0,0.0,4.0,16.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"RT @gvhd_hub: CONGRESS | #ASH20 | @DrCCutler, @DanaFarber, reported the top-line results from the ROCKstar phase 2 trial of belumosudil for‚Ä¶",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 21:46:17+00:00,"Ritcha Saxena, MD",http://twitter.com/,17.0,,1.335702126186668e+18,,0.0,0.0,,RT @YaleCancer: New research led by Dr. George Goshua .@classicalheme &amp; Dr. Alfred Lee at virtual #ASH20 shows caplacizumab is not cost-eff‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,13.0,4.0,https://twitter.com/RitchaSaxena/statuses/1335702126186668033,0.0,0.0,,0.0,0.0,0.0,4.0,13.0,False,False,False,False,True,Research Funding,0.0,0.0,1.0,RT @YaleCancer: New research led by Dr. George Goshua .@classicalheme &amp; Dr. Alfred Lee at virtual #ASH20 shows caplacizumab is not cost-eff‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-07 04:03:08+00:00,"Ritcha Saxena, MD",http://twitter.com/,40.0,,1.3357969645087744e+18,,0.0,0.0,,RT @RahmaWarsameMD: Promising results from phase 1 VSV-IFNb-NIS in pts with relapsed refractory hem malignancies. Strongest signal in TCL.‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,30.0,10.0,https://twitter.com/RitchaSaxena/statuses/1335796964508774411,0.0,0.0,,0.0,0.0,0.0,10.0,30.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @RahmaWarsameMD: Promising results from phase 1 VSV-IFNb-NIS in pts with relapsed refractory hem malignancies. Strongest signal in TCL.‚Ä¶,false
YaleCancer,Yale Cancer Center is a collaboration between renowned cancer researchers and physicians at Yale University and Smilow Cancer Hospital.,,"New Haven, Connecticut",,2020-12-06 20:06:08+00:00,Yale Cancer Center,http://twitter.com/,4.0,,1.335676921636647e+18,,0.0,0.0,,New research led by Dr. George Goshua .@classicalheme &amp; Dr. Alfred Lee at virtual #ASH20 shows caplacizumab is not‚Ä¶ https://t.co/7uTkjHnNRC,en,0.0,9957.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,4.0,https://twitter.com/YaleCancer/statuses/1335676921636646912,0.0,0.0,,0.0,0.0,0.0,4.0,0.0,False,False,False,False,True,Research Funding,0.0,0.0,1.0,New research led by Dr. George Goshua .@classicalheme &amp; Dr. Alfred Lee at virtual #ASH20 shows caplacizumab is not‚Ä¶ https://t.co/7uTkjHnNRC,true
KellyMi06345321,"Wife| Mother of 3| Sister| Daughter| Cook| Runner| RN BSN| Proud & Privileged to work for Abiomed as Dir, US Physician Programs| Tweets are my own",,"Delafield, WI",,2020-10-20 09:13:42+00:00,Kelly Miller,http://twitter.com/,43.0,,1.3184805013012562e+18,,0.0,0.0,,"RT @AGoldsweig: @Babar_Basir, @BillONeillMD, &amp; @Mike_Hacala lead the virtual #NCSI investigators meeting after #TCT2020. 

So exciting to s‚Ä¶",en,0.0,301.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,37.0,6.0,https://twitter.com/KellyMi06345321/statuses/1318480501301256194,0.0,0.0,,0.0,0.0,0.0,6.0,37.0,False,False,False,False,True,Cost of Care,1.0,0.0,0.0,"RT @AGoldsweig: @Babar_Basir, @BillONeillMD, &amp; @Mike_Hacala lead the virtual #NCSI investigators meeting after #TCT2020. 

So exciting to s‚Ä¶",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-05 19:03:28+00:00,"Ritcha Saxena, MD",http://twitter.com/,18.0,,1.335298761824891e+18,,0.0,0.0,,"RT @Elena_Kum: Excited to present the work of our community of practice at #ASH2020, part of a collaborative effort to improve stem cell do‚Ä¶",en,0.0,6875.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,16.0,2.0,https://twitter.com/RitchaSaxena/statuses/1335298761824890884,0.0,0.0,,0.0,0.0,0.0,2.0,16.0,False,False,False,False,True,Disease Advocacy,1.0,0.0,0.0,"RT @Elena_Kum: Excited to present the work of our community of practice at #ASH2020, part of a collaborative effort to improve stem cell do‚Ä¶",true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-12-05 20:15:20+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,0.0,,1.3353168504738324e+18,,0.0,0.0,,"In discussion, speaker mentions that it takes 5 days to meet release criteria, so patients could get LD chemo durin‚Ä¶ https://t.co/UUrrB4Lx2M",en,0.0,4813.0,,,0.0,hemedoc,1.3353161901057188e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/hemedoc/statuses/1335316850473832449,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Thought Leadership,0.0,0.0,1.0,"In discussion, speaker mentions that it takes 5 days to meet release criteria, so patients could get LD chemo durin‚Ä¶ https://t.co/UUrrB4Lx2M",true
weldeiry,Physician-Scientist; Translational Oncologist; Associate Dean @BrownMedicine Pubs https://t.co/LBFw6qi3zW Cancer Center Director @BrownUCancer https://t.co/6eeywx4qdG,,Pennsylvania,,2020-12-05 20:41:24+00:00,"Wafik S. El-Deiry, MD, PhD, FACP",http://twitter.com/,24.0,,1.335323409773949e+18,,0.0,0.0,,RT @DanaFarberNews: A phase 1 trial found cytokine-induced memory-like NK cells exhibit expansion and long-term persistence after infusion‚Ä¶,en,0.0,8168.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,21.0,3.0,https://twitter.com/weldeiry/statuses/1335323409773948929,0.0,0.0,,0.0,0.0,0.0,3.0,21.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,RT @DanaFarberNews: A phase 1 trial found cytokine-induced memory-like NK cells exhibit expansion and long-term persistence after infusion‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-05 18:20:32+00:00,"Ritcha Saxena, MD",http://twitter.com/,4.0,,1.3352879586272993e+18,,0.0,0.0,,"RT @amarkelkar: Phase II Trial of Cladribine/LDAC+Venetoclax in Older Adults presented by Dr.@TapKadia.
-Median OS not yet reached
-1-year‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,2.0,2.0,https://twitter.com/RitchaSaxena/statuses/1335287958627299332,0.0,0.0,,0.0,0.0,0.0,2.0,2.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"RT @amarkelkar: Phase II Trial of Cladribine/LDAC+Venetoclax in Older Adults presented by Dr.@TapKadia.
-Median OS not yet reached
-1-year‚Ä¶",false
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 13:01:21+00:00,Lisa Palacios,http://twitter.com/,45.0,,1.3352076352898294e+18,,0.0,0.0,,"RT @ppisters: Through teamwork and pioneering research, @MDAndersonNews experts are committed to improving outcomes for patients with blood‚Ä¶",en,0.0,657.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,39.0,6.0,https://twitter.com/Lisa_Palacios/statuses/1335207635289829377,0.0,0.0,,0.0,0.0,0.0,6.0,39.0,False,False,False,False,True,Disease Advocacy,1.0,0.0,0.0,"RT @ppisters: Through teamwork and pioneering research, @MDAndersonNews experts are committed to improving outcomes for patients with blood‚Ä¶",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 20:54:41+00:00,Lisa Palacios,http://twitter.com/,7.0,,1.3353267508097434e+18,,0.0,0.0,,RT @SaudiLeukemia: CPX-351 + Ven : Phase II study . Dr Tapan Kadia from @MDAndersonNews MDACC.  #ASH20  #ASH2020 https://t.co/Aou1OOAwKs,en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,4.0,https://twitter.com/Lisa_Palacios/statuses/1335326750809743361,0.0,0.0,,0.0,0.0,0.0,4.0,3.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,RT @SaudiLeukemia: CPX-351 + Ven : Phase II study . Dr Tapan Kadia from @MDAndersonNews MDACC.  #ASH20  #ASH2020 https://t.co/Aou1OOAwKs,true
PAMJ84,Ronin Haematologist,,Europe,,2020-12-05 20:28:26+00:00,P. A-M,http://twitter.com/,24.0,,1.3353201467941317e+18,,0.0,0.0,,RT @VincentRK: Myeloma Future State: New drugs bring challenges and opportunities. We could very well have triple-class refractoriness in 1‚Ä¶,en,0.0,110.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,18.0,6.0,https://twitter.com/PAMJ84/statuses/1335320146794131460,0.0,0.0,,0.0,0.0,0.0,6.0,18.0,False,False,False,False,True,Research Funding,1.0,0.0,0.0,RT @VincentRK: Myeloma Future State: New drugs bring challenges and opportunities. We could very well have triple-class refractoriness in 1‚Ä¶,true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 23:31:46+00:00,Lisa Palacios,http://twitter.com/,9.0,,1.3353662849476772e+18,,0.0,0.0,,"RT @VJHemOnc: Highlights from #MPNsm new therapies &amp; JAKi based combinations for #Myelofibrosis orals at #ASH20

Srdan Verstovesk presented‚Ä¶",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,3.0,https://twitter.com/Lisa_Palacios/statuses/1335366284947677184,0.0,0.0,,0.0,0.0,0.0,3.0,6.0,False,False,False,False,True,Research Funding,0.0,0.0,1.0,"RT @VJHemOnc: Highlights from #MPNsm new therapies &amp; JAKi based combinations for #Myelofibrosis orals at #ASH20

Srdan Verstovesk presented‚Ä¶",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 16:43:54+00:00,Lisa Palacios,http://twitter.com/,12.0,,1.3352636388951368e+18,,0.0,0.0,,RT @CanerSaygin: Phase II data on CPX-351 + venetoclax in newly diagnosed and R/R AML (38% with TP53m) by Dr Kadia. This combo is quite tox‚Ä¶,en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,2.0,https://twitter.com/Lisa_Palacios/statuses/1335263638895136769,0.0,0.0,,0.0,0.0,0.0,2.0,10.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @CanerSaygin: Phase II data on CPX-351 + venetoclax in newly diagnosed and R/R AML (38% with TP53m) by Dr Kadia. This combo is quite tox‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 12:41:41+00:00,"Ritcha Saxena, MD",http://twitter.com/,13.0,,1.335565072496812e+18,,0.0,0.0,,RT @anthonymatomd: Chemotherapy free pathways in #CLL! Newest review on this topic. Algorithms included. Approaches for relapsed #CLL after‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,9.0,4.0,https://twitter.com/RitchaSaxena/statuses/1335565072496812032,0.0,0.0,,0.0,0.0,0.0,4.0,9.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @anthonymatomd: Chemotherapy free pathways in #CLL! Newest review on this topic. Algorithms included. Approaches for relapsed #CLL after‚Ä¶,false
DrTonyLetai,"Physician-scientist @DanaFarber. Professor of Medicine @harvardmed. President, Society for Functional Precision Medicine. You probably should be BH3 profiling.",,"Boston, MA",,2020-12-07 23:32:40+00:00,Anthony Letai MD PhD,http://twitter.com/,26.0,,1.3360912843401503e+18,,0.0,0.0,,"RT @DanaFarberNews: Little is known about #mentalhealth disorders among patients with hematologic malignancies, but new research is underwa‚Ä¶",en,0.0,1809.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,18.0,8.0,https://twitter.com/DrTonyLetai/statuses/1336091284340150284,0.0,0.0,,0.0,0.0,0.0,8.0,18.0,False,False,False,False,True,Research Funding,0.0,0.0,1.0,"RT @DanaFarberNews: Little is known about #mentalhealth disorders among patients with hematologic malignancies, but new research is underwa‚Ä¶",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-07 15:12:40+00:00,Lisa Palacios,http://twitter.com/,3.0,,1.3359654552075674e+18,,0.0,0.0,,"RT @ImmuneOnc: Today Dr. Courtney DiNardo from @LeukemiaMDA presents poster (Abstract #2867) of Phase 1 trial of IO-202, a first-in-class a‚Ä¶",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,2.0,1.0,https://twitter.com/Lisa_Palacios/statuses/1335965455207567361,0.0,0.0,,0.0,0.0,0.0,1.0,2.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"RT @ImmuneOnc: Today Dr. Courtney DiNardo from @LeukemiaMDA presents poster (Abstract #2867) of Phase 1 trial of IO-202, a first-in-class a‚Ä¶",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-07 15:31:57+00:00,Lisa Palacios,http://twitter.com/,2.0,,1.3359703098124616e+18,,0.0,0.0,,RT @VJHemOnc: #MPNs updates from #ASH20: @bose_prithviraj of @MDAndersonNews discussed the Phase II study of #Sotatercept for #Anemia of #M‚Ä¶,en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,1.0,1.0,https://twitter.com/Lisa_Palacios/statuses/1335970309812461568,0.0,0.0,,0.0,0.0,0.0,1.0,1.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,RT @VJHemOnc: #MPNs updates from #ASH20: @bose_prithviraj of @MDAndersonNews discussed the Phase II study of #Sotatercept for #Anemia of #M‚Ä¶,true
SethRotz,Pediatric Hematologist/Oncologist/BMT @Cleveland Clinic Children's; opinions my own,,"Cleveland, OH",,2020-12-08 22:44:49+00:00,seth rotz,http://twitter.com/,29.0,,1.3364416331313357e+18,,0.0,0.0,,RT @DrStevenDevine: Superb presentation by Dr Shaw at #ASH20 Presidential symposium. @BeTheMatch is working with her and other great invest‚Ä¶,en,0.0,416.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,22.0,7.0,https://twitter.com/SethRotz/statuses/1336441633131335684,0.0,0.0,,0.0,0.0,0.0,7.0,22.0,False,False,False,False,True,Financial Performance,1.0,0.0,0.0,RT @DrStevenDevine: Superb presentation by Dr Shaw at #ASH20 Presidential symposium. @BeTheMatch is working with her and other great invest‚Ä¶,true
BMT_DrNemecek,"Pediatrician and Hematologist/ Oncologist. Director of Clinical Research, OHSU Knight Cancer Institute. Opinions in this platform are personal.",,"Oregon, USA",,2020-12-08 20:47:42+00:00,Eneida Nemecek,http://twitter.com/,29.0,,1.3364121593083085e+18,,0.0,0.0,,RT @DrStevenDevine: Superb presentation by Dr Shaw at #ASH20 Presidential symposium. @BeTheMatch is working with her and other great invest‚Ä¶,en,0.0,419.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,22.0,7.0,https://twitter.com/BMT_DrNemecek/statuses/1336412159308308485,0.0,0.0,,0.0,0.0,0.0,7.0,22.0,False,False,False,False,True,Financial Performance,1.0,0.0,0.0,RT @DrStevenDevine: Superb presentation by Dr Shaw at #ASH20 Presidential symposium. @BeTheMatch is working with her and other great invest‚Ä¶,true
AnnaSureda5,"Haematologist interested in lymphoid malignancies, stem cell transplantation and CART cells. #CART #BMT #lymphomas #immunotherapy #WomenInMedicine",,"Barcelona, Spain",,2020-12-08 05:57:15+00:00,Anna Sureda,http://twitter.com/,23.0,,1.336188069893038e+18,,0.0,0.0,,RT @MediHumdani: Dr. Jasmin Zain presenting Phase I Study of Yttrium-90 Labeled ANTI-CD25 (aTac) Monoclonal Antibody PLUS BEAM for Autologo‚Ä¶,en,0.0,658.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,19.0,4.0,https://twitter.com/AnnaSureda5/statuses/1336188069893038082,0.0,0.0,,0.0,0.0,0.0,4.0,19.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,RT @MediHumdani: Dr. Jasmin Zain presenting Phase I Study of Yttrium-90 Labeled ANTI-CD25 (aTac) Monoclonal Antibody PLUS BEAM for Autologo‚Ä¶,false
turilrh,"Interventional Cardiologist and Assistant Professor Cardiology MTI, LRH, Peshawar, KP, Pakistan",,,,2020-10-14 17:10:25+00:00,jabar,http://twitter.com/,26.0,,1.3164261437220209e+18,,0.0,0.0,,RT @mmamas1973: #TCTConnect if you missed the LBT session can see livestream below @CardioIAN @billgogas @GiuseppeGalati_ @gbiondizoccai @h‚Ä¶,en,0.0,999.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,18.0,8.0,https://twitter.com/turilrh/statuses/1316426143722020864,0.0,0.0,,0.0,0.0,0.0,8.0,18.0,False,False,False,False,True,Cost of Care,0.0,0.0,1.0,RT @mmamas1973: #TCTConnect if you missed the LBT session can see livestream below @CardioIAN @billgogas @GiuseppeGalati_ @gbiondizoccai @h‚Ä¶,true
VincentRK,"Professor, Mayo Clinic; Editor, Blood Cancer Journal; Oncologist; Health Costs; COVID threads @SurvivedCOVID Opinions=personal views https://t.co/TMq9vc5hZk",,"Rochester, MN, USA",,2020-12-04 15:06:32+00:00,Vincent Rajkumar,http://twitter.com/,3.0,,1.3348767472596623e+18,,0.0,0.0,,"12. Phase I results of TNB-383B, a BCMA/CD3 Bispecific Antibody, in Relapsed/Refractory Myeloma. #ASH20‚Ä¶ https://t.co/O4ZsgGcGOW",en,0.0,33590.0,,,0.0,VincentRK,1.3348757469013647e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/VincentRK/statuses/1334876747259662337,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"12. Phase I results of TNB-383B, a BCMA/CD3 Bispecific Antibody, in Relapsed/Refractory Myeloma. #ASH20‚Ä¶ https://t.co/O4ZsgGcGOW",true
CarinHagberg,"Chief Academic Officer; Professor and Division Head, Division of Anesthesiology and Critical Care, MD Anderson Cancer Center. Tweets are my own.",,"Houston, TX",,2020-12-05 21:34:36+00:00,"Carin Hagberg, MD",http://twitter.com/,45.0,,1.3353367969101947e+18,,0.0,0.0,,"RT @ppisters: Through teamwork and pioneering research, @MDAndersonNews experts are committed to improving outcomes for patients with blood‚Ä¶",en,0.0,1506.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,39.0,6.0,https://twitter.com/CarinHagberg/statuses/1335336796910194688,0.0,0.0,,0.0,0.0,0.0,6.0,39.0,False,False,False,False,True,Disease Advocacy,1.0,0.0,0.0,"RT @ppisters: Through teamwork and pioneering research, @MDAndersonNews experts are committed to improving outcomes for patients with blood‚Ä¶",true
sairah__ahmed,"Lymphoma/Cellular Therapy & SCT at MD Anderson Cancer Center, opinions/tweets shared= my own.",,"Houston, TX",,2020-12-05 23:17:40+00:00,Sairah Ahmed MD,http://twitter.com/,218.0,,1.3353627345573765e+18,,0.0,0.0,,"RT @hemedoc: #ASH20 #leusm Wei: We are all excited to have new therapeutic options in AML, but the overall message I get from this money sl‚Ä¶",en,0.0,491.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,168.0,50.0,https://twitter.com/sairah__ahmed/statuses/1335362734557376512,0.0,0.0,,0.0,0.0,0.0,50.0,168.0,False,False,False,False,True,Research Funding,1.0,0.0,0.0,"RT @hemedoc: #ASH20 #leusm Wei: We are all excited to have new therapeutic options in AML, but the overall message I get from this money sl‚Ä¶",true
HindRafei,Hematology and Oncology Fellow at MD Anderson Cancer Center. #NKcellRx #immunoRx #immunology  Tweets are my own.,,"Houston, TX",,2020-12-05 13:45:49+00:00,Hind Rafei,http://twitter.com/,45.0,,1.335218822828204e+18,,0.0,0.0,,"RT @ppisters: Through teamwork and pioneering research, @MDAndersonNews experts are committed to improving outcomes for patients with blood‚Ä¶",en,0.0,935.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,39.0,6.0,https://twitter.com/HindRafei/statuses/1335218822828204032,0.0,0.0,,0.0,0.0,0.0,6.0,39.0,False,False,False,False,True,Disease Advocacy,1.0,0.0,0.0,"RT @ppisters: Through teamwork and pioneering research, @MDAndersonNews experts are committed to improving outcomes for patients with blood‚Ä¶",true
dgermain21,MD-PhD. 2nd year Heme/Onc fellow focused on lymphoma and leukemia. Physician-scientist-in-training. Tweet/RT not medical advice or endorsement.,,"St. Louis, MO",,2020-12-05 13:40:45+00:00,David A. Russler-Germain,http://twitter.com/,13.0,,1.3352175501127967e+18,,0.0,0.0,,RT @anthonymatomd: Chemotherapy free pathways in #CLL! Newest review on this topic. Algorithms included. Approaches for relapsed #CLL after‚Ä¶,en,0.0,1612.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,9.0,4.0,https://twitter.com/dgermain21/statuses/1335217550112796673,0.0,0.0,,0.0,0.0,0.0,4.0,9.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @anthonymatomd: Chemotherapy free pathways in #CLL! Newest review on this topic. Algorithms included. Approaches for relapsed #CLL after‚Ä¶,false
mpdrc,Executive Director- Mays Cancer Center at UT Health San Antonio MD Anderson; (Views on Twitter are personal opinion),,"UT Health San Antonio ,TX, USA",,2020-12-05 23:11:12+00:00,"Ruben A. Mesa, MD",http://twitter.com/,9.0,,1.3353611086564844e+18,,0.0,0.0,,"RT @VJHemOnc: Highlights from #MPNsm new therapies &amp; JAKi based combinations for #Myelofibrosis orals at #ASH20

Srdan Verstovesk presented‚Ä¶",en,0.0,3222.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,3.0,https://twitter.com/mpdrc/statuses/1335361108656484352,0.0,0.0,,0.0,0.0,0.0,3.0,6.0,False,False,False,False,True,Research Funding,0.0,0.0,1.0,"RT @VJHemOnc: Highlights from #MPNsm new therapies &amp; JAKi based combinations for #Myelofibrosis orals at #ASH20

Srdan Verstovesk presented‚Ä¶",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 16:27:05+00:00,Lisa Palacios,http://twitter.com/,4.0,,1.3352594093548052e+18,,0.0,0.0,,"RT @amarkelkar: Phase II Trial of Cladribine/LDAC+Venetoclax in Older Adults presented by Dr.@TapKadia.
-Median OS not yet reached
-1-year‚Ä¶",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,2.0,2.0,https://twitter.com/Lisa_Palacios/statuses/1335259409354805250,0.0,0.0,,0.0,0.0,0.0,2.0,2.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"RT @amarkelkar: Phase II Trial of Cladribine/LDAC+Venetoclax in Older Adults presented by Dr.@TapKadia.
-Median OS not yet reached
-1-year‚Ä¶",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 17:43:01+00:00,Lisa Palacios,http://twitter.com/,3.0,,1.335278517085479e+18,,0.0,0.0,,RT @MarkGeyerMD: @wwierda presents on pts achieving MRD-undetectable (MRDu) on CAPTIVATE (phase 2 study of IBR/VEN x1 yr fixed) -&gt; at 1 yr‚Ä¶,en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,2.0,1.0,https://twitter.com/Lisa_Palacios/statuses/1335278517085478924,0.0,0.0,,0.0,0.0,0.0,1.0,2.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,RT @MarkGeyerMD: @wwierda presents on pts achieving MRD-undetectable (MRDu) on CAPTIVATE (phase 2 study of IBR/VEN x1 yr fixed) -&gt; at 1 yr‚Ä¶,true
KirovDoc,"MD, Ph.D., Hematologist at Kirov Research Institute of Hematology and Blood transfusion",,Russia,,2020-12-06 11:34:34+00:00,Alexander Luchinin,http://twitter.com/,16.0,,1.335548181439017e+18,,0.0,0.0,,RT @theMMRF: Talquetamab: 1st in class off-the-shelf GPRC5D X CD3 bispecific antibody. Phase 1 study of 102 pts with IV dosing and 55 pts w‚Ä¶,en,0.0,27.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,13.0,3.0,https://twitter.com/KirovDoc/statuses/1335548181439016960,0.0,0.0,,0.0,0.0,0.0,3.0,13.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,RT @theMMRF: Talquetamab: 1st in class off-the-shelf GPRC5D X CD3 bispecific antibody. Phase 1 study of 102 pts with IV dosing and 55 pts w‚Ä¶,true
StefanoLuminari,"Medical oncologist/hematologist , lymphomaniac, bike rider, chair of the Indolent Lymphoma committee of FIL @filinf.it  @unimore.it @irccs_re.it",,,,2020-12-06 22:12:26+00:00,"Stefano Luminari, MD",http://twitter.com/,0.0,,1.3357087045498552e+18,,0.0,0.0,,No progressions after pembro-gvd in rr HL by moskowitz et al #ASH2020 small phase II study but results used to take‚Ä¶ https://t.co/ltxM3qhqHb,en,0.0,2250.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/StefanoLuminari/statuses/1335708704549855236,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,No progressions after pembro-gvd in rr HL by moskowitz et al #ASH2020 small phase II study but results used to take‚Ä¶ https://t.co/ltxM3qhqHb,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 15:59:20+00:00,"Ritcha Saxena, MD",http://twitter.com/,3.0,,1.335614810722087e+18,,0.0,0.0,,RT @CanerSaygin: Another feasibility phase I/II study from Dr Yilmaz showing quizartinib + 10d decitabine and venetoclax in newly diagnosed‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,2.0,1.0,https://twitter.com/RitchaSaxena/statuses/1335614810722086913,0.0,0.0,,0.0,0.0,0.0,1.0,2.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,RT @CanerSaygin: Another feasibility phase I/II study from Dr Yilmaz showing quizartinib + 10d decitabine and venetoclax in newly diagnosed‚Ä¶,false
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-06 18:30:26+00:00,Lisa Palacios,http://twitter.com/,10.0,,1.3356528394362675e+18,,0.0,0.0,,RT @razan_mohty: Venetoclax + Gilteritinib for R/R FLT3-Mutated #AML in the Expansion Cohort of a Phase 1b Study by Dr Naval Daver - Nice r‚Ä¶,en,0.0,657.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,4.0,https://twitter.com/Lisa_Palacios/statuses/1335652839436267520,0.0,0.0,,0.0,0.0,0.0,4.0,6.0,False,False,False,False,True,FDA Approval,1.0,0.0,0.0,RT @razan_mohty: Venetoclax + Gilteritinib for R/R FLT3-Mutated #AML in the Expansion Cohort of a Phase 1b Study by Dr Naval Daver - Nice r‚Ä¶,true
RaajitRampal,"Physician-Scientist, focused on #MPN and #AML  @sloan_kettering #MPNSM",,"New York, NY",,2020-12-06 23:10:33+00:00,"Raajit Rampal, M.D.Ph.D.",http://twitter.com/,3.0,,1.33572333244928e+18,,0.0,0.0,,We‚Äôve been focusing on introducing new treatments at ASH thus far. Now we have data on the prospect of  INF discont‚Ä¶ https://t.co/L4pEmlg8Uy,en,0.0,607.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/RaajitRampal/statuses/1335723332449280001,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Drug Discovery,0.0,0.0,1.0,We‚Äôve been focusing on introducing new treatments at ASH thus far. Now we have data on the prospect of  INF discont‚Ä¶ https://t.co/L4pEmlg8Uy,true
bloodgenes,"Pediatric Hematologist/Oncologist, Geneticist, Stem Cell Biologist - @DFBC_PedCare, @BostonChildrens, @DanaFarber & @broadinstitute",,"Boston, MA",,2020-12-07 16:31:27+00:00,Vijay Sankaran,http://twitter.com/,12.0,,1.3359852832678707e+18,,0.0,0.0,,"RT @JoannaS_Yi: A longer-acting asparaginase soon be available for ALL pts, based on the single agent phase 2 trial NOR-GRASPALL2016 (NCT03‚Ä¶",en,0.0,4057.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,9.0,3.0,https://twitter.com/bloodgenes/statuses/1335985283267870722,0.0,0.0,,0.0,0.0,0.0,3.0,9.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"RT @JoannaS_Yi: A longer-acting asparaginase soon be available for ALL pts, based on the single agent phase 2 trial NOR-GRASPALL2016 (NCT03‚Ä¶",true
hemedoc,"UCSF hematology/BMT doc. Assoc Prof. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)",,"San Francisco, CA",,2020-12-07 18:14:05+00:00,"Aaron Logan, MD, PhD, MPhil ‚Äî DONATE BLOOD!",http://twitter.com/,0.0,,1.3360111109991834e+18,,0.0,0.0,,"#ASH20 #leusm Garcia (584): In MVA, the only variable predicting CSF relapse was MFC pos CSF at diagnosis. 3yr cumu‚Ä¶ https://t.co/gdvfT6xoz7",en,0.0,4813.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/hemedoc/statuses/1336011110999183360,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"#ASH20 #leusm Garcia (584): In MVA, the only variable predicting CSF relapse was MFC pos CSF at diagnosis. 3yr cumu‚Ä¶ https://t.co/gdvfT6xoz7",true
SarahCannonDocs,Fighting Cancer Together. Find out the latest news directly from Sarah Cannon physicians.,,"Nashville, TN",,2020-12-07 18:20:07+00:00,Sarah Cannon Docs,http://twitter.com/,8.0,,1.3360126286243717e+18,,0.0,0.0,,"RT @HCAhealthcare: New research is showing promising results for the treatment of sickle cell disease. @SarahCannonDocs, the Cancer Institu‚Ä¶",en,0.0,2504.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,2.0,https://twitter.com/SarahCannonDocs/statuses/1336012628624371712,0.0,0.0,,0.0,0.0,0.0,2.0,6.0,False,False,False,False,True,Research Funding,0.0,0.0,1.0,"RT @HCAhealthcare: New research is showing promising results for the treatment of sickle cell disease. @SarahCannonDocs, the Cancer Institu‚Ä¶",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-07 03:58:42+00:00,"Ritcha Saxena, MD",http://twitter.com/,6.0,,1.3357958492223035e+18,,0.0,0.0,,"RT @gjmccaughan: In first collaboration between @ALLGtrials #AMWG and Asian Myeloma Network, #@HangQuach1 presents at #ASH20 Phase II study‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,2.0,https://twitter.com/RitchaSaxena/statuses/1335795849222303749,0.0,0.0,,0.0,0.0,0.0,2.0,4.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"RT @gjmccaughan: In first collaboration between @ALLGtrials #AMWG and Asian Myeloma Network, #@HangQuach1 presents at #ASH20 Phase II study‚Ä¶",false
LohiOlli,"MD, PhD, Chief of Pediatric Hematology & Oncology Division, Tampere University Hospital, Finland. Translational research on ALL biology. @TampereUniMET",,"Tampere, Suomi",,2020-12-07 07:33:16+00:00,Olli Lohi,http://twitter.com/,12.0,,1.3358498452114596e+18,,0.0,0.0,,"RT @JoannaS_Yi: A longer-acting asparaginase soon be available for ALL pts, based on the single agent phase 2 trial NOR-GRASPALL2016 (NCT03‚Ä¶",en,0.0,460.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,9.0,3.0,https://twitter.com/LohiOlli/statuses/1335849845211459584,0.0,0.0,,0.0,0.0,0.0,3.0,9.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"RT @JoannaS_Yi: A longer-acting asparaginase soon be available for ALL pts, based on the single agent phase 2 trial NOR-GRASPALL2016 (NCT03‚Ä¶",true
andrewcowanmd,"Myeloma/plasma cell disorders MD, Immunotherapy/transplant attending, UW/SCCA/Fred Hutch, Seattle WA",,"Seattle, WA",,2020-12-07 19:44:39+00:00,Andrew Cowan,http://twitter.com/,0.0,,1.3360339034552934e+18,,0.0,0.0,,Our collaboration with @winsoncheung examining comparative outcomes in MM in Alberta vs SEER Medicare highlighted h‚Ä¶ https://t.co/0yq5EWdjK5,en,0.0,553.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/andrewcowanmd/statuses/1336033903455293441,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Insurance Coverage,0.0,0.0,1.0,Our collaboration with @winsoncheung examining comparative outcomes in MM in Alberta vs SEER Medicare highlighted h‚Ä¶ https://t.co/0yq5EWdjK5,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-07 04:01:23+00:00,"Ritcha Saxena, MD",http://twitter.com/,10.0,,1.335796520399106e+18,,0.0,0.0,,RT @AuclairDan: Paper 2295 - Lilly Wong at #ASH20 on PK/PD results from Phase I of novel CELMoD CC-92480 in relapse #myeloma. Very interest‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,4.0,https://twitter.com/RitchaSaxena/statuses/1335796520399106049,0.0,0.0,,0.0,0.0,0.0,4.0,6.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @AuclairDan: Paper 2295 - Lilly Wong at #ASH20 on PK/PD results from Phase I of novel CELMoD CC-92480 in relapse #myeloma. Very interest‚Ä¶,true
majorajay,"Hematology/oncology fellow. #lymsm & #mmsm outcomes researcher. Physician-publisher & founder of https://t.co/dPfLt8QVMr, @inTrainingDoc & @inHouseMag.",,"Chicago, IL",,2020-12-05 03:03:17+00:00,"Ajay Major, MD, MBA",http://twitter.com/,30.0,,1.3350571245488947e+18,,0.0,0.0,,"RT @VPrasadMDMPH: Agree with Bernie #ASH20 
We analyzed the benefit of new leukemia drugs here:
https://t.co/shpfPoghcW https://t.co/MzZHCa‚Ä¶",en,0.0,3518.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,22.0,8.0,https://twitter.com/majorajay/statuses/1335057124548894728,0.0,0.0,,0.0,0.0,0.0,8.0,22.0,False,False,False,False,True,Research Funding,0.0,0.0,1.0,"RT @VPrasadMDMPH: Agree with Bernie #ASH20 
We analyzed the benefit of new leukemia drugs here:
https://t.co/shpfPoghcW https://t.co/MzZHCa‚Ä¶",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-05 19:55:31+00:00,"Ritcha Saxena, MD",http://twitter.com/,14.0,,1.3353118624900751e+18,,0.0,0.0,,RT @mpdrc: Excited for the upcoming start of First #ASHFromHome MPN Clinical Session : New Therapies and JAKi-Based Combinations for Myelof‚Ä¶,en,0.0,6875.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,4.0,https://twitter.com/RitchaSaxena/statuses/1335311862490075138,0.0,0.0,,0.0,0.0,0.0,4.0,10.0,False,False,False,False,True,Research Funding,1.0,0.0,0.0,RT @mpdrc: Excited for the upcoming start of First #ASHFromHome MPN Clinical Session : New Therapies and JAKi-Based Combinations for Myelof‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 16:10:32+00:00,"Ritcha Saxena, MD",http://twitter.com/,22.0,,1.3356176292062904e+18,,0.0,0.0,,"RT @MM_Hub: Congress| #ASH20| @AlGarfall, @PennCancer, presented data on the phase I trial of teclistamab for R/R MM showing encouraging to‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,14.0,8.0,https://twitter.com/RitchaSaxena/statuses/1335617629206290438,0.0,0.0,,0.0,0.0,0.0,8.0,14.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"RT @MM_Hub: Congress| #ASH20| @AlGarfall, @PennCancer, presented data on the phase I trial of teclistamab for R/R MM showing encouraging to‚Ä¶",false
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 16:11:32+00:00,"Ritcha Saxena, MD",http://twitter.com/,7.0,,1.3356178817662935e+18,,0.0,0.0,,RT @SaudiLeukemia: CPX-351 + Ven : Phase II study . Dr Tapan Kadia from @MDAndersonNews MDACC.  #ASH20  #ASH2020 https://t.co/Aou1OOAwKs,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,4.0,https://twitter.com/RitchaSaxena/statuses/1335617881766293504,0.0,0.0,,0.0,0.0,0.0,4.0,3.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,RT @SaudiLeukemia: CPX-351 + Ven : Phase II study . Dr Tapan Kadia from @MDAndersonNews MDACC.  #ASH20  #ASH2020 https://t.co/Aou1OOAwKs,true
UrviShahMD,Oncologist and researcher on Myeloma service @sloan_kettering. Interested in nutrition for cancer and immune therapies. Views are my own,,"New York, NY",,2020-11-22 20:42:43+00:00,Urvi Shah,http://twitter.com/,0.0,,1.3306126988082463e+18,,0.0,0.0,,DREAMM-2 phase 2 study was published by @SagarLonialMD et al. in Lancet Oncol 2019. We will see 1 year outcomes at‚Ä¶ https://t.co/np1POJdgbt,en,0.0,1227.0,,,0.0,UrviShahMD,1.330612694387454e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/UrviShahMD/statuses/1330612698808246283,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,DREAMM-2 phase 2 study was published by @SagarLonialMD et al. in Lancet Oncol 2019. We will see 1 year outcomes at‚Ä¶ https://t.co/np1POJdgbt,true
UrviShahMD,Oncologist and researcher on Myeloma service @sloan_kettering. Interested in nutrition for cancer and immune therapies. Views are my own,,"New York, NY",,2020-11-22 20:03:22+00:00,Urvi Shah,http://twitter.com/,1.0,,1.3306027972267172e+18,,0.0,0.0,,"AMG-701 - Updates @ASH_hematology by Harrison et al. @SLentzsch Phase 1 study, 75 patients, ORR 36% at 3-12mg dose,‚Ä¶ https://t.co/kuacuDGmmm",en,0.0,1227.0,,,0.0,UrviShahMD,1.3306027953308918e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/UrviShahMD/statuses/1330602797226717189,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"AMG-701 - Updates @ASH_hematology by Harrison et al. @SLentzsch Phase 1 study, 75 patients, ORR 36% at 3-12mg dose,‚Ä¶ https://t.co/kuacuDGmmm",true
MDAndersonNews,"The official account of MD Anderson Cancer Center, a leader in cancer care, cancer research and the fight to #EndCancer. Appointments available: 1-877-632-6789.",,"Houston, TX",,2020-11-22 17:53:01+00:00,MD Anderson Cancer Center,http://twitter.com/,5.0,,1.330569993189208e+18,,0.0,0.0,,"When multiple myeloma relapsed after chemotherapy, a stem cell transplant and targeted therapy, Beth Norris is back‚Ä¶ https://t.co/OlOsDYIi5H",en,0.0,114120.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,5.0,https://twitter.com/MDAndersonNews/statuses/1330569993189208064,0.0,0.0,,0.0,0.0,0.0,5.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"When multiple myeloma relapsed after chemotherapy, a stem cell transplant and targeted therapy, Beth Norris is back‚Ä¶ https://t.co/OlOsDYIi5H",true
UrviShahMD,Oncologist and researcher on Myeloma service @sloan_kettering. Interested in nutrition for cancer and immune therapies. Views are my own,,"New York, NY",,2020-11-22 20:03:28+00:00,Urvi Shah,http://twitter.com/,0.0,,1.330602821335593e+18,,0.0,0.0,,BCFR4350A - FcRH5 bispecific. Phase 1 study ORR 52% at all dose levels. More data to be presented at #ASH20‚Ä¶ https://t.co/IqTM7ev4uY,en,0.0,1227.0,,,0.0,UrviShahMD,1.3306028164952924e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/UrviShahMD/statuses/1330602821335592969,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,BCFR4350A - FcRH5 bispecific. Phase 1 study ORR 52% at all dose levels. More data to be presented at #ASH20‚Ä¶ https://t.co/IqTM7ev4uY,true
Transplant_Doc,Stem Cell Transplant physician and clinical researcher at MD Anderson Cancer Center; special interest in myeloma. Opinions expressed are my own,,,,2020-11-10 18:48:49+00:00,Muzaffar Qazilbash,http://twitter.com/,12.0,,1.3262353788654633e+18,,0.0,0.0,,"RT @szusmani: 6/7
TOP 5 CLINICAL PHASE 2/3 Newly Diagnosed #ASH20SU #ASH20 #mmsm
-GRIFFIN Update (https://t.co/UBT5mcwA7Y)
-EMN02/HO95 Upda‚Ä¶",en,0.0,5455.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,2.0,https://twitter.com/Transplant_Doc/statuses/1326235378865463296,0.0,0.0,,0.0,0.0,0.0,2.0,10.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"RT @szusmani: 6/7
TOP 5 CLINICAL PHASE 2/3 Newly Diagnosed #ASH20SU #ASH20 #mmsm
-GRIFFIN Update (https://t.co/UBT5mcwA7Y)
-EMN02/HO95 Upda‚Ä¶",false
Transplant_Doc,Stem Cell Transplant physician and clinical researcher at MD Anderson Cancer Center; special interest in myeloma. Opinions expressed are my own,,,,2020-11-27 13:11:40+00:00,Muzaffar Qazilbash,http://twitter.com/,59.0,,1.3323111274061087e+18,,0.0,0.0,,RT @MediHumdani: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 shows early signal of activity in Relapsed/Refractory #Myelom‚Ä¶,en,0.0,5455.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,46.0,13.0,https://twitter.com/Transplant_Doc/statuses/1332311127406108672,0.0,0.0,,0.0,0.0,0.0,13.0,46.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @MediHumdani: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 shows early signal of activity in Relapsed/Refractory #Myelom‚Ä¶,true
AnnaSureda5,"Haematologist interested in lymphoid malignancies, stem cell transplantation and CART cells. #CART #BMT #lymphomas #immunotherapy #WomenInMedicine",,"Barcelona, Spain",,2020-11-27 06:39:10+00:00,Anna Sureda,http://twitter.com/,59.0,,1.3322123491561267e+18,,0.0,0.0,,RT @MediHumdani: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 shows early signal of activity in Relapsed/Refractory #Myelom‚Ä¶,en,0.0,658.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,46.0,13.0,https://twitter.com/AnnaSureda5/statuses/1332212349156126720,0.0,0.0,,0.0,0.0,0.0,13.0,46.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @MediHumdani: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 shows early signal of activity in Relapsed/Refractory #Myelom‚Ä¶,true
BotCardiology,"Created by Doctor @KrittanawongMD. A bot that collects Tweets about cardiology, medicine and new science",,Kepler-452b,,2020-11-27 16:47:35+00:00,Cardiology Bot,http://twitter.com/,4.0,,1.3323654653819576e+18,,0.0,0.0,,RT @PoppyBrooks1: This üëáüèª Fantastic case studies demonstrating this point from Dr Will Petchey #BSH2020VISION #nephrologistslikediuretics #‚Ä¶,en,0.0,328.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,1.0,https://twitter.com/BotCardiology/statuses/1332365465381957634,0.0,0.0,,0.0,0.0,0.0,1.0,3.0,False,False,False,False,True,Research Funding,1.0,0.0,0.0,RT @PoppyBrooks1: This üëáüèª Fantastic case studies demonstrating this point from Dr Will Petchey #BSH2020VISION #nephrologistslikediuretics #‚Ä¶,true
WilliamDale_MD,"Dad/Doctor/Scholar/Exec Producer
#GeriOnc #SupportiveCare,
City of Hope
 https://t.co/eX3ulsGvFG",,"City of Hope, wdale@coh.org",,2020-12-10 22:10:09+00:00,"William Dale, MD, PhD",http://twitter.com/,11.0,,1.3371576827849933e+18,,0.0,0.0,,RT @ShakiraG_MBBS: #ASH20 #hematology + #aging Poster Walk No:2628 Dr. Charity Oyedeji @DukeHealth üëáused physical+cognitive function measur‚Ä¶,en,0.0,5551.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,9.0,2.0,https://twitter.com/WilliamDale_MD/statuses/1337157682784993280,0.0,0.0,,0.0,0.0,0.0,2.0,9.0,False,False,False,False,True,Charity,0.0,0.0,1.0,RT @ShakiraG_MBBS: #ASH20 #hematology + #aging Poster Walk No:2628 Dr. Charity Oyedeji @DukeHealth üëáused physical+cognitive function measur‚Ä¶,true
ShakiraG_MBBS,BC Geriatrician + Hematologist + Oncologist. Assistant Professor + Clinical Researcher UNC-CH #geriheme #gerionc #mmsm #BlackWomanInMedicine. Tweets=my views,,"North Carolina, USA",,2020-12-10 16:14:39+00:00,Dr. Shakira J Grant MBBS,http://twitter.com/,2.0,,1.3370682167832617e+18,,0.0,0.0,,#ASH20 #hematology + #aging Poster Walk No:2628 Dr. Charity Oyedeji @DukeHealth üëáused physical+cognitive function m‚Ä¶ https://t.co/tTkeTlwyZf,en,0.0,340.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/ShakiraG_MBBS/statuses/1337068216783261696,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Charity,0.0,0.0,1.0,#ASH20 #hematology + #aging Poster Walk No:2628 Dr. Charity Oyedeji @DukeHealth üëáused physical+cognitive function m‚Ä¶ https://t.co/tTkeTlwyZf,true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-12-17 18:20:00+00:00,Oncology Tube,http://twitter.com/,0.0,,1.339636478025093e+18,,0.0,0.0,,"Phase 1 Study of Axatilimab (SNDX-6352) Mukta Arora, MD  @UMNews @UMNreasearch #ASH20 #cGVHD #GvHD #Cancer‚Ä¶ https://t.co/T157l9KcYA",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1339636478025093120,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"Phase 1 Study of Axatilimab (SNDX-6352) Mukta Arora, MD  @UMNews @UMNreasearch #ASH20 #cGVHD #GvHD #Cancer‚Ä¶ https://t.co/T157l9KcYA",false
MDedgeHemOnc,MDedge Hematology & Oncology provides the most important and up to date information and news for oncologists. Now part of the Medscape Professional Network.,,"Rockville, MD, Parsippany, NJ",,2020-12-16 15:01:00+00:00,MDedge Hematology & Oncology,http://twitter.com/,0.0,,1.3392240127911813e+18,,0.0,0.0,,News from #ASH20: Phase 1 study of synthetic T-cell receptor and antigen receptor shows efficacy in treating CD19+‚Ä¶ https://t.co/0psKARZn1F,en,0.0,6726.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/MDedgeHemOnc/statuses/1339224012791181313,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,News from #ASH20: Phase 1 study of synthetic T-cell receptor and antigen receptor shows efficacy in treating CD19+‚Ä¶ https://t.co/0psKARZn1F,true
KirovDoc,"MD, Ph.D., Hematologist at Kirov Research Institute of Hematology and Blood transfusion",,Russia,,2020-12-06 06:25:38+00:00,Alexander Luchinin,http://twitter.com/,22.0,,1.3354704361094597e+18,,0.0,0.0,,"RT @MM_Hub: Congress| #ASH20| @AlGarfall, @PennCancer, presented data on the phase I trial of teclistamab for R/R MM showing encouraging to‚Ä¶",en,0.0,27.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,14.0,8.0,https://twitter.com/KirovDoc/statuses/1335470436109459457,0.0,0.0,,0.0,0.0,0.0,8.0,14.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"RT @MM_Hub: Congress| #ASH20| @AlGarfall, @PennCancer, presented data on the phase I trial of teclistamab for R/R MM showing encouraging to‚Ä¶",true
SoniSmithMD,"Lymphoma doctor, University of Chicago, love cooking and family. Views and opinions my own.",,"Chicago, IL",,2020-12-06 18:35:08+00:00,Soni Smith MD,http://twitter.com/,1.0,,1.3356540204180357e+18,,0.0,0.0,,Very lucky to work with #ASH2020 Mentor recipient Dr Wendy Stock. The words of her mentees say it all! https://t.co/b7OJ4zB056,en,0.0,1106.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/SoniSmithMD/statuses/1335654020418035712,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Financial Performance,1.0,0.0,0.0,Very lucky to work with #ASH2020 Mentor recipient Dr Wendy Stock. The words of her mentees say it all! https://t.co/b7OJ4zB056,true
dgermain21,MD-PhD. 2nd year Heme/Onc fellow focused on lymphoma and leukemia. Physician-scientist-in-training. Tweet/RT not medical advice or endorsement.,,"St. Louis, MO",,2020-12-06 15:05:39+00:00,David A. Russler-Germain,http://twitter.com/,45.0,,1.3356013041278853e+18,,0.0,0.0,,RT @DrMiguelPerales: #ASH20 Abs 470 Impressive results in Phase II Study of Pembrolizumab Plus GVD As 2nd-Line Therapy for Rel/Ref Classica‚Ä¶,en,0.0,1612.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,34.0,11.0,https://twitter.com/dgermain21/statuses/1335601304127885314,0.0,0.0,,0.0,0.0,0.0,11.0,34.0,False,False,False,False,True,FDA Approval,1.0,0.0,0.0,RT @DrMiguelPerales: #ASH20 Abs 470 Impressive results in Phase II Study of Pembrolizumab Plus GVD As 2nd-Line Therapy for Rel/Ref Classica‚Ä¶,true
drjgauthier,"MD, MSc, Assistant Professor @fredhutch @UW focused on #CARTcell #immunotherapy #tcellrx 
Interests also include #rstats #bmtsm #epitwitter #bayes",,"Seattle, WA",,2020-12-06 22:54:00+00:00,Jordan Gauthier,http://twitter.com/,15.0,,1.3357191654165463e+18,,0.0,0.0,,"RT @fredhutch: Dr. Elizabeth Krakow to present ""Phase I Study of Adoptive Immunotherapy with HA-1-Specific CD8+ and CD4+ Memory T Cells for‚Ä¶",en,0.0,3295.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,13.0,2.0,https://twitter.com/drjgauthier/statuses/1335719165416546305,0.0,0.0,,0.0,0.0,0.0,2.0,13.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"RT @fredhutch: Dr. Elizabeth Krakow to present ""Phase I Study of Adoptive Immunotherapy with HA-1-Specific CD8+ and CD4+ Memory T Cells for‚Ä¶",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 21:14:59+00:00,"Ritcha Saxena, MD",http://twitter.com/,8.0,,1.335694249669636e+18,,0.0,0.0,,RT @DrOlaLandgren: @GretchenTap @DrPaulyDeSantis Immuno-PET is not yet available as standard of care. We will open a new phase 2 study for‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,2.0,https://twitter.com/RitchaSaxena/statuses/1335694249669636097,0.0,0.0,,0.0,0.0,0.0,2.0,6.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,RT @DrOlaLandgren: @GretchenTap @DrPaulyDeSantis Immuno-PET is not yet available as standard of care. We will open a new phase 2 study for‚Ä¶,false
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-06 22:30:10+00:00,Lisa Palacios,http://twitter.com/,1.0,,1.335713170011398e+18,,0.0,0.0,,RT @VJHemOnc: @NicholasShortMD of @LeukemiaMDA talked on the results from a Phase II study of #Blinatumomab following hyper-CVAD in B-cell‚Ä¶,en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/Lisa_Palacios/statuses/1335713170011398145,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,RT @VJHemOnc: @NicholasShortMD of @LeukemiaMDA talked on the results from a Phase II study of #Blinatumomab following hyper-CVAD in B-cell‚Ä¶,true
BroeckelmannPJ,"MD @UKKoeln & Physician Scientist Postdoc @MPIAGE. Hemato-Oncology. Lymphoma. Immunotherapies. DNA damage. Personal opinion, RT/like ‚â† endorsement.",,"Cologne, Germany",,2020-12-06 16:55:33+00:00,Paul Br√∂ckelmann,http://twitter.com/,0.0,,1.3356289604666573e+18,,0.0,0.0,,Excited to share updated data of the GHSG phase II NIVAHL trial investigating sequential and concomitant Nivo + AVD‚Ä¶ https://t.co/WaCFH51owb,en,0.0,243.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/BroeckelmannPJ/statuses/1335628960466657281,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Financial Performance,1.0,0.0,0.0,Excited to share updated data of the GHSG phase II NIVAHL trial investigating sequential and concomitant Nivo + AVD‚Ä¶ https://t.co/WaCFH51owb,true
majorajay,"Hematology/oncology fellow. #lymsm & #mmsm outcomes researcher. Physician-publisher & founder of https://t.co/dPfLt8QVMr, @inTrainingDoc & @inHouseMag.",,"Chicago, IL",,2020-12-06 00:05:35+00:00,"Ajay Major, MD, MBA",http://twitter.com/,0.0,,1.3353747947920548e+18,,0.0,0.0,,"I am privileged to have worked with Dr. Wendy Stock, this year's #ASH20 Mentor Award winner. Congratulations, Dr. S‚Ä¶ https://t.co/Qcn8jccquW",en,0.0,3518.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/majorajay/statuses/1335374794792054785,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Financial Performance,1.0,0.0,0.0,"I am privileged to have worked with Dr. Wendy Stock, this year's #ASH20 Mentor Award winner. Congratulations, Dr. S‚Ä¶ https://t.co/Qcn8jccquW",true
dgermain21,MD-PhD. 2nd year Heme/Onc fellow focused on lymphoma and leukemia. Physician-scientist-in-training. Tweet/RT not medical advice or endorsement.,,"St. Louis, MO",,2020-12-06 01:18:52+00:00,David A. Russler-Germain,http://twitter.com/,18.0,,1.335393235842298e+18,,0.0,0.0,,"RT @tobyeyre82: .@michaelwangmd et al
VLS-101 in R/R #MCL + #DLBCL
anti-ROR1 MMAE-ADC monotx data
phase I trial
MTD 2.5mg/kg
neutropenia +‚Ä¶",en,0.0,1612.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,14.0,4.0,https://twitter.com/dgermain21/statuses/1335393235842297857,0.0,0.0,,0.0,0.0,0.0,4.0,14.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"RT @tobyeyre82: .@michaelwangmd et al
VLS-101 in R/R #MCL + #DLBCL
anti-ROR1 MMAE-ADC monotx data
phase I trial
MTD 2.5mg/kg
neutropenia +‚Ä¶",true
Mikeypod50,"Podiatrist, now part-time, but still enjoying caring for patients. Father of 4, ""Baba"" to 7. Philly sports fan (sigh) for too many years",,,,2020-12-05 17:30:56+00:00,(((Michael Katz))),http://twitter.com/,68.0,,1.335275477645357e+18,,0.0,0.0,,"RT @BMS_Myeloma_US: During #ASH20, learn why new treatment options are needed in triple-class exposed* multiple myeloma. #MMSM",en,0.0,81.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,55.0,13.0,https://twitter.com/Mikeypod50/statuses/1335275477645357066,0.0,0.0,,0.0,0.0,0.0,13.0,55.0,False,False,False,False,True,Drug Discovery,0.0,0.0,1.0,"RT @BMS_Myeloma_US: During #ASH20, learn why new treatment options are needed in triple-class exposed* multiple myeloma. #MMSM",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-05 20:36:18+00:00,"Ritcha Saxena, MD",http://twitter.com/,1.0,,1.335322123603153e+18,,0.0,0.0,,RT @feldstej: 1404 Effect of Intravenous Immunoglobulin on Infections in Multiple Myeloma (MM) Patients Receiving Daratumumab https://t.co/‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/RitchaSaxena/statuses/1335322123603152903,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,RT @feldstej: 1404 Effect of Intravenous Immunoglobulin on Infections in Multiple Myeloma (MM) Patients Receiving Daratumumab https://t.co/‚Ä¶,false
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 16:43:05+00:00,Lisa Palacios,http://twitter.com/,1.0,,1.3352634354294415e+18,,0.0,0.0,,RT @afinch7: Common theme when combining venetoclax with intensive chemo ‚û°Ô∏è prolonged myelosuppresion &amp; INFECTION.  We see it with FlaV-Ida‚Ä¶,en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/Lisa_Palacios/statuses/1335263435429441536,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,RT @afinch7: Common theme when combining venetoclax with intensive chemo ‚û°Ô∏è prolonged myelosuppresion &amp; INFECTION.  We see it with FlaV-Ida‚Ä¶,true
VPrasadMDMPH,"Associate Prof, Physician, Epidemiology @ucsf_epibiostat, Podcast @Plenary_Session, Author: Malignant (2020); Ending Medical Reversal (2015); Views my own",,"San Francisco, Ca",,2020-12-05 02:53:46+00:00,Vinay Prasad MD MPH,http://twitter.com/,8.0,,1.3350547310314455e+18,,0.0,0.0,,"Agree with Bernie #ASH20 
We analyzed the benefit of new leukemia drugs here:
https://t.co/shpfPoghcW‚Ä¶ https://t.co/xeFzdquPkX",en,0.0,63817.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,8.0,https://twitter.com/VPrasadMDMPH/statuses/1335054731031445505,0.0,0.0,,0.0,0.0,0.0,8.0,0.0,False,False,False,False,True,Research Funding,0.0,0.0,1.0,"Agree with Bernie #ASH20 
We analyzed the benefit of new leukemia drugs here:
https://t.co/shpfPoghcW‚Ä¶ https://t.co/xeFzdquPkX",true
mav_jav,"Human,fighter,survivor. Passionate about helping and healing.Histopathologist",,"The Capital, Kuwait",,2020-12-05 19:55:21+00:00,Mawish javed,http://twitter.com/,16.0,,1.3353118213272412e+18,,0.0,0.0,,"RT @VincentRK: 11. Phase 1 results of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed/Refractory Myeloma. 61% response rate in heav‚Ä¶",en,0.0,956.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,10.0,6.0,https://twitter.com/mav_jav/statuses/1335311821327241219,0.0,0.0,,0.0,0.0,0.0,6.0,10.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @VincentRK: 11. Phase 1 results of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed/Refractory Myeloma. 61% response rate in heav‚Ä¶",true
majorajay,"Hematology/oncology fellow. #lymsm & #mmsm outcomes researcher. Physician-publisher & founder of https://t.co/dPfLt8QVMr, @inTrainingDoc & @inHouseMag.",,"Chicago, IL",,2020-12-05 00:59:02+00:00,"Ajay Major, MD, MBA",http://twitter.com/,0.0,,1.3350258551233536e+18,,0.0,0.0,,"Logged into the #ASH20 hemophilia A session tonight, with some exciting discussion about new therapies in the pipel‚Ä¶ https://t.co/W8Tr9Wy2o7",en,0.0,3518.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/majorajay/statuses/1335025855123353604,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Research Funding,1.0,0.0,0.0,"Logged into the #ASH20 hemophilia A session tonight, with some exciting discussion about new therapies in the pipel‚Ä¶ https://t.co/W8Tr9Wy2o7",true
szusmani,"Division Chief, Plasma Cell Disorders|Director, Clinical Research Hem Malignancies | Views are my own | RT not endorsement | Physician ‚â† Provider",,"Charlotte, NC",,2020-12-05 22:02:44+00:00,Saad Z. Usmani MD MBA FACP (he/his/him),http://twitter.com/,22.0,,1.335343877759361e+18,,0.0,0.0,,"RT @MM_Hub: Congress| #ASH20| @AlGarfall, @PennCancer, presented data on the phase I trial of teclistamab for R/R MM showing encouraging to‚Ä¶",en,0.0,5512.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,14.0,8.0,https://twitter.com/szusmani/statuses/1335343877759361025,0.0,0.0,,0.0,0.0,0.0,8.0,14.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"RT @MM_Hub: Congress| #ASH20| @AlGarfall, @PennCancer, presented data on the phase I trial of teclistamab for R/R MM showing encouraging to‚Ä¶",true
dgermain21,MD-PhD. 2nd year Heme/Onc fellow focused on lymphoma and leukemia. Physician-scientist-in-training. Tweet/RT not medical advice or endorsement.,,"St. Louis, MO",,2020-12-05 03:30:52+00:00,David A. Russler-Germain,http://twitter.com/,30.0,,1.3350640679129784e+18,,0.0,0.0,,"RT @VPrasadMDMPH: Agree with Bernie #ASH20 
We analyzed the benefit of new leukemia drugs here:
https://t.co/shpfPoghcW https://t.co/FZL43h‚Ä¶",en,0.0,1612.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,22.0,8.0,https://twitter.com/dgermain21/statuses/1335064067912978439,0.0,0.0,,0.0,0.0,0.0,8.0,22.0,False,False,False,False,True,Research Funding,0.0,0.0,1.0,"RT @VPrasadMDMPH: Agree with Bernie #ASH20 
We analyzed the benefit of new leukemia drugs here:
https://t.co/shpfPoghcW https://t.co/FZL43h‚Ä¶",false
johnde1MYELOMA,"myeloma survivor üêú, gastroenterologist, bicyclist, animal lover",,"Santa Fe, NM",,2020-12-05 18:57:41+00:00,John DeFlice,http://twitter.com/,1.0,,1.3352973068752036e+18,,0.0,0.0,,"CAR P-BCMA-101 using piggyBac system with low toxicity and significant efficacy in phase 1/2 study, Costello, et al‚Ä¶ https://t.co/WhGdGSI6gc",en,0.0,218.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/johnde1MYELOMA/statuses/1335297306875203584,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"CAR P-BCMA-101 using piggyBac system with low toxicity and significant efficacy in phase 1/2 study, Costello, et al‚Ä¶ https://t.co/WhGdGSI6gc",true
VincentRK,"Professor, Mayo Clinic; Editor, Blood Cancer Journal; Oncologist; Health Costs; COVID threads @SurvivedCOVID Opinions=personal views https://t.co/TMq9vc5hZk",,"Rochester, MN, USA",,2020-12-04 14:59:05+00:00,Vincent Rajkumar,http://twitter.com/,2.0,,1.3348748743687168e+18,,0.0,0.0,,10. ÔøºLummicar-2: A Phase 1b/2 BCMA CAR T trial results in Patients with Relapsed and/or Refractory Myeloma. #ASH20‚Ä¶ https://t.co/swKm8Vsn9K,en,0.0,33590.0,,,0.0,VincentRK,1.3348748725148262e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/VincentRK/statuses/1334874874368716801,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,10. ÔøºLummicar-2: A Phase 1b/2 BCMA CAR T trial results in Patients with Relapsed and/or Refractory Myeloma. #ASH20‚Ä¶ https://t.co/swKm8Vsn9K,true
VincentRK,"Professor, Mayo Clinic; Editor, Blood Cancer Journal; Oncologist; Health Costs; COVID threads @SurvivedCOVID Opinions=personal views https://t.co/TMq9vc5hZk",,"Rochester, MN, USA",,2020-12-04 15:02:33+00:00,Vincent Rajkumar,http://twitter.com/,6.0,,1.3348757469013647e+18,,0.0,0.0,,"11. Phase 1 results of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed/Refractory Myeloma. 61% response rat‚Ä¶ https://t.co/NDPVKo13sl",en,0.0,33590.0,,,0.0,VincentRK,1.3348748743687168e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,6.0,https://twitter.com/VincentRK/statuses/1334875746901364739,0.0,0.0,,0.0,0.0,0.0,6.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"11. Phase 1 results of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed/Refractory Myeloma. 61% response rat‚Ä¶ https://t.co/NDPVKo13sl",true
VincentRK,"Professor, Mayo Clinic; Editor, Blood Cancer Journal; Oncologist; Health Costs; COVID threads @SurvivedCOVID Opinions=personal views https://t.co/TMq9vc5hZk",,"Rochester, MN, USA",,2020-12-04 18:46:17+00:00,Vincent Rajkumar,http://twitter.com/,14.0,,1.3349320491997637e+18,,0.0,0.0,,RT @NorthTxMSG: This was Dr. @VincentRK 2019 #myaloma treatment algorithm. With the introduction of a couple new drugs to the approved list‚Ä¶,en,0.0,33590.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,11.0,3.0,https://twitter.com/VincentRK/statuses/1334932049199763459,0.0,0.0,,0.0,0.0,0.0,3.0,11.0,False,False,False,False,True,Research Funding,0.0,0.0,1.0,RT @NorthTxMSG: This was Dr. @VincentRK 2019 #myaloma treatment algorithm. With the introduction of a couple new drugs to the approved list‚Ä¶,true
SandyWong02111,UCSF Hematologist and BMT physician,,"San Francisco, CA",,2020-12-07 21:58:05+00:00,Sandy Wong,http://twitter.com/,36.0,,1.3360674839255e+18,,0.0,0.0,,"RT @ninashah33: Cyber IBER! Iber with dara dex or
BTZ dex with 35-50% ORR. I think this data useful to show us how to combine this new drug‚Ä¶",en,0.0,759.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,28.0,8.0,https://twitter.com/SandyWong02111/statuses/1336067483925499904,0.0,0.0,,0.0,0.0,0.0,8.0,28.0,False,False,False,False,True,Research Funding,0.0,0.0,1.0,"RT @ninashah33: Cyber IBER! Iber with dara dex or
BTZ dex with 35-50% ORR. I think this data useful to show us how to combine this new drug‚Ä¶",true
VincentRK,"Professor, Mayo Clinic; Editor, Blood Cancer Journal; Oncologist; Health Costs; COVID threads @SurvivedCOVID Opinions=personal views https://t.co/TMq9vc5hZk",,"Rochester, MN, USA",,2020-12-05 20:10:48+00:00,Vincent Rajkumar,http://twitter.com/,6.0,,1.3353157091744276e+18,,0.0,0.0,,Myeloma Future State: New drugs bring challenges and opportunities. We could very well have triple-class refractori‚Ä¶ https://t.co/utu8l2wEbg,en,0.0,33590.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,6.0,https://twitter.com/VincentRK/statuses/1335315709174427648,0.0,0.0,,0.0,0.0,0.0,6.0,0.0,False,False,False,False,True,Research Funding,1.0,0.0,0.0,Myeloma Future State: New drugs bring challenges and opportunities. We could very well have triple-class refractori‚Ä¶ https://t.co/utu8l2wEbg,false
MediHumdani,"Director, BMT & Cellular Therapy Program @Froedtert & @MedicalCollege | Lymphoma | Clinical Trials | @CIBMTR | @BMTCTN | Personal views | Physician ‚â† Provider",,"Milwaukee, WI",,2020-12-07 17:53:16+00:00,Mehdi Hamadani,http://twitter.com/,4.0,,1.3360058733243963e+18,,0.0,0.0,,Dr. Jasmin Zain presenting Phase I Study of Yttrium-90 Labeled ANTI-CD25 (aTac) Monoclonal Antibody PLUS BEAM for A‚Ä¶ https://t.co/47yhYoLfPg,en,0.0,4590.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,4.0,https://twitter.com/MediHumdani/statuses/1336005873324396546,0.0,0.0,,0.0,0.0,0.0,4.0,0.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,Dr. Jasmin Zain presenting Phase I Study of Yttrium-90 Labeled ANTI-CD25 (aTac) Monoclonal Antibody PLUS BEAM for A‚Ä¶ https://t.co/47yhYoLfPg,true
DrTonyLetai,"Physician-scientist @DanaFarber. Professor of Medicine @harvardmed. President, Society for Functional Precision Medicine. You probably should be BH3 profiling.",,"Boston, MA",,2020-12-07 22:14:12+00:00,Anthony Letai MD PhD,http://twitter.com/,12.0,,1.3360715375484723e+18,,0.0,0.0,,RT @DanaFarberNews: New research presented at #ASH20 finds #CARTcell therapy has meaningfully impacted patients with advanced indolent non-‚Ä¶,en,0.0,1809.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,8.0,4.0,https://twitter.com/DrTonyLetai/statuses/1336071537548472321,0.0,0.0,,0.0,0.0,0.0,4.0,8.0,False,False,False,False,True,Research Funding,0.0,0.0,1.0,RT @DanaFarberNews: New research presented at #ASH20 finds #CARTcell therapy has meaningfully impacted patients with advanced indolent non-‚Ä¶,true
TaylorJ_MD,"Assistant Professor, UM Sylvester Comprehensive Cancer Center. Physician scientist studying the role of nuclear export and splicing in hematologic cancers.",,"Miami, FL",,2020-12-07 17:24:05+00:00,Taylor Lab UM,http://twitter.com/,0.0,,1.3359985294461665e+18,,0.0,0.0,,"Finally, combo is being moved forward to Phase 1 study in R/R #CLL and Richter's transformation. Hopefully open ear‚Ä¶ https://t.co/ESgMYHkq8Y",en,0.0,1781.0,,,0.0,TaylorJ_MD,1.335998523892908e+18,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/TaylorJ_MD/statuses/1335998529446166528,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,FDA Approval,1.0,0.0,0.0,"Finally, combo is being moved forward to Phase 1 study in R/R #CLL and Richter's transformation. Hopefully open ear‚Ä¶ https://t.co/ESgMYHkq8Y",true
MDAndersonNews,"The official account of MD Anderson Cancer Center, a leader in cancer care, cancer research and the fight to #EndCancer. Appointments available: 1-877-632-6789.",,"Houston, TX",,2020-12-03 18:18:01+00:00,MD Anderson Cancer Center,http://twitter.com/,2.0,,1.334562551162671e+18,,0.0,0.0,,"Chemotherapy used to be the standard treatment option for mantle cell lymphoma. But what‚Äôs next? 

Our Dr. Michael‚Ä¶ https://t.co/MF9AetHetb",en,0.0,114120.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/MDAndersonNews/statuses/1334562551162671110,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Clinical Trials,0.0,0.0,1.0,"Chemotherapy used to be the standard treatment option for mantle cell lymphoma. But what‚Äôs next? 

Our Dr. Michael‚Ä¶ https://t.co/MF9AetHetb",true
sortoutbleeding,"Coagulation haematologist with a passion for bleeding disorders and women's health.

Advocate for better health for all. 

All views expressed are my own.",,Irish Centre for Vascular Biol,,2020-12-09 19:42:36+00:00,Michelle Lavin,http://twitter.com/,86.0,,1.3367581637905736e+18,,0.0,0.0,,RT @oconnn04: A big thank you to the clinical teams in the NCC and the Clinical research facility @stjamesdublin and the Irish participants‚Ä¶,en,0.0,1136.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,73.0,13.0,https://twitter.com/sortoutbleeding/statuses/1336758163790573580,0.0,0.0,,0.0,0.0,0.0,13.0,73.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,RT @oconnn04: A big thank you to the clinical teams in the NCC and the Clinical research facility @stjamesdublin and the Irish participants‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-09 00:22:34+00:00,"Ritcha Saxena, MD",http://twitter.com/,7.0,,1.3364662329508454e+18,,0.0,0.0,,"RT @VJHemOnc: At the #BestOfASH session the phase 1 study of #Talquetamab in R/R #Myeloma was highlighted

For more on this bispecific anti‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,1.0,https://twitter.com/RitchaSaxena/statuses/1336466232950845443,0.0,0.0,,0.0,0.0,0.0,1.0,6.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"RT @VJHemOnc: At the #BestOfASH session the phase 1 study of #Talquetamab in R/R #Myeloma was highlighted

For more on this bispecific anti‚Ä¶",false
MDedgeHemOnc,MDedge Hematology & Oncology provides the most important and up to date information and news for oncologists. Now part of the Medscape Professional Network.,,"Rockville, MD, Parsippany, NJ",,2020-12-23 15:16:00+00:00,MDedge Hematology & Oncology,http://twitter.com/,1.0,,1.3417645024513477e+18,,0.0,0.0,,Blinatumomab shows superiority to HC3 chemotherapy among children with ALL in a phase 3 trial.‚Ä¶ https://t.co/6rvynrgwGO,en,0.0,6723.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/MDedgeHemOnc/statuses/1341764502451347459,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,Blinatumomab shows superiority to HC3 chemotherapy among children with ALL in a phase 3 trial.‚Ä¶ https://t.co/6rvynrgwGO,true
TelehealthBot,Created by Doctor @KrittanawongMD. A bot that collects Tweets about medicine and medical innovation,,GJ 357 d,,2020-12-23 22:48:57+00:00,MedEd,http://twitter.com/,1.0,,1.3418784888239675e+18,,0.0,0.0,,RT @OncologyTimes: #ASH2020 Updates: New Treatments that Offer Hope for Patients with Multiple Myeloma https://t.co/E6xrZ83GfP #medtwitter‚Ä¶,en,0.0,683.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/TelehealthBot/statuses/1341878488823967746,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Drug Discovery,0.0,0.0,1.0,RT @OncologyTimes: #ASH2020 Updates: New Treatments that Offer Hope for Patients with Multiple Myeloma https://t.co/E6xrZ83GfP #medtwitter‚Ä¶,true
CleClinicMD,"News and insights for physicians and clinical professionals from @ClevelandClinic. Research, case studies and CME opportunities.",,"Cleveland, Ohio, United States",,2020-12-01 03:24:55+00:00,Cleveland Clinic MD,http://twitter.com/,0.0,,1.333613018538791e+18,,0.0,0.0,,New research shows the monoclonal antibody daratumumab is a safe and effective treatment for amyloid light-chain amyloidosis: #ASH20,en,0.0,302311.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/CleClinicMD/statuses/1333613018538790913,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Research Funding,1.0,0.0,0.0,New research shows the monoclonal antibody daratumumab is a safe and effective treatment for amyloid light-chain amyloidosis: #ASH20,true
AnnaSureda5,"Haematologist interested in lymphoid malignancies, stem cell transplantation and CART cells. #CART #BMT #lymphomas #immunotherapy #WomenInMedicine",,"Barcelona, Spain",,2020-12-01 04:01:55+00:00,Anna Sureda,http://twitter.com/,92.0,,1.333622327788118e+18,,0.0,0.0,,RT @DocHutchings: Pleased to present the final results from the dose escalation part of the Phase 1/2 study of epcoritamab in r/r B-NHL at‚Ä¶,en,0.0,658.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,69.0,23.0,https://twitter.com/AnnaSureda5/statuses/1333622327788118018,0.0,0.0,,0.0,0.0,0.0,23.0,69.0,False,False,False,False,True,FDA Approval,1.0,0.0,0.0,RT @DocHutchings: Pleased to present the final results from the dose escalation part of the Phase 1/2 study of epcoritamab in r/r B-NHL at‚Ä¶,true
olga45093932,"MD,PhD, hematologist of @NationalCancerInst of @oncohematologyDepart",,"Kiev, Ukraine",,2020-12-28 19:49:50+00:00,Olga,http://twitter.com/,40.0,,1.3436453509644575e+18,,0.0,0.0,,RT @RahmaWarsameMD: Promising results from phase 1 VSV-IFNb-NIS in pts with relapsed refractory hem malignancies. Strongest signal in TCL.‚Ä¶,en,0.0,64.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,30.0,10.0,https://twitter.com/olga45093932/statuses/1343645350964457472,0.0,0.0,,0.0,0.0,0.0,10.0,30.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @RahmaWarsameMD: Promising results from phase 1 VSV-IFNb-NIS in pts with relapsed refractory hem malignancies. Strongest signal in TCL.‚Ä¶,true
lepikurian,"Haematologist, researcher, biotech startup co-founder",,"Saint-Petersburg, Russia",,2020-12-28 05:49:46+00:00,Kirill Lepik M.D.,http://twitter.com/,45.0,,1.3434339420625306e+18,,0.0,0.0,,RT @DrMiguelPerales: #ASH20 Abs 470 Impressive results in Phase II Study of Pembrolizumab Plus GVD As 2nd-Line Therapy for Rel/Ref Classica‚Ä¶,en,0.0,89.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,34.0,11.0,https://twitter.com/lepikurian/statuses/1343433942062530561,0.0,0.0,,0.0,0.0,0.0,11.0,34.0,False,False,False,False,True,FDA Approval,1.0,0.0,0.0,RT @DrMiguelPerales: #ASH20 Abs 470 Impressive results in Phase II Study of Pembrolizumab Plus GVD As 2nd-Line Therapy for Rel/Ref Classica‚Ä¶,false
olga45093932,"MD,PhD, hematologist of @NationalCancerInst of @oncohematologyDepart",,"Kiev, Ukraine",,2020-12-28 19:51:27+00:00,Olga,http://twitter.com/,24.0,,1.3436457586382193e+18,,0.0,0.0,,RT @VincentRK: Myeloma Future State: New drugs bring challenges and opportunities. We could very well have triple-class refractoriness in 1‚Ä¶,en,0.0,64.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,18.0,6.0,https://twitter.com/olga45093932/statuses/1343645758638219270,0.0,0.0,,0.0,0.0,0.0,6.0,18.0,False,False,False,False,True,Research Funding,1.0,0.0,0.0,RT @VincentRK: Myeloma Future State: New drugs bring challenges and opportunities. We could very well have triple-class refractoriness in 1‚Ä¶,true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-12-15 20:27:00+00:00,Oncology Tube,http://twitter.com/,0.0,,1.3389436626595226e+18,,0.0,0.0,,"Update of MANIFEST Phase 2 Study John Mascarenhas, MD @TischCancer @IcahnMountSinai #ASH20 #Myelofibrosis #Cancer‚Ä¶ https://t.co/77gZQvTTBR",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1338943662659522560,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"Update of MANIFEST Phase 2 Study John Mascarenhas, MD @TischCancer @IcahnMountSinai #ASH20 #Myelofibrosis #Cancer‚Ä¶ https://t.co/77gZQvTTBR",true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-12-17 18:00:00+00:00,Oncology Tube,http://twitter.com/,0.0,,1.3396314465380065e+18,,0.0,0.0,,"Primary Efficacy and Safety Results from a Phase 1 Trial Andreas Hochhaus, MD @AndreasHochhaus @UniJena #ASH20‚Ä¶ https://t.co/W1h7FqYUNN",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1339631446538006529,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"Primary Efficacy and Safety Results from a Phase 1 Trial Andreas Hochhaus, MD @AndreasHochhaus @UniJena #ASH20‚Ä¶ https://t.co/W1h7FqYUNN",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-14 16:46:34+00:00,Lisa Palacios,http://twitter.com/,2.0,,1.3385258034291794e+18,,0.0,0.0,,"#ASH20 #MPN Daily Wrap-Up: New Research and Early Detection | Naveen Pemmaraju, MD, @doctorpemm of @MDAndersonNews‚Ä¶ https://t.co/Gxrz5sUFda",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/Lisa_Palacios/statuses/1338525803429179392,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Research Funding,0.0,0.0,1.0,"#ASH20 #MPN Daily Wrap-Up: New Research and Early Detection | Naveen Pemmaraju, MD, @doctorpemm of @MDAndersonNews‚Ä¶ https://t.co/Gxrz5sUFda",true
VincentRK,"Professor, Mayo Clinic; Editor, Blood Cancer Journal; Oncologist; Health Costs; COVID threads @SurvivedCOVID Opinions=personal views https://t.co/TMq9vc5hZk",,"Rochester, MN, USA",,2020-12-04 14:59:03+00:00,Vincent Rajkumar,http://twitter.com/,1.0,,1.3348748664414495e+18,,0.0,0.0,,"7. Phase III trial results of ixazomib, len, dex (IRd) vs placebo, len, dex (Rd) in newly diagnosed myeloma. #ASH20‚Ä¶ https://t.co/CtM7OCcFd6",en,0.0,33590.0,,,0.0,VincentRK,1.3348748628637327e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/VincentRK/statuses/1334874866441449473,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"7. Phase III trial results of ixazomib, len, dex (IRd) vs placebo, len, dex (Rd) in newly diagnosed myeloma. #ASH20‚Ä¶ https://t.co/CtM7OCcFd6",true
MediHumdani,"Director, BMT & Cellular Therapy Program @Froedtert & @MedicalCollege | Lymphoma | Clinical Trials | @CIBMTR | @BMTCTN | Personal views | Physician ‚â† Provider",,"Milwaukee, WI",,2020-11-26 23:35:36+00:00,Mehdi Hamadani,http://twitter.com/,13.0,,1.332105757689606e+18,,0.0,0.0,,An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 shows early signal of activity in Relapsed/Refractory‚Ä¶ https://t.co/ksfF2XwGVI,en,0.0,4590.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,13.0,https://twitter.com/MediHumdani/statuses/1332105757689606145,0.0,0.0,,0.0,0.0,0.0,13.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 shows early signal of activity in Relapsed/Refractory‚Ä¶ https://t.co/ksfF2XwGVI,false
CanerSaygin,"Heme-Onc Fellow @UChicago | Alumni of @OhioStateIMRes, @CCLRI | #Leukemia, #MDS, #CHIP physician-scientist. Tweets=own opinions.",,"Chicago, IL",,2020-12-06 18:00:48+00:00,"Caner Saygin, MD",http://twitter.com/,0.0,,1.3356453820811878e+18,,0.0,0.0,,Dr Aldoss showing early-phase data on Flotetuzumab (CD3xCD123) in primary refractory and early relapse #AML pts. It‚Ä¶ https://t.co/kM8E7c4uv8,en,0.0,743.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/CanerSaygin/statuses/1335645382081187842,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,Dr Aldoss showing early-phase data on Flotetuzumab (CD3xCD123) in primary refractory and early relapse #AML pts. It‚Ä¶ https://t.co/kM8E7c4uv8,true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-06 23:39:02+00:00,Lisa Palacios,http://twitter.com/,7.0,,1.3357304990300324e+18,,0.0,0.0,,"RT @AML_Hub: Congress| #ASH20| Farhad Ravandi, @LeukemiaMDA, presented data on a phase 1 study of vibecotamab that demonstrated a tolerable‚Ä¶",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,2.0,https://twitter.com/Lisa_Palacios/statuses/1335730499030032385,0.0,0.0,,0.0,0.0,0.0,2.0,5.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"RT @AML_Hub: Congress| #ASH20| Farhad Ravandi, @LeukemiaMDA, presented data on a phase 1 study of vibecotamab that demonstrated a tolerable‚Ä¶",true
NicoleKuderer,"Translational Oncologist (Biomarkers, Toxicities, Health Outcomes, Clinico-Genomic Big Data, @OncoAlert). Motto: ""Let's make a difference"". Tweets are my own.",,USA,,2020-12-06 01:23:07+00:00,Nicole Kuderer,http://twitter.com/,218.0,,1.3353943056917135e+18,,0.0,0.0,,"RT @hemedoc: #ASH20 #leusm Wei: We are all excited to have new therapeutic options in AML, but the overall message I get from this money sl‚Ä¶",en,0.0,6212.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,168.0,50.0,https://twitter.com/NicoleKuderer/statuses/1335394305691713538,0.0,0.0,,0.0,0.0,0.0,50.0,168.0,False,False,False,False,True,Research Funding,1.0,0.0,0.0,"RT @hemedoc: #ASH20 #leusm Wei: We are all excited to have new therapeutic options in AML, but the overall message I get from this money sl‚Ä¶",true
dgermain21,MD-PhD. 2nd year Heme/Onc fellow focused on lymphoma and leukemia. Physician-scientist-in-training. Tweet/RT not medical advice or endorsement.,,"St. Louis, MO",,2020-12-06 20:23:29+00:00,David A. Russler-Germain,http://twitter.com/,18.0,,1.3356812896141353e+18,,0.0,0.0,,"RT @lymphomahub: CONGRESS | #ASH20 | Rajat Bannerji, @RutgersCancer, presents the results from a phase I study investigating the CD20xCD3 b‚Ä¶",en,0.0,1612.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,14.0,4.0,https://twitter.com/dgermain21/statuses/1335681289614135298,0.0,0.0,,0.0,0.0,0.0,4.0,14.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"RT @lymphomahub: CONGRESS | #ASH20 | Rajat Bannerji, @RutgersCancer, presents the results from a phase I study investigating the CD20xCD3 b‚Ä¶",true
olga45093932,"MD,PhD, hematologist of @NationalCancerInst of @oncohematologyDepart",,"Kiev, Ukraine",,2020-12-06 07:33:09+00:00,Olga,http://twitter.com/,218.0,,1.3354874255864177e+18,,0.0,0.0,,"RT @hemedoc: #ASH20 #leusm Wei: We are all excited to have new therapeutic options in AML, but the overall message I get from this money sl‚Ä¶",en,0.0,64.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,168.0,50.0,https://twitter.com/olga45093932/statuses/1335487425586417665,0.0,0.0,,0.0,0.0,0.0,50.0,168.0,False,False,False,False,True,Research Funding,1.0,0.0,0.0,"RT @hemedoc: #ASH20 #leusm Wei: We are all excited to have new therapeutic options in AML, but the overall message I get from this money sl‚Ä¶",true
Joshuawolf,"Pediatrician, Infectious Diseases Physician and Researcher. Focus on infections in kids with cancer @StJudeResearch. Views are my own.",,"Memphis, TN",,2020-12-06 18:38:40+00:00,Josh Wolf,http://twitter.com/,13.0,,1.3356549118544568e+18,,0.0,0.0,,RT @AkshaySharmaMD: #ASH20 Richa Sharma from @StJudeResearch @marrowgenes lab #TBD #BMF https://t.co/TU4uUcXFWb,en,0.0,877.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,9.0,4.0,https://twitter.com/Joshuawolf/statuses/1335654911854456835,0.0,0.0,,0.0,0.0,0.0,4.0,9.0,False,False,False,False,True,Research Funding,0.0,0.0,1.0,RT @AkshaySharmaMD: #ASH20 Richa Sharma from @StJudeResearch @marrowgenes lab #TBD #BMF https://t.co/TU4uUcXFWb,false
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 21:12:43+00:00,"Ritcha Saxena, MD",http://twitter.com/,23.0,,1.335693677344256e+18,,0.0,0.0,,"RT @Mohty_EBMT: #ASH20 day 2: I have 2 general thoughts!
- Advances are not only about new drugs !
- Is there a regimen that cannot/shouldn‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,20.0,3.0,https://twitter.com/RitchaSaxena/statuses/1335693677344256007,0.0,0.0,,0.0,0.0,0.0,3.0,20.0,False,False,False,False,True,Research Funding,0.0,0.0,1.0,"RT @Mohty_EBMT: #ASH20 day 2: I have 2 general thoughts!
- Advances are not only about new drugs !
- Is there a regimen that cannot/shouldn‚Ä¶",true
jenweiying,Haematologist working on https://t.co/fiMAwrCDXt - #FOAMed for students and trainees. Collaborators welcome. Tweets are my own opinion and not medical advice.,,Singapore,,2020-12-06 05:05:32+00:00,Wei Ying Jen,http://twitter.com/,218.0,,1.335450278376575e+18,,0.0,0.0,,"RT @hemedoc: #ASH20 #leusm Wei: We are all excited to have new therapeutic options in AML, but the overall message I get from this money sl‚Ä¶",en,0.0,251.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,168.0,50.0,https://twitter.com/jenweiying/statuses/1335450278376574976,0.0,0.0,,0.0,0.0,0.0,50.0,168.0,False,False,False,False,True,Research Funding,1.0,0.0,0.0,"RT @hemedoc: #ASH20 #leusm Wei: We are all excited to have new therapeutic options in AML, but the overall message I get from this money sl‚Ä¶",true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-06 21:29:41+00:00,"Ritcha Saxena, MD",http://twitter.com/,8.0,,1.3356979475819438e+18,,0.0,0.0,,"RT @SeattleCCA: Coming up at #ASH20: Oral presentation with @stephanieleemd, MD, MPH - ""358 Phase 1 Study of Axatilimab (SNDX-6352), a CSF-‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,3.0,https://twitter.com/RitchaSaxena/statuses/1335697947581943819,0.0,0.0,,0.0,0.0,0.0,3.0,5.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"RT @SeattleCCA: Coming up at #ASH20: Oral presentation with @stephanieleemd, MD, MPH - ""358 Phase 1 Study of Axatilimab (SNDX-6352), a CSF-‚Ä¶",true
tanyawildes,"Hematologist/oncologist/geriatrician, studying the intersection of Myeloma & other cancers with Aging. Woman of faith/wife of Mr Doctor Wildes/Mom.",,,,2020-12-06 20:49:36+00:00,Tanya Wildes MD,http://twitter.com/,40.0,,1.335687860326953e+18,,0.0,0.0,,RT @RahmaWarsameMD: Promising results from phase 1 VSV-IFNb-NIS in pts with relapsed refractory hem malignancies. Strongest signal in TCL.‚Ä¶,en,0.0,2800.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,30.0,10.0,https://twitter.com/tanyawildes/statuses/1335687860326952967,0.0,0.0,,0.0,0.0,0.0,10.0,30.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @RahmaWarsameMD: Promising results from phase 1 VSV-IFNb-NIS in pts with relapsed refractory hem malignancies. Strongest signal in TCL.‚Ä¶,true
drjgauthier,"MD, MSc, Assistant Professor @fredhutch @UW focused on #CARTcell #immunotherapy #tcellrx 
Interests also include #rstats #bmtsm #epitwitter #bayes",,"Seattle, WA",,2020-12-06 18:12:30+00:00,Jordan Gauthier,http://twitter.com/,5.0,,1.3356483254715884e+18,,0.0,0.0,,"#ASH20 355 Dr. Pidala @MoffittNews 
Preclinical and Phase I Trial Results of Biological and Clinical Impact of JAK2‚Ä¶ https://t.co/yqo5d94ulv",en,0.0,3295.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,5.0,https://twitter.com/drjgauthier/statuses/1335648325471588353,0.0,0.0,,0.0,0.0,0.0,5.0,0.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"#ASH20 355 Dr. Pidala @MoffittNews 
Preclinical and Phase I Trial Results of Biological and Clinical Impact of JAK2‚Ä¶ https://t.co/yqo5d94ulv",true
drjsporter,Licensed Psychologist | Sickle Cell Researcher @stjuderesearch | Alum @UVA @FloridaState @VCU @NUFeinbergMed | Tweets are my own.,,"Memphis, TN",,2020-12-06 14:09:41+00:00,"Dr. Jerlym Porter, PhD",http://twitter.com/,13.0,,1.335587216702255e+18,,0.0,0.0,,RT @AkshaySharmaMD: #ASH20 Richa Sharma from @StJudeResearch @marrowgenes lab #TBD #BMF,en,0.0,447.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,9.0,4.0,https://twitter.com/drjsporter/statuses/1335587216702255106,0.0,0.0,,0.0,0.0,0.0,4.0,9.0,False,False,False,False,True,Research Funding,0.0,0.0,1.0,RT @AkshaySharmaMD: #ASH20 Richa Sharma from @StJudeResearch @marrowgenes lab #TBD #BMF,false
DrChrisHourigan,"Physician-Scientist, Acute Myeloid Leukemia Doctor, Human Immunologist, Laboratory PI, Measurable Residual Disease Advocate, Optimist.  Views are my own.",,"Washington, DC",,2020-12-06 23:03:54+00:00,Chris Hourigan,http://twitter.com/,218.0,,1.3357216595217695e+18,,0.0,0.0,,"RT @hemedoc: #ASH20 #leusm Wei: We are all excited to have new therapeutic options in AML, but the overall message I get from this money sl‚Ä¶",en,0.0,1169.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,168.0,50.0,https://twitter.com/DrChrisHourigan/statuses/1335721659521769476,0.0,0.0,,0.0,0.0,0.0,50.0,168.0,False,False,False,False,True,Research Funding,1.0,0.0,0.0,"RT @hemedoc: #ASH20 #leusm Wei: We are all excited to have new therapeutic options in AML, but the overall message I get from this money sl‚Ä¶",true
VincentRK,"Professor, Mayo Clinic; Editor, Blood Cancer Journal; Oncologist; Health Costs; COVID threads @SurvivedCOVID Opinions=personal views https://t.co/TMq9vc5hZk",,"Rochester, MN, USA",,2020-12-06 22:30:57+00:00,Vincent Rajkumar,http://twitter.com/,40.0,,1.3357133661202596e+18,,0.0,0.0,,RT @RahmaWarsameMD: Promising results from phase 1 VSV-IFNb-NIS in pts with relapsed refractory hem malignancies. Strongest signal in TCL.‚Ä¶,en,0.0,33590.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,30.0,10.0,https://twitter.com/VincentRK/statuses/1335713366120259586,0.0,0.0,,0.0,0.0,0.0,10.0,30.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @RahmaWarsameMD: Promising results from phase 1 VSV-IFNb-NIS in pts with relapsed refractory hem malignancies. Strongest signal in TCL.‚Ä¶,true
EladSharonMD,"#MedicalOncologist tweeting on #immunotherapy, #drugdevelopment, #COVID19 & #HealthEcon. #NCI #CancerMoonshot Adult Immunotherapy Co-Chair. Tweets are mine.",,"Washington, DC",,2020-12-06 01:19:40+00:00,Elad Sharon,http://twitter.com/,218.0,,1.33539343810841e+18,,0.0,0.0,,"RT @hemedoc: #ASH20 #leusm Wei: We are all excited to have new therapeutic options in AML, but the overall message I get from this money sl‚Ä¶",en,0.0,2113.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,168.0,50.0,https://twitter.com/EladSharonMD/statuses/1335393438108409856,0.0,0.0,,0.0,0.0,0.0,50.0,168.0,False,False,False,False,True,Research Funding,1.0,0.0,0.0,"RT @hemedoc: #ASH20 #leusm Wei: We are all excited to have new therapeutic options in AML, but the overall message I get from this money sl‚Ä¶",true
AKeyzner,"hematologist #BMT #leuksm physician ‚â†provider immigrant, opinions my own, likes‚â†endorsement",,,,2020-12-06 18:22:11+00:00,Alla Keyzner,http://twitter.com/,17.0,,1.3356507623540283e+18,,0.0,0.0,,"RT @drjgauthier: #ASH20 355 Dr. Pidala @MoffittNews 
Preclinical and Phase I Trial Results of Biological and Clinical Impact of JAK2 (pacri‚Ä¶",en,0.0,157.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,12.0,5.0,https://twitter.com/AKeyzner/statuses/1335650762354028545,0.0,0.0,,0.0,0.0,0.0,5.0,12.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"RT @drjgauthier: #ASH20 355 Dr. Pidala @MoffittNews 
Preclinical and Phase I Trial Results of Biological and Clinical Impact of JAK2 (pacri‚Ä¶",true
miljko,Hematologist/oncologist. Views are my own. #RWRI 14 attendee. @ Hemato-onkolog. MFUB 2002-2008. üéô https://t.co/xzLsKCsirz üñã https://t.co/NBAgn0OFhh * https://t.co/xD3CELCeVW,,DC,,2020-12-07 13:33:51+00:00,Milo≈° Miljkoviƒá,http://twitter.com/,0.0,,1.3359405879760937e+18,,0.0,0.0,,"#ASH20 Abstract 2071: Phase 1 Study of subQ rhIL-15 and i.v. alemtuzumab for R/R CD52+ TCL
‚úì IL-15 x 2 weeks follow‚Ä¶ https://t.co/wcsHXMehjm",en,0.0,2422.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/miljko/statuses/1335940587976093697,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"#ASH20 Abstract 2071: Phase 1 Study of subQ rhIL-15 and i.v. alemtuzumab for R/R CD52+ TCL
‚úì IL-15 x 2 weeks follow‚Ä¶ https://t.co/wcsHXMehjm",true
mav_jav,"Human,fighter,survivor. Passionate about helping and healing.Histopathologist",,"The Capital, Kuwait",,2020-12-05 19:55:28+00:00,Mawish javed,http://twitter.com/,8.0,,1.335311851190694e+18,,0.0,0.0,,"RT @VincentRK: 12. Phase I results of TNB-383B, a BCMA/CD3 Bispecific Antibody, in Relapsed/Refractory Myeloma. #ASH20 @MayoMyeloma @myelom‚Ä¶",en,0.0,956.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,3.0,https://twitter.com/mav_jav/statuses/1335311851190693889,0.0,0.0,,0.0,0.0,0.0,3.0,5.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @VincentRK: 12. Phase I results of TNB-383B, a BCMA/CD3 Bispecific Antibody, in Relapsed/Refractory Myeloma. #ASH20 @MayoMyeloma @myelom‚Ä¶",false
johnde1MYELOMA,"myeloma survivor üêú, gastroenterologist, bicyclist, animal lover",,"Santa Fe, NM",,2020-12-05 20:58:01+00:00,John DeFlice,http://twitter.com/,1.0,,1.3353275897920184e+18,,0.0,0.0,,BISPECIFIC phase 1 study Teclistamab-BCMC/CD3 ab in RRMM with deep/durable response with manageable safety profile‚Ä¶ https://t.co/rKSJ3uEfgZ,en,0.0,218.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/johnde1MYELOMA/statuses/1335327589792018432,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,BISPECIFIC phase 1 study Teclistamab-BCMC/CD3 ab in RRMM with deep/durable response with manageable safety profile‚Ä¶ https://t.co/rKSJ3uEfgZ,true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-06 05:20:32+00:00,Lisa Palacios,http://twitter.com/,16.0,,1.3354540524324045e+18,,0.0,0.0,,"RT @MDAndersonNews: ‚ÄúHaving new and specialized therapies like CAR T cells, new therapies that were invented here like CAR NK cells ‚Ä¶ creat‚Ä¶",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,13.0,3.0,https://twitter.com/Lisa_Palacios/statuses/1335454052432404483,0.0,0.0,,0.0,0.0,0.0,3.0,13.0,False,False,False,False,True,Research Funding,0.0,0.0,1.0,"RT @MDAndersonNews: ‚ÄúHaving new and specialized therapies like CAR T cells, new therapies that were invented here like CAR NK cells ‚Ä¶ creat‚Ä¶",true
fniainle,"Haematologist, passionate about VTE. Co-director @ConwaySphere; Director https://t.co/csdWq9XJ57; RT not endorsement, views my own",,"Dublin City, Ireland",,2020-12-06 18:15:46+00:00,Fionnuala N√≠ √Åinle,http://twitter.com/,1.0,,1.335649146301272e+18,,0.0,0.0,,Huge #ASHkudos to Dr Helen Chu on leading this cross-sectional community-based surveillance study of homeless shelt‚Ä¶ https://t.co/lcdfeZkEx1,en,0.0,2069.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/fniainle/statuses/1335649146301272077,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Disease Advocacy,0.0,0.0,1.0,Huge #ASHkudos to Dr Helen Chu on leading this cross-sectional community-based surveillance study of homeless shelt‚Ä¶ https://t.co/lcdfeZkEx1,true
AndreaAnampaG,"Medstudent @UNMSM_ with OCD ‚Ä¢ @ASCO & @AMWAdoctors Social Media
@CPsolvers Team Member ‚Ä¢ #Globaloncology #WomenInMedicine #MedEd #SurvOnc üáµüá™ #IMG üåà she/ella",,"Lima, Peru",,2020-12-06 20:58:56+00:00,Andrea Anampa-Guzm√°n,http://twitter.com/,40.0,,1.3356902100934902e+18,,0.0,0.0,,RT @RahmaWarsameMD: Promising results from phase 1 VSV-IFNb-NIS in pts with relapsed refractory hem malignancies. Strongest signal in TCL.‚Ä¶,en,0.0,1908.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,30.0,10.0,https://twitter.com/AndreaAnampaG/statuses/1335690210093490176,0.0,0.0,,0.0,0.0,0.0,10.0,30.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @RahmaWarsameMD: Promising results from phase 1 VSV-IFNb-NIS in pts with relapsed refractory hem malignancies. Strongest signal in TCL.‚Ä¶,true
rajshekharucms,Hem/Onc Physician/Clinical Researcher @ColumbiaCancer #MultipleMyeloma & #Amyloidosis. Asst. Prof of Medicine @ColumbiaMed #ClinicalTrials and Outcomes Research,,"New York, NY",,2020-12-07 23:51:57+00:00,Raj Chakraborty,http://twitter.com/,3.0,,1.3360961390037852e+18,,0.0,0.0,,RT @AuclairDan: Jason Valent at #ASH20 providing an update on ongoing Phase II trial of CAEL-101 in AL Amyloidosis #mmsm https://t.co/Hsb6n‚Ä¶,en,0.0,1148.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,2.0,1.0,https://twitter.com/rajshekharucms/statuses/1336096139003785220,0.0,0.0,,0.0,0.0,0.0,1.0,2.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,RT @AuclairDan: Jason Valent at #ASH20 providing an update on ongoing Phase II trial of CAEL-101 in AL Amyloidosis #mmsm https://t.co/Hsb6n‚Ä¶,true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-16 21:40:56+00:00,Lisa Palacios,http://twitter.com/,5.0,,1.3393246567723295e+18,,0.0,0.0,,"RT @PatientPower: NEW FROM #ASH20: Phase 2 Study Combining Navitoclax and Ruxolitinib Sees Promising Results

Dr. Srdan Verstovsek, from @L‚Ä¶",en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,2.0,https://twitter.com/Lisa_Palacios/statuses/1339324656772329473,0.0,0.0,,0.0,0.0,0.0,2.0,3.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"RT @PatientPower: NEW FROM #ASH20: Phase 2 Study Combining Navitoclax and Ruxolitinib Sees Promising Results

Dr. Srdan Verstovsek, from @L‚Ä¶",false
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-12-18 14:38:00+00:00,Oncology Tube,http://twitter.com/,1.0,,1.339942997723472e+18,,0.0,0.0,,"Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib Tycel J. Phillips, MD @UMRogelCancer @UMich #ASH20‚Ä¶ https://t.co/u7TJm5PWRR",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/oncologytube/statuses/1339942997723471873,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib Tycel J. Phillips, MD @UMRogelCancer @UMich #ASH20‚Ä¶ https://t.co/u7TJm5PWRR",true
CphtStoke,"CPHT Stoke trains local people to be Solution Focused Hypnotherapists. Its a fun, practical & fully accredited 10 month course that leads to 2 qualifications.",,,,2020-11-30 10:16:52+00:00,CPHT Stoke,http://twitter.com/,0.0,,1.3333542994396529e+18,,0.0,0.0,,"Jenny, one of the tutors of CPHT Stoke, helping to raise awareness of local charity, 'A child of mine' by doing a 2‚Ä¶ https://t.co/rUU8OaJcd1",en,0.0,5.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/CphtStoke/statuses/1333354299439652866,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Charity,1.0,0.0,0.0,"Jenny, one of the tutors of CPHT Stoke, helping to raise awareness of local charity, 'A child of mine' by doing a 2‚Ä¶ https://t.co/rUU8OaJcd1",true
AndreaAnampaG,"Medstudent @UNMSM_ with OCD ‚Ä¢ @ASCO & @AMWAdoctors Social Media
@CPsolvers Team Member ‚Ä¢ #Globaloncology #WomenInMedicine #MedEd #SurvOnc üáµüá™ #IMG üåà she/ella",,"Lima, Peru",,2020-12-04 15:53:52+00:00,Andrea Anampa-Guzm√°n,http://twitter.com/,18.0,,1.334888662924923e+18,,0.0,0.0,,RT @vasconez_w: Make sure to join the pre-conference CME on ‚ÄúAn optimized approach to Sickle Cell Disease Care in the New Era of Treatment‚Äù‚Ä¶,en,0.0,1908.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,14.0,4.0,https://twitter.com/AndreaAnampaG/statuses/1334888662924922881,0.0,0.0,,0.0,0.0,0.0,4.0,14.0,False,False,False,False,True,Drug Discovery,0.0,0.0,1.0,RT @vasconez_w: Make sure to join the pre-conference CME on ‚ÄúAn optimized approach to Sickle Cell Disease Care in the New Era of Treatment‚Äù‚Ä¶,true
TelehealthBot,Created by Doctor @KrittanawongMD. A bot that collects Tweets about medicine and medical innovation,,GJ 357 d,,2020-12-09 19:12:15+00:00,MedEd,http://twitter.com/,2.0,,1.3367505240377958e+18,,0.0,0.0,,RT @OncologyTimes: #ASH2020 Highlight: New Treatment for Achieving Hodgkin #Lymphoma Remission https://t.co/swfOKrjsCw #cancertreatment #me‚Ä¶,en,0.0,683.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,1.0,1.0,https://twitter.com/TelehealthBot/statuses/1336750524037795842,0.0,0.0,,0.0,0.0,0.0,1.0,1.0,False,False,False,False,True,Drug Discovery,0.0,0.0,1.0,RT @OncologyTimes: #ASH2020 Highlight: New Treatment for Achieving Hodgkin #Lymphoma Remission https://t.co/swfOKrjsCw #cancertreatment #me‚Ä¶,true
JWatch,Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.,,"Waltham, MA",,2020-12-09 15:52:59+00:00,NEJM Journal Watch,http://twitter.com/,3.0,,1.3367003772746506e+18,,0.0,0.0,,RT @Physns1stWatch: News from #ASH20: Dr. Christopher Gibson talks with Joe Elia about new findings that show it might not be necessary to‚Ä¶,en,0.0,39079.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,2.0,1.0,https://twitter.com/JWatch/statuses/1336700377274650624,0.0,0.0,,0.0,0.0,0.0,1.0,2.0,False,False,False,False,True,Research Funding,0.0,0.0,1.0,RT @Physns1stWatch: News from #ASH20: Dr. Christopher Gibson talks with Joe Elia about new findings that show it might not be necessary to‚Ä¶,true
oncologytube,"Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.",,"Temecula, CA",,2020-12-09 18:45:00+00:00,Oncology Tube,http://twitter.com/,0.0,,1.3367436671811338e+18,,0.0,0.0,,"Long-Term Efficacy and Safety Results from a Phase 2 Study Michael Wang, MD @michaelwangmd @MDAndersonnews #ASH20‚Ä¶ https://t.co/ykyk7qeJKc",en,0.0,14785.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/oncologytube/statuses/1336743667181133825,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,"Long-Term Efficacy and Safety Results from a Phase 2 Study Michael Wang, MD @michaelwangmd @MDAndersonnews #ASH20‚Ä¶ https://t.co/ykyk7qeJKc",false
KellySchoenbeck,"Hematology/Oncology Fellow @UCSFCancer | IM @ColumbiaMed | MD @OHSUSOM | hematology, myeloid malignancies #QOL #geriheme | tweets my own",,,,2020-12-07 02:23:20+00:00,Kelly Schoenbeck,http://twitter.com/,29.0,,1.3357718470240256e+18,,0.0,0.0,,RT @MazieTsangMD: #ASH20 #ASHKudos to @UCSFCancer fellow @SwethaKMD who worked so hard on this phase 2 study of Dara + Aza + Dex (Darazadex‚Ä¶,en,0.0,48.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,22.0,7.0,https://twitter.com/KellySchoenbeck/statuses/1335771847024025600,0.0,0.0,,0.0,0.0,0.0,7.0,22.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,RT @MazieTsangMD: #ASH20 #ASHKudos to @UCSFCancer fellow @SwethaKMD who worked so hard on this phase 2 study of Dara + Aza + Dex (Darazadex‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-07 00:56:25+00:00,"Ritcha Saxena, MD",http://twitter.com/,29.0,,1.3357499738755643e+18,,0.0,0.0,,RT @MazieTsangMD: #ASH20 #ASHKudos to @UCSFCancer fellow @SwethaKMD who worked so hard on this phase 2 study of Dara + Aza + Dex (Darazadex‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,22.0,7.0,https://twitter.com/RitchaSaxena/statuses/1335749973875564545,0.0,0.0,,0.0,0.0,0.0,7.0,22.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,RT @MazieTsangMD: #ASH20 #ASHKudos to @UCSFCancer fellow @SwethaKMD who worked so hard on this phase 2 study of Dara + Aza + Dex (Darazadex‚Ä¶,true
gjmccaughan,"Haematologist interested in plasma cell disorders Zamasa Foundation Myeloma Fellow, Kinghorn Cancer Centre, St Vincent‚Äôs Hospital, Sydney",,,,2020-12-07 03:13:50+00:00,Georgia McCaughan,http://twitter.com/,2.0,,1.335784558017409e+18,,0.0,0.0,,"In first collaboration between @ALLGtrials #AMWG and Asian Myeloma Network, #@HangQuach1 presents at #ASH20 Phase I‚Ä¶ https://t.co/eXiLSgEdgU",en,0.0,528.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,2.0,https://twitter.com/gjmccaughan/statuses/1335784558017409024,0.0,0.0,,0.0,0.0,0.0,2.0,0.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,"In first collaboration between @ALLGtrials #AMWG and Asian Myeloma Network, #@HangQuach1 presents at #ASH20 Phase I‚Ä¶ https://t.co/eXiLSgEdgU",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-07 21:42:32+00:00,Lisa Palacios,http://twitter.com/,10.0,,1.3360635692223898e+18,,0.0,0.0,,RT @razan_mohty: Ten-Day Decitabine with Venetoclax Versus Intensive Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia =&gt; ORR h‚Ä¶,en,0.0,657.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,4.0,https://twitter.com/Lisa_Palacios/statuses/1336063569222389761,0.0,0.0,,0.0,0.0,0.0,4.0,6.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @razan_mohty: Ten-Day Decitabine with Venetoclax Versus Intensive Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia =&gt; ORR h‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-09 00:34:35+00:00,"Ritcha Saxena, MD",http://twitter.com/,3.0,,1.3364692551145925e+18,,0.0,0.0,,RT @adctherapeutics: Updated preliminary data from the pivotal Phase 2 trial of our CD25-targeted #antibodydrugconjugate in #Hodgkinlymphom‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,2.0,1.0,https://twitter.com/RitchaSaxena/statuses/1336469255114592261,0.0,0.0,,0.0,0.0,0.0,1.0,2.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,RT @adctherapeutics: Updated preliminary data from the pivotal Phase 2 trial of our CD25-targeted #antibodydrugconjugate in #Hodgkinlymphom‚Ä¶,true
HKlepinMD,Geriatric oncologist,,,,2020-12-09 01:49:43+00:00,Heidi Klepin,http://twitter.com/,7.0,,1.3364881610867548e+18,,0.0,0.0,,RT @ShakiraG_MBBS: #ASH20 excellent qualitative study by Dr. Charity Oyedejiüëá@DukeHealth examining barriers and facilitators of Advance Car‚Ä¶,en,0.0,902.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,6.0,1.0,https://twitter.com/HKlepinMD/statuses/1336488161086754822,0.0,0.0,,0.0,0.0,0.0,1.0,6.0,False,False,False,False,True,Charity,1.0,0.0,0.0,RT @ShakiraG_MBBS: #ASH20 excellent qualitative study by Dr. Charity Oyedejiüëá@DukeHealth examining barriers and facilitators of Advance Car‚Ä¶,false
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-09 00:34:39+00:00,"Ritcha Saxena, MD",http://twitter.com/,5.0,,1.3364692720260792e+18,,0.0,0.0,,RT @adctherapeutics: Updated preliminary data from the pivotal Phase 2 trial of our CD25-targeted #antibodydrugconjugate in #Hodgkinlymphom‚Ä¶,en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,2.0,https://twitter.com/RitchaSaxena/statuses/1336469272026079236,0.0,0.0,,0.0,0.0,0.0,2.0,3.0,False,False,False,False,True,FDA Approval,0.0,0.0,1.0,RT @adctherapeutics: Updated preliminary data from the pivotal Phase 2 trial of our CD25-targeted #antibodydrugconjugate in #Hodgkinlymphom‚Ä¶,true
MedpageOnco,Breaking cancer + oncology news | Reports from all major oncology meetings | Peer-reviewed | Oncologist-trusted | Part of @MedPageToday,,,,2020-12-09 21:09:02+00:00,MedPage Oncology,http://twitter.com/,0.0,,1.3367799131107082e+18,,0.0,0.0,,A chemotherapy-free investigational combination reduced the risk of disease progression or death for patients with‚Ä¶ https://t.co/ZsiCqTkRKF,en,0.0,443.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/MedpageOnco/statuses/1336779913110708235,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,A chemotherapy-free investigational combination reduced the risk of disease progression or death for patients with‚Ä¶ https://t.co/ZsiCqTkRKF,true
EladSharonMD,"#MedicalOncologist tweeting on #immunotherapy, #drugdevelopment, #COVID19 & #HealthEcon. #NCI #CancerMoonshot Adult Immunotherapy Co-Chair. Tweets are mine.",,"Washington, DC",,2020-06-17 18:21:12+00:00,Elad Sharon,http://twitter.com/,15.0,,1.2733198003962225e+18,,0.0,0.0,,RT @Dr_AmerZeidan: My commentary on our first in human Phase 1 study of the protein degrader CC-90009 in refractory/relapsed aml that we pr‚Ä¶,en,0.0,2113.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,12.0,3.0,https://twitter.com/EladSharonMD/statuses/1273319800396222466,0.0,0.0,,0.0,0.0,0.0,3.0,12.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @Dr_AmerZeidan: My commentary on our first in human Phase 1 study of the protein degrader CC-90009 in refractory/relapsed aml that we pr‚Ä¶,true
MedInContext,"Medical Advisor, Molecular Oncologist, Healthcare Consultant, Cancer Patient Friend",,United States,,2020-02-19 14:39:56+00:00,Susanne Max Radke,http://twitter.com/,0.0,,1.2301399634523832e+18,,0.0,0.0,,"First day at #TCTM20
Looking forward to listening to new research and networking with scientists. https://t.co/rkfZJ7B6ET",en,0.0,358.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/MedInContext/statuses/1230139963452383234,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Research Funding,1.0,0.0,0.0,"First day at #TCTM20
Looking forward to listening to new research and networking with scientists. https://t.co/rkfZJ7B6ET",true
TAinaMDMPH,Sister.Daughter.Physician.PediatricAnesthesiologist.ClinicianEducator. Tweets are my own ‚ù§,,United States,,2020-08-27 16:55:23+00:00,"T.Aina, MD MPH",http://twitter.com/,1.0,,1.2990277453395927e+18,,0.0,0.0,,RT @Pedisedationdoc: Virtual Sickle Cell Disease fundraising brunch with live music from Karter James. #SickleTiniSaturday #SCDAA https://t‚Ä¶,en,0.0,150.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/TAinaMDMPH/statuses/1299027745339592704,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Charity,0.0,0.0,1.0,RT @Pedisedationdoc: Virtual Sickle Cell Disease fundraising brunch with live music from Karter James. #SickleTiniSaturday #SCDAA https://t‚Ä¶,true
Pedisedationdoc,"Pediatric emergency medicne physician. Passion for family-centered, quality pain & sedation management/research. tweets are my own",,"Houston, TX",,2020-08-27 16:48:50+00:00,Corrie Chumpitazi MD MS FAAP FACEP,http://twitter.com/,1.0,,1.299026095711359e+18,,0.0,0.0,,Virtual Sickle Cell Disease fundraising brunch with live music from Karter James. #SickleTiniSaturday #SCDAA‚Ä¶ https://t.co/KOl4Zf44iJ,en,0.0,942.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/Pedisedationdoc/statuses/1299026095711358983,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Charity,0.0,0.0,1.0,Virtual Sickle Cell Disease fundraising brunch with live music from Karter James. #SickleTiniSaturday #SCDAA‚Ä¶ https://t.co/KOl4Zf44iJ,false
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-09 00:34:49+00:00,"Ritcha Saxena, MD",http://twitter.com/,8.0,,1.3364693123711263e+18,,0.0,0.0,,"RT @adctherapeutics: Attending #ASH20? Check out interim results from LOTIS 3, the Phase 1/2 trial of our lead investigational product in c‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,4.0,https://twitter.com/RitchaSaxena/statuses/1336469312371126278,0.0,0.0,,0.0,0.0,0.0,4.0,4.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,"RT @adctherapeutics: Attending #ASH20? Check out interim results from LOTIS 3, the Phase 1/2 trial of our lead investigational product in c‚Ä¶",true
DrABurke,"Mum, wife, haematologist, daughter, sister, friend - in no particular order! Personal account #carecantwait RTs do not equal endorsement",,,,2020-12-09 09:35:51+00:00,Aine Burke,http://twitter.com/,86.0,,1.3366054682198712e+18,,0.0,0.0,,RT @oconnn04: A big thank you to the clinical teams in the NCC and the Clinical research facility @stjamesdublin and the Irish participants‚Ä¶,en,0.0,911.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,73.0,13.0,https://twitter.com/DrABurke/statuses/1336605468219871232,0.0,0.0,,0.0,0.0,0.0,13.0,73.0,False,False,False,False,True,Research Funding,1.0,0.0,0.0,RT @oconnn04: A big thank you to the clinical teams in the NCC and the Clinical research facility @stjamesdublin and the Irish participants‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-09 00:19:26+00:00,"Ritcha Saxena, MD",http://twitter.com/,86.0,,1.336465443314348e+18,,0.0,0.0,,RT @oconnn04: A big thank you to the clinical teams in the NCC and the Clinical research facility @stjamesdublin and the Irish participants‚Ä¶,en,0.0,6875.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,73.0,13.0,https://twitter.com/RitchaSaxena/statuses/1336465443314348034,0.0,0.0,,0.0,0.0,0.0,13.0,73.0,False,False,False,False,True,Research Funding,1.0,0.0,0.0,RT @oconnn04: A big thank you to the clinical teams in the NCC and the Clinical research facility @stjamesdublin and the Irish participants‚Ä¶,true
sheilsroc,Clinical Specialist Physiotherapist specialised in Haemophilia.,,Ireland,,2020-12-08 15:09:36+00:00,Sheila Roche,http://twitter.com/,86.0,,1.3363270733343457e+18,,0.0,0.0,,RT @oconnn04: A big thank you to the clinical teams in the NCC and the Clinical research facility @stjamesdublin and the Irish participants‚Ä¶,en,0.0,123.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,73.0,13.0,https://twitter.com/sheilsroc/statuses/1336327073334345739,0.0,0.0,,0.0,0.0,0.0,13.0,73.0,False,False,False,False,True,Research Funding,1.0,0.0,0.0,RT @oconnn04: A big thank you to the clinical teams in the NCC and the Clinical research facility @stjamesdublin and the Irish participants‚Ä¶,true
CBCIDocs,Thoughts and perspectives from the hematology and transplant physicians at Colorado Blood Cancer Institute @ColoradoBlood @SarahCannonDocs @PresStLukesDenv,,"Denver, CO",,2020-12-17 16:57:54+00:00,CBCI,http://twitter.com/,68.0,,1.3396158170178068e+18,,0.0,0.0,,"RT @BMS_Myeloma_US: During #ASH20, learn why new treatment options are needed in triple-class exposed* multiple myeloma. #MMSM",en,0.0,782.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,55.0,13.0,https://twitter.com/CBCIDocs/statuses/1339615817017806850,0.0,0.0,,0.0,0.0,0.0,13.0,55.0,False,False,False,False,True,Research Funding,0.0,0.0,1.0,"RT @BMS_Myeloma_US: During #ASH20, learn why new treatment options are needed in triple-class exposed* multiple myeloma. #MMSM",true
Rfonsi1,"Interim Executive Director, Mayo Clinic Cancer Center. Myeloma doctor. Visiting Healthcare Fellow @GoldwaterInst. Tweets-own/RT not an endorsement",,,,2020-11-29 17:50:31+00:00,Rafael Fonseca MD,http://twitter.com/,0.0,,1.3331060758815212e+18,,0.0,0.0,,Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Mul‚Ä¶ https://t.co/uOUH8Apo05,en,0.0,8301.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/Rfonsi1/statuses/1333106075881521156,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Mul‚Ä¶ https://t.co/uOUH8Apo05,false
Rfonsi1,"Interim Executive Director, Mayo Clinic Cancer Center. Myeloma doctor. Visiting Healthcare Fellow @GoldwaterInst. Tweets-own/RT not an endorsement",,,,2020-11-29 17:24:52+00:00,Rafael Fonseca MD,http://twitter.com/,3.0,,1.3330996225505198e+18,,0.0,0.0,,Two-Year Follow-up of Investigator-Initiated Phase 1 Trials of the Safety and Efficacy of Fully Human Anti-Bcma CAR‚Ä¶ https://t.co/M2wXxOc2qa,en,0.0,8301.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/Rfonsi1/statuses/1333099622550519808,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,Two-Year Follow-up of Investigator-Initiated Phase 1 Trials of the Safety and Efficacy of Fully Human Anti-Bcma CAR‚Ä¶ https://t.co/M2wXxOc2qa,true
oconnn04,"Haematologist, hiker and camper, Lyric FM fan, proud mother of three amazing daughters",,"Dublin City, Ireland",,2020-12-08 14:45:59+00:00,Niamh O'Connell,http://twitter.com/,13.0,,1.3363211273295913e+18,,0.0,0.0,,A big thank you to the clinical teams in the NCC and the Clinical research facility @stjamesdublin and the Irish pa‚Ä¶ https://t.co/WBXTEp7Ras,en,0.0,60.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,13.0,https://twitter.com/oconnn04/statuses/1336321127329591298,0.0,0.0,,0.0,0.0,0.0,13.0,0.0,False,False,False,False,True,Research Funding,1.0,0.0,0.0,A big thank you to the clinical teams in the NCC and the Clinical research facility @stjamesdublin and the Irish pa‚Ä¶ https://t.co/WBXTEp7Ras,true
ClinOncNews,"An independent source of unbiased, accurate, reliable news and in-depth expert analysis on issues oncologists and hematologist/oncologists care about most.",,New York City,,2020-10-05 17:15:13+00:00,ClinicalOncologyNews,http://twitter.com/,0.0,,1.313165860090114e+18,,0.0,0.0,,New treatment options for acute myeloid #leukemia are pushing out old standards. https://t.co/BOBlHYjaLu @ASCO‚Ä¶ https://t.co/s35v4MgaVH,en,0.0,3172.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/ClinOncNews/statuses/1313165860090114049,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Research Funding,0.0,0.0,1.0,New treatment options for acute myeloid #leukemia are pushing out old standards. https://t.co/BOBlHYjaLu @ASCO‚Ä¶ https://t.co/s35v4MgaVH,true
ClinOncNews,"An independent source of unbiased, accurate, reliable news and in-depth expert analysis on issues oncologists and hematologist/oncologists care about most.",,New York City,,2020-10-10 15:15:10+00:00,ClinicalOncologyNews,http://twitter.com/,1.0,,1.3149475894402458e+18,,0.0,0.0,,New treatment options for acute myeloid #leukemia are pushing out old standards. https://t.co/BOBlHYjaLu @ASCO‚Ä¶ https://t.co/PHcC0MSE5X,en,0.0,3172.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/ClinOncNews/statuses/1314947589440245762,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Research Funding,0.0,0.0,1.0,New treatment options for acute myeloid #leukemia are pushing out old standards. https://t.co/BOBlHYjaLu @ASCO‚Ä¶ https://t.co/PHcC0MSE5X,true
nycdoc29,"ASCO, ASH, EHA & ESMO Member, Hem/Onc - 11 MD specialty private practice, former full time academic, traveller, foodie & out of necessity now a business person!",,"Garden City, NY",,2020-06-13 22:19:04+00:00,NYCDoc29,http://twitter.com/,37.0,,1.2719301098224722e+18,,0.0,0.0,,"RT @tobyeyre82: #acalabrutinib in 1L #CLL 
phase II trial
n=99
53m median fup
14 d/c to date: 6 AEs (4 SPM, 2 infection), 3 PD
Tox profile:‚Ä¶",en,0.0,664.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,28.0,9.0,https://twitter.com/nycdoc29/statuses/1271930109822472193,0.0,0.0,,0.0,0.0,0.0,9.0,28.0,False,False,False,False,True,Side Effects,0.0,0.0,1.0,"RT @tobyeyre82: #acalabrutinib in 1L #CLL 
phase II trial
n=99
53m median fup
14 d/c to date: 6 AEs (4 SPM, 2 infection), 3 PD
Tox profile:‚Ä¶",true
chano_py,Sola Gracia. Medico Hematologo. Donante de √≥rganos. #DonaenVida. #HSCT Dr in #Paraguay. Patient Advocacy Co-Chair at #WBMT. Secretary at @LABMT2,,Paraguay,,2020-06-13 21:27:52+00:00,Cristobal Frutos,http://twitter.com/,7.0,,1.271917226036269e+18,,0.0,0.0,,"RT @Care4Access: . @jmikhaelmd: ""That first #remission is important because at every new #TreatmentLine, #myeloma #MM #patients die, especi‚Ä¶",en,0.0,903.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,4.0,https://twitter.com/chano_py/statuses/1271917226036269057,0.0,0.0,,0.0,0.0,0.0,4.0,3.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,"RT @Care4Access: . @jmikhaelmd: ""That first #remission is important because at every new #TreatmentLine, #myeloma #MM #patients die, especi‚Ä¶",false
SurvivingMD,Hematologist and oncologist and Professor of Clinical Medicine at City of Hope. Author of Surviving American Medicine. https://t.co/ZVx56FNk6v,,"Los Angeles, California",,2020-12-10 22:50:03+00:00,Dr. Cary Presant,http://twitter.com/,0.0,,1.3371677244396298e+18,,0.0,0.0,,The #ASH2020 meeting showed new treatments for #leukemia and #lymphoma. A new #CAR-T treatment in #CLL patients who‚Ä¶ https://t.co/2boqTBsAj3,en,0.0,549.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,0.0,https://twitter.com/SurvivingMD/statuses/1337167724439629827,0.0,0.0,,0.0,0.0,0.0,0.0,0.0,False,False,False,False,True,Research Funding,0.0,0.0,1.0,The #ASH2020 meeting showed new treatments for #leukemia and #lymphoma. A new #CAR-T treatment in #CLL patients who‚Ä¶ https://t.co/2boqTBsAj3,true
DrMJoyner,"Physiologist & anesthesiologist Interested in human performance, views my own. He/him/his",,,,2020-12-10 21:28:16+00:00,Michael Joyner,http://twitter.com/,8.0,,1.3371471443487662e+18,,0.0,0.0,,RT @mtmdphd: A National Collaborative Multicenter Phase II Study for Potential Safety Efficacy of Convalescent Plasma to Treat Severe COVID‚Ä¶,en,0.0,13041.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,5.0,3.0,https://twitter.com/DrMJoyner/statuses/1337147144348766213,0.0,0.0,,0.0,0.0,0.0,3.0,5.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,RT @mtmdphd: A National Collaborative Multicenter Phase II Study for Potential Safety Efficacy of Convalescent Plasma to Treat Severe COVID‚Ä¶,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-05 19:03:28+00:00,"Ritcha Saxena, MD",http://twitter.com/,18.0,,1.335298761824891e+18,,0.0,0.0,,"RT @Elena_Kum: Excited to present the work of our community of practice at #ASH2020, part of a collaborative effort to improve stem cell do‚Ä¶",en,0.0,6875.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,16.0,2.0,https://twitter.com/RitchaSaxena/statuses/1335298761824890884,0.0,0.0,,0.0,0.0,0.0,2.0,16.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,"RT @Elena_Kum: Excited to present the work of our community of practice at #ASH2020, part of a collaborative effort to improve stem cell do‚Ä¶",true
Lisa_Palacios,Program Manager for MD Anderson Leukemia @leukemiamda | #HoustonStrong,,"Houston, Texas",,2020-12-05 13:01:21+00:00,Lisa Palacios,http://twitter.com/,45.0,,1.3352076352898294e+18,,0.0,0.0,,"RT @ppisters: Through teamwork and pioneering research, @MDAndersonNews experts are committed to improving outcomes for patients with blood‚Ä¶",en,0.0,657.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,39.0,6.0,https://twitter.com/Lisa_Palacios/statuses/1335207635289829377,0.0,0.0,,0.0,0.0,0.0,6.0,39.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,"RT @ppisters: Through teamwork and pioneering research, @MDAndersonNews experts are committed to improving outcomes for patients with blood‚Ä¶",true
CarinHagberg,"Chief Academic Officer; Professor and Division Head, Division of Anesthesiology and Critical Care, MD Anderson Cancer Center. Tweets are my own.",,"Houston, TX",,2020-12-05 21:34:36+00:00,"Carin Hagberg, MD",http://twitter.com/,45.0,,1.3353367969101947e+18,,0.0,0.0,,"RT @ppisters: Through teamwork and pioneering research, @MDAndersonNews experts are committed to improving outcomes for patients with blood‚Ä¶",en,0.0,1506.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,39.0,6.0,https://twitter.com/CarinHagberg/statuses/1335336796910194688,0.0,0.0,,0.0,0.0,0.0,6.0,39.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,"RT @ppisters: Through teamwork and pioneering research, @MDAndersonNews experts are committed to improving outcomes for patients with blood‚Ä¶",true
HindRafei,Hematology and Oncology Fellow at MD Anderson Cancer Center. #NKcellRx #immunoRx #immunology  Tweets are my own.,,"Houston, TX",,2020-12-05 13:45:49+00:00,Hind Rafei,http://twitter.com/,45.0,,1.335218822828204e+18,,0.0,0.0,,"RT @ppisters: Through teamwork and pioneering research, @MDAndersonNews experts are committed to improving outcomes for patients with blood‚Ä¶",en,0.0,935.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,39.0,6.0,https://twitter.com/HindRafei/statuses/1335218822828204032,0.0,0.0,,0.0,0.0,0.0,6.0,39.0,False,False,False,False,True,Collaboration,1.0,0.0,0.0,"RT @ppisters: Through teamwork and pioneering research, @MDAndersonNews experts are committed to improving outcomes for patients with blood‚Ä¶",false
RaajitRampal,"Physician-Scientist, focused on #MPN and #AML  @sloan_kettering #MPNSM",,"New York, NY",,2020-12-06 23:10:33+00:00,"Raajit Rampal, M.D.Ph.D.",http://twitter.com/,3.0,,1.33572333244928e+18,,0.0,0.0,,We‚Äôve been focusing on introducing new treatments at ASH thus far. Now we have data on the prospect of  INF discont‚Ä¶ https://t.co/L4pEmlg8Uy,en,0.0,607.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,3.0,https://twitter.com/RaajitRampal/statuses/1335723332449280001,0.0,0.0,,0.0,0.0,0.0,3.0,0.0,False,False,False,False,True,Research Funding,0.0,0.0,1.0,We‚Äôve been focusing on introducing new treatments at ASH thus far. Now we have data on the prospect of  INF discont‚Ä¶ https://t.co/L4pEmlg8Uy,true
RitchaSaxena,"Hematopathologist, Professor | Insatiable reader & writer | Embracing and celebrating diversity, gratitude & compassion | Crazy about teaching, yoga & chocolate",,,,2020-12-07 03:58:42+00:00,"Ritcha Saxena, MD",http://twitter.com/,6.0,,1.3357958492223035e+18,,0.0,0.0,,"RT @gjmccaughan: In first collaboration between @ALLGtrials #AMWG and Asian Myeloma Network, #@HangQuach1 presents at #ASH20 Phase II study‚Ä¶",en,0.0,6875.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,4.0,2.0,https://twitter.com/RitchaSaxena/statuses/1335795849222303749,0.0,0.0,,0.0,0.0,0.0,2.0,4.0,False,False,False,False,True,Collaboration,0.0,0.0,1.0,"RT @gjmccaughan: In first collaboration between @ALLGtrials #AMWG and Asian Myeloma Network, #@HangQuach1 presents at #ASH20 Phase II study‚Ä¶",true
Mikeypod50,"Podiatrist, now part-time, but still enjoying caring for patients. Father of 4, ""Baba"" to 7. Philly sports fan (sigh) for too many years",,,,2020-12-05 17:30:56+00:00,(((Michael Katz))),http://twitter.com/,68.0,,1.335275477645357e+18,,0.0,0.0,,"RT @BMS_Myeloma_US: During #ASH20, learn why new treatment options are needed in triple-class exposed* multiple myeloma. #MMSM",en,0.0,81.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,55.0,13.0,https://twitter.com/Mikeypod50/statuses/1335275477645357066,0.0,0.0,,0.0,0.0,0.0,13.0,55.0,False,False,False,False,True,Research Funding,0.0,0.0,1.0,"RT @BMS_Myeloma_US: During #ASH20, learn why new treatment options are needed in triple-class exposed* multiple myeloma. #MMSM",true
sortoutbleeding,"Coagulation haematologist with a passion for bleeding disorders and women's health.

Advocate for better health for all. 

All views expressed are my own.",,Irish Centre for Vascular Biol,,2020-12-09 19:42:36+00:00,Michelle Lavin,http://twitter.com/,86.0,,1.3367581637905736e+18,,0.0,0.0,,RT @oconnn04: A big thank you to the clinical teams in the NCC and the Clinical research facility @stjamesdublin and the Irish participants‚Ä¶,en,0.0,1136.0,,,0.0,,,Positive,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,73.0,13.0,https://twitter.com/sortoutbleeding/statuses/1336758163790573580,0.0,0.0,,0.0,0.0,0.0,13.0,73.0,False,False,False,False,True,Research Funding,1.0,0.0,0.0,RT @oconnn04: A big thank you to the clinical teams in the NCC and the Clinical research facility @stjamesdublin and the Irish participants‚Ä¶,true
TelehealthBot,Created by Doctor @KrittanawongMD. A bot that collects Tweets about medicine and medical innovation,,GJ 357 d,,2020-12-23 22:48:57+00:00,MedEd,http://twitter.com/,1.0,,1.3418784888239675e+18,,0.0,0.0,,RT @OncologyTimes: #ASH2020 Updates: New Treatments that Offer Hope for Patients with Multiple Myeloma https://t.co/E6xrZ83GfP #medtwitter‚Ä¶,en,0.0,683.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/TelehealthBot/statuses/1341878488823967746,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Research Funding,0.0,0.0,1.0,RT @OncologyTimes: #ASH2020 Updates: New Treatments that Offer Hope for Patients with Multiple Myeloma https://t.co/E6xrZ83GfP #medtwitter‚Ä¶,true
VincentRK,"Professor, Mayo Clinic; Editor, Blood Cancer Journal; Oncologist; Health Costs; COVID threads @SurvivedCOVID Opinions=personal views https://t.co/TMq9vc5hZk",,"Rochester, MN, USA",,2020-12-04 14:59:03+00:00,Vincent Rajkumar,http://twitter.com/,1.0,,1.3348748664414495e+18,,0.0,0.0,,"7. Phase III trial results of ixazomib, len, dex (IRd) vs placebo, len, dex (Rd) in newly diagnosed myeloma. #ASH20‚Ä¶ https://t.co/CtM7OCcFd6",en,0.0,33590.0,,,0.0,VincentRK,1.3348748628637327e+18,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,0.0,1.0,https://twitter.com/VincentRK/statuses/1334874866441449473,0.0,0.0,,0.0,0.0,0.0,1.0,0.0,False,False,False,False,True,Diagnostic Tools,0.0,0.0,1.0,"7. Phase III trial results of ixazomib, len, dex (IRd) vs placebo, len, dex (Rd) in newly diagnosed myeloma. #ASH20‚Ä¶ https://t.co/CtM7OCcFd6",false
dgermain21,MD-PhD. 2nd year Heme/Onc fellow focused on lymphoma and leukemia. Physician-scientist-in-training. Tweet/RT not medical advice or endorsement.,,"St. Louis, MO",,2020-12-06 20:23:29+00:00,David A. Russler-Germain,http://twitter.com/,18.0,,1.3356812896141353e+18,,0.0,0.0,,"RT @lymphomahub: CONGRESS | #ASH20 | Rajat Bannerji, @RutgersCancer, presents the results from a phase I study investigating the CD20xCD3 b‚Ä¶",en,0.0,1612.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,14.0,4.0,https://twitter.com/dgermain21/statuses/1335681289614135298,0.0,0.0,,0.0,0.0,0.0,4.0,14.0,False,False,False,False,True,Financial Performance,0.0,0.0,1.0,"RT @lymphomahub: CONGRESS | #ASH20 | Rajat Bannerji, @RutgersCancer, presents the results from a phase I study investigating the CD20xCD3 b‚Ä¶",true
AndreaAnampaG,"Medstudent @UNMSM_ with OCD ‚Ä¢ @ASCO & @AMWAdoctors Social Media
@CPsolvers Team Member ‚Ä¢ #Globaloncology #WomenInMedicine #MedEd #SurvOnc üáµüá™ #IMG üåà she/ella",,"Lima, Peru",,2020-12-04 15:53:52+00:00,Andrea Anampa-Guzm√°n,http://twitter.com/,18.0,,1.334888662924923e+18,,0.0,0.0,,RT @vasconez_w: Make sure to join the pre-conference CME on ‚ÄúAn optimized approach to Sickle Cell Disease Care in the New Era of Treatment‚Äù‚Ä¶,en,0.0,1908.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,14.0,4.0,https://twitter.com/AndreaAnampaG/statuses/1334888662924922881,0.0,0.0,,0.0,0.0,0.0,4.0,14.0,False,False,False,False,True,Research Funding,0.0,0.0,1.0,RT @vasconez_w: Make sure to join the pre-conference CME on ‚ÄúAn optimized approach to Sickle Cell Disease Care in the New Era of Treatment‚Äù‚Ä¶,true
TelehealthBot,Created by Doctor @KrittanawongMD. A bot that collects Tweets about medicine and medical innovation,,GJ 357 d,,2020-12-09 19:12:15+00:00,MedEd,http://twitter.com/,2.0,,1.3367505240377958e+18,,0.0,0.0,,RT @OncologyTimes: #ASH2020 Highlight: New Treatment for Achieving Hodgkin #Lymphoma Remission https://t.co/swfOKrjsCw #cancertreatment #me‚Ä¶,en,0.0,683.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,1.0,1.0,https://twitter.com/TelehealthBot/statuses/1336750524037795842,0.0,0.0,,0.0,0.0,0.0,1.0,1.0,False,False,False,False,True,Diagnosis Progression,0.0,0.0,1.0,RT @OncologyTimes: #ASH2020 Highlight: New Treatment for Achieving Hodgkin #Lymphoma Remission https://t.co/swfOKrjsCw #cancertreatment #me‚Ä¶,true
chano_py,Sola Gracia. Medico Hematologo. Donante de √≥rganos. #DonaenVida. #HSCT Dr in #Paraguay. Patient Advocacy Co-Chair at #WBMT. Secretary at @LABMT2,,Paraguay,,2020-06-13 21:27:52+00:00,Cristobal Frutos,http://twitter.com/,7.0,,1.271917226036269e+18,,0.0,0.0,,"RT @Care4Access: . @jmikhaelmd: ""That first #remission is important because at every new #TreatmentLine, #myeloma #MM #patients die, especi‚Ä¶",en,0.0,903.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,3.0,4.0,https://twitter.com/chano_py/statuses/1271917226036269057,0.0,0.0,,0.0,0.0,0.0,4.0,3.0,False,False,False,False,True,Research Funding,0.0,0.0,1.0,"RT @Care4Access: . @jmikhaelmd: ""That first #remission is important because at every new #TreatmentLine, #myeloma #MM #patients die, especi‚Ä¶",true
TelehealthBot,Created by Doctor @KrittanawongMD. A bot that collects Tweets about medicine and medical innovation,,GJ 357 d,,2020-12-09 19:12:15+00:00,MedEd,http://twitter.com/,2.0,,1.3367505240377958e+18,,0.0,0.0,,RT @OncologyTimes: #ASH2020 Highlight: New Treatment for Achieving Hodgkin #Lymphoma Remission https://t.co/swfOKrjsCw #cancertreatment #me‚Ä¶,en,0.0,683.0,,,0.0,,,Neutral,,,,,,,,,SOCIALMEDIA_TWITTER,SOCIALMEDIA,,,,,,1.0,1.0,https://twitter.com/TelehealthBot/statuses/1336750524037795842,0.0,0.0,,0.0,0.0,0.0,1.0,1.0,False,False,False,False,True,Research Funding,0.0,0.0,1.0,RT @OncologyTimes: #ASH2020 Highlight: New Treatment for Achieving Hodgkin #Lymphoma Remission https://t.co/swfOKrjsCw #cancertreatment #me‚Ä¶,true